<SEC-DOCUMENT>0000785161-22-000008.txt : 20220225
<SEC-HEADER>0000785161-22-000008.hdr.sgml : 20220225
<ACCEPTANCE-DATETIME>20220225163815
ACCESSION NUMBER:		0000785161-22-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		130
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220225
DATE AS OF CHANGE:		20220225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Encompass Health Corp
		CENTRAL INDEX KEY:			0000785161
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				630860407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10315
		FILM NUMBER:		22680887

	BUSINESS ADDRESS:	
		STREET 1:		9001 LIBERTY PARKWAY
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35242
		BUSINESS PHONE:		205-967-7116

	MAIL ADDRESS:	
		STREET 1:		9001 LIBERTY PARKWAY
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35242

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHSOUTH CORP
		DATE OF NAME CHANGE:	19950113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHSOUTH REHABILITATION CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ehc-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:8fa73796-4641-417c-869a-a8efa97ec0d7,g:d7a996dc-3cad-46ef-bbb1-393716adc0de,d:34f6226a63dc43528534c2bfabd86ded--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ehc="http://www.encompasshealth.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ehc-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF80L2ZyYWc6NTk0NzJkODYzMWRhNGRhNjk4MzgzMzUyM2M0YTA1M2YvdGFibGU6MWFlYzlmNWRkY2ZjNDNkZjk1ZmFjY2JmYzU2ODFiZDUvdGFibGVyYW5nZToxYWVjOWY1ZGRjZmM0M2RmOTVmYWNjYmZjNTY4MWJkNV8zLTEtMS0xLTU1OTY4_a44f7b34-1c86-4e46-9fb4-471546e74591">0000785161</ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF80L2ZyYWc6NTk0NzJkODYzMWRhNGRhNjk4MzgzMzUyM2M0YTA1M2YvdGFibGU6MWFlYzlmNWRkY2ZjNDNkZjk1ZmFjY2JmYzU2ODFiZDUvdGFibGVyYW5nZToxYWVjOWY1ZGRjZmM0M2RmOTVmYWNjYmZjNTY4MWJkNV81LTEtMS0xLTU1OTY4_13ef36be-f5ed-419c-9d80-953907668739">2021</ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF80L2ZyYWc6NTk0NzJkODYzMWRhNGRhNjk4MzgzMzUyM2M0YTA1M2YvdGFibGU6MWFlYzlmNWRkY2ZjNDNkZjk1ZmFjY2JmYzU2ODFiZDUvdGFibGVyYW5nZToxYWVjOWY1ZGRjZmM0M2RmOTVmYWNjYmZjNTY4MWJkNV82LTEtMS0xLTU1OTY4_abe0ed5a-f736-4db6-88f8-f123863a2ff3">FY</ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF80L2ZyYWc6NTk0NzJkODYzMWRhNGRhNjk4MzgzMzUyM2M0YTA1M2YvdGFibGU6MWFlYzlmNWRkY2ZjNDNkZjk1ZmFjY2JmYzU2ODFiZDUvdGFibGVyYW5nZToxYWVjOWY1ZGRjZmM0M2RmOTVmYWNjYmZjNTY4MWJkNV83LTEtMS0xLTU1OTY4_b02b8e20-10c7-4b69-8b48-b799ce075667">false</ix:nonNumeric><ix:nonNumeric contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ehc-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66424ae9b2c44a4fb7238c492c20dd64_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if4d32bfff62740bba5b17d616f96ffc5_I20220211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia426808899a640b5963caeffaa5e5bcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cab8f26574d455bb0e444a22064322e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8ddf5948f941808c197344226a885d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cb543ef43ed40f1a7ee0241b7a11342_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f37180681db48768667c6ab12ad98b4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8199a59d951645668567ba119a46ab2c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a91751427448778fd75c271f59e770_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16dab19dcce146e486a875b0b0b69c08_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0992f803e1e34a4e90d50e779e344893_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d7707625cf434f9d6f3e0485591879_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923ea8f6bd4b4243a0033479742dddb7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548a41347a74411dad48274aece4d650_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56730ca5523d40a8bb4c79634fbac5c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a730b37d7846fd8c535e4701134ade_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbcfa3b248545d9b8cd1d01927d9fb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9fe6fdcb66c408182d54fd398242dfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d69e5017d07424e805b4bfb62fc3b6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b524f488ed479ab4120a3288ab25b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3747ac9e4f7a4b1eb2654738ec5cd6ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie331398123094f4cbf9f53387dd320e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74bebd850f4a4fccbaa89fd90826de06_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397d63e231e44fc79264c4127d701240_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8493b47598e8480aae3bec09697737b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9303df094ef6478caab5920b2de3b1fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iead3c9b8c76f4379b37747a26d26954b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6acc944f2fd94ce584242187a09963ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6943570c9ef04b01be3d3edd3c2634f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9983aeb86edb4167b0261e7526ff14e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>ehc:state</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ehc:segment</xbrli:measure></xbrli:unit><xbrli:context id="i50c41afde2c14f30868fae349870ae67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6271cffe1c904ccb98ba4fe7cc5181c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11cc4a44f3ce4c27b16c3a87f7e6c602_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie210db53eb0d412eaee1d6fcca151b10_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0201709f3946c08a6ab86ab34fd860_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefea4843724b48b09d4df201deaf65a4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc66028fb34c417d98f6aa0925fbaf46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf5dec126efa48feb647aa010d99768a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9441f0547a243a2b7b5a2b86b40a684_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e244b99f69648959e00b33e0813e62d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if62c48a4d00044a48498232bb8743644_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666da563adcc46e988ccb8361d06a266_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c288f844e548c49f2fadc07c0cb5de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f0c321a2cfe4aa5a8aede0de35b5d94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f340e8442bb423ca9425031c1a5d324_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ae81a511e14a958520030481b4f6ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad2d076cc6c74bf4b47595003b494784_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f10396a7e3b43ebb4e5c9e8ea06743f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90363214f544ed4a70ebfb5ebdad889_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc79562a0921430d8e1b5424ea7afd74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18fdd0edfd604ca0adf6e6978f89a471_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248e5b251d414ac992e37bdfa4007809_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id889fb2355f34e3fa69a032dca90b99d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife4a3b4a13f348b7bde0e4da0ad9fa60_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd44b56d04a47dab1d7f34a4a696e77_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc2201186bb441b862bf0c07fec3894_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9da587872f03428ebd0561751ad78968_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2080930973934f8c9f1b16798afc84c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f0c27770799485ab81f312f87261f13_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ab67a915ad4fccbdb5079bce262358_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8182e20f98d04c6190ceb6053df0ed57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bcebecfa11144f2882ac634ce41c2cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cbe87cd92944498b87689bf56f9f42f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0763338809c342129b7f8f9c3818bd70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9408ebc5eec943238d4bd413eb2752e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aae1d8057b04f22bf4c3a4c1a1de209_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57418ccab59c4872abdca8da71effd35_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b2e886e1d34c40a54db89ffdbe59e8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0186908fade24055a75bc3d6e203778b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93348aee51814bf9aecb0395b5cb93a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0839ac5ac72042bfb3800163f241925e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3e78919a4e4173a9a3c81b5ce115c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95dc4732a37c4b6da92a2818f2a80bc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fed2509c225447aa65e5e144d767dab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida50b0a668534d44aec233b93224cc40_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a9e5d1b654340c29ca65e2d0b0aa0eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idde0b5f5e38841389b722fd9e125c188_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7373562b9b1b43dfa90c43cfc477cd4d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb62cf7c2ebf425185cc1b842a56a99b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a535a2b9fd4b4a9dbbb62ad7109711_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49093b7f6f74a3a8a1db6448e4cc4b3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fd372b138034d8ebb56c465c676ff31_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e61058727a4dee885614cf27830c46_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f71b1e134644eb5be3d0b729fca8ce4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857d5dcdbfab46a6bbc20427b6491403_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaad37c17c8b34f8a94304d1a0bc269e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e6d0167938432a9aa75d163f6f83fc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic315543707c2438ca08eaee06a1f2450_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822b083e60b54e34844537cc70601ba7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd833c8e5a04bf6a99b0d8ec0b64e76_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d24912b1574d9cac401d0d2ee4bd93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b3c61991594fc08487d9b203777782_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4fab58433e548239f4f791ed6c5f399_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9977d16b4a094aad9e89217d4ee09815_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51e90e0735aa405787042bd27546ee2e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe668ae93474f95813ae6b7c49cdd11_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361e56a65aae4bc697d20f87ea1972e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7738b6274b504051923f6b91db1fcd16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a2078ca149443eafdafed5920c603a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f64ba8495734d8686feeecb04953b0c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a1b498ea6d4e5b8d189d76693cabb4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb58bd763fa9433e89fc2d61f1929408_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f3e24d5cd1f4b8ebdf4c2d6dd46c2fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62805e51679a413bb8bf0b46874d0827_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8338e0e37d4903bd2d5fd0e52481d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d168944b24b447dae54f7498ce0ba93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife450282edb048db9144cbdd9b90680e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3ec10c8f11e4192a9e80bbde7ba3a07_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7f4b3fa057413aa60a6ff5a64dbacd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia523cdf50d014242b78b83f266130520_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3e19f52f2f4397b2d5ea65c15ca225_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117d8f2dd52b4c849355026c48132be2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:RACAuditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7994f9fc04cd4840a17d1544f512fb8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9449e02ec44d508d4927471cdcc16a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903f3c96be49421cb34587eada9a3d73_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMedicareAdvantageandOtherDiscountPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee22bb7c53a47e38414ec76277b14a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMedicareAdvantageandOtherDiscountPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ad45dea4b44812b11a801895fbabbd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95424a9f833f49b7975ae1ef37013150_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ad81d8f2624817a96c259486c2c8f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261ac6208a0241d587f1681af3279429_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae4da8c0139452fafe3c4ebbfca7ed9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b77ac20c17f43f0a30fd0ec6609eeb5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6f62ec72ef49639c0efd8c8199879e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610608fd11384b56bc5a535b1530b9c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14868c106a174d0a8a6b3d5fcda73002_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c2b8cd85f64f408ee95281af4988eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b3dd4016124cdc94f5fc2e5ae4ee7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52accce1aeb84d6ea4f024105e7be7e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e30f37f543478e8e85ee391f748aa2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86cf609a63b04fb3b5b2972e6cb02c87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaafd14af4414d4ca561988c69f582b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida89837462c2402ebd51e087abc5f902_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if710bb04b24245de9a5f881c21cd788c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50efb55c2089401caaa0a82d59fa749b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc3915d64cb4cd186314ea29dfaa5e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af755a7159549e5992cc331710580a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d0e9fd8f4d4150b657b8c8b64a3458_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6195ee7b4d4edb890d0350b3e6cbc8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f353410c2e4dd5999e0aaa5dfb977a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f41d63c292477387fc936648de5818_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf20f07dc2a8494ebaf17ecb8a1ec09a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ff9c36be674ad1a655dbc573f502de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:InternalUseSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife3d75e297fe483392cb51c7d6a9d0af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:InternalUseSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad16be810f6b476785e37f9d09c58d8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddab4f4ba3d6483d872cadaede2070c3_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="bed"><xbrli:measure>ehc:bed</xbrli:measure></xbrli:unit><xbrli:context id="i724c634720d6417db699f31c4afa1e59_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HeritageValleyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3170e4011fc54daabed3c4a7be2b4ccc_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if216c8078722440e8bee9e82ecb4ce83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6567d29470494e9a12d3a1e62e4cb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd6ff10ad12e43968abb2d9fedd5e789_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i979989da0527439fb4dd5f80434b7799_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c84d8686d2346a48ae0771dc64c8d90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idffd6c8c86e648aea58449550ba84ab6_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89099d548c34496e95ffebc80afea24d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b4f00d1fd94454e92fb97f98bd493e9_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HeartOfTheRockiesHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa6dc46af56b486895888a4fb9a90e92_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HospiceOfSouthwestMontanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d940caeea84febbbbf878bafbcdbae_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b060236cfa44c0a9c3de61db94e9a3_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="location"><xbrli:measure>ehc:location</xbrli:measure></xbrli:unit><xbrli:context id="i13d51c190f6b4f5bb0c9fee6c0a3bc79_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6216b070ab640879f12d1cff0c7359e_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ae29baed2346a6b2cfd2b07ef1858b_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcaa5db830d74c41b04e18e3d712cbb4_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dee177e57f140e9a6c2ed09915a1349_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04050f083344efa8f61e38aff5f34c0_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i978416f27dae4c0896c015487892aa22_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecae4857993e469a9b571629b580ca06_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a3cd10f3d534263a36b46884d9b5925_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2a18b64b144278ab7fc3ca1e5665a1_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8279db1c332d4e708d8b00d2ec28fcee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b6c4b37b72430bb27cc893622797e5_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a84b415d07493e8cb918d0e2ea7f5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e771317f044433ebf4a8a2a5d5eb059_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibef0cafa72f949fabb0aba607529bb57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25e23730767f47b9a77ab3f4c276bfa8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f460ce531347859d5a7bfeec5a762d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i773106cd2a324d499116f825de895f7e_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb895620d9c4243b46d28ee569388c2_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53030c89936d407897671309bbeb1f7b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663e53be26e941ffbeb8afe0c5e46b4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc1955f816c34df2ba0316a625c6ba30_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75c35d2f7dc4b22824f5f5f2725d6cf_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9f063c376c4593a96e8f3e1c883a61_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02028d9ba724ca6b97593c19c98591a_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if670737e9dbc4e9fabc500e7e933390e_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26c3e316666b47b9bfa8484b5183985c_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if702652feabd4fd78b3453c3d867f5cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaddff5e45b144d06a0e4c066b7081b51_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3eb83f5d9b54bc49973f50a399a5c57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50245be41454844ab31b7a2899757ad_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ac3c94284cc42dcaefa48344e6f041c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic19f96ec376141aa841d8f70ab86a81b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37157c8e16b448a999811b4aa3779421_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ba70666ee904810aaab1057f142b141_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9b1260076c94869baae8e55f9ee99a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2020AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae1c4e4319c41439be0441090ee96a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2020AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b80143fe808479d88a8c886e315b0de_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25b5ad20ca94b278f0bb86ed76fb546_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HeritageValleyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusandHeritageValleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AlacareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a832df04afc419bb4147b4b673a3a50_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AlacareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83efdee8e727419e8877258c72d7d06e_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AlacareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33168cd12e06476282380e6f2e0e09ab_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:CareResourceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:TidewaterandCareResourceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc3bbc643a1a4af4b94038c460a77df9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AlacareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3480d46a606c42799ec28c3335bc60d5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2019AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib73cbdd803994190950116ec559457fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>ehc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i8fdff6f27e5f4de9b71d55e1a259b5d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff4da371722344eb96f964534004f0a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3a2f947eea4354801d07d1f2e1e80c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aba592c2b964f6eb203562691351ad5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602ba1aa1f984572880fe83f75fc4c63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15222b6444e842b6bdb5604f4703b8e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10b6ec76120d47a3be5eb18921f9202b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id746f8bfcc324f59bffb9b5c9b3a3d24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:AffiliateCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d0a191d08204ba6a56d0168e6d7c236_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:AffiliateCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6382b49a2de846faadc4af9c9f5ed24e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:SelfInsuredCaptiveFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id841d4ad284e4f34936f643391714d19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:SelfInsuredCaptiveFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c1ca2c1f30a41728732fec700a16e4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8516a1fe22324229af025f40b32d77f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bdb38e0060345f8a7f153c65b0ae589_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3869f5c4ac04881b2a7c48441f84658_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fc36ea770b490097eb1b8b155949d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e53fbc95c16440ebc2899f7ff225074_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f487c6319de4b2789e80cce58d82850_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd0053d81c5643ee947bbd55082c4aa7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a35614edf5643cda801a3adbda6f446_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia70f9dcbe8e24aeea62c485281cea06f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ehc:LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36f1e5c21e09435f94b9e6e1c8a4bc7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ehc:LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39344a1ae54d4b5a8df1f9ea9760ee2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6d18334d234593b48e1782c831116b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if750783979f34735a047752b07b25985_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d825afa781450ba456aff29ce70e22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b51d815c2e4db38d2976c4fb0c1889_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45ca43a183ee4af097404ac760bab1eb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702f98649cff4e8c868a271821368090_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6908c604f9704fdd859cda5b310c3f22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b8c9109fb524f078bf0bd4b28be8aa2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490945f79e4b4bb6aeef60a98f16bb9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da867bd58bd42c7829bba5db347624f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2be078a38c485caf0f9d2aff094488_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic844601724a84290b07683e4c14534a9_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f21e5f62784e5fad3a81733fafbc9b_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ac5a43d97b4d1f8b07571f7fd1b855_D20191001-20191001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dfa4bde6170492bb1256171952a8047_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc3f06fe25e4000958cb09124165dec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c9be624554e4aa4a376cd3b45cb1d46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f74947a4ced47148dc5c2e32cdb11ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e11b04c0c5145c3b6c956ff071c1203_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5716c39ae0e54b28a2f17fc8e1345352_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142b52fe614942e2a17e645d7b8dd1ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:TradeNameEncompassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40cc76eee7fb4c20a4d9ece9eadca6a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:TradeNameEncompassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc2019286614b4d9cb93eb114ddc287_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc1609b119ab410a9be9855c6f405555_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebc7abf48bdf4656b5449a56fc5811ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7674e95c82459ba38b39ec46c8f9b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcab17e249fe430bad4f7616edebf373_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa18ceb2e4824a189bed176eccf7312e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>ehc:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="ie64cfb56dcaf4d2dbd074d8ae766d3ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib75c417944a447ca93f748d0d3afe2f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee1bde62ffe249dfa8317c6305c6c843_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37665585786e4e83a76c3a3f771a86de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77309f128df04419abedd5fd33738b08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i196e74d41d844ce489461736995f7d1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:JupiterFloridaHomeHealthAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f008123b074f85973c4425cc5d7c42_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:YumaRehabilitationHospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda4f773f6c54fe581e21ee14d227bc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798f862fab8b4413a0c57906b428ab10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7915604b115c4cd6b70e206e17b2ce26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05884d3e63ee40d5907eaf0324564a18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475515e7171f46acb6ddebf2c000d90c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i098be77d49ab41099bfe946d54e9bcd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6689accfbb7543808abafce304019012_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e8dcadb39154f309a2431ebb274d483_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940f9d1a36544945a5314717176158e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42cd94791aee45c38596cfa00e2c22b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d481ea979b4b2dac6c075291e1ef68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708722e52f7b4e87879527c09b19006d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e435cfbee1d418aaa5b1e302438b2e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c70ba1acd6484e874b7cbf5ce32af3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95660f8d813c4751ade79f135d5b3a25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5951de1720a942e0a0e71cfd9f206587_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:FaceAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i844223c9a9da4adfb49e461dd0b62f85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NetAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d8e5cfdcdc4f0096543280be8e1479_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i797035a2e3fa4c98bd423b13b951a80e_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia643be6ec0c14729abfe4a71fb7d089d_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3208cda4b8e43a9a5f3510db5d5ced2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia259457e23e1485b8a1e9fd5e341cef6_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56bc6d52e31940afb1b7f3a0beb13a49_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134cca390d7c4cd4b8104ec05d7b8066_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ef59182ef74e5c957f25dd73b3a573_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fed9bbb5d24489bde193826b885d42_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16cf531547424c47bc386d720dfa4305_D20200701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c917e5fed374c46a90bd9500b43d72a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a551c0475024f75acffcd0aae3a51c2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17a5c6dc46234ee6839769c452e0a31b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i065696f54bd6452cb28eea433c352d7d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf2f41f6d0848b4b6dc77ea02f235d2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88e6abed3f9c4844a3856dbae44d3c29_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie61970e957d24746b800b3a4ca061b38_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i442e600335de44a4bcbc192cf1a0def6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f1b2314ba3e4d2c9434f9205fc3dd2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0738d83aff14b43981733b51cee43ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd006cc199943069830e5f0df2c5322_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc45972689104b858888baba8d5c3b2a_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf76ad690ab486bb10282ca094adb84_D20211201-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b2e62c3760743f3b11242bc8c1de996_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543ec7b3b23f4ccaac5a0b5e29eb4329_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37408f6809d84596aad486f8a90f4e53_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a20418879d4e958becfe001883e69b_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b11fbba37e419697f8c888119ebb62_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf18e7d48c9f48a98324da23bbf64a5a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9cd76a2420419799ae4a84b2cb8f1b_I20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d83e601b2be40eb9289618472d20e28_I20140930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe8c7bfd4394f1197ca833de3df2c09_I20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120953c681a546c1a1f10597d05382b8_I20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732f255021564a07ad138756673d00c8_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bcc19b1cd384ad2803fa192d9fd6f72_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735b93d85e2c4ffbbd677a2fed8689f2_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4c39a1fe44b40aea3426508dc786fe3_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05599bd9faa5433482a7fd2c5e801eff_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc40e1fe47f0401b929feacafbeade4a_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c812649e8f461984f6a55bf31af65b_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6728ee3fbad74c3f9120c35eb6bbb03d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ba4302b48948e6be58d84a07f42291_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aba6edb48cf4106a0de799690174657_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d4f1c1e34b4547bb895f17359f6c52_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia038a343f20045bc93b40477b4bb3e59_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf2c1b477bb4e80918f99b0e09a865b_D20190901-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8791e911ccc94436a4ccde3614131c9c_D20190901-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cdcf2b1d8654c6782039c26b7a57622_D20190901-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1756ab5e169c478f9663bb9168588a4d_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if45838f1a45e438091364b67a05bf7f6_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a2dc69c68d4800929ad19f067a9d3f_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e4a72722524946885cfe42cf42efa9_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13bbad57db694aae95b5e5b28b57c341_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2841dc9bff054904bae487294dbff306_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4816d28c19945fea8ea5bedc380aed9_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ae10b8be3c4f858f5f9ac1d488a263_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d7e73989884e299b452c135030ebcf_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff05368e33294deaba91e4d0daedb5b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic786d7283c4945f58da42a6add61877d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e3debe10554bb8adc998d7c9f34060_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia058d22308374baab4f7f83f431b2a7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied1386031d4644d3a4bd6b53278b051d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e342b38454245b785b3717eda590962_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50281083594e49c69e3436fc0ceb6eb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied075c1981574658804c0fe14ced2869_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74efb2cbd6fa40438ef2310cb2d0fa56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc42cb6979d645e294db913c6cc97edd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dcc3d612e364ad7a48e4ec4f0099438_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7048280062f4c379b09fb68447c12f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>ehc:claim</xbrli:measure></xbrli:unit><xbrli:context id="ieedaeba272bb466387acacba6de2f02b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife388829092541459cbc207156259fe1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa910c45e3ba432986f5de81016e67f2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b3ec367aa84b1b8b9ef9bdc970188a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c9d6a1911754260a1b0e06548e665cc_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i372fc03d1c144d9b84eb20ceee3d1d0e_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ce9b34009e450aaec6451916af0460_D20180221-20180221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-21</xbrli:startDate><xbrli:endDate>2018-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe4b642f98b44d9297f662ae777e6a48_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b95d9baa2a3472f8501b1064a01c601_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib32b4f07fc6c4852aa189147f3ac8f4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a724185f6047b2a7b0f3655af7f015_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2460d2c0ba7b42f591cc57a3b40a1eac_D20200218-20200218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-18</xbrli:startDate><xbrli:endDate>2020-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6104f61239694a209a6dd8bf3ea4229d_I20200218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d67ea997974c2d910a1b10bd43ff0d_I20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08537da18acf4dfaa0164d93a3f484c8_I20200306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i416581dd3fdc4322b8a32aa48b236e6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ehc:HoldingsAndEHHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied40dc1098204db7afa17d466e5ee54c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id93bba85033d46889357eea3753fda21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9114052e2fb44c2197290d9e9f558961_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4ed8fefa5143e8a3f5ad38cf8cbf30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26344215630447e2a32f1bb8fb1577c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d9ef1925864bf6bd6ebd083ceffcf4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72afa364a34540ae9695838e9d3f5468_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3e10e7837748aaba2310ed38697364_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07a527a70c444b8aa8dc851c08e1454_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie630f132fb654f72bc20deb38a5299e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb6e84f060341ee8f3a82d5fe595b1f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a96226e9a74277befd57b95ce89cad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f229fa2dcf94ada94372b94a004a511_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icedf57c7e28645bd80047694f8a37d7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i478de2031cff4407b9b5bd814b8fffbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc784810eec245a793b5bdaf468ad33d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41ca53159bc4b10a192181b3bca89ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i854aba59b7df49a79105db7602e291c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a611dd035e44c8fb3fb11d3061619d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5a1360b6acd4210bf3adb7d6d88bc50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f48f48c99b345bc8876378d756bf4e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36387f8be3fa45d09cbd0c2a0ab073ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i062d90846d5246a8a5ce15d4753ed256_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003153e059144500ba846eaaf3124397_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04aa7dec6a244bcba19b7d980b858fd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc744be7bb2e4378aa9465a42c569d4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eda38234466449a8e337a5d2c3279da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib71d169070664d258df1acb196a80bd8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib23c7a2789b540b5b31a5bc6e512ff63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3661453bf8d4cb888df6dfd0eb6ea49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4222e0b6d18348f19725e8257c08a4ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3d0325b6fab4784876511cde99c9a37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0971f6c0ba8347fb8bbf20251a8ef965_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e243e3007341bcaa8e6d60b76106d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c46ae7004334f3aaa8ec786ab9f4e60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ee5718dadc4409d81f3281961341d1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d918faf5c945fb8f815f7f3e0db8d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02851d306e4041dfa6105c00051182cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57c054ef40d45489612bbab7e3e448f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20ffead8b6274baf8242167d98ee9096_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb0dba2d7c8a4826b1f482f1349b6e95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac9bae069004607913ad2196139ca57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id35d77e9ba484f40ba51f2683301dea5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id114ce728e2345d89f4bd7890b37ac2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d4b4be5983f48d581aeb5aad62c2ca9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299d52f28a4c4d0f9f975d70786c40f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52cbb010926c4e229d2f2b20106351f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1fb54362ed14ca5bf853364666f1665_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ehc:A2016OmnibusPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7804d790b2414c79899e861637a8a2e5_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:EmploymentBasedSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib735bb4807dd484fbea2ba815c38a8a9_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:PerformanceandEmploymentBasedSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8c982d4bb944d5b92f0c669ef3ef9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:PerformanceandEmploymentBasedSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2acf2cc0fd7d4d09af40dfa207a99bd2_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6853550297dd40fd9673cf39d8bba361_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94fd694f8fd3453eb2468c49bd5270ba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80269d53cbb0459c9a42ac92da3a7665_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c72f09fce4043719ce2db102fc528ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6650fab69c11492c9077744e36f1f4c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a08b2b7b1b4149a37586883c795c5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6a233a73c164626b8371eab0e23471c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0980bb7516a2462090a8eb088e642d56_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2e0bbe25b944009128cefee2d0d142_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d10387a093410d85237a92db5c4dec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23170992103f4aea877de6980dd955ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4491cc424043bab594adb15a4e38fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8b7549430046a29b87cd735c3324cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d403e9e176d4ad1a0337c0b47804c60_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca59813d6ce47e690d0ffdf1c9e577c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>ehc:plan</xbrli:measure></xbrli:unit><xbrli:context id="if30d4b37dc324d81b38e9cf676a99627_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHealthRetirementInvestmentPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad3ac221c7e416b8039eccf0be81c30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHealthRetirementInvestmentPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:context id="i97f18be172de4a0895d8c7a7e9e5460a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHomeHealthSavingsPlanHHSPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0081857a985a4961b0157b55a3108ac9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHomeHealthSavingsPlanHHSPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9210832b6dd4034a40b13798dc82f01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd77f4eb1a44cd19a0e1f02f5b4d30e_I20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5509a74ccfac4681b49ffbf1a98e00a1_I20140201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d7a3624fe641b1a56f6e162c46212e_I20180724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i985e0db50aa74ba18de323dce42bcfc3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic11d995353124469aeb3ecc87464738d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45e50175dc9344b19c41346526f0d782_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914b6b0bf40d480abbbf07849b027534_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7b3e61b74c4a53b71221db5581c78c_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a9857d4f284bb4be2223bfda243937_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a8048f934624676bc2bb342d07afd90_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ehc:NicholsLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="hospital"><xbrli:measure>ehc:hospital</xbrli:measure></xbrli:unit><xbrli:context id="ia3193970835f48d291309e71942e3c0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c49d5b00b54d92a4203a7b4d46fe21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="facility"><xbrli:measure>ehc:facility</xbrli:measure></xbrli:unit><xbrli:context id="i629acb7e34ff462d830466f2f0283b24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda439a47d5b4d4b820c4a0e2bc953fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca76abaabe14804b27dbe68101f2b21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i886bc836155e45d099f360bf9159bb7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b20d1c1a4664c29b6e46e8c2743fd6d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9c5d61928d45b991a621d141539dfb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776c682b8b6f439fb66cde932ed76f45_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a9deb44ebc4734990673dcfd5a1fa2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3de5b67d1c443a38dfa663c544d2ffa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7deb25afaae4201a2e97e69747672e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5571918fc1b480a932b9aaa18cb0053_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941a80b49d3743a78f06a9e20d555c80_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1af801ecbfb49d2bc7b43640349d670_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia681297da5504ffaacf633a76dcb7a2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4752f09b329c46a7a5c722bebaadac64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i301c2e1d8eb641efb1ef724b3603ec49_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e9398a071b4c9a98203be3ab77177f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db2ff79c3674a52a089ddcc64324e9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c6808319b14ca9b78c39dcbbbd0052_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTEtMS0xLTU1OTY4_8c08c71d-5cc5-4114-a2b5-a12015439158 id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTMtMS0xLTU1OTY4_b1625715-3198-4ba4-b240-797414be8947 id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTMtMS0xLTU1OTY4_37065a94-0044-4a86-8cd6-196ede9333a6 id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTEtMS0xLTU1OTY4_0b58a3fa-b14c-46c1-b573-7fcf0c82ac10" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzM0NA_295907de-de5c-4a62-9d8b-958e93adf76f" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i34f6226a63dc43528534c2bfabd86ded_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg2_c8682fbc-22c2-4dab-b93d-46b2ba03fc76">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6N2YwMjBmMmQ5OGUxNDRkYmJmOTBlYjUwNTMyY2ZlYzgvdGFibGVyYW5nZTo3ZjAyMGYyZDk4ZTE0NGRiYmY5MGViNTA1MzJjZmVjOF8wLTAtMS0xLTU1OTY4_38c13698-33d1-463b-992d-98b9a94e1cf9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18xNTU_da0a09d4-12a2-4a3c-8104-80ad72dd2500"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18xNTU_08f9ca9b-b92b-4f57-b90d-1860ff454e3e">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6OTk1NTNmMzZmYWU1NDFmMjhhOGM0NmUyNTc0ZTk5ODUvdGFibGVyYW5nZTo5OTU1M2YzNmZhZTU0MWYyOGE4YzQ2ZTI1NzRlOTk4NV8wLTAtMS0xLTU1OTY4_5e15308f-66b1-4f78-8b54-71e23ab72c55">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDkz_5bce2352-a979-4802-9626-4e4bb20440a5">001-10315</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDc4_c5abcf9b-9d7e-44f7-93da-e5a3404349e7">Encompass Health Corporation</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6ODdhMGFhMmEzNDQyNDJiZTlkNThmZWNiMTUzODI2YTAvdGFibGVyYW5nZTo4N2EwYWEyYTM0NDI0MmJlOWQ1OGZlY2IxNTM4MjZhMF8wLTAtMS0xLTU1OTY4_11b9ad41-f289-40df-bee4-fd565bd0d11c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6ODdhMGFhMmEzNDQyNDJiZTlkNThmZWNiMTUzODI2YTAvdGFibGVyYW5nZTo4N2EwYWEyYTM0NDI0MmJlOWQ1OGZlY2IxNTM4MjZhMF8wLTEtMS0xLTU1OTY4_d1e30bd7-89a5-4253-840f-21f15780854d">63-0860407</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDc5_d9ddfcda-89c4-4cd2-9e57-7dc7189ac589">9001 Liberty Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg1_e95972b4-0921-4a22-bfdf-455af6255bc9">Birmingham</ix:nonNumeric>, <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg5_9cc9e3ab-d7de-4a2d-ae92-ec303e410390">Alabama</ix:nonNumeric> <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDgz_29a0563a-04eb-42f5-85f5-2f06a63ed45b">35242</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDk0_87549d0f-8bde-4729-8e08-37e2fa1e0e5c">205</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg3_dc2d0a91-b5da-4c66-970c-ae7bb7598c95">967-7116</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities Registered Pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:39.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6OGU4YzFlYjgwMTFiNDFmY2I3ZGQyNDhmMzg2NGQwZmYvdGFibGVyYW5nZTo4ZThjMWViODAxMWI0MWZjYjdkZDI0OGYzODY0ZDBmZl8xLTAtMS0xLTU1OTY4_8288389a-69b9-4330-9963-c1a3fb78a34a">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6OGU4YzFlYjgwMTFiNDFmY2I3ZGQyNDhmMzg2NGQwZmYvdGFibGVyYW5nZTo4ZThjMWViODAxMWI0MWZjYjdkZDI0OGYzODY0ZDBmZl8xLTEtMS0xLTU1OTY4_79754edd-382c-4449-8294-f52bb7dd3408">EHC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6OGU4YzFlYjgwMTFiNDFmY2I3ZGQyNDhmMzg2NGQwZmYvdGFibGVyYW5nZTo4ZThjMWViODAxMWI0MWZjYjdkZDI0OGYzODY0ZDBmZl8xLTItMS0xLTU1OTY4_dd7e3f3d-517b-407e-9ba7-fc5c8d454c27">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities Registered Pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act.  <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDc3_00151f18-dc15-422d-b1d5-9cca6466a3c7">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.  Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160; <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg0_f374b0f1-10b7-449c-b3d7-eeab6bbb43d0">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDgw_cb4e3276-687d-42aa-a7a4-4acfd57b4161">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDkx_af129d96-0ab5-4ad0-ab95-cd4a9a419a80">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDk1_260cfc00-d187-44f6-bf2d-7e714bc5ab1c">Large accelerated filer</ix:nonNumeric>   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDkw_9ffc097f-fb7a-4e4a-bf2e-c803dc7c0898">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Non-Accelerated filer   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDgx_aab86316-a28b-4839-b88d-e7d176103251">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDgy_15ddd187-1cf4-43b9-831b-c08b1c917ae4">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18yNzQ4Nzc5MDczMjA2_61a5e3ac-ca4f-4365-b01a-8b7f42e073de">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="i66424ae9b2c44a4fb7238c492c20dd64_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zMDM1_4e680231-05af-4bd4-872e-3cb35c4cf7b8">7.6</ix:nonFraction> billion. For purposes of the foregoing calculation only, executive officers and directors of the registrant have been deemed to be affiliates. There were <ix:nonFraction unitRef="shares" contextRef="if4d32bfff62740bba5b17d616f96ffc5_I20220211" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zMTg0_5c30003e-5074-4b3f-8683-b38ca4a813ba">99,438,215</ix:nonFraction> shares of common stock of the registrant outstanding, net of treasury shares, as of February&#160;11, 2022.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg4_4be09995-5835-4dc7-8733-498d4438cc89" escape="true">The definitive proxy statement relating to the registrant&#8217;s 2022 annual meeting of stockholders is incorporated by reference in Part III to the extent described therein.</ix:nonNumeric></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_10">Cautionary Statement Regarding Forward-Looking Statements and Summary of Risk Factors</a></span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_10">ii</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_19">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_22">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_25">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_28">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_31">54</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_34">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_37">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_40">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_43">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_85">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_85">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_88">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_88">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_88">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_91">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_91">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_91">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_94">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_94">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_97">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_97">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_97">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_2741">Item 9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_2741">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_2741">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_2741">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_2741">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_100">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_103">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_103">Directors and Executive Officers of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_103">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_106">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_106">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_106">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_109">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_109">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_109">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_112">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_112">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_112">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_115">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_115">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_115">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_118">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_121">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_121">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_121">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_124">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_124">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_121">87</a></span></div></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE TO READERS</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this report, the terms &#8220;Encompass Health,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Encompass Health Corporation and its consolidated subsidiaries, unless otherwise stated or indicated by context. This drafting style is suggested by the Securities and Exchange Commission and is not meant to imply that Encompass Health Corporation, the publicly traded parent company, owns or operates any specific asset, business, or property. The hospitals, operations, and businesses described in this filing are primarily owned and operated by subsidiaries of the parent company. In addition, we use the term &#8220;Encompass Health Corporation&#8221; to refer to Encompass Health Corporation alone wherever a distinction between Encompass Health Corporation and its subsidiaries is required or aids in the understanding of this filing. We may refer to our consolidated subsidiary, EHHI Holdings, Inc. and its subsidiaries, which collectively operate our home health and hospice business, as &#8220;EHHI.&#8221; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS<br/>AND SUMMARY OF RISK FACTORS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report contains historical information, as well as forward-looking statements that involve known and unknown risks and relate to, among other things, future events, the spread and impact of the COVID-19 pandemic, changes to Medicare reimbursement and other healthcare laws and regulations from time to time, our business strategy and ongoing strategic review, including the planned separation of our home health and hospice business, dividend and stock repurchase strategies, our financial plans, our growth plans, our future financial performance, our projected business results, or our projected capital expenditures. In some cases, the reader can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;targets,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Any forward-looking statement is based on information current as of the date of this report and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors that could cause, and in the case of the COVID-19 pandemic has already caused, actual results to differ materially from those estimated by us include, but are not limited to, each of the factors discussed in Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, summarized in the list below, as well as uncertainties and factors, if any, discussed elsewhere in this Form 10-K, in our other SEC filings from time to time, or in materials incorporated therein by reference. </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Strategic Review and Planned Spin Off of Our Home Health and Hospice Business</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ongoing strategic review and planned spin off of our home health and hospice business exposes us to a number of risks and uncertainties, including diversion of management&#8217;s time to the process; the incurrence of significant expenses associated with the review and pursuit of the planned separation or transaction; increased difficulties in attracting, retaining or motivating key management personnel; exposure to potential litigation; and inability to complete or realize anticipated benefits from the planned separation or other strategic alternative involving our home health and hospice business, any of which could adversely affect our business, financial results or condition, or stock price.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the spin off is completed, both the remaining company and the new company will be highly concentrated in their respective primary lines of business, particularly with respect to Medicare regulations and reimbursement, and each will be a less diversified company than we currently are.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the spin off is completed, there may be changes in our stockholder base, which may cause volatility in the price of our common stock. </span></div><div style="margin-bottom:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Novel Coronavirus Disease 2019 (&#8220;COVID-19&#8221;) Pandemic Risks </span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pandemic, epidemic, or other widespread outbreak of an infectious disease or other public health crisis could decrease our patient volumes, pricing, and revenues, lead to staffing and supply shortages and associated cost increases, otherwise interrupt operations, or lead to increased litigation risk and, in the case of the COVID-19 pandemic, has already done so in many instances.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental actions in response to the COVID-19 pandemic, such as limitations on elective procedures, vaccine mandates, shelter-in-place orders, new workplace regulations, facility closures and quarantines, could reduce volumes, lead to staffing shortages, increase staffing costs, and otherwise impair our ability to operate and provide care and in many instances already have done so.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to maintain infectious disease prevention and control efforts that are required and effectively minimize the spread of COVID-19 among patients and employees could decrease our patient volumes and revenues, lead to staffing shortages or otherwise interrupt operations, or lead to increased litigation risk.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement Risks</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our inability to obtain and retain favorable arrangements with third-party payors, could decrease our revenues and adversely affect other operating results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive interpretations of the regulations governing the claims that are reimbursable by Medicare could decrease our revenues and adversely affect other operating results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New or changing Medicare quality reporting requirements could adversely affect our operating costs or Medicare reimbursement.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement claims are subject to various audits from time to time and such audits may lead to assertions that we have been overpaid or have submitted improper claims, and such assertions may require us to incur additional costs to respond to requests for records and defend the validity of payments and claims and may ultimately require us to refund any amounts determined to have been overpaid.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays and other substantive and procedural deficiencies in the administrative appeals process associated with denied Medicare reimbursement claims, including from various Medicare audit programs, could delay or reduce our reimbursement for services previously provided, including through recoupment from other claims due to us from Medicare.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues or profitability.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in our payor mix or the acuity of our patients could reduce our revenues or profitability.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory Risks</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the rules and regulations of the healthcare industry at either or both of the federal and state levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction (such as the re-basing of payment systems, the introduction of site neutral payments or case-mix weightings across post-acute settings, and other payment system reforms) could decrease revenues and increase the costs of complying with the rules and regulations.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, could decrease our reimbursement rate or increase costs associated with our operations.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with the extensive and frequently changing laws and regulations applicable to healthcare providers, including those related to data privacy and security, anti-trust, and employment practices, requires substantial time, effort and expense, and if we fail to comply, we could incur penalties and significant costs of investigating and defending asserted claims, whether meritorious or not, or be required to make significant changes to our operations.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to maintain proper local, state and federal licensing, including compliance with the Medicare conditions of participation and provider enrollment requirements, such as the CMS vaccine mandate, could decrease our revenues.</span></div><div style="margin-bottom:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operational and Financial Risks</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Incidents affecting the proper operation, availability, or security of our or our vendors&#8217; or partners&#8217; information systems, including the patient information stored there, could cause substantial losses and adversely affect our operations, and governmental mandates to increase use of electronic records and interoperability exacerbate that risk.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including disclosed and undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suits could be difficult to predict and could adversely affect our financial results or condition or our operations, and we could experience increased costs of defending and insuring against alleged professional liability and other claims.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, productivity improvements arising from the related operations and avoidance of unanticipated difficulties, costs or liabilities that could arise from acquisitions or integrations could adversely affect our financial results or condition.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and potential union activity could increase staffing costs and adversely affect other financial and operating results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competitive pressures in the healthcare industry, including from other providers that may be participating in integrated delivery payment arrangements in which we do not participate, and our response to those pressures could adversely affect our revenues or other financial results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to provide a consistently high quality of care, including as represented in metrics publish by Medicare, could decrease our revenues.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to maintain or develop relationships with patient referral sources could decrease our revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our debt and the associated restrictive covenants could have negative consequences for our business and limit our ability to execute aspects of our business plan successfully.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock could adversely affect our willingness and ability to repurchase shares.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable or unwilling to continue to declare and pay dividends on our common stock.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General conditions in the economy and capital markets, including any disruption, instability, or uncertainty related to armed conflict or an act of terrorism, a governmental impasse over approval of the United States federal budget or an increase to the debt ceiling, an international trade war, or a sovereign debt crisis could adversely affect our financial results or condition, including access to the capital markets.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements referred to in this section also should be considered in connection with any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf. We undertake no duty to update these forward-looking statements, even though our situation may change in the future. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_16"></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Business </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of the Company</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a national leader in integrated healthcare services, offering both facility-based and home-based patient care through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. As of December 31, 2021, our national footprint spans 42 states and Puerto Rico and includes 145 hospitals and 251 home health and 96 hospice locations. We are committed to delivering high-quality, cost-effective integrated patient care.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Effective January 1, 2018, we changed our corporate name from HealthSouth Corporation to Encompass Health Corporation and the NYSE ticker symbol for our common stock from &#8220;HLS&#8221; to &#8220;EHC.&#8221; Our principal executive offices are located at 9001 Liberty Parkway, Birmingham, Alabama 35242, and the telephone number of the principal executive offices is (205)&#160;967-7116. Our website address is www.encompasshealth.com.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 9, 2020, we announced a formal process to explore strategic alternatives for our home health and hospice business. As a result of this process, we expect to separate the home health and hospice business from Encompass Health into an independent public company through a spin-off distribution in the first half of 2022. On January 19, 2022, we announced the home health and hospice business would be rebranded and operate under the name Enhabit Home Health &amp; Hospice. The rebranding of agency locations is expected to begin in mid-April 2022 and to be largely completed by the consummation of the spin off.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the discussion here, we encourage the reader to review Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Item&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which highlight additional considerations about our company.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manage our operations in two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. The table below provides selected operating and financial data for our inpatient rehabilitation hospitals, home health agencies, and hospice agencies. See Note&#160;19,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the accompanying consolidated financial statements for detailed financial information for each of our segments.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:57.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of or For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of hospitals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discharges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of licensed beds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of home health locations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health total admissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of hospice locations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,605.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts include one and two locations as of December 31, 2020, and 2019, respectively, which we account for using the equity method of accounting.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment on predominantly an inpatient basis. We operate hospitals in 35 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. In addition to our hospitals, we manage three inpatient rehabilitation units through management contracts.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive, high-quality, cost-effective patient care services. As participants in the Medicare program, our hospitals must be licensed and certified and otherwise comply with various requirements that are discussed below in the &#8220;Sources of Revenues&#8212;Medicare Reimbursement&#8212;Inpatient Rehabilitation&#8221; section. Substantially all (91%) of the patients we serve are admitted from acute care hospitals following physician referrals for specific acute inpatient rehabilitative care. Most of those patients have experienced significant physical and cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and a variety of debilitating neurological conditions, that are generally nondiscretionary in nature and require rehabilitative healthcare services in a facility-based setting. During the COVID-19 Pandemic (the &#8220;pandemic&#8221;), our hospitals have treated thousands of patients suffering or recovering from the COVID-19 virus. Our focus on specialized rehabilitative care also means that in many cases our hospitals are ideal settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity, and malnutrition. Our teams of highly skilled nurses and physical, occupational, and speech therapists utilize proven technology and clinical protocols with the objective of restoring our patients&#8217; physical and cognitive abilities. Patient care is provided by nursing and therapy staff as directed by physician orders while case managers monitor each patient&#8217;s progress and provide documentation and oversight of patient status, achievement of goals, discharge planning, and functional outcomes. Our hospitals provide a comprehensive interdisciplinary clinical approach to treatment that leverages innovative technologies and advanced therapies and leads to superior outcomes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health business is the nation&#8217;s fourth largest provider of Medicare-certified skilled home health services in terms of revenues. Our hospice business is the nation&#8217;s twelfth largest provider of Medicare-certified hospice services in terms of revenues. We operate home health and hospice agencies in 34 states, with a concentration in the southern half of the United States. As participants in the Medicare program, our agencies must comply with various requirements that are discussed below in the &#8220;Sources of Revenues&#8212;Medicare Reimbursement&#8212;Home Health&#8221; and &#8220;&#8212;Hospice&#8221; sections. We acquired a significant portion of our home health and hospice business when we purchased EHHI Holdings, Inc. (&#8220;EHHI&#8221;) on December&#160;31, 2014. In the acquisition, we acquired 83.3% of the issued and outstanding equity interests of EHHI, and certain members of EHHI management, acquired the remaining interests. In March 2020, we acquired 100% ownership of EHHI. See Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Liquidity and Capital Resources&#8221; for further discussion of the history of the ownership structure of our home health and hospice business. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health agencies provide a comprehensive range of Medicare-certified skilled home health services. These services include, among others, skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. We also offer evidence-based specialty programs related to post-operative care, fall prevention, chronic disease management, and transitional care. Our home health patients are typically older adults with three or more chronic conditions and significant functional limitations, who require greater than ten medications.&#160;Our home health business benefits from a diversity of referral sources, with patients arriving from acute care hospitals, inpatient rehabilitation facilities, surgery centers, assisted living facilities and skilled nursing facilities, as well as community physicians. As with our inpatient rehabilitation hospitals, our home health agencies have treated thousands of patients suffering or recovering from COVID-19. Our teams of registered nurses, licensed practical nurses, physical, speech and occupational therapists, medical social workers, and home health aides work closely with patients, their families and physicians to deliver care plans focused on patient needs and goals.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide hospice services to terminally ill patients and their families. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself. Our hospice care teams consist of physician medical directors, nurses, social workers, chaplains, therapists, hospice aides, and volunteers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rapid onset of the pandemic in the United States has resulted in significant changes to our operating environment. The willingness and ability of patients to seek healthcare services have been negatively affected by restrictive measures, such as travel bans, social distancing, quarantines, and shelter-in-place orders. From time to time in specific markets, elective procedures have been postponed by physicians and acute care hospitals and limited by governmental order to preserve capacity for the expected volume of COVID-19 patients and reduce the risk of the spread of COVID-19. Patients recovering from elective surgeries have historically represented approximately 15% of our home health admissions.&#160;While not a significant percentage of our inpatient rehabilitation population, we treat patients who are recovering from elective surgery with multiple comorbidities and qualify for inpatient rehabilitation care. Additionally, many in need of treatment for more severe medical conditions have chosen not to seek care because of fear of COVID-19 infection. The pandemic and governmental responses to it have created and continue to exacerbate staffing challenges for us and other healthcare providers, including our referral sources. Quarantines and vaccine mandates as well as apprehension and stress related to the pandemic have led to staffing shortages which in turn have led to increased labor costs. We have also experienced supply chain disruptions as a result of the pandemic, including increased time between ordering and receiving supplies. We have experienced and are likely to continue to experience significant price increases in medical supplies, particularly personal protective equipment (&#8220;PPE&#8221;). The federal government has undertaken numerous legislative and regulatory initiatives designed to provide relief to the healthcare industry during the pandemic as described below in the &#8220;Sources of Revenue&#8212;Medicare Reimbursement&#8221; section. These initiatives have provided enhanced flexibility to our hospitals and agencies to care for our patients and assist acute care hospitals in maintaining hospital capacity in the current environment. The pandemic is still evolving and its future impact remains unknown and difficult to predict, with the impact on our operations and financial performance being dependent on numerous factors, including the ongoing nature of the pandemic, such as its rate of spread, duration, and geographic coverage; the rate and extent to which the virus mutates and the severity of the symptoms of the variants; the rates of vaccination and therapeutic remedies; the legal, regulatory, and administrative developments related to the pandemic at federal, state, and local levels, such as vaccine mandates, anti-mandate laws and orders, shelter-in-place orders, suspended services, and quarantines; and our infectious disease prevention and control efforts. For discussion of the financial and operational impacts we have experienced as a result the pandemic, see Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the continuously changing operating environment during the pandemic, we have taken the following steps to ensure the safety and well-being of our patients and employees:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:476.25pt"><tr><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:460.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">staying current with the Centers for Disease Control and Prevention&#8217;s (the &#8220;CDC&#8221;) guidance on testing and the use of PPE, which is frequently updated;</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">working with our supply chain and securing secondary sources to ensure an adequate supply of PPE to protect our staff and patients;</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acquiring testing devices;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">limiting visitors in our hospitals;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">screening everyone entering our hospitals and self-screening all home health and hospice employees;</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">performing pre-visit telephone calls to assess risk factors within the home, including patient and caregiver health status;</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">following social distancing recommendations in our therapy gyms and performing therapy in patient rooms, if needed;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">changing hospital configurations to protect patients from potential exposure to the virus;</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">implementing work-at-home policies for many home office employees; and</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">halting all non-essential travel when appropriate.</span></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competitive Strengths</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. We also believe our competitive strengths discussed below give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">People</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe our employees share a steadfast commitment to providing outstanding care to our patients. We undertake significant efforts to ensure our clinical and support staff receives the education and training necessary to provide the highest quality care in the most cost-effective manner. We also have hospital staff trained for all patient acuity levels faced in the post-acute setting. We embrace the Encompass Health Way, our core set of values developed through input from a broad cross section of our employees. The Encompass Health Way calls on each of our employees to set the standard, lead with empathy, do what&#8217;s right, focus on the positive, and ensure we are stronger together. In light of well-publicized challenges to hire and retain qualified personnel in the healthcare industry, we believe our award-winning culture is essential to attracting and retaining talent. For further discussion of our human capital management and our award-winning culture, see the section titled &#8220;Human Capital Management&#8221; below.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Change Agility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have a demonstrated ability to adapt in the face of numerous and significant regulatory and legislative changes. We rapidly moved to adapt our operations to the unprecedented pandemic. Additionally, while addressing the urgent challenges presented by the pandemic, both operating segments successfully managed through significant changes in their respective Medicare reimbursement systems in 2020. We believe consistent and disciplined operating models allow us to be nimble and responsive to change.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Strategic Relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have a long and successful history of building strategic relationships with major healthcare systems. Approximately one-third of our inpatient rehabilitation hospitals currently operate as joint ventures with acute care hospitals or systems. Joint ventures with market leading acute care hospitals establish a solid foundation for providing integrated patient care that can improve the quality of outcomes and reduce the total cost of care.</span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical collaboration between our hospitals and home health agencies in overlap markets offers an excellent means to improve patient experience and outcomes and reduce the total cost of care across a post-acute episode. We believe the benefits of collaboration are available in non-overlap markets as well. </span></div><div style="padding-left:54pt"><span><br/></span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The post-acute innovation tools we have developed, and will continue to develop, support our strategic relationship initiatives by enhancing the effective and efficient management of patients across multiple post-acute care settings and facilitating high-quality patient care, improved care coordination, and network provider performance and cost management.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a strategic sponsorship with the American Heart Association/American Stroke Association on a nationwide basis to increase patient independence after a stroke and reduce stroke mortality through community outreach and information campaigns. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Home Health and Hospice Well-Positioned for Value-Based Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Value-based contracts are a growing focus for us, and as payors emphasize reimbursement models driven by value, we believe they will continue to seek out our clinical outcomes and appreciate our cost-efficient services. Our history and participation in these programs have allowed us to collaborate with approximately 160 alternative payment models, including Next Generation accountable care organizations (&#8220;ACOs&#8221;), Medicare Shared Savings Program ACOs, and Direct Contracting Models. In the fourth quarter of 2020, we executed a new national contract with UnitedHealthcare for our home health services.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Clinical Expertise and High-Quality Outcomes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have extensive facility-based and home-based clinical experience from which we have developed standardized best practices and protocols. We believe these clinical best practices and protocols, particularly as leveraged with our well-trained clinicians and industry-leading technology, help ensure the delivery of consistently high-quality healthcare services, reduced inefficiencies, and improved performance across a spectrum of operational areas. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Cost Effectiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our scale, density, data-driven business practices, consistent and disciplined operating model, and culture help us provide facility-based and home-based healthcare services on a cost-effective basis. We leverage our comprehensive IT capabilities and centralized administrative functions, identify best practices, utilize </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proven staffing models, and take advantage of supply chain efficiencies across our extensive platform of operations. Our information systems allow users to analyze data and trends and create custom reports on a timely basis. Additionally, our home-based healthcare services are part of the broader industry focus on reducing costs by delivering care, when clinically appropriate, in the significantly lower cost home setting. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Financial Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have a proven track record of generating strong cash flows from operations that have allowed us to successfully pursue our growth strategy, manage our financial leverage, and make significant shareholder distributions. As of December&#160;31, 2021, we have a strong, well-capitalized balance sheet, including ownership of approximately 74% of our hospital real estate, no significant debt maturities prior to 2024, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our business strategy.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Advanced Technology and Innovation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are focused on developing technology-enabled real-time strategies for the next generation of integrated healthcare. Our post-acute innovation strategy is based on using our clinical expertise, our large post-acute datasets, and our proven capabilities in enterprise-level electronic medical record technologies, data analytics, data integration, and predictive analytics to drive value-based performance across the healthcare continuum for our patients, our partners, and our payors. We believe our information systems and post-acute innovation solutions, in addition to improving patient care and operating efficiencies, allow us to collect, analyze, and share information on a timely basis making us an ideal partner for other healthcare providers in a coordinated care delivery environment. Our systems also emphasize interoperability with referral sources and other providers coordinating care. We have devoted substantial resources, effort and expertise to leveraging technology to create post-acute solutions that improve patient care and operating efficiencies.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Patients and Demographic Trends</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030. Even more specifically, the average age of our patients is approximately 76, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, post-acute services. In addition, we believe we can address the demand for facility-based and home-based post-acute care services in markets where we currently do not have a presence by constructing or acquiring new hospitals and by acquiring or opening home health and hospice agencies in those fragmented industries.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Strategy and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"> Strategic Priorities</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion of strategy and strategic priorities assumes the continuation of operations under a single ownership structure for a portion of 2022. As discussed above, we plan to separate our home health and hospice business into an independent public company. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our overall strategy is to expand our network of inpatient rehabilitation hospitals and home health and hospice locations, further strengthen our relationships with healthcare systems, provider networks, and payors in order to connect patient care across the healthcare continuum, and to deliver superior patient outcomes. We believe this strategy, along with our demonstrated ability to adapt to changes in healthcare, will position us for success in the evolving healthcare delivery system. In pursuit of our strategy, we established the following strategic priorities for 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In pursuit of our strategy, we established the following strategic priorities for 2022 for our inpatient rehabilitation segment. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We target the addition of 6 to 10 new inpatient rehabilitation hospitals per year. We also believe we will continue to have organic growth opportunities in our inpatient rehabilitation segment based on our pre-pandemic track record of consistent growth, planned bed additions at a number of existing hospitals, and the maturation of newly opened and acquired locations.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Operational Initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our priorities include operational initiatives that build on momentum from recent years. We will seek to continue to increase clinical collaboration in both overlap and non-overlap markets. We believe our clinical collaboration efforts have and will continue to contribute to reductions in discharges to skilled nursing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facilities, higher discharges to community, and improved patient experience. We will have to make some changes to our collaboration process in light of the pending separation of our businesses. </span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant number of stroke patients in need of post-acute care, we will continue working to build our stroke market share by leveraging our strategic sponsorship of the American Heart Association/American Stroke Association, the inpatient rehabilitation facility (&#8220;IRF&#8221;) treatment recommendations published by the Department of Veterans&#8217; Affairs and the Journal of the American Medical Association, our clinical collaboration, and our hospitals&#8217; participation in The Joint Commission&#8217;s Disease-Specific Care Certification Program. As of December&#160;31, 2021, 125 of our 145 hospitals held stroke-specific certifications that required us to demonstrate effective use of evidence-based clinical practice guidelines to manage and optimize stroke care and an organized approach to performance measurement and evaluation of clinical outcomes. </span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to develop and implement post-acute solutions that allow us to apply our clinical expertise, large post-acute datasets, electronic medical record technologies, and strategic partnerships to drive improved patient outcomes and lower the cost of care across the entire post-acute episode, such as our fall prevention model rolled out to hospitals in late 2021. </span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will seek to expand efforts and initiatives to recruit and retain a qualified clinical workforce. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our home health and hospice segment has the following strategic priorities for 2022.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe we will continue to have organic growth opportunities in our home health and hospice segment based on our pre-pandemic track record of consistent growth and the maturation of acquired locations. </span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We target $50 million to $100 million in home health and hospice acquisitions per year. In 2022, we will again identify and evaluate opportunities for strategic acquisitions in new and existing markets that will enhance our market position and increase our referral base. We plan to continue to focus on building overlap between our home health and hospice segments, as well as identifying attractive new geographies in which we currently do not have a home health and hospice presence. </span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will work to expand relationships with health systems through clinical collaboration and care transition programs and joint venture arrangements. We have a strong foundation of working with health systems, and we now will have a strategic focus on leveraging our historical success with health systems to identify, evaluate and develop joint venture arrangements. </span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to execute on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> strategy to complement the organic growth of our home health and hospice businesses. In 2022, we plan to open </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agencies in 10 markets. We also believe the ability to co-locate home health and hospice will allow us to grow with minimal incremental infrastructure costs while also leveraging our existing referral sources and brand. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Operational Initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe participation in the Centers for Medicare &amp; Medicaid Services&#8217; Innovation Center alternative delivery payments models will remain a key strategic initiative in 2022 and beyond. We will seek to increase our participation in these risk-based payment models. </span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our expertise in delivering high-quality and cost-efficient care positions us favorably to capture future Medicare Advantage volumes for our home health and hospice businesses. We will seek to negotiate additional value-based payment arrangements with Medicare Advantage payors.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically focused on skilled home health and hospice services. However, evolving alternatives for in-home care may present opportunities for us to develop adjacent service offerings. In 2022, we plan to seek to expand on existing and identify new collaborative arrangements with private duty home care providers, who deliver non-skilled patient care, to allow us to entertain strategic initiatives such as &#8220;SNF at Home&#8221; or &#8220;Hospital at Home&#8221; within specific markets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to integrate effective technologies and evidence-based data tools into our delivery of patient care. We are also piloting telehealth in the form of virtual visits and text messaging. </span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will work to enhance and grow our care transition program in both home health and hospice which fosters collaboration with other healthcare organizations including short-term acute care hospitals, long-term acute care hospitals, inpatient rehabilitation facilities, skilled nursing facilities, and ambulatory surgical centers.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will prioritize efforts and initiatives to recruit and retain a qualified clinical workforce. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Structure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will seek to maintain balance sheet flexibility, consider opportunistic refinancings and augment returns from investments in operations with shareholder distributions via common stock dividends and repurchases of our common stock.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our strategic priorities as well as our progress toward our priorities in 2022, including operating results, growth, and shareholder distributions, and our business outlook, see Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview,&#8221; &#8220;Results of Operations,&#8221; and &#8220;Liquidity and Capital Resources.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Capital Management </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Overview of Our Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the start of the pandemic in 2020, our employees have made inspiring sacrifices and showed extraordinary dedication to providing outstanding patient care in our hospitals and in our patients&#8217; homes across the country during the pandemic. As of December 31, 2021, we employed approximately 43,400 individuals. In the healthcare services sector, many professionals, such as nurses, desire flexible work arrangements. Accordingly, part-time and per diem employees represent a large percentage of our employee population. Except for 44 employees at one hospital (approximately 14% of that hospital&#8217;s workforce), none of our employees are represented by a labor union as of December 31, 2021. The chart below includes a breakdown of our employees by segment.</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.789%"><tr><td style="width:1.0%"></td><td style="width:31.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inpatient Rehabilitation</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total Employees</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32,463</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,899</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Full-time Employees</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19,914</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,086</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Part-time Employees</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,377</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pool/Per-diem Employees</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,172</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,603</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some markets, the shortage of clinical personnel is a significant operating issue facing healthcare providers. The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) vaccine mandate applicable to Medicare and Medicaid-certified healthcare providers has and will continue to exacerbate staffing shortages. Shortages of nurses and other clinical personnel, including therapists, may, from time to time, require us to increase use of more costly temporary personnel, which we refer to as &#8220;contract labor,&#8221; and other types of premium pay programs. In order to recruit and retain those clinical employees, we maintain a total rewards program that we view as a combination of the tangible components of pay and benefits with the intangible components of a culture that encourages learning, development, and a supportive work environment. We believe our outstanding employee engagement scores, discussed below, evidence that our human capital management efforts have been successful. We also believe our recognition as one of Fortune Magazine&#8217;s &#8220;100 Best Companies to Work For&#8221; and the recognition of both our segments in Modern Healthcare&#8217;s &#8220;Best Places to Work&#8221; is further evidence of that success. We focus on the following strategic human capital imperatives:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintaining competitive compensation and benefit programs that reward and recognize employee performance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fostering a strong culture that values diversity, equity, and inclusion; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Emphasizing employee development and engagement to attract talent and reduce turnover.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation and Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Maintaining competitive compensation and benefit programs that reward and recognize employee performance furthers our goal to attract, retain, and motivate employees who will help us deliver high-quality patient care. We are also committed to providing comprehensive benefit options that will allow our employees and their families to live healthier and more secure lives. In our compensation and benefit programs: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide employee wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we engage nationally recognized outside compensation and benefits consulting firms to independently evaluate the effectiveness of our compensation and benefit programs and to provide benchmarking against our peers within the industry and by specific market.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we base annual increases and incentive compensation on merit, which is communicated to employees through our talent management process as part of our annual review procedures.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all full-time and most part-time employees are eligible for health insurance, paid and unpaid leaves, a retirement plan, a wellness program, telemedicine, tuition reimbursement, an employee assistance program, and life and disability/accident coverage.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we provide an employer match on retirement plan contributions.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we also offer a wide variety of voluntary benefits that allow employees to select the options that meet their needs, including pre-paid legal services, dental insurance, vision insurance, hospital indemnity insurance, accident insurance, critical illness insurance, supplemental life insurance, disability insurance, health savings accounts, flexible spending accounts, auto/home insurance, and identity theft insurance.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have various short-term incentive plans for field leadership, most marketing/sales employees, and executives.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we make annual grants of restricted stock to employees (approximately 380 in 2021) at various levels, including non-executive management, to foster a strong sense of ownership and align the interests of management with those of our stockholders. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diversity, Equity, and Inclusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe fostering a strong culture that values diversity, equity, and inclusion, or DE&amp;I, allows us to be competitive in recruiting and retaining employees. We maintain a DE&amp;I program that is overseen by a committee of diverse individuals committed to our mission of a better way to care and supported by a dedicated DE&amp;I specialist role. The program is further supported by four distinct sub-committees comprised of a broad and cross-functional group, including our leadership and front line staff. The key components of our DE&amp;I program are:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Workforce Attraction and Development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; We are committed to ensuring that all of our employees are trained on DE&amp;I as a foundational element of our employee and leadership development curriculum. Our other DE&amp;I initiatives include: scholastic partnerships with historically black colleges, recruitment tools to help identify diverse talent, a website career tool to help veterans find jobs that closely align with their specific skills, and ongoing and policy reviews to incorporate language that supports DE&amp;I. In our home health and hospice segment, we also have a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welcome Ambassador</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program to ensure all employees are welcomed and aware of our organizational commitment to DE&amp;I and to accelerate onboarding.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Community Partnership &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partner with groups in our communities to establish and maintain relationships in an effort to improve health outcomes in those communities. One example of this type of partnership is our arrangement with Holy Family Cristo Rey Catholic High School in Birmingham. This partnership allows adolescents from disadvantaged groups to gain tangible working experience in our corporate office while earning funds for school tuition. In 2021, we sponsored six students. Our other community initiatives include a quarterly DE&amp;I digest that provides information on our DE&amp;I initiatives to people outside the company; membership in the National Association of Health Service Executives (&#8220;NAHSE&#8221;), an organization that promotes the advancement and development of minority healthcare leaders; participation in NAHSE&#8217;s minority male leadership academy; and participation in a regional working group of Alabama-based businesses convened to discuss and share DE&amp;I best practices.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Support and Equip</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; We use our weekly blasts and podcasts to educate our employees about DE&amp;I topics, such as unconscious bias. This education supports our employees by equipping them with the informational tools necessary to better foster an inclusive and diverse workplace. We also provide annual training on DE&amp;I to our employees, which 95% of our employees successfully completed in 2021. This training seeks to encourage conversations between employees and managers around ways to promote DE&amp;I throughout the organization.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Opportunity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; We are pursuing further specific initiatives, including a leadership DE&amp;I program in our inpatient rehabilitation business, to identify and create opportunities for diverse leaders.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Supplier Diversity &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We maintain a supplier base program that offers contracting opportunities with manufacturers, distributors and service providers that are certified as minority-owned, veteran-owned and small disadvantage-owned businesses, and we are researching diverse supplier certifying organizations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have undertaken other initiatives to emphasize the importance of DE&amp;I. For example, we participate in the CEO Action for Diversity and Inclusion Pledge. This coalition of more than 1,000 chief executive officers is dedicated to advancing DE&amp;I in the workplace. Every three to five years, we engage a third party consulting agency to help us evaluate our program and explore possible enhancements. We then provide the feedback to our board of directors. We have published a series of video conversations with various employees and members of executive management in order to highlight personal experience with prejudice and injustice and to promote DE&amp;I. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Development and Engagement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe promoting employee development and engagement furthers our ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment where staffing shortages are not uncommon. We track and measure therapist and nurse turnover in our inpatient rehabilitation segment and overall turnover for our full-time employees in our home health and hospice segment (excluding those at new stores and most at the corporate office) on a quarterly and annual basis for significant trends and outliers, but we do not believe comparisons to benchmarks are material given the variations in survey data across markets, hospital sizes, practice settings, and practice specialties. The table below shows those turnover rates for 2021 and 2020.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.877%"><tr><td style="width:1.0%"></td><td style="width:38.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Therapist (IRF)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse (IRF)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overall (HH&amp;H)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7%</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support the long-term career aspirations of our employees through education and personal development. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Education Opportunities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our nurses an opportunity to advance their academic degrees at a reduced tuition rate of 20% to 50% of the total program cost. To date, approximately 1,365 of our nurses have taken advantage of this opportunity. Additionally, our full-time inpatient nursing and therapy staff have unlimited access to online education and training to ensure continuing education units are available at no cost.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Tuition Reimbursement/Scholarship Programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Employees also have the opportunity to advance their education through our tuition reimbursement and scholarship programs. We reimbursed over $1.4 million in tuition and paid over $3 million toward employees&#8217; student loan debt in 2021. We also provide over 100 scholarships each year to employees seeking to improve professional licensing or certifications or achieve new academic degrees.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Academic Endowments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We endowed five scholarships for deserving students from underrepresented groups pursuing degrees in nursing and allied health fields.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Therapy Grants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We fund research projects to investigate the impact and effectiveness of therapy in the inpatient rehabilitation and home health settings. In recent years, we have funded studies and research on topics ranging from caregiver education to the effectiveness of occupation-centered interventions. The program is open to qualified candidates, including employees.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Employee Development Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We offer extensive on-site and remote courses to develop our employees in our home health and hospice segment. Courses include clinical, sales, operations, and leadership development programs that help our employees stay current on best practices, ensure compliance with policies and process, and promote continued growth and development at all levels of the organization. Two state-of-the-art classrooms have been designed to enhance the educational environment to support adult learning principles and sustained impact of our educational programs.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Other Employee Development Programs:</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">career ladders that offer paths to develop, demonstrate, and be rewarded for expanded responsibility in nursing, therapy and case management;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">formal coaching online development library that provides access to a wide range of readily available internal and external content on many topics important for success in current or desired jobs;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">developing future leaders program that develops nurses and therapists for supervisory positions and develops nurse and therapy supervisors for higher level positions;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">leadership precepting that provides new leaders 6-12 months of structured mentoring from experienced, high-performing peers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">leadership coaching that provides six months of executive coaching to high performing leaders;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">developing future chief nursing officers program that provides 12-18 months of intensive on-the-job experience to develop participants for future chief nursing officer job openings; and</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">developing future chief executive officers program that provides 18-24 months of intensive on-the-job experience to develop participants for future hospital chief executive officer openings.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further aid in employee development, we have invested money in best-in-class technology to offer on-demand learning and development programs, podcasts for our home health and hospice segment, and leadership coaching programs. Another important aspect of employee development is succession planning. We annually review our talent to identify potential successors for key positions and to identify candidates for accelerated development based on their performance and potential. The annual process includes an assessment of each employee&#8217;s promotability based on a set of leadership core competencies defined as part of the company&#8217;s talent strategy. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe employee engagement is another important driver of employee retention. We conduct an annual employee engagement survey open to all of our employees. In 2021, 78% of our employees participated in the survey, which measures perceptions based on responses to 39 questions. In 2021, we scored above healthcare benchmarks as a company in each of the following categories on the survey:</span></div><div style="margin-bottom:10pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">ethics and compliance</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">teamwork</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">culture of safety</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">engagement</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">diversity, equity, and inclusion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">culture of trust</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">work environment</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">individual value</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">leadership</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">communication</span></div></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The inpatient rehabilitation industry, outside of our leading position, is highly fragmented. Our inpatient rehabilitation hospitals compete primarily with rehabilitation units, most of which are within acute care hospitals, in the markets we serve. An acute care hospital, particularly one owned or operated by a large public company or not-for-profit that has a dominant position in the local market, can be a formidable competitor because 91% of our patients come from acute care hospitals. There are several privately held companies offering post-acute rehabilitation services that compete with us primarily in select geographic markets. In addition, there is a public company that is primarily focused on other post-acute care services, including approximately 1,900 outpatient clinics, but also operates approximately 30 freestanding inpatient rehabilitation hospitals. Other providers of post-acute care services compete for some rehabilitation patients. For example, nursing homes may market themselves as offering certain rehabilitation services, particularly to patients not in need of intensive rehabilitation therapy, even though those nursing homes are not required to offer the same level of care, and are not licensed, as hospitals.&#160;The primary competitive factors in any given market include the quality of care and service provided, the treatment outcomes achieved, the relationship and reputation with managed care and other private payors and the acute care hospitals, physicians, or other referral sources in the market, and the regulatory barriers to entry in certificate of need states. The ability to work as part of an integrated delivery payment model with other providers, including the ability to deliver quality patient outcomes and cost-effective care, could become an increasingly important factor in competition if a significant number of people in a market are participants in one or more of these models. See the &#8220;Regulation&#8212;Relationships with Physicians and Other Providers&#8221; and &#8220;Regulation&#8212;Certificates of Need&#8221; sections below for further discussion of some of these factors. For a list of our inpatient rehabilitation markets by state, see the table in Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The home health and hospice services industries are also highly competitive and fragmented. In 2020, there were more than 11,300 home health agencies and more than 5,000 hospice agencies nationwide certified to participate in Medicare. We are the fourth largest provider of Medicare-certified skilled home health services in the United States in terms of Medicare revenues. Our primary competition varies from market to market. Providers of home health and hospice services include both not-for-profit and for-profit organizations. There are two other public healthcare companies with significant presences in the Medicare-certified home health industry, and one insurance company that owns one of the largest providers of Medicare-certified skilled home health services. That insurance company not only owns one of the largest home health providers but, by nature of being a payor, can designate which home health and hospice agencies are in or out of the participating provider networks and can set reimbursement rates for network participants. The primary competitive factors </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in any given market include the quality and cost of care and service provided, the treatment outcomes achieved, the relationship and reputation with managed care and other private payors and the acute care hospitals, physicians, and other referral sources in the market, and the regulatory barriers to entry in certificate of need states. The entities that participate in these types of models are growing in their ability to influence the patient referral landscape in the geographies they cover. The ability to work as part of an integrated care delivery model with other providers could become an increasingly important factor in competition if a significant number of people in a market are participants in one or more of these models. As of December 31, 2021, our home health and hospice segment is collaborating with approximately 160 alternative payment models, including Next Generation ACOs, Medicare Shared Savings Program ACOs, and Direct Contracting Models. Home health providers with scale, which include the other public companies, may have competitive advantages, including professional management, efficient operations, sophisticated information systems, brand recognition, and large referral bases. For a list of our home health and hospice markets by state, see the table in Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory and Reimbursement Challenges</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare is a highly regulated industry facing many well-publicized regulatory and reimbursement challenges driven by escalating costs and the pursuit of better quality of care. The Medicare reimbursement systems for both inpatient rehabilitation and home health have recently undergone significant changes. The future of many aspects of healthcare regulation remains uncertain. Any regulatory or legislative changes impacting the healthcare industry ultimately may affect, among other things, reimbursement of healthcare providers, consumers&#8217; access to coverage of health services, including among non-Medicare aged population segments within commercial insurance markets and Medicaid enrollees, and competition among providers. Changes may also affect the delivery of healthcare services to patients by providers and the regulatory compliance obligations associated with those services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities &#8212; change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities &#8212; to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so. For more in-depth discussion of the primary challenges and risks related to our business, particularly the changes in Medicare reimbursement, increased compliance and enforcement burdens, and changes to our operating environment resulting from healthcare reform, see &#8220;Sources of Revenues&#8212;Medicare Reimbursement&#8221; and &#8220;Regulation&#8221; below in this section as well as Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sources of Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payment for patient care services from the federal government (primarily under the Medicare program), managed care plans and private insurers, and, to a considerably lesser degree, state governments (under their respective Medicaid or similar programs) and directly from patients. Revenues and receivables from Medicare are significant to our operations. The federal and state governments establish payment rates as described in more detail below. We negotiate the payment rates with non-governmental group purchasers of healthcare services that are included in &#8220;Managed care&#8221; in the tables below, including private insurance companies, employers, health maintenance organizations (&#8220;HMOs&#8221;), preferred provider organizations (&#8220;PPOs&#8221;), and other managed care plans. Patients are generally not responsible for the difference between established gross charges and amounts reimbursed for such services under Medicare, Medicaid, and other private insurance plans, HMOs, or PPOs but are responsible to the extent of any exclusions, deductibles, copayments, or coinsurance features of their coverage. Medicare, through its Medicare Advantage program, offers Medicare-eligible individuals an opportunity to participate in managed care plans. Revenues from Medicare and Medicare Advantage represent approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82% of total revenues.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables identify the sources and relative mix of our revenues for the periods stated for each of our business segments:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:60.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:60.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Reimbursement</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare is a federal program that provides hospital and medical insurance benefits to persons aged 65 and over, qualified disabled persons, and persons with end-stage renal disease. Medicare, through statutes and regulations, establishes reimbursement methodologies and rates for various types of healthcare providers, facilities, and services. Each year, the Medicare Payment Advisory Commission (&#8220;MedPAC&#8221;), an independent agency that advises the United States Congress on issues affecting Medicare, makes payment policy recommendations to Congress for a variety of Medicare payment systems including, among others, the inpatient rehabilitation facility prospective payment system (the &#8220;IRF-PPS&#8221;), the home health prospective payment system (the &#8220;HH-PPS&#8221;), and the hospice payment system (the &#8220;Hospice-PPS&#8221;). Congress is not obligated to adopt MedPAC recommendations, and, based on outcomes in previous years, there can be no assurance Congress will adopt </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedPAC&#8217;s recommendations in a given year.&#160;However, MedPAC&#8217;s recommendations have, and could in the future, become the basis for subsequent legislative or, as discussed below, regulatory action.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medicare statutes are subject to change from time to time. For example, in March 2010, President Obama signed the Patient Protection and Affordable Care Act (as subsequently amended, the &#8220;ACA&#8221;). In December 2018, a federal district court in Texas invalidated the ACA in their entirety but postponed enforcement of that decision pending appeal. On December&#160;18, 2019, the United States Court of Appeals for the Fifth Circuit affirmed the district court decision but remanded the case for additional analysis on the question of severability. A group of state attorneys general subsequently appealed the case to the Supreme Court of the United States. On June 17, 2021, the Supreme Court issued an opinion in the case of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">California v. Texas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, upholding the ACA. With respect to Medicare reimbursement, the ACA provides for specific reductions to healthcare providers&#8217; annual market basket updates and other payment policy changes. In August 2011, President Obama signed into law the Budget Control Act of 2011 providing for an automatic 2% reduction, or &#8220;sequestration,&#8221; of Medicare program payments for all healthcare providers. Sequestration took effect April 1, 2013 and, as a result of subsequent legislation, will continue through fiscal year 2030 unless Congress and the President take further action. In response to the public health emergency associated with the pandemic, Congress and the President suspended sequestration through March 31, 2022, as discussed further below. Additional Medicare payment reductions are also possible under the Statutory Pay-As-You-Go Act of 2010 (&#8220;Statutory PAYGO&#8221;). Statutory PAYGO requires, among other things, that mandatory spending and revenue legislation not increase the federal budget deficit over a 5- or 10-year period. If the Office of Management and Budget (the &#8220;OMB&#8221;) finds there is a deficit in the federal budget, Statutory PAYGO requires OMB to order sequestration of Medicare. The Congressional Budget Office estimated that the American Rescue Plan Act would result in budget deficits necessitating a 4% reduction in Medicare program payments for 2022 under the Statutory PAYGO, but the Protecting Medicare and American Farmers from Sequester Cuts Act suspended until 2023 the Statutory PAYGO reductions that would have gone into effect.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 9, 2018, President Trump signed into law the Bipartisan Budget Act of 2018 (the &#8220;2018 Budget Act&#8221;), which includes several provisions affecting Medicare reimbursement. Among those changes, the 2018 Budget Act mandated the adoption of a new Medicare payment model for home health providers which went into effect January 1, 2020. In the future, concerns about the federal deficit, national debt levels and the solvency of the Medicare trust fund could result in enactment of further federal spending reductions, further entitlement reform legislation affecting the Medicare program, or both. Healthcare will almost certainly be the subject of significant regulatory and legislative changes regardless of the party in control of the executive and legislative branches of state and federal governments. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, Medicare regulations, including reimbursement methodologies and rates, can be further modified by CMS. CMS, subject to its statutory authority, may make some prospective payment system changes, including in response to MedPAC recommendations. For example, CMS changed the IRF-PPS, effective October 1, 2019, to replace the FIM&#8482; assessment instrument with new patient assessment measures, which we refer to as &#8220;Section GG functional measures&#8221; or &#8220;Section GG&#8221; based on the designation CMS assigned to them. Section GG affects patients&#8217; classification into case-mix groupings, relative weights, and length-of-stay values under the IRF-PPS, which in turn affect our reimbursement amounts. In some instances, CMS&#8217;s modifications can have a substantial impact on healthcare providers. In accordance with Medicare laws and statutes, CMS makes annual adjustments to Medicare payment rates in prospective payment systems, including the IRF-PPS and HH-PPS, by what is commonly known as a &#8220;market basket update.&#8221; CMS may take other regulatory action affecting rates as well. For example, under the ACA, CMS requires IRFs to submit data on certain quality of care measures for the IRF quality reporting program. A facility&#8217;s failure to submit the required quality data results in a two percentage point reduction to that facility&#8217;s annual market basket increase factor for payments made for discharges in a subsequent Medicare fiscal year. IRFs began submitting quality data to CMS in October 2012. All of our inpatient rehabilitation hospitals have met the reporting deadlines to date resulting in no corresponding reimbursement reductions. Similarly, home health and hospice agencies are required to submit quality data to CMS each year, and the failure to do so in accordance with the rules will result in a two percentage point reduction in their market basket update. For 2022, we do not expect any of our home health and hospice agencies experience a reduction in reimbursement rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the adjustments to Medicare payment rates Congress or CMS may make in the future. Congress, MedPAC, and CMS will continue to address reimbursement rates for a variety of healthcare settings. Any additional downward adjustment to rates or limitations on reimbursement for the types of facilities we operate and services we provide could have a material adverse effect on our business, financial position, results of operations, and cash flows. For additional discussion of the risks associated with our concentration of revenues from the federal government or with potential changes to the statutes or regulations governing Medicare reimbursement, including the 2018 Budget Act, see Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges.&#8221;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although reductions or changes in reimbursement from governmental or third-party payors and regulatory changes affecting our business represent one of the most significant challenges to our business, our operations are also affected by other rules and regulations that indirectly affect reimbursement for our services, such as data coding rules and patient coverage rules </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and determinations. For example, Medicare providers like us can be negatively affected by the adoption of coverage policies, either at the national or local level, that determine whether an item or service is covered and under what clinical circumstances it is considered to be reasonable and necessary. Current CMS coverage rules require inpatient rehabilitation services to be ordered by a physician and be coordinated by an interdisciplinary team and the admission to the IRF must be reviewed and approved by a specialized rehabilitation physician. The interdisciplinary team must meet weekly to review patient status and make any needed adjustments to the individualized plan of care. Qualified personnel must provide the rehabilitation nursing, physical therapy, occupational therapy, speech-language pathology, social services, psychological services, and prosthetic and orthotic services that may be needed. Medicare contractors processing claims for CMS make coverage determinations regarding medical necessity that can represent novel or restrictive interpretations of the CMS coverage rules. Those interpretations are not made through a notice and comment review process. We cannot predict how future CMS coverage rule interpretations or any new local coverage determinations will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course, Medicare reimbursement claims made by healthcare providers, including inpatient rehabilitation hospitals as well as home health and hospice agencies, are subject to audit from time to time by governmental payors and their agents, such as the Medicare Administrative Contractors (&#8220;MACs&#8221;) that act as fiscal intermediaries for all Medicare billings, as well as the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;), CMS, and state Medicaid programs. In addition to those audits conducted by existing MACs, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. Some contractors are paid a percentage of the overpayments recovered. The Recovery Audit Contractors (&#8220;RACs&#8221;) conduct payment reviews of claims, which can examine coding, overall billing accuracy, and medical necessity. When conducting an audit, the RACs receive claims data directly from MACs on a monthly or quarterly basis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established Unified Program Integrity Contractors (&#8220;UPICs&#8221;), previously known as Zone Program Integrity Contractors, to perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the United States Department of Justice (&#8220;DOJ&#8221;). Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the payment errors they identify.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a matter of course, we undertake significant efforts through training, education, and documentation to ensure compliance with coding and medical necessity coverage rules. Despite our belief that our coding and assessment of patients are accurate, audits may lead to assertions that we have been underpaid or overpaid by Medicare or that we have submitted improper claims in some instances. Audits may also require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict when or how these audit programs will affect us. Any denial of a claim for payment, either as a result of an audit or ordinary course payment review by the MAC, is subject to an appeals process that is currently taking numerous years to complete. For additional discussion of these audits and the risks associated with them, see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the public health emergency associated with the pandemic, Congress and CMS adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care. On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;), which temporarily suspended sequestration for the period of May 1 through December 31, 2020. The CARES Act also authorized the cash distribution of relief funds from the United States Department of Health and Human Services (&#8220;HHS&#8221;) to healthcare providers. We did not accept any CARES Act relief funds. The Consolidated Appropriations Act, 2021 (the &#8220;2021 Budget Act&#8221;), signed into law on December 27, 2020, provided for additional provider relief funds. We intend to refuse any additional provider relief funds distributed in the future whether authorized under the 2021 Budget Act or other legislation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The sequestration suspension has been extended a number of times. Sequestration is currently scheduled to resume as of April 1, 2022 but will only be a 1% payment reduction through June&#160;30, 2022. Thereafter, the full 2% Medicare payment reduction will resume. Federal legislation, including the CARES Act and the 2021 Budget Act, and CMS regulatory actions include a number of other provisions, which are discussed below, affecting our reimbursement and operations in both segments. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A basic summary of current Medicare reimbursement in our business segments follows:</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As discussed above, our inpatient rehabilitation hospitals receive a fixed payment reimbursement amount per discharge under the IRF-PPS based on the patient&#8217;s rehabilitation impairment category and other characteristics and conditions identified by the attending clinicians. In order to qualify for reimbursement under the IRF-PPS, our hospitals must comply with various Medicare rules and regulations including documentation and coverage requirements, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specifications as to what conditions must be met to qualify for reimbursement. These requirements relate to, among other things, pre-admission screening, and individual treatment planning that all delineate the role of physicians in ordering and overseeing patient care. For example, a physician must approve admission of each patient and in doing so determine that the treatment of the patient in an IRF setting is reasonable and necessary. In addition, to qualify as an IRF under Medicare rules, a facility must be primarily focused on treating patients with one of 13 specified medical conditions that typically require intensive therapy and supervision, such as stroke, brain injury, hip fracture, certain neurological conditions, and spinal cord injury. Specifically, at least 60% of a facility&#8217;s patients must have a diagnosis or qualifying comorbidity from at least one of these 13 conditions, which requirement is known as the &#8220;60% Rule.&#8221; Also, each patient admitted to an IRF must be able to tolerate a minimum of three hours of therapy per day for five days per week and must have a registered nurse available 24 hours, each day of the week. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act temporarily suspends the requirement that patients must be able to tolerate a minimum of three hours of therapy per day for five days per week. Additionally, CMS has waived certain of the requirements, including the exclusion of COVID-19 admissions from the compliance calculation under the 60% Rule. CMS has also issued a waiver to permit the rehabilitation physician to conduct face-to-face visits using telehealth.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IRF-PPS, CMS is required to adjust the payment rates based on an IRF-specific market basket index. The annual market basket update is designed to reflect changes over time in the prices of a mix of goods and services used by IRFs. In setting annual market basket updates, CMS uses data furnished by the Bureau of Labor Statistics for price proxy purposes, primarily in three categories: Producer Price Indexes, Consumer Price Indexes, and Employment Cost Indexes. With IRF-PPS, our inpatient rehabilitation hospitals retain the difference, if any, between the fixed payment from Medicare and their operating costs. Thus, our hospitals benefit from being cost-effective providers.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, CMS released its notice of final rulemaking for fiscal year 2021 IRF-PPS (the &#8220;2021 IRF Rule&#8221;). The 2021 IRF Rule implemented a net 2.4% market basket increase effective for discharges between October 1, 2020 and September&#160;30, 2021. The 2021 IRF Rule also included changes that impacted our hospital-by-hospital base rate for Medicare reimbursement. Such changes included, but were not limited to, revisions to the wage index and labor-related share values and updates to the case-mix group relative weights and average lengths of stay values. Additionally, the 2021 IRF Rule codified certain inpatient rehabilitation coverage documentation requirements, and, under certain conditions, allowed the use of non-physician practitioners to perform the service and documentation requirements for one of the three required face-to-face physician visits in a patient&#8217;s second and subsequent weeks in an IRF stay.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2021, CMS released its notice of final rulemaking for fiscal year 2022 IRF-PPS (the &#8220;2022 IRF Rule&#8221;). The 2022 IRF Rule implements a net 1.9% market basket increase (market basket update of 2.6% reduced by a productivity adjustment of 0.7%) effective for discharges between October 1, 2021 and September 30, 2022. The productivity adjustment equals the trailing 10-year average of changes in annual economy-wide private nonfarm business multi-factor productivity. The 2022 IRF Rule also includes changes that impact our hospital-by-hospital base rate for Medicare reimbursement. Such changes include, but are not limited to, revisions to the wage index and labor-related share values, updates to outlier payments and updates to the case-mix group relative weights and average lengths of stay values. The 2022 IRF Rule will also add one new quality reporting measure and update the denominator of another measure. Based on our analysis, which utilizes, among other things, the acuity of our patients annualized over a six-month prior period, our experience with outlier payments over that same time frame, and other factors, we believe the 2022 IRF Rule will result in a net increase to our Medicare payment rates of approximately 1.9% effective October 1, 2021.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike our inpatient services, our outpatient services are primarily reimbursed under the Medicare Part B physician fee schedule. On November 2, 2021, CMS released its final notice of rulemaking for the payment policies under the physician fee schedule and other revisions to Part B policies for calendar year 2022. The updates to the fee schedule are not expected to be material to us. The rule also amended the hospital price transparency rule, discussed further below, by increasing the civil monetary penalties imposed on non-compliant hospitals and updating the list of activities that present barriers to allow access to the machine-readable file(s) enabling automated searches and direct downloads.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Medicare pays home health benefits for patients discharged from a hospital or patients otherwise suffering from chronic conditions that require ongoing but intermittent skilled care. As a condition of participation under Medicare, patients must be homebound (meaning unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, or have a continuing need for occupational therapy, and receive treatment under a plan of care established and periodically reviewed by a physician. A physician must document that he or she or a qualifying nurse practitioner has had a face-to-face encounter with the patient and then certify to CMS that a patient meets the eligibility requirements for the home health benefit. The CARES Act temporarily allows nurse practitioners and physician assistants under certain conditions to certify, establish and periodically review the plan of care, as well as supervise the provision of items and services for beneficiaries and expands the use of telehealth. For regulatory relief during the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic, CMS adopted a series of waivers, including expanding the definition of &#8220;homebound&#8221; to include patients needing skilled services who are homebound due solely to their COVID-19 diagnosis or patients susceptible to contract COVID-19 and limiting and delaying certain quality reporting requirements. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial certification of Medicare patient eligibility, plan of care, and comprehensive assessment is valid for a 60-day episode of care. Prior to January 1, 2020, Medicare paid home health providers under the HH-PPS for each 60-day episode of care for each patient. Providers typically received either 50% or 60% of the estimated base payment for the full 60 days for each patient upon submission of the initial claim at the beginning of the episode of care based on the patient&#8217;s condition and treatment needs. The provider received the remaining portion of the payment after the 60-day treatment period, subject to any applicable adjustments. This partial early payment process is referred to as the Request for Anticipated Payment or &#8220;RAP.&#8221;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2020, Medicare reimburses home health providers under a new payment system, referred to as the Patient-Driven Groupings Model (&#8220;PDGM&#8221;). PDGM replaced a 60-day episode of payment methodology with a 30-day payment period and relies more heavily on clinical characteristics and other patient information (such as principal diagnosis, functional level, referral source, and timing), rather than the therapy service-use thresholds under the prior system, to determine payments. Under PDGM, the initial certification remains valid for 60 days. If a patient remains eligible for care after the initial period as certified by a physician, a new treatment period may begin. There are currently no limits to the number of home health treatment periods a Medicare patient may receive assuming there is eligibility for each successive period. PDGM also reduced the early payment opportunity available through RAP in 2020. Beginning in 2021, providers no longer have the opportunity to receive early payment through the RAP process. However, providers are required to submit certain RAP documentation components within five days of the start of each payment period and are subject to reimbursement penalties if not timely filed. Beginning in 2022, home health providers are required to submit a Notice of Admission, or &#8220;NOA,&#8221; within five days of the start of the initial treatment period. CMS will reduce reimbursement for agencies that fail to submit a NOA timely. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home health Medicare payments are adjusted based on each patient&#8217;s condition and clinical treatment. This is referred to as the case-mix adjustment. In addition to the case-mix adjustment, payments for periods of care may be adjusted for other reasons, including unusually large (outlier) costs, low-utilization patients (such as those requiring one to five visits based on the case-mix group), and geographic differences in wages. Payments are also made for non-routine medical supplies that are used in treatment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2020, CMS released its notice of final rulemaking for calendar year 2021 for home health agencies under the HH-PPS (the &#8220;2021 HH Rule&#8221;). The 2021 HH Rule implemented a net 2.0% market basket increase (market basket update of 2.3% reduced by a productivity adjustment of 0.3%) and makes changes to the underlying wage index system. Making the previously temporary pandemic-related relief permanent, the 2021 HH Rule authorized the use of telecommunications technologies in providing care to beneficiaries under the Medicare home health benefit as long as the telecommunications technology meets certain criteria and does not replace in-person visits.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 2, 2021, CMS released its notice of final rulemaking for calendar year 2022 for home health agencies under the HH-PPS (the &#8220;2022 HH Rule&#8221;). The 2022 HH Rule implements a net 2.6% market basket increase (market basket update of 3.1% reduced by a productivity adjustment of 0.5%) and makes changes to the underlying wage index system. The 2022 HH Rule does not modify the current behavioral adjustment of 4.36% while they continue to analyze home health payments to ensure budget neutrality under PDGM. The 2022 HH Rule makes permanent previously temporary pandemic-related changes to Medicare home health conditions of participation, and expands the Home Health Value-Based Purchasing (&#8220;HHVBP&#8221;) Model to all Medicare-certified home health agencies in the 50 States, territories, and District of Columbia (with a maximum payment adjustment, upward or downward of 5%). Based on 2023 performance data, calendar year 2025 will be the first year in which payments may be impacted under HHVBP. Based on our preliminary analysis, which utilizes, among other things, our patient mix annualized over an eleven-month prior period, our specific geographic coverage area, and other factors, we believe the 2022 HH Rule will result in a net increase to our Medicare payment rates of approximately 3.4% effective for 30-day payment periods ending on or after January 1, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 16, 2021, CMS announced the full implementation of the home health Review Choice Demonstration will begin effective September 1, 2021 in North Carolina and Florida. CMS will discontinue exercising the existing phased-in approach for these two states.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Medicare pays hospice benefits for patients with life expectancies of six months or less, as documented by the patient&#8217;s physician(s). Under Medicare rules, patients seeking hospice benefits must agree to forgo curative treatment for their terminal medical conditions. Medicare hospice reimbursements are subject to a number of conditions of participation, including the use of volunteers and onsite visits to evaluate aides. Volunteers provide day-to-day administrative and direct patient care services in an amount that, at a minimum, equals five percent of the total patient care hours of all paid hospice </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees and contract staff. A nurse or other professional conducts an onsite visit every two weeks to evaluate if aides are providing care consistent with the care plan. The CARES Act includes the temporary waiver of the requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides and allows for the expanded use of telehealth. The 2021 Budget Act creates a new Medicare survey program for hospice agencies which will require a survey at least once every three years. Hospices that are found to be out of compliance could be subjected to new civil monetary penalties that accrue according to days out of compliance, as well as other forms of corrective action.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each day a patient elects hospice benefits, Medicare pays an adjusted daily rate based on patient location, and payments represent a prospective per diem amount tied to one of four different categories or levels of care: routine home care, continuous home care, inpatient respite care, and general inpatient care. Medicare hospice reimbursements to each provider are also subject to two annual caps, one limiting total hospice payments based on the average annual payment per beneficiary and another limiting payments based on the number of days of inpatient care billed by the hospice provider. There are currently no limits to the number of hospice benefit periods an eligible Medicare patient may receive, and a patient may revoke the benefit at any time.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, CMS released its notice of final rulemaking for fiscal year 2021 for hospice agencies under the Hospice-PPS (the &#8220;2021 Hospice Rule&#8221;). The 2021 Hospice Rule implemented a net 2.4% market basket increase from October&#160;1, 2020 through September 30, 2021. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 29, 2021, CMS released its notice of final rulemaking for fiscal year 2022 for hospice agencies under the Hospice-PPS (the &#8220;2022 Hospice Rule&#8221;). The 2022 Hospice Rule implements a net 2.0% market basket increase from October&#160;1, 2021 through September 30, 2022. The 2022 Hospice Rule also makes permanent certain changes to Medicare hospice conditions of participation that were previously temporarily in effect in response to the pandemic. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of the 2021 Medicare payment rules and other regulatory and legislative initiatives affecting Medicare reimbursement, including relief measures associated with the pandemic, that could impact our businesses, see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges.&#8221;</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Advantage, Managed Care and Other Discount Plans</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We negotiate payment rates with certain large group purchasers of healthcare services, including Medicare Advantage, managed care plans, private insurance companies, and third-party administrators. Managed care contracts typically have terms between one and three years, although we have a number of managed care contracts that automatically renew each year (with pre-defined rate increases) unless a party elects to terminate the contract. In 2021, typical rate increases for our inpatient rehabilitation contracts ranged from 2-4% and for our home health and hospice contracts ranged from 0-3%. We cannot provide any assurance we will continue to receive increases in the future. Our managed care staff focuses on establishing and re-negotiating contracts that provide equitable reimbursement for the services provided.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the percentage of Medicare-eligible beneficiaries choosing Medicare Advantage over traditional Medicare has grown, we have seen the percentage of our revenue derived from Medicare Advantage payors grow. </span><span style="background-color:#ffffff;color:#393d40;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2021, approximately 42% of M</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">edicare beneficiaries enrolled in Medicare Advantage plans. This percentage has steadily increased over time since 2003. The Congressional Budget Office</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> projects that the share of all Medicare beneficiaries enrolled in Medicare Advantage plans will rise to about 51% by 2030</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We expect the percentage of our total revenues attributable to Medicare Advantage plans to continue to grow as well. Typically, Medicare Advantage and other managed care plans reimburse us less than traditional Medicare for the same type of care and patient. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Medicaid Reimbursement</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid is a jointly administered and funded federal and state program that provides hospital and medical benefits to qualifying individuals who are deemed unable to afford healthcare. As the Medicaid program is administered by the individual states under the oversight of CMS in accordance with certain regulatory and statutory guidelines, there are substantial differences in reimbursement methodologies and coverage policies from state to state. Many states have experienced shortfalls in their Medicaid budgets and are implementing significant cuts in Medicaid reimbursement rates. Additionally, certain states control Medicaid expenditures through restricting or eliminating coverage of some services. Continuing downward pressure on Medicaid payment rates could cause a decline in that portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, for the year ended December&#160;31, 2021, Medicaid payments represented only 3.5% of our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In certain states in which we operate, we are experiencing an increase in Medicaid patients, partially the result of expanded coverage consistent with the intent of the ACA. For additional discussion, see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Changes in our payor mix or the acuity of our patients could adversely affect our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or our profitability.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost Reports</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of our participation in Medicare and Medicaid, we are required to meet certain financial reporting requirements. Federal and, where applicable, state regulations require the submission of annual cost reports covering the revenue, costs, and expenses associated with the services provided by inpatient hospital, home health, and hospice providers to Medicare beneficiaries and Medicaid recipients. These annual cost reports are subject to routine audits which may result in adjustments to the amounts ultimately determined to be due to us under these reimbursement programs. These audits are used for determining if any under- or over-payments were made to these programs and to set payment levels for future years. Medicare also makes retroactive adjustments to payments for certain low-income patients after comparing subsequently published statistical data from CMS to the cost report data. We cannot predict what retroactive adjustments, if any, will be made, but we do not anticipate these adjustments will have a material impact on us.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to significant federal, state, and local regulation that affects our business activities by controlling the reimbursement we receive for services provided, requiring licensure or certification of our operations, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and controlling our growth. State and local healthcare regulation may cover additional matters such as nurse staffing ratios, healthcare worker safety, marijuana legalization, and assisted suicide. We are also subject to the broader federal and state regulations that prohibit fraud and abuse in the delivery of healthcare services. Congress, HHS-OIG, and the DOJ have historically focused on fraud and abuse in healthcare. Since the 1980s, a steady stream of changes have stiffened penalties or made it easier for DOJ to impose liability on companies and individuals, and the pace of these changes has only been increasing. The 2018 Budget Act continues this emphasis by increasing the criminal and civil penalties that can be imposed for violating federal&#160;health care laws.&#160;As a healthcare provider, we are subject to periodic audits, examinations and investigations conducted by, or at the direction of, government investigative and oversight agencies. Failure to comply with applicable federal and state healthcare regulations can result in a provider&#8217;s exclusion from participation in government reimbursement programs and in substantial civil and criminal penalties.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We undertake significant effort and expense to provide the medical, nursing, therapy, and ancillary services required to comply with local, state, and federal regulations, as well as, for most facilities, accreditation standards of The Joint Commission and, for some facilities, the Commission on Accreditation of Rehabilitation Facilities. We also maintain accreditation for our home health and hospice agencies where required and in other instances where it facilitates more efficient Medicare enrollment. The Community Health Accreditation Program is the most common accrediting organization for our agencies.&#160;Accredited facilities and agencies are subject to periodic resurvey to ensure the standards are being met.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond healthcare specific regulations, we face increasing state and local regulation in areas, such as labor and employment and data privacy, traditionally subject to only or primarily federal regulation. In addition to the risk and burden of new, additional, or more stringent regulatory standards, these state and local regulations often conflict with federal regulation, and with each other. Given the number of locations in which we operate, increasing state and local regulation, which may be more stringent than federal regulation and may even conflict with federal or other state or local regulation, represents a significant burden and risk to us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a comprehensive ethics and compliance program to promote conduct and business practices that meet or exceed requirements under laws, regulations, and industry standards. The program monitors the Company&#8217;s performance on, and raises awareness of, various regulatory requirements among employees and emphasizes the importance of complying with governmental laws and regulations. As part of the compliance program, we provide annual compliance training to our employees, Board members, medical directors, vendors, and other non-employees that operate within our hospitals, and require all employees to report any violations to their supervisor or another person of authority or through a toll-free telephone hotline. Another integral part of our compliance program is a policy of non-retaliation against employees who report compliance concerns.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensure and Certification</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare facility construction and operation are subject to numerous federal, state, and local regulations relating to, among other things, the adequacy of medical care, equipment, personnel, operating policies and procedures, acquisition and dispensing of pharmaceuticals and controlled substances, infection control, maintenance of adequate records and patient privacy, fire prevention, and compliance with building codes and environmental protection laws. Our inpatient rehabilitation hospitals are subject to periodic inspection and other reviews by governmental and non-governmental certification authorities to ensure continued compliance with the various standards necessary for facility licensure. All of our hospitals are required to be licensed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, inpatient rehabilitation hospitals must be certified by CMS to participate in the Medicare program and generally must be certified by Medicaid state agencies to participate in Medicaid programs. Certification and participation in these programs involve numerous regulatory obligations. For example, hospitals must treat at least 20 patients without reimbursement prior to certification and eligibility for Medicare reimbursement. Once certified by Medicare, hospitals undergo periodic on-site surveys and revalidations in order to maintain their certification. All of our inpatient hospitals participate in the Medicare program.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health and hospice agencies are each licensed under applicable law, certified by CMS for participation in the Medicare program, and generally certified by the applicable state Medicaid agencies to participate in those programs.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable certification requirements may make our hospitals and agencies, as the case may be, ineligible for Medicare or Medicaid reimbursement. In addition, Medicare or Medicaid may seek retroactive reimbursement from noncompliant providers or otherwise impose sanctions for noncompliance. Non-governmental payors often have the right to terminate provider contracts if the provider loses its Medicare or Medicaid certification.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare providers are subject to employee screening requirements and associated fees. The screening of employees with patient access must include a licensure check and may include other procedures such as fingerprinting, criminal background checks, unscheduled and unannounced site visits, database checks, and other screening procedures prescribed by CMS. If a healthcare provider arranges or contracts with an individual or entity who is excluded by HHS-OIG from participation in a federal healthcare program, the provider may be subject to civil monetary penalties if the excluded person renders services reimbursed, directly or indirectly, by a program.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed operational systems to oversee compliance with the various standards and requirements of the Medicare program and have established ongoing quality assurance activities; however, given the complex nature of governmental healthcare regulations, there can be no assurance Medicare, Medicaid, or other regulatory authorities will not allege instances of noncompliance. A determination by a regulatory authority that a facility or agency is not in compliance with applicable requirements could also lead to the assessment of fines or other penalties, loss of licensure, exclusion from participation in Medicare and Medicaid, and the imposition of requirements that the offending facility or agency must take corrective action.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certificates of Need</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some states and U.S. territories where we operate, the construction or expansion of facilities, the acquisition of existing facilities or agencies, or the introduction of new beds or inpatient, home health, and hospice services may be subject to review by and prior approval of state regulatory bodies under a &#8220;certificate of need,&#8221; or &#8220;CON,&#8221; law. As of December&#160;31, 2021, approximately 40% of our licensed beds and 35% of our home health and hospice locations are in states or U.S. territories that have CON laws. CON laws require a reviewing authority or agency to determine the public need for additional or expanded healthcare facilities and services. These laws also generally require approvals for capital expenditures involving inpatient rehabilitation hospitals if such capital expenditures exceed certain thresholds. In addition, CON laws in some states require us to abide by certain charity care commitments as a condition for approving a CON. Any instance where we are subject to a CON law, we must obtain it before acquiring, opening, reclassifying, or expanding a healthcare facility, starting a new healthcare program, or opening a new home health or hospice agency.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We potentially face opposition any time we initiate a project requiring a new or amended CON or seek to acquire an existing CON. This opposition may arise either from competing national or regional companies or from local hospitals, agencies, or other providers which file competing applications or oppose the proposed CON project. Opposition to our applications may delay or prevent our future addition of beds, hospitals, or agencies in given markets or increase our costs in seeking those additions. The necessity for these approvals serves as a barrier to entry and has the potential to limit competition for us (in markets where we hold a CON) and for other providers (in markets where we are seeking a CON). We have generally been successful in obtaining CONs or similar approvals, although there can be no assurance we will achieve similar success in the future, and the likelihood of success varies by locality and state.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an attempt to reduce regulation and increase competition, lawmakers in several states have recently proposed modification or even full repeal of CON laws. In 2019, Florida enacted legislation to repeal CON laws for several provider types, including IRFs. We believe CON-related legislation and regulation changes, including both repeal and expansion of CON requirements, will continue to be proposed in various states for the foreseeable future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">False Claims</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act (the &#8220;FCA&#8221;) imposes liability for the knowing presentation of a false claim to the United States government and provides for penalties equal to three times the actual amount of any overpayments plus up to approximately $23,000 per claim. Federal civil penalties will be adjusted to account for inflation each year. In addition, the FCA allows private persons, known as &#8220;relators,&#8221; to file complaints under seal and provides a period of time for the government to investigate such complaints and determine whether to intervene in them and take over the handling of all or part of such complaints. The government and relators may also allege violations of the FCA for the knowing and improper failure to report and refund amounts owed to the government in a timely manner following identification of an overpayment. This is known as a &#8220;reverse false claim.&#8221; The government deems identification of the overpayment to occur when a person has, or should have through reasonable diligence, determined that an overpayment was received and quantified the overpayment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have hundreds of thousands of claims a year for which we are reimbursed by Medicare and other federal payors and there is a relatively long statute of limitations, a billing error, cost reporting error or disagreement over physician medical judgment could result in significant damages and civil and criminal penalties under the FCA. Many states have also adopted similar laws relating to state government payments for healthcare services. The ACA amended the FCA to expand the definition of false claim, to make it easier for the government to initiate and conduct investigations, to enhance the monetary reward to relators where prosecutions are ultimately successful, and to extend the statute of limitations on claims by the government. The federal government has become increasingly aggressive in asserting that incidents of erroneous billing or record keeping represent FCA violations and in challenging the medical judgment of independent physicians as the basis for FCA allegations. Furthermore, well-publicized enforcement actions indicate that the federal government has increasingly sought to use statistical sampling to extrapolate allegations to larger pools of claims or to infer liability without proving knowledge of falsity of individual claims. A violation of the FCA by us could have a material adverse effect upon our business, financial position, results of operations, or cash flows. Even the assertion of a violation could have an adverse effect upon our stock price or reputation. For additional discussion, see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationships with Physicians and Other Providers</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Kickback Law</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Various state and federal laws regulate relationships between providers of healthcare services, including management or service contracts and investment relationships. Among the most important of these restrictions is a federal law prohibiting the offer, payment, solicitation, or receipt of remuneration by individuals or entities to induce referrals of patients for services reimbursed under the Medicare or Medicaid programs (the &#8220;Anti-Kickback Law&#8221;). The ACA amended the federal Anti-Kickback Law to provide that proving violations of this law does not require proving actual knowledge or specific intent to commit a violation. Another amendment made it clear that Anti-Kickback Law violations can be the basis for claims under the FCA. These changes and those described above related to the FCA, when combined with other recent federal initiatives, are likely to increase investigation and enforcement efforts in the healthcare industry generally. In addition to standard federal criminal and civil sanctions, including imprisonment and penalties of up to $100,000 for each violation plus tripled damages for improper claims, violators of the Anti-Kickback Law may be subject to exclusion from the Medicare and/or Medicaid programs. Federal civil penalties will be adjusted to account for inflation each year. In 1991, HHS-OIG issued regulations describing compensation arrangements that are not viewed as illegal remuneration under the Anti-Kickback Law. Those regulations provide for certain safe harbors for identified types of compensation arrangements that, if fully complied with, assure participants in the particular arrangement that HHS-OIG will not treat that participation as a criminal offense under the Anti-Kickback Law or as the basis for an exclusion from the Medicare and Medicaid programs or the imposition of civil sanctions. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 20, 2020, HHS-OIG finalized a rule to modernize the Anti-Kickback Law by reducing regulatory barriers to care coordination and accelerating adoption of value-based delivery and payment models (the &#8220;2020 AKL Rule&#8221;). The 2020 AKL Rule adds several new safe harbors for value-based arrangements and modifies several existing safe harbors with the goal of encouraging innovations that are beneficial to patients while maintaining necessary safeguards to protect against fraud and abuse. The 2020 AKL Rule also expands the safe harbor for cybersecurity technology by covering remuneration in the form of cybersecurity technology and services. The new and modified value-based safe harbors are available to inpatient rehabilitation and home health providers if the applicable conditions are met. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to fall within a safe harbor does not constitute a violation of the Anti-Kickback Law, but HHS-OIG has indicated failure to fall within a safe harbor may subject an arrangement to increased scrutiny. A violation of the Anti-Kickback Law by us or one or more of our joint ventures could have a material adverse effect upon our business, financial position, results of operations, or cash flows. Even the assertion of a violation could have an adverse effect upon our stock price or reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a number of our rehabilitation hospitals and a few of our home health agencies through joint ventures with institutional healthcare providers that may be in a position to make or influence referrals to us. In addition, we have a number of relationships with physicians and other healthcare providers, including management or service contracts. Some of these investment relationships and contractual relationships may not fall within the protection offered by a safe harbor. Despite our compliance and monitoring efforts, there can be no assurance violations of the Anti-Kickback Law will not be asserted in the future, nor can there be any assurance our defense against any such assertion would be successful.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have entered into agreements to manage our hospitals that are owned by joint ventures. Most of these agreements incorporate a percentage-based management fee. Although there is a safe harbor for personal services and management contracts, this safe harbor requires, among other things, the aggregate compensation paid to the manager over the term of the agreement be set in advance. Because our management fee may be based on a percentage of revenues, the fee arrangement may not meet this requirement. However, we believe our management arrangements satisfy the other requirements of the safe harbor for personal services and management contracts and comply with the Anti-Kickback Law.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Physician Self-Referral Law</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The federal law commonly known as the &#8220;Stark law&#8221; and CMS regulations promulgated under the Stark law prohibit physicians from making referrals for &#8220;designated health services&#8221; including inpatient and outpatient hospital services, physical therapy, occupational therapy, radiology services, and home health services, to an entity in which the physician (or an immediate family member) has an investment interest or other financial relationship, subject to certain exceptions. The Stark law also prohibits those entities from filing claims or billing Medicare for those referred services. Violators of the Stark law and regulations may be subject to recoupments, civil monetary sanctions (up to $26,000 for each violation and assessments up to three times the amount claimed for each prohibited service) and exclusion from any federal, state, or other governmental healthcare programs. The statute also provides a penalty of up to $172,000 for a circumvention scheme. Federal civil penalties will be adjusted to account for inflation each year. There are statutory exceptions to the Stark law for many of the customary financial arrangements between physicians and providers, including personal services contracts and leases. However, in order to be afforded protection by a Stark law exception, the financial arrangement must comply with every requirement of the applicable exception.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ACA, the exception to the Stark law that currently permits physicians to refer patients to hospitals in which they have an investment or ownership interest has been dramatically limited by providing that only physician-owned hospitals with a provider agreement in place on December 31, 2010 are exempt from the general ban on self-referral. Existing physician-owned hospitals are prohibited from increasing the physician ownership percentage in the hospital after March 23, 2010. Additionally, physician-owned hospitals are prohibited from increasing the number of licensed beds after March 23, 2010, except when certain market and regulatory approval conditions are met. We have no hospitals that would be considered physician-owned under this law.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 20, 2020, CMS finalized a rule implementing various changes to the Stark law to provide better access and outcomes for patients by creating clearer paths for providers to serve patients through enhanced coordinated care agreements (the &#8220;2020 Stark Rule&#8221;). Notably, the 2020 Stark Rule creates permanent exceptions for value-based compensation arrangements that provide at least one value-based activity, which arrangements must further one value-based purpose, which may include: (1) coordinating and managing patient care; (2) improving quality of care for a target population; (3) reducing costs or expenditure growth without reducing quality of care; and (4) transitioning from health care delivery and payment mechanisms that are based on volume to outcome-based delivery and payment systems. In addition, the 2020 Stark Rule adopts a new exception regarding the provision of cybersecurity items to physicians and makes permanent the electronic health record exception under the Stark law. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complexity of the Stark law and the associated regulations and their associated strict liability provisions are a challenge for healthcare providers, who do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. We attempt to structure our relationships to meet one or more exceptions to the Stark law, but the regulations implementing the exceptions are detailed and complex. Accordingly, we cannot assure that every relationship complies fully with the Stark law.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, no assurances can be given that any agency charged with enforcement of the Stark law and regulations might not assert a violation under the Stark law, nor can there be any assurance our defense against any such assertion would be successful or that new federal or state laws governing physician relationships, or new interpretations of existing laws governing such relationships, might not adversely affect relationships we have established with physicians or result in the imposition of penalties on us. A violation of the Stark law by us could have a material adverse effect upon our business, financial position, results of operations, or cash flows. Even the assertion of a violation could have an adverse effect upon our stock price or reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIPAA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, commonly known as &#8220;HIPAA,&#8221; broadened the scope of certain fraud and abuse laws by adding several criminal provisions for healthcare fraud offenses that apply to all health benefit programs. HIPAA also added a prohibition against incentives intended to influence decisions by Medicare or Medicaid beneficiaries as to the provider from which they will receive services. In addition, HIPAA created new enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program, and an incentive program under which individuals can receive a monetary reward for providing information on Medicare fraud and abuse that leads to the recovery of at least Medicare funds. Penalties for violations of HIPAA include civil and criminal monetary penalties. The HHS Office of Civil Rights (&#8220;HHS-OCR&#8221;) implemented a permanent HIPAA audit program for healthcare providers nationwide in 2016. As of December&#160;31, 2021, we have not been selected for audit.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA and related HHS regulations contain certain administrative simplification provisions that require the use of uniform electronic data transmission standards for certain healthcare claims and payment transactions submitted or received electronically. HIPAA regulations also regulate the use and disclosure of individually identifiable health-related information, whether communicated electronically, on paper, or orally. The regulations provide patients with significant rights related to understanding and controlling how their health information is used or disclosed and require healthcare providers to implement administrative, physical, and technical practices to protect the security of individually identifiable health information.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act modifies and expands the privacy and security requirements of HIPAA. The HITECH Act applies certain of the HIPAA privacy and security requirements directly to business associates of covered entities. The modifications to existing HIPAA requirements include: expanded accounting requirements for electronic health records, tighter restrictions on marketing and fundraising, and heightened penalties and enforcement associated with noncompliance. Significantly, the HITECH Act also establishes new mandatory federal requirements for notification of breaches of security involving protected health information. HHS-OCR rules implementing the HITECH Act expand the potential liability for a breach involving protected health information to cover some instances where a subcontractor is responsible for the breaches and that individual or entity was acting within the scope of delegated authority under the related contract or engagement. These rules generally define &#8220;breach&#8221; to mean the acquisition, access, use or disclosure of protected health information in a manner not permitted by the HIPAA privacy standards, which compromises the security or privacy of protected health information. Under these rules, improper acquisition, access, use, or disclosure is presumed to be a reportable breach, unless the potentially breaching party can demonstrate a low probability that protected health information has been compromised.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, HHS-OCR proposed a new rule that would modify HIPAA regulations. According to HHS-OCR, the proposed rule is intended to promote care coordination and value-based care. The proposed changes to the HIPAA rules also provide for strengthening individuals&#8217; rights to access their own health information, including electronic information; improving information sharing for care coordination and case management for individuals; facilitating greater family and caregiver involvement in the care of individuals experiencing emergencies or health crises; enhancing flexibilities for disclosures in emergency or threatening circumstances, such as the opioid and COVID-19 public health emergencies; and reducing administrative burdens on HIPAA covered healthcare providers and health plans, while continuing to protect individuals&#8217; health information privacy interests. Although one of the stated purposes of the proposed rules is to reduce healthcare providers burdens, providers would have to engage in a number of activities to come into compliance if the changes are finalized, including changing policies and procedures, changing patient privacy notices and business associate agreements and training workforce members in the new requirements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HHS-OCR is responsible for enforcing the requirement that covered entities notify HHS and any individual whose protected health information has been improperly acquired, accessed, used, or disclosed. In certain cases, notice of a breach is required to be made to media outlets. The heightened penalties for noncompliance range from $100 to $50,000 per violation for most violations. In the event of violations due to willful neglect that are not corrected within 30 days, penalties start at $50,000 per violation and are not subject to a per violation statutory maximum. Penalties are also subject to an annual cap for multiple identical violations in a single calendar year. Pursuant to 2019 guidance from HHS-OCR, this enforcement cap ranges from a minimum of $25,000 per year to a maximum of $1,500,000 per year depending on an entity&#8217;s level of culpability. Importantly, HHS-OCR has indicated that the failure to conduct a security risk assessment or adequately implement HIPAA compliance policies could qualify as willful neglect.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are numerous legislative and regulatory initiatives at the federal and state levels addressing patient privacy concerns. Healthcare providers will continue to remain subject to any federal or state privacy-related laws, including but not limited to the California Consumer Privacy Act, that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties. HHS-OIG and other regulators have also increasingly interpreted laws and regulations in a manner as to increase exposure of healthcare providers to allegations of noncompliance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any actual or perceived violation of privacy-related laws and regulations, including HIPAA and the HITECH Act, could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Monetary Penalties Law</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Civil Monetary Penalties Law, HHS may impose civil monetary penalties on healthcare providers that present, or cause to be presented, ineligible reimbursement claims for services. The 2018 Budget Act increased the civil monetary penalties, which vary depending on the offense from $5,000 to $100,000&#160;per violation, plus treble damages for the amount at issue and may include exclusion from federal health care programs such as Medicare and Medicaid. The penalties are adjusted annually to account for inflation. HHS may seek to impose monetary penalties under this law for, among other things, offering inducements to beneficiaries for program services and filing false or fraudulent claims.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Home Health-related Services</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several currently evolving alternatives for home-based post-acute patient care that we believe could</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complement our existing home health and hospice services, including &#8220;skilled nursing facility-at-home&#8221; (or &#8220;SNF-at-home&#8221;),</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">palliative care and &#8220;hospital-at-home.&#8221; However, the regulatory and reimbursement landscape for these services remains</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to uncertainty.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While some healthcare industry stakeholders and clinicians believe that providing SNF-level care in patients&#8217;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">homes under certain circumstances may lead to improved patient outcomes and lower costs of care for payors, the licensure and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement status of the SNF-at-home delivery model are generally undefined at this time. A combination of federal and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state regulatory action, as well as payor reimbursement policies, will likely be needed in order to develop a framework and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funding for SNF-at-home services. Unless and until such actions are taken, home-based services designed to approximate the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">level of care furnished in skilled nursing facilities would need to be delivered in compliance with the existing Medicare</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certification, state licensure, and payor reimbursement frameworks.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Palliative care focuses on improving quality of life for patients, making the patient as comfortable as possible by</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipating, preventing, diagnosing and treating their symptoms, but does not seek to cure the patient&#8217;s underlying illness.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike hospice services, which are also palliative in nature, palliative care services are not limited to patients with terminal</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">illnesses. While the nature of the patient care is substantially similar, palliative care services and hospice are distinct from a</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state licensure and Medicare reimbursement perspective because patients have not yet elected (or have not qualified) to receive</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Medicare hospice benefit. Medicare does not recognize palliative care services as a separate reimbursement category, but</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rather subjects palliative care services delivered by physicians and non-physician practitioners to the normal Medicare Part B</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage and reimbursement rules. Individual categories of professionals, such as nurses, must comply with state professional</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensure regulations concerning the scope of practice as applied to palliative care services. In addition, some states may</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require an entity- or facility-level license, distinct from the hospice license, to provide palliative care services. Payor coverage</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reimbursement policies may vary greatly depending on the state, payor, and the patient&#8217;s health plan.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospital-at-home refers to the provision of acute care hospital services in patients&#8217; homes. The concept received</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant industry attention following a March 2020 announcement by CMS allowing Medicare-certified hospitals to request</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">waivers of applicable Medicare Conditions of Participation to provide acute care hospital services in patients&#8217; homes during the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 public health emergency. On November 25, 2020, CMS expanded and modified this program, which is now called</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Acute Hospital Care at Home program. Hospital-at-home care under Medicare still requires the provider to meet all of the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Conditions of Participation applicable to hospitals and involves a much higher intensity of care than home health agencies are generally equipped to provide. In order to provide hospital-at-home care, we would need to enter into an arrangement with a Medicare-certified hospital that has received one of these Acute Hospital Care at Home waivers from CMS to be able to provide home acute care services on behalf of the hospital. Furthermore, because the Acute Hospital Care at Home program is a Medicare program designed to address the COVID-19 public health emergency, non-Medicare payor reimbursement policies are unclear and would have to be addressed individually with each payor.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our website, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.encompasshealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the following documents, free of charge: our annual reports (Form 10-K), our quarterly reports (Form 10-Q), our current reports (Form 8-K), and any amendments to those reports promptly after we electronically file such material with, or furnish it to, the United States Securities and Exchange Commission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_19"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:34.8pt">Risk Factors</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, operations, and financial position are subject to various risks. Some of these risks are described below, and the reader should take such risks into account in evaluating Encompass Health or any investment decision involving Encompass Health. This section does not describe all risks that may be applicable to us, our industry, or our business, and it is intended only as a summary of material risk factors. More detailed information concerning other risks and uncertainties as well as those described below is contained in other sections of this annual report. Still other risks and uncertainties we have not or cannot foresee as material to us may also adversely affect us in the future. If any of the risks below or other risks or uncertainties discussed elsewhere in this annual report are actually realized, our business and financial condition, results of operations, and cash flows could be adversely affected. In the event the impact is materially adverse, the trading price of our common stock could decline.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to the Strategic Review and the Resulting Planned Spin Off of Our Home Health and Hospice Business</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Following our review of strategic alternatives for our home health and hospice business, we plan to effect a spin off of our home health and hospice business into an independent public company, but there can be no assurance that we will be successful in consummating the spin off or any other strategic alternatives, that the spin off or any other strategic alternatives will yield additional value for our stockholders, or that the planned spin off will not adversely impact our business, financial results or results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 9, 2020, we announced that our board of directors proceeded with a more formalized process for exploring strategic alternatives for our home health and hospice business. As a result of this process, we expect to effect a spin off of the home health and hospice business into an independent, publicly traded company by the end of the second quarter of 2022. Our board of directors believes that the separation of the inpatient rehabilitation business and the home health and hospice business into two independent, publicly traded companies will provide significant benefits to both businesses and their stakeholders, including improving the strategic and operational flexibility of each business, increasing the focus of each management team on its business strategy and operations, allowing each business to adopt a capital structure and investment policy best suited to its financial profile and business needs, and providing each company with its own equity currency to facilitate acquisitions and to better incentivize management. However, we cannot guarantee the spin off will occur. Speculation regarding the separation or any other developments related to the review of strategic alternatives for our home health and hospice business and perceived uncertainties related to the future of that business or Encompass Health could cause our stock price to fluctuate significantly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exploration of strategic alternatives and the resulting plan to spin off our home health and hospice business exposes us to a number of risks and uncertainties, including the risk that we may not be able to consummate any separation transaction successfully or at all; diversion of management&#8217;s time to the process; the incurrence of significant expenses associated with the review and pursuit of the spin off or any other transaction; increased difficulties in attracting, retaining or motivating key management personnel; and exposure to potential litigation. Any of these factors could disrupt our business and could have a material adverse effect on our business, financial condition, results of operations, cash flows or stock price.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may not be able to realize the anticipated benefits from the spin off or any other strategic alternative involving our home health and hospice business. There can be no assurance that the spin off or other strategic alternative, if identified, evaluated and consummated, will provide greater value to our stockholders than that reflected in our current stock price. Further, our board of directors may determine to suspend or terminate the spin off of our home health and hospice business at any time. The spin off or any other outcome of this review process is also dependent upon a number of factors that may be beyond our control, including among other factors, market conditions (including the impact of the COVID-19 pandemic), industry trends, regulatory developments, litigation, and the interest of third parties in our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The rebranding of the home health and hospice business will involve substantial costs and may not be favorably received by our referral sources, business partners, or investors.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Historically, we have conducted our home health and hospice business under the Encompass brand as an integrated post-acute healthcare provider.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In anticipation of the spin off, we expect the home health and hospice business will begin operating under the new &#8220;Enhabit&#8221; brand as soon as April in some locations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The new brand name may not improve upon the brand recognition associated with the &#8220;Encompass&#8221; name that we previously established with referral sources and business partners over a long period of time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the rebranding will involve significant costs and require the dedication of significant time and effort by management and other personnel. We cannot predict the impact of the rebranding on the business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">However, if the home health and hospice business fails to establish, maintain, or enhance brand recognition associated with the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Enhabit&#8221; name, it may affect patient referrals, which may adversely affect our ability to generate revenues and could impede the Enhabit business plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the costs and the dedication of time and effort associated with the rebranding may negatively affect our profitability.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If the spin off is completed, both Encompass Health&#8217;s and Enhabit&#8217;s operational and financial profiles will change and each will be a less diversified company than Encompass as it exists currently.</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The spin off of our home health and hospice business will result in Encompass and Enhabit being less diversified companies with more limited businesses concentrated in their respective industries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result, each company may be more vulnerable to changing market and regulatory conditions, which could have a material adverse effect on its business, financial condition and results of operations. In addition, the diversification of revenues, costs, and cash flows will diminish, such that each company&#8217;s results of operations, cash flows, working capital, effective tax rate, and financing requirements may be subject to increased volatility and its ability to fund capital expenditures and investments, pay dividends and service debt may be diminished. It is anticipated that the effective tax rate for each separate company will differ from the current consolidated effective tax rate. The regulatory and reimbursement risk for Encompass will be significantly concentrated in the Medicare inpatient rehabilitation rules and regulations. The regulatory and reimbursement risk for Enhabit will be significantly concentrated in the Medicare home health rules and regulations. For 2021, Medicare payments under the inpatient rehabilitation facility prospective payment system represented approximately 64% of the inpatient rehabilitation segment total revenue, and Medicare payments under the home health prospective payment system represented approximately 63% of the home health and hospice segment total revenue. A significant change in Medicare regulations governing either inpatient rehabilitation or home health could have a material adverse effect on business, financial condition and results of operations of the respective separate company. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If the spin off is completed, there may be changes in our stockholder base, which may cause volatility in the price of our common stock. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investors holding our common stock may hold our common stock because of a decision to invest in a company that provide a diverse or integrated healthcare services. If the spin off is completed, shares of Encompass common stock will represent an investment in a business concentrated in inpatient rehabilitation, and shares of the common stock of Enhabit will represent an investment in businesses concentrated in home health and hospice. These changes may not match some stockholders&#8217; investment strategies, which could cause them to sell their shares of our common stock or the common stock of Enhabit, and excessive selling pressure could cause the respective market prices to decrease following the consummation of the spin. Additionally, we cannot predict whether the combined market value of our common stock and the common stock of Enhabit after the spin off will be equal to or greater than the market value of our common stock prior to the spin off.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Novel Coronavirus Disease 2019 (&#8220;COVID-19&#8221;) Pandemic Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic (the &#8220;pandemic&#8221;) has significantly affected and is expected to continue to significantly affect our operations, business and financial condition, and our liquidity could be negatively impacted, particularly if the provision of healthcare services and the supplies for those services are disrupted for a lengthy period of time.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic has significantly affected and will continue to significantly affect our facilities, employees, business operations, and financial performance, as well as the United States economy and financial markets. The pandemic is still rapidly evolving and much of its impact remains unknown and difficult to predict, with the impact on our operations and financial performance being dependent on numerous factors, including the rate of spread, duration and geographic coverage of the pandemic; the rate and extent to which the virus mutates and the severity of the symptoms of the variants; the status of testing capabilities; the rates of vaccination and therapeutic remedies for COVID-19 and any variant strains; the legal, regulatory and administrative developments related to the pandemic at federal, state, and local levels, such as vaccine mandates, anti-mandate laws and orders, shelter-in-place orders, facility closures and quarantines; and the infectious disease prevention and control efforts of the Company, governments and third parties. </span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began experiencing a negative impact from the pandemic on our operations and financial results in March 2020. The most pronounced negative impacts occurred with the initial wave of the pandemic and the governmental reactions to it in the first half of 2020. Since then, our operational and financial performance has improved, but subsequent localized surges in case counts, particularly ones involving new COVID-19 variants, have also had a negative impact on us. The ongoing nature of the pandemic means that new or recurring problems are likely to arise and may have significant negative effects on our business, particularly in specific markets most affected by a new surge.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal and Regulatory Environment</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future federal, state or local laws, regulations, orders, or other governmental or regulatory actions addressing the pandemic have, and could in the the future, adversely affect our financial condition, results of operations and cash flow, including by exacerbating staffing shortages, increasing staffing and supply costs, reducing patient volumes, and increasing compliance costs and the associated risks of losing a license to operate. The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) imposed a COVID-19 vaccination requirement (the &#8220;CMS Vax Mandate&#8221;) as a condition of participating in the Medicare and Medicaid programs. The CMS Vax Mandate recognizes potential medical and religious exemptions but does not allow for testing as an alternative for employees that do not get the vaccine. Pursuant to CMS guidance, a healthcare provider must have policies and procedures in place to ensure all employees are vaccinated and 100% of employees must be fully vaccinated or have been granted qualifying exemption on or before the deadline for the provider&#8217;s state, the latest of which is March 21, 2022. Compliance with the CMS Vax Mandate will be assessed as part of initial certification, standard recertification or re-accreditation performed by existing surveying agencies and contractors. As is customary in the surveying process, non-compliance does not necessarily lead to termination, and providers will generally be given opportunities to return to compliance. If noncompliance is not resolved in the notice and remediation period, providers may as a final measure be subject to termination of participation from the Medicare and Medicaid programs. Home health and hospice agencies are also subject to civil monetary penalties and claims denials. Some states have adopted more onerous vaccine mandate requirements than CMS. Other states, including Florida and Texas, have promulgated laws and executive orders that purport to prohibit employers from instituting vaccine mandates for employees or to prevent state authorities from aiding in enforcement of federal vaccine mandates. It is unclear how these conflicting anti-mandate laws and orders might impact the administration of the CMS Vax Mandate or employers&#8217; attempts to comply with the CMS Vax Mandate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local executive actions in response to the pandemic, such as limitations on elective procedures, vaccine mandates, shelter-in-place orders, facility closures and quarantines, have in the past, and could in the future, impair our ability to operate or prevent people from seeking care from us. For example, local health departments have restricted our ability to take patients in specific markets for periods of time in reaction to perceived COVID-19 outbreaks. The imposition of a nationwide restriction on travel or other public activities by the federal government could have similar effects in all of our markets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to lawsuits from patients, employees and others alleging exposure to COVID-19 at our facilities. To date, six lawsuits have been filed on behalf of former patients alleging COVID-19 exposure during stays in our hospitals. Such actions may involve large damage claims as well as substantial defense costs. Our professional and general liability insurance may not cover all claims against us.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act, signed into law on March 27, 2020, authorized the cash distribution of relief funds to healthcare providers in response to the pandemic. On April&#160;10, 2020, HHS began distributing CARES Act relief funds, for which we did not apply, to various of our bank accounts. We refused the CARES Act relief funds, and our banks returned all the funds to HHS. The 2021 Budget Act, signed into law on December 27, 2020, provides for additional provider relief funds. We intend to refuse any additional provider relief funds distributed in the future whether authorized under the CARES Act, the 2021 Budget Act or the American Rescue Plan Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Volumes and Related Risks</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For various quarterly periods during the pandemic, we experienced decreased patient volumes in one or more of our business lines when compared to the prior year periods. We believe reduced patient volumes resulted, and will continue to result in specific markets, from a number of conditions related to the pandemic negatively affecting the willingness and ability of patients to seek and receive healthcare services, including: reductions in elective procedures by acute-care hospitals and physician practices; capacity and staffing constraints; restrictive governmental measures, such as travel bans, social distancing requirements, quarantines and shelter-in-place orders; and patient and caregiver fear of infection. In the home health and hospice segment, we also experienced decreases in visits per episode and institutional referrals because of the pandemic, both of which negatively affected pricing for home health.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe one of the primary drivers of our reduced volumes is the significant reduction in volumes of elective procedures by acute-care hospitals and physician practices. There is also reason to believe patients, because of fear of infection, have delayed or foregone treatment for conditions, such as stroke and heart attack, that are non-elective in nature. As a reminder, a large number of patients are referred to us following procedures or treatment at acute-care hospitals. Other factors related to the pandemic that have led to decreasing patient volumes include: lower acute-care hospital censuses due to shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, policies in assisted living facilities that limit our staff </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. Significant outbreaks of COVID-19 in our markets, hospitals or large acute-care referral sources could further increase patient anxiety and unwillingness to seek treatment from us or otherwise limit referrals. These factors have contributed, and could in the future contribute, to a decline in new patients for both of our operating segments as well as decreases in visits per episode in our home health business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Staffing and Related Risks</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial results have been and may in the future be adversely affected by staffing shortages and costs. The pandemic and governmental responses to it have created and continue to exacerbate staffing challenges for us and other healthcare providers, including our referral sources. Quarantines and vaccine mandates as well as employee apprehension and stress related to the pandemic have led to staffing shortages which in turn have led to increased staffing costs. We have, and the healthcare industry in general has, experienced staffing shortages at individual hospitals and agencies from time to time. Staffing shortages have limited, and may in the future limit, our ability to admit additional patients at a given facility or agency. Shortages in nurse staffing have led to significant increases in agency nursing and the compensation costs for nursing staff, both agency and employee. The CMS Vax Mandate may lead to the loss of some employees. In addition to staffing shortages, significant outbreaks of COVID-19 or PPE shortages in our markets or hospitals may reduce employee morale and create labor unrest or other workforce disruptions. Staffing shortages or employee relations issues related to COVID-19 may lead to limitations on the ability to admit new patients. We may also experience additional benefit costs related to increased workers&#8217; compensation claims and group health insurance expenses as a result of the pandemic. Additionally, as some employees work from home to comply with pandemic-mitigation protocols, they will rely on remote access to our information systems to a greater extent than normal, which could increase the likelihood and magnitude of a cyber attack on our information systems.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we experienced supply chain disruptions as a result of the pandemic, including shortages and delays, and we have experienced, and are likely to continue to experience, significant price increases in equipment, pharmaceuticals and medical supplies, particularly personal protective equipment, or &#8220;PPE.&#8221; Beginning in March 2020, we experienced increased supply expenses due to higher utilization of PPE and increased purchasing of other medical supplies and cleaning and sanitization materials as well as higher prices for supplies in shortage. Increased supply expenses are likely to continue in 2022. Shortages of essential PPE and pharmaceutical and medical supplies in the future may also limit our ability to admit and treat patients or lead to employee disputes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Factors</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing disruptions to our business as a result of the pandemic have had, and are likely to continue to have, an adverse effect on our business and could have a material adverse effect on our business, results of operations, financial condition and cash flows. Furthermore, assessing the CMS Vax Mandate and numerous other federal, state and local regulatory changes and formulating our responses to those regulatory changes and the effects of the pandemic has required, and will likely continue to require, extensive management involvement and company resources, which may negatively affect our ability to implement our business plan and respond to opportunities and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Reimbursement Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reductions or changes in reimbursement from government or third-party payors could adversely affect our Net operating revenues and other operating results.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive a substantial portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the Medicare program. See Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Sources of Revenues,&#8221; for a table identifying the sources and relative payor mix of our revenues. In addition to many ordinary course reimbursement rate changes that CMS adopts each year as part of its annual rulemaking process for various healthcare provider categories, Congress and some state legislatures have periodically proposed significant changes in laws and regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in pricing freezes, reimbursement reductions, or reduced levels of reimbursement increases that are less than the increases we experience in our costs of operation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2010, President Obama signed into law the ACA as a significant healthcare reform. Many provisions within the ACA have impacted or could in the future impact our business, including Medicare reimbursement reductions and promotion of alternative payment models, such as accountable care organizations (&#8220;ACOs&#8221;) and bundled payment initiatives. The nature and substance of state and federal healthcare laws are always subject to change, occasionally by means of both broad base healthcare reform legislation, like the ACA, and targeted legislative and regulatory action. Any future legislative and regulatory changes may ultimately impact the provisions of the ACA discussed below or other laws or regulations that either currently affect, or may in the future affect, our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare providers like us, these laws include reductions in CMS&#8217;s annual adjustments to Medicare reimbursement rates, commonly known as a &#8220;market basket update.&#8221; In accordance with Medicare laws and statutes, CMS makes market basket updates by provider type in an effort to compensate providers for rising operating costs. The ACA required reductions, the last of which ended in 2019, in the annual market basket updates for hospital providers ranging from 10 to 75 basis points and for hospice agencies 30 basis points. For home health agencies, the ACA directed CMS to improve home health payment accuracy through rebasing home health payments over four years starting in 2014. In addition, the ACA requires the market basket updates for hospital, home health, and hospice providers to be reduced by a productivity adjustment on an annual basis. The productivity adjustment equals the trailing 10-year average of changes in annual economy-wide private nonfarm business multi-factor productivity. To date, the productivity adjustments have typically resulted in decreases to the market basket updates ranging from 30 to 100 basis points. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal legislation can also have a significant direct impact on our Medicare reimbursement. On August 2, 2011, President Obama signed into law the Budget Control Act of 2011, which provided for an automatic 2% reduction of Medicare program payments. This automatic reduction, known as &#8220;sequestration,&#8221; began affecting payments received after April 1, 2013. Under current law, for each year through fiscal year 2030, the reimbursement we receive from Medicare, after first taking into account all annual payment adjustments including the market basket update, will be reduced by sequestration unless it is repealed or modified before then. The CARES Act temporarily suspended sequestration for the period of May 1 through December 31, 2020. The 2021 Budget Act extended the sequestration suspension through March 31, 2021, and a subsequent bill signed into law on April 14, 2021 continued the suspension of sequestration until the end of 2021. On December 10, 2021 President Biden signed the Protecting Medicare and American Farmers from Sequester Cuts Act, which suspends sequestration cuts until April 1, 2022. Sequestration is scheduled to resume at that time but will only be a 1% payment reduction through June&#160;30, 2022 before resuming the 2% reduction.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional Medicare payment reductions are also possible under the Statutory Pay-As-You-Go Act of 2010 (&#8220;Statutory PAYGO&#8221;). Statutory PAYGO requires, among other things, that mandatory spending and revenue legislation not increase the federal budget deficit over a 5- or 10-year period. If the Office of Management and Budget (the &#8220;OMB&#8221;) finds there is a deficit in the federal budget, Statutory PAYGO requires OMB to order sequestration of Medicare. In March 2021, President Biden signed the American Rescue Plan Act of 2021 (the &#8220;American Rescue Plan Act&#8221;). The Congressional Budget Office estimated that the American Rescue Plan Act would result in budget deficits necessitating a 4% reduction in Medicare program payments for 2022 under the Statutory PAYGO unless Congress and the President take action to waive the Statutory PAYGO reductions. The Protecting Medicare and American Farmers from Sequester Cuts Act suspends until 2023 the Statutory PAYGO reductions that would have gone into effect as a result of the American Rescue Plan Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, concerns held by federal policymakers about the federal deficit, national debt levels, or healthcare spending specifically, including solvency of the Medicare trust fund, could result in enactment of further federal spending reductions, further entitlement reform legislation affecting the Medicare program, and further reductions to provider payments. In October 2014, President Obama signed into law the Improving Medicare Post-Acute Care Transformation Act of 2014 (the &#8220;IMPACT Act&#8221;). The IMPACT Act directs HHS, in consultation with healthcare stakeholders, to implement standardized data collection processes for post-acute quality and outcome measures. Although the IMPACT Act does not specifically call for the implementation of a new post-acute payment system, we believe this act lays the foundation for possible future post-acute payment policies that would be based on patients&#8217; medical conditions and other clinical factors rather than the setting where the care is provided, also referred to as &#8220;site neutral&#8221; reimbursement. CMS has begun changing current post-acute payment systems to improve comparability of patient assessment data and clinical characteristics across settings, which will make it easier to create a unified payment system in the future. For example, CMS recently established new case-mix classification models for both home health, discussed further below, and skilled nursing facilities which rely on patient characteristics rather than the amount of therapy received to determine payments. Another example is CMS&#8217;s implementation of the new patient assessment measures for IRFs discussed below. The IMPACT Act also creates additional data reporting requirements for our hospitals and home health agencies. The precise details of these new reporting requirements, including timing and content, are being developed and implemented by CMS through the regulatory process that we expect will continue to take place over the next several years. We cannot quantify the potential effects of the IMPACT Act on us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year, the Medicare Payment Advisory Commission (&#8220;MedPAC&#8221;), an independent agency, advises Congress on issues affecting Medicare and makes payment policy recommendations to Congress for a variety of Medicare payment systems including, among others, the inpatient rehabilitation facility prospective payment system (the &#8220;IRF-PPS&#8221;), the home health prospective payment system (the &#8220;HH-PPS&#8221;), and the hospice payment system (the &#8220;Hospice-PPS&#8221;). MedPAC also provides comments to CMS on proposed rules, including the prospective payment system rules. Congress is not obligated to adopt MedPAC recommendations, and, based on outcomes in previous years, there can be no assurance Congress will adopt MedPAC&#8217;s recommendations in a given year. However, MedPAC&#8217;s recommendations have, and could in the future, become the basis for legislative or regulatory action.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with CMS&#8217;s final rulemaking for the IRF-PPS and the HH-PPS in each year since 2008, MedPAC has recommended either no updates to payments or reductions to payments. In a March 2020 report to Congress, MedPAC recommended, among other things, legislative changes to eliminate the update to the fiscal year 2020 Medicare base payment rates for hospice, reduce by 7% the base payment rate under the HH-PPS, and reduce by 5% the base payment rate under IRF-PPS. In the March 2020 report, MedPAC also reiterated a previous recommendation for Congress to increase the IRF outlier payment pool, to be funded by reductions to base Medicare payments rates under the IRF-PPS. This proposal would adversely affect us as we have a relatively low percentage of outlier patients compared to other inpatient rehabilitation providers. The March 2020 report also called on the HHS Secretary to conduct focused medical record reviews on IRFs. In an October 2020 report, MedPAC called for future research into Medicare hospice payments and expressed concerns that aggregate payments substantially exceed costs and that there are outlier utilization patterns in the industry. In its March 2021 report, MedPAC again recommended elimination of the update for the hospice-PPS base payment rate and reduction of the base payment rates under the HH-PPS and the IRF-PPS by 5%.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a June 2018 report mandated by the IMPACT Act, MedPAC reiterated its recommendation that Congress adopt a unified payment system for all post-acute care (a &#8220;PAC-PPS&#8221;) in lieu of separate systems for inpatient rehabilitation facilities (&#8220;IRFs&#8221;), skilled nursing facilities, long-term acute care hospitals, and home health agencies. A PAC-PPS would rely on &#8220;site neutral&#8221; reimbursement based on patients&#8217; medical conditions and other clinical factors rather than the care settings. MedPAC found a PAC-PPS to be feasible and desirable but also suggested many existing regulatory requirements, including the 60% rule discussed below and the requirement for a minimum of three hours of therapy per day, should be waived or modified as part of implementing a PAC-PPS. MedPAC previously estimated, although we cannot verify the methodology or the accuracy of that estimate, a PAC-PPS would result in 15% and 1% decreases to IRF and home health reimbursements, respectively. As a precursor to a PAC-PPS, MedPAC discussed in November 2017 a potential recommendation to change the case-mix weights in each post-acute setting for 2019 and 2020 to a blend of the current setting specific weight and the proposed PAC-PPS weight, which MedPAC suggested would shift money from for-profit and freestanding IRFs to non-profit and hospital-based IRFs. MedPAC has also called for aligning Medicare regulatory requirements across post-acute providers, although the agency has acknowledged it could take years to complete this effort. Additionally, MedPAC previously has suggested that Medicare should ultimately move from fee-for-service reimbursement to more integrated delivery payment models.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MedPAC also recommended significant changes to the HH-PPS, some of which CMS incorporated into the new payment system mandated by the Bipartisan Budget Act of 2018, referred to as Patient-Driven Groupings Model (&#8220;PDGM&#8221;), and set out in the final rule for the 2019 HH-PPS. Beginning in 2020, the PDGM replaced the prior 60-day episode of payment methodology with a 30-day payment period and eliminated therapy usage as a factor in setting payments (that is, more therapy visits led to higher reimbursement). CMS adopted a 4.4% reduction in the base payment rate intended to offset the provider behavioral changes that CMS assumed PDGM would drive. The reimbursement and other changes associated with PDGM could have a significant impact on our home health agencies. Likewise, MedPAC&#8217;s previously recommended changes to the Hospice-PS, including a wage adjustment and a reduction in the hospice aggregate cap by 20%, could have a significant impact on our hospice agencies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what alternative or additional deficit reduction initiatives, Medicare payment reductions, or post-acute care reforms, if any, will ultimately be adopted or enacted into law, or the timing or effect of any initiatives or reductions. Those initiatives or reductions would be in addition to many ordinary course reimbursement rate changes that CMS adopts each year as part of the market basket update rulemaking process for various provider categories. While we do not expect the drive toward integrated delivery payment models, value-based purchasing, and post-acute site neutrality in Medicare reimbursement to subside, there will almost certainly be new or alternative healthcare reforms in the future which may change these initiatives and other healthcare laws and regulations. We cannot predict the nature or timing of any changes to the laws or regulations that either currently affect, or may in the future affect, our business.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance future governmental action will not result in substantial changes to, or material reductions in, our reimbursements. Similarly, we may experience material increases in our operating costs. For example, in 2022, we expect our wage and benefit costs to increase at a rate in excess of our aggregate Medicare reimbursement rate increase. In any given year, the net effect of statutory and regulatory changes may result in a decrease in our reimbursement rate, and that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease may occur at a time when our expenses are increasing. As a result, there could be a material adverse effect on our business, financial position, results of operations, and cash flows. For additional discussion of how we are reimbursed by Medicare, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulatory and Reimbursement Challenges&#8221; and &#8220;Sources of Revenues&#8212;Medicare Reimbursement.&#8221;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are increasing pressures, including as a result of the ACA, from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors, such as health maintenance organizations and preferred provider organizations, are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and our ability to grow our business with these payors could be adversely affected if we are unable to negotiate and maintain favorable agreements with third-party payors.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality reporting requirements could adversely affect the Medicare reimbursement we receive.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The focus on alternative payment models and value-based purchasing of healthcare services has, in turn, led to more extensive quality of care reporting requirements. In many cases, the new reporting requirements are linked to reimbursement incentives. For example, under the ACA, CMS established new quality data reporting, effective October 1, 2012, for all IRFs. A facility&#8217;s failure to submit the required quality data results in a two percentage point reduction to that facility&#8217;s annual market basket increase factor for payments made for discharges in the subsequent Medicare fiscal year. Hospitals began submitting quality data to CMS in October 2012. All of our hospitals have met the reporting deadlines to date resulting in no corresponding reimbursement reductions. Similarly, home health and hospice agencies are required to submit quality data to CMS each year, and the failure to do so in accordance with the rules will result in a two percentage point reduction in their market basket updates. All of our home health and hospice agencies met the reporting deadlines resulting in no corresponding reimbursement reductions for 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the IMPACT Act mandated that CMS adopt several new quality reporting measures for the various post-acute provider types. The adoption of additional quality reporting measures to track and report will require additional time and expense and could affect reimbursement in the future. In healthcare generally, the burdens associated with collecting, recording, and reporting quality data are increasing. Currently, CMS requires IRF and home health providers to track and submit patient assessment data to support the calculation of 18 and 20 quality reporting measures, respectively.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2015, CMS established a five-year home health value-based purchasing model in nine states to test whether incentives for better care can improve outcomes in the delivery of home health services. The model, which began in 2016, applies a reduction or increase to current Medicare-certified home health agency payments, depending on quality performance, made to agencies in Massachusetts, Maryland, North Carolina, Florida, Washington, Arizona, Iowa, Nebraska, and Tennessee.  CMS assesses performance based on several process, outcome, and care satisfaction measures. In the 2022 HH Rule, CMS expanded the model to apply nationwide. The first performance year under the expanded, nationwide home health value-based purchasing model will be 2023 and any associated payment adjustments, capped at 5%, would occur in 2025. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not experienced a decrease in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in excess of $0.5 million in any year. There can be no assurance all of our hospitals and agencies will meet quality reporting requirements or quality performance in the future which may result in one or more of our hospitals or agencies seeing a reduction in its Medicare reimbursements. Regardless, we, like other healthcare providers, are likely to incur additional expenses in an effort to comply with additional and changing quality reporting requirements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement claims are subject to various audits from time to time and such audits may negatively affect our operations and our cash flows from operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenues from the Medicare program. Medicare reimbursement claims made by healthcare providers, including inpatient rehabilitation hospitals as well as home health and hospice agencies, are subject to audit from time to time by governmental payors and their agents, such as MACs that act as fiscal intermediaries for all Medicare billings, auditors contracted by CMS, and insurance carriers, as well as the HHS Office of Inspector General (the &#8220;HHS-OIG&#8221;), CMS and state Medicaid programs. As noted above, the clarity and completeness of each patient medical file, some of which is the work product of a physician not employed by us, is essential to successfully challenging any payment denials. If the physicians working with our patients do not adequately document, among other things, their diagnoses and plans of care, our risks related to audits and payment denials in general are greater. Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered systemic, the resolution of these audits could have a material adverse effect in the aggregate on our financial position, results of operation and liquidity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the context of our inpatient rehabilitation business, one of the prevalent grounds for denying a claim or challenging a previously paid Medicare claim in an audit is that the patient&#8217;s treatment in a hospital was not medically necessary. The medical record must support that both the documentation and coverage criteria requirements are met for the hospital stay to be considered medically reasonable and necessary. Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting. A Medicare claim may be denied or challenged based on an opinion of the auditor that the record did not evidence medical necessity for treatment in an IRF or lacked sufficient documentation to support the conclusion. In the past, we had a MAC that made determinations regarding medical necessity using its own uniquely restrictive interpretations of the CMS coverage rules or imposing otherwise arbitrary conditions not set out in the related rules, which resulted in a significant number of payment denials.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, we believe the reviewing party is not merely challenging the sufficiency of the medical record but is substituting its judgment of medical necessity for that of the attending physician or imposing documentation or other requirements that are not set out in the regulations. We argue that doing so is inappropriate and has no basis in law. When the government or its contractors reject the medical judgment of physicians or impose documentation and other requirements beyond the language of the statutes and regulations, patient access to inpatient rehabilitation as well as our Medicare reimbursement from the related claims may be adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2017, CMS announced the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). As of December 31, 2021, none of our hospitals or agencies have progressed beyond the third round of reviews, so it is unclear how the review process after TPE would proceed. We cannot predict whether the TPE initiative or similar probes or reviews will materially impact our reimbursement or the timeliness of collections from Medicare in the future.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has developed and instituted various audit programs under which CMS contracts with private companies to conduct claims and medical record audits. These audits are in addition to those conducted by existing MACs. Some contractors are paid a percentage of the overpayments recovered. One type of audit contractor, the Recovery Audit Contractors (&#8220;RACs&#8221;), receive claims data directly from MACs on a monthly or quarterly basis and are authorized to review previously paid claims. RAC audits of IRFs initially focused on coding errors but subsequently expanded to include medical necessity and billing accuracy reviews. CMS has, however, authorized RACs to conduct complex reviews of the medical records associated with both IRF and home health reimbursement claims. CMS has previously operated a demonstration project that expanded the RAC program to include prepayment review of Medicare fee-for-service claims from primarily acute care hospitals. It is unclear whether CMS intends to conduct RAC prepayment reviews in the future and if so, what providers and claims would be the focus of those reviews.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established contractors known as the Uniform Program Integrity Contractors (&#8220;UPICs,&#8221; formerly known as &#8220;ZPICs&#8221;). These contractors are successors to the Program Safeguard Contractors and conduct audits with a focus on potential fraud and abuse issues. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the United States Department of Justice (&#8220;DOJ&#8221;). Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. In some cases, the UPICs have extrapolated error rates to larger pools of our claims. In the most significant example to date, a UPIC denied less than $2 million in claims but recouped an extrapolated amount of approximately $30 million. We have appealed substantially all UPIC denials, including the recoupment noted above, arising from these audits using the same process we follow for appealing other denials by contractors and will continue to contest the use of extrapolation in any context.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audits may lead to assertions that we have been underpaid or overpaid by Medicare or have submitted improper claims in some instances. Such assertions may require us to incur additional costs to respond to requests for records and defend the validity of payments and claims and may ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors have the authority to extrapolate denial rationales to large pools of claims not actually audited, which could greatly increase the impact of the audit. As a result, we may suffer reduced profitability, and we may have to elect not to accept patients and conditions physicians believe can benefit from inpatient rehabilitation. We cannot predict when or how these audit programs will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations. Similarly, there can be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no assurance that our current or future MACs will not take restrictive interpretations of Medicare coverage rules. Because one MAC has jurisdiction over a significant number of our hospitals and our hospitals derive a substantial portion of their revenue from Medicare, the adoption of restrictive interpretations of coverage rules by that MAC could result in a large number of payment denials and materially and adversely affect our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in the administrative appeals process associated with denied Medicare reimbursement claims could delay or reduce  our reimbursement for services previously provided.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary course Medicare pre-payment denials by MACs, as well as denials resulting from widespread probes and audits, are subject to appeal by providers. We have historically appealed a majority of our denials. Due to the sheer number of appeals and various administrative inefficiencies, including a shortage of judges, appeals that are due to be resolved in a matter of months commonly take years to complete. For example, most of our appeals heard in 2021 related to denials received in 2015 and 2016. We believe the process for resolving individual Medicare payment claims that are denied will continue to take several years. Additionally, the number of new denials frequently exceeds the number of appeals resolved in a given year (CMS suspended payment reviews for several months because of the public health emergency in 2020) as shown in the following summary of our inpatient rehabilitation segment activity: </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"><tr><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">New Denials</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collections of Previously Denied Claims</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue Reserve for New Denials</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently record our estimates for pre-payment denials and for post-payment audit denials that will ultimately not be collected as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; to the accompanying consolidated financial statements. Given the continuing or increasing delays along with the increasing number of denials in the backlog, we may experience decreases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreases in cash flow as a result of increasing accounts receivable, which may in turn lead to a change in the patients and conditions we treat. Any of these impacts could have an adverse effect on our financial position, results of operations, and liquidity. Although Congress has considered legislation to reform and improve the Medicare audit and appeals process, we cannot predict what, if any, legislation will be adopted or what, if any, effect that legislation might have on the audit and appeals process.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2014, the American Hospital Association and others filed a lawsuit seeking to compel HHS to meet the statutory deadlines for adjudication of denied Medicare claims. In December 2016, the presiding federal district court judge in the lawsuit ordered HHS to eliminate the backlog of appeals by the end of 2020. HHS appealed the federal district court decision, and an appeals court remanded the order for further consideration of how HHS can eliminate the backlog. On November 1, 2018, the district court again ordered HHS to achieve the following reductions: 19% by the end of fiscal year 2019; 49% by the end of fiscal year 2020; 75% by the end of fiscal year 2021; and 100% by the end of fiscal year 2022. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;). Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. We are exploring various remedies to counter those deficiencies. We believe it is too early to determine what impact, if any, these recent changes in the appeals process will have on our long-term success rate or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We cannot predict what, if any, further action CMS will take to reduce the backlog or how long it will take to resolve our pending appeals of payment denials that are part of the backlog.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in our payor mix or the acuity of our patients could adversely affect our Net operating revenues or our profitability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many factors affect pricing of our services and, in turn, our revenues. For example, in the inpatient rehabilitation segment, these factors include the treating facility&#8217;s urban or rural status, the length of stay, the payor and its applicable rate of reimbursement, and the patient&#8217;s medical condition and impairment status (acuity). The reimbursement rates we receive from traditional Medicare fee-for-service are generally higher than those received from other payors, although the difference between traditional Medicare and Medicare Advantage payments for inpatient rehabilitation care has decreased in the last several years. Over the same period, we have seen a shift in the payor mix for both segments from traditional Medicare to Medicare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advantage and other managed care providers. In our home health and hospice segment, we are attempting to grow the number of Medicare Advantage networks in which we participate, so we would expect the payor mix to continue to shift with that growth. Not only do Medicare Advantage and managed care payors generally pay us less, but we would expect bad debt to be slightly higher for patients covered by Medicare Advantage and managed care as patients typically retain more payment responsibility under those arrangements. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our inpatient rehabilitation segment, we have also experienced a shift in recent years to a slightly larger percentage of Medicaid patients. Medicaid reimbursement rates are almost always the lowest among those of our payors, and frequently Medicaid patients come to us with other complicating conditions that make treatment more difficult and costly. We cannot predict the growth of, or changes to, Medicaid, but President Biden has stated that he favors extending public health insurance coverage to low income individuals currently ineligible for Medicaid.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also experience a shift to a lower average patient acuity. During the pandemic, the average acuity of our patients has frequently been higher than pre-pandemic averages, which has, in turn, had a positive impact on the reimbursement rates we have received. We would expect patient acuity to return to pre-pandemic levels once the public health effects of the pandemic subside. Both a shift in our payor mix away from Medicare fee-for-service and a shift to a lower patient acuity would likely adversely affect pricing growth. See the &#8220;Segment Results of Operations&#8212;Inpatient Rehabilitation&#8212;Net Operating Revenues&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the extent to which our payor mix may shift to lower reimbursement rate payors. We have in recent years experienced, and in the future may, experience shifts in our payor mix or the acuity of our patients that could adversely affect our pricing, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and profitability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in collection or non-collection of our accounts receivable could adversely affect our business, financial position, results of operations and liquidity.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement is typically conditioned on our documenting medical necessity and correctly applying diagnosis codes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorrect or incomplete documentation and billing information could result in non-payment for services rendered. Billing and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collection of our accounts receivable with Medicare and Medicaid are further subject to the complex regulations that govern</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare and Medicaid reimbursement and rules imposed by nongovernment payors. Our inability to bill and collect on a timely basis pursuant to these regulations and rules could subject us to payment delays that could have a material adverse effect on our business, financial position, results of operations and liquidity.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, timing delays in billings and collections may cause working capital shortages. Working capital</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management, including prompt and diligent billing and collection, is an important factor in our financial position and results of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations and in maintaining liquidity. It is possible that Medicare, Medicaid, documentation support, system problems or</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other provider issues or industry trends, particularly with respect to newly acquired entities for which we have limited</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operational experience, may extend our collection period, which may materially adversely affect our working capital, and our</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">working capital management procedures may not successfully mitigate this risk.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of payments made under the Medicare and Medicaid programs is subject to governmental budgetary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constraints, which may result in an increased period of time between submission of claims and subsequent payment under</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific programs, most notably under the Medicare and Medicaid managed care programs, which in many cases pay claims</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly slower than traditional Medicare or state Medicaid programs do as a result of more complicated authorization,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">billing and collecting processes that are required by Medicare and Medicaid managed care programs. In addition, we may</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience delays in reimbursement as a result of the failure to receive prompt approvals related to change of ownership</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications for acquired or other facilities or from delays caused by our or other third parties&#8217; information system failures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the proliferation of Medicare and Medicaid managed care programs could have a material adverse impact on the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results of our operations as a result of more complicated authorization, billing and collection requirements implemented by such</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in our estimates of collectability or a delay in collection of accounts receivable could adversely affect our</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results of operations and liquidity. The estimates are based on a variety of factors, including the length of time receivables are</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">past due, significant one-time events, contractual rights, client funding, political pressures, discussions with clients, and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">historical experience. A delay in collecting our accounts receivable, or the non-collection of accounts receivable, including,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without limitation, in connection with our transition and integration of acquired companies, and the attendant movement of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">underlying billing and collection operations from legacy systems to future systems, could have a material negative impact on</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our results of operations and liquidity and could be required to record impairment charges on our financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues and profitability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health insurers and managed care companies, including Medicare Advantage plans, may utilize certain third parties, known as conveners, to attempt to control costs. Conveners offer patient placement and care transition services to those payors as well as bundled payment participants, ACOs, and other healthcare providers with the intent of managing post-acute utilization and associated costs. Conveners may influence referral source decisions on which post-acute setting to recommend, as well as how long to remain in a particular setting. Given their focus on perceived financial savings, conveners customarily suggest that patients avoid higher acuity post-acute settings altogether or move as soon as practicable to lower acuity settings as those settings are reimbursed at lower rates due to the amount of care they are required to provide. Conveners are not healthcare providers and may suggest a post-acute setting or duration of care that may not be appropriate from a clinical perspective potentially resulting in a costly acute care hospital readmission.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also depend on referrals from physicians, acute care hospitals, and other healthcare providers in the communities we serve. As a result of various alternative payment models, many referral sources are becoming increasingly focused on reducing post-acute costs by eliminating post-acute care referrals or referring patients to post-acute settings other than perceived high-cost rehabilitation hospitals, sometimes without understanding the potential impact on patient outcomes over an entire episode of care. Our ability to attract patients could be adversely affected if any of our hospitals or agencies fail to provide or maintain a reputation for providing high-quality care on a cost-effective basis as compared to other providers.</span></div><div style="margin-bottom:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Regulatory Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, in the United States may significantly affect our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry in general is facing regulatory uncertainty around attempts to improve outcomes and reduce costs, including coordinated care and integrated delivery payment models. In an integrated delivery payment model, hospitals, physicians, and other care providers are reimbursed in a fashion meant to encourage coordinated healthcare on a more efficient, patient-centered basis. These providers are then paid based on the overall value and quality (as determined by outcomes) of the services they provide to a patient rather than the number of services they provide. While this is consistent with our goal and proven track record of being a high-quality, cost-effective provider, broad-based implementation of a new delivery payment model would represent a significant evolution or transformation of the healthcare industry, which may have a significant impact on our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, HHS has been studying the feasibility of bundling, including conducting a voluntary, multi-year bundling pilot program to test and evaluate alternative payment methodologies. CMS&#8217; voluntary Bundled Payments for Care Improvement Advanced (&#8220;BPCI Advanced&#8221;) initiative began October 1, 2018, runs through December 31, 2023, and covers 29 types of inpatient and three types of outpatient clinical episodes, including stroke and hip fracture. Providers participating in BPCI Advanced are subject to a semi-annual reconciliation process where CMS compares the aggregate Medicare expenditures for all items and services included in a clinical episode against the target price for that type of episode to determine whether the participant is eligible to receive a portion of the savings, or is required to repay a portion of the payment above target. Accordingly, reimbursement may be increased or decreased, compared to what would otherwise be due, based on whether the total Medicare expenditures and patient outcomes meet, exceed or fall short of the targets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, CMS has established per the ACA several separate ACO programs, the largest of which is the Medicare Shared Savings Program (&#8220;MSSP&#8221;), a voluntary ACO program in which hospitals, physicians, and other care providers pursue the delivery of coordinated healthcare on a more efficient, patient-centered basis. Conceptually, ACOs receive a portion of any savings generated above a certain threshold from care coordination as long as benchmarks for the quality of care are maintained. Under the MSSP, there are two ACO tracks from which participants can choose. Each track offers a different degree to which participants share any savings realized or any obligation to repay losses suffered. The ACO rules adopted by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS are extremely complex and remain subject to further refinement by CMS. Based on the CMS data below, the MSSP has not experienced meaningful growth in recent years. </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.134%"><tr><td style="width:1.0%"></td><td style="width:16.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of ACOs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assigned Beneficiaries</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate, on a case-by-case basis, appropriate BPCI Advanced and ACO participation opportunities for our hospitals and home health agencies. More than 35 of our inpatient rehabilitation hospitals have signed participation or preferred provider agreements with these alternative payment models. Those hospitals have treated only a limited number of patients under these alternative payment models to date. As of December 31, 2021, our home health and hospice segment is collaborating with approximately 160 alternative payment models, including Next Generation ACOs, MSSP ACOs, and Direct Contracting Models.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, CMS announced another voluntary alternative payment model initiative, the Geographic Direct Contracting Model (the &#8220;GDCM&#8221;). Under the GDCM, Direct Contracting Entities (&#8220;DCEs&#8221;), which can include ACOs, health systems, health care provider groups, and health plans, will take responsibility for the total cost of care for all Medicare beneficiaries in a specific geographic region. DCEs may enter into agreements with preferred providers that provide for payment risk-sharing and offer Medicare beneficiaries benefits not otherwise available under traditional Medicare. The GDCM will be tested over a six-year period in four to ten regions. Many specifics of the GDCM remain unknown at this time, and it is not clear if, or how, the Biden administration will implement the GDCM. CMS suspended the initial implementation of GDCM and currently has the program under review.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2015, CMS published its final rule establishing the Comprehensive Care for Joint Replacement (&#8220;CJR&#8221;) payment model, which holds acute care hospitals accountable for the quality of care they deliver to Medicare fee-for-service beneficiaries for lower extremity joint replacements (i.e., knees and hips) from surgery through recovery. The CJR originally was mandatory for the acute care hospitals in the 67 geographic areas covered. On November 30, 2017, CMS issued a final rule making the CJR voluntary in 33 of those areas. The CJR model&#8217;s original five-year term ended in December 2020, but CMS has proposed to extend the model for three years for most providers in the 34 geographic areas with mandatory participation. Under CJR, healthcare providers in the mandatory participation areas are paid under existing Medicare payment systems. However, the acute-care hospital where a joint replacement takes place are held accountable for the quality and costs of care for the entire episode of care &#8212; from the time of the original admission through 90 days after discharge. Depending on the quality and cost performance during the entire episode, the acute-care hospital may receive an additional payment or be required to repay Medicare a portion of the episode costs. As a result, CMS believes acute care hospitals are incented to work with physicians and post-acute care providers to ensure beneficiaries receive the coordinated care they need in an efficient manner. Acute care hospitals participating in the CJR model may enter into risk-sharing financial arrangements with post-acute providers, including IRFs and home health agencies. CJR has not had a material impact on our hospitals.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HHS and CMS continue to explore ways to encourage and facilitate increased participation in alternative payment models and value-based purchasing initiatives. For example, the HHS-OIG and CMS finalized rules in 2020 modernizing the Anti-Kickback Statute and Stark law to, in part, promote a more coordinated, value-based system of care. The bundling and ACO initiatives have served as motivating factors for regulators and healthcare industry participants to identify and implement workable coordinated care and integrated delivery payment models. Broad-based implementation of a new delivery payment model would represent a significant transformation for us and the healthcare industry generally. The nature and timing of the evolution or transformation of the current healthcare system to coordinated care delivery and integrated delivery payment models and value-based purchasing remain uncertain. The development of new delivery and payment systems will almost certainly take significant time and expense. Many of the alternative approaches, including those discussed above and the home health value-based purchasing model discussed below, being explored may not work or could change substantially prior to any nationwide implementations. While only a small percentage of our business currently is or is anticipated to be subject to the alternative payment models discussed above, we cannot be certain these models will not be expanded or made standard or new models will not be implemented broadly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as the number and types of bundling, direct contracting, and ACO models increase, the number of Medicare beneficiaries who are treated in one of the models increases. Our willingness or inability to participate in integrated delivery payment and other alternative payment models and the referral patterns of other providers participating in those models may limit our access to Medicare patients who would benefit from treatment in inpatient rehabilitation hospitals or by home care services. In an attempt to reduce costs, ACOs may seek to discourage referrals to post-acute care all together. To the extent that acute care hospitals participating in those models do not perceive our quality of care or cost efficiency favorably compared to alternative post-acute providers, we may experience a decrease in volumes and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which could adversely affect our financial position, results of operations, and cash flows. For further discussion of coordinated care and integrated delivery payment models and value-based purchasing initiatives, the associated challenges, and our efforts to respond to them, see the &#8220;Executive Overview&#8212;Key Challenges&#8212;Changes to Our Operating Environment Resulting from Healthcare Reform&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other legislative and regulatory initiatives and changes affecting the industry could adversely affect our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the legislative and regulatory actions that directly affect our reimbursement rates or further the evolution of the current healthcare delivery system, other legislative and regulatory changes, including as a result of ongoing healthcare reform, affect healthcare providers like us from time to time. For example, the ACA provides for the expansion of the federal Anti-Kickback Law and the False Claims Act (the &#8220;FCA&#8221;) that, when combined with other recent federal initiatives, are likely to increase investigation and enforcement efforts in the healthcare industry generally. Changes include increased resources for enforcement, lowered burden of proof for the government in healthcare fraud matters, expanded definition of claims under the FCA, enhanced penalties, and increased rewards for relators in successful prosecutions. CMS may also suspend payment for claims prospectively if, in its opinion, credible allegations of fraud exist. The initial suspension period may be up to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the HHS-OIG or DOJ. Any such suspension would adversely affect our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states in which we operate have also undertaken, or are considering, healthcare reform initiatives that address similar issues. While many of the stated goals of other federal and state reform initiatives are consistent with our own goal to provide care that is high-quality and cost-effective, legislation and regulatory proposals may lower reimbursements, increase the cost of compliance, decrease patient volumes, promote frivolous or baseless litigation, and otherwise adversely affect our business. We cannot predict what healthcare initiatives, if any, will be enacted, implemented or amended, or the effect any future legislation or regulation will have on us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2019, CMS adopted a new rule as called for by the IMPACT Act that revises the discharge planning requirements applicable to our inpatient rehabilitation hospitals and home health agencies. Effective November 29, 2019, CMS requires every hospital (including IRFs) to have a discharge planning process that focuses on patients&#8217; goals and preferences and on preparing them and, as appropriate, their caregivers, to be active partners in their post-discharge care. For our hospitals, this rule requires instituting standardized procedures to identify those patients who are likely to suffer adverse health consequences upon discharge in the absence of adequate discharge planning and to provide a discharge planning evaluation for such patients to ensure that appropriate arrangements for post-hospital care are made before discharge. At the time of discharge, a hospital must transfer or refer the patient, along with all necessary medical information pertaining to the patient&#8217;s current course of illness and treatment, post-discharge goals of care, and treatment preferences, to the appropriate post-acute care service providers and suppliers, facilities, agencies, and other outpatient service providers and practitioners responsible for the patient&#8217;s follow-up or ancillary care. Patients must also be informed of all post-acute providers in the area and, for patients enrolled in managed care organizations, in network providers must be identified if the hospital has that information. Additional information must be provided to patients who are discharged home and referred for home health agency services or who are referred to other post-acute care services. For home health agencies, the final rule includes several new requirements, including that home health agencies develop and implement an effective discharge planning process.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home health agencies must also send certain medical and other information to the post-discharge facility or health care practitioner, and comply with requests for additional information as may be necessary for treatment of the patient made by the receiving facility or health care practitioner. In areas where we are not part of a managed care network with significant enrollment, this discharge planning rule may negatively affect the number of patients choosing us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with requirements adopted pursuant to the IMPACT Act, CMS implemented requirements to publish certain Medicare spending per beneficiary measures for each inpatient rehabilitation hospital in October 2016 and each home health agency in January 2017. The intent of tracking and publishing this data is to evaluate a given provider&#8217;s payment efficiency relative to the efficiency of the national median provider in that provider&#8217;s post-acute segment. CMS believes this measure will encourage improved efficiency and coordination of care in the post-acute setting by holding providers accountable for Medicare resource use during an episode of care. However, the measures may be misleading as they do not incorporate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient outcomes associated with those resources used. CMS has not proposed to compare payment efficiency across provider segments.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, CMS commenced the Home Health Review Choice Demonstration (&#8220;RCD&#8221;) in Illinois. RCD is intended to test whether pre-claim review improves methods for the identification, investigation, and prosecution of Medicare fraud and whether the pre-claim review helps reduce expenditures while maintaining or improving quality of care. Under RCD, providers may choose pre-claim review or post-payment review of all Medicare claims submitted or elect not to participate, in which case they will incur a 25% payment reduction on all claims. If a home health agency elects to participate in the review and 90% or more of its claims are found to be valid during the six month pre-claim review period, that agency may then opt out of the RCD review, except for spot reviews of samples consisting of 5% of total claims. CMS implemented RCD in Ohio in September 2019. RCD was scheduled to expand to Texas in March 2020 and to North Carolina and Florida in May 2020. In late March 2020, however, CMS announced it was pausing the RCD for home health services in Illinois, Ohio, and Texas and that it would not start RCD in North Carolina and Florida until after the COVID-19 public health emergency ended. On August 21, 2020, CMS announced a new &#8220;phased-in approach&#8221; to the RCD due to the public health emergency and subsequently announced the delay of the phased-in participation of the RCD in Florida and North Carolina until March 31, 2021. As a result, North Carolina and Florida agencies may submit pre-claim review requests for billing periods beginning August 31, 2020. Cycle 1 of the RCD in Texas ended on September 30, 2020, and we achieved an affirmation rate greater than 90%. Effective September 1, 2021, CMS ended its phased-in approach to participation in the RCD in Florida and North Carolina and fully implemented the RCD in those states. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate agencies (representing approximately 42% of our home health Medicare claims) in the five RCD states. We expect this demonstration project will require us to incur additional administrative and staffing costs and may impact the timeliness of claims payment given that Medicare administrative contractors in Illinois in a prior version of the project had difficulty processing pre-claim reviews on a timely basis. Accordingly, we may experience temporary decreases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in cash flow, or we may incur costs associated with patient care for which the Medicare claim is subsequently denied, which could have an adverse effect on our financial position, results of operations, and liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, CMS announced the proposal of a five-year review choice demonstration for inpatient rehabilitation services. CMS plans to implement the demonstration in Alabama, and then expand to Pennsylvania, Texas, and California. The proposed timing of this demonstration is not known. We operate 46 inpatient rehabilitation hospitals (representing approximately 33% of our IRF Medicare claims) in those four states. After the initial four states, CMS intends to expand the demonstration to include additional IRFs based on the Medicare Administrative Contractor to which those IRFs submit claims. Under the demonstration, participating IRFs would have an initial choice between pre-claim or post-payment review of 100% of claims submitted to demonstrate compliance with applicable Medicare coverage and clinical documentation requirements. Under the pre-claim review choice, services could begin prior to the submission of the review request and continue while the decision is being made. The pre-claim review request with required documentation must be submitted and reviewed before the final claim is submitted for payment. Under the post-payment review choice, IRFs would provide services, submit all claims for payment following their normal processes, and then submit required documentation for medical review. If 90% or more of its claims are found to be valid, the IRF may then opt out of the RCD review, except for spot reviews of samples consisting of 5% of total claims. The IRF RCD would not create new documentation requirements. A number of key details on this proposal have yet to be released, and it is not clear how or when the Biden administration will implement this demonstration. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, MedPAC makes healthcare policy recommendations to Congress and provides comments to CMS on Medicare payment related issues. Congress is not obligated to adopt MedPAC&#8217;s recommendations, and, based on outcomes in previous years, there can be no assurance Congress will adopt any given MedPAC recommendation. For example, in March and June 2020, MedPAC issued reports to Congress again recommending several possible changes, which MedPAC has advocated previously, to various post-acute payment systems. One possible change discussed was an increase to outlier payments to be funded by reductions to non-outlier payments rates under the IRF-PPS. This change would adversely impact us compared to other IRF providers because our hospitals have also historically averaged significantly less Medicare reimbursement for high cost outlier patients than other providers have averaged.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what legislative or regulatory reforms or changes, if any, will ultimately be enacted, or the timing or effect any of those changes or reforms will have on us. If enacted, they may be challenging for all providers and have the effect of limiting Medicare beneficiaries&#8217; access to healthcare services and could have a material adverse impact on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, financial position, results of operations, and cash flows. For additional discussion of healthcare reform and other factors affecting reimbursement for our services, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulatory and Reimbursement Challenges&#8221; and &#8220;Sources of Revenues&#8212;Medicare Reimbursement.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with the extensive laws and government regulations applicable to healthcare providers requires substantial time, effort and expense, and if we fail to comply with them, we could suffer penalties or be required to make significant changes to our operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensure, certification, enrollments, and accreditation;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coding and billing for services;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements of the 60% compliance threshold under the 2007 Medicare Act;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality of medical care;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use and maintenance of medical supplies and equipment;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance and security of patient information and medical records;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">minimum staffing;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition and dispensing of pharmaceuticals and controlled substances; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disposal of medical and hazardous waste.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, and contractual arrangements, as well as the way in which we deliver home health and hospice services. Those changes could also affect reimbursements as well as future compliance, training, and staffing costs. For example, the 2021 Budget Act creates a new Medicare survey program for hospice agencies which will require a survey at least once every three years. Hospices that are found to be out of compliance could be subjected to new civil monetary penalties that accrue according to days out of compliance, as well as other forms of corrective action.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Examples of regulatory changes that can affect our business, beyond direct changes to Medicare reimbursement rates, can be found from time to time in CMS&#8217;s annual rulemaking. For example, the final rule for the fiscal year 2010 IRF-PPS implemented new coverage requirements which provided in part that a patient medical record must document a reasonable expectation that, at the time of admission to an IRF, the patient generally required and was able to participate in the intensive rehabilitation therapy services uniquely provided at IRFs. CMS has also taken the position that a patient&#8217;s medical file must appropriately document the rationale for the use of group therapies, as opposed to one-on-one therapy. Beginning on October 1, 2015, CMS instituted a new data collection requirement pursuant to which IRFs must capture the minutes and mode (individual, group, concurrent, or co-treatment) of therapy by specialty. Additionally, from time to time CMS has adopted changes in the medical conditions that will presumptively count toward the 60% compliance threshold to qualify for reimbursement as an inpatient rehabilitation hospital.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of note, the HHS-OIG periodically updates a work plan that identifies areas of compliance focus. In recent years, the HHS-OIG work plans for IRFs have focused on, among other items, the appropriate utilization of concurrent and group therapy and adverse and temporary harm events occurring in IRFs. In January 2020, the HHS-OIG announced an audit to review incentives under the IRF-PPS to </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discharge patients prematurely to home health agencies and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> appropriate documentation to support claims by home health and hospice agencies. Following this audit, the HHS-OIG announced in December 2021 its recommendation to establish an IRF transfer payment policy for early discharges to home health care in which the IRF would only receive a per diem rate in lieu of the full case-mix payment. The HHS-OIG estimated the policy could have reduced total Medicare payments to IRFs in 2017 and 2018 by between 6% and 7%. In July 2020, the HHS-OIG issued an audit report concluding that a signficant number of home health claims for episodes of care slightly above the Low Utilization payment Adjustment threshold (four visits per payment episode) because MACs failed to adequately audit home health claims with between five and seven visits per payment episode. The HHS-OIG directed MACs to target this category of claims for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional review. In September 2020, the HHS-OIG announced an active work plan to focus on infection control at home health agencies during the COVID-19 pandemic, also expected to be issued in 2021. In January 2021, the HHS-OIG announced an audit to </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluate home health services provided by agencies during the COVID-19 public health emergency to determine which types of skilled services were furnished via telehealth, and whether those services were administered and billed in accordance with Medicare requirements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another active work plan provides that the HHS-OIG will determine if hospice patients are receiving the required visits by registered nurses. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the HHS-OIG released a report purporting to identify a high error rate (approximately 80% of&#160;claims) among inpatient rehabilitation hospital admissions in a small sample of 220 claims. Based on its findings, the HHS-OIG extrapolated the error rate to the universe of inpatient rehabilitation claims and, among other things, recommended reevaluation of the IRF-PPS. However, that HHS-OIG report involved an extremely small sample size, was not a random sample of cases, included some citations to coverage requirements that did not match actual regulations, appeared to conflate technical documentation requirements with medical necessity determinations, and was at odds with actual MAC reviews of claims during that same timeframe which found substantially lower error rates. The HHS-OIG work plan, audit or similar future efforts could result in proposed changes to the payment systems for providers or increased denials of Medicare claims for patients notwithstanding the referring physicians&#8217; judgment that treatment is appropriate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the recent HHS-OIG work plans demonstrate, the clarity and completeness of each patient medical file, some of which is the work product of a physician not employed by us, are essential to demonstrating our compliance with various regulatory and reimbursement requirements. For example, to support the determination that a patient&#8217;s IRF treatment was reasonable and necessary, the file must contain, among other things, an admitting physician&#8217;s assessment of the patient as well as a post-admission assessment by the treating physician and other information from clinicians relating to the plan of care and the therapies being provided. These physicians are not employees. They exercise independent medical judgment. We and our hospital medical directors, who are independent contractors, provide training on a regular basis to the physicians who treat patients at our hospitals regarding appropriate documentation. However, we ultimately do not and cannot control the physicians&#8217; medical judgment. In connection with subsequent payment audits and investigations, there can be no assurance as to what opinion a third party may take regarding the status of patient files or the physicians&#8217; medical judgment evidenced in those files.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to four of our hospitals. On April 24, 2014, we received document subpoenas relating to an additional seven of our hospitals. Those subpoenas requested documents, including copies of patient medical records, related to reimbursement claims submitted during periods ranging from January 2008 through December 2013. The associated investigation led by DOJ was based on whistleblower claims of alleged improper or fraudulent claims submitted to Medicare and Medicaid and requested documents and materials relating to practices, procedures, protocols and policies of certain pre- and post-admissions activities at these hospitals including marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare 60% rule. Under the Medicare rule commonly referred to as the &#8220;60% Rule,&#8221; 60% or more of the patients of an IRF must have at least one of a specified list of medical conditions in order to be reimbursed at the IRF-PPS payment rates, rather than at the lower acute care hospital payment rates. We settled the DOJ investigation, together with the related </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or whistleblower lawsuits, in 2019 for a total payment of $48 million. In return for the settlement payment, the plaintiffs dismissed with prejudice their pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> claims, and DOJ provided Encompass Health and all its subsidiaries with a release from civil liability. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have invested, and will continue to invest, substantial time, effort, and expense in implementing and maintaining training programs as well as internal controls and procedures designed to ensure regulatory compliance, we have in the past been, and could in the future be, required to return portions of reimbursements for discharges alleged after the fact to have not been appropriate under the applicable reimbursement rules and change our patient admissions practices going forward. We could also be subjected to other liabilities, including (1)&#160;criminal penalties, (2)&#160;civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals, and (3)&#160;exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs, which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement or debt instruments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. As discussed above in connection with the ACA, the federal government has in the last couple of years made compliance enforcement and fighting healthcare fraud top priorities. In the past few years, DOJ and HHS as well as federal lawmakers have significantly increased efforts to ensure strict compliance with various reimbursement related regulations as well as combat healthcare fraud. DOJ has pursued and recovered record amounts based on alleged healthcare fraud. The increased enforcement efforts have frequently included aggressive arguments and interpretations of laws and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations that pose risks for all providers. For example, the federal government has increasingly asserted that incidents of erroneous billing or record keeping may represent violations of the FCA. Human error and oversight in record keeping and documentation, particularly where those activities are the responsibility of non-employees, are always a risk in business, and healthcare providers and independent physicians are no different. Additionally, the federal government has been willing to challenge the medical judgment of independent physicians in determining issues such as the medical necessity of a given treatment plan.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements of alleged violations or imposed reductions in reimbursements, substantial damages and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation and could cost us significant time and expense to defend.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The use of sub-regulatory guidance, statistical sampling, and extrapolation by CMS, Medicare contractors, HHS-OIG, and DOJ to deny claims, expand enforcement claims, and advocate for changes in reimbursement policy increases the risk that we could experience reduced revenue, suffer penalties, or be required to make significant changes to our operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. Our ability to operate in a compliant manner impacts the claims denials, compliance enforcement, and regulatory processes discussed in other risks above. The federal government&#8217;s reliance on sub-regulatory guidance, such as handbooks, FAQs, internal memoranda, and press releases, presents a unique challenge to compliance efforts. Such sub-regulatory guidance purports to explain validly promulgated regulations but often expands or supplements existing regulations without constitutionally and statutorily required notice and comment and other procedural protections. Without procedural protections, sub-regulatory guidance poses a risk above and beyond reasonable efforts to follow validly promulgated regulations, particularly when the agency or MAC seeking to enforce such sub-regulatory guidance is not the agency or MAC issuing the guidance and therefore not as familiar with the substance and nature of the underlying regulations or even clinical issues involved.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 6, 2020, CMS issued a proposed rule invoking a rarely used retroactive-rulemaking authority to support CMS&#8217;s application of a Medicare payment methodology that the U.S. Supreme Court found to be procedurally improper in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Azar v. Allina Health Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in 2019. CMS&#8217; invocation of its retroactive-rulemaking authority in response to this Supreme Court decision is an unfavorable precedent for providers because it demonstrates a willingness by CMS to revive adverse reimbursement actions after those actions are deemed deficient on administrative procedural grounds.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the federal government is increasingly turning to statistical sampling and extrapolation to expand claims denials and enforcement efforts and advocate for changes in reimbursement policy. Through sampling and extrapolation, the government takes a review of a small number of reimbursement claims and generalizes the results of that review to a much broader universe of claims, which can result in significant increases in the aggregate number and value of claims at issue. Increasing use of extrapolation can be found in payment review audits, such as those conducted by RACs and UPICs. In addition to payment reviews, government agencies may allege compliance violations, including submission of false claims, based on sampling and extrapolation and seek to change reimbursement policy. For example, the HHS-OIG issued a report in September 2018 purporting to identify a high error rate (approximately 80% of&#160;claims) among inpatient rehabilitation hospital admissions in a small sample of 220 claims. Based on its findings, the HHS-OIG extrapolated the error rate to the universe of inpatient rehabilitation claims and, among other things, recommended reevaluation of the IRF-PPS. However, the HHS-OIG report involves an extremely small sample size, is not a random sample of cases, includes incorrect references to coverage requirement regulations, appears to conflate technical documentation requirements with medical necessity determinations, and is at odds with actual MAC reviews of claims during that same timeframe which found substantially lower error rates. Notwithstanding the technical statistical flaws that can arise in sampling small groups of claims and the extremely problematic nature of extrapolation in the context of individualized decisions of medical judgment as some courts have noted, sampling and extrapolation pose a growing risk to healthcare providers in the form of more significant claims of overpayments and increased legal costs to defend against these problematic regulatory practices. In a recent federal court case, the fifth circuit court of appeals ruled in favor of CMS and affirmed the application of extrapolation errors identified in a sample of claims to support larger claims for overpayment. Any associated loss of revenue or increased legal costs could materially and adversely affect our financial position, results of operations, and cash flows.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hospital Pricing Transparency Rule could adversely affect our business and results of operations.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on January 1, 2021, the hospital price transparency rule requires hospitals to publish on the internet in a consumer-friendly format their standard charges based on negotiated rates for all items and services and up to 300 common shoppable services. Shoppable services are those routinely provided in non-urgent situations and include those ancillary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services that customarily accompany the primary service being provided. The charges for an individual item or service to be published include: </span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gross charge (charge as reflected on a hospital&#8217;s chargemaster, absent any discounts),</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payer-specific negotiated charge (charge negotiated with a third party payer for an item or service),</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">de-identified minimum negotiated charge (lowest charge negotiated with all third-party payers),</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">de-identified maximum negotiated charge (highest charge negotiated with all third-party payers), and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounted cash price (charge that applies to an individual who pays cash).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This rule imposes significant initial and ongoing burdens on hospitals to track and publish various billing information. In the event a hospital fails to comply with the new requirements and does not complete the prescribed corrective action, CMS may impose a civil monetary penalty of up to $300 per day. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Many states have also passed or are debating legislation establishing price transparency websites or mandating that health plans or hospitals make price information available to consumers. The associated reporting obligations vary from state to state. We cannot predict what the adverse effects, if any, of this new CMS rule or any state law or regulation, such as the effect on relations with managed care payors and referral sources, may be for us.&#160;The maximum penalty for violations is as much as $2 million per hospital, so our failure to maintain compliance with this rule could adversely affect our financial position, results of operations, and cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Efforts to comply with regulatory mandates to increase the use of electronic health data and health system interoperability&#160;may lead to enforcement and negative publicity which could adversely affect our business.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For many years, a primary focus of the healthcare industry has been to increase the use of electronic health records, or &#8220;EHR,&#8221; and the sharing of the health data among providers, payors and other members of the industry. The federal government has been a significant driver of that initiative through rules and regulations. In 2009, as part of the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act, the federal government set aside $27 billion of incentives for hospitals and providers to adopt EHR systems. In 2020, CMS and HHS&#8217;s Office of the National Coordinator for Health IT (&#8220;ONC&#8221;) finalized policy changes implementing interoperability, information blocking, and patient access provisions of the 21st Century Cures Act and supporting the MyHealthEData initiative, designed to allow patients to access their health claims information electronically through the application of their choosing. The companion rules will transform the way in which healthcare providers, health information technology developers, health information exchanges/health information networks (&#8220;HIEs/HINs&#8221;), and health plans share patient information. For example, the ONC rule prohibits healthcare providers, health IT developers, and HIEs/HINs from engaging in practices that are likely to interfere with, prevent, materially discourage, or otherwise inhibit the access, exchange or use of electronic health information, also known as &#8220;information blocking.&#8221; The ONC rule also requires regulated actors to respond to requests for electronic health information in the content and manner requested, with some exceptions. Enforcement of ONC&#8217;s and CMS&#8217; new health information access, exchange, and use standards promulgated in the 2020 rules began in 2021, and noncompliance can result in civil monetary penalties, exclusion from participation in federal health care programs and other appropriate &#8220;disincentives&#8221; that have not yet been identified by the agencies. The HHS-OCR patient right of access initiative, which began in late 2019 and has similar objectives to the new ONC initiative, such as promoting and enforcing patient access to health information, has led to 25 settlements of enforcement actions to date. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The goals of increased use of electronic health data and interoperability are improved quality of care and lower healthcare costs generally. However, increased use of electronic health data and interoperability inherently magnifies the risk of security breaches involving that data and information systems used to share it, which risk is discussed above. Additionally, interoperability and the sharing of health information have received increasingly negative publicity. There is at least one well publicized instance where organizations received significant negative publicity for sharing health data despite having appeared to comply in all respects with privacy law. There can be no assurance that our efforts to improve the care we deliver and to comply with the law through increasing use of electronic data and system interoperability will not receive negative publicity that may materially and adversely affect our ability to get patient referrals or enter into joint ventures with other providers or may lead to greater regulatory scrutiny. Negative publicity may also lead to federal or state regulation that conflicts with current federal policy and interferes with the healthcare industry&#8217;s efforts to improve care and reduce costs through use of electronic data and interoperability.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our hospitals or home health or hospice agencies fail to comply with the Medicare enrollment requirements or conditions of participation, that hospital or agency could be terminated from the Medicare program.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our hospitals and home health and hospice agencies must comply with extensive enrollment requirements and conditions of participation for the Medicare program. The Medicare conditions of participation include the newly instituted CMS Vax Mandate discussed above in &#8220;&#8212;Novel Coronavirus Disease 2019 (&#8220;COVID-19&#8221;) Pandemic Risks.&#8221; If any of our hospitals or agencies fail to meet any of the Medicare enrollment requirements or conditions of participation, we may receive a notice of deficiency from the applicable survey agency or contractor, as applicable. If that hospital or agency then fails to institute an acceptable plan of correction and correct the deficiency within the applicable correction period, it could lose the ability to bill Medicare. A hospital or agency could be terminated from the Medicare program if it fails to address the deficiency within the applicable correction period. If CMS terminates one hospital or agency, it may increase its scrutiny of others under common control.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 5, 2019, CMS released a final rule that will implement over a period time additional provider enrollment provisions and create several new revocation and denial authorities in an attempt to bolster CMS&#8217; efforts to prevent waste, fraud and abuse. A few provisions of this new rule could significantly increase the complexity of filing enrollment applications for all of our provider entities, including increased burden related to tracking and identifying required reporting data from our joint venture partners. This rule requires Medicare and Medicaid providers and suppliers to disclose any current or previous (in the last five years), direct or indirect affiliation with a provider or supplier that has ever had a disclosable event. A disclosable event is any uncollected debt to Medicare or Medicaid, payment suspension under a federal health care program, denial, revocation or termination of enrollment (even if it is under appeal), or exclusion by the HHS-OIG from participation in a federal health care program. The rule also broadens the definition of an affiliation, including many indirect ownership or control situations such as ownership interests in a publicly traded company. If CMS determines an affiliation with a disclosable event poses an undue risk of fraud, waste or abuse, then the provider reporting that affiliation may be subject to exclusion from Medicare. Currently, information regarding uncollected debt, payment suspensions and enrollment actions are not generally available, so obtaining such information on affiliates could prove difficult or impossible in some situations. CMS intends to issue further guidance on the level of effort it expects providers to undertake to uncover information on their affiliates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this new rule, CMS may revoke a provider&#8217;s Medicare enrollment, including all of the provider&#8217;s locations, if the provider bills for services performed at or items furnished from one location that it knew or should have known did not comply with Medicare enrollment requirements, including making the disclosures discussed above. CMS has the ability to prevent applicants from enrolling in the program for up to three years if a provider is found to have submitted false or misleading information in its initial enrollment application. Additionally, CMS can now block providers and suppliers who are revoked from re-entering the Medicare program for up to 10 years. CMS may also revoke a provider&#8217;s enrollment if it fails to report on a timely basis any change in ownership or control, revocation or suspension of a federal or state license or certification, or any other change in its enrollment data.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any termination of one or more of our hospitals or agencies from the Medicare program for failure to satisfy the enrollment requirements or conditions of participation could materially adversely affect our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found to have violated applicable privacy and security laws and regulations or our contractual obligations, we could be subject to sanctions, fines, damages and other additional civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial position, results of operation and liquidity.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of federal and state laws, rules and regulations, as well as contractual obligations, relating to the protection, collection, storage, use, retention, security, disclosure, transfer and other processing of confidential, sensitive and personal information, including certain patient health information, such as patient records. There are also foreign laws, rules and regulations that address these matters and have extraterritorial application. We do not believe we are currently subject to these non-United States regulatory regimes but that could change in the future. Existing laws and regulations are constantly evolving, and new laws and regulations that apply to our business are being enacted at every level of government in the United States. In many cases, these laws and regulations apply not only to third-party transactions, but also to transfers of information between or among us, our affiliates and other parties with whom we conduct business. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business. We monitor legal developments in data privacy and security regulations at the local, state and federal level, however, the regulatory framework for data privacy and security worldwide is continuously evolving and developing and, as a result, interpretation and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of protected health information (&#8220;PHI&#8221;) is subject to several regulations at the federal level, including the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and the HITECH Act. The HIPAA privacy and security regulations protect medical records and other personal health information by limiting their use and disclosure, giving individuals the right to access, amend, and seek accounting of their own health information, and limiting most uses and disclosures of health information to the minimum amount reasonably necessary to accomplish the intended purpose. The HITECH Act strengthened HIPAA enforcement provisions and authorized state attorneys general to bring civil actions for HIPAA violations. It also permits HHS to conduct audits of HIPAA compliance and impose significant civil monetary penalties even if we did not know and could not reasonably have known about a violation. If we are found to have violated the HIPAA privacy or security regulations or other federal or state laws protecting the confidentiality of patient health or personal information, including but not limited to the HITECH Act, we could be subject to litigation, sanctions, fines, damages and other additional civil or criminal penalties, which could increase our liabilities, harm our reputation, and have a material adverse effect on our business, financial position, results of operations and liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PHI. For example, various states, including Virginia, California, Massachusetts, Florida, and Colorado, have implemented privacy laws and regulations that impose restrictive requirements regulating the use and disclosure of personally identifiable information, including PHI, and many other states have proposed similar laws and regulations. These laws in many cases are more restrictive than, and may not be preempted by, the HIPAA rules, apply to employees as well as patients, and may be subject to varying interpretations by courts and government agencies, creating complex compliance issues and potentially exposing us to additional expense, adverse publicity and liability. We also expect that there will continue to be new laws, regulations and industry standards concerning privacy, data protection and information security proposed and enacted in various jurisdictions. The U.S. Congress has considered, but not yet passed, several comprehensive federal data privacy bills over the past few years, such as the CONSENT Act, which was intended to be similar to the landmark 2018 European Union General Data Protection Regulation. We expect federal data privacy laws to continue to evolve.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state and local level, there is increased focus on regulating the collection, storage, use, retention, security, disclosure, transfer and other processing of confidential, sensitive and personal information. In recent years, we have seen significant changes to data privacy regulations across the United States. New legislation proposed or enacted will continue to shape the data privacy environment. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which significantly complicates compliance efforts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all 50 U.S. states and the District of Columbia have enacted breach notification laws that may require us to notify patients, employees or regulators in the event of unauthorized access to or disclosure of personal or confidential information experienced by us or our service providers. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to changing regulatory requirements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may be contractually required to notify patients or other counterparties of a security breach. Although we have contractual protections with many of our service providers, any actual or perceived security breach could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach. Any contractual protections we may have from our service providers may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with these various laws, rules, regulations and standards could cause us to incur substantial costs that are likely to increase over time, require us to change our business practices in a manner adverse to our business, divert resources from other initiatives and projects, and restrict the way products and services involving data are offered, all of which may have a material adverse effect on our business. Given the rapid development of cybersecurity and data privacy laws, we expect to encounter inconsistent interpretation and enforcement of these laws and regulations, as well as frequent changes to these laws and regulations which may expose us to significant penalties or liability for noncompliance, the possibility of fines, lawsuits (including class action privacy litigation), regulatory investigations, criminal or civil sanctions, audits, adverse media coverage, public censure, other claims, significant costs for remediation and damage to our reputation, or otherwise have a material adverse effect on our business and operations. Any allegations of a failure to adequately address data privacy or security-related concerns, even if unfounded, or to comply with applicable laws, regulations, standards and other obligations relating to data </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">privacy and security, could result in additional cost and liability to us, damage our relationships with patients and have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make public statements about our use and disclosure of personal information through our privacy policies, information provided on our website and press statements. Although we endeavor to comply with our public statements and documentation about patient privacy, we may at times fail to do so or be accused of having failed to do so. The publication of our privacy policies and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. Moreover, from time to time, concerns may be expressed about whether our products and services compromise the privacy of patients and others. Any concerns about our data privacy and security practices, even if unfounded, could damage the reputation of our businesses, discourage potential patients from our products and services and have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal, state and local laws and regulations that govern our employment practices, including minimum wage, overtime, living wage and paid-time-off requirements. Failure to comply with these laws and regulations, or changes to these laws and regulations that increase our employment-related expenses, could adversely impact our operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with all applicable federal, state and locals laws and regulations relating to employment, including occupational safety and health requirements, minimum staffing, wage and hour, overtime and other compensation requirements, employee benefits and other leave and sick pay requirements, proper classification of workers as employee or independent contractors, and immigration and equal employment opportunity laws, among others. These laws and regulations can vary significantly among jurisdictions, can change, and can be highly technical and involve strict liability for noncompliance with a seemingly mundane technical detail. Costs and expenses related to these requirements are a significant operating expense and may increase as laws and regulations change. Any failure to comply with these requirements can result in significant penalties or litigation exposure and could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Operational and Financial Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The proper function, availability, and security of our information systems are critical to our business and failure to maintain proper function, availability, or security of our information systems or protect our data against unauthorized access could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and will remain dependent on the proper function, availability and security of our and third-party information systems, including our electronic clinical information system, referred to as ACE-IT, which plays a substantial role in the operations of the hospitals, and the information systems currently in use by our home health and hospice business. We undertake measures to protect the safety and security of our information systems and the data maintained within those systems, and we periodically test the adequacy of our security and disaster recovery measures. We have implemented administrative, technical and physical controls on our systems and devices in an attempt to prevent unauthorized access to that data, which includes patient information subject to the protections of HIPAA and the HITECH Act and other sensitive information. For additional discussion of these laws, see Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulation.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expend significant capital to protect against the threat of security breaches, including cyber attacks, email phishing schemes, malware and ransomware. Substantial additional expenditures may be required to respond to and remediate any problems caused by breaches, including the unauthorized access to or theft of patient data and protected health information stored in our information systems and the introduction of computer malware or ransomware to our systems. We also provide our employees annual training and regular reminders on important measures they can take to prevent breaches and other cyber threats, including phishing schemes. We routinely identify attempts to gain unauthorized access to our systems. However, given the rapidly evolving nature and proliferation of cyber threats, there can be no assurance our training and network security measures or other controls will detect, prevent or remediate security or data breaches in a timely manner or otherwise prevent unauthorized access to, damage to, or interruption of our systems and operations. For example, it has been widely reported that many well-organized international interests, in certain cases with the backing of sovereign governments, are targeting the theft of patient information and the disruption of healthcare services through the use of advanced persistent threats. Similarly, in recent years, several hospitals have reported being victims of ransomware attacks in which they lost access to their systems, including clinical systems, during the course of the attacks. In 2020, one large, national healthcare system reported a ransomware attack that forced its facilities to operate without access to information systems for some time. We are likely to face attempted attacks in the future. Accordingly, we may be vulnerable to losses associated with the improper functioning, breach or unavailability of our and our vendors&#8217; information systems, including systems used in acquired operations, and third-party systems we use. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, it was reported that a sophisticated, well-funded state-sponsored threat actor implanted a backdoor security vulnerability in a widely used network monitoring software sold by SolarWinds, which software was then distributed to thousands of customers, including numerous government agencies and companies in the private sector, via an automatic update platform used to push out new software updates. Three of our servers downloaded the compromised software. The vulnerability was designed to enable hackers to install and execute additional malware that could be used to exfiltrate and facilitate remote access to data possessed by these government agencies and companies. The full scope of the security threat and extent of exploitation of the vulnerability is not yet known. Promptly after we learned of the compromised SolarWinds software update, we identified, isolated and remediated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he malicious update then reviewed and ensured we were implementing the recommended security practices provided by industry and government experts. We also conducted a forensics investigation using all the indicators of compromise provided by leading security experts. Our forensic analysis to date has discovered no indicators of compromise. There have been other recent significant incidents of software vendor compromises. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Threat actors continue to attempt to exploit commonly used software and services to gain remote access to a large number of their customers&#8217; information systems. For example, in August 2021, Microsoft reported a vulnerability within their email exchange services which attackers can use to remotely bypass the access control list then elevate privileges. In December 2021, vulnerable logging software installed within thousands of applications and services gave threat actors the ability to execute code remotely and gain unrestricted control over the victims&#8217; systems. We conducted forensics investigations on our systems containing these software applications using all the indicators of compromise provided by leading security experts. Our forensic analysis to date has discovered no indicators of compromise. We continue to monitor each of these situations closely and work with our cyber security vendors, as well as industry and governmental cyber security partners combating this threat.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we are not aware of having experienced a material compromise from a cyber breach or attack. However, given the increasing cyber security threats in the healthcare industry, there can be no assurance we will not experience business interruptions; data loss, ransom, misappropriation or corruption; theft or misuse of proprietary data, patient or other personally identifiable information; or litigation, investigation, or regulatory action related to any of those, any of which could have a material adverse effect on our patient care, financial position, and results of operations and harm our business reputation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A compromise of our network security measures or other controls, or of those businesses or vendors with whom we interact, which results in confidential information being accessed, obtained, damaged or used by unauthorized persons, or unavailability of systems necessary to the operation of our business, could impact patient care, harm our reputation, and expose us to significant remedial costs as well as regulatory actions (fines and penalties) and claims from patients, financial institutions, regulatory and law enforcement agencies, and other persons, any of which could have a material adverse effect on our business, financial position, results of operations and cash flows. The nature of our business requires the sharing of protected health information and other sensitive information among employees and healthcare partners, many of whom carry and access portable devices outside of our physical locations, which in turn increases the risk of loss, theft or inadvertent disclosure of that information. Moreover, a security breach, or threat thereof, could require that we expend significant resources to repair or improve our information systems and infrastructure and could distract management and other key personnel from performing their primary operational duties. In the case of a material breach or cyber attack, the associated expenses and losses may exceed our current insurance coverage for such events. Some adverse consequences are not insurable, such as reputational harm and third-party business interruption. Failure to maintain proper function, security, or availability of our information systems or protect our data against unauthorized access, or the failure of one or more of our key partners, vendors, or other counterparties to do these things, could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACE-IT is subject to a licensing, implementation, technology hosting, and support agreement with Cerner Corporation. Similarly, we have an agreement to license, host, and support a comprehensive home care management and clinical information system, Homecare Homebase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we have a number of partners and non-software vendors with whom we share data in order to provide patient care and otherwise operate our business. In fact, federal laws and regulations require interoperability among healthcare entities in many circumstances. Our inability, or the inability of our partners or vendors, to continue to maintain and upgrade information systems, software, and hardware could disrupt or reduce the efficiency of our operations, including affecting patient care. A security breach or other system failure involving Cerner, Homecare Homebase or another third-party with whom we share data or system connectivity could compromise our patient data or proprietary information or disrupt our ability to operate. In addition, costs, unexpected problems, and interruptions associated with the implementation or transition to new systems or technology or with adequate support of those systems or technology across numerous hospitals and agencies could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition for patients from other healthcare providers.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in the highly competitive, fragmented inpatient rehabilitation and home health and hospice industries. Although we are the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, in any particular market we may encounter competition from local or national entities with longer operating histories or other competitive advantages. For example, acute care hospitals, including those owned and operated by large public companies, may choose to expand or begin offering post-acute rehabilitation services. Given that approximately 91% of our hospitals&#8217; referrals come from acute care hospitals, that increase in competition could materially and adversely affect our admission referrals in the related markets. There are also large acute care systems that may have more resources available to compete than we have. Other providers of post-acute care services may attempt to become competitors in the future. For example, some nursing homes, including at least one public company operator, have been marketing themselves as offering certain rehabilitation services, even though nursing homes are not required to offer the same level of care, and are not licensed, as hospitals.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the home health and hospice services industries, our primary competition comes from a large insurance company, other large public home health companies, locally owned private home health companies, or acute care hospitals with adjunct home health services and typically varies from market to market. The insurance company not only owns one of the largest providers of Medicare-certified skilled home health services but, by nature of being a payor, can designate which home health and hospice agencies are in or out of the participating provider networks and can set reimbursement rates for network participants. Other large health insurance companies have publicly announced their intentions to enter the home health business. Our largest competitors may have greater financial and other resources and may be more established in their respective communities. One public home health company has a strategy that emphasizes joint ventures with acute care hospitals, including a number of joint ventures with large systems, which frequently serve as the referral sources for home health patients in specific markets. Additionally, nursing homes compete for referrals in some instances when the patients may be suitable for home-based care.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competing companies may offer newer or different services from those we offer or have better relationships with referring physicians and may thereby attract patients who are presently, or would be candidates for, receiving our inpatient rehabilitation, home health, or hospice services. The other public companies and the insurance companies have or may obtain significantly greater marketing and financial resources or other advantages of scale than we have or may obtain. Relatively few barriers to entry exist in most of our local markets. Accordingly, other companies, including hospitals and other healthcare organizations that are not currently providing competing services, may expand their services to include inpatient rehabilitation, home health, hospice care, community care, or similar services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance this competition, or other competition which we may encounter in the future, will not adversely affect our business, financial position, results of operations, or cash flows. In addition, from time to time, there are efforts in states with certificate of need (&#8220;CON&#8221;) laws to weaken those laws, which could potentially increase competition in those states. For example, in 2019, Florida enacted legislation to repeal CON regulations for several provider types, including IRFs. Effective July 1, 2021, new IRFs can operate without first obtaining a CON. Conversely, competition and statutory procedural requirements in some CON states may inhibit our ability to expand our operations in those states. For a breakdown of the CON status of the states and territories in which we have operations, see Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to provide a consistently high quality of care, our business will be adversely impacted.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providing quality patient care is fundamental to our business. We believe hospitals, physicians and other referral</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sources refer patients to us in large part because of our reputation for delivering quality care. Clinical quality is becoming</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increasingly important within our industry. Effective October 2012, Medicare began to impose a financial penalty upon</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals that have excessive rates of patient readmissions within 30 days from hospital discharge. We believe this regulation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides a competitive advantage to post-acute providers who can differentiate themselves based upon quality, particularly by</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieving low acute-care hospital readmission rates and by implementing disease management programs designed to be</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsive to the needs of patients served by referring hospitals. If we should fail to attain our goals regarding acute-care</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospital readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could have a material adverse effect upon our business and consolidated financial condition, results of operations and</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash flows.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Medicare has established consumer-facing websites, Home Health Compare and Hospice Compare, that</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present data regarding our performance on certain quality measures compared to state and national averages. Failure to achieve</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or exceed these averages may adversely affect our ability to generate referrals, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or develop relationships with patient referral sources, our growth and profitability could be adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on referrals from physicians, hospitals, case managers and other patient referral sources in the communities we serve. By law, referral sources cannot be contractually obligated to refer patients to any specific provider. However, there can be no assurance that individuals will not attempt to steer patients to competing post-acute providers or otherwise limit our access to potential referrals. The establishment of joint ventures or networks between referral sources, such as acute care hospitals, and other post-acute providers may hinder patient referrals to us. The growing emphasis on integrated care delivery across the healthcare continuum increases that risk.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth and profitability depend on our ability to establish and maintain close working relationships with patient referral sources and to increase awareness and acceptance of the benefits of inpatient rehabilitation, home health, and hospice care by our referral sources and their patients. We cannot provide assurance that we will be able to maintain our existing referral source relationships or that we will be able to develop and maintain new relationships in existing or new markets. Our loss of, or failure to maintain, existing relationships or our failure to develop new relationships could adversely affect our ability to grow our business and operate profitably.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have difficulty completing investments and transactions that increase our capacity consistent with our growth strategy.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are selectively pursuing strategic acquisitions of, and in some instances joint ventures with, other healthcare providers. We may face limitations on our ability to identify sufficient acquisition or other development targets and to complete those transactions to meet goals. In the home health industry, there is significant competition among acquirors attempting to secure the acquisition of companies that have a large number of locations. Our large home health competitors may have the ability to out bid us for acquisitions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the inpatient rehabilitation industry, the costs of constructing new hospitals are increasing faster than reimbursement rates and the general inflation rate. In many states, the need to obtain governmental approvals, such as a CON or an approval of a change in ownership, may represent a significant obstacle to completing transactions. Additionally, in states with CON laws, it is not unusual for third-party providers to challenge the initial awards of CONs, the increase in the number of approved beds in an existing CON, or the expansion of the area served, and the adjudication of those challenges and related appeals may take many years.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in federal laws or regulations may also materially adversely impact our ability to acquire hospitals or agencies or open</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hospitals or agencies. For example, CMS has adopted a regulation known as the &#8220;36-Month Rule&#8221; that is applicable to home health agency acquisitions. Subject to certain exceptions, the 36-Month Rule prohibits buyers of certain home health agencies&#8212;those that either enrolled in Medicare or underwent a change in ownership fewer than 36 months prior to the acquisitions&#8212;from assuming the Medicare billing privileges of the acquired agency. Instead, the acquired home health agencies must enroll as new providers with Medicare. As a result, the 36-Month Rule may further increase competition for acquisition targets that are not subject to the rule and may cause significant Medicare billing delays for the purchases of home health agencies that are subject to the rule.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Biden administration, DOJ has announced its intention to be much more aggressive in challenging mergers and acquisitions it believes present anti-trust concerns. In a speech in January 2022, the head of DOJ&#8217;s anti-trust enforcement stated that negotiated settlements are frequently inadequate remedies and that DOJ needs to be more aggressive in its litigation to block business combinations. He also stated that litigation is preferable to settlements because it represents a chance to extend legal precedent for what constitutes unlawful anticompetitive activity. Increased DOJ enforcement of antitrust laws will likely increase the time, effort and expense associated with acquisitions and may ultimately make it less likely to consummate acquisitions. With respect to healthcare combinations specifically, President Biden issued an Executive Order on July 9, 2021 that encourages DOJ and the Federal Trade Commission to review and revise their merger guidelines for hospitals to ensure patients are not harmed by such mergers.</span></div><div style="margin-bottom:10pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These factors and others may delay, or increase the cost to us associated with, any acquisition or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development or prevent us from completing one or more acquisitions or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may make investments or complete transactions that could expose us to unforeseen risks and liabilities.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments, acquisitions, joint ventures or other development opportunities identified and completed may involve material cash expenditures, debt incurrence, operating losses, amortization of certain intangible assets of acquired companies, issuances of equity securities, liabilities, and expenses, some of which are unforeseen, that could materially and adversely affect our business, financial position, results of operations and liquidity. Acquisitions, investments, and joint ventures involve numerous risks, including:</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations, including state CONs as well as anti-trust, Medicare, and other regulatory approval requirements, on our ability to complete such acquisitions, particularly those involving not-for-profit providers, on terms, timetables, and valuations reasonable to us;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in obtaining financing for acquisitions at a cost reasonable to us;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired operations, personnel, and information systems, and in realizing projected revenues, efficiencies and cost savings, or returns on invested capital;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into markets, businesses or services in which we may have little or no experience;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of business resources or management&#8217;s attention from ongoing business operations; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to undisclosed or unforeseen liabilities of acquired operations, including liabilities for failure to comply with healthcare laws and anti-trust considerations as well as risks and liabilities related to previously compromised information systems.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our development activities, we intend to open new, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, inpatient rehabilitation hospitals and home health and hospice agencies. The construction of new hospitals involves numerous risks, including the receipt of all zoning and other regulatory approvals, such as a CON where necessary, construction delays and cost over-runs and unforeseen environmental liability exposure. Once built, new hospitals and agencies must undergo the state and Medicare certification process, the duration of which may be beyond our control. We may be unable to operate newly constructed hospitals and agencies as profitably as expected, and those hospitals and agencies may involve significant additional cash expenditures and operating expenses that could, in the aggregate, have an adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully integrate acquisitions or realize the anticipated benefits of any acquisitions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may undertake strategic acquisitions from time to time. For example, we completed the acquisitions of the home health and hospice business of Camellia Healthcare, Alacare Home Health and Hospice and Frontier Home Health and Hospice  in 2018, 2019, and 2021, respectively. Prior to consummation of any acquisition, the acquired business will have operated independently of us, with its own procedures, corporate culture, locations, employees and systems. We expect to integrate acquired businesses into our existing business utilizing certain common information systems, operating procedures, administrative functions, financial and internal controls and human resources practices to the extent practicable. There may be substantial difficulties, costs and delays involved in the integration of an acquired business with our business. Additionally, an acquisition could cause disruption to our business and operations and our relationships with customers, employees and other parties. In some cases, the acquired business has itself grown through acquisitions, and there may be legacy systems, operating policies and procedures, and financial and administrative practices yet to be fully integrated. To the extent we are attempting to integrate multiple businesses at the same time, we may not be able to do so as efficiently or effectively as we initially anticipate. The failure to successfully integrate on a timely basis any acquired business with our existing business could have an adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate our acquisitions will result in benefits including, among other things, increased revenues. However, acquired businesses may not contribute to our revenues or earnings to the extent anticipated, and any synergies we expect may not be realized after the acquisitions have been completed. If the acquired businesses underperform and any underperformance is other than temporary, we may be required to take an impairment charge. Failure to achieve the anticipated benefits could result in the diversion of management&#8217;s time and energy and could have an adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for staffing, shortages of qualified personnel, union activity or other factors may increase our staffing costs and reduce profitability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are dependent on the efforts, abilities, and experience of our medical personnel, such as physical therapists, occupational therapists, speech pathologists, nurses, and other healthcare professionals. We compete with other healthcare providers in recruiting and retaining qualified personnel responsible for the daily operations of each of our locations. In some markets, the lack of availability of medical personnel is a significant operating issue facing all healthcare providers. This issue may be exacerbated if immigration is limited in the future. As discussed above in &#8220;&#8212;Novel Coronavirus Disease 2019 (&#8220;COVID-19&#8221;) Pandemic Risks,&#8221; the pandemic has significantly affected the availability of clinical staff. A shortage may require us to continue to enhance wages and benefits to recruit and retain qualified personnel or to contract for more expensive temporary personnel. We also depend on the available labor pool of semi-skilled and unskilled employees in each of the markets in which we operate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our staffing costs increase, we may not experience reimbursement rate or pricing increases to offset these additional costs. Because a significant percentage of our revenues consists of fixed, prospective payments, our ability to pass along increased staffing costs is limited. In particular, if staffing costs rise at an annual rate greater than our net annual market basket update from Medicare, as is expected to happen in 2022, or we experience a significant shift in our payor mix to lower rate payors such as Medicaid, our results of operations and cash flows will be adversely affected. Conversely, decreases in reimbursement revenues, such as with sequestration and the PDGM reimbursement rate reductions, may limit our ability to increase compensation or benefits to the extent necessary to retain key employees, in turn increasing our turnover and associated costs. Union activity is another factor that may contribute to increased staffing costs. We currently have a minimal number of union employees, so an increase in labor union activity could have a significant impact on our staffing costs. Our failure to recruit and retain qualified medical personnel, or to control our staffing costs, could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a defendant in various lawsuits, and may be subject to liability under qui tam cases, the outcome of which could have a material adverse effect on us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are a defendant in a number of lawsuits, most of which are general and professional liability matters inherent in treating patients with medical conditions. Our more significant lawsuits and investigations, are discussed in Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial damages, fines, or other remedies assessed against us or agreed to in settlements could have a material adverse effect on our business, financial position, results of operations, and cash flows, including indirectly as a result of the covenant defaults under our credit agreement or debt instruments or other claims such as those in securities actions. Additionally, the costs of defending litigation and investigations, even if frivolous or nonmeritorious, could be significant.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCA allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we settled with DOJ to conclude an investigation that originated in 2013 based on the allegations made by relators. The seven-year investigation produced no evidence of falsity or fraudulent conduct. Eventually, the court overseeing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions refused to give DOJ more time to decide whether to intervene and unsealed the cases. DOJ chose not to intervene and prosecute the matter. We settled the DOJ investigation, together with the related </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or &#8220;whistleblower&#8221; lawsuits, for a payment of $48 million, and we expressly denied any wrongdoing. Even when a matter is without merit, as we believe was the case with this investigation, we may still incur significant costs of defense or settlement costs or both.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the FCA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare services we provide involve substantial risk of general and professional liability. Inpatient rehabilitative care involves three hours of daily intensive therapy for patients who are usually elderly and come to our hospitals with debilitating medical conditions, including COVID-19 and its associated conditions. Our clinicians must frequently assist patients who have difficulty with mobility. Home care services, by their very nature, are provided in an environment that is not in the substantial control of the healthcare provider. On any given day, we have thousands of care providers driving to and from the homes of patients. We cannot predict the impact any claims arising out of the travel, the home visits or the care being provided (regardless of their ultimate outcomes) could have on our business or reputation or on our ability to attract and retain patients and employees. We also cannot predict the adequacy of any reserves for such losses or recoveries from any insurance or re-insurance policies.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We self-insure a substantial portion of our professional, general, and workers&#8217; compensation liability risks, which may not include risks related to regulatory fines and penalties, through our captive insurance subsidiary, as discussed further in Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. Changes in the number of these liability claims and the cost to resolve them impact the reserves for these risks. A variance between our estimated and actual number of claims or average cost per claim could have a material impact, either favorable or unfavorable, on the adequacy of the reserves for these liability risks, which could have an effect on our financial position and results of operations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we operate in states in which the litigation environment may pose a significant business risk to us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For instance, we have been involved in lawsuits, including putative class actions, brought under California&#8217;s Private Attorneys General Act (&#8220;PAGA&#8221;). Under PAGA, individuals, including aggrieved employees, can bring individual or class-action claims alleging regulatory violations, including alleged violations of employment regulations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, judges and juries in California have demonstrated a willingness to grant large verdicts to plaintiffs in connection with employment and labor related cases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2017, the California Supreme Court held that plaintiffs bringing suit under PAGA are generally entitled to request and receive a significant amount of information from the employer early in the litigation, which creates pressure for employers to settle early to avoid substantial litigation costs and which has resulted in a significant increase PAGA claims in recent years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur additional indebtedness in the future, and that debt or the associated increased leverage may have negative consequences for our business. The restrictive covenants included in the terms of our indebtedness could affect our ability to execute aspects of our business plan successfully.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we have approximately $2.9 billion of long-term debt outstanding (including that portion of long-term debt classified as current and excluding $386.8 million in finance leases). See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. Subject to specified limitations, our credit agreement and the indentures governing our debt securities permit us and our subsidiaries to incur material additional debt. If new debt is added to our current debt levels, the risks described here could intensify.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness could have important consequences, including:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibiting us from completing the spin off of our home health and hospice business;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to borrow additional amounts to fund working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy and other general corporate purposes;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making us more vulnerable to adverse changes in general economic, industry and competitive conditions, in government regulation and in our business by limiting our flexibility in planning for, and making it more difficult for us to react quickly to, changing conditions;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">placing us at a competitive disadvantage compared with competing providers that have less debt; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposing us to risks inherent in interest rate fluctuations for outstanding amounts under our credit facility, which could result in higher interest expense in the event of increases in interest rates, as discussed in Item 7A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to contingent liabilities, prevailing economic conditions, and financial, business, and other factors beyond our control. Although we expect to make scheduled interest payments and principal reductions, we cannot provide assurance that changes in our business or other factors will not occur that may have the effect of preventing us from satisfying obligations under our credit agreement or debt instruments. If we are unable to generate sufficient cash flow from operations in the future to service our debt and meet our other needs or have an unanticipated cash payment obligation, we may have to refinance all or a portion of our debt, obtain additional financing or reduce expenditures or sell assets we deem necessary to our business. We cannot provide assurance these measures would be possible or any additional financing could be obtained.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of our credit agreement and the indentures governing our senior notes do, and our future debt instruments may, impose restrictions on us and our subsidiaries, including restrictions on our ability to, among other things, engage in one or more alternative separation transactions involving our home health and hospice segment (as discussed further above) or other transactions, pay dividends on or repurchase our capital stock, engage in transactions with affiliates, or incur or guarantee indebtedness. These covenants could also adversely affect our ability to finance our future operations or capital needs and pursue available business opportunities. For additional discussion of our material debt covenants, see the &#8220;Liquidity and Capital Resources&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our credit agreement requires us to maintain specified financial ratios and satisfy certain financial condition tests. See the &#8220;Liquidity and Capital Resources&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. Although we remained in compliance with the financial ratios and financial condition tests as of December 31, 2021, we cannot provide assurance we will continue to do so. Events beyond our control, including changes in general economic and business conditions, may affect our ability to meet those financial ratios and financial condition tests. A severe downturn in earnings, failure to realize anticipated earnings from acquisitions, or, if we have outstanding borrowings under our credit facility at the time, a rapid increase in interest rates could impair our ability to comply with those financial ratios and financial condition tests and we may need to obtain waivers from the required proportion of the lenders to avoid being in default. If we try to obtain a waiver or other relief from the required lenders, we may not be able to obtain it or such relief might have a material cost to us or be on terms less favorable than those in our existing debt. If a default occurs, the lenders could exercise their rights, including declaring all the funds borrowed (together with accrued and unpaid interest) to be immediately due and payable, terminating their commitments or instituting foreclosure proceedings against our assets, which, in turn, could cause the default and acceleration of the maturity of our other indebtedness. A breach of any other restrictive covenants contained in our credit agreement or the indentures governing our senior notes would also (after giving effect to applicable grace periods, if any) result in an event of default with the same outcome.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, approximately 73% of our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was held by our company and its guarantor subsidiaries under its credit agreement. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements, the &#8220;Liquidity and Capital Resources&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be more vulnerable to the effects of a public health catastrophe than other businesses due to the nature of our patients, and a regional or global socio-political or other catastrophic event could severely disrupt our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the majority of our patients are individuals with complex medical challenges, many of whom may be more</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vulnerable than the general public during a pandemic or other public health catastrophe. Our employees are also at greater risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of contracting contagious diseases due to their increased exposure to vulnerable patients. For example, if another pandemic</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were to occur, we could suffer significant losses to our consumer population or a reduction in the availability of our employees</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, at a high cost, be required to hire replacements for affected workers. Enrollment for our services could experience sharp</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">declines if families decide healthcare workers should not be brought into their homes during a health pandemic. Local, regional</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or national governments might limit or ban public interactions to halt or delay the spread of diseases causing business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disruptions and the temporary suspension of our services. Accordingly, certain public health catastrophes could have a material</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse effect on our financial condition and results of operations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unforeseen events, including acts of violence, war, terrorism and other international, regional or local instability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or conflicts (including labor issues), embargoes, natural disasters such as earthquakes, whether occurring in the United States or</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">abroad, could restrict or disrupt our operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to develop adjacent service offerings for our home health and hospice business is subject to a number of risks.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our home health and hospice business has historically focused mainly on the skilled home health and hospice industries, developing adjacent service offerings such as SNF-at-home, palliative care services, care management services, private duty services, and hospital-at-home care involves a number of risks, including reimbursement risks, regulatory risks, and staffing and operational risks, among others. The lack of well-developed regulations for these adjacent services magnifies those risks. Any of these risks could impact our ability to enter these service areas, or the attractiveness of these opportunities for our home health and hospice business. Furthermore, because these are new services that we have not previously provided, we may not be able to do so efficiently or effectively if we do develop these service areas.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">Unresolved Staff Comments</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_25"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Properties </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain our principal executive office at 9001 Liberty Parkway, Birmingham, Alabama, the lease for which expires in 2033 and has multiple renewal options for additional five-year terms. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our principal executive office and our home health and hospice corporate office, we leased or owned  hospital and agency locations as noted in the table below. All of our hospital leases, which represent the largest portion of our rent expense, have at least five years remaining on their terms after taking into consideration one or more renewal options. Our consolidated entities associated with our leased hospitals are generally responsible for property taxes, property and casualty insurance, and routine maintenance expenses. Our home health and hospice business is based in Dallas, Texas where it leases office space for corporate and administrative functions. The remaining home health and hospice locations are in the localities served by that business and are subject to relatively small space leases, primarily 5,000 square feet or less. Those space leases are typically five years or less in term. We do not believe any one of our individual properties is material to our consolidated operations.</span></div><div style="margin-bottom:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding our hospitals and our home health and hospice locations as of December&#160;31, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:17.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Hospitals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Licensed Beds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Building and Land Owned</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Building Owned and Land Leased</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Building and Land Leased</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Home Health and Hospice Locations</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Alabama *+ </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Alaska</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Arizona </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Arkansas +</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Colorado</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Connecticut *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Delaware *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Georgia *+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Idaho</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Illinois *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Indiana</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Iowa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kansas</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kentucky *+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Louisiana</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Maine *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Maryland *+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Massachusetts *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mississippi *+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Missouri *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Montana +</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nevada *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Hampshire </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Jersey *+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:17.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Hospitals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">North Carolina *+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Ohio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Oklahoma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Oregon *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Puerto Rico *+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rhode Island *+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">South Carolina *+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">South Dakota</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tennessee *+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utah</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Virginia *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Washington +</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">West Virginia *+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Wyoming</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;&#160;Hospital certificate of need state or U.S. territory.</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+     Home health or hospice certificate of need state or U.S. territory.</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inpatient rehabilitation hospitals in Augusta and Newnan, Georgia are parties to industrial development bond financings that reduce the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad valorem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> taxes payable by each hospital. In connection with each of these bond structures, title to the related property is held by the local development authority. We lease the related hospital property and hold the bonds issued by that authority, the payment on which equals the amount payable under the lease. We may terminate each bond financing and the associated lease at any time at our option without penalty, and fee title to the related hospital property will return to us.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This total includes 251 locations where we provide home health services and 96 locations where we provide hospice services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive office, hospitals, and other properties are suitable for their respective uses and are, in all material respects, adequate for our present needs. Information regarding the utilization of our licensed beds and other operating statistics can be found in Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_28"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Legal Proceedings</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide services in the highly regulated healthcare industry. In the ordinary course of our business, we are a party to various legal actions, proceedings, and claims as well as regulatory and other governmental audits and investigations. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these matters have been material to us in the past, and others in the future </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may, either individually or in the aggregate, be material and adverse to our business, financial position, results of operations, and liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, we filed suit in the district court of Dallas County, Texas against April K. Anthony, a former executive officer in our home health and hospice segment (&#8220;HH&amp;H&#8221;), for breach of her contractual noncompete, nonsolicitation, and nondisclosure obligations to us and for trade secret misappropriation. Ms. Anthony&#8217;s senior management agreement, dated October 7, 2019, provides, among other things, that she shall not (i) directly or indirectly engage in the provision of home health or hospice services in any state in which we are operating for a period one year following her departure, (ii) directly or indirectly induce or attempt to induce any of our employees to leave our employ or in any way interfere with the relationship between us and any employee for a period of two years following her departure, or (iii) disclose to any unauthorized person or directly or indirectly use for her own account any information, observations and data concerning our business and affairs. Ms. Anthony resigned from her position with HH&amp;H on June 18, 2021. In September 2021, we learned of evidence that Ms. Anthony during her tenure with us had engaged in, and was continuing to engage in, solicitation of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain HH&amp;H employees to join a competing home health and hospice venture. In this suit, we seek injunctions from the court ordering Ms. Anthony to comply with her senior management agreement, including its noncompete, nonsolicitation, and nondisclosure covenants, and to cease and desist all activities in furtherance of violations of those covenants. The trial is scheduled to begin April 18, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the False Claims Act (the &#8220;FCA&#8221;) allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. Therefore, from time to time, we may be party to one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the FCA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to certain legal proceedings in which we are involved is included in Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_31"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Mine Safety Disclosures</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_37"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock trade on the New York Stock Exchange under the ticker symbol &#8220;EHC.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;11, 2022, there were 99,438,215 shares of Encompass Health common stock issued and outstanding, net of treasury shares, held by approximately 6,863 holders of record (participant positions at The Depository Trust Corporation plus record holders).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2022, our board of directors declared a cash dividend of $0.28 per share, payable on April 18, 2022 to stockholders of record on April 1, 2022.&#160;We expect comparable quarterly dividends to continue to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board each quarter after consideration of various factors, including our capital position and alternative uses of funds.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, as of December&#160;31, 2021, information concerning compensation plans under which our securities are authorized for issuance. The table does not reflect grants, awards, exercises, terminations, or expirations since that date. All share amounts and exercise prices have been adjusted to reflect stock splits that occurred after the date on which any particular underlying plan was adopted, to the extent applicable.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:30.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities to be issued upon exercise of outstanding options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average exercise price of outstanding options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities available for future issuance</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plans approved by stockholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,119,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plans not approved by stockholders</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,830&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,119,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This calculation does not take into account awards of restricted stock, restricted stock units, or performance share units.</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This amount assumes maximum performance by performance-based awards for which the performance has not yet been determined.</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This amount represents the number of shares available for future equity grants under the 2016 Omnibus Performance Incentive Plan approved by our stockholders in May 2016.</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This amount represents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 86,830 restr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">icted stock units issued under the 2004 Amended and Restated Director Incentive Plan, the material terms of which are described below.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2004 Amended and Restated Director Incentive Plan</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2004 Amended and Restated Director Incentive Plan (the &#8220;2004 Plan&#8221;) provided for the grant of common stock, awards of restricted common stock, and the right to receive awards of common stock, which we refer to as &#8220;restricted stock units,&#8221; to our non-employee directors. The 2004 Plan expired in March 2008 and was replaced by the 2008 Equity Incentive Plan. Some awards remain outstanding. Awards granted under the 2004 Plan at the time of its termination will continue in effect in accordance with their terms. Awards of restricted stock units were fully vested when awarded and will be settled in shares of common stock on the earlier of the six-month anniversary of the date on which the director ceases to serve on the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">board of directors or certain change in control events. The restricted stock units generally cannot be transferred. Awards are generally protected against dilution upon the issuance of stock dividends and in the event of a stock split, recapitalization, or other major corporate restructuring.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our repurchases of equity securities during the three months ended December&#160;31, 2021:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:18.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share (or Unit) ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 through October 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 through November 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 through December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Except as noted in the following sentence, the number of shares reported in this column represents shares tendered by an employee as payment of the tax liabilities incident to the vesting of previously awarded shares of restricted stock. In October, 288 shares were purchased pursuant to our Directors&#8217; Deferred Stock Investment Plan. This plan is a nonqualified deferral plan allowing non-employee directors to make advance elections to defer a fixed percentage of their director fees. The plan administrator acquires the shares in the open market which are then held in a rabbi trust. The plan also provides that dividends paid on the shares held for the accounts of the directors will be reinvested in shares of our common stock which will also be held in the trust. The directors&#8217; rights to all shares in the trust are nonforfeitable, but the shares are only released to the directors after departure from our board.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">On October 28, 2013, we announced our board of directors authorized the repurchase of up to $200 million of our common stock. On February 14, 2014, our board approved an increase in this common stock repurchase authorization from $200 million to $250 million. On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Stock Performance</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a line graph comparing the total returns of our common stock, the Standard &amp; Poor&#8217;s 500 Index (&#8220;S&amp;P 500&#8221;), and the S&amp;P Health Care Services Select Industry Index (&#8220;SPSIHP&#8221;), an equal-weighted index of at least 35 companies in healthcare services that are also part of the S&amp;P Total Market Index and subject to float-adjusted market capitalization and liquidity requirements. Our compensation committee has in prior years used the SPSIHP as a benchmark for a portion of the awards under our long-term incentive program. The graph assumes $100 invested on December&#160;31, 2016 in our common stock and each of the indices. The returns below assume reinvestment of dividends paid on the related common stock. We have paid a quarterly cash dividend on our common stock since October 2013.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in the performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC nor shall such information be deemed incorporated by reference into any future filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent we specifically incorporate it by reference into such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons in the graph below are based upon historical data and are not indicative of, nor intended to forecast, future performance of our common stock. Research Data Group, Inc. provided the data for the indices presented below. We assume no responsibility for the accuracy of the indices&#8217; data, but we are not aware of any reason to doubt its accuracy.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Among Encompass Health Corporation, the S&amp;P 500 Index, and the S&amp;P Health Care Services Select Industry Index</span></div><div style="text-align:center"><img src="ehc-20211231_g1.jpg" alt="ehc-20211231_g1.jpg" style="height:461px;margin-bottom:5pt;vertical-align:text-bottom;width:680px"/></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Total Return</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company/Index Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Corporation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.35&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.23&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.32&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.20&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.41&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s 500 Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P Health Care Services Select Industry Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i34f6226a63dc43528534c2bfabd86ded_40"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.52pt">[Reserved]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.52pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) should be read in conjunction with the accompanying consolidated financial statements and related notes. This MD&amp;A is designed to provide the reader with information that will assist in understanding our consolidated financial statements, the changes in certain key items in those financial statements from year to year, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our consolidated financial statements. See &#8220;Cautionary Statement Regarding Forward-Looking Statements and Summary of Risk Factors&#8221; on page ii of this report for a description of important factors that could cause actual results to differ from expected results. See also Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, management&#8217;s discussion and analysis of our results of operations and cash flows for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 may be found in, Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the Securities and Exchange Commission on February 26, 2021.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_46"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Business</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a national leader in integrated healthcare services, offering both facility-based and home-based patient care through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. As of December 31, 2021, our national footprint spans 42 states and Puerto Rico. As discussed in this Item, &#8220;Segment Results of Operations,&#8221; we currently manage our operations in two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. For additional information about our business and reportable segments, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, Note 19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements, and the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 9, 2020, we announced a formal process to explore strategic alternatives for our home health and hospice business. As a result of this process, we expect to separate the home health and hospice business from Encompass Health into an independent public company through a spin-off distribution in the first half of 2022. On January 19, 2022, we announced the home health and hospice business would be rebranded and operate under the name Enhabit Home Health &amp; Hospice. The rebranding of agency locations is expected to begin in mid-April 2022 and to be largely completed by the consummation of the spin off.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. We operate hospitals in 35 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of December 31, 2021, we operate 145 inpatient rehabilitation hospitals and manage three inpatient rehabilitation units through management contracts. Our inpatient rehabilitation segment represented approximately 78% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health business is the nation&#8217;s fourth largest provider of Medicare-certified skilled home health services in terms of revenues. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. Our hospice business is the nation&#8217;s twelfth largest provider of Medicare-certified hospice services in terms of revenues. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself. As of December&#160;31, 2021, we provide home health services in 251 locations and hospice services in 96 locations across 34 states, with a concentration in the southern half of the United States. Our home health and hospice segment represented approximately 22% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Overview</span></div><div style="margin-bottom:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rapid onset of the COVID-19 Pandemic (the &#8220;pandemic&#8221;) in the United States has resulted in significant changes to our operating environment. For discussion of the financial and operational impacts we have experienced as a result of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">pandemic, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item.</span></div><div style="margin-bottom:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continued our development and expansion efforts during 2021. In our inpatient rehabilitation segment, we:</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in San Angelo, Texas with our joint venture partner Shannon Health in March 2021;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 50-bed inpatient rehabilitation hospital in North Tampa, Florida in April 2021;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 50-bed inpatient rehabilitation hospital in Cumming, Georgia in June 2021;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Waco, Texas in August 2021;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Shreveport, Louisiana in August 2021;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Greenville, South Carolina in August 2021;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Pensacola, Florida in September 2021;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 50-bed inpatient rehabilitation hospital in Henry County, Georgia in October 2021;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued our capacity expansions by adding 117 new beds to existing hospitals; and</span></div><div style="margin-bottom:4pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announced or continued the development of the following hospitals:</span></div><div style="margin-bottom:4pt;margin-top:5pt;padding-left:24.75pt;padding-right:24.75pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:48.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of New Beds</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shiloh, Illinois</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">St. Augustine, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Libertyville, Illinois</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lakeland, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cape Coral, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jacksonville, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Moline, Illinois</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Naples, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Grand Forks, North Dakota</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Eau Claire, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Owasso, Oklahoma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clermont, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Knoxville, Tennessee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Bowie, Maryland</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Columbus, Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prosper, Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Strongville, Ohio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fitchburg, Wisconsin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Louisville, Kentucky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kissimmee, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fort Mill, South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amarillo, Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Atlanta, Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Palm Beach Gardens, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lake Worth, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr></table></div><div style="padding-left:27pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected joint venture</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Piedmont Healthcare, our joint venture partner in these hospitals, assumed 50% ownership in our existing hospital in Newnan, Georgia during the second quarter of 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also continued our expansion efforts in our home health and hospice segment. On June 1, 2021, we completed the acquisition of the home health and hospice assets of Frontier Home Health and Hospice (&#8220;Frontier&#8221;) in Alaska, Colorado, Montana, Washington, and Wyoming for a cash purchase price of approximately $99 million. The Frontier acquisition included the purchase of a 50% equity interest in the Heart of the Rockies Home Health joint venture and a 90% equity interest in the Hospice of Southwest Montana joint venture (inclusive of an additional 40% equity interest purchased for approximately $4 million). We consolidate both of these joint ventures. On the acquisition date, nine home health and eleven hospice locations became part of our national network of home health and hospice locations. This acquisition was made to expand our existing presence in Colorado and Wyoming and extend our services to Alaska, Montana and Washington. We funded this transaction using cash on hand and borrowings under our revolving credit facility. For additional information regarding this transaction, see Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to the accompanying consolidated financial statements. In addition to the Frontier acquisition, we began accepting patients at our new hospice locations in Las Cruces, New Mexico (May 2021), Abilene, Texas (September 2021), and Tyler, Texas (November 2021).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 10.3% over 2020 due primarily to volume and pricing growth in our inpatient rehabilitation segment. See the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; section of this Item for additional financial information.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continued taking steps to further increase the strength and flexibility of our balance sheet as well as augment returns from investments in operations with shareholder distributions via common stock dividends. For additional information, see the &#8220;Liquidity and Capital Resources&#8221; section of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Outlook</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the current impacts from the pandemic, we remain optimistic regarding the intermediate and long-term prospects for both of our business segments. Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030. Even more specifically, the average age of our patients is approximately 76, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, post-acute services. In addition, we believe we can address the demand for facility-based and home-based post-acute care services in markets where we currently do not have a presence by constructing or acquiring new hospitals and by acquiring or opening home health and hospice agencies in those fragmented industries. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading provider of post-acute healthcare services, offering both facility-based and home-based patient care through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We are committed to delivering high-quality, cost-effective, integrated patient care. As the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, we believe we differentiate ourselves from our competitors based on the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. As the fourth largest provider of Medicare-certified skilled home health services in terms of revenues, we believe we differentiate ourselves from our competitors by the application of a highly integrated technology platform, our ability to manage a variety of care pathways, and a proven track record of consummating and integrating acquisitions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the healthcare industry is currently engaged in addressing the healthcare crisis caused by the pandemic, the industry also faces the prospect of ongoing efforts to transform the healthcare system to coordinated care delivery and payment models. The nature, timing and extent of that transformation remains uncertain, as the development and implementation of new care delivery and payment systems will require significant time and resources. Our short-term goal is to serve our communities and provide the best care possible during the pandemic. Our long-term goal is to position the Company in a prudent manner to be responsive to industry shifts. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. We have been disciplined in creating a capital structure that is flexible. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate and significant availability under our revolving credit facility. For these and other reasons, we believe we will be able to adapt to changes in reimbursement, sustain our business model, and grow through acquisition and consolidation opportunities as they arise. See also Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Competitive Strengths&#8221; and &#8220;Strategy and 2022 Strategic Priorities.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key Challenges</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare is a highly-regulated industry facing many well-publicized regulatory and reimbursement challenges. The Medicare reimbursement systems for both inpatient rehabilitation and home health have recently undergone significant changes. The future of many aspects of healthcare regulation remains uncertain. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities &#8212; change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities &#8212; to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to execute our business plan, the following are some of the challenges we face.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Operating in a Highly Regulated Industry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. More specifically, because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new capacity to existing hospitals and agencies. Ensuring continuous compliance with extensive laws and regulations is an operating requirement for all healthcare providers. See Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulation,&#8221; and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for detailed discussions of the most important regulations we face and our programs intended to ensure we comply with those regulations.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement claims made by healthcare providers, including inpatient rehabilitation hospitals as well as home health and hospice agencies, are subject to audit from time to time by governmental payors and their agents, such as the Medicare Administrative Contractors (&#8220;MACs&#8221;), fiscal intermediaries and carriers, as well as the Office of Inspector General, Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), and state Medicaid programs. These audits as well as the ordinary course claim reviews of our billings result in payment denials, including recoupment of previously paid claims from current accounts receivable. Healthcare providers can challenge any denials through an administrative appeals process that can be extremely lengthy, taking several years. For additional details of these claim reviews, See Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Sources of Revenues,&#8221; Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues&#8221; and &#8220;Accounts Receivable,&#8221; to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulation,&#8221; and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to this report.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Changes to Our Operating Environment Resulting from the COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In response to the public health emergency associated with the pandemic, Congress and CMS adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care. On March 27, 2020, former President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;), which suspended sequestration, an automatic 2% reduction of Medicare program payments for all healthcare providers, for the period of May 1 through December 31, 2020.  On December 27, 2020, the Consolidated Appropriations Act, 2021 (the &#8220;2021 Budget Act&#8221;) extended the sequestration suspension through March 31, 2021. On April 14, 2021, Congress further extended the sequestration suspension period through December 31, 2021. On December 10, 2021 President Biden signed the Protecting Medicare and American Farmers from Sequester Cuts Act, which suspends sequestration cuts until April 1, 2022, set sequestration at 1% for the period April 1, 2022 through June 30, 2022 and reinstated the full 2% sequestration effective July 1, 2022. During 2021, the sequestration suspension provided additional revenues in our inpatient rehabilitation segment and home health and hospice segment of approximately $62 million and $20 million, respectively. The CARES Act also authorized the cash distribution of relief funds from the United States Department of Health and Human Services (&#8220;HHS&#8221;) to healthcare providers. We did not accept any CARES Act relief funds. We intend to refuse any additional provider relief funds distributed in the future whether authorized under the 2021 Budget Act or other legislation. The CARES Act, the 2021 Budget Act, and CMS regulatory actions include a number of other provisions affecting our reimbursement and operations in both segments. The provisions are discussed in Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Sources of Revenue,&#8221; Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the &#8220;Results of Operations&#8221; section of this Item</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Medicare payment reductions are also possible under the Statutory Pay-As-You-Go Act of 2010 (&#8220;Statutory PAYGO&#8221;). For further discussion of Statutory PAYGO, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Sources of Revenue,&#8221; and Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Changes to Our Operating Environment Resulting from Healthcare Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Concerns held by federal policymakers about the federal deficit, national debt levels, and the solvency of the Medicare trust fund, as well as other healthcare policy priorities, could result in enactment of legislation affecting portions of the Medicare program, including post-acute care services we provide. It is not clear what, if any, Medicare-related changes may ultimately be enacted and signed into law or otherwise implemented, but it is possible that any reductions in Medicare spending will have a material impact on reimbursements for healthcare providers generally and post-acute providers specifically. We cannot predict what, if any, changes in Medicare spending or modifications to the healthcare laws and regulations will result from future budget or other legislative or regulatory initiatives.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many provisions within the Patient Protection and Affordable Care Act (as subsequently amended, the &#8220;ACA&#8221;) have impacted or could in the future impact our business, including Medicare reimbursement reductions, such as reductions to annual market basket updates to providers and reimbursement rate rebasing adjustments and promotion of alternative payment models, such as accountable care organizations (&#8220;ACOs&#8221;) and bundled payment initiatives including the Bundled Payments for Care Improvement Initiative Advanced (&#8220;BPCI Advanced&#8221;) and the Comprehensive Care for Joint Replacement (&#8220;CJR&#8221;) program. The Center for Medicare and Medicaid Innovation (&#8220;CMMI&#8221;) plays a key role in the development of many of these new payment and service delivery models. Our challenges related to healthcare reform are discussed in Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Sources of Revenues,&#8221; and Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, healthcare will almost certainly be the subject of significant regulatory and legislative changes regardless of party in control of the executive and legislative branches of state and federal governments. We will continue to evaluate these laws and regulations and position the Company for this industry shift. Based on our track record, we believe we can adapt to these regulatory and industry changes. Further, we have engaged, and will continue to engage, actively in discussions with key legislators and regulators to attempt to ensure any healthcare laws or regulations adopted or amended promote our goal of high-quality, cost-effective care.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year, CMS adopts rules that update pricing and otherwise amend the respective payment systems. On July&#160;29, 2021, CMS released its notice of final rulemaking for fiscal year 2022 under the inpatient rehabilitation facility prospective payment system (the &#8220;2022 IRF Rule&#8221;). Based on our analysis that utilizes, among other things, the acuity of our patients annualized over a six-month prior period, our experience with outlier payments over this same time frame, and other factors, we believe the 2022 IRF Rule will result in a net increase to our Medicare payment rates of approximately 1.9% effective October 1, 2021. On November 2, 2021, CMS released its notice of final rulemaking for calendar year 2022 for home health agencies under the home health prospective payment system (the &#8220;2022 HH Rule&#8221;). Based on our preliminary analysis, which utilizes, among other things, our patient mix annualized over an eleven-month prior period, our specific geographic coverage area, and other factors, we believe the 2022 HH Rule will result in a net increase to our Medicare payment rates of approximately 3.4% effective for 30-day payment periods ending on or after January 1, 2022. For additional details of the 2022 IRF Rule, 2022 HH Rule, and other proposed and adopted legislative and regulatory actions that may be material to our business, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Maintaining Strong Volume Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Various factors, including competition and increasing regulatory and administrative burdens, may impact our ability to maintain and grow our hospital, home health, and hospice volumes. In any particular market, we may encounter competition from local or national entities with longer operating histories or other competitive advantages, such as acute care hospitals who provide post-acute services similar to ours or other post-acute providers with relationships with referring acute care hospitals or physicians. Aggressive payment review practices by Medicare contractors, aggressive enforcement of regulatory policies by government agencies, and restrictive or burdensome rules, regulations or statutes governing admissions practices may lead us to not accept patients who would be appropriate for and would benefit from the services we provide. In addition, from time to time, we must get regulatory approval to expand our services and locations in states with certificate of need laws. This approval may be withheld or take longer than expected. In the case of new-store volume growth, the addition of hospitals, home health agencies, and hospice agencies to our portfolio also may be difficult and take longer than expected.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the factors described above, we believe a number of factors related to the pandemic negatively impacted volumes in 2021, predominately in the home health and hospice segment as discussed in the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item. While we continue to see our volumes recover in our inpatient rehabilitation segment, a current or future resurgence of COVID-19 infections could cause disruptions to our volume growth in both segments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="padding-left:54pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Recruiting and Retaining High-Quality Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Item 1A, Risk Factors, for a discussion of competition for staffing, shortages of qualified personnel, and other factors that may increase our labor costs. Recruiting and retaining qualified personnel, including management, for our inpatient hospitals and home health and hospice agencies remain a high priority for us. We attempt to maintain a comprehensive compensation and benefits package that allows us to remain competitive in this challenging staffing environment while remaining consistent with our goal of being a high-quality, cost-effective provider of post-acute services. Additionally, our operations have been affected and may in the future be affected by staffing shortages where employees must self-quarantine due to exposure to COVID-19 or where employees are unavailable due to a lack of childcare or care for elderly family. These factors have resulted in increased labor costs and increased use of contract labor as discussed in the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain confident in the prospects of both of our business segments based on the increasing demands for the services we provide to an aging population. This confidence is further supported by our strong financial foundation and the substantial investments we have made in our businesses. We have a proven track record of working through difficult situations, and we believe in our ability to overcome current and future challenges.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_49"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor Mix</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020, and 2019, we derived consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payor mix is weighted heavily towards Medicare. We receive Medicare reimbursements under the inpatient rehabilitation facility prospective payment system, the home health prospective payment system, and the hospice payment system. For additional information regarding Medicare reimbursement, see the &#8220;Sources of Revenues&#8221; section of Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Balanced Budget Act of 1997, Congress created a program of private, managed healthcare coverage for Medicare beneficiaries. This program has been referred to as Medicare Part C, or &#8220;Medicare Advantage.&#8221; The program offers beneficiaries a range of Medicare coverage options by providing a choice between the traditional fee-for-service program (under Medicare Parts A and B) or enrollment in a health maintenance organization, preferred provider organization, point-of-service plan, provider sponsor organization, or an insurance plan operated in conjunction with a medical savings account. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consist primarily of revenues derived from patient care services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also include other revenues generated from management and administrative fees and other non-patient care services. These other revenues are included in &#8220;other income&#8221; in the above table.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Results</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2019 through 2021, our consolidated results of operations were as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,605.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,573.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income tax expense</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Encompass Health</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discussion that follows, we use &#8220;same-store&#8221; comparisons to explain the changes in certain performance metrics and line items within our financial statements. We calculate same-store comparisons based on hospitals and home health and hospice locations open throughout both the full current period and prior periods presented. These comparisons include the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on our results of operations. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Compared to 2020</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in 2021 compared to 2020 primarily from volume and pricing growth in our inpatient rehabilitation segment. See additional discussion in the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For various quarterly periods during the pandemic, we experienced decreased patient volumes in one or more of our business lines when compared to the prior year periods. Beginning in mid-March 2020, we experienced decreased volumes in both segments which resulted from a number of conditions related to the COVID-19 pandemic including: lower acute-care hospital censuses due to the deferral of elective surgeries and shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, policies in assisted living facilities that prevent staff from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. Inpatient rehabilitation patient census and home health starts of episodes reached a low point the week ended April 12, 2020 (Easter weekend). These factors have contributed, and could in the future contribute, to a decline in new patients for both of our operating segments as well as decreases in visits per episode in our home health business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Salaries and Benefits</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are the most significant cost to us and represent an investment in our most important asset: our employees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include all amounts paid to full- and part-time employees who directly participate in or support the operations of our hospitals and home health and hospice agencies, including all related costs of benefits provided to employees. It also includes amounts paid for contract labor.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in terms of dollars increased in 2021 compared to 2020 primarily due to salary and benefit cost increases for our employees, increased contract labor to meet higher patient volumes, and the ramping up of new stores. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased in 2021 compared to 2020 primarily due to the additional paid-time-off awarded to employees in the second quarter of 2020 (discussed below) and improved labor productivity partially offset by higher clinician compensation costs due to staffing challenges resulting from the pandemic. See additional discussion in the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we initiated a program for eligible frontline employees to earn additional paid time off in recognition of their outstanding efforts responding to the pandemic. We accrued approximately $43 million in salary and benefits expense in the second quarter of 2020 in connection with this award (approximately $29 million in the inpatient rehabilitation segment; approximately $14 million in the home health and hospice segment).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include costs associated with managing and maintaining our hospitals and home health and hospice agencies. These expenses include such items as contract services, non-income related taxes, professional fees, utilities, insurance, and repairs and maintenance.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during 2021 compared to 2020 primarily due to the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discussed above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supplies</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expense includes all costs associated with supplies used while providing patient care. Specifically, these costs include personal protective equipment (&#8220;PPE&#8221;), pharmaceuticals, food, needles, bandages, and other similar items.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">upplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020 primarily due to the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discussed above. We expect to continue to see elevated utilization and cost of medical supplies in 2022 as a result of the pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily include administrative expenses such as information technology services, human resources, corporate accounting, legal services, and internal audit and controls that are managed from our home office in Birmingham, Alabama. These expenses also include stock-based compensation expenses and transaction costs.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in terms of dollars and as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to the transaction costs associated with the spin off of our home health and hospice business and higher costs associated with incentive compensation. See the &#8220;Executive Overview&#8221; section of this Item for additional information on the spin off.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Depreciation and Amortization</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during 2021 compared to 2020 due to our capital expenditures and development activities throughout 2020 and 2021. We expect </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to increase going forward as a result of our recent and ongoing capital investments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense and Amortization of Debt Discounts and Fees</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2021 compared to 2020 primarily resulted from the redemption of approximately $700 million in November 2020 for the remaining 5.75% Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) as well as the April and June 2021 redemptions of $100&#160;million in outstanding principal amount of the 5.125% Senior Notes due 2023 (the &#8220;2023 Notes&#8221;). Cash paid for interest approximated $168 million in 2021 and 2020, respectively. For additional information, see Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pre-tax income from continuing operations in 2021 increased compared to 2020 primarily due to the increase in earnings, as discussed in the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provision for Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in 2021 compared to 2020 primarily due to higher</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income from continuing operations before income tax expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the CARES Act provisions previously discussed in the &#8220;Executive Overview&#8221; section of this Item, the CARES Act also includes provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, technical corrections to tax depreciation methods for qualified improvement property, and deferral of employer payroll taxes. The CARES Act did not materially impact our effective tax rate for the year ended December 31, 2020 and 2021, although it has impacted the timing of future cash payments for taxes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash payments for income taxes approximated $130 and $33 million, net of refunds, in 2021 and 2020, respectively. These payments were based on estimates of taxable income. We estimate we will pay approximately $80 million to $100 million of cash income taxes, net of refunds, in 2022. These payments are expected to primarily result from federal and state income tax expenses based on estimates of taxable income for 2022. In 2021 and 2020, current income tax expense was $111.8 million and $51.4 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain jurisdictions, we do not expect to generate sufficient income to use all of the available state net operating losses and other credits prior to their expiration. This determination is based on our evaluation of all available evidence in these jurisdictions including results of operations during the preceding three years, our forecast of future earnings, and prudent tax planning strategies. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable tax jurisdiction, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements and the &#8220;Critical Accounting Estimates&#8221; section of this Item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Income Attributable to Noncontrolling Interests</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020 resulted from increased profitability of our existing joint ventures due to the impact of the pandemic on 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of Inflation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of inflation on the Company will be primarily in the area of labor costs. The healthcare industry is labor intensive. Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. There can be no guarantee we will not experience increases in the cost of labor, as the need for clinical healthcare professionals is expected to grow. In addition, increases in healthcare costs are typically higher than inflation and impact our costs under our employee benefit plans. Managing these costs remains a significant challenge and priority for us. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Suppliers pass along rising costs to us in the form of higher prices. In addition, we have experienced higher prices for our medical supplies, including PPE, as a result of the pandemic. Our supply chain efforts and our continual focus on monitoring and actively managing medical supplies and pharmaceutical costs has enabled us to accommodate increased pricing related to supplies and other operating expenses over the past few years. However, we cannot predict our ability to cover future cost increases including increase in the cost of PPE.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It should be noted that we have little or no ability to pass on these increased costs associated with providing services to Medicare and Medicaid patients due to federal and state laws that establish fixed reimbursement rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationships and Transactions with Related Parties</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party transactions were not material to our operations in 2021, 2020, or 2019, and therefore, are not presented as a separate discussion within this Item.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_52"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. For additional information regarding our business segments, including a detailed description of the services we provide, financial data for each segment, and a reconciliation of total segment Adjusted EBITDA to income from continuing operations before income tax expense, see Note&#160;19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, our inpatient rehabilitation segment derived its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our inpatient rehabilitation segment&#8217;s operating results for the years ended December&#160;31, 2021, 2020, and 2019, is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient rehabilitation segment revenues</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discharges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,639</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,897</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient revenue per discharge</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,825</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,220</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,323</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient visits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,070</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,257</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,525</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average length of stay (days)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy %</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># of licensed beds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,924</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,505</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full-time equivalents*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,193</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,076</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,967</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees per occupied bed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Full-time equivalents included in the above table represent our employees who participate in or support the operations of our hospitals and include an estimate of full-time equivalents related to contract labor.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage the productive portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing certain metrics, including employees per occupied bed, or &#8220;EPOB.&#8221; This metric is determined by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by our occupancy percentage.</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Compared to 2020 </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Net Operating Revenues </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inpatient revenue increased during 2021 compared to 2020 primarily due to increased volumes and favorable pricing.</span><span style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discharge growth included a 6.2% increase in same-store discharges. Discharge growth from new stores during 2021 resulted from our joint ventures in Coralville, Iowa (June 2020), San Angelo, Texas (March 2021), and Henry County, Georgia (October 2021), as well as wholly owned hospitals in Murrieta, California (February 2020), Sioux Falls, South Dakota (June 2020), Toledo, Ohio (November 2020), North Tampa, Florida (April 2021), Cumming, Georgia (June 2021), Waco, Texas (August 2021), Shreveport, Louisiana (August 2021), Greenville, South Carolina (August 2021), and Pensacola, Florida (September 2021). Growth in net patient revenue per discharge during 2021 compared to 2020 primarily resulted from an increase in reimbursement rates, a higher acuity patient mix and the suspension of sequestration starting in May 2020.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in outpatient and other revenue during 2021 compared to 2020 primarily resulted from an increase of $29.7 million in provider tax revenues (offset by $17.8 million of provider tax expense increases included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for information regarding our joint ventures discussed above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Adjusted EBITDA during 2021 compared to 2020 primarily resulted from the increase in net patient revenue as discussed above. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased in 2021 compared to 2020 due to the additional paid-time-off awarded to employees in the second quarter of 2020 (discussed above) and improved labor productivity (contributed to lower employees per occupied bed) partially offset by higher clinician compensation costs due to staffing shortages resulting from the pandemic. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses, Supplies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Occupancy costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased during 2021 compared to 2020 primarily due the increase in net patient revenue.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, our home health and hospice segment derived its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our home health and hospice segment&#8217;s operating results for the years ended December&#160;31, 2021, 2020, and 2019, is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home health and hospice segment revenues</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home health:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodic admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recertifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodic recertifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total starts of care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per episode</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodic visits per episode</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total visits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,139,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,431,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost per visit</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient days</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Compared to 2020 </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue growth during 2021 compared to 2020 was driven by increased volumes and pricing. Total starts of care increased during 2021 compared to 2020 primarily due to the acquisition of Frontier on June 1, 2021 and increased non-episodic admissions and recertifications as a result of our national contract with United Healthcare. Episodic admissions declined during 2021 compared to 2020 primarily due to the conversion of admissions to non-episodic under the national contract discussed above. The increase in revenue per episode during 2021 compared to 2020 resulted from an increase in reimbursement rates and the suspension of sequestration partially offset by the mix between early and late payment periods. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Adjusted EBITDA during 2021 compared to 2020 resulted from the increase in net patient revenues as discussed above and a decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased as a percent of revenues for 2021 compared to 2020 primarily due to lower visits per episode and lower cost per visit resulting from additional paid-time-off awarded to employees in the second quarter of 2020 (discussed above) partially offset by higher clinician compensation due to staffing shortages.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_55"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Liquidity and Capital Resources</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash on hand, cash flows from operations, and borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of our capital structure strategy are to ensure we maintain adequate liquidity and flexibility. Pursuing and achieving those objectives allow us to support the execution of our operating and strategic plans and weather temporary disruptions in the capital markets and general business environment. Maintaining adequate liquidity is a function of our unrestricted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our available borrowing capacity. Maintaining flexibility in our capital structure is a function of, among other things, the amount of debt maturities in any given year, the options for debt prepayments without onerous penalties, and limiting restrictive terms and maintenance covenants in our debt agreements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further enhance our liquidity and ensure availability under our credit agreement, in both April and June 2021, we redeemed $100&#160;million in outstanding principal amount of the 2023 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, these optional redemptions were made at a price of par. As a result of this redemption, we recorded a $1.0 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2021. In February 2022, we issued notice for redemption of the remaining $100&#160;million in outstanding principal amount of the 2023 Notes. Pursuant to the terms of the 2023 Notes, this full redemption will settle on March 15, 2022 and will be made at a price of par. We plan to use cash on hand and capacity under our revolving credit facility to fund the redemption. We expect to record an approximate $0.3&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we amended our credit agreement primarily to provide covenant relief due to business disruptions from the pandemic. The amendment included, among other things, the carve-out of the pandemic from the definition of material adverse effect for 364 days and modifications to the interest coverage and leverage ratios under the agreement. In May 2020, we issued an additional $300 million of our existing 4.50% Senior Notes due 2028 at a price of 99.0% of the principal amount and an additional $300 million of our existing 4.75% Senior Notes due 2030 at a price of 98.5% of the principal amount, which resulted in approximately $583 million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we issued $400&#160;million aggregate principal amount of 4.625% Senior Notes due 2031 at par. We used the net proceeds from this borrowing plus approximately $300 million of cash on hand to fully redeem approximately $700 million of the 2024 Notes at par in November 2020. As a result of this redemption, we recorded a $2.3 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2024. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and we have significant availability under our revolving credit facility. We continue to generate strong cash flows from operations, and we have significant flexibility with how we choose to invest our cash and return capital to shareholders.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Liquidity</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $54.8 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;This amount excludes $65.5 million in restricted cash ($65.1 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $0.4 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated balance sheet) and $82.2 million of restricted marketable securities (included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated balance sheet). Our restricted assets pertain primarily to obligations associated with our captive insurance company, as well as obligations we have under agreements with joint venture partners. See Note&#160;4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Marketable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as of December 31, 2021, we had approximately $762 million available to us under our revolving credit facility. Our credit agreement governs the substantial majority of our senior secured borrowing capacity and contains a leverage ratio and an interest coverage ratio as financial covenants. Our leverage ratio is defined in our credit agreement as the ratio of consolidated total debt (less up to $300 million of cash on hand) to Adjusted EBITDA for the trailing four quarters. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments resulting from (1) the dispositions and repayments or incurrence of debt and (2) the investments, acquisitions, mergers, amalgamations, consolidations and operational changes from acquisitions to the extent such items or effects are not yet reflected in our trailing four-quarter financial statements. Our interest coverage ratio is defined in our credit agreement as the ratio of Adjusted EBITDA to consolidated interest expense, excluding the amortization of financing fees, for the trailing four quarters. As of December 31, 2021, the maximum leverage ratio requirement per our credit agreement was 5.0x and the minimum interest coverage ratio requirement was 2.0x, and we were in compliance with these covenants. Based on Adjusted EBITDA for 2021 and the interest rate in effect under our credit agreement during the three-month period ended December 31, 2021, if we had drawn on the first day and maintained the maximum amount of outstanding draws under our revolving credit facility for the entire year, we would still be in compliance with the maximum leverage ratio and minimum interest coverage ratio requirements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively the &#8220;Notes&#8221;) for the adoption of certain amendments to the Indenture, which will provide us with greater flexibility in effecting the spin off discussed in the &#8220;Executive Overview&#8221; section of this Item. Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture by $200&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $40.5 million, excluding fees. We paid $20 million of this amount in January 2022. The remaining payment is contingent upon the execution of a Distribution and will be paid at such time.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not face near-term refinancing risk, as the amounts outstanding under our credit agreement do not mature until 2024, and after the March 2022 redemption of the 2023 Notes discussed above, our bonds all mature in 2025 and beyond. See the &#8220;Contractual Obligations&#8221; section below for information related to our contractual obligations as of December 31, 2021.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired a significant portion of our home health and hospice business when we purchased EHHI Holdings, Inc. (&#8220;EHHI&#8221;) on December 31, 2014. In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#8220;Holdings&#8221;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. The fair value was determined using the product of the trailing twelve-month adjusted EBITDA measure for Holdings and a specified median market price multiple based on a basket of public home health companies and transactions, after adding cash and deducting indebtedness that included the outstanding principal balance under any intercompany notes. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. In July 2019, we received additional exercise notices, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. In September 2019, Encompass Health settled the acquisition of those shares upon payment of approximately $163 million in cash. As of December 31, 2019, the value of those outstanding shares of Holdings owned by management investors was approximately $208 million. In January 2020, we received additional exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. In February 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#8220;Exchange Agreement&#8221;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#8220;EHC Shares&#8221;). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an &#8220;Exchange Notice&#8221;) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#8217;s common stock on the New York Stock Exchange (the &#8220;NYSE&#8221;) on the date of delivery of the Exchange Notice.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors.  Based on the last sales price of Encompass Health&#8217;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns 100% of Holdings and EHHI. See also Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the EHHI acquisition, we granted stock appreciation rights (&#8220;SARs&#8221;) based on Holdings common stock to certain members of EHHI management at closing. Half of the SARs vested on December&#160;31, 2018 and the remainder vested on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings&#8217; common stock on the exercise date exceeds the per share fair value on the grant date. In February 2019, members of the management team exercised a portion of their vested SARs for approximately $13 million in cash. In July&#160;2019, members of the management team exercised the remainder of the vested SARs, which resulted in cash distributions of approximately $55 million. As of December 31, 2019, the fair value of the remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,545</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SARs was approximately $101 million, all of which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying consolidated balance sheet. In January 2020, members of the management team exercised the remaining SARs and in February 2020, we settled those awards upon payment of approximately $101 million in cash. See also Note&#160;14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate we will continue to generate strong cash flows from operations that, together with availability under our revolving credit facility, will allow us to invest in growth opportunities and continue to improve our existing business. We also will continue to consider additional shareholder value-enhancing strategies such as repurchases of our common stock and distribution of common stock dividends, including the potential growth of the quarterly cash dividend on our common stock, recognizing that these actions may increase our leverage ratio. See also the &#8220;Authorizations for Returning Capital to Stakeholders&#8221; section of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of risks and uncertainties facing us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cash flows provided by or used in operating, investing, and financing activities for the years ended December&#160;31, 2021, 2020, and 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Compared to 2020 </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily resulted f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rom the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see the &#8220;Results of Operations&#8221; section of this Item) partially offset by the decrease in payroll accruals. The decrease in payroll accruals was attributable to the award of additional paid time off to employees during the second quarter of 2020 in response to the pandemic and the deferral of payroll taxes resulting from government relief efforts during the pandemic. Half of the payroll taxes were paid in December 2021, with the remaining half due in December 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020 primarily resulted from the acquisition of assets from Frontier and increased purchases of property and equipment. For additional information on the Frontier acquisition, see  Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020 primarily resulted from increased net debt payments partially offset by the purchase of equity interests held by the home health and hospice management team during the first quarter of 2020. See also Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated contractual obligations as of December&#160;31, 2021 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding revolving credit facility and finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,680.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,486.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.53pt">Included in long-term debt are amounts owed on our bonds payable and other notes payable. These borrowings are further explained in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Interest on our fixed rate debt is presented using the stated interest rate. Interest expense on our variable rate debt is estimated using the rate in effect as of December&#160;31, 2021. Interest pertaining to our credit agreement and bonds is included to their respective ultimate maturity dates. Interest related to finance lease obligations is excluded from this line (see Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements). Amounts exclude amortization of debt discounts, amortization of loan fees, or fees for lines of credit that would be included in interest expense in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.53pt">Amounts include interest portion of future minimum finance lease payments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our inpatient rehabilitation segment leases approximately 10% of its hospitals as well as other property and equipment under operating leases in the normal course of business. Our home health and hospice segment leases relatively small office spaces in the localities it serves, space for its corporate office, and other equipment under operating leases in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.53pt">Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on Encompass Health and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support and medical equipment. Purchase obligations are not recognized in our consolidated balance sheet.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital expenditures include costs associated with our hospital refresh program, de novo projects, capacity expansions, technology initiatives, and building and equipment upgrades and purchases. During the year ended December&#160;31, 2021, we made capital expenditures of approximately $551 million for property and equipment, intangible assets, and capitalized software. These expenditures in 2021 are exclusive of approximately $119 million in net cash related to our acquisition activity. During 2022, we expect to spend approximately $570 million to $660 million for capital expenditures using cash on hand and borrowings under our revolving credit facility. Approximately $200 million to $250 million of this budgeted amount is considered nondiscretionary expenditures, which we may refer to in other filings as &#8220;maintenance&#8221; expenditures. In addition, we expect to spend approximately $50 million to $100 million on home health and hospice acquisitions during 2022. Actual amounts spent will be dependent upon the timing of construction projects and acquisition opportunities for our home health and hospice business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorizations for Returning Capital to Stakeholders</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, February 2021, May 2021, July 2021, and October 2021, our board of directors declared cash dividends of $0.28 per share that were paid in January 2021, April 2021, July 2021, October 2021, and January 2022, respectively. We expect quarterly dividends to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board of directors after consideration of various factors, including our capital position and alternative uses of funds. Cash dividends are expected to be funded using cash flows from operations, cash on hand, and availability under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2013, we announced our board of directors authorized the repurchase of up to $200 million of our common stock, which amount was subsequently increased to $250 million. On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. As of December&#160;31, 2021, approximately $198 million remained under this authorization. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental Guarantor Financial Information</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:6.75pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness under our credit agreement and the 5.125% Senior Notes due 2023, 5.75% Senior Notes due 2025, 4.50% Senior Notes due 2028, 4.75% Senior Notes due 2030, and 4.625% Senior Notes due 2031, (collectively, the &#8220;Senior Notes&#8221;) are guaranteed by certain consolidated subsidiaries. These guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. The Senior Notes are guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The other subsidiaries of Encompass Health do not guarantee the Senior Notes (such subsidiaries are referred to as the &#8220;non-guarantor subsidiaries&#8221;).</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:6.75pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1)&#160;we are not in default under our credit agreement, and (2) either (a) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 2x and our leverage ratio (as defined in our credit agreement) remains less than or equal to 4.50x or (b) there is capacity under the Available Amount as defined in the credit agreement. The terms of our Senior Notes indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture&#8217;s restricted payments covenant to declare and pay dividends. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information is presented below for Encompass Health, the parent company, and the subsidiary guarantors on a combined basis after elimination of intercompany transactions and balances among Encompass Health and the subsidiary guarantors and does not include investments in and equity in the earnings of non-guarantor subsidiaries.</span></div><div style="margin-bottom:5pt;padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,692.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany revenues generated from non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,711.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,184.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany expenses incurred in transactions with non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany receivable due from non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,778.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes Adjusted EBITDA as defined in our credit agreement is a measure of our ability to service our debt and our ability to make capital expenditures. We reconcile Adjusted EBITDA to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use Adjusted EBITDA on a consolidated basis as a liquidity measure. We believe this financial measure on a consolidated basis is important in analyzing our liquidity because it is the key component of certain material covenants contained within our credit agreement, which is discussed in more detail in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under our credit agreement&#8212;our interest coverage ratio and our leverage ratio&#8212;could result in our lenders requiring us to immediately repay all amounts borrowed. If we anticipated a potential covenant violation, we would seek relief from our lenders, which would have some cost to us, and such relief might be on terms less favorable to us than those in our existing credit agreement. In addition, if we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to our assessment of our liquidity.</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as &#8220;Adjusted Consolidated EBITDA,&#8221; allows us to add back to consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> interest expense, income taxes, and depreciation and amortization and then add back to consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1) all unusual or nonrecurring items reducing consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3)&#160;non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4)&#160;share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment debt and acquisitions, and (7) any restructuring charges not in excess of 20% of Adjusted Consolidated EBITDA. We also subtract from consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> all unusual or nonrecurring items to the extent they increase consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the credit agreement, the Adjusted EBITDA calculation does not require us to deduct net income attributable to noncontrolling interests or&#160;gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or&#160;unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement&#8217;s &#8220;unusual or nonrecurring&#8221; classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, our ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Adjusted EBITDA for the years ended December&#160;31, 2021, 2020, and 2019 was as follows (in millions):</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Income to Adjusted EBITDA</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with the strategic alternatives review</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with the Frontier acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt-related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions from nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with the strategic alternatives review</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with the Frontier acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information see the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_61"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with GAAP. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures. We base our assumptions, estimates, and judgments on historical experience, current trends, and other factors we believe to be relevant at the time we prepared our consolidated financial statements. On a regular basis, we review the accounting policies, assumptions, estimates, and judgments to ensure our consolidated financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. We believe the following accounting estimates are the most critical to aid in fully understanding and evaluating our reported financial results, as they require our most difficult, subjective, or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain. We have reviewed these critical accounting estimates and related disclosures with the audit committee of our board of directors.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_64"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net operating revenue in the reporting period in which we perform the service based on our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances (principally for patients covered by Medicare, Medicare Advantage, Medicaid, and other third-party payors), potential adjustments that may arise from payment and other reviews, and uncollectible amounts. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; to the accompanying consolidated financial statements of this report for a complete discussion of our revenue recognition policies.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Certain other factors that are considered and could influence the estimated transaction price are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes, and additional adjustments are provided to account for these factors. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. In addition, laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation and review, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. However, we continually review the amounts actually collected in subsequent periods in order to determine the amounts by which our estimates differed. Historically, such differences have not been material from either a quantitative or qualitative perspective.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of outstanding receivables from third-party payors and patients is our primary source of cash and is critical to our operating performance. Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows a summary of our net accounts receivable balances as of December&#160;31, 2021 and 2020. Information on the concentration of total patient accounts receivable by payor class can be found in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Accounts Receivable,&#8221; to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 - 30 Days</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 - 60 Days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 - 90 Days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 - 120 Days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 + Days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in general economic conditions (such as increased unemployment rates or periods of recession), business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable. Our collection risks include patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and co-payments) remain outstanding, pre-payment claim reviews by our respective MACs, and reimbursement claims audits by governmental or other payors and their agents. As of December 31, 2021 and 2020, $77.8 million and $117.8 million of our patient accounts receivable represented denials that were under review or audit in our inpatient rehabilitation segment. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues&#8221; and &#8220;Accounts Receivable,&#8221; to the accompanying consolidated financial statements of this report.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_67"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are self-insured for certain losses related to professional liability, general liability, and workers&#8217; compensation risks. Although we obtain third-party insurance coverage to limit our exposure to these claims, a substantial portion of our professional liability, general liability, and workers&#8217; compensation risks are insured through a wholly owned insurance subsidiary. See Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for a more complete discussion of our self-insured risks.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our self-insured liabilities contain uncertainties because management must make assumptions and apply judgment to estimate the ultimate cost of reported claims and claims incurred but not reported as of the balance sheet date. Our reserves and provisions for professional liability, general liability, and workers&#8217; compensation risks are based largely upon semi-annual actuarial calculations prepared by third-party actuaries. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, we review our assumptions and the valuations provided by third-party actuaries to determine the adequacy of our self-insurance reserves. The following are certain of the key assumptions and other factors that significantly influence our estimate of self-insurance reserves: historical claims experience; trending of loss development factors; trends in the frequency and severity of claims; coverage limits of third-party insurance; demographic information; statistical confidence levels; medical cost inflation; payroll dollars; and hospital patient census.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time period to resolve claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. In addition, if current and future claims differ from historical trends, our estimated reserves for self-insured claims may be significantly affected. Our self-insurance reserves are not discounted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the number of factors used to establish our self-insurance reserves, we believe there is limited benefit to isolating any individual assumption or parameter from the detailed computational process and calculating the impact of changing that single item. Instead, we believe the sensitivity in our reserve estimates is best illustrated by changes in the statistical confidence level used in the computations. Using a higher statistical confidence level increases the estimated self-insurance reserves. The following table shows the sensitivity of our recorded self-insurance reserves to the statistical confidence level (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.637%"><tr><td style="width:1.0%"></td><td style="width:71.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net self-insurance reserves as of December 31, 2021:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As reported, with 50% statistical confidence level</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With 70% statistical confidence level</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our efforts to improve patient safety and overall quality of care, as well as our efforts to reduce workplace injuries, have helped contain our ultimate claim costs. See Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for additional information.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our self-insurance reserves are adequate to cover projected costs. Due to the considerable variability that is inherent in such estimates, there can be no assurance the ultimate liability will not exceed management&#8217;s estimates. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_70"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absent any impairment indicators, we evaluate goodwill for impairment as of October 1st of each year. We test goodwill for impairment at the reporting unit level and are required to make certain subjective and complex judgments on a number of matters, including assumptions and estimates used to determine the fair value of our inpatient rehabilitation and home health and hospice reporting units. We assess qualitative factors in each reporting unit to determine whether it is necessary to perform the quantitative goodwill impairment test. The quantitative impairment test is required only if we conclude it is more likely than not a reporting unit&#8217;s fair value is less than its carrying amount. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, based on our qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of the applicable reporting unit using generally accepted valuation techniques including the income approach and the market approach. We would validate our estimates under the income approach by reconciling the estimated fair value of the reporting units determined under the income approach to our market capitalization and estimated fair value determined under the market approach. Values from the income approach and market approach would then be evaluated and weighted to arrive at the estimated aggregate fair value of the reporting units.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income approach includes the use of each reporting unit&#8217;s projected operating results and cash flows that are discounted using a weighted-average cost of capital that reflects market participant assumptions. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. Other significant estimates and assumptions include cost-saving synergies and tax benefits that would accrue to a market participant under a fair value methodology. The market approach estimates fair value through the use of observable inputs, including the Company&#8217;s stock price.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Goodwill and Other Intangibles,&#8221; and Note&#160;8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for additional information.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following events and circumstances are certain of the qualitative factors we consider in evaluating whether it is more likely than not the fair value of a reporting unit is less than its carrying amount:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">macroeconomic conditions, such as deterioration in general economic conditions, limitations on accessing capital, or other developments in equity and credit markets;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry and market considerations and changes in healthcare regulations, including reimbursement and compliance requirements under the Medicare and Medicaid programs;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost factors, such as an increase in labor, supply, or other costs;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall financial performance, such as negative or declining cash flows or a decline in actual or forecasted revenue or earnings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other relevant company-specific events, such as material changes in management or key personnel or outstanding litigation;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">material events, such as a change in the composition or carrying amount of each reporting unit&#8217;s net assets, including acquisitions and dispositions;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consideration of the relationship of our market capitalization to our book value, as well as a sustained decrease in our share price; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">length of time since most recent quantitative analysis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we performed our annual evaluation of goodwill and determined no adjustment to impair goodwill was necessary. If actual results are not consistent with our assumptions and estimates, we may be exposed to goodwill impairment charges. However, at this time, we continue to believe our inpatient rehabilitation and home health and hospice reporting units are not at risk for any impairment charges.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_73"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the asset and liability method. We also evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Income Taxes,&#8221; and Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for a more complete discussion of income taxes and our policies related to income taxes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of income tax law is inherently complex. Laws and regulations in this area are voluminous and are often ambiguous. We are required to make many subjective assumptions and judgments regarding our income tax exposures. Interpretations of and guidance surrounding income tax laws and regulations change over time. As such, changes in our subjective assumptions and judgments can materially affect amounts recognized in our consolidated financial statements. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate recovery of certain of our deferred tax assets is dependent on the amount and timing of taxable income we will ultimately generate in the future, as well as other factors. A high degree of judgment is required to determine the extent a valuation allowance should be provided against deferred tax assets. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our operating performance in recent years, the scheduled reversal of temporary differences, our forecast of taxable income in future periods in each applicable tax jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment. Our forecast of future earnings includes assumptions about patient volumes, payor reimbursement, labor costs, hospital operating expenses, and interest expense. Based on the weight of available evidence, we determine if it is more likely than not our deferred tax assets will be realized in the future. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liability for unrecognized tax benefits contains uncertainties because management is required to make assumptions and to apply judgment to estimate the exposures associated with our various filing positions which are periodically audited by tax authorities. In addition, our effective income tax rate is affected by changes in tax law, the tax jurisdictions in which we operate, and the results of income tax audits.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we decreased our valuation allowance by $(3.1) million. As of December&#160;31, 2021, we had a remaining valuation allowance of $43.1 million which primarily related to state net operating losses. At the state jurisdiction level, we determined it was necessary to maintain a valuation allowance due to uncertainties related to our ability to utilize a portion of the net operating losses before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence, as described above, including management&#8217;s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While management believes the assumptions included in its forecast of future earnings are reasonable and it is more likely than not the net deferred tax asset balance as of December&#160;31, 2021 will be realized, no such assurances can be provided. If management&#8217;s expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in healthcare regulations, general economic conditions, or other factors, we may need to increase our valuation allowance, or reverse amounts recorded currently in the valuation allowance, for all or a portion of our deferred tax assets. Similarly, future adjustments to our valuation allowance may be necessary if the timing of future tax deductions is different than currently expected. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assessment of Loss Contingencies</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have legal and other contingencies that could result in significant losses upon the ultimate resolution of such contingencies. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Litigation Reserves,&#8221; and Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for additional information.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have provided for losses in situations where we have concluded it is probable a loss has been or will be incurred and the amount of loss is reasonably estimable. A significant amount of judgment is involved in determining whether a loss is probable and reasonably estimable due to the uncertainty involved in determining the likelihood of future events and estimating the financial statement impact of such events. If further developments or resolution of a contingent matter are not consistent with our assumptions and judgments, we may need to recognize a significant charge in a future period related to an existing contingent matter.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_79"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of entities that qualify as business combinations under the acquisition method of accounting. Under the acquisition method of accounting, the total consideration is allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair values of these identifiable assets and liabilities is recorded as goodwill. During the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value of assets acquired and liabilities assumed in a business combination, we primarily use the income and multi-period excess earnings approaches to estimate the value of our most significant acquired intangible assets. Both income approaches utilize projected operating results and cash flows and include significant assumptions such as base revenue, revenue growth rate, projected EBITDA margin, discount rates, rates of increase in operating expenses, and the future effective income tax rates. The valuations of our significant acquired businesses have been performed by a third-party valuation specialist under our management&#8217;s supervision. We believe that the estimated fair value assigned to the assets acquired and liabilities assumed is based on reasonable assumptions and estimates that marketplace participants would use. However, such assumptions are inherently uncertain and actual results could differ from those estimates. Future changes in our assumptions or the interrelationship of those assumptions may result in purchase price allocations that are different than those recorded in recent years.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition related costs are not considered part of the consideration paid and are expensed as operating expenses as incurred. Contingent consideration, if any, is measured at fair value initially on the acquisition date as well as subsequently at the end of each reporting period until the contingency is resolved and settlement occurs. Subsequent adjustments to contingent considerations are recorded in our consolidated statements of comprehensive income. We include the results of operations of the businesses acquired as of the beginning of the acquisition dates.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_82"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding recent accounting pronouncements, see Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_85"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.3pt">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary exposure to market risk is to changes in interest rates on our variable rate long-term debt. We use a sensitivity analysis model to evaluate the impact of interest rate changes on our variable rate debt. As of December&#160;31, 2021, our primary variable rate debt outstanding related to $200 million in advances under our revolving credit facility and $238.5 million outstanding under our term loan facilities. Assuming outstanding balances were to remain the same, a 1% increase in interest rates would result in an incremental negative cash flow of approximately $4.0 million over the next 12 months, while a 1% decrease in interest rates, assuming a floor of zero in the variable rate index, would result in an incremental positive cash flow of approximately $1.3 million over the next 12 months.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our fixed rate debt is determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy, and is summarized as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Instrument:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Book Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Book Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign operations, and the related market risks associated with foreign currencies, are currently, and have been, insignificant to our financial position, results of operations, and cash flows. See also Note&#160;10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_88"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.52pt">Financial Statements and Supplementary Data</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements and related notes are filed together with this report. See the index to financial statements on page F-1 for a list of financial statements filed with this report.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_91"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.52pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_94"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.3pt">Controls and Procedures</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, an evaluation was carried out by our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures. Based on our evaluation, our chief executive officer and chief financial officer concluded that, as of December&#160;31, 2021, our disclosure controls and procedures were effective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on its financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an assessment of the effectiveness of our internal control over financial reporting as of December&#160;31, 2021. In making this assessment, management used the criteria set forth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, the COSO framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on our evaluation, our chief executive officer and chief financial officer concluded that, as of December&#160;31, 2021, our internal control over financial reporting was effective.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_97"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">Other Information</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_2741"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. &#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to file a definitive proxy statement relating to our 2022 Annual Meeting of Stockholders (the &#8220;2022 Proxy Statement&#8221;) with the United States Securities and Exchange Commission, pursuant to Regulation 14A, not later than 120 days after the end of our most recent fiscal year. Accordingly, certain information required by Part&#160;III has been omitted under General Instruction G(3) to Form 10-K. Only the information from the 2022 Proxy Statement that specifically addresses disclosure requirements of Items&#160;10-14 below is incorporated by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_103"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Directors and Executive Officers of the Registrant</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;10 is hereby incorporated by reference from our 2022 Proxy Statement under the captions &#8220;Items of Business Requiring Your Vote&#8212;Proposal 1&#8212;Election of Directors,&#8221; &#8220;Corporate Governance and Board Structure&#8212;Corporate Governance&#8212;Code of Ethics,&#8221; &#8220;&#8212;Board Structure and Committees&#8212;Audit Committee,&#8221; &#8220;&#8212;Board Composition and Director Nomination Process&#8212;Director Nominees Proposed by Stockholders,&#8221; and &#8220;Executive Officers.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_106"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Executive Compensation </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;11 is hereby incorporated by reference from our 2022 Proxy Statement under the captions &#8220;Corporate Governance and Board Structure&#8212;Compensation of Directors,&#8221; &#8220;Compensation and Human Capital Committee Matters,&#8221; and &#8220;Executive Compensation.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_109"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;12 is hereby incorporated by reference from our 2022 Proxy Statement under the captions &#8220;Executive Compensation&#8212;Equity Compensation Plans&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_112"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Certain Relationships and Related Transactions and Director Independence </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;13 is hereby incorporated by reference from our 2022 Proxy Statement under the captions &#8220;Corporate Governance and Board Structure&#8212;Director Independence&#8221; and &#8220;Certain Relationships and Related Transactions.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_115"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Principal Accountant Fees and Services </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;14 is hereby incorporated by reference from our 2022 Proxy Statement under the caption &#8220;Items of Business Requiring Your Vote&#8212;Proposal 2&#8212;Ratification of Appointment of Independent Registered Public Accounting Firm.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_121"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying index on page F-1 for a list of financial statements filed as part of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Schedules</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Exhibit Index immediately following page F-62 of this report.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_124"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.02pt">Form 10-K Summary</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ENCOMPASS HEALTH CORPORATION</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160; M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mark J. Tarr</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">[Signatures continue on the following page]</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose signature appears below hereby constitutes and appoints Patrick Darby his true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him in his name, place and stead, in any and all capacities, to sign any and all amendments to this Report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:32.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capacity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark J. Tarr</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Douglas E. Coltharp</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NDREW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RICE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Andrew L. Price</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> I. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IGDON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leo I. Higdon, Jr.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">REG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARMICHAEL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greg D. Carmichael</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HIDSEY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John W. Chidsey</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ONALD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ORRELL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Donald L. Correll</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;Y</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VONNE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">URL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Yvonne M. Curl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HARLES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LSON</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Charles M. Elson</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ERMAN</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joan E. Herman</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ESLYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> G. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ATZ</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leslye G. Katz</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ATRICIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARYLAND</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patricia A. Maryland</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/&#160;&#160;CHRISTOPHER R. REIDY</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher R. Reidy</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AUPIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">R.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John E. Maupin, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ANCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CHLICHTING</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nancy M. Schlichting</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;L. E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">DWARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HAW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">L. Edward Shaw, Jr.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ERRANCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ILLIAMS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terrance Williams</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Financial Statements</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_133">Report of Independent Registered Public Accounting Firm (PCAOB ID </a></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzAvZnJhZzoyOGMxMDg3NzAzOWI0NWZjODI1ZGI0YWUzNmRkNjMwMS90YWJsZTpmZWMyOTdhNjMyNzA0YTNkYjg2ODIzZTcyNGU5MjQ0YS90YWJsZXJhbmdlOmZlYzI5N2E2MzI3MDRhM2RiODY4MjNlNzI0ZTkyNDRhXzAtMC0xLTEtMTA3Mzc3L3RleHRyZWdpb246N2JkN2ZmMmE0ZGYwNDc0ZTkwYzAyNjYxZDVmM2ZiY2FfMjE5OTAyMzI1NTg1OA_3001907f-0841-4025-a5e0-066b439d69db">238</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_133">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_133">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_136">Consolidated Statements of Comprehensive Income for each of the years in the three-year period ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_136"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_136">December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_136">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_142">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_142">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_145">Consolidated Statements of Shareholders&#8217; Equity for each of the years in the three-year period ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_145"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_145">December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_145">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_148">Consolidated Statements of Cash Flows for each of the years in the three-year period ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_148"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_148">December&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_148">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_151">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_151">10</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Encompass Health Corporation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Encompass Health Corporation and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of comprehensive income, of shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Internal Control - Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (2013) issued by the COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Inpatient Rehabilitation Segment Patient Accounts Receivable - Contractual Allowances and Uncollectible Amounts</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Notes 1 and 5 to the consolidated financial statements, revenues for inpatient rehabilitation services are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on management&#8217;s estimate of the respective transaction price.  Management&#8217;s estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts.  Revenues recognized by the inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related patient accounts receivable.  Factors considered by management in determining the estimated transaction price include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors.  Management assumes these factors will remain consistent with the experience for patients discharged in similar time periods for the same payor classes.  The Company&#8217;s consolidated accounts receivable balance is $763.8 million as of December 31, 2021.  Management estimates the allowance for uncollectible amounts based on the aging of accounts receivable, historical collection experience for each type of payor, and other relevant factors. As disclosed by management, changes in general economic conditions (such as increased unemployment rates or periods of recession) are also considered.      </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal considerations for our determination that performing procedures relating to the valuation of inpatient rehabilitation segment patient accounts receivable &#8211; contractual allowances and uncollectible amounts is a critical audit matter are the significant judgment by management to estimate patient accounts receivable and the amount that will ultimately be collected under the terms of the third-party payor contracts, which in turn led to significant auditor judgment and effort to evaluate the audit evidence obtained related to the valuation of inpatient rehabilitation segment patient accounts receivable.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of inpatient rehabilitation patient accounts receivable related to contractual allowances and uncollectible amounts, which included controls over management&#8217;s process, assumptions, and data used to estimate contractual allowances and uncollectible amounts and determine patient accounts receivable. These procedures also included, among others, i) evaluating management&#8217;s process for developing the estimate for contractual allowances and uncollectible amounts, ii) testing the completeness and accuracy of underlying data used in the model, iii) evaluating the historical accuracy of management&#8217;s process for developing the estimate of the amount which will ultimately be collected by comparing actual cash collections to the previously recorded patient accounts receivable, and iv) developing an independent expectation of the amount expected to be collected by management.  Developing an independent expectation involved calculating the percentage of cash collections as compared to the recorded patient accounts receivable balance for prior years and comparing that percentage to management&#8217;s collection expectation used to determine the current year estimate for contractual allowances and uncollectible amounts.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Inpatient Rehabilitation Segment Patient Accounts Receivable - Denied Claims</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 1 to the consolidated financial statements, the Company&#8217;s Medicare claims have been subject to review by Medicare Administrative Contractors (&#8220;MACs&#8221;) under various programs such as &#8220;widespread probes&#8221; and the Targeted Probe and Educate initiative.   The MACs reviews have resulted in denial of payment for claims billed under certain diagnosis codes.   As of December 31, 2021, $77.8 million of the Company&#8217;s patient accounts receivable represented denials that were under review or audit.  While the Company generally appeals most of the denials of claims by the MACs , the Medicare appeals adjudication process, which is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;), has been subject to significant delay resulting in a backlog of claims awaiting hearing, the resolution of which may take several years. As disclosed in Note 1, the Company&#8217;s historical experience and success in the adjudication of these appeals is a component of management&#8217;s estimate of the transaction price. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal considerations for our determination that performing procedures relating to the valuation of inpatient rehabilitation patient accounts receivable &#8211; denied claims is a critical audit matter are the significant judgment by management to estimate the ultimate expected amount of collectible accounts receivable related to denied claims. This in turn led to a high degree of auditor judgment and effort to evaluate the audit evidence obtained related to the valuation of such denied claims.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of inpatient rehabilitation patient accounts receivable related to denied claims, which included controls around the identification of denied claims at period-end, as well as controls to assess the reasonableness of the success rate estimates.  These procedures also included, among others, i) evaluating management&#8217;s process for developing the estimate for collectible amounts related to denied claims, as well as the relevance and use of the historical billing and collection data as an input to the valuation analysis, ii) evaluating the reasonableness of management&#8217;s analysis and success rate estimate for denied claims by comparing it to the Company&#8217;s adjudicated denied claim results, iii) performing testing over a sample of denied revenue transactions by inspecting evidence that the claim was denied, and iv) performing testing over a sample of cash collections from the historical collection data used in management&#8217;s estimation of collectability.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzMvZnJhZzo1NDQ5NjliYzA4Nzg0Y2E1YWYzNGI4MWE3Y2EwMDE0Yi90ZXh0cmVnaW9uOjU0NDk2OWJjMDg3ODRjYTVhZjM0YjgxYTdjYTAwMTRiXzIxOTkwMjMyNjg4NDA_33939e00-b7eb-4a2d-b99a-8fa569350393">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzMvZnJhZzo1NDQ5NjliYzA4Nzg0Y2E1YWYzNGI4MWE3Y2EwMDE0Yi90ZXh0cmVnaW9uOjU0NDk2OWJjMDg3ODRjYTVhZjM0YjgxYTdjYTAwMTRiXzIxOTkwMjMyNjg4Mzk_c8b246f4-c45f-4133-9dbb-6aebe544e8e0">Birmingham, Alabama</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2003.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Comprehensive Income</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMtMS0xLTEtNTU5Njg_419ade9e-ead9-469c-bb69-6ed987401d42">5,121.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMtMy0xLTEtNTU5Njg_3450c947-141c-4cc7-ad20-b7ceb864e056">4,644.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMtNS0xLTEtNTU5Njg_80f88782-a6e7-42e6-985d-a404280b976d">4,605.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzUtMS0xLTEtNTU5Njg_3966444e-6b72-4aab-87c4-6d534f5c1da7">2,886.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzUtMy0xLTEtNTU5Njg_38c28c7a-f3cb-4144-8509-86ca91c1011b">2,682.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzUtNS0xLTEtNTU5Njg_a7c438d0-af14-42c8-93c8-1d9f3c45c833">2,573.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzYtMS0xLTEtNTU5Njg_b9f63f33-b902-40d1-9a5c-8efe76b88c8e">685.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzYtMy0xLTEtNTU5Njg_48a9ece5-ebe6-4fee-afee-699617a9a3d7">634.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzYtNS0xLTEtNTU5Njg_5151cb32-067e-43d5-b668-9d7993d1c25e">623.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzctMS0xLTEtNTU5Njg_8387fe76-239e-46f5-a0b7-04ac9a8a3db1">80.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzctMy0xLTEtNTU5Njg_787ab3e8-4b14-4c70-a842-4f78a2e58e8c">81.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzctNS0xLTEtNTU5Njg_dcbe3c5f-2807-4923-8386-899c4176921e">82.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzgtMS0xLTEtNTU5Njg_f7b31ace-e6cc-4644-ac7c-11e950308472">209.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzgtMy0xLTEtNTU5Njg_64289c48-cba9-4598-875c-2930e69561aa">200.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzgtNS0xLTEtNTU5Njg_cc6f5236-2210-4ad3-93bb-36b828d0a45f">167.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzktMS0xLTEtNTU5Njg_62f15a53-b362-40ba-97e7-acc074e95b5c">197.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzktMy0xLTEtNTU5Njg_d5a70a2f-8d91-43d1-800f-ed67e2ad6718">155.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzktNS0xLTEtNTU5Njg_91bf9ee4-195e-4f65-af1e-8a36a388d032">247.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEwLTEtMS0xLTU1OTY4_25f3d126-f932-4d0f-b07a-1a89b3d0d7aa">256.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEwLTMtMS0xLTU1OTY4_a58efdd0-9552-4931-b62f-7b41e3c5d9c5">243.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEwLTUtMS0xLTU1OTY4_46c2ef15-dabf-4cc9-a77c-c41d6329daaa">218.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzExLTEtMS0xLTU1OTY4_621cc1c2-ede3-4e97-9441-38afcda8d3dc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzExLTMtMS0xLTU1OTY4_3144010f-c217-4526-b5df-a3bc2beb013e">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzExLTUtMS0xLTU1OTY4_8f99eaaa-6aa7-49d5-823e-cb7245c8dd51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEzLTEtMS0xLTU1OTY4_8de5dc22-4bbd-4fab-adb2-1a85970a434e">4,315.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEzLTMtMS0xLTU1OTY4_959021f1-b662-4d58-949d-a5041723cfc6">3,999.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEzLTUtMS0xLTU1OTY4_9ea01237-f2c0-4d15-a250-e6dcf61519f4">3,912.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE0LTEtMS0xLTU1OTY4_1298c3d1-3764-4cd5-8feb-6654926d165e">1.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE0LTMtMS0xLTU1OTY4_b6f15666-303f-42e3-a25e-163ff57bb983">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE0LTUtMS0xLTU1OTY4_676d4e20-4f8a-427f-99cb-a3d680d6a499">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE1LTEtMS0xLTU1OTY4_ea2a093f-04b2-4ba0-a2df-7590b211f8c6">164.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE1LTMtMS0xLTU1OTY4_19b0b165-d6a4-40c5-8887-4f1727c77d70">184.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE1LTUtMS0xLTU1OTY4_49e4c35e-3a84-4866-8492-9ba4c0996476">159.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE2LTEtMS0xLTU1OTY4_7622c6d0-55a2-4c8f-a5c2-2804ec9aa1f2">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE2LTMtMS0xLTU1OTY4_25fe570b-0df9-4170-b241-29c341c5f6e7">10.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE2LTUtMS0xLTU1OTY4_5e15db86-0879-45c1-8256-9ac59817f164">30.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE3LTEtMS0xLTU1OTY4_4311be71-dc9f-4492-abe6-9adb1f57151b">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE3LTMtMS0xLTU1OTY4_265214fa-320f-44f8-8513-be551b78b9a3">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE3LTUtMS0xLTU1OTY4_b6df95b1-5397-48ab-ae4c-6dd935437d1c">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE4LTEtMS0xLTU1OTY4_2ff215ff-7f53-4cec-897a-c1470f19b3b2">657.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE4LTMtMS0xLTU1OTY4_9707b68d-57ef-463a-8835-b05774c303a6">472.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE4LTUtMS0xLTU1OTY4_c6090429-f692-4b52-94cf-622651113e23">562.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE5LTEtMS0xLTU1OTY4_9b8ac022-492e-4fe6-a7f5-8cdcce06bdb7">139.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE5LTMtMS0xLTU1OTY4_d44d589e-2bae-4091-90cd-d31faac856be">103.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE5LTUtMS0xLTU1OTY4_ba90cf05-585e-4a3e-aa23-3e2b29e56455">115.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIwLTEtMS0xLTU1OTY4_13dedce1-4ac9-4fd2-8da1-b17209b2868f">517.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIwLTMtMS0xLTU1OTY4_52865ff3-4070-43a2-b9cb-64fb7e9f93cf">368.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIwLTUtMS0xLTU1OTY4_63377e12-bdca-42b2-8bdf-fc89fe5a650d">446.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIxLTEtMS0xLTU1OTY4_544eb58f-2047-4eb1-bb92-eceae1d941b1">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIxLTMtMS0xLTU1OTY4_f129c613-0c81-4afc-a669-4ab00071dbcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIxLTUtMS0xLTU1OTY4_1b38db6a-0570-434b-9714-95d0ecbe48b1">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net and comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTEtMS0xLTU1OTY4_3b0eec7d-abe6-411d-895a-33a6011be92d"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTEtMS0xLTU1OTY4_b12a3239-122c-4d63-ada1-c38ecb0d0fae">517.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTMtMS0xLTU1OTY4_a1dcc4bc-3f62-4c7a-9c11-1bc3401c0521"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTMtMS0xLTU1OTY4_fe7f7217-1dfe-4671-9af0-f89edd414026">368.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTUtMS0xLTU1OTY4_a41bef2e-0212-4474-94ce-537b86ff9f60"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTUtMS0xLTU1OTY4_f90fa218-c5d7-497a-978c-47ef7aa9c03c">445.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net and comprehensive income attributable to noncontrolling </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTEtMS0xLTU1OTY4_aff71157-5d97-4dc9-b510-4b6076b884e1"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTEtMS0xLTU1OTY4_b818beeb-e71c-4263-8787-c1f2ad453ca3">105.0</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTMtMS0xLTU1OTY4_d29fab87-8e71-42b9-a06f-3d6316b62362"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTMtMS0xLTU1OTY4_fb2003a0-be6b-4664-b196-0688e0a79f99">84.6</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTUtMS0xLTU1OTY4_dacb21c5-c902-419e-aa34-f2ca030473f4"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTUtMS0xLTU1OTY4_e7fad49f-60a8-49d7-b231-c5aefea5ed1e">87.1</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net and comprehensive income attributable to Encompass </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTEtMS0xLTU1OTY4_c41c1653-d07d-4417-9bd7-aa102624dc58"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTEtMS0xLTU1OTY4_ca177784-b6e8-4a72-b126-2ea634caa3f3">412.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTMtMS0xLTU1OTY4_398434da-716e-4136-8f91-ba96ff6f4c2b"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTMtMS0xLTU1OTY4_f97e5a47-d36a-4ab0-9407-2200261798f1">284.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTUtMS0xLTU1OTY4_7e50014b-e9a7-4b99-aeae-1d80aaa06ada"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTUtMS0xLTU1OTY4_a782ab1f-9ac1-472d-920a-316f89fc2061">358.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMwLTEtMS0xLTU1OTY4_8317ff40-200a-4853-804f-2fe7334131f3">99.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMwLTMtMS0xLTU1OTY4_52ecaf27-73b5-4b43-a5d2-719bbdd81f85">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMwLTUtMS0xLTU1OTY4_bd3b3bb5-ca74-4d32-9a39-78cda6cddef1">98.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMxLTEtMS0xLTU1OTY4_7dc12f60-3526-498a-9644-1721182c76bd">100.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMxLTMtMS0xLTU1OTY4_34660675-a4b1-4396-b99a-add568f9c2a1">99.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMxLTUtMS0xLTU1OTY4_3b47ab90-f231-4dc1-b39b-9397c52ce4b9">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM0LTEtMS0xLTU1OTY4_1860c46b-3a32-4028-894c-ec27c9806cf3">4.15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM0LTMtMS0xLTU1OTY4_de9e7505-b863-4e0f-9e84-054b993beb8d">2.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM0LTUtMS0xLTU1OTY4_d9b01077-46d2-4b4e-85d8-6a6dc64926ca">3.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM1LTEtMS0xLTU1OTY4_9e3cf7bb-2866-4a3d-b50e-860c540b05ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM1LTMtMS0xLTU1OTY4_69aea09a-6a85-4a71-9fb1-99578f4b4ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM1LTUtMS0xLTU1OTY4_fb05621c-1752-4ad0-898a-5d1e9b9a6043">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM2LTEtMS0xLTU1OTY4_b7bd3da4-f576-44be-b9c0-997f9c8e7e57">4.15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM2LTMtMS0xLTU1OTY4_b11e8c66-f68e-43bd-b25b-453baeb17616">2.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM2LTUtMS0xLTU1OTY4_0d8c4525-148d-47d3-9f40-bced574b50c6">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM4LTEtMS0xLTU1OTY4_e887b4d3-7215-452c-90f6-6058f45e5b3f">4.11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM4LTMtMS0xLTU1OTY4_4a96363f-d248-4945-a8ee-f5d1d636b764">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM4LTUtMS0xLTU1OTY4_d505c142-20a8-4625-96a0-789433a2dc85">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM5LTEtMS0xLTU1OTY4_c37c0902-75ea-4c0d-8da2-b5347e8ec412">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM5LTMtMS0xLTU1OTY4_0a7edad9-1fd6-4510-ada4-ac64a332d695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM5LTUtMS0xLTU1OTY4_304df0d0-756e-44c4-a6b5-526ad0558bdf">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQwLTEtMS0xLTU1OTY4_ea43490b-8fc2-4869-9c32-54f58f619730">4.11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQwLTMtMS0xLTU1OTY4_c7acb4a1-3e53-4534-bd3b-fdfa473c5814">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQwLTUtMS0xLTU1OTY4_eacc40fa-84e1-4418-bc99-0cb575a29236">3.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Encompass Health:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQzLTEtMS0xLTU1OTY4_b2e15242-8a83-454e-a5bf-48132c5cdb71">412.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQzLTMtMS0xLTU1OTY4_ffa25e2a-391a-4e2a-886d-968e7c2f1112">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQzLTUtMS0xLTU1OTY4_d46d476e-531b-484e-9868-820613dc7fd7">359.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ0LTEtMS0xLTU1OTY4_c93def55-71fb-46da-bd43-b7d2ce1c3fba">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ0LTMtMS0xLTU1OTY4_0f6dabe8-03d5-4b54-8929-32c49e1cddcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ0LTUtMS0xLTU1OTY4_c77333d3-ec2a-4c18-bec6-3949a001ed5d">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ1LTEtMS0xLTU1OTY4_858ae546-066d-4613-8028-d4a3b8f2ea5c">412.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ1LTMtMS0xLTU1OTY4_081aba99-74cd-48cb-afbf-7ca269303bcc">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ1LTUtMS0xLTU1OTY4_7ca7b2d8-767e-49fa-ba2d-ec758c2ea57e">358.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to consolidated financial statements are an integral part of these statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheets</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Share Data)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzUtMS0xLTEtNTU5Njg_3e89e212-54e7-4c83-b80b-6f461fb81569">54.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzUtMy0xLTEtNTU5Njg_06cde790-d759-4b97-b2fa-20bc2c222cc6">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzYtMS0xLTEtNTU5Njg_17a065a8-19a3-4aec-9c33-c82412ec7b7c">65.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzYtMy0xLTEtNTU5Njg_918d45af-e117-4e28-b9c3-cb850bb34293">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzctMS0xLTEtNTU5Njg_5584c9b0-0eb7-454a-bc53-3b54feddc064">680.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzctMy0xLTEtNTU5Njg_87b94f93-fd9a-461d-af44-5e3af7ce2d30">572.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzgtMS0xLTEtNTU5Njg_1ec620e3-2954-46d4-8c4d-795117a4a113">121.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzgtMy0xLTEtNTU5Njg_675f3498-93f9-4b43-9faa-33ea8de8a18b">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzktMS0xLTEtNTU5Njg_7b4cb41c-3a53-4eb7-b44b-ceb1f3884f00">921.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzktMy0xLTEtNTU5Njg_a7c607e1-b97e-4316-a0c4-e6fc12725500">948.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEwLTEtMS0xLTU1OTY4_49f06ad9-7cf8-4ec6-b15f-b75657d685fb">2,601.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEwLTMtMS0xLTU1OTY4_4a931e1f-7472-4d90-a001-db10181411f5">2,206.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzExLTEtMS0xLTU1OTY4_3da2f313-9244-4eea-8b0c-c74225eb33c7">242.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzExLTMtMS0xLTU1OTY4_9f4922ae-f5f8-46c8-9d4e-0974b9af1d5e">245.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEyLTEtMS0xLTU1OTY4_b581017b-134a-49f3-b78b-1a660a7e19ba">2,427.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEyLTMtMS0xLTU1OTY4_2ed6949e-2a17-4e51-a435-2a69256ce627">2,318.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEzLTEtMS0xLTU1OTY4_0f6f4315-6341-46c1-bbad-868286e9b0f9">417.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEzLTMtMS0xLTU1OTY4_f0e68450-2415-4a25-8d1b-c4e495fbdf35">431.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE1LTEtMS0xLTU1OTY4_73bd4c88-22b4-4070-90be-a2b5ce940759">254.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE1LTMtMS0xLTU1OTY4_02a2d833-b7a4-46c8-8b1f-a42bf0688370">295.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTEtMS0xLTU1OTY4_0b58a3fa-b14c-46c1-b573-7fcf0c82ac10">6,864.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTMtMS0xLTU1OTY4_b1625715-3198-4ba4-b240-797414be8947">6,445.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE5LTEtMS0xLTU1OTY4_c63ab688-f416-42f5-a6f7-9e446ca405d5">42.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE5LTMtMS0xLTU1OTY4_f2521048-58c5-4352-875d-cd33e95c1e11">38.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIwLTEtMS0xLTU1OTY4_f4343f8b-23dc-4367-a7c3-5cc4aa65da37">38.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIwLTMtMS0xLTU1OTY4_a882dc29-9060-41d5-bab9-24cda8d2f88c">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIxLTEtMS0xLTU1OTY4_adc8f4d8-6e3e-44fe-a735-2da6fdb44284">137.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIxLTMtMS0xLTU1OTY4_f88b42af-c4e9-4000-9421-74d460b2b4c4">115.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIyLTEtMS0xLTU1OTY4_94d6962f-0372-480a-aa4c-30ed69f99990">265.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIyLTMtMS0xLTU1OTY4_e09f3991-6aba-4343-9cc6-8c507be9397a">253.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIzLTEtMS0xLTU1OTY4_05599d81-2b45-492e-b7fd-ef3d4ec80ce6">44.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIzLTMtMS0xLTU1OTY4_c15f1288-5b72-42e8-aae3-66e01a0c33bd">47.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI0LTEtMS0xLTU1OTY4_b4adc9aa-9c0f-4fbe-9aee-e1e6cdc7a95a">219.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI0LTMtMS0xLTU1OTY4_a5b06bb7-7380-4473-99fa-0e0835f1fddb">218.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI1LTEtMS0xLTU1OTY4_9c54c62f-6d58-4976-bcdd-49f6604acfab">748.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI1LTMtMS0xLTU1OTY4_04d6ea94-73f3-4272-b903-ba70e8b43298">717.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI2LTEtMS0xLTU1OTY4_0662c9cf-63fe-4300-af90-5fa07ac86115">3,243.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI2LTMtMS0xLTU1OTY4_763857ac-6146-4e89-83b5-dc75e008e731">3,250.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI3LTEtMS0xLTU1OTY4_485abce6-8ae0-4c6a-83da-5418351069ae">213.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI3LTMtMS0xLTU1OTY4_61eace2e-8d2f-45b3-ab05-2bcceb288617">209.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured risks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:SelfInsuranceReserveNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI4LTEtMS0xLTU1OTY4_28bded1e-c54d-4717-b295-8c96decbb72f">123.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:SelfInsuranceReserveNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI4LTMtMS0xLTU1OTY4_895083a1-a1af-41e7-8064-835765d9f250">121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI5LTEtMS0xLTU1OTY4_8b9e53ae-3f5f-46e7-a7d4-060b98873a11">86.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI5LTMtMS0xLTU1OTY4_fce23e45-1170-4931-aa9d-55dec2f24259">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMwLTEtMS0xLTU1OTY4_42923137-a57f-4250-b72c-836b4ce6984f">49.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMwLTMtMS0xLTU1OTY4_a5ad151f-c7ed-43a5-9e13-6e5f2fe42fbd">93.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMxLTEtMS0xLTU1OTY4_b6a08e6b-4935-4970-a25d-fb641feb987e">4,465.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMxLTMtMS0xLTU1OTY4_87d75ab8-e724-4941-9db4-95c3083932cc">4,444.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMyLTEtMS0xLTU1OTY4_cbcedbb6-2435-4448-8f4f-b29edde51bbe"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMyLTMtMS0xLTU1OTY4_5baf9938-6a32-436e-9625-9c24c9e97aa1"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM0LTEtMS0xLTU1OTY4_c5c7e07f-58aa-4ae0-83ca-6bbaebaae6c8">42.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM0LTMtMS0xLTU1OTY4_e629f958-5bcd-4fa8-9c1f-81a90b8aa2a9">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfMTg_2996a2ec-86b4-4e1a-aea4-adacc3f8fd2d"><ix:nonFraction unitRef="usdPerShare" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfMTg_4543709e-83bb-49cb-b246-3e6ad648a3d6">.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfMzI_80c33129-368e-4586-b119-b0b06728d104"><ix:nonFraction unitRef="shares" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfMzI_b496f91a-de52-45dd-b554-16ddc1f377b6">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; issued: <ix:nonFraction unitRef="shares" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfNjI_0ef28af1-8e8f-49d8-ad99-424a8ce7d7e7">114,211,057</ix:nonFraction> in 2021; <ix:nonFraction unitRef="shares" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfNzI_5548804b-c2b5-4e16-9462-0a103598f2f8">113,835,708</ix:nonFraction> in 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTEtMS0xLTU1OTY4_22a3d93c-69d5-4750-a532-302a480b6613">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTMtMS0xLTU1OTY4_4302f2b6-81ac-46aa-8c31-66786adea8f8">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in excess of par value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM4LTEtMS0xLTU1OTY4_a28815f8-4f83-4079-8e18-7b2cf8513e2c">2,289.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM4LTMtMS0xLTU1OTY4_288fa00e-31f5-4f5f-99f1-e4c1c753e70c">2,326.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated income (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM5LTEtMS0xLTU1OTY4_39c473d7-c5a7-4469-a3a1-4ca91038195b">141.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM5LTMtMS0xLTU1OTY4_0f41ff48-e1bd-4504-a2d2-f66a356e67cb">242.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost (<ix:nonFraction unitRef="shares" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQxLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MDgyMTA0NTdlOTk1NDBmYmI0Mzc3ZWEyZTQ4YzRiYmJfMjk_ac70d974-12cf-4345-8835-b2f13321f3e5">14,719,662</ix:nonFraction> shares in 2021 and <ix:nonFraction unitRef="shares" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQxLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MDgyMTA0NTdlOTk1NDBmYmI0Mzc3ZWEyZTQ4YzRiYmJfNDk_717490e4-b9bd-4f70-8c76-054143386b3a">14,428,235</ix:nonFraction> shares in 2020)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQxLTEtMS0xLTU1OTY4_84ccb156-e449-4172-8ef7-ad14d2997d97">521.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQxLTMtMS0xLTU1OTY4_8d849a2d-10a6-428a-93af-b3f93176cec3">497.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Encompass Health shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQyLTEtMS0xLTU1OTY4_e75706da-027c-427f-b5c5-c785cc7ff3b5">1,911.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQyLTMtMS0xLTU1OTY4_4dfcc6fa-f959-4d70-8c97-c600afa18aac">1,588.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQzLTEtMS0xLTU1OTY4_a2422171-bc45-443d-bc63-6a8144249baa">445.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQzLTMtMS0xLTU1OTY4_0e5be666-53dc-4f5b-9662-5ef078583f12">382.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ0LTEtMS0xLTU1OTY4_f0daeba0-c35f-473b-b971-675deb5bbadd">2,357.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ0LTMtMS0xLTU1OTY4_13f891a8-f7b5-445b-ae80-4c72224852fc">1,970.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">and shareholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTEtMS0xLTU1OTY4_8c08c71d-5cc5-4114-a2b5-a12015439158">6,864.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTMtMS0xLTU1OTY4_37065a94-0044-4a86-8cd6-196ede9333a6">6,445.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzM0NA_295907de-de5c-4a62-9d8b-958e93adf76f" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of December&#160;31, 2021 and December&#160;31, 2020 include total assets of variable interest entities of $<ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzEwMw_4c5be3aa-4fa0-41d3-ae2e-6499aa232e6f">226.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzExMA_050ab071-70a5-462c-84b7-0902439983ef">221.2</ix:nonFraction> million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2021 and December&#160;31, 2020 include total liabilities of the variable interest entities of $<ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzMwOA_1961f6dd-1e96-4d87-8cc8-179b0c51bc51">38.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzMxNQ_2382abe7-bb32-4720-924b-198a822ab5cd">46.8</ix:nonFraction> million, respectively. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></ix:footnote></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to consolidated financial statements are an integral part of these statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_145"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:18.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Shareholders&#8217; Equity</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:5.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encompass Health Common Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common Shares Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>(Deficit) Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cab8f26574d455bb0e444a22064322e_I20181231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMS0xLTEtNTU5Njg_01ba288d-9270-4da4-be27-0ab1b7adb069">98.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cab8f26574d455bb0e444a22064322e_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMy0xLTEtNTU5Njg_726c4b45-3cba-4a49-8cb5-f85560a3e446">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8ddf5948f941808c197344226a885d_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtNS0xLTEtNTU5Njg_c7e6d55e-0627-4211-ab6d-f02f0a57d610">2,588.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cb543ef43ed40f1a7ee0241b7a11342_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtNy0xLTEtNTU5Njg_5857bfd5-b7b9-4fac-b834-7707e35e12c4">885.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f37180681db48768667c6ab12ad98b4_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMTEtMS0xLTU1OTY4_7cc37630-5be8-4be2-a1d4-b61054559f32">427.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8199a59d951645668567ba119a46ab2c_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMTMtMS0xLTU1OTY4_7947d473-9e23-4ffd-a910-67dd5e5da4c2">280.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMTUtMS0xLTU1OTY4_33c74ada-27fb-40d8-97e4-0297a10d1e89">1,557.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0a91751427448778fd75c271f59e770_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQtNy0xLTEtNTU5Njg_3861ce1b-d622-4469-8569-cee26a59fcfb">358.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQtMTMtMS0xLTU1OTY4_42c7137e-42be-44cd-bad6-156280a8b44a">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQtMTUtMS0xLTU1OTY4_b8fd7750-071b-41f3-b51e-b5a7bdc85d24">433.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzYtMS0xLTEtNTU5Njg_d0224222-e3c0-471b-a3ac-a8b909a93dc4">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16dab19dcce146e486a875b0b0b69c08_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzYtMTEtMS0xLTU1OTY4_d9ed9bf8-e7b3-4ca2-84f4-16ccef8670f3">16.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzYtMTUtMS0xLTU1OTY4_a8a8b6e1-acdf-440b-b6c2-54987ac7c004">16.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzctMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo0M2RhODBmMDMxNzI0MTliYWMyZmFjNzE2ODAxZTY3NF8yNA_731cd512-457e-4da4-ab17-09c224d603ee">1.10</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzctNS0xLTEtNTU5Njg_c66bd87a-3680-4e0d-8fec-429507e02512">109.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzctMTUtMS0xLTU1OTY4_f9ed367a-43ae-47d2-a511-10631e81675b">109.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzktNS0xLTEtNTU5Njg_b33a06e0-d909-4317-a656-3bff772be457">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzktMTUtMS0xLTU1OTY4_3bdfc7c5-483c-4309-9fc0-23e8be72b51e">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEwLTEtMS0xLTU1OTY4_9aaaa6c9-373e-4cc3-b564-08c1e7ab5bf7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEwLTUtMS0xLTU1OTY4_ed69dc94-3bfc-4ed7-ad28-64ca1c64d991">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEwLTE1LTEtMS01NTk2OA_db21d7b8-5232-46f0-83e5-9fa06db6e14c">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEyLTEzLTEtMS01NTk2OA_db667e35-c802-4b40-ac01-4a15a6b03880">70.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEyLTE1LTEtMS01NTk2OA_3b04c697-c814-4d5f-805d-8f43bac613e5">70.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock in open market</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEzLTEtMS0xLTU1OTY4_d09710aa-30a6-4bf4-933e-1cb9dcc80dd3">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16dab19dcce146e486a875b0b0b69c08_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEzLTExLTEtMS01NTk2OA_a3c7d25c-0fea-4c7c-bdf4-30a9e56e30e7">45.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEzLTE1LTEtMS01NTk2OA_951e839f-e2ca-4b1b-b413-fa8d080658a4">45.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE2LTEzLTEtMS01NTk2OA_76320942-efe9-4435-896f-7a17279c2ad6">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE2LTE1LTEtMS01NTk2OA_cbff294c-4038-4976-a3e6-03b568c6265c">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value adjustments to redeemable noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE3LTUtMS0xLTU1OTY4_fbd27982-d3a8-48d3-ab8e-97702320d099">147.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE3LTE1LTEtMS01NTk2OA_64e18621-d58b-47d9-9506-56634df40713">147.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidation of Yuma Rehabilitation Hospital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231" decimals="-5" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE5LTEzLTEtMS02NjA3OQ_8a9bf5f7-860a-492d-ae05-8cef98386e19">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE5LTE1LTEtMS02Njc4MA_3ba1ec09-acec-404a-b19a-52e526ced71e">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTEtMS0xLTU1OTY4_d64274f1-8686-42ac-aa73-bcfcc9c22f1c">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTUtMS0xLTU1OTY4_449834b9-b1d3-4206-9a46-a7e47f1b5c80">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0a91751427448778fd75c271f59e770_D20190101-20191231" decimals="-5" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTctMS0xLTU1OTY4_3a92a517-48a6-4600-806f-d29d467e12cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16dab19dcce146e486a875b0b0b69c08_D20190101-20191231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTExLTEtMS01NTk2OA_a4ca15fd-7f53-46d2-9791-6b87a19226aa">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTEzLTEtMS01NTk2OA_42622715-baa4-496c-ba00-74b3e0db8d9e">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTE1LTEtMS01NTk2OA_c10328f8-1c88-4ebd-a987-a03da56b5965">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0992f803e1e34a4e90d50e779e344893_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTEtMS0xLTU1OTY4_64929a52-220a-4fa2-bb65-3b6f1a62cfe6">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0992f803e1e34a4e90d50e779e344893_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTMtMS0xLTU1OTY4_676d0a34-04b7-4f15-8675-ab41ec4f676a">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d7707625cf434f9d6f3e0485591879_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTUtMS0xLTU1OTY4_3b15bcd0-56e4-4f9a-b4af-2f900804e4ee">2,369.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i923ea8f6bd4b4243a0033479742dddb7_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTctMS0xLTU1OTY4_27104033-6201-4267-8979-2287281a9cff">526.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i548a41347a74411dad48274aece4d650_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTExLTEtMS01NTk2OA_7bdd05da-aed9-4155-8663-707a67d653d1">492.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56730ca5523d40a8bb4c79634fbac5c5_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTEzLTEtMS01NTk2OA_eaf59f46-efda-4011-9f73-80b246f7e320">340.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTE1LTEtMS01NTk2OA_284ae030-31a4-4723-9f10-60a267c22f7a">1,693.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a730b37d7846fd8c535e4701134ade_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIyLTctMS0xLTU1OTY4_1ce96197-db8c-4b90-bf39-d42cff92c2a8">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIyLTEzLTEtMS01NTk2OA_70070454-ce10-478f-a6ad-e5ba108075f5">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIyLTE1LTEtMS01NTk2OA_1f59cabd-9f0e-4cdc-a50b-cae9504c06f3">361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI0LTEtMS0xLTU1OTY4_9b2d6ec3-6e87-4cee-a756-6670d181d3f7">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI0LTExLTEtMS01NTk2OA_5a81a537-4522-4041-bdde-01083a912d71">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI0LTE1LTEtMS01NTk2OA_0c96d55e-d97f-4fc9-886a-3e19d0df8291">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI1LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZWRmN2U3ZGRlZWI4NDA5MmIxMGVkNjkxMmRmNjcwN2JfMjQ_0232cc06-526b-463d-b0ba-e4c84f672e80">1.12</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI1LTUtMS0xLTU1OTY4_7c23dd2d-88fd-4798-a3ac-c5bfe385f473">111.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI1LTE1LTEtMS01NTk2OA_3d84469a-4929-47cb-b58d-063cf8cf1464">111.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange of Holdings shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI2LTEtMS0xLTY1OTAx_4ab37de4-c9b5-4d26-8626-d0d090018139">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI2LTUtMS0xLTY1OTAx_35cbef03-11a4-434f-a8be-b7052852f708">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI2LTExLTEtMS02NTkwMQ_b4e04dfb-d8fd-46b6-a71b-2f9e7465300a">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI2LTE1LTEtMS02NTkwMQ_543e1b20-3b13-4046-b165-65851b48404f">46.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI3LTUtMS0xLTU1OTY4_26851dbd-e33e-4a5d-a46a-da07bff22e58">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI3LTE1LTEtMS01NTk2OA_1c6e2859-65b8-4e0b-ab87-5cca29ab78d6">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI4LTEtMS0xLTU1OTY4_1847e8ce-fbce-42e4-a53e-612c0f3be1d6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI4LTUtMS0xLTU1OTY4_76ee5393-b8b1-4b07-b2d2-cb62239f98f6">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI4LTE1LTEtMS01NTk2OA_85442201-7acb-4f36-abef-b4d63b45618e">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMwLTEzLTEtMS01NTk2OA_06bf641b-cd0d-4afb-8e4e-3a571ab247ce">72.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMwLTE1LTEtMS01NTk2OA_5d672dbb-5726-4e9a-8fad-0957a3230667">72.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock in open market</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMxLTEtMS0xLTU1OTY4_4af85771-ad42-45c5-8073-5c03ac059215">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMxLTExLTEtMS01NTk2OA_35dc231d-36f8-4253-93c3-83f9f708dbdc">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMxLTE1LTEtMS01NTk2OA_ff6292e8-bf01-4817-85f8-e8fe6cbedd60">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMyLTEzLTEtMS01NTk2OA_0ab163a0-4aa6-43ce-a095-ae35b374308e">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMyLTE1LTEtMS01NTk2OA_5732f459-1f82-4b56-998e-57e88328368f">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value adjustments to redeemable noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMzLTUtMS0xLTU1OTY4_ab12dbef-d948-457f-893e-b9381c3f7903">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMzLTE1LTEtMS01NTk2OA_dd8e3540-402e-440e-bef3-7eca78d9a526">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTEtMS0xLTU1OTY4_92801907-979b-4892-9ab0-31197bb06c53">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTUtMS0xLTU1OTY4_db8a922b-c0d7-4e50-8cde-5ad3ea5d45ff">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a730b37d7846fd8c535e4701134ade_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTctMS0xLTU1OTY4_e618d65b-f7d9-47ad-836f-a30dde70c99f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTExLTEtMS01NTk2OA_77996fdd-97d1-41a3-bb2d-b43d044dd7db">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTEzLTEtMS01NTk2OA_ad2ad479-c5b1-4722-9b20-20943c2b1728">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTE1LTEtMS01NTk2OA_051f0ed9-cdda-47ce-b797-8082185bfada">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1dbcfa3b248545d9b8cd1d01927d9fb5_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTEtMS0xLTU1OTY4_b1c14982-53a4-46ed-83a0-a1ea082977ec">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dbcfa3b248545d9b8cd1d01927d9fb5_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTMtMS0xLTU1OTY4_243d1d4a-f6d9-4930-bdff-0c36f3a17822">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9fe6fdcb66c408182d54fd398242dfc_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTUtMS0xLTU1OTY4_89966cf9-6b0b-45ad-87cd-a4ecc4ce2c41">2,326.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d69e5017d07424e805b4bfb62fc3b6d_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTctMS0xLTU1OTY4_cedd1d30-6219-4a1e-b10f-72d21a0aab62">242.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b524f488ed479ab4120a3288ab25b0_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTExLTEtMS01NTk2OA_9f92cf31-6331-4912-958b-b7a5abe60efb">497.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3747ac9e4f7a4b1eb2654738ec5cd6ba_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTEzLTEtMS01NTk2OA_598a7325-5f58-468e-8a87-3344f713f5a8">382.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTE1LTEtMS01NTk2OA_ae3e2422-47d2-4c86-8b53-eb7cfe951041">1,970.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie331398123094f4cbf9f53387dd320e2_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM4LTctMS0xLTU1OTY4_f832aaaa-20b6-4b65-878d-903d17493acc">412.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM4LTEzLTEtMS01NTk2OA_3543a1fb-02e6-45af-8978-bc18ff4259ff">96.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM4LTE1LTEtMS01NTk2OA_1175c984-bc75-4bd4-8a7d-735e6ab23305">508.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i74bebd850f4a4fccbaa89fd90826de06_D20210101-20211231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQwLTEtMS0xLTU1OTY4_3a480756-1bc1-4152-a230-a37db2130348">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i397d63e231e44fc79264c4127d701240_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQwLTExLTEtMS01NTk2OA_4d1d7362-3e7e-4e6b-91d9-faeb023d2c92">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQwLTE1LTEtMS01NTk2OA_a69f5049-56e0-4d4a-bd1e-7507cb7dca6e">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQxLTAtMS0xLTU1OTY4L3RleHRyZWdpb246N2IyYWJhMjhhMmE3NGM0Mzg0ODM5MjEwZTYyMGNhZjNfMjQ_22d7c027-a6aa-425b-afb8-8ac40a9b9093">1.12</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8493b47598e8480aae3bec09697737b3_D20210101-20211231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQxLTUtMS0xLTU1OTY4_b6db95b0-fa64-460f-b130-60e7eacfe585">83.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie331398123094f4cbf9f53387dd320e2_D20210101-20211231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQxLTctMS0xLTU1OTY4_dab376e4-f240-48d0-a18e-a4a0e165cd31">28.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQxLTE1LTEtMS01NTk2OA_51b457a0-2893-40c8-90af-94577a0bf265">111.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8493b47598e8480aae3bec09697737b3_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQzLTUtMS0xLTU1OTY4_0c003000-c5f9-454d-82f7-61e2b9cac83e">32.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQzLTE1LTEtMS01NTk2OA_698e7af9-2833-45d3-b18d-132f9f18fe7a">32.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQ2LTEzLTEtMS01NTk2OA_d214d2e1-ef50-4588-84c6-682ed2a44ed5">87.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQ2LTE1LTEtMS01NTk2OA_eecd0e56-9d09-42fa-89a9-d92246b435ba">87.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQ4LTEzLTEtMS01NTk2OA_e21423f5-f900-4ee8-ac98-f7fb2dd3c59d">72.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQ4LTE1LTEtMS01NTk2OA_e74944cf-b68c-4751-b131-1492ae21cf9b">72.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74bebd850f4a4fccbaa89fd90826de06_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTEtMS0xLTU1OTY4_94a839e0-48a9-4d59-a524-29d760a79b85">0.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8493b47598e8480aae3bec09697737b3_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTUtMS0xLTU1OTY4_fb6ea00a-05a2-4f60-808a-c4d71936d5c1">14.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie331398123094f4cbf9f53387dd320e2_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTctMS0xLTU1OTY4_9c132335-0851-471c-b3cf-a942e872e74f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i397d63e231e44fc79264c4127d701240_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTExLTEtMS01NTk2OA_91892668-fd92-450c-86d2-a46b1d8e257c">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTEzLTEtMS01NTk2OA_affff205-08e0-406f-b5b7-901ff182b684">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTE1LTEtMS01NTk2OA_926fe16d-67e3-42f8-9aea-ecca98347283">10.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9303df094ef6478caab5920b2de3b1fc_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTEtMS0xLTU1OTY4_7e32722a-c610-41af-a152-e323f7f41ff9">99.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9303df094ef6478caab5920b2de3b1fc_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTMtMS0xLTU1OTY4_67d57eef-660f-4468-bce2-14a814aece5a">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead3c9b8c76f4379b37747a26d26954b_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTUtMS0xLTU1OTY4_f56dcd3d-e1b9-4cb6-84ec-5f953cfe904c">2,289.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6acc944f2fd94ce584242187a09963ae_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTctMS0xLTU1OTY4_637c1641-fd15-4a07-b573-6b796448e979">141.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6943570c9ef04b01be3d3edd3c2634f3_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTExLTEtMS01NTk2OA_b4d892b7-1603-4616-b782-d0df0f0ce0bb">521.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9983aeb86edb4167b0261e7526ff14e4_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTEzLTEtMS01NTk2OA_0fa012f3-f0d9-4596-acb0-b62f0dbd40f4">445.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTE1LTEtMS01NTk2OA_73d81795-0f61-4ddb-8351-ee994e34fe6b">2,357.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to consolidated financial statements are an integral part of these statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_148"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Cash Flows</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQtMS0xLTEtNTU5Njg_eee60d7d-d16d-43e1-a003-8d7321f810ca">517.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQtMy0xLTEtNTU5Njg_13d8b70a-2b24-4ec2-82af-147e80a9b6f8">368.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQtNS0xLTEtNTU5Njg_bb2ec563-760e-43e2-98bf-b9d784c6e37b">445.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzUtMS0xLTEtNTU5Njg_83b30750-eb17-4bd5-be9e-03c56f2c6c8b">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzUtMy0xLTEtNTU5Njg_20b1ac2d-f511-488b-8fba-3860dc0470cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzUtNS0xLTEtNTU5Njg_ce44a3cf-139e-4a8a-9b3d-859e84a762d0">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for government, class action, and related settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzctMS0xLTEtNTU5Njg_4e58a754-711a-4f9a-ab68-0112670d3635">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzctMy0xLTEtNTU5Njg_cd94bd9a-bc81-444b-aab8-d8b3b5d05fab">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzctNS0xLTEtNTU5Njg_7a7141ed-3049-407f-9108-f997cd306eaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzgtMS0xLTEtNTU5Njg_44b385db-857d-4294-bd1b-1f71c2cbd874">256.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzgtMy0xLTEtNTU5Njg_ab5314cb-27e3-4402-a429-c6d694646578">243.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzgtNS0xLTEtNTU5Njg_d7130823-8168-4260-93c4-217acbf34a89">218.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt-related items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzktMS0xLTEtNTU5Njg_3a6e702d-3003-4d1f-975e-57a5c10ed66c">7.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzktMy0xLTEtNTU5Njg_345555a5-8570-45a9-a8a0-21bc2ab53ccd">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzktNS0xLTEtNTU5Njg_ffaa16bb-6c31-4b51-8d8a-d24aacaaa022">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEwLTEtMS0xLTU1OTY4_97b0afac-4d33-40dd-b1f7-77e1cedc0f95">1.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEwLTMtMS0xLTU1OTY4_6002eebb-8c9d-4e59-9457-230b5d8a8364">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEwLTUtMS0xLTU1OTY4_c46d3cb0-3934-4db6-a8e5-e085aad3d6e5">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzExLTEtMS0xLTU1OTY4_28029e7d-ca35-4a9c-a6aa-4aa33f6c0fee">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzExLTMtMS0xLTU1OTY4_0fa460d0-28a9-4e0f-b4a8-5e0262803a7d">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzExLTUtMS0xLTU1OTY4_554d663a-a0b9-4b3f-82e8-1b5d1202d07a">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions from nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEyLTEtMS0xLTU1OTY4_1ddc22ac-ad17-4cf5-bbd7-d546c5fe662e">2.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEyLTMtMS0xLTU1OTY4_68e677c3-110a-408e-9d2d-c7494dd509a3">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEyLTUtMS0xLTU1OTY4_ea65afbc-bc54-416d-aa77-204dfca18809">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEzLTEtMS0xLTU1OTY4_13ccc6f2-0174-40a3-ab68-4226464b6b32">32.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEzLTMtMS0xLTU1OTY4_e8608fd4-5c16-4f48-b878-c2571eb3f2bc">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEzLTUtMS0xLTU1OTY4_b982b476-4e67-4b7d-a45d-4989ebb37f1e">114.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE0LTEtMS0xLTU1OTY4_ff434c50-62a0-4db5-b645-f6216c1e16a4">27.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE0LTMtMS0xLTU1OTY4_bcc1d52b-5bb0-448a-b3c8-416171cd867e">52.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE0LTUtMS0xLTU1OTY4_5570b0b7-88a9-4159-bad6-b38c01fe4560">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of Yuma Rehabilitation Hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE1LTEtMS0xLTU1OTY4_727f8869-2ef9-436e-bdf9-850cb83615c5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE1LTMtMS0xLTU1OTY4_bf119620-3ae2-4fa3-86f9-dd66f66cf607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE1LTUtMS0xLTU1OTY4_15451577-6ce7-46e3-9903-b60eb4face97">19.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE2LTEtMS0xLTU1OTY4_a7786311-1c46-41a6-88e0-c92725729abd">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE2LTMtMS0xLTU1OTY4_7bc46d31-05b5-4cfd-b4a5-aec4e15da602">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE2LTUtMS0xLTU1OTY4_7486adb1-cb2e-4a69-93d4-4c143ada453f">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions &#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE4LTEtMS0xLTU1OTY4_3d31b280-2334-41d2-8d23-4d190914e7bd">64.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE4LTMtMS0xLTU1OTY4_73f4db7b-e6a2-486a-82c4-be04c9ac4e94">38.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE4LTUtMS0xLTU1OTY4_256c1b34-aaad-49b7-8a3c-2fd64ecf7bcc">22.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE5LTEtMS0xLTU1OTY4_67b32fd8-3142-4e20-9e73-23cc206c7115">42.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE5LTMtMS0xLTU1OTY4_a61f0f5b-4244-4bf6-ac9c-a2cf14466b7b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE5LTUtMS0xLTU1OTY4_ee9c8c5d-f491-4b65-9486-4155db97659c">35.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIwLTEtMS0xLTU1OTY4_c4591ab5-d8d9-48e9-9dc1-28ff635528ac">14.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIwLTMtMS0xLTU1OTY4_f98bf91d-aa12-4013-93e7-b66108d8f12c">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIwLTUtMS0xLTU1OTY4_ca9501c8-c15f-41b1-9237-fd0225e93bce">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIxLTEtMS0xLTU1OTY4_6efec476-4f11-4d14-982a-254eff899cc7">38.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIxLTMtMS0xLTU1OTY4_016fec27-90a0-4ec6-9f5e-04f1c8123020">92.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIxLTUtMS0xLTU1OTY4_658acd98-7776-4823-a057-9a8691bc9afb">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIyLTEtMS0xLTU1OTY4_a0c000f8-459a-4ed7-82f8-1c4f244fc8d2">11.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIyLTMtMS0xLTU1OTY4_2c6d6f73-6055-40c8-aa36-96172440194a">74.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIyLTUtMS0xLTU1OTY4_87bfbdb8-ec29-4d16-b600-a1da5cea0b62">128.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI2LTEtMS0xLTU1OTY4_19c0058d-93dc-4b97-9e98-47a8fcfeb643">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI2LTMtMS0xLTU1OTY4_7706c243-072c-4044-8fec-21f4b6706bcf">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI2LTUtMS0xLTU1OTY4_88f5d46a-a7d9-4383-894a-220c9cef9ba7">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI3LTEtMS0xLTU1OTY4_593446dd-6837-4193-af7c-15eeb6473fa1">198.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI3LTMtMS0xLTU1OTY4_4fee8972-22ea-44bb-9ae2-bc8d3bd1a2e5">335.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI3LTUtMS0xLTU1OTY4_ccb24cb5-2ddb-4f52-a252-ea7f6443a626">188.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI4LTEtMS0xLTU1OTY4_fd810057-dc4e-4924-95bb-3438e2f91c8e">715.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI4LTMtMS0xLTU1OTY4_717bea55-979e-4ae9-a2fd-034526107c6e">704.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI4LTUtMS0xLTU1OTY4_7c416cba-0d6c-4603-9c76-418bf2200c03">635.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMwLTEtMS0xLTU1OTY4_f7051bd1-fb67-4b49-bb3a-c99f5fcaa6e0">118.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMwLTMtMS0xLTU1OTY4_e8edd5d0-4bfc-45bd-9c35-e81af051a208">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMwLTUtMS0xLTU1OTY4_9aa23fba-4a30-4c23-adbb-9429c8a0d573">231.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMxLTEtMS0xLTU1OTY4_e6e77825-4297-416e-b497-da25e696837a">528.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMxLTMtMS0xLTU1OTY4_1443a559-0248-412a-b2e0-36e1f3cbf6d5">396.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMxLTUtMS0xLTU1OTY4_c4e2b938-d87c-45c8-8fae-6e009e545064">372.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to capitalized software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMyLTEtMS0xLTU1OTY4_39e07064-d774-43d6-a2cd-0f714b4635e8">15.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMyLTMtMS0xLTU1OTY4_53acc46d-80de-4adc-9218-a38a9b9d91c2">8.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsForSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMyLTUtMS0xLTU1OTY4_0a1f0088-a466-4676-8b17-d14c117398bb">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMzLTEtMS0xLTU1OTY4_19fdda69-adb4-47f1-b3da-a7889050dec6">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMzLTMtMS0xLTU1OTY4_be37f96a-0c92-49ef-bb80-41ab19c838fd">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMzLTUtMS0xLTU1OTY4_9d18e00b-bb33-4dda-8db6-85a687d036e8">18.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM2LTEtMS0xLTU1OTY4_b2338b60-9fc6-4946-87b4-60eae3d47b5c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM2LTMtMS0xLTU1OTY4_94d92b7f-3773-4ada-8f59-7d08554f30b9">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM2LTUtMS0xLTU1OTY4_d12b55a7-7c67-417e-b336-c83707a7ef88">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM3LTEtMS0xLTU1OTY4_462a82ba-2433-4ce4-9ad2-e10be70dfc3f">9.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM3LTMtMS0xLTU1OTY4_a5a48c41-b640-45e7-a6de-5faaf998c6d0">8.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM3LTUtMS0xLTU1OTY4_d1b82325-ce0e-4c33-b2c6-fca43345237e">32.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM4LTEtMS0xLTU1OTY4_44a00917-1812-4a94-870a-e5852fd01a4e">12.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM4LTMtMS0xLTU1OTY4_fb7bc6cc-445c-4ac0-832f-795bf3a4448b">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM4LTUtMS0xLTU1OTY4_a313ce28-b81a-4594-817b-11b7b2138450">6.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQwLTEtMS0xLTU1OTY4_c7b3c43e-1dc0-4944-afc5-576d6177c931">666.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQwLTMtMS0xLTU1OTY4_45e26896-a11b-4317-b2c0-d5cca47e6ab0">407.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQwLTUtMS0xLTU1OTY4_e983f348-16ca-42f4-8c1a-e615d2eda29b">657.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Cash Flows (Continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from bond issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzUtMS0xLTEtNTU5Njg_eb77126f-7726-4c19-bf46-077bd601088a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzUtMy0xLTEtNTU5Njg_18a45057-4b51-48a7-8ef6-7882d6ffabb8">992.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzUtNS0xLTEtNTU5Njg_56ffa456-6f60-43f8-b504-4940a3a36056">1,000.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on debt, including pre-payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzYtMS0xLTEtNTU5Njg_e68fd2bc-f3b9-4771-9fc5-b8066b1fb606">214.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzYtMy0xLTEtNTU5Njg_388182b0-81c1-48a9-b25e-e83c5d2fefd4">718.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzYtNS0xLTEtNTU5Njg_cc39ca66-a600-4d1b-b0d2-1e76ef8c177d">519.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzktMS0xLTEtNTU5Njg_2a6bb9f0-26a5-4a1b-bddc-36addfb3b4ee">300.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzktMy0xLTEtNTU5Njg_8046fa5f-397b-4698-b19a-98f811039e16">330.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzktNS0xLTEtNTU5Njg_16b6d838-bba6-415a-a788-6c5a6be5dadf">635.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEwLTEtMS0xLTU1OTY4_64f2249d-d8f6-4d18-80ee-abb0f87d6294">100.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEwLTMtMS0xLTU1OTY4_980ffa81-53d3-47a7-8341-c7833e1e9485">375.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEwLTUtMS0xLTU1OTY4_f0575b36-de97-4cb1-b151-db0abb5d7ad6">620.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments under finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzExLTEtMS0xLTU1OTY4_f7b27b4e-3889-4ea0-8113-1b5d53560ff1">51.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzExLTMtMS0xLTU1OTY4_e5b649ed-bdec-49f0-a12c-9328d3f235c0">22.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzExLTUtMS0xLTU1OTY4_36565a11-eaa5-4991-8fe2-585747c58ff6">19.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt amendment and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEyLTEtMS0xLTU1OTY4_389ee180-a87f-4ebb-b7a9-3a38cc8dbae0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEyLTMtMS0xLTU1OTY4_869c7857-ac72-4207-a244-dc01cf248c87">20.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEyLTUtMS0xLTU1OTY4_ab088ad4-56a2-40a4-9fcf-01e0a053c037">21.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock, including fees and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEzLTEtMS0xLTU1OTY4_06d64ec0-ca6e-4d70-9c5b-c7397aede8b4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEzLTMtMS0xLTU1OTY4_b2569a16-f67f-4c85-a247-dacfbb69bba2">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEzLTUtMS0xLTU1OTY4_b24df8cd-1c0c-4517-a43a-94e8f3f53e3c">45.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid on common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE1LTEtMS0xLTU1OTY4_71446ae5-c62c-49cb-a282-be915c4f73ca">112.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE1LTMtMS0xLTU1OTY4_0ed0077b-ad74-4017-bd9a-d1e63721e7b0">111.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE1LTUtMS0xLTU1OTY4_5adf1576-0dcb-413a-9ab2-8dec9cfe8080">108.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of equity interests in consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE2LTEtMS0xLTU1OTY4_10527b2a-6fc3-48eb-90c3-7519f82ff3af">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE2LTMtMS0xLTU1OTY4_09315add-de8a-40ea-9948-973218909ad3">162.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE2LTUtMS0xLTU1OTY4_d2712f78-f585-4857-88be-8fb65f78a7e4">162.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests of consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE5LTEtMS0xLTU1OTY4_d4279a39-cc9b-45bb-8f38-982a9d33abc7">102.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE5LTMtMS0xLTU1OTY4_fb584215-d8a5-400b-8931-942522fa155f">72.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE5LTUtMS0xLTU1OTY4_db7ab481-df9e-4707-acf5-e023716aab4b">79.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid on behalf of employees for shares withheld</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIwLTEtMS0xLTU1OTY4_c4d2e093-9f81-4f51-9a1c-b15238d3d0df">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIwLTMtMS0xLTU1OTY4_915c6a4e-de7f-4ae4-87a3-ab7fd83f1fb5">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIwLTUtMS0xLTU1OTY4_4bda3af9-161a-4fb5-b3d0-b3ed94580168">16.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests of consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIxLTEtMS0xLTU1OTY4_95171a47-1434-4117-b572-f920d8384af6">57.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIxLTMtMS0xLTU1OTY4_1f718a2f-9aad-451c-ae43-c4e91e360032">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIxLTUtMS0xLTU1OTY4_946d6132-5d32-4bb2-87fd-99be9d34f4ed">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIyLTEtMS0xLTU1OTY4_4bd672a5-8257-4812-81c8-68b1fdf54054">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIyLTMtMS0xLTU1OTY4_99b6772a-9914-42c6-8966-d16b4b9ce126">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIyLTUtMS0xLTU1OTY4_fb8508ed-6802-49b3-85ca-2472132b4855">8.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIzLTEtMS0xLTU1OTY4_b4717585-2e6a-445b-b61f-be647c7555d3">240.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIzLTMtMS0xLTU1OTY4_05ae6885-d511-4826-b4db-502501af82a4">145.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIzLTUtMS0xLTU1OTY4_fd5ac953-2d1e-478a-b576-1b8bfbaa34cc">48.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Decrease) increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI0LTEtMS0xLTU1OTY4_36c88fbf-6911-42dd-bbaf-9edb83fed49d">190.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI0LTMtMS0xLTU1OTY4_610333d6-f30d-4619-a067-50b0e99f1248">151.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI0LTUtMS0xLTU1OTY4_76404b28-193a-427a-a32d-52ef59714f90">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents. and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI1LTEtMS0xLTU1OTY4_6fff4a0b-54ec-413d-9329-70abac4e7db2">310.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI1LTMtMS0xLTU1OTY4_9239e892-cfe1-468d-bc80-1ffe0b7a5187">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI1LTUtMS0xLTU1OTY4_3ef57c9d-03d1-40b9-baec-04c026603995">133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI2LTEtMS0xLTU1OTY4_a2041601-d72e-48b8-9fe2-17c6d1a6306b">120.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI2LTMtMS0xLTU1OTY4_0f901fa6-c6fa-4583-ac68-5fe5fe524343">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI2LTUtMS0xLTU1OTY4_db318ada-f530-488d-bbcb-8cf3d05d50bb">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI5LTEtMS0xLTU1OTY4_2cc93585-c14a-44f2-b8bc-ac13dd7fa069">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI5LTMtMS0xLTU1OTY4_89f5bc40-123f-457a-8939-be4eb18581d4">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI5LTUtMS0xLTU1OTY4_e2dddaec-f8e0-4b4d-90e1-a76742f44f87">69.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash at beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMwLTEtMS0xLTU1OTY4_76d60d37-6bfc-41fb-8cc1-3fdc0cbe0e19">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMwLTMtMS0xLTU1OTY4_baa08b46-580d-47ed-8b10-728b3c075c51">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMwLTUtMS0xLTU1OTY4_92a4ddca-195f-49c2-bc93-8408461f356d">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other long-term assets at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMxLTEtMS0xLTU1OTY4_bb3d550e-c220-4e2d-abf6-7a7059aa47fa">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMxLTMtMS0xLTU1OTY4_eeab325d-6418-4e53-84d0-811fdab8aae4">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMxLTUtMS0xLTU1OTY4_677766a7-035f-4262-86a6-fd9c0262f0c1">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMyLTEtMS0xLTU1OTY4_feb48df6-0f29-4cb2-b459-dcd387088e7a">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMyLTMtMS0xLTU1OTY4_5175d167-14fa-4acd-8aa2-331772ab8e4f">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMyLTUtMS0xLTU1OTY4_ac121328-2598-4d53-aaa0-eb851f1f791c">133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM0LTEtMS0xLTU1OTY4_a8673a8b-0459-41ed-b6e0-5d4e024eda4e">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM0LTMtMS0xLTU1OTY4_b726fe7a-3f77-430c-ba8c-e532844a1586">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM0LTUtMS0xLTU1OTY4_31366a5d-05d1-4d2a-8888-e065a262525f">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash at end of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM1LTEtMS0xLTU1OTY4_b7ace835-e50e-4f51-ad82-8f0b1efbb05c">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM1LTMtMS0xLTU1OTY4_78f7f9cf-3684-47d9-8816-ab6779b96b5f">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM1LTUtMS0xLTU1OTY4_93adfb88-687f-43cb-a499-c8de1cb4a066">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other long-term assets at end of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM2LTEtMS0xLTU1OTY4_29066043-c89e-4043-939d-efb8e7f52063">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM2LTMtMS0xLTU1OTY4_62559164-79b1-465a-8c3f-e578e08a877f">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM2LTUtMS0xLTU1OTY4_7a79b833-c551-4e68-a1f2-746bb7713ef0">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM3LTEtMS0xLTU1OTY4_545361fa-2aba-44f9-8545-47641ba5865e">120.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM3LTMtMS0xLTU1OTY4_4936acd9-87d7-41bc-abc0-ea92e3a1a72f">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM3LTUtMS0xLTU1OTY4_c339274f-b413-4a01-962f-701dd2b12cff">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (paid) received during the year for &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQxLTEtMS0xLTU1OTY4_9f998a8b-ea54-4c38-a672-d6d1a0137cd3">168.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQxLTMtMS0xLTU1OTY4_c1228588-b9f9-47e6-8d91-8f6ff7a842b4">168.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQxLTUtMS0xLTU1OTY4_d313a0be-38ed-4912-b2b5-be9a1364e268">155.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax refunds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQyLTEtMS0xLTU1OTY4_1b1dcbca-62d9-4ce7-8067-c34fb8cfde93">1.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQyLTMtMS0xLTU1OTY4_c022b1ec-754d-4227-b0d2-89b11d316ed4">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQyLTUtMS0xLTU1OTY4_107ce7ba-bbe0-4248-8df3-de2403688c4f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQzLTEtMS0xLTU1OTY4_46b7eca9-a8b5-4f48-8881-f2c399aca256">131.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQzLTMtMS0xLTU1OTY4_8f508591-9dc1-48b0-9125-dcb6572c0b73">34.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQzLTUtMS0xLTU1OTY4_ee76107f-4738-4f21-ba02-7622f69fb753">104.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental schedule of noncash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASC 842</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQ2LTUtMS0xLTU1OTY4_888c5369-7338-4722-b8ee-4bfe70963a74">349.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to consolidated financial statements are an integral part of these statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span><br/></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_154"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNTQvZnJhZzowNTYzMDFkNjQyOGM0MmJlYjkwZDg5YjgyNGYwZTU3Ny90ZXh0cmVnaW9uOjA1NjMwMWQ2NDI4YzQyYmViOTBkODliODI0ZjBlNTc3XzE1_924ed142-510d-46f5-9067-afd23108cace" continuedAt="i349cd737564245e2bd6f6ee06c16d48d" escape="true">Summary of Significant Accounting Policies:</ix:nonNumeric> </span></div><div id="i34f6226a63dc43528534c2bfabd86ded_157"></div><ix:continuation id="i349cd737564245e2bd6f6ee06c16d48d" continuedAt="i88a2a16e23c84d2ca00a2df18fb77c25"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization and Description of Business&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a national leader in integrated healthcare services, offering both facility-based and home-based post-acute services in <ix:nonFraction unitRef="state" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNTcvZnJhZzo2Y2FmMjI1MDA5ODQ0ZDBkYmViNjMzZDZiNjIyZjNkZC90ZXh0cmVnaW9uOjZjYWYyMjUwMDk4NDRkMGRiZWI2MzNkNmI2MjJmM2RkXzI4Mg_df7c15a3-7d91-4b9c-b1c6-0e2c684add04">42</ix:nonFraction> states and Puerto Rico through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using <ix:nonFraction unitRef="segment" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNTcvZnJhZzo2Y2FmMjI1MDA5ODQ0ZDBkYmViNjMzZDZiNjIyZjNkZC90ZXh0cmVnaW9uOjZjYWYyMjUwMDk4NDRkMGRiZWI2MzNkNmI2MjJmM2RkXzQ3Nw_8e6a258c-faf0-48e7-b417-72edc53b79ed">two</ix:nonFraction> reportable segments: (1) inpatient rehabilitation and (2)&#160;home health and hospice. See Note 19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 9, 2020, we announced a formal process to explore strategic alternatives for our home health and hospice business. As a result of this process, we expect to separate the home health and hospice business from Encompass Health into an independent public company through a spin-off distribution in the first half of 2022. On January 19, 2022, we announced the home health and hospice business would be rebranded and operate under the name Enhabit Home Health &amp; Hospice. The rebranding of agency locations is expected to begin in mid-April 2022 and to be largely completed by the consummation of the spin off.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_160"></div><ix:continuation id="i88a2a16e23c84d2ca00a2df18fb77c25" continuedAt="i24987287f4f140b8a018f495c1c15dc7"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNjAvZnJhZzpiYjExNTU3ZGU1ZjA0ZWVkYWQzODcyY2E1NzEwOWJhYS90ZXh0cmVnaW9uOmJiMTE1NTdkZTVmMDRlZWRhZDM4NzJjYTU3MTA5YmFhXzE1MjE_ed9f550c-98ca-4d12-9b0c-5bdbf0d968d7" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Consolidation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Encompass Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the measurement alternative to account for our investments in entities we do not control and for which we do not have the ability to exercise significant influence over operating and financial policies. In accordance with the measurement alternative, these investments are recorded at the lower of cost or fair value, as appropriate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We eliminate all significant intercompany accounts and transactions from our financial results.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_163"></div><ix:continuation id="i24987287f4f140b8a018f495c1c15dc7" continuedAt="iad0f55b00e9049d88c27b69ca2f40448"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNjMvZnJhZzpmZTA1NWFhNzY4NWU0N2YzYTU2MzIzNmNhMmU0Nzc1YS90ZXh0cmVnaW9uOmZlMDU1YWE3Njg1ZTQ3ZjNhNTYzMjM2Y2EyZTQ3NzVhXzYzMQ_a6271523-4bb0-4ed3-972d-abd290d6503f" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any entity considered a variable interest entity (&#8220;VIE&#8221;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_166"></div><ix:continuation id="iad0f55b00e9049d88c27b69ca2f40448" continuedAt="ic70c21fe7d484cd5a68f426eae724cba"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNjYvZnJhZzpiMzA4NzUxNzdhYjM0MDY5OTA3YjU0MGEzMjNlMTE5Zi90ZXh0cmVnaW9uOmIzMDg3NTE3N2FiMzQwNjk5MDdiNTQwYTMyM2UxMTlmXzE4MTE_c974a7e0-a08c-4393-8631-7a600066dbdd" continuedAt="i08b46dd9ad79473eb53a2835cd07fa76" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates and Assumptions&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#8217; compensation, and comprehensive general insurance liability risks; </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic70c21fe7d484cd5a68f426eae724cba" continuedAt="i305efdb3379e416bb37b3bd67e4dc28e"><ix:continuation id="i08b46dd9ad79473eb53a2835cd07fa76">and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.</ix:continuation></ix:continuation></span></div><div id="i34f6226a63dc43528534c2bfabd86ded_169"></div><ix:continuation id="i305efdb3379e416bb37b3bd67e4dc28e" continuedAt="i7c140b5f43dd4210bcf6d64e66664d11"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a healthcare provider, we are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensure, certification, and accreditation;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coding and billing for services;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements of the 60% compliance threshold under The Medicare, Medicaid and State Children&#8217;s Health Insurance Program (SCHIP) Extension Act of 2007;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality of medical care;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use and maintenance of medical supplies and equipment;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance and security of patient information and medical records;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition and dispensing of pharmaceuticals and controlled substances; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disposal of medical and hazardous waste.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, contractual arrangements, and patient admittance practices, as well as the way in which we deliver home health and hospice services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable laws and regulations, we could be required to return portions of reimbursements deemed after the fact to have not been appropriate. We could also be subjected to liabilities, including (1)&#160;criminal penalties, (2)&#160;civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals or agencies, and (3)&#160;exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement. Because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. Specifically, reductions in reimbursements, substantial damages, and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operation, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the United States Congress and some state legislatures have periodically proposed significant changes in regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in pricing roll-backs or freezes or reimbursement reductions. Because we receive a significant percentage of our revenues from Medicare, such changes in legislation might have a material adverse effect on our financial position, results of operations, and cash flows.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i7c140b5f43dd4210bcf6d64e66664d11" continuedAt="icb1a404a44b2404a8f5cf14324e34857"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are increasing pressures from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. We could be adversely affected in some of the markets where we operate if we are unable to negotiate and maintain favorable agreements with third-party payors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are a party to a number of lawsuits. We cannot predict the outcome of litigation filed against us. Substantial damages or other monetary remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Pandemic</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onset of the COVID-19 Pandemic (the &#8220;pandemic&#8221;)</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has caused a disruption to our nation&#8217;s healthcare system. Such disruption includes reductions in the availability of personal protective equipment (&#8220;PPE&#8221;) to prevent spread of the disease during patient treatment and increases in the cost of PPE. From time to time in specific markets, elective procedures were postponed by physicians and acute-care hospitals and limited by governmental order to preserve capacity for the expected volume of COVID-19 patients and reduce the risk of the spread of COVID-19. Initially, these postponements and limitations were widespread. Now, they are more market or state specific and driven by the extent of the pandemic in those areas. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For various quarterly periods during the pandemic, we experienced decreased patient volumes in one or more of our business lines when compared to the prior year periods. We believe reduced patient volumes resulted from a number of conditions related to the pandemic including: lower acute-care hospital censuses due to the deferral of elective surgeries and shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, policies in assisted living facilities that limit our staff from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. In the home health and hospice segment, we also experienced decreases in visits per episode and institutional referrals because of the pandemic, both of which negatively impacted pricing for home health.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the public health emergency associated with the pandemic, Congress and Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care. On March 27, 2020, former President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;), which temporarily suspended sequestration for the period of May 1 through December 31, 2020. The CARES Act also authorized the cash distribution of relief funds from the United States Department of Health and Human Services (&#8220;HHS&#8221;) to healthcare providers. We did not accept any CARES Act relief funds. The Consolidated Appropriations Act, 2021 (the &#8220;2021 Budget Act&#8221;), signed into law on December 27, 2020 provided for additional provider relief funds. We intend to refuse any additional provider relief funds distributed in the future whether authorized under the 2021 Budget Act or other legislation. The sequestration suspension has been extended a number of times. Sequestration is currently scheduled to resume as of April 1, 2022 but will only be a 1% payment reduction through June&#160;30, 2022. Thereafter, the full 2% Medicare payment reduction will resume. Federal legislation, including the CARES Act and the 2021 Budget Act, and CMS regulatory actions include a number of other provisions, which are discussed below, affecting our reimbursement and operations in both segments.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the CARES Act, 2021 Budget Act, and a series of waivers and guidance issued by CMS suspend various Medicare patient coverage criteria and documentation and care requirements in an effort to provide regulatory relief until the public health emergency for the pandemic has ended. For inpatient rehabilitation, the regulatory relief includes the temporary suspension of the requirement that patients must be able to tolerate a minimum of three hours of therapy per day for five days per week and waiver of certain of the requirements, including the exclusion of COVID-19 admissions from the compliance calculation under the 60% Rule. In addition, the requirement of physician face-to-face visits at least three days a week may be fulfilled using telehealth. For home health, the relief includes the allowance of nurse practitioners and physician assistants under certain conditions to certify, establish and periodically review the plan of care, as well as supervise the provision of items and services for beneficiaries under the Medicare home health benefit and expands the use of telehealth. Additionally, CMS expanded the definition of &#8220;homebound&#8221; to include patients needing skilled services who are homebound due solely to their COVID-19 diagnosis or patients susceptible to contract COVID-19. For hospice, the relief includes the temporary waiver of the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="icb1a404a44b2404a8f5cf14324e34857" continuedAt="ia49fca1c424742f59c03c90fad075634"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides, as well as the expanded use of telehealth for routine services and patient recertification.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in April 2020, we amended our credit agreement primarily to provide covenant relief due to business disruptions from the pandemic. The amendment included, among other things, the carve-out of the pandemic from the definition of material adverse effect for 364 days and modifications to the interest coverage and leverage ratios under the agreement. </span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia49fca1c424742f59c03c90fad075634" continuedAt="i5894c3d74cf640cd9c744619df9fdad6">The foregoing and other disruptions to our business as a result of the pandemic have had and are likely to continue to have an adverse effect on our business and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</ix:continuation> </span></div><div id="i34f6226a63dc43528534c2bfabd86ded_172"></div><ix:continuation id="i5894c3d74cf640cd9c744619df9fdad6" continuedAt="i20cef02bdff940ed9de5e0ea6f27fcbe"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues&#8212;</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90ZXh0cmVnaW9uOmYxOTY1ZGU3NmY0MjRiMGE4MWM2M2Q4NzU4NmMyNGU2XzE1NTc1_9e5a132e-5ada-4c63-9590-eeed73ae689f" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:20.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c41afde2c14f30868fae349870ae67_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMS0xLTEtNTU5Njg_65f7991c-9665-48a8-b946-3019251d0b6b">2,589.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6271cffe1c904ccb98ba4fe7cc5181c9_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMy0xLTEtNTU5Njg_1fb968c5-b9e3-49e7-9dff-dcfb8da11e42">2,375.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cc4a44f3ce4c27b16c3a87f7e6c602_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtNS0xLTEtNTU5Njg_f95adc90-6bc9-4a9e-a9ae-2eff1547b462">2,537.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie210db53eb0d412eaee1d6fcca151b10_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtNy0xLTEtNTU5Njg_2361dd7e-774a-4497-a087-0b1ca0e91065">906.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0201709f3946c08a6ab86ab34fd860_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtOS0xLTEtNTU5Njg_abe7cb3b-94a6-4be6-8204-16cd41d4924c">896.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefea4843724b48b09d4df201deaf65a4_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMTEtMS0xLTU1OTY4_f228eefc-c093-44c3-a56f-895c602bc27d">920.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc66028fb34c417d98f6aa0925fbaf46_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMTMtMS0xLTU1OTY4_c78e2e0f-ef5a-4a67-a022-d9cbb32542cd">3,496.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf5dec126efa48feb647aa010d99768a_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMTUtMS0xLTU1OTY4_92672054-f994-485f-a385-92282e666b38">3,271.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9441f0547a243a2b7b5a2b86b40a684_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMTctMS0xLTU1OTY4_d3653df5-1827-4702-8729-c37ee2bdc452">3,457.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e244b99f69648959e00b33e0813e62d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMS0xLTEtNTU5Njg_95f9afde-8417-4a6f-a1b1-3b26574ece83">609.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c48a4d00044a48498232bb8743644_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMy0xLTEtNTU5Njg_ff6c9074-b98d-4e58-a1da-2e105387e3df">544.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666da563adcc46e988ccb8361d06a266_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtNS0xLTEtNTU5Njg_c2161a97-337c-498c-9fb5-3b1f8e84f11e">375.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1c288f844e548c49f2fadc07c0cb5de_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtNy0xLTEtNTU5Njg_c3515959-b375-4ad2-b529-62593e6137fc">117.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0c321a2cfe4aa5a8aede0de35b5d94_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtOS0xLTEtNTU5Njg_bba224fa-952a-4f2c-b952-efaed1fd379d">116.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f340e8442bb423ca9425031c1a5d324_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMTEtMS0xLTU1OTY4_e18cd6c6-0184-4741-8b17-c072fbfd35cd">111.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ae81a511e14a958520030481b4f6ea_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMTMtMS0xLTU1OTY4_5e78d333-369d-467b-b194-e657819e8d77">727.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad2d076cc6c74bf4b47595003b494784_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMTUtMS0xLTU1OTY4_c58c86d6-bb5a-4402-a27d-e55e9a3dbd17">661.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f10396a7e3b43ebb4e5c9e8ea06743f_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMTctMS0xLTU1OTY4_b88fa8f2-4cbc-4d31-81ca-1115f9bc15f3">487.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90363214f544ed4a70ebfb5ebdad889_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMS0xLTEtNTU5Njg_998e9581-515d-44bc-9779-812d324ca4cd">484.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc79562a0921430d8e1b5424ea7afd74_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMy0xLTEtNTU5Njg_84973b79-ffef-4d25-bc7d-a305dad2e38d">371.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fdd0edfd604ca0adf6e6978f89a471_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtNS0xLTEtNTU5Njg_1f129d94-66b6-401e-ad2c-f6c06a599eb3">342.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248e5b251d414ac992e37bdfa4007809_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtNy0xLTEtNTU5Njg_5dd52190-d808-47f5-b0a4-e04d5a3fbce8">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889fb2355f34e3fa69a032dca90b99d_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtOS0xLTEtNTU5Njg_835b3e1e-2a90-45be-9465-b2e70b9ba67d">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4a3b4a13f348b7bde0e4da0ad9fa60_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMTEtMS0xLTU1OTY4_05390cee-2836-4eac-aaaa-9cf18bce5ad9">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd44b56d04a47dab1d7f34a4a696e77_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMTMtMS0xLTU1OTY4_90b9d1a6-6ab6-4110-b91b-11acd607e5a2">549.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc2201186bb441b862bf0c07fec3894_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMTUtMS0xLTU1OTY4_c4b94f1e-f191-4f7b-abe9-c34401a979a8">419.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da587872f03428ebd0561751ad78968_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMTctMS0xLTU1OTY4_d0bfb064-0b3a-4094-9e9f-c22fab147d33">381.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2080930973934f8c9f1b16798afc84c3_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMS0xLTEtNTU5Njg_a0e407cd-6eb3-44b6-9006-001d5035d230">163.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0c27770799485ab81f312f87261f13_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMy0xLTEtNTU5Njg_25032d8a-e425-4446-8fe7-67012cc0832f">140.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ab67a915ad4fccbdb5079bce262358_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtNS0xLTEtNTU5Njg_7d0af328-a89f-40ea-a1d0-ed8791bcf924">110.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8182e20f98d04c6190ceb6053df0ed57_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtNy0xLTEtNTU5Njg_437cdeb2-b57b-43e7-bc21-9e6c1f6e72b1">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcebecfa11144f2882ac634ce41c2cb_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtOS0xLTEtNTU5Njg_04ce5cb3-5018-47e3-987f-62ee3ef3a220">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbe87cd92944498b87689bf56f9f42f_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMTEtMS0xLTU1OTY4_3b1ecc55-16d1-42d5-9f43-3f71d1ef9a0b">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0763338809c342129b7f8f9c3818bd70_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMTMtMS0xLTU1OTY4_115ccaab-58a1-4a7f-a020-3caf80488581">178.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9408ebc5eec943238d4bd413eb2752e3_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMTUtMS0xLTU1OTY4_fa6f4bef-c615-4745-a7d0-2db7668e1580">155.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aae1d8057b04f22bf4c3a4c1a1de209_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMTctMS0xLTU1OTY4_0660f405-e7a2-4be4-afdb-350b342086a1">128.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57418ccab59c4872abdca8da71effd35_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMS0xLTEtNTU5Njg_38bc4ad4-055a-4ad3-81c9-5180eb6d162c">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b2e886e1d34c40a54db89ffdbe59e8_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMy0xLTEtNTU5Njg_5f4f16cf-5ba1-4512-8aa5-d1029406e689">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0186908fade24055a75bc3d6e203778b_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctNS0xLTEtNTU5Njg_56d16aaf-57ad-4134-ab5c-bfecfc5ff86c">43.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93348aee51814bf9aecb0395b5cb93a8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctNy0xLTEtNTU5Njg_090ed3cd-910d-4de8-a8e5-c08b8ff4a226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0839ac5ac72042bfb3800163f241925e_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctOS0xLTEtNTU5Njg_d7de794d-b870-4b1d-a757-8470b515e996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3e78919a4e4173a9a3c81b5ce115c8_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMTEtMS0xLTU1OTY4_9249838f-12ee-4579-821c-33d5d64010ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95dc4732a37c4b6da92a2818f2a80bc6_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMTMtMS0xLTU1OTY4_e736b2f8-2242-4012-b2fc-6cca4c4029f5">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fed2509c225447aa65e5e144d767dab_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMTUtMS0xLTU1OTY4_db808164-3b09-42fe-a710-b1c994e35dc8">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida50b0a668534d44aec233b93224cc40_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMTctMS0xLTU1OTY4_ca851c96-fc84-4899-a596-e28b69e4c252">43.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9e5d1b654340c29ca65e2d0b0aa0eb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMS0xLTEtNTU5Njg_befd2fbc-4319-4941-a78d-107019212caf">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde0b5f5e38841389b722fd9e125c188_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMy0xLTEtNTU5Njg_54ff0674-64b5-4dc1-a20a-3fdcb6a21dfd">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7373562b9b1b43dfa90c43cfc477cd4d_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtNS0xLTEtNTU5Njg_9f61f397-d4eb-437d-8cf1-a11cd2c6781b">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb62cf7c2ebf425185cc1b842a56a99b_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtNy0xLTEtNTU5Njg_7ffbc6ca-bed2-4236-8713-e27f17fd5b2c">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a535a2b9fd4b4a9dbbb62ad7109711_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtOS0xLTEtNTU5Njg_6b8737db-57e5-4037-b906-83f6e83dba60">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49093b7f6f74a3a8a1db6448e4cc4b3_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMTEtMS0xLTU1OTY4_e48e1e39-fd06-4233-bd4f-f4438b6e9552">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd372b138034d8ebb56c465c676ff31_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMTMtMS0xLTU1OTY4_25c0eddf-96f1-4a8f-8972-37288a530679">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e61058727a4dee885614cf27830c46_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMTUtMS0xLTU1OTY4_f80c73a9-7b9e-4670-9c73-7935101de9ac">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f71b1e134644eb5be3d0b729fca8ce4_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMTctMS0xLTU1OTY4_e57b3eca-0a07-4745-ada2-d1bec424a527">30.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857d5dcdbfab46a6bbc20427b6491403_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMS0xLTEtNTU5Njg_d9651f6a-6683-44d3-b2e5-6583dbef9553">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaad37c17c8b34f8a94304d1a0bc269e2_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMy0xLTEtNTU5Njg_f752d1dd-2f96-4bc2-aa70-17713031b193">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e6d0167938432a9aa75d163f6f83fc_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktNS0xLTEtNTU5Njg_ec6c82c5-4671-4fe3-bd4c-5dc6ea771990">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic315543707c2438ca08eaee06a1f2450_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktNy0xLTEtNTU5Njg_b7552a2d-0db0-495a-bc03-6fbc3b2a74d9">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822b083e60b54e34844537cc70601ba7_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktOS0xLTEtNTU5Njg_e835883b-8552-4645-a23b-674a4f92571a">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd833c8e5a04bf6a99b0d8ec0b64e76_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMTEtMS0xLTU1OTY4_bdc148a0-c83e-416b-8ad5-2b28eab4e796">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d24912b1574d9cac401d0d2ee4bd93_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMTMtMS0xLTU1OTY4_cc173975-ab32-4ec1-8c24-abe55c564ebc">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b3c61991594fc08487d9b203777782_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMTUtMS0xLTU1OTY4_5bf6a336-5698-44a6-9989-a6ff5afdd131">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4fab58433e548239f4f791ed6c5f399_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMTctMS0xLTU1OTY4_050b15dd-981d-43c8-bb42-a8b51fe3a1ce">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9977d16b4a094aad9e89217d4ee09815_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTEtMS0xLTU1OTY4_4570a962-29e5-464d-88bf-d1057a1fe701">79.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e90e0735aa405787042bd27546ee2e_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTMtMS0xLTU1OTY4_e1e25a92-f5ee-48a6-9efb-6381d721d08b">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe668ae93474f95813ae6b7c49cdd11_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTUtMS0xLTU1OTY4_3bfcaf5e-63ab-49da-9ee7-a7d1a20e0c50">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361e56a65aae4bc697d20f87ea1972e2_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTctMS0xLTU1OTY4_142353c5-e26b-47b2-b76d-f872a20d2ef4">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7738b6274b504051923f6b91db1fcd16_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTktMS0xLTU1OTY4_73b543aa-0903-4402-b14d-c839d58db9ee">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a2078ca149443eafdafed5920c603a_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTExLTEtMS01NTk2OA_32629e8e-fe41-4693-8aa2-22707433e5c6">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f64ba8495734d8686feeecb04953b0c_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTEzLTEtMS01NTk2OA_0780ed0d-9f9c-40a4-8b6a-7417fa1c9f11">80.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a1b498ea6d4e5b8d189d76693cabb4_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTE1LTEtMS01NTk2OA_ef33cefe-ee7b-4850-bee6-ee0128063487">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb58bd763fa9433e89fc2d61f1929408_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTE3LTEtMS01NTk2OA_903e327a-5647-43fc-8f03-73243e8358a1">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3e24d5cd1f4b8ebdf4c2d6dd46c2fa_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTEtMS0xLTU1OTY4_1a8bbf21-aaad-4c35-8e46-40bf8c3e2b59">4,015.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62805e51679a413bb8bf0b46874d0827_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTMtMS0xLTU1OTY4_0f2210c2-e827-4b3c-ad73-f85a0471a03d">3,566.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8338e0e37d4903bd2d5fd0e52481d9_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTUtMS0xLTU1OTY4_3e0adfef-c302-4fe7-a827-0294bb67a440">3,513.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d168944b24b447dae54f7498ce0ba93_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTctMS0xLTU1OTY4_1068d12a-3aca-49c8-8ced-6c7e66f16804">1,106.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife450282edb048db9144cbdd9b90680e_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTktMS0xLTU1OTY4_e7ed9b89-73c3-45b1-9a5c-6d91d7585a5d">1,078.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ec10c8f11e4192a9e80bbde7ba3a07_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTExLTEtMS01NTk2OA_cbafd1a5-7895-493c-a757-2658a725d9b2">1,092.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7f4b3fa057413aa60a6ff5a64dbacd_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTEzLTEtMS01NTk2OA_4bb0afed-9f1b-47cf-a532-35175e10a2fe">5,121.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia523cdf50d014242b78b83f266130520_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTE1LTEtMS01NTk2OA_bcd96ebc-ed3d-47af-b1f0-1cd71499319c">4,644.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3e19f52f2f4397b2d5ea65c15ca225_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTE3LTEtMS01NTk2OA_f5f3bef9-1c5d-4910-a3eb-44d446034b1b">4,605.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90ZXh0cmVnaW9uOmYxOTY1ZGU3NmY0MjRiMGE4MWM2M2Q4NzU4NmMyNGU2XzE1NTY1_169055da-d52a-46d3-825b-88e515706d84" continuedAt="ia79399e61de44fcda622263cc938c5da" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i20cef02bdff940ed9de5e0ea6f27fcbe" continuedAt="i8392e3416d29456a8874edc39b321f8e"><ix:continuation id="ia79399e61de44fcda622263cc938c5da" continuedAt="i57fce12d7b564d3398679a47503c537e"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;) or the United States Department of Justice (the &#8220;DOJ&#8221;). Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Administrative Contractors (&#8220;MACs&#8221;), under programs known as &#8220;widespread probes,&#8221; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#8220;appeal,&#8221; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OMHA practices continue, an increased number of unfavorable administrative law judge (&#8220;ALJ&#8221;) decisions could have a negative effect on our long-term ALJ success rate. The current OMHA practice has resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, CMS announced the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with CMS approved and announced Recovery Audit Contractors (&#8220;RACs&#8221;) audits related to inpatient rehabilitation facilities (&#8220;IRFs&#8221;), we received requests from 2013 to 2021 to review certain patient files for discharges occurring from 2010 to 2021.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established Unified Program Integrity Contractors (&#8220;UPICs&#8221;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8392e3416d29456a8874edc39b321f8e" continuedAt="i53de8c40612a42299277ef3733ee99c5"><ix:continuation id="i57fce12d7b564d3398679a47503c537e" continuedAt="i945366584d544b05bbc1a315d9fa93b9"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Medicare claims that are subject to these post-payment audit requests represent less than <ix:nonFraction unitRef="number" contextRef="i117d8f2dd52b4c849355026c48132be2_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90ZXh0cmVnaW9uOmYxOTY1ZGU3NmY0MjRiMGE4MWM2M2Q4NzU4NmMyNGU2XzgyNDE_adc30c43-f595-486e-af7d-06c3dad25950">1</ix:nonFraction>% of our Medicare patient discharges from 2010 to 2021. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2021, 2020, and 2019, our adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for claims that are part of this post-payment claims review process was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inpatient rehabilitation segment revenues are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice Revenues</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. The performance obligation is the rendering of services to the patient during the term of the episode of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal regulation. The base episode payment can be adjusted based on each patient&#8217;s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bill a portion of reimbursement from each Medicare episode near the start of each episode, and the resulting cash payment is typically received before all services are rendered. Effective January 1, 2021, this early payment process has been eliminated. As we provide home health services to our patients on a scheduled basis over the episode of care in a manner that approximates a pro rata pattern, revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of December&#160;31, 2021 and December&#160;31, 2020, the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not material and was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i53de8c40612a42299277ef3733ee99c5" continuedAt="if6ee9f0b0c594583990a1e9e0a251a5f"><ix:continuation id="i945366584d544b05bbc1a315d9fa93b9"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain Medicare regulations affecting outlier revenue if our patient&#8217;s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Adjustments to the transaction price for the outlier cap </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> not material</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, revenue is recorded on an accrual basis based upon the date of service at amounts equal to our estimated per-visit transaction price. Price concessions, including contractual allowances for the differences between our standard rates and the applicable contracted rates, as well as estimated uncollectible amounts from patients, are recorded as decreases to the transaction price.</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare revenues for hospice are recognized and recorded on an accrual basis using the input method based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The performance obligation is the rendering of services to the patient during each day that they are on hospice care. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the MAC. Adjustments to the transaction price for these caps </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> not material as of December&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our estimated per day transaction price. Price concessions, including contractual adjustments for the difference between our standard rates and the amounts estimated to be realizable from patients and third parties for services provided, are recorded as decreases to the transaction price and thus reduce our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_175"></div><ix:continuation id="if6ee9f0b0c594583990a1e9e0a251a5f" continuedAt="i41044c2cbf2e4a77a44ff55a4a7a1ea3"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzUvZnJhZzo3ZTg2ZDkyZDMzNDE0MDE2YTM0Yjk0Njk1MGQyMzliMS90ZXh0cmVnaW9uOjdlODZkOTJkMzM0MTQwMTZhMzRiOTQ2OTUwZDIzOWIxXzUzMw_193abe57-cec2-41ac-8e49-4b0571dcebfc" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include highly liquid investments with maturities of three months or less when purchased. Carrying values of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approximate fair value due to the short-term nature of these instruments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_178"></div><ix:continuation id="i41044c2cbf2e4a77a44ff55a4a7a1ea3" continuedAt="if622e95ead404679bcde2323b4454968"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzgvZnJhZzpiMWVjMWQyOTdjOWM0NmRiOTM0Y2RjMGZiYmQxZmYyZi90ZXh0cmVnaW9uOmIxZWMxZDI5N2M5YzQ2ZGI5MzRjZGMwZmJiZDFmZjJmXzEzNTM_f2a0326b-0522-41fe-a6ed-d0e14ade8fe6" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a separate component of shareholders&#8217; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_181"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if622e95ead404679bcde2323b4454968" continuedAt="i11c97b83bc884b349bc987ac944e1bcc"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90ZXh0cmVnaW9uOmE3ZmIyZWI5ZjY0NjRiNjM5YzY4NWJjY2UwNGM1ZDIzXzM1MTc_70b747b9-e0e4-4629-87b4-6ace6acc6097" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#8217; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90ZXh0cmVnaW9uOmE3ZmIyZWI5ZjY0NjRiNjM5YzY4NWJjY2UwNGM1ZDIzXzM1MDc_0657c896-3770-4312-86c7-5a4267fbe803" continuedAt="ie67c66d377184b0fb4897d93456948ac" escape="true">The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="ie67c66d377184b0fb4897d93456948ac"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7994f9fc04cd4840a17d1544f512fb8a_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzItMS0xLTEtNTU5Njg_e17fbe9c-3e22-4e09-812c-b3811e097197">63.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d9449e02ec44d508d4927471cdcc16a_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzItMy0xLTEtNTU5Njg_0ba2c0df-d18a-4341-aae7-d7afcedee649">66.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other discount plans, including Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i903f3c96be49421cb34587eada9a3d73_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzMtMS0xLTEtNTU5Njg_1d6f5b7c-82f2-4f71-8292-ec0ee8ada155">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ee22bb7c53a47e38414ec76277b14a0_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzMtMy0xLTEtNTU5Njg_e6bc2637-dad3-4750-89b5-e4bf3fa5da8e">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0ad45dea4b44812b11a801895fbabbd_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzQtMS0xLTEtNTU5Njg_14b0db49-ee7d-468a-8645-a258093c55e5">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95424a9f833f49b7975ae1ef37013150_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzQtMy0xLTEtNTU5Njg_9acf7fd4-fa79-4454-9011-e144b1d49479">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37ad81d8f2624817a96c259486c2c8f3_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzUtMS0xLTEtNTU5Njg_89d086a5-6eb0-412c-b7f5-d94a378a7d7f">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i261ac6208a0241d587f1681af3279429_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzUtMy0xLTEtNTU5Njg_e3039afa-48b2-40f2-9948-b18a108d49e7">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ae4da8c0139452fafe3c4ebbfca7ed9_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzYtMS0xLTEtNTU5Njg_1d5d58d2-daad-436a-b918-2ead9bb4bca2">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b77ac20c17f43f0a30fd0ec6609eeb5_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzYtMy0xLTEtNTU5Njg_60074553-afeb-4ed4-aee5-a522264ebd4b">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c6f62ec72ef49639c0efd8c8199879e_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzctMS0xLTEtNTU5Njg_d50e7390-52f6-4a8d-9fce-7a0d665c4978">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i610608fd11384b56bc5a535b1530b9c2_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzctMy0xLTEtNTU5Njg_ab0269a5-c9e2-4ec3-91ec-081069f6286b">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14868c106a174d0a8a6b3d5fcda73002_D20210101-20211231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzgtMS0xLTEtNTU5Njg_4391d22e-7a6a-494b-9cfb-2b00c392f493">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27c2b8cd85f64f408ee95281af4988eb_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzgtMy0xLTEtNTU5Njg_70cadeaa-df9e-4753-8f45-aa5e52d77961">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i11c97b83bc884b349bc987ac944e1bcc" continuedAt="i60f3c18269f34f32bd7f85684f0c2041"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90ZXh0cmVnaW9uOjYxNDU2ZmFiNTRhYjQ5MTc4ZjQ5YmFkYzUzNDhhYjZiXzE0ODM_c61df175-5704-4a81-81af-3deaa59476b9" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90ZXh0cmVnaW9uOjYxNDU2ZmFiNTRhYjQ5MTc4ZjQ5YmFkYzUzNDhhYjZiXzE0ODE_29645ad9-d2ea-4642-8553-71cc739b741b" continuedAt="iee1401148bd3476c80d222fff0e8d58c" escape="true">Useful lives are generally as follows:</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="iee1401148bd3476c80d222fff0e8d58c" continuedAt="i3015227c8550453fb424882c37480ff3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:84.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86b3dd4016124cdc94f5fc2e5ae4ee7c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzEtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3ZWE3ODYzZmNjMTE0ODM2YjAwM2EwZjZiZjQ4NjEyNV80_a7bfc753-0fe1-4c28-bf6e-7650a6c6cb31">10</ix:nonNumeric> to <ix:nonNumeric contextRef="i52accce1aeb84d6ea4f024105e7be7e4_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzEtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3ZWE3ODYzZmNjMTE0ODM2YjAwM2EwZjZiZjQ4NjEyNV8xMA_b937c97f-edc6-4af0-a9fb-6ae53ac3095b">30</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8e30f37f543478e8e85ee391f748aa2_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzItMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3NjIyYWExNTljYzk0YWEwYmY2NGI0NTI0ZDJkMmJkZF80_72c501f4-9a0b-4742-b5a8-8006d720ff23">2</ix:nonNumeric> to <ix:nonNumeric contextRef="i86cf609a63b04fb3b5b2972e6cb02c87_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzItMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3NjIyYWExNTljYzk0YWEwYmY2NGI0NTI0ZDJkMmJkZF8xMA_e969d883-7561-449c-86fb-f0781cbcdd1e">15</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaaafd14af4414d4ca561988c69f582b1_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzMtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2Y2YyMTE3NGIyMGI0Y2E3OThiNjFkZTQzNzA0Yjk2Ml80_de2f2ac3-c8f5-4c03-afb2-401c40bce02c">5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ida89837462c2402ebd51e087abc5f902_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzQtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo1ZDgyMDA3ZWE0NjU0ZWQwYjc5MmM3YjI4NWU0N2RiN180_c85919ba-54c8-4241-8858-162d2bd7a885">2</ix:nonNumeric> to <ix:nonNumeric contextRef="if710bb04b24245de9a5f881c21cd788c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzQtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo1ZDgyMDA3ZWE0NjU0ZWQwYjc5MmM3YjI4NWU0N2RiN18xMA_da3fbdd6-ae17-45f6-a7d0-6dbbbc67f9d4">10</ix:nonNumeric></span></div></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_187"></div><ix:continuation id="i60f3c18269f34f32bd7f85684f0c2041" continuedAt="if5c909e7986c45628a8658e5af8afada"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODcvZnJhZzo4ZTU2NjUzZmU3MGI0MTAwODBjYzRlZTdlNDJkMDhjNC90ZXh0cmVnaW9uOjhlNTY2NTNmZTcwYjQxMDA4MGNjNGVlN2U0MmQwOGM0XzE3OTk_8a9b0e87-7263-4210-b929-9dacf1a467ce" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8212;</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. We do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_190"></div><ix:continuation id="if5c909e7986c45628a8658e5af8afada" continuedAt="i45b0fb46403c4f8188a34a6d7134fa94"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90ZXh0cmVnaW9uOmMyYWJlYmYwYTgxODRiYzhiYjEzMTBkMWY3ZTNiMTM5XzQ2MTc_3a25baa3-e739-49df-95a6-f45186977aed" continuedAt="i5227814cd0e447f88b50382b44de6853" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets&#8212; </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i45b0fb46403c4f8188a34a6d7134fa94" continuedAt="iaced65155b3d4f1bbef9a36d5e227125"><ix:continuation id="i5227814cd0e447f88b50382b44de6853"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors in our inpatient rehabilitation and home health and hospice reporting units to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our reporting units using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of each reporting unit&#8217;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting units to our market capitalization. When we dispose of a hospital or home health or hospice agency, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2021, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount.</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90ZXh0cmVnaW9uOmMyYWJlYmYwYTgxODRiYzhiYjEzMTBkMWY3ZTNiMTM5XzQ2MTY_f3ea48a6-eb48-4d2f-a200-d0d945d2c11e" continuedAt="i31268c77d11e48bcbd5b2ebec600e04f" escape="true"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90ZXh0cmVnaW9uOmMyYWJlYmYwYTgxODRiYzhiYjEzMTBkMWY3ZTNiMTM5XzQ2MjM_180237e8-1109-46f6-9d52-581e3e076b90" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:62.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i50efb55c2089401caaa0a82d59fa749b_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzEtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpmMzVlMGYxMGVjYmE0NzEwOGU3NGQwYTYxYjczMzJlNV80_1a7dbe93-304a-4169-aa90-824c708d6aa9">10</ix:nonNumeric> to <ix:nonNumeric contextRef="i1dc3915d64cb4cd186314ea29dfaa5e3_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzEtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpmMzVlMGYxMGVjYmE0NzEwOGU3NGQwYTYxYjczMzJlNV8xMA_1d80bf43-f5fa-468c-85ef-b69bccf0d054">30</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7af755a7159549e5992cc331710580a2_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzItMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3ZmQ3ZDUxNTc5YTY0OGQzOTBhYmU1MzZjODZhYzEwMl80_c27bf64c-6431-4860-ab64-9fa02fda9162">10</ix:nonNumeric> to <ix:nonNumeric contextRef="i74d0e9fd8f4d4150b657b8c8b64a3458_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzItMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3ZmQ3ZDUxNTc5YTY0OGQzOTBhYmU1MzZjODZhYzEwMl8xMA_a890eb85-fe90-4c12-a772-f8054793ff76">20</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d6195ee7b4d4edb890d0350b3e6cbc8_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzMtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpkNjJmYjZiMTdlNTM0NzI0OTc4NTVjZjJiNGEyNjA1Nl80_62307cce-ca8c-4b19-a6d7-bc342c7b1711">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i36f353410c2e4dd5999e0aaa5dfb977a_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzMtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpkNjJmYjZiMTdlNTM0NzI0OTc4NTVjZjJiNGEyNjA1Nl8xMA_2a24391d-10e4-428a-97e1-6e5d6acd833c">18</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></div></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0f41d63c292477387fc936648de5818_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzYtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjozNmYwNDM3NDA3Nzk0YzEyOGQ3MGRiNWZjZTBhZWFmMF80_673d95d0-d1ed-489f-94d7-a2d9c1895c19">1</ix:nonNumeric> to <ix:nonNumeric contextRef="idf20f07dc2a8494ebaf17ecb8a1ec09a_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzYtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjozNmYwNDM3NDA3Nzk0YzEyOGQ3MGRiNWZjZTBhZWFmMF8xMA_623c1e8d-4bc7-4676-a27f-bdf34180d2b9">20</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43ff9c36be674ad1a655dbc573f502de_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzctMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpjMzgxM2Q0ZmE1NWE0YTFjYmM5MDg1M2YwOGFhNDJmMV80_6f9ae86f-24b7-44c4-8b46-da51f769641f">3</ix:nonNumeric> to <ix:nonNumeric contextRef="ife3d75e297fe483392cb51c7d6a9d0af_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzctMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpjMzgxM2Q0ZmE1NWE0YTFjYmM5MDg1M2YwOGFhNDJmMV8xMA_836d95ef-6bf1-4100-b936-c0542d0b0eca">7</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad16be810f6b476785e37f9d09c58d8b_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzgtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjoyN2ZkNDk3OTI1OGE0NzkzYThmZDk2MDkzMjQzNmU3Y180_55876c07-1853-4463-8259-1427ce0b0927">20</ix:nonNumeric> years using accelerated basis</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and directly related payroll costs. Amortization begins when the internal-use software is ready for its intended use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#8217;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over <ix:nonNumeric contextRef="iad16be810f6b476785e37f9d09c58d8b_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90ZXh0cmVnaW9uOmMyYWJlYmYwYTgxODRiYzhiYjEzMTBkMWY3ZTNiMTM5XzQ0Njc_55876c07-1853-4463-8259-1427ce0b0927">20</ix:nonNumeric> years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_193"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iaced65155b3d4f1bbef9a36d5e227125" continuedAt="i450691101fb44e5fb623f9ff9d809d1b"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="ehc:LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTMvZnJhZzplYjAxNjQ3OTcyYTQ0MTE3YmZhY2UzOTM0N2E1ODJmNy90ZXh0cmVnaW9uOmViMDE2NDc5NzJhNDQxMTdiZmFjZTM5MzQ3YTU4MmY3XzE1MjU_79d8ab21-01de-4c8b-a97c-34ba4a2bdcdd" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets and Other Intangible Assets&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_196"></div><ix:continuation id="i450691101fb44e5fb623f9ff9d809d1b" continuedAt="ia6ea026d24704236a817cc6bea15583d"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTYvZnJhZzpkZTkyNzFjZmMxMzE0NDA4YmZiMDBlYjFkODU1OGNlOS90ZXh0cmVnaW9uOmRlOTI3MWNmYzEzMTQ0MDhiZmIwMGViMWQ4NTU4Y2U5XzIwMjY_71605b4e-eafa-42b3-8d0b-5fcc8346e18c" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in and Advances to Nonconsolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities we do not control but in which we have the ability to exercise significant influence over the operating and financial policies of the investee are accounted for under the equity method. Equity method investments are recorded at original cost and adjusted periodically to recognize our proportionate share of the investees&#8217; net income or losses after the date of investment, additional contributions made, dividends or distributions received, and impairment losses resulting from adjustments to net realizable value. We record equity method losses in excess of the carrying amount of an investment when we guarantee obligations or we are otherwise committed to provide further financial support to the affiliate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the measurement alternative to account for equity investments for which the equity securities do not have readily determinable fair values and for which we do not have the ability to exercise significant influence. Under the measurement alternative, private equity investments are carried at cost and are adjusted only for other-than-temporary declines in fair value, additional investments, or distributions deemed to be a return of capital.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management periodically assesses the recoverability of our equity method and measurement alternative investments and equity method goodwill for impairment. We consider all available information, including the recoverability of the investment, the earnings and near-term prospects of the affiliate, factors related to the industry, conditions of the affiliate, and our ability, if any, to influence the management of the affiliate. We assess fair value based on valuation methodologies, as appropriate, including discounted cash flows, estimates of sales proceeds, and external appraisals, as appropriate. If an investment or equity method goodwill is considered to be impaired and the decline in value is other than temporary, we record an appropriate write-down.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_199"></div><ix:continuation id="ia6ea026d24704236a817cc6bea15583d" continuedAt="i3af71c239c474b088803957b72096553"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTkvZnJhZzpkZTliNTYwZjMzNjU0ZWRlYWYyYzZlNDQzOGFhZjQ3Zi90ZXh0cmVnaW9uOmRlOWI1NjBmMzM2NTRlZGVhZjJjNmU0NDM4YWFmNDdmXzg4NQ_40fdc0cb-3a6b-4369-87a3-dab273fb5352" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_202"></div><ix:continuation id="i3af71c239c474b088803957b72096553" continuedAt="i89e0e72f18794fb59ae373c9fdf9fb77"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMDIvZnJhZzo0M2U5ZjMxODY4NmM0NDMxYjAzYTdlNDViMjc0YjNmMS90ZXh0cmVnaW9uOjQzZTlmMzE4Njg2YzQ0MzFiMDNhN2U0NWIyNzRiM2YxXzM5MjQ_dcbc54f9-48d0-4daf-910d-18709dc3689c" continuedAt="i84e5853515104abfa84e428c9d3e7ba2" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i89e0e72f18794fb59ae373c9fdf9fb77" continuedAt="i0ee86284d1814cf68e89d4fbc934b553"><ix:continuation id="i84e5853515104abfa84e428c9d3e7ba2"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Observable inputs such as quoted prices in active markets;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also the &#8220;Redeemable Noncontrolling Interests&#8221; section of this note.</span></div></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_205"></div><ix:continuation id="i0ee86284d1814cf68e89d4fbc934b553" continuedAt="i4ba02b64240546a786e1e44f229c333d"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMDUvZnJhZzpjYTNjYmJkY2RjMmY0YTFjYmI5ZGY1NmQwMjUxZDYxZS90ZXh0cmVnaW9uOmNhM2NiYmRjZGMyZjRhMWNiYjlkZjU2ZDAyNTFkNjFlXzY0MQ_18ffe873-0681-4875-b775-416207783496" continuedAt="if8ac39d0b261452ebcf2068b5992575c" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interests in Consolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#8217; balance.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_208"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i4ba02b64240546a786e1e44f229c333d" continuedAt="i3f948c79626640cd92ee00f2d4a56f74"><ix:continuation id="if8ac39d0b261452ebcf2068b5992575c"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future. Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to certain members of the home health and hospice management team&#8217;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-6" name="ehc:RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMDgvZnJhZzpmNDM4NjJmYjA3NGM0OWQyODM3NzdmOWJiOWY3Y2Y4Zi90ZXh0cmVnaW9uOmY0Mzg2MmZiMDc0YzQ5ZDI4Mzc3N2Y5YmI5ZjdjZjhmXzEzNjI_d2373dbe-92fe-47fa-84c3-cc1c36343f88">400</ix:nonFraction> million or more. The fair value of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#8217; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.</span></div></ix:continuation></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_211"></div><ix:continuation id="i3f948c79626640cd92ee00f2d4a56f74" continuedAt="ia753498ec09f4ed89dd159b908f21818"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTEvZnJhZzo5ODYxMzgyZmJmOTQ0N2JiOWIzMzUzNDI5NTVmN2IwNS90ZXh0cmVnaW9uOjk4NjEzODJmYmY5NDQ3YmI5YjMzNTM0Mjk1NWY3YjA1XzY1MA_57186f8a-47c0-4eca-937d-9bc7cee5d612" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees, excluding stock appreciation rights (&#8220;SARs&#8221;), are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period. Share-based payments to employees in the form of SARs are recognized in the financial statements based on their current fair value and expensed ratably over the applicable service period.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_214"></div><ix:continuation id="ia753498ec09f4ed89dd159b908f21818" continuedAt="if1b9614e9f774e3a96df560c297c3f71"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTQvZnJhZzo4NTJlZjhlMDU4YzQ0MmIzYmQ0OTgwZjZkZDYyYmNmYi90ZXh0cmVnaW9uOjg1MmVmOGUwNThjNDQyYjNiZDQ5ODBmNmRkNjJiY2ZiXzc1Nw_23e6ad5c-441d-4bde-9376-978cba74c2f1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Reserves&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTQvZnJhZzo4NTJlZjhlMDU4YzQ0MmIzYmQ0OTgwZjZkZDYyYmNmYi90ZXh0cmVnaW9uOjg1MmVmOGUwNThjNDQyYjNiZDQ5ODBmNmRkNjJiY2ZiXzMwMA_7bb9d03a-bdb8-47be-a53d-c350c6be5463">5.0</ix:nonFraction> million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_217"></div><ix:continuation id="if1b9614e9f774e3a96df560c297c3f71" continuedAt="ic449a0a2791a4be79db7ffdfa4ae49a8"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTcvZnJhZzoyYzVmNTcyNTY0MDQ0YWI0OTRjOGRhNjRiZjFmZDg5OS90ZXh0cmVnaW9uOjJjNWY1NzI1NjQwNDRhYjQ5NGM4ZGE2NGJmMWZkODk5XzM0Mw_d9080803-4fb4-494b-bff6-5387264b7ae5" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the accompanying consolidated statements of comprehensive income, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTcvZnJhZzoyYzVmNTcyNTY0MDQ0YWI0OTRjOGRhNjRiZjFmZDg5OS90ZXh0cmVnaW9uOjJjNWY1NzI1NjQwNDRhYjQ5NGM4ZGE2NGJmMWZkODk5XzI1NQ_b231e0af-5410-424a-b2a1-486fc1819526">5.6</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTcvZnJhZzoyYzVmNTcyNTY0MDQ0YWI0OTRjOGRhNjRiZjFmZDg5OS90ZXh0cmVnaW9uOjJjNWY1NzI1NjQwNDRhYjQ5NGM4ZGE2NGJmMWZkODk5XzI1OQ_31d94a50-0409-4332-802a-6fab84e16cc2">4.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTcvZnJhZzoyYzVmNTcyNTY0MDQ0YWI0OTRjOGRhNjRiZjFmZDg5OS90ZXh0cmVnaW9uOjJjNWY1NzI1NjQwNDRhYjQ5NGM4ZGE2NGJmMWZkODk5XzI2Nw_7fbdb02f-9273-48c6-94d8-7e88ac2127b5">6.1</ix:nonFraction> million in each of the years ended December 31, 2021, 2020, and 2019, respectively.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_220"></div><ix:continuation id="ic449a0a2791a4be79db7ffdfa4ae49a8" continuedAt="i9fc324afaa4044d0b1cd3a922e6e8068"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMjAvZnJhZzo3NDUzYWFlMTY5YmU0YjNhYTcwNTg5Mjg4ZTljOTBhMC90ZXh0cmVnaW9uOjc0NTNhYWUxNjliZTRiM2FhNzA1ODkyODhlOWM5MGEwXzI0Njc_94fc692d-5503-4d22-af47-778a69cef6c0" continuedAt="i05ed9583bc3e4938b7bb6b0e986072f9" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the asset and liability method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i9fc324afaa4044d0b1cd3a922e6e8068" continuedAt="i034f7fca67d64415b04c2267e1403465"><ix:continuation id="i05ed9583bc3e4938b7bb6b0e986072f9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We include the allocable portion of each pass-through entity&#8217;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.</span></div></ix:continuation></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_223"></div><ix:continuation id="i034f7fca67d64415b04c2267e1403465" continuedAt="i2448c9baf4214fe48de6d70f3777c41e"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMjMvZnJhZzoxMDZlODcwNDM5NTc0YzljODdjYWI2NTEyYTcwMzBjYy90ZXh0cmVnaW9uOjEwNmU4NzA0Mzk1NzRjOWM4N2NhYjY1MTJhNzAzMGNjXzE3MDk_03e1c061-283b-4c4e-872c-fd2b3ce4570c" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities in and Results of Discontinued Operations&#8212;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Effective January 1, 2015, in connection with a new standard issued by the FASB, we changed our criteria for determining which disposals are presented as discontinued operations. Historically, any component that had been disposed of or was classified as held for sale qualified for discontinued operations reporting unless there was significant continuing involvement with the disposed component or continuing cash flows. In contrast, we now report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. As a result, the sale or disposal of a single Encompass Health facility or location no longer qualifies as a discontinued operation. This accounting change was made prospectively. No new components were recognized as discontinued operations since this guidance became effective.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Loss from discontinued operations, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_226"></div><ix:continuation id="i2448c9baf4214fe48de6d70f3777c41e" continuedAt="ic35e20166b1946bd933622ab07a033c1"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMjYvZnJhZzphODkzYjQyOWFhY2Y0YzI5YjI2YTU1YmE5YzNjMTA3ZC90ZXh0cmVnaW9uOmE4OTNiNDI5YWFjZjRjMjliMjZhNTViYTljM2MxMDdkXzk5Ng_48c7583d-91cd-4518-b6d1-1f9b0ba46152" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_229"></div><ix:continuation id="ic35e20166b1946bd933622ab07a033c1" continuedAt="i17705cc148c54a6899acac2057cc6be2"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMjkvZnJhZzoxZWY5MTkyYjY0Zjg0NmZhOTNjOTkxZDEyYzIzYmZlYi90ZXh0cmVnaW9uOjFlZjkxOTJiNjRmODQ2ZmE5M2M5OTFkMTJjMjNiZmViXzU1MA_58cac812-11b6-470e-983b-e70e22ba4c68" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We account for the retirement of treasury stock as a reduction of retained earnings.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_232"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i17705cc148c54a6899acac2057cc6be2" continuedAt="ibd8a545a63da4f1a8f8ed372cb262104"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzIvZnJhZzoyNTI5NDE1MTVjMjg0ZDMzODgyZDI2YzRmNDM2MTgwNC90ZXh0cmVnaW9uOjI1Mjk0MTUxNWMyODRkMzM4ODJkMjZjNGY0MzYxODA0XzIyMA_468b6e26-50ed-455c-9211-3f056aeab10a" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_235"></div><ix:continuation id="ibd8a545a63da4f1a8f8ed372cb262104"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzUvZnJhZzpjNjdmMzNiYmI3YjA0M2U4YWE0YzY5MjAxNDQzNDg0Yi90ZXh0cmVnaW9uOmM2N2YzM2JiYjdiMDQzZThhYTRjNjkyMDE0NDM0ODRiXzMxNzc_bdd272c1-37d2-47d6-949b-ad3a1c7eaf80" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. The new guidance was effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. The adoption of this guidance did not have a material impact to our consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_238"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxMTI1_17472f6f-c5b9-43b0-ac98-dce4538a7545" continuedAt="i5203d587b6b84fbdaf5460a971f2a122" escape="true">Business Combinations:</ix:nonNumeric></span></div><ix:continuation id="i5203d587b6b84fbdaf5460a971f2a122" continuedAt="i060a78306373464584b960d153668eac"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2021, we acquired <ix:nonFraction unitRef="number" contextRef="iddab4f4ba3d6483d872cadaede2070c3_I20210430" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MTc_4a6c8faa-6a7a-4cd0-a691-38844a3c4837">51</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="iddab4f4ba3d6483d872cadaede2070c3_I20210430" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MjI_05cbf43c-d63c-4886-a267-9a48bde9b7d1">14</ix:nonFraction>-bed inpatient rehabilitation unit in San Angelo, Texas when Shannon Medical contributed those operations to our existing joint venture entity.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2021, we acquired <ix:nonFraction unitRef="number" contextRef="i724c634720d6417db699f31c4afa1e59_I20210630" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MjY_9910e914-7504-47ac-b345-b949da30f92a">75</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i724c634720d6417db699f31c4afa1e59_I20210630" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MzE_e4094cd0-ee46-4d22-b7d0-87fffca18c34">16</ix:nonFraction>-bed inpatient rehabilitation unit in McKees Rocks, Pennsylvania through our existing joint venture with Heritage Valley Health System, Inc. The acquisition was funded using cash on hand.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2021, we acquired <ix:nonFraction unitRef="number" contextRef="i3170e4011fc54daabed3c4a7be2b4ccc_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MzU_68f4580b-ba4d-4834-8310-72f93bd0bd06">65</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i3170e4011fc54daabed3c4a7be2b4ccc_I20210731" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1NDA_b42cee8c-78fa-44ca-9574-8bf7c4319edb">22</ix:nonFraction>-bed inpatient rehabilitation unit in Odessa, Texas when ECHD Ventures contributed those operations to our existing joint venture entity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. <ix:nonFraction unitRef="usd" contextRef="if216c8078722440e8bee9e82ecb4ce83_I20211231" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1NDk_a008c652-9414-49fe-8f22-2c272eb5eede">None</ix:nonFraction> of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i060a78306373464584b960d153668eac" continuedAt="i065db33e333141d48a06c952f3646c1e"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxMDY1_17bc2f63-eebc-4879-9eab-854f3e1e013a" continuedAt="i944807fe74734308bfde8b01ed756b2c" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:87.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of <ix:nonNumeric contextRef="i0f6567d29470494e9a12d3a1e62e4cb8_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzMtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo1ZGU5MzFiNmRmNGE0MTc2ODM2NGE5ZDcxYTIwOGNmOF80Mw_cce7407b-e516-4be8-b4f3-c1e99ed3108b">3</ix:nonNumeric> to <ix:nonNumeric contextRef="icd6ff10ad12e43968abb2d9fedd5e789_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzMtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo1ZGU5MzFiNmRmNGE0MTc2ODM2NGE5ZDcxYTIwOGNmOF80OQ_05e89110-a3d8-4bb7-a90e-0e65b94f44ca">5</ix:nonNumeric> years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979989da0527439fb4dd5f80434b7799_I20210731" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzMtMS0xLTEtNTU5Njg_7797df4e-3986-4d92-bfa9-4209b504eeed">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of <ix:nonNumeric contextRef="i3c84d8686d2346a48ae0771dc64c8d90_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzQtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpjYjhjMmVkNGI1MmY0NDc0OWU4Yzg2MzY1YmYwY2JjOF8zMQ_de6bf02d-e262-4e8c-a824-4245568d8c2d">20</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idffd6c8c86e648aea58449550ba84ab6_I20210731" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzQtMS0xLTEtNTU5Njg_68f19426-40ba-4061-ba90-8beae8200e74">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzctMS0xLTEtNTU5Njg_8fc8367d-2390-4454-8fc9-60c09c47c4c4">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzgtMS0xLTEtODcyMzU_714cb4aa-8bd7-4f55-9c4f-cef177bb5689">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzgtMS0xLTEtNTU5Njg_04675795-1074-46d1-a9e3-93383325bf29">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxMTM2_dafdfbaa-ba35-40c7-9ffd-e9c3c742cb08" continuedAt="i3eea05bff2ab4a348fa14531638b5182" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:89.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTplYTE0NjhiYzFmMGM0N2E0YTA3NzE0NWU5ZGFkZjg1OS90YWJsZXJhbmdlOmVhMTQ2OGJjMWYwYzQ3YTRhMDc3MTQ1ZTlkYWRmODU5XzAtMS0xLTEtNTU5Njg_68004e56-2bb8-4470-81bf-3bd983afb00a">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTplYTE0NjhiYzFmMGM0N2E0YTA3NzE0NWU5ZGFkZjg1OS90YWJsZXJhbmdlOmVhMTQ2OGJjMWYwYzQ3YTRhMDc3MTQ1ZTlkYWRmODU5XzEtMS0xLTEtNTU5Njg_2a3ddea3-fd1f-49ab-a76b-c40c05cdbab9">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89099d548c34496e95ffebc80afea24d_I20211231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTplYTE0NjhiYzFmMGM0N2E0YTA3NzE0NWU5ZGFkZjg1OS90YWJsZXJhbmdlOmVhMTQ2OGJjMWYwYzQ3YTRhMDc3MTQ1ZTlkYWRmODU5XzMtMS0xLTEtNTU5Njg_b537af4a-a381-474e-9daa-241f91b68794">9.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTplYTE0NjhiYzFmMGM0N2E0YTA3NzE0NWU5ZGFkZjg1OS90YWJsZXJhbmdlOmVhMTQ2OGJjMWYwYzQ3YTRhMDc3MTQ1ZTlkYWRmODU5XzUtMS0xLTEtNTU5Njg_47d3d958-9124-4077-b8c8-e01fc06df4b4">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Frontier Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, we completed the acquisition of the home health and hospice assets of Frontier Home Health and Hospice (&#8220;Frontier&#8221;) in Alaska, Colorado, Montana, Washington, and Wyoming. The Frontier acquisition included the purchase of a <ix:nonFraction unitRef="number" contextRef="i9b4f00d1fd94454e92fb97f98bd493e9_I20210601" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4NTI_9d86ccd1-f9f6-441f-b363-d2e679c014a7">50</ix:nonFraction>% equity interest in the Heart of the Rockies Home Health joint venture and a <ix:nonFraction unitRef="number" contextRef="ifa6dc46af56b486895888a4fb9a90e92_I20210601" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4NTc_fae7fd56-0fa6-45a8-b117-f57c5dea7084">90</ix:nonFraction>% equity interest in the Hospice of Southwest Montana joint venture (inclusive of an additional <ix:nonFraction unitRef="number" contextRef="ifa6dc46af56b486895888a4fb9a90e92_I20210601" decimals="2" name="ehc:EquityMethodInvestmentAdditionalOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4NjI_52716df0-15bc-4cfb-bb08-dd05bd3fd0e1">40</ix:nonFraction>% equity interest purchased for approximately $<ix:nonFraction unitRef="usd" contextRef="i05d940caeea84febbbbf878bafbcdbae_D20210601-20210601" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4Njc_f86dcc8f-a527-4aa9-8c9f-f34836e28f1d">4</ix:nonFraction>&#160;million). We consolidate both of these joint ventures. On the acquisition date, <ix:nonFraction unitRef="location" contextRef="i28b060236cfa44c0a9c3de61db94e9a3_I20210601" decimals="INF" name="ehc:NumberofLocationsofanAcquiredEntity" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4ODQ_f28333ae-b32b-46c8-9ee5-d250e0cabc85">nine</ix:nonFraction> home health and <ix:nonFraction unitRef="location" contextRef="i13d51c190f6b4f5bb0c9fee6c0a3bc79_I20210601" decimals="INF" name="ehc:NumberofLocationsofanAcquiredEntity" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4OTY_2751d37d-18c8-42f8-ad23-238813c0534b">eleven</ix:nonFraction> hospice locations became part of our national network of home health and hospice locations. This acquisition was made to expand our existing presence in Colorado and Wyoming and extend our services to Alaska, Montana and Washington. We funded this transaction using cash on hand and borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of Frontier from its date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: replacement cost and continued use methods for property and equipment; an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets; an income approach utilizing the relief-from-royalty method for the trade name intangible asset; an income approach utilizing the excess earnings method for the certificates of need; and present value of remaining lease payments for leases. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. All goodwill recorded reflects our expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i065db33e333141d48a06c952f3646c1e" continuedAt="i656e1ad22eff41af8e8715b7bd9fd230"><ix:continuation id="i944807fe74734308bfde8b01ed756b2c" continuedAt="i9acc5be81ea24ae88674e8b6da4cce19"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzAtMS0xLTEtNjk4MTk_418c077b-bffb-41e2-b747-9292dd197529">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzEtMS0xLTEtNjk4MTk_83aebc5f-daf2-489a-a485-6906d9d25f7a">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzItMS0xLTEtNjk4MTk_bbb85ef8-efbc-42d4-af1a-95629a378592">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzMtMS0xLTEtNjk4MTk_c6ccd981-9cb2-484c-b952-e3a11d0619cd">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzQtMS0xLTEtNjk4MTk_643cda86-ce20-452e-990f-6c01dc2daa60">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of <ix:nonNumeric contextRef="ie0ae29baed2346a6b2cfd2b07ef1858b_D20210601-20210601" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzYtMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjoxNTI3NTJhYmUyMzA0MzUyYTkwYjRiOThkNjVjZWRlN18zMjk4NTM0ODgzMzg0_37900647-f415-4ae9-9d9f-5fe952bbc3be">5</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcaa5db830d74c41b04e18e3d712cbb4_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzYtMS0xLTEtNjk4MTk_432fb3f9-65f2-4678-9622-81501b0c1561">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of <ix:nonNumeric contextRef="i2dee177e57f140e9a6c2ed09915a1349_D20210601-20210601" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzctMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjozNmZhMmRjZTMzYzQ0ZTZhOTZhNGRkYjgxZTY0N2EzZV8zMjk4NTM0ODgzMzc2_5fe72295-8c72-4436-85ac-f7527fcdcfc9">3</ix:nonNumeric> months)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04050f083344efa8f61e38aff5f34c0_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzctMS0xLTEtNjk4MTk_e2fd5efc-4920-4e36-9ca5-28be2ce6aad4">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need (useful lives of <ix:nonNumeric contextRef="i978416f27dae4c0896c015487892aa22_D20210601-20210601" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzgtMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjo2NmVmM2U5NzAwNWI0NWQzOTE0N2NiYWU0YzhkYWYzOV8zMjk4NTM0ODgzMzg3_baeaf7e7-9aa8-4801-a214-0c51e53bb27d">10</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecae4857993e469a9b571629b580ca06_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzgtMS0xLTEtNjk4MTk_d62971bf-5c36-4676-8aa4-f8c7b01b0784">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of <ix:nonNumeric contextRef="i6a3cd10f3d534263a36b46884d9b5925_D20210601-20210601" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzktMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjo3NWM1YzA2ZDI4OGU0MGUwYWJlNzEzOTNkZDIzNGFkYV8zMjk4NTM0ODgzMzc1_7121d9e7-94a2-4176-81e0-91e133503b2a">10</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2a18b64b144278ab7fc3ca1e5665a1_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzktMS0xLTEtNjk4MTk_596f0312-fd0c-4889-8573-f4f529c37228">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzEwLTEtMS0xLTY5ODE5_c8882cbd-7351-46df-abce-e2ba3b8c369b">92.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzEyLTEtMS0xLTcxOTkw_c858ea5f-0663-4640-8fe7-f4ab991d2ef9">105.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzE0LTEtMS0xLTY5ODE5_ef041057-4c3a-422f-86cd-b5057cf9755b">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzE1LTEtMS0xLTY5ODE5_d3362981-4ec4-4ab4-8fad-3c8a924bdeb4">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzE2LTEtMS0xLTY5ODE5_cf12049c-4467-4a8a-ac85-91a2b4b3e52e">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzE4LTEtMS0xLTY5ODE5_88fc9f70-f74f-4708-9b85-0f78ba8ee8da">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzIwLTEtMS0xLTcxOTk0_1fce3b00-b25e-4386-a075-e990581bf1fa">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzIxLTEtMS0xLTY5ODE5_1342e73f-76e8-4ea3-a4d9-ae7bb9bf9494">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzIyLTEtMS0xLTcxOTk0_01898038-17a6-484b-9682-adc4ae6651aa">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="i3eea05bff2ab4a348fa14531638b5182" continuedAt="i08fbf6127dc74f1c91b647a7bbef6b0d"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for this acquisition is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired, net of $<ix:nonFraction unitRef="usd" contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzItMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjozY2RkNmFlMjkyZDM0YTI1YjQyMWUyM2NmYTFjNTI5ZF8zMjk4NTM0ODgzNDE5_418c077b-bffb-41e2-b747-9292dd197529">0.8</ix:nonFraction> million of cash acquired in 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzItMS0xLTEtNjk4MTk_f4019d1a-d035-4f39-90af-dc47cab81981">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzMtMS0xLTEtNjk4MTk_e1d02ac4-bb31-49a8-9d64-9b7764d6f0b3">92.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzQtMS0xLTEtNjk4MTk_53523a5d-dccb-4acc-afe1-6a5a368dceca">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzUtMS0xLTEtNjk4MTk_bf27653c-e74f-48dc-bf80-6c0706dd8a3f">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzUtMS0xLTEtNzIwMTE_30879a36-baff-4352-8c80-e5e71e0ab2b0">98.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Home Health and Hospice Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, using cash on hand, we acquired an additional <ix:nonFraction unitRef="number" contextRef="i8279db1c332d4e708d8b00d2ec28fcee_I20211231" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzg3OTYwOTMwODE5MjM_5b042b09-14f1-489c-a0e7-73da14a3bac1">29</ix:nonFraction>% equity interest from Baptist Outpatient Services, Inc. in our existing Encompass Health Home Health of South Florida, LLC joint venture. This transaction increased our ownership interest from <ix:nonFraction unitRef="number" contextRef="i46b6c4b37b72430bb27cc893622797e5_I20211130" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzM4NDgyOTA3NTY5MzY_e060788a-7990-4f4b-8c89-d8ce226d6bff">51</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8279db1c332d4e708d8b00d2ec28fcee_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzM4NDgyOTA3NTY5NDE_0602856d-367a-4535-96a5-645c5e7e0178">80</ix:nonFraction>% and resulted in change in accounting for this joint venture from the equity method of accounting to a consolidated entity. As a result of our consolidation of this entity and the remeasurement of our previously held equity interest to fair value, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $<ix:nonFraction unitRef="usd" contextRef="i27a84b415d07493e8cb918d0e2ea7f5d_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzE2NDkyNjc1MDcxMTc_c5b2ebc6-428a-40d3-842c-019922401eef">8.0</ix:nonFraction> million, and we recorded a $<ix:nonFraction unitRef="usd" contextRef="i27a84b415d07493e8cb918d0e2ea7f5d_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzE2NDkyNjc1MDcxMjE_822cb79a-956c-498d-b650-f37b5ffc05a6">3.2</ix:nonFraction> million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021. This transaction was made to increase our ownership in a profitable entity and continue to grow our business.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This acquisition was funded using cash on hand and was individually immaterial to our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i656e1ad22eff41af8e8715b7bd9fd230" continuedAt="i306b289efe2349778b9fe33e2df64c2b"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired locations&#8217; mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. The amount of goodwill recorded as a result of these transactions that is deductible for federal income tax purposes is $<ix:nonFraction unitRef="usd" contextRef="i8279db1c332d4e708d8b00d2ec28fcee_I20211231" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzEwOTk1MTE2OTg1MDM_972f722a-4c18-43d5-9ffe-917bc4f7587a">3.9</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.</span></div><ix:continuation id="i9acc5be81ea24ae88674e8b6da4cce19" continuedAt="ie0e8dec54e7d4d5fab509c12b3cb69b2"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:87.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzAtMS0xLTEtODc1Njc_6ed4d717-66af-40db-bec7-b1b645a9234f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzEtMS0xLTEtODc2NDA_df9c297a-adb0-4589-b7e6-189049addfd8">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of <ix:nonNumeric contextRef="i8e771317f044433ebf4a8a2a5d5eb059_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzQtMC0xLTEtODc1NjcvdGV4dHJlZ2lvbjpmMTNmNGQxMzRhOWQ0MDdkYWRlNGYzM2Y0OTRjZDFkY180Mw_e8d8897d-4ad7-4fe6-b907-55bc8a236113">2</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibef0cafa72f949fabb0aba607529bb57_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzQtMS0xLTEtODc1Njc_d680c2d0-0c26-4676-89e2-285b221b8f77">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of <ix:nonNumeric contextRef="i25e23730767f47b9a77ab3f4c276bfa8_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzctMC0xLTEtODc1NjcvdGV4dHJlZ2lvbjpjNWU3YzdjY2NiMWU0YmYyYjRmMzZkYjQ5NjQzMmE5Yl8zMA_828040b2-e559-4ae3-8b0b-69552dbf6f8a">10</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f460ce531347859d5a7bfeec5a762d_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzctMS0xLTEtODc1Njc_ec6aaa1d-0657-4e86-8f32-6879f814d120">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzgtMS0xLTEtODc1Njc_e704ed21-7477-46c2-a1b9-218b97f8edd5">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzExLTEtMS0xLTg5MDQ4_d949bfd9-f6e7-467a-ae26-338c53df255d">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzEyLTEtMS0xLTg3NTY3_cd5c7a7a-2006-43d3-8cb6-b7fdcc7541a8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzEzLTEtMS0xLTg3NTY3_8672eadf-791e-4149-b18a-035f3a077c44">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE0LTEtMS0xLTg3NTY3_9c0d2da8-ec91-44ff-a61b-89c691c112dc">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE3LTEtMS0xLTg3Njcx_1bf5e4b5-13a8-4ee4-ab1b-474d2c4bcb75">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE4LTEtMS0xLTg5MTAy_c5609457-5699-4df3-a7c4-4ccf80e056f7">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE5LTEtMS0xLTEwNjE0OA_d3f3817a-e4ec-4ae7-96d3-b2b1fa6d591b">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE5LTEtMS0xLTg5MTAy_e5f19f62-c38d-4106-ad59-4a02ddd818e4">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:continuation id="i08fbf6127dc74f1c91b647a7bbef6b0d" continuedAt="i581a3af7d0d94e478b06e50a8db08dc9">Information regarding the net cash paid for this acquisition is as follows (in millions):</ix:continuation></span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><ix:continuation id="i581a3af7d0d94e478b06e50a8db08dc9" continuedAt="id339fd434bb24bdea1fdc89213907e5c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:87.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired, net of $<ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzAtMC0xLTEtMTEzNzU1L3RleHRyZWdpb246ZGYwZjczYzgxMjcwNDNmZGJlNDhlNDQ3MGU1OTk5ZWVfMjE5OTAyMzI1NTYzNQ_6ed4d717-66af-40db-bec7-b1b645a9234f">0.8</ix:nonFraction> million of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzAtMS0xLTEtODc1Njc_1a5f2502-7ca1-4185-8ba6-29c7420f3b28">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzEtMS0xLTEtODc1Njc_d15dc6d9-ea3d-401d-9edb-a9cca4548c70">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzItMS0xLTEtODc1Njc_01490bf7-9242-43e6-b553-62f942fb78d1">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of redeemable noncontrolling interest owned by joint venture partner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231" decimals="-5" sign="-" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzMtMS0xLTEtODc1Njc_15a825e9-0f62-4359-b717-46fe16736ef5">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity interest prior to acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231" decimals="-5" sign="-" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzQtMS0xLTEtMTA2MTg1_f3774179-2993-43e1-bff7-0879ae632370">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzUtMS0xLTEtODkxMTA_b7b1ef6f-af1f-4aa0-9fa4-25d3510f4e4d">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2022, we acquired a <ix:nonFraction unitRef="number" contextRef="i773106cd2a324d499116f825de895f7e_I20220101" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzYwNDczMTQwMTkyMTQ_b80b87fe-34a2-41c3-9c1f-1ba4fce154bb">50</ix:nonFraction>% equity interest from Frontier in a joint venture with Saint Alphonsus System (&#8220;Saint Alphonsus&#8221;) which operates home health and hospice locations in Boise, Idaho. The total purchase price was $<ix:nonFraction unitRef="usd" contextRef="i9eb895620d9c4243b46d28ee569388c2_D20220101-20220101" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzE2NDkyNjc1MDY2NTA_12a99fdb-4dc2-4dac-9e6f-228e744cba06">15.9</ix:nonFraction> million and was funded on December 31, 2021. This payment is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Acquisition of business, net of cash acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statement of cash flow for the year end December 31, 2021. This transaction was not material to our financial position, results of operations, or cash flows.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i306b289efe2349778b9fe33e2df64c2b" continuedAt="ia47010193bec437f8509b3d873647504"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Pro Forma Results of Operations</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxMTM5_a56c979a-0f01-47f0-b3ec-d1ccc62117e7" continuedAt="ifae15473ebac4028a5f65e6bec56dadd" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzItMS0xLTEtNTU5Njg_aea36ee7-4ed9-42ce-aa5a-cbe80266292f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzItMy0xLTEtNTU5Njg_8bc363dc-6f35-43fb-a357-4f8e82679b2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzQtMS0xLTEtNTU5Njg_d06c78fc-130e-4e85-93a7-4e110bc36417">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzQtMy0xLTEtNTU5Njg_fb0c0e31-0f40-4667-a785-1c2aedf696a6">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53030c89936d407897671309bbeb1f7b_D20210101-20211231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzUtMS0xLTEtNTU5Njg_40d604f4-c2e2-4fc0-8f35-66425259b14b">5,152.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53030c89936d407897671309bbeb1f7b_D20210101-20211231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzUtMy0xLTEtNTU5Njg_82f9637f-e2c5-400f-a7df-938e29048583">413.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663e53be26e941ffbeb8afe0c5e46b4e_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzYtMS0xLTEtNTU5Njg_107503f0-8c7f-45cd-896a-5e4ce9424517">4,705.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663e53be26e941ffbeb8afe0c5e46b4e_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzYtMy0xLTEtNTU5Njg_b0153efe-7530-463e-bfb0-6b1031ec4f0b">286.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Acquisitions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2020, we acquired <ix:nonFraction unitRef="number" contextRef="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0MDc_1e567517-7246-4657-94d5-cf974e97fe80">68</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0MTU_34350452-6e74-443d-9d15-b1c5b450bb22">13</ix:nonFraction>-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing <ix:nonFraction unitRef="bed" contextRef="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131" decimals="INF" name="ehc:NumberofBedsContributed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0MjM_55fb2b21-afda-4d25-a05b-a2b6dba14715">40</ix:nonFraction>-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a <ix:nonFraction unitRef="bed" contextRef="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131" decimals="INF" name="ehc:NumberofBedsExpanded" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0MzE_6192a4cb-62ed-47b2-891f-aa4790060207">20</ix:nonFraction>-bed expansion to the Littleton hospital.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, we acquired <ix:nonFraction unitRef="number" contextRef="ibc1955f816c34df2ba0316a625c6ba30_I20200531" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0Mzk_47a3c741-4117-4a03-afc9-1e3bb71c72f4">51</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="ibc1955f816c34df2ba0316a625c6ba30_I20200531" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0NDc_5dd7fc2f-0ef9-4f52-85df-d924a05de4c1">45</ix:nonFraction>-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a <ix:nonFraction unitRef="bed" contextRef="ibc1955f816c34df2ba0316a625c6ba30_I20200531" decimals="INF" name="ehc:NumberofDeNovoBeds" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0NTU_2a18e7da-5a2e-416f-9ee4-87fb80cb412e">60</ix:nonFraction>-bed de novo inpatient rehabilitation hospital.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. <ix:nonFraction unitRef="usd" contextRef="if75c35d2f7dc4b22824f5f5f2725d6cf_I20200531" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0NjM_94b0e4fd-06e7-41ed-96ea-7222a7006934">None</ix:nonFraction> of the goodwill recorded as a result from these transactions are deductible for federal income tax purposes.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia47010193bec437f8509b3d873647504" continuedAt="i8d5562e7e1754af8ae7498baa6cd0859"><ix:continuation id="ie0e8dec54e7d4d5fab509c12b3cb69b2" continuedAt="iceb5b3ae077a43d4b36f1f6e105bc87c"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9f063c376c4593a96e8f3e1c883a61_I20200531" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzEtMS0xLTEtNTU5Njg_a330d58f-2fc6-4060-ab58-de63d117d377">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of <ix:nonNumeric contextRef="ia02028d9ba724ca6b97593c19c98591a_D20200501-20200531" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzMtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjphYTEyMzk3OTFkMjc0ODM2ODg0ZGNlNjdkMmMyNDVhZV8yMTk5MDIzMjU1NTk3_db53bf32-50ca-47af-8a03-cbc1c9cd072a">2</ix:nonNumeric> to <ix:nonNumeric contextRef="if670737e9dbc4e9fabc500e7e933390e_D20200501-20200531" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzMtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjphYTEyMzk3OTFkMjc0ODM2ODg0ZGNlNjdkMmMyNDVhZV80MQ_ce217c1c-aea8-4145-810d-c1b0fa52aa78">3</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c3e316666b47b9bfa8484b5183985c_I20200531" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzMtMS0xLTEtNTU5Njg_426b5977-b64f-44ef-a635-f8d7a8f7b1cb">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of <ix:nonNumeric contextRef="if702652feabd4fd78b3453c3d867f5cb_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzQtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjplNDVhYmFhMmQyNWU0NjIyODAzYTg1NzdlMTg2MzY4M18zMQ_37f92236-01f7-4289-8373-e59911346925">20</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaddff5e45b144d06a0e4c066b7081b51_I20200531" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzQtMS0xLTEtNTU5Njg_db4df60b-f851-4d64-a22b-094eb59ba683">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9f063c376c4593a96e8f3e1c883a61_I20200531" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzctMS0xLTEtNTU5Njg_b7ce4256-9606-4e3e-9f4e-d6eec158452d">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9f063c376c4593a96e8f3e1c883a61_I20200531" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzgtMS0xLTEtNTU5Njg_aab2a88a-ec6a-494d-b25e-68606d4ccae9">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><ix:continuation id="id339fd434bb24bdea1fdc89213907e5c" continuedAt="i2e864baa64c2451380299f6ac12a9380"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNjM1NTg4Njc1Zjc0ZmU1OTY3ZjkwZThjZmRhYWRjMy90YWJsZXJhbmdlOjI2MzU1ODg2NzVmNzRmZTU5NjdmOTBlOGNmZGFhZGMzXzAtMS0xLTEtNTU5Njg_a44ea03a-c246-4929-a66a-adc8b16b375e">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNjM1NTg4Njc1Zjc0ZmU1OTY3ZjkwZThjZmRhYWRjMy90YWJsZXJhbmdlOjI2MzU1ODg2NzVmNzRmZTU5NjdmOTBlOGNmZGFhZGMzXzEtMS0xLTEtNTU5Njg_f6c6d42c-bc71-42e1-97b6-510d7f4be7bc">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3eb83f5d9b54bc49973f50a399a5c57_I20201231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNjM1NTg4Njc1Zjc0ZmU1OTY3ZjkwZThjZmRhYWRjMy90YWJsZXJhbmdlOjI2MzU1ODg2NzVmNzRmZTU5NjdmOTBlOGNmZGFhZGMzXzMtMS0xLTEtNTU5Njg_40c373b7-d7ea-4178-8860-65996e296b41">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNjM1NTg4Njc1Zjc0ZmU1OTY3ZjkwZThjZmRhYWRjMy90YWJsZXJhbmdlOjI2MzU1ODg2NzVmNzRmZTU5NjdmOTBlOGNmZGFhZGMzXzUtMS0xLTEtNTU5Njg_72687810-6223-42af-8f51-3c2733f48361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we acquired the assets of Generation Solutions of Lynchburg, LLC in Lynchburg, Virginia. This acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in Central Virginia. The acquisition was funded using cash on hand and was immaterial to our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. The fair values of identifiable intangible assets were based on valuations using an income approach. The income approach is based on management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired location&#8217;s mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="iceb5b3ae077a43d4b36f1f6e105bc87c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of <ix:nonNumeric contextRef="id50245be41454844ab31b7a2899757ad_D20200301-20200331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo3MDNhMDBkMjA4YzM0MmUzYTNhYTg1MzY2NmNiMmFiNC90YWJsZXJhbmdlOjcwM2EwMGQyMDhjMzQyZTNhM2FhODUzNjY2Y2IyYWI0XzctMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpjZjgxOTAyNDM2NmE0MjUxYTdjMjMyYWM2ZWZkZWFhMl8yOA_b6b8ba77-35e1-4830-9d5f-98d334956131">10</ix:nonNumeric> years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac3c94284cc42dcaefa48344e6f041c_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo3MDNhMDBkMjA4YzM0MmUzYTNhYTg1MzY2NmNiMmFiNC90YWJsZXJhbmdlOjcwM2EwMGQyMDhjMzQyZTNhM2FhODUzNjY2Y2IyYWI0XzctMS0xLTEtNTU5Njg_d4afdbf9-570a-44e4-b5e2-03d21336c0b5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19f96ec376141aa841d8f70ab86a81b_I20200331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo3MDNhMDBkMjA4YzM0MmUzYTNhYTg1MzY2NmNiMmFiNC90YWJsZXJhbmdlOjcwM2EwMGQyMDhjMzQyZTNhM2FhODUzNjY2Y2IyYWI0XzgtMS0xLTEtNTU5Njg_c2e62059-846d-4526-904f-318aa0840788">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19f96ec376141aa841d8f70ab86a81b_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo3MDNhMDBkMjA4YzM0MmUzYTNhYTg1MzY2NmNiMmFiNC90YWJsZXJhbmdlOjcwM2EwMGQyMDhjMzQyZTNhM2FhODUzNjY2Y2IyYWI0XzktMS0xLTEtNTU5Njg_a6a6510a-1dca-4226-9373-569221c9add8">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><ix:continuation id="i2e864baa64c2451380299f6ac12a9380" continuedAt="i367d8edd8aa048eea2a780c72ce3a070"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the home health acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37157c8e16b448a999811b4aa3779421_D20200301-20200331" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjYjM2YmJjZDk3ZTc0NzNkODEzZGZhNWJlYjhjZjAyZC90YWJsZXJhbmdlOmNiMzZiYmNkOTdlNzQ3M2Q4MTNkZmE1YmViOGNmMDJkXzAtMS0xLTEtNTU5Njg_88d4dab8-bbe4-457b-b9c9-b3771dc674fc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37157c8e16b448a999811b4aa3779421_D20200301-20200331" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjYjM2YmJjZDk3ZTc0NzNkODEzZGZhNWJlYjhjZjAyZC90YWJsZXJhbmdlOmNiMzZiYmNkOTdlNzQ3M2Q4MTNkZmE1YmViOGNmMDJkXzEtMS0xLTEtNTU5Njg_4e4cf00b-0a04-427e-bc88-b9b26f2fd468">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37157c8e16b448a999811b4aa3779421_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjYjM2YmJjZDk3ZTc0NzNkODEzZGZhNWJlYjhjZjAyZC90YWJsZXJhbmdlOmNiMzZiYmNkOTdlNzQ3M2Q4MTNkZmE1YmViOGNmMDJkXzQtMS0xLTEtNTU5Njg_9172d982-1900-4760-9c13-549748088443">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8d5562e7e1754af8ae7498baa6cd0859" continuedAt="i808bf85c0f744c85aeefe1aafb3f777e"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Pro Forma Results of Operations</span></div><ix:continuation id="ifae15473ebac4028a5f65e6bec56dadd" continuedAt="i7ca7a76ae67a4131aa73b99887ce6b3a"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzItMS0xLTEtNTU5Njg_ae5f2de8-90c2-44bb-9e3e-2007e5431048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzItMy0xLTEtNTU5Njg_377a4f83-90db-430d-8301-859f715549f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ba70666ee904810aaab1057f142b141_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzQtMS0xLTEtNTU5Njg_39ae2548-5e27-493c-8329-3f81bb13aba7">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ba70666ee904810aaab1057f142b141_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzQtMy0xLTEtNTU5Njg_27d6747c-1ec5-4cdd-b567-c1d15fe84bcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9b1260076c94869baae8e55f9ee99a1_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzUtMS0xLTEtNTU5Njg_ed9b693d-9712-43cd-ad02-7f2ceafeed5c">4,650.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9b1260076c94869baae8e55f9ee99a1_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzUtMy0xLTEtNTU5Njg_8736870d-b498-4dd5-bf66-9cd7ed8be653">284.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae1c4e4319c41439be0441090ee96a3_D20190101-20191231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzYtMS0xLTEtNTU5Njg_844e8680-9ecf-44b8-a892-d9aa5060448b">4,626.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae1c4e4319c41439be0441090ee96a3_D20190101-20191231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzYtMy0xLTEtNTU5Njg_66061985-28b9-4a36-ac44-025b8e5dffb3">360.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Acquisitions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2019, we acquired approximately <ix:nonFraction unitRef="number" contextRef="i5b80143fe808479d88a8c886e315b0de_I20190731" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzYwNDczMTM5Nzg1MTU_d573524d-77d5-41a6-b43e-f5eb638309cc">51</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i5b80143fe808479d88a8c886e315b0de_I20190731" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MDkwODk_e6ba5ff9-3eea-477b-869e-b0f1c481429e">30</ix:nonFraction>-bed inpatient rehabilitation unit in Boise, Idaho when Saint Alphonsus Regional Medical Center contributed those operations to a joint venture with us. We funded our ownership interest in that consolidated joint venture through contributions of cash which the joint venture entity used to fund the construction of a <ix:nonFraction unitRef="location" contextRef="i5b80143fe808479d88a8c886e315b0de_I20190731" decimals="INF" name="ehc:NumberofDeNovoBeds" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MDkwOTc_4db4986e-3658-497d-9973-5e1159071cfc">40</ix:nonFraction>-bed de&#160;novo inpatient rehabilitation hospital. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2019, we acquired <ix:nonFraction unitRef="number" contextRef="ic25b5ad20ca94b278f0bb86ed76fb546_I20190930" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MDkxMDU_569a76d7-dc18-4d27-bf89-b80d18dbf328">75</ix:nonFraction>% of the operations of Heritage Valley Sewickley Hospital&#8217;s <ix:nonFraction unitRef="bed" contextRef="ic25b5ad20ca94b278f0bb86ed76fb546_I20190930" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MDkxMTM_be133253-bc1f-4926-bc42-aff10cd31104">11</ix:nonFraction>-bed inpatient rehabilitation unit in Sewickley, Pennsylvania, when Heritage Valley Health System, Inc. contributed those operations to our existing joint venture entity in connection with the opening of a new hospital.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the acquired hospitals from its respective date of acquisition. <ix:continuation id="i367d8edd8aa048eea2a780c72ce3a070" continuedAt="i8e60efed177b451d8c63162a8a5b1919">Information regarding the net cash paid for all inpatient rehabilitation acquisitions during 2019 is as follows (in millions):</ix:continuation></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="i8e60efed177b451d8c63162a8a5b1919" continuedAt="ibd58790d35ba47b7af50c59416e6721f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzAtMS0xLTEtNTU5Njg_3807e9e7-29d4-4068-b5eb-0d68b6f82548">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzEtMS0xLTEtNTU5Njg_0ab5ed5d-f65e-4ed2-8614-9dc95b2511a8">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzItMS0xLTEtNTU5Njg_de279d78-edc4-49f5-b9d2-01d987e66088">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231" decimals="-5" sign="-" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzMtMS0xLTEtNTU5Njg_e2a0acae-1c56-4c12-a793-2ee1912c2cac">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzUtMS0xLTEtNTU5Njg_b7649a82-a710-4d52-84cc-c7e4bee37918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alacare Acquisition</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we completed the acquisition of privately owned Alacare Home Health &amp; Hospice (&#8220;Alacare&#8221;) for a cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MTMyMTA_95b39dbe-af84-4d6a-8cc0-66ac65607eaf">217.8</ix:nonFraction>&#160;million. The Alacare portfolio consisted of <ix:nonFraction unitRef="usd" contextRef="i0a832df04afc419bb4147b4b673a3a50_I20190731" decimals="INF" name="ehc:NumberofLocationsofanAcquiredEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MTMyMTg_84eb6e26-ea82-4e4e-88fa-3924f3fa18c5">23</ix:nonFraction> home health locations and <ix:nonFraction unitRef="location" contextRef="i83efdee8e727419e8877258c72d7d06e_I20190731" decimals="INF" name="ehc:NumberofLocationsofanAcquiredEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MTMyMjY_27985077-58b7-40c0-b996-fe2c40bc1c6f">23</ix:nonFraction> hospice locations in Alabama. The acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients across Alabama. We funded the transaction with cash on hand and borrowings under our revolving credit facility.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i808bf85c0f744c85aeefe1aafb3f777e" continuedAt="iafc52f25620b48d0bbb4277dc666c534"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of Alacare from its date of acquisition. <ix:continuation id="ibd58790d35ba47b7af50c59416e6721f" continuedAt="i8e106d1bf01746628f2487a53799fa75">Information regarding the net cash paid for Alacare is as follows (in millions):</ix:continuation></span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><ix:continuation id="i8e106d1bf01746628f2487a53799fa75" continuedAt="i507d400b99e14016930b54cffbea6c51"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:88.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo2NGQ2ZWVhNWQxZmI0OTkwODRhNzVkYTc4M2I4M2U2ZC90YWJsZXJhbmdlOjY0ZDZlZWE1ZDFmYjQ5OTA4NGE3NWRhNzgzYjgzZTZkXzAtMS0xLTEtNTU5Njg_80fd664d-f635-4a67-b625-cbd329034865">68.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo2NGQ2ZWVhNWQxZmI0OTkwODRhNzVkYTc4M2I4M2U2ZC90YWJsZXJhbmdlOjY0ZDZlZWE1ZDFmYjQ5OTA4NGE3NWRhNzgzYjgzZTZkXzEtMS0xLTEtNTU5Njg_34a64b88-00ae-4dc8-bc34-ed90995d7d38">163.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo2NGQ2ZWVhNWQxZmI0OTkwODRhNzVkYTc4M2I4M2U2ZC90YWJsZXJhbmdlOjY0ZDZlZWE1ZDFmYjQ5OTA4NGE3NWRhNzgzYjgzZTZkXzItMS0xLTEtNTU5Njg_c1d46394-c6a8-4924-af1c-7b031f83a8b1">14.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo2NGQ2ZWVhNWQxZmI0OTkwODRhNzVkYTc4M2I4M2U2ZC90YWJsZXJhbmdlOjY0ZDZlZWE1ZDFmYjQ5OTA4NGE3NWRhNzgzYjgzZTZkXzUtMS0xLTEtNTU5Njg_cac4784f-c22a-41e2-9f72-6b05992ad557">217.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Home Health and Hospice Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we completed the following home health acquisitions,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> none</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in the applicable geographic areas. Each acquisition was funded using cash on hand.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2019, we acquired the assets of Tidewater Home Health, PA in Columbia, South Carolina.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2019, we acquired the assets and assumed the liabilities of <ix:nonFraction unitRef="location" contextRef="i33168cd12e06476282380e6f2e0e09ab_I20190331" decimals="INF" name="ehc:NumberofLocationsofanAcquiredEntity" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MTY1NDk_3556d253-6362-42b3-ab16-e97a5b31f682">two</ix:nonFraction> home health locations from Care Resource Group in East Providence, Rhode Island and Westport, Massachusetts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired locations from their respective dates of acquisition. <ix:continuation id="i507d400b99e14016930b54cffbea6c51" continuedAt="iffed95f253a44f08924888eb237b0074">Information regarding the net cash paid for the home health acquisitions during 2019 is as follows (in millions):</ix:continuation></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="iffed95f253a44f08924888eb237b0074"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMTJhNGUwNjM2NTY0OWRmYmI3Yjk4YWVmOGM4ZTc3NC90YWJsZXJhbmdlOjExMmE0ZTA2MzY1NjQ5ZGZiYjdiOThhZWY4YzhlNzc0XzAtMS0xLTEtNTU5Njg_10e751d9-adb7-40a9-b111-7ef0f873ef6a">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMTJhNGUwNjM2NTY0OWRmYmI3Yjk4YWVmOGM4ZTc3NC90YWJsZXJhbmdlOjExMmE0ZTA2MzY1NjQ5ZGZiYjdiOThhZWY4YzhlNzc0XzEtMS0xLTEtNTU5Njg_db4840cf-94c9-4427-a598-2abdbee2c620">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMTJhNGUwNjM2NTY0OWRmYmI3Yjk4YWVmOGM4ZTc3NC90YWJsZXJhbmdlOjExMmE0ZTA2MzY1NjQ5ZGZiYjdiOThhZWY4YzhlNzc0XzItMS0xLTEtNTU5Njg_afc26fb0-5a02-44cb-86fe-5d3f8129638f">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMTJhNGUwNjM2NTY0OWRmYmI3Yjk4YWVmOGM4ZTc3NC90YWJsZXJhbmdlOjExMmE0ZTA2MzY1NjQ5ZGZiYjdiOThhZWY4YzhlNzc0XzUtMS0xLTEtNTU5Njg_898b0ef5-5b8b-4d45-99bf-eb44cde77fdb">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Pro Forma Results of Operations</span></div><ix:continuation id="i7ca7a76ae67a4131aa73b99887ce6b3a"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (Loss) Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzItMS0xLTEtNTU5Njg_b3de91a9-608c-41fb-9222-cc23086d7df7">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzItMy0xLTEtNTU5Njg_58ea7468-9b8a-4056-b2fb-1509a23ad806">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alacare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3bbc643a1a4af4b94038c460a77df9_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzMtMS0xLTEtNTU5Njg_2cc671f6-c6ba-4651-aba1-afb41bbc435d">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3bbc643a1a4af4b94038c460a77df9_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzMtMy0xLTEtNTU5Njg_fb1b4792-5796-4da1-b62b-4e2b06e2979f">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Home Health and Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzQtMS0xLTEtNTU5Njg_e56976ff-fdcd-49f1-ad01-dff06fdeaa9d">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzQtMy0xLTEtNTU5Njg_e52b1160-0bae-416e-aec1-12521a0b45d9">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3480d46a606c42799ec28c3335bc60d5_D20190101-20191231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzUtMS0xLTEtNTU5Njg_2044a2da-0cd5-46d3-9c25-d780392ade6b">4,674.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3480d46a606c42799ec28c3335bc60d5_D20190101-20191231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzUtMy0xLTEtNTU5Njg_efc64522-9eb8-411c-b3a7-b692641dfb41">364.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iafc52f25620b48d0bbb4277dc666c534">&#160;&#160;&#160;&#160;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_241"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzEyNjc_4baeb40f-5271-4272-b8eb-ba19862f4187" continuedAt="i7b3e06cc5aa64a97a14fe1ae2b6f78c4" escape="true">Variable Interest Entities:</ix:nonNumeric></span></div><ix:continuation id="i7b3e06cc5aa64a97a14fe1ae2b6f78c4"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and December&#160;31, 2020, we consolidated <ix:nonFraction unitRef="entity" contextRef="ib73cbdd803994190950116ec559457fb_D20210101-20211231" decimals="INF" name="ehc:VariableInterestEntityNumberofEntitiesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzQz_aa6d8bc9-fe5c-435d-bc57-c835c3a2752b">ten</ix:nonFraction> and <ix:nonFraction unitRef="entity" contextRef="i8fdff6f27e5f4de9b71d55e1a259b5d1_D20200101-20201231" decimals="INF" name="ehc:VariableInterestEntityNumberofEntitiesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzUw_ce466613-e648-4689-91ef-c1e2190f865b">nine</ix:nonFraction>, respectively, limited partnership-like entities that are VIEs and of which we are the primary beneficiary. Our ownership percentages in these entities range from <ix:nonFraction unitRef="number" contextRef="iff4da371722344eb96f964534004f0a6_D20210101-20211231" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzIxNg_7d030961-b75f-4dfc-b5a2-3c1329b89caf">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7d3a2f947eea4354801d07d1f2e1e80c_D20210101-20211231" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzIyMg_74db1bbd-81bb-4429-bd86-9794b76d4fa3">90.0</ix:nonFraction>% as of December&#160;31, 2021. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzEyNjI_5d18d65e-5b8f-4667-aebc-eef9a3ab6f34" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzMtMS0xLTEtNTU5Njg_d7b71afd-9259-4e8b-be04-514b7a26a68c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzMtMy0xLTEtNTU5Njg_8be94427-0bc5-4152-b50f-9e789c66fbd6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzQtMS0xLTEtNTU5Njg_ae30b4a0-4d3a-4592-8fdb-e97214d4b95c">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzQtMy0xLTEtNTU5Njg_b933ed61-9cdd-4592-a00e-92fd0dc2e036">33.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzUtMS0xLTEtNTU5Njg_c9729c47-d55a-4580-8f48-5a2ff934be39">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzUtMy0xLTEtNTU5Njg_b0350955-bb9f-4217-b299-9cbd32bdab78">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzYtMS0xLTEtNTU5Njg_46c38d97-57ff-4499-a814-6818d6248ed0">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzYtMy0xLTEtNTU5Njg_fca26430-fc59-463f-a33b-70546ba1a2d3">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzctMS0xLTEtNTU5Njg_19556350-14a7-48eb-8f40-77c29b3cadde">116.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzctMy0xLTEtNTU5Njg_297991db-fb07-45ce-9019-f84549775243">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzgtMS0xLTEtNTU5Njg_f29ef1b1-c454-4158-88b1-83b4af28886a">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzgtMy0xLTEtNTU5Njg_efcd7171-8448-46a4-8f9b-02a0468fab75">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzktMS0xLTEtNTU5Njg_2b2c4f83-a2b2-4b97-aea1-1ee6eefc00a4">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzktMy0xLTEtNTU5Njg_47cb32b1-a534-4b22-90f1-4c79774bc862">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEwLTEtMS0xLTU1OTY4_64599434-a1d0-44ac-b3b9-77873a7cd138">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEwLTMtMS0xLTU1OTY4_87f6b2ad-fcc4-4a95-ad67-1d4a7824a64f">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzExLTEtMS0xLTU1OTY4_116b232c-6a43-4340-be9e-7362b6663bf7">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzExLTMtMS0xLTU1OTY4_b7877a87-9f77-498e-9236-dfae3c2551fe">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEyLTEtMS0xLTU1OTY4_c4bc32fe-f7e5-4c85-9f01-4a46b52f4fa1">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEyLTMtMS0xLTU1OTY4_6578f6fc-009f-4928-b9de-6b5c0bb1b4be">30.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEzLTEtMS0xLTU1OTY4_212e0239-ea52-42f8-80d1-9ca62104117f">226.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEzLTMtMS0xLTU1OTY4_49aa1981-5a0c-455a-9740-05ccd7b42981">221.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE2LTEtMS0xLTU1OTY4_65872e74-b2b3-4b28-adc5-f2f9d4e0dad7">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE2LTMtMS0xLTU1OTY4_566fbcbd-ee1e-4c5d-a80e-374b9273cb1b">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE3LTEtMS0xLTU1OTY4_f5625532-a648-4407-b5b5-1a3ece48216e">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE3LTMtMS0xLTU1OTY4_fb81fe07-4cf3-4769-8b57-bd524b41f625">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE4LTEtMS0xLTU1OTY4_7451c105-fd12-4932-b1d7-d868d20ca763">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE4LTMtMS0xLTU1OTY4_bf039be8-424d-43ed-b981-74bf7cd2bc2a">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE5LTEtMS0xLTU1OTY4_97883a0c-97cf-4370-a3d8-ae0511c6fcb7">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE5LTMtMS0xLTU1OTY4_5a307f07-4cac-4b74-b7cd-4a84459788d9">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIxLTEtMS0xLTU1OTY4_b7841526-41b9-41c0-8dbf-946fd9a772b6">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIxLTMtMS0xLTU1OTY4_0b9a8ea0-6a73-479e-aaba-a01a53a341e7">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIyLTEtMS0xLTU1OTY4_37027b44-47c7-40c8-bef3-3a059ae403c5">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIyLTMtMS0xLTU1OTY4_796e82f4-eed5-4a36-a61b-731024089ed0">31.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIzLTEtMS0xLTU1OTY4_2e78a667-f6d0-49a0-b349-4b176b52c3ed">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIzLTMtMS0xLTU1OTY4_75515189-e65c-4b98-b62e-2226d6c5e425">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI0LTEtMS0xLTU1OTY4_9f4831e3-21b8-40f4-8522-62ecb5ed3334">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI0LTMtMS0xLTU1OTY4_b97339dd-813c-49f0-9500-5040e25927fa">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI1LTEtMS0xLTU1OTY4_660f2d0a-4dbe-47bf-a4de-eae25410c958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI1LTMtMS0xLTU1OTY4_dc4baa98-139e-4789-b647-7552b36838df">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI2LTEtMS0xLTU1OTY4_d7c85b87-7930-4d99-9f57-45377e433fcc">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI2LTMtMS0xLTU1OTY4_2f49281e-1cc8-4fd3-bfc4-80e21c5fcc26">46.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_244"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzI5ODM_ce44690e-28db-4243-8594-7bd62e611e17" continuedAt="ibae8eaac95df402ab5a7b13cba008383" escape="true">Cash and Marketable Securities:</ix:nonNumeric></span></div><ix:continuation id="ibae8eaac95df402ab5a7b13cba008383" continuedAt="i4f7c729252704b1cb8590657dd474380"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzMwMDQ_c62eff3e-f64d-4ef9-999c-8bfda4a8808e" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2021 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aba592c2b964f6eb203562691351ad5_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzEtMS0xLTEtNTU5Njg_637866f4-1ab8-4f69-852e-58f2bcccc567">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aba592c2b964f6eb203562691351ad5_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzEtMy0xLTEtNTU5Njg_462a6946-ca41-451a-b9ae-dc8d2da292d1">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aba592c2b964f6eb203562691351ad5_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzEtNS0xLTEtNTU5Njg_5a37ee3f-d7c7-457b-a629-a0b665ee935c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aba592c2b964f6eb203562691351ad5_I20211231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzEtNy0xLTEtNTU5Njg_29a969d5-378a-48a6-8438-47dfd9d028c0">120.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602ba1aa1f984572880fe83f75fc4c63_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzItMS0xLTEtNTU5Njg_90008f11-8d5a-4919-866e-93d73424023e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602ba1aa1f984572880fe83f75fc4c63_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzItMy0xLTEtNTU5Njg_70faf229-1836-44e3-ac94-63412620fa26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602ba1aa1f984572880fe83f75fc4c63_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzItNS0xLTEtNTU5Njg_0f57f1f1-50f9-4114-9e12-f797d74f77ef">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602ba1aa1f984572880fe83f75fc4c63_I20211231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzItNy0xLTEtNTU5Njg_e17a0108-5e5c-46b9-8e5f-6d728cb991a2">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzQtMS0xLTEtNTU5Njg_5278eeeb-2bd8-4527-9669-eee48d53a872">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzQtMy0xLTEtNTU5Njg_566c3aab-bc97-40f1-a15e-6efe8bad72b3">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzQtNS0xLTEtNTU5Njg_9e1d05ec-8bdd-4957-aef5-77562181b869">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzQtNy0xLTEtNTU5Njg_4cbdb952-b596-472a-9263-ae0c11ec84fa">202.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2020 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15222b6444e842b6bdb5604f4703b8e5_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzEtMS0xLTEtNTU5Njg_71d68330-7862-403a-8962-fca271e2eb7a">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15222b6444e842b6bdb5604f4703b8e5_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzEtMy0xLTEtNTU5Njg_86be57ae-6568-40b0-a943-a181f2da847a">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15222b6444e842b6bdb5604f4703b8e5_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzEtNS0xLTEtNTU5Njg_1c8281d2-3855-40d2-ba3d-fc81df081fa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15222b6444e842b6bdb5604f4703b8e5_I20201231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzEtNy0xLTEtNTU5Njg_d90766bd-f1a0-4c2b-afb1-91321678f5cc">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b6ec76120d47a3be5eb18921f9202b_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzItMS0xLTEtNTU5Njg_c4f4f7b6-7247-4403-99d5-b8c656f74b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b6ec76120d47a3be5eb18921f9202b_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzItMy0xLTEtNTU5Njg_29665196-9ce6-411b-ae5c-998c761c8f3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b6ec76120d47a3be5eb18921f9202b_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzItNS0xLTEtNTU5Njg_9c170def-23ac-491d-bf37-fc1a5e768ffa">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b6ec76120d47a3be5eb18921f9202b_I20201231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzItNy0xLTEtNTU5Njg_2467237e-a75a-41c8-a78c-da2990fb6ca6">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzQtMS0xLTEtNTU5Njg_2c2de36f-b14a-4485-bd8a-eba12d75d2a5">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzQtMy0xLTEtNTU5Njg_6766618a-2458-4708-88ff-84afc1ca1f9f">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzQtNS0xLTEtNTU5Njg_7d531d1c-0604-4f40-80ca-209478adf383">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzQtNy0xLTEtNTU5Njg_27c7affb-69b8-4ed4-a76b-4d1bba10497a">383.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash&#8212;</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzMwMTg_d9568887-30ec-4145-b5ea-bbd0242d0460" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliate cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id746f8bfcc324f59bffb9b5c9b3a3d24_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzMtMS0xLTEtNTU5Njg_89c41d25-900c-4102-9d71-2de35305c94b">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0a191d08204ba6a56d0168e6d7c236_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzMtMy0xLTEtNTU5Njg_0e044548-3dad-4366-a068-a75615c124ee">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382b49a2de846faadc4af9c9f5ed24e_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzQtMS0xLTEtNTU5Njg_9d18fc6d-96da-4038-8f8e-673001b2bfa2">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id841d4ad284e4f34936f643391714d19_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzQtMy0xLTEtNTU5Njg_209c72dc-9e2f-40a7-85c0-108cd247caa2">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzYtMS0xLTEtNTU5Njg_e03d050d-9c2f-43cc-a0cd-083069b23342">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzYtMy0xLTEtNTU5Njg_f7395c1a-e3d9-4c47-a4ce-f81ddace775b">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382b49a2de846faadc4af9c9f5ed24e_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzktMS0xLTEtNTU5Njg_78e0fead-65e0-45c3-94d5-f8e80034230c">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id841d4ad284e4f34936f643391714d19_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzktMy0xLTEtNTU5Njg_f9a9719c-e6be-45be-bf95-023533f4756a">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzExLTEtMS0xLTU1OTY4_e35e0a6f-ae33-4111-9094-65d864a9f06a">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzExLTMtMS0xLTU1OTY4_e4179469-835a-4953-a673-a111dd4e5157">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliate cash represents cash accounts maintained by joint ventures in which we participate where one or more of our external partners requested, and we agreed, that the joint venture&#8217;s cash not be commingled with other corporate cash accounts and be used only to fund the operations of those joint ventures. Self-insured captive funds represent cash held at our wholly owned insurance captive, HCS, Ltd., as discussed in Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These funds are committed to pay third-party administrators for claims incurred and are restricted by insurance regulations and requirements. These funds cannot be used for purposes outside HCS without the permission of the Cayman Islands Monetary Authority.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification of restricted cash held by HCS as current or noncurrent depends on the classification of the corresponding claims liability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS. HCS insures a substantial portion of Encompass Health&#8217;s professional liability, workers&#8217; compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of December&#160;31, 2021 and 2020, $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:RestrictedDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE1NjY_1e995935-187f-4c97-bfd7-6e9bd6220ce3">82.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="ehc:RestrictedDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE1NzM_369a481d-5a72-4b92-957c-5f50df00c3c5">72.6</ix:nonFraction> million, respectively, of restricted marketable securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i4f7c729252704b1cb8590657dd474380"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheets. During the years ended December&#160;31, 2021, 2020, and 2019, $<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE3NDE_9eb8c33a-1646-4b33-b478-1e2999031892">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE3NDU_a1a03470-b243-4122-b428-079a6a029c23">0.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE3NTM_02f5d67e-39ef-47dd-b65e-25118ab5241d">1.2</ix:nonFraction>&#160;million, respectively, of unrealized net gains were recognized in our consolidated statements of comprehensive income on marketable securities still held at the reporting date.</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfRealizedGainLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzI5NzU_858cc48b-a5c1-4cf2-9ace-b2bd936b2f46" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing information related to our available-for-sale marketable securities is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of available-for-sale marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTphN2RiNTNmNWYyMzQ0MjFiODVjY2U4MzBhYTMxNjUxNS90YWJsZXJhbmdlOmE3ZGI1M2Y1ZjIzNDQyMWI4NWNjZTgzMGFhMzE2NTE1XzItMS0xLTEtNTU5Njg_bc3bf1eb-f4e4-4a04-9032-aaf5f95116ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTphN2RiNTNmNWYyMzQ0MjFiODVjY2U4MzBhYTMxNjUxNS90YWJsZXJhbmdlOmE3ZGI1M2Y1ZjIzNDQyMWI4NWNjZTgzMGFhMzE2NTE1XzItMy0xLTEtNTU5Njg_96da0bbf-672d-4563-8e50-48de4ec10dc0">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTphN2RiNTNmNWYyMzQ0MjFiODVjY2U4MzBhYTMxNjUxNS90YWJsZXJhbmdlOmE3ZGI1M2Y1ZjIzNDQyMWI4NWNjZTgzMGFhMzE2NTE1XzItNS0xLTEtNTU5Njg_38b4bf10-2aed-46a0-bc98-96df3ca8cd94">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketable securities is comprised of investments in mutual funds that hold investments in a variety of industries and geographies. As discussed in Note&#160;1,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Marketable Securities,&#8221; when our portfolio included marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, we examined the severity and duration of the impairments in relation to the cost of the individual investments. We also considered the industry and geography in which each investment is held and the near-term prospects for a recovery in each.</span></div></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_247"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90ZXh0cmVnaW9uOjg5YzEzMjBiNjJmYTQzMTA4NDA4NzI5YjA5NzE2YWY4XzUwMg_34664dfe-46ee-4cfc-9134-a293d8d560ba" continuedAt="ia1c9270143744b019344c075c8e0b469" escape="true">Accounts Receivable:</ix:nonNumeric></span></div><ix:continuation id="ia1c9270143744b019344c075c8e0b469"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90ZXh0cmVnaW9uOjg5YzEzMjBiNjJmYTQzMTA4NDA4NzI5YjA5NzE2YWY4XzUwMQ_6b519274-c8d9-4546-a6a7-1a611ee5cbdb" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzMtMS0xLTEtNTU5Njg_34bef982-2113-4593-8a97-ad9b033d3a29">666.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzMtMy0xLTEtNTU5Njg_12891611-0b3a-459c-9663-311d2eee5238">563.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzQtMS0xLTEtNTU5Njg_9e3931af-c886-48c2-944c-f8b7275f7d6b">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzQtMy0xLTEtNTU5Njg_1acdc67f-2818-4044-89cb-a2b1d35f2228">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzUtMS0xLTEtNTU5Njg_8938b018-0650-476a-b9f4-b8ead46f89ed">680.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzUtMy0xLTEtNTU5Njg_3d03cd32-baeb-469e-ac6e-6a38b1d4bfb7">572.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent patient accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzYtMS0xLTEtNTU5Njg_f25133a7-bfbd-4c08-914f-8f0dd61830f3">83.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzYtMy0xLTEtNTU5Njg_d7b41ec7-aa70-4475-81a7-93145430a79b">123.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzctMS0xLTEtNTU5Njg_af66c376-09ce-429b-a4f2-a0118107ea75">763.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzctMy0xLTEtNTU5Njg_720c981c-3613-458a-b890-aafccc094c0f">696.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the resolution of claims that are part of Medicare audit programs can take several years, we review the patient receivables that are part of this adjudication process to determine their appropriate classification as either current or noncurrent. Amounts considered noncurrent are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheet. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for additional information.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_250"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90ZXh0cmVnaW9uOjZlZDVmMWEzNTVhNTQxZGNiZjZhN2MzNjNlNTBkNGU1XzUwOQ_48025b0d-e2ac-459a-a3eb-8856787ff943" continuedAt="i4d463040a7c04762b62a43948be711f3" escape="true">Property and Equipment:</ix:nonNumeric></span></div><ix:continuation id="i4d463040a7c04762b62a43948be711f3"><ix:continuation id="i3015227c8550453fb424882c37480ff3"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1ca2c1f30a41728732fec700a16e4d_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzItMS0xLTEtNTU5Njg_f6b4592e-d2ab-4c83-99be-0b56843649e2">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8516a1fe22324229af025f40b32d77f2_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzItMy0xLTEtNTU5Njg_57c58898-8d13-4aef-a4ee-fdbad77f2306">217.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdb38e0060345f8a7f153c65b0ae589_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzMtMS0xLTEtNTU5Njg_8d88fb33-16e7-443c-8c4d-6cc0db9ad0f1">2,632.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3869f5c4ac04881b2a7c48441f84658_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzMtMy0xLTEtNTU5Njg_3b6024aa-46a3-485b-a89c-38e23ba1588d">2,357.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17fc36ea770b490097eb1b8b155949d7_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzQtMS0xLTEtNTU5Njg_3fe48a36-5e6f-4bcd-9c51-ade6743b673c">254.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e53fbc95c16440ebc2899f7ff225074_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzQtMy0xLTEtNTU5Njg_155c1139-dff9-41f7-af13-43613271115c">232.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f487c6319de4b2789e80cce58d82850_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzUtMS0xLTEtNTU5Njg_afe6b77b-3ccd-441e-b850-24f37ef13cef">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0053d81c5643ee947bbd55082c4aa7_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzUtMy0xLTEtNTU5Njg_866e86c8-ec43-4417-b770-40ccfdfe6102">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a35614edf5643cda801a3adbda6f446_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzYtMS0xLTEtNTU5Njg_8260416d-25e2-456a-bdca-9cb1ad964cfb">606.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia70f9dcbe8e24aeea62c485281cea06f_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzYtMy0xLTEtNTU5Njg_2240a91e-f6a0-42f8-b90d-5ff4bb20d3be">537.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzctMS0xLTEtNTU5Njg_442ff530-5ba9-41f5-b3e4-95fe71fbf5a6">3,787.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f1e5c21e09435f94b9e6e1c8a4bc7a_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzctMy0xLTEtNTU5Njg_21bcfb98-622d-4d44-849c-fdaf2da22089">3,378.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzgtMS0xLTEtNTU5Njg_94765a3f-853c-4ccf-b2ca-1c67b1a61d58">1,539.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36f1e5c21e09435f94b9e6e1c8a4bc7a_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzgtMy0xLTEtNTU5Njg_1e2fb63c-9bb9-4938-8d9a-1c40fc27e5af">1,374.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzktMS0xLTEtNTU5Njg_9b152c72-4314-401e-91a1-6e850a7a0627">2,248.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f1e5c21e09435f94b9e6e1c8a4bc7a_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzktMy0xLTEtNTU5Njg_88c0a775-f112-4343-aa4d-9732505fa55f">2,004.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39344a1ae54d4b5a8df1f9ea9760ee2f_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzEwLTEtMS0xLTU1OTY4_6660eb93-7eaa-424e-bc10-0e973353b44e">353.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6d18334d234593b48e1782c831116b_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzEwLTMtMS0xLTU1OTY4_6a441922-507b-4ea3-b717-bfa745cde53c">202.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzExLTEtMS0xLTU1OTY4_614c1fb0-b8d5-4c67-a818-9b1dc51ab114">2,601.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzExLTMtMS0xLTU1OTY4_81f171fd-74a4-40db-a06e-abcc3faf2f98">2,206.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, approximately <ix:nonFraction unitRef="number" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="2" name="ehc:Percentageofassetspledgedtolendersundercreditagreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90ZXh0cmVnaW9uOjZlZDVmMWEzNTVhNTQxZGNiZjZhN2MzNjNlNTBkNGU1XzEwMA_f55fcd95-28fb-481a-b5ce-3b842810931c">73</ix:nonFraction>% of our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> held by Encompass Health Corporation and its guarantor subsidiaries was pledged to the lenders under our credit agreement. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Liquidity and Capital Resources.&#8221;</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90ZXh0cmVnaW9uOjZlZDVmMWEzNTVhNTQxZGNiZjZhN2MzNjNlNTBkNGU1XzUyNQ_00cb52c0-a460-41da-a90c-40b439350ec6" escape="true"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of depreciation expense and interest capitalized is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzItMS0xLTEtNTU5Njg_3315177f-eb69-4276-9572-2f328042111a">166.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzItMy0xLTEtNTU5Njg_60360c62-c8f0-428c-8bc3-1133944eb4ea">151.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzItNS0xLTEtNTU5Njg_ea76d18b-cc14-4531-8cbd-c5c23869ac7b">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest capitalized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzQtMS0xLTEtNTU5Njg_fdb552cf-988a-411f-96ad-701d1051b1f6">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzQtMy0xLTEtNTU5Njg_66d426aa-1203-45ee-9726-2c2e666884e1">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzQtNS0xLTEtNTU5Njg_cdba6759-8f26-425a-8a96-c5503d5851d1">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_253"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDM_872a66be-90d9-4576-a069-354fba19bbf8" continuedAt="iefae59df2bec4c56818ff0a7d2851692" escape="true"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDQ_90d8753c-c652-47f9-9d1c-7212bca6614e" continuedAt="i29d6effda8ad4d969569209b635f2eda" escape="true">Leases:</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="iefae59df2bec4c56818ff0a7d2851692" continuedAt="i091ba98230ee4641a148a3633d030098"><ix:continuation id="i29d6effda8ad4d969569209b635f2eda" continuedAt="i0536c4db162a446192af34141a9fb757"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have <ix:nonNumeric contextRef="if750783979f34735a047752b07b25985_D20210101-20211231" name="ehc:Operatingandfinanceleasecontractterm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzIxNQ_7d6af2d4-ea79-4875-8e94-c1ed7886b75d">1</ix:nonNumeric>- to <ix:nonNumeric contextRef="ib3d825afa781450ba456aff29ce70e22_D20210101-20211231" name="ehc:Operatingandfinanceleasecontractterm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDE_3710d17f-06a6-4c26-bd84-e3532accc880">25-year</ix:nonNumeric> terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNTA_7a00f041-0452-4ff8-8108-cd457fce41e1" escape="true"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzItMS0xLTEtNTU5Njg_6516ffd2-1a50-4d7c-81f1-3ebbd528d898">66.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzItMy0xLTEtNTU5Njg_63f95596-e8d3-4447-bd42-4645ac384aa3">68.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzItNS0xLTEtMTIxMzcz_362f5ec3-2464-4eb5-9454-eeeb4fcf5c35">72.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzQtMS0xLTEtNTU5Njg_c7ad2727-97bd-49e0-a609-5954402ef054">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzQtMy0xLTEtNTU5Njg_b2d470c4-8596-448b-884f-1c79e4f09435">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzQtNS0xLTEtMTIxMzcz_f265d4e7-1d98-41e9-b940-5db8ffdf26a0">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzUtMS0xLTEtNTU5Njg_84ce68ce-a947-4413-ad28-5940986593fa">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzUtMy0xLTEtNTU5Njg_5272336b-2fca-49a9-a3ce-7680a15207d4">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzUtNS0xLTEtMTIxMzcz_72ca7f6e-9fa6-40de-b324-0998e8eccdd8">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:Totalfinanceleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzYtMS0xLTEtNTU5Njg_ea23f3d1-54a2-4068-b8ee-add89578fce7">64.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:Totalfinanceleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzYtMy0xLTEtNTU5Njg_6b441bc4-a72d-471f-b0e7-3f0a8011f002">61.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:Totalfinanceleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzYtNS0xLTEtMTIxNDM4_a29b8d1b-d52e-487a-9bf9-34577adfc9e2">59.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:Shorttermandvariableleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzctMS0xLTEtNTU5Njg_3365e4d3-2671-45fc-907b-834762620505">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:Shorttermandvariableleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzctMy0xLTEtNTU5Njg_949acdf4-cbee-4380-b6fe-1a74fdfc83bb">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:Shorttermandvariableleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzctNS0xLTEtMTIxMzgw_404533df-4b47-49e4-ba1b-21b76a54b7fd">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzgtMS0xLTEtNTU5Njg_f53cb485-5e02-43cb-8790-58b6432c4565">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzgtMy0xLTEtNTU5Njg_3755fe68-9555-42b6-b2c2-51111a8c3c3b">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzgtNS0xLTEtMTIxMzgw_547d533f-1d5a-46c2-b270-5078795b6c37">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzktMS0xLTEtNTU5Njg_a4edb9f3-4ba5-4fa0-af8b-8e5ce238ed92">130.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzktMy0xLTEtNTU5Njg_5f06b750-d72a-4d80-89d3-89aa23d3a366">130.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzktNS0xLTEtMTIxNDM4_269e9356-fe95-4079-9d72-bc228b99759e">131.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDg_2383a0e7-5e7f-4c50-a16a-014024f307d6" escape="true"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated balance sheet information related to leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzMtNC0xLTEtNTU5Njg_6cab6fff-7c77-43ae-a18b-1023235c835c">242.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzMtNi0xLTEtNTU5Njg_0cfe754d-1630-448a-954d-0112da3fba6a">245.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtNC0xLTEtNTU5Njg_ed595647-68fd-43f0-afd1-85fe6f40f71e">309.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtNi0xLTEtNTU5Njg_ebe00bfb-5eec-4d4c-8ba1-523089f38d4d">322.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:Totaloperatingandfinanceleaseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzUtNC0xLTEtNTU5Njg_330cfbbb-2bc6-4c68-9ae4-a448f3c2b283">551.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="ehc:Totaloperatingandfinanceleaseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzUtNi0xLTEtNTU5Njg_c2939e99-ab75-4e82-bd74-3f7030f0829c">568.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzktNC0xLTEtNTU5Njg_23c8bcf7-240e-405e-a187-bb540ec4006f">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzktNi0xLTEtNTU5Njg_38abe492-26a4-4cbc-98c9-21b225bfe622">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTQtMS0xLTU1OTY4_e5e115ea-c901-4194-b6a8-19109645ac05">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTYtMS0xLTU1OTY4_8a8ad2c2-df03-407a-93b4-94b4871f31ab">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEyLTQtMS0xLTU1OTY4_3fb08401-987b-476e-bc2e-4bb485175957">213.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEyLTYtMS0xLTU1OTY4_18d5082a-5157-4e6e-9434-50b247fcc6c5">209.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTQtMS0xLTU1OTY4_54893b56-327d-4bda-94c3-0b80f552badc">363.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTYtMS0xLTU1OTY4_5e98f410-790e-488e-a50d-0ff181c9366a">367.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:Totalleaseliabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzE0LTQtMS0xLTU1OTY4_db543d9e-b656-4017-a238-874b65c12f67">638.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="ehc:Totalleaseliabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzE0LTYtMS0xLTU1OTY4_0e24362d-85f6-468c-a6f1-d469d0e9b33e">646.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease assets are recorded net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3Xzk2NQ_c5d9a0b0-8083-46ae-9cda-21bc8341e7da">147.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzEwOTk1MTE2Mjg5NjU_ab85f086-46d1-43b4-a31a-c19aa4cea448">129.6</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i091ba98230ee4641a148a3633d030098"><ix:continuation id="i0536c4db162a446192af34141a9fb757"><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDI_1af929d4-51d5-4e13-b8f3-feb71194acf7" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzMtMS0xLTEtNTU5Njg_5690f83c-4d3f-4edd-b132-ca56ac9dd810">8.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzMtMy0xLTEtNTU5Njg_3da66ffb-b4b3-4186-8129-c6b70df8938c">8.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzQtMS0xLTEtNTU5Njg_6236c4ee-f2e3-4b2e-929d-d0ada5eb543c">11.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzQtMy0xLTEtNTU5Njg_0a81b3c6-e368-43cd-ae92-3ec40b493406">11.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzYtMS0xLTEtNTU5Njg_c60b3b37-945f-47ce-96e3-d9e13655d1e5">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzYtMy0xLTEtNTU5Njg_ede984d8-1ed0-4f03-a8a1-4dfc55533b95">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzctMS0xLTEtNTU5Njg_17b855de-e964-429d-bb9f-01304db0aee6">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzctMy0xLTEtNTU5Njg_09664187-acca-44f1-9170-a031758a1d5b">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDY_62dab224-846d-4ac8-96ca-30c8e3af3e27" escape="true"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDk_36e2f9a0-5569-4e26-a2e4-4fa4b74dab64" escape="true"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzEtMS0xLTEtNTU5Njg_749247ae-50f1-4047-b9e8-dbcbf905b204">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzEtMy0xLTEtNTU5Njg_e70b8679-810e-4856-84ab-d7c944b2d61d">52.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzItMS0xLTEtNTU5Njg_506bb108-fa2d-4b9d-93a6-34e633622c5c">50.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzItMy0xLTEtNTU5Njg_b0421d86-3c23-4e4c-9b2e-38622a805eba">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzMtMS0xLTEtNTU5Njg_1f9fbe38-bf1a-432e-98bb-091cc87c36b0">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzMtMy0xLTEtNTU5Njg_a6927bfb-15fc-4f24-a23c-e42fc321ed91">50.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzQtMS0xLTEtNTU5Njg_6d0f2b50-6d56-4e3f-934f-a67574f143ef">34.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzQtMy0xLTEtNTU5Njg_64599440-efaa-4255-8f09-99c5f986c5fc">50.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzUtMS0xLTEtNTU5Njg_448d0fa3-ae8c-4f17-b928-5d9d293a6ca0">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzUtMy0xLTEtNTU5Njg_066fb219-6ffe-405c-b11c-8c60959807b5">51.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzYtMS0xLTEtNTU5Njg_89e0edf6-966e-4a1a-a6f9-d6b75aecc726">116.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzYtMy0xLTEtNTU5Njg_f924cc88-9b34-46ff-b6c3-7c4a41e9f986">350.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzctMS0xLTEtNTU5Njg_bf0b6152-2ccd-4432-8cab-c26a90c23a72">326.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzctMy0xLTEtNTU5Njg_e0096684-c236-44a4-8ead-d449212f3736">606.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzgtMS0xLTEtNTU5Njg_a056d32f-96fe-4a6c-8f8f-0fe686bd45bd">75.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzgtMy0xLTEtNTU5Njg_115bbb92-c26b-4e57-b111-6f4b6aec2461">219.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzktMS0xLTEtNTU5Njg_27c3edf1-ae24-45e6-89fc-677989418bce">251.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzktMy0xLTEtNTU5Njg_a01aa2dd-4600-4e61-bf78-af14bfc27843">386.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="ehc:SupplementalCashFlowInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDc_b36b06e1-3e10-4e6f-ad89-2a6ba38224a7" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzMtMS0xLTEtNTU5Njg_85e52b84-3f18-4fd7-a925-723797c95dd4">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzMtMy0xLTEtNTU5Njg_8567fe92-020a-4942-90cf-b3bf7ee4cef4">66.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzMtNS0xLTEtMTIxNDA3_7eadbfa0-967b-4005-9f83-4c09a3a3af9e">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzQtMS0xLTEtNTU5Njg_f9c3182b-8836-49f5-a93d-837c8bfe368e">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzQtMy0xLTEtNTU5Njg_ff37617a-0331-4d3c-99b0-b98f5beec66a">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzQtNS0xLTEtMTIxNDA3_cf93b374-499a-4f89-9112-43ab96ca8da1">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzUtMS0xLTEtNTU5Njg_4acc0f96-27c5-4805-9c4b-eaf554d9b570">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzUtMy0xLTEtNTU5Njg_4c1f1441-47f3-477a-9872-8991cac523e0">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzUtNS0xLTEtMTIxNDA3_b8a1ab2d-3448-46ab-af09-fb0f31d3f3ee">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzgtMS0xLTEtNTU5Njg_823b023b-643d-48dd-a408-217debf351ae">51.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzgtMy0xLTEtNTU5Njg_1f425617-5df3-449e-9ebb-a42f82adaf71">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzgtNS0xLTEtMTIxNDA3_84eb1c37-f4dc-4bd7-8b42-cb5380d51ece">43.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzktMS0xLTEtNTU5Njg_acbed204-b001-4be1-b6d8-e3a881c314ab">50.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzktMy0xLTEtNTU5Njg_6b2fbffc-e911-4446-9f77-736868308215">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzktNS0xLTEtMTIxNDA3_7d24d07d-670d-4e36-8182-3f511d4d6c9f">34.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_259"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzEyODc_6017e310-ee31-4e23-8cc4-44219e91efb7" continuedAt="i33f13cf569784d628661d43e6df20115" escape="true">Goodwill and Other Intangible Assets:</ix:nonNumeric></span></div><ix:continuation id="i33f13cf569784d628661d43e6df20115" continuedAt="if049747573454da3b47a5cb8e1a04764"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzEyNzI_ad1aea42-fcd9-4a1f-bcc3-9c124eca2ac1" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b51d815c2e4db38d2976c4fb0c1889_I20181231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEtMS0xLTEtNTU5Njg_6caf47d4-580f-44a2-91d4-f51a5099b95b">1,189.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ca43a183ee4af097404ac760bab1eb_I20181231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEtMy0xLTEtNTU5Njg_86951d86-1e94-4e89-b09a-e30ffa75c8c9">911.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEtNS0xLTEtNTU5Njg_d4002477-61d8-46a7-959c-cc0586584d35">2,100.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzItMS0xLTEtNTU5Njg_0e9efb04-0cb9-4cdb-bf2c-d06e2309e19b">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzItMy0xLTEtNTU5Njg_07d7f9cd-1593-46df-8a63-8c4f1aceb2b7">174.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzItNS0xLTEtNTU5Njg_fbd43ab9-72f1-42cb-8f60-e8470f9240ae">179.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzMtMS0xLTEtNTU5Njg_8fa94551-4ac5-4859-8983-48fd56bb7d52">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzMtMy0xLTEtNTU5Njg_fb2daea4-561e-4f9c-8e2a-108e7b1a77b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzMtNS0xLTEtNzE4NjQ_3a43e414-9610-44a5-9063-561066fd3822">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6908c604f9704fdd859cda5b310c3f22_I20191231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzUtMS0xLTEtNTU5Njg_6577a525-df8b-464f-9992-dd5b18aa6f02">1,218.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b8c9109fb524f078bf0bd4b28be8aa2_I20191231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzUtMy0xLTEtNTU5Njg_901ea9a5-4f01-47dc-9f1c-eefc045c90ae">1,086.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzUtNS0xLTEtNTU5Njg_11192ef3-aa27-4db3-8b38-0f30b97af889">2,305.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzYtMS0xLTEtNTU5Njg_65bac8f0-f8fa-4933-9a2c-0b4305ea7a27">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzYtMy0xLTEtNTU5Njg_93389e46-0154-4e80-b716-146b6890b608">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzYtNS0xLTEtNTU5Njg_1477f83c-7ad9-4c81-863b-988a302cdd8c">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzctMS0xLTEtNTU5Njg_c2e738bb-9f53-426b-9be0-805a0e44ae6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzctMy0xLTEtNTU5Njg_d502a292-bd7e-497f-9255-aaf47691eed1">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzctNS0xLTEtNTU5Njg_0619f5cb-cd0a-46a2-be1b-34f518d579dc">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490945f79e4b4bb6aeef60a98f16bb9e_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzgtMS0xLTEtNTU5Njg_8ddb618b-e1ef-420e-9a7f-bd8b1ca47b96">1,228.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da867bd58bd42c7829bba5db347624f_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzgtMy0xLTEtNTU5Njg_e7abe5f1-09f6-4719-95b3-c1a8d210b1f7">1,090.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzgtNS0xLTEtNTU5Njg_ca7c40d9-4869-4791-aa02-1618698448a5">2,318.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzktMS0xLTEtNTU5Njg_c28e0447-0973-469d-8fc1-ca29ae1226a2">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzktMy0xLTEtNTU5Njg_1909ff7c-b3ae-4c2c-b5ab-f0a77f3c6c45">92.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzktNS0xLTEtNTU5Njg_0d6495f2-06cb-4683-a979-6ce6bc540a27">101.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEwLTEtMS0xLTU1OTY4_5725044b-9aac-4ea3-83c6-108add5d5ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEwLTMtMS0xLTU1OTY4_0a717027-a55e-4307-bb57-db1c03ea3ba0">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEwLTUtMS0xLTU1OTY4_7a3bf481-04dc-49a7-8021-f43f9ea87b43">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzExLTEtMS0xLTU1OTY4_46d2c3c4-2fa0-4546-86fe-113ef5e0d823">1,236.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzExLTMtMS0xLTU1OTY4_ddf56a8d-259d-47bb-95dd-e73131e0e1ae">1,191.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzExLTUtMS0xLTU1OTY4_1b377462-a66b-4c65-bb90-94f847246819">2,427.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in 2019 as a result of our consolidation of Yuma Rehabilitation Hospital and the remeasurement of our previously held equity interest at fair value and our acquisitions of Alacare and other inpatient and home health and hospice operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in 2020 as a result of our acquisitions of inpatient and home health operations as well as our consolidation of the Jupiter, Florida home health agency and the remeasurement of our previously held equity interest at fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in 2021 as a result of our acquisitions of Frontier and other inpatient and home health and hospice operations as well as our consolidation of the Home Health of South Florida joint venture and the remeasurement of our previously held equity interest at fair value. See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note&#160;9,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments in and Advances to Nonconsolidated Affiliates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed impairment reviews as of October&#160;1, 2021, 2020, and 2019 and concluded <ix:nonFraction unitRef="usd" contextRef="ic844601724a84290b07683e4c14534a9_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2Xzg2OA_2f6f3d70-11a8-4a4f-b0b4-01a302a52322"><ix:nonFraction unitRef="usd" contextRef="if4f21e5f62784e5fad3a81733fafbc9b_D20201001-20201001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2Xzg2OA_53e4baf1-f675-45e8-a3ab-d45cec64d7e6"><ix:nonFraction unitRef="usd" contextRef="i04ac5a43d97b4d1f8b07571f7fd1b855_D20191001-20191001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2Xzg2OA_a29415fd-fe53-4f2e-96d3-88b4a21d4429">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment existed. As of December&#160;31, 2021, we had <ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzkxNw_248c2464-64e9-40b3-8c0d-4c44d815ba65">no</ix:nonFraction> accumulated impairment losses related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if049747573454da3b47a5cb8e1a04764"><ix:continuation id="i31268c77d11e48bcbd5b2ebec600e04f"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our other intangible assets (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certificates of need:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dfa4bde6170492bb1256171952a8047_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzItMS0xLTEtNTU5Njg_b66a039b-7fbf-4b10-a424-e4ddb952ed67">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dfa4bde6170492bb1256171952a8047_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzItMy0xLTEtNTU5Njg_4d88fe8e-9d05-4e6b-b3da-81020089cb36">68.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dfa4bde6170492bb1256171952a8047_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzItNS0xLTEtNTU5Njg_e9b2817b-062f-4e4c-a7fb-e43c4d1dabd1">135.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc3f06fe25e4000958cb09124165dec_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzMtMS0xLTEtNTU5Njg_d29df009-f1d4-441c-8ed3-81ec5a262b09">197.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bc3f06fe25e4000958cb09124165dec_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzMtMy0xLTEtNTU5Njg_b1cfcdab-fa0d-4531-960e-0bdeb289f502">54.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc3f06fe25e4000958cb09124165dec_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzMtNS0xLTEtNTU5Njg_0be3e49d-5fd6-448d-b6c8-c13db7763127">142.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9be624554e4aa4a376cd3b45cb1d46_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzUtMS0xLTEtNTU5Njg_9bb7858a-33ef-4d1f-b12a-8bc825d0cafb">194.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9be624554e4aa4a376cd3b45cb1d46_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzUtMy0xLTEtNTU5Njg_c80c98ef-6de6-4bc9-94f5-9ab2313660d4">121.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9be624554e4aa4a376cd3b45cb1d46_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzUtNS0xLTEtNTU5Njg_87f27b2a-a775-47cf-9793-64f3ee220c12">73.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f74947a4ced47148dc5c2e32cdb11ad_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzYtMS0xLTEtNTU5Njg_6079c76f-5c0a-4d99-85db-b40df2fd68f6">187.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f74947a4ced47148dc5c2e32cdb11ad_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzYtMy0xLTEtNTU5Njg_c50ab456-7eac-4c38-9370-17f0e7dc2775">107.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f74947a4ced47148dc5c2e32cdb11ad_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzYtNS0xLTEtNTU5Njg_73189d7d-5eb5-46d0-8f23-8322f3e20715">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncompete agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e11b04c0c5145c3b6c956ff071c1203_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzgtMS0xLTEtNTU5Njg_6ae5a419-ef0f-4eae-af99-7c18dbb02293">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e11b04c0c5145c3b6c956ff071c1203_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzgtMy0xLTEtNTU5Njg_51af0027-4f26-4311-b52b-864b196387f8">69.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e11b04c0c5145c3b6c956ff071c1203_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzgtNS0xLTEtNTU5Njg_a7331dd0-5c17-435f-9cf4-abc3dea9112c">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5716c39ae0e54b28a2f17fc8e1345352_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzktMS0xLTEtNTU5Njg_74f827a6-c0a2-4bc7-acd5-7df25141a2c7">75.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5716c39ae0e54b28a2f17fc8e1345352_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzktMy0xLTEtNTU5Njg_b1c0e73d-47ea-4694-bb48-3e3fece653a1">65.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5716c39ae0e54b28a2f17fc8e1345352_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzktNS0xLTEtNTU5Njg_717f9d91-018e-4d1b-975c-c9897d8a6b5c">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade name - Encompass:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142b52fe614942e2a17e645d7b8dd1ca_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzExLTEtMS0xLTU1OTY4_01d71db1-9616-488c-886b-d6da8894525e">135.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142b52fe614942e2a17e645d7b8dd1ca_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzExLTMtMS0xLTU1OTY4_19642a52-e06e-4572-a358-185520350cbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142b52fe614942e2a17e645d7b8dd1ca_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzExLTUtMS0xLTU1OTY4_61a0852f-4f2c-424d-8ce7-ef8992c7bc1b">135.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40cc76eee7fb4c20a4d9ece9eadca6a6_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzEyLTEtMS0xLTU1OTY4_1ed978d7-fc28-4c24-b11d-d5ac1c8c8bef">135.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40cc76eee7fb4c20a4d9ece9eadca6a6_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzEyLTMtMS0xLTU1OTY4_e23e99dc-06ae-4b27-996a-c6c8e041019e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40cc76eee7fb4c20a4d9ece9eadca6a6_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzEyLTUtMS0xLTU1OTY4_bdb9e48e-09bb-49c2-af7c-60ee5ffb9e22">135.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade names - all other:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc2019286614b4d9cb93eb114ddc287_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE0LTEtMS0xLTU1OTY4_ddadeda9-6d5d-4b7e-b632-c5a1f292087f">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc2019286614b4d9cb93eb114ddc287_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE0LTMtMS0xLTU1OTY4_a49de464-910e-451e-829b-2d870485b190">27.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc2019286614b4d9cb93eb114ddc287_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE0LTUtMS0xLTU1OTY4_c6c43fc1-417d-4cdd-80e2-63e3d8cc7c58">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1609b119ab410a9be9855c6f405555_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE1LTEtMS0xLTU1OTY4_bf2ee965-4d07-40bf-8a59-480202117459">44.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc1609b119ab410a9be9855c6f405555_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE1LTMtMS0xLTU1OTY4_c004c28d-1ca8-4db0-b7a3-46e2b0b32783">25.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1609b119ab410a9be9855c6f405555_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE1LTUtMS0xLTU1OTY4_9c239252-49fa-4c35-bfbe-553270872acf">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal-use software:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc7abf48bdf4656b5449a56fc5811ca_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE3LTEtMS0xLTU1OTY4_49798452-00c6-4010-b64b-2c99db020032">209.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc7abf48bdf4656b5449a56fc5811ca_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE3LTMtMS0xLTU1OTY4_a8c2410c-3655-424b-b6a6-95235e4ac5cf">164.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc7abf48bdf4656b5449a56fc5811ca_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE3LTUtMS0xLTU1OTY4_5a075e9e-4a41-4ab3-847a-65ee304b8514">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7674e95c82459ba38b39ec46c8f9b1_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE4LTEtMS0xLTU1OTY4_1f6f549c-9d0b-4ec7-841b-a5e4db46aa15">184.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c7674e95c82459ba38b39ec46c8f9b1_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE4LTMtMS0xLTU1OTY4_6229af44-4647-47ae-8c29-35d853a281c9">141.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7674e95c82459ba38b39ec46c8f9b1_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE4LTUtMS0xLTU1OTY4_f8320eb9-f7af-4b30-8a01-b69848b57ff3">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market access assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcab17e249fe430bad4f7616edebf373_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIwLTEtMS0xLTU1OTY4_422e866b-15b2-4ea5-a781-2da7d7088a9f">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcab17e249fe430bad4f7616edebf373_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIwLTMtMS0xLTU1OTY4_d38d5b47-831d-4821-8c84-84d4227def04">11.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcab17e249fe430bad4f7616edebf373_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIwLTUtMS0xLTU1OTY4_f1b85a43-6fe7-497f-9ab0-01b3e1a4440b">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa18ceb2e4824a189bed176eccf7312e_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIxLTEtMS0xLTU1OTY4_1076a46b-c258-45a7-9001-aaeb9589c6b0">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa18ceb2e4824a189bed176eccf7312e_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIxLTMtMS0xLTU1OTY4_be03e651-b910-4202-9360-eb70cdcb6efa">11.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa18ceb2e4824a189bed176eccf7312e_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIxLTUtMS0xLTU1OTY4_a5e923c7-140d-47b2-8154-4008680d85d3">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIzLTEtMS0xLTU1OTY4_720abec8-f023-4106-8f8b-612b8798b279">879.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIzLTMtMS0xLTU1OTY4_cc19e45c-7b31-4ec5-951d-5c8b241743e6">462.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIzLTUtMS0xLTU1OTY4_b0bae5cb-1fea-4ca7-bd8a-9566d60cb191">417.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzI0LTEtMS0xLTU1OTY4_382b8e09-746d-4d8f-9464-6d9cf7f7b620">837.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzI0LTMtMS0xLTU1OTY4_65b9a898-c8b1-48e1-810a-919dc13b1efd">406.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzI0LTUtMS0xLTU1OTY4_e0c295e4-afcd-4a1c-81c4-5c0f54f02a2b">431.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzEzMTM_8bb4697d-9a76-471f-9b20-c279fa4ede5f" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for other intangible assets is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo3OGFkMTJiMWJlNWQ0MzY1ODhmMGI1OTVkYWFlNWEyZC90YWJsZXJhbmdlOjc4YWQxMmIxYmU1ZDQzNjU4OGYwYjU5NWRhYWU1YTJkXzItMS0xLTEtNTU5Njg_6f2e843e-6464-4c96-a3bf-cc61e8b8a922">56.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo3OGFkMTJiMWJlNWQ0MzY1ODhmMGI1OTVkYWFlNWEyZC90YWJsZXJhbmdlOjc4YWQxMmIxYmU1ZDQzNjU4OGYwYjU5NWRhYWU1YTJkXzItMy0xLTEtNTU5Njg_e2ac7743-bb22-4fc7-bcdb-41da9310295d">59.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo3OGFkMTJiMWJlNWQ0MzY1ODhmMGI1OTVkYWFlNWEyZC90YWJsZXJhbmdlOjc4YWQxMmIxYmU1ZDQzNjU4OGYwYjU5NWRhYWU1YTJkXzItNS0xLTEtNTU5Njg_6560f90a-db4e-498f-92fc-1b2ca946002c">58.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzEzMTc_ef5f572a-ad5b-4556-82fa-53097fb23d8f" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzEtMS0xLTEtNTU5Njg_acfeef44-68dd-4774-ad02-275479e112a3">53.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzItMS0xLTEtNTU5Njg_f05635a2-fdba-4178-8eca-d34837e8b1a8">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzMtMS0xLTEtNTU5Njg_6665e759-f335-4d26-b069-b9e9782558f1">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzQtMS0xLTEtNTU5Njg_43000c67-12c1-4d7e-bd91-966d65a17e75">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzUtMS0xLTEtNTU5Njg_455c59ff-93ef-4ca0-9b9a-d10608d381d3">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_262"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI5NjI_b2a2a0ff-6c77-4ed2-ba2e-51f67fc3d337" continuedAt="i38f2bb6e11b2430c81498fbd54dc0597" escape="true">Investments in and Advances to Nonconsolidated Affiliates:</ix:nonNumeric></span></div><ix:continuation id="i38f2bb6e11b2430c81498fbd54dc0597" continuedAt="i2dcf5412ee964599b85aac7dca4efda3"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in and advances to nonconsolidated affiliates as of December&#160;31, 2021 represents our investment in <ix:nonFraction unitRef="subsidiary" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="ehc:NumberOfPartiallyOwnedSubsidiariesNonconsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzEwNg_cd495213-a45e-4db2-926c-4fd899245465">three</ix:nonFraction> partially owned subsidiaries, of which <ix:nonFraction unitRef="subsidiary" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="ehc:NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzE0OA_bcc28107-d74a-4d1e-8b10-29df92b66716">two</ix:nonFraction> are general or limited partnerships, limited liability companies, or joint ventures in which Encompass Health or one of its subsidiaries is a general or limited partner, managing member, member, or venturer, as applicable. We do not control these affiliates but have the ability to exercise significant influence over the operating and financial policies of certain of these affiliates. Our ownership percentages in these affiliates range from approximately <ix:nonFraction unitRef="number" contextRef="ie64cfb56dcaf4d2dbd074d8ae766d3ff_I20211231" decimals="2" name="ehc:AffiliatesOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzYwOQ_496f2014-5093-4fb6-8067-b58dfe437882">5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib75c417944a447ca93f748d0d3afe2f8_I20211231" decimals="2" name="ehc:AffiliatesOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzYxNQ_c341167f-edb8-4062-9e08-c9fe790898b9">50</ix:nonFraction>%. We account for these investments using the equity method of accounting and measurement alternative. <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI5NzI_72b65836-9cce-4f98-940f-0a0db0ce713e" continuedAt="i8632fea5037a4941a990914715183021" escape="true">Our investments, which are included in </ix:nonNumeric></span><ix:continuation id="i8632fea5037a4941a990914715183021" continuedAt="i33943c43ff6c484d97d3ed9bb65cc0d2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets, consist of the following (in millions):</span></ix:continuation></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="i33943c43ff6c484d97d3ed9bb65cc0d2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contributions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzMtMS0xLTEtNTU5Njg_9db90c40-d418-49dd-8c72-e3618111e807">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzMtMy0xLTEtNTU5Njg_49d10238-aa06-4713-ace0-8006dc7e0674">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative share of income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzQtMS0xLTEtNTU5Njg_a749bd4b-35b0-45d0-8ea4-153839bf0841">68.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="ehc:EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzQtMy0xLTEtNTU5Njg_ad605854-ee9b-41cd-8a31-d5489de3dec7">68.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative share of distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" sign="-" name="ehc:EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzUtMS0xLTEtNTU5Njg_5f5572e0-a515-46b9-9118-59d0bc7c63a1">66.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" sign="-" name="ehc:EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzUtMy0xLTEtNTU5Njg_f92008d1-1fd4-439f-984e-9fe5b87cc863">66.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzYtMS0xLTEtNTU5Njg_f6028289-edc2-444d-921d-33d921d443a1">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzYtMy0xLTEtNTU5Njg_49d4da6a-b1a9-47ab-b41e-6749983bfa65">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contributions, net of distributions and impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzgtMS0xLTEtNTU5Njg_2c7ba024-68ac-464d-be7f-d8e3b2dc84db">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzgtMy0xLTEtNTU5Njg_2d586ec8-8ec6-43de-8e8c-e49419bb2cbc">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in and advances to nonconsolidated affiliates</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzktMS0xLTEtNTU5Njg_d6f0850c-0b6d-47e0-9204-3233bd7c2a2c">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzktMy0xLTEtNTU5Njg_f5985a12-0f96-4c87-b925-302947bc8828">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI5Nzk_3e915170-6b6e-4573-af70-eea3159fd816" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the combined assets, liabilities, and equity and the combined results of operations of our equity method affiliates (on a 100% basis, in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzMtMS0xLTEtNTU5Njg_6981cfcb-5ed7-4f3c-8cb5-1a1c2f1d667d">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzMtMy0xLTEtNTU5Njg_7f9cbe81-51d3-48f9-8707-fc6fe71652d8">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231" decimals="-5" name="us-gaap:AssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzQtMS0xLTEtNTU5Njg_f9d07cb2-9062-4ffb-85c9-72f7b302c1ed">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231" decimals="-5" name="us-gaap:AssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzQtMy0xLTEtNTU5Njg_b11bdd00-6d08-478d-97ee-ccc337b473ce">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzUtMS0xLTEtNTU5Njg_b8e24b1e-5438-46c2-8554-0eadf1181444">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzUtMy0xLTEtNTU5Njg_d2758769-f0ac-469d-9a48-65f7c13add9f">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and equity&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzctMS0xLTEtNTU5Njg_e42d0aab-3535-4ee1-b6c0-1ea076296bea">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzctMy0xLTEtNTU5Njg_25079be9-3530-48ae-ad22-2ce3d6de3515">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzgtMS0xLTEtNTU5Njg_dcd8f163-9c0f-46a6-8df9-f415d9c45e24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzgtMy0xLTEtNTU5Njg_6062ca22-9562-4c30-be9f-fed770d63a9d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partners&#8217; capital and shareholders&#8217; equity&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzEwLTEtMS0xLTU1OTY4_5f723492-329f-445c-b3c8-5b49563e6e8f">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzEwLTMtMS0xLTU1OTY4_bea8ba81-9f47-4532-b385-49e5db360a98">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzExLTEtMS0xLTU1OTY4_53ef467d-cb5c-4f71-914c-6b25f97350cd">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzExLTMtMS0xLTU1OTY4_f44d493c-97a8-4e34-a088-f00a1c1bf204">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzEyLTEtMS0xLTU1OTY4_54eb9c74-33cd-40a9-be46-3a3b35e6f2bd">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzEyLTMtMS0xLTU1OTY4_a02fe816-2f77-4234-8f97-43e97db87310">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed statements of comprehensive income (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzItMS0xLTEtNTU5Njg_39e6d99d-16b7-4049-882b-0bacddda74bb">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77309f128df04419abedd5fd33738b08_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzItMy0xLTEtNTU5Njg_09cb9a85-25d9-4d66-be7c-fc2cee5341a6">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzItNS0xLTEtNTU5Njg_280b85c3-7c85-460c-b9b4-c20ff5794ff1">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzMtMS0xLTEtNTU5Njg_6cd15315-ebb2-4103-91b0-6e75eaf63ee2">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77309f128df04419abedd5fd33738b08_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzMtMy0xLTEtNTU5Njg_2aedd6aa-2da6-4d92-b772-f4dcee012632">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzMtNS0xLTEtNTU5Njg_658b140b-2bec-4161-9547-5814d9969db2">19.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzQtMS0xLTEtNTU5Njg_1cdfe7f9-302a-4dd3-aee1-ea02493f5773">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77309f128df04419abedd5fd33738b08_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzQtMy0xLTEtNTU5Njg_ffc1d978-2996-41ed-bbc3-f18a4df1fa68">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzQtNS0xLTEtNTU5Njg_981a1287-f7ea-4772-9f52-ae108ba3a7f9">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzUtMS0xLTEtNTU5Njg_25d51b3f-b752-4f54-ae9c-96782818c2c6">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77309f128df04419abedd5fd33738b08_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzUtMy0xLTEtNTU5Njg_1c4146f1-fa9a-48c5-90d6-e8d6e607c864">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzUtNS0xLTEtNTU5Njg_e51fcd26-cf8d-45d3-ae0e-dcbc1f709540">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2dcf5412ee964599b85aac7dca4efda3"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of an amendment to the joint venture agreement related to our Jupiter, Florida home health agency, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective January 1, 2020.  The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of the Jupiter, Florida agency did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this home health agency and the remeasurement of our previously held equity interest at fair value, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased by $<ix:nonFraction unitRef="usd" contextRef="i196e74d41d844ce489461736995f7d1d_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzE5NDM_577771c1-46f2-4366-a8d4-9f85d0b5df68">3.3</ix:nonFraction>&#160;million and we recorded a $<ix:nonFraction unitRef="usd" contextRef="i196e74d41d844ce489461736995f7d1d_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzE5NjQ_d1e6a00f-85af-493f-8804-4ccc8d44cecc">2.2</ix:nonFraction>&#160;million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the year ended December 31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of an amendment to the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July&#160;1, 2019. The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of Yuma Rehabilitation Hospital did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased by $<ix:nonFraction unitRef="usd" contextRef="i96f008123b074f85973c4425cc5d7c42_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI4NjE_1902a5c8-bd9f-4824-8d8f-31b729990e34">24.9</ix:nonFraction> million and we recorded a $<ix:nonFraction unitRef="usd" contextRef="i96f008123b074f85973c4425cc5d7c42_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI4ODI_5f5edbaf-038e-4851-8301-e61efc38b4b7">19.2</ix:nonFraction> million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the year ended December 31, 2019.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations.</span></div></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_265"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwNjY1_e8f97c95-63f4-4d4e-a726-684cc72edc58" continuedAt="ia2093252b8b447cd94e670945c4d014a" escape="true">Long-term Debt:</ix:nonNumeric></span></div><ix:continuation id="ia2093252b8b447cd94e670945c4d014a" continuedAt="i2913af0cb1884e1e8f55c71359528416"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwNjMw_c192689c-e62b-4bd0-88da-32c328296200" continuedAt="ic27bde6e2fcc41e8a80eacc49dda3241" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda4f773f6c54fe581e21ee14d227bc7_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzMtMS0xLTEtNTU5Njg_154561be-10ba-47b8-89bd-dff210b591ed">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i798f862fab8b4413a0c57906b428ab10_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzMtMy0xLTEtNTU5Njg_a62df214-f6f7-4b34-9374-b8ed62a7fdf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7915604b115c4cd6b70e206e17b2ce26_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzQtMS0xLTEtNTU5Njg_1c245fa9-73da-48c6-9283-69cd72dfd959">238.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05884d3e63ee40d5907eaf0324564a18_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzQtMy0xLTEtNTU5Njg_4eaa07bd-976f-46fa-b044-1021d152cfa2">251.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i475515e7171f46acb6ddebf2c000d90c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzgtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjplZmZjNGU1NjEwMTk0MGY5OTI2YTE2YTM5MDA3ODg4OV80_4bdce726-ae99-4a41-946f-8f042393b0b2"><ix:nonFraction unitRef="number" contextRef="i098be77d49ab41099bfe946d54e9bcd7_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzgtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjplZmZjNGU1NjEwMTk0MGY5OTI2YTE2YTM5MDA3ODg4OV80_c9bf4c77-f771-4be6-a17a-06f3e07b9c0c">5.125</ix:nonFraction></ix:nonFraction>% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098be77d49ab41099bfe946d54e9bcd7_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzgtMS0xLTEtNTU5Njg_c54d539d-e52d-41ee-985d-c6c1d0872514">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475515e7171f46acb6ddebf2c000d90c_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzgtMy0xLTEtNTU5Njg_84ff540d-88bd-4ae6-9576-78e0dac304ed">298.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6689accfbb7543808abafce304019012_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEwLTAtMS0xLTU1OTY4L3RleHRyZWdpb246YWY4ZTllY2JiNTBhNGZjNThjMjAwYmY3MWFkZWYzNThfNA_16ba9a7f-74a7-4e73-9138-bedad8e0629f"><ix:nonFraction unitRef="number" contextRef="i8e8dcadb39154f309a2431ebb274d483_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEwLTAtMS0xLTU1OTY4L3RleHRyZWdpb246YWY4ZTllY2JiNTBhNGZjNThjMjAwYmY3MWFkZWYzNThfNA_5714a3a5-a7ce-47a5-8219-d1a0da65a9b8">5.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8dcadb39154f309a2431ebb274d483_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEwLTEtMS0xLTU1OTY4_cfb8caa9-4ace-44db-b126-41f24db13f25">347.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6689accfbb7543808abafce304019012_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEwLTMtMS0xLTU1OTY4_3655055c-864e-42a3-88df-0b6d8e9f6d52">346.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940f9d1a36544945a5314717176158e2_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzExLTAtMS0xLTU1OTY4L3RleHRyZWdpb246NDFlMjY0NzRmNWQ5NGUxODliMDBiNDQxMTJmYmJjOWJfNA_32fe7804-f0de-4120-8be8-35966d287d05"><ix:nonFraction unitRef="number" contextRef="i42cd94791aee45c38596cfa00e2c22b0_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzExLTAtMS0xLTU1OTY4L3RleHRyZWdpb246NDFlMjY0NzRmNWQ5NGUxODliMDBiNDQxMTJmYmJjOWJfNA_8d7b5273-0861-469c-a166-f39e3100ead2">4.50</ix:nonFraction></ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cd94791aee45c38596cfa00e2c22b0_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzExLTEtMS0xLTU1OTY4_852a0bb6-7760-445c-b2dd-fc6bd4c3aa87">786.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940f9d1a36544945a5314717176158e2_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzExLTMtMS0xLTU1OTY4_92cd51ae-001c-425b-b6d8-39270ceb948f">785.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62d481ea979b4b2dac6c075291e1ef68_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEyLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MGRjNTVjNDliNjJjNGE1ZjkyMmUxNzlhNGYxNWQwNTRfNA_12f9d30e-56d6-4ada-99a8-dc5b0b657b80"><ix:nonFraction unitRef="number" contextRef="i708722e52f7b4e87879527c09b19006d_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEyLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MGRjNTVjNDliNjJjNGE1ZjkyMmUxNzlhNGYxNWQwNTRfNA_d32cdf23-f33e-4e77-9029-1b3970701065">4.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708722e52f7b4e87879527c09b19006d_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEyLTEtMS0xLTU1OTY4_68bafb55-eb4a-4a7a-966a-af630d82fb7e">784.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d481ea979b4b2dac6c075291e1ef68_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEyLTMtMS0xLTU1OTY4_6d680ae0-3912-49a8-ae74-75249278642e">783.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e435cfbee1d418aaa5b1e302438b2e3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEzLTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZDdiY2NiNDk2Mzg5NDhmYWI2OTk5MWVmZTFhODhiNTVfNA_08623970-0df8-46b6-9d2f-86bc244ff8b2"><ix:nonFraction unitRef="number" contextRef="if6c70ba1acd6484e874b7cbf5ce32af3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEzLTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZDdiY2NiNDk2Mzg5NDhmYWI2OTk5MWVmZTFhODhiNTVfNA_64376f2c-6301-4ceb-88bc-548026db7c8a">4.625</ix:nonFraction></ix:nonFraction>% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c70ba1acd6484e874b7cbf5ce32af3_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEzLTEtMS0xLTU1OTY4_64c4c0ef-094f-42ff-838d-dd8db67c43e9">393.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e435cfbee1d418aaa5b1e302438b2e3_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEzLTMtMS0xLTU1OTY4_dbbbffea-fe71-4b8c-902a-0920fd516f9a">393.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95660f8d813c4751ade79f135d5b3a25_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE0LTEtMS0xLTU1OTY4_85f92389-0765-4c63-a13a-7f8a45ac9274">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5951de1720a942e0a0e71cfd9f206587_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE0LTMtMS0xLTU1OTY4_144156fc-ad43-47e8-a4bf-115a2ba9a4e3">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE1LTEtMS0xLTU1OTY4_51e193d9-164c-4b2e-992a-f45e3b4961e9">386.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE1LTMtMS0xLTU1OTY4_3ce59018-3fa2-4228-9761-26f8994a7434">391.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE2LTEtMS0xLTU1OTY4_5aba3aec-0ccf-4958-be2b-30c0f5b7b394">3,286.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE2LTMtMS0xLTU1OTY4_3c4a785a-b386-40a5-b0a0-2d5b9593c63b">3,288.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE3LTEtMS0xLTU1OTY4_bf238518-c105-4589-ae85-84c696290ff1">42.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE3LTMtMS0xLTU1OTY4_e67b62ca-294c-4fd4-a9b0-ce3dcfad74ec">38.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE4LTEtMS0xLTU1OTY4_3657be2b-f379-443c-83a4-1a52e2e8b4ac">3,243.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE4LTMtMS0xLTU1OTY4_789ee1c2-f082-49d3-9788-9d40da7d41ee">3,250.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2913af0cb1884e1e8f55c71359528416" continuedAt="id9b52bdffcfd44bf910ba2f4ace3fc5f"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwNjYy_c750fab3-07fd-4b9b-9fa5-210d4a260e06" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Face Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzEtMi0xLTEtNTU5Njg_b56544d9-eebd-4360-bae8-3a83cd63125a">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzEtNC0xLTEtNTU5Njg_929726f4-ca12-4873-8a25-194e9672cc06">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzItMi0xLTEtNTU5Njg_a0159776-01c3-45e1-8ea3-11f15ef4c0a3">143.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzItNC0xLTEtNTU5Njg_d272104e-0436-4cfb-8545-6c385c314e07">143.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzMtMi0xLTEtNTU5Njg_8506e3f8-d051-412a-9a20-4447ee188e77">453.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzMtNC0xLTEtNTU5Njg_49864305-2c2b-4f70-a792-2364e2d77579">452.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzQtMi0xLTEtNTU5Njg_161f2008-36b6-473d-9133-57354cec4064">384.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzQtNC0xLTEtNTU5Njg_6060ab57-08b1-49fd-a952-4686bb4a4392">381.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzUtMi0xLTEtNTU5Njg_d8a493ac-aa11-47be-8400-7c6c57b09d2e">29.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzUtNC0xLTEtNTU5Njg_a4949c0c-d24d-40f7-9ee3-0a7b5dc36ea4">29.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzYtMi0xLTEtNTU5Njg_6ae646ad-e7f7-4a5e-8cd8-ae437a951a1c">2,271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzYtNC0xLTEtNTU5Njg_25202d5c-2d33-4f16-b62b-366f6bed1d4e">2,236.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzctMi0xLTEtNTU5Njg_4b5010b8-b894-4b89-ab16-54d25de53a6e">3,326.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzctNC0xLTEtNTU5Njg_ab88a3d3-0810-4654-801e-32756c05bff3">3,286.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the redemptions discussed below, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzIxOTkwMjMyNjYzOTE_86b57416-d2dd-4709-bb29-3eab278fa6a1">1.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzI5Mw_aedec484-ea17-460d-a1e0-0bd55c51085b">2.3</ix:nonFraction> million, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzMwMA_7f10eef9-3df6-4045-ac9c-38eaa9309401">7.7</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2021, 2020, and 2019, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Agreement&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement, as amended in November 2019, provided for a $<ix:nonFraction unitRef="usd" contextRef="i95d8e5cfdcdc4f0096543280be8e1479_I20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU0OQ_ab07d516-c073-4b37-b273-d46689ddfe40">270</ix:nonFraction> million term loan commitment and a $<ix:nonFraction unitRef="usd" contextRef="i797035a2e3fa4c98bd423b13b951a80e_I20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU3OQ_0b4cb001-ba59-49c2-9cb6-e6f654903878">1</ix:nonFraction> billion revolving credit facility, with a $<ix:nonFraction unitRef="usd" contextRef="ia643be6ec0c14729abfe4a71fb7d089d_I20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzYxNg_613d7746-c64c-4fec-a6e4-65b86beeaac3">260</ix:nonFraction> million letter of credit subfacility and a swingline loan subfacility, all of which mature in November 2024. Outstanding term loan borrowings are payable in equal consecutive quarterly installments, commencing on December&#160;31, 2019, of <ix:nonFraction unitRef="number" contextRef="ic3208cda4b8e43a9a5f3510db5d5ced2_I20191231" decimals="INF" name="ehc:DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0Ng_1d303fe1-13ed-4823-833c-cf456e24d760">1.25</ix:nonFraction>% of the aggregate principal amount of the term loans outstanding as of December&#160;31, 2019, with the remainder due at maturity. We have the right at any time to prepay, in whole or in part, any borrowing under the term loan facilities.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts drawn on the term loan facilities and the revolving credit facility bear interest at a rate per annum of, at our option, (1) LIBOR or (2)&#160;the higher of (a)&#160;Barclays Bank PLC&#8217;s prime rate and (b)&#160;the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="ia259457e23e1485b8a1e9fd5e341cef6_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEzMjY_6ed1836b-ab21-4181-97c8-50d7784403ff">0.5</ix:nonFraction>%, in each case, plus, in each case, an applicable margin that varies depending upon our leverage ratio. We are also subject to a commitment fee of <ix:nonFraction unitRef="number" contextRef="i56bc6d52e31940afb1b7f3a0beb13a49_D20191101-20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzE0NzU_060f3ae5-f551-4570-9373-c71b0d944aa1">0.375</ix:nonFraction>% per annum on the daily amount of the unutilized commitments under the revolving credit facility. The current interest rate on borrowings under the credit agreement is LIBOR plus <ix:nonFraction unitRef="number" contextRef="i134cca390d7c4cd4b8104ec05d7b8066_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzE2ODE_d910efbf-7397-4309-a0a3-887b0ed63ff0">1.50</ix:nonFraction>%.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement contains affirmative and negative covenants and default and acceleration provisions, including a minimum interest coverage ratio and a maximum leverage ratio. Under one such negative covenant, we are restricted from paying common stock dividends, prepaying certain senior notes, making certain investments, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the credit agreement and (2) our senior secured leverage ratio, as defined in the credit agreement, does not exceed <ix:nonFraction unitRef="number" contextRef="i54ef59182ef74e5c957f25dd73b3a573_I20191130" decimals="2" name="ehc:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzIyMjY_e3803522-1c4c-4aa3-a62f-3e20a12a8057">2</ix:nonFraction>x. In the event the senior secured leverage ratio exceeds 2x, these payments are subject to a limit of $<ix:nonFraction unitRef="usd" contextRef="i56bc6d52e31940afb1b7f3a0beb13a49_D20191101-20191130" decimals="-6" name="ehc:CreditAgreementRestriction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzIzMzA_84107f43-9468-44da-a34d-22a4499d77e8">200</ix:nonFraction> million plus an amount equal to a portion of available excess cash flows each fiscal year. Our obligations under the credit agreement are secured by the current and future personal property of the Company and its subsidiary guarantors.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id9b52bdffcfd44bf910ba2f4ace3fc5f" continuedAt="i0ecf120de364480ea3af1b051f05672f"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we amended our existing credit agreement and the amendments included the following material provisions:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below.</span><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="ehc:ScheduleOfFinancialCovenantsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzE1MzkzMTYyODE3NDI2_ec09a34f-0edd-4df2-8a84-ec8d9be7d2eb" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:67.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5fed9bbb5d24489bde193826b885d42_D20200101-20200331" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0MjgzNWIzOGY0ZGY0YTA1ODUwYzQ5MGJkNjI2YmRkMy90YWJsZXJhbmdlOjQyODM1YjM4ZjRkZjRhMDU4NTBjNDkwYmQ2MjZiZGQzXzEtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246YjUxMjFiMGQwODU4NGFmNzlkN2Q1YWRhOTQ3YmQ2MTBfMzI5ODUzNDg4MzM0OA_711ac61b-bd79-4dad-a2bd-a9bcd3a49a1c">3.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16cf531547424c47bc386d720dfa4305_D20200701-20211231" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0MjgzNWIzOGY0ZGY0YTA1ODUwYzQ5MGJkNjI2YmRkMy90YWJsZXJhbmdlOjQyODM1YjM4ZjRkZjRhMDU4NTBjNDkwYmQ2MjZiZGQzXzItMS0xLTEtMTA0ODkwL3RleHRyZWdpb246NGQzNDk4NzhlZjYyNDFhYWIxOGUzN2I3NWIwYmM3OGZfMzI5ODUzNDg4MzM0OA_b781b80f-5f2c-4461-9ccd-e74bb8d6891a">2.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c917e5fed374c46a90bd9500b43d72a_D20220101-20220331" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0MjgzNWIzOGY0ZGY0YTA1ODUwYzQ5MGJkNjI2YmRkMy90YWJsZXJhbmdlOjQyODM1YjM4ZjRkZjRhMDU4NTBjNDkwYmQ2MjZiZGQzXzMtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246MGQ5ZWEzZmE3NDQ0NDkyODg2M2UzODk5ZjFhZTAxY2RfMzI5ODUzNDg4MzM0OA_669bae5a-abbe-4de5-a974-71999a07a46d">3.00</ix:nonFraction> to 1.00</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:67.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a551c0475024f75acffcd0aae3a51c2_I20200331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzEtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246MTA3YTRjNGUwZGI2NDU5NmExMWY0MDJmYThlYmRlNTVfMzI5ODUzNDg4MzM0OA_2025cedc-d09c-41fe-93e3-316148b11bd1">4.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17a5c6dc46234ee6839769c452e0a31b_I20200630" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzItMS0xLTEtMTA0ODkwL3RleHRyZWdpb246YzI2YjhmYzM3NDZmNGIwNWE0MzI4YmJkMzZiNDg4MGRfMzI5ODUzNDg4MzM0OA_b30b2eef-1cd9-41c8-9a94-30f11ba96c31">4.75</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i065696f54bd6452cb28eea433c352d7d_I20200930" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzMtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246ZmNiYzhjMGQ4NmJlNDYyYWJhYWI5OTMxN2Q0ZGJjMzhfMzI5ODUzNDg4MzM0OA_f11bdf03-b5d7-4a9d-8325-84d4dfea7ec9">5.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzQtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246YTQ1MTgyOWIwMTM1NDZkYjhiYTkzNTQxZDk5MDMwZWFfMzI5ODUzNDg4MzM0OA_30203a83-f645-44d5-80fa-0df0a70e1fe8">6.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcf2f41f6d0848b4b6dc77ea02f235d2_I20210331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzUtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246MTJiMTkyMmIzMmExNDE3ZTlkM2Y5NmU5Yjc1ODAzZDlfMzI5ODUzNDg4MzM0OA_911c8c98-523d-432b-b3c3-887f047159ef">6.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66424ae9b2c44a4fb7238c492c20dd64_I20210630" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzYtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246ZDZlNTY2MDJhMzkyNDdhODljNTMzYjhiMzRkOWVhYTZfMzI5ODUzNDg4MzM0OA_20faa37e-6e68-4f2e-911a-49fcdf001321">6.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88e6abed3f9c4844a3856dbae44d3c29_I20210930" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzctMS0xLTEtMTA0ODkwL3RleHRyZWdpb246OWY0MjQyZTliOWRkNGYyN2EwMmNjODliNDY0YTliY2ZfMzI5ODUzNDg4MzM0OA_12027374-a07e-4e2c-8cd7-ad4e9b23cf5e">5.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzgtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246MzY2Y2NiZjRmNGY3NGQxOGIwM2U0Y2FlZmQ4ZTk3Y2JfMzI5ODUzNDg4MzM0OA_8116b90f-0daf-4c0c-8e5c-9cc00c4773cb">5.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie61970e957d24746b800b3a4ca061b38_I20220331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzktMS0xLTEtMTA0ODkwL3RleHRyZWdpb246YzVkOGJiYTFiZWRlNGFkZmIzYjE5ZjNkN2EyMWU3NTBfMzI5ODUzNDg4MzM0OA_8c0b3a4e-f224-48fd-91e1-a3f00d77c807">4.25</ix:nonFraction> to 1.00</span></div></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Material Adverse Effect&#8221; to carve out the direct and indirect impacts of pandemic and the related legislative, regulatory and executive actions on us from that definition for a period of 364 days; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of 4.50x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of 2:00x) and the existence of no events of default in addition to the new leverage ratio condition.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="idda4f773f6c54fe581e21ee14d227bc7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzM1NTk_ca8be397-45f5-4211-a8d5-fc18d866a69d">200</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were drawn under the revolving credit facility with an interest rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i442e600335de44a4bcbc192cf1a0def6_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzIxOTkwMjMyNjY1MDg_ecacc9af-5892-4b1b-87b6-0416b0325094">2.6</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="usd" contextRef="i798f862fab8b4413a0c57906b428ab10_I20201231" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzM2Mzk_2d032cc0-1ccc-4324-bc7a-a9411f4fafef">no</ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount was drawn under the revolving credit facility. As of December&#160;31, 2021 and 2020, $<ix:nonFraction unitRef="usd" contextRef="i3f1b2314ba3e4d2c9434f9205fc3dd2d_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzM3NDc_d5b0d1e5-270c-4b3e-bf02-db91bc95bf85">38.2</ix:nonFraction> million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="ia0738d83aff14b43981733b51cee43ee_I20201231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzM3NTQ_0d734853-052f-4c75-94d9-a3fd22183f70">36.7</ix:nonFraction> million, respectively, were being </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilized under the letter of credit subfacility, which were being used in the ordinary course of business to secure workers&#8217; compensation and other insurance coverages and for general corporate purposes. Currently, there are no undrawn term loan commitments under the credit agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bonds Payable&#8212;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Senior Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2023 Notes, 2024 Notes, 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively, the &#8220;Senior Notes&#8221;) were issued pursuant to an indenture (the &#8220;Base Indenture&#8221;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#8217; respective supplemental indenture (together with the Base Indenture, the &#8220;Indenture&#8221;). Pursuant to the terms of the Indenture, the Senior Notes are jointly and severally guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our Credit Agreement and other capital markets debt. The Senior Notes are senior, unsecured obligations of Encompass Health and rank equally with our other senior indebtedness, senior to any of our subordinated indebtedness, and effectively junior to our secured indebtedness to the extent of the value of the collateral securing such indebtedness.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i0ecf120de364480ea3af1b051f05672f" continuedAt="id935b8d9406842ee890e1cf36b4938a6"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the Indenture), each holder of the Senior Notes may require us to repurchase all or a portion of the notes in cash at a price equal to <ix:nonFraction unitRef="number" contextRef="ibdd006cc199943069830e5f0df2c5322_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzUxODg_9040fc36-b0c9-4950-b400-e748b357b186">101</ix:nonFraction>% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes contain covenants and default and acceleration provisions, that, among other things, limit our and certain of our subsidiaries&#8217; ability to (1)&#160;incur additional debt, (2)&#160;make certain restricted payments, (3)&#160;consummate specified asset sales, (4)&#160;incur liens, and (5)&#160;merge or consolidate with another person.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively the &#8220;Notes&#8221;) for the adoption of certain amendments to the Indenture, which will provide us with greater flexibility in effecting the spin off discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Organization and Description of Business.&#8221; Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than <ix:nonFraction unitRef="number" contextRef="ibc45972689104b858888baba8d5c3b2a_I20211209" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwOTk1MTE2NDg3ODc_2872f60a-81cc-447f-9b81-442216b7c4ac">3.5</ix:nonFraction> to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture by $<ix:nonFraction unitRef="usd" contextRef="ibc45972689104b858888baba8d5c3b2a_I20211209" decimals="-6" name="ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwOTk1MTE2NDg3OTU_da13f90a-5662-4842-8066-08031699f9fb">200</ix:nonFraction>&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $<ix:nonFraction unitRef="usd" contextRef="i3bf76ad690ab486bb10282ca094adb84_D20211201-20220131" decimals="-5" name="ehc:DebtInstrumentAmendmentAgreementAmountToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzQ5NDc4MDIzNTQ3MjQ_5ad994d5-29b1-4794-b95d-cff2b300bc27">40.5</ix:nonFraction>&#160;million, excluding fees. We paid $<ix:nonFraction unitRef="usd" contextRef="i6b2e62c3760743f3b11242bc8c1de996_D20220131-20220131" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzQ5NDc4MDIzNTQ3MTE_54f7e141-22d4-40cc-829a-73bbe0a57940">20</ix:nonFraction>&#160;million of this amount in January 2022. The remaining payment is contingent upon the execution of a Distribution and will be paid at such time.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU2NTA_ac796108-9b8a-4428-982d-f548e8b96337">300</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU2NTY_ad556c1e-7f4f-40dc-9743-c8f758cd3e9a">5.125</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Senior Notes due 2023 (&#8220;the 2023 Notes&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at par, which resulted in approximately $<ix:nonFraction unitRef="usd" contextRef="i543ec7b3b23f4ccaac5a0b5e29eb4329_D20150301-20150331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU3NDA_14f1dc80-6b67-43bd-9a26-f28a62150fbc">295</ix:nonFraction> million in net proceeds from the public offering. The 2023 Notes mature on March 15, 2023 and bear interest at a per annum rate of <ix:nonFraction unitRef="number" contextRef="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU4NjY_81dfe447-3765-4c33-af30-c59ea4208f89">5.125</ix:nonFraction>%. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of financing costs, the effective interest rate on the 2023 Notes is <ix:nonFraction unitRef="number" contextRef="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU5NDk_dabe93c9-942b-4fb0-bf52-b6228402f613">5.4</ix:nonFraction>%.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest on the 2023 Notes is payable semiannually in arrears on March 15 and September 15. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In both April and June 2021, we redeemed $<ix:nonFraction unitRef="usd" contextRef="i37408f6809d84596aad486f8a90f4e53_D20210430-20210430" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwOTk1MTE2NTUzNDg_0afed242-08fd-412e-b869-e1bbc51443c2"><ix:nonFraction unitRef="usd" contextRef="ic8a20418879d4e958becfe001883e69b_D20210630-20210630" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwOTk1MTE2NTUzNDg_42a75493-6844-4117-8bc1-ec3d280f2606">100</ix:nonFraction></ix:nonFraction>&#160;million in outstanding principal amount of the 2023 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, these optional redemptions were made at a price of par.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2022, we issued notice for redemption of the remaining $<ix:nonFraction unitRef="usd" contextRef="ic8b11fbba37e419697f8c888119ebb62_I20220228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzMyOTg1MzQ5MTM4Nzk_762257a0-a419-4b41-996b-f739cd9c3560">100</ix:nonFraction>&#160;million in outstanding principal amount of the 2023 Notes. Pursuant to the terms of the 2023 Notes, this full redemption will settle on March 15, 2022 and will be made at a price of par. We plan to use cash on hand and capacity under our revolving credit facility to fund the redemption. We expect to record an approximate $<ix:nonFraction unitRef="usd" contextRef="icf18e7d48c9f48a98324da23bbf64a5a_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzMyOTg1MzQ5MTM4NjU_ce6f16cb-0be2-440d-87b1-de2c9f930059">0.3</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> in the first quarter of 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2012, we completed a public offering of $<ix:nonFraction unitRef="usd" contextRef="idf9cd76a2420419799ae4a84b2cb8f1b_I20120930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzYyOTA_9cb6e082-c0e0-4361-8476-78c218dcbf87">275</ix:nonFraction> million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="idf9cd76a2420419799ae4a84b2cb8f1b_I20120930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzYzMjc_408cb715-d2de-4d67-937b-593519d5d4e9">5.75</ix:nonFraction>% Senior Notes due 2024 (&#8220;the 2024 Notes&#8221;) at par. In September 2014, we issued an additional $<ix:nonFraction unitRef="usd" contextRef="i9d83e601b2be40eb9289618472d20e28_I20140930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY0MjI_b6e24198-0bec-4361-b499-ec16a92a6158">175</ix:nonFraction> million of the 2024 Notes at a price of <ix:nonFraction unitRef="number" contextRef="i9d83e601b2be40eb9289618472d20e28_I20140930" decimals="INF" name="ehc:DebtInstrumentIssuePricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY0NTc_2896a9e2-4968-41c2-800e-17551e535f9a">103.625</ix:nonFraction>% of the principal amount, in January 2015, we issued an additional $<ix:nonFraction unitRef="usd" contextRef="iebe8c7bfd4394f1197ca833de3df2c09_I20150131" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY1MjY_bdf93de0-27cf-4998-b1c2-6565c14f4c35">400</ix:nonFraction> million of the 2024 Notes at a price of <ix:nonFraction unitRef="number" contextRef="iebe8c7bfd4394f1197ca833de3df2c09_I20150131" decimals="INF" name="ehc:DebtInstrumentIssuePricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY1NjE_181b2e3a-8fc6-4af9-b585-e64482461ace">102</ix:nonFraction>% of the principal amount, and in August 2015, we issued an additional $<ix:nonFraction unitRef="usd" contextRef="i120953c681a546c1a1f10597d05382b8_I20150831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY2MzM_5b8df3f6-3a58-4fd1-aee5-7a5dd121fcd0">350</ix:nonFraction> million of our 2024 Notes at a price of <ix:nonFraction unitRef="number" contextRef="i120953c681a546c1a1f10597d05382b8_I20150831" decimals="INF" name="ehc:DebtInstrumentIssuePricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY2Njg_6b1942d2-deb5-4334-abf8-9234a33782cb">100.5</ix:nonFraction>% of the principal amount. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we redeemed $<ix:nonFraction unitRef="usd" contextRef="i732f255021564a07ad138756673d00c8_D20190601-20190630" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY3MjM_1ab7f8fe-6ec3-4140-9791-af19656e3863">100</ix:nonFraction> million of outstanding principal amount of our 2024 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2024 Notes, this optional redemption was made at a price of <ix:nonFraction unitRef="number" contextRef="i732f255021564a07ad138756673d00c8_D20190601-20190630" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY5MzQ_c8fbe42b-f25c-4b25-bdcc-b395fa3e9408">101.917</ix:nonFraction>%, which resulted in a total cash outlay of approximately $<ix:nonFraction unitRef="usd" contextRef="i732f255021564a07ad138756673d00c8_D20190601-20190630" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY5OTM_ce815af5-334d-4804-a8c4-50c92d42c7ab">102</ix:nonFraction> million. In November 2019, we redeemed $<ix:nonFraction unitRef="usd" contextRef="i6bcc19b1cd384ad2803fa192d9fd6f72_D20191101-20191130" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzcwMjc_36e4a8ac-d13f-49b1-a132-53af72f0e604">400</ix:nonFraction> million of the outstanding principal amount of our 2024 Notes. Pursuant to the terms of the 2024 Notes, this optional redemption was made at a price of <ix:nonFraction unitRef="number" contextRef="i6bcc19b1cd384ad2803fa192d9fd6f72_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzcxNzQ_5ee4b6ce-50e5-47fb-ac8f-643e26c83e95">100.958</ix:nonFraction>%, which resulted in a total cash outlay of approximately $<ix:nonFraction unitRef="usd" contextRef="i6bcc19b1cd384ad2803fa192d9fd6f72_D20191101-20191130" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzcyMzM_ac92b717-3c3c-41d1-b138-2b54e0ea5249">404</ix:nonFraction> million.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id935b8d9406842ee890e1cf36b4938a6" continuedAt="i79b30f17a5b247c1a80a93f0ad644dc2"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In November 2020, we redeemed the remaining $<ix:nonFraction unitRef="usd" contextRef="i735b93d85e2c4ffbbd677a2fed8689f2_I20201130" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzcyODE_88dfd235-3cce-405c-8d03-23377c43a59b">700</ix:nonFraction>&#160;million of outstanding principal amount of the 2024 Notes. Pursuant to the terms of the 2024 Notes, this full redemption was made at a price of par. We used the net proceeds from the 2031 Notes offering, discussed and defined below, together with approximately $<ix:nonFraction unitRef="usd" contextRef="ic4c39a1fe44b40aea3426508dc786fe3_D20201101-20201130" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc1Mzc_c03d1b24-2a53-4848-bf91-4e244afe8e48">300</ix:nonFraction>&#160;million of cash on hand to fund the redemption. The 2024 Notes would have matured on November&#160;1, 2024. Inclusive of premiums and financing costs, the effective interest rate on the 2024 Notes was <ix:nonFraction unitRef="number" contextRef="i735b93d85e2c4ffbbd677a2fed8689f2_I20201130" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc3Mjg_d622ef9b-81cd-4d61-b26c-398e796a6930">5.8</ix:nonFraction>%. Interest was payable semiannually in arrears on May 1 and November&#160;1 of each year. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc4NTY_245c7298-d96c-4a76-a800-f58312400cae">350</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc4NjI_c70f8fd9-a227-468b-a2e1-c6ee49e19a83">5.75</ix:nonFraction>% Senior Notes due 2025 (&#8220;the 2025 Notes&#8221;) at par. The 2025 Notes mature on September&#160;15, 2025 and bear interest at a per annum rate of <ix:nonFraction unitRef="number" contextRef="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc5OTk_98e2388c-7219-47ed-a3b7-9946a572ef0f">5.75</ix:nonFraction>%. Inclusive of financing costs, the effective interest rate on the 2025 Notes is <ix:nonFraction unitRef="number" contextRef="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzgwODI_cf49eb20-a730-43fc-9358-f5675ab50f39">6.0</ix:nonFraction>%. Interest on the 2025 Notes is payable semiannually in arrears on March 15 and September&#160;15. </span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:DebtInstrumentRedemptionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwNjM3_ecfd12a7-3a6c-4fdc-8edf-49bf1607fddc" continuedAt="idb1521e4440745f68d52bf3e22e5641d" escape="true"><div style="margin-bottom:7pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2021, at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05599bd9faa5433482a7fd2c5e801eff_D20150901-20150930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyOGJlZThjMWY5N2I0ZjBkOGNlYjRkNGY2OGEwYWE4My90YWJsZXJhbmdlOjI4YmVlOGMxZjk3YjRmMGQ4Y2ViNGQ0ZjY4YTBhYTgzXzItMi0xLTEtNTU5Njg_935ca9d8-9e71-401c-a2e9-c1562bb49b0a">101.917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc40e1fe47f0401b929feacafbeade4a_D20150901-20150930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyOGJlZThjMWY5N2I0ZjBkOGNlYjRkNGY2OGEwYWE4My90YWJsZXJhbmdlOjI4YmVlOGMxZjk3YjRmMGQ4Y2ViNGQ0ZjY4YTBhYTgzXzMtMi0xLTEtNTU5Njg_6e2c4e8d-5a7f-4500-9f3a-fc6afaacaeff">100.958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03c812649e8f461984f6a55bf31af65b_D20150901-20150930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyOGJlZThjMWY5N2I0ZjBkOGNlYjRkNGY2OGEwYWE4My90YWJsZXJhbmdlOjI4YmVlOGMxZjk3YjRmMGQ4Y2ViNGQ0ZjY4YTBhYTgzXzQtMi0xLTEtNTU5Njg_9240c661-b3ec-4c79-8b1b-d97a3adb4c28">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 and 2030 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we issued $<ix:nonFraction unitRef="usd" contextRef="i6728ee3fbad74c3f9120c35eb6bbb03d_I20190930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0MTM_f595d34d-0b4b-40a4-a21b-a170323b71b1">500</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i6728ee3fbad74c3f9120c35eb6bbb03d_I20190930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0MTk_27742dc4-11b8-4007-b68f-d6b2cae9f9ae">4.50</ix:nonFraction>% Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) at par and $<ix:nonFraction unitRef="usd" contextRef="i27ba4302b48948e6be58d84a07f42291_I20190930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0NzQ_127aa82b-6821-457a-a4e1-46a9deec6f20">500</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i27ba4302b48948e6be58d84a07f42291_I20190930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0ODA_eaf5c532-2e68-46bf-9ced-5c0ae6dca7bd">4.75</ix:nonFraction>% Senior Notes due 2030 (the &#8220;2030 Notes&#8221;) at par. The proceeds from this offering were used to fund the purchase of equity and vested stock appreciation rights from management investors of our home health and hospice segment, redeem a portion of our 2024 Notes as discussed above, and repay borrowings under our revolving credit facility. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued an additional $<ix:nonFraction unitRef="usd" contextRef="i7aba6edb48cf4106a0de799690174657_I20200531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg4NTk_311c940e-6429-401a-b698-349fa3e4d7b7">300</ix:nonFraction>&#160;million of our 2028 Notes at a price of <ix:nonFraction unitRef="number" contextRef="i7aba6edb48cf4106a0de799690174657_I20200531" decimals="3" name="ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg4OTQ_e4a381ef-6b49-417b-a1ad-8cc322edfb9d">99.0</ix:nonFraction>% of the principal amount and an additional $<ix:nonFraction unitRef="usd" contextRef="ie4d4f1c1e34b4547bb895f17359f6c52_I20200531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg5Mzk_b5ff1b2c-4680-4db3-9bae-1416afa6c884">300</ix:nonFraction>&#160;million of our 2030 Notes at a price of <ix:nonFraction unitRef="number" contextRef="ie4d4f1c1e34b4547bb895f17359f6c52_I20200531" decimals="3" name="ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg5NzQ_765ddab9-1211-4384-b3f2-e77e27195259">98.5</ix:nonFraction>% of the principal amount, which resulted in approximately $<ix:nonFraction unitRef="usd" contextRef="ia038a343f20045bc93b40477b4bb3e59_D20200501-20200531" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzkwMzQ_3201cb0a-e746-49ea-9c1b-5d750890d5fc">583</ix:nonFraction>&#160;million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.</span></div><div style="margin-bottom:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes mature on February 1, 2028. Inclusive of financing costs, the effective interest rate on the 2028 Notes is <ix:nonFraction unitRef="number" contextRef="i6728ee3fbad74c3f9120c35eb6bbb03d_I20190930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzkzMjA_f4468a16-3e67-4e91-a703-6ce4d06d9561">4.8</ix:nonFraction>%. Interest on the 2028 Notes is payable semiannually in arrears on February 1 and August 1. <ix:continuation id="idb1521e4440745f68d52bf3e22e5641d" continuedAt="i7f6fd27b570e4c4980d67d63dcb27007">We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:</ix:continuation></span></div><ix:continuation id="i7f6fd27b570e4c4980d67d63dcb27007" continuedAt="i8fa1c263e686443aa12a34dd30632259"><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cf2c1b477bb4e80918f99b0e09a865b_D20190901-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo2NTgzNWFiNGVkYzM0ZjQ0ODAxZjRmMWY3NDYzOWZlZC90YWJsZXJhbmdlOjY1ODM1YWI0ZWRjMzRmNDQ4MDFmNGYxZjc0NjM5ZmVkXzEtMi0xLTEtNTU5Njg_37a78efb-8dfd-49fc-b8be-18713b5ad649">102.250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8791e911ccc94436a4ccde3614131c9c_D20190901-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo2NTgzNWFiNGVkYzM0ZjQ0ODAxZjRmMWY3NDYzOWZlZC90YWJsZXJhbmdlOjY1ODM1YWI0ZWRjMzRmNDQ4MDFmNGYxZjc0NjM5ZmVkXzItMi0xLTEtNTU5Njg_d191078c-1432-4113-9570-a10a055b33c6">101.125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1cdcf2b1d8654c6782039c26b7a57622_D20190901-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo2NTgzNWFiNGVkYzM0ZjQ0ODAxZjRmMWY3NDYzOWZlZC90YWJsZXJhbmdlOjY1ODM1YWI0ZWRjMzRmNDQ4MDFmNGYxZjc0NjM5ZmVkXzMtMi0xLTEtNTU5Njg_8f64c5f3-3ba0-44d1-b223-23fbe36cb96e">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i79b30f17a5b247c1a80a93f0ad644dc2"><div style="margin-bottom:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes mature on February 1, 2030. Inclusive of financing costs, the effective interest rate on the 2030 Notes is <ix:nonFraction unitRef="number" contextRef="ie4d4f1c1e34b4547bb895f17359f6c52_I20200531" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzk3MTg_e4748863-0249-4bf4-be40-d789c6194551">5.2</ix:nonFraction>%. Interest on the 2030 Notes is payable semiannually in arrears on February 1 and August 1. <ix:continuation id="i8fa1c263e686443aa12a34dd30632259" continuedAt="i1adf1d06eac0470eb13bf5afd567b510">We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:</ix:continuation></span></div><ix:continuation id="i1adf1d06eac0470eb13bf5afd567b510" continuedAt="i39dd19a7a83941c8a21a514bb543c549"><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1756ab5e169c478f9663bb9168588a4d_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToxN2JiMDc3NTQyZjU0NjVjYTlkYWRmMmFiYmQzMmU5NS90YWJsZXJhbmdlOjE3YmIwNzc1NDJmNTQ2NWNhOWRhZGYyYWJiZDMyZTk1XzEtMi0xLTEtNTU5Njg_d8e0c52b-2c10-411e-b561-0b7daee38e06">102.375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if45838f1a45e438091364b67a05bf7f6_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToxN2JiMDc3NTQyZjU0NjVjYTlkYWRmMmFiYmQzMmU5NS90YWJsZXJhbmdlOjE3YmIwNzc1NDJmNTQ2NWNhOWRhZGYyYWJiZDMyZTk1XzItMi0xLTEtNTU5Njg_96ef917a-2ffe-44dd-82ec-9a012bae70c8">101.583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4a2dc69c68d4800929ad19f067a9d3f_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToxN2JiMDc3NTQyZjU0NjVjYTlkYWRmMmFiYmQzMmU5NS90YWJsZXJhbmdlOjE3YmIwNzc1NDJmNTQ2NWNhOWRhZGYyYWJiZDMyZTk1XzMtMi0xLTEtNTU5Njg_89e51d35-8a4d-41e6-a63f-bca2072db608">100.792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43e4a72722524946885cfe42cf42efa9_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToxN2JiMDc3NTQyZjU0NjVjYTlkYWRmMmFiYmQzMmU5NS90YWJsZXJhbmdlOjE3YmIwNzc1NDJmNTQ2NWNhOWRhZGYyYWJiZDMyZTk1XzQtMi0xLTEtNTU5Njg_f16dbfb2-233b-482d-8e5e-8c98f0b29371">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2031 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we issued $<ix:nonFraction unitRef="usd" contextRef="i13bbad57db694aae95b5e5b28b57c341_I20201031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwMDMy_165f500c-2b9c-4131-b80b-e030055341be">400</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i13bbad57db694aae95b5e5b28b57c341_I20201031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwMDY1_0a4ce1cf-e5ed-4bc4-9d1b-7b0b3838375d">4.625</ix:nonFraction>% Senior Notes due 2031 (the &#8220;2031 Notes&#8221;) at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of <ix:nonFraction unitRef="number" contextRef="i13bbad57db694aae95b5e5b28b57c341_I20201031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwMTk3_fc23038e-6aec-47f5-adc9-7f664df34858">4.625</ix:nonFraction>%. Inclusive of financing costs, the effective interest rate on the 2031 Notes is <ix:nonFraction unitRef="number" contextRef="i13bbad57db694aae95b5e5b28b57c341_I20201031" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwMjgw_5b884554-b41d-4e25-9113-7b31c3f0a1b5">4.8</ix:nonFraction>%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. <ix:continuation id="i39dd19a7a83941c8a21a514bb543c549" continuedAt="i4ac77df2643f42eeb8cc5b90d7ce28a8">We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:</ix:continuation></span></div><ix:continuation id="i4ac77df2643f42eeb8cc5b90d7ce28a8"><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2841dc9bff054904bae487294dbff306_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTplZDJlNjhjYmJlNTA0MjUzYjAyNTE0ZGMwMDFkMmE0ZS90YWJsZXJhbmdlOmVkMmU2OGNiYmU1MDQyNTNiMDI1MTRkYzAwMWQyYTRlXzEtMi0xLTEtNTU5Njg_10045bf9-b4b1-4d6f-bc47-d7f37845598f">102.313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4816d28c19945fea8ea5bedc380aed9_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTplZDJlNjhjYmJlNTA0MjUzYjAyNTE0ZGMwMDFkMmE0ZS90YWJsZXJhbmdlOmVkMmU2OGNiYmU1MDQyNTNiMDI1MTRkYzAwMWQyYTRlXzItMi0xLTEtNTU5Njg_838feb86-6e7b-43e4-9a20-be738ebab1ce">101.542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79ae10b8be3c4f858f5f9ac1d488a263_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTplZDJlNjhjYmJlNTA0MjUzYjAyNTE0ZGMwMDFkMmE0ZS90YWJsZXJhbmdlOmVkMmU2OGNiYmU1MDQyNTNiMDI1MTRkYzAwMWQyYTRlXzMtMi0xLTEtNTU5Njg_2dd8fca1-99c6-4bb0-9dcc-6a5710372a64">100.771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3d7e73989884e299b452c135030ebcf_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTplZDJlNjhjYmJlNTA0MjUzYjAyNTE0ZGMwMDFkMmE0ZS90YWJsZXJhbmdlOmVkMmU2OGNiYmU1MDQyNTNiMDI1MTRkYzAwMWQyYTRlXzQtMi0xLTEtNTU5Njg_f6f646e7-0921-430e-a13a-1527cfe1ac34">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Notes Payable&#8212;</span></div><ix:continuation id="ic27bde6e2fcc41e8a80eacc49dda3241"><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our notes payable consist of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.078%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale/leaseback transactions involving real estate accounted for as financings</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff05368e33294deaba91e4d0daedb5b5_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItMS0xLTEtNTU5Njg_9a436e63-246d-4103-a45f-b0c44a3e14d1">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic786d7283c4945f58da42a6add61877d_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItMy0xLTEtNTU5Njg_f59833a4-b97f-422f-868e-dbb990de14ee">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21e3debe10554bb8adc998d7c9f34060_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2OTkzYzkzNjc0Mzg0YmYzYjYyZDNmOGU4NGI5MWU0ZF8yMTk5MDIzMjU1NTY1_12f459d3-65f6-4912-a25a-981cec646a1a"><ix:nonFraction unitRef="number" contextRef="ia058d22308374baab4f7f83f431b2a7e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2OTkzYzkzNjc0Mzg0YmYzYjYyZDNmOGU4NGI5MWU0ZF8yMTk5MDIzMjU1NTY1_689c6755-1d29-43b8-901d-fe707fbcf3a1">6.1</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ied1386031d4644d3a4bd6b53278b051d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2OTkzYzkzNjc0Mzg0YmYzYjYyZDNmOGU4NGI5MWU0ZF8yMTk5MDIzMjU1NTY5_365a8cab-803f-4063-ac97-3d923b765d59"><ix:nonFraction unitRef="number" contextRef="i5e342b38454245b785b3717eda590962_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2OTkzYzkzNjc0Mzg0YmYzYjYyZDNmOGU4NGI5MWU0ZF8yMTk5MDIzMjU1NTY5_a8912af8-c5af-4da7-8e33-c488324a486f">11.2</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction of a new hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50281083594e49c69e3436fc0ceb6eb9_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzQtMS0xLTEtNTU5Njg_ec3abb06-3dd9-4808-a63f-55bfd1e5ed73">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied075c1981574658804c0fe14ced2869_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzQtMy0xLTEtNTU5Njg_655a61f7-6cc7-4fa4-8f72-f2832387460d">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied075c1981574658804c0fe14ced2869_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzQtNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpiYjgyYWY0YzFjMzM0ZDlkYjg5MTRhNmVjY2EyZTFiYV80_34ab6fe5-4820-484f-8d82-fb93d8187734"><ix:nonFraction unitRef="number" contextRef="i50281083594e49c69e3436fc0ceb6eb9_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzQtNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpiYjgyYWY0YzFjMzM0ZDlkYjg5MTRhNmVjY2EyZTFiYV80_5ca55fb8-c1af-4676-84d0-10f707896d65">5.0</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74efb2cbd6fa40438ef2310cb2d0fa56_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzUtMS0xLTEtNTU5Njg_c73b03cc-d130-4839-a2f3-4e9d71c90ed7">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc42cb6979d645e294db913c6cc97edd_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzUtMy0xLTEtNTU5Njg_206f23fc-48ac-4850-8eaa-698175f96d98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6dcc3d612e364ad7a48e4ec4f0099438_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzUtNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo5YzY1MGM0MzU2ZjU0OWEzOTFjNWZlZGZiMjFmNDllNV8xMA_6206766c-8d12-46d6-b77d-cfa99856b8b1"><ix:nonFraction unitRef="number" contextRef="if7048280062f4c379b09fb68447c12f9_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzUtNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo5YzY1MGM0MzU2ZjU0OWEzOTFjNWZlZGZiMjFmNDllNV8xMA_c16b9e38-26ee-414e-b684-c028660b8a07">2.8</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95660f8d813c4751ade79f135d5b3a25_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzYtMS0xLTEtNTU5Njg_d4bd765d-0bca-40b9-af8e-84edda496832">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5951de1720a942e0a0e71cfd9f206587_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzYtMy0xLTEtNTU5Njg_9140a0c1-4554-440b-9b5a-35bcd88b6174">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_271"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzIzMjU_2d2a47dd-18d0-4721-9992-bf211e4c1fce" continuedAt="i25b2611e3ee34b6c9d93a2c9d7f0f453" escape="true">Self-Insured Risks:</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i25b2611e3ee34b6c9d93a2c9d7f0f453" continuedAt="i81ea5b9666bf4024b349526a496eb363">We insure a substantial portion of our professional liability, general liability, and workers&#8217; compensation risks through a self-insured retention program (&#8220;SIR&#8221;) underwritten by our consolidated wholly owned offshore captive insurance subsidiary, HCS, Ltd., which we fund via regularly scheduled premium payments. HCS is an insurance company licensed by the Cayman Island Monetary Authority. We use HCS to fund the first $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:MaximumSelfInsuredAmountFirstLayerOfRisk" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzQ4MA_42962cda-5afe-4cb3-97d0-ca2520abbf5b">36</ix:nonFraction> million of insurance and an additional $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:MaximumSelfInsuredAmountThirdLayerRisk" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzIxOTkwMjMyNTc5MzE_d3821753-719f-4ac3-b6df-d25483facc1d">4</ix:nonFraction> million of insurance in excess of $<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:SelfInsuredRiskThresholdGeneralAndProfessionalLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzIxOTkwMjMyNTc5MTk_dbefd78f-d362-4cf4-af82-997b58e14a32">46</ix:nonFraction> million for annual aggregate losses associated with general and professional liability risks. Workers&#8217; compensation exposures are capped on a per claim basis. Risks in excess of specified limits per claim and in excess of our aggregate SIR amount are covered by unrelated commercial carriers.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i81ea5b9666bf4024b349526a496eb363"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzIzMzM_91adb584-0120-4237-915f-59fdc7fdd67e" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our self-insurance reserves for the years ended December&#160;31, 2021, 2020, and 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:53.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEtMS0xLTEtNTU5Njg_37d800f7-9751-455a-8726-4499986c5732">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEtMy0xLTEtNTU5Njg_6bdfcbab-df12-40ff-bcf4-89b5aba50436">157.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEtNS0xLTEtNTU5Njg_2d9ef7af-46fd-465e-aa6e-d5a6ff649bca">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzItMS0xLTEtNTU5Njg_c58b87ce-9b44-4f43-bca5-6015d34e0095">28.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzItMy0xLTEtNTU5Njg_e811b0e0-8801-4ce7-bae8-3e3ec75ee070">26.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzItNS0xLTEtNTU5Njg_cf5ccc75-4f0b-4d62-b744-e53bed1532f4">25.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzMtMS0xLTEtNTU5Njg_f5f069dd-f6c1-4799-b8b3-b941367b86c7">136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzMtMy0xLTEtNTU5Njg_68004ad7-95ce-478e-8519-c89bed9dd59f">130.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzMtNS0xLTEtNTU5Njg_47ae204a-34f4-4e5e-b4c6-d355923f80c3">135.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for the provision of current year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzQtMS0xLTEtNTU5Njg_5ec9cd98-cef1-4c2a-82c1-8e21ea825c30">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzQtMy0xLTEtNTU5Njg_d6790212-a2be-495c-9a4c-64a013c2966d">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzQtNS0xLTEtNTU5Njg_339866b1-1663-4e34-8251-07d6bfab289d">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease for the provision of prior year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzUtMS0xLTEtNTU5Njg_8bfac530-e641-4466-9d90-6ae1e782d7a9">6.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzUtMy0xLTEtNTU5Njg_2712b075-a92e-4cde-ae2c-067c749b4dc7">15.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzUtNS0xLTEtNTU5Njg_397a01d1-df2b-46c4-9697-183730c0177a">12.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses related to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzctMS0xLTEtNTU5Njg_947f50fe-3358-4935-b475-d0a6e52b8789">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzctMy0xLTEtNTU5Njg_b007bdde-597a-4576-a215-57ea651217a5">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzctNS0xLTEtNTU5Njg_f6001bea-5835-4783-a7eb-8294584363e4">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to current year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzgtMS0xLTEtNTU5Njg_9dc849bd-9a19-4985-a65b-d858b008d459">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzgtMy0xLTEtNTU5Njg_6cc01855-b56e-42b7-8626-92bad3200472">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzgtNS0xLTEtNTU5Njg_4b160d5e-7541-48c8-8410-0a1fc29044a3">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to prior year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzktMS0xLTEtNTU5Njg_a6a4f0af-ede6-4641-8801-d83b778c6324">30.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzktMy0xLTEtNTU5Njg_68218744-92d5-499e-be8c-2d36c2ea9b70">22.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzktNS0xLTEtNTU5Njg_e762f756-9da0-4129-b938-56541c2555c0">31.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzExLTEtMS0xLTU1OTY4_82d60993-3f02-41fa-aae3-96e527b53310">139.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzExLTMtMS0xLTU1OTY4_cc12e12a-2c17-4c3e-83bb-c91eb0996dd4">136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzExLTUtMS0xLTU1OTY4_0e1de70b-0cea-431e-b326-dc1865f6b35e">130.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEyLTEtMS0xLTU1OTY4_23f07d88-0416-4fb7-bbae-adcd2411bb5b">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEyLTMtMS0xLTU1OTY4_2fa119b5-3d6b-4601-9f01-77117049bf26">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEyLTUtMS0xLTU1OTY4_55c486ca-925f-4965-a6ec-7a1c9a7716af">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, gross</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEzLTEtMS0xLTU1OTY4_685f386f-a227-4022-bae8-b8357aa1f720">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEzLTMtMS0xLTU1OTY4_0c40cada-4a0c-4584-81d9-842469d0d453">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEzLTUtMS0xLTU1OTY4_19c8ccfe-b382-4c29-9ee8-459c82660cc7">157.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:SelfInsuranceReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzkwOQ_962aad04-62e1-4a47-937d-7242f742b626">45.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:SelfInsuranceReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzkxNg_4fc8902b-1a9a-42a7-8b16-71f2ce694b9a">44.0</ix:nonFraction> million, respectively, of these reserves are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these risks are based primarily upon actuarially determined estimates. These reserves represent the unpaid portion of the estimated ultimate cost of all reported and unreported losses incurred through the respective consolidated balance sheet dates. The reserves are estimated using individual case-basis valuations and actuarial analyses. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The changes to the estimated ultimate loss amounts are included in current operating results.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reserves for these self-insured risks cover approximately <ix:nonFraction unitRef="claim" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="0" name="ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzE3NTE_c31efeb7-da86-4134-ad2f-445b5344adf9">1,200</ix:nonFraction> and <ix:nonFraction unitRef="claim" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="0" name="ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzE3NTg_2c9b49b8-3f2e-4011-bb6a-a3165f0e78d5">1,600</ix:nonFraction> individual claims at December&#160;31, 2021 and 2020, respectively, and estimates for potential unreported claims. The time period required to resolve these claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in reserve estimates, management believes the reserves for losses and loss expenses are adequate; however, there can be no assurance the ultimate liability will not exceed management&#8217;s estimates.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_274"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQyMzk_91579e96-5b02-43c7-8d87-bd3fc6bec70a" continuedAt="iccdf263b11ed45078224a66b0c765871" escape="true">Redeemable Noncontrolling Interests:</ix:nonNumeric></span></div><ix:continuation id="iccdf263b11ed45078224a66b0c765871" continuedAt="ibb33767008a841d195a2c575e0b28904"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQyNDA_bf1f9782-a671-4b3f-891f-f2201dc4797e" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedaeba272bb466387acacba6de2f02b_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzItMS0xLTEtNTU5Njg_a733e649-2a13-4f53-8421-2de27cfffaaa">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife388829092541459cbc207156259fe1_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzItMy0xLTEtNTU5Njg_261f688b-4142-4b0b-bd5e-9fdeeb477555">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa910c45e3ba432986f5de81016e67f2_I20181231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzItNS0xLTEtNTU5Njg_a5011702-e16a-4673-abc4-894c43aeea1a">261.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzQtMS0xLTEtNTU5Njg_fd63ea93-b019-491b-b50d-a1236e143ded">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzQtMy0xLTEtNTU5Njg_e046c7ef-f478-4861-be72-94d65d594148">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzQtNS0xLTEtNTU5Njg_eb784e53-1344-4c03-941f-c1dfbaccbd0b">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzUtMS0xLTEtNTU5Njg_ae26b36a-2346-49c1-a650-dc7793298ff3">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzUtMy0xLTEtNTU5Njg_e239b6a4-4be8-4f03-9dbf-5ccf2ee6924b">8.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzUtNS0xLTEtNTU5Njg_15d9ee25-3091-4e58-9aea-c10c371d3f8c">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231" decimals="-5" name="ehc:Contributiontojointventure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzYtMS0xLTEtNTU5Njg_5a124d2f-815b-4f7a-9c60-52874a616f46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231" decimals="-5" name="ehc:Contributiontojointventure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzYtMy0xLTEtNTU5Njg_b04bc8fa-751f-42b2-b255-ec28862d68a2">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231" decimals="-5" name="ehc:Contributiontojointventure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzYtNS0xLTEtNTU5Njg_62f1097f-f9ff-4b6b-a413-cf3f287d3cca">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231" decimals="-5" name="ehc:Reclassificationtononcontrollinginterests" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzctMS0xLTEtNTU5Njg_42cfe9c7-9193-4cad-a25f-3f869a190da6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231" decimals="-5" name="ehc:Reclassificationtononcontrollinginterests" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzctMy0xLTEtNTU5Njg_a05944f9-bebb-41df-8e6e-7f28fe1c0ffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231" decimals="-5" name="ehc:Reclassificationtononcontrollinginterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzctNS0xLTEtNTU5Njg_e50f9e7f-2f33-4ce4-ae16-44a4d40a3bdd">11.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzgtMS0xLTEtNTU5Njg_3aa169d6-8bb6-4d81-ac37-44935c0b63d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzgtMy0xLTEtNTU5Njg_5742d141-1183-449e-b922-a73d11321dc7">162.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzgtNS0xLTEtNTU5Njg_d6720f1c-7860-4b64-a11c-1ea5013e1505">162.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231" decimals="-5" name="ehc:NoncontrollingInterestExchangeTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzktMS0xLTEtNTU5Njg_7a4fd949-6193-42e4-8cc9-24790f0d1d13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231" decimals="-5" name="ehc:NoncontrollingInterestExchangeTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzktMy0xLTEtNTU5Njg_4b13fcc2-4f2f-4b1f-b40e-4271ebc9c28f">46.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231" decimals="-5" name="ehc:NoncontrollingInterestExchangeTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzktNS0xLTEtNTU5Njg_f04852d2-e581-44a6-908a-e8340c1019ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzEwLTEtMS0xLTU1OTY4_2397d90f-b76b-4c62-aafd-b9196d7623f2">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzEwLTMtMS0xLTU1OTY4_557653a3-ed5c-4d66-8aba-ef40aa8f28c7">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231" decimals="-5" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzEwLTUtMS0xLTU1OTY4_cc108b35-b36c-4260-bf51-adb92e9e5521">147.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231" decimals="-5" name="ehc:NoncontrollingInterestOtherAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTEtMS0xLTEwMTQ5NA_36eec950-4d1f-49c6-a36b-682083c78969">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231" decimals="-5" name="ehc:NoncontrollingInterestOtherAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTMtMS0xLTEwMTQ5NA_55907239-398d-46e6-8a79-41fa143f5399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231" decimals="-5" name="ehc:NoncontrollingInterestOtherAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTUtMS0xLTEwMTQ5NA_c92b50a2-140f-46ca-a047-5dfd1bec96f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b3ec367aa84b1b8b9ef9bdc970188a_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTEtMS0xLTU1OTY4_689ce2a4-459e-4fab-acc4-3f26ba5ffc25">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedaeba272bb466387acacba6de2f02b_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTMtMS0xLTU1OTY4_e8fd8cec-29e6-45d8-8e73-d31018ee2052">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife388829092541459cbc207156259fe1_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTUtMS0xLTU1OTY4_5460aaa7-5728-4770-a875-590564937ff1">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQyNTQ_41a9a7bb-c90f-4a8e-86db-916348f27d25" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:64.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzItMS0xLTEtNTU5Njg_09187d45-5dbf-4d8f-bf9f-78ec3f2f2ae7">96.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzItMy0xLTEtNTU5Njg_3a64664e-9ebb-4b07-b607-9440d6415d09">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzItNS0xLTEtNTU5Njg_8a7b2ea3-e961-4e1e-be75-d6367f4da0b8">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzMtMS0xLTEtNTU5Njg_b1aab379-b30d-45c0-a7d1-130d8f714514">9.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzMtMy0xLTEtNTU5Njg_72d4ff63-302b-4bba-a217-0d109203dda5">7.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzMtNS0xLTEtNTU5Njg_006ec56f-aeef-4383-9925-4a125332b7af">12.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzQtMS0xLTEtNTU5Njg_f60f7630-cfe9-41d2-98e1-564693849056">105.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzQtMy0xLTEtNTU5Njg_5b569b61-a473-4956-b37d-08c35d879be9">84.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzQtNS0xLTEtNTU5Njg_a7b3cf65-947a-4755-920e-d132677321ba">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2014, we acquired <ix:nonFraction unitRef="number" contextRef="i5c9d6a1911754260a1b0e06548e665cc_I20141231" decimals="3" name="ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzYyNw_5e5529db-0ced-444a-808a-2d57fd469d4b">83.3</ix:nonFraction>% of our home health and hospice business when we purchased EHHI Holdings, Inc. (&#8220;EHHI&#8221;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#8220;Holdings&#8221;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $<ix:nonFraction unitRef="usd" contextRef="i5c9d6a1911754260a1b0e06548e665cc_I20141231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzExOTA_230eebe2-c81a-4594-a93a-cb2d7e95a746">64</ix:nonFraction> million on the acquisition date, in exchange for approximately <ix:nonFraction unitRef="number" contextRef="i5c9d6a1911754260a1b0e06548e665cc_I20141231" decimals="3" name="ehc:SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzEyNDg_3419e705-7ed8-4f38-9479-f07f1d055651">16.7</ix:nonFraction>% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately <ix:nonFraction unitRef="number" contextRef="i372fc03d1c144d9b84eb20ceee3d1d0e_D20180201-20180228" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzE3MTI_885182d0-23a5-4471-8593-b403670a7145">5.6</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i37ce9b34009e450aaec6451916af0460_D20180221-20180221" decimals="-6" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzE4ODM_58dd517f-0257-4aac-afa9-467c3c629fef">65</ix:nonFraction> million in cash. In July 2019, we received additional exercise notices, representing approximately <ix:nonFraction unitRef="number" contextRef="ibe4b642f98b44d9297f662ae777e6a48_D20190701-20190731" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzE5Nzc_18197d7d-ac1a-487f-96ec-11d849483ac4">5.6</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. In September&#160;2019, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i2b95d9baa2a3472f8501b1064a01c601_D20190901-20190930" decimals="-6" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzIxNDU_9c959a63-bbef-4e8c-aabb-902ea997791c">163</ix:nonFraction> million in cash. As of December 31, 2019, the value of the outstanding shares of Holdings owned by management investors was approximately $<ix:nonFraction unitRef="usd" contextRef="ib32b4f07fc6c4852aa189147f3ac8f4b_I20191231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzIyNzg_22ff7d78-96fe-4732-a82b-db7697361f7d">208</ix:nonFraction> million. In January 2020, we received additional exercise notices, representing approximately <ix:nonFraction unitRef="number" contextRef="ie9a724185f6047b2a7b0f3655af7f015_D20200101-20200131" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzIzNjc_feda4f78-4c79-4245-bd43-745bb8723636">4.3</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i2460d2c0ba7b42f591cc57a3b40a1eac_D20200218-20200218" decimals="-6" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzI1Mzg_c0f7f5e3-cdb3-4f09-a02a-08ce5fb37e69">162</ix:nonFraction> million in cash. Upon settlement of these exercises, approximately $<ix:nonFraction unitRef="usd" contextRef="i6104f61239694a209a6dd8bf3ea4229d_I20200218" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzI2MDA_d01bc4cc-e322-43f3-a4bc-e68101748bff">46</ix:nonFraction> million of the shares of Holdings held by two management investors remained outstanding. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#8220;Exchange Agreement&#8221;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#8220;EHC Shares&#8221;). Each of the Exchange Agreements provided </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ibb33767008a841d195a2c575e0b28904" continuedAt="i53b84b6392a04bf6bcff1ecd8d52afb7"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the management investor must deliver a written exchange notice (an &#8220;Exchange Notice&#8221;) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#8217;s common stock on the New York Stock Exchange (the &#8220;NYSE&#8221;) on the date of delivery of the Exchange Notice.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors.  Based on the last sales price of Encompass Health&#8217;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate <ix:nonFraction unitRef="shares" contextRef="if2d67ea997974c2d910a1b10bd43ff0d_I20200220" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzM4ODg_2465c1ae-0ab1-41c4-9747-0e90300e8b28">560,957</ix:nonFraction> EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than <ix:nonFraction unitRef="number" contextRef="i08537da18acf4dfaa0164d93a3f484c8_I20200306" decimals="3" name="ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQwNDQ_dd644c06-101b-4638-9b6a-21bb24c01295">0.6</ix:nonFraction>% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns <ix:nonFraction unitRef="number" contextRef="i416581dd3fdc4322b8a32aa48b236e6b_I20211231" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQxOTg_aaeef123-dbca-4ea8-8374-f7b61f8313a9">100</ix:nonFraction>% of Holdings and EHHI.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="i53b84b6392a04bf6bcff1ecd8d52afb7" continuedAt="i11339d9590344f7c9ebc3edb5e9d2133"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note&#160;13, </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i11339d9590344f7c9ebc3edb5e9d2133">Fair Value Measurements</ix:continuation>.</span></div><div id="i34f6226a63dc43528534c2bfabd86ded_277"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzI2MzI_e9421387-611d-4ed1-9ed9-df15bf929ca3" continuedAt="i4d9807c5755b473da51035f78bb371f5" escape="true">Fair Value Measurements:</ix:nonNumeric></span></div><ix:continuation id="i4d9807c5755b473da51035f78bb371f5" continuedAt="i2cb6db47f27545048180b91e3d18e9f1"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzI2NDI_8789eaae-51b5-436a-8c10-9254386ffa86" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied40dc1098204db7afa17d466e5ee54c_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzMtMi0xLTEtNTU5Njg_4cfd6d6c-ecca-44b1-bd0d-1edc83d7321f">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93bba85033d46889357eea3753fda21_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzMtNC0xLTEtNTU5Njg_a88d4e27-49f4-4c95-83a8-4217d9656115">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9114052e2fb44c2197290d9e9f558961_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzMtNi0xLTEtNTU5Njg_95404eea-ef44-463c-a866-5a4d2f8cc57f">78.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4ed8fefa5143e8a3f5ad38cf8cbf30_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzMtOC0xLTEtNTU5Njg_27f34689-2e7b-4cd2-a326-8a5d7f9ca539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied40dc1098204db7afa17d466e5ee54c_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzUtMi0xLTEtNTU5Njg_e24fb6a2-aa48-43b9-aabe-a06bd8b7f3b3">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93bba85033d46889357eea3753fda21_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzUtNC0xLTEtNTU5Njg_6078868a-0d0b-4c16-8a33-b902b290e16a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9114052e2fb44c2197290d9e9f558961_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzUtNi0xLTEtNTU5Njg_eef5995d-736a-4dff-8a16-baf8f028fae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4ed8fefa5143e8a3f5ad38cf8cbf30_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzUtOC0xLTEtNTU5Njg_79567125-8449-45a1-a002-015078e47ce7">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26344215630447e2a32f1bb8fb1577c3_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzgtMi0xLTEtNTU5Njg_e52dfae2-cdea-457d-9765-ef05130f871a">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d9ef1925864bf6bd6ebd083ceffcf4_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzgtNC0xLTEtNTU5Njg_71da9bda-f92d-4e1c-a3e2-87ed4af739d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72afa364a34540ae9695838e9d3f5468_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzgtNi0xLTEtNTU5Njg_86c167fd-8f6d-4512-8cb8-07963459b891">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3e10e7837748aaba2310ed38697364_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzgtOC0xLTEtNTU5Njg_8d3db53d-a46f-476e-a916-c6163b71b870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26344215630447e2a32f1bb8fb1577c3_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzEwLTItMS0xLTU1OTY4_c3b5192f-95af-47dc-bf3a-1b2768f9d6f5">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d9ef1925864bf6bd6ebd083ceffcf4_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzEwLTQtMS0xLTU1OTY4_0556ef45-7c7f-4a88-a5bb-f9ad07d9ca7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72afa364a34540ae9695838e9d3f5468_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzEwLTYtMS0xLTU1OTY4_794212cc-e044-4765-8bd7-a5032ab53ba9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3e10e7837748aaba2310ed38697364_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzEwLTgtMS0xLTU1OTY4_6316fb30-8347-466f-a600-662063bfdcdd">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our consolidation of certain joint venture entities and the remeasurement of our previously held equity interest at fair value, we recorded gains of $<ix:nonFraction unitRef="usd" contextRef="ic07a527a70c444b8aa8dc851c08e1454_D20210101-20211231" decimals="-5" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzI5Njg2ODEzOTUzNzMz_92d13531-e7b6-4b72-bc9f-be9b8ed3d7a2">3.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie630f132fb654f72bc20deb38a5299e9_D20200101-20201231" decimals="-5" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzg5Ng_9c311897-1b61-46a8-93e1-86e2772721a1">2.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i4bb6e84f060341ee8f3a82d5fe595b1f_D20190101-20191231" decimals="-5" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzExMzA_ef540884-816f-4e2f-b5c0-609136c0f6ff">19.2</ix:nonFraction> million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the years ended December 31, 2021, 2020, and 2019, respectively. We determined the fair value of our previously held equity interest using the income approach valuation technique. The income approach included the use of the hospital's or agency&#8217;s projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital or agency. The projected operating results use management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note&#160;9,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments in and Advances to Nonconsolidated Affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2cb6db47f27545048180b91e3d18e9f1"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our consolidated balance sheets. <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzI2NDk_158e1ff3-9093-4957-9e3d-7d6992a2a12d" continuedAt="ia1cdeb73f44f4075b1bbff0b1e351eb8" escape="true">The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="ia1cdeb73f44f4075b1bbff0b1e351eb8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15a96226e9a74277befd57b95ce89cad_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzMtMS0xLTEtNTU5Njg_f4afbe1f-ab7a-4564-9023-7f3e3feb1d90">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f229fa2dcf94ada94372b94a004a511_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzMtMy0xLTEtNTU5Njg_b53bf2f3-ff31-4109-ac5d-472cb8dc6675">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icedf57c7e28645bd80047694f8a37d7c_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzMtNS0xLTEtNTU5Njg_85709e49-3217-4d58-b60a-3d0633997edd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478de2031cff4407b9b5bd814b8fffbe_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzMtNy0xLTEtNTU5Njg_e98d76cb-6687-4d73-a034-16edba4b8d64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc784810eec245a793b5bdaf468ad33d_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzQtMS0xLTEtNTU5Njg_7728515c-b730-49ed-8b34-6af7861e5974">238.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41ca53159bc4b10a192181b3bca89ab_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzQtMy0xLTEtNTU5Njg_a94d5f20-cddb-426b-adc1-755fea1e251d">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854aba59b7df49a79105db7602e291c1_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzQtNS0xLTEtNTU5Njg_f4493832-20a1-4559-9e4e-f3861b589b2b">251.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a611dd035e44c8fb3fb11d3061619d7_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzQtNy0xLTEtNTU5Njg_3a1a552a-d199-4a32-bac6-7844da8b19a7">253.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i475515e7171f46acb6ddebf2c000d90c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjoxNDZhOTg4OThkMzg0MDc4ODAwYWY2MTVlMWQyYjU1OV80_4bdce726-ae99-4a41-946f-8f042393b0b2"><ix:nonFraction unitRef="number" contextRef="i098be77d49ab41099bfe946d54e9bcd7_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjoxNDZhOTg4OThkMzg0MDc4ODAwYWY2MTVlMWQyYjU1OV80_c9bf4c77-f771-4be6-a17a-06f3e07b9c0c">5.125</ix:nonFraction></ix:nonFraction>% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a1360b6acd4210bf3adb7d6d88bc50_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctMS0xLTEtNTU5Njg_76e3775c-2a68-496d-ba22-7809ed83535c">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f48f48c99b345bc8876378d756bf4e1_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctMy0xLTEtNTU5Njg_57f9fd92-4173-4c24-b567-db30a7930de0">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36387f8be3fa45d09cbd0c2a0ab073ed_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctNS0xLTEtNTU5Njg_ee20e2f2-1078-43c6-9877-318e2ed87afd">298.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i062d90846d5246a8a5ce15d4753ed256_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctNy0xLTEtNTU5Njg_d3a49d82-3385-4418-b39b-a66fd28849a5">302.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6689accfbb7543808abafce304019012_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpiYjU1MDQyMmRiM2Y0M2Y5YTVkY2ZhOTZlNDdhNmYyOV80_16ba9a7f-74a7-4e73-9138-bedad8e0629f"><ix:nonFraction unitRef="number" contextRef="i8e8dcadb39154f309a2431ebb274d483_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpiYjU1MDQyMmRiM2Y0M2Y5YTVkY2ZhOTZlNDdhNmYyOV80_5714a3a5-a7ce-47a5-8219-d1a0da65a9b8">5.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003153e059144500ba846eaaf3124397_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktMS0xLTEtNTU5Njg_cfbedd30-f98e-40a1-8d7c-489b0737704f">347.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04aa7dec6a244bcba19b7d980b858fd3_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktMy0xLTEtNTU5Njg_16a477be-c2eb-4bc1-8387-d72b126d5f50">357.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc744be7bb2e4378aa9465a42c569d4d_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktNS0xLTEtNTU5Njg_965c445b-34a6-46ca-8b81-d64247e4d551">346.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eda38234466449a8e337a5d2c3279da_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktNy0xLTEtNTU5Njg_afd88513-0c62-450a-b1b1-ccaef0745a86">361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940f9d1a36544945a5314717176158e2_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTAtMS0xLTU1OTY4L3RleHRyZWdpb246NTY5ZjMzNzExNDY0NDZjZWIzNTA1ZjRlNzIyOWVmZGFfNA_32fe7804-f0de-4120-8be8-35966d287d05"><ix:nonFraction unitRef="number" contextRef="i42cd94791aee45c38596cfa00e2c22b0_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTAtMS0xLTU1OTY4L3RleHRyZWdpb246NTY5ZjMzNzExNDY0NDZjZWIzNTA1ZjRlNzIyOWVmZGFfNA_8d7b5273-0861-469c-a166-f39e3100ead2">4.50</ix:nonFraction></ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71d169070664d258df1acb196a80bd8_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTEtMS0xLTU1OTY4_bebc1d1f-04ab-4f46-b184-7e08c49b427a">786.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23c7a2789b540b5b31a5bc6e512ff63_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTMtMS0xLTU1OTY4_1af224a4-f38d-4abe-990c-56ab3ed3dfa7">823.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3661453bf8d4cb888df6dfd0eb6ea49_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTUtMS0xLTU1OTY4_257ae67a-8bc4-4bfa-9a28-c0e4a2508cc7">785.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4222e0b6d18348f19725e8257c08a4ac_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTctMS0xLTU1OTY4_a48ec970-454f-4cf5-af4a-6fb684ee606e">840.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62d481ea979b4b2dac6c075291e1ef68_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MzhhNzFiMmNmODUyNGMzODgzN2Y0MTk0ZWMwOTViNjZfNA_12f9d30e-56d6-4ada-99a8-dc5b0b657b80"><ix:nonFraction unitRef="number" contextRef="i708722e52f7b4e87879527c09b19006d_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MzhhNzFiMmNmODUyNGMzODgzN2Y0MTk0ZWMwOTViNjZfNA_d32cdf23-f33e-4e77-9029-1b3970701065">4.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d0325b6fab4784876511cde99c9a37_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTEtMS0xLTU1OTY4_6ad6ab5b-6e29-431d-bd14-7c26bf61b708">784.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0971f6c0ba8347fb8bbf20251a8ef965_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTMtMS0xLTU1OTY4_9bf3f28b-dbf8-4bf7-aedc-69452c68f5f4">824.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e243e3007341bcaa8e6d60b76106d2_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTUtMS0xLTU1OTY4_3f265ec1-2c48-4e90-a155-dfc59c724740">783.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c46ae7004334f3aaa8ec786ab9f4e60_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTctMS0xLTU1OTY4_65a725e0-dc3c-4508-9adb-27b95e3e0154">856.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e435cfbee1d418aaa5b1e302438b2e3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTAtMS0xLTU1OTY4L3RleHRyZWdpb246N2Y3YTA1ZGViMGUwNDRjMWI2MjEzMjg2YmRmOGQ1OTdfNA_08623970-0df8-46b6-9d2f-86bc244ff8b2"><ix:nonFraction unitRef="number" contextRef="if6c70ba1acd6484e874b7cbf5ce32af3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTAtMS0xLTU1OTY4L3RleHRyZWdpb246N2Y3YTA1ZGViMGUwNDRjMWI2MjEzMjg2YmRmOGQ1OTdfNA_64376f2c-6301-4ceb-88bc-548026db7c8a">4.625</ix:nonFraction></ix:nonFraction>% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee5718dadc4409d81f3281961341d1e_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTEtMS0xLTU1OTY4_78c55a69-3151-4cf6-b562-47b953ccc466">393.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d918faf5c945fb8f815f7f3e0db8d1_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTMtMS0xLTU1OTY4_5e3ec674-a120-4741-83a5-dbdd45778064">407.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02851d306e4041dfa6105c00051182cc_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTUtMS0xLTU1OTY4_e71ad540-5911-4254-9857-04aee78830dc">393.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57c054ef40d45489612bbab7e3e448f_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTctMS0xLTU1OTY4_2c489154-eb4d-4dc2-8d0a-9ebf68c47c76">424.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ffead8b6274baf8242167d98ee9096_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEzLTEtMS0xLTU1OTY4_15bb0e0b-fee2-4422-826c-9cd85db05ee0">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb0dba2d7c8a4826b1f482f1349b6e95_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEzLTMtMS0xLTU1OTY4_d1649869-755c-44ca-80e8-a6eea93904ea">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac9bae069004607913ad2196139ca57_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEzLTUtMS0xLTU1OTY4_eade97a0-4139-42ba-ba39-e2958cdd6863">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id35d77e9ba484f40ba51f2683301dea5_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEzLTctMS0xLTU1OTY4_c6329326-9254-493d-89a0-76039af79e6a">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id114ce728e2345d89f4bd7890b37ac2c_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzE1LTEtMS0xLTU1OTY4_19dbf5f5-d11e-435c-bb42-6c3fe11eb2d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4b4be5983f48d581aeb5aad62c2ca9_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzE1LTMtMS0xLTU1OTY4_8ec59e5a-7809-4ec5-b755-c5dacef90b26">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299d52f28a4c4d0f9f975d70786c40f4_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzE1LTUtMS0xLTU1OTY4_ee26d40b-8ff6-42ce-a5d9-1f70f549705f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52cbb010926c4e229d2f2b20106351f2_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzE1LTctMS0xLTU1OTY4_bc165cec-7f84-44d4-9402-e630e431845d">36.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements&#8221; and &#8220;Redeemable Noncontrolling Interests.&#8221;</span></div></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_280"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc4OTM_21d5c34a-1ef8-4a1c-b8a7-d0163e64bb5b" continuedAt="i3932a3c9f0a94fe383103d6bae429229" escape="true">Share-Based Payments:</ix:nonNumeric></span></div><ix:continuation id="i3932a3c9f0a94fe383103d6bae429229" continuedAt="i7128cd1adc2740428431e5099d128f5b"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has awarded employee stock-based compensation in the form of stock options, SARs, and restricted stock awards (&#8220;RSAs&#8221;) under the terms of share-based incentive plans designed to align employee and executive interests to those of its stockholders. All employee stock-based compensation awarded during 2021, 2020, and 2019 was issued under the 2016 Omnibus Performance Incentive Plan, a stockholder-approved plan that reserves and provides for the grant of up to <ix:nonFraction unitRef="shares" contextRef="ia1fb54362ed14ca5bf853364666f1665_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzQ4Mw_ab6e7b02-da86-4d49-b041-accae26b4b8e">14,000,000</ix:nonFraction> shares of common stock. This plan allows for the grants of nonqualified stock options, incentive stock options, restricted stock, SARs, performance shares, performance share units, dividend equivalents, restricted stock units (&#8220;RSUs&#8221;),  and/or other stock-based awards.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our share-based incentive plans, officers and employees are given the right to purchase shares of Encompass Health common stock at a fixed grant price determined on the day the options are granted. The terms and conditions of the options, including exercise prices and the periods in which options are exercisable, are generally at the discretion of the compensation and human capital committee of our board of directors. However, no options are exercisable beyond <ix:nonNumeric contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzEyNDI_d50c0e8c-bddb-4789-81eb-9f5d5e3f58c9">ten years</ix:nonNumeric> from the date of grant. Granted options vest over the awards&#8217; requisite service periods, which are generally <ix:nonNumeric contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzEzNTQ_1ddbe7de-3f73-4fea-8be1-eef99ea45700">three years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i7128cd1adc2740428431e5099d128f5b" continuedAt="i8b08b1ff5c184bb284d341594fc633c7"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc4NjU_3a96ee1c-b2df-4139-9389-9ce19b910f74" continuedAt="ie1d7620d26ba4579bde4ff5c157af5c3" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the options granted during the years ended December&#160;31, 2021, 2020, and 2019 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzItMS0xLTEtNTU5Njg_b256da30-6d18-45e7-a2a2-ac5dc0111f67">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzItMy0xLTEtNTU5Njg_ae554b35-3d63-4b40-8987-d59105832e47">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzItNS0xLTEtNTU5Njg_1f33fa0b-4e81-4cf7-b019-8be71106f860">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzMtMS0xLTEtNTU5Njg_40b78976-c4a7-4c3a-8608-79a4f1add4a5">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzMtMy0xLTEtNTU5Njg_913e9c53-0064-47bb-83a0-5e73b36fc11f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzMtNS0xLTEtNTU5Njg_81f514eb-dee3-4957-9cd1-ce183231ba1b">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzQtMS0xLTEtNTU5Njg_48c802d8-ce87-420d-96a4-014d30d27170">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzQtMy0xLTEtNTU5Njg_33549fe9-ed1e-4c7f-8351-e862c2d3414f">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzQtNS0xLTEtNTU5Njg_e7051845-a926-4538-8395-4adf2d63d67d">7.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzUtMS0xLTEtNTU5Njg_f8cd92c1-0f62-4230-a433-1f70b1ce6c5f">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzUtMy0xLTEtNTU5Njg_9a78dac7-1c22-4759-84e9-2b990b0179cc">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzUtNS0xLTEtNTU5Njg_434202cc-25f5-4bba-9346-40fe2ec149b1">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including the expected stock price volatility. We estimate our expected term through an analysis of actual, historical post-vesting exercise, cancellation, and expiration behavior by our officers and employees and projected post-vesting activity of outstanding options. We calculate volatility based on the historical volatility of our common stock over the period commensurate with the expected term of the options. The risk-free interest rate is the implied daily yield currently available on U.S. Treasury issues with a remaining term closely approximating the expected term used as the input to the Black-Scholes option-pricing model. We estimated our dividend yield based on our annual dividend rate and our stock price on the dividend payment dates. Under the Black-Scholes option-pricing model, the weighted-average grant date fair value per share of employee stock options granted during the years ended December&#160;31, 2021, 2020, and 2019 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI3NjM_8569819f-174b-4710-b0db-eb5eb079487d">19.21</ix:nonFraction>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI3Njc_3ba1c29f-1c3e-4014-bd16-8cc6878c52c3">15.48</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI3NzU_a136533c-32fc-4252-8cc3-d9aa913b9b73">15.45</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc5MDE_caf35b12-5471-4a4b-a2d2-d32a5a8cbfdd" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzEtMS0xLTEtNTU5Njg_b3abe0cc-431c-437b-b196-b41293cfefc0">628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzEtMy0xLTEtNTU5Njg_5b630293-bd88-4147-9901-6af198ec528d">50.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzItMS0xLTEtNTU5Njg_6d5ab76d-4b17-4fb4-9495-99c08e74a0d1">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzItMy0xLTEtNTU5Njg_9a60ae86-0ed6-4413-855e-0dbfc07e464a">80.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzMtMS0xLTEtNTU5Njg_463780d1-084c-4903-ab2f-8e382c93a6b6">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzMtMy0xLTEtNTU5Njg_d0a9c57f-6191-45ba-876c-351df7c3713e">69.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzQtMS0xLTEtNTU5Njg_5448931d-243c-4383-913f-bde99e349c80">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzQtMy0xLTEtNTU5Njg_2b695e83-9a53-48dd-aa3a-44f494825ddf">77.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzYtMS0xLTEtNTU5Njg_ce5050c1-b0ed-4490-a903-228217c4272a">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzYtMy0xLTEtNTU5Njg_ef7bc807-1a9f-4b32-a446-7c01db49ffce">54.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzYtNS0xLTEtNTU5Njg_b91651c7-5fb1-46f8-80c7-cd5b8d29bfdf">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzYtNy0xLTEtNTU5Njg_9ab03291-bb46-470a-a7e6-f1a9f808d113">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzctMS0xLTEtNTU5Njg_a31d2037-a04e-4760-bfa0-b6841fd114f0">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzctMy0xLTEtNTU5Njg_8d994789-5a64-44d1-8d92-5b2498fde350">45.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzctNS0xLTEtNTU5Njg_26be4393-812a-4a98-84be-e094761be410">4.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzctNy0xLTEtNTU5Njg_e58bc985-a3d7-4bf8-8df3-0b9284d92d35">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximatel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y $<ix:nonFraction unitRef="usd" contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI5MDE_30ac92c5-d0b4-4310-b029-ce1829f14cb0">2.3</ix:nonFraction> million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI5MDU_37190c50-a44c-481c-905f-5398af9d0b43">1.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI5MTM_9a1723ce-a3a1-4154-8cfa-15d243c8cdd4">1.4</ix:nonFraction> million of compensation expense related to our stock options for the years ended December&#160;31, 2021, 2020, and 2019, respectively. As of December&#160;31, 2021, there was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMwMzk_4fcb813b-a0ed-46fb-b520-25d6c127fb89">1.4</ix:nonFraction> million o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of <ix:nonNumeric contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMxODQ_32673ca7-d839-497e-8cd7-69246027962d">19</ix:nonNumeric> months. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMyOTc_3a7aeafc-35f9-4287-8cb1-035c5422c74a">0.1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMzMDE_5c47bd10-d920-42e2-ba00-e60923144fb8">2.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMzMDk_48026f36-abe2-46d3-8fe4-54e498855077">3.6</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Appreciation Rights&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the EHHI acquisition, we granted SARs based on Holdings common stock to certain members of EHHI management at closing on December 31, 2014. Under a separate plan, we granted <ix:nonFraction unitRef="shares" contextRef="i7804d790b2414c79899e861637a8a2e5_D20170101-20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzM1NDg_1abe1219-2894-4fa2-9a85-dfcbeb58e69d">122,976</ix:nonFraction> SARs that vested based on continued employment and an additional maximum number of <ix:nonFraction unitRef="shares" contextRef="ib735bb4807dd484fbea2ba815c38a8a9_D20170101-20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzM2MzQ_5ee927c1-c17f-4042-bb8b-8a3012873955">129,124</ix:nonFraction> SARs that vested based on continued employment and the extent of the attainment of a specified 2017 performance measure. The maximum number of performance SARs was achieved. Half of the SARs of each type vested on December&#160;31, 2018 and the remainder vested on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings&#8217; common stock on the exercise date exceeded the per share fair value on the grant date. The fair value of Holdings&#8217; common stock was determined using the product of the trailing 12-month specified performance measure for Holdings and a specified median market price </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8b08b1ff5c184bb284d341594fc633c7" continuedAt="if4af8f5163ed41b59f7d30866404e5c6"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multiple based on a basket of public home health companies and publicly disclosed home health acquisitions with a value of $<ix:nonFraction unitRef="usd" contextRef="i3a8c982d4bb944d5b92f0c669ef3ef9a_I20211231" decimals="-6" name="ehc:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzQ0MTQ_4887349d-fbb2-4551-a06c-84ecbc9f46b1">400</ix:nonFraction> million or more. </span></div><ix:continuation id="ie1d7620d26ba4579bde4ff5c157af5c3"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the SARs granted in conjunction with the EHHI acquisition has been estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTpmOGNiYzI4ZDViMWI0MjMzYjlmNDZiOWY1Njg4YzdkMC90YWJsZXJhbmdlOmY4Y2JjMjhkNWIxYjQyMzNiOWY0NmI5ZjU2ODhjN2QwXzEtMS0xLTEtNTU5Njg_747ebc5c-8e67-4d1a-8aa1-f18bbd1b8880">38.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTpmOGNiYzI4ZDViMWI0MjMzYjlmNDZiOWY1Njg4YzdkMC90YWJsZXJhbmdlOmY4Y2JjMjhkNWIxYjQyMzNiOWY0NmI5ZjU2ODhjN2QwXzItMS0xLTEtNTU5Njg_40ff9bbf-f1ec-469d-aa34-75de93837ad2">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTpmOGNiYzI4ZDViMWI0MjMzYjlmNDZiOWY1Njg4YzdkMC90YWJsZXJhbmdlOmY4Y2JjMjhkNWIxYjQyMzNiOWY0NmI5ZjU2ODhjN2QwXzMtMS0xLTEtNTU5Njg_4bb37239-2cdf-4054-9e1f-3b955c15cd1a">0.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTpmOGNiYzI4ZDViMWI0MjMzYjlmNDZiOWY1Njg4YzdkMC90YWJsZXJhbmdlOmY4Y2JjMjhkNWIxYjQyMzNiOWY0NmI5ZjU2ODhjN2QwXzQtMS0xLTEtNTU5Njg_be1ce5eb-a3a1-40f9-bcd4-a71d5c4eca7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include a dividend payment as part of our pricing model because Holdings did not pay dividends on its common stock. Under the Black-Scholes option-pricing model, the weighted-average fair value per share of SARs granted in conjunction with the EHHI acquisition was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzQ5MDU_bc883a07-b455-4135-b6b8-cb170b4b2cb3">870.28</ix:nonFraction> as of December 31, 2019. In February 2019, members of the management team exercised a portion of their vested SARs for approximately $<ix:nonFraction unitRef="usd" contextRef="i2acf2cc0fd7d4d09af40dfa207a99bd2_D20190201-20190228" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzUwMjY_f5f36dcd-9c2d-415f-8480-c1e79ff3481f">13</ix:nonFraction> million in cash. In July 2019, members of the management team exercised the remainder of the vested SARs for approximately $<ix:nonFraction unitRef="usd" contextRef="i6853550297dd40fd9673cf39d8bba361_D20190701-20190731" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzUxNDQ_e5a9767e-0a3d-423e-8091-16e0226a6281">55</ix:nonFraction> million in cash. As of December 31, 2019, the fair value of the remaining <ix:nonFraction unitRef="shares" contextRef="i94fd694f8fd3453eb2468c49bd5270ba_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzUyMTM_ac684dc3-ce2e-4d20-900d-c434a6641059">115,545</ix:nonFraction> SARs was approximately $<ix:nonFraction unitRef="usd" contextRef="i94fd694f8fd3453eb2468c49bd5270ba_I20191231" decimals="-6" name="ehc:AllocatedSharebasedCompensationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzUyMzk_c1f87329-20e8-434c-b299-0415fa4a6ce5">101</ix:nonFraction>&#160;million, all of which was included in O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. In January 2020, members of the management team exercised the remaining SARs, and in February 2020, we settled those awards upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i80269d53cbb0459c9a42ac92da3a7665_D20200201-20200229" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzU0ODc_98003a08-645a-4406-b615-58fe5bc74baa">101</ix:nonFraction> million in cash.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i7c72f09fce4043719ce2db102fc528ff_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzU1MzE_9c4bd0a6-0e42-424a-938a-46e7af8e0340">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzU1Mzk_210d6eb2-0e2c-41fb-baf1-a97570f5095c">81.9</ix:nonFraction> million of compensation expense related to our SARs for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSAs granted in 2021, 2020, and 2019 included service-based awards and performance-based awards (that also included a service requirement). These awards generally vest over a <ix:nonNumeric contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzM4NDgyOTA3MDUzMDg_65d029cd-332b-4000-be44-ddff3645f9e8">three-year</ix:nonNumeric> requisite service period. For RSAs with a service and/or performance requirement, the fair value of the RSA is determined by the closing price of our common stock on the grant date.</span></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc4OTY_68af5f60-6008-4d20-88ff-8170a126ad0a" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our issued restricted stock awards is as follows (share information in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6650fab69c11492c9077744e36f1f4c0_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzEtMS0xLTEtNTU5Njg_8121bd23-e253-4b84-943a-9af125195bad">731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6650fab69c11492c9077744e36f1f4c0_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzEtMy0xLTEtNTU5Njg_6896c2d2-258a-4f1b-93bf-cbbf25fd987e">61.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzItMS0xLTEtNTU5Njg_b8d7e053-cd13-419e-ad6a-2947f9b02f74">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzItMy0xLTEtNTU5Njg_3024a770-83a1-4f4e-b84a-684b85b99752">73.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzMtMS0xLTEtNTU5Njg_8b6b6c78-88b3-41c8-a8bd-41fc97be6627">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzMtMy0xLTEtNTU5Njg_8dc8b68e-fefb-43e2-9fcf-dbee2d74f8b4">57.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzQtMS0xLTEtNTU5Njg_34079ecc-5e8a-4921-8c1d-c2b5e91493fb">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzQtMy0xLTEtNTU5Njg_a026e8d9-7439-45e8-a8ff-3a7b1aa48ac1">72.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4a08b2b7b1b4149a37586883c795c5c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzUtMS0xLTEtNTU5Njg_e678814c-2922-44af-b965-3e8130c09a14">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4a08b2b7b1b4149a37586883c795c5c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzUtMy0xLTEtNTU5Njg_def4cb59-3ffe-424a-9a3e-4e1bf281f1e5">74.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of restricted stock granted during the years ended&#160;December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia6a233a73c164626b8371eab0e23471c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYyMjc_d01a05a4-3b4a-469a-8387-92dcbe2868a5">61.81</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0980bb7516a2462090a8eb088e642d56_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYyMzQ_c8c082fe-4f3e-41be-83e4-f138df7376ae">49.84</ix:nonFraction> per share, respectively. We recognized approximate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly $<ix:nonFraction unitRef="usd" contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYyOTA_3c2ea0ea-bf32-42d3-98af-d1efe5c8c8ab">28.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia6a233a73c164626b8371eab0e23471c_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYyOTQ_af7ad7e9-537d-4a45-bb11-075d4c13d5c3">25.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i0980bb7516a2462090a8eb088e642d56_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYzMDI_1653ac29-729a-4ad3-9ba3-9319d414b3fb">29.5</ix:nonFraction> million of compensation expense related to our restricted stock awards for the years ended December&#160;31, 2021, 2020, and 2019, respectively. As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ia4a08b2b7b1b4149a37586883c795c5c_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY0Mzg_dd71ee61-6192-459c-8fd2-9eb99eac40b5">37.1</ix:nonFraction> million of unrecognized compensation expense related to unvested restricted stock. This cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY1ODk_599b4643-14f2-49be-9159-aab1562a8122">21</ix:nonNumeric> months. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he remaining unrecognized compensation expense for the performance-based awards may vary each reporting period based on changes in the expected achievement of performance measures. The total fair value of shares vested during the years ended December 31, 2021, 2020, and 2019 wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $<ix:nonFraction unitRef="usd" contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY4NzU_2e93aa7b-f3a7-4013-acc8-354a24f5d64c">46.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia6a233a73c164626b8371eab0e23471c_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY4Nzk_79f56b69-b938-4bd7-93ae-fb32f9e83e02">44.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="i0980bb7516a2462090a8eb088e642d56_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY4ODc_306bc8d9-d3b2-4225-b37a-18d089a04be8">45.2</ix:nonFraction> million, respectively. We accrue dividends on outstanding RSAs, which are paid upon vesting.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if4af8f5163ed41b59f7d30866404e5c6"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonemployee Stock-Based Compensation Plans&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, we provided incentives to our nonemployee members of our board of directors through the issuance of RSUs out of our share-based incentive plans. RSUs are fully vested when awarded and receive dividend equivalents in the form of additional RSUs upon the payment of a cash dividend on our common stock. During the years ended December&#160;31, 2021, 2020, and 2019, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued <ix:nonFraction unitRef="shares" contextRef="i1d2e0bbe25b944009128cefee2d0d142_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0MDg_d2238800-347a-4fb0-a52b-ed7af022403a">24,043</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="id4d10387a093410d85237a92db5c4dec_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0MTI_3789b36c-23e6-4815-867a-2c0e13186489">32,196</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i23170992103f4aea877de6980dd955ef_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0MjA_63b7b64c-7dfa-4873-9b6a-a6c8ca25bbc9">23,270</ix:nonFraction> RSUs, respectively, with a fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d2e0bbe25b944009128cefee2d0d142_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0NjQ_8bac05ae-0f1e-4689-8701-83637cd348ca">84.83</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="id4d10387a093410d85237a92db5c4dec_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0Njg_2c9f73e1-3964-4d78-9b44-46d8d34c8431">65.39</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i23170992103f4aea877de6980dd955ef_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0NzY_cb9e49bd-eb9a-49a5-8358-17e0ffac401f">64.48</ix:nonFraction>, respectively, per unit. We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i1d2e0bbe25b944009128cefee2d0d142_D20210101-20211231" decimals="-5" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc1MzI_8a2d6ec7-9485-424e-84fd-79e27b0f0d4c">2.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id4d10387a093410d85237a92db5c4dec_D20200101-20201231" decimals="-5" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc1MzY_89066ceb-2260-40de-ae49-3d2ee8cc86d4">2.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i23170992103f4aea877de6980dd955ef_D20190101-20191231" decimals="-5" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc1NDQ_d2ccfd73-668b-44a6-9d84-3661155aae43">1.5</ix:nonFraction> million, respectively, of compensation expense upon their issuance in 2021, 2020, and 2019. There was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="usd" contextRef="i4f4491cc424043bab594adb15a4e38fc_I20211231" decimals="INF" name="ehc:SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc2MzU_8e2cf433-21cd-4344-bca5-172dd898604a">no</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrecognized compensation related to unvested shares as of December&#160;31, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we issued an a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dditional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5a8b7549430046a29b87cd735c3324cd_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc3NjQ_c5f826da-ecef-4eab-819f-b0f1089b1e09">8,577</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i5d403e9e176d4ad1a0337c0b47804c60_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc3Njg_539654be-e856-4ff2-9fdc-648974625780">8,987</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="idca59813d6ce47e690d0ffdf1c9e577c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc3NzY_e3059bd6-5b22-4844-9276-1cdef6b6cf18">8,876</ix:nonFraction>, respectively, of RSUs as dividend equivalents. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i4f4491cc424043bab594adb15a4e38fc_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc4Mzc_e2a732b9-208f-4ca9-92f3-1dd5cff476f2">610,461</ix:nonFraction> RSUs were ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tstanding.</span></div></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_283"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzMwMzQ_261df4fe-2682-4897-934b-ce5c989c7bc9" continuedAt="i9be2232030624dfebd6fcbcf05e9f720" escape="true">Employee Benefit Plans:</ix:nonNumeric></span></div><ix:continuation id="i9be2232030624dfebd6fcbcf05e9f720"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all Encompass Health employees are eligible to enroll in Encompass Health-sponsored healthcare plans, including coverage for medical and dental benefits. Our primary healthcare plans are national plans administered by third-party administrators. We are self-insured for these plans. During 2021, 2020, and 2019, costs associated with these plans, net of amounts paid by employees and stop-loss recoveries, approximated $<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:HealthcarePlanExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzQzNw_cb881066-d1d9-4f05-8ff2-d50ad6f255ed">207.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:HealthcarePlanExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzQ0MQ_4a5a27a4-89bc-4f4a-a915-8080242f7fcf">189.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:HealthcarePlanExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzQ0OQ_b6d6b2df-6e0d-48e0-966f-0108102cf009">178.4</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health offers <ix:nonFraction unitRef="plan" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="INF" name="ehc:NumberOfQualifiedPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzQ5MQ_e7823723-53a7-40aa-8a94-f06af9d9ed5c">two</ix:nonFraction> qualified 401(k) savings plans, the Encompass Health Retirement Investment Plan (the &#8220;RIP&#8221;) and the Encompass Home Health Savings Plan (the &#8220;HHSP&#8221;). The RIP allows eligible employees to contribute up to <ix:nonFraction unitRef="number" contextRef="if30d4b37dc324d81b38e9cf676a99627_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzY5Nw_543b23e3-227c-4662-a0aa-d9571ed91ebc">100</ix:nonFraction>% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. Inpatient rehabilitation employees who are at least <ix:nonFraction unitRef="y" contextRef="i5ad3ac221c7e416b8039eccf0be81c30_I20211231" decimals="INF" name="ehc:RetirementInvestmentPlanAgeRequirement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzkyMA_ec31e3e4-d900-4471-968d-d8f27c798771">21</ix:nonFraction> years of age are eligible to participate in the RIP and all contributions to the plan are in the form of cash. Encompass Health&#8217;s employer matching contribution under the RIP is <ix:nonFraction unitRef="number" contextRef="if30d4b37dc324d81b38e9cf676a99627_D20210101-20211231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzExMDE_7a2664ba-5b18-4cf6-ab91-bfccffd17ac1">50</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="i5ad3ac221c7e416b8039eccf0be81c30_I20211231" decimals="2" name="ehc:RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzExMTc_4e9afe67-a225-4a48-9f29-7e28dacfc77c">6</ix:nonFraction>% of each participant&#8217;s elective deferrals, which vest <ix:nonFraction unitRef="number" contextRef="i5ad3ac221c7e416b8039eccf0be81c30_I20211231" decimals="INF" name="ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzExNzM_c9ef7ef3-394a-4602-84cd-61cf198bbb49">100</ix:nonFraction>% after <ix:nonNumeric contextRef="if30d4b37dc324d81b38e9cf676a99627_D20210101-20211231" name="ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzExODI_8050e2d5-ca5e-427c-9b6d-17f4d0f784a6">three years</ix:nonNumeric> of service. Participants are always fully vested in their own contributions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HHSP allows eligible employees to contribute up to <ix:nonFraction unitRef="number" contextRef="i97f18be172de4a0895d8c7a7e9e5460a_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzEzMTc_80242d2d-0121-4fc7-9bea-02b22b24c35b">60</ix:nonFraction>% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. All home health and hospice full-time and part-time employees are eligible to participate in the HHSP and all contributions to the plan are in the form of cash. Encompass Health&#8217;s employer matching contribution under the HHSP is <ix:nonFraction unitRef="number" contextRef="i97f18be172de4a0895d8c7a7e9e5460a_D20210101-20211231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE3MTc_c91f414a-6cdc-44a4-be4e-3093937d3d15">25</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="i0081857a985a4961b0157b55a3108ac9_I20211231" decimals="2" name="ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE3MzM_acfe9368-3874-423d-8a1c-62b8988e6828">3</ix:nonFraction>% of each participant&#8217;s elective deferrals, which vest gradually over a <ix:nonNumeric contextRef="i97f18be172de4a0895d8c7a7e9e5460a_D20210101-20211231" name="ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzMwMzU_8bc04b53-d492-44fc-9987-b46a279480f6">six-year</ix:nonNumeric> service period. Participants are always fully vested in their own contributions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employer contributions to the RIP and HHSP approximated $<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE5NTE_653d7b21-8b49-4188-b567-50598431493c">28.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE5NTU_1575226e-2478-42db-bfd7-66604d6153af">25.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE5NjM_240fe46c-0fa1-4ab8-b96d-afefea730471">23.4</ix:nonFraction> million in 2021, 2020, and 2019, respectively. In 2021, 2020, and 2019, approximately $<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzIwMzI_2c447f46-9bb9-4214-bb45-181e2778b8a9">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzIwMzY_b138f6c3-8d71-4350-bf1a-d0ec58f75b53">1.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzIwNDQ_8be93489-b7e4-47f0-8d0e-b7db2d79a85c">1.4</ix:nonFraction> million, respectively, from forfeited accounts were used to fund the matching contributions in accordance with the terms of the RIP and HHSP.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Management Bonus Program&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a Senior Management Bonus Program to reward senior management for performance based on a combination of corporate or regional goals for all periods presented and individual goals for 2019 and 2018 only. The corporate and regional goals are approved on an annual basis by our board of directors as part of our routine budgeting and financial planning process. The individual goals, which were weighted according to importance, were determined between each participant and his or her immediate supervisor. The program applies to persons who join the Company in, or are promoted to, senior management positions. In 2022, we expect to pay approximately $<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:SeniorManagementBonusProgramTotalCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzI4NzM_8c7d5b14-d528-48a6-9845-e366cfedbbed">27.8</ix:nonFraction> million under the program for the year ended December&#160;31, 2021. In March 2021 and February 2020, we paid $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:SeniorManagementBonusProgramTotalCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzI5NTQ_aa4b9680-81b4-4dfe-bfa1-b8b551403abf">17.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:SeniorManagementBonusProgramTotalCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzI5NjE_9a628d4f-6f71-4b65-a937-3219caea780d">18.4</ix:nonFraction> million, respectively, under the program for the years ended December&#160;31, 2020 and 2019.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_286"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzcyMjA_84acc1c9-a9b8-45fc-9d3f-3e92f38927d2" continuedAt="i88038ee828a043828ef238823c0b919b" escape="true">Income Taxes:</ix:nonNumeric></span></div><ix:continuation id="i88038ee828a043828ef238823c0b919b" continuedAt="i366367e09a774db3b27f4b2b6cb0e537"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzcyMTg_3f2e4c46-6b01-47a3-b85e-ef3a46540750" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to continuing operations are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzMtMS0xLTEtNTU5Njg_9a84f514-0eba-4e3a-b103-da4e7b6359c9">86.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzMtMy0xLTEtNTU5Njg_aef480d2-2b81-4a62-9949-4be29da5a16b">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzMtNS0xLTEtNTU5Njg_396cace6-6711-41fc-9923-d9d31dba1682">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzQtMS0xLTEtNTU5Njg_288f3141-0805-429a-8f8b-ad6111ee1534">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzQtMy0xLTEtNTU5Njg_2e3ee024-569f-4948-9c27-9d7e98c1b27e">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzQtNS0xLTEtNTU5Njg_d6a2b8ee-607e-4247-884f-cf2cf3aa75b0">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzUtMS0xLTEtNTU5Njg_36b91633-1c40-4720-8fd0-75c31493e61e">111.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzUtMy0xLTEtNTU5Njg_136d3ca6-f7b1-433b-9143-7a5d8628f160">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzUtNS0xLTEtNTU5Njg_448da15b-8ad4-4297-a0c5-6e5b6970380f">75.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzctMS0xLTEtNTU5Njg_13ae265d-4c06-4145-bf08-a9552bd479a7">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzctMy0xLTEtNTU5Njg_952cb7f3-09cf-4eed-be81-587976762635">39.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzctNS0xLTEtNTU5Njg_9cbb34d5-2ae2-494c-af74-276b2652ce41">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzgtMS0xLTEtNTU5Njg_65f9f548-5382-4b6f-a823-b8889efa7595">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzgtMy0xLTEtNTU5Njg_5425da19-2fe0-4c6a-8ce6-fe3904de39d8">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzgtNS0xLTEtNTU5Njg_bb945a01-272a-4c8e-9d2f-7e6ef9c5ed00">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzktMS0xLTEtNTU5Njg_ba4c1cdd-8946-4066-a8af-615830ef18f6">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzktMy0xLTEtNTU5Njg_e132e069-1ca8-4dfb-86be-f83e45f16c6a">52.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzktNS0xLTEtNTU5Njg_2029e3e6-b4f5-4c1e-8115-3257d2933a16">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense related to continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzEwLTEtMS0xLTU1OTY4_2b72c8f8-f83d-4d85-940e-692e505815c4">139.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzEwLTMtMS0xLTU1OTY4_0fcc75e1-c5f7-4870-8999-b5205b6507dc">103.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzEwLTUtMS0xLTU1OTY4_c1f49791-50a3-460c-a855-443ef3bb30d6">115.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzcyMzA_851cfe84-3365-487f-b459-90d10fb09dbf" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzItMS0xLTEtNTU5Njg_0389e34b-8eff-4722-b60d-a1e6851263e5">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzItMy0xLTEtNTU5Njg_52de50e2-15b9-4cd8-a8a7-922f876a63fd">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzItNS0xLTEtNTU5Njg_d000fa13-3447-4b59-9d6e-e36dae8e3503">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzQtMS0xLTEtNTU5Njg_bc237a4c-26af-4e2b-a0f7-ba9e010dea76">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzQtMy0xLTEtNTU5Njg_bec5c86c-c4ff-444f-a861-06e165f76b92">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzQtNS0xLTEtNTU5Njg_45c0c4c4-fb33-47da-b0a5-397ab2f7cab0">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzUtMS0xLTEtNTU5Njg_f7ed483d-1721-4796-bb93-0058766a1773">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzUtMy0xLTEtNTU5Njg_3374c86e-bd64-4962-91cd-4b8c3fa81c20">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzUtNS0xLTEtNTU5Njg_996b8ceb-035a-4719-9a0e-d6cdd2e4b02c">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzYtMS0xLTEtNTU5Njg_6fba2f55-1e5d-4f8d-92a6-fb526db89f5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzYtMy0xLTEtNTU5Njg_2b947916-cee0-46d4-864a-7a2f8dc1f5c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzYtNS0xLTEtNTU5Njg_a778b050-40c6-43d8-b905-09c2fc25ee46">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzctMS0xLTEtNTU5Njg_87e00720-aad3-4261-b4e7-b39d794070c3">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzctMy0xLTEtNTU5Njg_50bdd5bc-3cd4-4893-8ee4-cd6b53ca19b8">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzctNS0xLTEtNTU5Njg_577e283a-db4c-4170-9585-dd55ebd99cbe">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based windfall tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="3" sign="-" name="ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzktMS0xLTEtNTU5Njg_2880f5ec-a314-4a8c-916d-615b148a3218">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="3" sign="-" name="ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzktMy0xLTEtNTU5Njg_6d589a00-626a-41a7-aa3d-9f30f06097ad">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="3" sign="-" name="ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzktNS0xLTEtNTU5Njg_f8a3199a-2c66-4304-8867-124a8838f40a">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzExLTEtMS0xLTU1OTY4_eb255c91-90c3-4818-b575-ed009edbfe19">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzExLTMtMS0xLTU1OTY4_888f31c9-eb81-431e-83d3-a848ecc78e74">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzExLTUtMS0xLTU1OTY4_9b5df782-c050-493c-93d8-4797e3419590">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzEyLTEtMS0xLTU1OTY4_38e409e5-e19d-4809-8bcb-2e348f2c393a">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzEyLTMtMS0xLTU1OTY4_d6bcc33e-fcdc-41d1-a7ef-3d81bb54fedf">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzEyLTUtMS0xLTU1OTY4_9cec7e1a-3aff-4add-b209-bd9f3554300c">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2021 was greater than the federal statutory rate primarily due to: (1) state and other income tax expense offset by (2) the impact of noncontrolling interests, (3) share-based windfall tax benefits and (4) the decrease in valuation allowance. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2020 was greater than the federal statutory rate primarily due to: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) state and other income tax expense and (2) the increase in valuation allowance offset by (3) the impact of noncontrolling interests and (4) share-based windfall tax benefits. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2019 was less than the federal statutory rate primarily due to: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the impact of noncontrolling interests, (2) g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overnment, class action, and related settlements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and (3) share-based windfall tax benefits offset by (4) state and other income tax expense. See Note&#160;1, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Income Taxes,&#8221; for a discussion of the allocation of income or loss related to pass-through entities, which is referred to as the impact of noncontrolling interests in this discussion.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the CARES Act provisions previously discussed in Note&#160;1, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Risks and Uncertainties,&#8221; the CARES Act also includes provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, technical corrections to tax depreciation methods for qualified improvement property and deferral of employer payroll taxes. The CARES Act did not materially impact our effective tax rate for the years ended December 31, 2020 and 2021, although it has impacted the timing of cash payments for taxes. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i366367e09a774db3b27f4b2b6cb0e537" continuedAt="i34f7de755c164f219f2f5d67103d2d23"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes recognize the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes and the impact of available NOLs. <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzcyMjI_22812dbd-96b8-45ca-9806-fac1904a2afe" continuedAt="id918775790e54f049fd47f3768ebe31c" escape="true">The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="id918775790e54f049fd47f3768ebe31c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzMtMS0xLTEtNTU5Njg_edb2ba6c-6f98-4ef5-a1d4-5dd10218e0f8">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzMtMy0xLTEtNTU5Njg_07b2507d-b3e3-4285-950b-94c98d9558ab">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzQtMS0xLTEtNTU5Njg_2e013dd3-f552-4d00-bae7-dda06e83a4e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzQtMy0xLTEtNTU5Njg_68e1f988-9008-460d-aec3-d657c1c78647">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzUtMS0xLTEtNTU5Njg_f2af7342-e59b-4fe3-8aba-58a401207f71">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzUtMy0xLTEtNTU5Njg_abca28d7-add4-4a7c-a17b-b122297e666c">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzYtMS0xLTEtNTU5Njg_d9da7510-f398-438a-bd5a-170fb57ee7fa">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzYtMy0xLTEtNTU5Njg_b7ff7588-cbb5-46df-8fa3-1eb0a16e88b6">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzgtMS0xLTEtNTU5Njg_ded7b31c-bf6c-4ce1-ab8e-ae2955bd9c18">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="ehc:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzgtMy0xLTEtNTU5Njg_d9ed4df5-c679-4498-9563-445c0c576d22">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzExLTEtMS0xLTU1OTY4_b367e3c6-ed9f-404e-8878-134bf590215c">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzExLTMtMS0xLTU1OTY4_601458a1-1ca5-43fb-baa4-da374069a10f">43.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzEyLTEtMS0xLTU1OTY4_7842cf52-172e-4276-bb1d-2872e4de0e25">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzEyLTMtMS0xLTU1OTY4_97f5d8cb-09fb-45ac-b055-adc9044b72db">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzEzLTEtMS0xLTU1OTY4_6b77510f-5949-4f67-8751-6626e4fb8434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzEzLTMtMS0xLTU1OTY4_ddf2a90a-527b-46f9-bb3a-af0216c42e66">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE0LTEtMS0xLTU1OTY4_54a030a8-101a-4777-b2c9-5969a0726b81">148.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE0LTMtMS0xLTU1OTY4_78a201dd-cc3e-4497-a7c1-7d2d5fcb7ba6">173.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE1LTEtMS0xLTU1OTY4_0870e8bd-c8da-498b-8095-838ea33e9cbe">43.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE1LTMtMS0xLTU1OTY4_e2e8d386-d4bc-4500-a9c7-313e3968125f">46.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE2LTEtMS0xLTU1OTY4_dd649109-a79c-4caa-a450-092762d27726">105.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE2LTMtMS0xLTU1OTY4_6878ed2f-c2db-43ad-ac38-31c90f060713">127.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE4LTEtMS0xLTU1OTY4_7c86943b-f9ba-4011-a0ca-e3d73e44585c">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE4LTMtMS0xLTU1OTY4_9d9b93d9-da41-499b-b21b-f4e64fd05738">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE5LTEtMS0xLTU1OTY4_8222820a-f3f0-49c5-906e-6cf4a2b5e427">102.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE5LTMtMS0xLTU1OTY4_0adbff10-4dcb-4a18-bb07-5ab366e55466">99.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIwLTEtMS0xLTU1OTY4_fe0a3c9d-0ec0-4863-bce9-4f0150d57083">17.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIwLTMtMS0xLTU1OTY4_a5d49158-30e0-40ab-9b43-8baa4abb2f77">21.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIxLTEtMS0xLTk4NzU2_94960259-8ce3-435d-bab4-8c995fb17d17">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIxLTMtMS0xLTk4NzU2_621abe82-d028-4370-8b84-553ba5b829c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIyLTEtMS0xLTU1OTY4_e5a8bfce-5c8b-4207-867e-cd63cb09f820">67.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIyLTMtMS0xLTU1OTY4_0fd51154-86f9-4ba2-80fe-3897b43b5559">51.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIzLTEtMS0xLTU1OTY4_815ede73-2b82-4051-a88f-5dc9e66e1273">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIzLTMtMS0xLTU1OTY4_81704805-a92a-4540-8335-8d5429cd7fa9">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzI0LTEtMS0xLTU1OTY4_32891a0a-1ff6-4fa1-b121-812322e14452">192.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzI0LTMtMS0xLTU1OTY4_a36e4c1d-edce-4884-8a50-fbc8c3e11f95">178.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzI1LTEtMS0xLTU1OTY4_d75c0b29-bafe-4317-946c-ad5c29708a50">86.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzI1LTMtMS0xLTU1OTY4_3c5e7552-2651-48a7-b11f-ab9367ead440">51.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have state NOLs of $<ix:nonFraction unitRef="usd" contextRef="ic9210832b6dd4034a40b13798dc82f01_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzIzODA_4f58ae1b-ba11-4108-beec-a84a40acba10">50.4</ix:nonFraction> million that expire in various amounts at varying times through 2031. For the years ended December&#160;31, 2021 and 2020, the net (decrease) increase in our valuation allowance was $(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzI1Mzc_a4f02110-7fbc-404f-a443-0dbed9a78931">3.1</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzI1NDU_69ac4756-1a0b-4070-852a-e56fcd45291b">7.8</ix:nonFraction> million, respectively. The decrease in our valuation allowance in 2021 related primarily to changes in forecasted income. The increase in our valuation allowance in 2020 related primarily to our expected ability to use related net operating losses prior to their expiration.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have a remaining valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzI3OTE_0870e8bd-c8da-498b-8095-838ea33e9cbe">43.1</ix:nonFraction> million. This valuation allowance remains recorded due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management&#8217;s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during 2021, 2020, and 2019 was not material. Accrued interest income related to income taxes as of December 31, 2021 and 2020 was not material.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i34f7de755c164f219f2f5d67103d2d23"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we signed an agreement with the IRS to participate in their Compliance Assurance Process (&#8220;CAP&#8221;) for the 2017 tax year and have renewed this agreement each year since. CAP is a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax returns. The IRS is currently examining the 2020, 2021, and 2022 tax years. In September 2021, the IRS issued a no-change letter effectively closing our 2019 tax year audit. The statute of limitations has expired or we have settled federal income tax examinations with the IRS for all tax years through 2019. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by two states for tax years ranging from 2017 - 2019.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the tax years that remain open under the applicable statutes of limitations, management considered potential unrecognized tax benefits and determined there are no material unrecognized tax benefits that would impact prior years&#8217; income taxes.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-56</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_289"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzIwNjI_3a2c8166-0c36-4972-a16e-91fe3d4db1e8" continuedAt="i2ad79cfa439243af9325a17f184a49c6" escape="true">Earnings per Common Share:</ix:nonNumeric></span></div><ix:continuation id="i2ad79cfa439243af9325a17f184a49c6" continuedAt="ife1ea5bdcd9f4d22b7cc543b42d7f45b"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzIwNzE_ff0e9093-b816-4cfb-9a72-72f5d87c4b42" escape="true"><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzQtMS0xLTEtNTU5Njg_565ab567-53b4-43ee-be4f-0adb96f91d10">517.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzQtMy0xLTEtNTU5Njg_d12fc63f-73e5-4324-ae94-7aef53307f84">368.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzQtNS0xLTEtNTU5Njg_4876cb64-6a8a-4a6b-97de-7a99110d3bb9">446.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzUtMS0xLTEtNTU5Njg_c14b064e-9a45-488a-b739-42576de6a145">105.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzUtMy0xLTEtNTU5Njg_ab423cf5-d4bb-4f5d-bfa4-bfdfa79ff573">84.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzUtNS0xLTEtNTU5Njg_5f8a6dea-f2b8-4db8-8f07-37433d1f6523">87.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzYtMS0xLTEtNTU5Njg_a5cc5041-c503-45a6-aa92-336b35206bdc">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzYtMy0xLTEtNTU5Njg_713e0aea-c157-4a90-a4e0-c4ed52a3d77b">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzYtNS0xLTEtNTU5Njg_133c6b3d-e148-4d3c-adb3-81a808dbc12f">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzktMS0xLTEtNTU5Njg_f849f61c-6cf8-4ea6-8173-236f3b917072">410.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzktMy0xLTEtNTU5Njg_d78c3860-3768-4def-9224-138dfa92fb2a">283.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzktNS0xLTEtNTU5Njg_b8475c7a-891e-4f0b-8feb-f83f786ad6e9">358.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEwLTEtMS0xLTU1OTY4_c93def55-71fb-46da-bd43-b7d2ce1c3fba">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEwLTMtMS0xLTU1OTY4_0f6dabe8-03d5-4b54-8929-32c49e1cddcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEwLTUtMS0xLTU1OTY4_c77333d3-ec2a-4c18-bec6-3949a001ed5d">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEyLTEtMS0xLTU1OTY4_0862a4c5-56ad-47ad-a825-dd2940b694af">410.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEyLTMtMS0xLTU1OTY4_9d7999ef-e63f-41e1-8404-5585083797bb">283.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEyLTUtMS0xLTU1OTY4_8d5b08db-7f57-4a3e-bac8-01be4e081c7b">357.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE0LTEtMS0xLTU1OTY4_8317ff40-200a-4853-804f-2fe7334131f3">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE0LTMtMS0xLTU1OTY4_52ecaf27-73b5-4b43-a5d2-719bbdd81f85">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE0LTUtMS0xLTU1OTY4_bd3b3bb5-ca74-4d32-9a39-78cda6cddef1">98.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE2LTEtMS0xLTU1OTY4_1860c46b-3a32-4028-894c-ec27c9806cf3">4.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE2LTMtMS0xLTU1OTY4_de9e7505-b863-4e0f-9e84-054b993beb8d">2.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE2LTUtMS0xLTU1OTY4_d9b01077-46d2-4b4e-85d8-6a6dc64926ca">3.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE3LTEtMS0xLTU1OTY4_9e3cf7bb-2866-4a3d-b50e-860c540b05ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE3LTMtMS0xLTU1OTY4_69aea09a-6a85-4a71-9fb1-99578f4b4ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE3LTUtMS0xLTU1OTY4_fb05621c-1752-4ad0-898a-5d1e9b9a6043">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE4LTEtMS0xLTU1OTY4_44fa3e3e-7f1c-4d05-966e-9670b13ea20c">4.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE4LTMtMS0xLTU1OTY4_6ac2a0b6-ad62-4d45-919c-b5cd986894a7">2.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE4LTUtMS0xLTU1OTY4_31abedad-c763-435d-81c8-23cda46901e2">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIyLTEtMS0xLTU1OTY4_3c63684e-0c44-466a-9a79-051732b7f8cb">517.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIyLTMtMS0xLTU1OTY4_3960ebd1-e7a8-49b7-8dcc-6aa8d5c44ada">368.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIyLTUtMS0xLTU1OTY4_de181995-ab42-4b6b-9f8d-0192de967e93">446.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIzLTEtMS0xLTU1OTY4_0bd6d83e-104f-4596-b503-05fec3aa13ea">105.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIzLTMtMS0xLTU1OTY4_10b7e624-f984-49dc-8168-c3f614be6960">84.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIzLTUtMS0xLTU1OTY4_9d1ddd1f-f654-4cbe-97ca-437c9065437d">87.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI2LTEtMS0xLTU1OTY4_900903f7-5a0c-40cc-a107-43c7e65a79c9">412.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI2LTMtMS0xLTU1OTY4_9f69199d-9a77-46d8-a64a-0fbe270684dd">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI2LTUtMS0xLTU1OTY4_923f32d5-7914-4c87-98d5-5a5ca810aa59">359.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI3LTEtMS0xLTU1OTY4_c93def55-71fb-46da-bd43-b7d2ce1c3fba">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI3LTMtMS0xLTU1OTY4_0f6dabe8-03d5-4b54-8929-32c49e1cddcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI3LTUtMS0xLTU1OTY4_c77333d3-ec2a-4c18-bec6-3949a001ed5d">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI4LTEtMS0xLTU1OTY4_d52f46b4-4cb4-494f-b8fd-e5a66f42a788">412.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI4LTMtMS0xLTU1OTY4_346723ba-8cab-4503-b39f-6142b55f2995">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI4LTUtMS0xLTU1OTY4_f909b079-82d7-4f9f-8fe4-6fe51e9f01d5">358.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMwLTEtMS0xLTU1OTY4_6a4a841d-03f7-4085-9ff7-9ae438502bad">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMwLTMtMS0xLTU1OTY4_131f61fe-88f2-4f29-90c0-7667df457f65">99.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMwLTUtMS0xLTU1OTY4_d380091f-84de-47ef-84a8-6c063806ab65">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMyLTEtMS0xLTU1OTY4_6fba2c8c-3a5d-4e4e-af8f-4fcb3f2a668f">4.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMyLTMtMS0xLTU1OTY4_9f2e442b-ac26-4dda-a79c-0cf9c9db10cd">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMyLTUtMS0xLTU1OTY4_23acacf5-5fe6-47cf-8cd1-3b284f7df19c">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMzLTEtMS0xLTU1OTY4_06d9373e-7daa-42dc-9c25-cf53effa8c1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMzLTMtMS0xLTU1OTY4_e1440ee8-a779-40f7-9e66-098517dc284d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMzLTUtMS0xLTU1OTY4_3ef83916-c6ce-4ae4-a7e0-fc9d495ec7fb">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzM0LTEtMS0xLTU1OTY4_a3c66a06-5dcb-4181-938c-aa6f6fc5e321">4.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzM0LTMtMS0xLTU1OTY4_beacb91e-17b5-4d2b-9e9c-fd81970097ed">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzM0LTUtMS0xLTU1OTY4_2b41b97d-85c9-4113-9f10-5103a96aeb73">3.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ife1ea5bdcd9f4d22b7cc543b42d7f45b"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzIwNzg_9d50ba3e-7622-449a-9690-0ee55cb3aa38" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzItMS0xLTEtNTU5Njg_8317ff40-200a-4853-804f-2fe7334131f3">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzItMy0xLTEtNTU5Njg_52ecaf27-73b5-4b43-a5d2-719bbdd81f85">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzItNS0xLTEtNTU5Njg_bd3b3bb5-ca74-4d32-9a39-78cda6cddef1">98.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzUtMS0xLTEtNTU5Njg_85125ba1-d5b4-4897-82fc-1524dd41fe97">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzUtMy0xLTEtNTU5Njg_61f3fee3-0ecb-40c5-81e9-54374a281b76">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzUtNS0xLTEtNTU5Njg_553bc5c7-7097-4d93-83c7-bccaf6207760">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzYtMS0xLTEtNTU5Njg_5c240dcc-d459-41d4-9822-38b304cf5a2d">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzYtMy0xLTEtNTU5Njg_21a1096c-10db-4b02-8726-f76b0aa93859">99.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzYtNS0xLTEtNTU5Njg_4840f4e6-851e-46a8-9121-a2edf582d170">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzM2Mg_24ee7317-1d91-4a52-8c05-386247fc4e02">0.2</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzM2OQ_336ae71d-8b2d-40d6-a68e-b772a91dcca8">0.2</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzIxOTkwMjMyNTc4NDA_c12e8ed8-76e3-4e70-9ecb-014ae5420b66">0.1</ix:nonFraction> million shares of common stock were outstanding as of December&#160;31, 2021, 2020, and 2019, respectively, but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, our board of directors approved an increase in our common stock repurchase authorization from $<ix:nonFraction unitRef="usd" contextRef="ibcd77f4eb1a44cd19a0e1f02f5b4d30e_I20140131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzgwMg_18f973a9-c141-4bc3-977e-ed2e154b9500">200</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i5509a74ccfac4681b49ffbf1a98e00a1_I20140201" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzgwOA_140d3b0e-4797-447b-81c7-359144911740">250</ix:nonFraction> million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $<ix:nonFraction unitRef="usd" contextRef="i32d7a3624fe641b1a56f6e162c46212e_I20180724" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzExMTA_8c42eaa6-fe5b-461c-a533-d1eed6d9d803">250</ix:nonFraction> million. There were <ix:nonFraction unitRef="shares" contextRef="i985e0db50aa74ba18de323dce42bcfc3_D20210101-20211231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzMyOTg1MzQ4ODYwNzU_f54f0c0a-b26f-4c09-8458-9c47b6388e51">no</ix:nonFraction> repurchases of our common stock during 2021. During 2020 and 2019, we repurchased <ix:nonFraction unitRef="shares" contextRef="ic11d995353124469aeb3ecc87464738d_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzExNTE_6b787bb5-7595-4e9b-8f38-af237c26b57b">0.1</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i45e50175dc9344b19c41346526f0d782_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzExNTg_706921f3-901c-48c2-8f33-b62e954eb08f">0.8</ix:nonFraction> million shares of our common stock in the open market for $<ix:nonFraction unitRef="usd" contextRef="ic11d995353124469aeb3ecc87464738d_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzEyMTE_a99ecda8-ca29-461b-b73c-acdc0863de68">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i45e50175dc9344b19c41346526f0d782_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzEyMTg_bd70ca94-9321-45d2-86e8-d5ba1be28ba9">45.9</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i914b6b0bf40d480abbbf07849b027534_D20180701-20180731" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzE2NDA_555f93a0-d074-4168-8e1a-ce5d54f104d4">0.27</ix:nonFraction> per share. The cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i914b6b0bf40d480abbbf07849b027534_D20180701-20180731" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzE2NzU_5f78c6f8-b68d-49a5-bd56-b20d475399e6">0.27</ix:nonFraction> per common share was declared and paid in each quarter through July 2019. In July 2019, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b7b3e61b74c4a53b71221db5581c78c_D20190701-20190731" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzE4Njg_88fd2260-5944-4c7e-832d-5f0070f9ba93">0.28</ix:nonFraction> per share. The cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="id6a9857d4f284bb4be2223bfda243937_D20191001-20191031" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzE5MDM_d423e66d-b191-484a-84e7-b3100ec090ce">0.28</ix:nonFraction> per common share was declared and paid in each quarter through January 2022. Future dividend payments are subject to declaration by our board of directors.</span></div></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_292"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUyNTU_d96ab13f-03e5-4a3a-ba08-b3479b8637f7" continuedAt="i562de219a13144c4af7cb357691d7380" escape="true">Contingencies and Other Commitments:</ix:nonNumeric></span></div><ix:continuation id="i562de219a13144c4af7cb357691d7380" continuedAt="i8101279affeb4d298c8e1e63612ab0d5"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nichols Litigation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We were named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Nichols v. HealthSouth Corp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In July 2019, we entered into settlement agreements with all but one plaintiff and paid those settling plaintiffs an aggregate amount of cash less than $<ix:nonFraction unitRef="usd" contextRef="i0a8048f934624676bc2bb342d07afd90_D20190701-20190731" decimals="-5" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzIxOTkwMjMyNjQwMjA_43ba324f-5b29-4806-bf5e-9d45979f86ca">0.1</ix:nonFraction>&#160;million. The remaining plaintiff alleged that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiff sought compensatory and punitive damages. On June 9, 2021, the trial court granted our renewed motion for summary judgment on all of the plaintiff&#8217;s claims. The plaintiff did not appeal, so the matter has concluded. The conclusion of this matter did not have any impact on our consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8101279affeb4d298c8e1e63612ab0d5"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Commitments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to service and other contracts in connection with conducting our business. Minimum amounts due under these agreements are $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxMTc_9e9d9bd4-2b91-4020-9972-f5b835bb3741">55.4</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherCommitmentDueInSecondYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxMjc_ea82dae7-7a9b-4d8e-9bbf-2ff7a7dfc34c">35.0</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherCommitmentDueInThirdYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxMzc_dc831de3-1963-46e1-8120-21a190518d96">25.2</ix:nonFraction> million in 2024, $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherCommitmentDueInFourthYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxNDc_066dc8f1-5d0a-4d14-a1ed-2a961748b8ad">11.2</ix:nonFraction> million in 2025, $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherCommitmentDueInFifthYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxNTc_0aec42d3-e5d4-48cb-9ec0-171c9bce1623">9.0</ix:nonFraction> million in 2026, and $<ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:OtherCommitmentDueAfterFifthYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxNzE_31b266fd-c34a-40b9-9eba-3a64004ae285">13.0</ix:nonFraction> million thereafter. These contracts primarily relate to software licensing and support.</span></div></ix:continuation><div id="i34f6226a63dc43528534c2bfabd86ded_295"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"> <ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzMxODQ_97d206ad-c959-4390-a36f-59a4be2ea962" continuedAt="i99331d173fe04ffa9f464b6130f8a8df" escape="true">Segment Reporting</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i99331d173fe04ffa9f464b6130f8a8df" continuedAt="i43081cc36fb046cf8667d1093b58c993">: </ix:continuation></span></div><ix:continuation id="i43081cc36fb046cf8667d1093b58c993" continuedAt="if7bf1fca3dfd4854a0f5c7384b92ea6f"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using <ix:nonFraction unitRef="segment" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE3Mw_c4f4e4f4-f236-412a-9c49-4665a018b8c1">two</ix:nonFraction> operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our national network of inpatient rehabilitation hospitals stretches across <ix:nonFraction unitRef="state" contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzY2MA_46909067-56e7-4629-97d8-f6c4456e34d1">35</ix:nonFraction> states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of December&#160;31, 2021, we operate <ix:nonFraction unitRef="hospital" contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231" decimals="INF" name="ehc:NumberOfInpatientRehabilitationHospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzc5NA_a874884f-dc04-455e-86e0-518893961a1b">145</ix:nonFraction> inpatient rehabilitation hospitals. We are the sole owner of <ix:nonFraction unitRef="hospital" contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231" decimals="INF" name="ehc:Numberofsolelyownedinpatientrehabilitationhospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzg1OA_1dff01fa-bf68-419a-81f2-2e06ab21979a">91</ix:nonFraction> of these hospitals. We retain <ix:nonFraction unitRef="number" contextRef="ia3193970835f48d291309e71942e3c0b_I20211231" decimals="INF" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzg5MQ_050f8077-176f-4767-a869-7099a7108a97">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia3c49d5b00b54d92a4203a7b4d46fe21_I20211231" decimals="INF" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzg5Nw_90746a17-f556-4fde-8791-9e7fd31522c5">97.5</ix:nonFraction>% ownership in the remaining <ix:nonFraction unitRef="hospital" contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231" decimals="INF" name="ehc:Numberofjointlyownedinpatientrehabilitationhospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzkyNw_abd4531e-18b6-4d8d-aa63-e79fd6d20aac">54</ix:nonFraction> jointly owned hospitals. In addition, we manage <ix:nonFraction unitRef="facility" contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231" decimals="INF" name="ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzk3OA_f174fbb5-5e72-4f8e-b194-74479a719574">three</ix:nonFraction> inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Home Health and Hospice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- As of December&#160;31, 2021, we provide home health services in <ix:nonFraction unitRef="location" contextRef="i629acb7e34ff462d830466f2f0283b24_I20211231" decimals="INF" name="ehc:Numberofhomehealthlocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE0OTk_6c7784d9-f09f-4203-b0e2-2a2c4c971f98">251</ix:nonFraction> locations and hospice services in <ix:nonFraction unitRef="location" contextRef="ibda439a47d5b4d4b820c4a0e2bc953fe_I20211231" decimals="INF" name="ehc:Numberofhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE1MzY_33004c37-377b-479e-a6a4-0300e3e3e724">96</ix:nonFraction> locations across <ix:nonFraction unitRef="state" contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE1NTY_eb897e64-0712-457e-9fdc-7e746b98dcb6">34</ix:nonFraction> states with a concentration in the southern half of the United States. We are the sole owner of <ix:nonFraction unitRef="location" contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231" decimals="INF" name="ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE3ODk_3dac2d99-3803-4990-9afc-7567be30850f">336</ix:nonFraction> of these locations. We retain <ix:nonFraction unitRef="number" contextRef="i2ca76abaabe14804b27dbe68101f2b21_I20211231" decimals="INF" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE4MjI_ccc2dbd1-63f2-4bb3-84c1-11939be9d71c">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i886bc836155e45d099f360bf9159bb7b_I20211231" decimals="INF" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE4Mjg_5f5e1ffe-65fc-4246-b420-2c1ef5e5ffdb">90.0</ix:nonFraction>% ownership in the remaining <ix:nonFraction unitRef="location" contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231" decimals="INF" name="ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE4NTg_e6f41668-c776-4f72-b673-8f02fab643e9">11</ix:nonFraction> jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of our reportable segments are the same as those described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All revenues for our services are generated through external customers. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#8220;Segment Adjusted EBITDA&#8221;).</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if7bf1fca3dfd4854a0f5c7384b92ea6f" continuedAt="i8910a305aa744e1b8d15a8eb2e0725bc"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzMxOTA_4e92be71-d5a0-438e-85dd-97f68508abe2" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtMS0xLTEtNTU5Njg_3c94ff46-663f-4950-9d69-186dc32d5bdf">4,015.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtMy0xLTEtNTU5Njg_2cae42cc-962e-4d33-b364-dc83b1624ddf">3,566.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtNS0xLTEtNTU5Njg_d3d71313-7dc9-42e0-bd88-2052e4b440ab">3,513.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtNy0xLTEtNTU5Njg_c94546a9-da23-47ae-9643-d57a4f12260c">1,106.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtOS0xLTEtNTU5Njg_923725b7-c99a-4954-8508-29335e261a62">1,078.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtMTEtMS0xLTU1OTY4_e1601a4a-ff4b-44b0-9481-3ed08e2a8053">1,092.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtMS0xLTEtNTU5Njg_d9da852e-dd96-46b6-8438-1ed5c5d8fc51">2,127.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtMy0xLTEtNTU5Njg_69837e49-f4e0-46f8-907d-bcf26e747024">1,903.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtNS0xLTEtNTU5Njg_2d3f1122-1e74-4794-b566-1226645f8ffa">1,813.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtNy0xLTEtNTU5Njg_1c396487-09e8-40c1-9833-ca4819462896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtOS0xLTEtNTU5Njg_91cac5ab-e56b-4f66-9ac9-e213028181b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtMTEtMS0xLTU1OTY4_31dff74f-6769-4815-b7ed-1fa183f0d646">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctMS0xLTEtNTU5Njg_edf3ef8b-e922-4e5b-8abf-9d30913c19d4">594.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctMy0xLTEtNTU5Njg_8a2f119d-22fd-4af5-a763-000772bd43b7">534.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctNS0xLTEtNTU5Njg_0f79d162-a611-4f4d-bc2f-b20fea44fd9c">521.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctNy0xLTEtNTU5Njg_e9ccc175-e002-4127-b7c2-b3fd4a9c7399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctOS0xLTEtNTU5Njg_6c39af18-8ad6-4696-a0a9-eeadd1d6af1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctMTEtMS0xLTU1OTY4_40b2e10c-27b1-4d49-92f8-a7fb0235175f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtMS0xLTEtNTU5Njg_6aa37b3c-dd65-444d-9028-f2f78d393b97">184.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtMy0xLTEtNTU5Njg_a6e6549c-ec5c-4ca0-beed-138c3f963687">171.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtNS0xLTEtNTU5Njg_e5760662-ff1b-4c31-8e27-4c524e9c6912">147.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:SuppliesExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtNy0xLTEtNTU5Njg_a97b2a76-dba4-4756-8c37-d20da8f9ec3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:SuppliesExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtOS0xLTEtNTU5Njg_ec7b0583-0a20-4b0a-877a-cab5e91b5398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:SuppliesExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtMTEtMS0xLTU1OTY4_74751b8a-8c92-4c30-8016-9818d6668bbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktMS0xLTEtNTU5Njg_00c21434-64fc-47d8-af75-818c8ff04ca3">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktMy0xLTEtNTU5Njg_639c603a-dbd7-40db-a702-b667751457d2">61.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktNS0xLTEtNTU5Njg_00d7e70b-eadb-48ad-8e75-28ee35e280bb">64.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="ehc:OccupancyCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktNy0xLTEtNTU5Njg_5ef54195-143a-47fc-a6a9-22ef42c22761">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="ehc:OccupancyCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktOS0xLTEtNTU5Njg_2cf4520b-e0be-4682-ad53-ceed659cc02c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="ehc:OccupancyCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktMTEtMS0xLTU1OTY4_4b0edf6e-7e5a-480c-9642-c82bb2393987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTEtMS0xLTU1OTY4_f4a109a0-4bf2-42ca-a6b4-4aba2747dc58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTMtMS0xLTU1OTY4_0796933a-42ab-46cf-af18-8f687e6ca627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTUtMS0xLTU1OTY4_f7d675c8-db9d-4c1c-8843-2ea5641149a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTctMS0xLTU1OTY4_00df56bb-237a-4980-91e3-19f24e78d926">489.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTktMS0xLTU1OTY4_d39b0d03-d1f6-4ed8-92a7-df3de1e854ec">511.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTExLTEtMS01NTk2OA_36d844ae-657a-4e92-be26-bbb94a961765">506.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTEtMS0xLTU1OTY4_6ceed021-a574-45d0-9122-b32c1f6c4280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTMtMS0xLTU1OTY4_14385f92-767d-4787-b6e2-a32a514ca75a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTUtMS0xLTU1OTY4_0b7d1349-7d0a-4b79-ac7d-53a13a719832">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTctMS0xLTU1OTY4_ae88bb3f-5f10-47c0-b904-61647a406d03">406.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTktMS0xLTU1OTY4_5d2a115a-2a92-4dff-9073-5197dba9aa48">402.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTExLTEtMS01NTk2OA_bc6118ef-094c-48bd-9d31-3cd89dc20b78">381.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTEtMS0xLTU1OTY4_36d8701c-ab88-42de-89e8-eb16edcc5927">2,965.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTMtMS0xLTU1OTY4_7f27137f-1f90-4560-a490-b56630621bea">2,670.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTUtMS0xLTU1OTY4_b24fa91f-9df7-4375-bc6d-be47b91e1816">2,546.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTctMS0xLTU1OTY4_f5391cee-73c4-4144-a3af-b6579e90411f">895.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTktMS0xLTU1OTY4_2f25ef73-0bce-423e-9434-1715334cf639">914.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTExLTEtMS01NTk2OA_c5410fd3-ecb1-4a56-b947-2504dc22fb4b">887.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTEtMS0xLTU1OTY4_c5293aaa-e00a-43a9-8103-5aab86ef3b1b">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTMtMS0xLTU1OTY4_1ef17b5e-9307-4286-8423-799797d9cc23">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTUtMS0xLTU1OTY4_8cafdf87-e2e9-478b-8311-e721ca9dacc8">10.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTctMS0xLTU1OTY4_65034580-de5c-45e4-ac60-aa7c2afd8589">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTktMS0xLTU1OTY4_2869dc56-7436-42ed-8ca2-f31f6470e622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTExLTEtMS01NTk2OA_af85a122-f105-421d-815e-2d8c2eceabc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTEtMS0xLTU1OTY4_3546869c-b4a6-4b66-8477-a6b25feadf26">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTMtMS0xLTU1OTY4_3196e7d9-1400-47e9-9b7e-2e8fa38c1a43">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTUtMS0xLTU1OTY4_5099595b-f30b-4810-bcad-73834c18198d">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTctMS0xLTU1OTY4_6e987f11-3534-4543-874c-1f91ced69bf0">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTktMS0xLTU1OTY4_b92e9080-09c1-4b2d-a36e-6fdacc0d46cd">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTExLTEtMS01NTk2OA_bc2979f2-3333-400c-a996-f5a1c15e0483">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTEtMS0xLTU1OTY4_82e2ae68-6dbc-44e0-a1ea-3925fb3d7980">103.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTMtMS0xLTU1OTY4_67a53347-a837-46c6-a745-1abb96933c0f">83.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTUtMS0xLTU1OTY4_8f886943-77a3-4076-a71b-9f3f1807178b">82.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTctMS0xLTU1OTY4_8efb1968-a156-4381-a55b-6129567aeecc">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTktMS0xLTU1OTY4_e9344377-5d7d-4137-9443-c29e519ed0cd">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTExLTEtMS01NTk2OA_7738c86c-43c2-4e31-8ca7-9e9cf01b7524">9.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTEtMS0xLTU1OTY4_52ed9e69-0652-499a-8765-fbfe1087d068">956.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTMtMS0xLTU1OTY4_375b5434-d43b-490a-acac-956969f37306">823.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTUtMS0xLTU1OTY4_08df4973-c27f-4ca2-b001-43c1073c91dd">899.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTctMS0xLTU1OTY4_4ae89d17-6f1c-4dfc-80aa-2f91b43ed0eb">211.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTktMS0xLTU1OTY4_4ec3ed34-0c69-4c76-8c49-6cd17bcfcd4f">163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTExLTEtMS01NTk2OA_c7ee4f39-f846-41f2-a81c-04aad1ea0644">195.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTEtMS0xLTU1OTY4_919c0a02-08be-43b9-b183-ff54f3df6af0">545.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTMtMS0xLTU1OTY4_49c5469d-2415-4520-8e36-8d542c173bac">404.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTUtMS0xLTU1OTY4_2e60acf3-4549-4cbc-a0c5-31fc711aa871">391.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTctMS0xLTU1OTY4_99a92f1f-b4c3-46a4-831b-983a787b8430">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTktMS0xLTU1OTY4_d25526dd-b4cc-463b-b816-6b45c086b573">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTExLTEtMS01NTk2OA_4270f7af-be2b-4bd9-9b20-d6c86ca80105">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:center"><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE1OTQyOTE4NjA2MTE5_f3ffa8f0-441a-4e7b-8944-f53366a3d52a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:51.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzItMS0xLTEtMTAwNjY2_d4cbeca4-dd09-4d15-97d0-71723aaad0cb">5,143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzItMy0xLTEtMTAwNjY2_ffaf5306-4d78-43a2-b1fb-700fcebd08d6">1,721.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzItNS0xLTEtMTAwNjcw_bdb13f7c-7aad-458c-966e-09980e63a88d">6,864.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzMtMS0xLTEtMTAwODk1_e84804b1-a5b5-434e-a6cd-26b34a918885">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzMtMy0xLTEtMTAwNjcz_31272d3d-ca67-478b-8b2b-af495376c0dd">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzMtNS0xLTEtMTAwNjcz_c57835dd-154c-4838-9da0-1cd074a4b6fc">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490945f79e4b4bb6aeef60a98f16bb9e_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzUtMS0xLTEtMTAwNjU0_7761213f-8d94-4d0b-927d-ed8d9df52bbb">4,834.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da867bd58bd42c7829bba5db347624f_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzUtMy0xLTEtMTAwNjU0_1822ab05-9aef-49de-ad7e-899f40fe273d">1,611.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzUtNS0xLTEtMTAwNjU4_cc22832c-0544-4ba0-9fe2-07aa1acae0b4">6,445.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490945f79e4b4bb6aeef60a98f16bb9e_I20201231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzYtMS0xLTEtMTAwOTEz_1cec43e2-9106-4c0a-99be-57520d99a172">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da867bd58bd42c7829bba5db347624f_I20201231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzYtMy0xLTEtMTAwNjYw_81b37db3-b566-4bd9-93ba-f8d9fd1704e5">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzYtNS0xLTEtMTAwNjYw_9d8e43ff-fc5b-4745-a24e-7e4cc320afc3">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8910a305aa744e1b8d15a8eb2e0725bc"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzMyMDQ_7859b67b-f4fc-488e-8e46-2f575a3b8d10" continuedAt="i95980090050c48fdafb8ceb3c3774303" escape="true">Segment reconciliations (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="i95980090050c48fdafb8ceb3c3774303"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b20d1c1a4664c29b6e46e8c2743fd6d_D20210101-20211231" decimals="-5" name="ehc:AdjustedEBITDA" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzItMS0xLTEtNTU5Njg_fc02d0d0-40a4-4209-bf58-b3fe84f47dea">1,168.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9c5d61928d45b991a621d141539dfb_D20200101-20201231" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzItMy0xLTEtNTU5Njg_2164fda4-4add-42ec-b546-bd5aab45b482">986.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776c682b8b6f439fb66cde932ed76f45_D20190101-20191231" decimals="-5" name="ehc:AdjustedEBITDA" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzItNS0xLTEtNTU5Njg_4945f825-d981-4d34-b100-9dc0a06c0ccd">1,095.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzMtMS0xLTEtNTU5Njg_c5e13bfc-f143-4e85-947a-b0549023c914">197.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzMtMy0xLTEtNTU5Njg_28b2c2b2-44a5-4835-83f2-64f4bdea0e2f">155.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzMtNS0xLTEtNTU5Njg_0d13b5c0-f31a-4652-8c64-4f4fd4c1e72c">247.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzQtMS0xLTEtNTU5Njg_630c0c10-2b4a-4c48-bc67-58a38d440141">256.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzQtMy0xLTEtNTU5Njg_bf669b55-53d9-48c9-be8f-d341d971a73f">243.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzQtNS0xLTEtNTU5Njg_0494ab6b-4803-4440-9720-01d34813cf4e">218.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzUtMS0xLTEtNTU5Njg_fd0befa6-16be-4be7-bc29-782a83d33fe7">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzUtMy0xLTEtNTU5Njg_785f85b1-c453-448d-8627-1c467ca9c712">11.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzUtNS0xLTEtNTU5Njg_c8872ccc-1b44-499d-9dce-39d4eb855270">11.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzYtMS0xLTEtNTU5Njg_ac991380-4fb8-4057-b7fd-6c12249ee463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzYtMy0xLTEtNTU5Njg_fc31b8f4-05eb-44eb-823f-dea2c903221f">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzYtNS0xLTEtNTU5Njg_74ae8645-caf9-4dcd-bd34-dfb19121c12e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzgtMS0xLTEtNTU5Njg_b598fcbc-dfba-41c6-8aa8-204e590ac251">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzgtMy0xLTEtNTU5Njg_4fed73ab-2a6c-4c6e-ac1f-91b6ae0da315">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzgtNS0xLTEtNTU5Njg_f0ba3726-6a38-4eb8-a9dc-2ee1608421ef">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzktMS0xLTEtNTU5Njg_e1decec7-5674-4e17-934b-ae64afae3e46">164.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzktMy0xLTEtNTU5Njg_0c1af2a5-08e2-4545-a8c3-391efc649e32">184.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzktNS0xLTEtNTU5Njg_5acbb72e-e8aa-4b40-b7a3-c5bb52ed506e">159.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEwLTEtMS0xLTU1OTY4_bdfa76b7-5173-4710-885c-b9a17cc8fbd7">105.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEwLTMtMS0xLTU1OTY4_4b895b5e-ee30-461a-9f5f-4351176fa729">84.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEwLTUtMS0xLTU1OTY4_e7a5da1c-856b-4ab7-9b83-9ef644f9640a">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" name="ehc:SARsmarktomarketimpactonnoncontrollinginterests" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzExLTEtMS0xLTU1OTY4_258edacd-d6a2-478d-a302-9963a5245d60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" name="ehc:SARsmarktomarketimpactonnoncontrollinginterests" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzExLTMtMS0xLTU1OTY4_16afd369-8009-436c-92c7-db7e7a636228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" name="ehc:SARsmarktomarketimpactonnoncontrollinginterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzExLTUtMS0xLTU1OTY4_cc1fb2a3-a392-4d29-8e59-ddb42689dcf9">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEyLTEtMS0xLTU1OTY4_d7f63c6c-ee28-472c-810c-7e4eeb7d3bc6">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEyLTMtMS0xLTU1OTY4_e8e8df27-eb7a-407c-b74b-737ea5a1a809">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEyLTUtMS0xLTU1OTY4_f1a3af9d-76ce-4a87-b763-b2fe21c5de64">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE0LTEtMS0xLTU1OTY4_5c6a61b4-9b7b-4011-953e-1550e5239d95">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE0LTMtMS0xLTU1OTY4_df6ea5b7-c14e-4f1c-a6b2-a31efccdf817">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE0LTUtMS0xLTU1OTY4_ed39f106-f8bf-43ec-a758-a90828c023e3">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231" decimals="-5" name="ehc:PayrolltaxesonSARsexercise" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE1LTEtMS0xLTU1OTY4_2216c2e6-4c45-4882-8d51-e5f0de6368ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231" decimals="-5" name="ehc:PayrolltaxesonSARsexercise" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE1LTMtMS0xLTU1OTY4_3df251a1-215d-443b-9251-b7d76862f20d">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231" decimals="-5" name="ehc:PayrolltaxesonSARsexercise" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE1LTUtMS0xLTU1OTY4_a3af49a2-9a4b-42ce-a039-d315b3d9af97">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE2LTEtMS0xLTU1OTY4_f2e9aea0-60b9-4e78-840a-13ca7bfd95fe">657.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE2LTMtMS0xLTU1OTY4_ec94408c-bb32-4aa4-abc0-717ac87d70e9">472.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE2LTUtMS0xLTU1OTY4_b66109e2-5118-4082-9a0a-29b2e9b04557">562.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzMxOTU_575511e8-bcf1-4d88-93a3-bdc6ce92eb55" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.348%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a9deb44ebc4734990673dcfd5a1fa2_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzMtMS0xLTEtNTU5Njg_986b1bf9-1b4b-4ffe-b6a7-0382a12b2c86">3,918.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3de5b67d1c443a38dfa663c544d2ffa_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzMtMy0xLTEtNTU5Njg_e5a7961f-a69e-4e80-9c4d-fe7b20c3e892">3,496.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7deb25afaae4201a2e97e69747672e8_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzMtNS0xLTEtNTU5Njg_7b773abb-8144-4bf1-b4ab-a3569f07716c">3,423.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5571918fc1b480a932b9aaa18cb0053_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzQtMS0xLTEtNTU5Njg_62f5ff2a-76c2-478c-b916-bcd052480181">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i941a80b49d3743a78f06a9e20d555c80_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzQtMy0xLTEtNTU5Njg_e9e28278-48af-4949-8424-85014f1c7aaf">70.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1af801ecbfb49d2bc7b43640349d670_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzQtNS0xLTEtNTU5Njg_7728bfd3-54b4-4254-a2bc-eb41393e7be2">89.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzUtMS0xLTEtNTU5Njg_aa83c786-0262-40bc-b2fd-cf50bfc4cb73">4,015.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzUtMy0xLTEtNTU5Njg_263eb77d-ebc1-4bd3-9e64-90eb57ecf834">3,566.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzUtNS0xLTEtNTU5Njg_7e057b9d-e98d-42f5-814f-b70843ad82f3">3,513.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia681297da5504ffaacf633a76dcb7a2d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzctMS0xLTEtNTU5Njg_57421265-1b36-4d7b-953a-db7fea871e4a">897.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4752f09b329c46a7a5c722bebaadac64_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzctMy0xLTEtNTU5Njg_fea75f36-c7b2-43f5-9752-ad90c2bc07f7">877.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301c2e1d8eb641efb1ef724b3603ec49_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzctNS0xLTEtNTU5Njg_70af22e8-a9e8-470e-9999-b57acf30c847">918.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e9398a071b4c9a98203be3ab77177f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzgtMS0xLTEtNTU5Njg_c68ba7d6-643e-44c7-8d44-b43a831f98cb">209.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db2ff79c3674a52a089ddcc64324e9f_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzgtMy0xLTEtNTU5Njg_bea2a2f4-0b5c-4810-90d0-e0f1d22b5a08">200.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c6808319b14ca9b78c39dcbbbd0052_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzgtNS0xLTEtNTU5Njg_22709387-ac9c-42e7-9801-688ad3ec827b">174.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzktMS0xLTEtNTU5Njg_0253dbc7-4137-4946-85de-3e3b1fa4bfdd">1,106.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzktMy0xLTEtNTU5Njg_d7c5e538-cdc7-486c-8e78-0929bbe31603">1,078.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzktNS0xLTEtNTU5Njg_2e2de395-3224-4590-a28e-80afed9649bd">1,092.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzEwLTEtMS0xLTU1OTY4_24d0d68e-9668-402c-ad33-3d9a5e942e80">5,121.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzEwLTMtMS0xLTU1OTY4_147aa084-e114-47c5-9361-459c1346559c">4,644.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzEwLTUtMS0xLTU1OTY4_729872c6-4c62-4ff0-8faa-c22dcd9cdf5b">4,605.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-61</span></div></div></div><div id="i34f6226a63dc43528534c2bfabd86ded_313"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT LIST</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of January 1, 2018, we changed our name to Encompass Health Corporation. By operation of law, any reference to &#8220;HealthSouth&#8221; in these exhibits should be read as &#8220;Encompass Health&#8221; as set forth in the Exhibit List below.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:5.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex31.htm">3.1.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex31.htm">Amended and Restated Certificate of Incorporation of Encompass Health Corporation, effective as of January 1, 2018 (incorporated by reference to Exhibit 3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 25, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000134100406000665/healthsouthexhibit.txt">3.1.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000134100406000665/healthsouthexhibit.txt">Certificate of Designations of 6.50% Series A Convertible Perpetual Preferred Stock, as filed with the Secretary of State of the State of Delaware on March 7, 2006 (incorporated by reference to Exhibit 3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on March 9, 2006).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex32.htm">3.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex32.htm">Amended and Restated Bylaws of Encompass Health Corporation, effective as of January 1, 2018 (incorporated by reference to Exhibit 3.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 25, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000011/exhibit_4-7110k.htm">4.1.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000011/exhibit_4-7110k.htm">Indenture, dated as of December 1, 2009, between Encompass Health Corporation&#160;and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York, relating to Encompass Health&#8217;s 5.125% Senior Notes due 2023, 5.75% Senior Notes due 2024, and 5.75% Senior Notes due 2025 (incorporated by reference to Exhibit&#160;4.7.1 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 23, 2010).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000011/exhibit_4-7210k.htm">4.1.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000011/exhibit_4-7210k.htm">First Supplemental Indenture, dated December 1, 2009, among Encompass Health Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York (incorporated by reference to Exhibit 4.7.2 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 23, 2010).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000053/exhibit_4-2.htm">4.1.3</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000053/exhibit_4-2.htm">Second Supplemental Indenture, dated as of October 7, 2010, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York (incorporated by reference to Exhibit 4.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 12, 2010).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000053/exbibit_4-3.htm">4.1.4</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000053/exbibit_4-3.htm">Third Supplemental Indenture, dated October 7, 2010, among Encompass Health Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York (incorporated by reference to Exhibit 4.3 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 12, 2010).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516112000058/ex42fourthsupplementalinde.htm">4.1.5</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516112000058/ex42fourthsupplementalinde.htm">Fourth Supplemental Indenture, dated September 11, 2012, among Encompass Health Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York&#160;(incorporated by reference to Exhibit 4.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on September 11, 2012).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000032/ex42healthsouthfifthsupple.htm">4.1.6</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000032/ex42healthsouthfifthsupple.htm">Fifth Supplemental Indenture, dated as of March 12, 2015, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to Encompass Health&#8217;s 5.125% Senior Notes due 2023 (incorporated by reference to Exhibit 4.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on March 12, 2015).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000075/a2015augnotesoffclosingex44.htm">4.1.7</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000075/a2015augnotesoffclosingex44.htm">Sixth Supplemental Indenture, dated as of August 7, 2015, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee (incorporated by reference to Exhibit 4.4 to Encompass Health&#8217;s Current Report on Form 8-K filed on August 12, 2015).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000082/ex42seventhsupplementalind.htm">4.1.8</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000082/ex42seventhsupplementalind.htm">Seventh Supplemental Indenture, dated as of September 16, 2015, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York, relating to Encompass Health&#8217;s 5.75% Senior Notes due 2025 (incorporated by reference to Exhibit 4.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on September 21, 2015).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312519247756/d760186dex42.htm">4.1.9</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312519247756/d760186dex42.htm">Eighth Supplemental Indenture dated as of September&#160;18, 2019, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.500% Notes due 2028 (incorporated by referenced to Exhibit 4.2 to the Encompass Health&#8217;s Current Report on Form 8-K filed on September 18, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312519247756/d760186dex43.htm">4.1.10</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312519247756/d760186dex43.htm">Ninth Supplemental Indenture dated as of September&#160;18, 2019, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.750% Notes due 2030 (incorporated by referenced to Exhibit 4.3 to the Encompass Health&#8217;s Current Report on Form 8-K filed on September 18, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:5.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312520263689/d12659dex42.htm">4.1.11</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312520263689/d12659dex42.htm">Tenth Supplemental Indenture, dated as of October 5, 2020, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.625% Notes due 2031 (incorporated by reference to Exhibit 4.2 to the Encompass Health&#8217;s Current Report on Form 8-K filed on October 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">4.1.12</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">Ele</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">venth</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm"> Supplemental Indenture, dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">December 15, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">5.75</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">% Notes due 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">25</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm"> (incorporated by reference to Exhibit 4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm"> to the Encompass Health&#8217;s Current Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">December 17</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000003/twelfthsupplementalindeture.htm">4.1.13</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000003/twelfthsupplementalindeture.htm">Twelfth Supplemental Indenture, dated as of January 24, 2022, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.500% Notes due 2028, 4.750% Notes due 2030 and 4.625% Notes due 2031 (incorporated by reference to Exhibit 4.5 to the Encompass Health&#8217;s Current Report on Form 8-K filed on January 25, 2022).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex42.htm">4.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex42.htm">Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (Common Stock)(incorporated by reference to Exhibit 4.2 to Encompass Health's Annual Report on Form 10-K filed on February 27, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312506065473/dex10121.htm">10.1.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312506065473/dex10121.htm">Encompass Health Corporation Amended and Restated 2004 Director Incentive Plan (incorporated by reference to Exhibit 10.12.1 to Encompass Health&#8217;s Annual Report on Form 10-K filed on March 29, 2006).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312506065473/dex10122.htm">10.1.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312506065473/dex10122.htm">Form of Restricted Stock Unit Agreement (Amended and Restated 2004 Director Incentive Plan)(incorporated by reference to Exhibit 10.12.2 to Encompass Health&#8217;s Annual Report on Form 10-K filed on March 29, 2006).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312505131361/dex1031.htm">10.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312505131361/dex1031.htm">Form of Indemnity Agreement entered into between Encompass Health Corporation and the directors of Encompass Health (incorporated by reference to Exhibit 10.31 to Encompass Health&#8217;s Annual Report on Form 10-K filed on June 27, 2005).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000070/ehc10q93020ex101.htm">10.3</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000070/ehc10q93020ex101.htm">Encompass Health Corporation Fifth Amended and Restated Change in Control Benefits Plan (incorporated by reference to Exhibit 10.1 to Encompass Health&#8217;s Quarterly Report on Form 10-Q filed on November 2, 2020).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000144264309000050/form10q-32009.htm">10.4</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000144264309000050/form10q-32009.htm">Description of the Encompass Health Corporation Senior Management Compensation Recoupment Policy (incorporated by reference to Item 5, &#8220;Other Matters,&#8221; in Encompass Health&#8217;s Quarterly Report on Form 10-Q filed on November 4, 2009).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000014/a2021proxystatement.htm">10.5</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000014/a2021proxystatement.htm">Description of the Encompass Health Corporation Senior Management Bonus and Long-Term Incentive Plans (incorporated by reference to the section captioned &#8220;Executive Compensation &#8211; Compensation Discussion and Analysis &#8211; Elements of Executive Compensation&#8221; in Encompass Health&#8217;s Definitive Proxy Statement on Schedule&#160;14A filed on March 26, 2021).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000014/a2021proxystatement.htm">10.6</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000014/a2021proxystatement.htm">Description of the annual compensation arrangement for non-employee directors of Encompass Health Corporation (incorporated by reference to the section captioned &#8220;Corporate Governance and Board Structure&#160;&#8211;&#160;Compensation of Directors&#8221; in Encompass Health&#8217;s Definitive Proxy Statement on Schedule 14A, filed on March 26, 2021).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516118000050/ehc10q93018ex102.htm">10.7</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516118000050/ehc10q93018ex102.htm">Encompass Health Corporation Fifth Amended and Restated Executive Severance Plan (incorporated by reference to Exhibit 10.2 to Encompass Health&#8217;s Quarterly Report on Form 10-Q filed on October 31, 2018).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex108.htm">10.8</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex108.htm">Encompass Health Corporation Nonqualified 401(k) Plan (incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex108.htm">10.8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex108.htm"> to Encompass Health's Annual Report on Form 10-K filed on February 27, 2020).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516111000063/exhibit4_d.htm">10.9.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516111000063/exhibit4_d.htm">Encompass Health Corporation Amended and Restated 2008 Equity Incentive Plan (incorporated by reference to Exhibit&#160;4(d) to Encompass Health&#8217;s Registration Statement on Form S-8 filed on August 2, 2011).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000009/hls10-k123116ex10102.htm">10.9.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000009/hls10-k123116ex10102.htm">Form of Non-Qualified Stock Option Agreement (2008 Equity Incentive Plan)(incorporated by reference to Exhibit 10.10.2 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 22, 2017).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000009/hls10-k123116ex10103.htm">10.9.3</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000009/hls10-k123116ex10103.htm">Form of Non-Qualified Stock Option Agreement (Amended and Restated 2008 Equity Incentive Plan)(incorporated by reference to Exhibit 10.10.3 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 22, 2017).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516111000066/exhibit10_1-5.htm">10.9.4</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516111000066/exhibit10_1-5.htm">Form of Restricted Stock Unit Award (Amended and Restated 2008 Equity Incentive Plan)(incorporated by reference to Exhibit 10.1.5 to Encompass Health&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2011).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516113000012/hls10-k123112ex1015.htm">10.10</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516113000012/hls10-k123112ex1015.htm">Encompass Health Corporation Directors&#8217; Deferred Stock Investment Plan (incorporated by reference to Exhibit 10.15 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 19, 2013).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1011.htm">10.11.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1011.htm">Encompass Health Corporation 2016 Omnibus Performance Incentive Plan (incorporated by reference to Exhibit&#160;10.1.1 to Quarterly Report on Form 10-Q filed on July 29, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:5.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000153/ex101-formofstockoption.htm">10.11.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000153/ex101-formofstockoption.htm">Form of Non-Qualified Stock Option Agreement (2016 Omnibus Performance Incentive Plan)(incorporated by reference to Exhibit&#160;10.1 to Current Report on Form 8-K filed on December 12, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1013.htm">10.11.3</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1013.htm">Form of Restricted Stock Award (2016 Omnibus Performance Incentive Plan)(incorporated by reference to Exhibit&#160;10.1.3 to Quarterly Report on Form 10-Q filed on July 29, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1014.htm">10.11.4</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1014.htm">Form of Performance Share Unit Award (2016 Omnibus Performance Incentive Plan)(incorporated by reference to Exhibit&#160;10.1.4 to Quarterly Report on Form 10-Q filed on July 29, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1015.htm">10.11.5</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1015.htm">Form of Restricted Stock Unit Award (2016 Omnibus Performance Incentive Plan)(incorporated by reference to Exhibit&#160;10.1.5 to Quarterly Report on Form 10-Q filed on July 29, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516119000049/encompass-collateralan.htm">10.12</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516119000049/encompass-collateralan.htm">Second Amended and Restated Collateral and Guarantee Agreement, dated November 25, 2019, by and among Encompass Health Corporation, certain of its subsidiaries, and Barclays Bank PLC, as collateral agent (incorporated by reference to Exhibit 10.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on December 2, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516119000049/fiftharcreditagreement2.htm">10.13.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516119000049/fiftharcreditagreement2.htm">Fifth Amended and Restated Credit Agreement, dated November 25, 2019, by and among Encompass Health Corporation, certain of its subsidiaries, Barclays Bank PLC, as administrative agent and collateral agent, Citigroup Global Markets Inc., as syndication agent, Bank of America, N.A., Goldman Sachs Bank USA, and Morgan Stanley Senior Funding, Inc., as co-documentation agents, and various other lenders from time to time (incorporated by reference to Exhibit 10.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on December 2, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000026/firstamendmenttocredit.htm">10.13.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000026/firstamendmenttocredit.htm">First Amendment to Fifth Amended and Restated Credit Agreement, dated April 24, 2020, by and among Encompass Health Corporation, certain of its subsidiaries, and Barclays Bank PLC, as administrative agent and collateral agent (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000020/hls10-k123114ex1019.htm">10.14</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000020/hls10-k123114ex1019.htm">Homecare Homebase, L.L.C. Restated Client Service and License Agreement, dated December 31, 2014, by and between Homecare Homebase, L.L.C. and EHHI Holdings, Inc. (incorporated by reference to Exhibit 10.19 to Encompass Health&#8217;s Annual Report on Form 10-K filed on March 2, 2015).*</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex1015.htm">10.15</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex1015.htm">Second Amended and Restated Senior Management Agreement, dated as of October 7, 2019, by and among EHHI Holdings, Inc., April Anthony, and Encompass Health Corporation (incorporated by reference to Exhibit 4.2 to Encompass Health's Annual Report on Form 10-K filed on February 27, 2020).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000038/ehc10q63021ex101.htm">10.16</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000038/ehc10q63021ex101.htm">Letter Agreement, dated June 21, 2021, between Encompass Health Corporation and Barbara A. Jacobsmeyer (incorporated by reference to Exhibit 10.1 to Encompass Health's Quarterly Report on Form 10-Q filed on August 3, 2021).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex211.htm">21.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex211.htm">Subsidiaries of Encompass Health Corporation.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex221.htm">22.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex221.htm">Subsidiary Guarantors and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize Securities of the Registrant.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex231.htm">23.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex231.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_127">24.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_127">Power of Attorney (included as part of signature page).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex311.htm">31.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex311.htm">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex312.htm">31.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex312.htm">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex321.htm">32.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex322.htm">32.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123121ex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sections of the Encompass Health Corporation Annual Report on Form 10-K for the year ended December 31, 2021, formatted in XBRL (eXtensible Business Reporting Language), submitted in the following files:</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i34f6226a63dc43528534c2bfabd86ded_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:5.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ &#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment. The nonpublic information has been filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ehc10k123121ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifd2904bf85074e99bb513eb2baa46fb0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A&#38;B Home Health Solutions, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abba Home Health, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice </font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Homecare Management, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health and Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHM Action Home Health, LP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AnMed Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AnMed Health Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apex Hospice LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Best Home Care LP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Home Health of Alabama, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice - Huntsville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Home Health of East Tennessee, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Home Health of the Gulf Coast, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Home Health of the Gulf Coast</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of Central Mississippi, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Hospice of Central Mississippi</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of East Louisiana, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice of Vidalia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of Louisiana, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice of the Northshore</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of North Mississippi, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Hospice of North Mississippi</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of Northeast Alabama LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice - Rainbow City</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of Northeast Mississippi, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Hospice of Northeast Mississippi</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of South Alabama, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice - Dothan</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice - Prattville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of Southwest Mississippi, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Hospice of Southwest Mississippi</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camellia Hospice of the Gulf Coast, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Hospice of the Gulf Coast</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareServices of Bethesda, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Bethesda</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareServices of the Treasure Coast, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth Health System, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Columbus, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Dothan, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Gainesville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Greensboro, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Lexington, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Middle Georgia, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of North Florida, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Panama City, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Richmond, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of South Carolina, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health - Aiken</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health - Bluffton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health - Columbia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Tallahassee, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of the Bay Area, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of the Treasure Coast, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Jupiter Medical Center</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Valley, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Virginia, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Washington, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Western Carolina, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Winchester, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth HHA Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareSouth Hospice, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Arkansas Rehabilitation Associates, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHI St. Vincent Hot Springs Rehabilitation Hospital, a partner of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHI St. Vincent Sherwood Rehabilitation Hospital, a partner of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Louisiana Rehab Associates, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Alexandria</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS Rehab of WF, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Wichita Falls</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continental Home Care, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Eastern Oklahoma</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Day-By-Day Staff Relief, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Northeast Oklahoma</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DOSIK, INC.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DRC Health Systems, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Home Health of Alabama, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Home Health of Birmingham, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Home Health of Central Virginia, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Home Health of Florida, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Home Health of Kentucky, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Kentucky</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Home Health of Miami, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Home Health of New England, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Home Health of the Northwest, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Hospice of Alabama, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Albertville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Alexander City</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Anniston</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Birmingham</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Clanton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Cullman</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Decatur</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Enterprise</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Gadsden</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Greenville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Hamilton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Jasper</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Madison County</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Mobile</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Montgomery</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Muscle Shoals</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Northport</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Oneonta</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Opelika</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Pell City</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Rainsville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Scottsboro</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice Troy</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Hospice of Pennsylvania, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Hospice of the Midwest, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Hospice of the Northwest, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Hospice of the Southwest, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Ventures Boise, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Ventures Bozeman, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Health Ventures Salida, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of Austin, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of Colorado, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of DFW, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of East Texas, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of Roanoke, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of the Mid Atlantic, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of the Midwest, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of the Southeast, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Home Health of the West, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ID</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Eastern Idaho</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Southern Utah</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice of Southern Utah</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH Hospice of the West, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ID</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice of Eastern Idaho</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH of Fort Worth, LP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EH of West Texas, LP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EHHI Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Deaconess Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Deaconess Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health Corporation</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of South Florida, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Methodist Rehabilitation Hospital, LP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TN</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Memphis, a partner of Methodist Healthcare</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of North Memphis, a partner of Methodist Healthcare</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Abilene, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Abilene</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Albuquerque, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Albuquerque</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Altamonte Springs, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Altamonte Springs</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Altoona, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Center - Bedford</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Center - Meadowbrook Plaza</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Center - Regency Square</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Center - Tyrone</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Altoona</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Arlington, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Arlington</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Austin, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Austin</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bakersfield, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bakersfield</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bluffton, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bluffton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Braintree, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Braintree</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Braintree at Framingham</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Braintree at Taunton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Braintree Pediatric Center</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cardinal Hill, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Hill Outpatient Services</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Hill Pediatric Services</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Hill Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Hill Skilled Rehabilitation Unit</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Charleston, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MUSC Health Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cincinnati, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cincinnati</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cincinnati at Norwood</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of City View, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of City View</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Colorado Springs, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Colorado Springs</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Columbia, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Columbia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Concord, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Concord</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cypress, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cypress</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dallas, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dallas</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dayton, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Rehabilitation Institute of Ohio, a Joint Venture between Premier Health and Encompass Health</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Desert Canyon, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Desert Canyon</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dothan, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dothan</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of East Valley, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of East Valley</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Erie, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Erie</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Florence, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Florence</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fort Smith, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fort Smith</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Franklin, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Franklin</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fredericksburg, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fredericksburg</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Gadsden, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Gadsden</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Greenville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Greenville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Gulfport, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital, a partner of Memorial Hospital at Gulfport</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Harmarville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Harmarville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Henderson, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Henderson</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Humble, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Humble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Iowa City, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University of Iowa Health Network Rehabilitation Hospital, a venture with Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Jonesboro, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AR</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Jonesboro</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Katy, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Katy</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Kingsport, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Kingsport, a joint venture of Ballad Health and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Lakeview, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Lakeview</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Largo, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Largo</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Las Vegas, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Las Vegas</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Manati, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Manati</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Martin County, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital, an affiliate of Martin Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Mechanicsburg, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Mechanicsburg</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Mechanicsburg Outpatient Clinic</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Miami, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Miami</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Middletown, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Middletown</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Midland Odessa, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Midland Odessa</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Modesto, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Modesto</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Montgomery, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Montgomery</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Murrieta, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Murrieta</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of New England, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of New England</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of New England at Beverly</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of New England at Lowell</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of New England Outpatient Clinic at Billerica</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Nittany Valley, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Nittany Valley</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of North Tampa, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of North Tampa</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Kentucky, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Kentucky</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Virginia, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Virginia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northwest Tucson, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northwest Tucson</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Ocala, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Ocala</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Panama City, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Panama City</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pearland, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pearland</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pensacola, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pensacola</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Petersburg, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Petersburg</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Plano, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Plano</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Reading, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Reading</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Richardson, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Richardson</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Rock Hill, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Rock Hill</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Round Rock, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Round Rock</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Antonio, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Antonio</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Juan, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Juan</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sarasota, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sarasota</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Savannah, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Savannah</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Scottsdale, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Scottsdale</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sewickley, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sewickley</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sewickley at Heritage Valley Kennedy</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shelby County, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shelby County</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shreveport, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shreveport</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sioux Falls, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sioux Falls</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Spring Hill, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Spring Hill</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sugar Land, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sugar Land</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sunrise, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sunrise</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tallahassee, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tallahassee</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Texarkana, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Texarkana</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of the Mid-Cities, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of the Mid-Cities</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of The Woodlands, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of The Woodlands</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toledo, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toledo</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toms River, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toms River</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Treasure Coast, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of  Treasure Coast</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tustin, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tustin</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Utah, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Utah</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Vineland, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Vineland</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Waco, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Waco</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Western Massachusetts, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Western Massachusetts</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Westerville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mount Carmel Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of York, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of York</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital The Vintage, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital The Vintage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital Vision Park, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital Vision Park</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Institute of Tucson, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Institute of Tucson</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health ValleyofTheSun Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Valley of The Sun Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Walton Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walton Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass PAHS Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CO</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Littleton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXCELLA HEALTHCARE, INC.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXCELLA HOME HEALTH AGENCY, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXCELLA HOMECARE, INC.</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MA</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geisinger Encompass Health Limited Liability Company</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geisinger Encompass Health Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guardian Home Care, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ID</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Idaho</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice of Idaho</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hallmark Homecare, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCA Wesley Rehabilitation Hospital, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wesley Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthCare Innovations of Oklahoma, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Southeast Oklahoma</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HEALTHCARE INNOVATIONS OF WESTERN OKLAHOMA, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Western Oklahoma</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthCare Innovations-Travertine Health Services, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Central Oklahoma</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Forsyth County, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cumming</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart of the Rockies Home Health, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart of the Rockies Home Health &#38; Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health Care of Bogalusa, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of the Northshore</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health Care Systems, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Home Health &#38; Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice Care of Mississippi, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice of Southwest Montana, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K.C. Rehabilitation Hospital, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MidAmerica Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kansas Rehabilitation Hospital, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kansas Rehabilitation Hospital, a joint venture of Encompass Health and Stormont Vail Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMC Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NJ</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tinton Falls, a Joint Venture with Monmouth Medical Center</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myrtle Beach Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tidelands Health Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New England Rehabilitation Hospital of Portland, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ME</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New England Rehabilitation Hospital of Portland, a Joint Venture of Maine Medical Center and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New England Rehabilitation Services of Central Massachusetts, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fairlawn Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Northwest Arkansas Rehabilitation Associates</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AR</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital, a partner of Washington Regional</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novant Health Rehabilitation Hospital of Winston-Salem, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novant Health Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orion Homecare, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ID</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health of Western Idaho</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Piedmont Encompass Rehabilitation Hospitals, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Piedmont Healthcare Encompass Health Rehabilitation Hospital of Henry, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Henry</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Piedmont Healthcare Encompass Health Rehabilitation Hospital of Newnan, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Newnan</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Home Health, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quillen Rehabilitation Hospital of Johnson City, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quillen Rehabilitation Hospital, a  joint venture of Ballad Health and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebound, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Lakeshore Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Chattanooga</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Huntington</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Hospital Corporation of America, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Parkersburg</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Princeton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Richmond</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Salisbury</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Bristol, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Bristol, a joint venture of Ballad Health and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Hospital of North Alabama, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of North Alabama</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Phenix City, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rusk Rehabilitation Center, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MO</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rusk Rehabilitation Hospital, an affiliation of Encompass Health and MU Health Care</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saad Healthcare of St. Clair County LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Alphonsus Home Health and Hospice, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Alphonsus Home Health &#38; Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Alphonsus Regional Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ID</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Alphonsus Regional Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sea Pines Rehabilitation Hospital Limited Partnership</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sea Pines Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shannon Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shannon Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Plains Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Plains Rehabilitation Hospital, an affiliate of UMC and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. John Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. John Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. Joseph Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHI St. Joseph Health Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas Senior Care, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TH of San Antonio LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Rehabilitation Institute of St. Louis, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MO</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Rehabilitation Institute of St. Louis, an affiliation of BJC HealthCare and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyler Rehab Associates, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christus Trinity Mother Frances Rehabilitation Hospital, a partner of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UVA Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UVA Encompass Health Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Van Matre Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Van Matre Encompass Health Rehabilitation Institute</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanderbilt Stallworth Rehabilitation Hospital, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TN</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanderbilt Stallworth Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WellCare, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellmark Healthcare Services of El Paso, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Hospice </font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Mississippi Home Health Services, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health - Home Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Tennessee Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Tennessee Healthcare Rehabilitation Hospital Cane Creek, a partnership with Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Tennessee Healthcare Rehabilitation Hospital Jackson, a partnership with Encompass Health</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Virginia Rehabilitation Hospital, Inc.</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WV</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health MountainView at Bridgeport</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Morgantown</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yuma Rehabilitation Hospital, L.L.C.</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AZ</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yuma Rehabilitation Hospital, an affiliation of Encompass Health and Yuma Regional Medical Center</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22.1
<SEQUENCE>3
<FILENAME>ehc10k123121ex221.htm
<DESCRIPTION>EX-22.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia132780173f5473bace87a8d5527b01c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 22.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subsidiary Guarantors and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize Securities of the Registrant</font></div><div><font><br></font></div><div style="text-indent:42.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The entities listed in the table below are either direct or indirect subsidiaries of Encompass Health Corporation, and they each, jointly and severally, guarantee the payment of each series of unsecured senior notes issued by Encompass Health Corporation. There are no other outstanding debt securities of Encompass Health Corporation or its subsidiaries.</font></div><div style="text-indent:42.4pt"><font><br></font></div><div style="text-indent:42.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.320%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #5b9bd5;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subsidiaries of Encompass Health Corporation</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;border-top:1pt solid #5b9bd5;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A&#38;B Home Health Solutions, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Abba Home Health, L.P.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advanced Homecare Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advanced Homecare Management, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Action Home Health, LP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Texas GP, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Texas LP, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Apex Hospice LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Best Home Care LP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of Alabama, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of East Tennessee, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of the Gulf Coast, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Central Mississippi, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of East Louisiana, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Louisiana, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of North Mississippi, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Northeast Alabama LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Northeast Mississippi, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of South Alabama, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Southwest Mississippi, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of the Gulf Coast, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Medical Systems, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareServices of the Treasure Coast, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth Health System, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Columbus, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Dothan, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Gainesville, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Greensboro, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Lexington, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of North Florida, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Panama City, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Richmond, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of South Carolina, LLC</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:42.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.320%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Tallahassee, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of the Bay Area, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Valley, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Virginia, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Washington, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Western Carolina, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Winchester, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth Hospice, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Home Care, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Medical Systems, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Rehabilitation Hospital of Arizona, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CS Health &#38; Wellness, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Day-By-Day Staff Relief, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DOSIK, INC.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DRC Health Systems, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Alabama, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Birmingham, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Central Virginia, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Florida, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Kentucky, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of New England, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Ohio, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of the Northwest, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of the Southwest, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of Alabama, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of Pennsylvania, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of the Midwest, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of the Northwest, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of the Southwest, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Ventures Bozeman, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Ventures Salida, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of Austin, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of Colorado, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of DFW, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of East Texas, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of New England, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of the Mid Atlantic, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of the Midwest, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of the Southeast, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of the West, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Hospice of the West, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH of Fort Worth, LP</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:42.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.320%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH of West Texas, LP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EHHI Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Acquisition Holdings Subsidiary, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Acquisition Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Alabama Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Arizona Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Arkansas Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Boise Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Bryan Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health C Corp Sub Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health California Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Central Arkansas Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Charleston Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Colorado Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Dayton Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Deaconess Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Fairlawn Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health GKBJH Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Gulfport Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health Corporation</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Iowa City Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Iowa Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Johnson City Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Joint Ventures Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Jonesboro Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Kansas Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Kentucky Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Kingsport Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Littleton Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Louisiana Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Lubbock Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Martin County Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Maryland Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Massachusetts Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Midland Odessa Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Myrtle Beach Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Nevada Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health New Mexico Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Ohio Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Owned Hospitals Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Pennsylvania Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Properties, LLC</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:42.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.320%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Abilene, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Albuquerque, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Altamonte Springs, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Arlington, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Austin, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bakersfield, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bluffton, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Braintree, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cardinal Hill, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cincinnati, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of City View, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Colorado Springs, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Columbia, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Concord, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cypress, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dallas, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Desert Canyon, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dothan, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of East Valley, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Erie, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Florence, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fort Smith, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Franklin, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fredericksburg, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Gadsden, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Greenville, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Harmarville, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Henderson, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Humble, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Katy, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Lakeview, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Largo, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Las Vegas, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Littleton, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Manati, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Mechanicsburg, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Miami, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Middletown, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Modesto, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Montgomery, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Murrieta, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of New England, LLC</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:42.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.320%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Nittany Valley, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of North Tampa, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Kentucky, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Virginia, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northwest Tucson, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Ocala, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Panama City, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pearland, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pensacola, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Petersburg, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Plano, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Reading, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Richardson, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Round Rock, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Antonio, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Juan, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sarasota, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Scottsdale, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shelby County, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shreveport, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sioux Falls, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Spring Hill, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sugar Land, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sunrise, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tallahassee, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Texarkana, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of the Mid-Cities, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of The Woodlands, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toledo, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toms River, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Treasure Coast, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tustin, L.P.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Utah, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Vineland, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Waco, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Western Massachusetts, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of York, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital The Vintage, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital Vision Park, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Institute of Tucson, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health San Angelo Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Savannah Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Sea Pines Holdings, LLC</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:42.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.320%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Sewickley Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health South Carolina Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health South Dakota Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Support Companies, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Texas Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tucson Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tulsa Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tyler Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Utah Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health ValleyofTheSun Rehabilitation Hospital, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Virginia Real Estate, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Walton Rehabilitation Hospital, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health West Tennessee Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health West Virginia Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Westerville Holdings, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Winston-Salem Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Yuma Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA ASSOCIATES, L.L.C.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HEALTHCARE, INC.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HOME HEALTH AGENCY, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HOMECARE, INC.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Guardian Home Care, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hallmark Homecare, L.P.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthCare Innovations of Oklahoma, L.L.C.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HEALTHCARE INNOVATIONS OF WESTERN OKLAHOMA, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthCare Innovations-Travertine Health Services, L.L.C.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Austin, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Forsyth County, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Fort Worth, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Home Health Care of Bogalusa, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Home Health Care Systems, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hospice Care of Mississippi, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Idaho Homecare Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Orion Homecare, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preferred Home Health, L.P.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Promotions Group, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rebound, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital Corporation of America, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital of North Alabama, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Plano, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reliant Blocker Corp.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Saad Healthcare of St. Clair County LLC</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:42.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.320%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Texas Senior Care, L.P.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TH of San Antonio LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WellCare, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wellmark Healthcare Services of El Paso, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">West Mississippi Home Health Services, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ddebf7;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#2f75b5;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Western Neuro Care, Inc.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ehc10k123121ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaa8ff640fa58401bbec9eb7406ce309b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-157445, 333-175981, and 333-212840) and Form S-3 (No. 333-248942) of Encompass Health Corporation of our report dated February&#160;25, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10&#8209;K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Birmingham, Alabama</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ehc10k123121ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib1adcc5dd48448c79fe86b699a3b539f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark J. Tarr, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Encompass Health Corporation&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;25, 2022 </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160; Mark J. Tarr</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160; President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ehc10k123121ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibe7be369da774997899ca6c04d7a2021_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Douglas E. Coltharp, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Encompass Health Corporation&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;25, 2022 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160; Douglas E. Coltharp</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160; Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ehc10k123121ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie38f644aa76d4e3483329f8f992dac9f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATE OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Encompass Health Corporation on Form 10-K for the period ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mark J. Tarr, President and Chief Executive Officer of Encompass Health Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the &#8220;2002 Act&#8221;), that to the best of my knowledge and belief&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Encompass Health Corporation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;25, 2022 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160; Mark J. Tarr</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement has been provided to Encompass Health Corporation and will be retained by Encompass Health Corporation and furnished to the Securities and Exchange Commission or its staff upon request.  This written statement shall not, except to the extent required by the 2002 Act, be deemed filed by Encompass Health Corporation for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Encompass Health Corporation specifically incorporates it by reference.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ehc10k123121ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie6ceee6c74f1442e8985aa3533dfb3ce_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATE OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Encompass Health Corporation on Form 10-K for the period ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Douglas E. Coltharp, Executive Vice President and Chief Financial Officer of Encompass Health Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the &#8220;2002 Act&#8221;), that to the best of my knowledge and belief&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Encompass Health Corporation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2022 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160; Douglas E. Coltharp</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160; Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement has been provided to Encompass Health Corporation and will be retained by Encompass Health Corporation and furnished to the Securities and Exchange Commission or its staff upon request.  This written statement shall not, except to the extent required by the 2002 Act, be deemed filed by Encompass Health Corporation for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Encompass Health Corporation specifically incorporates it by reference.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ehc-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fa73796-4641-417c-869a-a8efa97ec0d7,g:d7a996dc-3cad-46ef-bbb1-393716adc0de-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ehc="http://www.encompasshealth.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.encompasshealth.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.encompasshealth.com/role/CoverPage">
        <link:definition>000010001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.encompasshealth.com/role/AuditInformation">
        <link:definition>000020002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>100010003 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome_1" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1">
        <link:definition>100010003 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets">
        <link:definition>100020004 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030005 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>100040006 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>100050007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>100060008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>210011001 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>220022001 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>230033001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTextualDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails">
        <link:definition>240044001 - Disclosure - Summary of Significant Accounting Policies - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails">
        <link:definition>240054002 - Disclosure - Summary of Significant Accounting Policies - Net Operating Revenues &amp; Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails">
        <link:definition>240064003 - Disclosure - Summary of Significant Accounting Policies - PP&amp;E Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails">
        <link:definition>240074004 - Disclosure - Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.encompasshealth.com/role/BusinessCombinations">
        <link:definition>210081002 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables">
        <link:definition>230093002 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTextualDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails">
        <link:definition>240104005 - Disclosure - Business Combinations - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails">
        <link:definition>240114006 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNetCashPaidforAcquisitionDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails">
        <link:definition>240124007 - Disclosure - Business Combinations - Net Cash Paid for Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsProFormaResultsofOperationDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails">
        <link:definition>240134008 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.encompasshealth.com/role/VariableInterestEntities">
        <link:definition>210141003 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTables" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables">
        <link:definition>230153003 - Disclosure - Variable Interest Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTextualsDetails" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails">
        <link:definition>240164009 - Disclosure - Variable Interest Entities - Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails">
        <link:definition>240174010 - Disclosure - Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecurities" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecurities">
        <link:definition>210181004 - Disclosure - Cash and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesTables" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables">
        <link:definition>230193004 - Disclosure - Cash and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesComponentsofInvestmentsDetails" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails">
        <link:definition>240204011 - Disclosure - Cash and Marketable Securities - Components of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesRestrictedCashDetails" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails">
        <link:definition>240214012 - Disclosure - Cash and Marketable Securities - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesTextualDetails" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails">
        <link:definition>240224013 - Disclosure - Cash and Marketable Securities - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails">
        <link:definition>240234014 - Disclosure - Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivable" roleURI="http://www.encompasshealth.com/role/AccountsReceivable">
        <link:definition>210241005 - Disclosure - Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableTables" roleURI="http://www.encompasshealth.com/role/AccountsReceivableTables">
        <link:definition>230253005 - Disclosure - Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableComponentsofAccountsReceivableDetails" roleURI="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails">
        <link:definition>240264015 - Disclosure - Accounts Receivable - Components of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.encompasshealth.com/role/PropertyandEquipment">
        <link:definition>210271006 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentTables">
        <link:definition>230283006 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentComponentsofPropertyandEquipmentDetails" roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails">
        <link:definition>240294016 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTextualDetails" roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails">
        <link:definition>240304017 - Disclosure - Property and Equipment - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails" roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails">
        <link:definition>240314018 - Disclosure - Property and Equipment - Depreciation, Capitalized Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.encompasshealth.com/role/Leases">
        <link:definition>210321007 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.encompasshealth.com/role/LeasesTables">
        <link:definition>230333007 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTextualsDetails" roleURI="http://www.encompasshealth.com/role/LeasesTextualsDetails">
        <link:definition>240344019 - Disclosure - Leases - Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseCostsDetails" roleURI="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails">
        <link:definition>240354020 - Disclosure - Leases - Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" roleURI="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails">
        <link:definition>240364021 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" roleURI="http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails">
        <link:definition>240374022 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>240384023 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>240384023 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>240394024 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>210401008 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>230413008 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails">
        <link:definition>240424025 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTextualsDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails">
        <link:definition>240434026 - Disclosure - Goodwill and Other Intangible Assets - Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails">
        <link:definition>240444027 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>240454028 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails">
        <link:definition>240464029 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinandAdvancestoNonconsolidatedAffiliates" roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliates">
        <link:definition>210471009 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables" roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables">
        <link:definition>230483009 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails" roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails">
        <link:definition>240494030 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails" roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails">
        <link:definition>240504031 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Schedule of Other Long-term Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails" roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails">
        <link:definition>240514032 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Combined Assets, Liabilities and Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.encompasshealth.com/role/LongtermDebt">
        <link:definition>210521010 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.encompasshealth.com/role/LongtermDebtTables">
        <link:definition>230533010 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtLongtermDebtOutstandingDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails">
        <link:definition>240544033 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtLongtermDebtOutstandingDetails_1" roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1">
        <link:definition>240544033 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails">
        <link:definition>240554034 - Disclosure - Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtFinancialCovenantsDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails">
        <link:definition>240564035 - Disclosure - Long-term Debt - Financial Covenants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTextualDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails">
        <link:definition>240574036 - Disclosure - Long-term Debt - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtSeniorNotesRedemptionPricesDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails">
        <link:definition>240584037 - Disclosure - Long-term Debt - Senior Notes Redemption Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtScheduleofNotesPayableDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails">
        <link:definition>240594038 - Disclosure - Long-term Debt - Schedule of Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelfInsuredRisks" roleURI="http://www.encompasshealth.com/role/SelfInsuredRisks">
        <link:definition>210601011 - Disclosure - Self-Insured Risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelfInsuredRisksTables" roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksTables">
        <link:definition>230613011 - Disclosure - Self-Insured Risks (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelfInsuredRisksTextualDetails" roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails">
        <link:definition>240624039 - Disclosure - Self-Insured Risks - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelfInsuredRisksChangesinSelfinsuranceReservesDetails" roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails">
        <link:definition>240634040 - Disclosure - Self-Insured Risks - Changes in Self-insurance Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterests" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests">
        <link:definition>210641012 - Disclosure - Redeemable Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsTables" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables">
        <link:definition>230653012 - Disclosure - Redeemable Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails">
        <link:definition>240664041 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails">
        <link:definition>240674042 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsTextualDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails">
        <link:definition>240684043 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.encompasshealth.com/role/FairValueMeasurements">
        <link:definition>210691013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables">
        <link:definition>230703013 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>240714044 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTextualDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails">
        <link:definition>240724045 - Disclosure - Fair Value Measurements - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails">
        <link:definition>240734046 - Disclosure - Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.encompasshealth.com/role/ShareBasedPayments">
        <link:definition>210741014 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTables">
        <link:definition>230753014 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTextualDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails">
        <link:definition>240764047 - Disclosure - Share-Based Payments - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsWeightedaverageAssumptionsDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails">
        <link:definition>240774048 - Disclosure - Share-Based Payments - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsStockOptionActivityDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails">
        <link:definition>240784049 - Disclosure - Share-Based Payments - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails">
        <link:definition>240794050 - Disclosure - Share-Based Payments - Summary of Restricted Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlans">
        <link:definition>210801015 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTextualDetails" roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails">
        <link:definition>240814051 - Disclosure - Employee Benefit Plans - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.encompasshealth.com/role/IncomeTaxes">
        <link:definition>210821016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.encompasshealth.com/role/IncomeTaxesTables">
        <link:definition>230833015 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails">
        <link:definition>240844052 - Disclosure - Income Taxes - Components of Provision for Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails">
        <link:definition>240854053 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails">
        <link:definition>240864054 - Disclosure - Income Taxes - Deferred Tax Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTextualDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails">
        <link:definition>240874055 - Disclosure - Income Taxes - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShare" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare">
        <link:definition>210881017 - Disclosure - Earnings per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareTables" roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTables">
        <link:definition>230893016 - Disclosure - Earnings Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails">
        <link:definition>240904056 - Disclosure - Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails">
        <link:definition>240914057 - Disclosure - Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareTextualDetails" roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails">
        <link:definition>240924058 - Disclosure - Earnings Per Common Share - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherCommitments" roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments">
        <link:definition>210931018 - Disclosure - Contingencies and Other Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherCommitmentsTextualDetails" roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails">
        <link:definition>240944059 - Disclosure - Contingencies and Other Commitments - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.encompasshealth.com/role/SegmentReporting">
        <link:definition>210951019 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.encompasshealth.com/role/SegmentReportingTables">
        <link:definition>230963017 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTextualsDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualsDetails">
        <link:definition>240974060 - Disclosure - Segment Reporting - Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails">
        <link:definition>240984061 - Disclosure - Segment Reporting - Selected Financial Information of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails">
        <link:definition>240994062 - Disclosure - Segment Reporting - Reconciliation of Segment Assets and Investments to Consolidated Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofAdjustedEBITDADetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails">
        <link:definition>241004063 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails">
        <link:definition>241014064 - Disclosure - Segment Reporting - Revenues of Operating Segments by Service Line (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ehc_AlacareMember" abstract="true" name="AlacareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RACAuditsMember" abstract="true" name="RACAuditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NoncontrollingInterestOtherAdjustment" abstract="false" name="NoncontrollingInterestOtherAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_EncompassHomeHealthSavingsPlanHHSPMember" abstract="true" name="EncompassHomeHealthSavingsPlanHHSPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_AdjustedEBITDA" abstract="false" name="AdjustedEBITDA" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" abstract="false" name="NumberOfInpatientRehabilitationUnitsUnderManagementContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_NotesPayableSoftwareContractsMember" abstract="true" name="NotesPayableSoftwareContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" abstract="true" name="CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_MaximumSelfInsuredAmountThirdLayerRisk" abstract="false" name="MaximumSelfInsuredAmountThirdLayerRisk" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SaintAlphonsusandHeritageValleyMember" abstract="true" name="SaintAlphonsusandHeritageValleyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SeniorManagementBonusProgramTotalCosts" abstract="false" name="SeniorManagementBonusProgramTotalCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_InternalUseSoftwareMember" abstract="true" name="InternalUseSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_HeartOfTheRockiesHomeHealthMember" abstract="true" name="HeartOfTheRockiesHomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_MarketAccessAssetsMember" abstract="false" name="MarketAccessAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" abstract="false" name="NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberOfInpatientRehabilitationHospitals" abstract="false" name="NumberOfInpatientRehabilitationHospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_TradeNameEncompassMember" abstract="true" name="TradeNameEncompassMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_OutpatientandotherMember" abstract="true" name="OutpatientandotherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_BaptistOutpatientServicesIncMember" abstract="true" name="BaptistOutpatientServicesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RetirementInvestmentPlanAgeRequirement" abstract="false" name="RetirementInvestmentPlanAgeRequirement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantLeverageRatio" abstract="false" name="DebtInstrumentCovenantLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" abstract="false" name="DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Totalfinanceleasecost" abstract="false" name="Totalfinanceleasecost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Shorttermandvariableleasecost" abstract="false" name="Shorttermandvariableleasecost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_PremierHealthPartnersMember" abstract="true" name="PremierHealthPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_HealthcarePlanExpense" abstract="false" name="HealthcarePlanExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated" abstract="false" name="NumberOfPartiallyOwnedSubsidiariesNonconsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_Operatingandfinanceleasecontractterm" abstract="false" name="Operatingandfinanceleasecontractterm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ehc_RestrictedDebtSecuritiesNoncurrent" abstract="false" name="RestrictedDebtSecuritiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" abstract="false" name="NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_SARsmarktomarketimpactonnoncontrollinginterests" abstract="false" name="SARsmarktomarketimpactonnoncontrollinginterests" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NoncontrollingInterestExchangeTransaction" abstract="false" name="NoncontrollingInterestExchangeTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ManagedCareMember" abstract="true" name="ManagedCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" abstract="true" name="ManagedCareMedicareAdvantageandOtherDiscountPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SaintAlphonsusMember" abstract="true" name="SaintAlphonsusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_VariableInterestEntityNumberofEntitiesConsolidated" abstract="false" name="VariableInterestEntityNumberofEntitiesConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_WorkersCompensationMember" abstract="true" name="WorkersCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" abstract="false" name="LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_PayrolltaxesonSARsexercise" abstract="false" name="PayrolltaxesonSARsexercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" abstract="false" name="SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_AffiliatesOwnershipPercentage" abstract="false" name="AffiliatesOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_TidewaterandCareResourceGroupMember" abstract="true" name="TidewaterandCareResourceGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_OccupancyCost" abstract="false" name="OccupancyCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_InpatientMember" abstract="true" name="InpatientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ScheduleOfFinancialCovenantsTableTextBlock" abstract="false" name="ScheduleOfFinancialCovenantsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_Reclassificationtononcontrollinginterests" abstract="false" name="Reclassificationtononcontrollinginterests" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DividendEquivalentRSUMember" abstract="true" name="DividendEquivalentRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_OtherIncomeSourceMember" abstract="true" name="OtherIncomeSourceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NonemployeeDirectorsMember" abstract="true" name="NonemployeeDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" abstract="false" name="EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NetAmountMember" abstract="false" name="NetAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NumberofBedsAcquired" abstract="false" name="NumberofBedsAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" abstract="false" name="RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" abstract="false" name="ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" abstract="false" name="LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_A2021AcquisitionsMember" abstract="true" name="A2021AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SeniorNotes05.125Due2023Member" abstract="true" name="SeniorNotes05.125Due2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Numberofhomehealthlocations" abstract="false" name="Numberofhomehealthlocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_SeniorNotes04.750Due2030Member" abstract="true" name="SeniorNotes04.750Due2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_A2016OmnibusPerformanceIncentivePlanMember" abstract="true" name="A2016OmnibusPerformanceIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_HomehealthMember" abstract="true" name="HomehealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" abstract="false" name="RetirementInvestmentPlanCompanyMatchVestingPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" abstract="false" name="RetirementInvestmentPlanCompanyMatchVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ehc_Totaloperatingandfinanceleaseassets" abstract="false" name="Totaloperatingandfinanceleaseassets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_InpatientRehabilitationSegmentMember" abstract="true" name="InpatientRehabilitationSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" abstract="false" name="ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_FaceAmountMember" abstract="false" name="FaceAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_PatientsMember" abstract="true" name="PatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" abstract="true" name="NotesPayableLIBORplus2.5ConstructionFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_FrontierHomeHealthAndHospiceMember" abstract="true" name="FrontierHomeHealthAndHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentIssuePricePercentage" abstract="false" name="DebtInstrumentIssuePricePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_PortercareAdventistMember" abstract="true" name="PortercareAdventistMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Totalleaseliabilities" abstract="false" name="Totalleaseliabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" abstract="false" name="TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_NumberofLocationsofanAcquiredEntity" abstract="false" name="NumberofLocationsofanAcquiredEntity" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_EmploymentBasedSARSMember" abstract="true" name="EmploymentBasedSARSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" abstract="false" name="SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" abstract="false" name="FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_GenerationSolutionsOfLynchburgMember" abstract="true" name="GenerationSolutionsOfLynchburgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_TheCreditAgreementMember" abstract="true" name="TheCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" abstract="false" name="GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_JupiterFloridaHomeHealthAgencyMember" abstract="true" name="JupiterFloridaHomeHealthAgencyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_HomeHealthandHospiceSegmentMember" abstract="true" name="HomeHealthandHospiceSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" abstract="true" name="ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_TermLoanFacilitiesMember" abstract="true" name="TermLoanFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NumberofBedsExpanded" abstract="false" name="NumberofBedsExpanded" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" abstract="false" name="MaximumSelfInsuredAmountFirstLayerOfRisk" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SupplementalCashFlowInformationTableTextBlock" abstract="false" name="SupplementalCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" abstract="false" name="NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_AllocatedSharebasedCompensationLiability" abstract="false" name="AllocatedSharebasedCompensationLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" abstract="true" name="StatementOfComprehensiveIncomeAndIncomeStatementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" abstract="true" name="RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_Numberofjointlyownedinpatientrehabilitationhospitals" abstract="false" name="Numberofjointlyownedinpatientrehabilitationhospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ECHDVenturesMember" abstract="true" name="ECHDVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Jointventureownershippercentage" abstract="false" name="Jointventureownershippercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_CareResourceGroupMember" abstract="true" name="CareResourceGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" abstract="false" name="RedeemableNoncontrollingInterestEquityAcquiredPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_PortercareAdventistAndPremierHealthPartnersMember" abstract="true" name="PortercareAdventistAndPremierHealthPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_A2020AcquisitionsMember" abstract="true" name="A2020AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_EHHIMember" abstract="true" name="EHHIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_OtherThirdpartyPayorsMember" abstract="true" name="OtherThirdpartyPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NumberofDeNovoBeds" abstract="false" name="NumberofDeNovoBeds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_EncompassHealthRetirementInvestmentPlanMember" abstract="true" name="EncompassHealthRetirementInvestmentPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_HospiceOfSouthwestMontanaMember" abstract="true" name="HospiceOfSouthwestMontanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability" abstract="false" name="SelfInsuredRiskThresholdGeneralAndProfessionalLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" abstract="false" name="RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_HeritageValleyMember" abstract="true" name="HeritageValleyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" abstract="false" name="ReconciliationOfNoncontrollingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_SeniorNotes4.50Due2028Member" abstract="true" name="SeniorNotes4.50Due2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" abstract="false" name="IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_CostofServicesExcludingDepreciationandAmortization" abstract="false" name="CostofServicesExcludingDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" abstract="false" name="DebtInstrumentDiscountRateAtIssuanceOfFaceValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_Contributiontojointventure" abstract="false" name="Contributiontojointventure" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberOfQualifiedPlans" abstract="false" name="NumberOfQualifiedPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_EquityMethodInvestmentAdditionalOwnershipPercentage" abstract="false" name="EquityMethodInvestmentAdditionalOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_PerformanceandEmploymentBasedSARSMember" abstract="true" name="PerformanceandEmploymentBasedSARSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Percentageofassetspledgedtolendersundercreditagreement" abstract="false" name="Percentageofassetspledgedtolendersundercreditagreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_HoldingsAndEHHIMember" abstract="true" name="HoldingsAndEHHIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_YumaRehabilitationHospitalMember" abstract="true" name="YumaRehabilitationHospitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_CreditAgreementRestriction" abstract="false" name="CreditAgreementRestriction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SeniorNotes04625Due2031Member" abstract="true" name="SeniorNotes04625Due2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NumberofBedsContributed" abstract="false" name="NumberofBedsContributed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_SeniorNotes05.75Due2025Member" abstract="true" name="SeniorNotes05.75Due2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" abstract="false" name="Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" abstract="false" name="IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" abstract="false" name="ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_BusinessCombinationNoncontrollingInterestFairValue" abstract="false" name="BusinessCombinationNoncontrollingInterestFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" abstract="false" name="LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" abstract="true" name="LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_CertificateOfNeedMember" abstract="false" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantInterestCoverageRatio" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" abstract="false" name="Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" abstract="true" name="RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_SelfInsuredCaptiveFundsMember" abstract="false" name="SelfInsuredCaptiveFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_OtherHomeHealthAndHospiceAcquisitionsMember" abstract="true" name="OtherHomeHealthAndHospiceAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Numberofsolelyownedinpatientrehabilitationhospitals" abstract="false" name="Numberofsolelyownedinpatientrehabilitationhospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_InvestmentsCashandRestrictedCash" abstract="false" name="InvestmentsCashandRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SeniorNotes0575Due2024Member" abstract="true" name="SeniorNotes0575Due2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestMember" abstract="true" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" abstract="true" name="NotesPayableRealEstateSaleLeasebackFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" abstract="false" name="DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" abstract="false" name="DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Numberofhospicelocations" abstract="false" name="Numberofhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_A2019AcquisitionsMember" abstract="true" name="A2019AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_PayorSourceMember" abstract="true" name="PayorSourceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ShannonMedicalMember" abstract="true" name="ShannonMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" abstract="false" name="DebtInstrumentAmendmentAgreementAmountToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_AffiliateCashMember" abstract="false" name="AffiliateCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" abstract="false" name="NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" abstract="false" name="EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NicholsLitigationMember" abstract="true" name="NicholsLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NetIncomeLossAvailabletoCommonStockholders" abstract="false" name="NetIncomeLossAvailabletoCommonStockholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>ehc-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fa73796-4641-417c-869a-a8efa97ec0d7,g:d7a996dc-3cad-46ef-bbb1-393716adc0de-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8589eee0-f186-46ed-a854-3b9558ff2436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0d469b99-53e7-42e6-a9df-f207fdb1d84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8589eee0-f186-46ed-a854-3b9558ff2436" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0d469b99-53e7-42e6-a9df-f207fdb1d84c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f4bb1d14-5f8c-42f8-aec4-7fb4369c30ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8589eee0-f186-46ed-a854-3b9558ff2436" xlink:to="loc_us-gaap_ProfitLoss_f4bb1d14-5f8c-42f8-aec4-7fb4369c30ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e7d052e7-4382-4fb0-9804-43c0c916c1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_99cbc599-104c-461d-b110-bd79d9e639d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_e7d052e7-4382-4fb0-9804-43c0c916c1ad" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_99cbc599-104c-461d-b110-bd79d9e639d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_268be67e-df1f-4481-afea-d8e8da22f557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_e7d052e7-4382-4fb0-9804-43c0c916c1ad" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_268be67e-df1f-4481-afea-d8e8da22f557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4fbacbc6-2911-4cf7-a055-bbc83dd30d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ed91b5c9-b7f7-4877-9b2a-225fb45b58da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_4fbacbc6-2911-4cf7-a055-bbc83dd30d80" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ed91b5c9-b7f7-4877-9b2a-225fb45b58da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e89c6a92-d88e-4f3d-991b-75626edc287e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_4fbacbc6-2911-4cf7-a055-bbc83dd30d80" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e89c6a92-d88e-4f3d-991b-75626edc287e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba5484c6-58bb-460c-8650-9aca12c9ac0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3f4e97b5-c453-4f6c-bd0e-1beeb2968fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba5484c6-58bb-460c-8650-9aca12c9ac0f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3f4e97b5-c453-4f6c-bd0e-1beeb2968fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2addb59b-e8db-428b-90f6-2e8228132e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba5484c6-58bb-460c-8650-9aca12c9ac0f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2addb59b-e8db-428b-90f6-2e8228132e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f5e4d291-d2c3-49db-8d1c-9e24c2ba2795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f285a0db-b962-432d-9b3d-0544dd756a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f5e4d291-d2c3-49db-8d1c-9e24c2ba2795" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f285a0db-b962-432d-9b3d-0544dd756a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1ff988b0-7286-45d8-a489-c6c261ffaa90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f5e4d291-d2c3-49db-8d1c-9e24c2ba2795" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1ff988b0-7286-45d8-a489-c6c261ffaa90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4b4ebe4d-513e-4a0a-8a5d-bd493f9a2eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_f504cecd-a504-4c53-a70f-fa5f3d4d954a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4b4ebe4d-513e-4a0a-8a5d-bd493f9a2eaa" xlink:to="loc_us-gaap_LaborAndRelatedExpense_f504cecd-a504-4c53-a70f-fa5f3d4d954a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_42dd389a-8710-4184-9c75-e79eec0844d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4b4ebe4d-513e-4a0a-8a5d-bd493f9a2eaa" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_42dd389a-8710-4184-9c75-e79eec0844d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_024e2080-7865-44f9-8de7-8657bdd681f0" xlink:href="ehc-20211231.xsd#ehc_OccupancyCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4b4ebe4d-513e-4a0a-8a5d-bd493f9a2eaa" xlink:to="loc_ehc_OccupancyCost_024e2080-7865-44f9-8de7-8657bdd681f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_57bf2828-e2ee-43ca-9f11-44e7904bd73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4b4ebe4d-513e-4a0a-8a5d-bd493f9a2eaa" xlink:to="loc_us-gaap_SuppliesExpense_57bf2828-e2ee-43ca-9f11-44e7904bd73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_32d10c07-8a2d-4b75-8171-118e84a9bc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4b4ebe4d-513e-4a0a-8a5d-bd493f9a2eaa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_32d10c07-8a2d-4b75-8171-118e84a9bc62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b6eeaee2-274b-4c9b-9ba3-19f360d2f298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4b4ebe4d-513e-4a0a-8a5d-bd493f9a2eaa" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b6eeaee2-274b-4c9b-9ba3-19f360d2f298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_392f514d-5d8c-4e0a-a485-722864aeaef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4b4ebe4d-513e-4a0a-8a5d-bd493f9a2eaa" xlink:to="loc_us-gaap_LitigationSettlementExpense_392f514d-5d8c-4e0a-a485-722864aeaef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e826aed9-ef2a-4921-b73e-86eece2f0305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16a4a0f3-76b6-4217-85ea-253378346ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e826aed9-ef2a-4921-b73e-86eece2f0305" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16a4a0f3-76b6-4217-85ea-253378346ef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5b895e2f-da1f-4581-984a-74c1a932c971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e826aed9-ef2a-4921-b73e-86eece2f0305" xlink:to="loc_us-gaap_CostsAndExpenses_5b895e2f-da1f-4581-984a-74c1a932c971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_303c9a5e-9eaa-4888-bada-e19cc9a53c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e826aed9-ef2a-4921-b73e-86eece2f0305" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_303c9a5e-9eaa-4888-bada-e19cc9a53c2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_be082711-03fd-41f5-9d7c-1c43d371b790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e826aed9-ef2a-4921-b73e-86eece2f0305" xlink:to="loc_us-gaap_InterestExpense_be082711-03fd-41f5-9d7c-1c43d371b790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_13daf595-1b25-4746-8a8a-33e5fe13b105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e826aed9-ef2a-4921-b73e-86eece2f0305" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_13daf595-1b25-4746-8a8a-33e5fe13b105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b42bd628-6002-4a58-99bb-4b19c96ddb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e826aed9-ef2a-4921-b73e-86eece2f0305" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b42bd628-6002-4a58-99bb-4b19c96ddb27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_85e89450-f3fa-4694-990f-5e3387b87711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e8db786c-edbe-48ff-a003-78498e03b3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_85e89450-f3fa-4694-990f-5e3387b87711" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e8db786c-edbe-48ff-a003-78498e03b3e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_bbbc5f3b-9343-4489-8612-c8fce16f0a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_85e89450-f3fa-4694-990f-5e3387b87711" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_bbbc5f3b-9343-4489-8612-c8fce16f0a9d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome_1"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c4c0039-3efb-4cc2-b3eb-18f8ae8ec789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_5a5e9b17-d8c8-43d9-945f-6c1aa18509cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5c4c0039-3efb-4cc2-b3eb-18f8ae8ec789" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_5a5e9b17-d8c8-43d9-945f-6c1aa18509cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_487ea273-1706-4b82-9038-c28a2402602c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5c4c0039-3efb-4cc2-b3eb-18f8ae8ec789" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_487ea273-1706-4b82-9038-c28a2402602c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_304742b1-7a96-4766-97ac-e104c2c3deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1827d738-1332-41ad-8e04-7d0457c9c111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_304742b1-7a96-4766-97ac-e104c2c3deb4" xlink:to="loc_us-gaap_Liabilities_1827d738-1332-41ad-8e04-7d0457c9c111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ab04a98e-2f45-4090-8ec0-11df1ddbd231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_304742b1-7a96-4766-97ac-e104c2c3deb4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ab04a98e-2f45-4090-8ec0-11df1ddbd231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_5fd26628-f3c5-4bdc-b109-13f6a12022bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_304742b1-7a96-4766-97ac-e104c2c3deb4" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_5fd26628-f3c5-4bdc-b109-13f6a12022bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4f607563-9d89-45b8-bbc5-c238b3e03286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_304742b1-7a96-4766-97ac-e104c2c3deb4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4f607563-9d89-45b8-bbc5-c238b3e03286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_118c2512-522d-4fe0-915b-dd0c48e7306e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20b881a5-6438-4890-b56f-22aaecffcc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_118c2512-522d-4fe0-915b-dd0c48e7306e" xlink:to="loc_us-gaap_StockholdersEquity_20b881a5-6438-4890-b56f-22aaecffcc8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e7689109-1f27-4892-ad37-a3f7ae6e3ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_118c2512-522d-4fe0-915b-dd0c48e7306e" xlink:to="loc_us-gaap_MinorityInterest_e7689109-1f27-4892-ad37-a3f7ae6e3ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd2d71fc-c784-4eb2-901b-dd8c57fa9585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3206ad72-959c-42b7-b9bd-c1c9bcafbb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd2d71fc-c784-4eb2-901b-dd8c57fa9585" xlink:to="loc_us-gaap_CommonStockValue_3206ad72-959c-42b7-b9bd-c1c9bcafbb94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_13d9ae89-020d-4b0b-91a9-f82394efd33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd2d71fc-c784-4eb2-901b-dd8c57fa9585" xlink:to="loc_us-gaap_AdditionalPaidInCapital_13d9ae89-020d-4b0b-91a9-f82394efd33e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12c03478-ebf9-4a5c-ba8a-e002c33c968a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd2d71fc-c784-4eb2-901b-dd8c57fa9585" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12c03478-ebf9-4a5c-ba8a-e002c33c968a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d202aa8a-f195-4bc3-bcc0-8fa21e74cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd2d71fc-c784-4eb2-901b-dd8c57fa9585" xlink:to="loc_us-gaap_TreasuryStockValue_d202aa8a-f195-4bc3-bcc0-8fa21e74cc35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3f7fb4b1-e3a7-4778-9a27-01a0b043ad8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_91be1422-fab8-43b3-a6b9-d7ec9a7a0d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f7fb4b1-e3a7-4778-9a27-01a0b043ad8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_91be1422-fab8-43b3-a6b9-d7ec9a7a0d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ee2c28f-968c-4a1f-811c-9e788d9269a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f7fb4b1-e3a7-4778-9a27-01a0b043ad8f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ee2c28f-968c-4a1f-811c-9e788d9269a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3dd3642e-1198-4aef-8971-a9c092b2c7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f7fb4b1-e3a7-4778-9a27-01a0b043ad8f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3dd3642e-1198-4aef-8971-a9c092b2c7a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_15a0b68c-73cd-41f2-9b12-31062954ffd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f7fb4b1-e3a7-4778-9a27-01a0b043ad8f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_15a0b68c-73cd-41f2-9b12-31062954ffd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f6df6756-b09d-42c8-92d8-489416fb6de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f7fb4b1-e3a7-4778-9a27-01a0b043ad8f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f6df6756-b09d-42c8-92d8-489416fb6de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6e08d0a2-2381-405e-a8a0-219a8a5909b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f7fb4b1-e3a7-4778-9a27-01a0b043ad8f" xlink:to="loc_us-gaap_Goodwill_6e08d0a2-2381-405e-a8a0-219a8a5909b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7137581d-5191-45d9-bef3-7ff41f7d773a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3f7fb4b1-e3a7-4778-9a27-01a0b043ad8f" xlink:to="loc_us-gaap_AssetsCurrent_7137581d-5191-45d9-bef3-7ff41f7d773a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b219f56c-8eea-48e6-b0b9-44734a21c11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f23eadc1-88f6-4bd2-a441-821fd30e93c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b219f56c-8eea-48e6-b0b9-44734a21c11d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f23eadc1-88f6-4bd2-a441-821fd30e93c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f700ef81-fbd9-499f-aded-4ab1f4df5661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b219f56c-8eea-48e6-b0b9-44734a21c11d" xlink:to="loc_us-gaap_RestrictedCashCurrent_f700ef81-fbd9-499f-aded-4ab1f4df5661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_acdcad2d-308e-4152-a4aa-0ccfab48b020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b219f56c-8eea-48e6-b0b9-44734a21c11d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_acdcad2d-308e-4152-a4aa-0ccfab48b020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_43c3ffb6-e3bb-46be-abac-21cb0bcbcf11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b219f56c-8eea-48e6-b0b9-44734a21c11d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_43c3ffb6-e3bb-46be-abac-21cb0bcbcf11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f2e79c0d-6b27-4c94-a23d-047196cbc66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7cb5bc1f-b011-4e2b-964f-abdbeb6ab462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2e79c0d-6b27-4c94-a23d-047196cbc66b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7cb5bc1f-b011-4e2b-964f-abdbeb6ab462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4e31dbb5-94d2-4004-b711-1ea72b2971cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2e79c0d-6b27-4c94-a23d-047196cbc66b" xlink:to="loc_us-gaap_AccountsPayableCurrent_4e31dbb5-94d2-4004-b711-1ea72b2971cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8fd3f742-7de5-4d4a-bb89-af80a489a802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2e79c0d-6b27-4c94-a23d-047196cbc66b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8fd3f742-7de5-4d4a-bb89-af80a489a802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_5a066878-5279-4e7d-aab4-556d323b8b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2e79c0d-6b27-4c94-a23d-047196cbc66b" xlink:to="loc_us-gaap_InterestPayableCurrent_5a066878-5279-4e7d-aab4-556d323b8b6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_02438b1e-5f3a-4475-8bab-02fd9cc8211f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2e79c0d-6b27-4c94-a23d-047196cbc66b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_02438b1e-5f3a-4475-8bab-02fd9cc8211f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_21120e18-31b5-4f95-a892-69930a370b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2e79c0d-6b27-4c94-a23d-047196cbc66b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_21120e18-31b5-4f95-a892-69930a370b23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7afd3cbf-35d9-4409-9f72-378b7a4b6656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent_d8b420c7-dbdb-4350-84e6-22ad3969c106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7afd3cbf-35d9-4409-9f72-378b7a4b6656" xlink:to="loc_us-gaap_SelfInsuranceReserveNoncurrent_d8b420c7-dbdb-4350-84e6-22ad3969c106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_103bffb6-a71f-49bc-a1e3-a9751f9f3ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7afd3cbf-35d9-4409-9f72-378b7a4b6656" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_103bffb6-a71f-49bc-a1e3-a9751f9f3ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_24791d26-6c06-439c-8635-ad79a95c44dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7afd3cbf-35d9-4409-9f72-378b7a4b6656" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_24791d26-6c06-439c-8635-ad79a95c44dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_10f0c30a-881f-4966-b62e-c0c88f2b9798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7afd3cbf-35d9-4409-9f72-378b7a4b6656" xlink:to="loc_us-gaap_LiabilitiesCurrent_10f0c30a-881f-4966-b62e-c0c88f2b9798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2209e27e-5df0-43c2-8b02-d49a4d97c896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7afd3cbf-35d9-4409-9f72-378b7a4b6656" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2209e27e-5df0-43c2-8b02-d49a4d97c896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8feb0e5d-c6b1-4dbb-9933-1c3b51f3db0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7afd3cbf-35d9-4409-9f72-378b7a4b6656" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8feb0e5d-c6b1-4dbb-9933-1c3b51f3db0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8aa4efb-ddea-4841-8278-11a4ff0fed51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0a358043-7fc0-4cf3-846f-bcd1ee7cca19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8aa4efb-ddea-4841-8278-11a4ff0fed51" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0a358043-7fc0-4cf3-846f-bcd1ee7cca19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6ed6797e-97da-43fa-8bcb-17206ee095f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8aa4efb-ddea-4841-8278-11a4ff0fed51" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6ed6797e-97da-43fa-8bcb-17206ee095f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_07d59b08-ec61-4d7a-8d85-14e958fd4d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8aa4efb-ddea-4841-8278-11a4ff0fed51" xlink:to="loc_us-gaap_PaymentsForSoftware_07d59b08-ec61-4d7a-8d85-14e958fd4d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2a36f986-cb2f-4dc5-9ee0-7ded4a795ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8aa4efb-ddea-4841-8278-11a4ff0fed51" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2a36f986-cb2f-4dc5-9ee0-7ded4a795ab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_8f176c0b-fd9a-4814-bc82-32fe8d484c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8aa4efb-ddea-4841-8278-11a4ff0fed51" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_8f176c0b-fd9a-4814-bc82-32fe8d484c25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_bf55b827-4b5e-4041-b202-6e6a7210fe9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8aa4efb-ddea-4841-8278-11a4ff0fed51" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_bf55b827-4b5e-4041-b202-6e6a7210fe9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_48c0ef45-f12c-4aba-820e-a61e12e19c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8aa4efb-ddea-4841-8278-11a4ff0fed51" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_48c0ef45-f12c-4aba-820e-a61e12e19c53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4745bfb3-eaa3-4a7c-a5f4-51a54366e459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1dc0156c-1b8c-4924-bd11-d624bc848854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4745bfb3-eaa3-4a7c-a5f4-51a54366e459" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1dc0156c-1b8c-4924-bd11-d624bc848854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd917efe-a213-41c2-9590-e862734daded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4745bfb3-eaa3-4a7c-a5f4-51a54366e459" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd917efe-a213-41c2-9590-e862734daded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_082196fd-ce0f-4620-9bff-7cf9ebf1532f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4745bfb3-eaa3-4a7c-a5f4-51a54366e459" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_082196fd-ce0f-4620-9bff-7cf9ebf1532f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce7c6a76-6c96-4d50-a427-be939434783d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b2549c69-88c2-4ad4-9fa8-64f9b4369641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce7c6a76-6c96-4d50-a427-be939434783d" xlink:to="loc_us-gaap_ProfitLoss_b2549c69-88c2-4ad4-9fa8-64f9b4369641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_643eeb56-ca64-427c-8e04-ddca24dd25e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce7c6a76-6c96-4d50-a427-be939434783d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_643eeb56-ca64-427c-8e04-ddca24dd25e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_114e8929-02b8-446d-9475-6d948ef9c11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce7c6a76-6c96-4d50-a427-be939434783d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_114e8929-02b8-446d-9475-6d948ef9c11e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_65213e52-ecf8-4116-9d3c-5d9439799a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_LitigationSettlementExpense_65213e52-ecf8-4116-9d3c-5d9439799a79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_05dad181-1e71-4156-b257-18889a0756c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_05dad181-1e71-4156-b257-18889a0756c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2fa716ef-6816-427f-a2f6-29dd2569ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2fa716ef-6816-427f-a2f6-29dd2569ef9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_814faffe-ee39-4461-899f-c801598868b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_814faffe-ee39-4461-899f-c801598868b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c99df97b-412b-4406-8b7f-ebd9718d6c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c99df97b-412b-4406-8b7f-ebd9718d6c21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_19967af1-0d66-48fc-bf63-34fe118fe5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_19967af1-0d66-48fc-bf63-34fe118fe5f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_86b8f3d9-e611-472f-8c4b-f74a48524486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_ShareBasedCompensation_86b8f3d9-e611-472f-8c4b-f74a48524486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2d95ce13-29a6-4e3b-9d27-58204e063ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2d95ce13-29a6-4e3b-9d27-58204e063ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f2183733-1fdb-469b-9822-7de13efddccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f2183733-1fdb-469b-9822-7de13efddccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ce413a3f-221e-43cd-b520-7670943eb58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ce413a3f-221e-43cd-b520-7670943eb58d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8408279a-d3b7-4cc4-8f90-3eac3a42daf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8408279a-d3b7-4cc4-8f90-3eac3a42daf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2355adbb-cc86-481c-b1aa-2bca16363abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2355adbb-cc86-481c-b1aa-2bca16363abc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8b2bbbe4-b984-4fb2-b11c-189f23936182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8b2bbbe4-b984-4fb2-b11c-189f23936182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_096ba6b9-6692-4edf-a8a8-e236f711cdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_096ba6b9-6692-4edf-a8a8-e236f711cdd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1736c181-f384-4779-871d-4c9cf655335f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1736c181-f384-4779-871d-4c9cf655335f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_cf72827f-e840-4ea2-8406-d6d831b5e85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_337581c4-9c10-4553-9c5e-e7f707d4a10a" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_cf72827f-e840-4ea2-8406-d6d831b5e85f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_e0805257-76e9-4223-a031-7d7dab48a995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_e0805257-76e9-4223-a031-7d7dab48a995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_2d87973e-091d-46fc-92e5-41e44ea0afeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_2d87973e-091d-46fc-92e5-41e44ea0afeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_a52de1be-4dcc-4607-8fb1-d07b87b78916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_a52de1be-4dcc-4607-8fb1-d07b87b78916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_8f5a848b-d2cf-48ee-b0ba-79f9164d8f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_8f5a848b-d2cf-48ee-b0ba-79f9164d8f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_de9ffe58-376d-4f7f-94c3-aa35e0d10018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_de9ffe58-376d-4f7f-94c3-aa35e0d10018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5c6f5c61-8cc7-4774-806c-18b7de87e2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5c6f5c61-8cc7-4774-806c-18b7de87e2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5f8487de-5830-4097-9838-c6b858598425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5f8487de-5830-4097-9838-c6b858598425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_9c7d2f5b-12c5-4934-babc-fd1226e1348d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_9c7d2f5b-12c5-4934-babc-fd1226e1348d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_57750f02-da76-4fe6-ac42-bd695e979558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_57750f02-da76-4fe6-ac42-bd695e979558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_d05b0c7e-30ff-49ae-a1a1-75b2d8099b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_d05b0c7e-30ff-49ae-a1a1-75b2d8099b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9ac741a1-2781-4bb0-884c-6a4210956ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9ac741a1-2781-4bb0-884c-6a4210956ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_3dde65bc-5546-47e9-81b4-436e239406fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_3dde65bc-5546-47e9-81b4-436e239406fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_62a5d1c6-899a-4457-ab45-d05c9f74ec73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfd7be9e-2fa4-4176-bbba-6dac97739bc9" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_62a5d1c6-899a-4457-ab45-d05c9f74ec73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_82ec5729-c067-4d71-b7ac-c47ca0d2183e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_82ec5729-c067-4d71-b7ac-c47ca0d2183e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9f3b66b4-2de5-49e4-815f-e6179b8ce5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9f3b66b4-2de5-49e4-815f-e6179b8ce5eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6de2e86f-c0a1-43e4-8fe7-7b13769f1e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:to="loc_us-gaap_Goodwill_6de2e86f-c0a1-43e4-8fe7-7b13769f1e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e81e1250-3fa8-4b7c-bcd7-d7e88f93adba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e81e1250-3fa8-4b7c-bcd7-d7e88f93adba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_63fbc098-3c2c-410a-94ab-abe5225a4117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_63fbc098-3c2c-410a-94ab-abe5225a4117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d4e57331-e1d7-4e90-9c7d-2e4dbea1a5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d4e57331-e1d7-4e90-9c7d-2e4dbea1a5d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_e3fa6de5-bbda-4218-b674-88d78e1043f7" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_e3fa6de5-bbda-4218-b674-88d78e1043f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ee24437e-d44d-420d-a982-081c44a8aa07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_201b468e-5a0e-42ba-aabc-bddb5c505007" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ee24437e-d44d-420d-a982-081c44a8aa07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e21c92ae-a17e-4ccd-9769-75c26e898443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_0ca91c53-9913-4421-8c97-c37bc14ac327" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e21c92ae-a17e-4ccd-9769-75c26e898443" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_0ca91c53-9913-4421-8c97-c37bc14ac327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_d75b4009-b1a3-45b4-8bdc-3432a0e11612" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e21c92ae-a17e-4ccd-9769-75c26e898443" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_d75b4009-b1a3-45b4-8bdc-3432a0e11612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_c3c20ce3-bc8c-4d6e-bdf8-a0a59b85ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e21c92ae-a17e-4ccd-9769-75c26e898443" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_c3c20ce3-bc8c-4d6e-bdf8-a0a59b85ef6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_525f48f6-d637-4a73-b582-7d2e9013edb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e21c92ae-a17e-4ccd-9769-75c26e898443" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_525f48f6-d637-4a73-b582-7d2e9013edb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_9d9b1bf2-c105-456a-ba32-91ca4a8df4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e21c92ae-a17e-4ccd-9769-75c26e898443" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_9d9b1bf2-c105-456a-ba32-91ca4a8df4e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6fa31b4a-437f-4254-92ef-3f082ad8da88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ac0738ec-a81e-40d2-b395-b2e87b3b81c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6fa31b4a-437f-4254-92ef-3f082ad8da88" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ac0738ec-a81e-40d2-b395-b2e87b3b81c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_941b24ea-087a-4975-8753-5a6d6be614c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6fa31b4a-437f-4254-92ef-3f082ad8da88" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_941b24ea-087a-4975-8753-5a6d6be614c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_2b15dac1-24e6-4e4e-ba9c-5d3d0a1e5f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6fa31b4a-437f-4254-92ef-3f082ad8da88" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_2b15dac1-24e6-4e4e-ba9c-5d3d0a1e5f5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32eb98b0-62cc-40ff-a4e3-f72338c02d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3a12cdd4-badf-4eb0-8f4a-50ac3b093f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_32eb98b0-62cc-40ff-a4e3-f72338c02d2b" xlink:to="loc_us-gaap_OtherAssetsCurrent_3a12cdd4-badf-4eb0-8f4a-50ac3b093f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_9cdc2cff-ad8e-45f6-b053-cf3bd40ab8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_32eb98b0-62cc-40ff-a4e3-f72338c02d2b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_9cdc2cff-ad8e-45f6-b053-cf3bd40ab8c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_370af67a-a161-4d83-98d8-f4de1c278005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_32eb98b0-62cc-40ff-a4e3-f72338c02d2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_370af67a-a161-4d83-98d8-f4de1c278005" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecuritiesComponentsofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InvestmentsCashandRestrictedCash_12551bde-597d-4803-b8d0-4f69fba497d0" xlink:href="ehc-20211231.xsd#ehc_InvestmentsCashandRestrictedCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20d5db37-1118-42fc-934f-86b272b998d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_InvestmentsCashandRestrictedCash_12551bde-597d-4803-b8d0-4f69fba497d0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20d5db37-1118-42fc-934f-86b272b998d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_62175df5-020d-4999-8fda-9ca183d47b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_InvestmentsCashandRestrictedCash_12551bde-597d-4803-b8d0-4f69fba497d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_62175df5-020d-4999-8fda-9ca183d47b84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_ce254937-14ca-4608-93a9-a68eacee9fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRestricted"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_InvestmentsCashandRestrictedCash_12551bde-597d-4803-b8d0-4f69fba497d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_ce254937-14ca-4608-93a9-a68eacee9fd5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#AccountsReceivableComponentsofAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_1ab220ab-c357-433d-a819-214e843f00e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_95b45b18-1f55-4488-bb6b-d7b5844ab54f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_1ab220ab-c357-433d-a819-214e843f00e6" xlink:to="loc_us-gaap_ReceivablesNetCurrent_95b45b18-1f55-4488-bb6b-d7b5844ab54f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_40bb55c9-639b-4e6e-94ba-001d79c3199e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_1ab220ab-c357-433d-a819-214e843f00e6" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_40bb55c9-639b-4e6e-94ba-001d79c3199e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5c2865d2-af21-4c87-a470-03e9fac84b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_169d19a5-cbf9-4ce1-a580-939e12b8f2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_5c2865d2-af21-4c87-a470-03e9fac84b13" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_169d19a5-cbf9-4ce1-a580-939e12b8f2bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_1c1fafb4-2780-4300-af05-148eca888bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_5c2865d2-af21-4c87-a470-03e9fac84b13" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_1c1fafb4-2780-4300-af05-148eca888bc0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7227685b-725e-495d-b3c4-0dde7a97a159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0c3875b1-31ed-42f1-9145-a3505961f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7227685b-725e-495d-b3c4-0dde7a97a159" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0c3875b1-31ed-42f1-9145-a3505961f2f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9bd17a7e-d276-4214-9576-6fc9976d13c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7227685b-725e-495d-b3c4-0dde7a97a159" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9bd17a7e-d276-4214-9576-6fc9976d13c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_388e4c60-a072-4fe3-b8a4-a595fd1dbcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_867c192e-1afa-4ba8-9f5b-b1ee161a8796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_388e4c60-a072-4fe3-b8a4-a595fd1dbcd2" xlink:to="loc_us-gaap_OperatingLeaseCost_867c192e-1afa-4ba8-9f5b-b1ee161a8796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Shorttermandvariableleasecost_a12b1830-2779-4cd0-9c35-57b07d9e9b63" xlink:href="ehc-20211231.xsd#ehc_Shorttermandvariableleasecost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_388e4c60-a072-4fe3-b8a4-a595fd1dbcd2" xlink:to="loc_ehc_Shorttermandvariableleasecost_a12b1830-2779-4cd0-9c35-57b07d9e9b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_bfbc3d6e-3d71-4096-acd5-15bff23d4830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_388e4c60-a072-4fe3-b8a4-a595fd1dbcd2" xlink:to="loc_us-gaap_SubleaseIncome_bfbc3d6e-3d71-4096-acd5-15bff23d4830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalfinanceleasecost_cfb48526-1ef5-4d39-9247-82ce2acec765" xlink:href="ehc-20211231.xsd#ehc_Totalfinanceleasecost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_388e4c60-a072-4fe3-b8a4-a595fd1dbcd2" xlink:to="loc_ehc_Totalfinanceleasecost_cfb48526-1ef5-4d39-9247-82ce2acec765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalfinanceleasecost_f1222690-9d13-4475-b7d3-8ea25e4805e7" xlink:href="ehc-20211231.xsd#ehc_Totalfinanceleasecost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4d2b9bfe-6c1c-47dc-9a79-81669b5217a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalfinanceleasecost_f1222690-9d13-4475-b7d3-8ea25e4805e7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4d2b9bfe-6c1c-47dc-9a79-81669b5217a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_9200d30c-61f8-458e-a8d8-f9bd1f619bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalfinanceleasecost_f1222690-9d13-4475-b7d3-8ea25e4805e7" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_9200d30c-61f8-458e-a8d8-f9bd1f619bc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalleaseliabilities_9d6dbcd6-3145-47a0-90d1-f57fa3e841bf" xlink:href="ehc-20211231.xsd#ehc_Totalleaseliabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fdc19616-eeb5-4552-9422-e8c8075f7a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalleaseliabilities_9d6dbcd6-3145-47a0-90d1-f57fa3e841bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fdc19616-eeb5-4552-9422-e8c8075f7a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7b285a03-9e92-424f-9a34-8e5162c382e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalleaseliabilities_9d6dbcd6-3145-47a0-90d1-f57fa3e841bf" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7b285a03-9e92-424f-9a34-8e5162c382e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5c46ada-d3b7-477b-aa8c-2532fd97c783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalleaseliabilities_9d6dbcd6-3145-47a0-90d1-f57fa3e841bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5c46ada-d3b7-477b-aa8c-2532fd97c783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a3128c94-5c25-4b8e-bd95-266251e88d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalleaseliabilities_9d6dbcd6-3145-47a0-90d1-f57fa3e841bf" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a3128c94-5c25-4b8e-bd95-266251e88d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totaloperatingandfinanceleaseassets_ce8dc0d7-cd4a-4c6a-b9df-c69e8b0208a4" xlink:href="ehc-20211231.xsd#ehc_Totaloperatingandfinanceleaseassets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f6097fb9-dd83-4e6d-b677-d8e050ff1ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totaloperatingandfinanceleaseassets_ce8dc0d7-cd4a-4c6a-b9df-c69e8b0208a4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f6097fb9-dd83-4e6d-b677-d8e050ff1ffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_b5bac2df-a8de-4668-9a8b-bd0e81d7285a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totaloperatingandfinanceleaseassets_ce8dc0d7-cd4a-4c6a-b9df-c69e8b0208a4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_b5bac2df-a8de-4668-9a8b-bd0e81d7285a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d1da0848-4ef3-484a-a767-62d3c65b4c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_d2db8685-a076-4f2c-995c-a26605bde5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d1da0848-4ef3-484a-a767-62d3c65b4c9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_d2db8685-a076-4f2c-995c-a26605bde5c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_777364bb-6037-4bd5-8155-34c0bec0f4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d1da0848-4ef3-484a-a767-62d3c65b4c9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_777364bb-6037-4bd5-8155-34c0bec0f4ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_4a042efc-c538-4685-b0ff-e90967cce980" xlink:href="ehc-20211231.xsd#ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d1da0848-4ef3-484a-a767-62d3c65b4c9a" xlink:to="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_4a042efc-c538-4685-b0ff-e90967cce980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8a1bcd92-1ba4-4b73-bab5-476667c366e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d1da0848-4ef3-484a-a767-62d3c65b4c9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8a1bcd92-1ba4-4b73-bab5-476667c366e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_640e3246-a802-4e1c-89c0-a7d2063a9a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d1da0848-4ef3-484a-a767-62d3c65b4c9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_640e3246-a802-4e1c-89c0-a7d2063a9a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a0e32406-18a1-4780-810c-2e106106a454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d1da0848-4ef3-484a-a767-62d3c65b4c9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a0e32406-18a1-4780-810c-2e106106a454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd776e23-115b-433b-b862-e80b6dcdc9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4e6c8904-b2cb-49c7-b93d-9a4a5cf9d35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd776e23-115b-433b-b862-e80b6dcdc9c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4e6c8904-b2cb-49c7-b93d-9a4a5cf9d35e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5b09641e-f7e3-438d-81ac-caac70b43743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd776e23-115b-433b-b862-e80b6dcdc9c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5b09641e-f7e3-438d-81ac-caac70b43743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5459ff49-b276-457f-863d-340882b9802c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd776e23-115b-433b-b862-e80b6dcdc9c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5459ff49-b276-457f-863d-340882b9802c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e54b28ed-e189-4e1c-a963-6dc4ac883126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd776e23-115b-433b-b862-e80b6dcdc9c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e54b28ed-e189-4e1c-a963-6dc4ac883126" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9f5853fc-f474-458a-a6f8-c3b0fc17ba72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd776e23-115b-433b-b862-e80b6dcdc9c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9f5853fc-f474-458a-a6f8-c3b0fc17ba72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_8337f44e-82e5-444c-89b3-fa4d4e2e12ab" xlink:href="ehc-20211231.xsd#ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd776e23-115b-433b-b862-e80b6dcdc9c0" xlink:to="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_8337f44e-82e5-444c-89b3-fa4d4e2e12ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2dc21e4c-2888-4446-ae48-b3fe1eec69b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d938e230-99b0-46b5-8a7d-a05dc104f999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2dc21e4c-2888-4446-ae48-b3fe1eec69b1" xlink:to="loc_us-gaap_FinanceLeaseLiability_d938e230-99b0-46b5-8a7d-a05dc104f999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3bbd6cb4-a515-471a-99dd-e259a9e684f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2dc21e4c-2888-4446-ae48-b3fe1eec69b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3bbd6cb4-a515-471a-99dd-e259a9e684f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d81103af-c0f1-4a02-9c19-085006f4aa14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_02b16140-d39d-4a8e-82b0-897a5b001b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d81103af-c0f1-4a02-9c19-085006f4aa14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_02b16140-d39d-4a8e-82b0-897a5b001b18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_efae5bd8-8785-47ca-820e-a50808a9f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d81103af-c0f1-4a02-9c19-085006f4aa14" xlink:to="loc_us-gaap_OperatingLeaseLiability_efae5bd8-8785-47ca-820e-a50808a9f72e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f21b0faa-6a9f-4c2f-9a72-15af13051087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_076dcb75-ff71-4ead-bbcf-3d61d230f815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f21b0faa-6a9f-4c2f-9a72-15af13051087" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_076dcb75-ff71-4ead-bbcf-3d61d230f815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4d143afe-c50e-4865-a291-911822cab316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f21b0faa-6a9f-4c2f-9a72-15af13051087" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4d143afe-c50e-4865-a291-911822cab316" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dadb22d9-a17d-4e96-aaff-6b6f5ad7c380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e60b89ee-b7a2-40cc-add6-506b4faf5593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestments_dadb22d9-a17d-4e96-aaff-6b6f5ad7c380" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e60b89ee-b7a2-40cc-add6-506b4faf5593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments_1d1239db-b2a6-4f0c-ad95-519dd3b2fe88" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestments_dadb22d9-a17d-4e96-aaff-6b6f5ad7c380" xlink:to="loc_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments_1d1239db-b2a6-4f0c-ad95-519dd3b2fe88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments_04203ce3-51c0-4564-8cc1-e22bdcfbe09b" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestments_dadb22d9-a17d-4e96-aaff-6b6f5ad7c380" xlink:to="loc_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments_04203ce3-51c0-4564-8cc1-e22bdcfbe09b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9de862d8-6926-4f5f-9998-25578bd83eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f045cd5e-9089-4f70-910d-99614cf660d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9de862d8-6926-4f5f-9998-25578bd83eaa" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f045cd5e-9089-4f70-910d-99614cf660d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1e06da9d-14fa-427c-b5e1-33c61b24c627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9de862d8-6926-4f5f-9998-25578bd83eaa" xlink:to="loc_us-gaap_EquityMethodInvestments_1e06da9d-14fa-427c-b5e1-33c61b24c627" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_f6d7180f-c85a-4e83-a2a7-49687aa87573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c8bf7717-3e45-4107-8e27-769bb11abf87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_f6d7180f-c85a-4e83-a2a7-49687aa87573" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c8bf7717-3e45-4107-8e27-769bb11abf87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_db1ce6cd-31c2-4c2a-b8db-10cd861c2285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_f6d7180f-c85a-4e83-a2a7-49687aa87573" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_db1ce6cd-31c2-4c2a-b8db-10cd861c2285" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtLongtermDebtOutstandingDetails_1"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_5e2bc6cd-6adf-4d71-bf1f-5be54ef80d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b0f39d64-09f1-481a-b0e0-44913a8cd1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_5e2bc6cd-6adf-4d71-bf1f-5be54ef80d23" xlink:to="loc_us-gaap_LongTermDebt_b0f39d64-09f1-481a-b0e0-44913a8cd1d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_b734a9e2-a7fc-4751-9e47-b2bb65069c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_5e2bc6cd-6adf-4d71-bf1f-5be54ef80d23" xlink:to="loc_us-gaap_FinanceLeaseLiability_b734a9e2-a7fc-4751-9e47-b2bb65069c2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_4243cd10-df5e-4174-af66-b16194ee640f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_c1fcf2c6-d2cd-4f8e-abd4-0a6f57662598" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_4243cd10-df5e-4174-af66-b16194ee640f" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_c1fcf2c6-d2cd-4f8e-abd4-0a6f57662598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_4bbf0b04-4c6e-4997-a487-987b815358e9" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_4243cd10-df5e-4174-af66-b16194ee640f" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_4bbf0b04-4c6e-4997-a487-987b815358e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_35173bf8-3d2d-4aae-8550-c09a89d559b8" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_4243cd10-df5e-4174-af66-b16194ee640f" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_35173bf8-3d2d-4aae-8550-c09a89d559b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_b73752d1-e65c-4c9b-8e01-9c73e6427a1e" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_4243cd10-df5e-4174-af66-b16194ee640f" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_b73752d1-e65c-4c9b-8e01-9c73e6427a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_222b5249-f268-408c-82ed-abeb46544cfb" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_4243cd10-df5e-4174-af66-b16194ee640f" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_222b5249-f268-408c-82ed-abeb46544cfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_729a51a2-a9e4-4db3-af27-805910e7fbfb" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_4243cd10-df5e-4174-af66-b16194ee640f" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_729a51a2-a9e4-4db3-af27-805910e7fbfb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SelfInsuredRisksChangesinSelfinsuranceReservesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_31f99eda-5540-4a26-8eb1-d86a63b6e919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_185b9035-12c0-460c-ab10-20ff5b7186f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_31f99eda-5540-4a26-8eb1-d86a63b6e919" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_185b9035-12c0-460c-ab10-20ff5b7186f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_63348c39-d2fb-47da-a51a-84922da70b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_31f99eda-5540-4a26-8eb1-d86a63b6e919" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_63348c39-d2fb-47da-a51a-84922da70b20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_65d468a8-5dc9-43e0-84d2-61c746ff0824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_ad86c848-6939-4c30-aff9-992394f0faa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_65d468a8-5dc9-43e0-84d2-61c746ff0824" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_ad86c848-6939-4c30-aff9-992394f0faa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_a4e8caac-0d5c-48f0-bbd2-f4e79ac16735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_65d468a8-5dc9-43e0-84d2-61c746ff0824" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_a4e8caac-0d5c-48f0-bbd2-f4e79ac16735" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8c886ad1-5423-40ba-b249-6bc352f51f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_962949f5-d932-423c-8d49-d3bb381eeac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8c886ad1-5423-40ba-b249-6bc352f51f4d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_962949f5-d932-423c-8d49-d3bb381eeac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a0f58635-0bb6-4792-91ec-b05fd23e154d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8c886ad1-5423-40ba-b249-6bc352f51f4d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a0f58635-0bb6-4792-91ec-b05fd23e154d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bcb72f17-2ef8-40dd-a9fe-3db789def430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b9928188-c9b9-4193-9b5c-b3a7fcac0e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bcb72f17-2ef8-40dd-a9fe-3db789def430" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b9928188-c9b9-4193-9b5c-b3a7fcac0e84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_67e638ee-2039-4f34-929b-f4a2e0eb88b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bcb72f17-2ef8-40dd-a9fe-3db789def430" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_67e638ee-2039-4f34-929b-f4a2e0eb88b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3dfd7392-7f47-48a4-bf96-c61983c6d6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c4d1325c-b7cd-4e39-a201-ace8a807e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3dfd7392-7f47-48a4-bf96-c61983c6d6bb" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c4d1325c-b7cd-4e39-a201-ace8a807e01b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7dd547b8-db2a-4eb9-8aac-6e1fe82d2035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3dfd7392-7f47-48a4-bf96-c61983c6d6bb" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7dd547b8-db2a-4eb9-8aac-6e1fe82d2035" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_597e364d-a658-49f8-b631-f23ccce29664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f5c4d328-d6a5-46ef-b59c-f5e6f46a67c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_597e364d-a658-49f8-b631-f23ccce29664" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f5c4d328-d6a5-46ef-b59c-f5e6f46a67c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_ba079bf2-f43a-4733-bae8-0ac557dac10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_597e364d-a658-49f8-b631-f23ccce29664" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_ba079bf2-f43a-4733-bae8-0ac557dac10a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2f0a1bd1-7a2b-4f8f-8847-8edb2132eb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_597e364d-a658-49f8-b631-f23ccce29664" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2f0a1bd1-7a2b-4f8f-8847-8edb2132eb8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5db1dfb5-8422-4960-853a-fac48b7c3a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_597e364d-a658-49f8-b631-f23ccce29664" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5db1dfb5-8422-4960-853a-fac48b7c3a87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c0fe14dc-5342-4f38-9a8b-61eae2ddf5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_597e364d-a658-49f8-b631-f23ccce29664" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c0fe14dc-5342-4f38-9a8b-61eae2ddf5e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_4e1fd874-6230-4ecd-9b6e-c28943bc8f79" xlink:href="ehc-20211231.xsd#ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_597e364d-a658-49f8-b631-f23ccce29664" xlink:to="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_4e1fd874-6230-4ecd-9b6e-c28943bc8f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_f4908e96-9d6d-494f-9a2a-7b2ece88ac50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_597e364d-a658-49f8-b631-f23ccce29664" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_f4908e96-9d6d-494f-9a2a-7b2ece88ac50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_706fc823-669b-41dd-a139-ababb0447094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2bf19d74-b0da-4791-821a-741c8c22fd39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_706fc823-669b-41dd-a139-ababb0447094" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2bf19d74-b0da-4791-821a-741c8c22fd39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e2e75615-2920-4bb3-95d6-8ac6b3c90cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_706fc823-669b-41dd-a139-ababb0447094" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e2e75615-2920-4bb3-95d6-8ac6b3c90cae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_e02cf058-0654-45dc-9f8a-a3b00adf15b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_706fc823-669b-41dd-a139-ababb0447094" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_e02cf058-0654-45dc-9f8a-a3b00adf15b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_2904a788-e044-41b7-8677-ce2f0c8c8a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_706fc823-669b-41dd-a139-ababb0447094" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_2904a788-e044-41b7-8677-ce2f0c8c8a76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_a7be7504-5fe6-49b3-ae49-2745ee0b5dbe" xlink:href="ehc-20211231.xsd#ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_706fc823-669b-41dd-a139-ababb0447094" xlink:to="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_a7be7504-5fe6-49b3-ae49-2745ee0b5dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e1d5c55a-4e63-4706-b57c-5dc46fa2ecec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_706fc823-669b-41dd-a139-ababb0447094" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e1d5c55a-4e63-4706-b57c-5dc46fa2ecec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f7aa9007-0a8b-4b6b-bc7b-8e339bc10d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cc1cde86-e085-4fe5-812b-41514fcebcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f7aa9007-0a8b-4b6b-bc7b-8e339bc10d3b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_cc1cde86-e085-4fe5-812b-41514fcebcdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_839d0dba-b157-4e16-a7a7-aa4aeb735265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f7aa9007-0a8b-4b6b-bc7b-8e339bc10d3b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_839d0dba-b157-4e16-a7a7-aa4aeb735265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ca5ac4a2-d417-4726-945f-6ef6cb4282c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ebcd0da6-e4ad-4d8e-bc26-acff2782aa54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ca5ac4a2-d417-4726-945f-6ef6cb4282c7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ebcd0da6-e4ad-4d8e-bc26-acff2782aa54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_69ce29e4-85a0-4b08-8dd0-e3ad870a19b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ca5ac4a2-d417-4726-945f-6ef6cb4282c7" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_69ce29e4-85a0-4b08-8dd0-e3ad870a19b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f480880f-0cc1-4998-a0f9-a61e65e0b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f480880f-0cc1-4998-a0f9-a61e65e0b16c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_732b2d38-a640-4c3f-ab13-662291e64005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_732b2d38-a640-4c3f-ab13-662291e64005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_d8235ecf-6a45-48b9-9472-c127d3c88447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_d8235ecf-6a45-48b9-9472-c127d3c88447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9853d1d2-f1f5-403c-b60c-f17772076046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9853d1d2-f1f5-403c-b60c-f17772076046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_b4e46c75-9912-4ffc-a41b-c87622d92bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_b4e46c75-9912-4ffc-a41b-c87622d92bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8ee326e0-94ce-4dcb-a480-b2f389213983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8ee326e0-94ce-4dcb-a480-b2f389213983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_9d7cea93-2232-4951-ac43-6dbccd22edc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_9d7cea93-2232-4951-ac43-6dbccd22edc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability_b4c41fc7-cc93-4358-99bb-5bf4b55ad451" xlink:href="ehc-20211231.xsd#ehc_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c7ef1fe8-7345-4ef2-9a50-8fc47fd2c9c8" xlink:to="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability_b4c41fc7-cc93-4358-99bb-5bf4b55ad451" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_794bfe10-4464-400b-b3c2-20a0bab9589e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_24655611-f4f4-4b32-bce7-60eb2f4fff46" xlink:href="ehc-20211231.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_794bfe10-4464-400b-b3c2-20a0bab9589e" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_24655611-f4f4-4b32-bce7-60eb2f4fff46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d3a3c760-9656-418e-a0e4-1d03f01c19cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_794bfe10-4464-400b-b3c2-20a0bab9589e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d3a3c760-9656-418e-a0e4-1d03f01c19cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_4a0eb8df-e8e4-493d-bfed-5957d16dd092" xlink:href="ehc-20211231.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1bf0a6aa-423e-44bb-be1c-c3a3ec14e4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_4a0eb8df-e8e4-493d-bfed-5957d16dd092" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1bf0a6aa-423e-44bb-be1c-c3a3ec14e4f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_589579b6-7876-406f-a2e7-bc6ebfe6ef31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_4a0eb8df-e8e4-493d-bfed-5957d16dd092" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_589579b6-7876-406f-a2e7-bc6ebfe6ef31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_df48fcd0-e939-45b9-9257-38f80f1394c0" xlink:href="ehc-20211231.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_fc6f7f8f-35ef-432e-a1ac-f41d007f7456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_df48fcd0-e939-45b9-9257-38f80f1394c0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_fc6f7f8f-35ef-432e-a1ac-f41d007f7456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d4d639b3-d94f-4b7b-9af3-b0362bf3b2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_df48fcd0-e939-45b9-9257-38f80f1394c0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d4d639b3-d94f-4b7b-9af3-b0362bf3b2d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_75d58147-1578-48f0-be12-a2059f3dd322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_df48fcd0-e939-45b9-9257-38f80f1394c0" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_75d58147-1578-48f0-be12-a2059f3dd322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_65cebaee-c7e2-4f56-92a5-cd8208543a10" xlink:href="ehc-20211231.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_dc02471b-a0e8-4174-bc1f-a1c8eb6eb16e" xlink:href="ehc-20211231.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_65cebaee-c7e2-4f56-92a5-cd8208543a10" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_dc02471b-a0e8-4174-bc1f-a1c8eb6eb16e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_110a9020-94e5-49dc-aca2-26b91c381c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_65cebaee-c7e2-4f56-92a5-cd8208543a10" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_110a9020-94e5-49dc-aca2-26b91c381c7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9d98c5a4-a6f5-49b8-94f5-79ae5f7bc1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_50bf1817-ab7d-453d-a2dd-d3e14d71a368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9d98c5a4-a6f5-49b8-94f5-79ae5f7bc1f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_50bf1817-ab7d-453d-a2dd-d3e14d71a368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77a81fe9-3d0d-4fe7-90e9-474d98a000d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9d98c5a4-a6f5-49b8-94f5-79ae5f7bc1f4" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77a81fe9-3d0d-4fe7-90e9-474d98a000d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a9830748-5dc2-4e2b-b67b-c4c580dccb93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_bdfa9e92-c641-42ca-a737-9c6f225f02d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9830748-5dc2-4e2b-b67b-c4c580dccb93" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_bdfa9e92-c641-42ca-a737-9c6f225f02d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_75d0449c-9c38-4970-ad4d-2af251daa616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9830748-5dc2-4e2b-b67b-c4c580dccb93" xlink:to="loc_us-gaap_LaborAndRelatedExpense_75d0449c-9c38-4970-ad4d-2af251daa616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_9902f1a5-4c77-45a2-aa51-7fac36718804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9830748-5dc2-4e2b-b67b-c4c580dccb93" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_9902f1a5-4c77-45a2-aa51-7fac36718804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_1efb6829-aa4d-4280-b30f-8eb95bed30a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9830748-5dc2-4e2b-b67b-c4c580dccb93" xlink:to="loc_us-gaap_SuppliesExpense_1efb6829-aa4d-4280-b30f-8eb95bed30a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_ac9083af-4c09-4033-b070-d877e2e0d104" xlink:href="ehc-20211231.xsd#ehc_OccupancyCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9830748-5dc2-4e2b-b67b-c4c580dccb93" xlink:to="loc_ehc_OccupancyCost_ac9083af-4c09-4033-b070-d877e2e0d104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_610a7fa9-d4f6-47e0-926c-846a2f084f4a" xlink:href="ehc-20211231.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9830748-5dc2-4e2b-b67b-c4c580dccb93" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_610a7fa9-d4f6-47e0-926c-846a2f084f4a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>ehc-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fa73796-4641-417c-869a-a8efa97ec0d7,g:d7a996dc-3cad-46ef-bbb1-393716adc0de-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i0e21291f42b64434b3740396326867c8_ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8054abda-6f22-4c55-861d-cc996e9e419a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8054abda-6f22-4c55-861d-cc996e9e419a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6b7bef3c-bd76-4a00-98b1-81d7e0414e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6b7bef3c-bd76-4a00-98b1-81d7e0414e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6d700cf6-d912-467d-a0dd-14c3f0eda3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_CommonStockSharesIssued_6d700cf6-d912-467d-a0dd-14c3f0eda3ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_6f15d3fa-249e-4bc7-aa93-f79eb771dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_TreasuryStockShares_6f15d3fa-249e-4bc7-aa93-f79eb771dcbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9c314cf2-3ff5-4fdc-b159-a4c2df3516b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_Assets_9c314cf2-3ff5-4fdc-b159-a4c2df3516b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d8fdad1d-4291-4315-9cef-7810fbd863ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_Liabilities_d8fdad1d-4291-4315-9cef-7810fbd863ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8410d70a-6d0f-4464-9e2d-3ffa33517416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_StatementTable_8410d70a-6d0f-4464-9e2d-3ffa33517416" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7659a530-af43-4656-969d-42813de3a99c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8410d70a-6d0f-4464-9e2d-3ffa33517416" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7659a530-af43-4656-969d-42813de3a99c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7659a530-af43-4656-969d-42813de3a99c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7659a530-af43-4656-969d-42813de3a99c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7659a530-af43-4656-969d-42813de3a99c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_28ecd91c-f4e1-4916-bf8d-92b8495660b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7659a530-af43-4656-969d-42813de3a99c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_28ecd91c-f4e1-4916-bf8d-92b8495660b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5bc54e98-6986-47c2-beef-39ce38bea3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_28ecd91c-f4e1-4916-bf8d-92b8495660b0" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5bc54e98-6986-47c2-beef-39ce38bea3cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i1cd7e02408604e53be2611c769cc839b_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f22335d6-0c1d-4ab4-99be-0c998384d803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f22335d6-0c1d-4ab4-99be-0c998384d803" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3b9b5812-632e-4acb-bbb5-c5b19e76a100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3b9b5812-632e-4acb-bbb5-c5b19e76a100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b58db187-346c-4cf0-89bb-9ac03d83daa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b58db187-346c-4cf0-89bb-9ac03d83daa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_9fcb6c4e-253d-47c9-88c5-f6ba983922cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_9fcb6c4e-253d-47c9-88c5-f6ba983922cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_0eee056a-e45e-4859-a961-b35ee4811fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_0eee056a-e45e-4859-a961-b35ee4811fc5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_fae78720-cf80-4d23-b547-49f47679fe00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_fae78720-cf80-4d23-b547-49f47679fe00" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_723dc4b8-1332-448f-9cd7-00df350091d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_DividendsCommonStockCash_723dc4b8-1332-448f-9cd7-00df350091d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8955292d-1d52-420a-84bf-875c235b3228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8955292d-1d52-420a-84bf-875c235b3228" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f655d700-0320-45ef-af09-18ec345bee39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f655d700-0320-45ef-af09-18ec345bee39" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f73a4250-6355-4363-9b60-bed8eff11dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f73a4250-6355-4363-9b60-bed8eff11dcd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_39cc5cda-1751-4c6d-916d-5db22fad6de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_39cc5cda-1751-4c6d-916d-5db22fad6de6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_076c17ac-b7be-46e3-aa84-17f5bc47edbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_076c17ac-b7be-46e3-aa84-17f5bc47edbb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_04f79b36-7011-452b-bde5-7dd2db6989a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_04f79b36-7011-452b-bde5-7dd2db6989a4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_da41bc8b-d889-40e3-b935-edc4493ffa05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_da41bc8b-d889-40e3-b935-edc4493ffa05" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_863d4597-e82b-4986-926b-71f0b852eba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_863d4597-e82b-4986-926b-71f0b852eba2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_71fa12f3-38fd-4c1c-b777-1cedaab2858e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_71fa12f3-38fd-4c1c-b777-1cedaab2858e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d9f117c1-4f2f-477d-8a36-f5a666fabe51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d9f117c1-4f2f-477d-8a36-f5a666fabe51" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_2f98e876-8bf4-49e2-8de9-20db04cd1eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_2f98e876-8bf4-49e2-8de9-20db04cd1eed" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_02be6c9f-2a2d-42c7-8c3c-9569ee9b9314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_02be6c9f-2a2d-42c7-8c3c-9569ee9b9314" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_36a516d5-110a-4381-939d-4bd239598649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockholdersEquityOther_36a516d5-110a-4381-939d-4bd239598649" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a606b04b-a7b7-412c-bef9-22c9575ee1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74387623-f763-4692-ba31-b9400e2e193e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5ca3a7e6-91fb-4411-876a-dcf4d1f64b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f22335d6-0c1d-4ab4-99be-0c998384d803" xlink:to="loc_us-gaap_StatementTable_5ca3a7e6-91fb-4411-876a-dcf4d1f64b6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dee8630d-2045-4803-b26c-87f3748a177c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5ca3a7e6-91fb-4411-876a-dcf4d1f64b6e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dee8630d-2045-4803-b26c-87f3748a177c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dee8630d-2045-4803-b26c-87f3748a177c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dee8630d-2045-4803-b26c-87f3748a177c" xlink:to="loc_us-gaap_EquityComponentDomain_dee8630d-2045-4803-b26c-87f3748a177c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dee8630d-2045-4803-b26c-87f3748a177c" xlink:to="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_73337af5-992f-46ec-8e16-006f35386ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_CommonStockMember_73337af5-992f-46ec-8e16-006f35386ad8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eefbc82c-6090-4dbd-8534-d30bbc380c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eefbc82c-6090-4dbd-8534-d30bbc380c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_66810e45-7162-43f0-93d6-8a7c35ad5218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_RetainedEarningsMember_66810e45-7162-43f0-93d6-8a7c35ad5218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_abcd12f5-5573-4de2-8b9b-d46c304911ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_TreasuryStockMember_abcd12f5-5573-4de2-8b9b-d46c304911ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9f19b34f-fa77-481e-b16e-12776908bbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9f19b34f-fa77-481e-b16e-12776908bbf8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="extended" id="i6dd1cc7074c34a59b46bac90f373bb7e_SummaryofSignificantAccountingPoliciesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_36118a9d-bbfa-4766-8730-88fe0a46d8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_36118a9d-bbfa-4766-8730-88fe0a46d8b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_06625bec-ed51-4c07-9ba9-8abf84b64bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_NumberOfReportableSegments_06625bec-ed51-4c07-9ba9-8abf84b64bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a1bbd68d-f81f-4154-ac89-7fc874290573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a1bbd68d-f81f-4154-ac89-7fc874290573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_deef5c43-0b7e-41e0-b71d-daf031e67543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_deef5c43-0b7e-41e0-b71d-daf031e67543" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_ef71f376-e693-442b-9252-d5ca675d1e7a" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_ef71f376-e693-442b-9252-d5ca675d1e7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_e36b856e-2b22-4c8b-827c-2c6ad16c5070" xlink:href="ehc-20211231.xsd#ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_e36b856e-2b22-4c8b-827c-2c6ad16c5070" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_33e9a288-f2d5-4f5e-a724-861a29dcc00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_AdvertisingExpense_33e9a288-f2d5-4f5e-a724-861a29dcc00d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cdb7914-9945-4656-a4ed-393526e0863a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_srt_RangeAxis_9cdb7914-9945-4656-a4ed-393526e0863a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cdb7914-9945-4656-a4ed-393526e0863a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9cdb7914-9945-4656-a4ed-393526e0863a" xlink:to="loc_srt_RangeMember_9cdb7914-9945-4656-a4ed-393526e0863a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4eb3adc8-9fc3-4a20-b442-01d569580615" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9cdb7914-9945-4656-a4ed-393526e0863a" xlink:to="loc_srt_RangeMember_4eb3adc8-9fc3-4a20-b442-01d569580615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c14cee59-2195-4664-9d03-09e1a72a06d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4eb3adc8-9fc3-4a20-b442-01d569580615" xlink:to="loc_srt_MinimumMember_c14cee59-2195-4664-9d03-09e1a72a06d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_779f49ac-4456-4139-bae9-f85c11d52290" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4eb3adc8-9fc3-4a20-b442-01d569580615" xlink:to="loc_srt_MaximumMember_779f49ac-4456-4139-bae9-f85c11d52290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_46ce1b4c-817e-40c0-a7b1-917f2d1533f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_46ce1b4c-817e-40c0-a7b1-917f2d1533f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_46ce1b4c-817e-40c0-a7b1-917f2d1533f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46ce1b4c-817e-40c0-a7b1-917f2d1533f7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_46ce1b4c-817e-40c0-a7b1-917f2d1533f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2c91c993-7db6-44b0-b928-824d04b53d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46ce1b4c-817e-40c0-a7b1-917f2d1533f7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2c91c993-7db6-44b0-b928-824d04b53d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember_bf09f91b-ef71-43f2-ac1b-8d8b00c2cefb" xlink:href="ehc-20211231.xsd#ehc_PayorSourceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2c91c993-7db6-44b0-b928-824d04b53d11" xlink:to="loc_ehc_PayorSourceMember_bf09f91b-ef71-43f2-ac1b-8d8b00c2cefb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f16edc22-348a-449d-ba0d-88c9cc4f386c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f16edc22-348a-449d-ba0d-88c9cc4f386c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f16edc22-348a-449d-ba0d-88c9cc4f386c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f16edc22-348a-449d-ba0d-88c9cc4f386c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f16edc22-348a-449d-ba0d-88c9cc4f386c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c87675de-fa41-4b69-a2ed-2a18c2879bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f16edc22-348a-449d-ba0d-88c9cc4f386c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c87675de-fa41-4b69-a2ed-2a18c2879bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_2f098700-a83c-4e5a-9a47-f808af89e2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c87675de-fa41-4b69-a2ed-2a18c2879bf8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_2f098700-a83c-4e5a-9a47-f808af89e2ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c79b327-7b54-4e61-8b3b-68db4a2f8942" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_srt_CounterpartyNameAxis_8c79b327-7b54-4e61-8b3b-68db4a2f8942" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79b327-7b54-4e61-8b3b-68db4a2f8942_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8c79b327-7b54-4e61-8b3b-68db4a2f8942" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c79b327-7b54-4e61-8b3b-68db4a2f8942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e127aa0-7261-4e70-9322-1ca2248fbb3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8c79b327-7b54-4e61-8b3b-68db4a2f8942" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e127aa0-7261-4e70-9322-1ca2248fbb3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_d4a7a55b-2f8c-40ca-940f-17d00304e34d" xlink:href="ehc-20211231.xsd#ehc_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e127aa0-7261-4e70-9322-1ca2248fbb3a" xlink:to="loc_ehc_MedicareMember_d4a7a55b-2f8c-40ca-940f-17d00304e34d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e905388e-e994-45c9-9444-e1581bcf8710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e905388e-e994-45c9-9444-e1581bcf8710" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_e905388e-e994-45c9-9444-e1581bcf8710_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e905388e-e994-45c9-9444-e1581bcf8710" xlink:to="loc_us-gaap_LossContingencyNatureDomain_e905388e-e994-45c9-9444-e1581bcf8710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b8b83274-0cf2-453e-a79f-5fb265472a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e905388e-e994-45c9-9444-e1581bcf8710" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b8b83274-0cf2-453e-a79f-5fb265472a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RACAuditsMember_2a0de3db-4f51-453c-a6e7-bbfb5c304997" xlink:href="ehc-20211231.xsd#ehc_RACAuditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b8b83274-0cf2-453e-a79f-5fb265472a66" xlink:to="loc_ehc_RACAuditsMember_2a0de3db-4f51-453c-a6e7-bbfb5c304997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e2ebc50-fb5f-403e-b14e-f86dc0338b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e2ebc50-fb5f-403e-b14e-f86dc0338b76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e2ebc50-fb5f-403e-b14e-f86dc0338b76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e2ebc50-fb5f-403e-b14e-f86dc0338b76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e2ebc50-fb5f-403e-b14e-f86dc0338b76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19bed023-213d-4448-8560-758c60d403f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e2ebc50-fb5f-403e-b14e-f86dc0338b76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19bed023-213d-4448-8560-758c60d403f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_b6078a37-13dd-495d-8de9-1e60370b4aae" xlink:href="ehc-20211231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19bed023-213d-4448-8560-758c60d403f8" xlink:to="loc_ehc_MarketAccessAssetsMember_b6078a37-13dd-495d-8de9-1e60370b4aae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails" xlink:type="extended" id="if35fc421538e471f801ab6800dfda6bc_SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8814c13c-a94c-40ea-a0cb-9eaf8bee1d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cd9f555-5151-4b16-8a3d-e36b15a52784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8814c13c-a94c-40ea-a0cb-9eaf8bee1d71" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cd9f555-5151-4b16-8a3d-e36b15a52784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f56c0798-8f45-4b5b-9d67-0df3434d00b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8814c13c-a94c-40ea-a0cb-9eaf8bee1d71" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f56c0798-8f45-4b5b-9d67-0df3434d00b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8814c13c-a94c-40ea-a0cb-9eaf8bee1d71" xlink:to="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_04080531-6db1-42f5-adaf-d1a281860d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_04080531-6db1-42f5-adaf-d1a281860d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_04080531-6db1-42f5-adaf-d1a281860d05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_04080531-6db1-42f5-adaf-d1a281860d05" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_04080531-6db1-42f5-adaf-d1a281860d05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b1da2344-ec62-4241-8455-712470a7ca5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_04080531-6db1-42f5-adaf-d1a281860d05" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b1da2344-ec62-4241-8455-712470a7ca5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember_d26e10d7-f754-4eca-a807-28b31172f04b" xlink:href="ehc-20211231.xsd#ehc_PayorSourceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b1da2344-ec62-4241-8455-712470a7ca5f" xlink:to="loc_ehc_PayorSourceMember_d26e10d7-f754-4eca-a807-28b31172f04b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f467ba06-4895-4cd1-b835-7d508910adaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f467ba06-4895-4cd1-b835-7d508910adaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f467ba06-4895-4cd1-b835-7d508910adaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f467ba06-4895-4cd1-b835-7d508910adaa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f467ba06-4895-4cd1-b835-7d508910adaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c96e771f-e207-4a6b-9a5f-51b527606ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f467ba06-4895-4cd1-b835-7d508910adaa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c96e771f-e207-4a6b-9a5f-51b527606ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_a0a0800a-d57e-43c9-b13d-091d58c2276c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c96e771f-e207-4a6b-9a5f-51b527606ee8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_a0a0800a-d57e-43c9-b13d-091d58c2276c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7c385f25-b67f-46b7-9b20-cd2edd8efdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c96e771f-e207-4a6b-9a5f-51b527606ee8" xlink:to="loc_us-gaap_AccountsReceivableMember_7c385f25-b67f-46b7-9b20-cd2edd8efdf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_641c0257-fa31-4c5d-bd5f-3d6e0b901258" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_srt_CounterpartyNameAxis_641c0257-fa31-4c5d-bd5f-3d6e0b901258" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_641c0257-fa31-4c5d-bd5f-3d6e0b901258_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_641c0257-fa31-4c5d-bd5f-3d6e0b901258" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_641c0257-fa31-4c5d-bd5f-3d6e0b901258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_641c0257-fa31-4c5d-bd5f-3d6e0b901258" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_a2320adb-016d-4411-b922-0b76899ddec2" xlink:href="ehc-20211231.xsd#ehc_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_MedicareMember_a2320adb-016d-4411-b922-0b76899ddec2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_01db27ee-234e-4eca-8acb-9c59d309d94e" xlink:href="ehc-20211231.xsd#ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_01db27ee-234e-4eca-8acb-9c59d309d94e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember_89991a4b-17e7-48d6-bcfc-3c27965e4ad9" xlink:href="ehc-20211231.xsd#ehc_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_MedicareAdvantageMember_89991a4b-17e7-48d6-bcfc-3c27965e4ad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember_94e50c51-f4d0-4b84-83c7-d5b772996c08" xlink:href="ehc-20211231.xsd#ehc_ManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_ManagedCareMember_94e50c51-f4d0-4b84-83c7-d5b772996c08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_56997b3b-555d-4d59-9cb0-e4c74e74b8be" xlink:href="ehc-20211231.xsd#ehc_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_MedicaidMember_56997b3b-555d-4d59-9cb0-e4c74e74b8be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_602f79ab-de42-4aa5-a178-3ce5f304b430" xlink:href="ehc-20211231.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_602f79ab-de42-4aa5-a178-3ce5f304b430" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_bcee339f-7edf-4bff-a2d5-f6f3f21439db" xlink:href="ehc-20211231.xsd#ehc_WorkersCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_WorkersCompensationMember_bcee339f-7edf-4bff-a2d5-f6f3f21439db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_7008f8f1-4272-4998-9e92-af86e9c78554" xlink:href="ehc-20211231.xsd#ehc_PatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_PatientsMember_7008f8f1-4272-4998-9e92-af86e9c78554" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember_f760a039-f5ed-479a-b47f-39ed1fae0c79" xlink:href="ehc-20211231.xsd#ehc_OtherIncomeSourceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_OtherIncomeSourceMember_f760a039-f5ed-479a-b47f-39ed1fae0c79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2334daa8-a6b8-4ffe-b3ce-36c91186254a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2334daa8-a6b8-4ffe-b3ce-36c91186254a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2334daa8-a6b8-4ffe-b3ce-36c91186254a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2334daa8-a6b8-4ffe-b3ce-36c91186254a" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2334daa8-a6b8-4ffe-b3ce-36c91186254a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d5c22b3e-da98-4f0b-97c0-b5c04675336b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2334daa8-a6b8-4ffe-b3ce-36c91186254a" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d5c22b3e-da98-4f0b-97c0-b5c04675336b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_9796bf77-eead-4a85-a751-0fb308f20251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d5c22b3e-da98-4f0b-97c0-b5c04675336b" xlink:to="loc_us-gaap_ThirdPartyPayorMember_9796bf77-eead-4a85-a751-0fb308f20251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfPayMember_c4bee847-9cb5-4594-93c4-c7b6c31009ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfPayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d5c22b3e-da98-4f0b-97c0-b5c04675336b" xlink:to="loc_us-gaap_SelfPayMember_c4bee847-9cb5-4594-93c4-c7b6c31009ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f960df69-3afa-454f-8e8d-386b65d5f49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f960df69-3afa-454f-8e8d-386b65d5f49f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f960df69-3afa-454f-8e8d-386b65d5f49f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f960df69-3afa-454f-8e8d-386b65d5f49f" xlink:to="loc_us-gaap_SegmentDomain_f960df69-3afa-454f-8e8d-386b65d5f49f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5e8759ce-4bc7-400e-a42b-3d7d3d849d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f960df69-3afa-454f-8e8d-386b65d5f49f" xlink:to="loc_us-gaap_SegmentDomain_5e8759ce-4bc7-400e-a42b-3d7d3d849d01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_4efd7537-cef1-4c3a-8e1a-424b5edcb28b" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5e8759ce-4bc7-400e-a42b-3d7d3d849d01" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_4efd7537-cef1-4c3a-8e1a-424b5edcb28b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_d75f561c-2cbb-477e-9378-da5d70f76598" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5e8759ce-4bc7-400e-a42b-3d7d3d849d01" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_d75f561c-2cbb-477e-9378-da5d70f76598" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" xlink:type="extended" id="ibc211d152ef14b8c822121e742d1402f_SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c56ddd0b-0afd-4f2f-9d6b-ce1e1fb1321f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_24563772-ad6c-4de1-af5b-62c2a50eb867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c56ddd0b-0afd-4f2f-9d6b-ce1e1fb1321f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_24563772-ad6c-4de1-af5b-62c2a50eb867" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c56ddd0b-0afd-4f2f-9d6b-ce1e1fb1321f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17d9c0b7-17a3-428e-9831-7a2e08d42d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17d9c0b7-17a3-428e-9831-7a2e08d42d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17d9c0b7-17a3-428e-9831-7a2e08d42d62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17d9c0b7-17a3-428e-9831-7a2e08d42d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17d9c0b7-17a3-428e-9831-7a2e08d42d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17d9c0b7-17a3-428e-9831-7a2e08d42d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_ccd61217-c449-415b-b26f-97e3922e466a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:to="loc_us-gaap_BuildingMember_ccd61217-c449-415b-b26f-97e3922e466a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9fb490a2-f2e5-4e4c-b69a-6fbc8619ebce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9fb490a2-f2e5-4e4c-b69a-6fbc8619ebce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_0aba069b-fc04-4d2f-a6e2-301716bfea87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:to="loc_us-gaap_VehiclesMember_0aba069b-fc04-4d2f-a6e2-301716bfea87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2e19403e-7460-4c98-ae90-3052ca9c85a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2e19403e-7460-4c98-ae90-3052ca9c85a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5fb8bba8-d9e9-48cf-8042-ad1144cf0246" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:to="loc_srt_RangeAxis_5fb8bba8-d9e9-48cf-8042-ad1144cf0246" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fb8bba8-d9e9-48cf-8042-ad1144cf0246_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5fb8bba8-d9e9-48cf-8042-ad1144cf0246" xlink:to="loc_srt_RangeMember_5fb8bba8-d9e9-48cf-8042-ad1144cf0246_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee3f1a24-1234-4da0-9989-e03adbbb4b3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5fb8bba8-d9e9-48cf-8042-ad1144cf0246" xlink:to="loc_srt_RangeMember_ee3f1a24-1234-4da0-9989-e03adbbb4b3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7b5803d9-898c-44a0-9753-11578c2afe66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ee3f1a24-1234-4da0-9989-e03adbbb4b3d" xlink:to="loc_srt_MinimumMember_7b5803d9-898c-44a0-9753-11578c2afe66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34c1b5b5-d3c4-4001-99c9-23a96d8a8bef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ee3f1a24-1234-4da0-9989-e03adbbb4b3d" xlink:to="loc_srt_MaximumMember_34c1b5b5-d3c4-4001-99c9-23a96d8a8bef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" xlink:type="extended" id="ib2107df6cf914959929bd32f96bbc19f_SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e94469c-b16c-48a7-9efb-84f0ee1085c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2487f235-6827-4970-9250-4b042bf73204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e94469c-b16c-48a7-9efb-84f0ee1085c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2487f235-6827-4970-9250-4b042bf73204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e94469c-b16c-48a7-9efb-84f0ee1085c5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9df36d96-42f5-44ea-81e8-df9eb576d169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9df36d96-42f5-44ea-81e8-df9eb576d169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9df36d96-42f5-44ea-81e8-df9eb576d169_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9df36d96-42f5-44ea-81e8-df9eb576d169" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9df36d96-42f5-44ea-81e8-df9eb576d169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9df36d96-42f5-44ea-81e8-df9eb576d169" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_48f7ef1a-4626-4e6d-9ac4-8c8d530cd37a" xlink:href="ehc-20211231.xsd#ehc_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_ehc_CertificateOfNeedMember_48f7ef1a-4626-4e6d-9ac4-8c8d530cd37a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_733cea4f-3609-487a-9a87-d2692841f052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_us-gaap_LicensingAgreementsMember_733cea4f-3609-487a-9a87-d2692841f052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_3cd7db88-1bb7-4a49-8c7a-6d789929ee76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_3cd7db88-1bb7-4a49-8c7a-6d789929ee76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7da27f35-2b5f-463d-b85f-9a5e94eb93ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_us-gaap_TradeNamesMember_7da27f35-2b5f-463d-b85f-9a5e94eb93ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InternalUseSoftwareMember_286b592a-eb28-48a3-a38a-05530c673529" xlink:href="ehc-20211231.xsd#ehc_InternalUseSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_ehc_InternalUseSoftwareMember_286b592a-eb28-48a3-a38a-05530c673529" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_2326e612-6cf4-4d8c-8f72-0f4db6f373eb" xlink:href="ehc-20211231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_ehc_MarketAccessAssetsMember_2326e612-6cf4-4d8c-8f72-0f4db6f373eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa8c77bd-106c-445c-9b16-74f449aff2d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:to="loc_srt_RangeAxis_fa8c77bd-106c-445c-9b16-74f449aff2d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa8c77bd-106c-445c-9b16-74f449aff2d0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fa8c77bd-106c-445c-9b16-74f449aff2d0" xlink:to="loc_srt_RangeMember_fa8c77bd-106c-445c-9b16-74f449aff2d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba1b7b42-2456-4853-85d7-c925fc23fe8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fa8c77bd-106c-445c-9b16-74f449aff2d0" xlink:to="loc_srt_RangeMember_ba1b7b42-2456-4853-85d7-c925fc23fe8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_850206ac-91e9-44b5-ab74-2c6a0d1dab0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba1b7b42-2456-4853-85d7-c925fc23fe8f" xlink:to="loc_srt_MinimumMember_850206ac-91e9-44b5-ab74-2c6a0d1dab0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ee0d114-7875-4b22-938e-5468cc6ae113" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba1b7b42-2456-4853-85d7-c925fc23fe8f" xlink:to="loc_srt_MaximumMember_5ee0d114-7875-4b22-938e-5468cc6ae113" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended" id="icc486df167e14b80af8f0bba0b48e909_BusinessCombinationsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3c831910-d86a-4602-b4bb-6da9870011cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3c831910-d86a-4602-b4bb-6da9870011cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsAcquired_a1d4c683-0273-4a11-98b2-a06ee7c8781f" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofBedsAcquired_a1d4c683-0273-4a11-98b2-a06ee7c8781f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_cce8478c-deb0-440c-8d71-ce2ba1299746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_cce8478c-deb0-440c-8d71-ce2ba1299746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fbc8ef10-e1e1-4d1b-9fa2-a961b8a353a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fbc8ef10-e1e1-4d1b-9fa2-a961b8a353a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9eac2387-8ed3-4cc5-8b81-e8e5b276c520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9eac2387-8ed3-4cc5-8b81-e8e5b276c520" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_7e34ecd5-a610-4335-9daf-990ae5fbd7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_7e34ecd5-a610-4335-9daf-990ae5fbd7b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage_803fe0b6-17b9-46ea-874d-cf87ed9d477d" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentAdditionalOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage_803fe0b6-17b9-46ea-874d-cf87ed9d477d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_99e5bbf1-f352-4cfd-8e51-083dfd34d73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_99e5bbf1-f352-4cfd-8e51-083dfd34d73d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofLocationsofanAcquiredEntity_351a447e-74c4-4365-bbdc-5bd0274f4c01" xlink:href="ehc-20211231.xsd#ehc_NumberofLocationsofanAcquiredEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofLocationsofanAcquiredEntity_351a447e-74c4-4365-bbdc-5bd0274f4c01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_00baca7f-3a33-4cb0-9712-7218c4a42bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_00baca7f-3a33-4cb0-9712-7218c4a42bfd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed_4b1027af-e9d6-4b1c-8197-ab4176472150" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsContributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofBedsContributed_4b1027af-e9d6-4b1c-8197-ab4176472150" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded_2ef4057b-1fb0-4ebf-8bdd-7d0edf141bb7" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsExpanded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofBedsExpanded_2ef4057b-1fb0-4ebf-8bdd-7d0edf141bb7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds_a0799cdf-249e-4476-ad56-d758ec374901" xlink:href="ehc-20211231.xsd#ehc_NumberofDeNovoBeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofDeNovoBeds_a0799cdf-249e-4476-ad56-d758ec374901" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28f3c5f-6565-4a3e-85a2-a4907c371534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28f3c5f-6565-4a3e-85a2-a4907c371534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d28f3c5f-6565-4a3e-85a2-a4907c371534_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28f3c5f-6565-4a3e-85a2-a4907c371534" xlink:to="loc_us-gaap_RelatedPartyDomain_d28f3c5f-6565-4a3e-85a2-a4907c371534_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_10c45c67-92cb-478f-82c7-eaec3c401b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28f3c5f-6565-4a3e-85a2-a4907c371534" xlink:to="loc_us-gaap_RelatedPartyDomain_10c45c67-92cb-478f-82c7-eaec3c401b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_2cb5e214-fd86-41c7-993b-4ecef0a9aa62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10c45c67-92cb-478f-82c7-eaec3c401b16" xlink:to="loc_us-gaap_CorporateJointVentureMember_2cb5e214-fd86-41c7-993b-4ecef0a9aa62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_714b42d0-8c96-48af-b609-f235af1ce924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_714b42d0-8c96-48af-b609-f235af1ce924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_714b42d0-8c96-48af-b609-f235af1ce924_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_714b42d0-8c96-48af-b609-f235af1ce924" xlink:to="loc_us-gaap_SegmentDomain_714b42d0-8c96-48af-b609-f235af1ce924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_714b42d0-8c96-48af-b609-f235af1ce924" xlink:to="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_eb4c77ac-362e-4895-841c-794a6b943db4" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_eb4c77ac-362e-4895-841c-794a6b943db4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_06db1c86-e593-40a3-82a3-61f1d97db251" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_06db1c86-e593-40a3-82a3-61f1d97db251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_488b20b9-b548-42d2-b65c-e06d54f24817" xlink:href="ehc-20211231.xsd#ehc_OtherHomeHealthAndHospiceAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:to="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_488b20b9-b548-42d2-b65c-e06d54f24817" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_52b73bc0-5ec6-4ef0-833a-320d65c73e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_SubsegmentsAxis_52b73bc0-5ec6-4ef0-833a-320d65c73e49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_52b73bc0-5ec6-4ef0-833a-320d65c73e49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_52b73bc0-5ec6-4ef0-833a-320d65c73e49" xlink:to="loc_us-gaap_SubsegmentsDomain_52b73bc0-5ec6-4ef0-833a-320d65c73e49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c6005e11-6e7a-4dd0-b762-807b5bcccbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_52b73bc0-5ec6-4ef0-833a-320d65c73e49" xlink:to="loc_us-gaap_SubsegmentsDomain_c6005e11-6e7a-4dd0-b762-807b5bcccbd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_6c3e96e8-ee11-4cc4-a105-5c74e1766c04" xlink:href="ehc-20211231.xsd#ehc_HomehealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c6005e11-6e7a-4dd0-b762-807b5bcccbd3" xlink:to="loc_ehc_HomehealthMember_6c3e96e8-ee11-4cc4-a105-5c74e1766c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_6010821f-21a0-4c59-b182-e2c7465644fa" xlink:href="ehc-20211231.xsd#ehc_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c6005e11-6e7a-4dd0-b762-807b5bcccbd3" xlink:to="loc_ehc_HospiceMember_6010821f-21a0-4c59-b182-e2c7465644fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b85ca35e-09e1-4a29-bdfc-329efeea572e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b85ca35e-09e1-4a29-bdfc-329efeea572e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b85ca35e-09e1-4a29-bdfc-329efeea572e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b85ca35e-09e1-4a29-bdfc-329efeea572e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b85ca35e-09e1-4a29-bdfc-329efeea572e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b85ca35e-09e1-4a29-bdfc-329efeea572e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalMember_bc128d24-2b24-4d06-a4a2-383551067b66" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_ShannonMedicalMember_bc128d24-2b24-4d06-a4a2-383551067b66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeritageValleyMember_a0428065-38c3-45e4-ae98-4f118bb76d61" xlink:href="ehc-20211231.xsd#ehc_HeritageValleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_HeritageValleyMember_a0428065-38c3-45e4-ae98-4f118bb76d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ECHDVenturesMember_04894e48-4083-4f89-bde9-edbd5e5df143" xlink:href="ehc-20211231.xsd#ehc_ECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_ECHDVenturesMember_04894e48-4083-4f89-bde9-edbd5e5df143" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_81a3984d-048a-41d5-bdb9-ec8f2831f034" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_81a3984d-048a-41d5-bdb9-ec8f2831f034" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeartOfTheRockiesHomeHealthMember_0c1006ac-b8fe-4c33-8111-228737c08117" xlink:href="ehc-20211231.xsd#ehc_HeartOfTheRockiesHomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_HeartOfTheRockiesHomeHealthMember_0c1006ac-b8fe-4c33-8111-228737c08117" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceOfSouthwestMontanaMember_b61f18bd-e6b8-4a1d-b5f3-91c224ff60d3" xlink:href="ehc-20211231.xsd#ehc_HospiceOfSouthwestMontanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_HospiceOfSouthwestMontanaMember_b61f18bd-e6b8-4a1d-b5f3-91c224ff60d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FrontierHomeHealthAndHospiceMember_64c16f0a-c81c-442c-acbd-3ef58dd8fc40" xlink:href="ehc-20211231.xsd#ehc_FrontierHomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_FrontierHomeHealthAndHospiceMember_64c16f0a-c81c-442c-acbd-3ef58dd8fc40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember_6e621c2e-3e42-4925-9240-ac5ecf9af345" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_PortercareAdventistMember_6e621c2e-3e42-4925-9240-ac5ecf9af345" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember_5b2d5101-8215-45d2-85e1-bf5f6ce27f6a" xlink:href="ehc-20211231.xsd#ehc_PremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_PremierHealthPartnersMember_5b2d5101-8215-45d2-85e1-bf5f6ce27f6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_48f0eef7-6c64-4878-bb80-edee79ec782e" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_48f0eef7-6c64-4878-bb80-edee79ec782e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember_8b5f2457-8863-4e09-a20e-bdf4b01fa9f9" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_SaintAlphonsusMember_8b5f2457-8863-4e09-a20e-bdf4b01fa9f9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember_7578fc68-31db-45ac-b46b-49e8310607d9" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_SaintAlphonsusandHeritageValleyMember_7578fc68-31db-45ac-b46b-49e8310607d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember_ae0c8e85-607f-4d72-8416-d8fb4d3cad06" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_AlacareMember_ae0c8e85-607f-4d72-8416-d8fb4d3cad06" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CareResourceGroupMember_fc1b9bfa-36b5-4937-b0b0-639677f71cf9" xlink:href="ehc-20211231.xsd#ehc_CareResourceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_CareResourceGroupMember_fc1b9bfa-36b5-4937-b0b0-639677f71cf9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember_debab1a8-8373-45c5-bb3a-6215e1b2fe99" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_TidewaterandCareResourceGroupMember_debab1a8-8373-45c5-bb3a-6215e1b2fe99" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BaptistOutpatientServicesIncMember_3234fd7a-0a98-4438-9bcd-4fbf913b895e" xlink:href="ehc-20211231.xsd#ehc_BaptistOutpatientServicesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_BaptistOutpatientServicesIncMember_3234fd7a-0a98-4438-9bcd-4fbf913b895e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_srt_RangeAxis_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee" xlink:to="loc_srt_RangeMember_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92740fb8-5906-4c45-938f-fe420b846fc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee" xlink:to="loc_srt_RangeMember_92740fb8-5906-4c45-938f-fe420b846fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4c583f3-bc56-411a-9e5c-5b25c9bd22a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92740fb8-5906-4c45-938f-fe420b846fc1" xlink:to="loc_srt_MinimumMember_e4c583f3-bc56-411a-9e5c-5b25c9bd22a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b273d52b-3758-47f7-b611-f20298b00613" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92740fb8-5906-4c45-938f-fe420b846fc1" xlink:to="loc_srt_MaximumMember_b273d52b-3758-47f7-b611-f20298b00613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6f5c4be6-378e-49ac-81fc-a34b6f918a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6f5c4be6-378e-49ac-81fc-a34b6f918a96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6f5c4be6-378e-49ac-81fc-a34b6f918a96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6f5c4be6-378e-49ac-81fc-a34b6f918a96" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6f5c4be6-378e-49ac-81fc-a34b6f918a96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2eac42ea-00ee-4dbb-ad6d-d35d80de1590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6f5c4be6-378e-49ac-81fc-a34b6f918a96" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2eac42ea-00ee-4dbb-ad6d-d35d80de1590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a8bd7dbb-abe2-4b2c-b843-7160e172a533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2eac42ea-00ee-4dbb-ad6d-d35d80de1590" xlink:to="loc_us-gaap_SubsequentEventMember_a8bd7dbb-abe2-4b2c-b843-7160e172a533" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended" id="idbb06f8ee88340e5a97d2053bebe0206_BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b9a2b6bf-7da6-451b-83ff-0bb477b6b928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b9a2b6bf-7da6-451b-83ff-0bb477b6b928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cda65815-6d26-4542-96c5-3e631126e592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cda65815-6d26-4542-96c5-3e631126e592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_426c06a6-eefa-4907-a491-a70bc76bc820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_426c06a6-eefa-4907-a491-a70bc76bc820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_08cbfa7b-5105-4616-92b6-c28ddf19d855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_08cbfa7b-5105-4616-92b6-c28ddf19d855" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_9eba3238-9d62-4672-8908-1060467d7d94" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_9eba3238-9d62-4672-8908-1060467d7d94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72c36860-69a9-4150-8288-b56a16de9b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72c36860-69a9-4150-8288-b56a16de9b84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_144af985-ab4e-44d7-8436-5d1b2c28464a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_Goodwill_144af985-ab4e-44d7-8436-5d1b2c28464a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b3d35144-0f0b-47ca-b766-84a83f1a0536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b3d35144-0f0b-47ca-b766-84a83f1a0536" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a4bddf4a-518a-41b7-94ee-868a35bb31c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a4bddf4a-518a-41b7-94ee-868a35bb31c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_db672821-0d19-4152-b6db-2ecc130814b2" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_db672821-0d19-4152-b6db-2ecc130814b2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_17b8f37d-d5cb-45b9-b7a9-a56fbdc4ccb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_17b8f37d-d5cb-45b9-b7a9-a56fbdc4ccb5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_722a1d8a-3c65-40d1-a7d3-c95492ea6151" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_722a1d8a-3c65-40d1-a7d3-c95492ea6151" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3d810c47-2789-45ed-890f-4469a50e6abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3d810c47-2789-45ed-890f-4469a50e6abd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_9a1cc90d-4714-48da-bc43-f7f5a2c70615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_9a1cc90d-4714-48da-bc43-f7f5a2c70615" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2a6dccdd-ee01-4840-9a56-36234d6432f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2a6dccdd-ee01-4840-9a56-36234d6432f6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3cb07409-1ac5-4b5a-b48f-6720e97fb507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3cb07409-1ac5-4b5a-b48f-6720e97fb507" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_d095097a-e4db-4684-b4c7-4a0720a3de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_d095097a-e4db-4684-b4c7-4a0720a3de0b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cd0fdde9-7c36-4fb9-bd65-2e78c057888d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cd0fdde9-7c36-4fb9-bd65-2e78c057888d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b3ae2527-6c5f-435d-85c0-aa59380de93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b3ae2527-6c5f-435d-85c0-aa59380de93a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_srt_RangeAxis_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b" xlink:to="loc_srt_RangeMember_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cb76a98-2925-480e-8ee0-0f57d62c9f36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b" xlink:to="loc_srt_RangeMember_9cb76a98-2925-480e-8ee0-0f57d62c9f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b46eb4ec-9df7-4041-bd08-7a4a438e0eea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9cb76a98-2925-480e-8ee0-0f57d62c9f36" xlink:to="loc_srt_MinimumMember_b46eb4ec-9df7-4041-bd08-7a4a438e0eea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_32291a3c-c2ad-4467-85c5-bf19693a0aec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9cb76a98-2925-480e-8ee0-0f57d62c9f36" xlink:to="loc_srt_MaximumMember_32291a3c-c2ad-4467-85c5-bf19693a0aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd" xlink:to="loc_us-gaap_SegmentDomain_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd" xlink:to="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_2b7901eb-11e0-4017-bac4-b7191206a2e7" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_2b7901eb-11e0-4017-bac4-b7191206a2e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_658f0fb5-4905-4a2e-af1c-7a04b4d7b128" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_658f0fb5-4905-4a2e-af1c-7a04b4d7b128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_ed7a89e5-4a88-4f17-94df-44b04bf25734" xlink:href="ehc-20211231.xsd#ehc_OtherHomeHealthAndHospiceAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:to="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_ed7a89e5-4a88-4f17-94df-44b04bf25734" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_e4a3bd14-02e5-433e-9c38-e71d870b363c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_e4a3bd14-02e5-433e-9c38-e71d870b363c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3db4776a-46be-4933-93f7-bfe4de83dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:to="loc_us-gaap_TradeNamesMember_3db4776a-46be-4933-93f7-bfe4de83dce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_68dfaed7-6549-48a6-8dd2-f7d812c15eb3" xlink:href="ehc-20211231.xsd#ehc_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:to="loc_ehc_CertificateOfNeedMember_68dfaed7-6549-48a6-8dd2-f7d812c15eb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3c742154-c22c-46d3-8215-930ebb2309a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:to="loc_us-gaap_LicensingAgreementsMember_3c742154-c22c-46d3-8215-930ebb2309a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dcfea458-5141-4188-96f2-7c192662849d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dcfea458-5141-4188-96f2-7c192662849d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfea458-5141-4188-96f2-7c192662849d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcfea458-5141-4188-96f2-7c192662849d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfea458-5141-4188-96f2-7c192662849d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcfea458-5141-4188-96f2-7c192662849d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_aa782c25-67bf-402f-a797-24dcc747a09f" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_aa782c25-67bf-402f-a797-24dcc747a09f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FrontierHomeHealthAndHospiceMember_05ba5c94-c750-4c35-88ea-f88ccec38724" xlink:href="ehc-20211231.xsd#ehc_FrontierHomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_FrontierHomeHealthAndHospiceMember_05ba5c94-c750-4c35-88ea-f88ccec38724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BaptistOutpatientServicesIncMember_cccafa76-be3c-43d3-8ca0-6570abdf043b" xlink:href="ehc-20211231.xsd#ehc_BaptistOutpatientServicesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_BaptistOutpatientServicesIncMember_cccafa76-be3c-43d3-8ca0-6570abdf043b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_31f86afd-969f-4aa9-b951-aa192351297b" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_31f86afd-969f-4aa9-b951-aa192351297b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsOfLynchburgMember_8b8c7402-133b-43f0-a513-72d61524ef2e" xlink:href="ehc-20211231.xsd#ehc_GenerationSolutionsOfLynchburgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_GenerationSolutionsOfLynchburgMember_8b8c7402-133b-43f0-a513-72d61524ef2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember_efedb742-eb15-43b0-a4b4-9008f20a0382" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_SaintAlphonsusandHeritageValleyMember_efedb742-eb15-43b0-a4b4-9008f20a0382" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember_e9dfb5c0-4218-40b9-9e5c-189c9594ef7e" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_AlacareMember_e9dfb5c0-4218-40b9-9e5c-189c9594ef7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember_2ef84b6f-692b-41c6-a432-e3450ed1d0fa" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_TidewaterandCareResourceGroupMember_2ef84b6f-692b-41c6-a432-e3450ed1d0fa" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsNetCashPaidforAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails" xlink:type="extended" id="i688e556a94f74fe791cbc864949b5ef0_BusinessCombinationsNetCashPaidforAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_2aedcec2-c115-4cb8-a224-289b7372d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_2aedcec2-c115-4cb8-a224-289b7372d7ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8f2ee8e3-bd91-4dd5-8394-2c1ac66a95ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8f2ee8e3-bd91-4dd5-8394-2c1ac66a95ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ffcf46f2-8db1-40b2-8fd3-3d771e67b65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ffcf46f2-8db1-40b2-8fd3-3d771e67b65b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_43f84922-4243-4b03-a4bc-0168f295d352" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_43f84922-4243-4b03-a4bc-0168f295d352" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3f37d8f1-08f4-4035-bbbb-6ee70afd88c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3f37d8f1-08f4-4035-bbbb-6ee70afd88c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_6a6c5d39-fb8f-4192-848b-9988df3c8378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_6a6c5d39-fb8f-4192-848b-9988df3c8378" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2fe12355-8c22-4e3b-a7cf-db7a73a778e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2fe12355-8c22-4e3b-a7cf-db7a73a778e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_470a3f13-4197-4bad-847e-d3203867e062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_470a3f13-4197-4bad-847e-d3203867e062" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e318fca5-6054-43d8-b7a2-36dedcff0a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e318fca5-6054-43d8-b7a2-36dedcff0a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e318fca5-6054-43d8-b7a2-36dedcff0a14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e318fca5-6054-43d8-b7a2-36dedcff0a14" xlink:to="loc_us-gaap_SegmentDomain_e318fca5-6054-43d8-b7a2-36dedcff0a14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e318fca5-6054-43d8-b7a2-36dedcff0a14" xlink:to="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_b8d9f83c-565d-4974-a36b-1a997771f2e0" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_b8d9f83c-565d-4974-a36b-1a997771f2e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_3b02ce3c-40a3-48e4-8c92-f2584e22c27b" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_3b02ce3c-40a3-48e4-8c92-f2584e22c27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_c021cc2f-cd2b-485b-b0fb-eb372747a6a3" xlink:href="ehc-20211231.xsd#ehc_OtherHomeHealthAndHospiceAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:to="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_c021cc2f-cd2b-485b-b0fb-eb372747a6a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7854762a-bfdd-4ba7-99f7-9488740945dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7854762a-bfdd-4ba7-99f7-9488740945dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7854762a-bfdd-4ba7-99f7-9488740945dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7854762a-bfdd-4ba7-99f7-9488740945dc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7854762a-bfdd-4ba7-99f7-9488740945dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7854762a-bfdd-4ba7-99f7-9488740945dc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_1a974008-33aa-4ac0-9fee-c7555b43422a" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_1a974008-33aa-4ac0-9fee-c7555b43422a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FrontierHomeHealthAndHospiceMember_43bb5ef8-08c6-4bea-873c-366b71460348" xlink:href="ehc-20211231.xsd#ehc_FrontierHomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_FrontierHomeHealthAndHospiceMember_43bb5ef8-08c6-4bea-873c-366b71460348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BaptistOutpatientServicesIncMember_6e68a73c-2c7c-4cfa-8b77-f4f992f25c8a" xlink:href="ehc-20211231.xsd#ehc_BaptistOutpatientServicesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_BaptistOutpatientServicesIncMember_6e68a73c-2c7c-4cfa-8b77-f4f992f25c8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_b715d60d-1695-4f28-8828-ec7059e190f0" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_b715d60d-1695-4f28-8828-ec7059e190f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsOfLynchburgMember_613da51e-7bcc-4478-b695-ffa72aa6b956" xlink:href="ehc-20211231.xsd#ehc_GenerationSolutionsOfLynchburgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_GenerationSolutionsOfLynchburgMember_613da51e-7bcc-4478-b695-ffa72aa6b956" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember_07a55299-8bca-4702-a676-322190aad458" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_SaintAlphonsusandHeritageValleyMember_07a55299-8bca-4702-a676-322190aad458" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember_36c619d2-388f-4c98-8b5b-1df8d1cb3b2f" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_AlacareMember_36c619d2-388f-4c98-8b5b-1df8d1cb3b2f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember_c775c6a4-0c5e-4d72-bf67-b4f894e41573" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_TidewaterandCareResourceGroupMember_c775c6a4-0c5e-4d72-bf67-b4f894e41573" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended" id="i3a3fba5f5e1a4ec0858458c1906827f0_BusinessCombinationsProFormaResultsofOperationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_eb5ea83a-7249-410d-9996-d9319808ecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_eb5ea83a-7249-410d-9996-d9319808ecb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d16e76c0-c07e-434c-9c2d-155bb16ee51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d16e76c0-c07e-434c-9c2d-155bb16ee51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_dacb9b22-eeea-4b59-8910-189c88669d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_dacb9b22-eeea-4b59-8910-189c88669d03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_1c0ce0dc-c1f0-43e0-b452-a67ca7728630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_1c0ce0dc-c1f0-43e0-b452-a67ca7728630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86" xlink:to="loc_us-gaap_SegmentDomain_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_617b340d-b71b-4779-b569-328e3d47a548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86" xlink:to="loc_us-gaap_SegmentDomain_617b340d-b71b-4779-b569-328e3d47a548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_534d83af-942b-4f2a-95f6-799fe8843f4a" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_617b340d-b71b-4779-b569-328e3d47a548" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_534d83af-942b-4f2a-95f6-799fe8843f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_267f079d-3ce0-4673-978b-e1f260304a21" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_617b340d-b71b-4779-b569-328e3d47a548" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_267f079d-3ce0-4673-978b-e1f260304a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_383cc4f8-06ba-44c2-a4d5-3eca7157628b" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_383cc4f8-06ba-44c2-a4d5-3eca7157628b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember_d0dc0300-3600-489d-affc-4a8b2f950761" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_SaintAlphonsusandHeritageValleyMember_d0dc0300-3600-489d-affc-4a8b2f950761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember_923084e0-1692-4770-8824-58cd09c27991" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_AlacareMember_923084e0-1692-4770-8824-58cd09c27991" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember_b4e16e14-7c76-4cd7-a1be-5541e1c9aa7b" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_TidewaterandCareResourceGroupMember_b4e16e14-7c76-4cd7-a1be-5541e1c9aa7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsOfLynchburgMember_7573b9e7-f9d3-40a6-aef4-57201cc38196" xlink:href="ehc-20211231.xsd#ehc_GenerationSolutionsOfLynchburgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_GenerationSolutionsOfLynchburgMember_7573b9e7-f9d3-40a6-aef4-57201cc38196" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2021AcquisitionsMember_edb4e621-0bc2-496e-9525-97d1a87ef425" xlink:href="ehc-20211231.xsd#ehc_A2021AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_A2021AcquisitionsMember_edb4e621-0bc2-496e-9525-97d1a87ef425" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2020AcquisitionsMember_9c21580e-b099-4fcd-8758-15c14ce0e563" xlink:href="ehc-20211231.xsd#ehc_A2020AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_A2020AcquisitionsMember_9c21580e-b099-4fcd-8758-15c14ce0e563" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2019AcquisitionsMember_f1283332-eab7-4bf0-9dfd-bd547ba792b6" xlink:href="ehc-20211231.xsd#ehc_A2019AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_A2019AcquisitionsMember_f1283332-eab7-4bf0-9dfd-bd547ba792b6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#VariableInterestEntitiesTextualsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails" xlink:type="extended" id="i754a30fa2c70437b9199427af4a7f315_VariableInterestEntitiesTextualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_280a07f2-99a7-4a0e-a05b-24400465672d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_2b5c420f-fdf2-43b3-8e05-4dbafe40b732" xlink:href="ehc-20211231.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_280a07f2-99a7-4a0e-a05b-24400465672d" xlink:to="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_2b5c420f-fdf2-43b3-8e05-4dbafe40b732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_e5c34133-f969-41d4-828e-628cfea0cabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_280a07f2-99a7-4a0e-a05b-24400465672d" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_e5c34133-f969-41d4-828e-628cfea0cabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_280a07f2-99a7-4a0e-a05b-24400465672d" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5f57f7bb-db28-4a9f-8d50-80d12394310d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:to="loc_srt_RangeAxis_5f57f7bb-db28-4a9f-8d50-80d12394310d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f57f7bb-db28-4a9f-8d50-80d12394310d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5f57f7bb-db28-4a9f-8d50-80d12394310d" xlink:to="loc_srt_RangeMember_5f57f7bb-db28-4a9f-8d50-80d12394310d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_511909e1-254a-448d-a193-35f42a71b197" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5f57f7bb-db28-4a9f-8d50-80d12394310d" xlink:to="loc_srt_RangeMember_511909e1-254a-448d-a193-35f42a71b197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0bee463b-96c2-4d24-a36b-9bcc84786490" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_511909e1-254a-448d-a193-35f42a71b197" xlink:to="loc_srt_MinimumMember_0bee463b-96c2-4d24-a36b-9bcc84786490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99c84a1f-69f0-46c8-a746-5003d44b1162" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_511909e1-254a-448d-a193-35f42a71b197" xlink:to="loc_srt_MaximumMember_99c84a1f-69f0-46c8-a746-5003d44b1162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ee8582b5-0e1c-479d-8613-6fe9b9078a4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ee8582b5-0e1c-479d-8613-6fe9b9078a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ee8582b5-0e1c-479d-8613-6fe9b9078a4b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ee8582b5-0e1c-479d-8613-6fe9b9078a4b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ee8582b5-0e1c-479d-8613-6fe9b9078a4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_aa552b6d-4fb3-4292-b7a0-0fd783147385" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ee8582b5-0e1c-479d-8613-6fe9b9078a4b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_aa552b6d-4fb3-4292-b7a0-0fd783147385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_adf4f563-efe4-42ed-b3c3-c2007332470d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_aa552b6d-4fb3-4292-b7a0-0fd783147385" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_adf4f563-efe4-42ed-b3c3-c2007332470d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="extended" id="i116e1df60a4b4a8b9c92094e812b96b5_VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_5ed26a19-ea56-42e8-99e0-bdec098f98d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5ed26a19-ea56-42e8-99e0-bdec098f98d4" xlink:to="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d45cb68-a90c-43be-a497-e152286d8ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d45cb68-a90c-43be-a497-e152286d8ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d2415ba2-cfa1-4e41-9810-07cb32d366bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d2415ba2-cfa1-4e41-9810-07cb32d366bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d49f3260-1924-42da-96d9-31b1eb0521a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:to="loc_us-gaap_OtherAssetsCurrent_d49f3260-1924-42da-96d9-31b1eb0521a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ed623d08-4600-4ff6-9a90-06d9a28ddfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:to="loc_us-gaap_AssetsCurrent_ed623d08-4600-4ff6-9a90-06d9a28ddfd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d320dac7-8dd8-4ecd-b6b2-7002367ff7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d320dac7-8dd8-4ecd-b6b2-7002367ff7dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c9f6e23-9222-48d1-8b62-dd5d0c166589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c9f6e23-9222-48d1-8b62-dd5d0c166589" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ac12d4c7-d42a-430c-b739-26b7eaa92d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_Goodwill_ac12d4c7-d42a-430c-b739-26b7eaa92d97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2f76d738-fd4f-48a8-ad76-c01d50015f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2f76d738-fd4f-48a8-ad76-c01d50015f01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_3d1df4b2-859d-4a28-859c-e77e824aad06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_3d1df4b2-859d-4a28-859c-e77e824aad06" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f8261545-6f0d-49f9-96b2-20fcfc35e901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f8261545-6f0d-49f9-96b2-20fcfc35e901" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f0dbdf97-efe4-4cbc-a186-87ff9e3a50da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_Assets_f0dbdf97-efe4-4cbc-a186-87ff9e3a50da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5ed26a19-ea56-42e8-99e0-bdec098f98d4" xlink:to="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9f5ed143-d3de-4706-bbfa-d57e0612a241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9f5ed143-d3de-4706-bbfa-d57e0612a241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f6bdde8-ddf7-47dd-8c03-e12e479153d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f6bdde8-ddf7-47dd-8c03-e12e479153d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e4e20cb8-eef0-4e88-a898-4c18fa48c504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_AccountsPayableCurrent_e4e20cb8-eef0-4e88-a898-4c18fa48c504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e083b192-25e3-4e2a-a6d9-5b018d4cd5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e083b192-25e3-4e2a-a6d9-5b018d4cd5b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c35b1c2b-7b72-4dd1-813f-cfb2ca357ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c35b1c2b-7b72-4dd1-813f-cfb2ca357ade" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_94e8eee9-daad-4f54-8599-ab6d9c6eb682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_LiabilitiesCurrent_94e8eee9-daad-4f54-8599-ab6d9c6eb682" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b9c9bf69-e7b6-49c3-a253-24a296930fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b9c9bf69-e7b6-49c3-a253-24a296930fa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f4f9244-0885-4304-bd25-0201242a39ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f4f9244-0885-4304-bd25-0201242a39ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7a0df515-975a-4144-9cde-6f3795da3b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7a0df515-975a-4144-9cde-6f3795da3b55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_adcd2ad5-672b-4a1d-b60b-9fb74b556089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_Liabilities_adcd2ad5-672b-4a1d-b60b-9fb74b556089" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7b3da02c-a9b1-4e8f-9956-8d64624ff6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5ed26a19-ea56-42e8-99e0-bdec098f98d4" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7b3da02c-a9b1-4e8f-9956-8d64624ff6d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0cf69d55-69de-4ac0-8655-2df36df1c903" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7b3da02c-a9b1-4e8f-9956-8d64624ff6d7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0cf69d55-69de-4ac0-8655-2df36df1c903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0cf69d55-69de-4ac0-8655-2df36df1c903_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0cf69d55-69de-4ac0-8655-2df36df1c903" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0cf69d55-69de-4ac0-8655-2df36df1c903_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8016d512-1cd6-4f3b-8a23-40c381028c31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0cf69d55-69de-4ac0-8655-2df36df1c903" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8016d512-1cd6-4f3b-8a23-40c381028c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c67042d8-dfad-49cb-82ab-4723b59ad59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8016d512-1cd6-4f3b-8a23-40c381028c31" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c67042d8-dfad-49cb-82ab-4723b59ad59e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecuritiesComponentsofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="extended" id="iad80f89c280d491ba5c7a0dc1cc38f8e_CashandMarketableSecuritiesComponentsofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff9ffeb-33f8-45f5-a4e5-e54fb767bfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff9ffeb-33f8-45f5-a4e5-e54fb767bfdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_78da2ebf-533b-48d5-abec-9d0eaee11a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_78da2ebf-533b-48d5-abec-9d0eaee11a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_62bbeb82-64e3-4020-ae19-5c17b436bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRestricted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_62bbeb82-64e3-4020-ae19-5c17b436bae2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InvestmentsCashandRestrictedCash_b5cabde5-0de5-4112-a1f6-bc7cef4e1bc7" xlink:href="ehc-20211231.xsd#ehc_InvestmentsCashandRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_ehc_InvestmentsCashandRestrictedCash_b5cabde5-0de5-4112-a1f6-bc7cef4e1bc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_548d6858-7733-4c9f-9ada-f04e43467439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_548d6858-7733-4c9f-9ada-f04e43467439" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f3187ede-f6ef-4559-9e78-cc3280245cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_548d6858-7733-4c9f-9ada-f04e43467439" xlink:to="loc_us-gaap_InvestmentTypeAxis_f3187ede-f6ef-4559-9e78-cc3280245cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f3187ede-f6ef-4559-9e78-cc3280245cb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f3187ede-f6ef-4559-9e78-cc3280245cb5" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f3187ede-f6ef-4559-9e78-cc3280245cb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4b2a3f68-807a-4df1-a8b4-a413630d814c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f3187ede-f6ef-4559-9e78-cc3280245cb5" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4b2a3f68-807a-4df1-a8b4-a413630d814c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_6f9b0f75-78e1-4cb4-b2ed-c5ee13f70c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b2a3f68-807a-4df1-a8b4-a413630d814c" xlink:to="loc_us-gaap_CashMember_6f9b0f75-78e1-4cb4-b2ed-c5ee13f70c8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_2026076f-3876-4632-8c15-3ba91d6e99d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b2a3f68-807a-4df1-a8b4-a413630d814c" xlink:to="loc_us-gaap_EquitySecuritiesMember_2026076f-3876-4632-8c15-3ba91d6e99d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecuritiesRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails" xlink:type="extended" id="i7b998c98be8f4861b3a0cab9f985d606_CashandMarketableSecuritiesRestrictedCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fc9af8e2-9b71-48ce-bfa6-ead56f31f016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bb2ee729-686e-411f-9567-dacff597a32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fc9af8e2-9b71-48ce-bfa6-ead56f31f016" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bb2ee729-686e-411f-9567-dacff597a32f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2e695e51-ba97-4fef-9393-491ff172721f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fc9af8e2-9b71-48ce-bfa6-ead56f31f016" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2e695e51-ba97-4fef-9393-491ff172721f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_24e16110-7793-489e-863a-92af9ecc9be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fc9af8e2-9b71-48ce-bfa6-ead56f31f016" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_24e16110-7793-489e-863a-92af9ecc9be6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cb4b5a05-206d-4683-9f7e-fb3f2e06affc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_24e16110-7793-489e-863a-92af9ecc9be6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cb4b5a05-206d-4683-9f7e-fb3f2e06affc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb4b5a05-206d-4683-9f7e-fb3f2e06affc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cb4b5a05-206d-4683-9f7e-fb3f2e06affc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb4b5a05-206d-4683-9f7e-fb3f2e06affc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f0ca0345-29db-44e2-95b3-6e51f6ec600b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cb4b5a05-206d-4683-9f7e-fb3f2e06affc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f0ca0345-29db-44e2-95b3-6e51f6ec600b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliateCashMember_d7045a88-168d-4d86-8ddf-a59eb6f9c2fa" xlink:href="ehc-20211231.xsd#ehc_AffiliateCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f0ca0345-29db-44e2-95b3-6e51f6ec600b" xlink:to="loc_ehc_AffiliateCashMember_d7045a88-168d-4d86-8ddf-a59eb6f9c2fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SelfInsuredCaptiveFundsMember_bfcd4533-fcb3-4d0b-81de-715c2587aad5" xlink:href="ehc-20211231.xsd#ehc_SelfInsuredCaptiveFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f0ca0345-29db-44e2-95b3-6e51f6ec600b" xlink:to="loc_ehc_SelfInsuredCaptiveFundsMember_bfcd4533-fcb3-4d0b-81de-715c2587aad5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended" id="if221fd9d4a6a447686fab3a312853bb2_PropertyandEquipmentComponentsofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a3befe73-91b2-4bae-8b7b-b789f699ccd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a3befe73-91b2-4bae-8b7b-b789f699ccd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_7aa2c6c7-e980-4246-9690-25db141e1663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_7aa2c6c7-e980-4246-9690-25db141e1663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0f687048-4510-418f-aa3c-cb61d5305e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0f687048-4510-418f-aa3c-cb61d5305e10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d66b7c59-7c4c-4733-9382-de2d36f859a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d66b7c59-7c4c-4733-9382-de2d36f859a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d0b1f24-b4dd-4482-9406-9fa2974925cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a3befe73-91b2-4bae-8b7b-b789f699ccd5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d0b1f24-b4dd-4482-9406-9fa2974925cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67449dbf-cf5f-4c0f-aa24-cc6326434351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d0b1f24-b4dd-4482-9406-9fa2974925cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67449dbf-cf5f-4c0f-aa24-cc6326434351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67449dbf-cf5f-4c0f-aa24-cc6326434351_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67449dbf-cf5f-4c0f-aa24-cc6326434351" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67449dbf-cf5f-4c0f-aa24-cc6326434351_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb734b46-7269-4b71-b9ef-ab8a4c351507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67449dbf-cf5f-4c0f-aa24-cc6326434351" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb734b46-7269-4b71-b9ef-ab8a4c351507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:href="ehc-20211231.xsd#ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb734b46-7269-4b71-b9ef-ab8a4c351507" xlink:to="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_01c5ebf8-388d-4f4c-b0a1-824067d90ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_LandMember_01c5ebf8-388d-4f4c-b0a1-824067d90ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_81f403be-25d0-43a8-9f76-454749496ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_BuildingMember_81f403be-25d0-43a8-9f76-454749496ef0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d02cb897-8d33-4662-9be0-3dfeab39c241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d02cb897-8d33-4662-9be0-3dfeab39c241" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_23bbdba2-df74-46f0-a3c3-4774fa07dc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_VehiclesMember_23bbdba2-df74-46f0-a3c3-4774fa07dc8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_971bf603-8afa-4e64-8db8-f228d16cffbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_971bf603-8afa-4e64-8db8-f228d16cffbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_efea0417-fe0f-43ee-8dcb-c6b17d972a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb734b46-7269-4b71-b9ef-ab8a4c351507" xlink:to="loc_us-gaap_ConstructionInProgressMember_efea0417-fe0f-43ee-8dcb-c6b17d972a15" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesTextualsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesTextualsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LeasesTextualsDetails" xlink:type="extended" id="i2d4f2436443f426ba93fcfb8aa7ce101_LeasesTextualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_83c41ddc-d754-4961-83ac-00b0c196076c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Operatingandfinanceleasecontractterm_f878c1a1-912a-48f1-bde5-555a3a992872" xlink:href="ehc-20211231.xsd#ehc_Operatingandfinanceleasecontractterm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83c41ddc-d754-4961-83ac-00b0c196076c" xlink:to="loc_ehc_Operatingandfinanceleasecontractterm_f878c1a1-912a-48f1-bde5-555a3a992872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1a660907-af32-44aa-98b9-7bf673b0d08f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83c41ddc-d754-4961-83ac-00b0c196076c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1a660907-af32-44aa-98b9-7bf673b0d08f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1a660907-af32-44aa-98b9-7bf673b0d08f" xlink:to="loc_srt_RangeAxis_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a" xlink:to="loc_srt_RangeMember_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f41e7f96-2372-40ee-8966-41edd53b0022" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a" xlink:to="loc_srt_RangeMember_f41e7f96-2372-40ee-8966-41edd53b0022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fc16bc1b-dc5e-4b71-9446-eb5188216d59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f41e7f96-2372-40ee-8966-41edd53b0022" xlink:to="loc_srt_MinimumMember_fc16bc1b-dc5e-4b71-9446-eb5188216d59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fae40b6f-8dca-45c7-8b6f-4898613bf043" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f41e7f96-2372-40ee-8966-41edd53b0022" xlink:to="loc_srt_MaximumMember_fae40b6f-8dca-45c7-8b6f-4898613bf043" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails" xlink:type="extended" id="ib450dd523d6947ab8e43784d7e5dea75_GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ebde400f-a278-4916-8145-cc01c3c8f810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ebde400f-a278-4916-8145-cc01c3c8f810" xlink:to="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9fee4af3-181b-41fe-89ef-5b3f6c280fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:to="loc_us-gaap_Goodwill_9fee4af3-181b-41fe-89ef-5b3f6c280fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0675da6b-d63c-4c82-8de6-203039a2cbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0675da6b-d63c-4c82-8de6-203039a2cbe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod_9e209cde-c70d-4a22-bfc7-a73a403c763c" xlink:href="ehc-20211231.xsd#ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:to="loc_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod_9e209cde-c70d-4a22-bfc7-a73a403c763c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_822ffd68-3ec9-4b19-a80f-20f3add88eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b675d3f2-9bd8-4d35-af0b-b3ff92164e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_ebde400f-a278-4916-8145-cc01c3c8f810" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b675d3f2-9bd8-4d35-af0b-b3ff92164e38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ec216204-4512-466d-81fd-652c1d082f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b675d3f2-9bd8-4d35-af0b-b3ff92164e38" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ec216204-4512-466d-81fd-652c1d082f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ec216204-4512-466d-81fd-652c1d082f88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ec216204-4512-466d-81fd-652c1d082f88" xlink:to="loc_us-gaap_SegmentDomain_ec216204-4512-466d-81fd-652c1d082f88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8276468d-f103-401a-a53e-3671505f42e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ec216204-4512-466d-81fd-652c1d082f88" xlink:to="loc_us-gaap_SegmentDomain_8276468d-f103-401a-a53e-3671505f42e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_c3bf4041-527f-4003-9617-16dcb065ac63" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8276468d-f103-401a-a53e-3671505f42e2" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_c3bf4041-527f-4003-9617-16dcb065ac63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_90ec00e4-9560-41a8-a22a-1a8952710e5f" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8276468d-f103-401a-a53e-3671505f42e2" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_90ec00e4-9560-41a8-a22a-1a8952710e5f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="extended" id="i8fd16c19f32d4500922c94350c473991_GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26205c02-965e-40f5-9b7c-4f9fd5aa846a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26205c02-965e-40f5-9b7c-4f9fd5aa846a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_342651d4-196d-4250-aa26-ccc975ece8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_342651d4-196d-4250-aa26-ccc975ece8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_798ff905-c53f-464c-88c4-967f0aec665f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_798ff905-c53f-464c-88c4-967f0aec665f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b257ba47-2404-41c5-9665-599c0032cdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b257ba47-2404-41c5-9665-599c0032cdd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1eeb3b2d-a7bb-4ceb-9deb-a7903f9b397c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26205c02-965e-40f5-9b7c-4f9fd5aa846a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1eeb3b2d-a7bb-4ceb-9deb-a7903f9b397c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76c9b711-d691-4eb9-9507-baafe524d660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1eeb3b2d-a7bb-4ceb-9deb-a7903f9b397c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76c9b711-d691-4eb9-9507-baafe524d660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76c9b711-d691-4eb9-9507-baafe524d660_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76c9b711-d691-4eb9-9507-baafe524d660" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76c9b711-d691-4eb9-9507-baafe524d660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76c9b711-d691-4eb9-9507-baafe524d660" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_bd084c4f-3a11-48dd-8ee7-d5098427f546" xlink:href="ehc-20211231.xsd#ehc_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_ehc_CertificateOfNeedMember_bd084c4f-3a11-48dd-8ee7-d5098427f546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_d388d3d5-b9dc-49da-9f40-0950b86f5bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_us-gaap_LicensingAgreementsMember_d388d3d5-b9dc-49da-9f40-0950b86f5bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_b7337059-c738-43b2-ae6c-326159a5dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_b7337059-c738-43b2-ae6c-326159a5dc19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TradeNameEncompassMember_ad3e0656-e566-4f26-95da-050c5aaef279" xlink:href="ehc-20211231.xsd#ehc_TradeNameEncompassMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_ehc_TradeNameEncompassMember_ad3e0656-e566-4f26-95da-050c5aaef279" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_878227ae-32ee-477a-aff6-516fa02f65fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_us-gaap_TradeNamesMember_878227ae-32ee-477a-aff6-516fa02f65fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ada98977-9f0e-4996-bc0b-7766cdf2f159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ada98977-9f0e-4996-bc0b-7766cdf2f159" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_40750c3e-7b46-4fe8-8a1b-f461c75e4e4f" xlink:href="ehc-20211231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_ehc_MarketAccessAssetsMember_40750c3e-7b46-4fe8-8a1b-f461c75e4e4f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails" xlink:type="extended" id="ib70bb4f187eb4e2bb647b754728808fc_InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated_13cb8914-166c-4ddb-ac6b-5cb9745a9851" xlink:href="ehc-20211231.xsd#ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated_13cb8914-166c-4ddb-ac6b-5cb9745a9851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures_e5ad4779-e07a-441a-84d4-eb813dcaf5da" xlink:href="ehc-20211231.xsd#ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures_e5ad4779-e07a-441a-84d4-eb813dcaf5da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliatesOwnershipPercentage_5f056b0a-a19c-4fa0-8864-64553b6672f1" xlink:href="ehc-20211231.xsd#ehc_AffiliatesOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_ehc_AffiliatesOwnershipPercentage_5f056b0a-a19c-4fa0-8864-64553b6672f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_895e8f94-3bcf-4fb8-a34d-ced58280f588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_895e8f94-3bcf-4fb8-a34d-ced58280f588" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_5f73918c-fb8b-4e38-812e-ea9ea4840903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_5f73918c-fb8b-4e38-812e-ea9ea4840903" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:to="loc_srt_RangeAxis_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab" xlink:to="loc_srt_RangeMember_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f5d9d4c-f25d-41a8-91ce-69a012c26f5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab" xlink:to="loc_srt_RangeMember_0f5d9d4c-f25d-41a8-91ce-69a012c26f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_25555743-94f7-4680-89d9-8bf761c86e3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0f5d9d4c-f25d-41a8-91ce-69a012c26f5a" xlink:to="loc_srt_MinimumMember_25555743-94f7-4680-89d9-8bf761c86e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5462ee75-a2c0-411a-aa62-9ef7d25f5305" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0f5d9d4c-f25d-41a8-91ce-69a012c26f5a" xlink:to="loc_srt_MaximumMember_5462ee75-a2c0-411a-aa62-9ef7d25f5305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89c55994-4c8b-468a-bb5d-de9795d0c4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89c55994-4c8b-468a-bb5d-de9795d0c4ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89c55994-4c8b-468a-bb5d-de9795d0c4ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89c55994-4c8b-468a-bb5d-de9795d0c4ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89c55994-4c8b-468a-bb5d-de9795d0c4ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91b00181-45ee-48fa-88f8-b4754c659e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89c55994-4c8b-468a-bb5d-de9795d0c4ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91b00181-45ee-48fa-88f8-b4754c659e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_JupiterFloridaHomeHealthAgencyMember_c9d183fa-3817-44ab-ba15-7b9ec7321baf" xlink:href="ehc-20211231.xsd#ehc_JupiterFloridaHomeHealthAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91b00181-45ee-48fa-88f8-b4754c659e43" xlink:to="loc_ehc_JupiterFloridaHomeHealthAgencyMember_c9d183fa-3817-44ab-ba15-7b9ec7321baf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_YumaRehabilitationHospitalMember_168c576f-7339-49ea-9bcd-c154143878a2" xlink:href="ehc-20211231.xsd#ehc_YumaRehabilitationHospitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91b00181-45ee-48fa-88f8-b4754c659e43" xlink:to="loc_ehc_YumaRehabilitationHospitalMember_168c576f-7339-49ea-9bcd-c154143878a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails" xlink:type="extended" id="i4202f692824841efbf2a8b82fa2dfe48_InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23eb7ba0-805e-4e24-bfd0-aef6285b9a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:to="loc_us-gaap_AssetsCurrent_23eb7ba0-805e-4e24-bfd0-aef6285b9a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_0aa49245-4b3b-4f8f-8c36-ffcf665de553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:to="loc_us-gaap_AssetsNoncurrent_0aa49245-4b3b-4f8f-8c36-ffcf665de553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_69457acf-f961-4a63-ad17-6d6a50ac00b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:to="loc_us-gaap_Assets_69457acf-f961-4a63-ad17-6d6a50ac00b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2c8c4bae-408c-4f12-a929-d3ee0d86556b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:to="loc_us-gaap_LiabilitiesCurrent_2c8c4bae-408c-4f12-a929-d3ee0d86556b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_68164dc9-779a-4090-a07e-c838cb665b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_68164dc9-779a-4090-a07e-c838cb665b2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:to="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c628e9c5-bcc3-451d-85a9-e6e942310c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:to="loc_us-gaap_StockholdersEquity_c628e9c5-bcc3-451d-85a9-e6e942310c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3d088def-6a47-429b-b382-307598a2f1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:to="loc_us-gaap_MinorityInterest_3d088def-6a47-429b-b382-307598a2f1b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a222de58-8d3d-4820-aea8-6d000337343d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a222de58-8d3d-4820-aea8-6d000337343d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bab6e29-321c-454e-a44b-03df967d8444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bab6e29-321c-454e-a44b-03df967d8444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_92915841-3ce6-428f-9ae4-34da6c989f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_CostsAndExpenses_92915841-3ce6-428f-9ae4-34da6c989f1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8c89f238-d697-47f0-afbc-f1a73b190688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8c89f238-d697-47f0-afbc-f1a73b190688" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_41a6ac2e-eba1-4f6f-9189-ddac59f4e9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_ProfitLoss_41a6ac2e-eba1-4f6f-9189-ddac59f4e9c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4bc2a74a-bb18-4db8-ab4f-69a34b8bb45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4bc2a74a-bb18-4db8-ab4f-69a34b8bb45c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_350e2f63-4464-49ec-93dc-85b0750264c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4bc2a74a-bb18-4db8-ab4f-69a34b8bb45c" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_350e2f63-4464-49ec-93dc-85b0750264c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_350e2f63-4464-49ec-93dc-85b0750264c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_350e2f63-4464-49ec-93dc-85b0750264c1" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_350e2f63-4464-49ec-93dc-85b0750264c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b1f965b7-ff9c-4a60-8f9a-95a16de9cb71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_350e2f63-4464-49ec-93dc-85b0750264c1" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b1f965b7-ff9c-4a60-8f9a-95a16de9cb71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_bc395c68-5634-4f68-8d30-6e4911dd3aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b1f965b7-ff9c-4a60-8f9a-95a16de9cb71" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_bc395c68-5634-4f68-8d30-6e4911dd3aca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended" id="i239c1aed6dd34529b37e9b417a51244a_LongtermDebtLongtermDebtOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f38eedb5-0420-423f-92c7-590b18512851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f38eedb5-0420-423f-92c7-590b18512851" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc8732da-d605-41ac-8039-aeffcbedf2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc8732da-d605-41ac-8039-aeffcbedf2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_23bf9d0b-6fa5-47c4-a9b0-64a2f9b8f556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_LongTermDebt_23bf9d0b-6fa5-47c4-a9b0-64a2f9b8f556" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5569be0f-fa17-44c7-8209-8ee1faae1526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_FinanceLeaseLiability_5569be0f-fa17-44c7-8209-8ee1faae1526" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_84493dce-0f1b-4d0b-9574-5f8b9e60e683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_84493dce-0f1b-4d0b-9574-5f8b9e60e683" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_14ba759b-bb8e-45e1-a23d-af2d42f6a23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_14ba759b-bb8e-45e1-a23d-af2d42f6a23e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_434b5f34-1129-4e26-b78c-244cf90c9f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_434b5f34-1129-4e26-b78c-244cf90c9f94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f38eedb5-0420-423f-92c7-590b18512851" xlink:to="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e4092122-47b3-4ac8-ac63-16b213821317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:to="loc_us-gaap_CreditFacilityAxis_e4092122-47b3-4ac8-ac63-16b213821317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e4092122-47b3-4ac8-ac63-16b213821317_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e4092122-47b3-4ac8-ac63-16b213821317" xlink:to="loc_us-gaap_CreditFacilityDomain_e4092122-47b3-4ac8-ac63-16b213821317_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f5b0cf2a-ba47-414c-881f-00b39644882e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e4092122-47b3-4ac8-ac63-16b213821317" xlink:to="loc_us-gaap_CreditFacilityDomain_f5b0cf2a-ba47-414c-881f-00b39644882e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_ecdc93bf-620b-4597-b8c5-d26d63673f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f5b0cf2a-ba47-414c-881f-00b39644882e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_ecdc93bf-620b-4597-b8c5-d26d63673f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_16e06b3e-bc27-4074-83b6-995a3230dbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_16e06b3e-bc27-4074-83b6-995a3230dbb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16e06b3e-bc27-4074-83b6-995a3230dbb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_16e06b3e-bc27-4074-83b6-995a3230dbb5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_16e06b3e-bc27-4074-83b6-995a3230dbb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_16e06b3e-bc27-4074-83b6-995a3230dbb5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_4c3f9c3c-c2a4-466d-904e-f50b70355cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:to="loc_us-gaap_LoansPayableMember_4c3f9c3c-c2a4-466d-904e-f50b70355cc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_da25809c-a4eb-4518-8ced-9752bd3f4cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:to="loc_us-gaap_SeniorNotesMember_da25809c-a4eb-4518-8ced-9752bd3f4cce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ca65b63d-2674-4933-bf97-b22eff6a6bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ca65b63d-2674-4933-bf97-b22eff6a6bdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5f2a96f6-413b-4d1a-b0b9-913868664fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:to="loc_us-gaap_DebtInstrumentAxis_5f2a96f6-413b-4d1a-b0b9-913868664fe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f2a96f6-413b-4d1a-b0b9-913868664fe0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f2a96f6-413b-4d1a-b0b9-913868664fe0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f2a96f6-413b-4d1a-b0b9-913868664fe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f2a96f6-413b-4d1a-b0b9-913868664fe0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_3acb468f-96b2-4b16-9b1e-59f41eddd7cf" xlink:href="ehc-20211231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_TermLoanFacilitiesMember_3acb468f-96b2-4b16-9b1e-59f41eddd7cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_faeddfa8-fba4-4d56-a8ad-52a33a263781" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_faeddfa8-fba4-4d56-a8ad-52a33a263781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_2c201dbd-606e-4e89-bf79-2d2e2388b5a2" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_2c201dbd-606e-4e89-bf79-2d2e2388b5a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_dd25878f-5c4e-413f-93be-099c6359a50e" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_dd25878f-5c4e-413f-93be-099c6359a50e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_d6bd55dc-1c87-47a0-9dbe-0a6ed44cb880" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_d6bd55dc-1c87-47a0-9dbe-0a6ed44cb880" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_b6928df6-8b2d-420e-9917-1bcd6c3fdde0" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_b6928df6-8b2d-420e-9917-1bcd6c3fdde0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="extended" id="ia643821cfb7241c492f033a115728523_LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_26b8a0fe-be68-4431-a84e-447164fb1b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26b8a0fe-be68-4431-a84e-447164fb1b1d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_faa00b10-2a4c-4d82-bd19-3040c3ff904c" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_faa00b10-2a4c-4d82-bd19-3040c3ff904c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_60618b98-9c02-42a0-9f13-fbad9b94feaf" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_60618b98-9c02-42a0-9f13-fbad9b94feaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_9a155c1d-2dd5-4714-9644-a677f8a0caa2" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_9a155c1d-2dd5-4714-9644-a677f8a0caa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_c6b6afc1-a586-4dcf-a33d-cee4210c89f1" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_c6b6afc1-a586-4dcf-a33d-cee4210c89f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_c5a23591-dbd1-45df-a84f-16f076458257" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_c5a23591-dbd1-45df-a84f-16f076458257" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_65a90a1f-b5b3-4abd-bb75-6db26dce5d23" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_65a90a1f-b5b3-4abd-bb75-6db26dce5d23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_73c233ba-bd0d-4d74-90c1-8a7c7d4d5050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_73c233ba-bd0d-4d74-90c1-8a7c7d4d5050" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_77a2faa6-feb9-4036-b984-3287e1776670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26b8a0fe-be68-4431-a84e-447164fb1b1d" xlink:to="loc_us-gaap_DebtInstrumentTable_77a2faa6-feb9-4036-b984-3287e1776670" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe3af7fc-6690-495f-bb27-a979040cb2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_77a2faa6-feb9-4036-b984-3287e1776670" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe3af7fc-6690-495f-bb27-a979040cb2b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe3af7fc-6690-495f-bb27-a979040cb2b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe3af7fc-6690-495f-bb27-a979040cb2b1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe3af7fc-6690-495f-bb27-a979040cb2b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e46cb863-0de3-4d5e-94b8-75491e9b1f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe3af7fc-6690-495f-bb27-a979040cb2b1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e46cb863-0de3-4d5e-94b8-75491e9b1f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FaceAmountMember_0dfa20fe-8015-40d3-afad-9382dac58cb7" xlink:href="ehc-20211231.xsd#ehc_FaceAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e46cb863-0de3-4d5e-94b8-75491e9b1f9a" xlink:to="loc_ehc_FaceAmountMember_0dfa20fe-8015-40d3-afad-9382dac58cb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetAmountMember_2ed00079-6b5c-44f3-b35f-90d22226ff83" xlink:href="ehc-20211231.xsd#ehc_NetAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e46cb863-0de3-4d5e-94b8-75491e9b1f9a" xlink:to="loc_ehc_NetAmountMember_2ed00079-6b5c-44f3-b35f-90d22226ff83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtFinancialCovenantsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="extended" id="i9353a4ee9ca845f1bdc0d09e1636b3da_LongtermDebtFinancialCovenantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b82b0869-7dc1-479a-ba57-db4ab0ffa2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_9ffd58e4-27c6-4724-9d81-7cc284ae3bcc" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b82b0869-7dc1-479a-ba57-db4ab0ffa2ce" xlink:to="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_9ffd58e4-27c6-4724-9d81-7cc284ae3bcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_781021c1-a08a-478b-b3ca-2918960a92f0" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b82b0869-7dc1-479a-ba57-db4ab0ffa2ce" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_781021c1-a08a-478b-b3ca-2918960a92f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_51ec69f0-2a84-45ca-b574-54ba0fa2ea11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b82b0869-7dc1-479a-ba57-db4ab0ffa2ce" xlink:to="loc_us-gaap_DebtInstrumentTable_51ec69f0-2a84-45ca-b574-54ba0fa2ea11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_24e38523-efd4-4a69-897e-13c1fe19ca5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_51ec69f0-2a84-45ca-b574-54ba0fa2ea11" xlink:to="loc_srt_StatementScenarioAxis_24e38523-efd4-4a69-897e-13c1fe19ca5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_24e38523-efd4-4a69-897e-13c1fe19ca5e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_24e38523-efd4-4a69-897e-13c1fe19ca5e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_24e38523-efd4-4a69-897e-13c1fe19ca5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_99486f69-03e1-421d-a3ac-d4dc28448c4c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_24e38523-efd4-4a69-897e-13c1fe19ca5e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_99486f69-03e1-421d-a3ac-d4dc28448c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d572540f-80f2-442d-a299-869509fff9fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_99486f69-03e1-421d-a3ac-d4dc28448c4c" xlink:to="loc_srt_ScenarioForecastMember_d572540f-80f2-442d-a299-869509fff9fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended" id="i167b5501c69b459599391783da6c5653_LongtermDebtTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f14e35bf-069b-481f-bd8b-74186a1302ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f14e35bf-069b-481f-bd8b-74186a1302ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dfc5831b-1467-4ecd-97f0-8988de89ee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dfc5831b-1467-4ecd-97f0-8988de89ee9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding_a25b62e4-bf0e-4c5e-b713-436abbbfa8b9" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding_a25b62e4-bf0e-4c5e-b713-436abbbfa8b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_16ae1679-0fce-4cc0-8eb3-4bda9fd41403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_16ae1679-0fce-4cc0-8eb3-4bda9fd41403" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e2bb3d83-9993-4ac8-8d74-56865d34b20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e2bb3d83-9993-4ac8-8d74-56865d34b20b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum_e9e73b23-0316-4906-93fd-64ef84fb733b" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum_e9e73b23-0316-4906-93fd-64ef84fb733b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CreditAgreementRestriction_34b8110f-2b5e-4c0a-ba1a-8778b76835e1" xlink:href="ehc-20211231.xsd#ehc_CreditAgreementRestriction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_CreditAgreementRestriction_34b8110f-2b5e-4c0a-ba1a-8778b76835e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8d6bf0ea-47a7-4db5-acde-54fb69173f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LongTermDebt_8d6bf0ea-47a7-4db5-acde-54fb69173f72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_d9b04610-12ab-4075-95c0-8b299fcfcc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_d9b04610-12ab-4075-95c0-8b299fcfcc33" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_46a3d4b9-fc7f-42a5-ae3b-e82df3fc0533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_46a3d4b9-fc7f-42a5-ae3b-e82df3fc0533" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_0cfd6255-5449-4117-9a42-0e09fcda92db" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_0cfd6255-5449-4117-9a42-0e09fcda92db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_12a2068a-ea3b-492d-a051-59dc4638251f" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_12a2068a-ea3b-492d-a051-59dc4638251f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_202547e5-fb52-41df-b0c7-ddd2980a4a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_202547e5-fb52-41df-b0c7-ddd2980a4a76" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6a2e5e68-42d7-422d-a2b3-143894e2f233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6a2e5e68-42d7-422d-a2b3-143894e2f233" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_d904932e-a919-47e2-9d75-4e61c2563c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_d904932e-a919-47e2-9d75-4e61c2563c2a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_db01b33a-6b51-41b5-b8bd-8998e9e7de4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_db01b33a-6b51-41b5-b8bd-8998e9e7de4c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2605747e-ce53-4fe6-8c64-675a1f0c056f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2605747e-ce53-4fe6-8c64-675a1f0c056f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5b1364ae-3765-49ea-8962-b0c805c40f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5b1364ae-3765-49ea-8962-b0c805c40f80" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentIssuePricePercentage_e5a5d20d-0438-42d4-998b-c65cd46dc878" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentIssuePricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentIssuePricePercentage_e5a5d20d-0438-42d4-998b-c65cd46dc878" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_2209088b-b1f5-4e9c-866a-2d138277a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_e81e3411-498d-419a-9714-fe8413cdd27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_RepaymentsOfDebt_e81e3411-498d-419a-9714-fe8413cdd27a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_9bc1bb30-2653-49a5-b8a1-691b7017bb57" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_9bc1bb30-2653-49a5-b8a1-691b7017bb57" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2e03f5d7-b597-4a1e-808e-5a4b92dfc712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2e03f5d7-b597-4a1e-808e-5a4b92dfc712" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_1eea0957-3555-46cd-ab6c-9d21dff8e7bf" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_1eea0957-3555-46cd-ab6c-9d21dff8e7bf" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_97d27914-794d-4445-95ec-fd16ecf0075a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_DebtInstrumentAxis_97d27914-794d-4445-95ec-fd16ecf0075a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97d27914-794d-4445-95ec-fd16ecf0075a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_97d27914-794d-4445-95ec-fd16ecf0075a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_97d27914-794d-4445-95ec-fd16ecf0075a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_97d27914-794d-4445-95ec-fd16ecf0075a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TheCreditAgreementMember_d8731031-4d8f-4248-8ce0-0f866aa6931b" xlink:href="ehc-20211231.xsd#ehc_TheCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_TheCreditAgreementMember_d8731031-4d8f-4248-8ce0-0f866aa6931b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_0744e032-d2b7-4818-85f1-f65718883026" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_0744e032-d2b7-4818-85f1-f65718883026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_e20740b2-6fe7-41f9-a1b9-40f3702dbafb" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_e20740b2-6fe7-41f9-a1b9-40f3702dbafb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_f17e5e3c-ee17-45bd-a62a-2ca4d63d706d" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_f17e5e3c-ee17-45bd-a62a-2ca4d63d706d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_9d5fef4c-a20b-4671-bf14-9bb2505c2b15" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_9d5fef4c-a20b-4671-bf14-9bb2505c2b15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_fa39a36a-336b-45c8-9565-9b4a3f41b2ff" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_fa39a36a-336b-45c8-9565-9b4a3f41b2ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_6c771b55-48d0-4d93-97d2-4ce68d071ce1" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_6c771b55-48d0-4d93-97d2-4ce68d071ce1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_9de46c50-58e0-43c9-aed3-40883e43bb4d" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1d3a3c0a-851a-404a-9ba5-73405868fb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_CreditFacilityAxis_1d3a3c0a-851a-404a-9ba5-73405868fb17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1d3a3c0a-851a-404a-9ba5-73405868fb17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1d3a3c0a-851a-404a-9ba5-73405868fb17" xlink:to="loc_us-gaap_CreditFacilityDomain_1d3a3c0a-851a-404a-9ba5-73405868fb17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1d3a3c0a-851a-404a-9ba5-73405868fb17" xlink:to="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_2836bded-0ad4-49a4-b10d-0a404850dbc5" xlink:href="ehc-20211231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:to="loc_ehc_TermLoanFacilitiesMember_2836bded-0ad4-49a4-b10d-0a404850dbc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_7e26370f-2166-400d-9dcb-952b70ba2b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_7e26370f-2166-400d-9dcb-952b70ba2b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_000130f9-9669-4831-8066-e79b943e2baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:to="loc_us-gaap_LetterOfCreditMember_000130f9-9669-4831-8066-e79b943e2baa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_75a91d11-984d-4903-9c4c-f456c25299bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_VariableRateAxis_75a91d11-984d-4903-9c4c-f456c25299bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_75a91d11-984d-4903-9c4c-f456c25299bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_75a91d11-984d-4903-9c4c-f456c25299bb" xlink:to="loc_us-gaap_VariableRateDomain_75a91d11-984d-4903-9c4c-f456c25299bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dd5bc1aa-347b-495f-8046-1e2434931dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_75a91d11-984d-4903-9c4c-f456c25299bb" xlink:to="loc_us-gaap_VariableRateDomain_dd5bc1aa-347b-495f-8046-1e2434931dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_75044409-4732-4007-a08b-80eb98bf9c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_dd5bc1aa-347b-495f-8046-1e2434931dd5" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_75044409-4732-4007-a08b-80eb98bf9c2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5c1c8b1-89f4-43b3-8e82-d207b3b6c903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_dd5bc1aa-347b-495f-8046-1e2434931dd5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5c1c8b1-89f4-43b3-8e82-d207b3b6c903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0617b670-e298-4175-9148-9d514b315994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0617b670-e298-4175-9148-9d514b315994" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0617b670-e298-4175-9148-9d514b315994_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0617b670-e298-4175-9148-9d514b315994" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0617b670-e298-4175-9148-9d514b315994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0da54b66-16b5-4be2-a334-9df40b49c434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0617b670-e298-4175-9148-9d514b315994" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0da54b66-16b5-4be2-a334-9df40b49c434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_d5e567b8-43a2-45cf-8cc1-13706fbc9e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0da54b66-16b5-4be2-a334-9df40b49c434" xlink:to="loc_us-gaap_LoansPayableMember_d5e567b8-43a2-45cf-8cc1-13706fbc9e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ebc984ca-5b1c-4210-ab0e-932f0cbf8853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0da54b66-16b5-4be2-a334-9df40b49c434" xlink:to="loc_us-gaap_SeniorNotesMember_ebc984ca-5b1c-4210-ab0e-932f0cbf8853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fe023f07-e2a4-4f91-a6f3-f3185a4743f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fe023f07-e2a4-4f91-a6f3-f3185a4743f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fe023f07-e2a4-4f91-a6f3-f3185a4743f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fe023f07-e2a4-4f91-a6f3-f3185a4743f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fe023f07-e2a4-4f91-a6f3-f3185a4743f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_882609fc-ff44-49b1-96cc-6b5a21a0045c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fe023f07-e2a4-4f91-a6f3-f3185a4743f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_882609fc-ff44-49b1-96cc-6b5a21a0045c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b3852e5c-fc9a-4775-a779-ca48185dc8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_882609fc-ff44-49b1-96cc-6b5a21a0045c" xlink:to="loc_us-gaap_SubsequentEventMember_b3852e5c-fc9a-4775-a779-ca48185dc8b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_srt_StatementScenarioAxis_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cb2d55ce-f127-4dcb-97ec-e8b6547a6b13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cb2d55ce-f127-4dcb-97ec-e8b6547a6b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1e25992c-8554-4a68-a5d1-3ff1da42d3e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_cb2d55ce-f127-4dcb-97ec-e8b6547a6b13" xlink:to="loc_srt_ScenarioForecastMember_1e25992c-8554-4a68-a5d1-3ff1da42d3e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtSeniorNotesRedemptionPricesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails" xlink:type="extended" id="ifeb4ba42b06b49c39798abff2a996b3d_LongtermDebtSeniorNotesRedemptionPricesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems_6dde8128-4d70-4c81-a4a3-b4aeca3df243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82953a2e-7985-418a-ba1b-5dc09ef05afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_6dde8128-4d70-4c81-a4a3-b4aeca3df243" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82953a2e-7985-418a-ba1b-5dc09ef05afb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_6dde8128-4d70-4c81-a4a3-b4aeca3df243" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2a057be2-701f-4a0b-b721-c118998025b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2a057be2-701f-4a0b-b721-c118998025b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2a057be2-701f-4a0b-b721-c118998025b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2a057be2-701f-4a0b-b721-c118998025b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2a057be2-701f-4a0b-b721-c118998025b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_247c27b8-6b53-4800-86c1-a1d34d9efee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2a057be2-701f-4a0b-b721-c118998025b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_247c27b8-6b53-4800-86c1-a1d34d9efee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a23b198a-3eee-41c5-9dd8-043fb95e86a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_247c27b8-6b53-4800-86c1-a1d34d9efee4" xlink:to="loc_us-gaap_SeniorNotesMember_a23b198a-3eee-41c5-9dd8-043fb95e86a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_45ed57f9-a05d-4a67-bfcb-2a8432a9c5f1" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_45ed57f9-a05d-4a67-bfcb-2a8432a9c5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_db41d19c-142b-4aff-8fb2-47240db7478c" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_db41d19c-142b-4aff-8fb2-47240db7478c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_df0d7ab6-7e6c-49f1-bbee-f1a08a7584c6" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_df0d7ab6-7e6c-49f1-bbee-f1a08a7584c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_eca6a166-1ac4-4d72-b6a4-0b09aa024d5d" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_eca6a166-1ac4-4d72-b6a4-0b09aa024d5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_2df8d55d-e892-44b6-8602-98aab8f5a559" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_2df8d55d-e892-44b6-8602-98aab8f5a559" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7e9fab21-9231-4c7c-bd2a-9b64cd639343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7e9fab21-9231-4c7c-bd2a-9b64cd639343" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9fab21-9231-4c7c-bd2a-9b64cd639343_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7e9fab21-9231-4c7c-bd2a-9b64cd639343" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9fab21-9231-4c7c-bd2a-9b64cd639343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7e9fab21-9231-4c7c-bd2a-9b64cd639343" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_263976c9-2579-419d-a9db-112f644a0e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_263976c9-2579-419d-a9db-112f644a0e3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_9c7f734a-f2e7-4e2b-8599-9cee0c0eb07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_9c7f734a-f2e7-4e2b-8599-9cee0c0eb07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_e22dca96-eb00-4cdd-8fd4-3b9a41fa7972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_e22dca96-eb00-4cdd-8fd4-3b9a41fa7972" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_0270b0d8-eb4d-4988-9747-b8d335c2d5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_0270b0d8-eb4d-4988-9747-b8d335c2d5c0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtScheduleofNotesPayableDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails" xlink:type="extended" id="ic144cc40f5674e938eea78dbefeec7b2_LongtermDebtScheduleofNotesPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3262abea-ab4f-4757-a307-c10de498134f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e741fbc8-1eec-44e2-a60a-5acdb294de30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3262abea-ab4f-4757-a307-c10de498134f" xlink:to="loc_us-gaap_LongTermDebt_e741fbc8-1eec-44e2-a60a-5acdb294de30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8dc3821a-1b19-4bd9-be02-8442c0c0cc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3262abea-ab4f-4757-a307-c10de498134f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8dc3821a-1b19-4bd9-be02-8442c0c0cc43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3262abea-ab4f-4757-a307-c10de498134f" xlink:to="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a2c6077-694a-48f8-a080-531d1324776e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_srt_RangeAxis_5a2c6077-694a-48f8-a080-531d1324776e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a2c6077-694a-48f8-a080-531d1324776e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5a2c6077-694a-48f8-a080-531d1324776e" xlink:to="loc_srt_RangeMember_5a2c6077-694a-48f8-a080-531d1324776e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9894eef4-d251-44be-9075-e05cdca62e30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5a2c6077-694a-48f8-a080-531d1324776e" xlink:to="loc_srt_RangeMember_9894eef4-d251-44be-9075-e05cdca62e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cbfef9f8-1b0b-4bb4-bdd5-01d11cdf4dcd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9894eef4-d251-44be-9075-e05cdca62e30" xlink:to="loc_srt_MinimumMember_cbfef9f8-1b0b-4bb4-bdd5-01d11cdf4dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7762acb0-9ecb-4149-acaf-db17607d588d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9894eef4-d251-44be-9075-e05cdca62e30" xlink:to="loc_srt_MaximumMember_7762acb0-9ecb-4149-acaf-db17607d588d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85013148-9931-4398-9db6-2b95309b13cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85013148-9931-4398-9db6-2b95309b13cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_85013148-9931-4398-9db6-2b95309b13cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85013148-9931-4398-9db6-2b95309b13cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_85013148-9931-4398-9db6-2b95309b13cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_75b45fbf-4f06-46cd-8d99-d1b370db1a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85013148-9931-4398-9db6-2b95309b13cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_75b45fbf-4f06-46cd-8d99-d1b370db1a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_b2218b79-c628-4dfa-82d5-23aa0ab5e63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_75b45fbf-4f06-46cd-8d99-d1b370db1a5d" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_b2218b79-c628-4dfa-82d5-23aa0ab5e63c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_10357466-0c74-4543-a1ae-b0ed9308d21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_us-gaap_DebtInstrumentAxis_10357466-0c74-4543-a1ae-b0ed9308d21c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_10357466-0c74-4543-a1ae-b0ed9308d21c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_10357466-0c74-4543-a1ae-b0ed9308d21c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_10357466-0c74-4543-a1ae-b0ed9308d21c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_10357466-0c74-4543-a1ae-b0ed9308d21c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_f1bc4bdc-317f-4101-affc-33454125811b" xlink:href="ehc-20211231.xsd#ehc_NotesPayableRealEstateSaleLeasebackFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:to="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_f1bc4bdc-317f-4101-affc-33454125811b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_b3e73d3a-9fb8-4808-a0fe-cc5f49f9f2c9" xlink:href="ehc-20211231.xsd#ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:to="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_b3e73d3a-9fb8-4808-a0fe-cc5f49f9f2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableSoftwareContractsMember_bac83599-8782-4e4b-b5ea-a90c0b670641" xlink:href="ehc-20211231.xsd#ehc_NotesPayableSoftwareContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:to="loc_ehc_NotesPayableSoftwareContractsMember_bac83599-8782-4e4b-b5ea-a90c0b670641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_13fa4c66-8e88-477a-8efd-82b2b4ffa52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_us-gaap_VariableRateAxis_13fa4c66-8e88-477a-8efd-82b2b4ffa52b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_13fa4c66-8e88-477a-8efd-82b2b4ffa52b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_13fa4c66-8e88-477a-8efd-82b2b4ffa52b" xlink:to="loc_us-gaap_VariableRateDomain_13fa4c66-8e88-477a-8efd-82b2b4ffa52b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6e1e4807-4347-45b9-9f96-60829e00b70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_13fa4c66-8e88-477a-8efd-82b2b4ffa52b" xlink:to="loc_us-gaap_VariableRateDomain_6e1e4807-4347-45b9-9f96-60829e00b70f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_97dc002d-b7af-49e0-8261-d951936e8f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6e1e4807-4347-45b9-9f96-60829e00b70f" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_97dc002d-b7af-49e0-8261-d951936e8f4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended" id="i442a8db2a3be444abf24308909a18635_RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_92f66583-c407-4114-af8c-5ee77347c269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_92f66583-c407-4114-af8c-5ee77347c269" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2aa50f7b-cde9-4b48-86d7-10e9eddc5e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2aa50f7b-cde9-4b48-86d7-10e9eddc5e63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_049dde9a-5a46-40b1-b2c4-afddece1143c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_049dde9a-5a46-40b1-b2c4-afddece1143c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c440e6b0-abda-4bcc-99c6-81f63822005f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c440e6b0-abda-4bcc-99c6-81f63822005f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure_537eb4fa-abdf-4061-888a-84e290673a53" xlink:href="ehc-20211231.xsd#ehc_Contributiontojointventure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_ehc_Contributiontojointventure_537eb4fa-abdf-4061-888a-84e290673a53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Reclassificationtononcontrollinginterests_bdf975eb-f6f8-42a1-91ed-3eac6344c563" xlink:href="ehc-20211231.xsd#ehc_Reclassificationtononcontrollinginterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_ehc_Reclassificationtononcontrollinginterests_bdf975eb-f6f8-42a1-91ed-3eac6344c563" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_51ba79bc-9d53-43c5-a093-09d298e6aff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_51ba79bc-9d53-43c5-a093-09d298e6aff8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction_b2de76d9-ace7-4612-a4c8-aa2205160e11" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_ehc_NoncontrollingInterestExchangeTransaction_b2de76d9-ace7-4612-a4c8-aa2205160e11" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_32f28424-d00e-4127-861c-583f8b211e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_32f28424-d00e-4127-861c-583f8b211e6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestOtherAdjustment_81ad286f-726a-4d02-82c9-15aa7744cffb" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestOtherAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_ehc_NoncontrollingInterestOtherAdjustment_81ad286f-726a-4d02-82c9-15aa7744cffb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_aa379752-c70a-469d-833f-aa7d07a4b623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0a0a9117-97b2-4a0f-b12a-dfd4921ff74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_92f66583-c407-4114-af8c-5ee77347c269" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0a0a9117-97b2-4a0f-b12a-dfd4921ff74e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e835e128-c46b-45a5-bdbc-63fe6613fb91" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0a0a9117-97b2-4a0f-b12a-dfd4921ff74e" xlink:to="loc_dei_LegalEntityAxis_e835e128-c46b-45a5-bdbc-63fe6613fb91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e835e128-c46b-45a5-bdbc-63fe6613fb91_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e835e128-c46b-45a5-bdbc-63fe6613fb91" xlink:to="loc_dei_EntityDomain_e835e128-c46b-45a5-bdbc-63fe6613fb91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4561b1a7-7cef-4ef0-96e6-814175d3e246" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e835e128-c46b-45a5-bdbc-63fe6613fb91" xlink:to="loc_dei_EntityDomain_4561b1a7-7cef-4ef0-96e6-814175d3e246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember_fe54b7c3-ba10-4a4e-bca8-78f6157685c0" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4561b1a7-7cef-4ef0-96e6-814175d3e246" xlink:to="loc_ehc_RedeemableNoncontrollingInterestMember_fe54b7c3-ba10-4a4e-bca8-78f6157685c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#RedeemableNoncontrollingInterestsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="extended" id="i347ccbf86a8c4bf183bbae5dec5bb67d_RedeemableNoncontrollingInterestsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_ed16e20c-4784-4093-89b5-63aa6cc5b289" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_ed16e20c-4784-4093-89b5-63aa6cc5b289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_20be97f2-1e7b-4c61-887a-1b9d866e752b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_20be97f2-1e7b-4c61-887a-1b9d866e752b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_837b13f2-aa6c-4dbe-bee8-5d307322f6d1" xlink:href="ehc-20211231.xsd#ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_837b13f2-aa6c-4dbe-bee8-5d307322f6d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_6e4321e4-aea5-4900-a49a-eb14821f549a" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_6e4321e4-aea5-4900-a49a-eb14821f549a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_1d4757b7-1077-4faf-970e-1e14f2a09ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_1d4757b7-1077-4faf-970e-1e14f2a09ee3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_e3bfdee9-c7fd-48a0-bb71-0b7c861660e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_e3bfdee9-c7fd-48a0-bb71-0b7c861660e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_624b9358-59bb-4d31-8a68-6378edcd15d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_624b9358-59bb-4d31-8a68-6378edcd15d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_b8591d33-5379-40f5-95ea-6e00d52af3aa" xlink:href="ehc-20211231.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_b8591d33-5379-40f5-95ea-6e00d52af3aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f3b06634-feb6-474a-8761-31de11d42114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f3b06634-feb6-474a-8761-31de11d42114" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ce45ef30-0709-4c46-a131-4d14c0e21326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ce45ef30-0709-4c46-a131-4d14c0e21326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ce45ef30-0709-4c46-a131-4d14c0e21326_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ce45ef30-0709-4c46-a131-4d14c0e21326" xlink:to="loc_us-gaap_SegmentDomain_ce45ef30-0709-4c46-a131-4d14c0e21326_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4222b8c6-5e7f-4219-ab44-6975f10833e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ce45ef30-0709-4c46-a131-4d14c0e21326" xlink:to="loc_us-gaap_SegmentDomain_4222b8c6-5e7f-4219-ab44-6975f10833e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_76962429-cdf9-4203-b249-96b1d926e93b" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4222b8c6-5e7f-4219-ab44-6975f10833e8" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_76962429-cdf9-4203-b249-96b1d926e93b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_68c3e14c-03ac-4d0a-80fa-20fca3b9245b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_68c3e14c-03ac-4d0a-80fa-20fca3b9245b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68c3e14c-03ac-4d0a-80fa-20fca3b9245b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68c3e14c-03ac-4d0a-80fa-20fca3b9245b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68c3e14c-03ac-4d0a-80fa-20fca3b9245b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b2751ac1-08f8-4792-9faa-f0c8ad8343e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68c3e14c-03ac-4d0a-80fa-20fca3b9245b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b2751ac1-08f8-4792-9faa-f0c8ad8343e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember_fc340f2f-9330-4baa-a4e1-5c218b7a4baf" xlink:href="ehc-20211231.xsd#ehc_EHHIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b2751ac1-08f8-4792-9faa-f0c8ad8343e1" xlink:to="loc_ehc_EHHIMember_fc340f2f-9330-4baa-a4e1-5c218b7a4baf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5b7d1824-c7f0-4a59-982d-9411af1a0f3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:to="loc_srt_OwnershipAxis_5b7d1824-c7f0-4a59-982d-9411af1a0f3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5b7d1824-c7f0-4a59-982d-9411af1a0f3a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5b7d1824-c7f0-4a59-982d-9411af1a0f3a" xlink:to="loc_srt_OwnershipDomain_5b7d1824-c7f0-4a59-982d-9411af1a0f3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2c49cbe9-68fb-41a6-807d-3d8021518414" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5b7d1824-c7f0-4a59-982d-9411af1a0f3a" xlink:to="loc_srt_OwnershipDomain_2c49cbe9-68fb-41a6-807d-3d8021518414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HoldingsAndEHHIMember_d52897e1-59c5-4b59-a06b-f23630047d7d" xlink:href="ehc-20211231.xsd#ehc_HoldingsAndEHHIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2c49cbe9-68fb-41a6-807d-3d8021518414" xlink:to="loc_ehc_HoldingsAndEHHIMember_d52897e1-59c5-4b59-a06b-f23630047d7d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i3f1354a8f706439d88c06b19489ee119_FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_436c590f-b6b9-44f8-8c57-e8834f62da95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_dfcae09f-2d6c-4723-a9d8-b776b6f0dad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_436c590f-b6b9-44f8-8c57-e8834f62da95" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_dfcae09f-2d6c-4723-a9d8-b776b6f0dad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_d20239ca-0c20-4a1a-8a25-90e0cab5ec10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_436c590f-b6b9-44f8-8c57-e8834f62da95" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_d20239ca-0c20-4a1a-8a25-90e0cab5ec10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_436c590f-b6b9-44f8-8c57-e8834f62da95" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bece7d19-ded6-4e20-b30b-24604245efce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bece7d19-ded6-4e20-b30b-24604245efce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bece7d19-ded6-4e20-b30b-24604245efce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bece7d19-ded6-4e20-b30b-24604245efce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bece7d19-ded6-4e20-b30b-24604245efce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_73842c95-7534-4852-894c-79f0f569a58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bece7d19-ded6-4e20-b30b-24604245efce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_73842c95-7534-4852-894c-79f0f569a58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dfd9a7ee-f7fe-411f-b75c-4ddb5fa7f417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_73842c95-7534-4852-894c-79f0f569a58d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dfd9a7ee-f7fe-411f-b75c-4ddb5fa7f417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d912943a-f1b8-4f84-b4fd-4cc78278a608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d912943a-f1b8-4f84-b4fd-4cc78278a608" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d912943a-f1b8-4f84-b4fd-4cc78278a608_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d912943a-f1b8-4f84-b4fd-4cc78278a608" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d912943a-f1b8-4f84-b4fd-4cc78278a608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d912943a-f1b8-4f84-b4fd-4cc78278a608" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cbbfd449-dac3-4e06-9dcc-23948d322e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cbbfd449-dac3-4e06-9dcc-23948d322e7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_24f4d7dd-7479-4827-b687-d0afc0f7667e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_24f4d7dd-7479-4827-b687-d0afc0f7667e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0b1f3603-50f2-435c-b665-a47833d3a124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0b1f3603-50f2-435c-b665-a47833d3a124" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#FairValueMeasurementsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="extended" id="ia667c2969b8f4973a00c83ec900408e3_FairValueMeasurementsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f20175a5-7fcf-43c2-8f24-b0ea9ae5793b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_a9198998-b637-449d-b932-0fedadc2f37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f20175a5-7fcf-43c2-8f24-b0ea9ae5793b" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_a9198998-b637-449d-b932-0fedadc2f37f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2b9999d4-463f-45ff-882b-3c185139f515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f20175a5-7fcf-43c2-8f24-b0ea9ae5793b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2b9999d4-463f-45ff-882b-3c185139f515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0c083f08-6d53-4fec-a821-2523e7706046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2b9999d4-463f-45ff-882b-3c185139f515" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0c083f08-6d53-4fec-a821-2523e7706046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c083f08-6d53-4fec-a821-2523e7706046_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0c083f08-6d53-4fec-a821-2523e7706046" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c083f08-6d53-4fec-a821-2523e7706046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_213c9a6e-f88a-4545-a1bb-3862d97c748a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0c083f08-6d53-4fec-a821-2523e7706046" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_213c9a6e-f88a-4545-a1bb-3862d97c748a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_1c5965ca-79cf-4fb8-aa75-c3f103d524d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_213c9a6e-f88a-4545-a1bb-3862d97c748a" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_1c5965ca-79cf-4fb8-aa75-c3f103d524d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" xlink:type="extended" id="i6bac14dff8e6442fbf4049afe9ab15d8_FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fca084c7-ae28-4d2a-a068-f1318305406d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_48b09e26-5588-4e11-ad1a-18c25128b960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fca084c7-ae28-4d2a-a068-f1318305406d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_48b09e26-5588-4e11-ad1a-18c25128b960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_45419de8-745a-461e-9daa-52b50c12d9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fca084c7-ae28-4d2a-a068-f1318305406d" xlink:to="loc_us-gaap_LongTermDebtFairValue_45419de8-745a-461e-9daa-52b50c12d9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fca084c7-ae28-4d2a-a068-f1318305406d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d747477c-3419-453d-bf13-67c0185ef115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_DebtInstrumentAxis_d747477c-3419-453d-bf13-67c0185ef115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d747477c-3419-453d-bf13-67c0185ef115_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d747477c-3419-453d-bf13-67c0185ef115" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d747477c-3419-453d-bf13-67c0185ef115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d747477c-3419-453d-bf13-67c0185ef115" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_b37c13f5-1e63-4aee-8782-c3983c539a0f" xlink:href="ehc-20211231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_TermLoanFacilitiesMember_b37c13f5-1e63-4aee-8782-c3983c539a0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_39dfff46-5035-49eb-8d5a-274e0f09c82e" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_39dfff46-5035-49eb-8d5a-274e0f09c82e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_89c53938-5cf7-46f3-8043-c0d52129c7e9" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_89c53938-5cf7-46f3-8043-c0d52129c7e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_1dcca1a0-44b7-49ad-a34f-281e598d30ee" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_1dcca1a0-44b7-49ad-a34f-281e598d30ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_2450a5f9-ceca-43ab-858a-3d3a4127258c" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_2450a5f9-ceca-43ab-858a-3d3a4127258c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_efb7133d-aedc-4b69-962a-596954117846" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_efb7133d-aedc-4b69-962a-596954117846" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a558a6c9-64d3-4084-954d-97f17517b902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_CreditFacilityAxis_a558a6c9-64d3-4084-954d-97f17517b902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a558a6c9-64d3-4084-954d-97f17517b902_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a558a6c9-64d3-4084-954d-97f17517b902" xlink:to="loc_us-gaap_CreditFacilityDomain_a558a6c9-64d3-4084-954d-97f17517b902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_62de2550-1cda-4d0f-a508-a5f37c69c991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a558a6c9-64d3-4084-954d-97f17517b902" xlink:to="loc_us-gaap_CreditFacilityDomain_62de2550-1cda-4d0f-a508-a5f37c69c991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1fa0e794-9dbb-4900-b892-cd3ab27256ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_62de2550-1cda-4d0f-a508-a5f37c69c991" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1fa0e794-9dbb-4900-b892-cd3ab27256ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0b4b8ea6-15dc-420c-b202-d26dc915ea32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_62de2550-1cda-4d0f-a508-a5f37c69c991" xlink:to="loc_us-gaap_LetterOfCreditMember_0b4b8ea6-15dc-420c-b202-d26dc915ea32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b1e11318-1f9e-429e-a3bc-cff87ffe7cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b1e11318-1f9e-429e-a3bc-cff87ffe7cca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1e11318-1f9e-429e-a3bc-cff87ffe7cca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1e11318-1f9e-429e-a3bc-cff87ffe7cca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1e11318-1f9e-429e-a3bc-cff87ffe7cca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1e11318-1f9e-429e-a3bc-cff87ffe7cca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_953f62e9-ee14-4961-a64a-82c463e4d74f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:to="loc_us-gaap_LoansPayableMember_953f62e9-ee14-4961-a64a-82c463e4d74f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1a007fad-53be-4f22-8816-3ce73de15f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:to="loc_us-gaap_SeniorNotesMember_1a007fad-53be-4f22-8816-3ce73de15f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_577d400f-59ed-4079-839e-4a4b62089f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_577d400f-59ed-4079-839e-4a4b62089f44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_7c5d4f3a-4482-45d9-a2d2-595d84cf2440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_7c5d4f3a-4482-45d9-a2d2-595d84cf2440" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7c5d4f3a-4482-45d9-a2d2-595d84cf2440_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7c5d4f3a-4482-45d9-a2d2-595d84cf2440" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7c5d4f3a-4482-45d9-a2d2-595d84cf2440_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7c5d4f3a-4482-45d9-a2d2-595d84cf2440" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0c53821d-03fd-4370-97ea-572f76db7c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0c53821d-03fd-4370-97ea-572f76db7c55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9556b30d-fceb-4b9a-a3cd-fe32f244b703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9556b30d-fceb-4b9a-a3cd-fe32f244b703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ddf868d3-d2f2-477d-b294-b45ac12f3e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ddf868d3-d2f2-477d-b294-b45ac12f3e60" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPaymentsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails" xlink:type="extended" id="i151fb013783c4300802341d45160de64_ShareBasedPaymentsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f07b8624-c98d-4dff-8242-fb427cb863a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f07b8624-c98d-4dff-8242-fb427cb863a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fb49177c-dc73-4c97-987a-66795b53085c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fb49177c-dc73-4c97-987a-66795b53085c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a405d8c7-2610-47fa-a7dd-b5d6a435c7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a405d8c7-2610-47fa-a7dd-b5d6a435c7e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dd6c1b1-fac3-4d38-ac57-da3d968a97f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dd6c1b1-fac3-4d38-ac57-da3d968a97f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7e8fe70d-b2ec-4470-8ffb-2f32891d13db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7e8fe70d-b2ec-4470-8ffb-2f32891d13db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_db3de3db-5172-4399-b4f0-8afafe53fbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_db3de3db-5172-4399-b4f0-8afafe53fbc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_217f1981-a12d-4ef9-a7f8-c114586b754c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_217f1981-a12d-4ef9-a7f8-c114586b754c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b9964ae6-7f6d-48f5-ab3c-cd16182daa35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b9964ae6-7f6d-48f5-ab3c-cd16182daa35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_07b04d9f-d9ed-42be-9f64-3fca1b3a238d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_07b04d9f-d9ed-42be-9f64-3fca1b3a238d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_f3f8e850-7c19-4c78-8723-f72d507f2f3c" xlink:href="ehc-20211231.xsd#ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_f3f8e850-7c19-4c78-8723-f72d507f2f3c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c868c563-510f-4d48-854b-e16fc6d86f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c868c563-510f-4d48-854b-e16fc6d86f7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_da5cd402-e26c-45c4-9539-86464c4fd576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_da5cd402-e26c-45c4-9539-86464c4fd576" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2fc0ace8-4591-4081-a86c-84d294dedd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2fc0ace8-4591-4081-a86c-84d294dedd78" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AllocatedSharebasedCompensationLiability_c7e0cac6-94f0-4f99-9fe4-228174fd3170" xlink:href="ehc-20211231.xsd#ehc_AllocatedSharebasedCompensationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_ehc_AllocatedSharebasedCompensationLiability_c7e0cac6-94f0-4f99-9fe4-228174fd3170" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ab81be53-a1b7-4c71-ba46-f9cfae876373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ab81be53-a1b7-4c71-ba46-f9cfae876373" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0ae7f509-a0a2-4903-a8c6-cac16bb9d635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0ae7f509-a0a2-4903-a8c6-cac16bb9d635" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_26fb855c-1013-437e-a87d-c543da98a468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_26fb855c-1013-437e-a87d-c543da98a468" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_983dde82-4a26-4585-ab47-b9131cd9c0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_983dde82-4a26-4585-ab47-b9131cd9c0df" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_edfa89a4-2871-4e24-9870-42d52ff7bfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_edfa89a4-2871-4e24-9870-42d52ff7bfc2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5962f5dc-eccc-4368-85bc-6d0762438ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5962f5dc-eccc-4368-85bc-6d0762438ae6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_f9d74ce3-66cb-4655-b3ed-54c84ecad065" xlink:href="ehc-20211231.xsd#ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_f9d74ce3-66cb-4655-b3ed-54c84ecad065" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6f778344-4e1f-430b-bbe9-cfd9477d9b45" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:to="loc_srt_TitleOfIndividualAxis_6f778344-4e1f-430b-bbe9-cfd9477d9b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6f778344-4e1f-430b-bbe9-cfd9477d9b45_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6f778344-4e1f-430b-bbe9-cfd9477d9b45" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6f778344-4e1f-430b-bbe9-cfd9477d9b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aab5c710-a9db-4e62-a463-330b29f83428" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6f778344-4e1f-430b-bbe9-cfd9477d9b45" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aab5c710-a9db-4e62-a463-330b29f83428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NonemployeeDirectorsMember_47156fad-cea2-4ee2-81a2-d4624e3125ac" xlink:href="ehc-20211231.xsd#ehc_NonemployeeDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aab5c710-a9db-4e62-a463-330b29f83428" xlink:to="loc_ehc_NonemployeeDirectorsMember_47156fad-cea2-4ee2-81a2-d4624e3125ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_363c77a0-2873-43a3-baad-d64e398ccccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:to="loc_us-gaap_AwardTypeAxis_363c77a0-2873-43a3-baad-d64e398ccccb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_363c77a0-2873-43a3-baad-d64e398ccccb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_363c77a0-2873-43a3-baad-d64e398ccccb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_363c77a0-2873-43a3-baad-d64e398ccccb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_363c77a0-2873-43a3-baad-d64e398ccccb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9a03f32e-8bc8-41d7-9757-db3ea0e7df5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9a03f32e-8bc8-41d7-9757-db3ea0e7df5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EmploymentBasedSARSMember_7ad235d0-a539-4a84-8213-55640ae4648d" xlink:href="ehc-20211231.xsd#ehc_EmploymentBasedSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_ehc_EmploymentBasedSARSMember_7ad235d0-a539-4a84-8213-55640ae4648d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_e75d45b1-cd39-48d1-8f5e-7ac6c0574507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_e75d45b1-cd39-48d1-8f5e-7ac6c0574507" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PerformanceandEmploymentBasedSARSMember_5ae7dcce-3573-431c-b49d-708110cbba2f" xlink:href="ehc-20211231.xsd#ehc_PerformanceandEmploymentBasedSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_ehc_PerformanceandEmploymentBasedSARSMember_5ae7dcce-3573-431c-b49d-708110cbba2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c45a19f7-b089-42e2-b796-a81d47125185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_us-gaap_RestrictedStockMember_c45a19f7-b089-42e2-b796-a81d47125185" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7bc926c2-b635-409c-bd25-235f68485c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7bc926c2-b635-409c-bd25-235f68485c46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DividendEquivalentRSUMember_06fc1d77-18be-4cd8-894a-7c0158ee68ae" xlink:href="ehc-20211231.xsd#ehc_DividendEquivalentRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_ehc_DividendEquivalentRSUMember_06fc1d77-18be-4cd8-894a-7c0158ee68ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27870d41-59c8-4bb3-b365-2492b6d83d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:to="loc_us-gaap_PlanNameAxis_27870d41-59c8-4bb3-b365-2492b6d83d5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_27870d41-59c8-4bb3-b365-2492b6d83d5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_27870d41-59c8-4bb3-b365-2492b6d83d5d" xlink:to="loc_us-gaap_PlanNameDomain_27870d41-59c8-4bb3-b365-2492b6d83d5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5e4195a6-7506-4b07-bb43-912d7129f06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_27870d41-59c8-4bb3-b365-2492b6d83d5d" xlink:to="loc_us-gaap_PlanNameDomain_5e4195a6-7506-4b07-bb43-912d7129f06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember_66974ca1-bf4a-4423-aac4-4c46698c617b" xlink:href="ehc-20211231.xsd#ehc_A2016OmnibusPerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5e4195a6-7506-4b07-bb43-912d7129f06b" xlink:to="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember_66974ca1-bf4a-4423-aac4-4c46698c617b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPaymentsWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails" xlink:type="extended" id="i1904beb4c68a4b458aa922545a3bb48f_ShareBasedPaymentsWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afc58042-a2de-44dd-a694-b6e7e2610ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afc58042-a2de-44dd-a694-b6e7e2610ca9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_5948e913-952d-4355-a756-4d71ee13d758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_5948e913-952d-4355-a756-4d71ee13d758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_377c8293-3b03-471d-8f3d-d60d8546f046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_377c8293-3b03-471d-8f3d-d60d8546f046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd35e176-4a85-4e84-b660-1b5e6f11d018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd35e176-4a85-4e84-b660-1b5e6f11d018" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d270203-3afa-40f7-ab30-83ed348f7cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d270203-3afa-40f7-ab30-83ed348f7cd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52102b3a-40ac-48bb-b4d6-a006c3a49be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afc58042-a2de-44dd-a694-b6e7e2610ca9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52102b3a-40ac-48bb-b4d6-a006c3a49be0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ca89bdf-be1a-4351-9139-07a6cee784ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52102b3a-40ac-48bb-b4d6-a006c3a49be0" xlink:to="loc_us-gaap_AwardTypeAxis_2ca89bdf-be1a-4351-9139-07a6cee784ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ca89bdf-be1a-4351-9139-07a6cee784ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2ca89bdf-be1a-4351-9139-07a6cee784ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ca89bdf-be1a-4351-9139-07a6cee784ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237d724b-77b6-4f79-8317-f7d841707506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2ca89bdf-be1a-4351-9139-07a6cee784ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237d724b-77b6-4f79-8317-f7d841707506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2ea1db44-a498-4df1-8486-2b4b3208197b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237d724b-77b6-4f79-8317-f7d841707506" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2ea1db44-a498-4df1-8486-2b4b3208197b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_d82aaf0f-c582-4d85-a4f8-8033a0a1d501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237d724b-77b6-4f79-8317-f7d841707506" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_d82aaf0f-c582-4d85-a4f8-8033a0a1d501" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" xlink:type="extended" id="i6243ae3a337a49fc9667e0f1102872a0_ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6feae2a1-1a34-47aa-b7e0-dffc4bb05c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6feae2a1-1a34-47aa-b7e0-dffc4bb05c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d5e5510-bbae-4de8-a0e7-0b46ed00ffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d5e5510-bbae-4de8-a0e7-0b46ed00ffbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6405286-0916-4979-a3f8-215c87f6c6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6405286-0916-4979-a3f8-215c87f6c6c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_461d65dc-0946-4c9e-aed0-c9169c4cea8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_461d65dc-0946-4c9e-aed0-c9169c4cea8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21e5e457-1412-4eaf-91e6-45849e6657a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21e5e457-1412-4eaf-91e6-45849e6657a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5254882-7e75-4e41-aca2-8c2daa0c97d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6feae2a1-1a34-47aa-b7e0-dffc4bb05c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a149799a-e365-4012-8430-160dd1260da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a149799a-e365-4012-8430-160dd1260da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d32caee-d676-4de5-9de6-9c2a8e6a5881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d32caee-d676-4de5-9de6-9c2a8e6a5881" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_78eb0703-4ec9-4e5a-8808-46f12a97473c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_78eb0703-4ec9-4e5a-8808-46f12a97473c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f46abd9b-d409-4097-85ed-2dc0cc6cada0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f46abd9b-d409-4097-85ed-2dc0cc6cada0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cbf76ff9-ca80-404b-b981-0a0e224e7063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_375a145c-b3fc-4999-8501-091407e7bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6feae2a1-1a34-47aa-b7e0-dffc4bb05c09" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_375a145c-b3fc-4999-8501-091407e7bf3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_120abdc4-3d9e-463b-83cb-988fdf486961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_375a145c-b3fc-4999-8501-091407e7bf3b" xlink:to="loc_us-gaap_AwardTypeAxis_120abdc4-3d9e-463b-83cb-988fdf486961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_120abdc4-3d9e-463b-83cb-988fdf486961_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_120abdc4-3d9e-463b-83cb-988fdf486961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_120abdc4-3d9e-463b-83cb-988fdf486961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c55ed75-d914-4bc0-941f-bdfe10345e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_120abdc4-3d9e-463b-83cb-988fdf486961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c55ed75-d914-4bc0-941f-bdfe10345e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1ff9a260-4a61-4bdb-949f-00198e5b1d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c55ed75-d914-4bc0-941f-bdfe10345e30" xlink:to="loc_us-gaap_RestrictedStockMember_1ff9a260-4a61-4bdb-949f-00198e5b1d7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#EmployeeBenefitPlansTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails" xlink:type="extended" id="iaca88938ce0645c69071fb7e0423311c_EmployeeBenefitPlansTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HealthcarePlanExpense_c9787e18-e7c9-486a-95e1-0919271d9825" xlink:href="ehc-20211231.xsd#ehc_HealthcarePlanExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_HealthcarePlanExpense_c9787e18-e7c9-486a-95e1-0919271d9825" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfQualifiedPlans_9e088760-5696-4604-9976-92d7c71a16f5" xlink:href="ehc-20211231.xsd#ehc_NumberOfQualifiedPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_NumberOfQualifiedPlans_9e088760-5696-4604-9976-92d7c71a16f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_77ab0d00-d856-4a1d-bebd-5c9f665de68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_77ab0d00-d856-4a1d-bebd-5c9f665de68f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanAgeRequirement_a3d8ca24-0341-48da-ba6a-dcc2acea2003" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanAgeRequirement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_RetirementInvestmentPlanAgeRequirement_a3d8ca24-0341-48da-ba6a-dcc2acea2003" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7a4ae2f6-c381-436a-b0b5-09ce6d4b9fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7a4ae2f6-c381-436a-b0b5-09ce6d4b9fba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_af272bc6-5719-499c-9932-dccfbf360063" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_af272bc6-5719-499c-9932-dccfbf360063" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_3c658433-f386-4884-a35b-8f5b40df731f" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_3c658433-f386-4884-a35b-8f5b40df731f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_d2034c24-f9ba-4ade-a944-1a257e3c773c" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_d2034c24-f9ba-4ade-a944-1a257e3c773c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f26aa575-30b6-48c0-89a4-2e1e7ea1cd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f26aa575-30b6-48c0-89a4-2e1e7ea1cd72" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_265ce070-8fce-4c12-9ab0-efa4fd9da013" xlink:href="ehc-20211231.xsd#ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_265ce070-8fce-4c12-9ab0-efa4fd9da013" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorManagementBonusProgramTotalCosts_17022603-466a-4407-b1aa-71cdc44f2fe3" xlink:href="ehc-20211231.xsd#ehc_SeniorManagementBonusProgramTotalCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_SeniorManagementBonusProgramTotalCosts_17022603-466a-4407-b1aa-71cdc44f2fe3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_16e99ac5-7239-41c2-a31a-40b783eb9a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_us-gaap_DefinedContributionPlanTable_16e99ac5-7239-41c2-a31a-40b783eb9a56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_c071d9a7-e9e2-4eac-a180-53b7840d304e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_16e99ac5-7239-41c2-a31a-40b783eb9a56" xlink:to="loc_us-gaap_RetirementPlanNameAxis_c071d9a7-e9e2-4eac-a180-53b7840d304e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_c071d9a7-e9e2-4eac-a180-53b7840d304e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_c071d9a7-e9e2-4eac-a180-53b7840d304e" xlink:to="loc_us-gaap_RetirementPlanNameDomain_c071d9a7-e9e2-4eac-a180-53b7840d304e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_c8291b1f-66ed-4c6c-bbbc-c97d331832f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_c071d9a7-e9e2-4eac-a180-53b7840d304e" xlink:to="loc_us-gaap_RetirementPlanNameDomain_c8291b1f-66ed-4c6c-bbbc-c97d331832f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHealthRetirementInvestmentPlanMember_38f615e1-1146-4d2f-92a8-1bfd483b6a51" xlink:href="ehc-20211231.xsd#ehc_EncompassHealthRetirementInvestmentPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_c8291b1f-66ed-4c6c-bbbc-c97d331832f9" xlink:to="loc_ehc_EncompassHealthRetirementInvestmentPlanMember_38f615e1-1146-4d2f-92a8-1bfd483b6a51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHomeHealthSavingsPlanHHSPMember_8c7577ed-0317-4f02-bb18-70768e16dfa4" xlink:href="ehc-20211231.xsd#ehc_EncompassHomeHealthSavingsPlanHHSPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_c8291b1f-66ed-4c6c-bbbc-c97d331832f9" xlink:to="loc_ehc_EncompassHomeHealthSavingsPlanHHSPMember_8c7577ed-0317-4f02-bb18-70768e16dfa4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails" xlink:type="extended" id="id35bd1a212a84b1fa8d8896ddddd627f_IncomeTaxesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c8b5a675-810a-4408-8171-f2be893c8c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c8b5a675-810a-4408-8171-f2be893c8c89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b4e9c0e2-bb49-4a79-91ad-ff21d0382b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b4e9c0e2-bb49-4a79-91ad-ff21d0382b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c06b8ef9-ce10-49ee-8d72-741339ef18d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c06b8ef9-ce10-49ee-8d72-741339ef18d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_34c9c23b-adeb-49a6-912f-241766e355c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:to="loc_us-gaap_ValuationAllowanceTable_34c9c23b-adeb-49a6-912f-241766e355c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_46bc5a07-fc42-459d-8b35-c462a434ecb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_34c9c23b-adeb-49a6-912f-241766e355c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_46bc5a07-fc42-459d-8b35-c462a434ecb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_46bc5a07-fc42-459d-8b35-c462a434ecb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46bc5a07-fc42-459d-8b35-c462a434ecb4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_46bc5a07-fc42-459d-8b35-c462a434ecb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_19d1176b-9607-4db7-87f0-a189dff6b6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46bc5a07-fc42-459d-8b35-c462a434ecb4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_19d1176b-9607-4db7-87f0-a189dff6b6db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_fafa0f0d-640c-4c0d-86bf-38df4f02b8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_19d1176b-9607-4db7-87f0-a189dff6b6db" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_fafa0f0d-640c-4c0d-86bf-38df4f02b8ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#EarningsPerCommonShareTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails" xlink:type="extended" id="ifd803f62ffe14924baa9d7e7649ef819_EarningsPerCommonShareTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e8d80235-f8ed-4b6e-ab1d-4a48bdb07b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e8d80235-f8ed-4b6e-ab1d-4a48bdb07b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ca8f8ae2-0bd5-4c60-8596-441d86d094c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ca8f8ae2-0bd5-4c60-8596-441d86d094c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6e6eb9b8-2624-47e1-9bc2-dee2d23ae846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6e6eb9b8-2624-47e1-9bc2-dee2d23ae846" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1e9e7a21-f2fa-4bce-81d2-34dbfb6f3b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1e9e7a21-f2fa-4bce-81d2-34dbfb6f3b78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_5e73edd7-3d62-4251-82cc-090b9662f9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_5e73edd7-3d62-4251-82cc-090b9662f9ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_f22ecfdc-4375-43d6-9635-b43a376ac95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_f22ecfdc-4375-43d6-9635-b43a376ac95d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_075dad37-ee29-44a6-9ca9-c4e6bd3263e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_075dad37-ee29-44a6-9ca9-c4e6bd3263e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8098e60d-b6a4-4eb4-824b-445cdd8db3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_075dad37-ee29-44a6-9ca9-c4e6bd3263e6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8098e60d-b6a4-4eb4-824b-445cdd8db3a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8098e60d-b6a4-4eb4-824b-445cdd8db3a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8098e60d-b6a4-4eb4-824b-445cdd8db3a6" xlink:to="loc_us-gaap_ClassOfStockDomain_8098e60d-b6a4-4eb4-824b-445cdd8db3a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b9f484c0-41c3-4d3b-a5ac-bf1fbe5881af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8098e60d-b6a4-4eb4-824b-445cdd8db3a6" xlink:to="loc_us-gaap_ClassOfStockDomain_b9f484c0-41c3-4d3b-a5ac-bf1fbe5881af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3f5c266b-4dcc-4409-aa4a-1d05fe5c5aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9f484c0-41c3-4d3b-a5ac-bf1fbe5881af" xlink:to="loc_us-gaap_CommonStockMember_3f5c266b-4dcc-4409-aa4a-1d05fe5c5aa9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ContingenciesandOtherCommitmentsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails" xlink:type="extended" id="i2132290c1e53432a8d7f3897d3cc6b0b_ContingenciesandOtherCommitmentsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_9c9fbbdd-e35f-4bcc-87a2-fdc83e6b9c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_cc3082e2-6b9a-4fa4-9bb8-902b03c55435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9c9fbbdd-e35f-4bcc-87a2-fdc83e6b9c4e" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_cc3082e2-6b9a-4fa4-9bb8-902b03c55435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentFiscalYearMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9c9fbbdd-e35f-4bcc-87a2-fdc83e6b9c4e" xlink:to="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_1ff5fe43-32cf-423f-9621-27755b5e0791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_1ff5fe43-32cf-423f-9621-27755b5e0791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_dae86cc6-faa3-40d3-94c6-64731302402f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_dae86cc6-faa3-40d3-94c6-64731302402f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_19334efa-a82a-4e25-84c2-951eb230fe51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_19334efa-a82a-4e25-84c2-951eb230fe51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_cdcd34c5-f786-400f-b5e1-535df56b6b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_cdcd34c5-f786-400f-b5e1-535df56b6b21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_cd09b40c-5bfe-4081-8375-12ede5970bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_cd09b40c-5bfe-4081-8375-12ede5970bae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear_702cf0e1-aef3-4d7e-a67c-c8fe0c046e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueAfterFifthYear_702cf0e1-aef3-4d7e-a67c-c8fe0c046e02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_9c9fbbdd-e35f-4bcc-87a2-fdc83e6b9c4e" xlink:to="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_282b7446-adc6-4c29-8c3e-0c695d92e60f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:to="loc_srt_RangeAxis_282b7446-adc6-4c29-8c3e-0c695d92e60f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_282b7446-adc6-4c29-8c3e-0c695d92e60f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_282b7446-adc6-4c29-8c3e-0c695d92e60f" xlink:to="loc_srt_RangeMember_282b7446-adc6-4c29-8c3e-0c695d92e60f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a302262f-a91e-43dc-96aa-2aa78e0b5c18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_282b7446-adc6-4c29-8c3e-0c695d92e60f" xlink:to="loc_srt_RangeMember_a302262f-a91e-43dc-96aa-2aa78e0b5c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59a31ce4-9a26-4a60-94fd-adeaf9e3ba75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a302262f-a91e-43dc-96aa-2aa78e0b5c18" xlink:to="loc_srt_MaximumMember_59a31ce4-9a26-4a60-94fd-adeaf9e3ba75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b1ef93d9-acf3-46c3-a605-02f8ae6243b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:to="loc_us-gaap_LitigationStatusAxis_b1ef93d9-acf3-46c3-a605-02f8ae6243b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b1ef93d9-acf3-46c3-a605-02f8ae6243b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_b1ef93d9-acf3-46c3-a605-02f8ae6243b8" xlink:to="loc_us-gaap_LitigationStatusDomain_b1ef93d9-acf3-46c3-a605-02f8ae6243b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3605a9df-ee53-4d97-bf84-aeecba92c9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_b1ef93d9-acf3-46c3-a605-02f8ae6243b8" xlink:to="loc_us-gaap_LitigationStatusDomain_3605a9df-ee53-4d97-bf84-aeecba92c9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_da6e4aab-eaf4-483f-a916-636fb0c380e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3605a9df-ee53-4d97-bf84-aeecba92c9be" xlink:to="loc_us-gaap_SettledLitigationMember_da6e4aab-eaf4-483f-a916-636fb0c380e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c34fec35-5eec-4c3a-9e01-c5077f5da588" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:to="loc_srt_LitigationCaseAxis_c34fec35-5eec-4c3a-9e01-c5077f5da588" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c34fec35-5eec-4c3a-9e01-c5077f5da588_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c34fec35-5eec-4c3a-9e01-c5077f5da588" xlink:to="loc_srt_LitigationCaseTypeDomain_c34fec35-5eec-4c3a-9e01-c5077f5da588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_069f323c-9faf-4763-bf21-82074c7ffc53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c34fec35-5eec-4c3a-9e01-c5077f5da588" xlink:to="loc_srt_LitigationCaseTypeDomain_069f323c-9faf-4763-bf21-82074c7ffc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NicholsLitigationMember_28bc20bc-fa34-4a76-bba3-b02fef7709fa" xlink:href="ehc-20211231.xsd#ehc_NicholsLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_069f323c-9faf-4763-bf21-82074c7ffc53" xlink:to="loc_ehc_NicholsLitigationMember_28bc20bc-fa34-4a76-bba3-b02fef7709fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingTextualsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTextualsDetails" xlink:type="extended" id="ie1c8b290d53a489d9eb8ed4f3bd337bd_SegmentReportingTextualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c17dbc02-4c4a-4e52-a9c1-2fd11e5370b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c17dbc02-4c4a-4e52-a9c1-2fd11e5370b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_3b884f95-eeea-47f9-bb68-c5f0f50fa094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_3b884f95-eeea-47f9-bb68-c5f0f50fa094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals_5c3278e9-5b1c-40c8-b36d-558404223bba" xlink:href="ehc-20211231.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitals_5c3278e9-5b1c-40c8-b36d-558404223bba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_d58b3064-410e-464c-8ea3-1c5f722c8f1f" xlink:href="ehc-20211231.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_d58b3064-410e-464c-8ea3-1c5f722c8f1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage_b167b25a-bee2-4fa9-bcdc-60283b420f64" xlink:href="ehc-20211231.xsd#ehc_Jointventureownershippercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Jointventureownershippercentage_b167b25a-bee2-4fa9-bcdc-60283b420f64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_af8d84af-b908-4572-8c51-f5f0a3114324" xlink:href="ehc-20211231.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_af8d84af-b908-4572-8c51-f5f0a3114324" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_8cfbfdc4-c5c8-4391-9eee-db0c248fe8b9" xlink:href="ehc-20211231.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_8cfbfdc4-c5c8-4391-9eee-db0c248fe8b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations_7807dad6-29bf-4479-b501-65fcb6fc619a" xlink:href="ehc-20211231.xsd#ehc_Numberofhomehealthlocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofhomehealthlocations_7807dad6-29bf-4479-b501-65fcb6fc619a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations_4e74a319-d532-4c36-92a0-7963e52bee59" xlink:href="ehc-20211231.xsd#ehc_Numberofhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofhospicelocations_4e74a319-d532-4c36-92a0-7963e52bee59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_37e87da4-c59a-458f-ba7d-808864f1c681" xlink:href="ehc-20211231.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_37e87da4-c59a-458f-ba7d-808864f1c681" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_916c4b95-cf30-416a-8f7c-687c2614e63b" xlink:href="ehc-20211231.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_916c4b95-cf30-416a-8f7c-687c2614e63b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c472c86b-411e-4058-96c8-d0526d7728f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:to="loc_srt_RangeAxis_c472c86b-411e-4058-96c8-d0526d7728f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c472c86b-411e-4058-96c8-d0526d7728f5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c472c86b-411e-4058-96c8-d0526d7728f5" xlink:to="loc_srt_RangeMember_c472c86b-411e-4058-96c8-d0526d7728f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9bbaa65b-88d4-4872-864e-3dd0ccae531d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c472c86b-411e-4058-96c8-d0526d7728f5" xlink:to="loc_srt_RangeMember_9bbaa65b-88d4-4872-864e-3dd0ccae531d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4de187fb-e0ff-41b1-baa7-c778a70b3004" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9bbaa65b-88d4-4872-864e-3dd0ccae531d" xlink:to="loc_srt_MinimumMember_4de187fb-e0ff-41b1-baa7-c778a70b3004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_88c1e762-71a6-43a5-9cc7-f2535f298c38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9bbaa65b-88d4-4872-864e-3dd0ccae531d" xlink:to="loc_srt_MaximumMember_88c1e762-71a6-43a5-9cc7-f2535f298c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e4517fbe-b83c-48ce-b02a-2be12eeae375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e4517fbe-b83c-48ce-b02a-2be12eeae375" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e4517fbe-b83c-48ce-b02a-2be12eeae375_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4517fbe-b83c-48ce-b02a-2be12eeae375" xlink:to="loc_us-gaap_SegmentDomain_e4517fbe-b83c-48ce-b02a-2be12eeae375_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4517fbe-b83c-48ce-b02a-2be12eeae375" xlink:to="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_7d2d1503-4787-45e8-94ec-96b7db1e0aa0" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_7d2d1503-4787-45e8-94ec-96b7db1e0aa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_12f5ba33-dc50-45e4-b5b1-e46b1be98fc2" xlink:href="ehc-20211231.xsd#ehc_HomehealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:to="loc_ehc_HomehealthMember_12f5ba33-dc50-45e4-b5b1-e46b1be98fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_74445a29-7d32-4018-b9c5-cdd5faf79f56" xlink:href="ehc-20211231.xsd#ehc_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:to="loc_ehc_HospiceMember_74445a29-7d32-4018-b9c5-cdd5faf79f56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_51f4c7e6-c7ce-4d18-9d57-4fed9c9c5211" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_51f4c7e6-c7ce-4d18-9d57-4fed9c9c5211" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails" xlink:type="extended" id="ibd9166ebe33e400986e622dad76d1ae8_SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0536f4b4-57ee-48c9-8533-001820e219ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0536f4b4-57ee-48c9-8533-001820e219ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_4cf14d6f-b6ee-4dd5-8352-9230d038bdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_LaborAndRelatedExpense_4cf14d6f-b6ee-4dd5-8352-9230d038bdf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_32834a1b-713d-4167-95ce-6fc67398cdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_32834a1b-713d-4167-95ce-6fc67398cdbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_668bb75d-bdeb-4f9e-9886-cbf655d69fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_SuppliesExpense_668bb75d-bdeb-4f9e-9886-cbf655d69fce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_23a56f1a-5743-4322-a438-677d1f9c449a" xlink:href="ehc-20211231.xsd#ehc_OccupancyCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_ehc_OccupancyCost_23a56f1a-5743-4322-a438-677d1f9c449a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_e73b3839-2b11-48e7-b04d-3fed4772f809" xlink:href="ehc-20211231.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_e73b3839-2b11-48e7-b04d-3fed4772f809" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_0e7224ba-6752-4255-baca-a524ff5101ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_0e7224ba-6752-4255-baca-a524ff5101ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5dc47c89-ac05-48d0-b8b3-8ce55cfc7b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_CostsAndExpenses_5dc47c89-ac05-48d0-b8b3-8ce55cfc7b79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cf167e82-955f-48e3-8f8b-0b5f2df291cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cf167e82-955f-48e3-8f8b-0b5f2df291cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_087720ff-b018-438c-9e19-9e9803197395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_087720ff-b018-438c-9e19-9e9803197395" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6d6a3254-3b56-417d-8f08-cc91ac967a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6d6a3254-3b56-417d-8f08-cc91ac967a3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_3745a388-29a7-4613-b9a2-36e61595cc2a" xlink:href="ehc-20211231.xsd#ehc_AdjustedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_ehc_AdjustedEBITDA_3745a388-29a7-4613-b9a2-36e61595cc2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_c3b3bc8f-d71e-4f44-8f17-9b308f702ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_c3b3bc8f-d71e-4f44-8f17-9b308f702ddc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e723aee7-f6a7-4813-a234-d3703abf5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e723aee7-f6a7-4813-a234-d3703abf5fe2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8d39f499-b044-4db5-9694-b5c46e5934b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e723aee7-f6a7-4813-a234-d3703abf5fe2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8d39f499-b044-4db5-9694-b5c46e5934b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8d39f499-b044-4db5-9694-b5c46e5934b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8d39f499-b044-4db5-9694-b5c46e5934b4" xlink:to="loc_us-gaap_SegmentDomain_8d39f499-b044-4db5-9694-b5c46e5934b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93e4253a-acc1-4a9c-ac69-6fe3cbbc2d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8d39f499-b044-4db5-9694-b5c46e5934b4" xlink:to="loc_us-gaap_SegmentDomain_93e4253a-acc1-4a9c-ac69-6fe3cbbc2d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_17a4eae4-4319-4625-aae4-a014e8cfa484" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93e4253a-acc1-4a9c-ac69-6fe3cbbc2d8f" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_17a4eae4-4319-4625-aae4-a014e8cfa484" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_e3d67e13-51a8-4ac5-95ca-929b318bc718" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93e4253a-acc1-4a9c-ac69-6fe3cbbc2d8f" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_e3d67e13-51a8-4ac5-95ca-929b318bc718" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails" xlink:type="extended" id="i7cb462172a5045148868379be010eb23_SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_41922962-b67a-4007-aae2-93b4bcf02b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3d485e29-c264-4117-8105-40647916f723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_41922962-b67a-4007-aae2-93b4bcf02b51" xlink:to="loc_us-gaap_Assets_3d485e29-c264-4117-8105-40647916f723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_3aa5e13f-88c3-4d7e-8825-418cad9cda03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_41922962-b67a-4007-aae2-93b4bcf02b51" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_3aa5e13f-88c3-4d7e-8825-418cad9cda03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_9ea697f5-75ba-43d2-8db6-8c8467516a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_41922962-b67a-4007-aae2-93b4bcf02b51" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_9ea697f5-75ba-43d2-8db6-8c8467516a00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ac35b2df-4b19-4761-9460-f18fe9e04761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_9ea697f5-75ba-43d2-8db6-8c8467516a00" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ac35b2df-4b19-4761-9460-f18fe9e04761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ac35b2df-4b19-4761-9460-f18fe9e04761_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ac35b2df-4b19-4761-9460-f18fe9e04761" xlink:to="loc_us-gaap_SegmentDomain_ac35b2df-4b19-4761-9460-f18fe9e04761_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6d816acd-3a84-4c5f-805e-a62adaf965b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ac35b2df-4b19-4761-9460-f18fe9e04761" xlink:to="loc_us-gaap_SegmentDomain_6d816acd-3a84-4c5f-805e-a62adaf965b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_5a44ff2c-f297-4465-b45a-3df112a92040" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d816acd-3a84-4c5f-805e-a62adaf965b5" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_5a44ff2c-f297-4465-b45a-3df112a92040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_09f661a0-5af0-40df-862f-e25cd2841c2b" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d816acd-3a84-4c5f-805e-a62adaf965b5" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_09f661a0-5af0-40df-862f-e25cd2841c2b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended" id="icac766a6ed13463181ee7bb2f3273288_SegmentReportingReconciliationofAdjustedEBITDADetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_ebd55afe-4dde-4078-935b-77a59eaddcd4" xlink:href="ehc-20211231.xsd#ehc_AdjustedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_ehc_AdjustedEBITDA_ebd55afe-4dde-4078-935b-77a59eaddcd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7a1b4816-43f2-4d02-af6c-e08ea9b2f9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7a1b4816-43f2-4d02-af6c-e08ea9b2f9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_14350a45-956c-41b5-ae9d-e7afdb875139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_14350a45-956c-41b5-ae9d-e7afdb875139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_dcc31990-4394-46d7-9623-151ce9f1f233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_dcc31990-4394-46d7-9623-151ce9f1f233" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_3fcdea71-5724-42db-b6b2-d920a8e5f1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_LitigationSettlementExpense_3fcdea71-5724-42db-b6b2-d920a8e5f1e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c77c31f8-c415-4071-9adc-e75c614073ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c77c31f8-c415-4071-9adc-e75c614073ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_d74c6b11-1fef-4d3e-af83-e4a3d31fc745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_InterestExpenseDebt_d74c6b11-1fef-4d3e-af83-e4a3d31fc745" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4ae07822-643b-4d7f-ad1d-b4dc0300c572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4ae07822-643b-4d7f-ad1d-b4dc0300c572" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_151298b1-bfe0-491d-850b-4c678f6a1631" xlink:href="ehc-20211231.xsd#ehc_SARsmarktomarketimpactonnoncontrollinginterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_151298b1-bfe0-491d-850b-4c678f6a1631" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_a2e4d6d4-5169-4528-aa60-27214c84c46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_a2e4d6d4-5169-4528-aa60-27214c84c46a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f9ad0699-b2a2-4985-b09d-d855b604a115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f9ad0699-b2a2-4985-b09d-d855b604a115" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayrolltaxesonSARsexercise_d720713d-0ebe-4b37-96b1-6a57c9a72c41" xlink:href="ehc-20211231.xsd#ehc_PayrolltaxesonSARsexercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_ehc_PayrolltaxesonSARsexercise_d720713d-0ebe-4b37-96b1-6a57c9a72c41" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57d433de-7647-4d7c-8e73-c95150677f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57d433de-7647-4d7c-8e73-c95150677f85" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d11c367b-c996-4da6-9092-4e17b3ee8209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d11c367b-c996-4da6-9092-4e17b3ee8209" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d11c367b-c996-4da6-9092-4e17b3ee8209" xlink:to="loc_srt_ConsolidationItemsAxis_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd" xlink:to="loc_srt_ConsolidationItemsDomain_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4ebfa000-1a2e-4c9b-ba5b-17f8bb88b05c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd" xlink:to="loc_srt_ConsolidationItemsDomain_4ebfa000-1a2e-4c9b-ba5b-17f8bb88b05c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6fd13c6e-e067-4ba5-a1dc-cb3788c05f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4ebfa000-1a2e-4c9b-ba5b-17f8bb88b05c" xlink:to="loc_us-gaap_OperatingSegmentsMember_6fd13c6e-e067-4ba5-a1dc-cb3788c05f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_2b4872d9-6c8f-4218-85cb-5f3d3bb6d635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4ebfa000-1a2e-4c9b-ba5b-17f8bb88b05c" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_2b4872d9-6c8f-4218-85cb-5f3d3bb6d635" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails" xlink:type="extended" id="i3f9b517ddf1f4d4fb684524ded35feb8_SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_0441b6ea-a1d1-4a2d-a046-ecd0532eba17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d392ba41-6a19-4bad-842b-8eed8c9a89da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_0441b6ea-a1d1-4a2d-a046-ecd0532eba17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d392ba41-6a19-4bad-842b-8eed8c9a89da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_0441b6ea-a1d1-4a2d-a046-ecd0532eba17" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2" xlink:to="loc_us-gaap_SegmentDomain_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e6a9944c-a6f7-4e8c-9c66-315fa12c602d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2" xlink:to="loc_us-gaap_SegmentDomain_e6a9944c-a6f7-4e8c-9c66-315fa12c602d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_71d17878-cdca-4435-933f-1d2c8a14aa33" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e6a9944c-a6f7-4e8c-9c66-315fa12c602d" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_71d17878-cdca-4435-933f-1d2c8a14aa33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_95c9100e-51a1-4635-855e-6f6a5bb0e205" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e6a9944c-a6f7-4e8c-9c66-315fa12c602d" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_95c9100e-51a1-4635-855e-6f6a5bb0e205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_728e79c9-2966-4dfe-a3c4-362620e8fa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:to="loc_us-gaap_SubsegmentsAxis_728e79c9-2966-4dfe-a3c4-362620e8fa3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_728e79c9-2966-4dfe-a3c4-362620e8fa3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_728e79c9-2966-4dfe-a3c4-362620e8fa3f" xlink:to="loc_us-gaap_SubsegmentsDomain_728e79c9-2966-4dfe-a3c4-362620e8fa3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_728e79c9-2966-4dfe-a3c4-362620e8fa3f" xlink:to="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember_31586725-10c1-431f-ba5c-7b93ccb25faf" xlink:href="ehc-20211231.xsd#ehc_InpatientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:to="loc_ehc_InpatientMember_31586725-10c1-431f-ba5c-7b93ccb25faf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember_71b41760-8449-44cd-9e55-f52cf2ab488e" xlink:href="ehc-20211231.xsd#ehc_OutpatientandotherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:to="loc_ehc_OutpatientandotherMember_71b41760-8449-44cd-9e55-f52cf2ab488e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_fa96c1fd-6dd1-41ac-befe-30220f02af29" xlink:href="ehc-20211231.xsd#ehc_HomehealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:to="loc_ehc_HomehealthMember_fa96c1fd-6dd1-41ac-befe-30220f02af29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_df1f6057-4cde-40ba-89cb-44441f943464" xlink:href="ehc-20211231.xsd#ehc_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:to="loc_ehc_HospiceMember_df1f6057-4cde-40ba-89cb-44441f943464" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>ehc-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fa73796-4641-417c-869a-a8efa97ec0d7,g:d7a996dc-3cad-46ef-bbb1-393716adc0de-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_8739ce5d-6a35-4e9e-9030-955aea92c1bd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2abce78a-7d26-4dc7-98b7-552a34375d02_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_9ce34e0c-be34-49b7-ae8e-e4f5be851553_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_bfea777d-8ca0-40fc-a83e-8ad3f21e0265_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_18abe82d-ce9b-4ce2-8c42-22be7bcec690_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_348a4017-40a5-4b13-9cbd-b2f2963ff59e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_74489bda-156e-4f7c-91f9-70622f4c3e31_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_a5c414df-350c-4c10-a178-4f2c662546f4_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9b8d81cc-34af-4207-9218-7735dace9b40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncash or Part Noncash Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_fc0ac3c4-6536-48b7-b634-42c6479298c9_terseLabel_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:href="ehc-20211231.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:to="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c0a5531c-2c58-4e83-9d0f-29016d030e11_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow agent cost</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AllocatedSharebasedCompensationLiability_f4b886ad-6a64-4c73-9a64-068fc9891f8a_terseLabel_en-US" xlink:label="lab_ehc_AllocatedSharebasedCompensationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of SARs</link:label>
    <link:label id="lab_ehc_AllocatedSharebasedCompensationLiability_label_en-US" xlink:label="lab_ehc_AllocatedSharebasedCompensationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Liability</link:label>
    <link:label id="lab_ehc_AllocatedSharebasedCompensationLiability_documentation_en-US" xlink:label="lab_ehc_AllocatedSharebasedCompensationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AllocatedSharebasedCompensationLiability" xlink:href="ehc-20211231.xsd#ehc_AllocatedSharebasedCompensationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AllocatedSharebasedCompensationLiability" xlink:to="lab_ehc_AllocatedSharebasedCompensationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_57259ec6-fc37-44c4-90c1-bdf5e5025fa6_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of face value (percent)</link:label>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_label_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Discount Rate At Issuance Of Face Value</link:label>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Discount Rate at Issuance of Face Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:to="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_fb3882e5-f5fc-42ac-92ea-10cb411b8d10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8ff74d86-ae2e-4719-9bac-6fa51642a573_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_dcb365bf-a69a-4761-bd78-c23a4af5937b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dac7fa0e-7329-4049-9e54-622a11828a52_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_6efab605-e2d1-4bf8-be93-57a02b5972d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5bcb12c9-744c-4c9c-bf1c-a01b17efcc37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_041e110a-625b-422e-8d15-2fafd4ec2010_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_db3585a3-9da0-42dd-9eff-96a85fd9b6c1_terseLabel_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Covenants</link:label>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Financial Covenants [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Financial Covenants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:href="ehc-20211231.xsd#ehc_ScheduleOfFinancialCovenantsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:to="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a3262b-9d8b-4466-a370-f26366c9f0ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_95f7eeac-3adf-4b97-b6a6-52e1ebfbd8ed_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_91f0dd60-1233-43b3-9495-0c8ce8c702ea_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f187b28d-87b8-47e7-9e34-0d335f2d2db8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_36a52e20-afff-4c7f-b69d-c05da30a73b6_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year One</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage_ea0d3686-55e8-47b0-bfb2-63146e09f820_terseLabel_en-US" xlink:label="lab_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, additional ownership percentage</link:label>
    <link:label id="lab_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage_label_en-US" xlink:label="lab_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Ownership Percentage</link:label>
    <link:label id="lab_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage_documentation_en-US" xlink:label="lab_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentAdditionalOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage" xlink:to="lab_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_507782ae-3fa7-4822-8890-c4d499b249f5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2d89cc79-4ea0-4ce2-86e2-7d72474b0231_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_65df0392-b0e9-4ef9-9fa9-7e44f5296aed_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8f737ff0-6833-456b-af29-2e4d35cb1faf_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_12dbff0c-f761-4f99-a8e3-9efec4b11044_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_bf6a64d7-9d47-4311-a9fd-59d79a34e43e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bond issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Senior Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e27eae7-091c-40cd-8483-ae1b999abb5e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares excluded from computation of diluted weighted-average shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e13e08af-2b31-4cf8-b615-48368abd5ec5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests_6af73d24-57d7-4398-81f2-6515e3893d07_terseLabel_en-US" xlink:label="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARs mark-to-market impact on noncontrolling interests</link:label>
    <link:label id="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests_label_en-US" xlink:label="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARs mark-to-market impact on noncontrolling interests</link:label>
    <link:label id="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests_documentation_en-US" xlink:label="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in noncontrolling interest during the period as a result of SARs mark-to-market adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:href="ehc-20211231.xsd#ehc_SARsmarktomarketimpactonnoncontrollinginterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:to="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_661332c2-2df8-4146-bf62-dd499d2f5568_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_7e7d487b-8d24-4e22-8992-e7938a52ca39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_551db3bd-1594-40d6-ba5c-32b9df7fabb5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_ac3d7f44-b8bf-4972-9ecc-06e8fe24689d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d9f71ff6-c780-45e4-9c43-c14960ca9612_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_48495d41-2311-4970-abbc-74bc74769d7e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_5c8fbf61-2e95-446e-89cd-1eb55caf4747_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Basis of Other Indefinite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_d343d21d-4199-47de-b51e-8d2efda4eff6_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b25357b-43dc-4c60-9ec5-acc4632bb5ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_ca3467ec-4b43-4fd3-809a-27ad8b6777fa_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Estimated Amortization Expense, Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_5c9dde66-223d-45bd-b558-d16b0a3dbd09_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5d16c15a-f11a-4b00-aa1e-6495baf39e5b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_41a26f36-0a2b-4f25-96b7-a51291563e6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_f9f72145-d74e-4328-881f-38fb2fd21c5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49284618-ce79-4b95-af45-84e283033c4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, December 31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_ba5b6c17-2579-43d6-a4af-5569fb0b83a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0a548674-9d95-4b33-959a-ecec63b8bf6f_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SaintAlphonsusMember_528f95df-f26e-4313-835a-226ee75ff8da_terseLabel_en-US" xlink:label="lab_ehc_SaintAlphonsusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus</link:label>
    <link:label id="lab_ehc_SaintAlphonsusMember_label_en-US" xlink:label="lab_ehc_SaintAlphonsusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus [Member]</link:label>
    <link:label id="lab_ehc_SaintAlphonsusMember_documentation_en-US" xlink:label="lab_ehc_SaintAlphonsusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SaintAlphonsusMember" xlink:to="lab_ehc_SaintAlphonsusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8930ec09-accf-47cb-b8f8-a27b98a31eb0_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions declared</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_4b0ea49a-8c3c-4e9c-a7ba-33e3883b440a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions declared</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_796fd177-7263-49f9-aeb5-db92c5071188_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_397dcd9b-cd5b-4dc3-abc9-290ec23ee3a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments other than options, share-based liabilities paid</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Share-based Liabilities Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6b33ce57-d2b5-45af-adb5-9ac804f46610_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1cfd48f8-1fbf-49be-bc81-ff7cb2005a0b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated (Deficit) Income</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_26934d60-3f3e-43cb-af40-fd1733a7ff03_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_54f120b5-330b-417e-a8f9-89db69f5e1b0_terseLabel_en-US" xlink:label="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options</link:label>
    <link:label id="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_documentation_en-US" xlink:label="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:href="ehc-20211231.xsd#ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:to="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_99fbaf8a-16b1-483c-8f2b-85f12ad88b9a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in the consolidated entities (percent)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_ce704a88-6d4d-423b-bd0a-f5023d4f0ad6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Four</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_3678e946-8f66-4a9e-8615-6924b848bf9a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesGainLoss_eb85566f-653e-4d65-ba62-4b0e86d01376_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair market value of equity securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5555cdd4-c570-43e5-a89f-0bbe47316ac4_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement alternative investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6e5a9f17-31fa-4e4d-89c3-af379c50a483_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofhospicelocations_0a3d50c4-44dd-40fd-bb53-12d45c73df22_terseLabel_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations</link:label>
    <link:label id="lab_ehc_Numberofhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations</link:label>
    <link:label id="lab_ehc_Numberofhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations" xlink:href="ehc-20211231.xsd#ehc_Numberofhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofhospicelocations" xlink:to="lab_ehc_Numberofhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_1432e42e-69ef-4bd7-8497-90bee04c13f1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_201ae52e-cae8-4e6f-b6de-a6a01e794011_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3f6acaf7-df02-497a-a289-6906425f0257_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5480700c-d046-4263-a255-d6d3f1b11446_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c04ae178-5314-495a-9452-a650ce732362_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_a3975519-920d-41ee-a724-0df993001eb1_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_045a7f29-4824-467d-a6eb-8d4714fbfbba_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_03c339ef-ccb2-4a19-9288-8e1db4037a75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease for the provision of prior year claims</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_38ce637b-5ebd-448e-927c-07c10c5616d3_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_384c6892-8993-41cc-9ce4-6d84c491b19e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ec9cdf91-825b-42d9-8fdf-5393ad1c6797_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested shares, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e6f03bb-8516-4b75-9a9e-55156762db8f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested shares, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PremierHealthPartnersMember_629ae0d1-f3b3-4cb1-a30b-94fe7ed0d333_terseLabel_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners</link:label>
    <link:label id="lab_ehc_PremierHealthPartnersMember_label_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners [Member]</link:label>
    <link:label id="lab_ehc_PremierHealthPartnersMember_documentation_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember" xlink:href="ehc-20211231.xsd#ehc_PremierHealthPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PremierHealthPartnersMember" xlink:to="lab_ehc_PremierHealthPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofhomehealthlocations_bf0d0821-5e6b-4f10-8141-0636ba1af725_terseLabel_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations</link:label>
    <link:label id="lab_ehc_Numberofhomehealthlocations_label_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations</link:label>
    <link:label id="lab_ehc_Numberofhomehealthlocations_documentation_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations" xlink:href="ehc-20211231.xsd#ehc_Numberofhomehealthlocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofhomehealthlocations" xlink:to="lab_ehc_Numberofhomehealthlocations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_03bd75fd-9662-41c4-b848-565c2aab4bf9_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes due 2025</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_e216d9a2-05d8-4f25-bbab-9afbf7accc10_verboseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes due 2025</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_label_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2025 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes05.75Due2025Member" xlink:to="lab_ehc_SeniorNotes05.75Due2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_a6e4917e-3416-4c78-87d0-b8d338cefbd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and amortization of debt discounts and fees</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_dcf27963-395a-4e65-ae5c-f9ea75da6783_terseLabel_en-US" xlink:label="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:href="ehc-20211231.xsd#ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:to="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_8240d6e6-2224-4618-920d-f60fe0214c1b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Disclosure Item Amounts [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_5cc67b82-e98b-45ff-98e8-f2bf28e2d481_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PerformanceandEmploymentBasedSARSMember_a483f3a8-c1ce-4c1b-8681-bc772814127c_terseLabel_en-US" xlink:label="lab_ehc_PerformanceandEmploymentBasedSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance and Employment Based SARS</link:label>
    <link:label id="lab_ehc_PerformanceandEmploymentBasedSARSMember_label_en-US" xlink:label="lab_ehc_PerformanceandEmploymentBasedSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance and Employment Based SARS [Member]</link:label>
    <link:label id="lab_ehc_PerformanceandEmploymentBasedSARSMember_documentation_en-US" xlink:label="lab_ehc_PerformanceandEmploymentBasedSARSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance and Employment Based SARS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PerformanceandEmploymentBasedSARSMember" xlink:href="ehc-20211231.xsd#ehc_PerformanceandEmploymentBasedSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PerformanceandEmploymentBasedSARSMember" xlink:to="lab_ehc_PerformanceandEmploymentBasedSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicaidMember_63364e5a-7be0-4b76-9416-9cab79ea4831_terseLabel_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ehc_MedicaidMember_label_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ehc_MedicaidMember_documentation_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember" xlink:href="ehc-20211231.xsd#ehc_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicaidMember" xlink:to="lab_ehc_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_d5cccfdc-842c-4420-8a68-9f5c6e3878a7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_b87aad57-1d29-41f0-8812-ab16e77c1dfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_70806e5f-d8a1-4ddd-9caa-9a776c10fd4e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_d0c6b8bc-1422-444f-9f04-9b29f5f4c67b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_85b93dfd-d16b-4d40-a351-732b856bee78_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance reserve</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_66250989-c983-4f69-b69b-715a4d3b2753_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e70b8145-6908-4a2e-93ae-cccac5574fb6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_821ce0d0-2610-4ce2-bb26-dfa7dfb125eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_27144c5f-bec2-46b5-a174-f405a58a5508_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_13c3e432-cc74-4363-9803-66afe781c6af_totalLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, current</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Operatingandfinanceleasecontractterm_ccf4f179-b377-4937-98f4-93b14f16be8a_terseLabel_en-US" xlink:label="lab_ehc_Operatingandfinanceleasecontractterm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and finance lease contract term</link:label>
    <link:label id="lab_ehc_Operatingandfinanceleasecontractterm_label_en-US" xlink:label="lab_ehc_Operatingandfinanceleasecontractterm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and finance lease contract term</link:label>
    <link:label id="lab_ehc_Operatingandfinanceleasecontractterm_documentation_en-US" xlink:label="lab_ehc_Operatingandfinanceleasecontractterm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of lessee's operating and finance leases, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Operatingandfinanceleasecontractterm" xlink:href="ehc-20211231.xsd#ehc_Operatingandfinanceleasecontractterm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Operatingandfinanceleasecontractterm" xlink:to="lab_ehc_Operatingandfinanceleasecontractterm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ea2bbcbd-d306-48c1-963d-f8b4345f2552_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f79a5dd1-57a1-4907-9218-940b4ba29fe3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b26284e6-1566-4575-ac7f-07d5dfb2d281_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f8078ab3-2859-42ea-846f-f04014cefe3e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8d9e98ca-61ac-4151-930e-cec17b2df955_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7efe7169-924a-47e4-a3d2-95131bb048b8_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5dba47dc-1bfb-4223-95cf-0153b180a6d8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a92a0b3b-38da-4fb3-ad55-c41b1562fd16_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_ccd5c82f-e165-4e4b-9b0d-b5126da36319_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_601c7adc-fe41-412f-9e71-a4560656116d_terseLabel_en-US" xlink:label="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual claims covered by reserves</link:label>
    <link:label id="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_label_en-US" xlink:label="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Individual Claims Covered by Self-Insured Risk Reserves</link:label>
    <link:label id="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_documentation_en-US" xlink:label="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual claims covered by the Company's self-insured risk reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:href="ehc-20211231.xsd#ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:to="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTable_fdfd2c02-da14-4a76-a6bc-cf6856d6e0b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable" xlink:to="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_05c46f85-7721-4cde-8065-a0a78491a02d_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities in and Results of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fb3a0d63-12fa-41e7-a6cb-01e06f0bd993_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_b0bc2198-faa4-4a24-a087-e9dcc0ad7df0_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_64c9ba42-b4e6-49fd-a312-577602ad2a6b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_5b93ba66-5ab0-44f6-a613-c331d35c3356_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_93453703-46b2-47b9-a9f2-542a6aeb10cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4db0204f-b4f0-45c3-b1af-5047bb214a89_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a1b9fc2-3be1-4294-bb2b-907021a044e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_225368a3-9dad-46d0-8cda-21c7c8aef8d3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_89b2be63-de0b-48bd-bdbc-08735f82a690_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests in Consolidated Affiliates and Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_9438e166-91fe-4379-a407-a9a5a2e5feb3_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_0f13b221-6eb6-4825-923e-6d3e968584a7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill increase</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_417a11ec-81bd-429b-98e2-d31f405752d6_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_f9010f10-8ff1-465f-ae59-82c3112cfa84_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e806adfd-c3b2-4892-8fcf-3eb27a9926a9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda43be0-870a-4373-8084-3f07a1c06706_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_30108610-959e-470b-9f6b-26151b3b677f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f415c7fc-119a-4cff-b58c-679ec7d00272_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_3ba379e0-33ba-42e4-90b1-0497e6f2e60a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled the acquisition shares upon payment</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1bdfc19e-ff87-4106-b5d4-f520ef4c44e7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b110ed70-4c22-47c0-b82f-b6f43cd4b683_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_0dbfeb47-d27f-4b74-bc42-97bcf108c85e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_a6da02e0-43ce-4c39-a18d-3bfdd3c0a0eb_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_e70f6ef6-9ccd-4280-8977-c6fe42d7bf5e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ee7740d9-d46c-4998-9cfd-916ee38f11f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net and comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_7c0ef839-baa0-4e3f-bf30-e8bb4d6ab005_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1e998cf4-9d8c-4d0c-a5ed-0bef9a6586fb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1625c6cf-ba0d-48f4-af42-dcd815bbf21d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_06d10a02-0230-42a3-9bbf-2dc77db3d397_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_cda816d6-efeb-49a0-9318-1da48ddbee26_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest, equity, acquired percent</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Acquired Percent</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Acquired Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:to="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_3c84cbdc-a36f-4eb1-9976-5ec35cf05f4b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_9947e4b5-1449-473b-90bc-e93a2c79a8f5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ced943c0-e2c2-4ed2-a028-dd5a5f9d4918_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ddfac934-a8fa-49ab-a142-e65f22a19283_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7671200a-fc16-4e51-a22b-d3f7c9fb732b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_14b6f531-14a0-4e2b-9c6a-e34f825d4383_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_042d9cd6-66c3-4c06-ad87-06ff0f919efa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, December 31, 2021 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_c8a48450-9d87-4767-9860-ac19bcf7e763_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax refunds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_fec3599c-9df3-4e83-b31e-fd5acc28a4b5_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_00f7d3ec-c0c8-4b3d-ba1d-2b3c406f4714_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4292d533-fe54-4b3a-92b7-26e4d91cefd8_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2021</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_776a6ebb-3e9c-4a56-8b34-b71ad8e877a2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e1d6846a-ad83-4cb8-84bb-8e90530b5f3c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_c1cb3cb0-3605-4adb-a68c-48acf094cd1c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3688a68d-2923-4664-820a-3e500866fa5b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_40dea47a-bcb2-41af-a4bb-3c4dc7556433_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_6f0890c6-95e1-4c40-9c38-eeed61003665_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_bf5ee795-a859-4a37-a2cf-264f1d0c8154_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_44928305-40b3-4c74-8efa-00b0db82313d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AlacareMember_ada8a2d2-6776-4d7b-9a7a-a15a0f65e5f6_terseLabel_en-US" xlink:label="lab_ehc_AlacareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alacare</link:label>
    <link:label id="lab_ehc_AlacareMember_label_en-US" xlink:label="lab_ehc_AlacareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alacare [Member]</link:label>
    <link:label id="lab_ehc_AlacareMember_documentation_en-US" xlink:label="lab_ehc_AlacareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alacare Home Health &amp; Hospice ("Alacare") [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AlacareMember" xlink:to="lab_ehc_AlacareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5cf1bf8e-529c-4ccc-acc3-85d551937182_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.01 par value; 200,000,000 shares authorized; issued: 114,211,057 in 2021; 113,835,708 in 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_f7587681-f25a-4f9c-a9c9-b6be31752a41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_be862cb1-fac3-4382-89bb-07fea7eb3745_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease (in percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0c9c05a1-2625-4cba-ab4b-4bb15abf8b6b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average recognition period for unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6b0ee928-d175-4188-b055-e818bf8375cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested shares, Beginning Balance (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3450a2ec-6f50-4035-ad0f-dbf55ab3ebe9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested shares, Ending Balance (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_9ca28bbe-c47c-4c10-848d-5215419a7abf_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment agreement, amount to be paid</link:label>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_label_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amendment Agreement, Amount To Be Paid</link:label>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amendment Agreement, Amount To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:to="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a1a02b1e-cc34-49ec-b6ce-4c38770ca841_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1f420449-4d2d-4829-8735-4c6f185709d3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0cd05f4c-4d06-4e93-b061-0c2737263672_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a8238434-ad45-4418-8a02-2af608202646_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_148581bb-9181-491b-a99f-233385de58c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used to Determine Fair Value of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_abfed0e7-966c-43ac-a232-53d70788aa50_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock_cccc4f90-4160-48b8-915c-63ebcc3c4df2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Redemption Prices for Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:to="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_8d2abf8d-0313-4516-bb61-91cf1db35c5b_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f559025d-96cb-40b0-84e1-58240357e4f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, dilutive stock options, and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_07dc91c5-480f-4614-b134-4a34f2f880c0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f1a95416-67a0-4a29-9154-2698edfe8848_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_90197eec-9366-418c-b425-ed24b0590362_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7b216048-383e-4f3e-beb7-4187f5901bd6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, pro forma net income (loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ecf2d304-6323-49bf-acbe-0665b381fa69_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_b86dfd6f-650c-4e0e-acc5-7619b5eba3cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_24b83874-216f-4279-bf9e-005686610f8c_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_e5780ad3-b6af-4af1-91bc-a46c76dafde8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f4b001db-e402-41b9-a0b0-e647da708928_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on consolidation of Yuma Rehabilitation Hospital</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_3fcd5922-3117-4190-ac84-f2089c599c9f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_9fd97790-3068-4685-ac10-1e15727fb319_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ff5e2e7-a18e-4127-a1a8-ff4235d2a94f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_28b112e6-6a18-4caa-b747-5c450ee145fe_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_c1542125-ea9c-44ee-aa6b-92d9dc4b99f4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f216a396-0dbf-41a3-884f-1cd044447734_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_df1dd355-ff7b-41fc-bd2a-53f6c9187f72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ef7fc580-738d-40d2-b87e-9d941c61be3e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_c155d0c3-9a8d-447c-9317-873df7a8228d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions &#8212;</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_8b8d3091-69ef-4712-bfba-7f3bd7241a1d_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b0b044d4-103d-4ff1-9d16-5a4012a8deac_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_47be9129-a61d-4c67-ab75-5650457b7eac_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f7c07c51-0f1c-4d98-a51b-5297e257b8f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_d8e6876f-ad06-4218-a52d-ac3207a863fd_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partners&#8217; capital and shareholders&#8217; equity&#8212;</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d73678f2-dfbf-4aa5-a79a-a64578052f24_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_c37d38d5-3407-40df-a619-e6cbcafc405b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_772b5de1-041b-4168-9f47-f85b5adb92ef_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_590ce7ce-8990-4380-a1f1-b1b669a3b73e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_0871a058-0d1e-4f6e-a57e-bdcb03d3d9d6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_4c05b919-5453-4fe1-8b18-50b8ce6daf7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b4dc4580-c9cc-4354-a647-a7b49cc3fc39_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease (in years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f76f5ad1-aed2-4b23-9e38-26cdc57c52e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_bb4334d5-3362-4523-b477-b5ea140c0f77_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement_92ce0947-5cd6-411e-aa4d-5244b5b3851e_terseLabel_en-US" xlink:label="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of property and equipment, net pledged to lenders under credit agreement (percent)</link:label>
    <link:label id="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement_label_en-US" xlink:label="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of assets pledged to lenders under credit agreement</link:label>
    <link:label id="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement_documentation_en-US" xlink:label="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of assets pledged to lenders under credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:href="ehc-20211231.xsd#ehc_Percentageofassetspledgedtolendersundercreditagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:to="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherIncomeSourceMember_d9a75992-7a53-446e-ada2-d6415a574503_terseLabel_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ehc_OtherIncomeSourceMember_label_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Source [Member]</link:label>
    <link:label id="lab_ehc_OtherIncomeSourceMember_documentation_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Source [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember" xlink:href="ehc-20211231.xsd#ehc_OtherIncomeSourceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherIncomeSourceMember" xlink:to="lab_ehc_OtherIncomeSourceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_00f79b82-42e1-4149-adcf-477dfc8a4a9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b8b7f346-5725-437e-bc76-0427764dc060_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_01d98bc7-f117-4ebe-aa3a-a1fe3c44ef29_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d1212d02-8c0d-4771-872a-76e8fbd607a8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a9dc2d0b-40a9-4f5e-b2b6-371113f645ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_a989a16b-3dcd-430c-896d-d3dbaa1886f0_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod_55740acf-5afd-4093-831c-af215cc935ab_terseLabel_en-US" xlink:label="lab_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation of joint venture formerly accounted for under the equity method of accounting</link:label>
    <link:label id="lab_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod_label_en-US" xlink:label="lab_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Consolidation Of Joint Venture Formerly Accounted For Under Equity Method</link:label>
    <link:label id="lab_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod_documentation_en-US" xlink:label="lab_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Consolidation Of Joint Venture Formerly Accounted For Under Equity Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" xlink:href="ehc-20211231.xsd#ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" xlink:to="lab_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_649a283e-d5f7-49bb-a4d4-aea6f2fe04c4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_344ba345-0374-4046-a3f6-d1f90ca5c4bb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_f20ab725-ea97-46a8-8726-f9778110f4b1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_c98df4b7-08c9-4620-8c3b-bdc62ab79d81_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_e4a50519-fbb1-43aa-b097-94709d3de362_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated_abcea18d-b3ed-458d-b064-0aeef1a66f39_terseLabel_en-US" xlink:label="lab_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of partially-owned subsidiaries</link:label>
    <link:label id="lab_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated_label_en-US" xlink:label="lab_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Partially Owned Subsidiaries Nonconsolidated</link:label>
    <link:label id="lab_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated_documentation_en-US" xlink:label="lab_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of partially owned subsidiaries in which the Company has investments but are not consolidated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated" xlink:href="ehc-20211231.xsd#ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated" xlink:to="lab_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3e75e316-5f54-4d1d-9e3e-3c4d783949a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_4f4887d8-b2ef-4ad2-9be8-f58ddcfbc131_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amounts and estimated fair values of financial instruments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_19cb9032-0c39-4239-8193-c915fbc2ea0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a4d3c719-5e15-44c1-8495-bd60a8c869d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TradeNameEncompassMember_6e5a4941-7337-4b1b-a8c2-f573b3d3fd29_terseLabel_en-US" xlink:label="lab_ehc_TradeNameEncompassMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name - Encompass</link:label>
    <link:label id="lab_ehc_TradeNameEncompassMember_label_en-US" xlink:label="lab_ehc_TradeNameEncompassMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name - Encompass [Member]</link:label>
    <link:label id="lab_ehc_TradeNameEncompassMember_documentation_en-US" xlink:label="lab_ehc_TradeNameEncompassMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name - Encompass [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TradeNameEncompassMember" xlink:href="ehc-20211231.xsd#ehc_TradeNameEncompassMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TradeNameEncompassMember" xlink:to="lab_ehc_TradeNameEncompassMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_4ea2c979-66a8-4665-8033-6d7b90c95775_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d38f7673-5a16-4352-abe4-e30a72362e2a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4f11f65c-57a9-4266-86a9-52fb7428c21f_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in tax rate resulting from:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd9d0d58-ae9c-447d-96cc-681b3aed9a47_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_15ba4391-a1eb-40b1-987a-1d91ea2da304_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_450c571e-69f6-4547-a20d-b7e6c2896dc5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6595726c-1a06-4232-bab1-0ac395555f95_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b7059f8-8f6c-4939-9271-76968fb13de0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1adaa7c5-a5a0-4d40-abaf-d2a77f675012_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Encompass Health shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9d21beea-53c0-4a2a-8a52-a9d85eb043ea_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_f1528aac-ba48-4f6e-9a25-e1c01491d195_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2c680ad6-2a1b-4b36-bcf7-97aafb8979fa_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0f44496e-b259-40f6-ba82-d1d714a2c9eb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1e02fb5-7cd8-4e35-878b-c76cb00e7e23_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, December 31, 2021</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_94db6042-4ef7-480c-bbf1-f72c8e884e76_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c0712e8a-f667-411e-b115-c2e56421d7b5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AuditInformationAbstract_label_en-US" xlink:label="lab_ehc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ehc_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ehc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AuditInformationAbstract" xlink:href="ehc-20211231.xsd#ehc_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AuditInformationAbstract" xlink:to="lab_ehc_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_7de5d1a6-a1f3-45f3-8391-865b52ac79ba_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on debt, including pre-payments</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_aeb36e9b-42a2-4330-8079-de31e5ac11cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock, including fees and expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_900bcde3-c774-44ac-b72a-77b8c1023fc6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_f13e1b62-4099-40e4-9ad7-7035a2694fb1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Contributiontojointventure_2991a5f5-de2a-4c1e-aeb3-a226708a0f1c_terseLabel_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to joint ventures</link:label>
    <link:label id="lab_ehc_Contributiontojointventure_label_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to joint venture</link:label>
    <link:label id="lab_ehc_Contributiontojointventure_documentation_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of primarily intangible assets relating to a joint venture agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure" xlink:href="ehc-20211231.xsd#ehc_Contributiontojointventure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Contributiontojointventure" xlink:to="lab_ehc_Contributiontojointventure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_07361fa3-4472-4fd9-b118-305e74e67ac7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EHHIMember_6ac2500f-196f-4955-8409-b8a9d5ba3a0a_terseLabel_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI</link:label>
    <link:label id="lab_ehc_EHHIMember_label_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI [Member]</link:label>
    <link:label id="lab_ehc_EHHIMember_documentation_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember" xlink:href="ehc-20211231.xsd#ehc_EHHIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EHHIMember" xlink:to="lab_ehc_EHHIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_947756b0-3ea0-480e-9591-4339027e0d0e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_cb6f6824-ef2e-4053-950e-3b9ef7900986_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_4f6f28ab-bb31-45b0-bbf1-8593776e824d_terseLabel_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor</link:label>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_label_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_e6d268e1-8e66-47fa-af54-5bcff63e91c7_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_fcda3282-721e-46f0-90c0-1545f4578de7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HeartOfTheRockiesHomeHealthMember_e09a9c21-4b0d-4764-8a35-719010e39b6c_terseLabel_en-US" xlink:label="lab_ehc_HeartOfTheRockiesHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heart of the Rockies Home Health</link:label>
    <link:label id="lab_ehc_HeartOfTheRockiesHomeHealthMember_label_en-US" xlink:label="lab_ehc_HeartOfTheRockiesHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heart of the Rockies Home Health [Member]</link:label>
    <link:label id="lab_ehc_HeartOfTheRockiesHomeHealthMember_documentation_en-US" xlink:label="lab_ehc_HeartOfTheRockiesHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heart of the Rockies Home Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeartOfTheRockiesHomeHealthMember" xlink:href="ehc-20211231.xsd#ehc_HeartOfTheRockiesHomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HeartOfTheRockiesHomeHealthMember" xlink:to="lab_ehc_HeartOfTheRockiesHomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_4c1f52d2-0cc3-4797-8e85-d8becc1d8cff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation Hospital and Home Health and Hospice</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_c7b94984-78eb-425f-92fe-3d732bf1cd6d_terseLabel_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_8f269c45-154a-4da0-94d9-b468c1ee2850_verboseLabel_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_label_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment [Member]</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_documentation_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HomeHealthandHospiceSegmentMember" xlink:to="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_40d91e10-f034-482f-908d-b47034de453d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_6742db8d-7a31-479e-94a8-b35140eea33e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_ba09829b-d6c2-4981-8f9b-f13076fc365b_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_29874d29-ddb4-4a43-a2ef-1b179b38864d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_54079d54-62e3-4b11-ba12-f77f755215ee_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_30dda59e-0ab4-4876-8a6c-1cd0ff14b4aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_82a5e8d8-bdae-4694-b271-f2ffaa7521c2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_27f19487-1842-43ad-b220-2df69311e1af_totalLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_50ffd64f-36d2-4d57-9ebb-a504f4e3057b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fc200f4f-f5a8-4b18-b3db-42a200d4b4a3_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_829037e4-cd48-4f83-8813-9299b8c7cb9d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3b764c00-e29e-4107-9f4f-3ac7faae2e2e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_6d7d84e9-e436-4a4c-ac99-cc93c3519f9d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_b4553ea1-3903-4719-aa3c-66ce11320c8c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_0b131f48-f9aa-49a4-bdda-42ce2ee7cffb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dfdcf111-0171-4cf6-a752-e58e2f4110e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9653ea8f-9e16-4b60-8a74-52abfae3ccc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ef0b33bc-239b-4cbd-9b17-0a00bf7e9cea_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense related to continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_02606084-8f47-4abb-9c65-d5bba619588d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to nonredeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5411956f-45b6-4ea6-9680-766a4d6ffc8d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_24765bac-6fa6-4e94-9403-36c0b8aa1603_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b16ae7c6-68ab-4834-9f09-dc75d2bc499a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Components</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_84821c43-952b-49e2-9ac0-6a51aa14a829_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_e1a4c3ea-7258-47d9-87ce-a69a12f71b16_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_cd4c0581-e4d4-448c-8a89-d6086749aa1b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SaintAlphonsusandHeritageValleyMember_31676b32-a24a-497f-8519-4c20dd5e123a_terseLabel_en-US" xlink:label="lab_ehc_SaintAlphonsusandHeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus and Heritage Valley</link:label>
    <link:label id="lab_ehc_SaintAlphonsusandHeritageValleyMember_label_en-US" xlink:label="lab_ehc_SaintAlphonsusandHeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus and Heritage Valley [Member]</link:label>
    <link:label id="lab_ehc_SaintAlphonsusandHeritageValleyMember_documentation_en-US" xlink:label="lab_ehc_SaintAlphonsusandHeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus and Heritage Valley</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SaintAlphonsusandHeritageValleyMember" xlink:to="lab_ehc_SaintAlphonsusandHeritageValleyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6373799d-ab37-43d7-8cd2-6397257fb8a2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_d5f860c6-b871-4a12-a159-2a9752ae3db2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9be969b4-beb8-4848-bfdc-e4407df69e30_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6a8f9c88-b1b6-452b-9ce9-d788c05c454a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c2b2c726-4d8e-4506-a2f1-96c806b50a71_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EncompassHomeHealthSavingsPlanHHSPMember_51382c28-ccc6-4b18-b511-b04176b2be46_terseLabel_en-US" xlink:label="lab_ehc_EncompassHomeHealthSavingsPlanHHSPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Home Health Savings Plan HHSP</link:label>
    <link:label id="lab_ehc_EncompassHomeHealthSavingsPlanHHSPMember_label_en-US" xlink:label="lab_ehc_EncompassHomeHealthSavingsPlanHHSPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Home Health Savings Plan HHSP [Member]</link:label>
    <link:label id="lab_ehc_EncompassHomeHealthSavingsPlanHHSPMember_documentation_en-US" xlink:label="lab_ehc_EncompassHomeHealthSavingsPlanHHSPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Home Health Savings Plan HHSP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHomeHealthSavingsPlanHHSPMember" xlink:href="ehc-20211231.xsd#ehc_EncompassHomeHealthSavingsPlanHHSPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EncompassHomeHealthSavingsPlanHHSPMember" xlink:to="lab_ehc_EncompassHomeHealthSavingsPlanHHSPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_98e1ed1a-68fb-4f51-bf77-445fb927f0ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_3ea6f1dc-08b6-4b4e-b424-acf32ee910d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0b9576ca-0c85-4493-88d6-52a0778469a0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_ef8498a9-47d4-41a3-b32f-e7c105599ffa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_d8b33c82-de89-4610-a74a-a11b36d50a8c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_8918d690-6b1b-4551-b26c-5f1df67e17ec_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation of Yuma Rehabilitation Hospital</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2794a179-07b8-433c-82db-43bc96d1147e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_50fb70d8-05bd-434a-963e-529d17b07b4b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8c4f057d-caf2-4fd5-9fe9-20b4d9bfa1ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_14b761b8-6789-4444-8d12-a1f8d805c810_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Weighted Average Number of Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_31c60429-ca44-4394-abed-8d8b92c9169c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2c541f69-8e6b-4eb8-b48a-4a70dea44af4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52142f1f-200a-467a-8457-d7f6b537ca3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b9f18017-6d9b-4288-902e-c54cf0a6b7f8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_16049b64-4094-475c-b602-3032379948b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of remaining shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_df3d6437-0bc8-43a9-a41f-8c7738b2e23f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a3428dde-062c-4528-a50d-628fc55fcc15_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PayrolltaxesonSARsexercise_6809b28b-3d10-4fe8-90ea-ccafa40a4b2b_negatedTerseLabel_en-US" xlink:label="lab_ehc_PayrolltaxesonSARsexercise" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll taxes on SARs exercise</link:label>
    <link:label id="lab_ehc_PayrolltaxesonSARsexercise_label_en-US" xlink:label="lab_ehc_PayrolltaxesonSARsexercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll taxes on SARs exercise</link:label>
    <link:label id="lab_ehc_PayrolltaxesonSARsexercise_documentation_en-US" xlink:label="lab_ehc_PayrolltaxesonSARsexercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll taxes on SARs exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayrolltaxesonSARsexercise" xlink:href="ehc-20211231.xsd#ehc_PayrolltaxesonSARsexercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PayrolltaxesonSARsexercise" xlink:to="lab_ehc_PayrolltaxesonSARsexercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5cce6805-a0f1-4362-a101-c63b66d55a63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_244883d4-b581-4020-8054-f7ef1910c25f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfQualifiedPlans_29e5ef20-6b93-486b-8459-7715e4f8232d_terseLabel_en-US" xlink:label="lab_ehc_NumberOfQualifiedPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of qualified savings plans offered</link:label>
    <link:label id="lab_ehc_NumberOfQualifiedPlans_label_en-US" xlink:label="lab_ehc_NumberOfQualifiedPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Qualified Plans</link:label>
    <link:label id="lab_ehc_NumberOfQualifiedPlans_documentation_en-US" xlink:label="lab_ehc_NumberOfQualifiedPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Qualified Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfQualifiedPlans" xlink:href="ehc-20211231.xsd#ehc_NumberOfQualifiedPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfQualifiedPlans" xlink:to="lab_ehc_NumberOfQualifiedPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_7ad281c4-3b4e-4bf0-9f39-071950af74a1_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_eb1b141e-1122-47e3-9c66-1c73f1c7d8b5_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, reduction in capacity under restricted payments builder basket</link:label>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_label_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</link:label>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:to="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_5055efbe-c607-478e-b33a-ff0fb302ca04_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a7313f8b-e2de-499e-b015-5b90968f1547_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_26759e3b-d41b-4c0d-8b91-46377410c01a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_912c71a2-59e4-4e31-89dd-9a8d6c270f85_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_5eb0a5df-a1ea-408c-a6b0-8d1c8869db1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other long-term assets at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_d3288aa2-512c-4430-b8c3-493a825c5f9a_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other long-term assets at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_310d23c8-7fdf-41c0-b4a1-1e171267cf40_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Shorttermandvariableleasecost_2508b34e-62fd-4dd7-a1d9-21972542c2a7_terseLabel_en-US" xlink:label="lab_ehc_Shorttermandvariableleasecost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and variable lease cost</link:label>
    <link:label id="lab_ehc_Shorttermandvariableleasecost_label_en-US" xlink:label="lab_ehc_Shorttermandvariableleasecost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and variable lease cost</link:label>
    <link:label id="lab_ehc_Shorttermandvariableleasecost_documentation_en-US" xlink:label="lab_ehc_Shorttermandvariableleasecost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of short-term lease cost, excluding expense for lease with term of one month or less, plus the amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Shorttermandvariableleasecost" xlink:href="ehc-20211231.xsd#ehc_Shorttermandvariableleasecost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Shorttermandvariableleasecost" xlink:to="lab_ehc_Shorttermandvariableleasecost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_793d26df-7eba-4dfd-8bda-b71d77f88c70_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f321571c-bb13-4c47-86d3-50b5f1a724e7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in valuation allowance (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7954ea9c-3da8-46c7-ae2a-66efd66ce6eb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInSecondYear_ef4c56fa-a94a-412e-837f-536c63b26aa9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:to="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_00f927ef-2d89-4f0c-81e3-592a8815d218_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_a056183c-c180-4977-beab-dba5622b8dbb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NetAmountMember_bd57fc34-6832-43c2-87e3-9e9fc06c302d_terseLabel_en-US" xlink:label="lab_ehc_NetAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount</link:label>
    <link:label id="lab_ehc_NetAmountMember_label_en-US" xlink:label="lab_ehc_NetAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount [Member]</link:label>
    <link:label id="lab_ehc_NetAmountMember_documentation_en-US" xlink:label="lab_ehc_NetAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetAmountMember" xlink:href="ehc-20211231.xsd#ehc_NetAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NetAmountMember" xlink:to="lab_ehc_NetAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9346d2a0-3df8-4c78-be33-6fa1f8bfa00b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0351f881-2a22-4642-8ab6-57c38cd6e66e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_664f9d8b-1c77-48be-b230-161bbcf28542_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_8e24c310-f640-4d7d-a681-75cef1183c8e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_1ceabf9b-0070-4545-8d34-13c3147a053f_terseLabel_en-US" xlink:label="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical, Heritage Valley &amp; ECHD Ventures</link:label>
    <link:label id="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_label_en-US" xlink:label="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical, Heritage Valley Health System And ECHD Ventures [Member]</link:label>
    <link:label id="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_documentation_en-US" xlink:label="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical, Heritage Valley Health System And ECHD Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:to="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InternalUseSoftwareMember_d55e1376-c064-4666-82b8-fc114ca1bbd2_terseLabel_en-US" xlink:label="lab_ehc_InternalUseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_ehc_InternalUseSoftwareMember_label_en-US" xlink:label="lab_ehc_InternalUseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software [Member]</link:label>
    <link:label id="lab_ehc_InternalUseSoftwareMember_documentation_en-US" xlink:label="lab_ehc_InternalUseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalizable costs for computer software developed internally by the Company which will have future probable benefits to the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InternalUseSoftwareMember" xlink:href="ehc-20211231.xsd#ehc_InternalUseSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InternalUseSoftwareMember" xlink:to="lab_ehc_InternalUseSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be45cb3f-ef8b-4968-a84a-26d2e1a98930_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_5e99db2f-0bd8-44b0-9dcf-089df2c60fa4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_99f357a1-29ef-42ea-9a5c-253353376b7a_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_026d1218-1aec-4595-8336-2a054bf15ef4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a556e421-1e98-42dc-89fa-10b585731261_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f119bb71-943b-4b2a-ac19-184e33f58799_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_046d329a-4a70-4b18-aad2-676b9d1bb6b6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions paid to noncontrolling interests of consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a27afedc-6180-4b3a-b861-1b3122a5430a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofBedsContributed_60779d9a-13e5-406d-92c9-b90fa83df266_terseLabel_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds contributed</link:label>
    <link:label id="lab_ehc_NumberofBedsContributed_label_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Contributed</link:label>
    <link:label id="lab_ehc_NumberofBedsContributed_documentation_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Contributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsContributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofBedsContributed" xlink:to="lab_ehc_NumberofBedsContributed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_53d6e3c2-70f8-4014-ae0c-fa3ef9af79a9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_16dd03bd-cd97-4439-a739-d592f04f6f3c_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Coverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:to="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_8c750811-9bff-4a30-ad95-16d5b8ceac32_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government, class action, and related settlements (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_b317aec6-d880-4499-83a6-cde0b8037b10_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_17719924-d819-4a59-a32a-854a84cf662c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_b87c3af3-c3c5-4f37-81de-24132f70676c_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_19ce6e87-0d9a-46eb-903c-6a275abeece0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Insurance Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_JupiterFloridaHomeHealthAgencyMember_ba90f79c-8bcd-4480-a6b9-a96cd1d40b00_terseLabel_en-US" xlink:label="lab_ehc_JupiterFloridaHomeHealthAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jupiter Florida Home Health Agency</link:label>
    <link:label id="lab_ehc_JupiterFloridaHomeHealthAgencyMember_label_en-US" xlink:label="lab_ehc_JupiterFloridaHomeHealthAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jupiter Florida Home Health Agency [Member]</link:label>
    <link:label id="lab_ehc_JupiterFloridaHomeHealthAgencyMember_documentation_en-US" xlink:label="lab_ehc_JupiterFloridaHomeHealthAgencyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jupiter Florida Home Health Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_JupiterFloridaHomeHealthAgencyMember" xlink:href="ehc-20211231.xsd#ehc_JupiterFloridaHomeHealthAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_JupiterFloridaHomeHealthAgencyMember" xlink:to="lab_ehc_JupiterFloridaHomeHealthAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_68560bc0-7c8b-4b97-af49-6edc4391a4f8_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnersCapitalAccountContributions_53ae20bd-4dca-4f64-8e21-1235d977a234_terseLabel_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions from consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PartnersCapitalAccountContributions_label_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partners' Capital Account, Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountContributions" xlink:to="lab_us-gaap_PartnersCapitalAccountContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_41e36607-f29b-4d1c-a6fd-a92c5e6bd82d_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net and comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1cbd722c-fe42-4be9-96ff-f3830d0ca8c0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_718cc911-2a5b-4e52-b392-07c397632048_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_42e7b03e-c2e0-4bc3-ac5f-cc3fe963cc73_negatedNetLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_cbab69bf-4d51-440b-8d55-f644add92c28_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a777e56-5f97-4674-90d7-066d111b3b48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_8c76eb8b-8465-4795-afcb-ab46a36a98a5_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_eebc6d4f-068e-403c-82da-356bec3f4efb_terseLabel_en-US" xlink:label="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care and other discount plans, including Medicare Advantage</link:label>
    <link:label id="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_label_en-US" xlink:label="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care, Medicare Advantage and Other Discount Plans [Member]</link:label>
    <link:label id="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_documentation_en-US" xlink:label="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care, Medicare Advantage and Other Discount Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:href="ehc-20211231.xsd#ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:to="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_da9f2a77-9aab-4f74-83a3-3cf305575740_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0420036d-0b50-40f1-b2da-b3c43e7e21ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_5cbc7374-6baf-4b59-b68b-1113bf1e4760_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Least Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_03d97892-d5b4-4886-b734-ca67277fa2ce_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_96180b5c-7dc2-43cf-ab1d-2254e6c90933_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountThirdLayerRisk_a0816197-a19f-48f3-a516-a3b9313d3239_terseLabel_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountThirdLayerRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional insurance</link:label>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountThirdLayerRisk_label_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountThirdLayerRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Self Insured Amount, Third Layer Risk</link:label>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountThirdLayerRisk_documentation_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountThirdLayerRisk" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Self Insured Amount, Third Layer Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MaximumSelfInsuredAmountThirdLayerRisk" xlink:href="ehc-20211231.xsd#ehc_MaximumSelfInsuredAmountThirdLayerRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MaximumSelfInsuredAmountThirdLayerRisk" xlink:to="lab_ehc_MaximumSelfInsuredAmountThirdLayerRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AdjustedEBITDA_7051257f-c159-46eb-94db-85d74373210a_terseLabel_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_4a08371d-5d76-4327-b1a4-04275911e8db_verboseLabel_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_label_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_documentation_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA" xlink:href="ehc-20211231.xsd#ehc_AdjustedEBITDA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AdjustedEBITDA" xlink:to="lab_ehc_AdjustedEBITDA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ab6c82a2-b94a-4eed-975a-12d172222007_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d39e71f8-6604-40ac-931c-adc1812e2623_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill expected to be tax-deductible</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ed10241c-a606-48e5-8703-09ccbd0e8c04_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_8015da22-9356-4afc-9f4d-0c4f474c4d0d_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (14,719,662 shares in 2021 and 14,428,235 shares in 2020)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0516b26-daf6-4ae0-89ad-260ba45760e0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9de756b3-f1a7-4ec2-9412-cf6526e4e554_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_14d22054-c7d3-45a6-aa6d-75b816797903_terseLabel_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_label_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Payroll</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued payroll assumed at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:to="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_de6f7a97-ea63-4382-85a2-c7ff461ddc8a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_0937d7e8-c727-430f-9c22-ecfdae194e80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_f21108b5-492c-4c7e-91ee-32e1f72f787c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4dcb0894-143c-4182-a614-bff249467255_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_052d28a5-31dd-4268-b7b3-62139f5e867a_terseLabel_en-US" xlink:label="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_label_en-US" xlink:label="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Six And Thereafter</link:label>
    <link:label id="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_documentation_en-US" xlink:label="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payments for finance lease, due in the sixth fiscal year following the latest fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:href="ehc-20211231.xsd#ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:to="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_10f590b5-a47f-47a3-87fe-90fe869809a9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_97fcb557-5fc2-4537-90de-d3472ad5ce50_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_5bc7e3be-38c5-4e1c-b54a-b5c37f62a6b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d086088c-fb98-4284-93e2-a14931669ca6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_11bf4739-a008-454a-b0a0-b93913325692_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_bede2299-7dc1-4f0c-8e57-0669d326f5c6_terseLabel_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:href="ehc-20211231.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:to="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_f6d7efda-3b2e-4797-b616-272d08d166bb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9e55d695-0477-428d-b0a4-9071e16adc37_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of equity interest prior to acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_e691cd79-a041-469b-a85c-494a55ef6724_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_be74b653-0a88-4dac-8a7b-36f437b220d5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HealthcarePlanExpense_8fc9f24e-0f15-44e6-828b-5addfb7a517c_terseLabel_en-US" xlink:label="lab_ehc_HealthcarePlanExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company healthcare plan costs, net of employee payments</link:label>
    <link:label id="lab_ehc_HealthcarePlanExpense_label_en-US" xlink:label="lab_ehc_HealthcarePlanExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Plan Expense</link:label>
    <link:label id="lab_ehc_HealthcarePlanExpense_documentation_en-US" xlink:label="lab_ehc_HealthcarePlanExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs for the period associated with the Company's sponsored self-insured healthcare plans that include coverage for medical and dental benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HealthcarePlanExpense" xlink:href="ehc-20211231.xsd#ehc_HealthcarePlanExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HealthcarePlanExpense" xlink:to="lab_ehc_HealthcarePlanExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_df0903aa-217a-4974-918e-3d602d7b4f82_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding_4b267044-3cbf-4ef9-b68a-82b6434f2c45_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of aggregate principal amount outstanding (percent)</link:label>
    <link:label id="lab_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding_label_en-US" xlink:label="lab_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Percentage of Principal Outstanding</link:label>
    <link:label id="lab_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage owed on principal amount outstanding for amounts drawn under the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" xlink:to="lab_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1c15a0d2-e6c9-4970-b446-028429faceb7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eaa3469c-aa41-4321-b89f-f288ac7c3460_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_22050d76-fd14-4ad9-9a18-f4624d14d3a0_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8594e6ac-0f4b-4625-8a3e-4ff721961be4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other income taxes, net of federal tax benefit (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0f48494f-ba8e-4fa8-9fc5-22fea0fbb82a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_26c98bb0-cb2f-4429-97bf-3aaa8fb518ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a4485f15-aa0d-422c-9b20-cee38daa0b28_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32a15551-fe08-4454-9b79-b13901936a57_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_e4114b9a-f117-40b5-9268-da1050a77a79_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delivering EHC shares to management investors (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofLocationsofanAcquiredEntity_61aa7a02-1854-4eca-8509-9e7c3f424436_terseLabel_en-US" xlink:label="lab_ehc_NumberofLocationsofanAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of locations</link:label>
    <link:label id="lab_ehc_NumberofLocationsofanAcquiredEntity_label_en-US" xlink:label="lab_ehc_NumberofLocationsofanAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Locations of an Acquired Entity</link:label>
    <link:label id="lab_ehc_NumberofLocationsofanAcquiredEntity_documentation_en-US" xlink:label="lab_ehc_NumberofLocationsofanAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of locations acquired as part of a facility acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofLocationsofanAcquiredEntity" xlink:href="ehc-20211231.xsd#ehc_NumberofLocationsofanAcquiredEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofLocationsofanAcquiredEntity" xlink:to="lab_ehc_NumberofLocationsofanAcquiredEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_de5c9ca0-b0c3-41bb-a73a-944a739b2176_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Estimated Amortization Expense, Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4a684a84-526d-4fa6-8de9-c252534acb74_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_82e3f61c-4cc1-409e-b452-d77687e8b4a0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CreditAgreementRestriction_50a5f6ea-586a-4ee5-9ef0-f2c876f47291_terseLabel_en-US" xlink:label="lab_ehc_CreditAgreementRestriction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment limit under the credit agreement's negative covenant</link:label>
    <link:label id="lab_ehc_CreditAgreementRestriction_label_en-US" xlink:label="lab_ehc_CreditAgreementRestriction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement, Restriction</link:label>
    <link:label id="lab_ehc_CreditAgreementRestriction_documentation_en-US" xlink:label="lab_ehc_CreditAgreementRestriction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">We are restricted from paying common stock dividends, prepaying certain senior notes, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the Credit Agreement and (2)&#160;the amount of such payments, when added to the aggregate amount of prior restricted payments (as defined in the Credit Agreement) does not exceed $200 million, which amount is subject to increase by a portion of excess cash flows each fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CreditAgreementRestriction" xlink:href="ehc-20211231.xsd#ehc_CreditAgreementRestriction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CreditAgreementRestriction" xlink:to="lab_ehc_CreditAgreementRestriction" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments_97d12cec-ceae-409a-b1c5-0dd101dc070c_terseLabel_en-US" xlink:label="lab_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative share of distributions</link:label>
    <link:label id="lab_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments_label_en-US" xlink:label="lab_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Accumulated Dividends or Distributions from Equity Method Investments</link:label>
    <link:label id="lab_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments_documentation_en-US" xlink:label="lab_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company's cumulative and proportionate receipt of distributed earnings since inception of its investment in an equity method affiliate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" xlink:to="lab_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_1e5f3739-2bad-4b96-8c33-efd40f2f8ddc_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_89af3013-99cc-4d5f-a73c-4209de797cbb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_8daf993c-68fe-43f5-87fd-a23768145a7d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_78f214bf-35c1-4217-89d5-9cce9b159613_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of outstanding shares of Holdings</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Other, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b751b5ff-8348-4228-b4a5-100b2433f0ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_22870b65-b6b8-4f29-a688-6f97d73a0e36_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_266f1759-ddaf-4f84-aab6-ecb5437bc26d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_300b59a7-e394-4764-b3c4-ca5eeb3466aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2021 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_77406355-9df2-4a68-91b3-e3088c3f433e_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_71d2eb5b-b1cf-4c73-be9a-5cd6ad807be4_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_0a5bf15e-b1d6-4576-851a-04dfd0d03525_terseLabel_en-US" xlink:label="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions funded by forfeited accounts</link:label>
    <link:label id="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_label_en-US" xlink:label="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount</link:label>
    <link:label id="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_documentation_en-US" xlink:label="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:href="ehc-20211231.xsd#ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:to="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RetirementInvestmentPlanAgeRequirement_afd432de-cc20-4032-9844-3368270e0360_terseLabel_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanAgeRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Age requirement to participate in the Plan</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanAgeRequirement_label_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanAgeRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Age Requirement</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanAgeRequirement_documentation_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanAgeRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum age required for an employee to be eligible to participate in the Company's Retirement Investment Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanAgeRequirement" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanAgeRequirement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RetirementInvestmentPlanAgeRequirement" xlink:to="lab_ehc_RetirementInvestmentPlanAgeRequirement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e075186e-c520-4e4e-a784-9dd9a85c249f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_7954c13d-fe98-4df9-8512-813d39dc145c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use asset accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c57524e0-e365-4dfc-a8a7-eeea6f2a8920_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dfdbb846-16f6-4590-9ad5-014f491ce4a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PatientsMember_b50ca7b5-410a-40ee-b8d2-c8b4a576bada_terseLabel_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_ehc_PatientsMember_label_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:label id="lab_ehc_PatientsMember_documentation_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember" xlink:href="ehc-20211231.xsd#ehc_PatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PatientsMember" xlink:to="lab_ehc_PatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98fbc7f5-5090-4bc7-8ecf-840624d1de45_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_f3d8231a-27b7-4bf3-9eef-9e6d74dc73ae_terseLabel_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_4608b3d2-db20-4fec-adbc-b457aea55860_verboseLabel_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_label_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_documentation_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember" xlink:href="ehc-20211231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TermLoanFacilitiesMember" xlink:to="lab_ehc_TermLoanFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfPayMember_3aa9ba3a-23fb-4d95-97f8-bc83753451ab_terseLabel_en-US" xlink:label="lab_us-gaap_SelfPayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay</link:label>
    <link:label id="lab_us-gaap_SelfPayMember_label_en-US" xlink:label="lab_us-gaap_SelfPayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfPayMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfPayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfPayMember" xlink:to="lab_us-gaap_SelfPayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TidewaterandCareResourceGroupMember_7ac3bbb9-9094-4a85-aed3-fcc0ebab1cf0_terseLabel_en-US" xlink:label="lab_ehc_TidewaterandCareResourceGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tidewater and Care Resource Group</link:label>
    <link:label id="lab_ehc_TidewaterandCareResourceGroupMember_label_en-US" xlink:label="lab_ehc_TidewaterandCareResourceGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tidewater and Care Resource Group [Member]</link:label>
    <link:label id="lab_ehc_TidewaterandCareResourceGroupMember_documentation_en-US" xlink:label="lab_ehc_TidewaterandCareResourceGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tidewater and Care Resource Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TidewaterandCareResourceGroupMember" xlink:to="lab_ehc_TidewaterandCareResourceGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7d9a9459-e861-4c7b-8127-b0adb4c015d0_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments_bb6aeead-fe3d-4c09-af76-488c52cd7be0_terseLabel_en-US" xlink:label="lab_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative share of income</link:label>
    <link:label id="lab_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments_label_en-US" xlink:label="lab_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Accumulated Income (Loss) from Equity Method Investments</link:label>
    <link:label id="lab_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments_documentation_en-US" xlink:label="lab_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company's cumulative and proportionate share of income earned since inception of its investment in an equity method affiliate as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" xlink:to="lab_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_aef05e24-b3f8-4206-b8e1-3bd99f08dc48_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4df9ef57-c41d-43da-a38f-b58c5e34b64c_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Net Operating Revenues and Net Patient Service Accounts Receivable by Payor and Payor Class</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e05b8ee9-be6a-4b67-b7c1-1a3b5ef1b37e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_7c2ac98a-bfe3-4fec-86a8-432643758c7a_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0249be60-5d38-4096-81bb-ee6cc43c4e2b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_6f98998e-2d85-4bf6-847a-c5420527e384_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_3a805c58-7df6-4057-b009-6e0cb7b492a7_totalLabel_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_label_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss from Continuing Operations Attributable to Common Shareholders Diluted</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_documentation_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations attributable to common shareholders diluted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:href="ehc-20211231.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:to="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_14212317-457a-4cd3-a8e2-6fc04f9e8393_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period, gross</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_61ec5478-b964-459b-a93b-a5818d465b35_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period, gross</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_17fe7e65-3496-473e-8db3-931002c1c2e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c6f8e0b2-e595-4f06-b5be-9649d9087fd7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_852dc2ad-03d3-42d7-b5ee-eaeb6d2457d4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb244532-e936-4147-80a2-a87cc11d8a6a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2ff8f469-b503-415a-b363-b86fa0569cb9_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_dba7c5c6-717a-4c31-8256-d684480297e3_verboseLabel_en-US" xlink:label="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets and Other Intangible Assets</link:label>
    <link:label id="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_label_en-US" xlink:label="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets and Other Intangible Assets, Impairment [Policy Text Block]</link:label>
    <link:label id="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_documentation_en-US" xlink:label="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for assessing and recognizing impairments of the Company's long-lived assets and intangible assets with finite lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:href="ehc-20211231.xsd#ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:to="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_17f979a4-76bd-493c-be1a-85551f9b31df_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_WorkersCompensationMember_6a0a54ca-1054-408c-9b35-561fce4451ce_terseLabel_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_ehc_WorkersCompensationMember_label_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation [Member]</link:label>
    <link:label id="lab_ehc_WorkersCompensationMember_documentation_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember" xlink:href="ehc-20211231.xsd#ehc_WorkersCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_WorkersCompensationMember" xlink:to="lab_ehc_WorkersCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_d3fefef0-9774-4fa7-b512-e087bfcc38be_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d4fbe4ab-23e7-47d5-b405-3e796da6e77a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c78c11df-ad54-4f2e-82c8-8f487a5c8788_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_606e3e0d-a1ac-43c9-bd60-378c9bf49bd3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_232f0c24-9bd1-4ae9-8a5b-f7d081cff1ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spread on variable rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_37fbded3-d2e2-41d2-9f67-978b6c791fcd_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0f9adddd-d685-42cc-a9f2-58008dacff8d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_add996e8-18ee-4a20-b597-2da45c8660bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_88fa7a84-b5af-4ca8-b421-33e64d8d66be_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_dbd3c1e8-684b-417d-a277-28ba1c879302_negatedTerseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange transaction</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Exchange Transaction</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Exchange Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestExchangeTransaction" xlink:to="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7d0553e0-2a15-4541-b73a-20bc7d56e572_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_72c4a710-579b-4115-bd86-a5ba6879ac0e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e5e3f6-cbc1-4d0d-981b-b99e62018b44_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived or Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3a094cc7-01d8-4657-83ac-ae9cbb84038d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_FrontierHomeHealthAndHospiceMember_bdefc711-998c-4a62-ba28-81d6a0c55915_terseLabel_en-US" xlink:label="lab_ehc_FrontierHomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frontier Home Health And Hospice</link:label>
    <link:label id="lab_ehc_FrontierHomeHealthAndHospiceMember_label_en-US" xlink:label="lab_ehc_FrontierHomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frontier Home Health And Hospice [Member]</link:label>
    <link:label id="lab_ehc_FrontierHomeHealthAndHospiceMember_documentation_en-US" xlink:label="lab_ehc_FrontierHomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frontier Home Health And Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FrontierHomeHealthAndHospiceMember" xlink:href="ehc-20211231.xsd#ehc_FrontierHomeHealthAndHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_FrontierHomeHealthAndHospiceMember" xlink:to="lab_ehc_FrontierHomeHealthAndHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24beca90-cf17-49a0-abbb-7677eef8444f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_32706d27-2c5a-4725-9fd6-215de9ca17d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ec4e2fd5-8854-4184-b473-8d629cc609b8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9326d4d-dab7-4708-a793-f9ad923e01cf_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f7c839c2-e5a8-4df5-9066-a1438932bdbe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0bb11bba-6cff-49ec-a1dc-7fd084a93142_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a98cbc9f-a96c-43cc-9c04-591415b18eb9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid on behalf of employees for shares withheld</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_4357aa85-c80a-42b3-94f7-8a5d49895aa1_terseLabel_en-US" xlink:label="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Building, Improvements, Equipment, Vehicles and Furniture</link:label>
    <link:label id="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_label_en-US" xlink:label="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Building, Improvements, Equipment, Vehicles and Furniture [Member]</link:label>
    <link:label id="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_documentation_en-US" xlink:label="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Building, Improvements, Equipment, Vehicles and Furniture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:href="ehc-20211231.xsd#ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:to="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AffiliateCashMember_e92039bf-edbe-473e-8189-903fd59e409d_terseLabel_en-US" xlink:label="lab_ehc_AffiliateCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate cash</link:label>
    <link:label id="lab_ehc_AffiliateCashMember_label_en-US" xlink:label="lab_ehc_AffiliateCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate Cash [Member]</link:label>
    <link:label id="lab_ehc_AffiliateCashMember_documentation_en-US" xlink:label="lab_ehc_AffiliateCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held and maintained by joint ventures in which we have an ownership interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliateCashMember" xlink:href="ehc-20211231.xsd#ehc_AffiliateCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AffiliateCashMember" xlink:to="lab_ehc_AffiliateCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_c377229a-2c28-4ed4-b429-e12762eadaf9_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_1da1df04-b0a3-426f-8585-3d5e66511bd6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cddaa31c-557b-4750-a677-506614608a02_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_ac3343bb-1a6b-4f22-b1be-e488cc7de8b7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6b310e9f-1487-43e3-8d9e-262e457ba1d0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_cbfbe5b8-ff96-4aee-9990-9f4de52eb533_totalLabel_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_label_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss from Continuing Operations Attributable to Common Shareholders Basic</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_documentation_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:href="ehc-20211231.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:to="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PortercareAdventistMember_448088c9-ed01-4f5f-a59c-f62c281213ff_terseLabel_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist</link:label>
    <link:label id="lab_ehc_PortercareAdventistMember_label_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist [Member]</link:label>
    <link:label id="lab_ehc_PortercareAdventistMember_documentation_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PortercareAdventistMember" xlink:to="lab_ehc_PortercareAdventistMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_3637904d-9c9c-40ff-af4d-73955285d692_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures_3251a55b-dd77-4d26-ab63-de1d03aaa0f3_terseLabel_en-US" xlink:label="lab_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of general or limited partnerships, limited liability companies, or joint ventures</link:label>
    <link:label id="lab_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures_label_en-US" xlink:label="lab_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of General or Limited Partnerships, Limited Liability Companies, or Joint Ventures</link:label>
    <link:label id="lab_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures_documentation_en-US" xlink:label="lab_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of general or limited partnerships, limited liability companies, or joint ventures of which the Company has investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" xlink:href="ehc-20211231.xsd#ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" xlink:to="lab_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_36ffac9f-bb2a-47cc-843c-1433a8f80a05_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_e233060f-40cb-4a3f-b57d-042131506f3d_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, After Year Five</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_WeightedAverageRemainingLeaseTermAbstract_6236bd89-53ad-4e6f-896b-cdd594b853db_terseLabel_en-US" xlink:label="lab_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_ehc_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_ehc_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:href="ehc-20211231.xsd#ehc_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5876393f-17f7-4a85-ba61-e8cf7fe30b0f_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_75beb749-7fad-4b2b-ba95-cc178ce68642_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0503c74e-d84d-49a1-afd7-b0fa4e5c90fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_aa142728-679b-4500-a03d-a73f19f2ac79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_38eaf2cc-7f82-4380-b60b-7b527cd07aae_terseLabel_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_label_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Company Match, Vesting Period</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_documentation_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time over which the Company's contributions to a participant's retirement account fully vests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:to="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_18b0abdd-8233-4d29-ab17-5a8d02f3a9da_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareMember_caf34b92-5f1b-4221-8005-91e719a6bf42_terseLabel_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ehc_MedicareMember_label_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ehc_MedicareMember_documentation_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember" xlink:href="ehc-20211231.xsd#ehc_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareMember" xlink:to="lab_ehc_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b3050da9-dde1-4d89-910f-fab37de3843f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_4ac4bb0a-8d3b-423f-8efc-dd2cb1660da8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_023db31f-c79a-46b3-97df-0f866174088f_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_76aa0d03-6eba-4821-911d-9e2295a37847_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_b71ad179-ea48-4cbe-a859-8356697697c4_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_582e434e-b8e2-41c6-94d2-0dde4663776b_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_778fb927-1df3-4be3-b89f-f0036ced3163_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_240430b9-a890-45d7-ad74-0be627d41cfe_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_888d95d4-e677-4654-ae40-11c82e769f2c_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_29cd3caf-a89c-4a3c-a5d9-97eb5b9f0f8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_8b50cb12-025e-431e-b0de-0a97564f91ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7aa2691f-c9af-4f44-beca-769b32c3c3db_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_51d9f74f-057d-422e-9546-395b402e1b11_negatedLabel_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of redeemable noncontrolling interest owned by joint venture partner</link:label>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncontrolling Interest, Fair Value</link:label>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:to="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_99f1daf9-84e9-4506-b678-4637742d3ff8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_acf933af-749b-4dd3-b780-921477674c6e_verboseLabel_en-US" xlink:label="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of depreciation expense and interest capitalized</link:label>
    <link:label id="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation, Interest Capitalized Expense [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of depreciation expense, interest capitalized, under operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:href="ehc-20211231.xsd#ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:to="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_a1d2eed1-43d8-42ef-bd1a-28de8402c23f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability_6e9bd1eb-ef3a-40ee-bac5-8ccaa6792337_terseLabel_en-US" xlink:label="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="ehc-20211231.xsd#ehc_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentIssuePricePercentage_bd5d90b0-7644-4a95-8698-85e9263aa938_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentIssuePricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issue price as percentage of principal (percent)</link:label>
    <link:label id="lab_ehc_DebtInstrumentIssuePricePercentage_label_en-US" xlink:label="lab_ehc_DebtInstrumentIssuePricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issue Price, Percentage</link:label>
    <link:label id="lab_ehc_DebtInstrumentIssuePricePercentage_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentIssuePricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value of debt instrument issued plus or minus a premium or a discount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentIssuePricePercentage" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentIssuePricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentIssuePricePercentage" xlink:to="lab_ehc_DebtInstrumentIssuePricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b41a46ef-d25b-41f0-9626-1d09b5225a9f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution as percentage of salary allowed under the Plan (percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a97b437e-c732-40dc-a780-b287d66d1d19_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_f5bbd198-ad42-493c-afcc-34f8f6496b7d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6b042f26-4445-45dd-89ce-90eafec7aed2_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchase authorization</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_A2019AcquisitionsMember_41f0b85b-ea44-4a7a-9d20-a3b3b2a8a2a4_terseLabel_en-US" xlink:label="lab_ehc_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Acquisitions</link:label>
    <link:label id="lab_ehc_A2019AcquisitionsMember_label_en-US" xlink:label="lab_ehc_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2019 Acquisitions [Member]</link:label>
    <link:label id="lab_ehc_A2019AcquisitionsMember_documentation_en-US" xlink:label="lab_ehc_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2019 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2019AcquisitionsMember" xlink:href="ehc-20211231.xsd#ehc_A2019AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_A2019AcquisitionsMember" xlink:to="lab_ehc_A2019AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_728a0759-13c8-45ac-b746-f85ea580d30a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense at statutory rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_fc9dadef-e99f-437b-8db1-16f27454e7fa_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_453c9919-4cf4-48bb-a28a-0d8fc357f9b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ff2b0aad-9699-4513-9ee2-38a340fa785f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income attributable to Encompass Health</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_3f56addc-d2d6-481a-8a74-e8ad0a064d2f_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_8430fe74-62ee-4939-a649-3e0351e53880_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% Senior Notes due 2023</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_da76309b-d320-4755-8943-393a4a0b0c7d_verboseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% Senior Notes due 2023</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_label_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 05.125%, Due 2023 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 05.125%, Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes05.125Due2023Member" xlink:to="lab_ehc_SeniorNotes05.125Due2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fbdc9e72-4207-4524-ad6b-c09836a0c372_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_77ecc971-faff-4947-a3da-c52ff8537a7d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a02e38ba-26b2-4a63-ba21-ea236ef9595f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_03739ba6-a9ea-4344-9074-3632fbd67d9d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bd805878-8d91-44e4-a38f-d1514b470bfb_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1bb42798-8692-4c23-99f4-d83b934b3aad_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_7a339af0-450a-4f49-b415-a03f4a9476c5_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Two</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_4fe5c632-c0f8-4ebd-8d72-2dd9ffa08f0b_terseLabel_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consolidated limited partnership-like entities</link:label>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_label_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Entities Consolidated</link:label>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_documentation_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities consolidated as variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:href="ehc-20211231.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:to="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_08982f34-fad8-41ea-bcc4-6a89628558f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Totalfinanceleasecost_d1617b54-b4e9-4750-9904-ea5efef15172_totalLabel_en-US" xlink:label="lab_ehc_Totalfinanceleasecost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_ehc_Totalfinanceleasecost_label_en-US" xlink:label="lab_ehc_Totalfinanceleasecost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_ehc_Totalfinanceleasecost_documentation_en-US" xlink:label="lab_ehc_Totalfinanceleasecost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of finance lease cost recognized by lessee for lease contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalfinanceleasecost" xlink:href="ehc-20211231.xsd#ehc_Totalfinanceleasecost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Totalfinanceleasecost" xlink:to="lab_ehc_Totalfinanceleasecost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_c94c884e-2c13-4c9b-9919-f61820107968_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment information related to restricted marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_42195943-fe2f-4954-b881-52fe43313242_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_1c54e718-afb3-409e-926e-f61b3fbcbfd1_terseLabel_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use-assets</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_509555bf-d4ff-485b-a202-9704ca4aeeaf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b6d0bd8e-782c-4ec0-83f7-b5fa3b767358_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_3e3f1353-5983-43cf-b3cb-e8f5c32cd48b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_81f7635f-694a-48a2-8901-e512168ccd5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_103c60dd-f328-4d8f-ac5c-2c6ce707f10e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_73368b32-34f3-44f6-a0b7-58ba13ec59c3_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_14524481-ab3e-4e7d-be15-e4dc331e1776_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_f8b6ddfd-ab19-49d6-b478-bb0413016621_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_1e94a5ae-6f83-4169-b29a-c0aa51026fcd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7bc1caaf-20fe-4b15-862e-b21417166668_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OccupancyCost_26bfdce3-cfe0-4623-9bf2-ed49fadcf6fc_terseLabel_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy costs</link:label>
    <link:label id="lab_ehc_OccupancyCost_label_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy Cost</link:label>
    <link:label id="lab_ehc_OccupancyCost_documentation_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost" xlink:href="ehc-20211231.xsd#ehc_OccupancyCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OccupancyCost" xlink:to="lab_ehc_OccupancyCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_a44d4554-d070-4fba-bbc6-e04629a047aa_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofDeNovoBeds_634c2f9e-4bcd-4165-b961-a7f49069cfba_terseLabel_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of de novo beds</link:label>
    <link:label id="lab_ehc_NumberofDeNovoBeds_label_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of De Novo Beds</link:label>
    <link:label id="lab_ehc_NumberofDeNovoBeds_documentation_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of De Novo Beds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds" xlink:href="ehc-20211231.xsd#ehc_NumberofDeNovoBeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofDeNovoBeds" xlink:to="lab_ehc_NumberofDeNovoBeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31aa6546-3593-4ae2-a716-c56141cf82c9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_f4f0f754-e461-45f8-bac8-e9ef9bc33fdc_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government, class action, and related settlements</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_000a819a-a574-4344-961c-aad1779c630b_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for government, class action, and related settlements</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_a10dca19-f362-4fab-9cf2-e51ccdc0343b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government, class action, and related settlements</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_66ecfc41-294d-4f9d-9d9f-cda305f6b465_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_df720f90-020f-400f-af1f-c9c8d6988540_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MarketAccessAssetsMember_b9b8321c-a121-40dc-b362-32aea3671a88_verboseLabel_en-US" xlink:label="lab_ehc_MarketAccessAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market access assets</link:label>
    <link:label id="lab_ehc_MarketAccessAssetsMember_label_en-US" xlink:label="lab_ehc_MarketAccessAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Access Assets [Member]</link:label>
    <link:label id="lab_ehc_MarketAccessAssetsMember_documentation_en-US" xlink:label="lab_ehc_MarketAccessAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalizable costs associated with gaining access to and pentetrating a historical market base.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember" xlink:href="ehc-20211231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MarketAccessAssetsMember" xlink:to="lab_ehc_MarketAccessAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_b4a20699-6211-4e3f-b49d-4e65f12ad2ee_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_96b37ef5-ba22-494e-b9c8-4ab1ea3976c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_306388bd-9927-4ef7-ad2f-c585462bb03d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of vested shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13bb2fd1-1236-45a7-b7e7-16bf9fd27105_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per share of awards granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74b09f59-66cd-4b46-aad8-24447ef598c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_4f9378ed-4f4e-4368-935b-80d42434992c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_e07e8079-dcb3-4dea-9df6-656a1e969414_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_fd03f7a5-ce7d-4466-9113-27c6bc7f144f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_47d33a0e-3e88-4742-99a8-ac88ff54fb11_terseLabel_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insured amount</link:label>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_label_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Self Insured Amount, First Layer of Risk</link:label>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_documentation_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Self Insured Amount, First Layer of Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:href="ehc-20211231.xsd#ehc_MaximumSelfInsuredAmountFirstLayerOfRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:to="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_f1129a28-39ae-4c13-a040-8e87ad250060_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of restricted investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_7426a3c9-dff3-4f08-9571-38689d4affd0_terseLabel_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_label_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_documentation_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:href="ehc-20211231.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:to="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_6c861645-3628-4260-8bff-63387deeaa7c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HoldingsAndEHHIMember_aad2349d-1861-46ef-b9ea-e5744975775a_terseLabel_en-US" xlink:label="lab_ehc_HoldingsAndEHHIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdings And EHHI</link:label>
    <link:label id="lab_ehc_HoldingsAndEHHIMember_label_en-US" xlink:label="lab_ehc_HoldingsAndEHHIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdings And EHHI [Member]</link:label>
    <link:label id="lab_ehc_HoldingsAndEHHIMember_documentation_en-US" xlink:label="lab_ehc_HoldingsAndEHHIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdings And EHHI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HoldingsAndEHHIMember" xlink:href="ehc-20211231.xsd#ehc_HoldingsAndEHHIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HoldingsAndEHHIMember" xlink:to="lab_ehc_HoldingsAndEHHIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_label_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income and Income Statement [Abstract]</link:label>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_documentation_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income and Income Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:href="ehc-20211231.xsd#ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:to="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_a9bba8c8-59ff-41af-8eb5-ab6e465a26fa_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_58b0ff42-547f-4efc-afe9-53ffbf2ac134_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_fbae507a-1df4-4481-ad05-600a4040faf0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_99670883-f0d1-4871-b64d-85a98a709ab0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_e3be29c3-30a6-4d7a-9b58-b2406d7d9790_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_bf5fb7f0-8168-4ca9-b452-91bb7cb429ae_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_9d2678d1-615b-40f5-b550-78de798e5a24_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_d9f370f8-ecb9-4a5d-bb8d-ad16c2702ded_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_0dbfeb04-00a5-4bc6-8f18-654e800377cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_d4ea265a-63d6-445d-9497-889074c6c39b_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_01847c2f-3013-499c-aaf1-36867ce6dd8b_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d781b189-dbcc-4bb0-81b1-cd0fe3ac9cca_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_78d6270d-faf9-4f17-9aa1-8e7bde40ace1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_60f9befc-0131-4e3f-9037-aded023153e7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Information Related to Restricted Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Realized Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_f0f84df1-668e-4a40-bedf-6c1e7861d81f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_55f5cb2b-5540-4290-a735-c264119a8e03_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_375777f0-e8ea-4f46-89e0-7a64841e50be_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Medicare patient discharges (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_9f129b05-669a-42c4-b238-e91a61cd9fb1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues by payor source (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_89d99cbf-86fc-45b7-95f5-cbb48057365c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_b62da08f-fb7e-41c8-b48e-edaf5e0b5748_terseLabel_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_label_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_documentation_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:href="ehc-20211231.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:to="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c9d59b9b-b11f-4a4d-b441-454e59ba2e20_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7fdbb790-2e4e-4ea5-8eb6-2716bca725b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_b785dfa0-422c-4ad4-a64b-1a452dc210a6_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b80d2cc4-43bd-49f6-adf4-9d0e03881542_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_e69b1f7c-5063-4975-8536-dc900b7c95da_terseLabel_en-US" xlink:label="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</link:label>
    <link:label id="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_label_en-US" xlink:label="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]</link:label>
    <link:label id="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_documentation_en-US" xlink:label="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:href="ehc-20211231.xsd#ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:to="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6f47001a-bbd3-4e9a-a102-410d8b11590e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NicholsLitigationMember_0ba9ac5f-59af-4e80-a21e-fff7bb5c14a2_terseLabel_en-US" xlink:label="lab_ehc_NicholsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nichols Litigation</link:label>
    <link:label id="lab_ehc_NicholsLitigationMember_label_en-US" xlink:label="lab_ehc_NicholsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nichols Litigation [Member]</link:label>
    <link:label id="lab_ehc_NicholsLitigationMember_documentation_en-US" xlink:label="lab_ehc_NicholsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nichols Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NicholsLitigationMember" xlink:href="ehc-20211231.xsd#ehc_NicholsLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NicholsLitigationMember" xlink:to="lab_ehc_NicholsLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_899336f1-ab1e-4567-a147-65de5f3555e8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_83bc0048-65fe-43a0-a763-17a37cb8751e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_08baf8a6-2b58-4ef4-b0cb-38263b553f65_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0facf036-8042-4c43-97c8-db92fb096379_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Other Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_78faebe1-4d04-49c7-a8f1-0ffd7d9a96c5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PayorSourceMember_e028fe18-6959-47bc-9229-6a60bd54b46a_terseLabel_en-US" xlink:label="lab_ehc_PayorSourceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Source</link:label>
    <link:label id="lab_ehc_PayorSourceMember_label_en-US" xlink:label="lab_ehc_PayorSourceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Source [Member]</link:label>
    <link:label id="lab_ehc_PayorSourceMember_documentation_en-US" xlink:label="lab_ehc_PayorSourceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Source [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember" xlink:href="ehc-20211231.xsd#ehc_PayorSourceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PayorSourceMember" xlink:to="lab_ehc_PayorSourceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_01d4afa9-2907-481f-aabb-b2032de4f7b8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_46e3cfb6-86e1-4ed4-91d6-5cc0dfbae405_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Actual and Pro Forma Results of Operations for Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_647f709b-a7be-4912-8820-50e98e11c798_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_fdeb9284-1bd2-4aae-93be-88c61a4d4516_terseLabel_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage in employer contributions (percent)</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_label_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_documentation_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:to="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_2772e16f-6e80-4c80-928d-f0f04d2a21c9_terseLabel_en-US" xlink:label="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of ASC 842</link:label>
    <link:label id="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_label_en-US" xlink:label="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Financing Activities, Adoption Of Accounting Standard Update</link:label>
    <link:label id="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_documentation_en-US" xlink:label="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Financing Activities, Adoption Of Accounting Standard Update</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:href="ehc-20211231.xsd#ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:to="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ddfff769-1e34-425d-9935-97b106719d6a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_afa410c1-81cd-4027-bf1c-71cc3baf9c39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to prior year claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8a091792-94fb-4d87-9749-fb974687fdaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5a9c7bb6-885a-4763-96a5-99b21b57fb13_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_1be568f7-e334-4ce8-91d9-3596a8ba098e_terseLabel_en-US" xlink:label="lab_ehc_OtherHomeHealthAndHospiceAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Home Health and Hospice Acquisitions</link:label>
    <link:label id="lab_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_label_en-US" xlink:label="lab_ehc_OtherHomeHealthAndHospiceAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Home Health and Hospice Acquisitions [Member]</link:label>
    <link:label id="lab_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_documentation_en-US" xlink:label="lab_ehc_OtherHomeHealthAndHospiceAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Home Health and Hospice Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember" xlink:href="ehc-20211231.xsd#ehc_OtherHomeHealthAndHospiceAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember" xlink:to="lab_ehc_OtherHomeHealthAndHospiceAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_49caaf82-743e-4e19-90d4-83720a76dc54_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_004be0ca-d5f8-4f65-a835-05bc540f2023_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Reserves</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_79b4f2e7-4ef3-48fa-9eb2-8d22de7a4743_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Net Operating Revenues by Payor</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f26944f4-27b6-4980-9987-29fee4dca0d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_41b6f1ad-f8c0-41a7-8e69-1272ec02edcc_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ea00aacd-623f-41e7-bcda-2c8bf8052cb8_verboseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_e2e01446-c16b-4495-bcce-c3fbaec4d8ad_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8c6fd6c3-334a-4f00-85b0-bf9ca13a2713_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SupplementalCashFlowInformationTableTextBlock_b5f0e8a1-6b0e-4594-886b-73f676a32c22_terseLabel_en-US" xlink:label="lab_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_ehc_SupplementalCashFlowInformationTableTextBlock_label_en-US" xlink:label="lab_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Table Text Block]</link:label>
    <link:label id="lab_ehc_SupplementalCashFlowInformationTableTextBlock_documentation_en-US" xlink:label="lab_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:href="ehc-20211231.xsd#ehc_SupplementalCashFlowInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:to="lab_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EmploymentBasedSARSMember_2d7479e7-4c8e-4dd0-a8d6-81d1074c347b_terseLabel_en-US" xlink:label="lab_ehc_EmploymentBasedSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Based SARS</link:label>
    <link:label id="lab_ehc_EmploymentBasedSARSMember_label_en-US" xlink:label="lab_ehc_EmploymentBasedSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Based SARS [Member]</link:label>
    <link:label id="lab_ehc_EmploymentBasedSARSMember_documentation_en-US" xlink:label="lab_ehc_EmploymentBasedSARSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Based SARS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EmploymentBasedSARSMember" xlink:href="ehc-20211231.xsd#ehc_EmploymentBasedSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EmploymentBasedSARSMember" xlink:to="lab_ehc_EmploymentBasedSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bffd96ed-1ca3-46dc-a01e-1946f44d725c_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of treasury stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4d557d5-4bcb-4231-81b4-d55ba7ca105f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized for grant under the Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_5d3eadb8-e4b7-4d54-bda4-b9132a943f43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_a597cddb-bb3b-4ec1-92ba-dd4cbaf19a40_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reinsurance receivables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_f768c93a-fc83-40e7-9f72-05528644cd4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Reinsurance receivables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable for Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:to="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_38a9ff19-32e7-48dc-ab61-bcf816b10c9a_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1372c9a3-4096-45cb-9c61-931262c32ba0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_87a7896b-62e0-4823-a71b-c835479bb085_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HeritageValleyMember_3633eca4-caa3-45bb-a915-6e9cfa2b875a_terseLabel_en-US" xlink:label="lab_ehc_HeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Valley</link:label>
    <link:label id="lab_ehc_HeritageValleyMember_label_en-US" xlink:label="lab_ehc_HeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Valley [Member]</link:label>
    <link:label id="lab_ehc_HeritageValleyMember_documentation_en-US" xlink:label="lab_ehc_HeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Valley [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeritageValleyMember" xlink:href="ehc-20211231.xsd#ehc_HeritageValleyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HeritageValleyMember" xlink:to="lab_ehc_HeritageValleyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_899331db-5e76-4b2b-bb90-9f6a05f726c7_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Notes due 2028</link:label>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_label_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due 2028 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes4.50Due2028Member" xlink:to="lab_ehc_SeniorNotes4.50Due2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_0b5323e9-1717-4f58-a457-5fe2e4c99306_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_86b2a328-37ee-400b-a695-8a3d128a2e3f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5c5d09d1-359e-48c4-ac92-cc625f39f4dd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_12a6ad7b-6adb-40b7-8c07-c2e7ea0bd06a_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Notes due 2030</link:label>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_label_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.750%, Due 2030 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.750%, Due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes04.750Due2030Member" xlink:to="lab_ehc_SeniorNotes04.750Due2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_f7a803cd-3a1d-46ce-be4f-419066db6630_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_6c01f6bf-3cfe-45bf-8348-2b062e1c94ec_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a4f49830-96bc-412c-a840-90aaed790cc7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NotesPayableSoftwareContractsMember_e30d680c-8144-4829-8e42-977374d7ae82_terseLabel_en-US" xlink:label="lab_ehc_NotesPayableSoftwareContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software contracts</link:label>
    <link:label id="lab_ehc_NotesPayableSoftwareContractsMember_label_en-US" xlink:label="lab_ehc_NotesPayableSoftwareContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Software Contracts [Member]</link:label>
    <link:label id="lab_ehc_NotesPayableSoftwareContractsMember_documentation_en-US" xlink:label="lab_ehc_NotesPayableSoftwareContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Software Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableSoftwareContractsMember" xlink:href="ehc-20211231.xsd#ehc_NotesPayableSoftwareContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NotesPayableSoftwareContractsMember" xlink:to="lab_ehc_NotesPayableSoftwareContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eda1bd52-cc0a-4117-ae2c-9cfd50ae541e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_48b31225-99d9-4738-9b37-5cf05b125a6c_terseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of redeemable noncontrolling interests, percent</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests, Decrease from Redemptions or Purchase of Interests, Percent</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:to="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_498f8fe9-7968-4237-8215-1ed5c36b4ac5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_63c2b455-8c10-430d-b248-e5e29dc164b6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_9e0a6d86-087a-4afd-89bc-efb55824b21c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c5df52cf-87bd-42c3-915d-4c59dedaa0ba_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_e3c6fe92-0f67-48d2-83de-9681c54fa89a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock in open market</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_d5269e76-ce4a-4248-aa03-6a7c29a70d0f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_bda0426a-afb2-4f37-b6a9-ddd5b0eb2053_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrentAbstract_15eb70d5-b701-42d9-a1af-58bf23a0e354_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="lab_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c11cfc7f-8d80-497b-b2c2-c75535deb98e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFifthYear_90036149-43a4-42bb-847a-d1a6e70c6552_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_802d1e20-c79b-4d5d-ac09-5f72598be79f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_6777f8f6-330f-47f9-9536-e74c569a5964_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from noncontrolling interests of consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ad2a0207-e3d0-4a74-bf1d-62eb19afb993_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ManagedCareMember_862594b6-720c-4fe3-9480-99945e27a863_terseLabel_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care</link:label>
    <link:label id="lab_ehc_ManagedCareMember_label_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:label id="lab_ehc_ManagedCareMember_documentation_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember" xlink:href="ehc-20211231.xsd#ehc_ManagedCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ManagedCareMember" xlink:to="lab_ehc_ManagedCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SelfInsuredCaptiveFundsMember_d395e1c2-028c-4684-9b98-5fb9b51cd768_terseLabel_en-US" xlink:label="lab_ehc_SelfInsuredCaptiveFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insured captive funds</link:label>
    <link:label id="lab_ehc_SelfInsuredCaptiveFundsMember_label_en-US" xlink:label="lab_ehc_SelfInsuredCaptiveFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insured Captive Funds [Member]</link:label>
    <link:label id="lab_ehc_SelfInsuredCaptiveFundsMember_documentation_en-US" xlink:label="lab_ehc_SelfInsuredCaptiveFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held by the Company's wholly owned captive subsidiary which is restricted for use in paying self-insured work comp or professional liability claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SelfInsuredCaptiveFundsMember" xlink:href="ehc-20211231.xsd#ehc_SelfInsuredCaptiveFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SelfInsuredCaptiveFundsMember" xlink:to="lab_ehc_SelfInsuredCaptiveFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6de23ef7-9535-4a87-93ba-272ca2e02f84_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HospiceMember_6651cfe0-792a-4f3d-bb2f-3c0f1707479c_terseLabel_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice</link:label>
    <link:label id="lab_ehc_HospiceMember_label_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_ehc_HospiceMember_documentation_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember" xlink:href="ehc-20211231.xsd#ehc_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HospiceMember" xlink:to="lab_ehc_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_69ef86d4-52f3-4b01-b5d5-69e351ff70d7_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Five</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead_8319c6a6-2c24-4530-9bee-4cc6b794fbd1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Support and overhead costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Overhead</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_033e0175-745c-44d2-846c-1d321e852667_verboseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Insured Risks</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Totaloperatingandfinanceleaseassets_4b9b05ba-7dba-4108-b343-15b9292479b6_totalLabel_en-US" xlink:label="lab_ehc_Totaloperatingandfinanceleaseassets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leased assets</link:label>
    <link:label id="lab_ehc_Totaloperatingandfinanceleaseassets_label_en-US" xlink:label="lab_ehc_Totaloperatingandfinanceleaseassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating and finance lease assets</link:label>
    <link:label id="lab_ehc_Totaloperatingandfinanceleaseassets_documentation_en-US" xlink:label="lab_ehc_Totaloperatingandfinanceleaseassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lessee's right to use underlying asset under operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totaloperatingandfinanceleaseassets" xlink:href="ehc-20211231.xsd#ehc_Totaloperatingandfinanceleaseassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Totaloperatingandfinanceleaseassets" xlink:to="lab_ehc_Totaloperatingandfinanceleaseassets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_04edcd79-47a0-4e28-9ac9-45ae6e6577db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_cba2a0bd-513a-450d-b056-f199c82ae925_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_45d73da2-0cde-4bed-9789-4257f2a1ec9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_649a8381-3859-47f6-9711-fb01d2fbdf45_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f2a41579-250c-4172-98c8-72dbff2408fe_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2c0c7b42-b3ec-4166-8df0-713426ccc70e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f782be25-38ca-4137-a43d-f76c8d6a13ed_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareAdvantageMember_9e2def03-a2ae-4f7f-bdb4-19ffe159a58f_terseLabel_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_ehc_MedicareAdvantageMember_label_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_ehc_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember" xlink:href="ehc-20211231.xsd#ehc_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareAdvantageMember" xlink:to="lab_ehc_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_82681f13-7540-4e98-b38b-ab390f04abe3_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_8b431688-a24b-4143-a741-bc299c769270_verboseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Redeemable noncontrolling interests</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:to="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4f107c4d-a31c-40ce-9f52-1dadafe97af5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_f0123874-0b05-48e8-a4ce-8b1e3477430a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_0bb1d2a5-e147-405c-bfb4-0245c11dad3d_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of noncontrolling interest owned by joint venture partner</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_dc50745c-27a0-4c38-8ddb-2c4a49b1c942_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid on common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3f728aa8-c0d7-4152-97dd-aea58af0d89d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e54790ea-6221-4554-a897-feedb8fdf909_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InpatientMember_b966909c-6f13-49cf-ae85-a1d5329379ca_terseLabel_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient</link:label>
    <link:label id="lab_ehc_InpatientMember_label_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient [Member]</link:label>
    <link:label id="lab_ehc_InpatientMember_documentation_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember" xlink:href="ehc-20211231.xsd#ehc_InpatientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InpatientMember" xlink:to="lab_ehc_InpatientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember_5a432294-089f-4aa1-a2d8-a4688cd43447_terseLabel_en-US" xlink:label="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners</link:label>
    <link:label id="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember_label_en-US" xlink:label="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners [Member]</link:label>
    <link:label id="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember_documentation_en-US" xlink:label="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:to="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_787f6a44-75f1-45d2-afdb-aae726271670_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of partnerships</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_11e1b99e-980a-4b2a-a1c2-ae2230b82ba8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to settle the acquisition of Holdings common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_11cd78d2-a350-437a-8285-0e17fd3f2ea8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_6aad0bf1-bc97-4002-92a9-5826bcd6efd4_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under letter of credit facility</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_dddb6a76-7cf5-42e1-8a91-406b2d1427fb_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum accrual of loss contingency needed to accrue for related legal fees</link:label>
    <link:label id="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_label_en-US" xlink:label="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Minimum Amount to Consider Accruing an Estimate of Related Legal Fees</link:label>
    <link:label id="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_documentation_en-US" xlink:label="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum dollar amount that must be accrued for a loss contingency related to a specific legal dispute that can be utilized for consideration prior to accruing an estimate of the legal fees related to this specific legal dispute.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:href="ehc-20211231.xsd#ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:to="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_71446d20-dbf1-4580-8574-ce27f8e61c93_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantLeverageRatio" xlink:to="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_5ea50d5d-2969-4b32-b0ae-7bdb09441e2c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_f4c6041f-13d7-43ea-84c0-5cf50ac0285f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8fcccb8b-50ba-4d15-a988-0566da24c8e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_f807f4da-19be-499a-af10-561d6f82e14d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_424a7e28-c244-41d3-b8d1-aa7d9f0582a9_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e62382d6-4711-4bd9-950f-5189f1fc5b37_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_e2306c4d-1123-4a6a-bc72-5075b22bfc76_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_1b609a75-2699-4a53-a90f-1f9e3f94c4fa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_828a1f6d-8194-4c04-b31f-97719c86c627_verboseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8ed56c25-eaea-4891-8cd3-17013e744ee7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt amendment and issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_cfbe184f-119c-444d-90b7-c4ce891dc660_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_58fbf714-56d4-430b-8c10-6e40e835e248_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds for offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_5fc1e24d-c61d-453d-a13c-195c59ad6fce_terseLabel_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_label_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Company Match, Vesting Percentage</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_documentation_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total percentage of the Company's matching contributions that will vest in the Retirement Investment Plan after an employee service requirement has been met.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:to="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_96237a4b-5a8d-406c-b894-e1ccb798bc46_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c8d177aa-f0a5-430d-827e-a1d4ee72cf93_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_0ef973d8-b1ff-412d-92de-49a3d00515b7_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_817659d0-632b-43b5-b061-b37a0c723902_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c5a37f95-df99-47ed-86ab-9743591db221_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_e4c475f9-4d85-4332-952f-741240a50df0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9d29b9b6-236b-4494-9723-e795b455f07d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_6b2d07b5-9f04-4ba1-a0c7-ec6ec363d608_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_53ab6a3e-b626-420c-b906-d2aa3da90f56_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest portion</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_802c96e8-a31d-402a-8ecd-c2a934184764_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HomehealthMember_af5536a5-442a-49dd-9fbc-e833f07c84a0_terseLabel_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health</link:label>
    <link:label id="lab_ehc_HomehealthMember_label_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health [Member]</link:label>
    <link:label id="lab_ehc_HomehealthMember_documentation_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember" xlink:href="ehc-20211231.xsd#ehc_HomehealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HomehealthMember" xlink:to="lab_ehc_HomehealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_52bd44b3-5900-493c-b611-c3536f6b4f1c_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Reclassificationtononcontrollinginterests_ea3f0e90-3dfa-4333-81dc-80f095004d72_negatedTerseLabel_en-US" xlink:label="lab_ehc_Reclassificationtononcontrollinginterests" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to noncontrolling interests</link:label>
    <link:label id="lab_ehc_Reclassificationtononcontrollinginterests_label_en-US" xlink:label="lab_ehc_Reclassificationtononcontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to noncontrolling interests</link:label>
    <link:label id="lab_ehc_Reclassificationtononcontrollinginterests_documentation_en-US" xlink:label="lab_ehc_Reclassificationtononcontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of redeemable noncontrolling interests reclassified to noncontrolling interests during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Reclassificationtononcontrollinginterests" xlink:href="ehc-20211231.xsd#ehc_Reclassificationtononcontrollinginterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Reclassificationtononcontrollinginterests" xlink:to="lab_ehc_Reclassificationtononcontrollinginterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_5e675c48-9196-4060-88dc-def2949b8b49_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Three</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_465fa178-3a7f-4ec1-8678-1d81cb9669f0_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock_3daf21a3-9c24-4cba-b0c3-44d65d6e17ed_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Aggregate Equity and Cost Method Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_7f97bdc8-f3fe-4510-ad0c-d4d14557705e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9ecaad7a-1cbe-466a-990c-00940e2e6596_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_77b49e1a-ce4e-4b57-bacc-59c0118838e4_terseLabel_en-US" xlink:label="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary's common stock held by subsidiary 's management, percent</link:label>
    <link:label id="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_label_en-US" xlink:label="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary's common stock held by subsidiary 's management, Percent</link:label>
    <link:label id="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_documentation_en-US" xlink:label="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of subsidiary's common stock held by subsidiary 's management, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:href="ehc-20211231.xsd#ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:to="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cfd9daeb-c910-49d2-ac26-86320ef980ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5f568cb3-be31-4c37-8583-578b8208d197_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_dfcec5c7-30bf-4e1d-9344-dee263e495c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9d0a5e70-6706-46df-839e-44c062838876_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9475515-4c4c-464e-8844-7edd39416796_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4c9e06b-99e2-4288-8f4f-c1116866e1c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5fe11d12-23e8-4780-8d71-7e2d0f1da40a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_bdf51382-538c-44ec-82d5-5e0ba9d1920c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash &amp; Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_52281fd6-3cf8-4454-981d-538053430244_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestOtherAdjustment_858d7135-5b74-4f24-99a2-325faa368486_terseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestOtherAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestOtherAdjustment_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestOtherAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Other Adjustment</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestOtherAdjustment_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestOtherAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Other Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestOtherAdjustment" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestOtherAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestOtherAdjustment" xlink:to="lab_ehc_NoncontrollingInterestOtherAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NonemployeeDirectorsMember_841f3fc2-b636-499b-b5b1-6e18a1e7fbed_terseLabel_en-US" xlink:label="lab_ehc_NonemployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors</link:label>
    <link:label id="lab_ehc_NonemployeeDirectorsMember_label_en-US" xlink:label="lab_ehc_NonemployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label id="lab_ehc_NonemployeeDirectorsMember_documentation_en-US" xlink:label="lab_ehc_NonemployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NonemployeeDirectorsMember" xlink:href="ehc-20211231.xsd#ehc_NonemployeeDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NonemployeeDirectorsMember" xlink:to="lab_ehc_NonemployeeDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_4aa6285c-4cc2-4d42-8fa6-77f3091d4e07_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BaptistOutpatientServicesIncMember_b2f6bbfe-c1e4-4d95-9857-02341dffb459_terseLabel_en-US" xlink:label="lab_ehc_BaptistOutpatientServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baptist Outpatient Services, Inc</link:label>
    <link:label id="lab_ehc_BaptistOutpatientServicesIncMember_label_en-US" xlink:label="lab_ehc_BaptistOutpatientServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baptist Outpatient Services, Inc [Member]</link:label>
    <link:label id="lab_ehc_BaptistOutpatientServicesIncMember_documentation_en-US" xlink:label="lab_ehc_BaptistOutpatientServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baptist Outpatient Services, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BaptistOutpatientServicesIncMember" xlink:href="ehc-20211231.xsd#ehc_BaptistOutpatientServicesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BaptistOutpatientServicesIncMember" xlink:to="lab_ehc_BaptistOutpatientServicesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_c26fc266-835c-4f29-afeb-99f1b085823a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_41fe3bc5-5134-4cef-9af9-87b714e16664_terseLabel_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services (excluding depreciation and amortization)</link:label>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_label_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Services, Excluding Depreciation and Amortization</link:label>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_documentation_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:href="ehc-20211231.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:to="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_5c2840c6-ccc1-4b4e-87b5-33bfc7a6f198_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a48260af-5e4a-4d48-93b6-521ad1bc1337_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_69d7103f-065b-4fb4-91f5-1904d071c043_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c25b0d4d-c25a-4342-8072-d6d375a042b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_b14191e8-6813-4516-baf6-466cbcafa160_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_62aea857-ffc9-4e10-a205-1dec948b412b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable interest rate under credit facility (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_e5658843-9f43-4ee5-bee3-2a86e3bdb364_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestMember" xlink:to="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7e61d9a9-9159-4ff3-ae3d-083bed510294_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_39c3235e-3784-4d16-845e-69bf4c477203_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_GenerationSolutionsOfLynchburgMember_f58aa416-b413-491c-bc6b-4776d501d210_terseLabel_en-US" xlink:label="lab_ehc_GenerationSolutionsOfLynchburgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generation Solutions of Lynchburg</link:label>
    <link:label id="lab_ehc_GenerationSolutionsOfLynchburgMember_label_en-US" xlink:label="lab_ehc_GenerationSolutionsOfLynchburgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generation Solutions of Lynchburg [Member]</link:label>
    <link:label id="lab_ehc_GenerationSolutionsOfLynchburgMember_documentation_en-US" xlink:label="lab_ehc_GenerationSolutionsOfLynchburgMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generation Solutions of Lynchburg</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsOfLynchburgMember" xlink:href="ehc-20211231.xsd#ehc_GenerationSolutionsOfLynchburgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_GenerationSolutionsOfLynchburgMember" xlink:to="lab_ehc_GenerationSolutionsOfLynchburgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_62c25b41-731f-4227-bcf4-f44b0ed1eaf3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7d9c208a-bbf3-43a3-ae5b-e58bd88f2e3d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_6c7f077f-09b8-4855-8da2-b7d75b9428e1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Holdings shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5f65c695-8f50-40c9-bad3-06761dc7d482_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_67c88ddf-d9c7-48ac-bca7-5635e8ece492_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2021</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_ba03a3ca-ccf7-4518-ba7b-2e499ed8d32f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_07375365-0d70-47e9-b717-3b920f9f8613_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase for the provision of current year claims</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0410f51b-3e36-4e80-913d-a4282c6a386f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_86c2f97d-88f5-410a-9335-5580a8183380_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ShannonMedicalMember_ac85c1a4-34c2-4400-849f-a9ca08fb25f0_terseLabel_en-US" xlink:label="lab_ehc_ShannonMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical</link:label>
    <link:label id="lab_ehc_ShannonMedicalMember_label_en-US" xlink:label="lab_ehc_ShannonMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical [Member]</link:label>
    <link:label id="lab_ehc_ShannonMedicalMember_documentation_en-US" xlink:label="lab_ehc_ShannonMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalMember" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ShannonMedicalMember" xlink:to="lab_ehc_ShannonMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_007a78de-52af-4642-93c3-b0ccce4444ec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_089e3d0f-5065-4a84-a16a-aa5e608a7e17_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_16b157e6-1826-48a3-8702-35943e54dbe5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1013e369-6a7b-4ef8-9ba0-6f20d40fdd7b_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionLineItems_56247097-73f3-4734-8ebe-c232ce8e8c87_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems" xlink:to="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_58cc60f1-d8c3-408c-92b3-8b689f5e03e2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_5fcdedd3-dfb8-4c7d-9a90-77ac521a005d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ECHDVenturesMember_92708768-f3dd-4b43-b089-75193fe0adec_terseLabel_en-US" xlink:label="lab_ehc_ECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ECHD Ventures</link:label>
    <link:label id="lab_ehc_ECHDVenturesMember_label_en-US" xlink:label="lab_ehc_ECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ECHD Ventures [Member]</link:label>
    <link:label id="lab_ehc_ECHDVenturesMember_documentation_en-US" xlink:label="lab_ehc_ECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ECHD Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ECHDVenturesMember" xlink:href="ehc-20211231.xsd#ehc_ECHDVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ECHDVenturesMember" xlink:to="lab_ehc_ECHDVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_df4e8e1c-932a-461d-8f15-bef2f6018a83_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625% Senior Notes due 2031</link:label>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_label_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.625%, Due 2031 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.625%, Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes04625Due2031Member" xlink:to="lab_ehc_SeniorNotes04625Due2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_22583483-37c1-4f37-8ce7-a49892efff6f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c0043eca-b109-44ae-8852-ed9cedadb144_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5737d2d2-35cf-4fed-a100-967ca83443e9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and amortization of debt discounts and fees</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a8a203d5-0ad7-456d-bab1-0b76eb44d88d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_WeightedAverageDiscountRateAbstract_93f6d728-ebee-43fa-b774-a0644edb3f0a_terseLabel_en-US" xlink:label="lab_ehc_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_ehc_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ehc_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_ehc_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_ehc_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WeightedAverageDiscountRateAbstract" xlink:href="ehc-20211231.xsd#ehc_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_WeightedAverageDiscountRateAbstract" xlink:to="lab_ehc_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_001a9c4d-2d82-4dcb-90c3-4655424fb268_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8338459c-a6aa-4a13-8898-a670515ad30a_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense recognized</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_32429d36-c26e-4c7e-ae35-d1a1ec53006d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_A2021AcquisitionsMember_822a4a73-8ea4-4fe0-a128-9a063293326b_terseLabel_en-US" xlink:label="lab_ehc_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions</link:label>
    <link:label id="lab_ehc_A2021AcquisitionsMember_label_en-US" xlink:label="lab_ehc_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions [Member]</link:label>
    <link:label id="lab_ehc_A2021AcquisitionsMember_documentation_en-US" xlink:label="lab_ehc_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2021AcquisitionsMember" xlink:href="ehc-20211231.xsd#ehc_A2021AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_A2021AcquisitionsMember" xlink:to="lab_ehc_A2021AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_6fd421c9-1fd9-47c8-bd18-7b14c567fc25_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies by Nature of Contingency [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2c54bc47-8bec-4a4c-a6a2-41cd202f6f16_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_A2020AcquisitionsMember_b93df884-f32a-4737-b50b-20f3afb4254f_terseLabel_en-US" xlink:label="lab_ehc_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:label id="lab_ehc_A2020AcquisitionsMember_label_en-US" xlink:label="lab_ehc_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions [Member]</link:label>
    <link:label id="lab_ehc_A2020AcquisitionsMember_documentation_en-US" xlink:label="lab_ehc_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2020AcquisitionsMember" xlink:href="ehc-20211231.xsd#ehc_A2020AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_A2020AcquisitionsMember" xlink:to="lab_ehc_A2020AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_159e135a-0a91-4e58-a85d-607e9e18d568_terseLabel_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third-party payors</link:label>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_label_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third-party Payors [Member]</link:label>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_documentation_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third-party Payors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember" xlink:href="ehc-20211231.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherThirdpartyPayorsMember" xlink:to="lab_ehc_OtherThirdpartyPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e9f582d6-3ba2-4f0b-979e-02948c31c71e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated income (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_8af990a3-7060-4579-a150-8f08e314a4e9_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_27456179-6076-4a7d-ae6e-79fc4c129cd3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserveCurrent_6497617d-eb12-442b-b7ef-7fc34163b828_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insurance reserves included in Other current liabilities</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserveCurrent_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c03f7ecf-8828-46ed-893b-d7b05be414d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_87a6fcc6-b8c8-49d0-9af8-5d4890820686_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Combined Assets, Liabilities, and Equity of Equity Method Affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4e5f48f0-bd5d-46fc-8657-80d2434d0750_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_bff2d075-0880-4e23-bcd6-ad6070a2b272_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_da712dad-f25d-49c3-88b8-1b55d9c8560a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_c9c1643b-0dab-4e67-85f0-0549e2618350_terseLabel_en-US" xlink:label="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based windfall tax benefits (percent)</link:label>
    <link:label id="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_label_en-US" xlink:label="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, Percent</link:label>
    <link:label id="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_documentation_en-US" xlink:label="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:href="ehc-20211231.xsd#ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:to="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_e06bd86c-03c7-451d-8b1d-738fe72cbcfd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9cb855d4-c43f-4c9c-88e4-5d9ab8859e0c_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_a9a53aa1-2ce8-46c3-8856-dca3426182d4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_44990553-5c98-49f8-9391-b9a8982f1988_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests included in continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OutpatientandotherMember_28e249f9-19ba-4223-9d6e-fdd182c2d986_terseLabel_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other</link:label>
    <link:label id="lab_ehc_OutpatientandotherMember_label_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other [Member]</link:label>
    <link:label id="lab_ehc_OutpatientandotherMember_documentation_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember" xlink:href="ehc-20211231.xsd#ehc_OutpatientandotherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OutpatientandotherMember" xlink:to="lab_ehc_OutpatientandotherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3fc09143-2aa4-4d58-bcfb-d9be4c213e75_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5027a00-fa5f-4790-9308-bc1f2ed0150e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_93cc95a4-0850-448b-b7bd-9551ea7554e4_netLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d86006c-df43-4a85-8168-487e91cdd2f8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b494391f-e832-4af8-963e-aa52325370f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7563fe77-0e2b-4acd-8120-21570b6ba2e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_07c5ed2b-f267-4e2e-8093-83d8eb99e1a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c1424683-8aba-4866-935f-4055dc840a4a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3fdba2bf-2b05-4851-b932-ece32677b277_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_157c6b1d-bf4e-4bf2-b7a4-0d099a3a43cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_595c934c-2119-4370-8301-1fe0fcd072b8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5226d70c-00ca-4522-85e8-dc34a21f15f1_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5919a591-b24c-4e84-bfa5-8b8b90750c4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Selected Financial Information of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4ef18495-ed34-4ef8-89e1-135ad1b9aa8e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3bc5ee03-a221-494a-a116-6886d515d773_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d791dece-d138-4a08-b6b2-33eb70b6fd70_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_ac198d83-5106-4ad3-91ab-3ef76014a83d_terseLabel_en-US" xlink:label="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:href="ehc-20211231.xsd#ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:to="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b46b49f6-e0e8-4234-9527-00b143e32c35_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes to valuation allowance during the period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f0b097d5-7e38-47f9-b67c-9726d4508fd4_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_b97e38cd-877f-46e3-aa53-df530c369766_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_13221e7f-762b-4506-9694-3467f6700fa6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions, net of distributions and impairments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_85e917fe-08ad-42dd-a335-00ac7ecc61fe_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_fdd4b5b7-aa16-417a-8c91-cc331ea48da3_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InvestmentsCashandRestrictedCash_eb4b0f42-629c-4503-b7c7-06fe81f6febc_totalLabel_en-US" xlink:label="lab_ehc_InvestmentsCashandRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ehc_InvestmentsCashandRestrictedCash_label_en-US" xlink:label="lab_ehc_InvestmentsCashandRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Cash and Restricted Cash</link:label>
    <link:label id="lab_ehc_InvestmentsCashandRestrictedCash_documentation_en-US" xlink:label="lab_ehc_InvestmentsCashandRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments of the Company which includes cash, cash equivalents, restricted cash, and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InvestmentsCashandRestrictedCash" xlink:href="ehc-20211231.xsd#ehc_InvestmentsCashandRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InvestmentsCashandRestrictedCash" xlink:to="lab_ehc_InvestmentsCashandRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f1ef5df9-1225-4bcc-92bb-dfdc31468366_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CertificateOfNeedMember_d026cfdf-cdff-47e2-a5af-c97d5d4a063a_verboseLabel_en-US" xlink:label="lab_ehc_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of need</link:label>
    <link:label id="lab_ehc_CertificateOfNeedMember_label_en-US" xlink:label="lab_ehc_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_ehc_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_ehc_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A statement or certificate issued by a governmental agency for proposed construction or modification of a health facility. The certificate process is intended to prevent duplication of services in a community.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember" xlink:href="ehc-20211231.xsd#ehc_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CertificateOfNeedMember" xlink:to="lab_ehc_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DividendEquivalentRSUMember_b40cc3c4-ade5-4e30-a8d1-94cea40cb32c_terseLabel_en-US" xlink:label="lab_ehc_DividendEquivalentRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Equivalent, RSU</link:label>
    <link:label id="lab_ehc_DividendEquivalentRSUMember_label_en-US" xlink:label="lab_ehc_DividendEquivalentRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Equivalent, RSU [Member]</link:label>
    <link:label id="lab_ehc_DividendEquivalentRSUMember_documentation_en-US" xlink:label="lab_ehc_DividendEquivalentRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Equivalent, RSU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DividendEquivalentRSUMember" xlink:href="ehc-20211231.xsd#ehc_DividendEquivalentRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DividendEquivalentRSUMember" xlink:to="lab_ehc_DividendEquivalentRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AffiliatesOwnershipPercentage_f3d8e468-afe7-4702-bed1-cdda45adbb4e_terseLabel_en-US" xlink:label="lab_ehc_AffiliatesOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates ownership percentage</link:label>
    <link:label id="lab_ehc_AffiliatesOwnershipPercentage_label_en-US" xlink:label="lab_ehc_AffiliatesOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Ownership Percentage</link:label>
    <link:label id="lab_ehc_AffiliatesOwnershipPercentage_documentation_en-US" xlink:label="lab_ehc_AffiliatesOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of ownership by the Company in the investee accounted for under the equity or cost methods of accounting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliatesOwnershipPercentage" xlink:href="ehc-20211231.xsd#ehc_AffiliatesOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AffiliatesOwnershipPercentage" xlink:to="lab_ehc_AffiliatesOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1d7de90c-73c0-4965-8939-d6fdf0080749_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of restricted investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_4e98864f-d47a-4080-871f-81ad5f9f562e_terseLabel_en-US" xlink:label="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Income Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_label_en-US" xlink:label="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Noncontrolling Interests [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:href="ehc-20211231.xsd#ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:to="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_b970c49d-64b2-4bb3-94c2-913f232e118a_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_87f8deb5-da42-458c-8e1a-e18cdac902b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9f5f70d1-a06d-48f8-be9d-82c63937b6e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofBedsExpanded_04e7be6b-4ea4-4efa-9d4c-dd1798be8d9e_terseLabel_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds expanded</link:label>
    <link:label id="lab_ehc_NumberofBedsExpanded_label_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Expanded</link:label>
    <link:label id="lab_ehc_NumberofBedsExpanded_documentation_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Expanded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsExpanded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofBedsExpanded" xlink:to="lab_ehc_NumberofBedsExpanded" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_660d8243-7366-4589-b3df-a9fabfbd39a7_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2024</link:label>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_label_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2024 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes0575Due2024Member" xlink:to="lab_ehc_SeniorNotes0575Due2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0dddeb86-365d-4a9a-a851-afe740b8db8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum_ecbef23f-6292-4316-ada1-3bd55d510d5f_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured leverage ratio maximum</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Max senior secured leverage ratio to permit restricted payments under credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_3cb00eed-4cfc-4c82-8554-d7aa3f7f0d44_terseLabel_en-US" xlink:label="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale/leaseback transactions involving real estate accounted for as financings</link:label>
    <link:label id="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_label_en-US" xlink:label="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Real Estate Sale / Leaseback Financing [Member]</link:label>
    <link:label id="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_documentation_en-US" xlink:label="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Real Estate Sale / Leaseback Financing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:href="ehc-20211231.xsd#ehc_NotesPayableRealEstateSaleLeasebackFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:to="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d9a0dab0-37b6-471f-93c9-9586e96ef2b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserveNoncurrent_f53783af-c524-4756-88f4-0ba4067a9ced_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insured risks</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveNoncurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d944576-92c2-4c16-9af9-b07413d5b9db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2b4ad4e8-4a52-4b24-a913-fb3eccaeb923_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_782aa956-7ec4-45ce-8f55-dd2ec4075407_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_34c6c3e1-72d6-44d6-a776-511497212139_terseLabel_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation units under management contracts</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_label_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Units Under Management Contracts</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_documentation_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:href="ehc-20211231.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:to="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d44a25b5-ef12-44a5-ae40-6e5916ed3dc3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_040a7b1a-d296-4d9e-bd59-3c7f0eb0efdd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_e75c7b7b-5687-4529-92d4-77a5e32060c5_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_04990722-ec4d-465a-bb09-539a29100009_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_8b3eb806-3fdc-45f6-b33e-33007ae51b78_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_46dc2823-8ca5-4e31-b45a-4bda9ed3c073_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_a8e1b360-0153-4bbb-9f0e-7e931d15d820_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_9ab3a409-ab61-46dd-ad68-e0c7fa7cbcbd_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7bedcd5d-ee92-4d36-a2eb-6ba8f6a64678_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_e73b0751-aec2-46cd-8548-3764326f119a_totalLabel_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_label_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders</link:label>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_documentation_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:href="ehc-20211231.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:to="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_b4dd6db1-6bf2-4e55-b0b8-dabecad35d1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains or losses related to non-financial assets and liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_032be311-03ef-41a0-8ef5-84f40cd6c4ad_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_b9b4bbb7-141c-4be7-af93-ad6b5d2c5489_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts attributable to Encompass Health:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_883c125b-1ee5-4463-afc9-d6a33e132a4f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Totalleaseliabilities_dcc35fc6-52f1-4022-bade-d6b4fe865077_totalLabel_en-US" xlink:label="lab_ehc_Totalleaseliabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_ehc_Totalleaseliabilities_label_en-US" xlink:label="lab_ehc_Totalleaseliabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_ehc_Totalleaseliabilities_documentation_en-US" xlink:label="lab_ehc_Totalleaseliabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lessee's discounted obligation for lease payments from operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalleaseliabilities" xlink:href="ehc-20211231.xsd#ehc_Totalleaseliabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Totalleaseliabilities" xlink:to="lab_ehc_Totalleaseliabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_74bdf8ec-464a-4c74-9fdc-b28e7df082d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_b6b771e3-26b2-4589-bb57-c18de3016254_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HospiceOfSouthwestMontanaMember_ec33ce4b-4fb5-480e-a81e-1f7fc3b9a687_terseLabel_en-US" xlink:label="lab_ehc_HospiceOfSouthwestMontanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice of Southwest Montana</link:label>
    <link:label id="lab_ehc_HospiceOfSouthwestMontanaMember_label_en-US" xlink:label="lab_ehc_HospiceOfSouthwestMontanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice of Southwest Montana [Member]</link:label>
    <link:label id="lab_ehc_HospiceOfSouthwestMontanaMember_documentation_en-US" xlink:label="lab_ehc_HospiceOfSouthwestMontanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice of Southwest Montana</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceOfSouthwestMontanaMember" xlink:href="ehc-20211231.xsd#ehc_HospiceOfSouthwestMontanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HospiceOfSouthwestMontanaMember" xlink:to="lab_ehc_HospiceOfSouthwestMontanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_cb8b125e-9a7a-48fe-bede-4270613b79d7_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_62e7a55b-8bbb-4a69-93c5-781eab6607be_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c9a5be3-733a-427a-b2d3-a1637acfaf80_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_d800d929-f7dd-4fcc-bd4b-0111eb235a62_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_18337919-634b-44c2-8d49-b99409cfabcf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a2fffcdc-b0ee-4252-8bd1-290e14be25a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_29e55fae-f28e-4612-b115-0ccb6486f639_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_67255c09-514b-4a10-9ab4-77d7704f4011_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_afa429a6-e065-4a50-baff-bd26cf22b95b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4b788ff8-20f3-48fc-abf0-76d8464c553f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueAfterFifthYear_ea101ec2-e178-4f7c-bcab-dfa8d2ad3c4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_65572124-f8e1-439a-81b5-16a25a309e79_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_266bbaa7-d39d-4d16-8897-65dd50e17901_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7439d15b-7f8e-4ba4-a608-a15798cc1a39_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_0df98db1-0094-4e20-8ebe-9ee3a8e74b9d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_4710fa9e-7bc6-4cf1-95f0-e7b777099b63_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2d80ec2d-63a3-4e61-a883-4ee4e20d9a4d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt-related items</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_41d71590-f725-491f-a0e9-65a935419eca_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_68de6303-51bd-43e3-a59b-a3ef33359e8d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_1af65392-7c94-49bb-86dd-dcb30d086e5f_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments in and advances to nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_840bd9c5-d738-4ea7-81b4-433b0b425bae_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and advances to nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_e941ae77-b5c1-47fa-b32d-157b85ce9deb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortization Expense, Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_438a431a-340e-42f6-aa8b-a87f09c8f7d4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5a1abe3b-6d3f-41c1-8583-b28d318ff6bc_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3444c9ce-6653-4f2a-a685-89be7b8390ef_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7533cb61-e68c-4713-a3c9-d61de8b09909_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income attributable to Encompass Health</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_757b0ee2-25a8-4b8f-bd27-91deb27003b1_terseLabel_en-US" xlink:label="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction of a new hospital</link:label>
    <link:label id="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_label_en-US" xlink:label="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, LIBOR plus 2.5% Construction Financing [Member]</link:label>
    <link:label id="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_documentation_en-US" xlink:label="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, LIBOR plus 2.5% Construction Financing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:href="ehc-20211231.xsd#ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:to="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_b891f446-2a41-40fb-adac-0b5ae5df85f4_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_dc50f87e-82ee-4974-a167-7082af6f2a0e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_a0bc5779-150d-414a-be6b-2feef4395a37_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFourthYear_3a4265dc-a753-4371-bebf-8247a91bb442_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6d527f88-bf4d-4589-875f-d7511a58cc5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Holdings shares (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_e686a429-18f2-4e52-9ff8-9fa55cac0c8e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c3f513e8-d649-427a-9d41-de596c958527_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_007b22b0-62ef-4e30-8e2e-fe6c1744733f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c170cad7-66b6-41d1-aaf1-392e6aee2330_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_46419fd4-a79c-497c-8f1c-c10385f6936e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5297de4e-c737-4e7c-9f49-0eb350ee3dbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_f65054cf-2a02-4142-b411-fe15215cd8ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_9aa2d0e3-cddc-49de-8674-7d7eba6cc2d6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_12df0e3d-98c4-4b68-beee-8e79e7a18bfa_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_45cf27d3-6b8e-47eb-bdb7-0a602cda73b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_67defb4d-92ad-40d8-a754-1d24a8bb0a8e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2dc801e6-13a4-4b99-b496-17989f51b3c9_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9ff187e9-0b7e-48f7-9ead-187d23622f3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember_da2d5a72-5fa3-4703-ae75-1d54dfccb5a0_terseLabel_en-US" xlink:label="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Omnibus Performance Incentive Plan</link:label>
    <link:label id="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember_label_en-US" xlink:label="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Omnibus Performance Incentive Plan [Member]</link:label>
    <link:label id="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember_documentation_en-US" xlink:label="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Omnibus Performance Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:href="ehc-20211231.xsd#ehc_A2016OmnibusPerformanceIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:to="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6268c234-99e8-4b1a-9341-6126080ea47e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_8b38953a-a00a-4949-8862-eea778eb6c6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_4d23ab04-7518-4064-afc1-db410f255525_terseLabel_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation</link:label>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_a88150b4-9262-4b6e-8f53-29288f8bd1a5_verboseLabel_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation Segment</link:label>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_label_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation Segment [Member]</link:label>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_documentation_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InpatientRehabilitationSegmentMember" xlink:to="lab_ehc_InpatientRehabilitationSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c2c76d3c-aae7-4229-8b13-9fac6f51a56b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c5a15028-77ca-4259-a356-ebd7266a185c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c0c5363b-9be1-4091-a014-72ce2998ae33_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal or impairment of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrentAbstract_82fee0cb-1230-4d1b-9438-563e7307a483_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Net, Current</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_295836e3-afba-4dd6-bbd0-a839ec1a7f57_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_48d0a651-13d5-4814-962b-d6f86a0b47b4_terseLabel_en-US" xlink:label="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term and Discount Rate</link:label>
    <link:label id="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:href="ehc-20211231.xsd#ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:to="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_49a01ef8-f215-4a06-a310-86461e6eca3d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_242bc6a4-8b1b-4fc7-b716-adc05a4b96a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_1edffb20-8ef4-469e-9ca6-363ad8d78b3f_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract] [Abstract]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:to="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_9a4c27e1-b826-4637-941c-1d974808e011_terseLabel_en-US" xlink:label="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_label_en-US" xlink:label="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Six And Thereafter</link:label>
    <link:label id="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_documentation_en-US" xlink:label="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth fiscal year following latest fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:href="ehc-20211231.xsd#ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:to="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_b0ad7763-f0bd-4160-a524-2b95542bb991_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c9928f6f-d892-42aa-9a1a-eb0bdec2d20d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_6d656e01-daa3-4fce-8a95-f81716b739e2_negatedTerseLabel_en-US" xlink:label="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to discontinued operations</link:label>
    <link:label id="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_label_en-US" xlink:label="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations</link:label>
    <link:label id="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_documentation_en-US" xlink:label="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:href="ehc-20211231.xsd#ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:to="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_6ec8a8f3-f984-42e1-8ecc-2aa2b920340d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability_9aba283d-6cd1-48b5-82f0-f8d0fa92ba42_terseLabel_en-US" xlink:label="lab_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of annual aggregate losses associated with general and professional liability</link:label>
    <link:label id="lab_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability_label_en-US" xlink:label="lab_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insured Risk, Threshold, General And Professional Liability</link:label>
    <link:label id="lab_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability_documentation_en-US" xlink:label="lab_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insured Risk, Threshold, General And Professional Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability" xlink:href="ehc-20211231.xsd#ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability" xlink:to="lab_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c45216d2-31d9-444a-bbfb-ea0a36b32be5_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_037c4674-33bf-4a0e-a1f5-f825662778b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_780afa24-c7af-4784-a993-2a4541fce980_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_24e9ef34-4615-425f-a7b2-8e1822dc2d0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock in open market (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_dd8fe9c2-9ce0-4938-83b6-2ea51d734746_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_60b79809-6dd6-40ac-9749-2865e7dac25e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4ef44b96-2611-4443-b418-3b07c961f406_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_a4015a82-3c08-4e4d-ace0-96d010d17b28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, pro forma revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_46465572-df17-4db4-bb9c-64a07dc28db7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CareResourceGroupMember_c200fa31-c093-4c8e-9015-22109c6d1db4_terseLabel_en-US" xlink:label="lab_ehc_CareResourceGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Care Resource Group</link:label>
    <link:label id="lab_ehc_CareResourceGroupMember_label_en-US" xlink:label="lab_ehc_CareResourceGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Care Resource Group [Member]</link:label>
    <link:label id="lab_ehc_CareResourceGroupMember_documentation_en-US" xlink:label="lab_ehc_CareResourceGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Care Resource Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CareResourceGroupMember" xlink:href="ehc-20211231.xsd#ehc_CareResourceGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CareResourceGroupMember" xlink:to="lab_ehc_CareResourceGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6bc8d014-e6c2-4761-a9b2-e98d14bcf92b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_f824c123-2413-4938-953b-3ad2eea97306_totalLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and Capital lease obligations</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_0e6815d6-b9f8-4e64-8075-81d0820e37f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_1b5d2ce7-1fc8-422a-bbb7-fe247db93c05_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RACAuditsMember_5aa0d120-f58e-44ea-8c7b-c7b32af9be30_terseLabel_en-US" xlink:label="lab_ehc_RACAuditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RAC Audits</link:label>
    <link:label id="lab_ehc_RACAuditsMember_label_en-US" xlink:label="lab_ehc_RACAuditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RAC Audits [Member]</link:label>
    <link:label id="lab_ehc_RACAuditsMember_documentation_en-US" xlink:label="lab_ehc_RACAuditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS post-payment audit initiative of inpatient rehabilitation providers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RACAuditsMember" xlink:href="ehc-20211231.xsd#ehc_RACAuditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RACAuditsMember" xlink:to="lab_ehc_RACAuditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0e024399-c2dd-4891-ad4f-94ec6a862e87_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6aee6d2a-ffba-46ec-b645-7700ce63878a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, December 31, 2021</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_f204ea00-f2a9-45cb-9c78-bec3f4e02a94_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_7cbda821-5dc7-4876-9c77-757ffd2e8596_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_2397ee48-2bad-4c64-aa8c-b233cb92bf57_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt by Maturity</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Including Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_88f53247-a1b5-4f44-915f-57c744c6741d_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_553b9587-a46c-40da-bf44-484425398935_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_be1366e7-6165-4cec-92df-f156d5ac62e9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofBedsAcquired_cf4f9195-9a64-45ac-b736-095ccae5d932_terseLabel_en-US" xlink:label="lab_ehc_NumberofBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds acquired</link:label>
    <link:label id="lab_ehc_NumberofBedsAcquired_label_en-US" xlink:label="lab_ehc_NumberofBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Acquired</link:label>
    <link:label id="lab_ehc_NumberofBedsAcquired_documentation_en-US" xlink:label="lab_ehc_NumberofBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospital beds acquired as part of a facility acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsAcquired" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofBedsAcquired" xlink:to="lab_ehc_NumberofBedsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_39c3ec1a-29f7-42e2-bf8f-d76e7469e80f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_1cb85220-9cd6-4d64-9b27-44658069edf6_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_1ad6cefe-7a61-41d6-bf69-1b225949eb4b_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4d50a87b-79f5-47a3-82a4-3f42dec4bb07_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_99faa8b2-da19-4404-a533-4065d880905c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32e9d930-b1fd-43cd-8e26-db7d545ab892_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents. and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6655a5a2-dffa-43d2-9697-7a3aa528e25a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_YumaRehabilitationHospitalMember_127b5634-93a8-4fe6-b905-95668b02279d_terseLabel_en-US" xlink:label="lab_ehc_YumaRehabilitationHospitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yuma Rehabilitation Hospital</link:label>
    <link:label id="lab_ehc_YumaRehabilitationHospitalMember_label_en-US" xlink:label="lab_ehc_YumaRehabilitationHospitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yuma Rehabilitation Hospital [Member]</link:label>
    <link:label id="lab_ehc_YumaRehabilitationHospitalMember_documentation_en-US" xlink:label="lab_ehc_YumaRehabilitationHospitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yuma Rehabilitation Hospital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_YumaRehabilitationHospitalMember" xlink:href="ehc-20211231.xsd#ehc_YumaRehabilitationHospitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_YumaRehabilitationHospitalMember" xlink:to="lab_ehc_YumaRehabilitationHospitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_861e2c77-0733-4479-b2b1-9eb3f8345468_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0dd58d8d-9968-4106-98b2-558e00011d54_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bc24f3de-cc45-439b-8647-f6f321e6570f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b4a84f40-655d-4f27-90c8-69939ae45ae3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9751ca40-613a-400e-be97-60cde58a8c73_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b87ebeea-7136-4644-8069-438d763b5d0b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_62e0ffb3-b42e-4a6f-b0ba-916aad2c5b61_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives and Amortization Basis of Other Finite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8ae82bd9-c021-40a7-aa53-cf235e69c122_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_6143b90a-4d53-4da6-b513-fb930cf14b30_terseLabel_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_label_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Hospitals</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_documentation_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals" xlink:href="ehc-20211231.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfInpatientRehabilitationHospitals" xlink:to="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted_38e79223-02ad-453d-a4ee-756b562503cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Restricted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRestricted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_3155935b-60e6-4320-8360-2485198702b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_44d7e214-61ca-4fe1-b714-ea8f9fbbeeca_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b87ae931-e9f4-4c1b-91e0-5acf79783d03_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_06f4b57e-9b67-441a-9d2f-85f1d5d807b6_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_026dc870-ec54-41e0-9dad-9d80e0dc56c4_negatedTerseLabel_en-US" xlink:label="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="ehc-20211231.xsd#ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6bb562bf-0a24-49f3-8184-e23ccb8aadc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorManagementBonusProgramTotalCosts_a26a3068-8ae9-4e8d-ae14-efe09d0e9fd1_terseLabel_en-US" xlink:label="lab_ehc_SeniorManagementBonusProgramTotalCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments under the Senior Management Bonus Program</link:label>
    <link:label id="lab_ehc_SeniorManagementBonusProgramTotalCosts_label_en-US" xlink:label="lab_ehc_SeniorManagementBonusProgramTotalCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Management Bonus Program, Total Costs</link:label>
    <link:label id="lab_ehc_SeniorManagementBonusProgramTotalCosts_documentation_en-US" xlink:label="lab_ehc_SeniorManagementBonusProgramTotalCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of payments made or expected to be made during a reporting period to participants that are entitled under the Senior Management Bonus Program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorManagementBonusProgramTotalCosts" xlink:href="ehc-20211231.xsd#ehc_SeniorManagementBonusProgramTotalCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorManagementBonusProgramTotalCosts" xlink:to="lab_ehc_SeniorManagementBonusProgramTotalCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_a026d266-38d3-4576-9892-33560f73004e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_f7a90081-7b53-4438-9a15-b011c2463c83_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_FaceAmountMember_04c58338-6406-4107-9a40-72bd74fc8dad_terseLabel_en-US" xlink:label="lab_ehc_FaceAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face Amount</link:label>
    <link:label id="lab_ehc_FaceAmountMember_label_en-US" xlink:label="lab_ehc_FaceAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face Amount [Member]</link:label>
    <link:label id="lab_ehc_FaceAmountMember_documentation_en-US" xlink:label="lab_ehc_FaceAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FaceAmountMember" xlink:href="ehc-20211231.xsd#ehc_FaceAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_FaceAmountMember" xlink:to="lab_ehc_FaceAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_8437c1e4-bbd8-4948-9b6e-7f61f19abd31_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_a6d73e88-3850-4055-b8fb-849ad0e587d5_terseLabel_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_label_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:to="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_ead29098-bb02-4148-a204-a531102a897e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_76fb62ed-fd4f-4598-85ae-428539a100c7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_15f48e25-96e4-494b-bff5-0d1682868232_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Four</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_b7139a9b-e5f2-4999-97e9-851f98571654_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_54741c64-3061-4de0-8eee-c5b9955478d7_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f936ddf-cc69-441a-924f-a6e43326153c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_28c26315-3eee-4d94-bb96-7e494d2b2b74_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d6b379c2-f900-41e6-8a27-00e77828a172_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_56b77f5a-cbf7-4eca-95dc-e03ca232936e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_318bddc6-c1e7-42b6-9cdd-4275b440fb57_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of equity interest prior to acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_9997f91f-de4d-420a-b7c4-8e1ed1118fc8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f2d21b89-f879-4d7d-b839-25e30f845165_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_faf5fd87-4a25-4173-8497-e838bcb4f6c9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_a1ef92a2-e7bb-4590-8c78-8fa53f75250e_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments:</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Financial Statement, Reported Amounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_2f45246a-40f9-47e4-952b-d554e882470c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_0d5dc1f0-10dd-4ef7-a1b3-c393626b44a2_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RestrictedDebtSecuritiesNoncurrent_f8aedfba-3b2c-4ced-938b-4bbf315a8dba_terseLabel_en-US" xlink:label="lab_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted marketable securities</link:label>
    <link:label id="lab_ehc_RestrictedDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Debt Securities, Noncurrent</link:label>
    <link:label id="lab_ehc_RestrictedDebtSecuritiesNoncurrent_documentation_en-US" xlink:label="lab_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for greater than one year or the normal operating cycle, whichever is longer and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:href="ehc-20211231.xsd#ehc_RestrictedDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:to="lab_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7f76a1ea-9150-4b0a-938a-e8f7e1970bc0_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Nonconsolidated Affiliates</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1806e814-75c3-45a7-aeac-1f8caf68eb35_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_eb3e2735-6145-4468-a778-d4f6520ad747_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_14dc998e-c591-497e-93bb-97eee45c5f87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_1786368f-2031-4314-a84c-10c28121073a_terseLabel_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to issued to the management investors pursuant to the exchange agreements represents (in percent)</link:label>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_label_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</link:label>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_documentation_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:href="ehc-20211231.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:to="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TheCreditAgreementMember_4132be59-5092-4fe1-905d-5a69254ad5c4_terseLabel_en-US" xlink:label="lab_ehc_TheCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Agreement</link:label>
    <link:label id="lab_ehc_TheCreditAgreementMember_label_en-US" xlink:label="lab_ehc_TheCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Agreement [Member]</link:label>
    <link:label id="lab_ehc_TheCreditAgreementMember_documentation_en-US" xlink:label="lab_ehc_TheCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TheCreditAgreementMember" xlink:href="ehc-20211231.xsd#ehc_TheCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TheCreditAgreementMember" xlink:to="lab_ehc_TheCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInThirdYear_8074d374-d962-4bed-978e-effd0269d26b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:to="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_9f189dde-4dec-45cd-9f16-71449c1c06a9_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_dc3bcb5c-32f3-49ea-82fd-dc0c1fa0a265_terseLabel_en-US" xlink:label="lab_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value threshold for determining fair value of common stock</link:label>
    <link:label id="lab_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_label_en-US" xlink:label="lab_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</link:label>
    <link:label id="lab_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_documentation_en-US" xlink:label="lab_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:href="ehc-20211231.xsd#ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:to="lab_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_41de828c-7b94-4650-b264-7bd6f5d6c2b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to capitalized software costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EncompassHealthRetirementInvestmentPlanMember_e1516ebe-9649-4e87-9eed-13f24798a3cc_terseLabel_en-US" xlink:label="lab_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health Retirement Investment Plan</link:label>
    <link:label id="lab_ehc_EncompassHealthRetirementInvestmentPlanMember_label_en-US" xlink:label="lab_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health Retirement Investment Plan [Member]</link:label>
    <link:label id="lab_ehc_EncompassHealthRetirementInvestmentPlanMember_documentation_en-US" xlink:label="lab_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health Retirement Investment Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:href="ehc-20211231.xsd#ehc_EncompassHealthRetirementInvestmentPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:to="lab_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_293d6f35-0e54-47fc-b1a0-864020bf78d1_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Nonconsolidated Affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates, Schedule of Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_0a009dc7-476c-4aad-9318-1e6513c6b6df_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equity interests in consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Distributions to Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_bf36f8bb-6408-4764-915a-a2fb25f1dd60_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redeemed</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f950358-41ee-4c69-9d0c-0aeab99ac6a6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_31ef7c1b-8be5-41e4-a601-94285ad466c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Jointventureownershippercentage_07aeada8-8974-4d4a-90a6-b1949f21b3a3_terseLabel_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_ehc_Jointventureownershippercentage_label_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_ehc_Jointventureownershippercentage_documentation_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage" xlink:href="ehc-20211231.xsd#ehc_Jointventureownershippercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Jointventureownershippercentage" xlink:to="lab_ehc_Jointventureownershippercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_54cc4d12-3802-4358-ba41-d50d5b15875d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c4f46eac-b0ca-49da-8406-4923a73054d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_24fe1810-8af8-4258-9ab5-69156a0a22c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to current year claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa73421e-1b1a-4f4c-b752-f0973b44a755_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities&#8212;</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>ehc-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8fa73796-4641-417c-869a-a8efa97ec0d7,g:d7a996dc-3cad-46ef-bbb1-393716adc0de-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CoverPage" xlink:type="simple" xlink:href="ehc-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ea9dd344-a7d6-4d70-90c8-e57446b64361" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_DocumentType_ea9dd344-a7d6-4d70-90c8-e57446b64361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_fcbdd782-98cc-4bd2-bbc4-c263a202c912" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_DocumentAnnualReport_fcbdd782-98cc-4bd2-bbc4-c263a202c912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fd406547-7082-49a9-ad53-ebef92b6346b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_DocumentPeriodEndDate_fd406547-7082-49a9-ad53-ebef92b6346b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fe5e3bf3-77ea-4e5c-b309-d05501b92bf3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_CurrentFiscalYearEndDate_fe5e3bf3-77ea-4e5c-b309-d05501b92bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7e1664bc-91a8-4bdb-bd96-5fadad328349" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_DocumentTransitionReport_7e1664bc-91a8-4bdb-bd96-5fadad328349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d267e168-019b-4dd8-8443-58f8bb7160d5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityFileNumber_d267e168-019b-4dd8-8443-58f8bb7160d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1f775205-3ccd-42a5-977c-df02bd437e69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityRegistrantName_1f775205-3ccd-42a5-977c-df02bd437e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bef0877e-39f4-43b9-a25f-afa753f1decf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bef0877e-39f4-43b9-a25f-afa753f1decf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_09830aef-a3c1-4564-ba4d-814bfc98b399" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityTaxIdentificationNumber_09830aef-a3c1-4564-ba4d-814bfc98b399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9290cf97-8ea6-45b8-99d7-98b18f9c2b51" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityAddressAddressLine1_9290cf97-8ea6-45b8-99d7-98b18f9c2b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7e7e3376-e2bf-4d85-8b7e-779b31bfd170" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityAddressCityOrTown_7e7e3376-e2bf-4d85-8b7e-779b31bfd170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_07f02a6f-dc8b-4fe0-a468-fd77375f76ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityAddressStateOrProvince_07f02a6f-dc8b-4fe0-a468-fd77375f76ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_98ab4d8f-6838-4d47-b393-a48238aaa58a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityAddressPostalZipCode_98ab4d8f-6838-4d47-b393-a48238aaa58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_026931ee-b12d-4b44-8406-1b45a1a61c59" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_CityAreaCode_026931ee-b12d-4b44-8406-1b45a1a61c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2e15db1f-b2f0-4c02-86aa-d15aa0020224" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_LocalPhoneNumber_2e15db1f-b2f0-4c02-86aa-d15aa0020224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b3028022-b8aa-4b16-a507-011cb04e9d02" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_Security12bTitle_b3028022-b8aa-4b16-a507-011cb04e9d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_72099339-5eaf-4a59-9ee8-db87f0090b03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_TradingSymbol_72099339-5eaf-4a59-9ee8-db87f0090b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_aae1a79e-4384-401a-b29e-871962bb07f8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_SecurityExchangeName_aae1a79e-4384-401a-b29e-871962bb07f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6c262418-1d36-4aec-a058-c1a25565152d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6c262418-1d36-4aec-a058-c1a25565152d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_29c1e047-f533-4c3b-8021-01b33e5cd27e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityVoluntaryFilers_29c1e047-f533-4c3b-8021-01b33e5cd27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_04aba268-8f43-4207-abeb-951356db7f2a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityCurrentReportingStatus_04aba268-8f43-4207-abeb-951356db7f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d3bddae5-fc8f-4485-a7c6-bd04b80ee48a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityInteractiveDataCurrent_d3bddae5-fc8f-4485-a7c6-bd04b80ee48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_89ec02dc-f296-43db-8429-0a3fd64a752d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityFilerCategory_89ec02dc-f296-43db-8429-0a3fd64a752d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_459989c8-d27c-40b5-908e-d3896aa5502e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityEmergingGrowthCompany_459989c8-d27c-40b5-908e-d3896aa5502e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_46b31c43-b67a-49d6-a082-d6f590135435" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntitySmallBusiness_46b31c43-b67a-49d6-a082-d6f590135435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1cb5ed60-fa8b-46a3-8883-b7737a2d18c9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityShellCompany_1cb5ed60-fa8b-46a3-8883-b7737a2d18c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_19f6d744-bc67-40ca-b5bf-b2a4d9d3b00f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_IcfrAuditorAttestationFlag_19f6d744-bc67-40ca-b5bf-b2a4d9d3b00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_227f0f03-5660-44b2-ad39-60556038afae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityPublicFloat_227f0f03-5660-44b2-ad39-60556038afae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_44c26794-1fbd-4e8c-a287-a0d062b3d8f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_44c26794-1fbd-4e8c-a287-a0d062b3d8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f53eba5f-cd51-4f5b-a8a4-d13ad56cd7fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f53eba5f-cd51-4f5b-a8a4-d13ad56cd7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3b4de8bc-0859-42da-90ba-56a178faf951" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_EntityCentralIndexKey_3b4de8bc-0859-42da-90ba-56a178faf951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_10ee8d51-3fd7-441d-bc46-cd309aef8ef8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_DocumentFiscalYearFocus_10ee8d51-3fd7-441d-bc46-cd309aef8ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7be0e794-7441-437e-9765-06f6dbc22e4f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7be0e794-7441-437e-9765-06f6dbc22e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2098858e-9407-4f92-94d1-daa4901c3991" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d3170fb6-c490-4623-83a7-0008214c8796" xlink:to="loc_dei_AmendmentFlag_2098858e-9407-4f92-94d1-daa4901c3991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AuditInformation" xlink:type="simple" xlink:href="ehc-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AuditInformationAbstract_d32a7f59-e919-479d-99d6-cea95f7699f1" xlink:href="ehc-20211231.xsd#ehc_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_fe0fa14a-e10b-4580-a9dc-fdc50162d31f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_AuditInformationAbstract_d32a7f59-e919-479d-99d6-cea95f7699f1" xlink:to="loc_dei_AuditorFirmId_fe0fa14a-e10b-4580-a9dc-fdc50162d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_726a8ed2-7f07-438d-9f6c-7f2130e7bbc7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_AuditInformationAbstract_d32a7f59-e919-479d-99d6-cea95f7699f1" xlink:to="loc_dei_AuditorName_726a8ed2-7f07-438d-9f6c-7f2130e7bbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_e49b4c92-355f-4b4d-a8c6-669e89722688" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_AuditInformationAbstract_d32a7f59-e919-479d-99d6-cea95f7699f1" xlink:to="loc_dei_AuditorLocation_e49b4c92-355f-4b4d-a8c6-669e89722688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:href="ehc-20211231.xsd#ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1015038f-5d7b-4430-8e2a-21c15955e3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1015038f-5d7b-4430-8e2a-21c15955e3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_2e6c241a-0d3a-4865-8e05-276fe1feb160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:to="loc_us-gaap_LaborAndRelatedExpense_2e6c241a-0d3a-4865-8e05-276fe1feb160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_5c1d2c70-c9fc-4b7e-ab21-c98fc6f7ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_5c1d2c70-c9fc-4b7e-ab21-c98fc6f7ca02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_2aaaaac6-f14b-4dec-9494-f18b6fb59a46" xlink:href="ehc-20211231.xsd#ehc_OccupancyCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:to="loc_ehc_OccupancyCost_2aaaaac6-f14b-4dec-9494-f18b6fb59a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_8f5ab090-efd9-421e-a9a4-f56fcb3079d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:to="loc_us-gaap_SuppliesExpense_8f5ab090-efd9-421e-a9a4-f56fcb3079d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_50aecdf9-078b-46c3-a793-e53543913f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_50aecdf9-078b-46c3-a793-e53543913f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_703918a8-c1a7-4f90-90fc-396dee5bc0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_703918a8-c1a7-4f90-90fc-396dee5bc0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_96083e1d-d240-46d4-a86a-113480a52f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:to="loc_us-gaap_LitigationSettlementExpense_96083e1d-d240-46d4-a86a-113480a52f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_24d1ef31-b24b-45f5-a078-22561ebb0421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_080cbf4e-e85f-4ce3-a7cf-65d3279e5ad9" xlink:to="loc_us-gaap_CostsAndExpenses_24d1ef31-b24b-45f5-a078-22561ebb0421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_07c363fa-1f6c-475e-8b3c-3472866119a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_07c363fa-1f6c-475e-8b3c-3472866119a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f7742324-0884-4eb4-8d89-d0614c0d8d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_InterestExpense_f7742324-0884-4eb4-8d89-d0614c0d8d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a45c0e0d-718f-477d-80e4-d728d3d5b224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a45c0e0d-718f-477d-80e4-d728d3d5b224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e6a98533-b705-4277-abf8-7caaeab2ed65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e6a98533-b705-4277-abf8-7caaeab2ed65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f0d6251-6365-4e92-a24c-51e0aa2c0e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f0d6251-6365-4e92-a24c-51e0aa2c0e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bb154964-ecb6-4002-9e08-e1085dd4d704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bb154964-ecb6-4002-9e08-e1085dd4d704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b1145d17-f50e-410d-925f-0a27b2772b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b1145d17-f50e-410d-925f-0a27b2772b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4bc3baef-59b7-42cd-a35d-f9546f83cbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4bc3baef-59b7-42cd-a35d-f9546f83cbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cd69c9d2-207c-48f8-8c60-07b85b56096a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_ProfitLoss_cd69c9d2-207c-48f8-8c60-07b85b56096a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_de1ba2df-828f-4934-86a5-28703d197e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_de1ba2df-828f-4934-86a5-28703d197e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0710fd45-a654-4c58-9b44-03a61dadaebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0710fd45-a654-4c58-9b44-03a61dadaebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_04c9d246-dd48-43ca-a9f9-a39ea0c5afa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_04c9d246-dd48-43ca-a9f9-a39ea0c5afa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee7f1291-f70e-4e9f-9322-29e3e846e2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_NetIncomeLoss_ee7f1291-f70e-4e9f-9322-29e3e846e2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_476809a7-83cf-4952-ae3e-67f79aebb9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_476809a7-83cf-4952-ae3e-67f79aebb9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cc46de3d-2df4-4d6b-9371-3dbba3df71a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cc46de3d-2df4-4d6b-9371-3dbba3df71a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5ead915-42a3-4e1c-89b9-e507a1c15f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cc46de3d-2df4-4d6b-9371-3dbba3df71a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5ead915-42a3-4e1c-89b9-e507a1c15f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1546c815-5089-4963-904b-d982ca5baaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cc46de3d-2df4-4d6b-9371-3dbba3df71a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1546c815-5089-4963-904b-d982ca5baaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_194325ec-b22e-4c1f-8c93-c5eddcc4137c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_a059627a-f028-4d6d-8bbd-b5038f924104" xlink:to="loc_us-gaap_EarningsPerShareAbstract_194325ec-b22e-4c1f-8c93-c5eddcc4137c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_22a58e0d-7f42-474c-a4ff-6a3b84b51c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_194325ec-b22e-4c1f-8c93-c5eddcc4137c" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_22a58e0d-7f42-474c-a4ff-6a3b84b51c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c76acd99-bc81-4261-ab0b-132618a36a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_22a58e0d-7f42-474c-a4ff-6a3b84b51c9e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c76acd99-bc81-4261-ab0b-132618a36a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_601e9b0b-3426-4b67-b931-7c0cf553c5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_22a58e0d-7f42-474c-a4ff-6a3b84b51c9e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_601e9b0b-3426-4b67-b931-7c0cf553c5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_492323d2-8109-4aeb-9a06-00c2a1434026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_22a58e0d-7f42-474c-a4ff-6a3b84b51c9e" xlink:to="loc_us-gaap_EarningsPerShareBasic_492323d2-8109-4aeb-9a06-00c2a1434026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_4be1a253-96e6-4133-86a2-ba07b6f9b71b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_194325ec-b22e-4c1f-8c93-c5eddcc4137c" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_4be1a253-96e6-4133-86a2-ba07b6f9b71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_58a59f5d-dd47-41e8-967b-3afe1b546971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4be1a253-96e6-4133-86a2-ba07b6f9b71b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_58a59f5d-dd47-41e8-967b-3afe1b546971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_401a6e32-bf8c-45cb-9aa6-750cd826bc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4be1a253-96e6-4133-86a2-ba07b6f9b71b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_401a6e32-bf8c-45cb-9aa6-750cd826bc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8e2e8da4-cc7e-4fd1-9f15-a06a317518d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4be1a253-96e6-4133-86a2-ba07b6f9b71b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8e2e8da4-cc7e-4fd1-9f15-a06a317518d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_44fbf5e6-4b18-4000-8253-509198539ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_194325ec-b22e-4c1f-8c93-c5eddcc4137c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_44fbf5e6-4b18-4000-8253-509198539ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_c453b73a-2f85-48b0-945a-0000b73dc3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_44fbf5e6-4b18-4000-8253-509198539ca1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_c453b73a-2f85-48b0-945a-0000b73dc3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9ec772ec-4de2-4a16-9243-577d2f61d09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_44fbf5e6-4b18-4000-8253-509198539ca1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9ec772ec-4de2-4a16-9243-577d2f61d09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c6c1fd8a-c2e6-4945-acad-a37e719a85d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_44fbf5e6-4b18-4000-8253-509198539ca1" xlink:to="loc_us-gaap_NetIncomeLoss_c6c1fd8a-c2e6-4945-acad-a37e719a85d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome_1"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6a8aab-179f-4bb9-b51e-b98b75e62e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6a8aab-179f-4bb9-b51e-b98b75e62e4a" xlink:to="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_398fb718-88b6-4dd0-bf0d-157b8d582f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:to="loc_us-gaap_AssetsCurrentAbstract_398fb718-88b6-4dd0-bf0d-157b8d582f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67177d2e-0be5-4c38-bc0a-fbb70a91d4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_398fb718-88b6-4dd0-bf0d-157b8d582f3a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67177d2e-0be5-4c38-bc0a-fbb70a91d4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ef8db347-3fe3-4544-8aff-7a5e7aadc584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_398fb718-88b6-4dd0-bf0d-157b8d582f3a" xlink:to="loc_us-gaap_RestrictedCashCurrent_ef8db347-3fe3-4544-8aff-7a5e7aadc584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_56e70b8c-ce1b-4ba8-91ed-9743e232bb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_398fb718-88b6-4dd0-bf0d-157b8d582f3a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_56e70b8c-ce1b-4ba8-91ed-9743e232bb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_99489d8b-99d8-480e-b9e3-d825393c4876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_398fb718-88b6-4dd0-bf0d-157b8d582f3a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_99489d8b-99d8-480e-b9e3-d825393c4876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5f2cb42f-c922-466d-bd22-b08e8b83fba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_398fb718-88b6-4dd0-bf0d-157b8d582f3a" xlink:to="loc_us-gaap_AssetsCurrent_5f2cb42f-c922-466d-bd22-b08e8b83fba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5ffc41f5-7f9d-4ca6-91ee-1b26aa8d860a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5ffc41f5-7f9d-4ca6-91ee-1b26aa8d860a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7af77607-868e-47f5-990e-80cc9dc2cfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7af77607-868e-47f5-990e-80cc9dc2cfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5fd0c7c7-f0e8-441c-b464-64652f5dc662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:to="loc_us-gaap_Goodwill_5fd0c7c7-f0e8-441c-b464-64652f5dc662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_11bce1ef-8cbe-4599-8397-6676ac345fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_11bce1ef-8cbe-4599-8397-6676ac345fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2895857c-99ac-4636-9d8c-d0c22ad3febf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2895857c-99ac-4636-9d8c-d0c22ad3febf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4ac039e3-5e20-4e40-9f53-c418ebd97b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d5cf6e93-f061-43e6-977e-78f81749ac76" xlink:to="loc_us-gaap_Assets_4ac039e3-5e20-4e40-9f53-c418ebd97b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6a8aab-179f-4bb9-b51e-b98b75e62e4a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e7de669c-d873-4b41-bf24-cb1dd11d582e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e7de669c-d873-4b41-bf24-cb1dd11d582e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2b062ffb-66f0-4a25-9ed5-6b176d680a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2b062ffb-66f0-4a25-9ed5-6b176d680a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_75761b41-ef0b-4448-a8a4-67b857cfbd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:to="loc_us-gaap_AccountsPayableCurrent_75761b41-ef0b-4448-a8a4-67b857cfbd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e06f2381-87c5-49ce-bc18-ef03fc9e6b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e06f2381-87c5-49ce-bc18-ef03fc9e6b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_dd7c8103-5adc-464c-9b0a-318df228e94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:to="loc_us-gaap_InterestPayableCurrent_dd7c8103-5adc-464c-9b0a-318df228e94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c138a1a8-c6cb-4406-b8e2-708715bc71f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c138a1a8-c6cb-4406-b8e2-708715bc71f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b6f30884-2c98-402c-ae15-f8eb83a912ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d97bc8ed-5e27-493c-8810-102e4958dc4d" xlink:to="loc_us-gaap_LiabilitiesCurrent_b6f30884-2c98-402c-ae15-f8eb83a912ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5cb707f7-9acb-4f9f-8a11-b77f5ebcdcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5cb707f7-9acb-4f9f-8a11-b77f5ebcdcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b88a9342-e40d-407d-8e2c-d7a264056094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b88a9342-e40d-407d-8e2c-d7a264056094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent_3cbdf0e5-e671-4bb5-8d1c-ca18f8994959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_SelfInsuranceReserveNoncurrent_3cbdf0e5-e671-4bb5-8d1c-ca18f8994959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_22ccf102-f921-4fb4-b7f3-f1a1d78d2f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_22ccf102-f921-4fb4-b7f3-f1a1d78d2f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c1af1aa4-dcce-49b9-8557-c9ba1ae4b011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c1af1aa4-dcce-49b9-8557-c9ba1ae4b011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f23dddcd-0a4e-4a7a-b460-6a21521d104d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_Liabilities_f23dddcd-0a4e-4a7a-b460-6a21521d104d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9ce3be09-a641-4a57-a0c0-23264dbe27c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9ce3be09-a641-4a57-a0c0-23264dbe27c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2227bfdf-e606-4c90-8844-d413eccb40e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2227bfdf-e606-4c90-8844-d413eccb40e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9c4b5488-c15c-44a0-8c7b-c937aa611d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9c4b5488-c15c-44a0-8c7b-c937aa611d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_25acf691-b683-4f84-99b8-95692a9c6dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9c4b5488-c15c-44a0-8c7b-c937aa611d1e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_25acf691-b683-4f84-99b8-95692a9c6dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7af8e2b3-43b5-4695-9096-c687437734a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25acf691-b683-4f84-99b8-95692a9c6dbf" xlink:to="loc_us-gaap_CommonStockValue_7af8e2b3-43b5-4695-9096-c687437734a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_00ba5e04-6983-4a5c-8984-09c71bd0f120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25acf691-b683-4f84-99b8-95692a9c6dbf" xlink:to="loc_us-gaap_AdditionalPaidInCapital_00ba5e04-6983-4a5c-8984-09c71bd0f120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a46d15e-b469-49e2-a4ce-a2058580dd65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25acf691-b683-4f84-99b8-95692a9c6dbf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a46d15e-b469-49e2-a4ce-a2058580dd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_cee054a4-7562-465b-8a50-a89e8346a37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25acf691-b683-4f84-99b8-95692a9c6dbf" xlink:to="loc_us-gaap_TreasuryStockValue_cee054a4-7562-465b-8a50-a89e8346a37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5d544d19-e088-4a8a-804c-b61047440214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25acf691-b683-4f84-99b8-95692a9c6dbf" xlink:to="loc_us-gaap_StockholdersEquity_5d544d19-e088-4a8a-804c-b61047440214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_83a81849-dbff-4a6e-801a-0c64ae678c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9c4b5488-c15c-44a0-8c7b-c937aa611d1e" xlink:to="loc_us-gaap_MinorityInterest_83a81849-dbff-4a6e-801a-0c64ae678c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_947397be-eea9-4b61-b20e-d257ace57e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9c4b5488-c15c-44a0-8c7b-c937aa611d1e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_947397be-eea9-4b61-b20e-d257ace57e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c40d3423-13b3-4942-abc6-62f96d7d7451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e58f85b-1c79-4d5c-b34d-4a966988e9cf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c40d3423-13b3-4942-abc6-62f96d7d7451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_28403e71-3ad1-4353-ae68-190e66ab25ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8410d70a-6d0f-4464-9e2d-3ffa33517416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28403e71-3ad1-4353-ae68-190e66ab25ae" xlink:to="loc_us-gaap_StatementTable_8410d70a-6d0f-4464-9e2d-3ffa33517416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7659a530-af43-4656-969d-42813de3a99c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8410d70a-6d0f-4464-9e2d-3ffa33517416" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7659a530-af43-4656-969d-42813de3a99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_28ecd91c-f4e1-4916-bf8d-92b8495660b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7659a530-af43-4656-969d-42813de3a99c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_28ecd91c-f4e1-4916-bf8d-92b8495660b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5bc54e98-6986-47c2-beef-39ce38bea3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_28ecd91c-f4e1-4916-bf8d-92b8495660b0" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5bc54e98-6986-47c2-beef-39ce38bea3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8410d70a-6d0f-4464-9e2d-3ffa33517416" xlink:to="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8054abda-6f22-4c55-861d-cc996e9e419a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8054abda-6f22-4c55-861d-cc996e9e419a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6b7bef3c-bd76-4a00-98b1-81d7e0414e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6b7bef3c-bd76-4a00-98b1-81d7e0414e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6d700cf6-d912-467d-a0dd-14c3f0eda3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_CommonStockSharesIssued_6d700cf6-d912-467d-a0dd-14c3f0eda3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_6f15d3fa-249e-4bc7-aa93-f79eb771dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_TreasuryStockShares_6f15d3fa-249e-4bc7-aa93-f79eb771dcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9c314cf2-3ff5-4fdc-b159-a4c2df3516b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_Assets_9c314cf2-3ff5-4fdc-b159-a4c2df3516b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d8fdad1d-4291-4315-9cef-7810fbd863ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_354d1ab1-723e-4705-a844-0bf2a68cef58" xlink:to="loc_us-gaap_Liabilities_d8fdad1d-4291-4315-9cef-7810fbd863ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dfed7945-a896-41a4-ba1d-12edd335364a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5ca3a7e6-91fb-4411-876a-dcf4d1f64b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dfed7945-a896-41a4-ba1d-12edd335364a" xlink:to="loc_us-gaap_StatementTable_5ca3a7e6-91fb-4411-876a-dcf4d1f64b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dee8630d-2045-4803-b26c-87f3748a177c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5ca3a7e6-91fb-4411-876a-dcf4d1f64b6e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dee8630d-2045-4803-b26c-87f3748a177c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dee8630d-2045-4803-b26c-87f3748a177c" xlink:to="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_73337af5-992f-46ec-8e16-006f35386ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_CommonStockMember_73337af5-992f-46ec-8e16-006f35386ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eefbc82c-6090-4dbd-8534-d30bbc380c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eefbc82c-6090-4dbd-8534-d30bbc380c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_66810e45-7162-43f0-93d6-8a7c35ad5218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_RetainedEarningsMember_66810e45-7162-43f0-93d6-8a7c35ad5218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_abcd12f5-5573-4de2-8b9b-d46c304911ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_TreasuryStockMember_abcd12f5-5573-4de2-8b9b-d46c304911ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9f19b34f-fa77-481e-b16e-12776908bbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5394ade2-6800-47f0-8cca-8b014f9ae169" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9f19b34f-fa77-481e-b16e-12776908bbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f22335d6-0c1d-4ab4-99be-0c998384d803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5ca3a7e6-91fb-4411-876a-dcf4d1f64b6e" xlink:to="loc_us-gaap_StatementLineItems_f22335d6-0c1d-4ab4-99be-0c998384d803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f22335d6-0c1d-4ab4-99be-0c998384d803" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3b9b5812-632e-4acb-bbb5-c5b19e76a100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3b9b5812-632e-4acb-bbb5-c5b19e76a100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b58db187-346c-4cf0-89bb-9ac03d83daa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b58db187-346c-4cf0-89bb-9ac03d83daa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_9fcb6c4e-253d-47c9-88c5-f6ba983922cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_9fcb6c4e-253d-47c9-88c5-f6ba983922cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_0eee056a-e45e-4859-a961-b35ee4811fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_0eee056a-e45e-4859-a961-b35ee4811fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_fae78720-cf80-4d23-b547-49f47679fe00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_fae78720-cf80-4d23-b547-49f47679fe00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_723dc4b8-1332-448f-9cd7-00df350091d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_DividendsCommonStockCash_723dc4b8-1332-448f-9cd7-00df350091d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8955292d-1d52-420a-84bf-875c235b3228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8955292d-1d52-420a-84bf-875c235b3228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f655d700-0320-45ef-af09-18ec345bee39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f655d700-0320-45ef-af09-18ec345bee39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f73a4250-6355-4363-9b60-bed8eff11dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f73a4250-6355-4363-9b60-bed8eff11dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_39cc5cda-1751-4c6d-916d-5db22fad6de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_39cc5cda-1751-4c6d-916d-5db22fad6de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_076c17ac-b7be-46e3-aa84-17f5bc47edbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_076c17ac-b7be-46e3-aa84-17f5bc47edbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_04f79b36-7011-452b-bde5-7dd2db6989a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_04f79b36-7011-452b-bde5-7dd2db6989a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_da41bc8b-d889-40e3-b935-edc4493ffa05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_da41bc8b-d889-40e3-b935-edc4493ffa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_863d4597-e82b-4986-926b-71f0b852eba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_863d4597-e82b-4986-926b-71f0b852eba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_71fa12f3-38fd-4c1c-b777-1cedaab2858e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_71fa12f3-38fd-4c1c-b777-1cedaab2858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d9f117c1-4f2f-477d-8a36-f5a666fabe51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d9f117c1-4f2f-477d-8a36-f5a666fabe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_2f98e876-8bf4-49e2-8de9-20db04cd1eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_2f98e876-8bf4-49e2-8de9-20db04cd1eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_02be6c9f-2a2d-42c7-8c3c-9569ee9b9314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_02be6c9f-2a2d-42c7-8c3c-9569ee9b9314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_36a516d5-110a-4381-939d-4bd239598649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockholdersEquityOther_36a516d5-110a-4381-939d-4bd239598649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a606b04b-a7b7-412c-bef9-22c9575ee1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a606b04b-a7b7-412c-bef9-22c9575ee1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74387623-f763-4692-ba31-b9400e2e193e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3cfa0317-3890-4041-9fbd-fdf969d7c26d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74387623-f763-4692-ba31-b9400e2e193e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_117c747e-a49f-43dc-afd8-1117a79fc85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_b6e16f14-209c-4a2f-ac58-e64253e995d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_117c747e-a49f-43dc-afd8-1117a79fc85b" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_b6e16f14-209c-4a2f-ac58-e64253e995d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ehc-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0959b2b0-ce7d-43f6-bb92-052ecc74e47f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0959b2b0-ce7d-43f6-bb92-052ecc74e47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a4dbe434-6047-49a2-a98f-20b759eb875b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0959b2b0-ce7d-43f6-bb92-052ecc74e47f" xlink:to="loc_us-gaap_ProfitLoss_a4dbe434-6047-49a2-a98f-20b759eb875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d9182c97-4cd2-4ac7-8a86-e87c38afc9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0959b2b0-ce7d-43f6-bb92-052ecc74e47f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d9182c97-4cd2-4ac7-8a86-e87c38afc9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0959b2b0-ce7d-43f6-bb92-052ecc74e47f" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2226a509-d370-4e18-90e3-088ab99d4bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_LitigationSettlementExpense_2226a509-d370-4e18-90e3-088ab99d4bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fd8c2d58-0b44-4741-9a92-6f2e0908c066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fd8c2d58-0b44-4741-9a92-6f2e0908c066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1c0e8e38-bb2e-4f42-bce1-c3bd7f7d8592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1c0e8e38-bb2e-4f42-bce1-c3bd7f7d8592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_44a2b0fd-4cca-415f-8847-6f387747583e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_44a2b0fd-4cca-415f-8847-6f387747583e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ba7c1d59-bdba-4021-8873-659c2eeb3587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ba7c1d59-bdba-4021-8873-659c2eeb3587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_434fd008-6389-477d-8271-f812a76f4366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_434fd008-6389-477d-8271-f812a76f4366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e7c32f78-e53a-4405-a6c8-5f9848115e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_ShareBasedCompensation_e7c32f78-e53a-4405-a6c8-5f9848115e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fe58cdcc-a7ce-465c-a86e-72e36ee67630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fe58cdcc-a7ce-465c-a86e-72e36ee67630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_b60621cd-3743-4226-8724-9173496a03f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_b60621cd-3743-4226-8724-9173496a03f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b747145c-eb85-4e35-970d-9167789da6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b747145c-eb85-4e35-970d-9167789da6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9fd097f5-1246-4790-8e0e-0489f08acf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9fd097f5-1246-4790-8e0e-0489f08acf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_440b4a40-1059-40ad-9906-857ef1aad9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9fd097f5-1246-4790-8e0e-0489f08acf2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_440b4a40-1059-40ad-9906-857ef1aad9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c19eeba0-4943-48c6-90e3-4a53c8b7a171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9fd097f5-1246-4790-8e0e-0489f08acf2b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c19eeba0-4943-48c6-90e3-4a53c8b7a171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a9319e0d-193c-4520-a2f9-73dffd1e7a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9fd097f5-1246-4790-8e0e-0489f08acf2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a9319e0d-193c-4520-a2f9-73dffd1e7a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_063bf4bb-c43d-4628-ac48-e007e87f4959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9fd097f5-1246-4790-8e0e-0489f08acf2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_063bf4bb-c43d-4628-ac48-e007e87f4959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a3524639-ebf8-428e-abc0-b1ee55d4b4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9fd097f5-1246-4790-8e0e-0489f08acf2b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a3524639-ebf8-428e-abc0-b1ee55d4b4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_8c864098-9336-4e02-8856-a14ec9a8cdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_8c864098-9336-4e02-8856-a14ec9a8cdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_448f85d3-95c9-4d96-9684-918f24c4bb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_349e2552-b94f-474e-ba50-a531e0c29d7a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_448f85d3-95c9-4d96-9684-918f24c4bb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a76f74d4-f807-4969-9a6e-1b6c0db451f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0959b2b0-ce7d-43f6-bb92-052ecc74e47f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a76f74d4-f807-4969-9a6e-1b6c0db451f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8313084f-4776-49eb-8edb-cd15150d43e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8313084f-4776-49eb-8edb-cd15150d43e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c9cda881-8df3-462a-83ca-093a037bfe56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c9cda881-8df3-462a-83ca-093a037bfe56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_22e2ef42-5558-437d-b368-b93e85df3092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:to="loc_us-gaap_PaymentsForSoftware_22e2ef42-5558-437d-b368-b93e85df3092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_145918ba-bf20-4da8-b04e-1fc1ba012c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_145918ba-bf20-4da8-b04e-1fc1ba012c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_5cdc45e3-e18e-4d9c-a67b-a0648b86c51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_5cdc45e3-e18e-4d9c-a67b-a0648b86c51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_177a3e0e-c22e-486a-9d07-274cfdb9d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_177a3e0e-c22e-486a-9d07-274cfdb9d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bde5e817-4dad-4341-b7de-877adc1af630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bde5e817-4dad-4341-b7de-877adc1af630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c146a871-fbbe-4398-a3cf-b402ea4c4b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c09da2-825c-459a-8cb7-d15977db4dd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c146a871-fbbe-4398-a3cf-b402ea4c4b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_537da078-30cd-416e-9d16-7cf689268d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_537da078-30cd-416e-9d16-7cf689268d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_7757e848-8172-4687-a2bc-28e0b453f551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_7757e848-8172-4687-a2bc-28e0b453f551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_90e68dbf-f0e2-4d87-a62c-7825dbac1c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_90e68dbf-f0e2-4d87-a62c-7825dbac1c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_1cf5a2df-abb4-4c88-897e-2124e6419073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_1cf5a2df-abb4-4c88-897e-2124e6419073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_a7bfffd3-7ec8-41a8-a423-26847dfe2c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_a7bfffd3-7ec8-41a8-a423-26847dfe2c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f6d2e370-964c-4756-934c-e31b249f5198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f6d2e370-964c-4756-934c-e31b249f5198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cce6cf10-61ab-4ebf-8de8-72a723756b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cce6cf10-61ab-4ebf-8de8-72a723756b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_7134447f-cbe1-4287-9ffc-b7152f2c3188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_7134447f-cbe1-4287-9ffc-b7152f2c3188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_34bf0141-9af4-4913-b913-4bc706ed6218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_34bf0141-9af4-4913-b913-4bc706ed6218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_f842ca0b-bc34-4f13-b0d6-121fe8a93ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_f842ca0b-bc34-4f13-b0d6-121fe8a93ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8a9b363f-35e7-4efc-94c9-95c13527f0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8a9b363f-35e7-4efc-94c9-95c13527f0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_29f39a4c-dc61-4994-a641-da5e435daaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_29f39a4c-dc61-4994-a641-da5e435daaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a9a21cf4-12bf-4d6d-886c-96db01a6bef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a9a21cf4-12bf-4d6d-886c-96db01a6bef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ad85e31-9ac6-440c-99fc-f8d6d387e708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128ccfc4-7b8e-47be-8a04-4a9a154e9d35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ad85e31-9ac6-440c-99fc-f8d6d387e708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_24d57f4d-59b8-4f83-a039-990d7065c74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_24d57f4d-59b8-4f83-a039-990d7065c74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d5343a0-ad60-405b-89c3-6d5ef499f5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d5343a0-ad60-405b-89c3-6d5ef499f5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_075bcbae-994f-4d62-8630-0d2df2c686a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_075bcbae-994f-4d62-8630-0d2df2c686a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ee995f51-ce78-4a36-b225-ac4e03cda6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ee995f51-ce78-4a36-b225-ac4e03cda6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_775e26ad-3951-47ef-91af-20d65d0c2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:to="loc_us-gaap_RestrictedCashCurrent_775e26ad-3951-47ef-91af-20d65d0c2c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4ad590b6-aa0f-41c3-a516-b49ad91feed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4ad590b6-aa0f-41c3-a516-b49ad91feed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddd27db3-044c-48f1-98a1-de74232df9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddd27db3-044c-48f1-98a1-de74232df9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_62e3b044-3597-462e-9ea3-a1a74b47404c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_62e3b044-3597-462e-9ea3-a1a74b47404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_4faadd4d-a913-4369-92c0-afcefa73d061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:to="loc_us-gaap_RestrictedCashCurrent_4faadd4d-a913-4369-92c0-afcefa73d061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_986dc1d7-d1ca-497f-afdc-dc18c8ef8652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_986dc1d7-d1ca-497f-afdc-dc18c8ef8652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9cb95b9-df03-4bcd-bf37-1c055bdb6f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc8c1245-d002-4b0f-9415-af817311bce3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9cb95b9-df03-4bcd-bf37-1c055bdb6f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0014fee1-a4f2-4430-8c7c-729198e9afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c100c5f3-1083-4ecd-a898-65bb59c7133e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0014fee1-a4f2-4430-8c7c-729198e9afc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e482684f-f468-448f-a2f8-9f87fd34023a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0014fee1-a4f2-4430-8c7c-729198e9afc9" xlink:to="loc_us-gaap_InterestPaidNet_e482684f-f468-448f-a2f8-9f87fd34023a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_64e96cd2-7f32-4b7d-89e6-704ba2852e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0014fee1-a4f2-4430-8c7c-729198e9afc9" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_64e96cd2-7f32-4b7d-89e6-704ba2852e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_c8c52c54-4fa1-42c9-9c1a-c9991bbc4a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0014fee1-a4f2-4430-8c7c-729198e9afc9" xlink:to="loc_us-gaap_IncomeTaxesPaid_c8c52c54-4fa1-42c9-9c1a-c9991bbc4a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d74770e6-81e4-431e-892a-17c19b94e7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0014fee1-a4f2-4430-8c7c-729198e9afc9" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d74770e6-81e4-431e-892a-17c19b94e7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_75b1d003-ed38-49ea-99e4-acf547429d86" xlink:href="ehc-20211231.xsd#ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d74770e6-81e4-431e-892a-17c19b94e7d0" xlink:to="loc_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_75b1d003-ed38-49ea-99e4-acf547429d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e0e5d2b-018c-4aa0-8dd8-bbd2185729bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3beba3a0-d60e-40b3-8576-7ff4929acdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e0e5d2b-018c-4aa0-8dd8-bbd2185729bd" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3beba3a0-d60e-40b3-8576-7ff4929acdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3c34546c-5dd9-4a30-9986-9af26221eafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3c34546c-5dd9-4a30-9986-9af26221eafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_b74887c2-f839-47f9-a3dd-0f82b657de46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_b74887c2-f839-47f9-a3dd-0f82b657de46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d2105ad3-88df-4450-94dc-cdec6bd90910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_UseOfEstimates_d2105ad3-88df-4450-94dc-cdec6bd90910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_45665709-56de-457b-ba12-63491a97027b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_45665709-56de-457b-ba12-63491a97027b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_00c9cf49-e80d-4fb6-9f24-43fd26151a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_00c9cf49-e80d-4fb6-9f24-43fd26151a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1c4488b6-2814-4029-892d-fc98d7338341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1c4488b6-2814-4029-892d-fc98d7338341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_572da986-8333-4775-becb-f9680689e112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_572da986-8333-4775-becb-f9680689e112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_53ab8548-95f5-4bf3-94c5-2208eec48483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_53ab8548-95f5-4bf3-94c5-2208eec48483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_64882d79-aaea-4ed4-ac1b-00e13179500d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_64882d79-aaea-4ed4-ac1b-00e13179500d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_8456f3c2-c353-454b-9f57-d21596088085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_8456f3c2-c353-454b-9f57-d21596088085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_197e0efb-b59d-43b5-9634-baa8ff8557c2" xlink:href="ehc-20211231.xsd#ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_197e0efb-b59d-43b5-9634-baa8ff8557c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_c3868f96-e93f-4796-9d10-fc65b3ac049e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_c3868f96-e93f-4796-9d10-fc65b3ac049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_a7cc6ae2-8909-4560-9732-bd0d55df8c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_DebtPolicyTextBlock_a7cc6ae2-8909-4560-9732-bd0d55df8c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d99adf86-9f4d-4530-9a5b-889848834480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d99adf86-9f4d-4530-9a5b-889848834480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_88faa31c-889d-46ce-971a-1c319027d3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_88faa31c-889d-46ce-971a-1c319027d3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_00791b8e-5c51-43f5-954b-54f4c464b6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_00791b8e-5c51-43f5-954b-54f4c464b6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2ed3f56f-081d-4448-8d97-45cce78f4081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2ed3f56f-081d-4448-8d97-45cce78f4081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_829125ee-a4ea-4426-b603-9751266f9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_829125ee-a4ea-4426-b603-9751266f9ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_56dbad1e-9ba8-4eda-bc5c-b4e5f777aaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_56dbad1e-9ba8-4eda-bc5c-b4e5f777aaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_21db8f20-aff7-4c45-a8d3-185a43c3a95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_21db8f20-aff7-4c45-a8d3-185a43c3a95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6d060d1d-f162-4dd6-984d-e4c735aaf8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_6d060d1d-f162-4dd6-984d-e4c735aaf8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_d5078f38-f179-45f2-9d9f-b075fe2e8d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_d5078f38-f179-45f2-9d9f-b075fe2e8d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d809d5f7-8502-4226-8ef5-4b934dad636d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d809d5f7-8502-4226-8ef5-4b934dad636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_534395c5-2dd4-4120-94b1-b16ae5fe6b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54faf339-aff4-40b1-832e-29e5ae3475e8" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_534395c5-2dd4-4120-94b1-b16ae5fe6b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_461d21b2-3d76-4a42-8fa5-6d68bc123e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6e638cd6-b2a4-46bd-a1ef-7c7aab085294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461d21b2-3d76-4a42-8fa5-6d68bc123e73" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6e638cd6-b2a4-46bd-a1ef-7c7aab085294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4b709f88-79a2-4553-9b79-372889d24d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461d21b2-3d76-4a42-8fa5-6d68bc123e73" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4b709f88-79a2-4553-9b79-372889d24d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0f42242a-1ddb-41bf-ba93-859f00f31e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461d21b2-3d76-4a42-8fa5-6d68bc123e73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0f42242a-1ddb-41bf-ba93-859f00f31e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a3195ef6-0968-44cd-8e32-de6330ea5f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461d21b2-3d76-4a42-8fa5-6d68bc123e73" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a3195ef6-0968-44cd-8e32-de6330ea5f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8eba7912-946f-48ff-aa55-b70927e2498c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461d21b2-3d76-4a42-8fa5-6d68bc123e73" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8eba7912-946f-48ff-aa55-b70927e2498c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6471e116-0791-4dfc-8eeb-0b670b9748dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6471e116-0791-4dfc-8eeb-0b670b9748dd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cdb7914-9945-4656-a4ed-393526e0863a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_srt_RangeAxis_9cdb7914-9945-4656-a4ed-393526e0863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4eb3adc8-9fc3-4a20-b442-01d569580615" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9cdb7914-9945-4656-a4ed-393526e0863a" xlink:to="loc_srt_RangeMember_4eb3adc8-9fc3-4a20-b442-01d569580615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c14cee59-2195-4664-9d03-09e1a72a06d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4eb3adc8-9fc3-4a20-b442-01d569580615" xlink:to="loc_srt_MinimumMember_c14cee59-2195-4664-9d03-09e1a72a06d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_779f49ac-4456-4139-bae9-f85c11d52290" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4eb3adc8-9fc3-4a20-b442-01d569580615" xlink:to="loc_srt_MaximumMember_779f49ac-4456-4139-bae9-f85c11d52290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_46ce1b4c-817e-40c0-a7b1-917f2d1533f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_46ce1b4c-817e-40c0-a7b1-917f2d1533f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2c91c993-7db6-44b0-b928-824d04b53d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46ce1b4c-817e-40c0-a7b1-917f2d1533f7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2c91c993-7db6-44b0-b928-824d04b53d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember_bf09f91b-ef71-43f2-ac1b-8d8b00c2cefb" xlink:href="ehc-20211231.xsd#ehc_PayorSourceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2c91c993-7db6-44b0-b928-824d04b53d11" xlink:to="loc_ehc_PayorSourceMember_bf09f91b-ef71-43f2-ac1b-8d8b00c2cefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f16edc22-348a-449d-ba0d-88c9cc4f386c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f16edc22-348a-449d-ba0d-88c9cc4f386c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c87675de-fa41-4b69-a2ed-2a18c2879bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f16edc22-348a-449d-ba0d-88c9cc4f386c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c87675de-fa41-4b69-a2ed-2a18c2879bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_2f098700-a83c-4e5a-9a47-f808af89e2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c87675de-fa41-4b69-a2ed-2a18c2879bf8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_2f098700-a83c-4e5a-9a47-f808af89e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c79b327-7b54-4e61-8b3b-68db4a2f8942" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_srt_CounterpartyNameAxis_8c79b327-7b54-4e61-8b3b-68db4a2f8942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e127aa0-7261-4e70-9322-1ca2248fbb3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8c79b327-7b54-4e61-8b3b-68db4a2f8942" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e127aa0-7261-4e70-9322-1ca2248fbb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_d4a7a55b-2f8c-40ca-940f-17d00304e34d" xlink:href="ehc-20211231.xsd#ehc_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e127aa0-7261-4e70-9322-1ca2248fbb3a" xlink:to="loc_ehc_MedicareMember_d4a7a55b-2f8c-40ca-940f-17d00304e34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e905388e-e994-45c9-9444-e1581bcf8710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e905388e-e994-45c9-9444-e1581bcf8710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b8b83274-0cf2-453e-a79f-5fb265472a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e905388e-e994-45c9-9444-e1581bcf8710" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b8b83274-0cf2-453e-a79f-5fb265472a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RACAuditsMember_2a0de3db-4f51-453c-a6e7-bbfb5c304997" xlink:href="ehc-20211231.xsd#ehc_RACAuditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b8b83274-0cf2-453e-a79f-5fb265472a66" xlink:to="loc_ehc_RACAuditsMember_2a0de3db-4f51-453c-a6e7-bbfb5c304997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e2ebc50-fb5f-403e-b14e-f86dc0338b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e2ebc50-fb5f-403e-b14e-f86dc0338b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19bed023-213d-4448-8560-758c60d403f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e2ebc50-fb5f-403e-b14e-f86dc0338b76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19bed023-213d-4448-8560-758c60d403f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_b6078a37-13dd-495d-8de9-1e60370b4aae" xlink:href="ehc-20211231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19bed023-213d-4448-8560-758c60d403f8" xlink:to="loc_ehc_MarketAccessAssetsMember_b6078a37-13dd-495d-8de9-1e60370b4aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa9076cc-fe0d-4342-85bc-5d109e7745bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_36118a9d-bbfa-4766-8730-88fe0a46d8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_36118a9d-bbfa-4766-8730-88fe0a46d8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_06625bec-ed51-4c07-9ba9-8abf84b64bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_NumberOfReportableSegments_06625bec-ed51-4c07-9ba9-8abf84b64bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a1bbd68d-f81f-4154-ac89-7fc874290573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a1bbd68d-f81f-4154-ac89-7fc874290573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_deef5c43-0b7e-41e0-b71d-daf031e67543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_deef5c43-0b7e-41e0-b71d-daf031e67543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_ef71f376-e693-442b-9252-d5ca675d1e7a" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_ef71f376-e693-442b-9252-d5ca675d1e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_e36b856e-2b22-4c8b-827c-2c6ad16c5070" xlink:href="ehc-20211231.xsd#ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_e36b856e-2b22-4c8b-827c-2c6ad16c5070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_33e9a288-f2d5-4f5e-a724-861a29dcc00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8738546-9289-4122-ad4b-f94c15e3c74b" xlink:to="loc_us-gaap_AdvertisingExpense_33e9a288-f2d5-4f5e-a724-861a29dcc00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_19978b78-3061-44c2-8115-3b2a9c2d37df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19978b78-3061-44c2-8115-3b2a9c2d37df" xlink:to="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_04080531-6db1-42f5-adaf-d1a281860d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_04080531-6db1-42f5-adaf-d1a281860d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b1da2344-ec62-4241-8455-712470a7ca5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_04080531-6db1-42f5-adaf-d1a281860d05" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b1da2344-ec62-4241-8455-712470a7ca5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember_d26e10d7-f754-4eca-a807-28b31172f04b" xlink:href="ehc-20211231.xsd#ehc_PayorSourceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b1da2344-ec62-4241-8455-712470a7ca5f" xlink:to="loc_ehc_PayorSourceMember_d26e10d7-f754-4eca-a807-28b31172f04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f467ba06-4895-4cd1-b835-7d508910adaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f467ba06-4895-4cd1-b835-7d508910adaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c96e771f-e207-4a6b-9a5f-51b527606ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f467ba06-4895-4cd1-b835-7d508910adaa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c96e771f-e207-4a6b-9a5f-51b527606ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_a0a0800a-d57e-43c9-b13d-091d58c2276c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c96e771f-e207-4a6b-9a5f-51b527606ee8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_a0a0800a-d57e-43c9-b13d-091d58c2276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7c385f25-b67f-46b7-9b20-cd2edd8efdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c96e771f-e207-4a6b-9a5f-51b527606ee8" xlink:to="loc_us-gaap_AccountsReceivableMember_7c385f25-b67f-46b7-9b20-cd2edd8efdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_641c0257-fa31-4c5d-bd5f-3d6e0b901258" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_srt_CounterpartyNameAxis_641c0257-fa31-4c5d-bd5f-3d6e0b901258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_641c0257-fa31-4c5d-bd5f-3d6e0b901258" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_a2320adb-016d-4411-b922-0b76899ddec2" xlink:href="ehc-20211231.xsd#ehc_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_MedicareMember_a2320adb-016d-4411-b922-0b76899ddec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_01db27ee-234e-4eca-8acb-9c59d309d94e" xlink:href="ehc-20211231.xsd#ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_01db27ee-234e-4eca-8acb-9c59d309d94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember_89991a4b-17e7-48d6-bcfc-3c27965e4ad9" xlink:href="ehc-20211231.xsd#ehc_MedicareAdvantageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_MedicareAdvantageMember_89991a4b-17e7-48d6-bcfc-3c27965e4ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember_94e50c51-f4d0-4b84-83c7-d5b772996c08" xlink:href="ehc-20211231.xsd#ehc_ManagedCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_ManagedCareMember_94e50c51-f4d0-4b84-83c7-d5b772996c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_56997b3b-555d-4d59-9cb0-e4c74e74b8be" xlink:href="ehc-20211231.xsd#ehc_MedicaidMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_MedicaidMember_56997b3b-555d-4d59-9cb0-e4c74e74b8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_602f79ab-de42-4aa5-a178-3ce5f304b430" xlink:href="ehc-20211231.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_602f79ab-de42-4aa5-a178-3ce5f304b430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_bcee339f-7edf-4bff-a2d5-f6f3f21439db" xlink:href="ehc-20211231.xsd#ehc_WorkersCompensationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_WorkersCompensationMember_bcee339f-7edf-4bff-a2d5-f6f3f21439db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_7008f8f1-4272-4998-9e92-af86e9c78554" xlink:href="ehc-20211231.xsd#ehc_PatientsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_PatientsMember_7008f8f1-4272-4998-9e92-af86e9c78554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember_f760a039-f5ed-479a-b47f-39ed1fae0c79" xlink:href="ehc-20211231.xsd#ehc_OtherIncomeSourceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cbaf4d28-76f6-4533-bcf5-d0f86edd7f01" xlink:to="loc_ehc_OtherIncomeSourceMember_f760a039-f5ed-479a-b47f-39ed1fae0c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2334daa8-a6b8-4ffe-b3ce-36c91186254a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2334daa8-a6b8-4ffe-b3ce-36c91186254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d5c22b3e-da98-4f0b-97c0-b5c04675336b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2334daa8-a6b8-4ffe-b3ce-36c91186254a" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d5c22b3e-da98-4f0b-97c0-b5c04675336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_9796bf77-eead-4a85-a751-0fb308f20251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d5c22b3e-da98-4f0b-97c0-b5c04675336b" xlink:to="loc_us-gaap_ThirdPartyPayorMember_9796bf77-eead-4a85-a751-0fb308f20251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfPayMember_c4bee847-9cb5-4594-93c4-c7b6c31009ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfPayMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d5c22b3e-da98-4f0b-97c0-b5c04675336b" xlink:to="loc_us-gaap_SelfPayMember_c4bee847-9cb5-4594-93c4-c7b6c31009ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f960df69-3afa-454f-8e8d-386b65d5f49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f960df69-3afa-454f-8e8d-386b65d5f49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5e8759ce-4bc7-400e-a42b-3d7d3d849d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f960df69-3afa-454f-8e8d-386b65d5f49f" xlink:to="loc_us-gaap_SegmentDomain_5e8759ce-4bc7-400e-a42b-3d7d3d849d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_4efd7537-cef1-4c3a-8e1a-424b5edcb28b" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5e8759ce-4bc7-400e-a42b-3d7d3d849d01" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_4efd7537-cef1-4c3a-8e1a-424b5edcb28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_d75f561c-2cbb-477e-9378-da5d70f76598" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5e8759ce-4bc7-400e-a42b-3d7d3d849d01" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_d75f561c-2cbb-477e-9378-da5d70f76598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8814c13c-a94c-40ea-a0cb-9eaf8bee1d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3d88a524-23bc-4b78-acad-552d87759bc5" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_8814c13c-a94c-40ea-a0cb-9eaf8bee1d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cd9f555-5151-4b16-8a3d-e36b15a52784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8814c13c-a94c-40ea-a0cb-9eaf8bee1d71" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cd9f555-5151-4b16-8a3d-e36b15a52784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f56c0798-8f45-4b5b-9d67-0df3434d00b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8814c13c-a94c-40ea-a0cb-9eaf8bee1d71" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f56c0798-8f45-4b5b-9d67-0df3434d00b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f5bd12df-4d03-4fdf-8f4a-292b2d19ff93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f5bd12df-4d03-4fdf-8f4a-292b2d19ff93" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17d9c0b7-17a3-428e-9831-7a2e08d42d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17d9c0b7-17a3-428e-9831-7a2e08d42d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17d9c0b7-17a3-428e-9831-7a2e08d42d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_ccd61217-c449-415b-b26f-97e3922e466a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:to="loc_us-gaap_BuildingMember_ccd61217-c449-415b-b26f-97e3922e466a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9fb490a2-f2e5-4e4c-b69a-6fbc8619ebce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9fb490a2-f2e5-4e4c-b69a-6fbc8619ebce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_0aba069b-fc04-4d2f-a6e2-301716bfea87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:to="loc_us-gaap_VehiclesMember_0aba069b-fc04-4d2f-a6e2-301716bfea87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2e19403e-7460-4c98-ae90-3052ca9c85a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_898d5b6f-70c9-4df4-a231-1488aaa3bac9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2e19403e-7460-4c98-ae90-3052ca9c85a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5fb8bba8-d9e9-48cf-8042-ad1144cf0246" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:to="loc_srt_RangeAxis_5fb8bba8-d9e9-48cf-8042-ad1144cf0246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee3f1a24-1234-4da0-9989-e03adbbb4b3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5fb8bba8-d9e9-48cf-8042-ad1144cf0246" xlink:to="loc_srt_RangeMember_ee3f1a24-1234-4da0-9989-e03adbbb4b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7b5803d9-898c-44a0-9753-11578c2afe66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ee3f1a24-1234-4da0-9989-e03adbbb4b3d" xlink:to="loc_srt_MinimumMember_7b5803d9-898c-44a0-9753-11578c2afe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34c1b5b5-d3c4-4001-99c9-23a96d8a8bef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ee3f1a24-1234-4da0-9989-e03adbbb4b3d" xlink:to="loc_srt_MaximumMember_34c1b5b5-d3c4-4001-99c9-23a96d8a8bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c56ddd0b-0afd-4f2f-9d6b-ce1e1fb1321f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abefd1b1-ad09-4ac5-a320-b7262e0960c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c56ddd0b-0afd-4f2f-9d6b-ce1e1fb1321f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_24563772-ad6c-4de1-af5b-62c2a50eb867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c56ddd0b-0afd-4f2f-9d6b-ce1e1fb1321f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_24563772-ad6c-4de1-af5b-62c2a50eb867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48ed92be-55a5-4905-bea2-3eed019828b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48ed92be-55a5-4905-bea2-3eed019828b4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9df36d96-42f5-44ea-81e8-df9eb576d169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9df36d96-42f5-44ea-81e8-df9eb576d169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9df36d96-42f5-44ea-81e8-df9eb576d169" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_48f7ef1a-4626-4e6d-9ac4-8c8d530cd37a" xlink:href="ehc-20211231.xsd#ehc_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_ehc_CertificateOfNeedMember_48f7ef1a-4626-4e6d-9ac4-8c8d530cd37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_733cea4f-3609-487a-9a87-d2692841f052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_us-gaap_LicensingAgreementsMember_733cea4f-3609-487a-9a87-d2692841f052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_3cd7db88-1bb7-4a49-8c7a-6d789929ee76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_3cd7db88-1bb7-4a49-8c7a-6d789929ee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7da27f35-2b5f-463d-b85f-9a5e94eb93ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_us-gaap_TradeNamesMember_7da27f35-2b5f-463d-b85f-9a5e94eb93ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InternalUseSoftwareMember_286b592a-eb28-48a3-a38a-05530c673529" xlink:href="ehc-20211231.xsd#ehc_InternalUseSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_ehc_InternalUseSoftwareMember_286b592a-eb28-48a3-a38a-05530c673529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_2326e612-6cf4-4d8c-8f72-0f4db6f373eb" xlink:href="ehc-20211231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3101d663-7248-4ed7-b86a-fa0447f612d6" xlink:to="loc_ehc_MarketAccessAssetsMember_2326e612-6cf4-4d8c-8f72-0f4db6f373eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa8c77bd-106c-445c-9b16-74f449aff2d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:to="loc_srt_RangeAxis_fa8c77bd-106c-445c-9b16-74f449aff2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba1b7b42-2456-4853-85d7-c925fc23fe8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fa8c77bd-106c-445c-9b16-74f449aff2d0" xlink:to="loc_srt_RangeMember_ba1b7b42-2456-4853-85d7-c925fc23fe8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_850206ac-91e9-44b5-ab74-2c6a0d1dab0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba1b7b42-2456-4853-85d7-c925fc23fe8f" xlink:to="loc_srt_MinimumMember_850206ac-91e9-44b5-ab74-2c6a0d1dab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ee0d114-7875-4b22-938e-5468cc6ae113" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba1b7b42-2456-4853-85d7-c925fc23fe8f" xlink:to="loc_srt_MaximumMember_5ee0d114-7875-4b22-938e-5468cc6ae113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e94469c-b16c-48a7-9efb-84f0ee1085c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddab33c-c959-4c8d-98b5-2723c965bd7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e94469c-b16c-48a7-9efb-84f0ee1085c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2487f235-6827-4970-9250-4b042bf73204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e94469c-b16c-48a7-9efb-84f0ee1085c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2487f235-6827-4970-9250-4b042bf73204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2fa3cdad-afab-4831-a96d-1b7713f65b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1946f41e-708a-4f57-ba17-94b855ee1084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2fa3cdad-afab-4831-a96d-1b7713f65b86" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1946f41e-708a-4f57-ba17-94b855ee1084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_38d300e1-c897-464e-89e8-214be6a5766a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2787a751-fd91-4a8c-9e55-735d0bf86181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_38d300e1-c897-464e-89e8-214be6a5766a" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2787a751-fd91-4a8c-9e55-735d0bf86181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0018a476-84ae-4d4a-91e7-cbca751df454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_38d300e1-c897-464e-89e8-214be6a5766a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0018a476-84ae-4d4a-91e7-cbca751df454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_15278f77-3e39-4bdb-994b-3c1d36e694c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_38d300e1-c897-464e-89e8-214be6a5766a" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_15278f77-3e39-4bdb-994b-3c1d36e694c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b3eb58b4-67c8-4ff5-99f8-43f3c9c94d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b3eb58b4-67c8-4ff5-99f8-43f3c9c94d6b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28f3c5f-6565-4a3e-85a2-a4907c371534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28f3c5f-6565-4a3e-85a2-a4907c371534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_10c45c67-92cb-478f-82c7-eaec3c401b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28f3c5f-6565-4a3e-85a2-a4907c371534" xlink:to="loc_us-gaap_RelatedPartyDomain_10c45c67-92cb-478f-82c7-eaec3c401b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_2cb5e214-fd86-41c7-993b-4ecef0a9aa62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10c45c67-92cb-478f-82c7-eaec3c401b16" xlink:to="loc_us-gaap_CorporateJointVentureMember_2cb5e214-fd86-41c7-993b-4ecef0a9aa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_714b42d0-8c96-48af-b609-f235af1ce924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_714b42d0-8c96-48af-b609-f235af1ce924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_714b42d0-8c96-48af-b609-f235af1ce924" xlink:to="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_eb4c77ac-362e-4895-841c-794a6b943db4" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_eb4c77ac-362e-4895-841c-794a6b943db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_06db1c86-e593-40a3-82a3-61f1d97db251" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_06db1c86-e593-40a3-82a3-61f1d97db251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_488b20b9-b548-42d2-b65c-e06d54f24817" xlink:href="ehc-20211231.xsd#ehc_OtherHomeHealthAndHospiceAcquisitionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5f46b1e9-401a-4fd9-b802-b2239e0c6e28" xlink:to="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_488b20b9-b548-42d2-b65c-e06d54f24817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_52b73bc0-5ec6-4ef0-833a-320d65c73e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_SubsegmentsAxis_52b73bc0-5ec6-4ef0-833a-320d65c73e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c6005e11-6e7a-4dd0-b762-807b5bcccbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_52b73bc0-5ec6-4ef0-833a-320d65c73e49" xlink:to="loc_us-gaap_SubsegmentsDomain_c6005e11-6e7a-4dd0-b762-807b5bcccbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_6c3e96e8-ee11-4cc4-a105-5c74e1766c04" xlink:href="ehc-20211231.xsd#ehc_HomehealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c6005e11-6e7a-4dd0-b762-807b5bcccbd3" xlink:to="loc_ehc_HomehealthMember_6c3e96e8-ee11-4cc4-a105-5c74e1766c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_6010821f-21a0-4c59-b182-e2c7465644fa" xlink:href="ehc-20211231.xsd#ehc_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c6005e11-6e7a-4dd0-b762-807b5bcccbd3" xlink:to="loc_ehc_HospiceMember_6010821f-21a0-4c59-b182-e2c7465644fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b85ca35e-09e1-4a29-bdfc-329efeea572e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b85ca35e-09e1-4a29-bdfc-329efeea572e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b85ca35e-09e1-4a29-bdfc-329efeea572e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalMember_bc128d24-2b24-4d06-a4a2-383551067b66" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_ShannonMedicalMember_bc128d24-2b24-4d06-a4a2-383551067b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeritageValleyMember_a0428065-38c3-45e4-ae98-4f118bb76d61" xlink:href="ehc-20211231.xsd#ehc_HeritageValleyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_HeritageValleyMember_a0428065-38c3-45e4-ae98-4f118bb76d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ECHDVenturesMember_04894e48-4083-4f89-bde9-edbd5e5df143" xlink:href="ehc-20211231.xsd#ehc_ECHDVenturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_ECHDVenturesMember_04894e48-4083-4f89-bde9-edbd5e5df143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_81a3984d-048a-41d5-bdb9-ec8f2831f034" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_81a3984d-048a-41d5-bdb9-ec8f2831f034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeartOfTheRockiesHomeHealthMember_0c1006ac-b8fe-4c33-8111-228737c08117" xlink:href="ehc-20211231.xsd#ehc_HeartOfTheRockiesHomeHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_HeartOfTheRockiesHomeHealthMember_0c1006ac-b8fe-4c33-8111-228737c08117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceOfSouthwestMontanaMember_b61f18bd-e6b8-4a1d-b5f3-91c224ff60d3" xlink:href="ehc-20211231.xsd#ehc_HospiceOfSouthwestMontanaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_HospiceOfSouthwestMontanaMember_b61f18bd-e6b8-4a1d-b5f3-91c224ff60d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FrontierHomeHealthAndHospiceMember_64c16f0a-c81c-442c-acbd-3ef58dd8fc40" xlink:href="ehc-20211231.xsd#ehc_FrontierHomeHealthAndHospiceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_FrontierHomeHealthAndHospiceMember_64c16f0a-c81c-442c-acbd-3ef58dd8fc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember_6e621c2e-3e42-4925-9240-ac5ecf9af345" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_PortercareAdventistMember_6e621c2e-3e42-4925-9240-ac5ecf9af345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember_5b2d5101-8215-45d2-85e1-bf5f6ce27f6a" xlink:href="ehc-20211231.xsd#ehc_PremierHealthPartnersMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_PremierHealthPartnersMember_5b2d5101-8215-45d2-85e1-bf5f6ce27f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_48f0eef7-6c64-4878-bb80-edee79ec782e" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_48f0eef7-6c64-4878-bb80-edee79ec782e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember_8b5f2457-8863-4e09-a20e-bdf4b01fa9f9" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_SaintAlphonsusMember_8b5f2457-8863-4e09-a20e-bdf4b01fa9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember_7578fc68-31db-45ac-b46b-49e8310607d9" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_SaintAlphonsusandHeritageValleyMember_7578fc68-31db-45ac-b46b-49e8310607d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember_ae0c8e85-607f-4d72-8416-d8fb4d3cad06" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_AlacareMember_ae0c8e85-607f-4d72-8416-d8fb4d3cad06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CareResourceGroupMember_fc1b9bfa-36b5-4937-b0b0-639677f71cf9" xlink:href="ehc-20211231.xsd#ehc_CareResourceGroupMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_CareResourceGroupMember_fc1b9bfa-36b5-4937-b0b0-639677f71cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember_debab1a8-8373-45c5-bb3a-6215e1b2fe99" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_TidewaterandCareResourceGroupMember_debab1a8-8373-45c5-bb3a-6215e1b2fe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BaptistOutpatientServicesIncMember_3234fd7a-0a98-4438-9bcd-4fbf913b895e" xlink:href="ehc-20211231.xsd#ehc_BaptistOutpatientServicesIncMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae07a90-e49f-49d1-a39a-d1a2d4adea36" xlink:to="loc_ehc_BaptistOutpatientServicesIncMember_3234fd7a-0a98-4438-9bcd-4fbf913b895e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_srt_RangeAxis_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92740fb8-5906-4c45-938f-fe420b846fc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b0fd2685-2a7c-4da5-a5be-2693e77eb0ee" xlink:to="loc_srt_RangeMember_92740fb8-5906-4c45-938f-fe420b846fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4c583f3-bc56-411a-9e5c-5b25c9bd22a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92740fb8-5906-4c45-938f-fe420b846fc1" xlink:to="loc_srt_MinimumMember_e4c583f3-bc56-411a-9e5c-5b25c9bd22a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b273d52b-3758-47f7-b611-f20298b00613" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92740fb8-5906-4c45-938f-fe420b846fc1" xlink:to="loc_srt_MaximumMember_b273d52b-3758-47f7-b611-f20298b00613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6f5c4be6-378e-49ac-81fc-a34b6f918a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6f5c4be6-378e-49ac-81fc-a34b6f918a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2eac42ea-00ee-4dbb-ad6d-d35d80de1590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6f5c4be6-378e-49ac-81fc-a34b6f918a96" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2eac42ea-00ee-4dbb-ad6d-d35d80de1590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a8bd7dbb-abe2-4b2c-b843-7160e172a533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2eac42ea-00ee-4dbb-ad6d-d35d80de1590" xlink:to="loc_us-gaap_SubsequentEventMember_a8bd7dbb-abe2-4b2c-b843-7160e172a533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b290f61-4fa8-4604-bf1d-d31e7f1c7278" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3c831910-d86a-4602-b4bb-6da9870011cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3c831910-d86a-4602-b4bb-6da9870011cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsAcquired_a1d4c683-0273-4a11-98b2-a06ee7c8781f" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofBedsAcquired_a1d4c683-0273-4a11-98b2-a06ee7c8781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_cce8478c-deb0-440c-8d71-ce2ba1299746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_cce8478c-deb0-440c-8d71-ce2ba1299746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fbc8ef10-e1e1-4d1b-9fa2-a961b8a353a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fbc8ef10-e1e1-4d1b-9fa2-a961b8a353a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9eac2387-8ed3-4cc5-8b81-e8e5b276c520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9eac2387-8ed3-4cc5-8b81-e8e5b276c520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_7e34ecd5-a610-4335-9daf-990ae5fbd7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_7e34ecd5-a610-4335-9daf-990ae5fbd7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage_803fe0b6-17b9-46ea-874d-cf87ed9d477d" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentAdditionalOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage_803fe0b6-17b9-46ea-874d-cf87ed9d477d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_99e5bbf1-f352-4cfd-8e51-083dfd34d73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_99e5bbf1-f352-4cfd-8e51-083dfd34d73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofLocationsofanAcquiredEntity_351a447e-74c4-4365-bbdc-5bd0274f4c01" xlink:href="ehc-20211231.xsd#ehc_NumberofLocationsofanAcquiredEntity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofLocationsofanAcquiredEntity_351a447e-74c4-4365-bbdc-5bd0274f4c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_00baca7f-3a33-4cb0-9712-7218c4a42bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_00baca7f-3a33-4cb0-9712-7218c4a42bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed_4b1027af-e9d6-4b1c-8197-ab4176472150" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsContributed"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofBedsContributed_4b1027af-e9d6-4b1c-8197-ab4176472150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded_2ef4057b-1fb0-4ebf-8bdd-7d0edf141bb7" xlink:href="ehc-20211231.xsd#ehc_NumberofBedsExpanded"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofBedsExpanded_2ef4057b-1fb0-4ebf-8bdd-7d0edf141bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds_a0799cdf-249e-4476-ad56-d758ec374901" xlink:href="ehc-20211231.xsd#ehc_NumberofDeNovoBeds"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed91b09-f9dc-44b3-a2c3-ca0665593bbe" xlink:to="loc_ehc_NumberofDeNovoBeds_a0799cdf-249e-4476-ad56-d758ec374901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e43ecb50-3138-4a40-8e33-e1537b583da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e43ecb50-3138-4a40-8e33-e1537b583da0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_srt_RangeAxis_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cb76a98-2925-480e-8ee0-0f57d62c9f36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5799cdd3-faf3-4ce3-8d6b-a52b37ca451b" xlink:to="loc_srt_RangeMember_9cb76a98-2925-480e-8ee0-0f57d62c9f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b46eb4ec-9df7-4041-bd08-7a4a438e0eea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9cb76a98-2925-480e-8ee0-0f57d62c9f36" xlink:to="loc_srt_MinimumMember_b46eb4ec-9df7-4041-bd08-7a4a438e0eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_32291a3c-c2ad-4467-85c5-bf19693a0aec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9cb76a98-2925-480e-8ee0-0f57d62c9f36" xlink:to="loc_srt_MaximumMember_32291a3c-c2ad-4467-85c5-bf19693a0aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fa39f5a8-6e2f-4668-8e97-59e70ab22cbd" xlink:to="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_2b7901eb-11e0-4017-bac4-b7191206a2e7" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_2b7901eb-11e0-4017-bac4-b7191206a2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_658f0fb5-4905-4a2e-af1c-7a04b4d7b128" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_658f0fb5-4905-4a2e-af1c-7a04b4d7b128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_ed7a89e5-4a88-4f17-94df-44b04bf25734" xlink:href="ehc-20211231.xsd#ehc_OtherHomeHealthAndHospiceAcquisitionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0a087ec5-c99c-4598-9b30-9c2386c05331" xlink:to="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_ed7a89e5-4a88-4f17-94df-44b04bf25734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9f62f538-dfd9-47ee-bda0-fb3ab6cb3661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_e4a3bd14-02e5-433e-9c38-e71d870b363c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_e4a3bd14-02e5-433e-9c38-e71d870b363c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3db4776a-46be-4933-93f7-bfe4de83dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:to="loc_us-gaap_TradeNamesMember_3db4776a-46be-4933-93f7-bfe4de83dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_68dfaed7-6549-48a6-8dd2-f7d812c15eb3" xlink:href="ehc-20211231.xsd#ehc_CertificateOfNeedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:to="loc_ehc_CertificateOfNeedMember_68dfaed7-6549-48a6-8dd2-f7d812c15eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3c742154-c22c-46d3-8215-930ebb2309a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b16a388-2ae8-4a0e-9f97-19b136843821" xlink:to="loc_us-gaap_LicensingAgreementsMember_3c742154-c22c-46d3-8215-930ebb2309a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dcfea458-5141-4188-96f2-7c192662849d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dcfea458-5141-4188-96f2-7c192662849d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcfea458-5141-4188-96f2-7c192662849d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_aa782c25-67bf-402f-a797-24dcc747a09f" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_aa782c25-67bf-402f-a797-24dcc747a09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FrontierHomeHealthAndHospiceMember_05ba5c94-c750-4c35-88ea-f88ccec38724" xlink:href="ehc-20211231.xsd#ehc_FrontierHomeHealthAndHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_FrontierHomeHealthAndHospiceMember_05ba5c94-c750-4c35-88ea-f88ccec38724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BaptistOutpatientServicesIncMember_cccafa76-be3c-43d3-8ca0-6570abdf043b" xlink:href="ehc-20211231.xsd#ehc_BaptistOutpatientServicesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_BaptistOutpatientServicesIncMember_cccafa76-be3c-43d3-8ca0-6570abdf043b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_31f86afd-969f-4aa9-b951-aa192351297b" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_31f86afd-969f-4aa9-b951-aa192351297b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsOfLynchburgMember_8b8c7402-133b-43f0-a513-72d61524ef2e" xlink:href="ehc-20211231.xsd#ehc_GenerationSolutionsOfLynchburgMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_GenerationSolutionsOfLynchburgMember_8b8c7402-133b-43f0-a513-72d61524ef2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember_efedb742-eb15-43b0-a4b4-9008f20a0382" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_SaintAlphonsusandHeritageValleyMember_efedb742-eb15-43b0-a4b4-9008f20a0382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember_e9dfb5c0-4218-40b9-9e5c-189c9594ef7e" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_AlacareMember_e9dfb5c0-4218-40b9-9e5c-189c9594ef7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember_2ef84b6f-692b-41c6-a432-e3450ed1d0fa" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9dbd972c-c254-4b82-9c17-455b15f42739" xlink:to="loc_ehc_TidewaterandCareResourceGroupMember_2ef84b6f-692b-41c6-a432-e3450ed1d0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1741f982-b608-46f5-ae0c-56333cc6c503" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b9a2b6bf-7da6-451b-83ff-0bb477b6b928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b9a2b6bf-7da6-451b-83ff-0bb477b6b928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cda65815-6d26-4542-96c5-3e631126e592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cda65815-6d26-4542-96c5-3e631126e592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_426c06a6-eefa-4907-a491-a70bc76bc820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_426c06a6-eefa-4907-a491-a70bc76bc820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_08cbfa7b-5105-4616-92b6-c28ddf19d855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_08cbfa7b-5105-4616-92b6-c28ddf19d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_9eba3238-9d62-4672-8908-1060467d7d94" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_9eba3238-9d62-4672-8908-1060467d7d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72c36860-69a9-4150-8288-b56a16de9b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72c36860-69a9-4150-8288-b56a16de9b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_144af985-ab4e-44d7-8436-5d1b2c28464a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_Goodwill_144af985-ab4e-44d7-8436-5d1b2c28464a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b3d35144-0f0b-47ca-b766-84a83f1a0536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b3d35144-0f0b-47ca-b766-84a83f1a0536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a4bddf4a-518a-41b7-94ee-868a35bb31c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a4bddf4a-518a-41b7-94ee-868a35bb31c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_db672821-0d19-4152-b6db-2ecc130814b2" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_db672821-0d19-4152-b6db-2ecc130814b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_17b8f37d-d5cb-45b9-b7a9-a56fbdc4ccb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_17b8f37d-d5cb-45b9-b7a9-a56fbdc4ccb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_722a1d8a-3c65-40d1-a7d3-c95492ea6151" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_722a1d8a-3c65-40d1-a7d3-c95492ea6151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3d810c47-2789-45ed-890f-4469a50e6abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3d810c47-2789-45ed-890f-4469a50e6abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_9a1cc90d-4714-48da-bc43-f7f5a2c70615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_9a1cc90d-4714-48da-bc43-f7f5a2c70615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2a6dccdd-ee01-4840-9a56-36234d6432f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2a6dccdd-ee01-4840-9a56-36234d6432f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3cb07409-1ac5-4b5a-b48f-6720e97fb507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3cb07409-1ac5-4b5a-b48f-6720e97fb507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_d095097a-e4db-4684-b4c7-4a0720a3de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_d095097a-e4db-4684-b4c7-4a0720a3de0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cd0fdde9-7c36-4fb9-bd65-2e78c057888d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cd0fdde9-7c36-4fb9-bd65-2e78c057888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b3ae2527-6c5f-435d-85c0-aa59380de93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d847aef0-8052-4127-b22b-739ed444d8e0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b3ae2527-6c5f-435d-85c0-aa59380de93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsNetCashPaidforAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6e9f94d6-8464-4e8d-b964-f3c7eec53bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6e9f94d6-8464-4e8d-b964-f3c7eec53bc1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e318fca5-6054-43d8-b7a2-36dedcff0a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e318fca5-6054-43d8-b7a2-36dedcff0a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e318fca5-6054-43d8-b7a2-36dedcff0a14" xlink:to="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_b8d9f83c-565d-4974-a36b-1a997771f2e0" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_b8d9f83c-565d-4974-a36b-1a997771f2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_3b02ce3c-40a3-48e4-8c92-f2584e22c27b" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_3b02ce3c-40a3-48e4-8c92-f2584e22c27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_c021cc2f-cd2b-485b-b0fb-eb372747a6a3" xlink:href="ehc-20211231.xsd#ehc_OtherHomeHealthAndHospiceAcquisitionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_aa55bc89-b0a1-4c37-84cb-61309a397c21" xlink:to="loc_ehc_OtherHomeHealthAndHospiceAcquisitionsMember_c021cc2f-cd2b-485b-b0fb-eb372747a6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7854762a-bfdd-4ba7-99f7-9488740945dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7854762a-bfdd-4ba7-99f7-9488740945dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7854762a-bfdd-4ba7-99f7-9488740945dc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_1a974008-33aa-4ac0-9fee-c7555b43422a" xlink:href="ehc-20211231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_1a974008-33aa-4ac0-9fee-c7555b43422a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FrontierHomeHealthAndHospiceMember_43bb5ef8-08c6-4bea-873c-366b71460348" xlink:href="ehc-20211231.xsd#ehc_FrontierHomeHealthAndHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_FrontierHomeHealthAndHospiceMember_43bb5ef8-08c6-4bea-873c-366b71460348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BaptistOutpatientServicesIncMember_6e68a73c-2c7c-4cfa-8b77-f4f992f25c8a" xlink:href="ehc-20211231.xsd#ehc_BaptistOutpatientServicesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_BaptistOutpatientServicesIncMember_6e68a73c-2c7c-4cfa-8b77-f4f992f25c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_b715d60d-1695-4f28-8828-ec7059e190f0" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_b715d60d-1695-4f28-8828-ec7059e190f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsOfLynchburgMember_613da51e-7bcc-4478-b695-ffa72aa6b956" xlink:href="ehc-20211231.xsd#ehc_GenerationSolutionsOfLynchburgMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_GenerationSolutionsOfLynchburgMember_613da51e-7bcc-4478-b695-ffa72aa6b956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember_07a55299-8bca-4702-a676-322190aad458" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_SaintAlphonsusandHeritageValleyMember_07a55299-8bca-4702-a676-322190aad458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember_36c619d2-388f-4c98-8b5b-1df8d1cb3b2f" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_AlacareMember_36c619d2-388f-4c98-8b5b-1df8d1cb3b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember_c775c6a4-0c5e-4d72-bf67-b4f894e41573" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4043bf13-9fdd-40ec-b00b-443aa0763d2b" xlink:to="loc_ehc_TidewaterandCareResourceGroupMember_c775c6a4-0c5e-4d72-bf67-b4f894e41573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e11b2835-606d-430c-bf45-bafa80243844" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_2aedcec2-c115-4cb8-a224-289b7372d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_2aedcec2-c115-4cb8-a224-289b7372d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8f2ee8e3-bd91-4dd5-8394-2c1ac66a95ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8f2ee8e3-bd91-4dd5-8394-2c1ac66a95ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ffcf46f2-8db1-40b2-8fd3-3d771e67b65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ffcf46f2-8db1-40b2-8fd3-3d771e67b65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_43f84922-4243-4b03-a4bc-0168f295d352" xlink:href="ehc-20211231.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_43f84922-4243-4b03-a4bc-0168f295d352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3f37d8f1-08f4-4035-bbbb-6ee70afd88c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3f37d8f1-08f4-4035-bbbb-6ee70afd88c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_6a6c5d39-fb8f-4192-848b-9988df3c8378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_6a6c5d39-fb8f-4192-848b-9988df3c8378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2fe12355-8c22-4e3b-a7cf-db7a73a778e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2fe12355-8c22-4e3b-a7cf-db7a73a778e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_470a3f13-4197-4bad-847e-d3203867e062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bed333d-6c7e-4fec-b380-d941eb199e37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_470a3f13-4197-4bad-847e-d3203867e062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_641360f1-d7fb-4edb-9151-e770469b5ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_641360f1-d7fb-4edb-9151-e770469b5ec8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_617b340d-b71b-4779-b569-328e3d47a548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5d4d95c5-3f18-495b-9d4e-20f8ff90ba86" xlink:to="loc_us-gaap_SegmentDomain_617b340d-b71b-4779-b569-328e3d47a548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_534d83af-942b-4f2a-95f6-799fe8843f4a" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_617b340d-b71b-4779-b569-328e3d47a548" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_534d83af-942b-4f2a-95f6-799fe8843f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_267f079d-3ce0-4673-978b-e1f260304a21" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_617b340d-b71b-4779-b569-328e3d47a548" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_267f079d-3ce0-4673-978b-e1f260304a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5f69bc0a-a29f-44f5-ba64-0ed15a55ae9d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_383cc4f8-06ba-44c2-a4d5-3eca7157628b" xlink:href="ehc-20211231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_383cc4f8-06ba-44c2-a4d5-3eca7157628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusandHeritageValleyMember_d0dc0300-3600-489d-affc-4a8b2f950761" xlink:href="ehc-20211231.xsd#ehc_SaintAlphonsusandHeritageValleyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_SaintAlphonsusandHeritageValleyMember_d0dc0300-3600-489d-affc-4a8b2f950761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AlacareMember_923084e0-1692-4770-8824-58cd09c27991" xlink:href="ehc-20211231.xsd#ehc_AlacareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_AlacareMember_923084e0-1692-4770-8824-58cd09c27991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TidewaterandCareResourceGroupMember_b4e16e14-7c76-4cd7-a1be-5541e1c9aa7b" xlink:href="ehc-20211231.xsd#ehc_TidewaterandCareResourceGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_TidewaterandCareResourceGroupMember_b4e16e14-7c76-4cd7-a1be-5541e1c9aa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsOfLynchburgMember_7573b9e7-f9d3-40a6-aef4-57201cc38196" xlink:href="ehc-20211231.xsd#ehc_GenerationSolutionsOfLynchburgMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_GenerationSolutionsOfLynchburgMember_7573b9e7-f9d3-40a6-aef4-57201cc38196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2021AcquisitionsMember_edb4e621-0bc2-496e-9525-97d1a87ef425" xlink:href="ehc-20211231.xsd#ehc_A2021AcquisitionsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_A2021AcquisitionsMember_edb4e621-0bc2-496e-9525-97d1a87ef425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2020AcquisitionsMember_9c21580e-b099-4fcd-8758-15c14ce0e563" xlink:href="ehc-20211231.xsd#ehc_A2020AcquisitionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_A2020AcquisitionsMember_9c21580e-b099-4fcd-8758-15c14ce0e563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2019AcquisitionsMember_f1283332-eab7-4bf0-9dfd-bd547ba792b6" xlink:href="ehc-20211231.xsd#ehc_A2019AcquisitionsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f7beec-74ed-45b8-930f-96848d45fcf8" xlink:to="loc_ehc_A2019AcquisitionsMember_f1283332-eab7-4bf0-9dfd-bd547ba792b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d71e5427-8caa-470e-89a9-275dd0879305" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_eb5ea83a-7249-410d-9996-d9319808ecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_eb5ea83a-7249-410d-9996-d9319808ecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d16e76c0-c07e-434c-9c2d-155bb16ee51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d16e76c0-c07e-434c-9c2d-155bb16ee51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_dacb9b22-eeea-4b59-8910-189c88669d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_dacb9b22-eeea-4b59-8910-189c88669d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_1c0ce0dc-c1f0-43e0-b452-a67ca7728630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1776115f-819c-412e-adc2-c03ad2c1f55c" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_1c0ce0dc-c1f0-43e0-b452-a67ca7728630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="ehc-20211231.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7e3bb679-6aa4-4a8e-aca7-46ffe9b902ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_0751ec1b-d889-4541-b55e-ce8af70cd049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7e3bb679-6aa4-4a8e-aca7-46ffe9b902ba" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_0751ec1b-d889-4541-b55e-ce8af70cd049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#VariableInterestEntitiesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c89fc401-484b-4bd5-8fd1-eb3353b28a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_03e89bde-bd17-4bca-b5c9-ef18d130702d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c89fc401-484b-4bd5-8fd1-eb3353b28a08" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_03e89bde-bd17-4bca-b5c9-ef18d130702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#VariableInterestEntitiesTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e76bb50b-e743-4bdf-ae7f-d19ebe5abbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e76bb50b-e743-4bdf-ae7f-d19ebe5abbdd" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5f57f7bb-db28-4a9f-8d50-80d12394310d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:to="loc_srt_RangeAxis_5f57f7bb-db28-4a9f-8d50-80d12394310d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_511909e1-254a-448d-a193-35f42a71b197" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5f57f7bb-db28-4a9f-8d50-80d12394310d" xlink:to="loc_srt_RangeMember_511909e1-254a-448d-a193-35f42a71b197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0bee463b-96c2-4d24-a36b-9bcc84786490" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_511909e1-254a-448d-a193-35f42a71b197" xlink:to="loc_srt_MinimumMember_0bee463b-96c2-4d24-a36b-9bcc84786490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99c84a1f-69f0-46c8-a746-5003d44b1162" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_511909e1-254a-448d-a193-35f42a71b197" xlink:to="loc_srt_MaximumMember_99c84a1f-69f0-46c8-a746-5003d44b1162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ee8582b5-0e1c-479d-8613-6fe9b9078a4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ee8582b5-0e1c-479d-8613-6fe9b9078a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_aa552b6d-4fb3-4292-b7a0-0fd783147385" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ee8582b5-0e1c-479d-8613-6fe9b9078a4b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_aa552b6d-4fb3-4292-b7a0-0fd783147385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_adf4f563-efe4-42ed-b3c3-c2007332470d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_aa552b6d-4fb3-4292-b7a0-0fd783147385" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_adf4f563-efe4-42ed-b3c3-c2007332470d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_280a07f2-99a7-4a0e-a05b-24400465672d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_06ffb1dc-3a19-4d4e-9626-8de22b5a9037" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_280a07f2-99a7-4a0e-a05b-24400465672d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_2b5c420f-fdf2-43b3-8e05-4dbafe40b732" xlink:href="ehc-20211231.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_280a07f2-99a7-4a0e-a05b-24400465672d" xlink:to="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_2b5c420f-fdf2-43b3-8e05-4dbafe40b732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_e5c34133-f969-41d4-828e-628cfea0cabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_280a07f2-99a7-4a0e-a05b-24400465672d" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_e5c34133-f969-41d4-828e-628cfea0cabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b07012e3-109c-4026-a0e4-ccd6daacf553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7b3da02c-a9b1-4e8f-9956-8d64624ff6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b07012e3-109c-4026-a0e4-ccd6daacf553" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7b3da02c-a9b1-4e8f-9956-8d64624ff6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0cf69d55-69de-4ac0-8655-2df36df1c903" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7b3da02c-a9b1-4e8f-9956-8d64624ff6d7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0cf69d55-69de-4ac0-8655-2df36df1c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8016d512-1cd6-4f3b-8a23-40c381028c31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0cf69d55-69de-4ac0-8655-2df36df1c903" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8016d512-1cd6-4f3b-8a23-40c381028c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c67042d8-dfad-49cb-82ab-4723b59ad59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8016d512-1cd6-4f3b-8a23-40c381028c31" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c67042d8-dfad-49cb-82ab-4723b59ad59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_5ed26a19-ea56-42e8-99e0-bdec098f98d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7b3da02c-a9b1-4e8f-9956-8d64624ff6d7" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_5ed26a19-ea56-42e8-99e0-bdec098f98d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5ed26a19-ea56-42e8-99e0-bdec098f98d4" xlink:to="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d45cb68-a90c-43be-a497-e152286d8ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d45cb68-a90c-43be-a497-e152286d8ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d2415ba2-cfa1-4e41-9810-07cb32d366bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d2415ba2-cfa1-4e41-9810-07cb32d366bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d49f3260-1924-42da-96d9-31b1eb0521a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:to="loc_us-gaap_OtherAssetsCurrent_d49f3260-1924-42da-96d9-31b1eb0521a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ed623d08-4600-4ff6-9a90-06d9a28ddfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25cab455-e4ac-40be-849e-eb5ef1edf40d" xlink:to="loc_us-gaap_AssetsCurrent_ed623d08-4600-4ff6-9a90-06d9a28ddfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d320dac7-8dd8-4ecd-b6b2-7002367ff7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d320dac7-8dd8-4ecd-b6b2-7002367ff7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c9f6e23-9222-48d1-8b62-dd5d0c166589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c9f6e23-9222-48d1-8b62-dd5d0c166589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ac12d4c7-d42a-430c-b739-26b7eaa92d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_Goodwill_ac12d4c7-d42a-430c-b739-26b7eaa92d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2f76d738-fd4f-48a8-ad76-c01d50015f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2f76d738-fd4f-48a8-ad76-c01d50015f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_3d1df4b2-859d-4a28-859c-e77e824aad06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_3d1df4b2-859d-4a28-859c-e77e824aad06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f8261545-6f0d-49f9-96b2-20fcfc35e901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f8261545-6f0d-49f9-96b2-20fcfc35e901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f0dbdf97-efe4-4cbc-a186-87ff9e3a50da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80648961-3b1d-4866-8576-690d12e4cf9f" xlink:to="loc_us-gaap_Assets_f0dbdf97-efe4-4cbc-a186-87ff9e3a50da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5ed26a19-ea56-42e8-99e0-bdec098f98d4" xlink:to="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9f5ed143-d3de-4706-bbfa-d57e0612a241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9f5ed143-d3de-4706-bbfa-d57e0612a241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f6bdde8-ddf7-47dd-8c03-e12e479153d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f6bdde8-ddf7-47dd-8c03-e12e479153d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e4e20cb8-eef0-4e88-a898-4c18fa48c504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_AccountsPayableCurrent_e4e20cb8-eef0-4e88-a898-4c18fa48c504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e083b192-25e3-4e2a-a6d9-5b018d4cd5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e083b192-25e3-4e2a-a6d9-5b018d4cd5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c35b1c2b-7b72-4dd1-813f-cfb2ca357ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c35b1c2b-7b72-4dd1-813f-cfb2ca357ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_94e8eee9-daad-4f54-8599-ab6d9c6eb682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96d577ae-aa3f-4810-9f6c-bae3bc5c8486" xlink:to="loc_us-gaap_LiabilitiesCurrent_94e8eee9-daad-4f54-8599-ab6d9c6eb682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b9c9bf69-e7b6-49c3-a253-24a296930fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b9c9bf69-e7b6-49c3-a253-24a296930fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f4f9244-0885-4304-bd25-0201242a39ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f4f9244-0885-4304-bd25-0201242a39ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7a0df515-975a-4144-9cde-6f3795da3b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7a0df515-975a-4144-9cde-6f3795da3b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_adcd2ad5-672b-4a1d-b60b-9fb74b556089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c30c52da-59d2-40e8-a59f-57c057e47478" xlink:to="loc_us-gaap_Liabilities_adcd2ad5-672b-4a1d-b60b-9fb74b556089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecurities" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_28c77653-e9c7-4688-9271-c8a1a8edba39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_d47cd740-28aa-4ccc-8474-eff69aa52f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_28c77653-e9c7-4688-9271-c8a1a8edba39" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_d47cd740-28aa-4ccc-8474-eff69aa52f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_acd8e93d-c97b-454b-9fc6-bff4a2650b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_e5de1048-04ad-41b2-9243-8dc9c2a6823f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_acd8e93d-c97b-454b-9fc6-bff4a2650b63" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_e5de1048-04ad-41b2-9243-8dc9c2a6823f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5d73195e-c30c-4965-910c-843646c5f9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_acd8e93d-c97b-454b-9fc6-bff4a2650b63" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5d73195e-c30c-4965-910c-843646c5f9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_7bee2597-e8e5-458b-a414-031a38cc7f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_acd8e93d-c97b-454b-9fc6-bff4a2650b63" xlink:to="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_7bee2597-e8e5-458b-a414-031a38cc7f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecuritiesComponentsofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_31d201d9-df34-468c-b760-c402132f0517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_548d6858-7733-4c9f-9ada-f04e43467439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_31d201d9-df34-468c-b760-c402132f0517" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_548d6858-7733-4c9f-9ada-f04e43467439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f3187ede-f6ef-4559-9e78-cc3280245cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_548d6858-7733-4c9f-9ada-f04e43467439" xlink:to="loc_us-gaap_InvestmentTypeAxis_f3187ede-f6ef-4559-9e78-cc3280245cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4b2a3f68-807a-4df1-a8b4-a413630d814c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f3187ede-f6ef-4559-9e78-cc3280245cb5" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4b2a3f68-807a-4df1-a8b4-a413630d814c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_6f9b0f75-78e1-4cb4-b2ed-c5ee13f70c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b2a3f68-807a-4df1-a8b4-a413630d814c" xlink:to="loc_us-gaap_CashMember_6f9b0f75-78e1-4cb4-b2ed-c5ee13f70c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_2026076f-3876-4632-8c15-3ba91d6e99d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b2a3f68-807a-4df1-a8b4-a413630d814c" xlink:to="loc_us-gaap_EquitySecuritiesMember_2026076f-3876-4632-8c15-3ba91d6e99d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_548d6858-7733-4c9f-9ada-f04e43467439" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff9ffeb-33f8-45f5-a4e5-e54fb767bfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff9ffeb-33f8-45f5-a4e5-e54fb767bfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_78da2ebf-533b-48d5-abec-9d0eaee11a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_78da2ebf-533b-48d5-abec-9d0eaee11a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_62bbeb82-64e3-4020-ae19-5c17b436bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRestricted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_62bbeb82-64e3-4020-ae19-5c17b436bae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InvestmentsCashandRestrictedCash_b5cabde5-0de5-4112-a1f6-bc7cef4e1bc7" xlink:href="ehc-20211231.xsd#ehc_InvestmentsCashandRestrictedCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_c10e89d8-11ec-486f-85e4-b4add1f339b6" xlink:to="loc_ehc_InvestmentsCashandRestrictedCash_b5cabde5-0de5-4112-a1f6-bc7cef4e1bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecuritiesRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_b86eac25-6f85-4870-a158-0af2dbf185f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_24e16110-7793-489e-863a-92af9ecc9be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b86eac25-6f85-4870-a158-0af2dbf185f9" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_24e16110-7793-489e-863a-92af9ecc9be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cb4b5a05-206d-4683-9f7e-fb3f2e06affc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_24e16110-7793-489e-863a-92af9ecc9be6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cb4b5a05-206d-4683-9f7e-fb3f2e06affc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f0ca0345-29db-44e2-95b3-6e51f6ec600b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cb4b5a05-206d-4683-9f7e-fb3f2e06affc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f0ca0345-29db-44e2-95b3-6e51f6ec600b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliateCashMember_d7045a88-168d-4d86-8ddf-a59eb6f9c2fa" xlink:href="ehc-20211231.xsd#ehc_AffiliateCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f0ca0345-29db-44e2-95b3-6e51f6ec600b" xlink:to="loc_ehc_AffiliateCashMember_d7045a88-168d-4d86-8ddf-a59eb6f9c2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SelfInsuredCaptiveFundsMember_bfcd4533-fcb3-4d0b-81de-715c2587aad5" xlink:href="ehc-20211231.xsd#ehc_SelfInsuredCaptiveFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f0ca0345-29db-44e2-95b3-6e51f6ec600b" xlink:to="loc_ehc_SelfInsuredCaptiveFundsMember_bfcd4533-fcb3-4d0b-81de-715c2587aad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fc9af8e2-9b71-48ce-bfa6-ead56f31f016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_24e16110-7793-489e-863a-92af9ecc9be6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fc9af8e2-9b71-48ce-bfa6-ead56f31f016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bb2ee729-686e-411f-9567-dacff597a32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fc9af8e2-9b71-48ce-bfa6-ead56f31f016" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bb2ee729-686e-411f-9567-dacff597a32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2e695e51-ba97-4fef-9393-491ff172721f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fc9af8e2-9b71-48ce-bfa6-ead56f31f016" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2e695e51-ba97-4fef-9393-491ff172721f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecuritiesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_3db733e0-f69d-407c-a7f9-b9bc9f672153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RestrictedDebtSecuritiesNoncurrent_eac94fc8-0941-4ede-9a17-68580ab97a7c" xlink:href="ehc-20211231.xsd#ehc_RestrictedDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3db733e0-f69d-407c-a7f9-b9bc9f672153" xlink:to="loc_ehc_RestrictedDebtSecuritiesNoncurrent_eac94fc8-0941-4ede-9a17-68580ab97a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1e19c8f6-edbd-4e7d-bfa0-6a4e209e41f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3db733e0-f69d-407c-a7f9-b9bc9f672153" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1e19c8f6-edbd-4e7d-bfa0-6a4e209e41f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_b6f948b4-7417-4fe5-8dd0-064e195fa700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_3f5c77c6-5917-458e-8445-10a3ac64bedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b6f948b4-7417-4fe5-8dd0-064e195fa700" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_3f5c77c6-5917-458e-8445-10a3ac64bedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_102c125f-765e-49ab-ba49-ca51df1e02d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_3f5c77c6-5917-458e-8445-10a3ac64bedb" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_102c125f-765e-49ab-ba49-ca51df1e02d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AccountsReceivable" xlink:type="simple" xlink:href="ehc-20211231.xsd#AccountsReceivable"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/AccountsReceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_6fe27506-af33-4ab6-94ae-10d18e9d7383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_bc19ca8e-befa-4e41-b717-e86ec21d9f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6fe27506-af33-4ab6-94ae-10d18e9d7383" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_bc19ca8e-befa-4e41-b717-e86ec21d9f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AccountsReceivableTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#AccountsReceivableTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/AccountsReceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_1ea5a9ec-e1c7-4624-b206-5fe4647aaf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_360aa230-095c-4806-a744-5995bf258722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_1ea5a9ec-e1c7-4624-b206-5fe4647aaf6c" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_360aa230-095c-4806-a744-5995bf258722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#AccountsReceivableComponentsofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_9191af86-7c32-4bc7-a1b2-5a401bd7b720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract_65158dd4-1c95-443b-9c43-3301d9e9e656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_9191af86-7c32-4bc7-a1b2-5a401bd7b720" xlink:to="loc_us-gaap_AccountsReceivableNetCurrentAbstract_65158dd4-1c95-443b-9c43-3301d9e9e656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrentAbstract_068e4e37-923d-4e55-a0c0-17cd25bb160c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_65158dd4-1c95-443b-9c43-3301d9e9e656" xlink:to="loc_us-gaap_OtherReceivablesNetCurrentAbstract_068e4e37-923d-4e55-a0c0-17cd25bb160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43c57033-1338-4bec-b7a2-9813dae322f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherReceivablesNetCurrentAbstract_068e4e37-923d-4e55-a0c0-17cd25bb160c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43c57033-1338-4bec-b7a2-9813dae322f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_5453b568-6b08-49d6-8b5f-7e8e198921d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherReceivablesNetCurrentAbstract_068e4e37-923d-4e55-a0c0-17cd25bb160c" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_5453b568-6b08-49d6-8b5f-7e8e198921d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_80ada6a3-6967-495a-9ae1-0eea500b0f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_9191af86-7c32-4bc7-a1b2-5a401bd7b720" xlink:to="loc_us-gaap_ReceivablesNetCurrent_80ada6a3-6967-495a-9ae1-0eea500b0f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_ece8c9d2-4d48-4379-be21-f59bdeec1b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_9191af86-7c32-4bc7-a1b2-5a401bd7b720" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_ece8c9d2-4d48-4379-be21-f59bdeec1b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d7294416-f596-4bc3-80be-1b1960592f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_9191af86-7c32-4bc7-a1b2-5a401bd7b720" xlink:to="loc_us-gaap_AccountsReceivableNet_d7294416-f596-4bc3-80be-1b1960592f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="ehc-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2326e8d8-b2d7-4151-9b22-03c228f6b089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ff15610e-a590-46c6-8e3a-4b7846780ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2326e8d8-b2d7-4151-9b22-03c228f6b089" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ff15610e-a590-46c6-8e3a-4b7846780ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d757810f-0627-4772-a23d-1e6483501039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_431f46f5-2e56-4753-9b7a-fe59844f3e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d757810f-0627-4772-a23d-1e6483501039" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_431f46f5-2e56-4753-9b7a-fe59844f3e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_60c3a33a-5053-4a6d-b9b1-184b41f7f817" xlink:href="ehc-20211231.xsd#ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d757810f-0627-4772-a23d-1e6483501039" xlink:to="loc_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_60c3a33a-5053-4a6d-b9b1-184b41f7f817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1bfd148d-aa58-430b-b45a-6656375db153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d0b1f24-b4dd-4482-9406-9fa2974925cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1bfd148d-aa58-430b-b45a-6656375db153" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d0b1f24-b4dd-4482-9406-9fa2974925cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67449dbf-cf5f-4c0f-aa24-cc6326434351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d0b1f24-b4dd-4482-9406-9fa2974925cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67449dbf-cf5f-4c0f-aa24-cc6326434351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb734b46-7269-4b71-b9ef-ab8a4c351507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67449dbf-cf5f-4c0f-aa24-cc6326434351" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb734b46-7269-4b71-b9ef-ab8a4c351507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:href="ehc-20211231.xsd#ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb734b46-7269-4b71-b9ef-ab8a4c351507" xlink:to="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_01c5ebf8-388d-4f4c-b0a1-824067d90ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_LandMember_01c5ebf8-388d-4f4c-b0a1-824067d90ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_81f403be-25d0-43a8-9f76-454749496ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_BuildingMember_81f403be-25d0-43a8-9f76-454749496ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d02cb897-8d33-4662-9be0-3dfeab39c241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d02cb897-8d33-4662-9be0-3dfeab39c241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_23bbdba2-df74-46f0-a3c3-4774fa07dc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_VehiclesMember_23bbdba2-df74-46f0-a3c3-4774fa07dc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_971bf603-8afa-4e64-8db8-f228d16cffbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_f3c8d105-a9dd-4ab3-942f-f51cf0e06831" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_971bf603-8afa-4e64-8db8-f228d16cffbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_efea0417-fe0f-43ee-8dcb-c6b17d972a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb734b46-7269-4b71-b9ef-ab8a4c351507" xlink:to="loc_us-gaap_ConstructionInProgressMember_efea0417-fe0f-43ee-8dcb-c6b17d972a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a3befe73-91b2-4bae-8b7b-b789f699ccd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d0b1f24-b4dd-4482-9406-9fa2974925cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a3befe73-91b2-4bae-8b7b-b789f699ccd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a3befe73-91b2-4bae-8b7b-b789f699ccd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_7aa2c6c7-e980-4246-9690-25db141e1663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_7aa2c6c7-e980-4246-9690-25db141e1663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0f687048-4510-418f-aa3c-cb61d5305e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0f687048-4510-418f-aa3c-cb61d5305e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d66b7c59-7c4c-4733-9382-de2d36f859a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_6d6d6294-d42f-427d-9b67-83c8cebb4f06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d66b7c59-7c4c-4733-9382-de2d36f859a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#PropertyandEquipmentTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c86a6f02-1ae7-4b2e-98aa-2fbfff31f67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Percentageofassetspledgedtolendersundercreditagreement_45d443fe-b9ae-4c6c-add0-59572c0d9216" xlink:href="ehc-20211231.xsd#ehc_Percentageofassetspledgedtolendersundercreditagreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c86a6f02-1ae7-4b2e-98aa-2fbfff31f67e" xlink:to="loc_ehc_Percentageofassetspledgedtolendersundercreditagreement_45d443fe-b9ae-4c6c-add0-59572c0d9216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c2894a12-1cad-4454-b380-f9e6e721b26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2fd1b189-2011-4ea2-ba4b-453927ee2c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c2894a12-1cad-4454-b380-f9e6e721b26d" xlink:to="loc_us-gaap_Depreciation_2fd1b189-2011-4ea2-ba4b-453927ee2c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_11a1db79-8a92-44eb-93fa-913fe1fdd645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c2894a12-1cad-4454-b380-f9e6e721b26d" xlink:to="loc_us-gaap_InterestCostsCapitalized_11a1db79-8a92-44eb-93fa-913fe1fdd645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/Leases" xlink:type="simple" xlink:href="ehc-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f3421a08-289d-4472-9710-e6a9e0abef85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_de5d8c42-9136-43ce-bbee-129e832370ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f3421a08-289d-4472-9710-e6a9e0abef85" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_de5d8c42-9136-43ce-bbee-129e832370ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_a8d4a25e-d0f8-4cd3-bb52-11f93640e766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f3421a08-289d-4472-9710-e6a9e0abef85" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_a8d4a25e-d0f8-4cd3-bb52-11f93640e766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8e448e18-be03-4602-8637-eba10cce891b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c9c5671e-cf44-438d-8784-5885424fdf96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e448e18-be03-4602-8637-eba10cce891b" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c9c5671e-cf44-438d-8784-5885424fdf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_2eba7c41-536d-4695-bcd1-e4de156833c6" xlink:href="ehc-20211231.xsd#ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e448e18-be03-4602-8637-eba10cce891b" xlink:to="loc_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_2eba7c41-536d-4695-bcd1-e4de156833c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_26af6412-80b6-40c2-93bf-e51c514b748b" xlink:href="ehc-20211231.xsd#ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e448e18-be03-4602-8637-eba10cce891b" xlink:to="loc_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_26af6412-80b6-40c2-93bf-e51c514b748b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6de220c5-a8a9-4e1e-8a76-6f94d74e4391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e448e18-be03-4602-8637-eba10cce891b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6de220c5-a8a9-4e1e-8a76-6f94d74e4391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_2b8c052c-5d2b-44bc-8654-6e7ae1c22b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e448e18-be03-4602-8637-eba10cce891b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_2b8c052c-5d2b-44bc-8654-6e7ae1c22b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SupplementalCashFlowInformationTableTextBlock_58a62c42-a520-4761-9bef-c26e072e1958" xlink:href="ehc-20211231.xsd#ehc_SupplementalCashFlowInformationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e448e18-be03-4602-8637-eba10cce891b" xlink:to="loc_ehc_SupplementalCashFlowInformationTableTextBlock_58a62c42-a520-4761-9bef-c26e072e1958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesTextualsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8096669a-9019-468f-b9a7-d80e3d2352e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1a660907-af32-44aa-98b9-7bf673b0d08f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8096669a-9019-468f-b9a7-d80e3d2352e1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1a660907-af32-44aa-98b9-7bf673b0d08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1a660907-af32-44aa-98b9-7bf673b0d08f" xlink:to="loc_srt_RangeAxis_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f41e7f96-2372-40ee-8966-41edd53b0022" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ccfae890-7cc3-4e6c-bbdd-64f04ee2b46a" xlink:to="loc_srt_RangeMember_f41e7f96-2372-40ee-8966-41edd53b0022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fc16bc1b-dc5e-4b71-9446-eb5188216d59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f41e7f96-2372-40ee-8966-41edd53b0022" xlink:to="loc_srt_MinimumMember_fc16bc1b-dc5e-4b71-9446-eb5188216d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fae40b6f-8dca-45c7-8b6f-4898613bf043" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f41e7f96-2372-40ee-8966-41edd53b0022" xlink:to="loc_srt_MaximumMember_fae40b6f-8dca-45c7-8b6f-4898613bf043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_83c41ddc-d754-4961-83ac-00b0c196076c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1a660907-af32-44aa-98b9-7bf673b0d08f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_83c41ddc-d754-4961-83ac-00b0c196076c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Operatingandfinanceleasecontractterm_f878c1a1-912a-48f1-bde5-555a3a992872" xlink:href="ehc-20211231.xsd#ehc_Operatingandfinanceleasecontractterm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83c41ddc-d754-4961-83ac-00b0c196076c" xlink:to="loc_ehc_Operatingandfinanceleasecontractterm_f878c1a1-912a-48f1-bde5-555a3a992872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a2cd2aa2-c234-41dd-8dc2-be78440ab1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_29010643-4674-48b2-ac47-0244e5d59f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2cd2aa2-c234-41dd-8dc2-be78440ab1cb" xlink:to="loc_us-gaap_OperatingLeaseCost_29010643-4674-48b2-ac47-0244e5d59f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_c9e94344-c282-455c-b017-398a91244b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2cd2aa2-c234-41dd-8dc2-be78440ab1cb" xlink:to="loc_us-gaap_LeaseCostAbstract_c9e94344-c282-455c-b017-398a91244b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_26d9b214-a62b-4eaa-93db-082bf433a6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c9e94344-c282-455c-b017-398a91244b72" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_26d9b214-a62b-4eaa-93db-082bf433a6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_56034336-ce64-4b5f-831f-51afdae06cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c9e94344-c282-455c-b017-398a91244b72" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_56034336-ce64-4b5f-831f-51afdae06cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalfinanceleasecost_d59416dd-7c95-4b5c-a35e-e83b222b5285" xlink:href="ehc-20211231.xsd#ehc_Totalfinanceleasecost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c9e94344-c282-455c-b017-398a91244b72" xlink:to="loc_ehc_Totalfinanceleasecost_d59416dd-7c95-4b5c-a35e-e83b222b5285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Shorttermandvariableleasecost_2b1de56d-360f-49ac-82b4-21cda0d50742" xlink:href="ehc-20211231.xsd#ehc_Shorttermandvariableleasecost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2cd2aa2-c234-41dd-8dc2-be78440ab1cb" xlink:to="loc_ehc_Shorttermandvariableleasecost_2b1de56d-360f-49ac-82b4-21cda0d50742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_de12b568-2775-4d4d-b65e-74c87ec4f358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2cd2aa2-c234-41dd-8dc2-be78440ab1cb" xlink:to="loc_us-gaap_SubleaseIncome_de12b568-2775-4d4d-b65e-74c87ec4f358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9046ba77-d0d6-40a3-8f04-fafde41d006f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2cd2aa2-c234-41dd-8dc2-be78440ab1cb" xlink:to="loc_us-gaap_LeaseCost_9046ba77-d0d6-40a3-8f04-fafde41d006f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ae21a624-effc-46c7-9636-d092e2c38d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_96e00c78-787c-4346-ac9a-e3e5e8c1dd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae21a624-effc-46c7-9636-d092e2c38d97" xlink:to="loc_us-gaap_AssetsAbstract_96e00c78-787c-4346-ac9a-e3e5e8c1dd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_40806bd0-73db-4728-b70f-98ff9c3c8a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_96e00c78-787c-4346-ac9a-e3e5e8c1dd0b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_40806bd0-73db-4728-b70f-98ff9c3c8a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_9adabafe-76e7-4ab7-bf3e-061092ae5bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_96e00c78-787c-4346-ac9a-e3e5e8c1dd0b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_9adabafe-76e7-4ab7-bf3e-061092ae5bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totaloperatingandfinanceleaseassets_23f2379d-8bf8-43c9-bbf3-18b6e01faefb" xlink:href="ehc-20211231.xsd#ehc_Totaloperatingandfinanceleaseassets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_96e00c78-787c-4346-ac9a-e3e5e8c1dd0b" xlink:to="loc_ehc_Totaloperatingandfinanceleaseassets_23f2379d-8bf8-43c9-bbf3-18b6e01faefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_1450c93a-9f0e-4a4c-8c6e-08bbc1daffdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae21a624-effc-46c7-9636-d092e2c38d97" xlink:to="loc_us-gaap_LiabilitiesAbstract_1450c93a-9f0e-4a4c-8c6e-08bbc1daffdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_43f90523-b3be-4195-b19d-67fcabe4ec4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1450c93a-9f0e-4a4c-8c6e-08bbc1daffdc" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_43f90523-b3be-4195-b19d-67fcabe4ec4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_126f40fe-5ebf-40a2-a5ca-91dfbdb35bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43f90523-b3be-4195-b19d-67fcabe4ec4b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_126f40fe-5ebf-40a2-a5ca-91dfbdb35bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_880d1045-8b41-457b-8477-f863623c8474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43f90523-b3be-4195-b19d-67fcabe4ec4b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_880d1045-8b41-457b-8477-f863623c8474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_265d0c18-7895-4a52-aa40-9e2b0007d9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1450c93a-9f0e-4a4c-8c6e-08bbc1daffdc" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_265d0c18-7895-4a52-aa40-9e2b0007d9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_24bbd833-b057-46ef-afe3-4a01a21f3c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_265d0c18-7895-4a52-aa40-9e2b0007d9f8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_24bbd833-b057-46ef-afe3-4a01a21f3c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c71a8ae2-c93e-4b18-8546-09b2709c0e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_265d0c18-7895-4a52-aa40-9e2b0007d9f8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c71a8ae2-c93e-4b18-8546-09b2709c0e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalleaseliabilities_1f5df009-5cad-4be1-8657-48e801412cc8" xlink:href="ehc-20211231.xsd#ehc_Totalleaseliabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae21a624-effc-46c7-9636-d092e2c38d97" xlink:to="loc_ehc_Totalleaseliabilities_1f5df009-5cad-4be1-8657-48e801412cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_6a322956-4644-4604-9726-b78fc62f664d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae21a624-effc-46c7-9636-d092e2c38d97" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_6a322956-4644-4604-9726-b78fc62f664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_169e5ee3-fe1b-46dd-b5f1-40b2dfec91d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae21a624-effc-46c7-9636-d092e2c38d97" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_169e5ee3-fe1b-46dd-b5f1-40b2dfec91d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8d9b7cdc-0710-4839-b6e8-5143470ca4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae21a624-effc-46c7-9636-d092e2c38d97" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8d9b7cdc-0710-4839-b6e8-5143470ca4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_7caf0edb-ccd7-4fe9-a271-7e0b2bf33323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ae21a624-effc-46c7-9636-d092e2c38d97" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_7caf0edb-ccd7-4fe9-a271-7e0b2bf33323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_66f881f1-ad74-47c4-815b-a6d7a486f129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WeightedAverageRemainingLeaseTermAbstract_ede3a41c-a6cc-4535-8827-a59595a1090e" xlink:href="ehc-20211231.xsd#ehc_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66f881f1-ad74-47c4-815b-a6d7a486f129" xlink:to="loc_ehc_WeightedAverageRemainingLeaseTermAbstract_ede3a41c-a6cc-4535-8827-a59595a1090e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b5eab31b-f0f6-4d1f-895b-d2532f7a7bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_WeightedAverageRemainingLeaseTermAbstract_ede3a41c-a6cc-4535-8827-a59595a1090e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b5eab31b-f0f6-4d1f-895b-d2532f7a7bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b49d8e73-650d-4321-9da2-c066fd3fdc34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_WeightedAverageRemainingLeaseTermAbstract_ede3a41c-a6cc-4535-8827-a59595a1090e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b49d8e73-650d-4321-9da2-c066fd3fdc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WeightedAverageDiscountRateAbstract_e4ec051e-de7f-4396-886a-738c0df2d29c" xlink:href="ehc-20211231.xsd#ehc_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66f881f1-ad74-47c4-815b-a6d7a486f129" xlink:to="loc_ehc_WeightedAverageDiscountRateAbstract_e4ec051e-de7f-4396-886a-738c0df2d29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7eb054f9-4e3d-4987-a68f-434235aff74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_WeightedAverageDiscountRateAbstract_e4ec051e-de7f-4396-886a-738c0df2d29c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7eb054f9-4e3d-4987-a68f-434235aff74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_5c57b67c-266a-4682-8386-4c56eb00d861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_WeightedAverageDiscountRateAbstract_e4ec051e-de7f-4396-886a-738c0df2d29c" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_5c57b67c-266a-4682-8386-4c56eb00d861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0817319e-768e-4351-9096-88b48ed1a993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0817319e-768e-4351-9096-88b48ed1a993" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e3566c44-8470-4e3c-904a-339d8d36a67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e3566c44-8470-4e3c-904a-339d8d36a67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_236ec498-dbe7-4671-b82e-9f23dff9e80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_236ec498-dbe7-4671-b82e-9f23dff9e80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8e85892-3e85-425e-b23a-5b79a5551273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8e85892-3e85-425e-b23a-5b79a5551273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3de32b86-5a44-40f7-b7bc-d3c885fceff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3de32b86-5a44-40f7-b7bc-d3c885fceff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_11be946d-c2ef-4555-9c27-6b57173c6e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_11be946d-c2ef-4555-9c27-6b57173c6e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_cea45378-2042-4750-8634-aed86a9e171a" xlink:href="ehc-20211231.xsd#ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_cea45378-2042-4750-8634-aed86a9e171a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_569338bd-10c8-4e2e-b752-35bb43f23cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_569338bd-10c8-4e2e-b752-35bb43f23cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_da99ec23-d625-4a7b-83c7-b14c032835df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_da99ec23-d625-4a7b-83c7-b14c032835df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b6113d87-21fa-41f6-9a4f-e9b14f2d916a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_128e3f66-5f80-4be2-bb99-8cb2f14f9ce9" xlink:to="loc_us-gaap_OperatingLeaseLiability_b6113d87-21fa-41f6-9a4f-e9b14f2d916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0817319e-768e-4351-9096-88b48ed1a993" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3ef062e6-1eb7-4b7f-b7c6-fb3013b501e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3ef062e6-1eb7-4b7f-b7c6-fb3013b501e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ea6e297b-27d3-413e-b353-b4e61bf09f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ea6e297b-27d3-413e-b353-b4e61bf09f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9e172563-023f-4ce9-bcb7-ad3d3bf1a4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9e172563-023f-4ce9-bcb7-ad3d3bf1a4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8d06d0c3-8991-440b-83b1-7a613e0e35f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8d06d0c3-8991-440b-83b1-7a613e0e35f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b35d1c88-ca2e-4721-8e86-07cafa138279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b35d1c88-ca2e-4721-8e86-07cafa138279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_d47c766e-e492-4314-bf90-2b38a96f713e" xlink:href="ehc-20211231.xsd#ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_d47c766e-e492-4314-bf90-2b38a96f713e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9a1963c1-b585-4a7b-a9cf-f6093096ef09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9a1963c1-b585-4a7b-a9cf-f6093096ef09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d9dcdd8d-2a6e-4ed4-b06f-9db10ddd37d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d9dcdd8d-2a6e-4ed4-b06f-9db10ddd37d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_2cb43a8e-c23c-4026-9993-55616dd25393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ee9800d-2300-4cd9-8056-0644ca9c7f8a" xlink:to="loc_us-gaap_FinanceLeaseLiability_2cb43a8e-c23c-4026-9993-55616dd25393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_36bb7cdb-8f88-4d34-a3ea-b369cf9034ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_ad1d891f-8edb-4580-894e-ee737c931d81" xlink:href="ehc-20211231.xsd#ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36bb7cdb-8f88-4d34-a3ea-b369cf9034ee" xlink:to="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_ad1d891f-8edb-4580-894e-ee737c931d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_40b15208-2205-4537-8776-14e3cb750afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_ad1d891f-8edb-4580-894e-ee737c931d81" xlink:to="loc_us-gaap_OperatingLeasePayments_40b15208-2205-4537-8776-14e3cb750afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_7a3b8a10-4d77-4ed9-94ba-e0944a3b8055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_ad1d891f-8edb-4580-894e-ee737c931d81" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_7a3b8a10-4d77-4ed9-94ba-e0944a3b8055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_66852bfb-7452-4bdc-96b1-349abe5474c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_ad1d891f-8edb-4580-894e-ee737c931d81" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_66852bfb-7452-4bdc-96b1-349abe5474c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_331c33e9-8159-4f10-985b-6a1d5d2e29a2" xlink:href="ehc-20211231.xsd#ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36bb7cdb-8f88-4d34-a3ea-b369cf9034ee" xlink:to="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_331c33e9-8159-4f10-985b-6a1d5d2e29a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b2aef4d7-bd03-4add-ab87-46542e804009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_331c33e9-8159-4f10-985b-6a1d5d2e29a2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b2aef4d7-bd03-4add-ab87-46542e804009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_994e4dc3-6dda-48db-ba36-03711612a1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_331c33e9-8159-4f10-985b-6a1d5d2e29a2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_994e4dc3-6dda-48db-ba36-03711612a1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6396263a-796f-4454-b6e1-c4329d4af160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1b4fe767-68fa-47ad-80c8-c1d3ac2606dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6396263a-796f-4454-b6e1-c4329d4af160" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1b4fe767-68fa-47ad-80c8-c1d3ac2606dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8f32eb05-0790-4243-a963-db48752ee516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_6c601f2e-1185-4afb-aa25-37b5e7fd5f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8f32eb05-0790-4243-a963-db48752ee516" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_6c601f2e-1185-4afb-aa25-37b5e7fd5f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a66e8866-b31a-49fa-86c6-5c0f516fa06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8f32eb05-0790-4243-a963-db48752ee516" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a66e8866-b31a-49fa-86c6-5c0f516fa06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_48cbb3fd-6104-4c0f-8ad8-796af0b257d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8f32eb05-0790-4243-a963-db48752ee516" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_48cbb3fd-6104-4c0f-8ad8-796af0b257d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8ec01cb8-b26c-4414-8fc2-305e0f4a421d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8f32eb05-0790-4243-a963-db48752ee516" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8ec01cb8-b26c-4414-8fc2-305e0f4a421d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b9cdf21-02db-428b-868b-1dc717da6307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b675d3f2-9bd8-4d35-af0b-b3ff92164e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b9cdf21-02db-428b-868b-1dc717da6307" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b675d3f2-9bd8-4d35-af0b-b3ff92164e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ec216204-4512-466d-81fd-652c1d082f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b675d3f2-9bd8-4d35-af0b-b3ff92164e38" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ec216204-4512-466d-81fd-652c1d082f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8276468d-f103-401a-a53e-3671505f42e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ec216204-4512-466d-81fd-652c1d082f88" xlink:to="loc_us-gaap_SegmentDomain_8276468d-f103-401a-a53e-3671505f42e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_c3bf4041-527f-4003-9617-16dcb065ac63" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8276468d-f103-401a-a53e-3671505f42e2" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_c3bf4041-527f-4003-9617-16dcb065ac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_90ec00e4-9560-41a8-a22a-1a8952710e5f" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8276468d-f103-401a-a53e-3671505f42e2" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_90ec00e4-9560-41a8-a22a-1a8952710e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ebde400f-a278-4916-8145-cc01c3c8f810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b675d3f2-9bd8-4d35-af0b-b3ff92164e38" xlink:to="loc_us-gaap_GoodwillLineItems_ebde400f-a278-4916-8145-cc01c3c8f810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ebde400f-a278-4916-8145-cc01c3c8f810" xlink:to="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9fee4af3-181b-41fe-89ef-5b3f6c280fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:to="loc_us-gaap_Goodwill_9fee4af3-181b-41fe-89ef-5b3f6c280fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0675da6b-d63c-4c82-8de6-203039a2cbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0675da6b-d63c-4c82-8de6-203039a2cbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod_9e209cde-c70d-4a22-bfc7-a73a403c763c" xlink:href="ehc-20211231.xsd#ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:to="loc_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod_9e209cde-c70d-4a22-bfc7-a73a403c763c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_822ffd68-3ec9-4b19-a80f-20f3add88eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_755db064-bf38-4723-8d7d-1f18eb599755" xlink:to="loc_us-gaap_Goodwill_822ffd68-3ec9-4b19-a80f-20f3add88eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_13cbd45c-da21-4812-8443-30bff7537e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f5c3a157-63f9-41bf-96cc-c59f3a8268e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_13cbd45c-da21-4812-8443-30bff7537e33" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f5c3a157-63f9-41bf-96cc-c59f3a8268e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6f45cf5e-5830-4e38-a20f-a69e55b3fb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_13cbd45c-da21-4812-8443-30bff7537e33" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6f45cf5e-5830-4e38-a20f-a69e55b3fb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_abe027d5-bbec-4aa4-8e2b-5e669f9e174d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1eeb3b2d-a7bb-4ceb-9deb-a7903f9b397c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_abe027d5-bbec-4aa4-8e2b-5e669f9e174d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1eeb3b2d-a7bb-4ceb-9deb-a7903f9b397c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76c9b711-d691-4eb9-9507-baafe524d660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1eeb3b2d-a7bb-4ceb-9deb-a7903f9b397c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76c9b711-d691-4eb9-9507-baafe524d660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76c9b711-d691-4eb9-9507-baafe524d660" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_bd084c4f-3a11-48dd-8ee7-d5098427f546" xlink:href="ehc-20211231.xsd#ehc_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_ehc_CertificateOfNeedMember_bd084c4f-3a11-48dd-8ee7-d5098427f546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_d388d3d5-b9dc-49da-9f40-0950b86f5bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_us-gaap_LicensingAgreementsMember_d388d3d5-b9dc-49da-9f40-0950b86f5bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_b7337059-c738-43b2-ae6c-326159a5dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_b7337059-c738-43b2-ae6c-326159a5dc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TradeNameEncompassMember_ad3e0656-e566-4f26-95da-050c5aaef279" xlink:href="ehc-20211231.xsd#ehc_TradeNameEncompassMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_ehc_TradeNameEncompassMember_ad3e0656-e566-4f26-95da-050c5aaef279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_878227ae-32ee-477a-aff6-516fa02f65fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_us-gaap_TradeNamesMember_878227ae-32ee-477a-aff6-516fa02f65fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ada98977-9f0e-4996-bc0b-7766cdf2f159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ada98977-9f0e-4996-bc0b-7766cdf2f159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_40750c3e-7b46-4fe8-8a1b-f461c75e4e4f" xlink:href="ehc-20211231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abcc8145-0275-456a-b461-5b5ecd41c370" xlink:to="loc_ehc_MarketAccessAssetsMember_40750c3e-7b46-4fe8-8a1b-f461c75e4e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26205c02-965e-40f5-9b7c-4f9fd5aa846a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1eeb3b2d-a7bb-4ceb-9deb-a7903f9b397c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26205c02-965e-40f5-9b7c-4f9fd5aa846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26205c02-965e-40f5-9b7c-4f9fd5aa846a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_342651d4-196d-4250-aa26-ccc975ece8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_342651d4-196d-4250-aa26-ccc975ece8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_798ff905-c53f-464c-88c4-967f0aec665f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_798ff905-c53f-464c-88c4-967f0aec665f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b257ba47-2404-41c5-9665-599c0032cdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_12bda3de-f724-4ae2-b472-e02df9bae038" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b257ba47-2404-41c5-9665-599c0032cdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_df9152e4-0abb-4560-ae1b-14b94d0c3692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_40f2eeb2-1c94-49ef-8d92-821c777f58f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_df9152e4-0abb-4560-ae1b-14b94d0c3692" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_40f2eeb2-1c94-49ef-8d92-821c777f58f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9e042f1-f47d-458c-8ce3-b661acbdeee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_eca77b88-8e1e-4fed-a325-c7473edfe013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9e042f1-f47d-458c-8ce3-b661acbdeee9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_eca77b88-8e1e-4fed-a325-c7473edfe013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5bf46117-067f-49b5-95a7-162b9776799f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_eca77b88-8e1e-4fed-a325-c7473edfe013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5bf46117-067f-49b5-95a7-162b9776799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_04bb38f9-8c39-484b-91d2-047c609d6ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_eca77b88-8e1e-4fed-a325-c7473edfe013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_04bb38f9-8c39-484b-91d2-047c609d6ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bfc998f8-af33-4207-a7c8-16ce053e892f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_eca77b88-8e1e-4fed-a325-c7473edfe013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bfc998f8-af33-4207-a7c8-16ce053e892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ec7eb977-cc61-42b4-bfa8-a98e675e358d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_eca77b88-8e1e-4fed-a325-c7473edfe013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ec7eb977-cc61-42b4-bfa8-a98e675e358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6a9ef828-9f4f-46eb-a0d9-5ea5cc7e8d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_eca77b88-8e1e-4fed-a325-c7473edfe013" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6a9ef828-9f4f-46eb-a0d9-5ea5cc7e8d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliates" xlink:type="simple" xlink:href="ehc-20211231.xsd#InvestmentsinandAdvancestoNonconsolidatedAffiliates"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_2e839941-e5ad-430a-81a4-954ddef3ec12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_76a49498-e188-4810-80ce-ac5be3b9dd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_2e839941-e5ad-430a-81a4-954ddef3ec12" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_76a49498-e188-4810-80ce-ac5be3b9dd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_d630d9c8-e0e3-4ae8-b6d8-5bb6b00fabc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock_7b490a38-0f28-4aff-9917-1055bb8d5802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_d630d9c8-e0e3-4ae8-b6d8-5bb6b00fabc6" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock_7b490a38-0f28-4aff-9917-1055bb8d5802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_86aebec2-47e2-4354-a617-e47d218819fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_d630d9c8-e0e3-4ae8-b6d8-5bb6b00fabc6" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_86aebec2-47e2-4354-a617-e47d218819fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_c12876e4-f5c4-4a16-b247-efc96fcf8161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_c12876e4-f5c4-4a16-b247-efc96fcf8161" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:to="loc_srt_RangeAxis_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f5d9d4c-f25d-41a8-91ce-69a012c26f5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aecdd3c2-35bd-48d6-9075-b0fc2858f9ab" xlink:to="loc_srt_RangeMember_0f5d9d4c-f25d-41a8-91ce-69a012c26f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_25555743-94f7-4680-89d9-8bf761c86e3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0f5d9d4c-f25d-41a8-91ce-69a012c26f5a" xlink:to="loc_srt_MinimumMember_25555743-94f7-4680-89d9-8bf761c86e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5462ee75-a2c0-411a-aa62-9ef7d25f5305" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0f5d9d4c-f25d-41a8-91ce-69a012c26f5a" xlink:to="loc_srt_MaximumMember_5462ee75-a2c0-411a-aa62-9ef7d25f5305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89c55994-4c8b-468a-bb5d-de9795d0c4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89c55994-4c8b-468a-bb5d-de9795d0c4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91b00181-45ee-48fa-88f8-b4754c659e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89c55994-4c8b-468a-bb5d-de9795d0c4ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91b00181-45ee-48fa-88f8-b4754c659e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_JupiterFloridaHomeHealthAgencyMember_c9d183fa-3817-44ab-ba15-7b9ec7321baf" xlink:href="ehc-20211231.xsd#ehc_JupiterFloridaHomeHealthAgencyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91b00181-45ee-48fa-88f8-b4754c659e43" xlink:to="loc_ehc_JupiterFloridaHomeHealthAgencyMember_c9d183fa-3817-44ab-ba15-7b9ec7321baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_YumaRehabilitationHospitalMember_168c576f-7339-49ea-9bcd-c154143878a2" xlink:href="ehc-20211231.xsd#ehc_YumaRehabilitationHospitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91b00181-45ee-48fa-88f8-b4754c659e43" xlink:to="loc_ehc_YumaRehabilitationHospitalMember_168c576f-7339-49ea-9bcd-c154143878a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_00622566-1c25-4f4d-a77b-41a05dea3197" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated_13cb8914-166c-4ddb-ac6b-5cb9745a9851" xlink:href="ehc-20211231.xsd#ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated_13cb8914-166c-4ddb-ac6b-5cb9745a9851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures_e5ad4779-e07a-441a-84d4-eb813dcaf5da" xlink:href="ehc-20211231.xsd#ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures_e5ad4779-e07a-441a-84d4-eb813dcaf5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliatesOwnershipPercentage_5f056b0a-a19c-4fa0-8864-64553b6672f1" xlink:href="ehc-20211231.xsd#ehc_AffiliatesOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_ehc_AffiliatesOwnershipPercentage_5f056b0a-a19c-4fa0-8864-64553b6672f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_895e8f94-3bcf-4fb8-a34d-ced58280f588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_895e8f94-3bcf-4fb8-a34d-ced58280f588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_5f73918c-fb8b-4e38-812e-ea9ea4840903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_fb0a051f-6423-4aff-930f-e15aa64f85b0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_5f73918c-fb8b-4e38-812e-ea9ea4840903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_6ed80026-fef4-4d0f-aaf4-54527aead0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_7470fdf7-6d08-49d9-b582-05f5e20e445b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_6ed80026-fef4-4d0f-aaf4-54527aead0f4" xlink:to="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_7470fdf7-6d08-49d9-b582-05f5e20e445b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_74ca8fa7-d197-44c8-84e3-1e200527907c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_7470fdf7-6d08-49d9-b582-05f5e20e445b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_74ca8fa7-d197-44c8-84e3-1e200527907c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments_8d3ac04d-d73a-4185-9f87-e530644d1256" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_7470fdf7-6d08-49d9-b582-05f5e20e445b" xlink:to="loc_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments_8d3ac04d-d73a-4185-9f87-e530644d1256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments_5cb656a1-7f27-41c7-978b-0379332d3660" xlink:href="ehc-20211231.xsd#ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_7470fdf7-6d08-49d9-b582-05f5e20e445b" xlink:to="loc_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments_5cb656a1-7f27-41c7-978b-0379332d3660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_746e72a9-ed02-46d4-8750-6bc9e3ed3b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract_7470fdf7-6d08-49d9-b582-05f5e20e445b" xlink:to="loc_us-gaap_EquityMethodInvestments_746e72a9-ed02-46d4-8750-6bc9e3ed3b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0f4414eb-c729-4df2-85e3-b407325d7441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_6ed80026-fef4-4d0f-aaf4-54527aead0f4" xlink:to="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0f4414eb-c729-4df2-85e3-b407325d7441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e98f8a9d-13cf-4083-a1ff-3ef2b9461ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0f4414eb-c729-4df2-85e3-b407325d7441" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e98f8a9d-13cf-4083-a1ff-3ef2b9461ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d16d105b-cd21-432f-af37-4cab2172f18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_6ed80026-fef4-4d0f-aaf4-54527aead0f4" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d16d105b-cd21-432f-af37-4cab2172f18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_653fc864-bbd9-43a1-bce5-653f3a5a68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4bc2a74a-bb18-4db8-ab4f-69a34b8bb45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_653fc864-bbd9-43a1-bce5-653f3a5a68fe" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4bc2a74a-bb18-4db8-ab4f-69a34b8bb45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_350e2f63-4464-49ec-93dc-85b0750264c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4bc2a74a-bb18-4db8-ab4f-69a34b8bb45c" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_350e2f63-4464-49ec-93dc-85b0750264c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b1f965b7-ff9c-4a60-8f9a-95a16de9cb71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_350e2f63-4464-49ec-93dc-85b0750264c1" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b1f965b7-ff9c-4a60-8f9a-95a16de9cb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_bc395c68-5634-4f68-8d30-6e4911dd3aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b1f965b7-ff9c-4a60-8f9a-95a16de9cb71" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_bc395c68-5634-4f68-8d30-6e4911dd3aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4bc2a74a-bb18-4db8-ab4f-69a34b8bb45c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23eb7ba0-805e-4e24-bfd0-aef6285b9a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:to="loc_us-gaap_AssetsCurrent_23eb7ba0-805e-4e24-bfd0-aef6285b9a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_0aa49245-4b3b-4f8f-8c36-ffcf665de553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:to="loc_us-gaap_AssetsNoncurrent_0aa49245-4b3b-4f8f-8c36-ffcf665de553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_69457acf-f961-4a63-ad17-6d6a50ac00b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ec1d693-e80a-4222-a64a-884668c27846" xlink:to="loc_us-gaap_Assets_69457acf-f961-4a63-ad17-6d6a50ac00b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2c8c4bae-408c-4f12-a929-d3ee0d86556b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:to="loc_us-gaap_LiabilitiesCurrent_2c8c4bae-408c-4f12-a929-d3ee0d86556b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_68164dc9-779a-4090-a07e-c838cb665b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_68164dc9-779a-4090-a07e-c838cb665b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_371a300c-22de-4519-9b00-b59d97da4e5e" xlink:to="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c628e9c5-bcc3-451d-85a9-e6e942310c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:to="loc_us-gaap_StockholdersEquity_c628e9c5-bcc3-451d-85a9-e6e942310c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3d088def-6a47-429b-b382-307598a2f1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:to="loc_us-gaap_MinorityInterest_3d088def-6a47-429b-b382-307598a2f1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a222de58-8d3d-4820-aea8-6d000337343d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c4d431f3-b9e5-42cb-b5d8-8c8f6bd22460" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a222de58-8d3d-4820-aea8-6d000337343d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bab6e29-321c-454e-a44b-03df967d8444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bab6e29-321c-454e-a44b-03df967d8444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_92915841-3ce6-428f-9ae4-34da6c989f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_CostsAndExpenses_92915841-3ce6-428f-9ae4-34da6c989f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8c89f238-d697-47f0-afbc-f1a73b190688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8c89f238-d697-47f0-afbc-f1a73b190688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_41a6ac2e-eba1-4f6f-9189-ddac59f4e9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a269c268-cf08-4772-8b93-7451eae95ff5" xlink:to="loc_us-gaap_ProfitLoss_41a6ac2e-eba1-4f6f-9189-ddac59f4e9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8ad940f8-b59b-418a-aece-fabbdf126039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_240c7470-66e8-40ae-96c8-f44cd337544a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ad940f8-b59b-418a-aece-fabbdf126039" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_240c7470-66e8-40ae-96c8-f44cd337544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fa7ddd67-d818-497e-9880-89a203f51793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b63768d9-2dee-4d98-8315-7c822d274836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fa7ddd67-d818-497e-9880-89a203f51793" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b63768d9-2dee-4d98-8315-7c822d274836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0e258d19-ed76-4121-8ced-52a9c79262bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fa7ddd67-d818-497e-9880-89a203f51793" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0e258d19-ed76-4121-8ced-52a9c79262bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock_ddf54179-14e8-46dd-93ac-03ec290db291" xlink:href="ehc-20211231.xsd#ehc_ScheduleOfFinancialCovenantsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fa7ddd67-d818-497e-9880-89a203f51793" xlink:to="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock_ddf54179-14e8-46dd-93ac-03ec290db291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock_a571d7bb-30dc-4429-bf83-594f38bfb960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fa7ddd67-d818-497e-9880-89a203f51793" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock_a571d7bb-30dc-4429-bf83-594f38bfb960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_19ea8f2a-b986-4927-a46e-574f13bfc63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_19ea8f2a-b986-4927-a46e-574f13bfc63b" xlink:to="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e4092122-47b3-4ac8-ac63-16b213821317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:to="loc_us-gaap_CreditFacilityAxis_e4092122-47b3-4ac8-ac63-16b213821317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f5b0cf2a-ba47-414c-881f-00b39644882e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e4092122-47b3-4ac8-ac63-16b213821317" xlink:to="loc_us-gaap_CreditFacilityDomain_f5b0cf2a-ba47-414c-881f-00b39644882e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_ecdc93bf-620b-4597-b8c5-d26d63673f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f5b0cf2a-ba47-414c-881f-00b39644882e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_ecdc93bf-620b-4597-b8c5-d26d63673f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_16e06b3e-bc27-4074-83b6-995a3230dbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_16e06b3e-bc27-4074-83b6-995a3230dbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_16e06b3e-bc27-4074-83b6-995a3230dbb5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_4c3f9c3c-c2a4-466d-904e-f50b70355cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:to="loc_us-gaap_LoansPayableMember_4c3f9c3c-c2a4-466d-904e-f50b70355cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_da25809c-a4eb-4518-8ced-9752bd3f4cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:to="loc_us-gaap_SeniorNotesMember_da25809c-a4eb-4518-8ced-9752bd3f4cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ca65b63d-2674-4933-bf97-b22eff6a6bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4756f3d8-20a9-44a6-8713-c45bdb3be5cf" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ca65b63d-2674-4933-bf97-b22eff6a6bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5f2a96f6-413b-4d1a-b0b9-913868664fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:to="loc_us-gaap_DebtInstrumentAxis_5f2a96f6-413b-4d1a-b0b9-913868664fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f2a96f6-413b-4d1a-b0b9-913868664fe0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_3acb468f-96b2-4b16-9b1e-59f41eddd7cf" xlink:href="ehc-20211231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_TermLoanFacilitiesMember_3acb468f-96b2-4b16-9b1e-59f41eddd7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_faeddfa8-fba4-4d56-a8ad-52a33a263781" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_faeddfa8-fba4-4d56-a8ad-52a33a263781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_2c201dbd-606e-4e89-bf79-2d2e2388b5a2" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_2c201dbd-606e-4e89-bf79-2d2e2388b5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_dd25878f-5c4e-413f-93be-099c6359a50e" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_dd25878f-5c4e-413f-93be-099c6359a50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_d6bd55dc-1c87-47a0-9dbe-0a6ed44cb880" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_d6bd55dc-1c87-47a0-9dbe-0a6ed44cb880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_b6928df6-8b2d-420e-9917-1bcd6c3fdde0" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7fa70c0-6ac3-466d-b0d9-45187ef108a3" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_b6928df6-8b2d-420e-9917-1bcd6c3fdde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f38eedb5-0420-423f-92c7-590b18512851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5fd1b3ca-34ae-4a9d-819d-afdbd0eaeddb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f38eedb5-0420-423f-92c7-590b18512851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f38eedb5-0420-423f-92c7-590b18512851" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc8732da-d605-41ac-8039-aeffcbedf2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bc8732da-d605-41ac-8039-aeffcbedf2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_23bf9d0b-6fa5-47c4-a9b0-64a2f9b8f556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_LongTermDebt_23bf9d0b-6fa5-47c4-a9b0-64a2f9b8f556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5569be0f-fa17-44c7-8209-8ee1faae1526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_FinanceLeaseLiability_5569be0f-fa17-44c7-8209-8ee1faae1526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_84493dce-0f1b-4d0b-9574-5f8b9e60e683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_84493dce-0f1b-4d0b-9574-5f8b9e60e683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_14ba759b-bb8e-45e1-a23d-af2d42f6a23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_14ba759b-bb8e-45e1-a23d-af2d42f6a23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_434b5f34-1129-4e26-b78c-244cf90c9f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_158fea0b-b7e1-4846-9291-93238bbcf1c9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_434b5f34-1129-4e26-b78c-244cf90c9f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtLongtermDebtOutstandingDetails_1"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_05a70e9e-40df-4df9-8f8e-ad3ac61688e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_77a2faa6-feb9-4036-b984-3287e1776670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05a70e9e-40df-4df9-8f8e-ad3ac61688e9" xlink:to="loc_us-gaap_DebtInstrumentTable_77a2faa6-feb9-4036-b984-3287e1776670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe3af7fc-6690-495f-bb27-a979040cb2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_77a2faa6-feb9-4036-b984-3287e1776670" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe3af7fc-6690-495f-bb27-a979040cb2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e46cb863-0de3-4d5e-94b8-75491e9b1f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe3af7fc-6690-495f-bb27-a979040cb2b1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e46cb863-0de3-4d5e-94b8-75491e9b1f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FaceAmountMember_0dfa20fe-8015-40d3-afad-9382dac58cb7" xlink:href="ehc-20211231.xsd#ehc_FaceAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e46cb863-0de3-4d5e-94b8-75491e9b1f9a" xlink:to="loc_ehc_FaceAmountMember_0dfa20fe-8015-40d3-afad-9382dac58cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetAmountMember_2ed00079-6b5c-44f3-b35f-90d22226ff83" xlink:href="ehc-20211231.xsd#ehc_NetAmountMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e46cb863-0de3-4d5e-94b8-75491e9b1f9a" xlink:to="loc_ehc_NetAmountMember_2ed00079-6b5c-44f3-b35f-90d22226ff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_26b8a0fe-be68-4431-a84e-447164fb1b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_77a2faa6-feb9-4036-b984-3287e1776670" xlink:to="loc_us-gaap_DebtInstrumentLineItems_26b8a0fe-be68-4431-a84e-447164fb1b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26b8a0fe-be68-4431-a84e-447164fb1b1d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_faa00b10-2a4c-4d82-bd19-3040c3ff904c" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_faa00b10-2a4c-4d82-bd19-3040c3ff904c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_60618b98-9c02-42a0-9f13-fbad9b94feaf" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_60618b98-9c02-42a0-9f13-fbad9b94feaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_9a155c1d-2dd5-4714-9644-a677f8a0caa2" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_9a155c1d-2dd5-4714-9644-a677f8a0caa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_c6b6afc1-a586-4dcf-a33d-cee4210c89f1" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_c6b6afc1-a586-4dcf-a33d-cee4210c89f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_c5a23591-dbd1-45df-a84f-16f076458257" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_c5a23591-dbd1-45df-a84f-16f076458257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_65a90a1f-b5b3-4abd-bb75-6db26dce5d23" xlink:href="ehc-20211231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_65a90a1f-b5b3-4abd-bb75-6db26dce5d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_73c233ba-bd0d-4d74-90c1-8a7c7d4d5050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_b8e0a956-dcb7-422c-8344-14efc47d91e0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_73c233ba-bd0d-4d74-90c1-8a7c7d4d5050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtFinancialCovenantsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_77f557a6-22df-4906-a08b-822c3c1f9ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_51ec69f0-2a84-45ca-b574-54ba0fa2ea11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_77f557a6-22df-4906-a08b-822c3c1f9ab2" xlink:to="loc_us-gaap_DebtInstrumentTable_51ec69f0-2a84-45ca-b574-54ba0fa2ea11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_24e38523-efd4-4a69-897e-13c1fe19ca5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51ec69f0-2a84-45ca-b574-54ba0fa2ea11" xlink:to="loc_srt_StatementScenarioAxis_24e38523-efd4-4a69-897e-13c1fe19ca5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_99486f69-03e1-421d-a3ac-d4dc28448c4c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_24e38523-efd4-4a69-897e-13c1fe19ca5e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_99486f69-03e1-421d-a3ac-d4dc28448c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d572540f-80f2-442d-a299-869509fff9fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_99486f69-03e1-421d-a3ac-d4dc28448c4c" xlink:to="loc_srt_ScenarioForecastMember_d572540f-80f2-442d-a299-869509fff9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b82b0869-7dc1-479a-ba57-db4ab0ffa2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51ec69f0-2a84-45ca-b574-54ba0fa2ea11" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b82b0869-7dc1-479a-ba57-db4ab0ffa2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_9ffd58e4-27c6-4724-9d81-7cc284ae3bcc" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b82b0869-7dc1-479a-ba57-db4ab0ffa2ce" xlink:to="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_9ffd58e4-27c6-4724-9d81-7cc284ae3bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_781021c1-a08a-478b-b3ca-2918960a92f0" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b82b0869-7dc1-479a-ba57-db4ab0ffa2ce" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_781021c1-a08a-478b-b3ca-2918960a92f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_42f25510-b524-48a9-80e1-52b114e798f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42f25510-b524-48a9-80e1-52b114e798f4" xlink:to="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_97d27914-794d-4445-95ec-fd16ecf0075a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_DebtInstrumentAxis_97d27914-794d-4445-95ec-fd16ecf0075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_97d27914-794d-4445-95ec-fd16ecf0075a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TheCreditAgreementMember_d8731031-4d8f-4248-8ce0-0f866aa6931b" xlink:href="ehc-20211231.xsd#ehc_TheCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_TheCreditAgreementMember_d8731031-4d8f-4248-8ce0-0f866aa6931b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_0744e032-d2b7-4818-85f1-f65718883026" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_0744e032-d2b7-4818-85f1-f65718883026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_e20740b2-6fe7-41f9-a1b9-40f3702dbafb" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_e20740b2-6fe7-41f9-a1b9-40f3702dbafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_f17e5e3c-ee17-45bd-a62a-2ca4d63d706d" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_f17e5e3c-ee17-45bd-a62a-2ca4d63d706d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_9d5fef4c-a20b-4671-bf14-9bb2505c2b15" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_9d5fef4c-a20b-4671-bf14-9bb2505c2b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_fa39a36a-336b-45c8-9565-9b4a3f41b2ff" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_fa39a36a-336b-45c8-9565-9b4a3f41b2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_6c771b55-48d0-4d93-97d2-4ce68d071ce1" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80111397-759a-4018-91df-f47551750248" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_6c771b55-48d0-4d93-97d2-4ce68d071ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_9de46c50-58e0-43c9-aed3-40883e43bb4d" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1d3a3c0a-851a-404a-9ba5-73405868fb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_CreditFacilityAxis_1d3a3c0a-851a-404a-9ba5-73405868fb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1d3a3c0a-851a-404a-9ba5-73405868fb17" xlink:to="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_2836bded-0ad4-49a4-b10d-0a404850dbc5" xlink:href="ehc-20211231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:to="loc_ehc_TermLoanFacilitiesMember_2836bded-0ad4-49a4-b10d-0a404850dbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_7e26370f-2166-400d-9dcb-952b70ba2b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_7e26370f-2166-400d-9dcb-952b70ba2b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_000130f9-9669-4831-8066-e79b943e2baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7daedf64-ce8f-4d72-ac75-a5746b60167b" xlink:to="loc_us-gaap_LetterOfCreditMember_000130f9-9669-4831-8066-e79b943e2baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_75a91d11-984d-4903-9c4c-f456c25299bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_VariableRateAxis_75a91d11-984d-4903-9c4c-f456c25299bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dd5bc1aa-347b-495f-8046-1e2434931dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_75a91d11-984d-4903-9c4c-f456c25299bb" xlink:to="loc_us-gaap_VariableRateDomain_dd5bc1aa-347b-495f-8046-1e2434931dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_75044409-4732-4007-a08b-80eb98bf9c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_dd5bc1aa-347b-495f-8046-1e2434931dd5" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_75044409-4732-4007-a08b-80eb98bf9c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5c1c8b1-89f4-43b3-8e82-d207b3b6c903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_dd5bc1aa-347b-495f-8046-1e2434931dd5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5c1c8b1-89f4-43b3-8e82-d207b3b6c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0617b670-e298-4175-9148-9d514b315994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0617b670-e298-4175-9148-9d514b315994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0da54b66-16b5-4be2-a334-9df40b49c434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0617b670-e298-4175-9148-9d514b315994" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0da54b66-16b5-4be2-a334-9df40b49c434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_d5e567b8-43a2-45cf-8cc1-13706fbc9e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0da54b66-16b5-4be2-a334-9df40b49c434" xlink:to="loc_us-gaap_LoansPayableMember_d5e567b8-43a2-45cf-8cc1-13706fbc9e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ebc984ca-5b1c-4210-ab0e-932f0cbf8853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0da54b66-16b5-4be2-a334-9df40b49c434" xlink:to="loc_us-gaap_SeniorNotesMember_ebc984ca-5b1c-4210-ab0e-932f0cbf8853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fe023f07-e2a4-4f91-a6f3-f3185a4743f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fe023f07-e2a4-4f91-a6f3-f3185a4743f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_882609fc-ff44-49b1-96cc-6b5a21a0045c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fe023f07-e2a4-4f91-a6f3-f3185a4743f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_882609fc-ff44-49b1-96cc-6b5a21a0045c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b3852e5c-fc9a-4775-a779-ca48185dc8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_882609fc-ff44-49b1-96cc-6b5a21a0045c" xlink:to="loc_us-gaap_SubsequentEventMember_b3852e5c-fc9a-4775-a779-ca48185dc8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_srt_StatementScenarioAxis_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cb2d55ce-f127-4dcb-97ec-e8b6547a6b13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_bb3d0825-cf1e-4158-8bf6-f9c5ead1ef5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cb2d55ce-f127-4dcb-97ec-e8b6547a6b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1e25992c-8554-4a68-a5d1-3ff1da42d3e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_cb2d55ce-f127-4dcb-97ec-e8b6547a6b13" xlink:to="loc_srt_ScenarioForecastMember_1e25992c-8554-4a68-a5d1-3ff1da42d3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0225f3e1-385f-4958-8935-b4be192b33fd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f14e35bf-069b-481f-bd8b-74186a1302ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f14e35bf-069b-481f-bd8b-74186a1302ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dfc5831b-1467-4ecd-97f0-8988de89ee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dfc5831b-1467-4ecd-97f0-8988de89ee9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding_a25b62e4-bf0e-4c5e-b713-436abbbfa8b9" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding_a25b62e4-bf0e-4c5e-b713-436abbbfa8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_16ae1679-0fce-4cc0-8eb3-4bda9fd41403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_16ae1679-0fce-4cc0-8eb3-4bda9fd41403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e2bb3d83-9993-4ac8-8d74-56865d34b20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e2bb3d83-9993-4ac8-8d74-56865d34b20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum_e9e73b23-0316-4906-93fd-64ef84fb733b" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum_e9e73b23-0316-4906-93fd-64ef84fb733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CreditAgreementRestriction_34b8110f-2b5e-4c0a-ba1a-8778b76835e1" xlink:href="ehc-20211231.xsd#ehc_CreditAgreementRestriction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_CreditAgreementRestriction_34b8110f-2b5e-4c0a-ba1a-8778b76835e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8d6bf0ea-47a7-4db5-acde-54fb69173f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LongTermDebt_8d6bf0ea-47a7-4db5-acde-54fb69173f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_d9b04610-12ab-4075-95c0-8b299fcfcc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_d9b04610-12ab-4075-95c0-8b299fcfcc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_46a3d4b9-fc7f-42a5-ae3b-e82df3fc0533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_46a3d4b9-fc7f-42a5-ae3b-e82df3fc0533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_0cfd6255-5449-4117-9a42-0e09fcda92db" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_0cfd6255-5449-4117-9a42-0e09fcda92db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_12a2068a-ea3b-492d-a051-59dc4638251f" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_12a2068a-ea3b-492d-a051-59dc4638251f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_202547e5-fb52-41df-b0c7-ddd2980a4a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_202547e5-fb52-41df-b0c7-ddd2980a4a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6a2e5e68-42d7-422d-a2b3-143894e2f233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6a2e5e68-42d7-422d-a2b3-143894e2f233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_d904932e-a919-47e2-9d75-4e61c2563c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_d904932e-a919-47e2-9d75-4e61c2563c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_db01b33a-6b51-41b5-b8bd-8998e9e7de4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_db01b33a-6b51-41b5-b8bd-8998e9e7de4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2605747e-ce53-4fe6-8c64-675a1f0c056f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2605747e-ce53-4fe6-8c64-675a1f0c056f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5b1364ae-3765-49ea-8962-b0c805c40f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5b1364ae-3765-49ea-8962-b0c805c40f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentIssuePricePercentage_e5a5d20d-0438-42d4-998b-c65cd46dc878" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentIssuePricePercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentIssuePricePercentage_e5a5d20d-0438-42d4-998b-c65cd46dc878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_2209088b-b1f5-4e9c-866a-2d138277a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_e81e3411-498d-419a-9714-fe8413cdd27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_RepaymentsOfDebt_e81e3411-498d-419a-9714-fe8413cdd27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_9bc1bb30-2653-49a5-b8a1-691b7017bb57" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_9bc1bb30-2653-49a5-b8a1-691b7017bb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2e03f5d7-b597-4a1e-808e-5a4b92dfc712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2e03f5d7-b597-4a1e-808e-5a4b92dfc712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_1eea0957-3555-46cd-ab6c-9d21dff8e7bf" xlink:href="ehc-20211231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a021df69-1334-4dfa-b575-6c080369fa85" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_1eea0957-3555-46cd-ab6c-9d21dff8e7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtSeniorNotesRedemptionPricesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ae0f686a-d591-4573-8d34-21d4a202b074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ae0f686a-d591-4573-8d34-21d4a202b074" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2a057be2-701f-4a0b-b721-c118998025b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2a057be2-701f-4a0b-b721-c118998025b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_247c27b8-6b53-4800-86c1-a1d34d9efee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2a057be2-701f-4a0b-b721-c118998025b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_247c27b8-6b53-4800-86c1-a1d34d9efee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a23b198a-3eee-41c5-9dd8-043fb95e86a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_247c27b8-6b53-4800-86c1-a1d34d9efee4" xlink:to="loc_us-gaap_SeniorNotesMember_a23b198a-3eee-41c5-9dd8-043fb95e86a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a55e9ac-8806-4e33-9e78-97fe2f8eb32b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_45ed57f9-a05d-4a67-bfcb-2a8432a9c5f1" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_45ed57f9-a05d-4a67-bfcb-2a8432a9c5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_db41d19c-142b-4aff-8fb2-47240db7478c" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_db41d19c-142b-4aff-8fb2-47240db7478c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_df0d7ab6-7e6c-49f1-bbee-f1a08a7584c6" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_df0d7ab6-7e6c-49f1-bbee-f1a08a7584c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_eca6a166-1ac4-4d72-b6a4-0b09aa024d5d" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_eca6a166-1ac4-4d72-b6a4-0b09aa024d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_2df8d55d-e892-44b6-8602-98aab8f5a559" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01c04b73-bffd-48e7-999c-b322aa9385ad" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_2df8d55d-e892-44b6-8602-98aab8f5a559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7e9fab21-9231-4c7c-bd2a-9b64cd639343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7e9fab21-9231-4c7c-bd2a-9b64cd639343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_7e9fab21-9231-4c7c-bd2a-9b64cd639343" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_263976c9-2579-419d-a9db-112f644a0e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_263976c9-2579-419d-a9db-112f644a0e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_9c7f734a-f2e7-4e2b-8599-9cee0c0eb07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_9c7f734a-f2e7-4e2b-8599-9cee0c0eb07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_e22dca96-eb00-4cdd-8fd4-3b9a41fa7972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_e22dca96-eb00-4cdd-8fd4-3b9a41fa7972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_0270b0d8-eb4d-4988-9747-b8d335c2d5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7ef110b3-dafa-4bd1-b74a-bb27c7c30f50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_0270b0d8-eb4d-4988-9747-b8d335c2d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems_6dde8128-4d70-4c81-a4a3-b4aeca3df243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_6f209f6a-5d7a-4109-b7c9-f2e37353ee4b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionLineItems_6dde8128-4d70-4c81-a4a3-b4aeca3df243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82953a2e-7985-418a-ba1b-5dc09ef05afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_6dde8128-4d70-4c81-a4a3-b4aeca3df243" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_82953a2e-7985-418a-ba1b-5dc09ef05afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#LongtermDebtScheduleofNotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_97510561-3aa0-4c2c-9192-4753733f8054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97510561-3aa0-4c2c-9192-4753733f8054" xlink:to="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a2c6077-694a-48f8-a080-531d1324776e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_srt_RangeAxis_5a2c6077-694a-48f8-a080-531d1324776e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9894eef4-d251-44be-9075-e05cdca62e30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5a2c6077-694a-48f8-a080-531d1324776e" xlink:to="loc_srt_RangeMember_9894eef4-d251-44be-9075-e05cdca62e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cbfef9f8-1b0b-4bb4-bdd5-01d11cdf4dcd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9894eef4-d251-44be-9075-e05cdca62e30" xlink:to="loc_srt_MinimumMember_cbfef9f8-1b0b-4bb4-bdd5-01d11cdf4dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7762acb0-9ecb-4149-acaf-db17607d588d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9894eef4-d251-44be-9075-e05cdca62e30" xlink:to="loc_srt_MaximumMember_7762acb0-9ecb-4149-acaf-db17607d588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85013148-9931-4398-9db6-2b95309b13cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85013148-9931-4398-9db6-2b95309b13cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_75b45fbf-4f06-46cd-8d99-d1b370db1a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85013148-9931-4398-9db6-2b95309b13cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_75b45fbf-4f06-46cd-8d99-d1b370db1a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_b2218b79-c628-4dfa-82d5-23aa0ab5e63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_75b45fbf-4f06-46cd-8d99-d1b370db1a5d" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_b2218b79-c628-4dfa-82d5-23aa0ab5e63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_10357466-0c74-4543-a1ae-b0ed9308d21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_us-gaap_DebtInstrumentAxis_10357466-0c74-4543-a1ae-b0ed9308d21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_10357466-0c74-4543-a1ae-b0ed9308d21c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_f1bc4bdc-317f-4101-affc-33454125811b" xlink:href="ehc-20211231.xsd#ehc_NotesPayableRealEstateSaleLeasebackFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:to="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_f1bc4bdc-317f-4101-affc-33454125811b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_b3e73d3a-9fb8-4808-a0fe-cc5f49f9f2c9" xlink:href="ehc-20211231.xsd#ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:to="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_b3e73d3a-9fb8-4808-a0fe-cc5f49f9f2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableSoftwareContractsMember_bac83599-8782-4e4b-b5ea-a90c0b670641" xlink:href="ehc-20211231.xsd#ehc_NotesPayableSoftwareContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f862ba5e-6fc9-41a6-a921-1fd891e20251" xlink:to="loc_ehc_NotesPayableSoftwareContractsMember_bac83599-8782-4e4b-b5ea-a90c0b670641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_13fa4c66-8e88-477a-8efd-82b2b4ffa52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_us-gaap_VariableRateAxis_13fa4c66-8e88-477a-8efd-82b2b4ffa52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6e1e4807-4347-45b9-9f96-60829e00b70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_13fa4c66-8e88-477a-8efd-82b2b4ffa52b" xlink:to="loc_us-gaap_VariableRateDomain_6e1e4807-4347-45b9-9f96-60829e00b70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_97dc002d-b7af-49e0-8261-d951936e8f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6e1e4807-4347-45b9-9f96-60829e00b70f" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_97dc002d-b7af-49e0-8261-d951936e8f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3262abea-ab4f-4757-a307-c10de498134f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_044f79a1-bfd2-4ddd-bfeb-8ae0d77e556e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3262abea-ab4f-4757-a307-c10de498134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e741fbc8-1eec-44e2-a60a-5acdb294de30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3262abea-ab4f-4757-a307-c10de498134f" xlink:to="loc_us-gaap_LongTermDebt_e741fbc8-1eec-44e2-a60a-5acdb294de30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8dc3821a-1b19-4bd9-be02-8442c0c0cc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3262abea-ab4f-4757-a307-c10de498134f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8dc3821a-1b19-4bd9-be02-8442c0c0cc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisks" xlink:type="simple" xlink:href="ehc-20211231.xsd#SelfInsuredRisks"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisks" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_60008cdc-7694-4fcc-bb22-e4de85356c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_2628b01a-59f1-47ff-a80d-59e2409f9c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_60008cdc-7694-4fcc-bb22-e4de85356c88" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_2628b01a-59f1-47ff-a80d-59e2409f9c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#SelfInsuredRisksTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisksTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_a51146cd-f6c3-46b9-84ee-203cf58aa48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_3d38a78c-6397-4e8a-8fde-3ee6172285d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_a51146cd-f6c3-46b9-84ee-203cf58aa48e" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_3d38a78c-6397-4e8a-8fde-3ee6172285d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SelfInsuredRisksTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_03a8f62c-716b-4e0b-b098-ba6a13f5b0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_2c33af11-7c31-467d-b3b7-82a3f3ba0e2f" xlink:href="ehc-20211231.xsd#ehc_MaximumSelfInsuredAmountFirstLayerOfRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_03a8f62c-716b-4e0b-b098-ba6a13f5b0c9" xlink:to="loc_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_2c33af11-7c31-467d-b3b7-82a3f3ba0e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MaximumSelfInsuredAmountThirdLayerRisk_ca592215-ee75-482a-9588-03020a9eb2e8" xlink:href="ehc-20211231.xsd#ehc_MaximumSelfInsuredAmountThirdLayerRisk"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_03a8f62c-716b-4e0b-b098-ba6a13f5b0c9" xlink:to="loc_ehc_MaximumSelfInsuredAmountThirdLayerRisk_ca592215-ee75-482a-9588-03020a9eb2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability_550b732d-d25a-428e-9252-f01c5c859470" xlink:href="ehc-20211231.xsd#ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_03a8f62c-716b-4e0b-b098-ba6a13f5b0c9" xlink:to="loc_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability_550b732d-d25a-428e-9252-f01c5c859470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent_948b157b-b0a4-4605-94ee-23ec5199bdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_03a8f62c-716b-4e0b-b098-ba6a13f5b0c9" xlink:to="loc_us-gaap_SelfInsuranceReserveCurrent_948b157b-b0a4-4605-94ee-23ec5199bdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_5cfed57e-44c6-49a1-9d2b-f3674805b0f8" xlink:href="ehc-20211231.xsd#ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_03a8f62c-716b-4e0b-b098-ba6a13f5b0c9" xlink:to="loc_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_5cfed57e-44c6-49a1-9d2b-f3674805b0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SelfInsuredRisksChangesinSelfinsuranceReservesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_0b8b7d11-33c1-4711-82a8-7ccb05b7cc92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_0b8b7d11-33c1-4711-82a8-7ccb05b7cc92" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f364bb13-b49f-4d0c-9115-79767d7e5eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f364bb13-b49f-4d0c-9115-79767d7e5eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_7f8d1c54-be2f-4f3b-88d3-6670bcfc6d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_7f8d1c54-be2f-4f3b-88d3-6670bcfc6d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_1a1e32f2-2b1b-4f6d-9533-e154a2caef62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_1a1e32f2-2b1b-4f6d-9533-e154a2caef62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_f449b2d5-2af9-414a-bb05-a314cf419a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_f449b2d5-2af9-414a-bb05-a314cf419a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_19e8d792-56e4-4901-9dc2-b73d65745926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_19e8d792-56e4-4901-9dc2-b73d65745926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_5bdbb9d3-953e-4e24-8690-1e6ecabac245" xlink:href="ehc-20211231.xsd#ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_5bdbb9d3-953e-4e24-8690-1e6ecabac245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_48e4b698-14ab-4ccb-a93f-c2ffb5bea4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_48e4b698-14ab-4ccb-a93f-c2ffb5bea4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_3740bd66-150e-4f66-bb35-1bbf3ebd324f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_3740bd66-150e-4f66-bb35-1bbf3ebd324f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_f59a4982-b945-43cc-aff0-11bff54cfd31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_f59a4982-b945-43cc-aff0-11bff54cfd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_29badd50-38dc-417c-b5b4-b6d58b49a006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_29badd50-38dc-417c-b5b4-b6d58b49a006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_000bdff9-920a-433e-b918-ccf61ec738df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ec140d6f-f7fe-48de-8e60-e4a839fb1c17" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_000bdff9-920a-433e-b918-ccf61ec738df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="simple" xlink:href="ehc-20211231.xsd#RedeemableNoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_2dd8dcdd-24d5-49be-99dd-5ba094b6bedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_700aaded-6ff9-4696-93c8-f948464daeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_2dd8dcdd-24d5-49be-99dd-5ba094b6bedc" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_700aaded-6ff9-4696-93c8-f948464daeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#RedeemableNoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_94a3dd77-8695-4475-87a4-3f1c9ed93947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_fd99b51a-9290-4e7c-8074-420ce03244a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_94a3dd77-8695-4475-87a4-3f1c9ed93947" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_fd99b51a-9290-4e7c-8074-420ce03244a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_b7ed61cc-16e1-46b2-b473-ba0e90d15413" xlink:href="ehc-20211231.xsd#ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_94a3dd77-8695-4475-87a4-3f1c9ed93947" xlink:to="loc_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_b7ed61cc-16e1-46b2-b473-ba0e90d15413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_f68aa4da-d010-40e1-b9ed-75f836dbd6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0a0a9117-97b2-4a0f-b12a-dfd4921ff74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_f68aa4da-d010-40e1-b9ed-75f836dbd6c1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0a0a9117-97b2-4a0f-b12a-dfd4921ff74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e835e128-c46b-45a5-bdbc-63fe6613fb91" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0a0a9117-97b2-4a0f-b12a-dfd4921ff74e" xlink:to="loc_dei_LegalEntityAxis_e835e128-c46b-45a5-bdbc-63fe6613fb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4561b1a7-7cef-4ef0-96e6-814175d3e246" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e835e128-c46b-45a5-bdbc-63fe6613fb91" xlink:to="loc_dei_EntityDomain_4561b1a7-7cef-4ef0-96e6-814175d3e246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember_fe54b7c3-ba10-4a4e-bca8-78f6157685c0" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4561b1a7-7cef-4ef0-96e6-814175d3e246" xlink:to="loc_ehc_RedeemableNoncontrollingInterestMember_fe54b7c3-ba10-4a4e-bca8-78f6157685c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_92f66583-c407-4114-af8c-5ee77347c269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_0a0a9117-97b2-4a0f-b12a-dfd4921ff74e" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_92f66583-c407-4114-af8c-5ee77347c269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_92f66583-c407-4114-af8c-5ee77347c269" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2aa50f7b-cde9-4b48-86d7-10e9eddc5e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2aa50f7b-cde9-4b48-86d7-10e9eddc5e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_049dde9a-5a46-40b1-b2c4-afddece1143c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_049dde9a-5a46-40b1-b2c4-afddece1143c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c440e6b0-abda-4bcc-99c6-81f63822005f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c440e6b0-abda-4bcc-99c6-81f63822005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure_537eb4fa-abdf-4061-888a-84e290673a53" xlink:href="ehc-20211231.xsd#ehc_Contributiontojointventure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_ehc_Contributiontojointventure_537eb4fa-abdf-4061-888a-84e290673a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Reclassificationtononcontrollinginterests_bdf975eb-f6f8-42a1-91ed-3eac6344c563" xlink:href="ehc-20211231.xsd#ehc_Reclassificationtononcontrollinginterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_ehc_Reclassificationtononcontrollinginterests_bdf975eb-f6f8-42a1-91ed-3eac6344c563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_51ba79bc-9d53-43c5-a093-09d298e6aff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_51ba79bc-9d53-43c5-a093-09d298e6aff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction_b2de76d9-ace7-4612-a4c8-aa2205160e11" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_ehc_NoncontrollingInterestExchangeTransaction_b2de76d9-ace7-4612-a4c8-aa2205160e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_32f28424-d00e-4127-861c-583f8b211e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_32f28424-d00e-4127-861c-583f8b211e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestOtherAdjustment_81ad286f-726a-4d02-82c9-15aa7744cffb" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestOtherAdjustment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_ehc_NoncontrollingInterestOtherAdjustment_81ad286f-726a-4d02-82c9-15aa7744cffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_aa379752-c70a-469d-833f-aa7d07a4b623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_5975af39-0a97-464c-a89d-9eda670c0c51" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_aa379752-c70a-469d-833f-aa7d07a4b623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_fb3c6a65-8c1a-4b65-acab-5878d1518a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_4325c89e-a4ea-41c7-b5a4-897cfb5f2455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_fb3c6a65-8c1a-4b65-acab-5878d1518a6c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_4325c89e-a4ea-41c7-b5a4-897cfb5f2455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_ee071566-b762-49be-a6a5-46d389bb602e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_fb3c6a65-8c1a-4b65-acab-5878d1518a6c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_ee071566-b762-49be-a6a5-46d389bb602e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_92d83a7f-84f9-47d3-9f97-b60892d768fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_fb3c6a65-8c1a-4b65-acab-5878d1518a6c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_92d83a7f-84f9-47d3-9f97-b60892d768fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#RedeemableNoncontrollingInterestsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_765eb835-c29e-487b-9284-87c8312fbca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_765eb835-c29e-487b-9284-87c8312fbca9" xlink:to="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ce45ef30-0709-4c46-a131-4d14c0e21326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ce45ef30-0709-4c46-a131-4d14c0e21326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4222b8c6-5e7f-4219-ab44-6975f10833e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ce45ef30-0709-4c46-a131-4d14c0e21326" xlink:to="loc_us-gaap_SegmentDomain_4222b8c6-5e7f-4219-ab44-6975f10833e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_76962429-cdf9-4203-b249-96b1d926e93b" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4222b8c6-5e7f-4219-ab44-6975f10833e8" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_76962429-cdf9-4203-b249-96b1d926e93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_68c3e14c-03ac-4d0a-80fa-20fca3b9245b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_68c3e14c-03ac-4d0a-80fa-20fca3b9245b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b2751ac1-08f8-4792-9faa-f0c8ad8343e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68c3e14c-03ac-4d0a-80fa-20fca3b9245b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b2751ac1-08f8-4792-9faa-f0c8ad8343e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember_fc340f2f-9330-4baa-a4e1-5c218b7a4baf" xlink:href="ehc-20211231.xsd#ehc_EHHIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b2751ac1-08f8-4792-9faa-f0c8ad8343e1" xlink:to="loc_ehc_EHHIMember_fc340f2f-9330-4baa-a4e1-5c218b7a4baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5b7d1824-c7f0-4a59-982d-9411af1a0f3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:to="loc_srt_OwnershipAxis_5b7d1824-c7f0-4a59-982d-9411af1a0f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2c49cbe9-68fb-41a6-807d-3d8021518414" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5b7d1824-c7f0-4a59-982d-9411af1a0f3a" xlink:to="loc_srt_OwnershipDomain_2c49cbe9-68fb-41a6-807d-3d8021518414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HoldingsAndEHHIMember_d52897e1-59c5-4b59-a06b-f23630047d7d" xlink:href="ehc-20211231.xsd#ehc_HoldingsAndEHHIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2c49cbe9-68fb-41a6-807d-3d8021518414" xlink:to="loc_ehc_HoldingsAndEHHIMember_d52897e1-59c5-4b59-a06b-f23630047d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ab7bb55d-ba2a-4708-80cc-384a2cbb92ea" xlink:to="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_ed16e20c-4784-4093-89b5-63aa6cc5b289" xlink:href="ehc-20211231.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_ed16e20c-4784-4093-89b5-63aa6cc5b289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_20be97f2-1e7b-4c61-887a-1b9d866e752b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_20be97f2-1e7b-4c61-887a-1b9d866e752b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_837b13f2-aa6c-4dbe-bee8-5d307322f6d1" xlink:href="ehc-20211231.xsd#ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_837b13f2-aa6c-4dbe-bee8-5d307322f6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_6e4321e4-aea5-4900-a49a-eb14821f549a" xlink:href="ehc-20211231.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_6e4321e4-aea5-4900-a49a-eb14821f549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_1d4757b7-1077-4faf-970e-1e14f2a09ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_1d4757b7-1077-4faf-970e-1e14f2a09ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_e3bfdee9-c7fd-48a0-bb71-0b7c861660e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_e3bfdee9-c7fd-48a0-bb71-0b7c861660e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_624b9358-59bb-4d31-8a68-6378edcd15d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_624b9358-59bb-4d31-8a68-6378edcd15d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_b8591d33-5379-40f5-95ea-6e00d52af3aa" xlink:href="ehc-20211231.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_b8591d33-5379-40f5-95ea-6e00d52af3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f3b06634-feb6-474a-8761-31de11d42114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5fe1c275-f969-473c-9783-2db6e55c2ce4" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f3b06634-feb6-474a-8761-31de11d42114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ehc-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d2f62552-3ed9-4035-9465-f0e0bbf08ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_be68dbea-5f6d-4e6b-8add-a36d1ba24ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d2f62552-3ed9-4035-9465-f0e0bbf08ac3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_be68dbea-5f6d-4e6b-8add-a36d1ba24ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_73956e4c-b045-43f9-b2a9-473906897919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b8f159d8-9390-4375-a45c-0130313cd56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_73956e4c-b045-43f9-b2a9-473906897919" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b8f159d8-9390-4375-a45c-0130313cd56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_7e34ca70-7000-44e1-98e8-7e8b502ba023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_73956e4c-b045-43f9-b2a9-473906897919" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_7e34ca70-7000-44e1-98e8-7e8b502ba023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b161e175-8821-4848-ad93-439af651f224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b161e175-8821-4848-ad93-439af651f224" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bece7d19-ded6-4e20-b30b-24604245efce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bece7d19-ded6-4e20-b30b-24604245efce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_73842c95-7534-4852-894c-79f0f569a58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bece7d19-ded6-4e20-b30b-24604245efce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_73842c95-7534-4852-894c-79f0f569a58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dfd9a7ee-f7fe-411f-b75c-4ddb5fa7f417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_73842c95-7534-4852-894c-79f0f569a58d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dfd9a7ee-f7fe-411f-b75c-4ddb5fa7f417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d912943a-f1b8-4f84-b4fd-4cc78278a608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d912943a-f1b8-4f84-b4fd-4cc78278a608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d912943a-f1b8-4f84-b4fd-4cc78278a608" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cbbfd449-dac3-4e06-9dcc-23948d322e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cbbfd449-dac3-4e06-9dcc-23948d322e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_24f4d7dd-7479-4827-b687-d0afc0f7667e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_24f4d7dd-7479-4827-b687-d0afc0f7667e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0b1f3603-50f2-435c-b665-a47833d3a124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1321b1f-1650-4667-bbd1-6739ca3c852f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0b1f3603-50f2-435c-b665-a47833d3a124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_436c590f-b6b9-44f8-8c57-e8834f62da95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ea96a2-5112-4446-9b44-0ceb224fac5f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_436c590f-b6b9-44f8-8c57-e8834f62da95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_dfcae09f-2d6c-4723-a9d8-b776b6f0dad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_436c590f-b6b9-44f8-8c57-e8834f62da95" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_dfcae09f-2d6c-4723-a9d8-b776b6f0dad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_d20239ca-0c20-4a1a-8a25-90e0cab5ec10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_436c590f-b6b9-44f8-8c57-e8834f62da95" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_d20239ca-0c20-4a1a-8a25-90e0cab5ec10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#FairValueMeasurementsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e0efc3aa-2c37-4d83-8457-f7530f6162d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2b9999d4-463f-45ff-882b-3c185139f515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e0efc3aa-2c37-4d83-8457-f7530f6162d9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2b9999d4-463f-45ff-882b-3c185139f515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0c083f08-6d53-4fec-a821-2523e7706046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2b9999d4-463f-45ff-882b-3c185139f515" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0c083f08-6d53-4fec-a821-2523e7706046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_213c9a6e-f88a-4545-a1bb-3862d97c748a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0c083f08-6d53-4fec-a821-2523e7706046" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_213c9a6e-f88a-4545-a1bb-3862d97c748a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_1c5965ca-79cf-4fb8-aa75-c3f103d524d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_213c9a6e-f88a-4545-a1bb-3862d97c748a" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_1c5965ca-79cf-4fb8-aa75-c3f103d524d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f20175a5-7fcf-43c2-8f24-b0ea9ae5793b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2b9999d4-463f-45ff-882b-3c185139f515" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f20175a5-7fcf-43c2-8f24-b0ea9ae5793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_a9198998-b637-449d-b932-0fedadc2f37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f20175a5-7fcf-43c2-8f24-b0ea9ae5793b" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_a9198998-b637-449d-b932-0fedadc2f37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4334ca3f-8d58-44c7-9fed-ae8ef9481e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4334ca3f-8d58-44c7-9fed-ae8ef9481e15" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d747477c-3419-453d-bf13-67c0185ef115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_DebtInstrumentAxis_d747477c-3419-453d-bf13-67c0185ef115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d747477c-3419-453d-bf13-67c0185ef115" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_b37c13f5-1e63-4aee-8782-c3983c539a0f" xlink:href="ehc-20211231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_TermLoanFacilitiesMember_b37c13f5-1e63-4aee-8782-c3983c539a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_39dfff46-5035-49eb-8d5a-274e0f09c82e" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_39dfff46-5035-49eb-8d5a-274e0f09c82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_89c53938-5cf7-46f3-8043-c0d52129c7e9" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_89c53938-5cf7-46f3-8043-c0d52129c7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_1dcca1a0-44b7-49ad-a34f-281e598d30ee" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_1dcca1a0-44b7-49ad-a34f-281e598d30ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_2450a5f9-ceca-43ab-858a-3d3a4127258c" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_2450a5f9-ceca-43ab-858a-3d3a4127258c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_efb7133d-aedc-4b69-962a-596954117846" xlink:href="ehc-20211231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9913a35f-842f-4585-b5f2-0cbadc90e87f" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_efb7133d-aedc-4b69-962a-596954117846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a558a6c9-64d3-4084-954d-97f17517b902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_CreditFacilityAxis_a558a6c9-64d3-4084-954d-97f17517b902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_62de2550-1cda-4d0f-a508-a5f37c69c991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a558a6c9-64d3-4084-954d-97f17517b902" xlink:to="loc_us-gaap_CreditFacilityDomain_62de2550-1cda-4d0f-a508-a5f37c69c991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1fa0e794-9dbb-4900-b892-cd3ab27256ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_62de2550-1cda-4d0f-a508-a5f37c69c991" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1fa0e794-9dbb-4900-b892-cd3ab27256ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0b4b8ea6-15dc-420c-b202-d26dc915ea32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_62de2550-1cda-4d0f-a508-a5f37c69c991" xlink:to="loc_us-gaap_LetterOfCreditMember_0b4b8ea6-15dc-420c-b202-d26dc915ea32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b1e11318-1f9e-429e-a3bc-cff87ffe7cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b1e11318-1f9e-429e-a3bc-cff87ffe7cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b1e11318-1f9e-429e-a3bc-cff87ffe7cca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_953f62e9-ee14-4961-a64a-82c463e4d74f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:to="loc_us-gaap_LoansPayableMember_953f62e9-ee14-4961-a64a-82c463e4d74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1a007fad-53be-4f22-8816-3ce73de15f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:to="loc_us-gaap_SeniorNotesMember_1a007fad-53be-4f22-8816-3ce73de15f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_577d400f-59ed-4079-839e-4a4b62089f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_768ddc03-9d3b-4cb3-8d3b-e2510971dccc" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_577d400f-59ed-4079-839e-4a4b62089f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_7c5d4f3a-4482-45d9-a2d2-595d84cf2440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_7c5d4f3a-4482-45d9-a2d2-595d84cf2440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7c5d4f3a-4482-45d9-a2d2-595d84cf2440" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0c53821d-03fd-4370-97ea-572f76db7c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0c53821d-03fd-4370-97ea-572f76db7c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9556b30d-fceb-4b9a-a3cd-fe32f244b703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9556b30d-fceb-4b9a-a3cd-fe32f244b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ddf868d3-d2f2-477d-b294-b45ac12f3e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46807911-b472-41d9-8d72-76eb936769f3" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ddf868d3-d2f2-477d-b294-b45ac12f3e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fca084c7-ae28-4d2a-a068-f1318305406d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3b20aecb-1eef-417d-a6d3-bead4e99e565" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fca084c7-ae28-4d2a-a068-f1318305406d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_48b09e26-5588-4e11-ad1a-18c25128b960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fca084c7-ae28-4d2a-a068-f1318305406d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_48b09e26-5588-4e11-ad1a-18c25128b960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_45419de8-745a-461e-9daa-52b50c12d9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fca084c7-ae28-4d2a-a068-f1318305406d" xlink:to="loc_us-gaap_LongTermDebtFairValue_45419de8-745a-461e-9daa-52b50c12d9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e5df05f-b730-423d-a819-6be8fdd3ac57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8d5fdcf0-8df3-465a-958d-028d39874e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e5df05f-b730-423d-a819-6be8fdd3ac57" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8d5fdcf0-8df3-465a-958d-028d39874e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8d53e2e-11b0-475d-a63b-7f721310542b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cd046ab8-9fa8-4623-bc47-058526fbc0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8d53e2e-11b0-475d-a63b-7f721310542b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cd046ab8-9fa8-4623-bc47-058526fbc0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_53f6ba1c-5cd7-4534-a247-2e0735c8bb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8d53e2e-11b0-475d-a63b-7f721310542b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_53f6ba1c-5cd7-4534-a247-2e0735c8bb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_689b7d53-9f34-4f29-b339-d362cc3ba89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8d53e2e-11b0-475d-a63b-7f721310542b" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_689b7d53-9f34-4f29-b339-d362cc3ba89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPaymentsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca997b0e-7248-4a5f-9b77-4b47306e810a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca997b0e-7248-4a5f-9b77-4b47306e810a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6f778344-4e1f-430b-bbe9-cfd9477d9b45" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:to="loc_srt_TitleOfIndividualAxis_6f778344-4e1f-430b-bbe9-cfd9477d9b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aab5c710-a9db-4e62-a463-330b29f83428" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_6f778344-4e1f-430b-bbe9-cfd9477d9b45" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aab5c710-a9db-4e62-a463-330b29f83428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NonemployeeDirectorsMember_47156fad-cea2-4ee2-81a2-d4624e3125ac" xlink:href="ehc-20211231.xsd#ehc_NonemployeeDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aab5c710-a9db-4e62-a463-330b29f83428" xlink:to="loc_ehc_NonemployeeDirectorsMember_47156fad-cea2-4ee2-81a2-d4624e3125ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_363c77a0-2873-43a3-baad-d64e398ccccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:to="loc_us-gaap_AwardTypeAxis_363c77a0-2873-43a3-baad-d64e398ccccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_363c77a0-2873-43a3-baad-d64e398ccccb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9a03f32e-8bc8-41d7-9757-db3ea0e7df5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9a03f32e-8bc8-41d7-9757-db3ea0e7df5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EmploymentBasedSARSMember_7ad235d0-a539-4a84-8213-55640ae4648d" xlink:href="ehc-20211231.xsd#ehc_EmploymentBasedSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_ehc_EmploymentBasedSARSMember_7ad235d0-a539-4a84-8213-55640ae4648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_e75d45b1-cd39-48d1-8f5e-7ac6c0574507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_e75d45b1-cd39-48d1-8f5e-7ac6c0574507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PerformanceandEmploymentBasedSARSMember_5ae7dcce-3573-431c-b49d-708110cbba2f" xlink:href="ehc-20211231.xsd#ehc_PerformanceandEmploymentBasedSARSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_ehc_PerformanceandEmploymentBasedSARSMember_5ae7dcce-3573-431c-b49d-708110cbba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c45a19f7-b089-42e2-b796-a81d47125185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_us-gaap_RestrictedStockMember_c45a19f7-b089-42e2-b796-a81d47125185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7bc926c2-b635-409c-bd25-235f68485c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7bc926c2-b635-409c-bd25-235f68485c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DividendEquivalentRSUMember_06fc1d77-18be-4cd8-894a-7c0158ee68ae" xlink:href="ehc-20211231.xsd#ehc_DividendEquivalentRSUMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_137213bb-6ae5-41e5-8a01-858394086d8a" xlink:to="loc_ehc_DividendEquivalentRSUMember_06fc1d77-18be-4cd8-894a-7c0158ee68ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27870d41-59c8-4bb3-b365-2492b6d83d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:to="loc_us-gaap_PlanNameAxis_27870d41-59c8-4bb3-b365-2492b6d83d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5e4195a6-7506-4b07-bb43-912d7129f06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_27870d41-59c8-4bb3-b365-2492b6d83d5d" xlink:to="loc_us-gaap_PlanNameDomain_5e4195a6-7506-4b07-bb43-912d7129f06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember_66974ca1-bf4a-4423-aac4-4c46698c617b" xlink:href="ehc-20211231.xsd#ehc_A2016OmnibusPerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5e4195a6-7506-4b07-bb43-912d7129f06b" xlink:to="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember_66974ca1-bf4a-4423-aac4-4c46698c617b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6484b934-9786-4632-9f70-cc68599750ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f07b8624-c98d-4dff-8242-fb427cb863a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f07b8624-c98d-4dff-8242-fb427cb863a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fb49177c-dc73-4c97-987a-66795b53085c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fb49177c-dc73-4c97-987a-66795b53085c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a405d8c7-2610-47fa-a7dd-b5d6a435c7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a405d8c7-2610-47fa-a7dd-b5d6a435c7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dd6c1b1-fac3-4d38-ac57-da3d968a97f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dd6c1b1-fac3-4d38-ac57-da3d968a97f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7e8fe70d-b2ec-4470-8ffb-2f32891d13db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7e8fe70d-b2ec-4470-8ffb-2f32891d13db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_db3de3db-5172-4399-b4f0-8afafe53fbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_db3de3db-5172-4399-b4f0-8afafe53fbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_217f1981-a12d-4ef9-a7f8-c114586b754c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_217f1981-a12d-4ef9-a7f8-c114586b754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b9964ae6-7f6d-48f5-ab3c-cd16182daa35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b9964ae6-7f6d-48f5-ab3c-cd16182daa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_07b04d9f-d9ed-42be-9f64-3fca1b3a238d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_07b04d9f-d9ed-42be-9f64-3fca1b3a238d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_f3f8e850-7c19-4c78-8723-f72d507f2f3c" xlink:href="ehc-20211231.xsd#ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_f3f8e850-7c19-4c78-8723-f72d507f2f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c868c563-510f-4d48-854b-e16fc6d86f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c868c563-510f-4d48-854b-e16fc6d86f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_da5cd402-e26c-45c4-9539-86464c4fd576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_da5cd402-e26c-45c4-9539-86464c4fd576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2fc0ace8-4591-4081-a86c-84d294dedd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2fc0ace8-4591-4081-a86c-84d294dedd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AllocatedSharebasedCompensationLiability_c7e0cac6-94f0-4f99-9fe4-228174fd3170" xlink:href="ehc-20211231.xsd#ehc_AllocatedSharebasedCompensationLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_ehc_AllocatedSharebasedCompensationLiability_c7e0cac6-94f0-4f99-9fe4-228174fd3170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ab81be53-a1b7-4c71-ba46-f9cfae876373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ab81be53-a1b7-4c71-ba46-f9cfae876373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0ae7f509-a0a2-4903-a8c6-cac16bb9d635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0ae7f509-a0a2-4903-a8c6-cac16bb9d635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_26fb855c-1013-437e-a87d-c543da98a468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_26fb855c-1013-437e-a87d-c543da98a468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_983dde82-4a26-4585-ab47-b9131cd9c0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_983dde82-4a26-4585-ab47-b9131cd9c0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_edfa89a4-2871-4e24-9870-42d52ff7bfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_edfa89a4-2871-4e24-9870-42d52ff7bfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5962f5dc-eccc-4368-85bc-6d0762438ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5962f5dc-eccc-4368-85bc-6d0762438ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_f9d74ce3-66cb-4655-b3ed-54c84ecad065" xlink:href="ehc-20211231.xsd#ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc21e0f1-e7f2-4073-87f4-de26e0423da2" xlink:to="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_f9d74ce3-66cb-4655-b3ed-54c84ecad065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPaymentsWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82fa3779-c038-4a09-a7cd-789597c9b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52102b3a-40ac-48bb-b4d6-a006c3a49be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82fa3779-c038-4a09-a7cd-789597c9b9dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52102b3a-40ac-48bb-b4d6-a006c3a49be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ca89bdf-be1a-4351-9139-07a6cee784ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52102b3a-40ac-48bb-b4d6-a006c3a49be0" xlink:to="loc_us-gaap_AwardTypeAxis_2ca89bdf-be1a-4351-9139-07a6cee784ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237d724b-77b6-4f79-8317-f7d841707506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2ca89bdf-be1a-4351-9139-07a6cee784ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237d724b-77b6-4f79-8317-f7d841707506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2ea1db44-a498-4df1-8486-2b4b3208197b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237d724b-77b6-4f79-8317-f7d841707506" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2ea1db44-a498-4df1-8486-2b4b3208197b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_d82aaf0f-c582-4d85-a4f8-8033a0a1d501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237d724b-77b6-4f79-8317-f7d841707506" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_d82aaf0f-c582-4d85-a4f8-8033a0a1d501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afc58042-a2de-44dd-a694-b6e7e2610ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52102b3a-40ac-48bb-b4d6-a006c3a49be0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afc58042-a2de-44dd-a694-b6e7e2610ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afc58042-a2de-44dd-a694-b6e7e2610ca9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_5948e913-952d-4355-a756-4d71ee13d758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_5948e913-952d-4355-a756-4d71ee13d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_377c8293-3b03-471d-8f3d-d60d8546f046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_377c8293-3b03-471d-8f3d-d60d8546f046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd35e176-4a85-4e84-b660-1b5e6f11d018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd35e176-4a85-4e84-b660-1b5e6f11d018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d270203-3afa-40f7-ab30-83ed348f7cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dc1d51e8-f840-4f17-bfa1-7eab9490e982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d270203-3afa-40f7-ab30-83ed348f7cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPaymentsStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21391f1c-2df7-41f2-903e-037a8cbd404b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8664af93-91ff-41c1-8059-97b681fefe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21391f1c-2df7-41f2-903e-037a8cbd404b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8664af93-91ff-41c1-8059-97b681fefe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1102dcf4-c9b2-4a43-b9a4-3b54506b0a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8664af93-91ff-41c1-8059-97b681fefe4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1102dcf4-c9b2-4a43-b9a4-3b54506b0a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d5094e36-9097-4c81-86d4-ba672f91d6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8664af93-91ff-41c1-8059-97b681fefe4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d5094e36-9097-4c81-86d4-ba672f91d6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_06036aae-1795-4e7f-a467-ff859bc7c8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8664af93-91ff-41c1-8059-97b681fefe4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_06036aae-1795-4e7f-a467-ff859bc7c8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2ec8c0a2-5049-4078-953a-a9da849fa3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8664af93-91ff-41c1-8059-97b681fefe4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2ec8c0a2-5049-4078-953a-a9da849fa3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b57d8eea-1eb3-482e-a07b-33d4a2e4c205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8664af93-91ff-41c1-8059-97b681fefe4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b57d8eea-1eb3-482e-a07b-33d4a2e4c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_776723db-5271-4259-b24b-f80e62a811e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21391f1c-2df7-41f2-903e-037a8cbd404b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_776723db-5271-4259-b24b-f80e62a811e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_978ac818-fe24-4393-896f-315b867e8507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21391f1c-2df7-41f2-903e-037a8cbd404b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_978ac818-fe24-4393-896f-315b867e8507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_73f52edd-472c-4329-a09a-450cf5147e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_978ac818-fe24-4393-896f-315b867e8507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_73f52edd-472c-4329-a09a-450cf5147e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b12ad198-a55f-47dd-b03d-8a7040cb4c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_978ac818-fe24-4393-896f-315b867e8507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b12ad198-a55f-47dd-b03d-8a7040cb4c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a6600437-522c-4745-8b03-f278a310daf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_978ac818-fe24-4393-896f-315b867e8507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a6600437-522c-4745-8b03-f278a310daf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4fd149cb-fda3-457b-adab-9ec55a5e6a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_978ac818-fe24-4393-896f-315b867e8507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4fd149cb-fda3-457b-adab-9ec55a5e6a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c85dab79-11f4-4922-955c-372c6219bc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_978ac818-fe24-4393-896f-315b867e8507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c85dab79-11f4-4922-955c-372c6219bc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5af9c5e7-cd93-4406-a29d-c01d764d7e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21391f1c-2df7-41f2-903e-037a8cbd404b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5af9c5e7-cd93-4406-a29d-c01d764d7e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5e358d4-0180-4e4d-af6e-1494451af9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21391f1c-2df7-41f2-903e-037a8cbd404b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5e358d4-0180-4e4d-af6e-1494451af9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74e36723-8871-41d4-a17c-319e6b22025d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5e358d4-0180-4e4d-af6e-1494451af9b1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74e36723-8871-41d4-a17c-319e6b22025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24ccfcca-5742-475b-be9e-3389f7964ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5e358d4-0180-4e4d-af6e-1494451af9b1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24ccfcca-5742-475b-be9e-3389f7964ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_3d6d1b51-540e-472e-bd4b-9bea3188a6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21391f1c-2df7-41f2-903e-037a8cbd404b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_3d6d1b51-540e-472e-bd4b-9bea3188a6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d0ddfa6-9367-47cd-84f8-f9ce7cbecafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_3d6d1b51-540e-472e-bd4b-9bea3188a6a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d0ddfa6-9367-47cd-84f8-f9ce7cbecafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a0d0dc93-3597-4e44-8a2b-85de9cfb2a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_3d6d1b51-540e-472e-bd4b-9bea3188a6a0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a0d0dc93-3597-4e44-8a2b-85de9cfb2a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48067f5b-51ff-4651-bffa-56362cf43d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_375a145c-b3fc-4999-8501-091407e7bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48067f5b-51ff-4651-bffa-56362cf43d7e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_375a145c-b3fc-4999-8501-091407e7bf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_120abdc4-3d9e-463b-83cb-988fdf486961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_375a145c-b3fc-4999-8501-091407e7bf3b" xlink:to="loc_us-gaap_AwardTypeAxis_120abdc4-3d9e-463b-83cb-988fdf486961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c55ed75-d914-4bc0-941f-bdfe10345e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_120abdc4-3d9e-463b-83cb-988fdf486961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c55ed75-d914-4bc0-941f-bdfe10345e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1ff9a260-4a61-4bdb-949f-00198e5b1d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c55ed75-d914-4bc0-941f-bdfe10345e30" xlink:to="loc_us-gaap_RestrictedStockMember_1ff9a260-4a61-4bdb-949f-00198e5b1d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6feae2a1-1a34-47aa-b7e0-dffc4bb05c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_375a145c-b3fc-4999-8501-091407e7bf3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6feae2a1-1a34-47aa-b7e0-dffc4bb05c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6feae2a1-1a34-47aa-b7e0-dffc4bb05c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d5e5510-bbae-4de8-a0e7-0b46ed00ffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d5e5510-bbae-4de8-a0e7-0b46ed00ffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6405286-0916-4979-a3f8-215c87f6c6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6405286-0916-4979-a3f8-215c87f6c6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_461d65dc-0946-4c9e-aed0-c9169c4cea8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_461d65dc-0946-4c9e-aed0-c9169c4cea8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21e5e457-1412-4eaf-91e6-45849e6657a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21e5e457-1412-4eaf-91e6-45849e6657a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5254882-7e75-4e41-aca2-8c2daa0c97d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5af7b9ed-72e6-49c7-8ae2-a17ed649516a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5254882-7e75-4e41-aca2-8c2daa0c97d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6feae2a1-1a34-47aa-b7e0-dffc4bb05c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a149799a-e365-4012-8430-160dd1260da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a149799a-e365-4012-8430-160dd1260da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d32caee-d676-4de5-9de6-9c2a8e6a5881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d32caee-d676-4de5-9de6-9c2a8e6a5881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_78eb0703-4ec9-4e5a-8808-46f12a97473c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_78eb0703-4ec9-4e5a-8808-46f12a97473c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f46abd9b-d409-4097-85ed-2dc0cc6cada0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f46abd9b-d409-4097-85ed-2dc0cc6cada0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cbf76ff9-ca80-404b-b981-0a0e224e7063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_924cbd5c-81d8-4172-98d1-a96d25e6c505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cbf76ff9-ca80-404b-b981-0a0e224e7063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="ehc-20211231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45c6808b-fb47-4096-bfc0-849a418e23bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_8cd13db3-d897-4c48-b784-428f032d7166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_45c6808b-fb47-4096-bfc0-849a418e23bd" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_8cd13db3-d897-4c48-b784-428f032d7166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#EmployeeBenefitPlansTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f4fd744b-b6ea-46b4-87d4-e5454e61232f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_16e99ac5-7239-41c2-a31a-40b783eb9a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f4fd744b-b6ea-46b4-87d4-e5454e61232f" xlink:to="loc_us-gaap_DefinedContributionPlanTable_16e99ac5-7239-41c2-a31a-40b783eb9a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_c071d9a7-e9e2-4eac-a180-53b7840d304e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_16e99ac5-7239-41c2-a31a-40b783eb9a56" xlink:to="loc_us-gaap_RetirementPlanNameAxis_c071d9a7-e9e2-4eac-a180-53b7840d304e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_c8291b1f-66ed-4c6c-bbbc-c97d331832f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_c071d9a7-e9e2-4eac-a180-53b7840d304e" xlink:to="loc_us-gaap_RetirementPlanNameDomain_c8291b1f-66ed-4c6c-bbbc-c97d331832f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHealthRetirementInvestmentPlanMember_38f615e1-1146-4d2f-92a8-1bfd483b6a51" xlink:href="ehc-20211231.xsd#ehc_EncompassHealthRetirementInvestmentPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_c8291b1f-66ed-4c6c-bbbc-c97d331832f9" xlink:to="loc_ehc_EncompassHealthRetirementInvestmentPlanMember_38f615e1-1146-4d2f-92a8-1bfd483b6a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHomeHealthSavingsPlanHHSPMember_8c7577ed-0317-4f02-bb18-70768e16dfa4" xlink:href="ehc-20211231.xsd#ehc_EncompassHomeHealthSavingsPlanHHSPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_c8291b1f-66ed-4c6c-bbbc-c97d331832f9" xlink:to="loc_ehc_EncompassHomeHealthSavingsPlanHHSPMember_8c7577ed-0317-4f02-bb18-70768e16dfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_16e99ac5-7239-41c2-a31a-40b783eb9a56" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HealthcarePlanExpense_c9787e18-e7c9-486a-95e1-0919271d9825" xlink:href="ehc-20211231.xsd#ehc_HealthcarePlanExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_HealthcarePlanExpense_c9787e18-e7c9-486a-95e1-0919271d9825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfQualifiedPlans_9e088760-5696-4604-9976-92d7c71a16f5" xlink:href="ehc-20211231.xsd#ehc_NumberOfQualifiedPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_NumberOfQualifiedPlans_9e088760-5696-4604-9976-92d7c71a16f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_77ab0d00-d856-4a1d-bebd-5c9f665de68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_77ab0d00-d856-4a1d-bebd-5c9f665de68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanAgeRequirement_a3d8ca24-0341-48da-ba6a-dcc2acea2003" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanAgeRequirement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_RetirementInvestmentPlanAgeRequirement_a3d8ca24-0341-48da-ba6a-dcc2acea2003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7a4ae2f6-c381-436a-b0b5-09ce6d4b9fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7a4ae2f6-c381-436a-b0b5-09ce6d4b9fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_af272bc6-5719-499c-9932-dccfbf360063" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_af272bc6-5719-499c-9932-dccfbf360063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_3c658433-f386-4884-a35b-8f5b40df731f" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_3c658433-f386-4884-a35b-8f5b40df731f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_d2034c24-f9ba-4ade-a944-1a257e3c773c" xlink:href="ehc-20211231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_d2034c24-f9ba-4ade-a944-1a257e3c773c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f26aa575-30b6-48c0-89a4-2e1e7ea1cd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f26aa575-30b6-48c0-89a4-2e1e7ea1cd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_265ce070-8fce-4c12-9ab0-efa4fd9da013" xlink:href="ehc-20211231.xsd#ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_265ce070-8fce-4c12-9ab0-efa4fd9da013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorManagementBonusProgramTotalCosts_17022603-466a-4407-b1aa-71cdc44f2fe3" xlink:href="ehc-20211231.xsd#ehc_SeniorManagementBonusProgramTotalCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_705b0e66-538a-4535-8eb8-573ca98ad057" xlink:to="loc_ehc_SeniorManagementBonusProgramTotalCosts_17022603-466a-4407-b1aa-71cdc44f2fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ffd83fc0-d046-4acd-9f24-34966df046d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0e1ffd81-dcf0-4d34-902d-0062be44824c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ffd83fc0-d046-4acd-9f24-34966df046d2" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0e1ffd81-dcf0-4d34-902d-0062be44824c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_36905e59-3891-4b31-8157-104f7f98d59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_420fc9e5-fb7d-418d-8825-6f8236baad12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36905e59-3891-4b31-8157-104f7f98d59d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_420fc9e5-fb7d-418d-8825-6f8236baad12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0f0ae588-f4aa-429c-b2e1-83e57078971d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36905e59-3891-4b31-8157-104f7f98d59d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0f0ae588-f4aa-429c-b2e1-83e57078971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_07cc6b11-f4ba-477a-bce5-b6461748fb32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36905e59-3891-4b31-8157-104f7f98d59d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_07cc6b11-f4ba-477a-bce5-b6461748fb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d1bc920f-d7ac-4ee8-ab56-4263e30bd8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4c9694bc-6f98-4dfa-80a9-eade635550f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1bc920f-d7ac-4ee8-ab56-4263e30bd8a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4c9694bc-6f98-4dfa-80a9-eade635550f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1a5b70a3-9d4a-41af-a73c-37879b81e86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4c9694bc-6f98-4dfa-80a9-eade635550f3" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1a5b70a3-9d4a-41af-a73c-37879b81e86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_88fddc09-09b8-42e1-b5a8-158d7d920273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1a5b70a3-9d4a-41af-a73c-37879b81e86c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_88fddc09-09b8-42e1-b5a8-158d7d920273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1ddef50e-c06b-4174-9a88-077d3aced656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1a5b70a3-9d4a-41af-a73c-37879b81e86c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1ddef50e-c06b-4174-9a88-077d3aced656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d381b1ce-1a79-44fe-a63b-d5ca1d6fe144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1a5b70a3-9d4a-41af-a73c-37879b81e86c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d381b1ce-1a79-44fe-a63b-d5ca1d6fe144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b2669313-b868-4be4-b9cd-e01275aa2512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4c9694bc-6f98-4dfa-80a9-eade635550f3" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b2669313-b868-4be4-b9cd-e01275aa2512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6cccbce7-b38a-4803-a642-7250a3095143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b2669313-b868-4be4-b9cd-e01275aa2512" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6cccbce7-b38a-4803-a642-7250a3095143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8acaec51-4d70-42e6-a5ac-5dd0571bf683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b2669313-b868-4be4-b9cd-e01275aa2512" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8acaec51-4d70-42e6-a5ac-5dd0571bf683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9e4893d2-e115-46c1-88a1-8cbefb107030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b2669313-b868-4be4-b9cd-e01275aa2512" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9e4893d2-e115-46c1-88a1-8cbefb107030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a625f867-b553-4693-8ae0-85d8a6a6e791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4c9694bc-6f98-4dfa-80a9-eade635550f3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a625f867-b553-4693-8ae0-85d8a6a6e791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a3942e95-a931-4cd0-91a4-06fe92805b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_56bbd033-1c91-4783-849f-5921d0ebac23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a3942e95-a931-4cd0-91a4-06fe92805b1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_56bbd033-1c91-4783-849f-5921d0ebac23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_39a7dd34-da2b-4b1d-9f35-514b50f5946a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a3942e95-a931-4cd0-91a4-06fe92805b1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_39a7dd34-da2b-4b1d-9f35-514b50f5946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b3e26145-b8a7-4336-a9ad-a65150f11686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_39a7dd34-da2b-4b1d-9f35-514b50f5946a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b3e26145-b8a7-4336-a9ad-a65150f11686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ed519196-a194-450e-a0ab-29863ebe751c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_39a7dd34-da2b-4b1d-9f35-514b50f5946a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ed519196-a194-450e-a0ab-29863ebe751c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_fcd5dbdb-5352-406f-a61c-6b7f4eee4ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_39a7dd34-da2b-4b1d-9f35-514b50f5946a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_fcd5dbdb-5352-406f-a61c-6b7f4eee4ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_18c22740-0bcf-407b-bd44-1ad0f1a92668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_39a7dd34-da2b-4b1d-9f35-514b50f5946a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_18c22740-0bcf-407b-bd44-1ad0f1a92668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_833c1354-2d95-4465-a9bb-65648a56c327" xlink:href="ehc-20211231.xsd#ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_39a7dd34-da2b-4b1d-9f35-514b50f5946a" xlink:to="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_833c1354-2d95-4465-a9bb-65648a56c327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ac352f62-09e4-4fb5-8b73-7701129a32b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_39a7dd34-da2b-4b1d-9f35-514b50f5946a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ac352f62-09e4-4fb5-8b73-7701129a32b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_859ff9cc-cac6-4528-a9e0-b4dfd03b84ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a3942e95-a931-4cd0-91a4-06fe92805b1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_859ff9cc-cac6-4528-a9e0-b4dfd03b84ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_66b06b4a-1522-47de-b228-9697a9955099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b06b4a-1522-47de-b228-9697a9955099" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9afe62ba-a02a-48b3-af02-5f130f806f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9afe62ba-a02a-48b3-af02-5f130f806f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_71f9045a-9703-4cfd-8cf8-5a85e7cfdf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_71f9045a-9703-4cfd-8cf8-5a85e7cfdf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_1fed3770-32d7-48b8-af66-e99be8f88075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_1fed3770-32d7-48b8-af66-e99be8f88075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_57ad99dc-0f2d-4d5c-a2ad-61055abd581b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_57ad99dc-0f2d-4d5c-a2ad-61055abd581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability_277749f8-22b8-44ef-a2c0-2aaf7c888056" xlink:href="ehc-20211231.xsd#ehc_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability_277749f8-22b8-44ef-a2c0-2aaf7c888056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_0601dd1a-04e7-4848-bade-afb3c0c4faef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_0601dd1a-04e7-4848-bade-afb3c0c4faef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1253a372-90c0-4685-81fd-50f9c30bf4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1253a372-90c0-4685-81fd-50f9c30bf4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_cf2cdd1f-7cc2-4815-b1ef-8596133e5ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_cf2cdd1f-7cc2-4815-b1ef-8596133e5ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3e78710c-1f00-462a-afdf-2dbd1190d853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_3e78710c-1f00-462a-afdf-2dbd1190d853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_70385c29-a94e-4d85-8bb8-ce1c91610906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_70385c29-a94e-4d85-8bb8-ce1c91610906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_549074bb-ada2-45d6-9d17-a073cf3e9ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3ade0dcb-8d54-4287-9323-359ba03808c7" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_549074bb-ada2-45d6-9d17-a073cf3e9ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b06b4a-1522-47de-b228-9697a9955099" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_1921f370-a5c0-4320-ba6b-3f31e9c185d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_1921f370-a5c0-4320-ba6b-3f31e9c185d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_bf9f4d0e-63c8-4707-b66f-433eb5675c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_bf9f4d0e-63c8-4707-b66f-433eb5675c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_b5aa9dd6-39b4-4a9f-9e38-546d7c8f2747" xlink:href="ehc-20211231.xsd#ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:to="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_b5aa9dd6-39b4-4a9f-9e38-546d7c8f2747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fa8e9212-43c8-4249-ae2d-f7c8613eefb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fa8e9212-43c8-4249-ae2d-f7c8613eefb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_ecf34dc8-470a-412f-a9b5-c5a6573ceec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_ecf34dc8-470a-412f-a9b5-c5a6573ceec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_675cc344-a7c0-47a5-97fd-b3a33c4aa43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_675cc344-a7c0-47a5-97fd-b3a33c4aa43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_84889633-5fad-48e8-9891-dfbdbbeb0350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_129af659-c881-4b23-99ba-ac2979b21469" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_84889633-5fad-48e8-9891-dfbdbbeb0350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a195269a-5d21-4ceb-94f4-91ce06692c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66b06b4a-1522-47de-b228-9697a9955099" xlink:to="loc_us-gaap_DeferredTaxLiabilities_a195269a-5d21-4ceb-94f4-91ce06692c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#IncomeTaxesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_274f3ea1-d9de-4788-82cb-e2558aa7f8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_34c9c23b-adeb-49a6-912f-241766e355c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_274f3ea1-d9de-4788-82cb-e2558aa7f8ed" xlink:to="loc_us-gaap_ValuationAllowanceTable_34c9c23b-adeb-49a6-912f-241766e355c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_46bc5a07-fc42-459d-8b35-c462a434ecb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_34c9c23b-adeb-49a6-912f-241766e355c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_46bc5a07-fc42-459d-8b35-c462a434ecb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_19d1176b-9607-4db7-87f0-a189dff6b6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46bc5a07-fc42-459d-8b35-c462a434ecb4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_19d1176b-9607-4db7-87f0-a189dff6b6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_fafa0f0d-640c-4c0d-86bf-38df4f02b8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_19d1176b-9607-4db7-87f0-a189dff6b6db" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_fafa0f0d-640c-4c0d-86bf-38df4f02b8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_34c9c23b-adeb-49a6-912f-241766e355c3" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c8b5a675-810a-4408-8171-f2be893c8c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c8b5a675-810a-4408-8171-f2be893c8c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b4e9c0e2-bb49-4a79-91ad-ff21d0382b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b4e9c0e2-bb49-4a79-91ad-ff21d0382b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c06b8ef9-ce10-49ee-8d72-741339ef18d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_0674ca42-1d7c-4d9e-8a11-674276e93f49" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c06b8ef9-ce10-49ee-8d72-741339ef18d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="simple" xlink:href="ehc-20211231.xsd#EarningsperCommonShare"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b4551b23-ea8b-4927-a316-74807c65c8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_cfc0048b-0d9f-406e-83d0-469cce25e500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b4551b23-ea8b-4927-a316-74807c65c8d7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_cfc0048b-0d9f-406e-83d0-469cce25e500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#EarningsPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fa553164-1b67-4a7c-9796-2491333c8874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5340b2f6-ef13-4c73-a3bf-e6b483f0092f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fa553164-1b67-4a7c-9796-2491333c8874" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5340b2f6-ef13-4c73-a3bf-e6b483f0092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e064470d-0bc0-421e-bbf2-83c1d0395232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fa553164-1b67-4a7c-9796-2491333c8874" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e064470d-0bc0-421e-bbf2-83c1d0395232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0dd968be-a90a-4761-b675-dccc45ed9d43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be8e221-db78-4d3e-8d53-abbce31bd120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0dd968be-a90a-4761-b675-dccc45ed9d43" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be8e221-db78-4d3e-8d53-abbce31bd120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1bac6350-b211-4937-8e0b-b6980db8b844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be8e221-db78-4d3e-8d53-abbce31bd120" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1bac6350-b211-4937-8e0b-b6980db8b844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_e24520e8-0561-43b9-a828-de9f7f6bc1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be8e221-db78-4d3e-8d53-abbce31bd120" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_e24520e8-0561-43b9-a828-de9f7f6bc1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_c961e37c-6059-43b4-88d6-1faac7dc26da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be8e221-db78-4d3e-8d53-abbce31bd120" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_c961e37c-6059-43b4-88d6-1faac7dc26da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_48da9477-c7d9-4c15-b7ea-869137faf670" xlink:href="ehc-20211231.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be8e221-db78-4d3e-8d53-abbce31bd120" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_48da9477-c7d9-4c15-b7ea-869137faf670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_107912ff-4e47-4acb-93b7-2ebe47aec18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be8e221-db78-4d3e-8d53-abbce31bd120" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_107912ff-4e47-4acb-93b7-2ebe47aec18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_fcc8ae84-6139-46e4-ad54-1c79f6e539e5" xlink:href="ehc-20211231.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be8e221-db78-4d3e-8d53-abbce31bd120" xlink:to="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_fcc8ae84-6139-46e4-ad54-1c79f6e539e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_08bcf1dd-4bff-4a18-bfa0-b159c4d93c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0dd968be-a90a-4761-b675-dccc45ed9d43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_08bcf1dd-4bff-4a18-bfa0-b159c4d93c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ce7cf31-20f1-478f-80fd-c584758bbc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_08bcf1dd-4bff-4a18-bfa0-b159c4d93c45" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ce7cf31-20f1-478f-80fd-c584758bbc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_efdc3c5c-d311-4450-89ae-8d59f03c8bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0dd968be-a90a-4761-b675-dccc45ed9d43" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_efdc3c5c-d311-4450-89ae-8d59f03c8bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0cb10d20-3e73-45e0-aa70-feed7d866c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_efdc3c5c-d311-4450-89ae-8d59f03c8bfd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0cb10d20-3e73-45e0-aa70-feed7d866c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_4b6d1852-b399-48e8-aa04-56786c32985b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_efdc3c5c-d311-4450-89ae-8d59f03c8bfd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_4b6d1852-b399-48e8-aa04-56786c32985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1f9fc087-a5f0-461a-90a2-0bd6763107bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_efdc3c5c-d311-4450-89ae-8d59f03c8bfd" xlink:to="loc_us-gaap_EarningsPerShareBasic_1f9fc087-a5f0-461a-90a2-0bd6763107bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ad126ed0-84ce-4f00-a9eb-8f955b0a1cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0dd968be-a90a-4761-b675-dccc45ed9d43" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ad126ed0-84ce-4f00-a9eb-8f955b0a1cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a9bd0764-f9d5-4c36-acb1-4f170fc63494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ad126ed0-84ce-4f00-a9eb-8f955b0a1cf8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a9bd0764-f9d5-4c36-acb1-4f170fc63494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_81e823ea-9b05-41a9-955d-3659abb007c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ad126ed0-84ce-4f00-a9eb-8f955b0a1cf8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_81e823ea-9b05-41a9-955d-3659abb007c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_2ebdaae8-9403-41b5-976c-da9faf65f058" xlink:href="ehc-20211231.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ad126ed0-84ce-4f00-a9eb-8f955b0a1cf8" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_2ebdaae8-9403-41b5-976c-da9faf65f058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8cfc3340-695f-4df4-b5f9-8ef050bca511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ad126ed0-84ce-4f00-a9eb-8f955b0a1cf8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8cfc3340-695f-4df4-b5f9-8ef050bca511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5e9884b3-17c0-48c8-941f-775eab3e0519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ad126ed0-84ce-4f00-a9eb-8f955b0a1cf8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5e9884b3-17c0-48c8-941f-775eab3e0519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b4f7c184-cbe2-4835-b6a1-be14257050e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0dd968be-a90a-4761-b675-dccc45ed9d43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b4f7c184-cbe2-4835-b6a1-be14257050e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_078f7de3-01a5-4139-86c7-b3b594c62891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b4f7c184-cbe2-4835-b6a1-be14257050e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_078f7de3-01a5-4139-86c7-b3b594c62891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_66d3c486-86b4-47f4-92fa-6b5d78ad5e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0dd968be-a90a-4761-b675-dccc45ed9d43" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_66d3c486-86b4-47f4-92fa-6b5d78ad5e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_22da8013-7706-4451-9c16-3a83f44ee856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_66d3c486-86b4-47f4-92fa-6b5d78ad5e2c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_22da8013-7706-4451-9c16-3a83f44ee856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1c31cc69-8b19-4138-bed9-e995499e1325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_66d3c486-86b4-47f4-92fa-6b5d78ad5e2c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1c31cc69-8b19-4138-bed9-e995499e1325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_61f928db-55f7-4827-94eb-1f0e8ed8960f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_66d3c486-86b4-47f4-92fa-6b5d78ad5e2c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_61f928db-55f7-4827-94eb-1f0e8ed8960f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08cba0df-e0dd-4040-8662-15e9e31038b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118a0b34-5822-4961-9c82-aebf44c95057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08cba0df-e0dd-4040-8662-15e9e31038b8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118a0b34-5822-4961-9c82-aebf44c95057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_01d38b14-248e-4781-80f4-ad87e40bffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08cba0df-e0dd-4040-8662-15e9e31038b8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_01d38b14-248e-4781-80f4-ad87e40bffb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d1ab2c1-eb28-473a-9f75-b245289a1d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08cba0df-e0dd-4040-8662-15e9e31038b8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d1ab2c1-eb28-473a-9f75-b245289a1d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#EarningsPerCommonShareTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_01f998a1-cf5f-4cc1-a699-a645553aa0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_075dad37-ee29-44a6-9ca9-c4e6bd3263e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01f998a1-cf5f-4cc1-a699-a645553aa0f2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_075dad37-ee29-44a6-9ca9-c4e6bd3263e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8098e60d-b6a4-4eb4-824b-445cdd8db3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_075dad37-ee29-44a6-9ca9-c4e6bd3263e6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8098e60d-b6a4-4eb4-824b-445cdd8db3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b9f484c0-41c3-4d3b-a5ac-bf1fbe5881af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8098e60d-b6a4-4eb4-824b-445cdd8db3a6" xlink:to="loc_us-gaap_ClassOfStockDomain_b9f484c0-41c3-4d3b-a5ac-bf1fbe5881af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3f5c266b-4dcc-4409-aa4a-1d05fe5c5aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9f484c0-41c3-4d3b-a5ac-bf1fbe5881af" xlink:to="loc_us-gaap_CommonStockMember_3f5c266b-4dcc-4409-aa4a-1d05fe5c5aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_075dad37-ee29-44a6-9ca9-c4e6bd3263e6" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e8d80235-f8ed-4b6e-ab1d-4a48bdb07b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e8d80235-f8ed-4b6e-ab1d-4a48bdb07b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ca8f8ae2-0bd5-4c60-8596-441d86d094c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ca8f8ae2-0bd5-4c60-8596-441d86d094c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6e6eb9b8-2624-47e1-9bc2-dee2d23ae846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6e6eb9b8-2624-47e1-9bc2-dee2d23ae846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1e9e7a21-f2fa-4bce-81d2-34dbfb6f3b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1e9e7a21-f2fa-4bce-81d2-34dbfb6f3b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_5e73edd7-3d62-4251-82cc-090b9662f9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_5e73edd7-3d62-4251-82cc-090b9662f9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_f22ecfdc-4375-43d6-9635-b43a376ac95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7937bb5f-c933-4370-bf30-2656c859e516" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_f22ecfdc-4375-43d6-9635-b43a376ac95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="simple" xlink:href="ehc-20211231.xsd#ContingenciesandOtherCommitments"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_600a37a0-7322-4c54-ab2b-428ee979fdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_33af8dd2-dd1b-4f3b-854f-b5d4a1be5904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_600a37a0-7322-4c54-ab2b-428ee979fdd4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_33af8dd2-dd1b-4f3b-854f-b5d4a1be5904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#ContingenciesandOtherCommitmentsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7052e2e3-e070-482d-a33a-81877447944d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7052e2e3-e070-482d-a33a-81877447944d" xlink:to="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_282b7446-adc6-4c29-8c3e-0c695d92e60f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:to="loc_srt_RangeAxis_282b7446-adc6-4c29-8c3e-0c695d92e60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a302262f-a91e-43dc-96aa-2aa78e0b5c18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_282b7446-adc6-4c29-8c3e-0c695d92e60f" xlink:to="loc_srt_RangeMember_a302262f-a91e-43dc-96aa-2aa78e0b5c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59a31ce4-9a26-4a60-94fd-adeaf9e3ba75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a302262f-a91e-43dc-96aa-2aa78e0b5c18" xlink:to="loc_srt_MaximumMember_59a31ce4-9a26-4a60-94fd-adeaf9e3ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b1ef93d9-acf3-46c3-a605-02f8ae6243b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:to="loc_us-gaap_LitigationStatusAxis_b1ef93d9-acf3-46c3-a605-02f8ae6243b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3605a9df-ee53-4d97-bf84-aeecba92c9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_b1ef93d9-acf3-46c3-a605-02f8ae6243b8" xlink:to="loc_us-gaap_LitigationStatusDomain_3605a9df-ee53-4d97-bf84-aeecba92c9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_da6e4aab-eaf4-483f-a916-636fb0c380e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3605a9df-ee53-4d97-bf84-aeecba92c9be" xlink:to="loc_us-gaap_SettledLitigationMember_da6e4aab-eaf4-483f-a916-636fb0c380e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c34fec35-5eec-4c3a-9e01-c5077f5da588" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:to="loc_srt_LitigationCaseAxis_c34fec35-5eec-4c3a-9e01-c5077f5da588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_069f323c-9faf-4763-bf21-82074c7ffc53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c34fec35-5eec-4c3a-9e01-c5077f5da588" xlink:to="loc_srt_LitigationCaseTypeDomain_069f323c-9faf-4763-bf21-82074c7ffc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NicholsLitigationMember_28bc20bc-fa34-4a76-bba3-b02fef7709fa" xlink:href="ehc-20211231.xsd#ehc_NicholsLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_069f323c-9faf-4763-bf21-82074c7ffc53" xlink:to="loc_ehc_NicholsLitigationMember_28bc20bc-fa34-4a76-bba3-b02fef7709fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_9c9fbbdd-e35f-4bcc-87a2-fdc83e6b9c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c2ac5c54-7cc1-4309-8fa6-4fd8c132b598" xlink:to="loc_us-gaap_LossContingenciesLineItems_9c9fbbdd-e35f-4bcc-87a2-fdc83e6b9c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_cc3082e2-6b9a-4fa4-9bb8-902b03c55435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9c9fbbdd-e35f-4bcc-87a2-fdc83e6b9c4e" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_cc3082e2-6b9a-4fa4-9bb8-902b03c55435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9c9fbbdd-e35f-4bcc-87a2-fdc83e6b9c4e" xlink:to="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_1ff5fe43-32cf-423f-9621-27755b5e0791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_1ff5fe43-32cf-423f-9621-27755b5e0791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_dae86cc6-faa3-40d3-94c6-64731302402f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_dae86cc6-faa3-40d3-94c6-64731302402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_19334efa-a82a-4e25-84c2-951eb230fe51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_19334efa-a82a-4e25-84c2-951eb230fe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_cdcd34c5-f786-400f-b5e1-535df56b6b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_cdcd34c5-f786-400f-b5e1-535df56b6b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_cd09b40c-5bfe-4081-8375-12ede5970bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_cd09b40c-5bfe-4081-8375-12ede5970bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear_702cf0e1-aef3-4d7e-a67c-c8fe0c046e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentFiscalYearMaturityAbstract_f7492c7c-39bc-4c08-bf7e-9618cba4fa4e" xlink:to="loc_us-gaap_OtherCommitmentDueAfterFifthYear_702cf0e1-aef3-4d7e-a67c-c8fe0c046e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c5505537-f782-4643-a94a-3fd0d47f9b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_59b4e55c-c60f-4235-8cc3-138c0584e5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c5505537-f782-4643-a94a-3fd0d47f9b53" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_59b4e55c-c60f-4235-8cc3-138c0584e5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_364c5fc0-e245-43ee-a98f-4b7f2db68bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ff5ee566-ce22-41ba-b0a4-de3b5e673c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_364c5fc0-e245-43ee-a98f-4b7f2db68bff" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ff5ee566-ce22-41ba-b0a4-de3b5e673c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_0a776d8e-e5f3-42e9-aea5-2efa9d5106be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_364c5fc0-e245-43ee-a98f-4b7f2db68bff" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_0a776d8e-e5f3-42e9-aea5-2efa9d5106be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_c1105002-4ef2-4a6c-86a6-0a2b183b6990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_364c5fc0-e245-43ee-a98f-4b7f2db68bff" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_c1105002-4ef2-4a6c-86a6-0a2b183b6990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_72aee7d4-fcb9-4222-bc9e-dd0b68f2bfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_364c5fc0-e245-43ee-a98f-4b7f2db68bff" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_72aee7d4-fcb9-4222-bc9e-dd0b68f2bfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9705fe55-d689-4a74-86f9-5a1760755554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9705fe55-d689-4a74-86f9-5a1760755554" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c472c86b-411e-4058-96c8-d0526d7728f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:to="loc_srt_RangeAxis_c472c86b-411e-4058-96c8-d0526d7728f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9bbaa65b-88d4-4872-864e-3dd0ccae531d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c472c86b-411e-4058-96c8-d0526d7728f5" xlink:to="loc_srt_RangeMember_9bbaa65b-88d4-4872-864e-3dd0ccae531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4de187fb-e0ff-41b1-baa7-c778a70b3004" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9bbaa65b-88d4-4872-864e-3dd0ccae531d" xlink:to="loc_srt_MinimumMember_4de187fb-e0ff-41b1-baa7-c778a70b3004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_88c1e762-71a6-43a5-9cc7-f2535f298c38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9bbaa65b-88d4-4872-864e-3dd0ccae531d" xlink:to="loc_srt_MaximumMember_88c1e762-71a6-43a5-9cc7-f2535f298c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e4517fbe-b83c-48ce-b02a-2be12eeae375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e4517fbe-b83c-48ce-b02a-2be12eeae375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4517fbe-b83c-48ce-b02a-2be12eeae375" xlink:to="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_7d2d1503-4787-45e8-94ec-96b7db1e0aa0" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_7d2d1503-4787-45e8-94ec-96b7db1e0aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_12f5ba33-dc50-45e4-b5b1-e46b1be98fc2" xlink:href="ehc-20211231.xsd#ehc_HomehealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:to="loc_ehc_HomehealthMember_12f5ba33-dc50-45e4-b5b1-e46b1be98fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_74445a29-7d32-4018-b9c5-cdd5faf79f56" xlink:href="ehc-20211231.xsd#ehc_HospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:to="loc_ehc_HospiceMember_74445a29-7d32-4018-b9c5-cdd5faf79f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_51f4c7e6-c7ce-4d18-9d57-4fed9c9c5211" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3e0d72cf-3442-4c55-9e24-14b6fe3c831b" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_51f4c7e6-c7ce-4d18-9d57-4fed9c9c5211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cdad2ae1-358d-42a6-aa76-d4fc1c9fd44b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c17dbc02-4c4a-4e52-a9c1-2fd11e5370b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c17dbc02-4c4a-4e52-a9c1-2fd11e5370b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_3b884f95-eeea-47f9-bb68-c5f0f50fa094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_3b884f95-eeea-47f9-bb68-c5f0f50fa094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals_5c3278e9-5b1c-40c8-b36d-558404223bba" xlink:href="ehc-20211231.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitals_5c3278e9-5b1c-40c8-b36d-558404223bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_d58b3064-410e-464c-8ea3-1c5f722c8f1f" xlink:href="ehc-20211231.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_d58b3064-410e-464c-8ea3-1c5f722c8f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage_b167b25a-bee2-4fa9-bcdc-60283b420f64" xlink:href="ehc-20211231.xsd#ehc_Jointventureownershippercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Jointventureownershippercentage_b167b25a-bee2-4fa9-bcdc-60283b420f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_af8d84af-b908-4572-8c51-f5f0a3114324" xlink:href="ehc-20211231.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_af8d84af-b908-4572-8c51-f5f0a3114324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_8cfbfdc4-c5c8-4391-9eee-db0c248fe8b9" xlink:href="ehc-20211231.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_8cfbfdc4-c5c8-4391-9eee-db0c248fe8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations_7807dad6-29bf-4479-b501-65fcb6fc619a" xlink:href="ehc-20211231.xsd#ehc_Numberofhomehealthlocations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofhomehealthlocations_7807dad6-29bf-4479-b501-65fcb6fc619a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations_4e74a319-d532-4c36-92a0-7963e52bee59" xlink:href="ehc-20211231.xsd#ehc_Numberofhospicelocations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofhospicelocations_4e74a319-d532-4c36-92a0-7963e52bee59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_37e87da4-c59a-458f-ba7d-808864f1c681" xlink:href="ehc-20211231.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_37e87da4-c59a-458f-ba7d-808864f1c681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_916c4b95-cf30-416a-8f7c-687c2614e63b" xlink:href="ehc-20211231.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_88b12b4d-23b4-4a37-a6c6-a1c2b8da5087" xlink:to="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_916c4b95-cf30-416a-8f7c-687c2614e63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d0cb4ee8-cd54-47c4-996d-32683dd436bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e723aee7-f6a7-4813-a234-d3703abf5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d0cb4ee8-cd54-47c4-996d-32683dd436bd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e723aee7-f6a7-4813-a234-d3703abf5fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8d39f499-b044-4db5-9694-b5c46e5934b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e723aee7-f6a7-4813-a234-d3703abf5fe2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8d39f499-b044-4db5-9694-b5c46e5934b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93e4253a-acc1-4a9c-ac69-6fe3cbbc2d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8d39f499-b044-4db5-9694-b5c46e5934b4" xlink:to="loc_us-gaap_SegmentDomain_93e4253a-acc1-4a9c-ac69-6fe3cbbc2d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_17a4eae4-4319-4625-aae4-a014e8cfa484" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93e4253a-acc1-4a9c-ac69-6fe3cbbc2d8f" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_17a4eae4-4319-4625-aae4-a014e8cfa484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_e3d67e13-51a8-4ac5-95ca-929b318bc718" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93e4253a-acc1-4a9c-ac69-6fe3cbbc2d8f" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_e3d67e13-51a8-4ac5-95ca-929b318bc718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e723aee7-f6a7-4813-a234-d3703abf5fe2" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0536f4b4-57ee-48c9-8533-001820e219ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0536f4b4-57ee-48c9-8533-001820e219ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_4cf14d6f-b6ee-4dd5-8352-9230d038bdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_LaborAndRelatedExpense_4cf14d6f-b6ee-4dd5-8352-9230d038bdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_32834a1b-713d-4167-95ce-6fc67398cdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_32834a1b-713d-4167-95ce-6fc67398cdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_668bb75d-bdeb-4f9e-9886-cbf655d69fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_SuppliesExpense_668bb75d-bdeb-4f9e-9886-cbf655d69fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_23a56f1a-5743-4322-a438-677d1f9c449a" xlink:href="ehc-20211231.xsd#ehc_OccupancyCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_ehc_OccupancyCost_23a56f1a-5743-4322-a438-677d1f9c449a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_e73b3839-2b11-48e7-b04d-3fed4772f809" xlink:href="ehc-20211231.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_e73b3839-2b11-48e7-b04d-3fed4772f809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_0e7224ba-6752-4255-baca-a524ff5101ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_0e7224ba-6752-4255-baca-a524ff5101ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5dc47c89-ac05-48d0-b8b3-8ce55cfc7b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_23ed03a5-caa5-4580-8f3c-8095ebeac1e1" xlink:to="loc_us-gaap_CostsAndExpenses_5dc47c89-ac05-48d0-b8b3-8ce55cfc7b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cf167e82-955f-48e3-8f8b-0b5f2df291cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cf167e82-955f-48e3-8f8b-0b5f2df291cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_087720ff-b018-438c-9e19-9e9803197395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_087720ff-b018-438c-9e19-9e9803197395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6d6a3254-3b56-417d-8f08-cc91ac967a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6d6a3254-3b56-417d-8f08-cc91ac967a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_3745a388-29a7-4613-b9a2-36e61595cc2a" xlink:href="ehc-20211231.xsd#ehc_AdjustedEBITDA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_ehc_AdjustedEBITDA_3745a388-29a7-4613-b9a2-36e61595cc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_c3b3bc8f-d71e-4f44-8f17-9b308f702ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_56c47acb-10be-42b3-b7d0-e36033a6a3af" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_c3b3bc8f-d71e-4f44-8f17-9b308f702ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6fec0625-81f5-42bb-8ffa-a10bb077d0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_9ea697f5-75ba-43d2-8db6-8c8467516a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6fec0625-81f5-42bb-8ffa-a10bb077d0bb" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_9ea697f5-75ba-43d2-8db6-8c8467516a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ac35b2df-4b19-4761-9460-f18fe9e04761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_9ea697f5-75ba-43d2-8db6-8c8467516a00" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ac35b2df-4b19-4761-9460-f18fe9e04761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6d816acd-3a84-4c5f-805e-a62adaf965b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ac35b2df-4b19-4761-9460-f18fe9e04761" xlink:to="loc_us-gaap_SegmentDomain_6d816acd-3a84-4c5f-805e-a62adaf965b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_5a44ff2c-f297-4465-b45a-3df112a92040" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d816acd-3a84-4c5f-805e-a62adaf965b5" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_5a44ff2c-f297-4465-b45a-3df112a92040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_09f661a0-5af0-40df-862f-e25cd2841c2b" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d816acd-3a84-4c5f-805e-a62adaf965b5" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_09f661a0-5af0-40df-862f-e25cd2841c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_41922962-b67a-4007-aae2-93b4bcf02b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_9ea697f5-75ba-43d2-8db6-8c8467516a00" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_41922962-b67a-4007-aae2-93b4bcf02b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3d485e29-c264-4117-8105-40647916f723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_41922962-b67a-4007-aae2-93b4bcf02b51" xlink:to="loc_us-gaap_Assets_3d485e29-c264-4117-8105-40647916f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_3aa5e13f-88c3-4d7e-8825-418cad9cda03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_41922962-b67a-4007-aae2-93b4bcf02b51" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_3aa5e13f-88c3-4d7e-8825-418cad9cda03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4aa05f90-2d8e-429c-800f-3453e8864858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d11c367b-c996-4da6-9092-4e17b3ee8209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4aa05f90-2d8e-429c-800f-3453e8864858" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d11c367b-c996-4da6-9092-4e17b3ee8209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d11c367b-c996-4da6-9092-4e17b3ee8209" xlink:to="loc_srt_ConsolidationItemsAxis_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4ebfa000-1a2e-4c9b-ba5b-17f8bb88b05c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_82db41d6-eb8b-4b7e-8d1b-01adf93de5fd" xlink:to="loc_srt_ConsolidationItemsDomain_4ebfa000-1a2e-4c9b-ba5b-17f8bb88b05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6fd13c6e-e067-4ba5-a1dc-cb3788c05f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4ebfa000-1a2e-4c9b-ba5b-17f8bb88b05c" xlink:to="loc_us-gaap_OperatingSegmentsMember_6fd13c6e-e067-4ba5-a1dc-cb3788c05f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_2b4872d9-6c8f-4218-85cb-5f3d3bb6d635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4ebfa000-1a2e-4c9b-ba5b-17f8bb88b05c" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_2b4872d9-6c8f-4218-85cb-5f3d3bb6d635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d11c367b-c996-4da6-9092-4e17b3ee8209" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_ebd55afe-4dde-4078-935b-77a59eaddcd4" xlink:href="ehc-20211231.xsd#ehc_AdjustedEBITDA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_ehc_AdjustedEBITDA_ebd55afe-4dde-4078-935b-77a59eaddcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7a1b4816-43f2-4d02-af6c-e08ea9b2f9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7a1b4816-43f2-4d02-af6c-e08ea9b2f9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_14350a45-956c-41b5-ae9d-e7afdb875139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_14350a45-956c-41b5-ae9d-e7afdb875139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_dcc31990-4394-46d7-9623-151ce9f1f233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_dcc31990-4394-46d7-9623-151ce9f1f233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_3fcdea71-5724-42db-b6b2-d920a8e5f1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_LitigationSettlementExpense_3fcdea71-5724-42db-b6b2-d920a8e5f1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c77c31f8-c415-4071-9adc-e75c614073ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c77c31f8-c415-4071-9adc-e75c614073ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_d74c6b11-1fef-4d3e-af83-e4a3d31fc745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_InterestExpenseDebt_d74c6b11-1fef-4d3e-af83-e4a3d31fc745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4ae07822-643b-4d7f-ad1d-b4dc0300c572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4ae07822-643b-4d7f-ad1d-b4dc0300c572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_151298b1-bfe0-491d-850b-4c678f6a1631" xlink:href="ehc-20211231.xsd#ehc_SARsmarktomarketimpactonnoncontrollinginterests"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_151298b1-bfe0-491d-850b-4c678f6a1631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_a2e4d6d4-5169-4528-aa60-27214c84c46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_a2e4d6d4-5169-4528-aa60-27214c84c46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f9ad0699-b2a2-4985-b09d-d855b604a115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f9ad0699-b2a2-4985-b09d-d855b604a115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayrolltaxesonSARsexercise_d720713d-0ebe-4b37-96b1-6a57c9a72c41" xlink:href="ehc-20211231.xsd#ehc_PayrolltaxesonSARsexercise"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_ehc_PayrolltaxesonSARsexercise_d720713d-0ebe-4b37-96b1-6a57c9a72c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57d433de-7647-4d7c-8e73-c95150677f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_27206c80-a88e-437e-aa41-1f419aeb41d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57d433de-7647-4d7c-8e73-c95150677f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails" xlink:type="simple" xlink:href="ehc-20211231.xsd#SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_52303697-d6ac-4011-801e-207ed7ac0864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_52303697-d6ac-4011-801e-207ed7ac0864" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e6a9944c-a6f7-4e8c-9c66-315fa12c602d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_be340c24-e3aa-4e5a-a2f4-16ab473a7fb2" xlink:to="loc_us-gaap_SegmentDomain_e6a9944c-a6f7-4e8c-9c66-315fa12c602d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_71d17878-cdca-4435-933f-1d2c8a14aa33" xlink:href="ehc-20211231.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e6a9944c-a6f7-4e8c-9c66-315fa12c602d" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_71d17878-cdca-4435-933f-1d2c8a14aa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_95c9100e-51a1-4635-855e-6f6a5bb0e205" xlink:href="ehc-20211231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e6a9944c-a6f7-4e8c-9c66-315fa12c602d" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_95c9100e-51a1-4635-855e-6f6a5bb0e205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_728e79c9-2966-4dfe-a3c4-362620e8fa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:to="loc_us-gaap_SubsegmentsAxis_728e79c9-2966-4dfe-a3c4-362620e8fa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_728e79c9-2966-4dfe-a3c4-362620e8fa3f" xlink:to="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember_31586725-10c1-431f-ba5c-7b93ccb25faf" xlink:href="ehc-20211231.xsd#ehc_InpatientMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:to="loc_ehc_InpatientMember_31586725-10c1-431f-ba5c-7b93ccb25faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember_71b41760-8449-44cd-9e55-f52cf2ab488e" xlink:href="ehc-20211231.xsd#ehc_OutpatientandotherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:to="loc_ehc_OutpatientandotherMember_71b41760-8449-44cd-9e55-f52cf2ab488e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_fa96c1fd-6dd1-41ac-befe-30220f02af29" xlink:href="ehc-20211231.xsd#ehc_HomehealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:to="loc_ehc_HomehealthMember_fa96c1fd-6dd1-41ac-befe-30220f02af29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_df1f6057-4cde-40ba-89cb-44441f943464" xlink:href="ehc-20211231.xsd#ehc_HospiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_232087cb-e35a-4e3b-991d-8a27118f457f" xlink:to="loc_ehc_HospiceMember_df1f6057-4cde-40ba-89cb-44441f943464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_0441b6ea-a1d1-4a2d-a046-ecd0532eba17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_49dcf1b2-6c3a-4eea-b24d-bf16ab8617f3" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_0441b6ea-a1d1-4a2d-a046-ecd0532eba17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d392ba41-6a19-4bad-842b-8eed8c9a89da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_0441b6ea-a1d1-4a2d-a046-ecd0532eba17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d392ba41-6a19-4bad-842b-8eed8c9a89da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ehc-20211231_g1.jpg
<TEXT>
begin 644 ehc-20211231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*1'61!(C95AD$=Q2T %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'Y@?\ !9C_ ()6WVK?$_1?^"E?[ 'Q+;P!\>V\;^&-*O(7EW:!XPN#JUG;
MV8U2'##=#,L#>9M<$6ZAD+*LB?2/_!)[_@HKXO\ V]/AIXO\,?'?X-R?#SXP
M_"7Q.?#'Q6\'"7S;:WU!4W+<VLFYMUO, S("S$;6 :1=DK\Q\:/V+_V\/"\^
ML:?^S_\ 'CPEXG\*>(/CCI/C:P\+^,/",B77A9_[<MK^[\J\BOXDNK19$EN#
M T2S'=(J2$LH'2^!O^"<_P 6O@Y\!?BQI?P0_:SBT/XV?&GQ)+KOC7XT7W@1
M+Q8;N15A5;+3!=QK!%!;J(K=))Y?+)+N9B3D A_:[^&EC_P48^-GA7]E6RA6
MZ^&GPQ\<6'BGXPZMC,-_J-EBXT[PW$>DCF5HKN[Q_JH8H8S\US\GI7[:G_!.
MG]C3_@H?X7TSP?\ MB?!.U\966BFX;1A/J=W:R6+S!!(\3VTL;*Q$:<Y_A]S
MGY3\#?\ !*3_ (+"?#/X9VGP?^'O_!>R#0]!LX'B2+3/V6-#6Y82,SS2FX>]
M>5IY'=Y'N&9I7D=I&8NQ8_0_Q\_9I_;M;QO\/M?_ &*OVX-+\%>'_"7A_P#L
MC7O!'Q \ #Q'8Z^JA1'=RW"7-M>+.JJ 2LXW]<KE]X!\U_\ !,+X*_&?_@FE
M_P %'_'/_!+/2/BQKWC/X':C\)$^(GPG;Q1=&YN_"174X]/N-)\W S$S2F15
M "[8P0 [2EJ?_!IQ87NB_P#!*1_#NOHZ:[IGQ8\26OB6*7_61WZ3Q^8LG?=C
M9G/-?;WP#_9JN/A?XOU[XT?$_P ?OXU^)'BJSM;+7?%3Z6MC!!8VQE:WT^QM
M5>3[):))//*$:261Y)W:260[=ODUA_P3\^,'P*\??%C5_P!B/]H+1/ ?A_XT
MZW)X@\3:/K?@Z34WT'7YXEAO-6TIX[R!4DN$2-VAG25%GC60'86A8 ^>O^#7
M"WU27]D?XY>)G5AI&N?M5^+K[PZQ^X]H8K"/<G;9YD<HX[JU?IC7FO[('[*/
MPA_8?_9N\*?LM_ K2IK7PUX2T[[-9M=RB2XNI6=I9KF=P 'FEE>25V  +.<!
M1@#TJ@"*^L+'5+233]3LHKBWE7;+!/&'1QZ%3P16/_PJ[X9_]$[T+_P40_\
MQ-;M% 'A'_!/^""Z^"NJ-=0I(4\;ZNB&10=JK<$*HST ' ':O<?[.T__ )\8
M?^_0KQ'_ ()[_P#)$]6_['O6?_2DU[I0!#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-
M10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10
M!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/
MC#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-
M10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10
M!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/
MC#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10   # & .@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%? '_  <B_P#!2+_AW?\
M\$X]>_X0K7OLGQ"^)OF^%_!'DR[9K;S8S]LOUQR/(MRVUQ]V:6#UH ^_Z*^
M/^#;K_@I%_P\0_X)QZ#_ ,)KKWVOXA?#+RO"_C?SI=TUSY48^QW[9Y/GVX7<
MY^]-%/Z5]_T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q
M[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK^(7PR\KPOXW\Z7=-<^5&/L=^V>3Y]N%W.?O313^E 'W_1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"CYO\ S&7AC_Y64?\ $4=_P77_ .CYO_,9>&/_ )65\ 44 ??_ /Q%'?\
M!=?_ */F_P#,9>&/_E97]?M?P!U_?Y0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%5]2U72]&MUN]8U*WM(GGB@26YF6-6ED=8XT!8@%F=E11U+,
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M\8]!\3>(_A__ ,)4/&NF:'?K<G1WNCI @BG=,HDK&UGS%NWIL^95W+G]&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHKPG]MO_ (*4_L9?\$]?"\.O?M/_ !FL=)U"_7&A>$[!
M3>:UK+D[52UL8<RR[GPF_ C5B-SKUH ]VKYM_;D_X*P_L7?L R6WA7XO_$&?
M6?'>J[4\._"SP19'5?$FKRO_ *M(K*$[DW_PO,8T8C 8GBOG'_A+_P#@L_\
M\%6/W?P[T*Z_8R^"5[_S']?MDN_B+KML>\-KGR]&##(RY\Z,X9&D!Q7TG^PW
M_P $I_V+?^"?D=SKOP1^&TFH>,]4W-XB^)GC"[.J>(]8D?F1Y[Z4;EWGEDB$
M<9/.S/- 'S9_PKS_ (+-?\%5_P!]\8/%-U^QO\$[[_F4_"=ZEW\0M=M3VN;W
M'EZ0'7!VQCS4.Y)$<<U]7_L4?\$X?V-?^">_A&7PM^RU\%=.T.YO5_XG?B2X
MS=:QK#YW,]W>REIILMEMA8(I)VJHXKW&B@ HHHH **** "BBB@#SS]IS]D_]
MG']LSX5WGP5_:@^#^B^,_#5[DMI^L6VXP28($T$JD26\H!.)8F5QDX89KX:/
M[-G_  5*_P""/W_$T_8B\4:G^TY\ [+YIO@GXYU4#Q;X:MAU71M2(Q>1(H^6
MVE&0JJD:,S&2OTHHH ^>/V$O^"H?[(?_  4,T>]A^!WCB>Q\6Z)E/%GPU\66
MAT[Q%H$RG:\=U92'< K?*9(R\>[Y=^00/H>OEW]N[_@DA^RO^W5K%G\5]5M]
M6^'_ ,6M#P_A7XR_#J].F>(=,E1<1[IX\?:8AT\N7=A2P0QEMU?/EK^WW_P4
M,_X)074?@_\ X*S_  ZD^*GPC@D$-A^U!\+M"9I+"'.%?Q!I,0+6QY&Z> %/
MNJHF<D@ _26BN4^"?QT^#?[2/PVT[XP? 3XFZ+XO\,:M%OT_6] U!+FWE]5W
M(3M=3PR-AE.0P!!%=70 4444 %%%% !03@9 S[5\?_MZ_P#!6_P+^S)\0+7]
MDK]F;X;W_P ;/VB=>A_XD/PH\)S*3IX8 B\U:YYCTZU4,KDR$,5*G"H3(O9_
M\$[/@A^W7\-?"OB7XC_\%!?VG+?QMXX\<ZA!?R>$O#NGI;^'_!<:(RBPT[*^
M=*,%?,DD8[VC4@%M\LH!\R^,/A#_ ,%&_P#@L]XSU3PC\?M(\4?LR_LO:?J<
M]E=>"HKE(?&OQ&6*1HW%Y+&673M/<JP\M"QE0GF5'25/O3]G_P#9W^"'[*WP
MHTKX'?L[_#+2?"/A318?+T_1M'MA'&G]YV/+2R,>7D<L[L2S,22:[.B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BOSL^*/[>?[0_P"U!^T-\4_@K^SI\8-*^&^C?!7XU>!_!>H,
MFAB_UG6[O4=2M4N+J7S)EC@L%WO"D0C9KCRY2944[*^B/ /QL_;/\%? SXGR
M?&GX7:)XQ^(/@GQD=!\$IX-L;C3+'QA'<6NGR:?=NEQ).;)3-?\ E7+AY(X/
MLT[@E4Q0!]%T5^6_[4W[:7_!:3_@EGK'@[]I[]M+6/@S\3/@SX@\766B>/M#
M^'7AZ]L+[PE]LDV1SVDMQ(6NHT;Y=TH)=MJ%4WB1/J7]N/\ ;:\;?"_]HSX.
M?L&?LZC2O^%H?&G4+^6/6-;M&N;3PQH.GV[7%]J4D".AGF*J8K>(NB/*26)$
M91P#ZCHKY2^#?[8?Q+^&_P#P4*U'_@FI^T[XCT_7M5U?P GC7X6^.;/2UL&U
MFQ2=[>]T^[@1C&+R"1/-5X@J20/DHC1DOR7P1_:Z_:K_ ."BGB+XS>-OV-/B
M)X6\'^!_A7XSO?!G@FXUSPR=2/C37;&)'N[BZ?SHS!IOFRQP1BWQ*X\R4RCY
M8@ ?;5%>$_\ !-O]N3PK_P %$?V0O#/[3?A_P[)H5]?FXT_Q3X:GF\R31=7M
M96AN[1FP-P612R,0"T;QL0"V![M0 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=
M*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"->Z44 ?.'_!/'P%HT'P-U*W2ZOBL7C358E)O&)(2;8,GN<*,GN<FO=_\
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
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MUMHA''#&H 5%50 J@   < "IJ ,9? NC(H1+B\  P +IL 4O_"#Z1_S\WO\
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M/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110
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M^"6'C^?XR?!JV8RWO[,WQ.UQOMNE0 Y9/#^K29:( 9VV\^5 R?WTC#'Z344
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\*Y\::?K/_".>(+G0]>_L^X$GV'4K?;Y]K)C[LJ;UW+VW"@#H***^)?VU?\
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MM\$OA_I7PI^$'@72O#/AK0[1;72-#T2Q2WM;2(=%2-  .22>Y)).22:WZ**
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M70-5E)>S;D[89B8\EF9I6*K7OG["G_!7;]ES]M_Q#=_!K;K'PV^,.B93Q/\
M!CXCV9TW7K"55RYBBDP+N(#YA)%DA2K.L>X"@#ZGHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW
M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOD#_@O5^U'\=OV+O^
M"3WQ6_:7_9H\<_\ "->-O#7]A?V)K?\ 9EK>?9OM&NZ?:S?N;J*6%]T,\J?,
MAQNR,, 1_.#_ ,11W_!=?_H^;_S&7AC_ .5E ']?M%?R!?\ $4=_P77_ .CY
MO_,9>&/_ )64?\11W_!=?_H^;_S&7AC_ .5E ']?M%?F1_P3Q_X+H_"?P-_P
M1Y^$7[6'_!3+]IVSU+XE>-1K@CTK3=)MSK?B*2#7]0LK=+72]/B3/[N"&+>L
M:1[@"[@L6.O_ ,)-_P %H/\ @JQ\G@C2+O\ 8P^"5[_S&=9@2[^(VO6I[Q6^
M1'HP89&6(GC.&5I%.* /HO\ ;D_X*R_L7_L"7%MX.^+'CVYUWQ_JNU/#OPJ\
M"V)U;Q+JTKC]VD5E"=T>_P#A>8QHV" Q/%?.G_"LO^"S'_!5?]_\;O%]S^QS
M\$[[_F3?!M\EW\0==MC_  W5_CR])#*0=L:^:OS)(C#FOI7]AO\ X)6?L6_\
M$^K>YU;X%?#)KOQ?JFYO$7Q)\671U/Q'K,CG,CSWTHWC>>6CB$<9/.S/-?1=
M 'B/[%7_  3G_8W_ ."?'@V3PC^RO\%--T"6\4?VUXAF!NM6U=\[B]W>REII
MLMEMI;8I)VJHXKVZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHR,[<\GM0!\X?\%9_V^/#?_!-;]@SQU^U/JDMO)J^G:?\ 8?!N
MG7!!%_K=P#':1;?XE5\RR <^5#(>U?@3_P &NO\ P6-TS]E#]KCQY\)OVP?C
M#%8>!_BZEUK^I>*?$E^$@L/$4"23O=S2.<+]IB\V-VZO*EL*F_X.]?\ @I*W
M[2O[9=C^P_\ #O6FD\(?!EF&N&&4&*^\1SQJ9R<'#?9HBMN,X*RM=#H17Y#6
MES+9745Y $+Q2*Z"2-77(.1E6!##V((/>@#^X/\ ;!^#GQ%_;E_9?LO!G[+_
M .V/J/PSL/%D]C>77CWP5:PW=UJ.@2H7EALIRP^SO-&Z,EU&2R8! (8BM7]B
MK]A']E__ ()]?""+X+_LO?#6WT/3F<3:MJ,K>=J&M76/FNKVY;Y[B9B3RQPH
M.U%10%'$_P#!(?\ ;F\%_P#!1#_@GW\/?VC_  G:6-C>3:2FE^*=$TZ-8XM*
MU:T58KFW2->(X\@21K_SQEB/>OI:@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "OG[]NO_ ()B_L@_\%#_  ]:6WQ^^'\D7B31B'\*_$+PU<G3
M_$/A^96W)):7L8WKM?YA&^^(L 2A(!'T#10!^:__  OW_@JG_P $>_\ B7_M
M?>'-6_:G^ %EQ%\7O!NF@>-/"]J/XM6T\'&H1(H^:YC.[:K22/DK'7W!^RU^
MUY^S5^VO\*[7XT_LM?&/1?&?AVZPIO-)N,R6TF,^3<0L!+;2@$$QRJK@$'&"
M*](KX>_:F_X(K>!O$'Q5N_VO/^"=WQ:U#]G#XX/F2Z\1>#K93HGB5L[O)U?2
MC^XND9LDR!0VYM["4J!0!]PT5^>WPM_X+)?$_P#96\?:;^S5_P %L_@C;_![
MQ'?7 M/#OQET!Y+KP#XJD'1DNVRVFRD?,8KCA0"SM$"JU^@.D:OI/B#2K;7=
M!U.WO;&]@2>SO+2=9(IXG 971U)#*00002"#D4 6**** "BBOFC]JG_@L;_P
M3$_8I\33^!_VD_VR_".@Z]:MMO= LY9M3U"T;&=LUK8QS2PDCD!U4D'B@#Z7
MHKYH_96_X+&_\$Q?VUO$T'@C]FS]LOPCKVO73;;+0+R6;3-0NVQG;#:WT<,L
MQ Y(16('6OI>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K
M?]CWK/\ Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKP']J[_@J
M=_P3R_8B2>']IS]KCP;X:U&W!,GA\:E]LU7\+"U$ER?3/EXS0!\_?\'1W_*"
MCXY_]RS_ .I/I-?R!5_1K_P7C_X*U^(_VVO^"4?Q5\%?L]_\$^_C-'\,+[^P
MVUGXU>/-%30-*MXTUW3Y89+."<F;4%EF2&#Y1&4\XN1A#G^<J@ HHHH _J=_
MX-3?V"/V1/"__!-'X9_MNV?P.T:Y^*OBUM<_M+QKJ41NKR!+?6[^SCCM3*6%
MFODP(&$(0N<EBV:_5^O@#_@UQ_Y04? S_N9O_4GU:OO^@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHR,XS7Q)^T=_P4G_;:U+XW^(_
MV6O^">__  3*\9^-O$7AR^^PZO\ $?XD7">'O!UE*45Q)%<.QDU)0KJ3'#L?
M# C- 'VW7GO[5'[1.D?LI_ ?7?CWK7PT\9>,;;0T@_XIOX?Z"=3U>_>:>.".
M.WM@RF5B\JYY 5<L< $U\7_\.B?VW?VU?^)K_P %;O\ @HYK^L:+<\W/P7^
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MP)XJTSQQX._8SN--U?1M0AOM*U&T^*/BA);6YA<212HPU/Y65U5@>Q K[OH
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M (*P?\$=_P#1?CSI.N?M<?L]6/">//#UF/\ A8'A.U'.Z_M<[=6B1>LZMYF
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M>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH ****
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M?'7Q,\9W&JW^K-;>;Y.58B&)4,\VW8@;#X9FP*^B*** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\
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M^!_A.'P'\%OA?X=\(Z';_P"HT?PQHL%A:Q\8^6*!%0?E71T4 %%%% !1110
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M1^,=;_MO7)-:\1>(/'?BNXU?4M6U&2**%[J:64[5=DAB!$:(IV [<Y->ST4
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M0O[/P1; *1:Z3;%1';*)-SK(5:1=WRL"6+_3U 'G_P"S+^RM^SS^QM\)-/\
M@9^S'\)M(\'>%]-&8=-TF#:99, ---(Q,D\S8&Z61F=L#+&O0*** /YP?^"]
M7_!!7_@K#^VC_P %8OBM^TO^S1^RG_PDO@GQ+_87]B:W_P )UH5G]I^SZ%I]
MK-^YNKZ*9-LT$J?,@SMR,J03\@?\0N/_  77_P"C&?\ S)OAC_Y9U_7[10!_
M(%_Q"X_\%U_^C&?_ #)OAC_Y9U]?_P#!!7_@@K_P5A_8N_X*Q?"G]I?]I?\
M93_X1KP3X:_MW^V];_X3K0KS[-]HT+4+6']S:WTLS[IIXD^5#C=DX4$C^CZB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&5_]7''8V^73?G"O+Y<9/&ZOG?\ X4C_ ,%OO^"DO^D_M&_&.P_9 ^%U[R?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'Y@?\%F/^"5M]JWQ/T7_ (*5_L ?$MO 'Q[;QOX8TJ\A>7=H'C"X.K6=O9C5
M(<,-T,RP-YFUP1;J&0LJR)](_P#!)[_@HKXO_;T^&GB_PQ\=_@W)\//C#\)?
M$Y\,?%;P<)?-MK?4%3<MS:R;FW6\P#,@+,1M8!I%V2OS'QH_8O\ V\/"\^L:
M?^S_ /'CPEXG\*>(/CCI/C:P\+^,/",B77A9_P"W+:_N_*O(K^)+JT61);@P
M-$LQW2*DA+*![)^Q/^Q1I'[(UMXY\7ZYX[E\8?$#XI^+Y?$OQ%\82Z:MDE_>
M,BQ10V]LKO\ 9K2")%CBB,DC ;BTCLQ- 'S+\#_^5F7XX?\ 9L?A[_TXK7T_
M^VI_P3I_8T_X*'^%],\'_MB?!.U\966BFX;1A/J=W:R6+S!!(\3VTL;*Q$:<
MY_A]SGS;X;_\$[_COX'_ ."GGBW_ (*.:G^U'X6OX_&'@FR\*:AX)A^%UQ (
M;"VFCF1H[PZPY$Y*N"[1,GS_ '..>U_:K^!_[?7C;XQ>$OBA^Q[^VOH'@32-
M(L)K3Q-X"\9?#=-<TO6R[ADN3)%<VMU%(@&W:DRJ0!ROS;P#Y:_X)A?!7XS_
M /!-+_@H_P".?^"6>D?%C7O&?P.U'X2)\1/A.WBBZ-S=^$BNIQZ?<:3YN!F)
MFE,BJ %VQ@@!VE+4_P#@TXL+W1?^"4C^'=?1TUW3/BQXDM?$L4O^LCOTGC\Q
M9.^[&S.>:^WO@'^S5<?"_P 7Z]\:/B?X_?QK\2/%5G:V6N^*GTM;&""QMC*U
MOI]C:J\GV2T22>>4(TDLCR3NTDLAV[?)K#_@GY\8/@5X^^+&K_L1_M!:)X#\
M/_&G6Y/$'B;1];\'2:F^@Z_/$L-YJVE/'>0*DEPB1NT,Z2HL\:R ["T+ 'SU
M_P &N%OJDO[(_P <O$SJPTC7/VJ_%U]X=8_<>T,5A'N3ML\R.4<=U:OTQKS7
M]D#]E'X0_L/_ +-WA3]EOX%:5-:^&O"6G?9K-KN427%U*SM+-<SN  \TLKR2
MNP !9S@*, >E4 9/CKP=I?Q!\(W_ (+UNXNX;348##/)8W+0S*I(.4=>5/'4
M5Y#_ ,.]_@G_ -#;X[_\+*Y_QKW2B@#YP_X)X^ M&@^!NI6Z75\5B\::K$I-
MXQ)"3;!D]SA1D]SDU[O_ ,(/I'_/S>_^!;5Y'_P3W_Y(GJW_ &/>L_\ I2:]
MTH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_
M #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\
M_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_
M (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-
M[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6
MU;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%0:IJFF:'IMQK6M:C!9V
M=I"TUU=W4RQQ0QJ"6=V8@*H )))P * ,[_A!](_Y^;W_ ,"VJEXBTKP1X0T*
M[\4>+/$_]EZ9I]NT]_J.HZJ((+:)1EI))'(5% Y+$@ 5XY^S9_P5-_8R_;#_
M &C/$?[-7[+WQ#N_'-_X2TAK[7_%/AW1Y[CP];.)8XQ:C4POD2SMY@=5C9E9
M4<AB48#A/VH/^"/?@/\ ;F_:7NOBM^V?^T9X^\=?#2U-I)X5^ J:@--\-6$\
M42"2:Z6U*2ZB[2JTJF5@4\QD)=,* #RCXD_\%B;3X\^-M0^ ?_!'/]GGQ!^T
M5XOLIS;:IXY2_DT_P+X>E_O7.JR;5NB!\XB@/[U0=DA/%?7/Q=_8X^#'[77P
M,LOA)^V)\+-+\265U_9]_KGAU]1GN+%-1@9)OW4A$;R1K,I +*OF)E77:[(?
M1?AM\,?AQ\&_!.G_  U^$G@+1O#'A[2H!#IFAZ!IL5I:6L8_ACBB540=^!U-
M;E 'BWQQ_9!'B?\ 9-\1_LS?LP^.K?X23ZGX9FT7PYK6CZ")[?P]%*NQI+>R
MBFMUW+&S[-KH$<J_.W:?QJ_X@8_^LHO_ )A/_P"_5?O]10!^ /\ Q Q_]91?
M_,)__?JC_B!C_P"LHO\ YA/_ ._5?O\ 44 >4_LM_L[>,?@C^SOX.^#_ ,7/
MC/=^/O$/AC08-,U'QD+!].;5O)78D[VYGGV2&-4WGS&W.&?Y=VT=]_P@^D?\
M_-[_ .!;5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?
M\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO
M_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _
M-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;
M5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!
M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M;CU+'ECR23S73444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH%E8'4+U[R_-G:I%]IN' #S2;0-\C!5!<Y)P,GBKM%% !1110 4444 %%%%
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MW7)&YA7Z!^%?"?A7P)X<L_!W@CPSI^C:1IT"P:?I6E626]M:Q#HD<48"HH[
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M/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?S@_
M\%ZO^"]7_!6']B[_ (*Q?%;]FC]FC]JS_A&O!/AK^PO[$T3_ (070KS[-]HT
M+3[J;]]=6,LS[IIY7^9SC=@84   _H^HK^0+_B*._P""Z_\ T?-_YC+PQ_\
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MG_+O9O'KGQ U*W/K)\MOI>Y<?=VSPL<$/BO=?V+_ /@CK^PG^P]KS_$KX?\
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M#0?"6A6^G6<<CG+N(;=$0,QY9L9)Y)- 'SQXP_X+G_\ !(CP'JEWHGBC]O\
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M>_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@
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MUOXX0?!'Q[\17T4VV?!WPQ\/_P!JZY?B6YB@8VUKO3S3&)#*PW#$<3GJ,'Y
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ME=S1,P&<'&>N#Z4 ;U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\8SQ-=:C-/<N7E6*:=G:VA8G_4PE(^!\M>TT44 %%%% !1110 4444 %%%%
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MG^'KZ.[B\"^$[73;F_BC*+>W:KNN;D*?NB6=I9,=M^*]9HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \F_:G_8
M1_8Y_;<T*#P]^UA^S?X3\=16B,EA<ZYI2-=V2L<L(+E<30 GKY;KGO7A?PJ_
MX-Z?^",7P:\5Q^-/!G[ OA*>^AE\R(>([R_UJ!6SD$0:A<3Q<'I\G':OLVB@
M"*QL;'2[&'3-,LXK:VMXEBM[>",(D2*,*JJ.%    '  J6BB@ HHHH ****
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MAUJ=A*\6X;]OV1R VT'';)YKZN_:R\1?M2^%?@GJ&M_L:_#GPMXK\>Q7-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^_\ !L7_ ,$;?V??%EWXTA_9B;QG>S:C+<V<?Q"UJ?5K6QC>0NMNELY$$L:
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M"T;&=LUK8QS2PDCD!U4D'BC]E;_@L;_P3%_;6\30>"/V;/VR_".O:]=-MLM
MO)9M,U"[;&=L-K?1PRS$#DA%8@=: /I>BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^8'_@[W_P""D7_#2?[9
M.G_L0_#G7O.\(_!K=_;WV>7,=YXDG0>?G'#?9HBL [K(]RO>OR!K^B+_ (+F
M?L\?\&XG_!+^";6/B+^PQ=?$?XT^.Y+C5K#PH/B]XGCDF,LKF34M0N/[18PQ
M-*7Q\K/,X8* %=T_ WXK?$KP/\0/%4FO>#/V?/"?@:Q:7='HGAN_UB>W1<\+
MOU&_N9C[G?\ 3% '/^$_%?B3P)XJTSQQX.UJXTW5]&U"&^TK4;20I+:W,+B2
M*5&'W65U5@>Q K^UW_@DQ^WQX;_X*4_L&>!?VI]+EMX]7U'3_L/C+3K<@"PU
MNW CNXMO\*L^)8P>?*FC/>OY9O\ @G!^T]_P2+T?QUIWP\_X*7?\$U]'UKPS
M>3)#-\0?!OCKQ3:ZAIF3@SW%FFJ-%=1@XR(5B=5W$+*<(?ZI/^"='[#?[ W[
M%_PBGO?^">/@R+2/!7Q %KKHFL/&6I:O9:ENA ANX3>W4X3?$RY:/;O"INSL
M7 !]"445XU^TY_P4/_89_8S#0_M1?M6^!O!=X(!,NCZQK\(U"6,]'CLT+7$B
MG'58S0![+17F/[(W[8?[/W[='P9M_P!H']F3QG-K_A*\U"YL[/59])N;(S/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2
MDU[I0 4444 %%%% !17)_&/X]? _]G?PD_CWX^_&+POX)T1&VMJWBS7K?3[?
M=_=$D[JI;V!R?2OBGQ)_P<6?LB^/?%E]\+?^"?WP>^*7[37BZQPMS9?"GP;<
M'3K%F+!6N[^Z6..&%BK8F42(<<$\X /T"K.\5^+O"?@/P_=>+?''B?3M&TJQ
MC\R]U/5KV.WM[=/[SR2$*@]R17YE>,?'G_!TM^V-XAN?#'PT^!GPA_9.\+EH
MRNO>)/$=MXFUGRV +"-H!<0.X!QAK:'Y@<2="*_AC_@V \"?&SQ#:_$/_@JC
M^WW\8?VC-;@E,JZ7J.NRZ7HL);[T<<"R2S1J.@\F:$8S\HS@ 'L'[0?_  <;
M_P#!,/X,WFH^&?AC\1]=^-7B/3+62YNO#_P3\/2Z\8X4&6E:[3;9B,8)9A.=
MH!./7Y^D_P""G/\ P<+?M[?Z%_P3_P#^"5]E\&_#%V=L7C_XZ7K)<+$?NW$5
MM,(",_[$%VN.YSFOTX_9^_9M^ W[*GPTT[X/?LZ_"G1O"'AS2[6."UTW1[01
M@JBA5:1SEYY,#F21F=CDLQ))KMZ /RD^'/\ P;]?MB?M/>.-/^(?_!:7_@IM
MXE^,>DQR-+J/P>\*37>E^&[ERI #-;R6PVABK?NK:%CL +$$K7VY\-?^"4W_
M  31^#[Z)/\ #K]@[X4:=<>'5D_L:^'@>RENK=GV;I//EC:1Y3Y:#S&8O@8W
M8)S[_10 D<:1((HD"JH 55& !Z4M%% !1110 4444 %%%5=8UW1/#MDVI^(-
M8M;&V4X:XO+A8D'U9B!0!:HK/T_Q=X4U;P[_ ,)AI7B;3[K2?*>7^U+:\22W
MV(2';S%)7"E6R<\;3GI7S!KO_!='_@D)X?U:WT.?_@H+\.+VZNKE(+>+1=9.
MH[Y&8*J@VJR#DD#.<4 ?5]%>:_M9_M4_#/\ 8Q^"E_\ 'KXMZ;XAN]$T^ZM[
M::W\+Z!-J=X\D\JQ1A((07;+LH)Z#.3@5XI^R5_P5Z^&_P"V1\:K'X._#K]C
M;]H[1+6^M+B<>.O&GPCFTOP_!Y49?RY;N27*.^-J I\S$#(S0!]:U^.G_!U=
M_P %I/B1^Q!X(T3]A_\ 96\7SZ'\0?'NC-J?B?Q/I\I2ZT/16D>&-+9Q_J[B
MX>.8>8"'BCA8KAI$=/O_ /;B_:N_;/\ V>=?T#P]^R7_ ,$WM;^.SZQ9SRWU
MY8?$+3M MM+D1U"Q2R7BMDN&+ @8^4U_+5_P<*_$']J?XI_\%0_&'CG]L#]G
MG_A57BR]T/1O*\"+XL@UQ--LUL(DCVWMN!%,'99)#L "M(RGE22 ?$]U=7-[
M<R7M[</--,Y>665RS.Q.2Q)Y))YS1:W5S97,=[97#PS0N'BEB<JR,#D,".00
M><TRB@#^G'_@U1_X+2_$C]M_P1K?[#_[5/BZ?7/B#X"T9=3\,>)]0E+W6N:*
MLB0R)<N?]9<6[R0CS"2\L<RELM&[O^Q=?QV_\&X/A7]I'QG_ ,%:OA]H/[+W
MQ6@\%ZXUEJ<NJ:_>:&NHP)ID=G))<0O Y"L)0JPJQ(V/(CC)4 _UB?M=?#;]
MICXK_!FX\(?LE?M*VOPF\927]O+;^,+OP;;:\D4"MF6$VEPRHV]>-V<KU% '
MIU%?)_[(G[)?_!4OX2_&:W\>_M9_\%<8/BYX26PN(KGP!;_ 31] 1YW7$4PO
MK:5IAY9^;;C#9P:Z+]M_]EC]N;]H/Q-H6K_LE_\ !2S4O@38:=82PZQI=C\+
M],\0#5)F<,DQDO'5H2JY7:O!SDT ?1U%>'?L0?LW?M._LX>&-=T;]IO]N;7/
MCE>ZG?Q3Z7JFN>$;+2'TN)4*M"J6A(D#-ALMR,8KR+]H#_@FS^W%\8?C-XA^
M(/@3_@LK\5/ /AO6;\SV'@OP_P"%=,>'2HMJCR8IY 9",@G)YY(H ^SJ*\_^
M%'P=\;^ /V<[#X)^+OCSXB\5Z]::#+I]S\0]32*/4[J9PX%VP0;!*NX$8&,H
M*^3_  M_P1P_:3T?Q/INO^(O^"W'[4.K6^G7\-TVFMX@LX8KK8X8Q2[8,O&P
M!5EXR#0!]X45YA^UW^S;J7[5OP9N/A#I7[1'Q%^%TT]_;W(\6?"W7QIFK1")
MLF)9S&X$;]&7;R*\>_9$_P""6.L?LJ?&:W^-&L_\%+/VI/BC);6%Q:+X6^*'
MQ274=#D65<>:]HMLFZ5#DH^X;3V- 'UA17SC^V__ ,$W?#W[<?B?0O%&M?M?
M_'WX:-H5A+:I9?![XEOH5M>AW#^9<1K"_FR#&%;C .*WOV(/V%?"_P"PSX7U
MWPSX:_:#^+?Q#/B"_BN[K4OBYXY?7+J%T0H%AD=$\M"#DJ!R0#0![A17QC^T
M!_P0\_9O_:,^,OB'XW>+?VC_ -H#2=1\27YN[S3/"_Q?O+#3X&*A=L%N@VQ)
M\OW1W)KZ.^%/[-W@'X0?LY6'[+WAW5->O/#FGZ#+I$5UK.MRW6H26\@<,7NF
M/F-)ASA\Y''I0!Z!17PAX5_X-S/^"</A'Q1IOBRR;XJW%QI=_#>6T-]\7M8E
MA:6)Q(F]#/A@&4'!X..:^H/VN_V.OV?_ -NGX-7'P!_:8\(W6M^%KF_@O9K"
MTUJ[L',T+%HV\ZUDCD&"3P&P>X- 'I]5[[5])TLJ-3U2WMR^=@GG5-V.N,GF
MOE?]D3_@B/\ \$W?V%_C+!^T!^S7\$=3T;Q9:V$]E:ZE?>.M8U!8H9E"RJ(K
MJZDB)8#&2I([8KJOVT/^"4O[ '_!0WQ/HOC+]L;]GFV\::EX=L)++1KF?7]1
ML_LT#OO= MI<Q*V6YRP)]Z /?K#5M*U3?_9FIV]SLQO\B97VYZ9P>.A_*L+6
M_C/\'O#6J2Z)XC^+'AK3[V!L3VE[KMO%+&<9PR,X(X/<5YY^Q?\ \$\OV./^
M">?A?6O!G['/P6M_!>F>(K^.]UFV@U>]O/M,Z)Y:N6NYI67"\84@>V:\^^,O
M_!$;_@E5^T)\4M<^-?QG_8P\,^(/%/B2^-YKFLWMU>>;=SD %V"SA1P ,  <
M4 ?3EEXD\.ZEH0\4Z=K]E<:8T!F748+I'@,8R2_F [=HP<G..*X.U_;,_8_O
MM0CTFQ_:M^&TUU-,(8;:+QUI[2/(3M"!1-DL3P .<UK_  X_9[^#'PB^!]E^
MS;\./A]9:5X&T[1WTJR\-P%V@BLW#!X1O8L5(=@<DGFO"_#W_!$?_@DIX4UB
MQ\0^'?\ @G]\-;2^TVYBN+&[BT%?,AEC8,CAB<[@P!!]10!]#?$SXL?"SX*^
M%)?'GQD^)?A_PEH<$BQS:SXFUF"PM(W;[JM-.ZH"<' )YQ7)?"W]M7]C?XY>
M+$\!?!/]K3X9>,-=D@>:/1?"WCS3M0NVB09=Q#!,[E5'4XP.];WQP_9_^!_[
M2_@5OAA^T)\)O#_C7PY)=Q74FA>)M+CO+1YHFW1NT4H*L5/(R*XOX+?\$\?V
M#?V;_',?Q._9^_8V^&7@KQ'#;26\6N^%O!-E8W:12##H)88U8*PX(S@T :WQ
M\_;3_8^_96O['2?VF/VIOA[\/[S5(&FTVR\8^,;+39[N)6VM)%'/(K2(&X+*
M" >":O? +]JS]F7]JO2-0\0?LS?M >#O']CI-RMOJ=YX.\16^HQVDK+N6.1H
M'8(Q7D X)%,^,?[)'[*7[1.M6/B3]H']F3X>^.M1TNV>WTR_\9>"['4YK2%V
MW-'$]S$[1H6 )52 2,UH_![]G?\ 9_\ V>--O='^ 'P,\'>!K349UFU"U\'>
M&+33([J11M5Y%MHT#L!P"V2!Q0!_%!_P4<_:R\8?MP_MQ?$S]I[QEJDMR_B?
MQ7=2:7'*^X6FFQN8K*V7MMBMDBC'KMR>237B=>V_\%'?V3?&'[#O[<7Q,_9@
M\9:5+;/X8\5W4>E22IM%WILCF6RN5[;9;9XG'INP>017B5 !7]!7_!LU\?\
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M:-<VGAC0=/MVN+[4I($=#/,54Q6\1=$>4DL2(RC@'U'17RE\&_VP_B7\-_\
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MLL/_  KOPY+NGE;=(^9-/8C+<XS@=@*W?^(H[_@NO_T?-_YC+PQ_\K*^ **
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M&$NG:7;:%;+$Q1OL2,79<JJ;$QC</2O7_P!N+Q__ ,%!O VB>'E_8!_9_P#
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M9]#^(7CW1DTWPQX8OXBEUH6BM(DTCW*'_5W%P\<+>60'BCA4-AI'1/V)HHH
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MYX=L81;V7VB&,$D)%<%0">O J7_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8H
MH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MB
MB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C
M_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_
M^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_
MY^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_
M )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8H
MH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MB
MB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C
M_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_
M^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_
MY^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_
M )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8H
MH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVK8HH 2-!%&L:DX50!D\TM%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^
M">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P $
M]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O
M^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^
ME)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[
M_P#)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@UZ#0!X+_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/7O5% '@O\
MP[J^!_\ T-WCO_PKYZ/^'=7P/_Z&[QW_ .%?/7O5% '@O_#NKX'_ /0W>.__
M  KYZ/\ AW5\#_\ H;O'?_A7SU[U10!X+_P[J^!__0W>._\ PKYZ/^'=7P/_
M .AN\=_^%?/7O5% '@O_  [J^!__ $-WCO\ \*^>C_AW5\#_ /H;O'?_ (5\
M]>]44 >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO
M@?\ ]#=X[_\ "OGH_P"'=7P/_P"AN\=_^%?/7O5% '@O_#NKX'_]#=X[_P#"
MOGH_X=U? _\ Z&[QW_X5\]>]44 >"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\
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MJ^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^%?/7O5% '@O_  [J^!__ $-WCO\
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M3HK%8V$D30L27)Z$'->@T >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\
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MNKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\ ]#=X[_\
M"OGKRS]D3]CCX9_%GX9ZAXD\5>*O%ZW,'BK4K*,67B::)/*AG*)D#JV.I[U]
MFUY]^S7\&=3^!G@*]\(:KK4%_)=>(;[45FMXV556>4N$P>X!P: .&_X=U? _
M_H;O'?\ X5\]'_#NKX'_ /0W>.__  KYZ]ZHH \%_P"'=7P/_P"AN\=_^%?/
M1_P[J^!__0W>._\ PKYZ]ZHH \%_X=U? _\ Z&[QW_X5\]'_  [J^!__ $-W
MCO\ \*^>O>J* /!?^'=7P/\ ^AN\=_\ A7ST?\.ZO@?_ -#=X[_\*^>O>J*
M/!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO_P *^>O>J* /!?\ AW5\#_\
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MNM07\EUXAOM16:WC9559Y2X3![@'!KT&@ HHHH **** "BBB@ HHHH ****
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M^SQM-J5YY*[KJ]:X:94#EHHX8H\)NDDR ?6-%?G[_P $$O&/[3NE:/\ '_\
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M2'Q(^./_  3+^$_[47[3TT&G:_K7PWM=9\4ZA+"((Y%$)<WS* %C66)5N"%
M4>9P ,"@#Z)HKX^^ W[+WBC]J/\ 9#L/$'C[XD^*O!=M\:/$M]\0?B%9^%M0
METS6+^UU##:;I+WL3":TC@TY=/MIO**RO]B5!(B-(K>7_P#!-K]F7XL?LA_\
M%3?C;\#/@G\7?&GB;]G"P\ Z5=MIOC/Q-<:LOASQE<3!SIUI<7+,_%B#<2KN
M+ 7=KYA.4) /T1HK\ZO^#E&Z^*G@O]BG0OBA\-/C]XU\*FV^)_AK3K_1?#>K
M+9VFIVUS?>7*ER8T$\JL&7*&7RSY8RG+9_16@ HKXY\,_#;XL_M<R_&;XO\
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M_;1\1>%?%4OQ+TBPEL=+\2Q?%#Q##]DM)'=WM8[>._6W2!FD<F$1A#G[O P
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MJ^)M0U4V5M%&D44$4M_/-*D2(BJL8;8H' '- ':4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M./[5/PT_:;^)6F>(_P#A5/QJ?PUX6?1_#<6F6]O8I!N 6-6>0ECAB9996!R
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MXG^#Y?"_[/WBW3M(TS^P?!+VMWK:7GVUE>>1[N18BB6R@A%^9G)RH&" ??\
M17Y__P#!0G]LK]N#]G;_ (*9_LU?LE?!_P"*7@^'PC\?M5UBWOY-:\$-<WNB
MIIR02R>3*EW&LGF)-M7>GR,N3O!VC[ZTV"\MM.M[;4+[[5<1PHL]SY03S7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYLZ@E-MN9G7 Y9%7O7]'_P#PT/\ \'''_2.K]G__ ,.[<?\ QNOP _X-<?\
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MO>"/VF/"/_!2?_@G[+\?OV@/#OC6&?X\3#3(M#^'S:(;1@;#>SL;ZY\T,"H
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M/P.NGP/!K?B_X@3:=>M<D'S4,*(0%4XP<\U]7T4 >7_LA^*OVLO&7P;@UO\
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M/C!^V5\2?@/XL\#?M;Z-X*TG]GSQGI_B;PEIFJ_#BYUV[U"\M/LQC6]NWU>
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MOA*>^.AZU:^#WT>?RKJ^N+V1)D:]NED(EN7"LI3"@ @GF@#XH_X*U->^'O\
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M* 2WOBC2?AM-X0\6Z?;_  VM(+74+4WOVQ8+)//8V-N9/OB1KB<C?MG0NK1
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MN7C1YE7*^; 94@WH&1MT<95XV :O>_V;_@<O[/WPMM? M]X]U?Q=K4UQ+?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\'?LI?L]>%O EE=;?MQT'2TCGO2OW3<3G,MP1DX,CL17J5%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M234+<PW;O<_VNIC.2&CQ&=FT!O,Y)^M* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#R9?V&_P!EU/VBO^&ME^&;_P#"
MROL_V;_A,O[>O_MIM=^_[)O\_P#X]=W_ "[8\G'&S'%>LT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604877544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-10315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Encompass Health Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">63-0860407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9001 Liberty Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Birmingham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">35242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-7116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,438,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">The definitive proxy statement relating to the registrant&#8217;s 2022 annual meeting of stockholders is incorporated by reference in Part III to the extent described therein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000785161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604876504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Birmingham, Alabama<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606824792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract', window );"><strong>Statement of Comprehensive Income and Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 5,121.6<span></span>
</td>
<td class="nump">$ 4,644.4<span></span>
</td>
<td class="nump">$ 4,605.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">2,886.5<span></span>
</td>
<td class="nump">2,682.0<span></span>
</td>
<td class="nump">2,573.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">685.2<span></span>
</td>
<td class="nump">634.4<span></span>
</td>
<td class="nump">623.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">82.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">209.3<span></span>
</td>
<td class="nump">200.5<span></span>
</td>
<td class="nump">167.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">197.3<span></span>
</td>
<td class="nump">155.5<span></span>
</td>
<td class="nump">247.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">256.6<span></span>
</td>
<td class="nump">243.0<span></span>
</td>
<td class="nump">218.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,315.1<span></span>
</td>
<td class="nump">3,999.4<span></span>
</td>
<td class="nump">3,912.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense and amortization of debt discounts and fees</a></td>
<td class="nump">164.6<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">159.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(12.3)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(30.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income tax expense</a></td>
<td class="nump">657.2<span></span>
</td>
<td class="nump">472.6<span></span>
</td>
<td class="nump">562.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">139.6<span></span>
</td>
<td class="nump">103.8<span></span>
</td>
<td class="nump">115.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">517.6<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
<td class="nump">446.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net and comprehensive income</a></td>
<td class="nump">517.2<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
<td class="nump">445.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Net and comprehensive income</a></td>
<td class="nump">517.2<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
<td class="nump">445.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net and comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="num">(87.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Net and comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="num">(87.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net and comprehensive income attributable to Encompass Health</a></td>
<td class="nump">412.2<span></span>
</td>
<td class="nump">284.2<span></span>
</td>
<td class="nump">358.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net and comprehensive income attributable to Encompass Health</a></td>
<td class="nump">$ 412.2<span></span>
</td>
<td class="nump">$ 284.2<span></span>
</td>
<td class="nump">$ 358.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">99.8<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">4.15<span></span>
</td>
<td class="nump">2.87<span></span>
</td>
<td class="nump">3.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">4.11<span></span>
</td>
<td class="nump">2.85<span></span>
</td>
<td class="nump">3.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Amounts attributable to Encompass Health:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations</a></td>
<td class="nump">$ 412.6<span></span>
</td>
<td class="nump">$ 284.2<span></span>
</td>
<td class="nump">$ 359.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net and comprehensive income attributable to Encompass Health</a></td>
<td class="nump">$ 412.2<span></span>
</td>
<td class="nump">$ 284.2<span></span>
</td>
<td class="nump">$ 358.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OccupancyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OccupancyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statement of Comprehensive Income and Income Statement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606756824">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54.8<span></span>
</td>
<td class="nump">$ 224.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">65.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">680.3<span></span>
</td>
<td class="nump">572.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">121.2<span></span>
</td>
<td class="nump">86.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">921.4<span></span>
</td>
<td class="nump">948.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,601.6<span></span>
</td>
<td class="nump">2,206.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">242.0<span></span>
</td>
<td class="nump">245.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,427.9<span></span>
</td>
<td class="nump">2,318.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">417.5<span></span>
</td>
<td class="nump">431.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254.5<span></span>
</td>
<td class="nump">295.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,864.9<span></span>
</td>
<td class="nump">6,445.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">38.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">137.6<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">265.8<span></span>
</td>
<td class="nump">253.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44.5<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219.7<span></span>
</td>
<td class="nump">218.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">748.8<span></span>
</td>
<td class="nump">717.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,243.9<span></span>
</td>
<td class="nump">3,250.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">213.1<span></span>
</td>
<td class="nump">209.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveNoncurrent', window );">Self-insured risks</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">123.8<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86.7<span></span>
</td>
<td class="nump">51.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49.4<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,465.7<span></span>
</td>
<td class="nump">4,444.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.2<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Encompass Health shareholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value; 200,000,000 shares authorized; issued: 114,211,057 in 2021; 113,835,708 in 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital in excess of par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,289.6<span></span>
</td>
<td class="nump">2,326.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated income (deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">141.8<span></span>
</td>
<td class="num">(242.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost (14,719,662 shares in 2021 and 14,428,235 shares in 2020)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(521.2)<span></span>
</td>
<td class="num">(497.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Encompass Health shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,911.3<span></span>
</td>
<td class="nump">1,588.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">445.7<span></span>
</td>
<td class="nump">382.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,357.0<span></span>
</td>
<td class="nump">1,970.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,864.9<span></span>
</td>
<td class="nump">$ 6,445.9<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of December&#160;31, 2021 and December&#160;31, 2020 include total assets of variable interest entities of $226.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2021 and December&#160;31, 2020 include total liabilities of the variable interest entities of $38.2 million and $46.8 million, respectively. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604919224">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114,211,057<span></span>
</td>
<td class="nump">113,835,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,719,662<span></span>
</td>
<td class="nump">14,428,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,864.9<span></span>
</td>
<td class="nump">$ 6,445.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,465.7<span></span>
</td>
<td class="nump">4,444.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">226.2<span></span>
</td>
<td class="nump">221.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of December&#160;31, 2021 and December&#160;31, 2020 include total assets of variable interest entities of $226.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2021 and December&#160;31, 2020 include total liabilities of the variable interest entities of $38.2 million and $46.8 million, respectively. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605899384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated (Deficit) Income</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 1,557.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 2,588.7<span></span>
</td>
<td class="num">$ (885.2)<span></span>
</td>
<td class="num">$ (427.9)<span></span>
</td>
<td class="nump">$ 280.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">433.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(16.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(109.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">32.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(70.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock in open market (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock in open market</a></td>
<td class="num">(45.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value adjustments to redeemable noncontrolling interests</a></td>
<td class="num">(147.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Consolidation of Yuma Rehabilitation Hospital</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">1,693.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,369.9<span></span>
</td>
<td class="num">(526.5)<span></span>
</td>
<td class="num">(492.3)<span></span>
</td>
<td class="nump">340.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">361.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(15.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(111.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(111.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(72.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock in open market (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock in open market</a></td>
<td class="num">(6.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">42.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value adjustments to redeemable noncontrolling interests</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange of Holdings shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments', window );">Exchange of Holdings shares</a></td>
<td class="nump">46.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(6.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">1,970.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,326.6<span></span>
</td>
<td class="num">(242.3)<span></span>
</td>
<td class="num">(497.4)<span></span>
</td>
<td class="nump">382.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">508.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(111.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83.8)<span></span>
</td>
<td class="num">(28.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (shares)</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">$ (87.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(10.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 2,357.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 2,289.6<span></span>
</td>
<td class="nump">$ 141.8<span></span>
</td>
<td class="num">$ (521.2)<span></span>
</td>
<td class="nump">$ 445.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total contributions made by each class of partners (i.e., general, limited and preferred partners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612771416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605546232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 517.2<span></span>
</td>
<td class="nump">$ 368.8<span></span>
</td>
<td class="nump">$ 445.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Provision for government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">256.6<span></span>
</td>
<td class="nump">243.0<span></span>
</td>
<td class="nump">218.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt-related items</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from nonconsolidated affiliates</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">32.8<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="nump">114.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">52.4<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of Yuma Rehabilitation Hospital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="num">(8.2)<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions &#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(64.3)<span></span>
</td>
<td class="num">(38.1)<span></span>
</td>
<td class="num">(22.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(42.0)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(35.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued payroll</a></td>
<td class="num">(38.1)<span></span>
</td>
<td class="nump">92.0<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="num">(74.9)<span></span>
</td>
<td class="num">(128.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities of discontinued operations</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">198.2<span></span>
</td>
<td class="nump">335.9<span></span>
</td>
<td class="nump">188.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">715.8<span></span>
</td>
<td class="nump">704.7<span></span>
</td>
<td class="nump">635.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash acquired</a></td>
<td class="num">(118.6)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(231.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(528.9)<span></span>
</td>
<td class="num">(396.0)<span></span>
</td>
<td class="num">(372.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to capitalized software costs</a></td>
<td class="num">(15.8)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(6.5)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(18.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of restricted investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of restricted investments</a></td>
<td class="num">(9.0)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="num">(32.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(666.3)<span></span>
</td>
<td class="num">(407.5)<span></span>
</td>
<td class="num">(657.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from bond issuance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">992.5<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Principal payments on debt, including pre-payments</a></td>
<td class="num">(214.5)<span></span>
</td>
<td class="num">(718.3)<span></span>
</td>
<td class="num">(519.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings on revolving credit facility</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="nump">330.0<span></span>
</td>
<td class="nump">635.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payments on revolving credit facility</a></td>
<td class="num">(100.0)<span></span>
</td>
<td class="num">(375.0)<span></span>
</td>
<td class="num">(620.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments under finance lease obligations</a></td>
<td class="num">(51.8)<span></span>
</td>
<td class="num">(22.5)<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt amendment and issuance costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(20.3)<span></span>
</td>
<td class="num">(21.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock, including fees and expenses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(45.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid on common stock</a></td>
<td class="num">(112.4)<span></span>
</td>
<td class="num">(111.9)<span></span>
</td>
<td class="num">(108.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Purchase of equity interests in consolidated affiliates</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
<td class="num">(162.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions paid to noncontrolling interests of consolidated affiliates</a></td>
<td class="num">(102.9)<span></span>
</td>
<td class="num">(72.2)<span></span>
</td>
<td class="num">(79.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on behalf of employees for shares withheld</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Contributions from noncontrolling interests of consolidated affiliates</a></td>
<td class="nump">57.2<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(240.1)<span></span>
</td>
<td class="num">(145.9)<span></span>
</td>
<td class="nump">48.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(190.6)<span></span>
</td>
<td class="nump">151.3<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents. and restricted cash at beginning of year</a></td>
<td class="nump">310.9<span></span>
</td>
<td class="nump">159.6<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
<td class="nump">159.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of Cash, Cash Equivalents, and Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">224.0<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">69.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash at beginning of period</a></td>
<td class="nump">65.4<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other long-term assets at beginning of period</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents. and restricted cash at beginning of year</a></td>
<td class="nump">310.9<span></span>
</td>
<td class="nump">159.6<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">224.0<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash at end of period</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">65.4<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other long-term assets at end of period</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
<td class="nump">159.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="num">(168.4)<span></span>
</td>
<td class="num">(168.4)<span></span>
</td>
<td class="num">(155.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refunds</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax payments</a></td>
<td class="num">$ (131.4)<span></span>
</td>
<td class="num">$ (34.3)<span></span>
</td>
<td class="num">(104.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate', window );">Adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Financing Activities, Adoption Of Accounting Standard Update</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814607947416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies:<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization and Description of Business&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a national leader in integrated healthcare services, offering both facility-based and home-based post-acute services in 42 states and Puerto Rico through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2)&#160;home health and hospice. See Note 19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Consolidation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Encompass Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the measurement alternative to account for our investments in entities we do not control and for which we do not have the ability to exercise significant influence over operating and financial policies. In accordance with the measurement alternative, these investments are recorded at the lower of cost or fair value, as appropriate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We eliminate all significant intercompany accounts and transactions from our financial results.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any entity considered a variable interest entity (&#8220;VIE&#8221;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates and Assumptions&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#8217; compensation, and comprehensive general insurance liability risks; </span></div>and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a healthcare provider, we are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensure, certification, and accreditation;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coding and billing for services;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements of the 60% compliance threshold under The Medicare, Medicaid and State Children&#8217;s Health Insurance Program (SCHIP) Extension Act of 2007;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality of medical care;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use and maintenance of medical supplies and equipment;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance and security of patient information and medical records;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition and dispensing of pharmaceuticals and controlled substances; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disposal of medical and hazardous waste.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, contractual arrangements, and patient admittance practices, as well as the way in which we deliver home health and hospice services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable laws and regulations, we could be required to return portions of reimbursements deemed after the fact to have not been appropriate. We could also be subjected to liabilities, including (1)&#160;criminal penalties, (2)&#160;civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals or agencies, and (3)&#160;exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement. Because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. Specifically, reductions in reimbursements, substantial damages, and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operation, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the United States Congress and some state legislatures have periodically proposed significant changes in regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in pricing roll-backs or freezes or reimbursement reductions. Because we receive a significant percentage of our revenues from Medicare, such changes in legislation might have a material adverse effect on our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are increasing pressures from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. We could be adversely affected in some of the markets where we operate if we are unable to negotiate and maintain favorable agreements with third-party payors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are a party to a number of lawsuits. We cannot predict the outcome of litigation filed against us. Substantial damages or other monetary remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Pandemic</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onset of the COVID-19 Pandemic (the &#8220;pandemic&#8221;)</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has caused a disruption to our nation&#8217;s healthcare system. Such disruption includes reductions in the availability of personal protective equipment (&#8220;PPE&#8221;) to prevent spread of the disease during patient treatment and increases in the cost of PPE. From time to time in specific markets, elective procedures were postponed by physicians and acute-care hospitals and limited by governmental order to preserve capacity for the expected volume of COVID-19 patients and reduce the risk of the spread of COVID-19. Initially, these postponements and limitations were widespread. Now, they are more market or state specific and driven by the extent of the pandemic in those areas. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For various quarterly periods during the pandemic, we experienced decreased patient volumes in one or more of our business lines when compared to the prior year periods. We believe reduced patient volumes resulted from a number of conditions related to the pandemic including: lower acute-care hospital censuses due to the deferral of elective surgeries and shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, policies in assisted living facilities that limit our staff from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. In the home health and hospice segment, we also experienced decreases in visits per episode and institutional referrals because of the pandemic, both of which negatively impacted pricing for home health.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the public health emergency associated with the pandemic, Congress and Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care. On March 27, 2020, former President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;), which temporarily suspended sequestration for the period of May 1 through December 31, 2020. The CARES Act also authorized the cash distribution of relief funds from the United States Department of Health and Human Services (&#8220;HHS&#8221;) to healthcare providers. We did not accept any CARES Act relief funds. The Consolidated Appropriations Act, 2021 (the &#8220;2021 Budget Act&#8221;), signed into law on December 27, 2020 provided for additional provider relief funds. We intend to refuse any additional provider relief funds distributed in the future whether authorized under the 2021 Budget Act or other legislation. The sequestration suspension has been extended a number of times. Sequestration is currently scheduled to resume as of April 1, 2022 but will only be a 1% payment reduction through June&#160;30, 2022. Thereafter, the full 2% Medicare payment reduction will resume. Federal legislation, including the CARES Act and the 2021 Budget Act, and CMS regulatory actions include a number of other provisions, which are discussed below, affecting our reimbursement and operations in both segments.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the CARES Act, 2021 Budget Act, and a series of waivers and guidance issued by CMS suspend various Medicare patient coverage criteria and documentation and care requirements in an effort to provide regulatory relief until the public health emergency for the pandemic has ended. For inpatient rehabilitation, the regulatory relief includes the temporary suspension of the requirement that patients must be able to tolerate a minimum of three hours of therapy per day for five days per week and waiver of certain of the requirements, including the exclusion of COVID-19 admissions from the compliance calculation under the 60% Rule. In addition, the requirement of physician face-to-face visits at least three days a week may be fulfilled using telehealth. For home health, the relief includes the allowance of nurse practitioners and physician assistants under certain conditions to certify, establish and periodically review the plan of care, as well as supervise the provision of items and services for beneficiaries under the Medicare home health benefit and expands the use of telehealth. Additionally, CMS expanded the definition of &#8220;homebound&#8221; to include patients needing skilled services who are homebound due solely to their COVID-19 diagnosis or patients susceptible to contract COVID-19. For hospice, the relief includes the temporary waiver of the </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides, as well as the expanded use of telehealth for routine services and patient recertification.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in April 2020, we amended our credit agreement primarily to provide covenant relief due to business disruptions from the pandemic. The amendment included, among other things, the carve-out of the pandemic from the definition of material adverse effect for 364 days and modifications to the interest coverage and leverage ratios under the agreement. </span></div>The foregoing and other disruptions to our business as a result of the pandemic have had and are likely to continue to have an adverse effect on our business and could have a material adverse effect on our business, results of operations, financial condition and cash flows.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:20.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,605.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;) or the United States Department of Justice (the &#8220;DOJ&#8221;). Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Administrative Contractors (&#8220;MACs&#8221;), under programs known as &#8220;widespread probes,&#8221; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#8220;appeal,&#8221; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OMHA practices continue, an increased number of unfavorable administrative law judge (&#8220;ALJ&#8221;) decisions could have a negative effect on our long-term ALJ success rate. The current OMHA practice has resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, CMS announced the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with CMS approved and announced Recovery Audit Contractors (&#8220;RACs&#8221;) audits related to inpatient rehabilitation facilities (&#8220;IRFs&#8221;), we received requests from 2013 to 2021 to review certain patient files for discharges occurring from 2010 to 2021.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established Unified Program Integrity Contractors (&#8220;UPICs&#8221;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Medicare claims that are subject to these post-payment audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2021. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2021, 2020, and 2019, our adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for claims that are part of this post-payment claims review process was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inpatient rehabilitation segment revenues are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice Revenues</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. The performance obligation is the rendering of services to the patient during the term of the episode of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal regulation. The base episode payment can be adjusted based on each patient&#8217;s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bill a portion of reimbursement from each Medicare episode near the start of each episode, and the resulting cash payment is typically received before all services are rendered. Effective January 1, 2021, this early payment process has been eliminated. As we provide home health services to our patients on a scheduled basis over the episode of care in a manner that approximates a pro rata pattern, revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of December&#160;31, 2021 and December&#160;31, 2020, the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not material and was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain Medicare regulations affecting outlier revenue if our patient&#8217;s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Adjustments to the transaction price for the outlier cap </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> not material</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, revenue is recorded on an accrual basis based upon the date of service at amounts equal to our estimated per-visit transaction price. Price concessions, including contractual allowances for the differences between our standard rates and the applicable contracted rates, as well as estimated uncollectible amounts from patients, are recorded as decreases to the transaction price.</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare revenues for hospice are recognized and recorded on an accrual basis using the input method based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The performance obligation is the rendering of services to the patient during each day that they are on hospice care. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the MAC. Adjustments to the transaction price for these caps </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> not material as of December&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our estimated per day transaction price. Price concessions, including contractual adjustments for the difference between our standard rates and the amounts estimated to be realizable from patients and third parties for services provided, are recorded as decreases to the transaction price and thus reduce our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include highly liquid investments with maturities of three months or less when purchased. Carrying values of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approximate fair value due to the short-term nature of these instruments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a separate component of shareholders&#8217; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#8217; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other discount plans, including Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:84.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 10</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8212;</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. We do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets&#8212; </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors in our inpatient rehabilitation and home health and hospice reporting units to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our reporting units using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of each reporting unit&#8217;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting units to our market capitalization. When we dispose of a hospital or home health or hospice agency, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2021, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></div></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and directly related payroll costs. Amortization begins when the internal-use software is ready for its intended use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#8217;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets and Other Intangible Assets&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in and Advances to Nonconsolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities we do not control but in which we have the ability to exercise significant influence over the operating and financial policies of the investee are accounted for under the equity method. Equity method investments are recorded at original cost and adjusted periodically to recognize our proportionate share of the investees&#8217; net income or losses after the date of investment, additional contributions made, dividends or distributions received, and impairment losses resulting from adjustments to net realizable value. We record equity method losses in excess of the carrying amount of an investment when we guarantee obligations or we are otherwise committed to provide further financial support to the affiliate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the measurement alternative to account for equity investments for which the equity securities do not have readily determinable fair values and for which we do not have the ability to exercise significant influence. Under the measurement alternative, private equity investments are carried at cost and are adjusted only for other-than-temporary declines in fair value, additional investments, or distributions deemed to be a return of capital.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management periodically assesses the recoverability of our equity method and measurement alternative investments and equity method goodwill for impairment. We consider all available information, including the recoverability of the investment, the earnings and near-term prospects of the affiliate, factors related to the industry, conditions of the affiliate, and our ability, if any, to influence the management of the affiliate. We assess fair value based on valuation methodologies, as appropriate, including discounted cash flows, estimates of sales proceeds, and external appraisals, as appropriate. If an investment or equity method goodwill is considered to be impaired and the decline in value is other than temporary, we record an appropriate write-down.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Observable inputs such as quoted prices in active markets;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also the &#8220;Redeemable Noncontrolling Interests&#8221; section of this note.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interests in Consolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#8217; balance.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future. Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to certain members of the home health and hospice management team&#8217;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $400 million or more. The fair value of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#8217; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees, excluding stock appreciation rights (&#8220;SARs&#8221;), are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period. Share-based payments to employees in the form of SARs are recognized in the financial statements based on their current fair value and expensed ratably over the applicable service period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Reserves&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the accompanying consolidated statements of comprehensive income, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $4.6 million, and $6.1 million in each of the years ended December 31, 2021, 2020, and 2019, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the asset and liability method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We include the allocable portion of each pass-through entity&#8217;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities in and Results of Discontinued Operations&#8212;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Effective January 1, 2015, in connection with a new standard issued by the FASB, we changed our criteria for determining which disposals are presented as discontinued operations. Historically, any component that had been disposed of or was classified as held for sale qualified for discontinued operations reporting unless there was significant continuing involvement with the disposed component or continuing cash flows. In contrast, we now report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. As a result, the sale or disposal of a single Encompass Health facility or location no longer qualifies as a discontinued operation. This accounting change was made prospectively. No new components were recognized as discontinued operations since this guidance became effective.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Loss from discontinued operations, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We account for the retirement of treasury stock as a reduction of retained earnings.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. The new guidance was effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. The adoption of this guidance did not have a material impact to our consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814689161416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations:<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2021, we acquired 51% of the operations of a 14-bed inpatient rehabilitation unit in San Angelo, Texas when Shannon Medical contributed those operations to our existing joint venture entity.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2021, we acquired 75% of the operations of a 16-bed inpatient rehabilitation unit in McKees Rocks, Pennsylvania through our existing joint venture with Heritage Valley Health System, Inc. The acquisition was funded using cash on hand.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2021, we acquired 65% of the operations of a 22-bed inpatient rehabilitation unit in Odessa, Texas when ECHD Ventures contributed those operations to our existing joint venture entity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 3 to 5 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:89.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Frontier Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, we completed the acquisition of the home health and hospice assets of Frontier Home Health and Hospice (&#8220;Frontier&#8221;) in Alaska, Colorado, Montana, Washington, and Wyoming. The Frontier acquisition included the purchase of a 50% equity interest in the Heart of the Rockies Home Health joint venture and a 90% equity interest in the Hospice of Southwest Montana joint venture (inclusive of an additional 40% equity interest purchased for approximately $4&#160;million). We consolidate both of these joint ventures. On the acquisition date, nine home health and eleven hospice locations became part of our national network of home health and hospice locations. This acquisition was made to expand our existing presence in Colorado and Wyoming and extend our services to Alaska, Montana and Washington. We funded this transaction using cash on hand and borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of Frontier from its date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: replacement cost and continued use methods for property and equipment; an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets; an income approach utilizing the relief-from-royalty method for the trade name intangible asset; an income approach utilizing the excess earnings method for the certificates of need; and present value of remaining lease payments for leases. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. All goodwill recorded reflects our expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of 5 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 3 months)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need (useful lives of 10 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for this acquisition is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired, net of $0.8 million of cash acquired in 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Home Health and Hospice Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, using cash on hand, we acquired an additional 29% equity interest from Baptist Outpatient Services, Inc. in our existing Encompass Health Home Health of South Florida, LLC joint venture. This transaction increased our ownership interest from 51% to 80% and resulted in change in accounting for this joint venture from the equity method of accounting to a consolidated entity. As a result of our consolidation of this entity and the remeasurement of our previously held equity interest to fair value, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $8.0 million, and we recorded a $3.2 million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021. This transaction was made to increase our ownership in a profitable entity and continue to grow our business.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This acquisition was funded using cash on hand and was individually immaterial to our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired locations&#8217; mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. The amount of goodwill recorded as a result of these transactions that is deductible for federal income tax purposes is $3.9&#160;million.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of 2 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding the net cash paid for this acquisition is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired, net of $0.8 million of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of redeemable noncontrolling interest owned by joint venture partner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity interest prior to acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2022, we acquired a 50% equity interest from Frontier in a joint venture with Saint Alphonsus System (&#8220;Saint Alphonsus&#8221;) which operates home health and hospice locations in Boise, Idaho. The total purchase price was $15.9 million and was funded on December 31, 2021. This payment is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Acquisition of business, net of cash acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statement of cash flow for the year end December 31, 2021. This transaction was not material to our financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Pro Forma Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,705.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Acquisitions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2020, we acquired 68% of the operations of a 13-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing 40-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a 20-bed expansion to the Littleton hospital.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, we acquired 51% of the operations of a 45-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a 60-bed de novo inpatient rehabilitation hospital.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions are deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 2 to 3 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we acquired the assets of Generation Solutions of Lynchburg, LLC in Lynchburg, Virginia. This acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in Central Virginia. The acquisition was funded using cash on hand and was immaterial to our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. The fair values of identifiable intangible assets were based on valuations using an income approach. The income approach is based on management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired location&#8217;s mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the home health acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Pro Forma Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,650.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Acquisitions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2019, we acquired approximately 51% of the operations of a 30-bed inpatient rehabilitation unit in Boise, Idaho when Saint Alphonsus Regional Medical Center contributed those operations to a joint venture with us. We funded our ownership interest in that consolidated joint venture through contributions of cash which the joint venture entity used to fund the construction of a 40-bed de&#160;novo inpatient rehabilitation hospital. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2019, we acquired 75% of the operations of Heritage Valley Sewickley Hospital&#8217;s 11-bed inpatient rehabilitation unit in Sewickley, Pennsylvania, when Heritage Valley Health System, Inc. contributed those operations to our existing joint venture entity in connection with the opening of a new hospital.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the acquired hospitals from its respective date of acquisition. Information regarding the net cash paid for all inpatient rehabilitation acquisitions during 2019 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.450%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alacare Acquisition</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we completed the acquisition of privately owned Alacare Home Health &amp; Hospice (&#8220;Alacare&#8221;) for a cash purchase price of $217.8&#160;million. The Alacare portfolio consisted of 23 home health locations and 23 hospice locations in Alabama. The acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients across Alabama. We funded the transaction with cash on hand and borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of Alacare from its date of acquisition. Information regarding the net cash paid for Alacare is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:88.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Home Health and Hospice Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we completed the following home health acquisitions,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> none</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in the applicable geographic areas. Each acquisition was funded using cash on hand.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2019, we acquired the assets of Tidewater Home Health, PA in Columbia, South Carolina.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2019, we acquired the assets and assumed the liabilities of two home health locations from Care Resource Group in East Providence, Rhode Island and Westport, Massachusetts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired locations from their respective dates of acquisition. Information regarding the net cash paid for the home health acquisitions during 2019 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Pro Forma Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (Loss) Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alacare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Home Health and Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>&#160;&#160;&#160;&#160;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608832712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text">Variable Interest Entities:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and December&#160;31, 2020, we consolidated ten and nine, respectively, limited partnership-like entities that are VIEs and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 90.0% as of December&#160;31, 2021. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608598536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash and Marketable Securities</a></td>
<td class="text">Cash and Marketable Securities:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2021 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2020 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliate cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliate cash represents cash accounts maintained by joint ventures in which we participate where one or more of our external partners requested, and we agreed, that the joint venture&#8217;s cash not be commingled with other corporate cash accounts and be used only to fund the operations of those joint ventures. Self-insured captive funds represent cash held at our wholly owned insurance captive, HCS, Ltd., as discussed in Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These funds are committed to pay third-party administrators for claims incurred and are restricted by insurance regulations and requirements. These funds cannot be used for purposes outside HCS without the permission of the Cayman Islands Monetary Authority.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification of restricted cash held by HCS as current or noncurrent depends on the classification of the corresponding claims liability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS. HCS insures a substantial portion of Encompass Health&#8217;s professional liability, workers&#8217; compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of December&#160;31, 2021 and 2020, $82.2 million and $72.6 million, respectively, of restricted marketable securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheets. During the years ended December&#160;31, 2021, 2020, and 2019, $0.6&#160;million, $0.4 million, and $1.2&#160;million, respectively, of unrealized net gains were recognized in our consolidated statements of comprehensive income on marketable securities still held at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing information related to our available-for-sale marketable securities is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of available-for-sale marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketable securities is comprised of investments in mutual funds that hold investments in a variety of industries and geographies. As discussed in Note&#160;1,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Marketable Securities,&#8221; when our portfolio included marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, we examined the severity and duration of the impairments in relation to the cost of the individual investments. We also considered the industry and geography in which each investment is held and the near-term prospects for a recovery in each.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612895704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable</a></td>
<td class="text">Accounts Receivable:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent patient accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the resolution of claims that are part of Medicare audit programs can take several years, we review the patient receivables that are part of this adjudication process to determine their appropriate classification as either current or noncurrent. Amounts considered noncurrent are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheet. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608664072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,378.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,539.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,374.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,601.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, approximately 73% of our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> held by Encompass Health Corporation and its guarantor subsidiaries was pledged to the lenders under our credit agreement. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Liquidity and Capital Resources.&#8221;</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of depreciation expense and interest capitalized is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest capitalized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814696340200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1- to 25-year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated balance sheet information related to leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease assets are recorded net of accumulated amortization of $147.8 million and $129.6 million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1- to 25-year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated balance sheet information related to leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease assets are recorded net of accumulated amortization of $147.8 million and $129.6 million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608742152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text">Goodwill and Other Intangible Assets:<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,318.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in 2019 as a result of our consolidation of Yuma Rehabilitation Hospital and the remeasurement of our previously held equity interest at fair value and our acquisitions of Alacare and other inpatient and home health and hospice operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in 2020 as a result of our acquisitions of inpatient and home health operations as well as our consolidation of the Jupiter, Florida home health agency and the remeasurement of our previously held equity interest at fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in 2021 as a result of our acquisitions of Frontier and other inpatient and home health and hospice operations as well as our consolidation of the Home Health of South Florida joint venture and the remeasurement of our previously held equity interest at fair value. See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note&#160;9,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments in and Advances to Nonconsolidated Affiliates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed impairment reviews as of October&#160;1, 2021, 2020, and 2019 and concluded no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment existed. As of December&#160;31, 2021, we had no accumulated impairment losses related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our other intangible assets (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certificates of need:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncompete agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade name - Encompass:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade names - all other:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal-use software:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market access assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for other intangible assets is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608646952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in and Advances to Nonconsolidated Affiliates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock', window );">Investments in and Advances to Nonconsolidated Affiliates</a></td>
<td class="text">Investments in and Advances to Nonconsolidated Affiliates:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in and advances to nonconsolidated affiliates as of December&#160;31, 2021 represents our investment in three partially owned subsidiaries, of which two are general or limited partnerships, limited liability companies, or joint ventures in which Encompass Health or one of its subsidiaries is a general or limited partner, managing member, member, or venturer, as applicable. We do not control these affiliates but have the ability to exercise significant influence over the operating and financial policies of certain of these affiliates. Our ownership percentages in these affiliates range from approximately 5% to 50%. We account for these investments using the equity method of accounting and measurement alternative. Our investments, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets, consist of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contributions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative share of income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative share of distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contributions, net of distributions and impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in and advances to nonconsolidated affiliates</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the combined assets, liabilities, and equity and the combined results of operations of our equity method affiliates (on a 100% basis, in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and equity&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partners&#8217; capital and shareholders&#8217; equity&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed statements of comprehensive income (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of an amendment to the joint venture agreement related to our Jupiter, Florida home health agency, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective January 1, 2020.  The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of the Jupiter, Florida agency did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this home health agency and the remeasurement of our previously held equity interest at fair value, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased by $3.3&#160;million and we recorded a $2.2&#160;million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the year ended December 31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of an amendment to the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July&#160;1, 2019. The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of Yuma Rehabilitation Hospital did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased by $24.9 million and we recorded a $19.2 million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the year ended December 31, 2019.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608464440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,243.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Face Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the redemptions discussed below, we recorded a $1.0&#160;million, $2.3 million, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2021, 2020, and 2019, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Agreement&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement, as amended in November 2019, provided for a $270 million term loan commitment and a $1 billion revolving credit facility, with a $260 million letter of credit subfacility and a swingline loan subfacility, all of which mature in November 2024. Outstanding term loan borrowings are payable in equal consecutive quarterly installments, commencing on December&#160;31, 2019, of 1.25% of the aggregate principal amount of the term loans outstanding as of December&#160;31, 2019, with the remainder due at maturity. We have the right at any time to prepay, in whole or in part, any borrowing under the term loan facilities.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts drawn on the term loan facilities and the revolving credit facility bear interest at a rate per annum of, at our option, (1) LIBOR or (2)&#160;the higher of (a)&#160;Barclays Bank PLC&#8217;s prime rate and (b)&#160;the federal funds rate plus 0.5%, in each case, plus, in each case, an applicable margin that varies depending upon our leverage ratio. We are also subject to a commitment fee of 0.375% per annum on the daily amount of the unutilized commitments under the revolving credit facility. The current interest rate on borrowings under the credit agreement is LIBOR plus 1.50%.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement contains affirmative and negative covenants and default and acceleration provisions, including a minimum interest coverage ratio and a maximum leverage ratio. Under one such negative covenant, we are restricted from paying common stock dividends, prepaying certain senior notes, making certain investments, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the credit agreement and (2) our senior secured leverage ratio, as defined in the credit agreement, does not exceed 2x. In the event the senior secured leverage ratio exceeds 2x, these payments are subject to a limit of $200 million plus an amount equal to a portion of available excess cash flows each fiscal year. Our obligations under the credit agreement are secured by the current and future personal property of the Company and its subsidiary guarantors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we amended our existing credit agreement and the amendments included the following material provisions:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Material Adverse Effect&#8221; to carve out the direct and indirect impacts of pandemic and the related legislative, regulatory and executive actions on us from that definition for a period of 364 days; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of 4.50x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of 2:00x) and the existence of no events of default in addition to the new leverage ratio condition.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $200 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were drawn under the revolving credit facility with an interest rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount was drawn under the revolving credit facility. As of December&#160;31, 2021 and 2020, $38.2 million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $36.7 million, respectively, were being </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilized under the letter of credit subfacility, which were being used in the ordinary course of business to secure workers&#8217; compensation and other insurance coverages and for general corporate purposes. Currently, there are no undrawn term loan commitments under the credit agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bonds Payable&#8212;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Senior Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2023 Notes, 2024 Notes, 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively, the &#8220;Senior Notes&#8221;) were issued pursuant to an indenture (the &#8220;Base Indenture&#8221;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#8217; respective supplemental indenture (together with the Base Indenture, the &#8220;Indenture&#8221;). Pursuant to the terms of the Indenture, the Senior Notes are jointly and severally guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our Credit Agreement and other capital markets debt. The Senior Notes are senior, unsecured obligations of Encompass Health and rank equally with our other senior indebtedness, senior to any of our subordinated indebtedness, and effectively junior to our secured indebtedness to the extent of the value of the collateral securing such indebtedness.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the Indenture), each holder of the Senior Notes may require us to repurchase all or a portion of the notes in cash at a price equal to 101% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes contain covenants and default and acceleration provisions, that, among other things, limit our and certain of our subsidiaries&#8217; ability to (1)&#160;incur additional debt, (2)&#160;make certain restricted payments, (3)&#160;consummate specified asset sales, (4)&#160;incur liens, and (5)&#160;merge or consolidate with another person.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively the &#8220;Notes&#8221;) for the adoption of certain amendments to the Indenture, which will provide us with greater flexibility in effecting the spin off discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Organization and Description of Business.&#8221; Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture by $200&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $40.5&#160;million, excluding fees. We paid $20&#160;million of this amount in January 2022. The remaining payment is contingent upon the execution of a Distribution and will be paid at such time.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we issued $300 million of 5.125%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Senior Notes due 2023 (&#8220;the 2023 Notes&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at par, which resulted in approximately $295 million in net proceeds from the public offering. The 2023 Notes mature on March 15, 2023 and bear interest at a per annum rate of 5.125%. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of financing costs, the effective interest rate on the 2023 Notes is 5.4%.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest on the 2023 Notes is payable semiannually in arrears on March 15 and September 15. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In both April and June 2021, we redeemed $100&#160;million in outstanding principal amount of the 2023 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, these optional redemptions were made at a price of par.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2022, we issued notice for redemption of the remaining $100&#160;million in outstanding principal amount of the 2023 Notes. Pursuant to the terms of the 2023 Notes, this full redemption will settle on March 15, 2022 and will be made at a price of par. We plan to use cash on hand and capacity under our revolving credit facility to fund the redemption. We expect to record an approximate $0.3&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> in the first quarter of 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2012, we completed a public offering of $275 million aggregate principal amount of the 5.75% Senior Notes due 2024 (&#8220;the 2024 Notes&#8221;) at par. In September 2014, we issued an additional $175 million of the 2024 Notes at a price of 103.625% of the principal amount, in January 2015, we issued an additional $400 million of the 2024 Notes at a price of 102% of the principal amount, and in August 2015, we issued an additional $350 million of our 2024 Notes at a price of 100.5% of the principal amount. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we redeemed $100 million of outstanding principal amount of our 2024 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2024 Notes, this optional redemption was made at a price of 101.917%, which resulted in a total cash outlay of approximately $102 million. In November 2019, we redeemed $400 million of the outstanding principal amount of our 2024 Notes. Pursuant to the terms of the 2024 Notes, this optional redemption was made at a price of 100.958%, which resulted in a total cash outlay of approximately $404 million.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In November 2020, we redeemed the remaining $700&#160;million of outstanding principal amount of the 2024 Notes. Pursuant to the terms of the 2024 Notes, this full redemption was made at a price of par. We used the net proceeds from the 2031 Notes offering, discussed and defined below, together with approximately $300&#160;million of cash on hand to fund the redemption. The 2024 Notes would have matured on November&#160;1, 2024. Inclusive of premiums and financing costs, the effective interest rate on the 2024 Notes was 5.8%. Interest was payable semiannually in arrears on May 1 and November&#160;1 of each year. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we issued $350 million of 5.75% Senior Notes due 2025 (&#8220;the 2025 Notes&#8221;) at par. The 2025 Notes mature on September&#160;15, 2025 and bear interest at a per annum rate of 5.75%. Inclusive of financing costs, the effective interest rate on the 2025 Notes is 6.0%. Interest on the 2025 Notes is payable semiannually in arrears on March 15 and September&#160;15. </span></div><div style="margin-bottom:7pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2021, at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 and 2030 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we issued $500 million of 4.50% Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) at par and $500 million of 4.75% Senior Notes due 2030 (the &#8220;2030 Notes&#8221;) at par. The proceeds from this offering were used to fund the purchase of equity and vested stock appreciation rights from management investors of our home health and hospice segment, redeem a portion of our 2024 Notes as discussed above, and repay borrowings under our revolving credit facility. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued an additional $300&#160;million of our 2028 Notes at a price of 99.0% of the principal amount and an additional $300&#160;million of our 2030 Notes at a price of 98.5% of the principal amount, which resulted in approximately $583&#160;million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.</span></div><div style="margin-bottom:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes mature on February 1, 2028. Inclusive of financing costs, the effective interest rate on the 2028 Notes is 4.8%. Interest on the 2028 Notes is payable semiannually in arrears on February 1 and August 1. We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><div style="margin-bottom:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes mature on February 1, 2030. Inclusive of financing costs, the effective interest rate on the 2030 Notes is 5.2%. Interest on the 2030 Notes is payable semiannually in arrears on February 1 and August 1. We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2031 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we issued $400&#160;million aggregate principal amount of 4.625% Senior Notes due 2031 (the &#8220;2031 Notes&#8221;) at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of 4.625%. Inclusive of financing costs, the effective interest rate on the 2031 Notes is 4.8%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Notes Payable&#8212;</span></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our notes payable consist of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.078%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale/leaseback transactions involving real estate accounted for as financings</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1% to 11.2%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction of a new hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608464440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Self-Insured Risks<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Self-Insured Risks</a></td>
<td class="text">Self-Insured Risks:We insure a substantial portion of our professional liability, general liability, and workers&#8217; compensation risks through a self-insured retention program (&#8220;SIR&#8221;) underwritten by our consolidated wholly owned offshore captive insurance subsidiary, HCS, Ltd., which we fund via regularly scheduled premium payments. HCS is an insurance company licensed by the Cayman Island Monetary Authority. We use HCS to fund the first $36 million of insurance and an additional $4 million of insurance in excess of $46 million for annual aggregate losses associated with general and professional liability risks. Workers&#8217; compensation exposures are capped on a per claim basis. Risks in excess of specified limits per claim and in excess of our aggregate SIR amount are covered by unrelated commercial carriers.<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our self-insurance reserves for the years ended December&#160;31, 2021, 2020, and 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:53.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for the provision of current year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease for the provision of prior year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses related to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to current year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to prior year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, gross</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, $45.6 million and $44.0 million, respectively, of these reserves are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these risks are based primarily upon actuarially determined estimates. These reserves represent the unpaid portion of the estimated ultimate cost of all reported and unreported losses incurred through the respective consolidated balance sheet dates. The reserves are estimated using individual case-basis valuations and actuarial analyses. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The changes to the estimated ultimate loss amounts are included in current operating results.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reserves for these self-insured risks cover approximately 1,200 and 1,600 individual claims at December&#160;31, 2021 and 2020, respectively, and estimates for potential unreported claims. The time period required to resolve these claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in reserve estimates, management believes the reserves for losses and loss expenses are adequate; however, there can be no assurance the ultimate liability will not exceed management&#8217;s estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI http://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814613859176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Redeemable Noncontrolling Interests</a></td>
<td class="text">Redeemable Noncontrolling Interests:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:51.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:64.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2014, we acquired 83.3% of our home health and hospice business when we purchased EHHI Holdings, Inc. (&#8220;EHHI&#8221;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#8220;Holdings&#8221;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. In July 2019, we received additional exercise notices, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. In September&#160;2019, Encompass Health settled the acquisition of those shares upon payment of approximately $163 million in cash. As of December 31, 2019, the value of the outstanding shares of Holdings owned by management investors was approximately $208 million. In January 2020, we received additional exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#8220;Exchange Agreement&#8221;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#8220;EHC Shares&#8221;). Each of the Exchange Agreements provided </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the management investor must deliver a written exchange notice (an &#8220;Exchange Notice&#8221;) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#8217;s common stock on the New York Stock Exchange (the &#8220;NYSE&#8221;) on the date of delivery of the Exchange Notice.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors.  Based on the last sales price of Encompass Health&#8217;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns 100% of Holdings and EHHI.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note&#160;13, </span>Fair Value Measurements<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608833096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our consolidation of certain joint venture entities and the remeasurement of our previously held equity interest at fair value, we recorded gains of $3.2 million, $2.2 million, and $19.2 million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the years ended December 31, 2021, 2020, and 2019, respectively. We determined the fair value of our previously held equity interest using the income approach valuation technique. The income approach included the use of the hospital's or agency&#8217;s projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital or agency. The projected operating results use management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note&#160;9,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments in and Advances to Nonconsolidated Affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our consolidated balance sheets. The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements&#8221; and &#8220;Redeemable Noncontrolling Interests.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608467448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has awarded employee stock-based compensation in the form of stock options, SARs, and restricted stock awards (&#8220;RSAs&#8221;) under the terms of share-based incentive plans designed to align employee and executive interests to those of its stockholders. All employee stock-based compensation awarded during 2021, 2020, and 2019 was issued under the 2016 Omnibus Performance Incentive Plan, a stockholder-approved plan that reserves and provides for the grant of up to 14,000,000 shares of common stock. This plan allows for the grants of nonqualified stock options, incentive stock options, restricted stock, SARs, performance shares, performance share units, dividend equivalents, restricted stock units (&#8220;RSUs&#8221;),  and/or other stock-based awards.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our share-based incentive plans, officers and employees are given the right to purchase shares of Encompass Health common stock at a fixed grant price determined on the day the options are granted. The terms and conditions of the options, including exercise prices and the periods in which options are exercisable, are generally at the discretion of the compensation and human capital committee of our board of directors. However, no options are exercisable beyond ten years from the date of grant. Granted options vest over the awards&#8217; requisite service periods, which are generally three years.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the options granted during the years ended December&#160;31, 2021, 2020, and 2019 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including the expected stock price volatility. We estimate our expected term through an analysis of actual, historical post-vesting exercise, cancellation, and expiration behavior by our officers and employees and projected post-vesting activity of outstanding options. We calculate volatility based on the historical volatility of our common stock over the period commensurate with the expected term of the options. The risk-free interest rate is the implied daily yield currently available on U.S. Treasury issues with a remaining term closely approximating the expected term used as the input to the Black-Scholes option-pricing model. We estimated our dividend yield based on our annual dividend rate and our stock price on the dividend payment dates. Under the Black-Scholes option-pricing model, the weighted-average grant date fair value per share of employee stock options granted during the years ended December&#160;31, 2021, 2020, and 2019 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$19.21,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $15.48, and $15.45, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximatel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y $2.3 million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.5 million, and $1.4 million of compensation expense related to our stock options for the years ended December&#160;31, 2021, 2020, and 2019, respectively. As of December&#160;31, 2021, there was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.4 million o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 19 months. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020, and 2019 was $0.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $2.3 million, and $3.6 million, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Appreciation Rights&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the EHHI acquisition, we granted SARs based on Holdings common stock to certain members of EHHI management at closing on December 31, 2014. Under a separate plan, we granted 122,976 SARs that vested based on continued employment and an additional maximum number of 129,124 SARs that vested based on continued employment and the extent of the attainment of a specified 2017 performance measure. The maximum number of performance SARs was achieved. Half of the SARs of each type vested on December&#160;31, 2018 and the remainder vested on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings&#8217; common stock on the exercise date exceeded the per share fair value on the grant date. The fair value of Holdings&#8217; common stock was determined using the product of the trailing 12-month specified performance measure for Holdings and a specified median market price </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multiple based on a basket of public home health companies and publicly disclosed home health acquisitions with a value of $400 million or more. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the SARs granted in conjunction with the EHHI acquisition has been estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include a dividend payment as part of our pricing model because Holdings did not pay dividends on its common stock. Under the Black-Scholes option-pricing model, the weighted-average fair value per share of SARs granted in conjunction with the EHHI acquisition was $870.28 as of December 31, 2019. In February 2019, members of the management team exercised a portion of their vested SARs for approximately $13 million in cash. In July 2019, members of the management team exercised the remainder of the vested SARs for approximately $55 million in cash. As of December 31, 2019, the fair value of the remaining 115,545 SARs was approximately $101&#160;million, all of which was included in O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. In January 2020, members of the management team exercised the remaining SARs, and in February 2020, we settled those awards upon payment of approximately $101 million in cash.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $0.1 million and $81.9 million of compensation expense related to our SARs for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSAs granted in 2021, 2020, and 2019 included service-based awards and performance-based awards (that also included a service requirement). These awards generally vest over a three-year requisite service period. For RSAs with a service and/or performance requirement, the fair value of the RSA is determined by the closing price of our common stock on the grant date.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our issued restricted stock awards is as follows (share information in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of restricted stock granted during the years ended&#160;December&#160;31, 2020 and 2019 was $61.81 and $49.84 per share, respectively. We recognized approximate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly $28.4 million, $25.8 million, and $29.5 million of compensation expense related to our restricted stock awards for the years ended December&#160;31, 2021, 2020, and 2019, respectively. As of December&#160;31, 2021, there was $37.1 million of unrecognized compensation expense related to unvested restricted stock. This cost is expected to be recognized over a weighted-average period of 21 months. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he remaining unrecognized compensation expense for the performance-based awards may vary each reporting period based on changes in the expected achievement of performance measures. The total fair value of shares vested during the years ended December 31, 2021, 2020, and 2019 wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $46.0 million, $44.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $45.2 million, respectively. We accrue dividends on outstanding RSAs, which are paid upon vesting.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonemployee Stock-Based Compensation Plans&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, we provided incentives to our nonemployee members of our board of directors through the issuance of RSUs out of our share-based incentive plans. RSUs are fully vested when awarded and receive dividend equivalents in the form of additional RSUs upon the payment of a cash dividend on our common stock. During the years ended December&#160;31, 2021, 2020, and 2019, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued 24,043, 32,196, and 23,270 RSUs, respectively, with a fair value of $84.83, $65.39, and $64.48, respectively, per unit. We recognized approximately $2.0 million, $2.1 million, and $1.5 million, respectively, of compensation expense upon their issuance in 2021, 2020, and 2019. There was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrecognized compensation related to unvested shares as of December&#160;31, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we issued an a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dditional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,577</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 8,987, and 8,876, respectively, of RSUs as dividend equivalents. As of December&#160;31, 2021, 610,461 RSUs were ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814609932152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all Encompass Health employees are eligible to enroll in Encompass Health-sponsored healthcare plans, including coverage for medical and dental benefits. Our primary healthcare plans are national plans administered by third-party administrators. We are self-insured for these plans. During 2021, 2020, and 2019, costs associated with these plans, net of amounts paid by employees and stop-loss recoveries, approximated $207.6 million, $189.2 million, and $178.4 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health offers two qualified 401(k) savings plans, the Encompass Health Retirement Investment Plan (the &#8220;RIP&#8221;) and the Encompass Home Health Savings Plan (the &#8220;HHSP&#8221;). The RIP allows eligible employees to contribute up to 100% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. Inpatient rehabilitation employees who are at least 21 years of age are eligible to participate in the RIP and all contributions to the plan are in the form of cash. Encompass Health&#8217;s employer matching contribution under the RIP is 50% of the first 6% of each participant&#8217;s elective deferrals, which vest 100% after three years of service. Participants are always fully vested in their own contributions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HHSP allows eligible employees to contribute up to 60% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. All home health and hospice full-time and part-time employees are eligible to participate in the HHSP and all contributions to the plan are in the form of cash. Encompass Health&#8217;s employer matching contribution under the HHSP is 25% of the first 3% of each participant&#8217;s elective deferrals, which vest gradually over a six-year service period. Participants are always fully vested in their own contributions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employer contributions to the RIP and HHSP approximated $28.8 million, $25.4 million, and $23.4 million in 2021, 2020, and 2019, respectively. In 2021, 2020, and 2019, approximately $1.3 million, $1.5 million, and $1.4 million, respectively, from forfeited accounts were used to fund the matching contributions in accordance with the terms of the RIP and HHSP.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Management Bonus Program&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a Senior Management Bonus Program to reward senior management for performance based on a combination of corporate or regional goals for all periods presented and individual goals for 2019 and 2018 only. The corporate and regional goals are approved on an annual basis by our board of directors as part of our routine budgeting and financial planning process. The individual goals, which were weighted according to importance, were determined between each participant and his or her immediate supervisor. The program applies to persons who join the Company in, or are promoted to, senior management positions. In 2022, we expect to pay approximately $27.8 million under the program for the year ended December&#160;31, 2021. In March 2021 and February 2020, we paid $17.4 million and $18.4 million, respectively, under the program for the years ended December&#160;31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608742152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to continuing operations are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense related to continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based windfall tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2021 was greater than the federal statutory rate primarily due to: (1) state and other income tax expense offset by (2) the impact of noncontrolling interests, (3) share-based windfall tax benefits and (4) the decrease in valuation allowance. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2020 was greater than the federal statutory rate primarily due to: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) state and other income tax expense and (2) the increase in valuation allowance offset by (3) the impact of noncontrolling interests and (4) share-based windfall tax benefits. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2019 was less than the federal statutory rate primarily due to: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the impact of noncontrolling interests, (2) g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overnment, class action, and related settlements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and (3) share-based windfall tax benefits offset by (4) state and other income tax expense. See Note&#160;1, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Income Taxes,&#8221; for a discussion of the allocation of income or loss related to pass-through entities, which is referred to as the impact of noncontrolling interests in this discussion.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the CARES Act provisions previously discussed in Note&#160;1, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Risks and Uncertainties,&#8221; the CARES Act also includes provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, technical corrections to tax depreciation methods for qualified improvement property and deferral of employer payroll taxes. The CARES Act did not materially impact our effective tax rate for the years ended December 31, 2020 and 2021, although it has impacted the timing of cash payments for taxes. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes recognize the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes and the impact of available NOLs. The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have state NOLs of $50.4 million that expire in various amounts at varying times through 2031. For the years ended December&#160;31, 2021 and 2020, the net (decrease) increase in our valuation allowance was $(3.1) million and $7.8 million, respectively. The decrease in our valuation allowance in 2021 related primarily to changes in forecasted income. The increase in our valuation allowance in 2020 related primarily to our expected ability to use related net operating losses prior to their expiration.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have a remaining valuation allowance of $43.1 million. This valuation allowance remains recorded due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management&#8217;s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during 2021, 2020, and 2019 was not material. Accrued interest income related to income taxes as of December 31, 2021 and 2020 was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we signed an agreement with the IRS to participate in their Compliance Assurance Process (&#8220;CAP&#8221;) for the 2017 tax year and have renewed this agreement each year since. CAP is a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax returns. The IRS is currently examining the 2020, 2021, and 2022 tax years. In September 2021, the IRS issued a no-change letter effectively closing our 2019 tax year audit. The statute of limitations has expired or we have settled federal income tax examinations with the IRS for all tax years through 2019. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by two states for tax years ranging from 2017 - 2019.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the tax years that remain open under the applicable statutes of limitations, management considered potential unrecognized tax benefits and determined there are no material unrecognized tax benefits that would impact prior years&#8217; income taxes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608601048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Common Share</a></td>
<td class="text">Earnings per Common Share:<div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase approximately 0.2 million, 0.2 million, and 0.1 million shares of common stock were outstanding as of December&#160;31, 2021, 2020, and 2019, respectively, but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, our board of directors approved an increase in our common stock repurchase authorization from $200 million to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. There were no repurchases of our common stock during 2021. During 2020 and 2019, we repurchased 0.1&#160;million and 0.8 million shares of our common stock in the open market for $6.1 million and $45.9 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.27 per share. The cash dividend of $0.27 per common share was declared and paid in each quarter through July 2019. In July 2019, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.28 per share. The cash dividend of $0.28 per common share was declared and paid in each quarter through January 2022. Future dividend payments are subject to declaration by our board of directors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608581560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Other Commitments</a></td>
<td class="text">Contingencies and Other Commitments:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nichols Litigation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We were named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Nichols v. HealthSouth Corp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In July 2019, we entered into settlement agreements with all but one plaintiff and paid those settling plaintiffs an aggregate amount of cash less than $0.1&#160;million. The remaining plaintiff alleged that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiff sought compensatory and punitive damages. On June 9, 2021, the trial court granted our renewed motion for summary judgment on all of the plaintiff&#8217;s claims. The plaintiff did not appeal, so the matter has concluded. The conclusion of this matter did not have any impact on our consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Commitments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to service and other contracts in connection with conducting our business. Minimum amounts due under these agreements are $55.4 million in 2022, $35.0 million in 2023, $25.2 million in 2024, $11.2 million in 2025, $9.0 million in 2026, and $13.0 million thereafter. These contracts primarily relate to software licensing and support.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608521576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting: <div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our national network of inpatient rehabilitation hospitals stretches across 35 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of December&#160;31, 2021, we operate 145 inpatient rehabilitation hospitals. We are the sole owner of 91 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 54 jointly owned hospitals. In addition, we manage three inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Home Health and Hospice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- As of December&#160;31, 2021, we provide home health services in 251 locations and hospice services in 96 locations across 34 states with a concentration in the southern half of the United States. We are the sole owner of 336 of these locations. We retain 50.0% to 90.0% ownership in the remaining 11 jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of our reportable segments are the same as those described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All revenues for our services are generated through external customers. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#8220;Segment Adjusted EBITDA&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,965.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Segment reconciliations (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.348%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,605.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605563976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Consolidation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Encompass Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the measurement alternative to account for our investments in entities we do not control and for which we do not have the ability to exercise significant influence over operating and financial policies. In accordance with the measurement alternative, these investments are recorded at the lower of cost or fair value, as appropriate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We eliminate all significant intercompany accounts and transactions from our financial results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any entity considered a variable interest entity (&#8220;VIE&#8221;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Assumptions</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates and Assumptions&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#8217; compensation, and comprehensive general insurance liability risks; </span></div>and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Net Operating Revenues</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;) or the United States Department of Justice (the &#8220;DOJ&#8221;). Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Administrative Contractors (&#8220;MACs&#8221;), under programs known as &#8220;widespread probes,&#8221; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#8220;appeal,&#8221; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OMHA practices continue, an increased number of unfavorable administrative law judge (&#8220;ALJ&#8221;) decisions could have a negative effect on our long-term ALJ success rate. The current OMHA practice has resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, CMS announced the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with CMS approved and announced Recovery Audit Contractors (&#8220;RACs&#8221;) audits related to inpatient rehabilitation facilities (&#8220;IRFs&#8221;), we received requests from 2013 to 2021 to review certain patient files for discharges occurring from 2010 to 2021.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established Unified Program Integrity Contractors (&#8220;UPICs&#8221;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Medicare claims that are subject to these post-payment audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2021. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2021, 2020, and 2019, our adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for claims that are part of this post-payment claims review process was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inpatient rehabilitation segment revenues are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice Revenues</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. The performance obligation is the rendering of services to the patient during the term of the episode of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal regulation. The base episode payment can be adjusted based on each patient&#8217;s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bill a portion of reimbursement from each Medicare episode near the start of each episode, and the resulting cash payment is typically received before all services are rendered. Effective January 1, 2021, this early payment process has been eliminated. As we provide home health services to our patients on a scheduled basis over the episode of care in a manner that approximates a pro rata pattern, revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of December&#160;31, 2021 and December&#160;31, 2020, the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not material and was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain Medicare regulations affecting outlier revenue if our patient&#8217;s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Adjustments to the transaction price for the outlier cap </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> not material</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, revenue is recorded on an accrual basis based upon the date of service at amounts equal to our estimated per-visit transaction price. Price concessions, including contractual allowances for the differences between our standard rates and the applicable contracted rates, as well as estimated uncollectible amounts from patients, are recorded as decreases to the transaction price.</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare revenues for hospice are recognized and recorded on an accrual basis using the input method based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The performance obligation is the rendering of services to the patient during each day that they are on hospice care. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the MAC. Adjustments to the transaction price for these caps </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> not material as of December&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our estimated per day transaction price. Price concessions, including contractual adjustments for the difference between our standard rates and the amounts estimated to be realizable from patients and third parties for services provided, are recorded as decreases to the transaction price and thus reduce our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include highly liquid investments with maturities of three months or less when purchased. Carrying values of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approximate fair value due to the short-term nature of these instruments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a separate component of shareholders&#8217; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#8217; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other discount plans, including Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:84.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 10</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8212;</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. We do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets&#8212; </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors in our inpatient rehabilitation and home health and hospice reporting units to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our reporting units using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of each reporting unit&#8217;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting units to our market capitalization. When we dispose of a hospital or home health or hospice agency, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2021, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></div></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and directly related payroll costs. Amortization begins when the internal-use software is ready for its intended use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#8217;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock', window );">Impairment of Long-Lived Assets and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets and Other Intangible Assets&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock', window );">Investments in and Advances to Nonconsolidated Affiliates</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in and Advances to Nonconsolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities we do not control but in which we have the ability to exercise significant influence over the operating and financial policies of the investee are accounted for under the equity method. Equity method investments are recorded at original cost and adjusted periodically to recognize our proportionate share of the investees&#8217; net income or losses after the date of investment, additional contributions made, dividends or distributions received, and impairment losses resulting from adjustments to net realizable value. We record equity method losses in excess of the carrying amount of an investment when we guarantee obligations or we are otherwise committed to provide further financial support to the affiliate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the measurement alternative to account for equity investments for which the equity securities do not have readily determinable fair values and for which we do not have the ability to exercise significant influence. Under the measurement alternative, private equity investments are carried at cost and are adjusted only for other-than-temporary declines in fair value, additional investments, or distributions deemed to be a return of capital.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management periodically assesses the recoverability of our equity method and measurement alternative investments and equity method goodwill for impairment. We consider all available information, including the recoverability of the investment, the earnings and near-term prospects of the affiliate, factors related to the industry, conditions of the affiliate, and our ability, if any, to influence the management of the affiliate. We assess fair value based on valuation methodologies, as appropriate, including discounted cash flows, estimates of sales proceeds, and external appraisals, as appropriate. If an investment or equity method goodwill is considered to be impaired and the decline in value is other than temporary, we record an appropriate write-down.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Financing Costs</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Observable inputs such as quoted prices in active markets;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling Interests in Consolidated Affiliates and Redeemable Noncontrolling Interests</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interests in Consolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#8217; balance.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future. Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to certain members of the home health and hospice management team&#8217;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $400 million or more. The fair value of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#8217; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees, excluding stock appreciation rights (&#8220;SARs&#8221;), are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period. Share-based payments to employees in the form of SARs are recognized in the financial statements based on their current fair value and expensed ratably over the applicable service period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Litigation Reserves</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Reserves&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the accompanying consolidated statements of comprehensive income, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $4.6 million, and $6.1 million in each of the years ended December 31, 2021, 2020, and 2019, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the asset and liability method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We include the allocable portion of each pass-through entity&#8217;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Assets and Liabilities in and Results of Discontinued Operations</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities in and Results of Discontinued Operations&#8212;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Effective January 1, 2015, in connection with a new standard issued by the FASB, we changed our criteria for determining which disposals are presented as discontinued operations. Historically, any component that had been disposed of or was classified as held for sale qualified for discontinued operations reporting unless there was significant continuing involvement with the disposed component or continuing cash flows. In contrast, we now report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. As a result, the sale or disposal of a single Encompass Health facility or location no longer qualifies as a discontinued operation. This accounting change was made prospectively. No new components were recognized as discontinued operations since this guidance became effective.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Loss from discontinued operations, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Common Share</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We account for the retirement of treasury stock as a reduction of retained earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. The new guidance was effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. The adoption of this guidance did not have a material impact to our consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of the Company's long-lived assets and intangible assets with finite lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606753224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Concentration of Net Operating Revenues by Payor</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:20.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,605.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Concentration of Net Operating Revenues and Net Patient Service Accounts Receivable by Payor and Payor Class</a></td>
<td class="text">The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other discount plans, including Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Useful Lives of Property and Equipment</a></td>
<td class="text">Useful lives are generally as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:84.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 10</span></div></td></tr></table><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,378.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,539.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,374.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,601.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Estimated Useful Lives and Amortization Basis of Other Finite-lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></div></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our other intangible assets (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certificates of need:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncompete agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade name - Encompass:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade names - all other:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal-use software:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market access assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Estimated Basis of Other Indefinite-lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></div></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814609977960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 3 to 5 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of 5 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 3 months)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need (useful lives of 10 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of 2 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 2 to 3 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Noncash or Part Noncash Acquisitions</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:89.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for this acquisition is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired, net of $0.8 million of cash acquired in 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Information regarding the net cash paid for this acquisition is as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired, net of $0.8 million of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of redeemable noncontrolling interest owned by joint venture partner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity interest prior to acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the home health acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Information regarding the net cash paid for all inpatient rehabilitation acquisitions during 2019 is as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.450%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>Information regarding the net cash paid for Alacare is as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:88.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisition</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>Information regarding the net cash paid for the home health acquisitions during 2019 is as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Summary of Actual and Pro Forma Results of Operations for Acquisitions</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,705.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,650.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (Loss) Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alacare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Home Health and Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608652504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814689196216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Investment Components</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2021 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2020 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliate cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock', window );">Investment Information Related to Restricted Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing information related to our available-for-sale marketable securities is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of available-for-sale marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814689173928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent patient accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606917336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of Property and equipment</a></td>
<td class="text">Useful lives are generally as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:84.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 10</span></div></td></tr></table><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,378.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,539.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,374.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,601.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock', window );">Schedule of depreciation expense and interest capitalized</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of depreciation expense and interest capitalized is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest capitalized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of depreciation expense, interest capitalized, under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605213896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Least Costs</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated balance sheet information related to leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease assets are recorded net of accumulated amortization of $147.8 million and $129.6 million as of December&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Term and Discount Rate</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SupplementalCashFlowInformationTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Information [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612604904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in the Carrying Amount of Goodwill</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,318.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation of joint venture formerly accounted for under the equity method of accounting</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets by Major Class</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></div></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our other intangible assets (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certificates of need:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncompete agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade name - Encompass:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade names - all other:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal-use software:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market access assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense, Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for other intangible assets is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Estimated Amortization Expense, Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608598536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in and Advances to Nonconsolidated Affiliates (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock', window );">Schedule of Aggregate Equity and Cost Method Investments</a></td>
<td class="text">Our investments, which are included in <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets, consist of the following (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contributions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative share of income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative share of distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contributions, net of distributions and impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in and advances to nonconsolidated affiliates</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Combined Assets, Liabilities, and Equity of Equity Method Affiliates</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the combined assets, liabilities, and equity and the combined results of operations of our equity method affiliates (on a 100% basis, in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and equity&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partners&#8217; capital and shareholders&#8217; equity&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed statements of comprehensive income (in millions):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investments in and advances to affiliates.  Does not include the tabular disclosure of the disaggregation of investments in and advances to affiliates across legal entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611322-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612771080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Outstanding Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,243.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our notes payable consist of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.078%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale/leaseback transactions involving real estate accounted for as financings</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1% to 11.2%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction of a new hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Debt Maturities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Face Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ScheduleOfFinancialCovenantsTableTextBlock', window );">Schedule of Financial Covenants</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionTableTextBlock', window );">Schedule of Redemption Prices for Senior Notes</a></td>
<td class="text"><div style="margin-bottom:7pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2021, at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div>We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:<div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div>We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:<div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div>We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:<div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleOfFinancialCovenantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Financial Covenants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleOfFinancialCovenantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608689832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Self-Insured Risks (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Self-Insurance Reserves</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our self-insurance reserves for the years ended December&#160;31, 2021, 2020, and 2019 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:53.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for the provision of current year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease for the provision of prior year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses related to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to current year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to prior year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, gross</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612611848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:51.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock', window );">Reconciliation of Net Income Attributable to Noncontrolling Interests</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:64.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of Noncontrolling Interests [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608679256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments</a></td>
<td class="text">The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814689152232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used to Determine Fair Value of Stock Options</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the options granted during the years ended December&#160;31, 2021, 2020, and 2019 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the SARs granted in conjunction with the EHHI acquisition has been estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our issued restricted stock awards is as follows (share information in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814689231192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to continuing operations are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense related to continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based windfall tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608832712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earnings per Common Share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Weighted Average Number of Shares Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605547752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Selected Financial Information of Reportable Segments</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,965.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Reconciliation of Assets from Segment to Consolidated</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense</a></td>
<td class="text">Segment reconciliations (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Revenue from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.348%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,605.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606562008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold', window );">Fair value of the Redeemable noncontrolling interests</a></td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees', window );">Minimum accrual of loss contingency needed to accrue for related legal fees</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember', window );">Market access assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicare | RAC Audits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of Medicare patient discharges (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum dollar amount that must be accrued for a loss contingency related to a specific legal dispute that can be utilized for consideration prior to accruing an estimate of the legal fees related to this specific legal dispute.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_RACAuditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_RACAuditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814600158504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Operating Revenues &amp; Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 5,121.6<span></span>
</td>
<td class="nump">$ 4,644.4<span></span>
</td>
<td class="nump">$ 4,605.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">4,015.0<span></span>
</td>
<td class="nump">3,566.2<span></span>
</td>
<td class="nump">3,513.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">1,106.6<span></span>
</td>
<td class="nump">1,078.2<span></span>
</td>
<td class="nump">1,092.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">5,121.6<span></span>
</td>
<td class="nump">4,644.4<span></span>
</td>
<td class="nump">4,605.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">4,015.0<span></span>
</td>
<td class="nump">3,566.2<span></span>
</td>
<td class="nump">3,513.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">1,106.6<span></span>
</td>
<td class="nump">1,078.2<span></span>
</td>
<td class="nump">1,092.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicare | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">3,496.2<span></span>
</td>
<td class="nump">3,271.5<span></span>
</td>
<td class="nump">3,457.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicare | Third-Party Payor | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">2,589.7<span></span>
</td>
<td class="nump">2,375.5<span></span>
</td>
<td class="nump">2,537.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicare | Third-Party Payor | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">906.5<span></span>
</td>
<td class="nump">896.0<span></span>
</td>
<td class="nump">920.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicare Advantage | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">727.0<span></span>
</td>
<td class="nump">661.1<span></span>
</td>
<td class="nump">487.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicare Advantage | Third-Party Payor | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">609.6<span></span>
</td>
<td class="nump">544.9<span></span>
</td>
<td class="nump">375.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicare Advantage | Third-Party Payor | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">117.4<span></span>
</td>
<td class="nump">116.2<span></span>
</td>
<td class="nump">111.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Managed Care | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">549.9<span></span>
</td>
<td class="nump">419.2<span></span>
</td>
<td class="nump">381.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Managed Care | Third-Party Payor | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">484.5<span></span>
</td>
<td class="nump">371.4<span></span>
</td>
<td class="nump">342.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Managed Care | Third-Party Payor | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">65.4<span></span>
</td>
<td class="nump">47.8<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicaid | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">178.6<span></span>
</td>
<td class="nump">155.7<span></span>
</td>
<td class="nump">128.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicaid | Third-Party Payor | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">163.1<span></span>
</td>
<td class="nump">140.1<span></span>
</td>
<td class="nump">110.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicaid | Third-Party Payor | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Other third-party payors | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">46.0<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">43.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Other third-party payors | Third-Party Payor | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">46.0<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">43.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Other third-party payors | Third-Party Payor | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Workers&#8217; compensation | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Workers&#8217; compensation | Third-Party Payor | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Workers&#8217; compensation | Third-Party Payor | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Patients | Self-Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">23.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Patients | Self-Pay | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Patients | Self-Pay | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">80.4<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">52.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Other income | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Other income | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Accounts Receivable | Medicare | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">63.60%<span></span>
</td>
<td class="nump">66.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Accounts Receivable | Managed care and other discount plans, including Medicare Advantage | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">27.40%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Accounts Receivable | Medicaid | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Accounts Receivable | Other third-party payors | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Accounts Receivable | Workers&#8217; compensation | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Accounts Receivable | Patients | Self-Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_ManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_ManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_OtherThirdpartyPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_OtherThirdpartyPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_WorkersCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_WorkersCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_PatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_PatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_OtherIncomeSourceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_OtherIncomeSourceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814600136488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - PP&amp;E Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608827176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember', window );">Certificates of need | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember', window );">Certificates of need | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">18 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_InternalUseSoftwareMember', window );">Internal-use software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_InternalUseSoftwareMember', window );">Internal-use software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember', window );">Market access assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_InternalUseSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_InternalUseSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814597808552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Textual (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>USD ($) </div>
<div>location</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>location </div>
<div>bed</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>bed</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>bed</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>bed</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>bed</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>bed</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>bed</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>location</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Alacare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Fair value of equity interest prior to acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Care Resource Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofLocationsofanAcquiredEntity', window );">Number of locations | location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Home health | Alacare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofLocationsofanAcquiredEntity', window );">Number of locations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Hospice | Alacare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofLocationsofanAcquiredEntity', window );">Number of locations | location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Inpatient Rehabilitation | Shannon Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsAcquired', window );">Number of beds acquired | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Inpatient Rehabilitation | Heritage Valley</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsAcquired', window );">Number of beds acquired | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Inpatient Rehabilitation | ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsAcquired', window );">Number of beds acquired | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Inpatient Rehabilitation | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be tax-deductible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Inpatient Rehabilitation | Portercare Adventist</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsAcquired', window );">Number of beds acquired | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsContributed', window );">Number of beds contributed | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsExpanded', window );">Number of beds expanded | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Inpatient Rehabilitation | Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsAcquired', window );">Number of beds acquired | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofDeNovoBeds', window );">Number of de novo beds | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Inpatient Rehabilitation | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be tax-deductible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Inpatient Rehabilitation | Saint Alphonsus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsAcquired', window );">Number of beds acquired | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofDeNovoBeds', window );">Number of de novo beds | location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Fair value of equity interest prior to acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Home Health and Hospice | Heart of the Rockies Home Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Home Health and Hospice | Hospice of Southwest Montana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage', window );">Equity method investment, additional ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Home Health and Hospice | Home health | Frontier Home Health And Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofLocationsofanAcquiredEntity', window );">Number of locations | location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Home Health and Hospice | Hospice | Frontier Home Health And Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofLocationsofanAcquiredEntity', window );">Number of locations | location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Other Home Health and Hospice Acquisitions | Saint Alphonsus | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Escrow agent cost</a></td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Other Home Health and Hospice Acquisitions | Baptist Outpatient Services, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be tax-deductible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Goodwill increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_EquityMethodInvestmentAdditionalOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Additional Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_EquityMethodInvestmentAdditionalOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofBedsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of hospital beds acquired as part of a facility acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofBedsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofBedsContributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Beds Contributed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofBedsContributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofBedsExpanded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Beds Expanded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofBedsExpanded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofDeNovoBeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of De Novo Beds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofDeNovoBeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofLocationsofanAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of locations acquired as part of a facility acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofLocationsofanAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_AlacareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_AlacareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_CareResourceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_CareResourceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_HomehealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_HomehealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_HeritageValleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_HeritageValleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_HeartOfTheRockiesHomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_HeartOfTheRockiesHomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_HospiceOfSouthwestMontanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_HospiceOfSouthwestMontanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_FrontierHomeHealthAndHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_FrontierHomeHealthAndHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_BaptistOutpatientServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_BaptistOutpatientServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814598221400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Fair Value of Assets and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,427.9<span></span>
</td>
<td class="nump">$ 2,318.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,305.2<span></span>
</td>
<td class="nump">$ 2,100.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,236.9<span></span>
</td>
<td class="nump">1,228.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,218.9<span></span>
</td>
<td class="nump">1,189.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Noncompete agreements | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Noncompete agreements | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Trade names | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Trade names | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,191.0<span></span>
</td>
<td class="nump">$ 1,090.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,086.3<span></span>
</td>
<td class="nump">$ 911.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Frontier Home Health And Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use-assets</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">92.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">105.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability', window );">Current operating lease liabilities</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll', window );">Accrued payroll</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Long-term operating lease liabilities</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">99.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Generation Solutions of Lynchburg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Noncompete agreements | Frontier Home Health And Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Trade names | Frontier Home Health And Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Certificates of need | Frontier Home Health And Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Licenses | Frontier Home Health And Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Licenses | Generation Solutions of Lynchburg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember', window );">Other Home Health and Hospice Acquisitions | Baptist Outpatient Services, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll', window );">Accrued payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember', window );">Other Home Health and Hospice Acquisitions | Noncompete agreements | Baptist Outpatient Services, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember', window );">Other Home Health and Hospice Acquisitions | Licenses | Baptist Outpatient Services, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Inpatient Rehabilitation | Noncompete agreements | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Inpatient Rehabilitation | Noncompete agreements | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Inpatient Rehabilitation | Noncompete agreements | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Inpatient Rehabilitation | Noncompete agreements | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued payroll assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_FrontierHomeHealthAndHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_FrontierHomeHealthAndHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsOfLynchburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsOfLynchburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_BaptistOutpatientServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_BaptistOutpatientServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814601198712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Net Cash Paid for Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101.2<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="nump">$ 179.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.6<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">231.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9.1)<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Saint Alphonsus and Heritage Valley</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationNoncontrollingInterestFairValue', window );">Fair value of redeemable noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.4<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Frontier Home Health And Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationNoncontrollingInterestFairValue', window );">Fair value of redeemable noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Generation Solutions of Lynchburg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Alacare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Tidewater and Care Resource Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember', window );">Other Home Health and Hospice Acquisitions | Baptist Outpatient Services, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationNoncontrollingInterestFairValue', window );">Fair value of redeemable noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Fair value of equity interest prior to acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Noncontrolling Interest, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusandHeritageValleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusandHeritageValleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_FrontierHomeHealthAndHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_FrontierHomeHealthAndHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsOfLynchburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsOfLynchburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_AlacareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_AlacareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_TidewaterandCareResourceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_TidewaterandCareResourceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_OtherHomeHealthAndHospiceAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_BaptistOutpatientServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_BaptistOutpatientServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814597676184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Pro Forma Results of Operation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_A2021AcquisitionsMember', window );">2021 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisition, pro forma revenue</a></td>
<td class="nump">$ 5,152.2<span></span>
</td>
<td class="nump">$ 4,705.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisition, pro forma net income (loss)</a></td>
<td class="nump">413.0<span></span>
</td>
<td class="nump">286.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_A2020AcquisitionsMember', window );">2020 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisition, pro forma revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,650.3<span></span>
</td>
<td class="nump">$ 4,626.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisition, pro forma net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284.8<span></span>
</td>
<td class="nump">360.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_A2019AcquisitionsMember', window );">2019 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisition, pro forma revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,674.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisition, pro forma net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation Segment | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation Segment | Saint Alphonsus and Heritage Valley</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Alacare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Tidewater and Care Resource Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Generation Solutions of Lynchburg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_A2021AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_A2021AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_A2020AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_A2020AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_A2019AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_A2019AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusandHeritageValleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusandHeritageValleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_AlacareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_AlacareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_TidewaterandCareResourceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_TidewaterandCareResourceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsOfLynchburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsOfLynchburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612729272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities - Textuals (Details) - Variable Interest Entity, Primary Beneficiary - entity<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_VariableInterestEntityNumberofEntitiesConsolidated', window );">Number of consolidated limited partnership-like entities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership interest in the consolidated entities (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership interest in the consolidated entities (percent)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_VariableInterestEntityNumberofEntitiesConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of facilities consolidated as variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_VariableInterestEntityNumberofEntitiesConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605106104">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54.8<span></span>
</td>
<td class="nump">$ 224.0<span></span>
</td>
<td class="nump">$ 94.8<span></span>
</td>
<td class="nump">$ 69.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">680.3<span></span>
</td>
<td class="nump">572.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">921.4<span></span>
</td>
<td class="nump">948.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,601.6<span></span>
</td>
<td class="nump">2,206.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">242.0<span></span>
</td>
<td class="nump">245.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,427.9<span></span>
</td>
<td class="nump">2,318.7<span></span>
</td>
<td class="nump">$ 2,305.2<span></span>
</td>
<td class="nump">$ 2,100.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">417.5<span></span>
</td>
<td class="nump">431.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254.5<span></span>
</td>
<td class="nump">295.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,864.9<span></span>
</td>
<td class="nump">6,445.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">38.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">137.6<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">265.8<span></span>
</td>
<td class="nump">253.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219.7<span></span>
</td>
<td class="nump">218.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">748.8<span></span>
</td>
<td class="nump">717.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,243.9<span></span>
</td>
<td class="nump">3,250.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">213.1<span></span>
</td>
<td class="nump">209.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49.4<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,465.7<span></span>
</td>
<td class="nump">4,444.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">33.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116.3<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30.5<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">226.2<span></span>
</td>
<td class="nump">221.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of December&#160;31, 2021 and December&#160;31, 2020 include total assets of variable interest entities of $226.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2021 and December&#160;31, 2020 include total liabilities of the variable interest entities of $38.2 million and $46.8 million, respectively. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605004248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Components of Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">$ 54.8<span></span>
</td>
<td class="nump">$ 224.0<span></span>
</td>
<td class="nump">$ 94.8<span></span>
</td>
<td class="nump">$ 69.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
<td class="nump">65.5<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRestricted', window );">Restricted Marketable Securities</a></td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_InvestmentsCashandRestrictedCash', window );">Total</a></td>
<td class="nump">202.5<span></span>
</td>
<td class="nump">383.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">224.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
<td class="nump">65.5<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRestricted', window );">Restricted Marketable Securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_InvestmentsCashandRestrictedCash', window );">Total</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRestricted', window );">Restricted Marketable Securities</a></td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_InvestmentsCashandRestrictedCash', window );">Total</a></td>
<td class="nump">$ 82.2<span></span>
</td>
<td class="nump">$ 72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_InvestmentsCashandRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total investments of the Company which includes cash, cash equivalents, restricted cash, and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_InvestmentsCashandRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606885816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 65.1<span></span>
</td>
<td class="nump">$ 65.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Noncurrent restricted cash</a></td>
<td class="nump">65.5<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_AffiliateCashMember', window );">Affiliate cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">17.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_SelfInsuredCaptiveFundsMember', window );">Self-insured captive funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Noncurrent restricted cash</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 21.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_AffiliateCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_AffiliateCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_SelfInsuredCaptiveFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_SelfInsuredCaptiveFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814607101304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RestrictedDebtSecuritiesNoncurrent', window );">Restricted marketable securities</a></td>
<td class="nump">$ 82.2<span></span>
</td>
<td class="nump">$ 72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net gain (loss) on marketable securities</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RestrictedDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for greater than one year or the normal operating cycle, whichever is longer and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RestrictedDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814613884392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract', window );"><strong>Investment information related to restricted marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales and maturities of available-for-sale marketable securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814607099704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable - Components of Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrentAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">$ 666.6<span></span>
</td>
<td class="nump">$ 563.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other accounts receivable</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, current</a></td>
<td class="nump">680.3<span></span>
</td>
<td class="nump">572.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">Noncurrent patient accounts receivable</a></td>
<td class="nump">83.5<span></span>
</td>
<td class="nump">123.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 763.8<span></span>
</td>
<td class="nump">$ 696.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604049944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Components of Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">$ 2,601.6<span></span>
</td>
<td class="nump">$ 2,206.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember', window );">Land, Building, Improvements, Equipment, Vehicles and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">3,787.8<span></span>
</td>
<td class="nump">3,378.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(1,539.4)<span></span>
</td>
<td class="num">(1,374.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">2,248.4<span></span>
</td>
<td class="nump">2,004.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">2,632.8<span></span>
</td>
<td class="nump">2,357.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">254.1<span></span>
</td>
<td class="nump">232.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">606.1<span></span>
</td>
<td class="nump">537.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">$ 353.2<span></span>
</td>
<td class="nump">$ 202.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608496456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Textual (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Percentageofassetspledgedtolendersundercreditagreement', window );">Percentage of property and equipment, net pledged to lenders under credit agreement (percent)</a></td>
<td class="nump">73.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Percentageofassetspledgedtolendersundercreditagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of assets pledged to lenders under credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Percentageofassetspledgedtolendersundercreditagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605230376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Depreciation, Capitalized Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 166.2<span></span>
</td>
<td class="nump">$ 151.1<span></span>
</td>
<td class="nump">$ 130.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest capitalized</a></td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612592696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Textuals (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Operatingandfinanceleasecontractterm', window );">Operating and finance lease contract term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Operatingandfinanceleasecontractterm', window );">Operating and finance lease contract term</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Operatingandfinanceleasecontractterm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating and finance leases, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Operatingandfinanceleasecontractterm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814609812824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="nump">$ 68.5<span></span>
</td>
<td class="nump">$ 72.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="nump">32.1<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">30.9<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Totalfinanceleasecost', window );">Total finance lease cost</a></td>
<td class="nump">64.9<span></span>
</td>
<td class="nump">61.4<span></span>
</td>
<td class="nump">59.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Shorttermandvariableleasecost', window );">Short-term and variable lease cost</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 130.8<span></span>
</td>
<td class="nump">$ 130.4<span></span>
</td>
<td class="nump">$ 131.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Shorttermandvariableleasecost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less, plus the amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Shorttermandvariableleasecost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Totalfinanceleasecost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of finance lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Totalfinanceleasecost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814597659336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 242.0<span></span>
</td>
<td class="nump">$ 245.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease</a></td>
<td class="nump">309.6<span></span>
</td>
<td class="nump">322.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Totaloperatingandfinanceleaseassets', window );">Total leased assets</a></td>
<td class="nump">551.6<span></span>
</td>
<td class="nump">568.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">213.1<span></span>
</td>
<td class="nump">209.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease</a></td>
<td class="nump">363.7<span></span>
</td>
<td class="nump">367.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Totalleaseliabilities', window );">Total lease liabilities</a></td>
<td class="nump">638.3<span></span>
</td>
<td class="nump">646.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance lease right-of-use asset accumulated amortization</a></td>
<td class="nump">$ 147.8<span></span>
</td>
<td class="nump">$ 129.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Current portion of long-term debt<span></span>
</td>
<td class="text">Current portion of long-term debt<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Long-term debt, net of current portion<span></span>
</td>
<td class="text">Long-term debt, net of current portion<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Totalleaseliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Totalleaseliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Totaloperatingandfinanceleaseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Totaloperatingandfinanceleaseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814598184696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease (in years)</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease (in years)</a></td>
<td class="text">11 years 9 months 18 days<span></span>
</td>
<td class="text">11 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease (in percent)</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease (in percent)</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814598087832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 51.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">50.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">34.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter', window );">2027 and thereafter</a></td>
<td class="nump">116.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">326.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest portion</a></td>
<td class="num">(75.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">251.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">52.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">50.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">51.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter', window );">2027 and thereafter</a></td>
<td class="nump">350.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">606.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest portion</a></td>
<td class="num">(219.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 386.8<span></span>
</td>
<td class="nump">$ 391.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in the sixth fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605280616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 61.5<span></span>
</td>
<td class="nump">$ 66.9<span></span>
</td>
<td class="nump">$ 70.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">31.3<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">51.8<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">51.1<span></span>
</td>
<td class="nump">39.0<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="nump">$ 34.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814600143384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Schedule of Changes in the Carrying Amount of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 2,318.7<span></span>
</td>
<td class="nump">$ 2,305.2<span></span>
</td>
<td class="nump">$ 2,100.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">101.2<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">179.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod', window );">Consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">2,427.9<span></span>
</td>
<td class="nump">2,318.7<span></span>
</td>
<td class="nump">2,305.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Schedule of Changes in the Carrying Amount of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">1,228.1<span></span>
</td>
<td class="nump">1,218.9<span></span>
</td>
<td class="nump">1,189.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod', window );">Consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">1,236.9<span></span>
</td>
<td class="nump">1,228.1<span></span>
</td>
<td class="nump">1,218.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Schedule of Changes in the Carrying Amount of Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">1,090.6<span></span>
</td>
<td class="nump">1,086.3<span></span>
</td>
<td class="nump">911.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">92.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod', window );">Consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 1,191.0<span></span>
</td>
<td class="nump">$ 1,090.6<span></span>
</td>
<td class="nump">$ 1,086.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Consolidation Of Joint Venture Formerly Accounted For Under Equity Method</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605556728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Textuals (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604017112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Other Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 879.9<span></span>
</td>
<td class="nump">$ 837.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(462.4)<span></span>
</td>
<td class="num">(406.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">417.5<span></span>
</td>
<td class="nump">431.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember', window );">Certificates of need</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">204.5<span></span>
</td>
<td class="nump">197.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(68.8)<span></span>
</td>
<td class="num">(54.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">135.7<span></span>
</td>
<td class="nump">142.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">194.5<span></span>
</td>
<td class="nump">187.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(121.0)<span></span>
</td>
<td class="num">(107.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">73.5<span></span>
</td>
<td class="nump">80.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">75.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(69.0)<span></span>
</td>
<td class="num">(65.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_TradeNameEncompassMember', window );">Trade name - Encompass</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">135.2<span></span>
</td>
<td class="nump">135.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">135.2<span></span>
</td>
<td class="nump">135.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(27.0)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Internal-use Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">209.0<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(164.9)<span></span>
</td>
<td class="num">(141.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">44.1<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember', window );">Market access assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">13.2<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(11.7)<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_TradeNameEncompassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_TradeNameEncompassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605866808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="nump">$ 59.8<span></span>
</td>
<td class="nump">$ 58.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606733656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Schedule of Future Estimated Amortization Expense, Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 53.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">45.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">37.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">$ 21.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814597690760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in and Advances to Nonconsolidated Affiliates - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated', window );">Number of partially-owned subsidiaries | subsidiary</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures', window );">Number of general or limited partnerships, limited liability companies, or joint ventures | subsidiary</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_JupiterFloridaHomeHealthAgencyMember', window );">Jupiter Florida Home Health Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Goodwill increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_YumaRehabilitationHospitalMember', window );">Yuma Rehabilitation Hospital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Goodwill increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AffiliatesOwnershipPercentage', window );">Affiliates ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AffiliatesOwnershipPercentage', window );">Affiliates ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AffiliatesOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership by the Company in the investee accounted for under the equity or cost methods of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AffiliatesOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of general or limited partnerships, limited liability companies, or joint ventures of which the Company has investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of partially owned subsidiaries in which the Company has investments but are not consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_JupiterFloridaHomeHealthAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_JupiterFloridaHomeHealthAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_YumaRehabilitationHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_YumaRehabilitationHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612363768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in and Advances to Nonconsolidated Affiliates - Schedule of Other Long-term Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract', window );"><strong>Equity method investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Capital contributions</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments', window );">Cumulative share of income</a></td>
<td class="nump">68.5<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments', window );">Cumulative share of distributions</a></td>
<td class="num">(66.9)<span></span>
</td>
<td class="num">(66.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Measurement alternative investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Capital contributions, net of distributions and impairments</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Total investments in and advances to nonconsolidated affiliates</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company's cumulative and proportionate receipt of distributed earnings since inception of its investment in an equity method affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company's cumulative and proportionate share of income earned since inception of its investment in an equity method affiliate as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605757464">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments in and Advances to Nonconsolidated Affiliates - Combined Assets, Liabilities and Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 921.4<span></span>
</td>
<td class="nump">$ 948.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,864.9<span></span>
</td>
<td class="nump">6,445.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Shareholders&#8217; Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">748.8<span></span>
</td>
<td class="nump">717.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Partners&#8217; capital and shareholders&#8217; equity&#8212;</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Encompass Health shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,911.3<span></span>
</td>
<td class="nump">1,588.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">445.7<span></span>
</td>
<td class="nump">382.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,864.9<span></span>
</td>
<td class="nump">6,445.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,121.6<span></span>
</td>
<td class="nump">4,644.4<span></span>
</td>
<td class="nump">$ 4,605.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,315.1)<span></span>
</td>
<td class="num">(3,999.4)<span></span>
</td>
<td class="num">(3,912.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">517.6<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
<td class="nump">446.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net and comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">517.2<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
<td class="nump">445.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Shareholders&#8217; Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Partners&#8217; capital and shareholders&#8217; equity&#8212;</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Encompass Health shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(19.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net and comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of December&#160;31, 2021 and December&#160;31, 2020 include total assets of variable interest entities of $226.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2021 and December&#160;31, 2020 include total liabilities of the variable interest entities of $38.2 million and $46.8 million, respectively. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814597919864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Long-term Debt Outstanding (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">$ 386,800,000<span></span>
</td>
<td class="nump">$ 391,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt and Capital lease obligations</a></td>
<td class="nump">3,286,700,000<span></span>
</td>
<td class="nump">3,288,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current portion</a></td>
<td class="num">(42,800,000)<span></span>
</td>
<td class="num">(38,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="nump">3,243,900,000<span></span>
</td>
<td class="nump">3,250,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan facilities | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 238,500,000<span></span>
</td>
<td class="nump">$ 251,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 99,600,000<span></span>
</td>
<td class="nump">$ 298,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 347,000,000.0<span></span>
</td>
<td class="nump">$ 346,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 786,800,000<span></span>
</td>
<td class="nump">$ 785,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 784,700,000<span></span>
</td>
<td class="nump">$ 783,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 393,700,000<span></span>
</td>
<td class="nump">$ 393,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">49,600,000<span></span>
</td>
<td class="nump">39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604018936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_FaceAmountMember', window );">Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract', window );"><strong>Long-term Debt by Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne', window );">2022</a></td>
<td class="nump">$ 42.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo', window );">2023</a></td>
<td class="nump">143.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree', window );">2024</a></td>
<td class="nump">453.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour', window );">2025</a></td>
<td class="nump">384.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive', window );">2026</a></td>
<td class="nump">29.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,271.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total</a></td>
<td class="nump">3,326.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_NetAmountMember', window );">Net Amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract', window );"><strong>Long-term Debt by Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne', window );">2022</a></td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo', window );">2023</a></td>
<td class="nump">143.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree', window );">2024</a></td>
<td class="nump">452.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour', window );">2025</a></td>
<td class="nump">381.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive', window );">2026</a></td>
<td class="nump">29.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,236.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total</a></td>
<td class="nump">$ 3,286.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, After Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_FaceAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_FaceAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_NetAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_NetAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606764248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Financial Covenants (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantInterestCoverageRatio', window );">Interest Coverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">6.00<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantInterestCoverageRatio', window );">Interest Coverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814591144456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Textual (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 09, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket', window );">Debt instrument, reduction in capacity under restricted payments builder basket</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 583,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid', window );">Amendment agreement, amount to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Amounts outstanding under letter of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,200,000<span></span>
</td>
<td class="nump">36,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatioMaximum', window );">Senior secured leverage ratio maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_CreditAgreementRestriction', window );">Payment limit under the credit agreement's negative covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Fed Funds Effective Rate Overnight Index Swap Rate | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | LIBOR | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding', window );">Percentage of aggregate principal amount outstanding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Applicable interest rate under credit facility (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,600,000<span></span>
</td>
<td class="nump">$ 298,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net proceeds for offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Senior Notes | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member', window );">Senior Notes; 05.75%; Due 2024 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.958%<span></span>
</td>
<td class="nump">101.917%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentIssuePricePercentage', window );">Debt issue price as percentage of principal (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.50%<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
<td class="nump">103.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 404,000,000<span></span>
</td>
<td class="nump">$ 102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member', window );">5.75% Senior Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,000,000.0<span></span>
</td>
<td class="nump">$ 346,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member', window );">4.50% Senior Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 786,800,000<span></span>
</td>
<td class="nump">$ 785,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue', window );">Issuance of face value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member', window );">4.75% Senior Notes due 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,700,000<span></span>
</td>
<td class="nump">$ 783,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue', window );">Issuance of face value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member', window );">4.625% Senior Notes due 2031 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393,700,000<span></span>
</td>
<td class="nump">$ 393,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_CreditAgreementRestriction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>We are restricted from paying common stock dividends, prepaying certain senior notes, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the Credit Agreement and (2)&#160;the amount of such payments, when added to the aggregate amount of prior restricted payments (as defined in the Credit Agreement) does not exceed $200 million, which amount is subject to increase by a portion of excess cash flows each fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_CreditAgreementRestriction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amendment Agreement, Amount To Be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentAmendmentAgreementAmountToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Max senior secured leverage ratio to permit restricted payments under credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Discount Rate at Issuance of Face Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentIssuePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Par value of debt instrument issued plus or minus a premium or a discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentIssuePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage owed on principal amount outstanding for amounts drawn under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606519560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Senior Notes Redemption Prices (Details) - Senior Notes<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">5.75% Senior Notes due 2025 | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.917%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">5.75% Senior Notes due 2025 | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.958%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">5.75% Senior Notes due 2025 | Redemption Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.50% Senior Notes due 2028 | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.50% Senior Notes due 2028 | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.50% Senior Notes due 2028 | Redemption Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.75% Senior Notes due 2030 | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.75% Senior Notes due 2030 | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.583%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.75% Senior Notes due 2030 | Redemption Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.75% Senior Notes due 2030 | Redemption Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.625% Senior Notes due 2031 | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="nump">102.313%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.625% Senior Notes due 2031 | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="nump">101.542%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.625% Senior Notes due 2031 | Redemption Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="nump">100.771%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.625% Senior Notes due 2031 | Redemption Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814598125624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Schedule of Notes Payable (Details) - Other notes payable - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">$ 49.6<span></span>
</td>
<td class="nump">$ 39.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Sale/leaseback transactions involving real estate accounted for as financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Construction of a new hospital | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Software contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Sale/leaseback transactions involving real estate accounted for as financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Sale/leaseback transactions involving real estate accounted for as financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Software contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_NotesPayableRealEstateSaleLeasebackFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_NotesPayableRealEstateSaleLeasebackFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_NotesPayableSoftwareContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_NotesPayableSoftwareContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604944552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Self-Insured Risks - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk', window );">Self-insured amount</a></td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_MaximumSelfInsuredAmountThirdLayerRisk', window );">Additional insurance</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability', window );">Threshold of annual aggregate losses associated with general and professional liability</a></td>
<td class="nump">46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveCurrent', window );">Self-insurance reserves included in Other current liabilities</a></td>
<td class="nump">$ 45.6<span></span>
</td>
<td class="nump">$ 44.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves', window );">Number of individual claims covered by reserves | claim</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Self Insured Amount, First Layer of Risk</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_MaximumSelfInsuredAmountFirstLayerOfRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_MaximumSelfInsuredAmountThirdLayerRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Self Insured Amount, Third Layer Risk</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_MaximumSelfInsuredAmountThirdLayerRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of individual claims covered by the Company's self-insured risk reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Self Insured Risk, Threshold, General And Professional Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604038824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Self-Insured Risks - Changes in Self-insurance Reserves (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance at beginning of period, gross</a></td>
<td class="nump">$ 165.2<span></span>
</td>
<td class="nump">$ 157.3<span></span>
</td>
<td class="nump">$ 160.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Less: Reinsurance receivables</a></td>
<td class="num">(28.3)<span></span>
</td>
<td class="num">(26.4)<span></span>
</td>
<td class="num">(25.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Balance at beginning of period, net</a></td>
<td class="nump">136.9<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
<td class="nump">135.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Increase for the provision of current year claims</a></td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">52.5<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Decrease for the provision of prior year claims</a></td>
<td class="num">(6.8)<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
<td class="num">(12.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations', window );">Expenses related to discontinued operations</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Payments related to current year claims</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Payments related to prior year claims</a></td>
<td class="num">(30.4)<span></span>
</td>
<td class="num">(22.9)<span></span>
</td>
<td class="num">(31.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Balance at end of period, net</a></td>
<td class="nump">139.4<span></span>
</td>
<td class="nump">136.9<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Add: Reinsurance receivables</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">26.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance at end of period, gross</a></td>
<td class="nump">$ 169.4<span></span>
</td>
<td class="nump">$ 165.2<span></span>
</td>
<td class="nump">$ 157.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814601145944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract', window );"><strong>Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="nump">$ 31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(87.8)<span></span>
</td>
<td class="num">(72.1)<span></span>
</td>
<td class="num">(70.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="num">(147.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">42.2<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract', window );"><strong>Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
<td class="nump">261.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Contributiontojointventure', window );">Contribution to joint ventures</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Reclassificationtononcontrollinginterests', window );">Reclassification to noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
<td class="num">(162.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NoncontrollingInterestExchangeTransaction', window );">Exchange transaction</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(46.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in fair value</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">147.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NoncontrollingInterestOtherAdjustment', window );">Other</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Contributiontojointventure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contribution of primarily intangible assets relating to a joint venture agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Contributiontojointventure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestExchangeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Exchange Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestExchangeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestOtherAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Other Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestOtherAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Reclassificationtononcontrollinginterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of redeemable noncontrolling interests reclassified to noncontrolling interests during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Reclassificationtononcontrollinginterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605276344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to nonredeemable noncontrolling interests</a></td>
<td class="nump">$ 96.0<span></span>
</td>
<td class="nump">$ 77.2<span></span>
</td>
<td class="nump">$ 74.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to redeemable noncontrolling interests</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">$ 105.0<span></span>
</td>
<td class="nump">$ 84.6<span></span>
</td>
<td class="nump">$ 87.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of net income (loss) attributable to nonredeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606436792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 18, 2020</div></th>
<th class="th"><div>Feb. 21, 2018</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 06, 2020</div></th>
<th class="th"><div>Feb. 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent', window );">Purchase of redeemable noncontrolling interests, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to settle the acquisition of Holdings common stock</a></td>
<td class="nump">$ 162.0<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Delivering EHC shares to management investors (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages', window );">Shares to issued to the management investors pursuant to the exchange agreements represents (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ehc_HoldingsAndEHHIMember', window );">Holdings And EHHI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember', window );">EHHI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue', window );">Value of outstanding shares of Holdings</a></td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | EHHI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent', window );">Redeemable noncontrolling interest, equity, acquired percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent', window );">Subsidiary's common stock held by subsidiary 's management, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Equity, Acquired Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsidiary's common stock held by subsidiary 's management, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of noncontrolling interests which are redeemable by the parent entity and classified as other equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ehc_HoldingsAndEHHIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ehc_HoldingsAndEHHIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604054808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 82.2<span></span>
</td>
<td class="nump">$ 72.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">42.2<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">78.1<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814613869560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Gains or losses related to non-financial assets and liabilities</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814601101800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 49.6<span></span>
</td>
<td class="nump">$ 39.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">39.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">36.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember', window );">Term loan facilities | Term loan facilities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">238.5<span></span>
</td>
<td class="nump">251.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember', window );">Term loan facilities | Term loan facilities | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="nump">$ 253.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Senior Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 99.6<span></span>
</td>
<td class="nump">$ 298.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Senior Notes | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 100.2<span></span>
</td>
<td class="nump">$ 302.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member', window );">5.75% Senior Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member', window );">5.75% Senior Notes due 2025 | Senior Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 347.0<span></span>
</td>
<td class="nump">$ 346.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member', window );">5.75% Senior Notes due 2025 | Senior Notes | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 357.9<span></span>
</td>
<td class="nump">$ 361.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member', window );">4.50% Senior Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member', window );">4.50% Senior Notes due 2028 | Senior Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 786.8<span></span>
</td>
<td class="nump">$ 785.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member', window );">4.50% Senior Notes due 2028 | Senior Notes | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 823.0<span></span>
</td>
<td class="nump">$ 840.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member', window );">4.75% Senior Notes due 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member', window );">4.75% Senior Notes due 2030 | Senior Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 784.7<span></span>
</td>
<td class="nump">$ 783.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member', window );">4.75% Senior Notes due 2030 | Senior Notes | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 824.0<span></span>
</td>
<td class="nump">$ 856.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member', window );">4.625% Senior Notes due 2031 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member', window );">4.625% Senior Notes due 2031 | Senior Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 393.7<span></span>
</td>
<td class="nump">$ 393.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member', window );">4.625% Senior Notes due 2031 | Senior Notes | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 407.0<span></span>
</td>
<td class="nump">$ 424.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814591024504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.21<span></span>
</td>
<td class="nump">$ 15.48<span></span>
</td>
<td class="nump">$ 15.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ehc_A2016OmnibusPerformanceIncentivePlanMember', window );">2016 Omnibus Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for grant under the Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period for unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ehc_EmploymentBasedSARSMember', window );">Employment Based SARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Shares granted during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 81,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share of awards granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 870.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid', window );">Share-based compensation arrangement by share-based payment award, equity instruments other than options, share-based liabilities paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of remaining shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AllocatedSharebasedCompensationLiability', window );">Fair value of SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Settled the acquisition shares upon payment</a></td>
<td class="nump">$ 101,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ehc_PerformanceandEmploymentBasedSARSMember', window );">Performance and Employment Based SARS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Shares granted during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold', window );">Value threshold for determining fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,400,000<span></span>
</td>
<td class="nump">$ 25,800,000<span></span>
</td>
<td class="nump">$ 29,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period for unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share of awards granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.89<span></span>
</td>
<td class="nump">$ 61.81<span></span>
</td>
<td class="nump">$ 49.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000,000<span></span>
</td>
<td class="nump">$ 44,200,000<span></span>
</td>
<td class="nump">$ 45,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards issued during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ehc_NonemployeeDirectorsMember', window );">Non-employee Directors | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share of awards granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84.83<span></span>
</td>
<td class="nump">$ 65.39<span></span>
</td>
<td class="nump">$ 64.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of remaining shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards issued during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,043<span></span>
</td>
<td class="nump">32,196<span></span>
</td>
<td class="nump">23,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ehc_NonemployeeDirectorsMember', window );">Non-employee Directors | Dividend Equivalent, RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards issued during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,577<span></span>
</td>
<td class="nump">8,987<span></span>
</td>
<td class="nump">8,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AllocatedSharebasedCompensationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocated Share-based Compensation Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AllocatedSharebasedCompensationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to settle liability for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ehc_A2016OmnibusPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ehc_A2016OmnibusPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ehc_EmploymentBasedSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ehc_EmploymentBasedSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ehc_PerformanceandEmploymentBasedSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ehc_PerformanceandEmploymentBasedSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ehc_NonemployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ehc_NonemployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ehc_DividendEquivalentRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ehc_DividendEquivalentRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814606453944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Weighted-average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility (percent)</a></td>
<td class="nump">28.40%<span></span>
</td>
<td class="nump">24.80%<span></span>
</td>
<td class="nump">25.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (percent)</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605756184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Stock Option Activity (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2020 (in shares) | shares</a></td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures (in shares) | shares</a></td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2021 (in shares) | shares</a></td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, December 31, 2021 (in shares) | shares</a></td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2020 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 50.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">80.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">69.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeitures (in dollars per share) | $ / shares</a></td>
<td class="nump">77.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2021 (in dollars per share) | $ / shares</a></td>
<td class="nump">54.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, December 31, 2021 (in USD per share) | $ / shares</a></td>
<td class="nump">$ 45.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, December 31, 2021</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, December 31, 2021</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, December 31, 2021 | $</a></td>
<td class="nump">$ 10.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, December 31, 2021 | $</a></td>
<td class="nump">$ 10.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604019064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Restricted Stock Awards (Details) - Restricted Stock - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested shares, Beginning Balance (in shares)</a></td>
<td class="nump">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested shares, Ending Balance (in shares)</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested shares, Beginning Balance (in dollar per share)</a></td>
<td class="nump">$ 61.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollar per share)</a></td>
<td class="nump">73.89<span></span>
</td>
<td class="nump">$ 61.81<span></span>
</td>
<td class="nump">$ 49.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollar per share)</a></td>
<td class="nump">57.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollar per share)</a></td>
<td class="nump">72.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested shares, Ending Balance (in dollar per share)</a></td>
<td class="nump">$ 74.46<span></span>
</td>
<td class="nump">$ 61.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814598104488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>plan </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_HealthcarePlanExpense', window );">Company healthcare plan costs, net of employee payments</a></td>
<td class="nump">$ 207.6<span></span>
</td>
<td class="nump">$ 189.2<span></span>
</td>
<td class="nump">$ 178.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfQualifiedPlans', window );">Number of qualified savings plans offered | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">$ 28.8<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount', window );">Employer contributions funded by forfeited accounts</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SeniorManagementBonusProgramTotalCosts', window );">Payments under the Senior Management Bonus Program</a></td>
<td class="nump">$ 27.8<span></span>
</td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="nump">$ 18.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=ehc_EncompassHealthRetirementInvestmentPlanMember', window );">Encompass Health Retirement Investment Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Contribution as percentage of salary allowed under the Plan (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanAgeRequirement', window );">Age requirement to participate in the Plan | yr</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution', window );">Vesting percentage in employer contributions (percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage', window );">Vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=ehc_EncompassHomeHealthSavingsPlanHHSPMember', window );">Encompass Home Health Savings Plan HHSP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Contribution as percentage of salary allowed under the Plan (percent)</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage', window );">Vesting percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod', window );">Vesting period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_HealthcarePlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs for the period associated with the Company's sponsored self-insured healthcare plans that include coverage for medical and dental benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_HealthcarePlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfQualifiedPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Qualified Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfQualifiedPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RetirementInvestmentPlanAgeRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum age required for an employee to be eligible to participate in the Company's Retirement Investment Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RetirementInvestmentPlanAgeRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total percentage of the Company's matching contributions that will vest in the Retirement Investment Plan after an employee service requirement has been met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time over which the Company's contributions to a participant's retirement account fully vests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SeniorManagementBonusProgramTotalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of payments made or expected to be made during a reporting period to participants that are entitled under the Senior Management Bonus Program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SeniorManagementBonusProgramTotalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=ehc_EncompassHealthRetirementInvestmentPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=ehc_EncompassHealthRetirementInvestmentPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=ehc_EncompassHomeHealthSavingsPlanHHSPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=ehc_EncompassHomeHealthSavingsPlanHHSPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814598055608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Provision for Income Tax Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 86.8<span></span>
</td>
<td class="nump">$ 37.7<span></span>
</td>
<td class="nump">$ 58.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and other</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current expense</a></td>
<td class="nump">111.8<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">75.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and other</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred expense</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">52.4<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense related to continuing operations</a></td>
<td class="nump">$ 139.6<span></span>
</td>
<td class="nump">$ 103.8<span></span>
</td>
<td class="nump">$ 115.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612295192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax expense at statutory rate (percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Increase (decrease) in tax rate resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and other income taxes, net of federal tax benefit (percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">(Decrease) increase in valuation allowance (percent)</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Government, class action, and related settlements (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Noncontrolling interests (percent)</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent', window );">Share-based windfall tax benefits (percent)</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net (percent)</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense (percent)</a></td>
<td class="nump">21.20%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814597856840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Asset and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 50.4<span></span>
</td>
<td class="nump">$ 57.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance', window );">Insurance reserve</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">22.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accruals</a></td>
<td class="nump">35.1<span></span>
</td>
<td class="nump">43.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">148.5<span></span>
</td>
<td class="nump">173.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(43.1)<span></span>
</td>
<td class="num">(46.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">105.4<span></span>
</td>
<td class="nump">127.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Revenue reserves</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(102.9)<span></span>
</td>
<td class="num">(99.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="num">(17.7)<span></span>
</td>
<td class="num">(21.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, net</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Carrying value of partnerships</a></td>
<td class="num">(67.0)<span></span>
</td>
<td class="num">(51.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(192.1)<span></span>
</td>
<td class="num">(178.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax liabilities</a></td>
<td class="num">$ (86.7)<span></span>
</td>
<td class="num">$ (51.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605296680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Changes to valuation allowance during the period</a></td>
<td class="num">$ (3.1)<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Remaining valuation allowance</a></td>
<td class="nump">43.1<span></span>
</td>
<td class="nump">$ 46.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 50.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814597879496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 517.6<span></span>
</td>
<td class="nump">$ 368.8<span></span>
</td>
<td class="nump">$ 446.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests included in continuing operations</a></td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="num">(87.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Income allocated to participating securities</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic', window );">Income from continuing operations attributable to Encompass Health common shareholders</a></td>
<td class="nump">410.8<span></span>
</td>
<td class="nump">283.2<span></span>
</td>
<td class="nump">358.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NetIncomeLossAvailabletoCommonStockholders', window );">Net income attributable to Encompass Health common shareholders</a></td>
<td class="nump">$ 410.4<span></span>
</td>
<td class="nump">$ 283.2<span></span>
</td>
<td class="nump">$ 357.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 3.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 517.6<span></span>
</td>
<td class="nump">$ 368.8<span></span>
</td>
<td class="nump">$ 446.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net and comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="num">(87.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted', window );">Income from continuing operations attributable to Encompass Health common shareholders</a></td>
<td class="nump">412.6<span></span>
</td>
<td class="nump">284.2<span></span>
</td>
<td class="nump">359.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Encompass Health common shareholders</a></td>
<td class="nump">$ 412.2<span></span>
</td>
<td class="nump">$ 284.2<span></span>
</td>
<td class="nump">$ 358.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">99.8<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations attributable to common shareholders diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NetIncomeLossAvailabletoCommonStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NetIncomeLossAvailabletoCommonStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814612801784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Restricted stock awards, dilutive stock options, and restricted stock units (in shares)</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">99.8<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814598013288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 24, 2018</div></th>
<th class="th"><div>Feb. 01, 2014</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of diluted weighted-average shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock repurchase authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid per common share (in dollars per share)</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814608792792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Commitments - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentFiscalYearMaturityAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthYear', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFifthYear', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Settled Litigation | Nichols Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss contingency accrual, payments</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ehc_NicholsLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ehc_NicholsLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814601177672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Textuals (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>location </div>
<div>hospital </div>
<div>state </div>
<div>segment </div>
<div>facility</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfInpatientRehabilitationHospitals', window );">Number of inpatient rehabilitation hospitals | hospital</a></td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofsolelyownedinpatientrehabilitationhospitals', window );">Number of solely owned inpatient rehabilitation hospitals | hospital</a></td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofjointlyownedinpatientrehabilitationhospitals', window );">Number of jointly owned inpatient rehabilitation hospitals | hospital</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts', window );">Number of inpatient rehabilitation units under management contracts | facility</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomehealthMember', window );">Home health</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofhomehealthlocations', window );">Number of home health locations</a></td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HospiceMember', window );">Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofhospicelocations', window );">Number of hospice locations</a></td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations', window );">Number of solely owned hospital based home health and hospice locations</a></td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations', window );">Number of jointly owned hospital based home health and hospice locations</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">97.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Jointventureownershippercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture ownership percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Jointventureownershippercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfInpatientRehabilitationHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfInpatientRehabilitationHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofhomehealthlocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of home health locations the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofhomehealthlocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of hospice locations the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofjointlyownedinpatientrehabilitationhospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofjointlyownedinpatientrehabilitationhospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofsolelyownedinpatientrehabilitationhospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofsolelyownedinpatientrehabilitationhospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomehealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomehealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814605823560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Selected Financial Information of Reportable Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 5,121.6<span></span>
</td>
<td class="nump">$ 4,644.4<span></span>
</td>
<td class="nump">$ 4,605.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">2,886.5<span></span>
</td>
<td class="nump">2,682.0<span></span>
</td>
<td class="nump">2,573.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">685.2<span></span>
</td>
<td class="nump">634.4<span></span>
</td>
<td class="nump">623.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">209.3<span></span>
</td>
<td class="nump">200.5<span></span>
</td>
<td class="nump">167.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">82.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,315.1<span></span>
</td>
<td class="nump">3,999.4<span></span>
</td>
<td class="nump">3,912.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(12.3)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(30.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="num">(87.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">4,015.0<span></span>
</td>
<td class="nump">3,566.2<span></span>
</td>
<td class="nump">3,513.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">2,127.3<span></span>
</td>
<td class="nump">1,903.8<span></span>
</td>
<td class="nump">1,813.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">594.8<span></span>
</td>
<td class="nump">534.7<span></span>
</td>
<td class="nump">521.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">171.0<span></span>
</td>
<td class="nump">147.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">61.4<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_CostofServicesExcludingDepreciationandAmortization', window );">Cost of services (excluding depreciation and amortization)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldOverhead', window );">Support and overhead costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,965.3<span></span>
</td>
<td class="nump">2,670.9<span></span>
</td>
<td class="nump">2,546.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="nump">103.2<span></span>
</td>
<td class="nump">83.3<span></span>
</td>
<td class="nump">82.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Segment Adjusted EBITDA</a></td>
<td class="nump">956.8<span></span>
</td>
<td class="nump">823.0<span></span>
</td>
<td class="nump">899.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">545.6<span></span>
</td>
<td class="nump">404.6<span></span>
</td>
<td class="nump">391.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">1,106.6<span></span>
</td>
<td class="nump">1,078.2<span></span>
</td>
<td class="nump">1,092.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_CostofServicesExcludingDepreciationandAmortization', window );">Cost of services (excluding depreciation and amortization)</a></td>
<td class="nump">489.3<span></span>
</td>
<td class="nump">511.3<span></span>
</td>
<td class="nump">506.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldOverhead', window );">Support and overhead costs</a></td>
<td class="nump">406.2<span></span>
</td>
<td class="nump">402.8<span></span>
</td>
<td class="nump">381.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">895.5<span></span>
</td>
<td class="nump">914.1<span></span>
</td>
<td class="nump">887.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Segment Adjusted EBITDA</a></td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">163.3<span></span>
</td>
<td class="nump">195.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_CostofServicesExcludingDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_CostofServicesExcludingDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OccupancyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OccupancyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldOverhead">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indirect cost incurred related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldOverhead</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814604924728">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Assets and Investments to Consolidated Amounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,864.9<span></span>
</td>
<td class="nump">$ 6,445.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,143.0<span></span>
</td>
<td class="nump">4,834.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,721.9<span></span>
</td>
<td class="nump">1,611.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of December&#160;31, 2021 and December&#160;31, 2020 include total assets of variable interest entities of $226.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2021 and December&#160;31, 2020 include total liabilities of the variable interest entities of $38.2 million and $46.8 million, respectively. See Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAssetReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814601205208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">$ (197.3)<span></span>
</td>
<td class="num">$ (155.5)<span></span>
</td>
<td class="num">$ (247.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(256.6)<span></span>
</td>
<td class="num">(243.0)<span></span>
</td>
<td class="num">(218.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="num">(87.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income tax expense</a></td>
<td class="nump">657.2<span></span>
</td>
<td class="nump">472.6<span></span>
</td>
<td class="nump">562.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Inpatient Rehabilitation Hospital and Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Total Segment Adjusted EBITDA</a></td>
<td class="nump">1,168.3<span></span>
</td>
<td class="nump">986.3<span></span>
</td>
<td class="nump">1,095.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(197.3)<span></span>
</td>
<td class="num">(155.5)<span></span>
</td>
<td class="num">(247.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(256.6)<span></span>
</td>
<td class="num">(243.0)<span></span>
</td>
<td class="num">(218.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Loss on disposal or impairment of assets</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense and amortization of debt discounts and fees</a></td>
<td class="num">(164.6)<span></span>
</td>
<td class="num">(184.2)<span></span>
</td>
<td class="num">(159.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">84.6<span></span>
</td>
<td class="nump">87.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SARsmarktomarketimpactonnoncontrollinginterests', window );">SARs mark-to-market impact on noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Change in fair market value of equity securities</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_PayrolltaxesonSARsexercise', window );">Payroll taxes on SARs exercise</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_PayrolltaxesonSARsexercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll taxes on SARs exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_PayrolltaxesonSARsexercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SARsmarktomarketimpactonnoncontrollinginterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of SARs mark-to-market adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SARsmarktomarketimpactonnoncontrollinginterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139814601106008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenues of Operating Segments by Service Line (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 5,121.6<span></span>
</td>
<td class="nump">$ 4,644.4<span></span>
</td>
<td class="nump">$ 4,605.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">4,015.0<span></span>
</td>
<td class="nump">3,566.2<span></span>
</td>
<td class="nump">3,513.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Inpatient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">3,918.1<span></span>
</td>
<td class="nump">3,496.1<span></span>
</td>
<td class="nump">3,423.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Outpatient and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">96.9<span></span>
</td>
<td class="nump">70.1<span></span>
</td>
<td class="nump">89.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">1,106.6<span></span>
</td>
<td class="nump">1,078.2<span></span>
</td>
<td class="nump">1,092.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Home health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">897.3<span></span>
</td>
<td class="nump">877.6<span></span>
</td>
<td class="nump">918.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 209.3<span></span>
</td>
<td class="nump">$ 200.6<span></span>
</td>
<td class="nump">$ 174.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_InpatientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_InpatientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_OutpatientandotherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_OutpatientandotherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_HomehealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_HomehealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>ehc-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ehc="http://www.encompasshealth.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ehc-20211231.xsd" xlink:type="simple"/>
    <context id="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66424ae9b2c44a4fb7238c492c20dd64_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if4d32bfff62740bba5b17d616f96ffc5_I20220211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb5aa4ae49684bf895fa6b9c4d819454_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i879908aa2e6542e3a0652e1ed683b4b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia426808899a640b5963caeffaa5e5bcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cab8f26574d455bb0e444a22064322e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2e8ddf5948f941808c197344226a885d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1cb543ef43ed40f1a7ee0241b7a11342_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4f37180681db48768667c6ab12ad98b4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8199a59d951645668567ba119a46ab2c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1769921a6d9648258a5bf2ec2f81c72c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id0a91751427448778fd75c271f59e770_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16dab19dcce146e486a875b0b0b69c08_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0992f803e1e34a4e90d50e779e344893_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i29d7707625cf434f9d6f3e0485591879_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i923ea8f6bd4b4243a0033479742dddb7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i548a41347a74411dad48274aece4d650_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i56730ca5523d40a8bb4c79634fbac5c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0a730b37d7846fd8c535e4701134ade_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1dbcfa3b248545d9b8cd1d01927d9fb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9fe6fdcb66c408182d54fd398242dfc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d69e5017d07424e805b4bfb62fc3b6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56b524f488ed479ab4120a3288ab25b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3747ac9e4f7a4b1eb2654738ec5cd6ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie331398123094f4cbf9f53387dd320e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74bebd850f4a4fccbaa89fd90826de06_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i397d63e231e44fc79264c4127d701240_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8493b47598e8480aae3bec09697737b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9303df094ef6478caab5920b2de3b1fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iead3c9b8c76f4379b37747a26d26954b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6acc944f2fd94ce584242187a09963ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6943570c9ef04b01be3d3edd3c2634f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9983aeb86edb4167b0261e7526ff14e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50c41afde2c14f30868fae349870ae67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6271cffe1c904ccb98ba4fe7cc5181c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11cc4a44f3ce4c27b16c3a87f7e6c602_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie210db53eb0d412eaee1d6fcca151b10_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e0201709f3946c08a6ab86ab34fd860_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iefea4843724b48b09d4df201deaf65a4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc66028fb34c417d98f6aa0925fbaf46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf5dec126efa48feb647aa010d99768a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9441f0547a243a2b7b5a2b86b40a684_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e244b99f69648959e00b33e0813e62d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if62c48a4d00044a48498232bb8743644_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i666da563adcc46e988ccb8361d06a266_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia1c288f844e548c49f2fadc07c0cb5de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f0c321a2cfe4aa5a8aede0de35b5d94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f340e8442bb423ca9425031c1a5d324_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i39ae81a511e14a958520030481b4f6ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad2d076cc6c74bf4b47595003b494784_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f10396a7e3b43ebb4e5c9e8ea06743f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id90363214f544ed4a70ebfb5ebdad889_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc79562a0921430d8e1b5424ea7afd74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18fdd0edfd604ca0adf6e6978f89a471_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i248e5b251d414ac992e37bdfa4007809_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id889fb2355f34e3fa69a032dca90b99d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife4a3b4a13f348b7bde0e4da0ad9fa60_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifcd44b56d04a47dab1d7f34a4a696e77_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iddc2201186bb441b862bf0c07fec3894_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9da587872f03428ebd0561751ad78968_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2080930973934f8c9f1b16798afc84c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f0c27770799485ab81f312f87261f13_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88ab67a915ad4fccbdb5079bce262358_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8182e20f98d04c6190ceb6053df0ed57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5bcebecfa11144f2882ac634ce41c2cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5cbe87cd92944498b87689bf56f9f42f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0763338809c342129b7f8f9c3818bd70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9408ebc5eec943238d4bd413eb2752e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8aae1d8057b04f22bf4c3a4c1a1de209_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57418ccab59c4872abdca8da71effd35_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1b2e886e1d34c40a54db89ffdbe59e8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0186908fade24055a75bc3d6e203778b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i93348aee51814bf9aecb0395b5cb93a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0839ac5ac72042bfb3800163f241925e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a3e78919a4e4173a9a3c81b5ce115c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95dc4732a37c4b6da92a2818f2a80bc6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4fed2509c225447aa65e5e144d767dab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida50b0a668534d44aec233b93224cc40_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2a9e5d1b654340c29ca65e2d0b0aa0eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idde0b5f5e38841389b722fd9e125c188_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7373562b9b1b43dfa90c43cfc477cd4d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieb62cf7c2ebf425185cc1b842a56a99b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38a535a2b9fd4b4a9dbbb62ad7109711_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia49093b7f6f74a3a8a1db6448e4cc4b3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3fd372b138034d8ebb56c465c676ff31_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i55e61058727a4dee885614cf27830c46_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f71b1e134644eb5be3d0b729fca8ce4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i857d5dcdbfab46a6bbc20427b6491403_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaad37c17c8b34f8a94304d1a0bc269e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41e6d0167938432a9aa75d163f6f83fc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic315543707c2438ca08eaee06a1f2450_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i822b083e60b54e34844537cc70601ba7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8fd833c8e5a04bf6a99b0d8ec0b64e76_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i97d24912b1574d9cac401d0d2ee4bd93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5b3c61991594fc08487d9b203777782_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4fab58433e548239f4f791ed6c5f399_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9977d16b4a094aad9e89217d4ee09815_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i51e90e0735aa405787042bd27546ee2e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fe668ae93474f95813ae6b7c49cdd11_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i361e56a65aae4bc697d20f87ea1972e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7738b6274b504051923f6b91db1fcd16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47a2078ca149443eafdafed5920c603a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f64ba8495734d8686feeecb04953b0c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6a1b498ea6d4e5b8d189d76693cabb4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb58bd763fa9433e89fc2d61f1929408_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f3e24d5cd1f4b8ebdf4c2d6dd46c2fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62805e51679a413bb8bf0b46874d0827_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc8338e0e37d4903bd2d5fd0e52481d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5d168944b24b447dae54f7498ce0ba93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife450282edb048db9144cbdd9b90680e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3ec10c8f11e4192a9e80bbde7ba3a07_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a7f4b3fa057413aa60a6ff5a64dbacd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia523cdf50d014242b78b83f266130520_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf3e19f52f2f4397b2d5ea65c15ca225_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i117d8f2dd52b4c849355026c48132be2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:RACAuditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7994f9fc04cd4840a17d1544f512fb8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d9449e02ec44d508d4927471cdcc16a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i903f3c96be49421cb34587eada9a3d73_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMedicareAdvantageandOtherDiscountPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ee22bb7c53a47e38414ec76277b14a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMedicareAdvantageandOtherDiscountPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0ad45dea4b44812b11a801895fbabbd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95424a9f833f49b7975ae1ef37013150_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37ad81d8f2624817a96c259486c2c8f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i261ac6208a0241d587f1681af3279429_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ae4da8c0139452fafe3c4ebbfca7ed9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b77ac20c17f43f0a30fd0ec6609eeb5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c6f62ec72ef49639c0efd8c8199879e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i610608fd11384b56bc5a535b1530b9c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14868c106a174d0a8a6b3d5fcda73002_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27c2b8cd85f64f408ee95281af4988eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86b3dd4016124cdc94f5fc2e5ae4ee7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52accce1aeb84d6ea4f024105e7be7e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8e30f37f543478e8e85ee391f748aa2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86cf609a63b04fb3b5b2972e6cb02c87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaaafd14af4414d4ca561988c69f582b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida89837462c2402ebd51e087abc5f902_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if710bb04b24245de9a5f881c21cd788c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50efb55c2089401caaa0a82d59fa749b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1dc3915d64cb4cd186314ea29dfaa5e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7af755a7159549e5992cc331710580a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74d0e9fd8f4d4150b657b8c8b64a3458_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d6195ee7b4d4edb890d0350b3e6cbc8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i36f353410c2e4dd5999e0aaa5dfb977a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0f41d63c292477387fc936648de5818_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf20f07dc2a8494ebaf17ecb8a1ec09a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43ff9c36be674ad1a655dbc573f502de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife3d75e297fe483392cb51c7d6a9d0af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad16be810f6b476785e37f9d09c58d8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iddab4f4ba3d6483d872cadaede2070c3_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i724c634720d6417db699f31c4afa1e59_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HeritageValleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3170e4011fc54daabed3c4a7be2b4ccc_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="if216c8078722440e8bee9e82ecb4ce83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f6567d29470494e9a12d3a1e62e4cb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd6ff10ad12e43968abb2d9fedd5e789_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i979989da0527439fb4dd5f80434b7799_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i3c84d8686d2346a48ae0771dc64c8d90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idffd6c8c86e648aea58449550ba84ab6_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89099d548c34496e95ffebc80afea24d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b4f00d1fd94454e92fb97f98bd493e9_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HeartOfTheRockiesHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="ifa6dc46af56b486895888a4fb9a90e92_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HospiceOfSouthwestMontanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i05d940caeea84febbbbf878bafbcdbae_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="i28b060236cfa44c0a9c3de61db94e9a3_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i13d51c190f6b4f5bb0c9fee6c0a3bc79_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="ia6216b070ab640879f12d1cff0c7359e_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="ie0ae29baed2346a6b2cfd2b07ef1858b_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="idcaa5db830d74c41b04e18e3d712cbb4_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i2dee177e57f140e9a6c2ed09915a1349_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="ic04050f083344efa8f61e38aff5f34c0_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i978416f27dae4c0896c015487892aa22_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="iecae4857993e469a9b571629b580ca06_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i6a3cd10f3d534263a36b46884d9b5925_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="i0d2a18b64b144278ab7fc3ca1e5665a1_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:FrontierHomeHealthAndHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8279db1c332d4e708d8b00d2ec28fcee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46b6c4b37b72430bb27cc893622797e5_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="i27a84b415d07493e8cb918d0e2ea7f5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9a8d3d5ad454cf0990137e147a296d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e771317f044433ebf4a8a2a5d5eb059_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibef0cafa72f949fabb0aba607529bb57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25e23730767f47b9a77ab3f4c276bfa8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32f460ce531347859d5a7bfeec5a762d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:BaptistOutpatientServicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i773106cd2a324d499116f825de895f7e_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i9eb895620d9c4243b46d28ee569388c2_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:OtherHomeHealthAndHospiceAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53030c89936d407897671309bbeb1f7b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2021AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i663e53be26e941ffbeb8afe0c5e46b4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2021AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ibc1955f816c34df2ba0316a625c6ba30_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="if75c35d2f7dc4b22824f5f5f2725d6cf_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ife9f063c376c4593a96e8f3e1c883a61_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ia02028d9ba724ca6b97593c19c98591a_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="if670737e9dbc4e9fabc500e7e933390e_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i26c3e316666b47b9bfa8484b5183985c_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="if702652feabd4fd78b3453c3d867f5cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaddff5e45b144d06a0e4c066b7081b51_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3eb83f5d9b54bc49973f50a399a5c57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id50245be41454844ab31b7a2899757ad_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1ac3c94284cc42dcaefa48344e6f041c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic19f96ec376141aa841d8f70ab86a81b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i37157c8e16b448a999811b4aa3779421_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ba70666ee904810aaab1057f142b141_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsOfLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9b1260076c94869baae8e55f9ee99a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2020AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ae1c4e4319c41439be0441090ee96a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2020AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b80143fe808479d88a8c886e315b0de_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="ic25b5ad20ca94b278f0bb86ed76fb546_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HeritageValleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusandHeritageValleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AlacareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i0a832df04afc419bb4147b4b673a3a50_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AlacareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i83efdee8e727419e8877258c72d7d06e_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AlacareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i33168cd12e06476282380e6f2e0e09ab_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:CareResourceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:TidewaterandCareResourceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc3bbc643a1a4af4b94038c460a77df9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AlacareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3480d46a606c42799ec28c3335bc60d5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2019AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib73cbdd803994190950116ec559457fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fdff6f27e5f4de9b71d55e1a259b5d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff4da371722344eb96f964534004f0a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d3a2f947eea4354801d07d1f2e1e80c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8aba592c2b964f6eb203562691351ad5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i602ba1aa1f984572880fe83f75fc4c63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15222b6444e842b6bdb5604f4703b8e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10b6ec76120d47a3be5eb18921f9202b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id746f8bfcc324f59bffb9b5c9b3a3d24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:AffiliateCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d0a191d08204ba6a56d0168e6d7c236_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:AffiliateCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6382b49a2de846faadc4af9c9f5ed24e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:SelfInsuredCaptiveFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id841d4ad284e4f34936f643391714d19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:SelfInsuredCaptiveFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c1ca2c1f30a41728732fec700a16e4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8516a1fe22324229af025f40b32d77f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bdb38e0060345f8a7f153c65b0ae589_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3869f5c4ac04881b2a7c48441f84658_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17fc36ea770b490097eb1b8b155949d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e53fbc95c16440ebc2899f7ff225074_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f487c6319de4b2789e80cce58d82850_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd0053d81c5643ee947bbd55082c4aa7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a35614edf5643cda801a3adbda6f446_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia70f9dcbe8e24aeea62c485281cea06f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ehc:LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36f1e5c21e09435f94b9e6e1c8a4bc7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ehc:LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39344a1ae54d4b5a8df1f9ea9760ee2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac6d18334d234593b48e1782c831116b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if750783979f34735a047752b07b25985_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3d825afa781450ba456aff29ce70e22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76b51d815c2e4db38d2976c4fb0c1889_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i45ca43a183ee4af097404ac760bab1eb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i702f98649cff4e8c868a271821368090_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2583215bdc1749f5851758facd2ed865_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6908c604f9704fdd859cda5b310c3f22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b8c9109fb524f078bf0bd4b28be8aa2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i490945f79e4b4bb6aeef60a98f16bb9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6da867bd58bd42c7829bba5db347624f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec5091f5ce8647a69ad189e4df7acdc5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice2be078a38c485caf0f9d2aff094488_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic844601724a84290b07683e4c14534a9_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if4f21e5f62784e5fad3a81733fafbc9b_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i04ac5a43d97b4d1f8b07571f7fd1b855_D20191001-20191001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-01</endDate>
        </period>
    </context>
    <context id="i7dfa4bde6170492bb1256171952a8047_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bc3f06fe25e4000958cb09124165dec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c9be624554e4aa4a376cd3b45cb1d46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f74947a4ced47148dc5c2e32cdb11ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e11b04c0c5145c3b6c956ff071c1203_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5716c39ae0e54b28a2f17fc8e1345352_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i142b52fe614942e2a17e645d7b8dd1ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:TradeNameEncompassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40cc76eee7fb4c20a4d9ece9eadca6a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:TradeNameEncompassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcc2019286614b4d9cb93eb114ddc287_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc1609b119ab410a9be9855c6f405555_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebc7abf48bdf4656b5449a56fc5811ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c7674e95c82459ba38b39ec46c8f9b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifcab17e249fe430bad4f7616edebf373_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa18ceb2e4824a189bed176eccf7312e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie64cfb56dcaf4d2dbd074d8ae766d3ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib75c417944a447ca93f748d0d3afe2f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee1bde62ffe249dfa8317c6305c6c843_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37665585786e4e83a76c3a3f771a86de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i77309f128df04419abedd5fd33738b08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i196e74d41d844ce489461736995f7d1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:JupiterFloridaHomeHealthAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96f008123b074f85973c4425cc5d7c42_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:YumaRehabilitationHospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idda4f773f6c54fe581e21ee14d227bc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i798f862fab8b4413a0c57906b428ab10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7915604b115c4cd6b70e206e17b2ce26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05884d3e63ee40d5907eaf0324564a18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i475515e7171f46acb6ddebf2c000d90c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i098be77d49ab41099bfe946d54e9bcd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6689accfbb7543808abafce304019012_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e8dcadb39154f309a2431ebb274d483_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i940f9d1a36544945a5314717176158e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42cd94791aee45c38596cfa00e2c22b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62d481ea979b4b2dac6c075291e1ef68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i708722e52f7b4e87879527c09b19006d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e435cfbee1d418aaa5b1e302438b2e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6c70ba1acd6484e874b7cbf5ce32af3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95660f8d813c4751ade79f135d5b3a25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5951de1720a942e0a0e71cfd9f206587_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:FaceAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i844223c9a9da4adfb49e461dd0b62f85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NetAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95d8e5cfdcdc4f0096543280be8e1479_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i797035a2e3fa4c98bd423b13b951a80e_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ia643be6ec0c14729abfe4a71fb7d089d_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ic3208cda4b8e43a9a5f3510db5d5ced2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia259457e23e1485b8a1e9fd5e341cef6_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i56bc6d52e31940afb1b7f3a0beb13a49_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i134cca390d7c4cd4b8104ec05d7b8066_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i54ef59182ef74e5c957f25dd73b3a573_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ie5fed9bbb5d24489bde193826b885d42_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i16cf531547424c47bc386d720dfa4305_D20200701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c917e5fed374c46a90bd9500b43d72a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a551c0475024f75acffcd0aae3a51c2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i17a5c6dc46234ee6839769c452e0a31b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i065696f54bd6452cb28eea433c352d7d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibcf2f41f6d0848b4b6dc77ea02f235d2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88e6abed3f9c4844a3856dbae44d3c29_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie61970e957d24746b800b3a4ca061b38_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i442e600335de44a4bcbc192cf1a0def6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f1b2314ba3e4d2c9434f9205fc3dd2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0738d83aff14b43981733b51cee43ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdd006cc199943069830e5f0df2c5322_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc45972689104b858888baba8d5c3b2a_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="i3bf76ad690ab486bb10282ca094adb84_D20211201-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i6b2e62c3760743f3b11242bc8c1de996_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i543ec7b3b23f4ccaac5a0b5e29eb4329_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i37408f6809d84596aad486f8a90f4e53_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ic8a20418879d4e958becfe001883e69b_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic8b11fbba37e419697f8c888119ebb62_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="icf18e7d48c9f48a98324da23bbf64a5a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf9cd76a2420419799ae4a84b2cb8f1b_I20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-09-30</instant>
        </period>
    </context>
    <context id="i9d83e601b2be40eb9289618472d20e28_I20140930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-09-30</instant>
        </period>
    </context>
    <context id="iebe8c7bfd4394f1197ca833de3df2c09_I20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-31</instant>
        </period>
    </context>
    <context id="i120953c681a546c1a1f10597d05382b8_I20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="i732f255021564a07ad138756673d00c8_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6bcc19b1cd384ad2803fa192d9fd6f72_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i735b93d85e2c4ffbbd677a2fed8689f2_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ic4c39a1fe44b40aea3426508dc786fe3_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="i05599bd9faa5433482a7fd2c5e801eff_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="icc40e1fe47f0401b929feacafbeade4a_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i03c812649e8f461984f6a55bf31af65b_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i6728ee3fbad74c3f9120c35eb6bbb03d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i27ba4302b48948e6be58d84a07f42291_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7aba6edb48cf4106a0de799690174657_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ie4d4f1c1e34b4547bb895f17359f6c52_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ia038a343f20045bc93b40477b4bb3e59_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i5cf2c1b477bb4e80918f99b0e09a865b_D20190901-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i8791e911ccc94436a4ccde3614131c9c_D20190901-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i1cdcf2b1d8654c6782039c26b7a57622_D20190901-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i1756ab5e169c478f9663bb9168588a4d_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="if45838f1a45e438091364b67a05bf7f6_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ic4a2dc69c68d4800929ad19f067a9d3f_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i43e4a72722524946885cfe42cf42efa9_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i13bbad57db694aae95b5e5b28b57c341_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i2841dc9bff054904bae487294dbff306_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ie4816d28c19945fea8ea5bedc380aed9_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i79ae10b8be3c4f858f5f9ac1d488a263_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ia3d7e73989884e299b452c135030ebcf_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="iff05368e33294deaba91e4d0daedb5b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic786d7283c4945f58da42a6add61877d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21e3debe10554bb8adc998d7c9f34060_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia058d22308374baab4f7f83f431b2a7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied1386031d4644d3a4bd6b53278b051d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e342b38454245b785b3717eda590962_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50281083594e49c69e3436fc0ceb6eb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied075c1981574658804c0fe14ced2869_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74efb2cbd6fa40438ef2310cb2d0fa56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc42cb6979d645e294db913c6cc97edd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dcc3d612e364ad7a48e4ec4f0099438_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7048280062f4c379b09fb68447c12f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieedaeba272bb466387acacba6de2f02b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife388829092541459cbc207156259fe1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa910c45e3ba432986f5de81016e67f2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic1b3ec367aa84b1b8b9ef9bdc970188a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c9d6a1911754260a1b0e06548e665cc_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i372fc03d1c144d9b84eb20ceee3d1d0e_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i37ce9b34009e450aaec6451916af0460_D20180221-20180221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2018-02-21</startDate>
            <endDate>2018-02-21</endDate>
        </period>
    </context>
    <context id="ibe4b642f98b44d9297f662ae777e6a48_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i2b95d9baa2a3472f8501b1064a01c601_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib32b4f07fc6c4852aa189147f3ac8f4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9a724185f6047b2a7b0f3655af7f015_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i2460d2c0ba7b42f591cc57a3b40a1eac_D20200218-20200218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-02-18</startDate>
            <endDate>2020-02-18</endDate>
        </period>
    </context>
    <context id="i6104f61239694a209a6dd8bf3ea4229d_I20200218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-18</instant>
        </period>
    </context>
    <context id="if2d67ea997974c2d910a1b10bd43ff0d_I20200220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="i08537da18acf4dfaa0164d93a3f484c8_I20200306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-03-06</instant>
        </period>
    </context>
    <context id="i416581dd3fdc4322b8a32aa48b236e6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ehc:HoldingsAndEHHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied40dc1098204db7afa17d466e5ee54c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id93bba85033d46889357eea3753fda21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9114052e2fb44c2197290d9e9f558961_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb4ed8fefa5143e8a3f5ad38cf8cbf30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26344215630447e2a32f1bb8fb1577c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8d9ef1925864bf6bd6ebd083ceffcf4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72afa364a34540ae9695838e9d3f5468_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c3e10e7837748aaba2310ed38697364_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic07a527a70c444b8aa8dc851c08e1454_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie630f132fb654f72bc20deb38a5299e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bb6e84f060341ee8f3a82d5fe595b1f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i15a96226e9a74277befd57b95ce89cad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f229fa2dcf94ada94372b94a004a511_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icedf57c7e28645bd80047694f8a37d7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i478de2031cff4407b9b5bd814b8fffbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc784810eec245a793b5bdaf468ad33d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic41ca53159bc4b10a192181b3bca89ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i854aba59b7df49a79105db7602e291c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a611dd035e44c8fb3fb11d3061619d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5a1360b6acd4210bf3adb7d6d88bc50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f48f48c99b345bc8876378d756bf4e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36387f8be3fa45d09cbd0c2a0ab073ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i062d90846d5246a8a5ce15d4753ed256_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i003153e059144500ba846eaaf3124397_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04aa7dec6a244bcba19b7d980b858fd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc744be7bb2e4378aa9465a42c569d4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3eda38234466449a8e337a5d2c3279da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib71d169070664d258df1acb196a80bd8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib23c7a2789b540b5b31a5bc6e512ff63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3661453bf8d4cb888df6dfd0eb6ea49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4222e0b6d18348f19725e8257c08a4ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3d0325b6fab4784876511cde99c9a37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0971f6c0ba8347fb8bbf20251a8ef965_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42e243e3007341bcaa8e6d60b76106d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c46ae7004334f3aaa8ec786ab9f4e60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ee5718dadc4409d81f3281961341d1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9d918faf5c945fb8f815f7f3e0db8d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02851d306e4041dfa6105c00051182cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id57c054ef40d45489612bbab7e3e448f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20ffead8b6274baf8242167d98ee9096_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb0dba2d7c8a4826b1f482f1349b6e95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ac9bae069004607913ad2196139ca57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id35d77e9ba484f40ba51f2683301dea5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id114ce728e2345d89f4bd7890b37ac2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d4b4be5983f48d581aeb5aad62c2ca9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i299d52f28a4c4d0f9f975d70786c40f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52cbb010926c4e229d2f2b20106351f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1fb54362ed14ca5bf853364666f1665_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ehc:A2016OmnibusPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7804d790b2414c79899e861637a8a2e5_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:EmploymentBasedSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib735bb4807dd484fbea2ba815c38a8a9_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:PerformanceandEmploymentBasedSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i3a8c982d4bb944d5b92f0c669ef3ef9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:PerformanceandEmploymentBasedSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2acf2cc0fd7d4d09af40dfa207a99bd2_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i6853550297dd40fd9673cf39d8bba361_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i94fd694f8fd3453eb2468c49bd5270ba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80269d53cbb0459c9a42ac92da3a7665_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i7c72f09fce4043719ce2db102fc528ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6650fab69c11492c9077744e36f1f4c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4a08b2b7b1b4149a37586883c795c5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6a233a73c164626b8371eab0e23471c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0980bb7516a2462090a8eb088e642d56_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d2e0bbe25b944009128cefee2d0d142_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4d10387a093410d85237a92db5c4dec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23170992103f4aea877de6980dd955ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f4491cc424043bab594adb15a4e38fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a8b7549430046a29b87cd735c3324cd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d403e9e176d4ad1a0337c0b47804c60_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idca59813d6ce47e690d0ffdf1c9e577c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if30d4b37dc324d81b38e9cf676a99627_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHealthRetirementInvestmentPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ad3ac221c7e416b8039eccf0be81c30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHealthRetirementInvestmentPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97f18be172de4a0895d8c7a7e9e5460a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHomeHealthSavingsPlanHHSPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0081857a985a4961b0157b55a3108ac9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHomeHealthSavingsPlanHHSPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9210832b6dd4034a40b13798dc82f01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcd77f4eb1a44cd19a0e1f02f5b4d30e_I20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="i5509a74ccfac4681b49ffbf1a98e00a1_I20140201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-01</instant>
        </period>
    </context>
    <context id="i32d7a3624fe641b1a56f6e162c46212e_I20180724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-24</instant>
        </period>
    </context>
    <context id="i985e0db50aa74ba18de323dce42bcfc3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic11d995353124469aeb3ecc87464738d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45e50175dc9344b19c41346526f0d782_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i914b6b0bf40d480abbbf07849b027534_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i7b7b3e61b74c4a53b71221db5581c78c_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="id6a9857d4f284bb4be2223bfda243937_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i0a8048f934624676bc2bb342d07afd90_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ehc:NicholsLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ia3193970835f48d291309e71942e3c0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3c49d5b00b54d92a4203a7b4d46fe21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i629acb7e34ff462d830466f2f0283b24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibda439a47d5b4d4b820c4a0e2bc953fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ca76abaabe14804b27dbe68101f2b21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i886bc836155e45d099f360bf9159bb7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b20d1c1a4664c29b6e46e8c2743fd6d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f9c5d61928d45b991a621d141539dfb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i776c682b8b6f439fb66cde932ed76f45_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i31a9deb44ebc4734990673dcfd5a1fa2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id3de5b67d1c443a38dfa663c544d2ffa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7deb25afaae4201a2e97e69747672e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie5571918fc1b480a932b9aaa18cb0053_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i941a80b49d3743a78f06a9e20d555c80_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1af801ecbfb49d2bc7b43640349d670_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia681297da5504ffaacf633a76dcb7a2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4752f09b329c46a7a5c722bebaadac64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i301c2e1d8eb641efb1ef724b3603ec49_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36e9398a071b4c9a98203be3ab77177f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8db2ff79c3674a52a089ddcc64324e9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18c6808319b14ca9b78c39dcbbbd0052_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="state">
        <measure>ehc:state</measure>
    </unit>
    <unit id="segment">
        <measure>ehc:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="bed">
        <measure>ehc:bed</measure>
    </unit>
    <unit id="location">
        <measure>ehc:location</measure>
    </unit>
    <unit id="entity">
        <measure>ehc:entity</measure>
    </unit>
    <unit id="subsidiary">
        <measure>ehc:subsidiary</measure>
    </unit>
    <unit id="claim">
        <measure>ehc:claim</measure>
    </unit>
    <unit id="plan">
        <measure>ehc:plan</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="hospital">
        <measure>ehc:hospital</measure>
    </unit>
    <unit id="facility">
        <measure>ehc:facility</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF80L2ZyYWc6NTk0NzJkODYzMWRhNGRhNjk4MzgzMzUyM2M0YTA1M2YvdGFibGU6MWFlYzlmNWRkY2ZjNDNkZjk1ZmFjY2JmYzU2ODFiZDUvdGFibGVyYW5nZToxYWVjOWY1ZGRjZmM0M2RmOTVmYWNjYmZjNTY4MWJkNV8zLTEtMS0xLTU1OTY4_a44f7b34-1c86-4e46-9fb4-471546e74591">0000785161</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF80L2ZyYWc6NTk0NzJkODYzMWRhNGRhNjk4MzgzMzUyM2M0YTA1M2YvdGFibGU6MWFlYzlmNWRkY2ZjNDNkZjk1ZmFjY2JmYzU2ODFiZDUvdGFibGVyYW5nZToxYWVjOWY1ZGRjZmM0M2RmOTVmYWNjYmZjNTY4MWJkNV81LTEtMS0xLTU1OTY4_13ef36be-f5ed-419c-9d80-953907668739">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF80L2ZyYWc6NTk0NzJkODYzMWRhNGRhNjk4MzgzMzUyM2M0YTA1M2YvdGFibGU6MWFlYzlmNWRkY2ZjNDNkZjk1ZmFjY2JmYzU2ODFiZDUvdGFibGVyYW5nZToxYWVjOWY1ZGRjZmM0M2RmOTVmYWNjYmZjNTY4MWJkNV82LTEtMS0xLTU1OTY4_abe0ed5a-f736-4db6-88f8-f123863a2ff3">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF80L2ZyYWc6NTk0NzJkODYzMWRhNGRhNjk4MzgzMzUyM2M0YTA1M2YvdGFibGU6MWFlYzlmNWRkY2ZjNDNkZjk1ZmFjY2JmYzU2ODFiZDUvdGFibGVyYW5nZToxYWVjOWY1ZGRjZmM0M2RmOTVmYWNjYmZjNTY4MWJkNV83LTEtMS0xLTU1OTY4_b02b8e20-10c7-4b69-8b48-b799ce075667">false</dei:AmendmentFlag>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg2_c8682fbc-22c2-4dab-b93d-46b2ba03fc76">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6N2YwMjBmMmQ5OGUxNDRkYmJmOTBlYjUwNTMyY2ZlYzgvdGFibGVyYW5nZTo3ZjAyMGYyZDk4ZTE0NGRiYmY5MGViNTA1MzJjZmVjOF8wLTAtMS0xLTU1OTY4_38c13698-33d1-463b-992d-98b9a94e1cf9">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18xNTU_da0a09d4-12a2-4a3c-8104-80ad72dd2500">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18xNTU_08f9ca9b-b92b-4f57-b90d-1860ff454e3e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6OTk1NTNmMzZmYWU1NDFmMjhhOGM0NmUyNTc0ZTk5ODUvdGFibGVyYW5nZTo5OTU1M2YzNmZhZTU0MWYyOGE4YzQ2ZTI1NzRlOTk4NV8wLTAtMS0xLTU1OTY4_5e15308f-66b1-4f78-8b54-71e23ab72c55">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDkz_5bce2352-a979-4802-9626-4e4bb20440a5">001-10315</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDc4_c5abcf9b-9d7e-44f7-93da-e5a3404349e7">Encompass Health Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6ODdhMGFhMmEzNDQyNDJiZTlkNThmZWNiMTUzODI2YTAvdGFibGVyYW5nZTo4N2EwYWEyYTM0NDI0MmJlOWQ1OGZlY2IxNTM4MjZhMF8wLTAtMS0xLTU1OTY4_11b9ad41-f289-40df-bee4-fd565bd0d11c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6ODdhMGFhMmEzNDQyNDJiZTlkNThmZWNiMTUzODI2YTAvdGFibGVyYW5nZTo4N2EwYWEyYTM0NDI0MmJlOWQ1OGZlY2IxNTM4MjZhMF8wLTEtMS0xLTU1OTY4_d1e30bd7-89a5-4253-840f-21f15780854d">63-0860407</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDc5_d9ddfcda-89c4-4cd2-9e57-7dc7189ac589">9001 Liberty Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg1_e95972b4-0921-4a22-bfdf-455af6255bc9">Birmingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg5_9cc9e3ab-d7de-4a2d-ae92-ec303e410390">AL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDgz_29a0563a-04eb-42f5-85f5-2f06a63ed45b">35242</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDk0_87549d0f-8bde-4729-8e08-37e2fa1e0e5c">205</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg3_dc2d0a91-b5da-4c66-970c-ae7bb7598c95">967-7116</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6OGU4YzFlYjgwMTFiNDFmY2I3ZGQyNDhmMzg2NGQwZmYvdGFibGVyYW5nZTo4ZThjMWViODAxMWI0MWZjYjdkZDI0OGYzODY0ZDBmZl8xLTAtMS0xLTU1OTY4_8288389a-69b9-4330-9963-c1a3fb78a34a">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6OGU4YzFlYjgwMTFiNDFmY2I3ZGQyNDhmMzg2NGQwZmYvdGFibGVyYW5nZTo4ZThjMWViODAxMWI0MWZjYjdkZDI0OGYzODY0ZDBmZl8xLTEtMS0xLTU1OTY4_79754edd-382c-4449-8294-f52bb7dd3408">EHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGFibGU6OGU4YzFlYjgwMTFiNDFmY2I3ZGQyNDhmMzg2NGQwZmYvdGFibGVyYW5nZTo4ZThjMWViODAxMWI0MWZjYjdkZDI0OGYzODY0ZDBmZl8xLTItMS0xLTU1OTY4_dd7e3f3d-517b-407e-9ba7-fc5c8d454c27">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDc3_00151f18-dc15-422d-b1d5-9cca6466a3c7">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg0_f374b0f1-10b7-449c-b3d7-eeab6bbb43d0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDgw_cb4e3276-687d-42aa-a7a4-4acfd57b4161">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDkx_af129d96-0ab5-4ad0-ab95-cd4a9a419a80">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDk1_260cfc00-d187-44f6-bf2d-7e714bc5ab1c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDkw_9ffc097f-fb7a-4e4a-bf2e-c803dc7c0898">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDgx_aab86316-a28b-4839-b88d-e7d176103251">false</dei:EntitySmallBusiness>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDgy_15ddd187-1cf4-43b9-831b-c08b1c917ae4">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18yNzQ4Nzc5MDczMjA2_61a5e3ac-ca4f-4365-b01a-8b7f42e073de">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i66424ae9b2c44a4fb7238c492c20dd64_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zMDM1_4e680231-05af-4bd4-872e-3cb35c4cf7b8"
      unitRef="usd">7600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if4d32bfff62740bba5b17d616f96ffc5_I20220211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zMTg0_5c30003e-5074-4b3f-8683-b38ca4a813ba"
      unitRef="shares">99438215</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xL2ZyYWc6MTY4OTExNzE0ZDNjNGUzMjliM2Q3Nzg4YTcxNjZkZTMvdGV4dHJlZ2lvbjoxNjg5MTE3MTRkM2M0ZTMyOWIzZDc3ODhhNzE2NmRlM18zNDg4_4be09995-5835-4dc7-8733-498d4438cc89">The definitive proxy statement relating to the registrant&#x2019;s 2022 annual meeting of stockholders is incorporated by reference in Part III to the extent described therein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzAvZnJhZzoyOGMxMDg3NzAzOWI0NWZjODI1ZGI0YWUzNmRkNjMwMS90YWJsZTpmZWMyOTdhNjMyNzA0YTNkYjg2ODIzZTcyNGU5MjQ0YS90YWJsZXJhbmdlOmZlYzI5N2E2MzI3MDRhM2RiODY4MjNlNzI0ZTkyNDRhXzAtMC0xLTEtMTA3Mzc3L3RleHRyZWdpb246N2JkN2ZmMmE0ZGYwNDc0ZTkwYzAyNjYxZDVmM2ZiY2FfMjE5OTAyMzI1NTg1OA_3001907f-0841-4025-a5e0-066b439d69db">238</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzMvZnJhZzo1NDQ5NjliYzA4Nzg0Y2E1YWYzNGI4MWE3Y2EwMDE0Yi90ZXh0cmVnaW9uOjU0NDk2OWJjMDg3ODRjYTVhZjM0YjgxYTdjYTAwMTRiXzIxOTkwMjMyNjg4NDA_33939e00-b7eb-4a2d-b99a-8fa569350393">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzMvZnJhZzo1NDQ5NjliYzA4Nzg0Y2E1YWYzNGI4MWE3Y2EwMDE0Yi90ZXh0cmVnaW9uOjU0NDk2OWJjMDg3ODRjYTVhZjM0YjgxYTdjYTAwMTRiXzIxOTkwMjMyNjg4Mzk_c8b246f4-c45f-4133-9dbb-6aebe544e8e0">Birmingham, Alabama</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMtMS0xLTEtNTU5Njg_419ade9e-ead9-469c-bb69-6ed987401d42"
      unitRef="usd">5121600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMtMy0xLTEtNTU5Njg_3450c947-141c-4cc7-ad20-b7ceb864e056"
      unitRef="usd">4644400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMtNS0xLTEtNTU5Njg_80f88782-a6e7-42e6-985d-a404280b976d"
      unitRef="usd">4605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzUtMS0xLTEtNTU5Njg_3966444e-6b72-4aab-87c4-6d534f5c1da7"
      unitRef="usd">2886500000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzUtMy0xLTEtNTU5Njg_38c28c7a-f3cb-4144-8509-86ca91c1011b"
      unitRef="usd">2682000000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzUtNS0xLTEtNTU5Njg_a7c438d0-af14-42c8-93c8-1d9f3c45c833"
      unitRef="usd">2573000000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzYtMS0xLTEtNTU5Njg_b9f63f33-b902-40d1-9a5c-8efe76b88c8e"
      unitRef="usd">685200000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzYtMy0xLTEtNTU5Njg_48a9ece5-ebe6-4fee-afee-699617a9a3d7"
      unitRef="usd">634400000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzYtNS0xLTEtNTU5Njg_5151cb32-067e-43d5-b668-9d7993d1c25e"
      unitRef="usd">623600000</us-gaap:OtherCostAndExpenseOperating>
    <ehc:OccupancyCost
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzctMS0xLTEtNTU5Njg_8387fe76-239e-46f5-a0b7-04ac9a8a3db1"
      unitRef="usd">80200000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzctMy0xLTEtNTU5Njg_787ab3e8-4b14-4c70-a842-4f78a2e58e8c"
      unitRef="usd">81200000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzctNS0xLTEtNTU5Njg_dcbe3c5f-2807-4923-8386-899c4176921e"
      unitRef="usd">82300000</ehc:OccupancyCost>
    <us-gaap:SuppliesExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzgtMS0xLTEtNTU5Njg_f7b31ace-e6cc-4644-ac7c-11e950308472"
      unitRef="usd">209300000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzgtMy0xLTEtNTU5Njg_64289c48-cba9-4598-875c-2930e69561aa"
      unitRef="usd">200500000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzgtNS0xLTEtNTU5Njg_cc6f5236-2210-4ad3-93bb-36b828d0a45f"
      unitRef="usd">167900000</us-gaap:SuppliesExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzktMS0xLTEtNTU5Njg_62f15a53-b362-40ba-97e7-acc074e95b5c"
      unitRef="usd">197300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzktMy0xLTEtNTU5Njg_d5a70a2f-8d91-43d1-800f-ed67e2ad6718"
      unitRef="usd">155500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzktNS0xLTEtNTU5Njg_91bf9ee4-195e-4f65-af1e-8a36a388d032"
      unitRef="usd">247000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEwLTEtMS0xLTU1OTY4_25f3d126-f932-4d0f-b07a-1a89b3d0d7aa"
      unitRef="usd">256600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEwLTMtMS0xLTU1OTY4_a58efdd0-9552-4931-b62f-7b41e3c5d9c5"
      unitRef="usd">243000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEwLTUtMS0xLTU1OTY4_46c2ef15-dabf-4cc9-a77c-c41d6329daaa"
      unitRef="usd">218700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LitigationSettlementExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzExLTEtMS0xLTU1OTY4_621cc1c2-ede3-4e97-9441-38afcda8d3dc"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzExLTMtMS0xLTU1OTY4_3144010f-c217-4526-b5df-a3bc2beb013e"
      unitRef="usd">2800000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzExLTUtMS0xLTU1OTY4_8f99eaaa-6aa7-49d5-823e-cb7245c8dd51"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEzLTEtMS0xLTU1OTY4_8de5dc22-4bbd-4fab-adb2-1a85970a434e"
      unitRef="usd">4315100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEzLTMtMS0xLTU1OTY4_959021f1-b662-4d58-949d-a5041723cfc6"
      unitRef="usd">3999400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzEzLTUtMS0xLTU1OTY4_9ea01237-f2c0-4d15-a250-e6dcf61519f4"
      unitRef="usd">3912500000</us-gaap:CostsAndExpenses>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE0LTEtMS0xLTU1OTY4_1298c3d1-3764-4cd5-8feb-6654926d165e"
      unitRef="usd">-1000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE0LTMtMS0xLTU1OTY4_b6f15666-303f-42e3-a25e-163ff57bb983"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE0LTUtMS0xLTU1OTY4_676d4e20-4f8a-427f-99cb-a3d680d6a499"
      unitRef="usd">-7700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE1LTEtMS0xLTU1OTY4_ea2a093f-04b2-4ba0-a2df-7590b211f8c6"
      unitRef="usd">164600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE1LTMtMS0xLTU1OTY4_19b0b165-d6a4-40c5-8887-4f1727c77d70"
      unitRef="usd">184200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE1LTUtMS0xLTU1OTY4_49e4c35e-3a84-4866-8492-9ba4c0996476"
      unitRef="usd">159700000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE2LTEtMS0xLTU1OTY4_7622c6d0-55a2-4c8f-a5c2-2804ec9aa1f2"
      unitRef="usd">12300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE2LTMtMS0xLTU1OTY4_25fe570b-0df9-4170-b241-29c341c5f6e7"
      unitRef="usd">10600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE2LTUtMS0xLTU1OTY4_5e15db86-0879-45c1-8256-9ac59817f164"
      unitRef="usd">30500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE3LTEtMS0xLTU1OTY4_4311be71-dc9f-4492-abe6-9adb1f57151b"
      unitRef="usd">4000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE3LTMtMS0xLTU1OTY4_265214fa-320f-44f8-8513-be551b78b9a3"
      unitRef="usd">3500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE3LTUtMS0xLTU1OTY4_b6df95b1-5397-48ab-ae4c-6dd935437d1c"
      unitRef="usd">6700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE4LTEtMS0xLTU1OTY4_2ff215ff-7f53-4cec-897a-c1470f19b3b2"
      unitRef="usd">657200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE4LTMtMS0xLTU1OTY4_9707b68d-57ef-463a-8835-b05774c303a6"
      unitRef="usd">472600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE4LTUtMS0xLTU1OTY4_c6090429-f692-4b52-94cf-622651113e23"
      unitRef="usd">562300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE5LTEtMS0xLTU1OTY4_9b8ac022-492e-4fe6-a7f5-8cdcce06bdb7"
      unitRef="usd">139600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE5LTMtMS0xLTU1OTY4_d44d589e-2bae-4091-90cd-d31faac856be"
      unitRef="usd">103800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzE5LTUtMS0xLTU1OTY4_ba90cf05-585e-4a3e-aa23-3e2b29e56455"
      unitRef="usd">115900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIwLTEtMS0xLTU1OTY4_13dedce1-4ac9-4fd2-8da1-b17209b2868f"
      unitRef="usd">517600000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIwLTMtMS0xLTU1OTY4_52865ff3-4070-43a2-b9cb-64fb7e9f93cf"
      unitRef="usd">368800000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIwLTUtMS0xLTU1OTY4_63377e12-bdca-42b2-8bdf-fc89fe5a650d"
      unitRef="usd">446400000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIxLTEtMS0xLTU1OTY4_544eb58f-2047-4eb1-bb92-eceae1d941b1"
      unitRef="usd">-400000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIxLTMtMS0xLTU1OTY4_f129c613-0c81-4afc-a669-4ab00071dbcf"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIxLTUtMS0xLTU1OTY4_1b38db6a-0570-434b-9714-95d0ecbe48b1"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTEtMS0xLTU1OTY4_3b0eec7d-abe6-411d-895a-33a6011be92d"
      unitRef="usd">517200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTEtMS0xLTU1OTY4_b12a3239-122c-4d63-ada1-c38ecb0d0fae"
      unitRef="usd">517200000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTMtMS0xLTU1OTY4_a1dcc4bc-3f62-4c7a-9c11-1bc3401c0521"
      unitRef="usd">368800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTMtMS0xLTU1OTY4_fe7f7217-1dfe-4671-9af0-f89edd414026"
      unitRef="usd">368800000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTUtMS0xLTU1OTY4_a41bef2e-0212-4474-94ce-537b86ff9f60"
      unitRef="usd">445800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIyLTUtMS0xLTU1OTY4_f90fa218-c5d7-497a-978c-47ef7aa9c03c"
      unitRef="usd">445800000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTEtMS0xLTU1OTY4_aff71157-5d97-4dc9-b510-4b6076b884e1"
      unitRef="usd">105000000.0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTEtMS0xLTU1OTY4_b818beeb-e71c-4263-8787-c1f2ad453ca3"
      unitRef="usd">105000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTMtMS0xLTU1OTY4_d29fab87-8e71-42b9-a06f-3d6316b62362"
      unitRef="usd">84600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTMtMS0xLTU1OTY4_fb2003a0-be6b-4664-b196-0688e0a79f99"
      unitRef="usd">84600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTUtMS0xLTU1OTY4_dacb21c5-c902-419e-aa34-f2ca030473f4"
      unitRef="usd">87100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzIzLTUtMS0xLTU1OTY4_e7fad49f-60a8-49d7-b231-c5aefea5ed1e"
      unitRef="usd">87100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTEtMS0xLTU1OTY4_c41c1653-d07d-4417-9bd7-aa102624dc58"
      unitRef="usd">412200000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTEtMS0xLTU1OTY4_ca177784-b6e8-4a72-b126-2ea634caa3f3"
      unitRef="usd">412200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTMtMS0xLTU1OTY4_398434da-716e-4136-8f91-ba96ff6f4c2b"
      unitRef="usd">284200000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTMtMS0xLTU1OTY4_f97e5a47-d36a-4ab0-9407-2200261798f1"
      unitRef="usd">284200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTUtMS0xLTU1OTY4_7e50014b-e9a7-4b99-aeae-1d80aaa06ada"
      unitRef="usd">358700000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzI0LTUtMS0xLTU1OTY4_a782ab1f-9ac1-472d-920a-316f89fc2061"
      unitRef="usd">358700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMwLTEtMS0xLTU1OTY4_8317ff40-200a-4853-804f-2fe7334131f3"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMwLTMtMS0xLTU1OTY4_52ecaf27-73b5-4b43-a5d2-719bbdd81f85"
      unitRef="shares">98600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMwLTUtMS0xLTU1OTY4_bd3b3bb5-ca74-4d32-9a39-78cda6cddef1"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMxLTEtMS0xLTU1OTY4_7dc12f60-3526-498a-9644-1721182c76bd"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMxLTMtMS0xLTU1OTY4_34660675-a4b1-4396-b99a-add568f9c2a1"
      unitRef="shares">99800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzMxLTUtMS0xLTU1OTY4_3b47ab90-f231-4dc1-b39b-9397c52ce4b9"
      unitRef="shares">99400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM0LTEtMS0xLTU1OTY4_1860c46b-3a32-4028-894c-ec27c9806cf3"
      unitRef="usdPerShare">4.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM0LTMtMS0xLTU1OTY4_de9e7505-b863-4e0f-9e84-054b993beb8d"
      unitRef="usdPerShare">2.87</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM0LTUtMS0xLTU1OTY4_d9b01077-46d2-4b4e-85d8-6a6dc64926ca"
      unitRef="usdPerShare">3.66</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM1LTEtMS0xLTU1OTY4_9e3cf7bb-2866-4a3d-b50e-860c540b05ec"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM1LTMtMS0xLTU1OTY4_69aea09a-6a85-4a71-9fb1-99578f4b4ab2"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM1LTUtMS0xLTU1OTY4_fb05621c-1752-4ad0-898a-5d1e9b9a6043"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM2LTEtMS0xLTU1OTY4_b7bd3da4-f576-44be-b9c0-997f9c8e7e57"
      unitRef="usdPerShare">4.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM2LTMtMS0xLTU1OTY4_b11e8c66-f68e-43bd-b25b-453baeb17616"
      unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM2LTUtMS0xLTU1OTY4_0d8c4525-148d-47d3-9f40-bced574b50c6"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM4LTEtMS0xLTU1OTY4_e887b4d3-7215-452c-90f6-6058f45e5b3f"
      unitRef="usdPerShare">4.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM4LTMtMS0xLTU1OTY4_4a96363f-d248-4945-a8ee-f5d1d636b764"
      unitRef="usdPerShare">2.85</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM4LTUtMS0xLTU1OTY4_d505c142-20a8-4625-96a0-789433a2dc85"
      unitRef="usdPerShare">3.62</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM5LTEtMS0xLTU1OTY4_c37c0902-75ea-4c0d-8da2-b5347e8ec412"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM5LTMtMS0xLTU1OTY4_0a7edad9-1fd6-4510-ada4-ac64a332d695"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzM5LTUtMS0xLTU1OTY4_304df0d0-756e-44c4-a6b5-526ad0558bdf"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQwLTEtMS0xLTU1OTY4_ea43490b-8fc2-4869-9c32-54f58f619730"
      unitRef="usdPerShare">4.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQwLTMtMS0xLTU1OTY4_c7acb4a1-3e53-4534-bd3b-fdfa473c5814"
      unitRef="usdPerShare">2.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQwLTUtMS0xLTU1OTY4_eacc40fa-84e1-4418-bc99-0cb575a29236"
      unitRef="usdPerShare">3.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQzLTEtMS0xLTU1OTY4_b2e15242-8a83-454e-a5bf-48132c5cdb71"
      unitRef="usd">412600000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQzLTMtMS0xLTU1OTY4_ffa25e2a-391a-4e2a-886d-968e7c2f1112"
      unitRef="usd">284200000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQzLTUtMS0xLTU1OTY4_d46d476e-531b-484e-9868-820613dc7fd7"
      unitRef="usd">359300000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ0LTEtMS0xLTU1OTY4_c93def55-71fb-46da-bd43-b7d2ce1c3fba"
      unitRef="usd">-400000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ0LTMtMS0xLTU1OTY4_0f6dabe8-03d5-4b54-8929-32c49e1cddcd"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ0LTUtMS0xLTU1OTY4_c77333d3-ec2a-4c18-bec6-3949a001ed5d"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ1LTEtMS0xLTU1OTY4_858ae546-066d-4613-8028-d4a3b8f2ea5c"
      unitRef="usd">412200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ1LTMtMS0xLTU1OTY4_081aba99-74cd-48cb-afbf-7ca269303bcc"
      unitRef="usd">284200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xMzYvZnJhZzpiNTRmNTMyNTk1OWI0YWU5ODkwMmU0MzliMzE2YTcxNi90YWJsZToyODU1MThhNTNhMTA0OTIwYWJhOTUwZjQwMDI4YTc2NC90YWJsZXJhbmdlOjI4NTUxOGE1M2ExMDQ5MjBhYmE5NTBmNDAwMjhhNzY0XzQ1LTUtMS0xLTU1OTY4_7ca7b2d8-767e-49fa-ba2d-ec758c2ea57e"
      unitRef="usd">358700000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzUtMS0xLTEtNTU5Njg_3e89e212-54e7-4c83-b80b-6f461fb81569"
      unitRef="usd">54800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzUtMy0xLTEtNTU5Njg_06cde790-d759-4b97-b2fa-20bc2c222cc6"
      unitRef="usd">224000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzYtMS0xLTEtNTU5Njg_17a065a8-19a3-4aec-9c33-c82412ec7b7c"
      unitRef="usd">65100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzYtMy0xLTEtNTU5Njg_918d45af-e117-4e28-b9c3-cb850bb34293"
      unitRef="usd">65400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzctMS0xLTEtNTU5Njg_5584c9b0-0eb7-454a-bc53-3b54feddc064"
      unitRef="usd">680300000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzctMy0xLTEtNTU5Njg_87b94f93-fd9a-461d-af44-5e3af7ce2d30"
      unitRef="usd">572800000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzgtMS0xLTEtNTU5Njg_1ec620e3-2954-46d4-8c4d-795117a4a113"
      unitRef="usd">121200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzgtMy0xLTEtNTU5Njg_675f3498-93f9-4b43-9faa-33ea8de8a18b"
      unitRef="usd">86400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzktMS0xLTEtNTU5Njg_7b4cb41c-3a53-4eb7-b44b-ceb1f3884f00"
      unitRef="usd">921400000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzktMy0xLTEtNTU5Njg_a7c607e1-b97e-4316-a0c4-e6fc12725500"
      unitRef="usd">948600000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEwLTEtMS0xLTU1OTY4_49f06ad9-7cf8-4ec6-b15f-b75657d685fb"
      unitRef="usd">2601600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEwLTMtMS0xLTU1OTY4_4a931e1f-7472-4d90-a001-db10181411f5"
      unitRef="usd">2206600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzExLTEtMS0xLTU1OTY4_3da2f313-9244-4eea-8b0c-c74225eb33c7"
      unitRef="usd">242000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzExLTMtMS0xLTU1OTY4_9f4922ae-f5f8-46c8-9d4e-0974b9af1d5e"
      unitRef="usd">245700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEyLTEtMS0xLTU1OTY4_b581017b-134a-49f3-b78b-1a660a7e19ba"
      unitRef="usd">2427900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEyLTMtMS0xLTU1OTY4_2ed6949e-2a17-4e51-a435-2a69256ce627"
      unitRef="usd">2318700000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEzLTEtMS0xLTU1OTY4_0f6f4315-6341-46c1-bbad-868286e9b0f9"
      unitRef="usd">417500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzEzLTMtMS0xLTU1OTY4_f0e68450-2415-4a25-8d1b-c4e495fbdf35"
      unitRef="usd">431300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE1LTEtMS0xLTU1OTY4_73bd4c88-22b4-4070-90be-a2b5ce940759"
      unitRef="usd">254500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE1LTMtMS0xLTU1OTY4_02a2d833-b7a4-46c8-8b1f-a42bf0688370"
      unitRef="usd">295000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTEtMS0xLTU1OTY4_0b58a3fa-b14c-46c1-b573-7fcf0c82ac10"
      unitRef="usd">6864900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTMtMS0xLTU1OTY4_b1625715-3198-4ba4-b240-797414be8947"
      unitRef="usd">6445900000</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE5LTEtMS0xLTU1OTY4_c63ab688-f416-42f5-a6f7-9e446ca405d5"
      unitRef="usd">42800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE5LTMtMS0xLTU1OTY4_f2521048-58c5-4352-875d-cd33e95c1e11"
      unitRef="usd">38300000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIwLTEtMS0xLTU1OTY4_f4343f8b-23dc-4367-a7c3-5cc4aa65da37"
      unitRef="usd">38400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIwLTMtMS0xLTU1OTY4_a882dc29-9060-41d5-bab9-24cda8d2f88c"
      unitRef="usd">44800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIxLTEtMS0xLTU1OTY4_adc8f4d8-6e3e-44fe-a735-2da6fdb44284"
      unitRef="usd">137600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIxLTMtMS0xLTU1OTY4_f88b42af-c4e9-4000-9421-74d460b2b4c4"
      unitRef="usd">115000000.0</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIyLTEtMS0xLTU1OTY4_94d6962f-0372-480a-aa4c-30ed69f99990"
      unitRef="usd">265800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIyLTMtMS0xLTU1OTY4_e09f3991-6aba-4343-9cc6-8c507be9397a"
      unitRef="usd">253800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIzLTEtMS0xLTU1OTY4_05599d81-2b45-492e-b7fd-ef3d4ec80ce6"
      unitRef="usd">44500000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzIzLTMtMS0xLTU1OTY4_c15f1288-5b72-42e8-aae3-66e01a0c33bd"
      unitRef="usd">47100000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI0LTEtMS0xLTU1OTY4_b4adc9aa-9c0f-4fbe-9aee-e1e6cdc7a95a"
      unitRef="usd">219700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI0LTMtMS0xLTU1OTY4_a5b06bb7-7380-4473-99fa-0e0835f1fddb"
      unitRef="usd">218300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI1LTEtMS0xLTU1OTY4_9c54c62f-6d58-4976-bcdd-49f6604acfab"
      unitRef="usd">748800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI1LTMtMS0xLTU1OTY4_04d6ea94-73f3-4272-b903-ba70e8b43298"
      unitRef="usd">717300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI2LTEtMS0xLTU1OTY4_0662c9cf-63fe-4300-af90-5fa07ac86115"
      unitRef="usd">3243900000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI2LTMtMS0xLTU1OTY4_763857ac-6146-4e89-83b5-dc75e008e731"
      unitRef="usd">3250600000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI3LTEtMS0xLTU1OTY4_485abce6-8ae0-4c6a-83da-5418351069ae"
      unitRef="usd">213100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI3LTMtMS0xLTU1OTY4_61eace2e-8d2f-45b3-ab05-2bcceb288617"
      unitRef="usd">209600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SelfInsuranceReserveNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI4LTEtMS0xLTU1OTY4_28bded1e-c54d-4717-b295-8c96decbb72f"
      unitRef="usd">123800000</us-gaap:SelfInsuranceReserveNoncurrent>
    <us-gaap:SelfInsuranceReserveNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI4LTMtMS0xLTU1OTY4_895083a1-a1af-41e7-8064-835765d9f250"
      unitRef="usd">121200000</us-gaap:SelfInsuranceReserveNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI5LTEtMS0xLTU1OTY4_8b9e53ae-3f5f-46e7-a7d4-060b98873a11"
      unitRef="usd">86700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzI5LTMtMS0xLTU1OTY4_fce23e45-1170-4931-aa9d-55dec2f24259"
      unitRef="usd">51800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMwLTEtMS0xLTU1OTY4_42923137-a57f-4250-b72c-836b4ce6984f"
      unitRef="usd">49400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMwLTMtMS0xLTU1OTY4_a5ad151f-c7ed-43a5-9e13-6e5f2fe42fbd"
      unitRef="usd">93800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMxLTEtMS0xLTU1OTY4_b6a08e6b-4935-4970-a25d-fb641feb987e"
      unitRef="usd">4465700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMxLTMtMS0xLTU1OTY4_87d75ab8-e724-4941-9db4-95c3083932cc"
      unitRef="usd">4444300000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMyLTEtMS0xLTU1OTY4_cbcedbb6-2435-4448-8f4f-b29edde51bbe"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzMyLTMtMS0xLTU1OTY4_5baf9938-6a32-436e-9625-9c24c9e97aa1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM0LTEtMS0xLTU1OTY4_c5c7e07f-58aa-4ae0-83ca-6bbaebaae6c8"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM0LTMtMS0xLTU1OTY4_e629f958-5bcd-4fa8-9c1f-81a90b8aa2a9"
      unitRef="usd">31600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfMTg_2996a2ec-86b4-4e1a-aea4-adacc3f8fd2d"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfMTg_4543709e-83bb-49cb-b246-3e6ad648a3d6"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfMzI_80c33129-368e-4586-b119-b0b06728d104"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfMzI_b496f91a-de52-45dd-b554-16ddc1f377b6"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfNjI_0ef28af1-8e8f-49d8-ad99-424a8ce7d7e7"
      unitRef="shares">114211057</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZGNhNTdiZmNjYWU0NGE3ZDliMzc3NzBhZDRhYzQwMWNfNzI_5548804b-c2b5-4e16-9462-0a103598f2f8"
      unitRef="shares">113835708</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTEtMS0xLTU1OTY4_22a3d93c-69d5-4750-a532-302a480b6613"
      unitRef="usd">1100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM3LTMtMS0xLTU1OTY4_4302f2b6-81ac-46aa-8c31-66786adea8f8"
      unitRef="usd">1100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM4LTEtMS0xLTU1OTY4_a28815f8-4f83-4079-8e18-7b2cf8513e2c"
      unitRef="usd">2289600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM4LTMtMS0xLTU1OTY4_288fa00e-31f5-4f5f-99f1-e4c1c753e70c"
      unitRef="usd">2326600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM5LTEtMS0xLTU1OTY4_39c473d7-c5a7-4469-a3a1-4ca91038195b"
      unitRef="usd">141800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzM5LTMtMS0xLTU1OTY4_0f41ff48-e1bd-4504-a2d2-f66a356e67cb"
      unitRef="usd">-242300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQxLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MDgyMTA0NTdlOTk1NDBmYmI0Mzc3ZWEyZTQ4YzRiYmJfMjk_ac70d974-12cf-4345-8835-b2f13321f3e5"
      unitRef="shares">14719662</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQxLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MDgyMTA0NTdlOTk1NDBmYmI0Mzc3ZWEyZTQ4YzRiYmJfNDk_717490e4-b9bd-4f70-8c76-054143386b3a"
      unitRef="shares">14428235</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQxLTEtMS0xLTU1OTY4_84ccb156-e449-4172-8ef7-ad14d2997d97"
      unitRef="usd">521200000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQxLTMtMS0xLTU1OTY4_8d849a2d-10a6-428a-93af-b3f93176cec3"
      unitRef="usd">497400000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQyLTEtMS0xLTU1OTY4_e75706da-027c-427f-b5c5-c785cc7ff3b5"
      unitRef="usd">1911300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQyLTMtMS0xLTU1OTY4_4dfcc6fa-f959-4d70-8c97-c600afa18aac"
      unitRef="usd">1588000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQzLTEtMS0xLTU1OTY4_a2422171-bc45-443d-bc63-6a8144249baa"
      unitRef="usd">445700000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQzLTMtMS0xLTU1OTY4_0e5be666-53dc-4f5b-9662-5ef078583f12"
      unitRef="usd">382000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ0LTEtMS0xLTU1OTY4_f0daeba0-c35f-473b-b971-675deb5bbadd"
      unitRef="usd">2357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ0LTMtMS0xLTU1OTY4_13f891a8-f7b5-445b-ae80-4c72224852fc"
      unitRef="usd">1970000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTEtMS0xLTU1OTY4_8c08c71d-5cc5-4114-a2b5-a12015439158"
      unitRef="usd">6864900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTMtMS0xLTU1OTY4_37065a94-0044-4a86-8cd6-196ede9333a6"
      unitRef="usd">6445900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzEwMw_4c5be3aa-4fa0-41d3-ae2e-6499aa232e6f"
      unitRef="usd">226200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzExMA_050ab071-70a5-462c-84b7-0902439983ef"
      unitRef="usd">221200000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzMwOA_1961f6dd-1e96-4d87-8cc8-179b0c51bc51"
      unitRef="usd">38200000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzMxNQ_2382abe7-bb32-4720-924b-198a822ab5cd"
      unitRef="usd">46800000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0cab8f26574d455bb0e444a22064322e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMS0xLTEtNTU5Njg_01ba288d-9270-4da4-be27-0ab1b7adb069"
      unitRef="shares">98900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cab8f26574d455bb0e444a22064322e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMy0xLTEtNTU5Njg_726c4b45-3cba-4a49-8cb5-f85560a3e446"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e8ddf5948f941808c197344226a885d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtNS0xLTEtNTU5Njg_c7e6d55e-0627-4211-ab6d-f02f0a57d610"
      unitRef="usd">2588700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cb543ef43ed40f1a7ee0241b7a11342_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtNy0xLTEtNTU5Njg_5857bfd5-b7b9-4fac-b834-7707e35e12c4"
      unitRef="usd">-885200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f37180681db48768667c6ab12ad98b4_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMTEtMS0xLTU1OTY4_7cc37630-5be8-4be2-a1d4-b61054559f32"
      unitRef="usd">-427900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8199a59d951645668567ba119a46ab2c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMTMtMS0xLTU1OTY4_7947d473-9e23-4ffd-a910-67dd5e5da4c2"
      unitRef="usd">280300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMtMTUtMS0xLTU1OTY4_33c74ada-27fb-40d8-97e4-0297a10d1e89"
      unitRef="usd">1557000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="id0a91751427448778fd75c271f59e770_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQtNy0xLTEtNTU5Njg_3861ce1b-d622-4469-8569-cee26a59fcfb"
      unitRef="usd">358700000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQtMTMtMS0xLTU1OTY4_42c7137e-42be-44cd-bad6-156280a8b44a"
      unitRef="usd">74500000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQtMTUtMS0xLTU1OTY4_b8fd7750-071b-41f3-b51e-b5a7bdc85d24"
      unitRef="usd">433200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzYtMS0xLTEtNTU5Njg_d0224222-e3c0-471b-a3ac-a8b909a93dc4"
      unitRef="shares">300000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i16dab19dcce146e486a875b0b0b69c08_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzYtMTEtMS0xLTU1OTY4_d9ed9bf8-e7b3-4ca2-84f4-16ccef8670f3"
      unitRef="usd">16600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzYtMTUtMS0xLTU1OTY4_a8a8b6e1-acdf-440b-b6c2-54987ac7c004"
      unitRef="usd">16600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzctMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo0M2RhODBmMDMxNzI0MTliYWMyZmFjNzE2ODAxZTY3NF8yNA_731cd512-457e-4da4-ab17-09c224d603ee"
      unitRef="usdPerShare">1.10</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzctNS0xLTEtNTU5Njg_c66bd87a-3680-4e0d-8fec-429507e02512"
      unitRef="usd">109300000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzctMTUtMS0xLTU1OTY4_f9ed367a-43ae-47d2-a511-10631e81675b"
      unitRef="usd">109300000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzktNS0xLTEtNTU5Njg_b33a06e0-d909-4317-a656-3bff772be457"
      unitRef="usd">32400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzktMTUtMS0xLTU1OTY4_3bdfc7c5-483c-4309-9fc0-23e8be72b51e"
      unitRef="usd">32400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEwLTEtMS0xLTU1OTY4_9aaaa6c9-373e-4cc3-b564-08c1e7ab5bf7"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEwLTUtMS0xLTU1OTY4_ed69dc94-3bfc-4ed7-ad28-64ca1c64d991"
      unitRef="usd">1400000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEwLTE1LTEtMS01NTk2OA_db21d7b8-5232-46f0-83e5-9fa06db6e14c"
      unitRef="usd">1400000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEyLTEzLTEtMS01NTk2OA_db667e35-c802-4b40-ac01-4a15a6b03880"
      unitRef="usd">70200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEyLTE1LTEtMS01NTk2OA_3b04c697-c814-4d5f-805d-8f43bac613e5"
      unitRef="usd">70200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEzLTEtMS0xLTU1OTY4_d09710aa-30a6-4bf4-933e-1cb9dcc80dd3"
      unitRef="shares">800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i16dab19dcce146e486a875b0b0b69c08_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEzLTExLTEtMS01NTk2OA_a3c7d25c-0fea-4c7c-bdf4-30a9e56e30e7"
      unitRef="usd">45900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzEzLTE1LTEtMS01NTk2OA_951e839f-e2ca-4b1b-b413-fa8d080658a4"
      unitRef="usd">45900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE2LTEzLTEtMS01NTk2OA_76320942-efe9-4435-896f-7a17279c2ad6"
      unitRef="usd">20000000.0</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE2LTE1LTEtMS01NTk2OA_cbff294c-4038-4976-a3e6-03b568c6265c"
      unitRef="usd">20000000.0</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE3LTUtMS0xLTU1OTY4_fbd27982-d3a8-48d3-ab8e-97702320d099"
      unitRef="usd">-147600000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE3LTE1LTEtMS01NTk2OA_64e18621-d58b-47d9-9506-56634df40713"
      unitRef="usd">-147600000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE5LTEzLTEtMS02NjA3OQ_8a9bf5f7-860a-492d-ae05-8cef98386e19"
      unitRef="usd">25000000.0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzE5LTE1LTEtMS02Njc4MA_3ba1ec09-acec-404a-b19a-52e526ced71e"
      unitRef="usd">25000000.0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i246e2a07189f48c39c2b0bd6e6011e5d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTEtMS0xLTU1OTY4_d64274f1-8686-42ac-aa73-bcfcc9c22f1c"
      unitRef="shares">700000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i93ee097883324efdbe5a444251baaa8a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTUtMS0xLTU1OTY4_449834b9-b1d3-4206-9a46-a7e47f1b5c80"
      unitRef="usd">-4300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="id0a91751427448778fd75c271f59e770_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTctMS0xLTU1OTY4_3a92a517-48a6-4600-806f-d29d467e12cf"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i16dab19dcce146e486a875b0b0b69c08_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTExLTEtMS01NTk2OA_a4ca15fd-7f53-46d2-9791-6b87a19226aa"
      unitRef="usd">1900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i45f2e8c4b9e84c6992632f0755ffe5d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTEzLTEtMS01NTk2OA_42622715-baa4-496c-ba00-74b3e0db8d9e"
      unitRef="usd">-11300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIwLTE1LTEtMS01NTk2OA_c10328f8-1c88-4ebd-a987-a03da56b5965"
      unitRef="usd">-13700000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0992f803e1e34a4e90d50e779e344893_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTEtMS0xLTU1OTY4_64929a52-220a-4fa2-bb65-3b6f1a62cfe6"
      unitRef="shares">98600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0992f803e1e34a4e90d50e779e344893_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTMtMS0xLTU1OTY4_676d0a34-04b7-4f15-8675-ab41ec4f676a"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29d7707625cf434f9d6f3e0485591879_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTUtMS0xLTU1OTY4_3b15bcd0-56e4-4f9a-b4af-2f900804e4ee"
      unitRef="usd">2369900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i923ea8f6bd4b4243a0033479742dddb7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTctMS0xLTU1OTY4_27104033-6201-4267-8979-2287281a9cff"
      unitRef="usd">-526500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i548a41347a74411dad48274aece4d650_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTExLTEtMS01NTk2OA_7bdd05da-aed9-4155-8663-707a67d653d1"
      unitRef="usd">-492300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56730ca5523d40a8bb4c79634fbac5c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTEzLTEtMS01NTk2OA_eaf59f46-efda-4011-9f73-80b246f7e320"
      unitRef="usd">340900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIxLTE1LTEtMS01NTk2OA_284ae030-31a4-4723-9f10-60a267c22f7a"
      unitRef="usd">1693100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ic0a730b37d7846fd8c535e4701134ade_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIyLTctMS0xLTU1OTY4_1ce96197-db8c-4b90-bf39-d42cff92c2a8"
      unitRef="usd">284200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIyLTEzLTEtMS01NTk2OA_70070454-ce10-478f-a6ad-e5ba108075f5"
      unitRef="usd">77200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzIyLTE1LTEtMS01NTk2OA_1f59cabd-9f0e-4cdc-a50b-cae9504c06f3"
      unitRef="usd">361400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI0LTEtMS0xLTU1OTY4_9b2d6ec3-6e87-4cee-a756-6670d181d3f7"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI0LTExLTEtMS01NTk2OA_5a81a537-4522-4041-bdde-01083a912d71"
      unitRef="usd">15700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI0LTE1LTEtMS01NTk2OA_0c96d55e-d97f-4fc9-886a-3e19d0df8291"
      unitRef="usd">15700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI1LTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZWRmN2U3ZGRlZWI4NDA5MmIxMGVkNjkxMmRmNjcwN2JfMjQ_0232cc06-526b-463d-b0ba-e4c84f672e80"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI1LTUtMS0xLTU1OTY4_7c23dd2d-88fd-4798-a3ac-c5bfe385f473"
      unitRef="usd">111600000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI1LTE1LTEtMS01NTk2OA_3d84469a-4929-47cb-b58d-063cf8cf1464"
      unitRef="usd">111600000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI2LTEtMS0xLTY1OTAx_4ab37de4-c9b5-4d26-8626-d0d090018139"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI2LTUtMS0xLTY1OTAx_35cbef03-11a4-434f-a8be-b7052852f708"
      unitRef="usd">27100000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI2LTExLTEtMS02NTkwMQ_b4e04dfb-d8fd-46b6-a71b-2f9e7465300a"
      unitRef="usd">19200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI2LTE1LTEtMS02NTkwMQ_543e1b20-3b13-4046-b165-65851b48404f"
      unitRef="usd">46300000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI3LTUtMS0xLTU1OTY4_26851dbd-e33e-4a5d-a46a-da07bff22e58"
      unitRef="usd">29500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI3LTE1LTEtMS01NTk2OA_1c6e2859-65b8-4e0b-ab87-5cca29ab78d6"
      unitRef="usd">29500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI4LTEtMS0xLTU1OTY4_1847e8ce-fbce-42e4-a53e-612c0f3be1d6"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI4LTUtMS0xLTU1OTY4_76ee5393-b8b1-4b07-b2d2-cb62239f98f6"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzI4LTE1LTEtMS01NTk2OA_85442201-7acb-4f36-abef-b4d63b45618e"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMwLTEzLTEtMS01NTk2OA_06bf641b-cd0d-4afb-8e4e-3a571ab247ce"
      unitRef="usd">72100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMwLTE1LTEtMS01NTk2OA_5d672dbb-5726-4e9a-8fad-0957a3230667"
      unitRef="usd">72100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMxLTEtMS0xLTU1OTY4_4af85771-ad42-45c5-8073-5c03ac059215"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMxLTExLTEtMS01NTk2OA_35dc231d-36f8-4253-93c3-83f9f708dbdc"
      unitRef="usd">6100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMxLTE1LTEtMS01NTk2OA_ff6292e8-bf01-4817-85f8-e8fe6cbedd60"
      unitRef="usd">6100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMyLTEzLTEtMS01NTk2OA_0ab163a0-4aa6-43ce-a095-ae35b374308e"
      unitRef="usd">42800000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMyLTE1LTEtMS01NTk2OA_5732f459-1f82-4b56-998e-57e88328368f"
      unitRef="usd">42800000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMzLTUtMS0xLTU1OTY4_ab12dbef-d948-457f-893e-b9381c3f7903"
      unitRef="usd">1400000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzMzLTE1LTEtMS01NTk2OA_dd8e3540-402e-440e-bef3-7eca78d9a526"
      unitRef="usd">1400000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i1b6a8333cde24ead88f1c9027d4cbb3f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTEtMS0xLTU1OTY4_92801907-979b-4892-9ab0-31197bb06c53"
      unitRef="shares">400000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i00fd8e2166b44f648e05329e18822aad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTUtMS0xLTU1OTY4_db8a922b-c0d7-4e50-8cde-5ad3ea5d45ff"
      unitRef="usd">-9200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ic0a730b37d7846fd8c535e4701134ade_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTctMS0xLTU1OTY4_e618d65b-f7d9-47ad-836f-a30dde70c99f"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0751e61d8a3f4b6d9cbf348aeb4811a7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTExLTEtMS01NTk2OA_77996fdd-97d1-41a3-bb2d-b43d044dd7db"
      unitRef="usd">2500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i8534fbf3c34748288042d2966e639b6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTEzLTEtMS01NTk2OA_ad2ad479-c5b1-4722-9b20-20943c2b1728"
      unitRef="usd">6800000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM2LTE1LTEtMS01NTk2OA_051f0ed9-cdda-47ce-b797-8082185bfada"
      unitRef="usd">100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1dbcfa3b248545d9b8cd1d01927d9fb5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTEtMS0xLTU1OTY4_b1c14982-53a4-46ed-83a0-a1ea082977ec"
      unitRef="shares">99400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1dbcfa3b248545d9b8cd1d01927d9fb5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTMtMS0xLTU1OTY4_243d1d4a-f6d9-4930-bdff-0c36f3a17822"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9fe6fdcb66c408182d54fd398242dfc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTUtMS0xLTU1OTY4_89966cf9-6b0b-45ad-87cd-a4ecc4ce2c41"
      unitRef="usd">2326600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d69e5017d07424e805b4bfb62fc3b6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTctMS0xLTU1OTY4_cedd1d30-6219-4a1e-b10f-72d21a0aab62"
      unitRef="usd">-242300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56b524f488ed479ab4120a3288ab25b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTExLTEtMS01NTk2OA_9f92cf31-6331-4912-958b-b7a5abe60efb"
      unitRef="usd">-497400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3747ac9e4f7a4b1eb2654738ec5cd6ba_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTEzLTEtMS01NTk2OA_598a7325-5f58-468e-8a87-3344f713f5a8"
      unitRef="usd">382000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM3LTE1LTEtMS01NTk2OA_ae3e2422-47d2-4c86-8b53-eb7cfe951041"
      unitRef="usd">1970000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ie331398123094f4cbf9f53387dd320e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM4LTctMS0xLTU1OTY4_f832aaaa-20b6-4b65-878d-903d17493acc"
      unitRef="usd">412200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM4LTEzLTEtMS01NTk2OA_3543a1fb-02e6-45af-8978-bc18ff4259ff"
      unitRef="usd">96000000.0</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzM4LTE1LTEtMS01NTk2OA_1175c984-bc75-4bd4-8a7d-735e6ab23305"
      unitRef="usd">508200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i74bebd850f4a4fccbaa89fd90826de06_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQwLTEtMS0xLTU1OTY4_3a480756-1bc1-4152-a230-a37db2130348"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i397d63e231e44fc79264c4127d701240_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQwLTExLTEtMS01NTk2OA_4d1d7362-3e7e-4e6b-91d9-faeb023d2c92"
      unitRef="usd">16400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQwLTE1LTEtMS01NTk2OA_a69f5049-56e0-4d4a-bd1e-7507cb7dca6e"
      unitRef="usd">16400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQxLTAtMS0xLTU1OTY4L3RleHRyZWdpb246N2IyYWJhMjhhMmE3NGM0Mzg0ODM5MjEwZTYyMGNhZjNfMjQ_22d7c027-a6aa-425b-afb8-8ac40a9b9093"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8493b47598e8480aae3bec09697737b3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQxLTUtMS0xLTU1OTY4_b6db95b0-fa64-460f-b130-60e7eacfe585"
      unitRef="usd">83800000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie331398123094f4cbf9f53387dd320e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQxLTctMS0xLTU1OTY4_dab376e4-f240-48d0-a18e-a4a0e165cd31"
      unitRef="usd">28100000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQxLTE1LTEtMS01NTk2OA_51b457a0-2893-40c8-90af-94577a0bf265"
      unitRef="usd">111900000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8493b47598e8480aae3bec09697737b3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQzLTUtMS0xLTU1OTY4_0c003000-c5f9-454d-82f7-61e2b9cac83e"
      unitRef="usd">32800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQzLTE1LTEtMS01NTk2OA_698e7af9-2833-45d3-b18d-132f9f18fe7a"
      unitRef="usd">32800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQ2LTEzLTEtMS01NTk2OA_d214d2e1-ef50-4588-84c6-682ed2a44ed5"
      unitRef="usd">87800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQ2LTE1LTEtMS01NTk2OA_eecd0e56-9d09-42fa-89a9-d92246b435ba"
      unitRef="usd">87800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQ4LTEzLTEtMS01NTk2OA_e21423f5-f900-4ee8-ac98-f7fb2dd3c59d"
      unitRef="usd">72500000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzQ4LTE1LTEtMS01NTk2OA_e74944cf-b68c-4751-b131-1492ae21cf9b"
      unitRef="usd">72500000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i74bebd850f4a4fccbaa89fd90826de06_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTEtMS0xLTU1OTY4_94a839e0-48a9-4d59-a524-29d760a79b85"
      unitRef="shares">300000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i8493b47598e8480aae3bec09697737b3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTUtMS0xLTU1OTY4_fb6ea00a-05a2-4f60-808a-c4d71936d5c1"
      unitRef="usd">-14000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ie331398123094f4cbf9f53387dd320e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTctMS0xLTU1OTY4_9c132335-0851-471c-b3cf-a942e872e74f"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i397d63e231e44fc79264c4127d701240_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTExLTEtMS01NTk2OA_91892668-fd92-450c-86d2-a46b1d8e257c"
      unitRef="usd">7400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4f6104af023c420b8bcc5ae2905be661_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTEzLTEtMS01NTk2OA_affff205-08e0-406f-b5b7-901ff182b684"
      unitRef="usd">17000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUyLTE1LTEtMS01NTk2OA_926fe16d-67e3-42f8-9aea-ecca98347283"
      unitRef="usd">10400000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9303df094ef6478caab5920b2de3b1fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTEtMS0xLTU1OTY4_7e32722a-c610-41af-a152-e323f7f41ff9"
      unitRef="shares">99500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9303df094ef6478caab5920b2de3b1fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTMtMS0xLTU1OTY4_67d57eef-660f-4468-bce2-14a814aece5a"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iead3c9b8c76f4379b37747a26d26954b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTUtMS0xLTU1OTY4_f56dcd3d-e1b9-4cb6-84ec-5f953cfe904c"
      unitRef="usd">2289600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6acc944f2fd94ce584242187a09963ae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTctMS0xLTU1OTY4_637c1641-fd15-4a07-b573-6b796448e979"
      unitRef="usd">141800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6943570c9ef04b01be3d3edd3c2634f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTExLTEtMS01NTk2OA_b4d892b7-1603-4616-b782-d0df0f0ce0bb"
      unitRef="usd">-521200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9983aeb86edb4167b0261e7526ff14e4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTEzLTEtMS01NTk2OA_0fa012f3-f0d9-4596-acb0-b62f0dbd40f4"
      unitRef="usd">445700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDUvZnJhZzo1ZGNmMzQ5MzE5MjQ0ZTU4OWUwN2M2YTAwNzlhMWNmMC90YWJsZTo5MmU5MGQ3YzIxNmE0ODZiYmM2ZThmMjRiM2Q1ZTFiZS90YWJsZXJhbmdlOjkyZTkwZDdjMjE2YTQ4NmJiYzZlOGYyNGIzZDVlMWJlXzUzLTE1LTEtMS01NTk2OA_73d81795-0f61-4ddb-8351-ee994e34fe6b"
      unitRef="usd">2357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQtMS0xLTEtNTU5Njg_eee60d7d-d16d-43e1-a003-8d7321f810ca"
      unitRef="usd">517200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQtMy0xLTEtNTU5Njg_13d8b70a-2b24-4ec2-82af-147e80a9b6f8"
      unitRef="usd">368800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQtNS0xLTEtNTU5Njg_bb2ec563-760e-43e2-98bf-b9d784c6e37b"
      unitRef="usd">445800000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzUtMS0xLTEtNTU5Njg_83b30750-eb17-4bd5-be9e-03c56f2c6c8b"
      unitRef="usd">-400000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzUtMy0xLTEtNTU5Njg_20b1ac2d-f511-488b-8fba-3860dc0470cc"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzUtNS0xLTEtNTU5Njg_ce44a3cf-139e-4a8a-9b3d-859e84a762d0"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:LitigationSettlementExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzctMS0xLTEtNTU5Njg_4e58a754-711a-4f9a-ab68-0112670d3635"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzctMy0xLTEtNTU5Njg_cd94bd9a-bc81-444b-aab8-d8b3b5d05fab"
      unitRef="usd">2800000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzctNS0xLTEtNTU5Njg_7a7141ed-3049-407f-9108-f997cd306eaa"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzgtMS0xLTEtNTU5Njg_44b385db-857d-4294-bd1b-1f71c2cbd874"
      unitRef="usd">256600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzgtMy0xLTEtNTU5Njg_ab5314cb-27e3-4402-a429-c6d694646578"
      unitRef="usd">243000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzgtNS0xLTEtNTU5Njg_d7130823-8168-4260-93c4-217acbf34a89"
      unitRef="usd">218700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzktMS0xLTEtNTU5Njg_3a6e702d-3003-4d1f-975e-57a5c10ed66c"
      unitRef="usd">7800000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzktMy0xLTEtNTU5Njg_345555a5-8570-45a9-a8a0-21bc2ab53ccd"
      unitRef="usd">7200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzktNS0xLTEtNTU5Njg_ffaa16bb-6c31-4b51-8d8a-d24aacaaa022"
      unitRef="usd">4500000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEwLTEtMS0xLTU1OTY4_97b0afac-4d33-40dd-b1f7-77e1cedc0f95"
      unitRef="usd">-1000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEwLTMtMS0xLTU1OTY4_6002eebb-8c9d-4e59-9457-230b5d8a8364"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEwLTUtMS0xLTU1OTY4_c46d3cb0-3934-4db6-a8e5-e085aad3d6e5"
      unitRef="usd">-7700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzExLTEtMS0xLTU1OTY4_28029e7d-ca35-4a9c-a6aa-4aa33f6c0fee"
      unitRef="usd">4000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzExLTMtMS0xLTU1OTY4_0fa460d0-28a9-4e0f-b4a8-5e0262803a7d"
      unitRef="usd">3500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzExLTUtMS0xLTU1OTY4_554d663a-a0b9-4b3f-82e8-1b5d1202d07a"
      unitRef="usd">6700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEyLTEtMS0xLTU1OTY4_1ddc22ac-ad17-4cf5-bbd7-d546c5fe662e"
      unitRef="usd">2900000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEyLTMtMS0xLTU1OTY4_68e677c3-110a-408e-9d2d-c7494dd509a3"
      unitRef="usd">3800000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEyLTUtMS0xLTU1OTY4_ea65afbc-bc54-416d-aa77-204dfca18809"
      unitRef="usd">6600000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:ShareBasedCompensation
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEzLTEtMS0xLTU1OTY4_13ccc6f2-0174-40a3-ab68-4226464b6b32"
      unitRef="usd">32800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEzLTMtMS0xLTU1OTY4_e8608fd4-5c16-4f48-b878-c2571eb3f2bc"
      unitRef="usd">29500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzEzLTUtMS0xLTU1OTY4_b982b476-4e67-4b7d-a45d-4989ebb37f1e"
      unitRef="usd">114400000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE0LTEtMS0xLTU1OTY4_ff434c50-62a0-4db5-b645-f6216c1e16a4"
      unitRef="usd">27800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE0LTMtMS0xLTU1OTY4_bcc1d52b-5bb0-448a-b3c8-416171cd867e"
      unitRef="usd">52400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE0LTUtMS0xLTU1OTY4_5570b0b7-88a9-4159-bad6-b38c01fe4560"
      unitRef="usd">40000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE1LTEtMS0xLTU1OTY4_727f8869-2ef9-436e-bdf9-850cb83615c5"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE1LTMtMS0xLTU1OTY4_bf119620-3ae2-4fa3-86f9-dd66f66cf607"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE1LTUtMS0xLTU1OTY4_15451577-6ce7-46e3-9903-b60eb4face97"
      unitRef="usd">19200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE2LTEtMS0xLTU1OTY4_a7786311-1c46-41a6-88e0-c92725729abd"
      unitRef="usd">8200000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE2LTMtMS0xLTU1OTY4_7bc46d31-05b5-4cfd-b4a5-aec4e15da602"
      unitRef="usd">-5900000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE2LTUtMS0xLTU1OTY4_7486adb1-cb2e-4a69-93d4-4c143ada453f"
      unitRef="usd">-7400000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE4LTEtMS0xLTU1OTY4_3d31b280-2334-41d2-8d23-4d190914e7bd"
      unitRef="usd">64300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE4LTMtMS0xLTU1OTY4_73f4db7b-e6a2-486a-82c4-be04c9ac4e94"
      unitRef="usd">38100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE4LTUtMS0xLTU1OTY4_256c1b34-aaad-49b7-8a3c-2fd64ecf7bcc"
      unitRef="usd">22900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE5LTEtMS0xLTU1OTY4_67b32fd8-3142-4e20-9e73-23cc206c7115"
      unitRef="usd">42000000.0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE5LTMtMS0xLTU1OTY4_a61f0f5b-4244-4bf6-ac9c-a2cf14466b7b"
      unitRef="usd">-100000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzE5LTUtMS0xLTU1OTY4_ee9c8c5d-f491-4b65-9486-4155db97659c"
      unitRef="usd">35400000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIwLTEtMS0xLTU1OTY4_c4591ab5-d8d9-48e9-9dc1-28ff635528ac"
      unitRef="usd">14900000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIwLTMtMS0xLTU1OTY4_f98bf91d-aa12-4013-93e7-b66108d8f12c"
      unitRef="usd">13600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIwLTUtMS0xLTU1OTY4_ca9501c8-c15f-41b1-9237-fd0225e93bce"
      unitRef="usd">-6100000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIxLTEtMS0xLTU1OTY4_6efec476-4f11-4d14-982a-254eff899cc7"
      unitRef="usd">-38100000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIxLTMtMS0xLTU1OTY4_016fec27-90a0-4ec6-9f5e-04f1c8123020"
      unitRef="usd">92000000.0</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIxLTUtMS0xLTU1OTY4_658acd98-7776-4823-a057-9a8691bc9afb"
      unitRef="usd">13200000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIyLTEtMS0xLTU1OTY4_a0c000f8-459a-4ed7-82f8-1c4f244fc8d2"
      unitRef="usd">11500000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIyLTMtMS0xLTU1OTY4_2c6d6f73-6055-40c8-aa36-96172440194a"
      unitRef="usd">-74900000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzIyLTUtMS0xLTU1OTY4_87bfbdb8-ec29-4d16-b600-a1da5cea0b62"
      unitRef="usd">-128900000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI2LTEtMS0xLTU1OTY4_19c0058d-93dc-4b97-9e98-47a8fcfeb643"
      unitRef="usd">-500000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI2LTMtMS0xLTU1OTY4_7706c243-072c-4044-8fec-21f4b6706bcf"
      unitRef="usd">-200000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI2LTUtMS0xLTU1OTY4_88f5d46a-a7d9-4383-894a-220c9cef9ba7"
      unitRef="usd">-4400000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI3LTEtMS0xLTU1OTY4_593446dd-6837-4193-af7c-15eeb6473fa1"
      unitRef="usd">198200000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI3LTMtMS0xLTU1OTY4_4fee8972-22ea-44bb-9ae2-bc8d3bd1a2e5"
      unitRef="usd">335900000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI3LTUtMS0xLTU1OTY4_ccb24cb5-2ddb-4f52-a252-ea7f6443a626"
      unitRef="usd">188900000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI4LTEtMS0xLTU1OTY4_fd810057-dc4e-4924-95bb-3438e2f91c8e"
      unitRef="usd">715800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI4LTMtMS0xLTU1OTY4_717bea55-979e-4ae9-a2fd-034526107c6e"
      unitRef="usd">704700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzI4LTUtMS0xLTU1OTY4_7c416cba-0d6c-4603-9c76-418bf2200c03"
      unitRef="usd">635300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMwLTEtMS0xLTU1OTY4_f7051bd1-fb67-4b49-bb3a-c99f5fcaa6e0"
      unitRef="usd">118600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMwLTMtMS0xLTU1OTY4_e8edd5d0-4bfc-45bd-9c35-e81af051a208"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMwLTUtMS0xLTU1OTY4_9aa23fba-4a30-4c23-adbb-9429c8a0d573"
      unitRef="usd">231500000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMxLTEtMS0xLTU1OTY4_e6e77825-4297-416e-b497-da25e696837a"
      unitRef="usd">528900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMxLTMtMS0xLTU1OTY4_1443a559-0248-412a-b2e0-36e1f3cbf6d5"
      unitRef="usd">396000000.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMxLTUtMS0xLTU1OTY4_c4e2b938-d87c-45c8-8fae-6e009e545064"
      unitRef="usd">372400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForSoftware
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMyLTEtMS0xLTU1OTY4_39e07064-d774-43d6-a2cd-0f714b4635e8"
      unitRef="usd">15800000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMyLTMtMS0xLTU1OTY4_53acc46d-80de-4adc-9218-a38a9b9d91c2"
      unitRef="usd">8700000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMyLTUtMS0xLTU1OTY4_0a1f0088-a466-4676-8b17-d14c117398bb"
      unitRef="usd">13000000.0</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMzLTEtMS0xLTU1OTY4_19fdda69-adb4-47f1-b3da-a7889050dec6"
      unitRef="usd">6500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMzLTMtMS0xLTU1OTY4_be37f96a-0c92-49ef-bb80-41ab19c838fd"
      unitRef="usd">3500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzMzLTUtMS0xLTU1OTY4_9d18e00b-bb33-4dda-8db6-85a687d036e8"
      unitRef="usd">18700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM2LTEtMS0xLTU1OTY4_b2338b60-9fc6-4946-87b4-60eae3d47b5c"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM2LTMtMS0xLTU1OTY4_94d92b7f-3773-4ada-8f59-7d08554f30b9"
      unitRef="usd">12600000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM2LTUtMS0xLTU1OTY4_d12b55a7-7c67-417e-b336-c83707a7ef88"
      unitRef="usd">17600000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM3LTEtMS0xLTU1OTY4_462a82ba-2433-4ce4-9ad2-e10be70dfc3f"
      unitRef="usd">9000000.0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM3LTMtMS0xLTU1OTY4_a5a48c41-b640-45e7-a6de-5faaf998c6d0"
      unitRef="usd">8700000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM3LTUtMS0xLTU1OTY4_d1b82325-ce0e-4c33-b2c6-fca43345237e"
      unitRef="usd">32900000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM4LTEtMS0xLTU1OTY4_44a00917-1812-4a94-870a-e5852fd01a4e"
      unitRef="usd">-12500000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM4LTMtMS0xLTU1OTY4_fb7bc6cc-445c-4ac0-832f-795bf3a4448b"
      unitRef="usd">2100000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzM4LTUtMS0xLTU1OTY4_a313ce28-b81a-4594-817b-11b7b2138450"
      unitRef="usd">6500000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQwLTEtMS0xLTU1OTY4_c7b3c43e-1dc0-4944-afc5-576d6177c931"
      unitRef="usd">-666300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQwLTMtMS0xLTU1OTY4_45e26896-a11b-4317-b2c0-d5cca47e6ab0"
      unitRef="usd">-407500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTozZjI4NDM1NWIyNWY0YTIyOGFhNzQ5Njc5ZTljOWM4My90YWJsZXJhbmdlOjNmMjg0MzU1YjI1ZjRhMjI4YWE3NDk2NzllOWM5YzgzXzQwLTUtMS0xLTU1OTY4_e983f348-16ca-42f4-8c1a-e615d2eda29b"
      unitRef="usd">-657400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzUtMS0xLTEtNTU5Njg_eb77126f-7726-4c19-bf46-077bd601088a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzUtMy0xLTEtNTU5Njg_18a45057-4b51-48a7-8ef6-7882d6ffabb8"
      unitRef="usd">992500000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzUtNS0xLTEtNTU5Njg_56ffa456-6f60-43f8-b504-4940a3a36056"
      unitRef="usd">1000000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzYtMS0xLTEtNTU5Njg_e68fd2bc-f3b9-4771-9fc5-b8066b1fb606"
      unitRef="usd">214500000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzYtMy0xLTEtNTU5Njg_388182b0-81c1-48a9-b25e-e83c5d2fefd4"
      unitRef="usd">718300000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzYtNS0xLTEtNTU5Njg_cc39ca66-a600-4d1b-b0d2-1e76ef8c177d"
      unitRef="usd">519500000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzktMS0xLTEtNTU5Njg_2a6bb9f0-26a5-4a1b-bddc-36addfb3b4ee"
      unitRef="usd">300000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzktMy0xLTEtNTU5Njg_8046fa5f-397b-4698-b19a-98f811039e16"
      unitRef="usd">330000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzktNS0xLTEtNTU5Njg_16b6d838-bba6-415a-a788-6c5a6be5dadf"
      unitRef="usd">635000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEwLTEtMS0xLTU1OTY4_64f2249d-d8f6-4d18-80ee-abb0f87d6294"
      unitRef="usd">100000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEwLTMtMS0xLTU1OTY4_980ffa81-53d3-47a7-8341-c7833e1e9485"
      unitRef="usd">375000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEwLTUtMS0xLTU1OTY4_f0575b36-de97-4cb1-b151-db0abb5d7ad6"
      unitRef="usd">620000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzExLTEtMS0xLTU1OTY4_f7b27b4e-3889-4ea0-8113-1b5d53560ff1"
      unitRef="usd">51800000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzExLTMtMS0xLTU1OTY4_e5b649ed-bdec-49f0-a12c-9328d3f235c0"
      unitRef="usd">22500000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzExLTUtMS0xLTU1OTY4_36565a11-eaa5-4991-8fe2-585747c58ff6"
      unitRef="usd">19500000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEyLTEtMS0xLTU1OTY4_389ee180-a87f-4ebb-b7a9-3a38cc8dbae0"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEyLTMtMS0xLTU1OTY4_869c7857-ac72-4207-a244-dc01cf248c87"
      unitRef="usd">20300000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEyLTUtMS0xLTU1OTY4_ab088ad4-56a2-40a4-9fcf-01e0a053c037"
      unitRef="usd">21500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEzLTEtMS0xLTU1OTY4_06d64ec0-ca6e-4d70-9c5b-c7397aede8b4"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEzLTMtMS0xLTU1OTY4_b2569a16-f67f-4c85-a247-dacfbb69bba2"
      unitRef="usd">6100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzEzLTUtMS0xLTU1OTY4_b24df8cd-1c0c-4517-a43a-94e8f3f53e3c"
      unitRef="usd">45900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE1LTEtMS0xLTU1OTY4_71446ae5-c62c-49cb-a282-be915c4f73ca"
      unitRef="usd">112400000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE1LTMtMS0xLTU1OTY4_0ed0077b-ad74-4017-bd9a-d1e63721e7b0"
      unitRef="usd">111900000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE1LTUtMS0xLTU1OTY4_5adf1576-0dcb-413a-9ab2-8dec9cfe8080"
      unitRef="usd">108700000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE2LTEtMS0xLTU1OTY4_10527b2a-6fc3-48eb-90c3-7519f82ff3af"
      unitRef="usd">0</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE2LTMtMS0xLTU1OTY4_09315add-de8a-40ea-9948-973218909ad3"
      unitRef="usd">162300000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE2LTUtMS0xLTU1OTY4_d2712f78-f585-4857-88be-8fb65f78a7e4"
      unitRef="usd">162900000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE5LTEtMS0xLTU1OTY4_d4279a39-cc9b-45bb-8f38-982a9d33abc7"
      unitRef="usd">102900000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE5LTMtMS0xLTU1OTY4_fb584215-d8a5-400b-8931-942522fa155f"
      unitRef="usd">72200000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzE5LTUtMS0xLTU1OTY4_db7ab481-df9e-4707-acf5-e023716aab4b"
      unitRef="usd">79800000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIwLTEtMS0xLTU1OTY4_c4d2e093-9f81-4f51-9a1c-b15238d3d0df"
      unitRef="usd">16400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIwLTMtMS0xLTU1OTY4_915c6a4e-de7f-4ae4-87a3-ab7fd83f1fb5"
      unitRef="usd">15700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIwLTUtMS0xLTU1OTY4_4bda3af9-161a-4fb5-b3d0-b3ed94580168"
      unitRef="usd">16600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIxLTEtMS0xLTU1OTY4_95171a47-1434-4117-b572-f920d8384af6"
      unitRef="usd">57200000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIxLTMtMS0xLTU1OTY4_1f718a2f-9aad-451c-ae43-c4e91e360032"
      unitRef="usd">34900000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIxLTUtMS0xLTU1OTY4_946d6132-5d32-4bb2-87fd-99be9d34f4ed"
      unitRef="usd">15900000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIyLTEtMS0xLTU1OTY4_4bd672a5-8257-4812-81c8-68b1fdf54054"
      unitRef="usd">700000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIyLTMtMS0xLTU1OTY4_99b6772a-9914-42c6-8966-d16b4b9ce126"
      unitRef="usd">1000000.0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIyLTUtMS0xLTU1OTY4_fb8508ed-6802-49b3-85ca-2472132b4855"
      unitRef="usd">-8300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIzLTEtMS0xLTU1OTY4_b4717585-2e6a-445b-b61f-be647c7555d3"
      unitRef="usd">-240100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIzLTMtMS0xLTU1OTY4_05ae6885-d511-4826-b4db-502501af82a4"
      unitRef="usd">-145900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzIzLTUtMS0xLTU1OTY4_fd5ac953-2d1e-478a-b576-1b8bfbaa34cc"
      unitRef="usd">48200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI0LTEtMS0xLTU1OTY4_36c88fbf-6911-42dd-bbaf-9edb83fed49d"
      unitRef="usd">-190600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI0LTMtMS0xLTU1OTY4_610333d6-f30d-4619-a067-50b0e99f1248"
      unitRef="usd">151300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI0LTUtMS0xLTU1OTY4_76404b28-193a-427a-a32d-52ef59714f90"
      unitRef="usd">26100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI1LTEtMS0xLTU1OTY4_6fff4a0b-54ec-413d-9329-70abac4e7db2"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI1LTMtMS0xLTU1OTY4_9239e892-cfe1-468d-bc80-1ffe0b7a5187"
      unitRef="usd">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI1LTUtMS0xLTU1OTY4_3ef57c9d-03d1-40b9-baec-04c026603995"
      unitRef="usd">133500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI2LTEtMS0xLTU1OTY4_a2041601-d72e-48b8-9fe2-17c6d1a6306b"
      unitRef="usd">120300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI2LTMtMS0xLTU1OTY4_0f901fa6-c6fa-4583-ac68-5fe5fe524343"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI2LTUtMS0xLTU1OTY4_db318ada-f530-488d-bbcb-8cf3d05d50bb"
      unitRef="usd">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI5LTEtMS0xLTU1OTY4_2cc93585-c14a-44f2-b8bc-ac13dd7fa069"
      unitRef="usd">224000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI5LTMtMS0xLTU1OTY4_89f5bc40-123f-457a-8939-be4eb18581d4"
      unitRef="usd">94800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzI5LTUtMS0xLTU1OTY4_e2dddaec-f8e0-4b4d-90e1-a76742f44f87"
      unitRef="usd">69200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMwLTEtMS0xLTU1OTY4_76d60d37-6bfc-41fb-8cc1-3fdc0cbe0e19"
      unitRef="usd">65400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMwLTMtMS0xLTU1OTY4_baa08b46-580d-47ed-8b10-728b3c075c51"
      unitRef="usd">57400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMwLTUtMS0xLTU1OTY4_92a4ddca-195f-49c2-bc93-8408461f356d"
      unitRef="usd">59000000.0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMxLTEtMS0xLTU1OTY4_bb3d550e-c220-4e2d-abf6-7a7059aa47fa"
      unitRef="usd">21500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMxLTMtMS0xLTU1OTY4_eeab325d-6418-4e53-84d0-811fdab8aae4"
      unitRef="usd">7400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMxLTUtMS0xLTU1OTY4_677766a7-035f-4262-86a6-fd9c0262f0c1"
      unitRef="usd">5300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMyLTEtMS0xLTU1OTY4_feb48df6-0f29-4cb2-b459-dcd387088e7a"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMyLTMtMS0xLTU1OTY4_5175d167-14fa-4acd-8aa2-331772ab8e4f"
      unitRef="usd">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzMyLTUtMS0xLTU1OTY4_ac121328-2598-4d53-aaa0-eb851f1f791c"
      unitRef="usd">133500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM0LTEtMS0xLTU1OTY4_a8673a8b-0459-41ed-b6e0-5d4e024eda4e"
      unitRef="usd">54800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM0LTMtMS0xLTU1OTY4_b726fe7a-3f77-430c-ba8c-e532844a1586"
      unitRef="usd">224000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM0LTUtMS0xLTU1OTY4_31366a5d-05d1-4d2a-8888-e065a262525f"
      unitRef="usd">94800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM1LTEtMS0xLTU1OTY4_b7ace835-e50e-4f51-ad82-8f0b1efbb05c"
      unitRef="usd">65100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM1LTMtMS0xLTU1OTY4_78f7f9cf-3684-47d9-8816-ab6779b96b5f"
      unitRef="usd">65400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM1LTUtMS0xLTU1OTY4_93adfb88-687f-43cb-a499-c8de1cb4a066"
      unitRef="usd">57400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM2LTEtMS0xLTU1OTY4_29066043-c89e-4043-939d-efb8e7f52063"
      unitRef="usd">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM2LTMtMS0xLTU1OTY4_62559164-79b1-465a-8c3f-e578e08a877f"
      unitRef="usd">21500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM2LTUtMS0xLTU1OTY4_7a79b833-c551-4e68-a1f2-746bb7713ef0"
      unitRef="usd">7400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM3LTEtMS0xLTU1OTY4_545361fa-2aba-44f9-8545-47641ba5865e"
      unitRef="usd">120300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM3LTMtMS0xLTU1OTY4_4936acd9-87d7-41bc-abc0-ea92e3a1a72f"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzM3LTUtMS0xLTU1OTY4_c339274f-b413-4a01-962f-701dd2b12cff"
      unitRef="usd">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQxLTEtMS0xLTU1OTY4_9f998a8b-ea54-4c38-a672-d6d1a0137cd3"
      unitRef="usd">168400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQxLTMtMS0xLTU1OTY4_c1228588-b9f9-47e6-8d91-8f6ff7a842b4"
      unitRef="usd">168400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQxLTUtMS0xLTU1OTY4_d313a0be-38ed-4912-b2b5-be9a1364e268"
      unitRef="usd">155700000</us-gaap:InterestPaidNet>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQyLTEtMS0xLTU1OTY4_1b1dcbca-62d9-4ce7-8067-c34fb8cfde93"
      unitRef="usd">1800000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQyLTMtMS0xLTU1OTY4_c022b1ec-754d-4227-b0d2-89b11d316ed4"
      unitRef="usd">1400000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQyLTUtMS0xLTU1OTY4_107ce7ba-bbe0-4248-8df3-de2403688c4f"
      unitRef="usd">100000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQzLTEtMS0xLTU1OTY4_46b7eca9-a8b5-4f48-8881-f2c399aca256"
      unitRef="usd">131400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQzLTMtMS0xLTU1OTY4_8f508591-9dc1-48b0-9125-dcb6572c0b73"
      unitRef="usd">34300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQzLTUtMS0xLTU1OTY4_ee76107f-4738-4f21-ba02-7622f69fb753"
      unitRef="usd">104200000</us-gaap:IncomeTaxesPaid>
    <ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDgvZnJhZzo3M2EyMzhmNWI4MmM0MzA2OWE2NDU3M2MxMGIyYzI3OS90YWJsZTo4MmM2ZWIwOGJjYzk0OGNhYjkzZTFiZDk4MjBmNjMwZi90YWJsZXJhbmdlOjgyYzZlYjA4YmNjOTQ4Y2FiOTNlMWJkOTgyMGY2MzBmXzQ2LTUtMS0xLTU1OTY4_888c5369-7338-4722-b8ee-4bfe70963a74"
      unitRef="usd">349400000</ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNTQvZnJhZzowNTYzMDFkNjQyOGM0MmJlYjkwZDg5YjgyNGYwZTU3Ny90ZXh0cmVnaW9uOjA1NjMwMWQ2NDI4YzQyYmViOTBkODliODI0ZjBlNTc3XzE1_924ed142-510d-46f5-9067-afd23108cace">Summary of Significant Accounting Policies:&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Organization and Description of Business&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a national leader in integrated healthcare services, offering both facility-based and home-based post-acute services in 42 states and Puerto Rico through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2)&#160;home health and hospice. See Note 19, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Consolidation&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to Encompass Health&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the measurement alternative to account for our investments in entities we do not control and for which we do not have the ability to exercise significant influence over operating and financial policies. In accordance with the measurement alternative, these investments are recorded at the lower of cost or fair value, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We eliminate all significant intercompany accounts and transactions from our financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any entity considered a variable interest entity (&#x201c;VIE&#x201d;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates and Assumptions&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#x2019; compensation, and comprehensive general insurance liability risks; &lt;/span&gt;&lt;/div&gt;and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a healthcare provider, we are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;licensure, certification, and accreditation;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;coding and billing for services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;requirements of the 60% compliance threshold under The Medicare, Medicaid and State Children&#x2019;s Health Insurance Program (SCHIP) Extension Act of 2007;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;quality of medical care;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;use and maintenance of medical supplies and equipment;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;maintenance and security of patient information and medical records;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;acquisition and dispensing of pharmaceuticals and controlled substances; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;disposal of medical and hazardous waste.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, contractual arrangements, and patient admittance practices, as well as the way in which we deliver home health and hospice services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we fail to comply with applicable laws and regulations, we could be required to return portions of reimbursements deemed after the fact to have not been appropriate. We could also be subjected to liabilities, including (1)&#160;criminal penalties, (2)&#160;civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals or agencies, and (3)&#160;exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement. Because Medicare comprises a significant portion of our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. Specifically, reductions in reimbursements, substantial damages, and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operation, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, the United States Congress and some state legislatures have periodically proposed significant changes in regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in pricing roll-backs or freezes or reimbursement reductions. Because we receive a significant percentage of our revenues from Medicare, such changes in legislation might have a material adverse effect on our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there are increasing pressures from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. We could be adversely affected in some of the markets where we operate if we are unable to negotiate and maintain favorable agreements with third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note&#160;18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Other Commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we are a party to a number of lawsuits. We cannot predict the outcome of litigation filed against us. Substantial damages or other monetary remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rapid &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;onset of the COVID-19 Pandemic (the &#x201c;pandemic&#x201d;)&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has caused a disruption to our nation&#x2019;s healthcare system. Such disruption includes reductions in the availability of personal protective equipment (&#x201c;PPE&#x201d;) to prevent spread of the disease during patient treatment and increases in the cost of PPE. From time to time in specific markets, elective procedures were postponed by physicians and acute-care hospitals and limited by governmental order to preserve capacity for the expected volume of COVID-19 patients and reduce the risk of the spread of COVID-19. Initially, these postponements and limitations were widespread. Now, they are more market or state specific and driven by the extent of the pandemic in those areas. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For various quarterly periods during the pandemic, we experienced decreased patient volumes in one or more of our business lines when compared to the prior year periods. We believe reduced patient volumes resulted from a number of conditions related to the pandemic including: lower acute-care hospital censuses due to the deferral of elective surgeries and shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, policies in assisted living facilities that limit our staff from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. In the home health and hospice segment, we also experienced decreases in visits per episode and institutional referrals because of the pandemic, both of which negatively impacted pricing for home health.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In response to the public health emergency associated with the pandemic, Congress and Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;) adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care. On March 27, 2020, former President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#x201c;CARES Act&#x201d;), which temporarily suspended sequestration for the period of May 1 through December 31, 2020. The CARES Act also authorized the cash distribution of relief funds from the United States Department of Health and Human Services (&#x201c;HHS&#x201d;) to healthcare providers. We did not accept any CARES Act relief funds. The Consolidated Appropriations Act, 2021 (the &#x201c;2021 Budget Act&#x201d;), signed into law on December 27, 2020 provided for additional provider relief funds. We intend to refuse any additional provider relief funds distributed in the future whether authorized under the 2021 Budget Act or other legislation. The sequestration suspension has been extended a number of times. Sequestration is currently scheduled to resume as of April 1, 2022 but will only be a 1% payment reduction through June&#160;30, 2022. Thereafter, the full 2% Medicare payment reduction will resume. Federal legislation, including the CARES Act and the 2021 Budget Act, and CMS regulatory actions include a number of other provisions, which are discussed below, affecting our reimbursement and operations in both segments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, the CARES Act, 2021 Budget Act, and a series of waivers and guidance issued by CMS suspend various Medicare patient coverage criteria and documentation and care requirements in an effort to provide regulatory relief until the public health emergency for the pandemic has ended. For inpatient rehabilitation, the regulatory relief includes the temporary suspension of the requirement that patients must be able to tolerate a minimum of three hours of therapy per day for five days per week and waiver of certain of the requirements, including the exclusion of COVID-19 admissions from the compliance calculation under the 60% Rule. In addition, the requirement of physician face-to-face visits at least three days a week may be fulfilled using telehealth. For home health, the relief includes the allowance of nurse practitioners and physician assistants under certain conditions to certify, establish and periodically review the plan of care, as well as supervise the provision of items and services for beneficiaries under the Medicare home health benefit and expands the use of telehealth. Additionally, CMS expanded the definition of &#x201c;homebound&#x201d; to include patients needing skilled services who are homebound due solely to their COVID-19 diagnosis or patients susceptible to contract COVID-19. For hospice, the relief includes the temporary waiver of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides, as well as the expanded use of telehealth for routine services and patient recertification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in April 2020, we amended our credit agreement primarily to provide covenant relief due to business disruptions from the pandemic. The amendment included, among other things, the carve-out of the pandemic from the definition of material adverse effect for 364 days and modifications to the interest coverage and leverage ratios under the agreement. &lt;/span&gt;&lt;/div&gt;The foregoing and other disruptions to our business as a result of the pandemic have had and are likely to continue to have an adverse effect on our business and could have a material adverse effect on our business, results of operations, financial condition and cash flows.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Operating Revenues&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by payor source and segment are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,496.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,271.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,513.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,644.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,605.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#x201c;HHS-OIG&#x201d;) or the United States Department of Justice (the &#x201c;DOJ&#x201d;). Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Administrative Contractors (&#x201c;MACs&#x201d;), under programs known as &#x201c;widespread probes,&#x201d; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#x201c;appeal,&#x201d; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#x201c;OMHA&#x201d;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OMHA practices continue, an increased number of unfavorable administrative law judge (&#x201c;ALJ&#x201d;) decisions could have a negative effect on our long-term ALJ success rate. The current OMHA practice has resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, CMS announced the Targeted Probe and Educate (&#x201c;TPE&#x201d;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with CMS approved and announced Recovery Audit Contractors (&#x201c;RACs&#x201d;) audits related to inpatient rehabilitation facilities (&#x201c;IRFs&#x201d;), we received requests from 2013 to 2021 to review certain patient files for discharges occurring from 2010 to 2021.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#x2019;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS has also established Unified Program Integrity Contractors (&#x201c;UPICs&#x201d;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Medicare claims that are subject to these post-payment audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2021. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2021, 2020, and 2019, our adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for claims that are part of this post-payment claims review process was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inpatient Rehabilitation Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inpatient rehabilitation segment revenues are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#x2019;s total length of stay for in-house patients, each patient&#x2019;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Home Health and Hospice Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. The performance obligation is the rendering of services to the patient during the term of the episode of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal regulation. The base episode payment can be adjusted based on each patient&#x2019;s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We bill a portion of reimbursement from each Medicare episode near the start of each episode, and the resulting cash payment is typically received before all services are rendered. Effective January 1, 2021, this early payment process has been eliminated. As we provide home health services to our patients on a scheduled basis over the episode of care in a manner that approximates a pro rata pattern, revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of December&#160;31, 2021 and December&#160;31, 2020, the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not material and was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to certain Medicare regulations affecting outlier revenue if our patient&#x2019;s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Adjustments to the transaction price for the outlier cap &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; not material&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of December&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, revenue is recorded on an accrual basis based upon the date of service at amounts equal to our estimated per-visit transaction price. Price concessions, including contractual allowances for the differences between our standard rates and the applicable contracted rates, as well as estimated uncollectible amounts from patients, are recorded as decreases to the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare revenues for hospice are recognized and recorded on an accrual basis using the input method based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The performance obligation is the rendering of services to the patient during each day that they are on hospice care. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the MAC. Adjustments to the transaction price for these caps &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; not material as of December&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our estimated per day transaction price. Price concessions, including contractual adjustments for the difference between our standard rates and the amounts estimated to be realizable from patients and third parties for services provided, are recorded as decreases to the transaction price and thus reduce our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; include highly liquid investments with maturities of three months or less when purchased. Carrying values of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; approximate fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is a separate component of shareholders&#x2019; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#x2019; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care and other discount plans, including Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#x2019;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. We do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other Intangible Assets&#x2014; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess qualitative factors in our inpatient rehabilitation and home health and hospice reporting units to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our reporting units using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of each reporting unit&#x2019;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting units to our market capitalization. When we dispose of a hospital or home health or hospice agency, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2021, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#x2019;s carrying amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;br/&gt;and Amortization Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 18 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;indefinite-lived asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market access assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years using accelerated basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and directly related payroll costs. Amortization begins when the internal-use software is ready for its intended use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#x2019;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets and Other Intangible Assets&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#x2019;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in and Advances to Nonconsolidated Affiliates&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities we do not control but in which we have the ability to exercise significant influence over the operating and financial policies of the investee are accounted for under the equity method. Equity method investments are recorded at original cost and adjusted periodically to recognize our proportionate share of the investees&#x2019; net income or losses after the date of investment, additional contributions made, dividends or distributions received, and impairment losses resulting from adjustments to net realizable value. We record equity method losses in excess of the carrying amount of an investment when we guarantee obligations or we are otherwise committed to provide further financial support to the affiliate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the measurement alternative to account for equity investments for which the equity securities do not have readily determinable fair values and for which we do not have the ability to exercise significant influence. Under the measurement alternative, private equity investments are carried at cost and are adjusted only for other-than-temporary declines in fair value, additional investments, or distributions deemed to be a return of capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management periodically assesses the recoverability of our equity method and measurement alternative investments and equity method goodwill for impairment. We consider all available information, including the recoverability of the investment, the earnings and near-term prospects of the affiliate, factors related to the industry, conditions of the affiliate, and our ability, if any, to influence the management of the affiliate. We assess fair value based on valuation methodologies, as appropriate, including discounted cash flows, estimates of sales proceeds, and external appraisals, as appropriate. If an investment or equity method goodwill is considered to be impaired and the decline in value is other than temporary, we record an appropriate write-down.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Costs&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cost approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See also the &#x201c;Redeemable Noncontrolling Interests&#x201d; section of this note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling Interests in Consolidated Affiliates&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#x2019; balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future. Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital in excess of par value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to certain members of the home health and hospice management team&#x2019;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $400 million or more. The fair value of our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#x2019; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inputs. The projected operating results use management&#x2019;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees, excluding stock appreciation rights (&#x201c;SARs&#x201d;), are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period. Share-based payments to employees in the form of SARs are recognized in the financial statements based on their current fair value and expensed ratably over the applicable service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Reserves&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advertising Costs&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within the accompanying consolidated statements of comprehensive income, were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.6 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $4.6 million, and $6.1 million in each of the years ended December 31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the asset and liability method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We include the allocable portion of each pass-through entity&#x2019;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities in and Results of Discontinued Operations&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Effective January 1, 2015, in connection with a new standard issued by the FASB, we changed our criteria for determining which disposals are presented as discontinued operations. Historically, any component that had been disposed of or was classified as held for sale qualified for discontinued operations reporting unless there was significant continuing involvement with the disposed component or continuing cash flows. In contrast, we now report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. As a result, the sale or disposal of a single Encompass Health facility or location no longer qualifies as a discontinued operation. This accounting change was made prospectively. No new components were recognized as discontinued operations since this guidance became effective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Loss from discontinued operations, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Common Share&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury Stock&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital in excess of par value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We account for the retirement of treasury stock as a reduction of retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is comprised of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#x201d; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. The new guidance was effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. The adoption of this guidance did not have a material impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNTcvZnJhZzo2Y2FmMjI1MDA5ODQ0ZDBkYmViNjMzZDZiNjIyZjNkZC90ZXh0cmVnaW9uOjZjYWYyMjUwMDk4NDRkMGRiZWI2MzNkNmI2MjJmM2RkXzI4Mg_df7c15a3-7d91-4b9c-b1c6-0e2c684add04"
      unitRef="state">42</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:NumberOfReportableSegments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNTcvZnJhZzo2Y2FmMjI1MDA5ODQ0ZDBkYmViNjMzZDZiNjIyZjNkZC90ZXh0cmVnaW9uOjZjYWYyMjUwMDk4NDRkMGRiZWI2MzNkNmI2MjJmM2RkXzQ3Nw_8e6a258c-faf0-48e7-b417-72edc53b79ed"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNjAvZnJhZzpiYjExNTU3ZGU1ZjA0ZWVkYWQzODcyY2E1NzEwOWJhYS90ZXh0cmVnaW9uOmJiMTE1NTdkZTVmMDRlZWRhZDM4NzJjYTU3MTA5YmFhXzE1MjE_ed9f550c-98ca-4d12-9b0c-5bdbf0d968d7">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Consolidation&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to Encompass Health&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the measurement alternative to account for our investments in entities we do not control and for which we do not have the ability to exercise significant influence over operating and financial policies. In accordance with the measurement alternative, these investments are recorded at the lower of cost or fair value, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We eliminate all significant intercompany accounts and transactions from our financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNjMvZnJhZzpmZTA1NWFhNzY4NWU0N2YzYTU2MzIzNmNhMmU0Nzc1YS90ZXh0cmVnaW9uOmZlMDU1YWE3Njg1ZTQ3ZjNhNTYzMjM2Y2EyZTQ3NzVhXzYzMQ_a6271523-4bb0-4ed3-972d-abd290d6503f">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any entity considered a variable interest entity (&#x201c;VIE&#x201d;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:UseOfEstimates
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNjYvZnJhZzpiMzA4NzUxNzdhYjM0MDY5OTA3YjU0MGEzMjNlMTE5Zi90ZXh0cmVnaW9uOmIzMDg3NTE3N2FiMzQwNjk5MDdiNTQwYTMyM2UxMTlmXzE4MTE_c974a7e0-a08c-4393-8631-7a600066dbdd">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates and Assumptions&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#x2019; compensation, and comprehensive general insurance liability risks; &lt;/span&gt;&lt;/div&gt;and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90ZXh0cmVnaW9uOmYxOTY1ZGU3NmY0MjRiMGE4MWM2M2Q4NzU4NmMyNGU2XzE1NTc1_9e5a132e-5ada-4c63-9590-eeed73ae689f">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by payor source and segment are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,496.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,271.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,513.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,644.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,605.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50c41afde2c14f30868fae349870ae67_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMS0xLTEtNTU5Njg_65f7991c-9665-48a8-b946-3019251d0b6b"
      unitRef="usd">2589700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6271cffe1c904ccb98ba4fe7cc5181c9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMy0xLTEtNTU5Njg_1fb968c5-b9e3-49e7-9dff-dcfb8da11e42"
      unitRef="usd">2375500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11cc4a44f3ce4c27b16c3a87f7e6c602_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtNS0xLTEtNTU5Njg_f95adc90-6bc9-4a9e-a9ae-2eff1547b462"
      unitRef="usd">2537300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie210db53eb0d412eaee1d6fcca151b10_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtNy0xLTEtNTU5Njg_2361dd7e-774a-4497-a087-0b1ca0e91065"
      unitRef="usd">906500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e0201709f3946c08a6ab86ab34fd860_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtOS0xLTEtNTU5Njg_abe7cb3b-94a6-4be6-8204-16cd41d4924c"
      unitRef="usd">896000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefea4843724b48b09d4df201deaf65a4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMTEtMS0xLTU1OTY4_f228eefc-c093-44c3-a56f-895c602bc27d"
      unitRef="usd">920000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc66028fb34c417d98f6aa0925fbaf46_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMTMtMS0xLTU1OTY4_c78e2e0f-ef5a-4a67-a022-d9cbb32542cd"
      unitRef="usd">3496200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf5dec126efa48feb647aa010d99768a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMTUtMS0xLTU1OTY4_92672054-f994-485f-a385-92282e666b38"
      unitRef="usd">3271500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9441f0547a243a2b7b5a2b86b40a684_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzMtMTctMS0xLTU1OTY4_d3653df5-1827-4702-8729-c37ee2bdc452"
      unitRef="usd">3457300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e244b99f69648959e00b33e0813e62d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMS0xLTEtNTU5Njg_95f9afde-8417-4a6f-a1b1-3b26574ece83"
      unitRef="usd">609600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if62c48a4d00044a48498232bb8743644_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMy0xLTEtNTU5Njg_ff6c9074-b98d-4e58-a1da-2e105387e3df"
      unitRef="usd">544900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i666da563adcc46e988ccb8361d06a266_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtNS0xLTEtNTU5Njg_c2161a97-337c-498c-9fb5-3b1f8e84f11e"
      unitRef="usd">375500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1c288f844e548c49f2fadc07c0cb5de_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtNy0xLTEtNTU5Njg_c3515959-b375-4ad2-b529-62593e6137fc"
      unitRef="usd">117400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f0c321a2cfe4aa5a8aede0de35b5d94_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtOS0xLTEtNTU5Njg_bba224fa-952a-4f2c-b952-efaed1fd379d"
      unitRef="usd">116200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f340e8442bb423ca9425031c1a5d324_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMTEtMS0xLTU1OTY4_e18cd6c6-0184-4741-8b17-c072fbfd35cd"
      unitRef="usd">111900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39ae81a511e14a958520030481b4f6ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMTMtMS0xLTU1OTY4_5e78d333-369d-467b-b194-e657819e8d77"
      unitRef="usd">727000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad2d076cc6c74bf4b47595003b494784_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMTUtMS0xLTU1OTY4_c58c86d6-bb5a-4402-a27d-e55e9a3dbd17"
      unitRef="usd">661100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f10396a7e3b43ebb4e5c9e8ea06743f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzQtMTctMS0xLTU1OTY4_b88fa8f2-4cbc-4d31-81ca-1115f9bc15f3"
      unitRef="usd">487400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id90363214f544ed4a70ebfb5ebdad889_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMS0xLTEtNTU5Njg_998e9581-515d-44bc-9779-812d324ca4cd"
      unitRef="usd">484500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc79562a0921430d8e1b5424ea7afd74_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMy0xLTEtNTU5Njg_84973b79-ffef-4d25-bc7d-a305dad2e38d"
      unitRef="usd">371400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18fdd0edfd604ca0adf6e6978f89a471_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtNS0xLTEtNTU5Njg_1f129d94-66b6-401e-ad2c-f6c06a599eb3"
      unitRef="usd">342700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i248e5b251d414ac992e37bdfa4007809_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtNy0xLTEtNTU5Njg_5dd52190-d808-47f5-b0a4-e04d5a3fbce8"
      unitRef="usd">65400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id889fb2355f34e3fa69a032dca90b99d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtOS0xLTEtNTU5Njg_835b3e1e-2a90-45be-9465-b2e70b9ba67d"
      unitRef="usd">47800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife4a3b4a13f348b7bde0e4da0ad9fa60_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMTEtMS0xLTU1OTY4_05390cee-2836-4eac-aaaa-9cf18bce5ad9"
      unitRef="usd">39100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcd44b56d04a47dab1d7f34a4a696e77_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMTMtMS0xLTU1OTY4_90b9d1a6-6ab6-4110-b91b-11acd607e5a2"
      unitRef="usd">549900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddc2201186bb441b862bf0c07fec3894_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMTUtMS0xLTU1OTY4_c4b94f1e-f191-4f7b-abe9-c34401a979a8"
      unitRef="usd">419200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9da587872f03428ebd0561751ad78968_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzUtMTctMS0xLTU1OTY4_d0bfb064-0b3a-4094-9e9f-c22fab147d33"
      unitRef="usd">381800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2080930973934f8c9f1b16798afc84c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMS0xLTEtNTU5Njg_a0e407cd-6eb3-44b6-9006-001d5035d230"
      unitRef="usd">163100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f0c27770799485ab81f312f87261f13_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMy0xLTEtNTU5Njg_25032d8a-e425-4446-8fe7-67012cc0832f"
      unitRef="usd">140100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88ab67a915ad4fccbdb5079bce262358_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtNS0xLTEtNTU5Njg_7d0af328-a89f-40ea-a1d0-ed8791bcf924"
      unitRef="usd">110300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8182e20f98d04c6190ceb6053df0ed57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtNy0xLTEtNTU5Njg_437cdeb2-b57b-43e7-bc21-9e6c1f6e72b1"
      unitRef="usd">15500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bcebecfa11144f2882ac634ce41c2cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtOS0xLTEtNTU5Njg_04ce5cb3-5018-47e3-987f-62ee3ef3a220"
      unitRef="usd">15600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cbe87cd92944498b87689bf56f9f42f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMTEtMS0xLTU1OTY4_3b1ecc55-16d1-42d5-9f43-3f71d1ef9a0b"
      unitRef="usd">18400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0763338809c342129b7f8f9c3818bd70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMTMtMS0xLTU1OTY4_115ccaab-58a1-4a7f-a020-3caf80488581"
      unitRef="usd">178600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9408ebc5eec943238d4bd413eb2752e3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMTUtMS0xLTU1OTY4_fa6f4bef-c615-4745-a7d0-2db7668e1580"
      unitRef="usd">155700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aae1d8057b04f22bf4c3a4c1a1de209_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzYtMTctMS0xLTU1OTY4_0660f405-e7a2-4be4-afdb-350b342086a1"
      unitRef="usd">128700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57418ccab59c4872abdca8da71effd35_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMS0xLTEtNTU5Njg_38bc4ad4-055a-4ad3-81c9-5180eb6d162c"
      unitRef="usd">46000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1b2e886e1d34c40a54db89ffdbe59e8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMy0xLTEtNTU5Njg_5f4f16cf-5ba1-4512-8aa5-d1029406e689"
      unitRef="usd">43000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0186908fade24055a75bc3d6e203778b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctNS0xLTEtNTU5Njg_56d16aaf-57ad-4134-ab5c-bfecfc5ff86c"
      unitRef="usd">43400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93348aee51814bf9aecb0395b5cb93a8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctNy0xLTEtNTU5Njg_090ed3cd-910d-4de8-a8e5-c08b8ff4a226"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0839ac5ac72042bfb3800163f241925e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctOS0xLTEtNTU5Njg_d7de794d-b870-4b1d-a757-8470b515e996"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a3e78919a4e4173a9a3c81b5ce115c8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMTEtMS0xLTU1OTY4_9249838f-12ee-4579-821c-33d5d64010ce"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95dc4732a37c4b6da92a2818f2a80bc6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMTMtMS0xLTU1OTY4_e736b2f8-2242-4012-b2fc-6cca4c4029f5"
      unitRef="usd">46000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fed2509c225447aa65e5e144d767dab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMTUtMS0xLTU1OTY4_db808164-3b09-42fe-a710-b1c994e35dc8"
      unitRef="usd">43000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida50b0a668534d44aec233b93224cc40_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzctMTctMS0xLTU1OTY4_ca851c96-fc84-4899-a596-e28b69e4c252"
      unitRef="usd">43400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a9e5d1b654340c29ca65e2d0b0aa0eb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMS0xLTEtNTU5Njg_befd2fbc-4319-4941-a78d-107019212caf"
      unitRef="usd">23100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idde0b5f5e38841389b722fd9e125c188_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMy0xLTEtNTU5Njg_54ff0674-64b5-4dc1-a20a-3fdcb6a21dfd"
      unitRef="usd">21500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7373562b9b1b43dfa90c43cfc477cd4d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtNS0xLTEtNTU5Njg_9f61f397-d4eb-437d-8cf1-a11cd2c6781b"
      unitRef="usd">29200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb62cf7c2ebf425185cc1b842a56a99b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtNy0xLTEtNTU5Njg_7ffbc6ca-bed2-4236-8713-e27f17fd5b2c"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38a535a2b9fd4b4a9dbbb62ad7109711_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtOS0xLTEtNTU5Njg_6b8737db-57e5-4037-b906-83f6e83dba60"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia49093b7f6f74a3a8a1db6448e4cc4b3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMTEtMS0xLTU1OTY4_e48e1e39-fd06-4233-bd4f-f4438b6e9552"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fd372b138034d8ebb56c465c676ff31_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMTMtMS0xLTU1OTY4_25c0eddf-96f1-4a8f-8972-37288a530679"
      unitRef="usd">23400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55e61058727a4dee885614cf27830c46_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMTUtMS0xLTU1OTY4_f80c73a9-7b9e-4670-9c73-7935101de9ac"
      unitRef="usd">22500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f71b1e134644eb5be3d0b729fca8ce4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzgtMTctMS0xLTU1OTY4_e57b3eca-0a07-4745-ada2-d1bec424a527"
      unitRef="usd">30200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i857d5dcdbfab46a6bbc20427b6491403_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMS0xLTEtNTU5Njg_d9651f6a-6683-44d3-b2e5-6583dbef9553"
      unitRef="usd">19300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaad37c17c8b34f8a94304d1a0bc269e2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMy0xLTEtNTU5Njg_f752d1dd-2f96-4bc2-aa70-17713031b193"
      unitRef="usd">19200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41e6d0167938432a9aa75d163f6f83fc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktNS0xLTEtNTU5Njg_ec6c82c5-4671-4fe3-bd4c-5dc6ea771990"
      unitRef="usd">23300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic315543707c2438ca08eaee06a1f2450_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktNy0xLTEtNTU5Njg_b7552a2d-0db0-495a-bc03-6fbc3b2a74d9"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i822b083e60b54e34844537cc70601ba7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktOS0xLTEtNTU5Njg_e835883b-8552-4645-a23b-674a4f92571a"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fd833c8e5a04bf6a99b0d8ec0b64e76_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMTEtMS0xLTU1OTY4_bdc148a0-c83e-416b-8ad5-2b28eab4e796"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97d24912b1574d9cac401d0d2ee4bd93_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMTMtMS0xLTU1OTY4_cc173975-ab32-4ec1-8c24-abe55c564ebc"
      unitRef="usd">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5b3c61991594fc08487d9b203777782_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMTUtMS0xLTU1OTY4_5bf6a336-5698-44a6-9989-a6ff5afdd131"
      unitRef="usd">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4fab58433e548239f4f791ed6c5f399_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzktMTctMS0xLTU1OTY4_050b15dd-981d-43c8-bb42-a8b51fe3a1ce"
      unitRef="usd">23900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9977d16b4a094aad9e89217d4ee09815_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTEtMS0xLTU1OTY4_4570a962-29e5-464d-88bf-d1057a1fe701"
      unitRef="usd">79700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51e90e0735aa405787042bd27546ee2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTMtMS0xLTU1OTY4_e1e25a92-f5ee-48a6-9efb-6381d721d08b"
      unitRef="usd">50600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fe668ae93474f95813ae6b7c49cdd11_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTUtMS0xLTU1OTY4_3bfcaf5e-63ab-49da-9ee7-a7d1a20e0c50"
      unitRef="usd">51300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i361e56a65aae4bc697d20f87ea1972e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTctMS0xLTU1OTY4_142353c5-e26b-47b2-b76d-f872a20d2ef4"
      unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7738b6274b504051923f6b91db1fcd16_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTktMS0xLTU1OTY4_73b543aa-0903-4402-b14d-c839d58db9ee"
      unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47a2078ca149443eafdafed5920c603a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTExLTEtMS01NTk2OA_32629e8e-fe41-4693-8aa2-22707433e5c6"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f64ba8495734d8686feeecb04953b0c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTEzLTEtMS01NTk2OA_0780ed0d-9f9c-40a4-8b6a-7417fa1c9f11"
      unitRef="usd">80400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6a1b498ea6d4e5b8d189d76693cabb4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTE1LTEtMS01NTk2OA_ef33cefe-ee7b-4850-bee6-ee0128063487"
      unitRef="usd">51300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb58bd763fa9433e89fc2d61f1929408_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzEwLTE3LTEtMS01NTk2OA_903e327a-5647-43fc-8f03-73243e8358a1"
      unitRef="usd">52300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f3e24d5cd1f4b8ebdf4c2d6dd46c2fa_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTEtMS0xLTU1OTY4_1a8bbf21-aaad-4c35-8e46-40bf8c3e2b59"
      unitRef="usd">4015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62805e51679a413bb8bf0b46874d0827_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTMtMS0xLTU1OTY4_0f2210c2-e827-4b3c-ad73-f85a0471a03d"
      unitRef="usd">3566200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc8338e0e37d4903bd2d5fd0e52481d9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTUtMS0xLTU1OTY4_3e0adfef-c302-4fe7-a827-0294bb67a440"
      unitRef="usd">3513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d168944b24b447dae54f7498ce0ba93_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTctMS0xLTU1OTY4_1068d12a-3aca-49c8-8ced-6c7e66f16804"
      unitRef="usd">1106600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife450282edb048db9144cbdd9b90680e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTktMS0xLTU1OTY4_e7ed9b89-73c3-45b1-9a5c-6d91d7585a5d"
      unitRef="usd">1078200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3ec10c8f11e4192a9e80bbde7ba3a07_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTExLTEtMS01NTk2OA_cbafd1a5-7895-493c-a757-2658a725d9b2"
      unitRef="usd">1092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a7f4b3fa057413aa60a6ff5a64dbacd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTEzLTEtMS01NTk2OA_4bb0afed-9f1b-47cf-a532-35175e10a2fe"
      unitRef="usd">5121600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia523cdf50d014242b78b83f266130520_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTE1LTEtMS01NTk2OA_bcd96ebc-ed3d-47af-b1f0-1cd71499319c"
      unitRef="usd">4644400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf3e19f52f2f4397b2d5ea65c15ca225_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90YWJsZTo5ZTIyOTdmMGIwMDA0YjRjYmViOTllMGZiMDcwNmNmOC90YWJsZXJhbmdlOjllMjI5N2YwYjAwMDRiNGNiZWI5OWUwZmIwNzA2Y2Y4XzExLTE3LTEtMS01NTk2OA_f5f3bef9-1c5d-4910-a3eb-44d446034b1b"
      unitRef="usd">4605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90ZXh0cmVnaW9uOmYxOTY1ZGU3NmY0MjRiMGE4MWM2M2Q4NzU4NmMyNGU2XzE1NTY1_169055da-d52a-46d3-825b-88e515706d84">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#x201c;HHS-OIG&#x201d;) or the United States Department of Justice (the &#x201c;DOJ&#x201d;). Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Administrative Contractors (&#x201c;MACs&#x201d;), under programs known as &#x201c;widespread probes,&#x201d; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#x201c;appeal,&#x201d; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#x201c;OMHA&#x201d;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OMHA practices continue, an increased number of unfavorable administrative law judge (&#x201c;ALJ&#x201d;) decisions could have a negative effect on our long-term ALJ success rate. The current OMHA practice has resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, CMS announced the Targeted Probe and Educate (&#x201c;TPE&#x201d;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with CMS approved and announced Recovery Audit Contractors (&#x201c;RACs&#x201d;) audits related to inpatient rehabilitation facilities (&#x201c;IRFs&#x201d;), we received requests from 2013 to 2021 to review certain patient files for discharges occurring from 2010 to 2021.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#x2019;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS has also established Unified Program Integrity Contractors (&#x201c;UPICs&#x201d;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Medicare claims that are subject to these post-payment audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2021. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2021, 2020, and 2019, our adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for claims that are part of this post-payment claims review process was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inpatient Rehabilitation Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inpatient rehabilitation segment revenues are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#x2019;s total length of stay for in-house patients, each patient&#x2019;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Home Health and Hospice Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. The performance obligation is the rendering of services to the patient during the term of the episode of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal regulation. The base episode payment can be adjusted based on each patient&#x2019;s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We bill a portion of reimbursement from each Medicare episode near the start of each episode, and the resulting cash payment is typically received before all services are rendered. Effective January 1, 2021, this early payment process has been eliminated. As we provide home health services to our patients on a scheduled basis over the episode of care in a manner that approximates a pro rata pattern, revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of December&#160;31, 2021 and December&#160;31, 2020, the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not material and was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to certain Medicare regulations affecting outlier revenue if our patient&#x2019;s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Adjustments to the transaction price for the outlier cap &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; not material&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of December&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, revenue is recorded on an accrual basis based upon the date of service at amounts equal to our estimated per-visit transaction price. Price concessions, including contractual allowances for the differences between our standard rates and the applicable contracted rates, as well as estimated uncollectible amounts from patients, are recorded as decreases to the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare revenues for hospice are recognized and recorded on an accrual basis using the input method based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The performance obligation is the rendering of services to the patient during each day that they are on hospice care. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the MAC. Adjustments to the transaction price for these caps &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; not material as of December&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our estimated per day transaction price. Price concessions, including contractual adjustments for the difference between our standard rates and the amounts estimated to be realizable from patients and third parties for services provided, are recorded as decreases to the transaction price and thus reduce our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i117d8f2dd52b4c849355026c48132be2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzIvZnJhZzpmMTk2NWRlNzZmNDI0YjBhODFjNjNkODc1ODZjMjRlNi90ZXh0cmVnaW9uOmYxOTY1ZGU3NmY0MjRiMGE4MWM2M2Q4NzU4NmMyNGU2XzgyNDE_adc30c43-f595-486e-af7d-06c3dad25950"
      unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzUvZnJhZzo3ZTg2ZDkyZDMzNDE0MDE2YTM0Yjk0Njk1MGQyMzliMS90ZXh0cmVnaW9uOjdlODZkOTJkMzM0MTQwMTZhMzRiOTQ2OTUwZDIzOWIxXzUzMw_193abe57-cec2-41ac-8e49-4b0571dcebfc">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; include highly liquid investments with maturities of three months or less when purchased. Carrying values of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; approximate fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNzgvZnJhZzpiMWVjMWQyOTdjOWM0NmRiOTM0Y2RjMGZiYmQxZmYyZi90ZXh0cmVnaW9uOmIxZWMxZDI5N2M5YzQ2ZGI5MzRjZGMwZmJiZDFmZjJmXzEzNTM_f2a0326b-0522-41fe-a6ed-d0e14ade8fe6">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is a separate component of shareholders&#x2019; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90ZXh0cmVnaW9uOmE3ZmIyZWI5ZjY0NjRiNjM5YzY4NWJjY2UwNGM1ZDIzXzM1MTc_70b747b9-e0e4-4629-87b4-6ace6acc6097">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#x2019; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care and other discount plans, including Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#x2019;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90ZXh0cmVnaW9uOmE3ZmIyZWI5ZjY0NjRiNjM5YzY4NWJjY2UwNGM1ZDIzXzM1MDc_0657c896-3770-4312-86c7-5a4267fbe803">The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care and other discount plans, including Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7994f9fc04cd4840a17d1544f512fb8a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzItMS0xLTEtNTU5Njg_e17fbe9c-3e22-4e09-812c-b3811e097197"
      unitRef="number">0.636</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5d9449e02ec44d508d4927471cdcc16a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzItMy0xLTEtNTU5Njg_0ba2c0df-d18a-4341-aae7-d7afcedee649"
      unitRef="number">0.665</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i903f3c96be49421cb34587eada9a3d73_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzMtMS0xLTEtNTU5Njg_1d6f5b7c-82f2-4f71-8292-ec0ee8ada155"
      unitRef="number">0.274</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1ee22bb7c53a47e38414ec76277b14a0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzMtMy0xLTEtNTU5Njg_e6bc2637-dad3-4750-89b5-e4bf3fa5da8e"
      unitRef="number">0.250</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id0ad45dea4b44812b11a801895fbabbd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzQtMS0xLTEtNTU5Njg_14b0db49-ee7d-468a-8645-a258093c55e5"
      unitRef="number">0.037</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i95424a9f833f49b7975ae1ef37013150_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzQtMy0xLTEtNTU5Njg_9acf7fd4-fa79-4454-9011-e144b1d49479"
      unitRef="number">0.037</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i37ad81d8f2624817a96c259486c2c8f3_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzUtMS0xLTEtNTU5Njg_89d086a5-6eb0-412c-b7f5-d94a378a7d7f"
      unitRef="number">0.026</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i261ac6208a0241d587f1681af3279429_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzUtMy0xLTEtNTU5Njg_e3039afa-48b2-40f2-9948-b18a108d49e7"
      unitRef="number">0.027</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5ae4da8c0139452fafe3c4ebbfca7ed9_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzYtMS0xLTEtNTU5Njg_1d5d58d2-daad-436a-b918-2ead9bb4bca2"
      unitRef="number">0.015</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8b77ac20c17f43f0a30fd0ec6609eeb5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzYtMy0xLTEtNTU5Njg_60074553-afeb-4ed4-aee5-a522264ebd4b"
      unitRef="number">0.012</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7c6f62ec72ef49639c0efd8c8199879e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzctMS0xLTEtNTU5Njg_d50e7390-52f6-4a8d-9fce-7a0d665c4978"
      unitRef="number">0.012</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i610608fd11384b56bc5a535b1530b9c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzctMy0xLTEtNTU5Njg_ab0269a5-c9e2-4ec3-91ec-081069f6286b"
      unitRef="number">0.009</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14868c106a174d0a8a6b3d5fcda73002_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzgtMS0xLTEtNTU5Njg_4391d22e-7a6a-494b-9cfb-2b00c392f493"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i27c2b8cd85f64f408ee95281af4988eb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODEvZnJhZzphN2ZiMmViOWY2NDY0YjYzOWM2ODViY2NlMDRjNWQyMy90YWJsZTpmMzUzMmNiY2Y2MjI0MTNiODc4N2UxOGM5YzdhZjlhYS90YWJsZXJhbmdlOmYzNTMyY2JjZjYyMjQxM2I4Nzg3ZTE4YzljN2FmOWFhXzgtMy0xLTEtNTU5Njg_70cadeaa-df9e-4753-8f45-aa5e52d77961"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90ZXh0cmVnaW9uOjYxNDU2ZmFiNTRhYjQ5MTc4ZjQ5YmFkYzUzNDhhYjZiXzE0ODM_c61df175-5704-4a81-81af-3deaa59476b9">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90ZXh0cmVnaW9uOjYxNDU2ZmFiNTRhYjQ5MTc4ZjQ5YmFkYzUzNDhhYjZiXzE0ODE_29645ad9-d2ea-4642-8553-71cc739b741b">Useful lives are generally as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,357.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,378.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,539.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,374.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,601.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i86b3dd4016124cdc94f5fc2e5ae4ee7c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzEtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3ZWE3ODYzZmNjMTE0ODM2YjAwM2EwZjZiZjQ4NjEyNV80_a7bfc753-0fe1-4c28-bf6e-7650a6c6cb31">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i52accce1aeb84d6ea4f024105e7be7e4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzEtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3ZWE3ODYzZmNjMTE0ODM2YjAwM2EwZjZiZjQ4NjEyNV8xMA_b937c97f-edc6-4af0-a9fb-6ae53ac3095b">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic8e30f37f543478e8e85ee391f748aa2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzItMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3NjIyYWExNTljYzk0YWEwYmY2NGI0NTI0ZDJkMmJkZF80_72c501f4-9a0b-4742-b5a8-8006d720ff23">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i86cf609a63b04fb3b5b2972e6cb02c87_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzItMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3NjIyYWExNTljYzk0YWEwYmY2NGI0NTI0ZDJkMmJkZF8xMA_e969d883-7561-449c-86fb-f0781cbcdd1e">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iaaafd14af4414d4ca561988c69f582b1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzMtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2Y2YyMTE3NGIyMGI0Y2E3OThiNjFkZTQzNzA0Yjk2Ml80_de2f2ac3-c8f5-4c03-afb2-401c40bce02c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ida89837462c2402ebd51e087abc5f902_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzQtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo1ZDgyMDA3ZWE0NjU0ZWQwYjc5MmM3YjI4NWU0N2RiN180_c85919ba-54c8-4241-8858-162d2bd7a885">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if710bb04b24245de9a5f881c21cd788c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODQvZnJhZzo2MTQ1NmZhYjU0YWI0OTE3OGY0OWJhZGM1MzQ4YWI2Yi90YWJsZTowNDBjMmQ3Mjc3MjU0YjI2ODMzYTRjNjEyOTQ3YzA5Mi90YWJsZXJhbmdlOjA0MGMyZDcyNzcyNTRiMjY4MzNhNGM2MTI5NDdjMDkyXzQtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo1ZDgyMDA3ZWE0NjU0ZWQwYjc5MmM3YjI4NWU0N2RiN18xMA_da3fbdd6-ae17-45f6-a7d0-6dbbbc67f9d4">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xODcvZnJhZzo4ZTU2NjUzZmU3MGI0MTAwODBjYzRlZTdlNDJkMDhjNC90ZXh0cmVnaW9uOjhlNTY2NTNmZTcwYjQxMDA4MGNjNGVlN2U0MmQwOGM0XzE3OTk_8a9b0e87-7263-4210-b929-9dacf1a467ce">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. We do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90ZXh0cmVnaW9uOmMyYWJlYmYwYTgxODRiYzhiYjEzMTBkMWY3ZTNiMTM5XzQ2MTc_3a25baa3-e739-49df-95a6-f45186977aed">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other Intangible Assets&#x2014; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess qualitative factors in our inpatient rehabilitation and home health and hospice reporting units to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our reporting units using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of each reporting unit&#x2019;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting units to our market capitalization. When we dispose of a hospital or home health or hospice agency, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2021, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#x2019;s carrying amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;br/&gt;and Amortization Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 18 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;indefinite-lived asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market access assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years using accelerated basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and directly related payroll costs. Amortization begins when the internal-use software is ready for its intended use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#x2019;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90ZXh0cmVnaW9uOmMyYWJlYmYwYTgxODRiYzhiYjEzMTBkMWY3ZTNiMTM5XzQ2MTY_f3ea48a6-eb48-4d2f-a200-d0d945d2c11e">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;br/&gt;and Amortization Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 18 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;indefinite-lived asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market access assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years using accelerated basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information regarding our other intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Certificates of need:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Licenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncompete agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Trade name - Encompass:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Trade names - all other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Internal-use software:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Market access assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(462.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90ZXh0cmVnaW9uOmMyYWJlYmYwYTgxODRiYzhiYjEzMTBkMWY3ZTNiMTM5XzQ2MjM_180237e8-1109-46f6-9d52-581e3e076b90">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;br/&gt;and Amortization Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 18 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;indefinite-lived asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market access assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years using accelerated basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i50efb55c2089401caaa0a82d59fa749b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzEtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpmMzVlMGYxMGVjYmE0NzEwOGU3NGQwYTYxYjczMzJlNV80_1a7dbe93-304a-4169-aa90-824c708d6aa9">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1dc3915d64cb4cd186314ea29dfaa5e3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzEtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpmMzVlMGYxMGVjYmE0NzEwOGU3NGQwYTYxYjczMzJlNV8xMA_1d80bf43-f5fa-468c-85ef-b69bccf0d054">P30Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7af755a7159549e5992cc331710580a2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzItMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3ZmQ3ZDUxNTc5YTY0OGQzOTBhYmU1MzZjODZhYzEwMl80_c27bf64c-6431-4860-ab64-9fa02fda9162">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i74d0e9fd8f4d4150b657b8c8b64a3458_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzItMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo3ZmQ3ZDUxNTc5YTY0OGQzOTBhYmU1MzZjODZhYzEwMl8xMA_a890eb85-fe90-4c12-a772-f8054793ff76">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0d6195ee7b4d4edb890d0350b3e6cbc8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzMtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpkNjJmYjZiMTdlNTM0NzI0OTc4NTVjZjJiNGEyNjA1Nl80_62307cce-ca8c-4b19-a6d7-bc342c7b1711">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i36f353410c2e4dd5999e0aaa5dfb977a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzMtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpkNjJmYjZiMTdlNTM0NzI0OTc4NTVjZjJiNGEyNjA1Nl8xMA_2a24391d-10e4-428a-97e1-6e5d6acd833c">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if0f41d63c292477387fc936648de5818_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzYtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjozNmYwNDM3NDA3Nzk0YzEyOGQ3MGRiNWZjZTBhZWFmMF80_673d95d0-d1ed-489f-94d7-a2d9c1895c19">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idf20f07dc2a8494ebaf17ecb8a1ec09a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzYtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjozNmYwNDM3NDA3Nzk0YzEyOGQ3MGRiNWZjZTBhZWFmMF8xMA_623c1e8d-4bc7-4676-a27f-bdf34180d2b9">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i43ff9c36be674ad1a655dbc573f502de_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzctMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpjMzgxM2Q0ZmE1NWE0YTFjYmM5MDg1M2YwOGFhNDJmMV80_6f9ae86f-24b7-44c4-8b46-da51f769641f">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ife3d75e297fe483392cb51c7d6a9d0af_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzctMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpjMzgxM2Q0ZmE1NWE0YTFjYmM5MDg1M2YwOGFhNDJmMV8xMA_836d95ef-6bf1-4100-b936-c0542d0b0eca">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iad16be810f6b476785e37f9d09c58d8b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90YWJsZToyM2NmMDY1ZjAxNGI0M2FkODVhY2QxMTRkYjMyN2JhOC90YWJsZXJhbmdlOjIzY2YwNjVmMDE0YjQzYWQ4NWFjZDExNGRiMzI3YmE4XzgtMS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjoyN2ZkNDk3OTI1OGE0NzkzYThmZDk2MDkzMjQzNmU3Y180_55876c07-1853-4463-8259-1427ce0b0927">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iad16be810f6b476785e37f9d09c58d8b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTAvZnJhZzpjMmFiZWJmMGE4MTg0YmM4YmIxMzEwZDFmN2UzYjEzOS90ZXh0cmVnaW9uOmMyYWJlYmYwYTgxODRiYzhiYjEzMTBkMWY3ZTNiMTM5XzQ0Njc_55876c07-1853-4463-8259-1427ce0b0927">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <ehc:LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTMvZnJhZzplYjAxNjQ3OTcyYTQ0MTE3YmZhY2UzOTM0N2E1ODJmNy90ZXh0cmVnaW9uOmViMDE2NDc5NzJhNDQxMTdiZmFjZTM5MzQ3YTU4MmY3XzE1MjU_79d8ab21-01de-4c8b-a97c-34ba4a2bdcdd">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets and Other Intangible Assets&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#x2019;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.&lt;/span&gt;&lt;/div&gt;</ehc:LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTYvZnJhZzpkZTkyNzFjZmMxMzE0NDA4YmZiMDBlYjFkODU1OGNlOS90ZXh0cmVnaW9uOmRlOTI3MWNmYzEzMTQ0MDhiZmIwMGViMWQ4NTU4Y2U5XzIwMjY_71605b4e-eafa-42b3-8d0b-5fcc8346e18c">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in and Advances to Nonconsolidated Affiliates&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities we do not control but in which we have the ability to exercise significant influence over the operating and financial policies of the investee are accounted for under the equity method. Equity method investments are recorded at original cost and adjusted periodically to recognize our proportionate share of the investees&#x2019; net income or losses after the date of investment, additional contributions made, dividends or distributions received, and impairment losses resulting from adjustments to net realizable value. We record equity method losses in excess of the carrying amount of an investment when we guarantee obligations or we are otherwise committed to provide further financial support to the affiliate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the measurement alternative to account for equity investments for which the equity securities do not have readily determinable fair values and for which we do not have the ability to exercise significant influence. Under the measurement alternative, private equity investments are carried at cost and are adjusted only for other-than-temporary declines in fair value, additional investments, or distributions deemed to be a return of capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management periodically assesses the recoverability of our equity method and measurement alternative investments and equity method goodwill for impairment. We consider all available information, including the recoverability of the investment, the earnings and near-term prospects of the affiliate, factors related to the industry, conditions of the affiliate, and our ability, if any, to influence the management of the affiliate. We assess fair value based on valuation methodologies, as appropriate, including discounted cash flows, estimates of sales proceeds, and external appraisals, as appropriate. If an investment or equity method goodwill is considered to be impaired and the decline in value is other than temporary, we record an appropriate write-down.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xOTkvZnJhZzpkZTliNTYwZjMzNjU0ZWRlYWYyYzZlNDQzOGFhZjQ3Zi90ZXh0cmVnaW9uOmRlOWI1NjBmMzM2NTRlZGVhZjJjNmU0NDM4YWFmNDdmXzg4NQ_40fdc0cb-3a6b-4369-87a3-dab273fb5352">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Costs&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMDIvZnJhZzo0M2U5ZjMxODY4NmM0NDMxYjAzYTdlNDViMjc0YjNmMS90ZXh0cmVnaW9uOjQzZTlmMzE4Njg2YzQ0MzFiMDNhN2U0NWIyNzRiM2YxXzM5MjQ_dcbc54f9-48d0-4daf-910d-18709dc3689c">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cost approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMDUvZnJhZzpjYTNjYmJkY2RjMmY0YTFjYmI5ZGY1NmQwMjUxZDYxZS90ZXh0cmVnaW9uOmNhM2NiYmRjZGMyZjRhMWNiYjlkZjU2ZDAyNTFkNjFlXzY0MQ_18ffe873-0681-4875-b775-416207783496">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling Interests in Consolidated Affiliates&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#x2019; balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future. Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital in excess of par value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to certain members of the home health and hospice management team&#x2019;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $400 million or more. The fair value of our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#x2019; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inputs. The projected operating results use management&#x2019;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <ehc:RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMDgvZnJhZzpmNDM4NjJmYjA3NGM0OWQyODM3NzdmOWJiOWY3Y2Y4Zi90ZXh0cmVnaW9uOmY0Mzg2MmZiMDc0YzQ5ZDI4Mzc3N2Y5YmI5ZjdjZjhmXzEzNjI_d2373dbe-92fe-47fa-84c3-cc1c36343f88"
      unitRef="usd">400000000</ehc:RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTEvZnJhZzo5ODYxMzgyZmJmOTQ0N2JiOWIzMzUzNDI5NTVmN2IwNS90ZXh0cmVnaW9uOjk4NjEzODJmYmY5NDQ3YmI5YjMzNTM0Mjk1NWY3YjA1XzY1MA_57186f8a-47c0-4eca-937d-9bc7cee5d612">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees, excluding stock appreciation rights (&#x201c;SARs&#x201d;), are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period. Share-based payments to employees in the form of SARs are recognized in the financial statements based on their current fair value and expensed ratably over the applicable service period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTQvZnJhZzo4NTJlZjhlMDU4YzQ0MmIzYmQ0OTgwZjZkZDYyYmNmYi90ZXh0cmVnaW9uOjg1MmVmOGUwNThjNDQyYjNiZDQ5ODBmNmRkNjJiY2ZiXzc1Nw_23e6ad5c-441d-4bde-9376-978cba74c2f1">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Reserves&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <ehc:LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTQvZnJhZzo4NTJlZjhlMDU4YzQ0MmIzYmQ0OTgwZjZkZDYyYmNmYi90ZXh0cmVnaW9uOjg1MmVmOGUwNThjNDQyYjNiZDQ5ODBmNmRkNjJiY2ZiXzMwMA_7bb9d03a-bdb8-47be-a53d-c350c6be5463"
      unitRef="usd">5000000</ehc:LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTcvZnJhZzoyYzVmNTcyNTY0MDQ0YWI0OTRjOGRhNjRiZjFmZDg5OS90ZXh0cmVnaW9uOjJjNWY1NzI1NjQwNDRhYjQ5NGM4ZGE2NGJmMWZkODk5XzM0Mw_d9080803-4fb4-494b-bff6-5387264b7ae5">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advertising Costs&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within the accompanying consolidated statements of comprehensive income, were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.6 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $4.6 million, and $6.1 million in each of the years ended December 31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTcvZnJhZzoyYzVmNTcyNTY0MDQ0YWI0OTRjOGRhNjRiZjFmZDg5OS90ZXh0cmVnaW9uOjJjNWY1NzI1NjQwNDRhYjQ5NGM4ZGE2NGJmMWZkODk5XzI1NQ_b231e0af-5410-424a-b2a1-486fc1819526"
      unitRef="usd">5600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTcvZnJhZzoyYzVmNTcyNTY0MDQ0YWI0OTRjOGRhNjRiZjFmZDg5OS90ZXh0cmVnaW9uOjJjNWY1NzI1NjQwNDRhYjQ5NGM4ZGE2NGJmMWZkODk5XzI1OQ_31d94a50-0409-4332-802a-6fab84e16cc2"
      unitRef="usd">4600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMTcvZnJhZzoyYzVmNTcyNTY0MDQ0YWI0OTRjOGRhNjRiZjFmZDg5OS90ZXh0cmVnaW9uOjJjNWY1NzI1NjQwNDRhYjQ5NGM4ZGE2NGJmMWZkODk5XzI2Nw_7fbdb02f-9273-48c6-94d8-7e88ac2127b5"
      unitRef="usd">6100000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMjAvZnJhZzo3NDUzYWFlMTY5YmU0YjNhYTcwNTg5Mjg4ZTljOTBhMC90ZXh0cmVnaW9uOjc0NTNhYWUxNjliZTRiM2FhNzA1ODkyODhlOWM5MGEwXzI0Njc_94fc692d-5503-4d22-af47-778a69cef6c0">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the asset and liability method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We include the allocable portion of each pass-through entity&#x2019;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMjMvZnJhZzoxMDZlODcwNDM5NTc0YzljODdjYWI2NTEyYTcwMzBjYy90ZXh0cmVnaW9uOjEwNmU4NzA0Mzk1NzRjOWM4N2NhYjY1MTJhNzAzMGNjXzE3MDk_03e1c061-283b-4c4e-872c-fd2b3ce4570c">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities in and Results of Discontinued Operations&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Effective January 1, 2015, in connection with a new standard issued by the FASB, we changed our criteria for determining which disposals are presented as discontinued operations. Historically, any component that had been disposed of or was classified as held for sale qualified for discontinued operations reporting unless there was significant continuing involvement with the disposed component or continuing cash flows. In contrast, we now report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. As a result, the sale or disposal of a single Encompass Health facility or location no longer qualifies as a discontinued operation. This accounting change was made prospectively. No new components were recognized as discontinued operations since this guidance became effective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Loss from discontinued operations, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMjYvZnJhZzphODkzYjQyOWFhY2Y0YzI5YjI2YTU1YmE5YzNjMTA3ZC90ZXh0cmVnaW9uOmE4OTNiNDI5YWFjZjRjMjliMjZhNTViYTljM2MxMDdkXzk5Ng_48c7583d-91cd-4518-b6d1-1f9b0ba46152">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Common Share&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMjkvZnJhZzoxZWY5MTkyYjY0Zjg0NmZhOTNjOTkxZDEyYzIzYmZlYi90ZXh0cmVnaW9uOjFlZjkxOTJiNjRmODQ2ZmE5M2M5OTFkMTJjMjNiZmViXzU1MA_58cac812-11b6-470e-983b-e70e22ba4c68">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury Stock&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital in excess of par value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We account for the retirement of treasury stock as a reduction of retained earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzIvZnJhZzoyNTI5NDE1MTVjMjg0ZDMzODgyZDI2YzRmNDM2MTgwNC90ZXh0cmVnaW9uOjI1Mjk0MTUxNWMyODRkMzM4ODJkMjZjNGY0MzYxODA0XzIyMA_468b6e26-50ed-455c-9211-3f056aeab10a">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is comprised of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzUvZnJhZzpjNjdmMzNiYmI3YjA0M2U4YWE0YzY5MjAxNDQzNDg0Yi90ZXh0cmVnaW9uOmM2N2YzM2JiYjdiMDQzZThhYTRjNjkyMDE0NDM0ODRiXzMxNzc_bdd272c1-37d2-47d6-949b-ad3a1c7eaf80">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#x201d; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. The new guidance was effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. The adoption of this guidance did not have a material impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxMTI1_17472f6f-c5b9-43b0-ac98-dce4538a7545">Business Combinations:&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In April 2021, we acquired 51% of the operations of a 14-bed inpatient rehabilitation unit in San Angelo, Texas when Shannon Medical contributed those operations to our existing joint venture entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In June 2021, we acquired 75% of the operations of a 16-bed inpatient rehabilitation unit in McKees Rocks, Pennsylvania through our existing joint venture with Heritage Valley Health System, Inc. The acquisition was funded using cash on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In July 2021, we acquired 65% of the operations of a 22-bed inpatient rehabilitation unit in Odessa, Texas when ECHD Ventures contributed those operations to our existing joint venture entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#x2019;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition dates were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 3 to 5 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Frontier Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2021, we completed the acquisition of the home health and hospice assets of Frontier Home Health and Hospice (&#x201c;Frontier&#x201d;) in Alaska, Colorado, Montana, Washington, and Wyoming. The Frontier acquisition included the purchase of a 50% equity interest in the Heart of the Rockies Home Health joint venture and a 90% equity interest in the Hospice of Southwest Montana joint venture (inclusive of an additional 40% equity interest purchased for approximately $4&#160;million). We consolidate both of these joint ventures. On the acquisition date, nine home health and eleven hospice locations became part of our national network of home health and hospice locations. This acquisition was made to expand our existing presence in Colorado and Wyoming and extend our services to Alaska, Montana and Washington. We funded this transaction using cash on hand and borrowings under our revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We accounted for this transaction under the acquisition method of accounting and reported the results of operations of Frontier from its date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: replacement cost and continued use methods for property and equipment; an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets; an income approach utilizing the relief-from-royalty method for the trade name intangible asset; an income approach utilizing the excess earnings method for the certificates of need; and present value of remaining lease payments for leases. The aforementioned income methods utilize management&#x2019;s estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. All goodwill recorded reflects our expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use-assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreement (useful life of 5 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 3 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for this acquisition is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired, net of $0.8 million of cash acquired in 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Home Health and Hospice Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, using cash on hand, we acquired an additional 29% equity interest from Baptist Outpatient Services, Inc. in our existing Encompass Health Home Health of South Florida, LLC joint venture. This transaction increased our ownership interest from 51% to 80% and resulted in change in accounting for this joint venture from the equity method of accounting to a consolidated entity. As a result of our consolidation of this entity and the remeasurement of our previously held equity interest to fair value, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; increased $8.0 million, and we recorded a $3.2 million gain as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during 2021. This transaction was made to increase our ownership in a profitable entity and continue to grow our business.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This acquisition was funded using cash on hand and was individually immaterial to our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets. The aforementioned income methods utilize management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired locations&#x2019; mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. The amount of goodwill recorded as a result of these transactions that is deductible for federal income tax purposes is $3.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreement (useful life of 2 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Information regarding the net cash paid for this acquisition is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired, net of $0.8 million of cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of redeemable noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of equity interest prior to acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 1, 2022, we acquired a 50% equity interest from Frontier in a joint venture with Saint Alphonsus System (&#x201c;Saint Alphonsus&#x201d;) which operates home health and hospice locations in Boise, Idaho. The total purchase price was $15.9 million and was funded on December 31, 2021. This payment is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Acquisition of business, net of cash acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated statement of cash flow for the year end December 31, 2021. This transaction was not material to our financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Pro Forma Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,705.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In January 2020, we acquired 68% of the operations of a 13-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing 40-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a 20-bed expansion to the Littleton hospital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In May 2020, we acquired 51% of the operations of a 45-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a 60-bed de novo inpatient rehabilitation hospital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#x2019;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions are deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 2 to 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, we acquired the assets of Generation Solutions of Lynchburg, LLC in Lynchburg, Virginia. This acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in Central Virginia. The acquisition was funded using cash on hand and was immaterial to our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. The fair values of identifiable intangible assets were based on valuations using an income approach. The income approach is based on management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired location&#x2019;s mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the home health acquisitions during 2020 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Pro Forma Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,650.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,626.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In July 2019, we acquired approximately 51% of the operations of a 30-bed inpatient rehabilitation unit in Boise, Idaho when Saint Alphonsus Regional Medical Center contributed those operations to a joint venture with us. We funded our ownership interest in that consolidated joint venture through contributions of cash which the joint venture entity used to fund the construction of a 40-bed de&#160;novo inpatient rehabilitation hospital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In September 2019, we acquired 75% of the operations of Heritage Valley Sewickley Hospital&#x2019;s 11-bed inpatient rehabilitation unit in Sewickley, Pennsylvania, when Heritage Valley Health System, Inc. contributed those operations to our existing joint venture entity in connection with the opening of a new hospital.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for these transactions under the acquisition method of accounting and reported the results of operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the acquired hospitals from its respective date of acquisition. Information regarding the net cash paid for all inpatient rehabilitation acquisitions during 2019 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alacare Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, we completed the acquisition of privately owned Alacare Home Health &amp;amp; Hospice (&#x201c;Alacare&#x201d;) for a cash purchase price of $217.8&#160;million. The Alacare portfolio consisted of 23 home health locations and 23 hospice locations in Alabama. The acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients across Alabama. We funded the transaction with cash on hand and borrowings under our revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for this transaction under the acquisition method of accounting and reported the results of operations of Alacare from its date of acquisition. Information regarding the net cash paid for Alacare is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Home Health and Hospice Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, we completed the following home health acquisitions,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; none&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in the applicable geographic areas. Each acquisition was funded using cash on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In February 2019, we acquired the assets of Tidewater Home Health, PA in Columbia, South Carolina.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In March 2019, we acquired the assets and assumed the liabilities of two home health locations from Care Resource Group in East Providence, Rhode Island and Westport, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired locations from their respective dates of acquisition. Information regarding the net cash paid for the home health acquisitions during 2019 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Pro Forma Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net (Loss) Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alacare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,674.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="iddab4f4ba3d6483d872cadaede2070c3_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MTc_4a6c8faa-6a7a-4cd0-a691-38844a3c4837"
      unitRef="number">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="iddab4f4ba3d6483d872cadaede2070c3_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MjI_05cbf43c-d63c-4886-a267-9a48bde9b7d1"
      unitRef="bed">14</ehc:NumberofBedsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i724c634720d6417db699f31c4afa1e59_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MjY_9910e914-7504-47ac-b345-b949da30f92a"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="i724c634720d6417db699f31c4afa1e59_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MzE_e4094cd0-ee46-4d22-b7d0-87fffca18c34"
      unitRef="bed">16</ehc:NumberofBedsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i3170e4011fc54daabed3c4a7be2b4ccc_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1MzU_68f4580b-ba4d-4834-8310-72f93bd0bd06"
      unitRef="number">0.65</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="i3170e4011fc54daabed3c4a7be2b4ccc_I20210731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1NDA_b42cee8c-78fa-44ca-9574-8bf7c4319edb"
      unitRef="bed">22</ehc:NumberofBedsAcquired>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="if216c8078722440e8bee9e82ecb4ce83_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzY1NDk_a008c652-9414-49fe-8f22-2c272eb5eede"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxMDY1_17bc2f63-eebc-4879-9eab-854f3e1e013a">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition dates were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 3 to 5 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use-assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreement (useful life of 5 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 3 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreement (useful life of 2 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 2 to 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0f6567d29470494e9a12d3a1e62e4cb8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzMtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo1ZGU5MzFiNmRmNGE0MTc2ODM2NGE5ZDcxYTIwOGNmOF80Mw_cce7407b-e516-4be8-b4f3-c1e99ed3108b">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="icd6ff10ad12e43968abb2d9fedd5e789_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzMtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo1ZGU5MzFiNmRmNGE0MTc2ODM2NGE5ZDcxYTIwOGNmOF80OQ_05e89110-a3d8-4bb7-a90e-0e65b94f44ca">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i979989da0527439fb4dd5f80434b7799_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzMtMS0xLTEtNTU5Njg_7797df4e-3986-4d92-bfa9-4209b504eeed"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i3c84d8686d2346a48ae0771dc64c8d90_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzQtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpjYjhjMmVkNGI1MmY0NDc0OWU4Yzg2MzY1YmYwY2JjOF8zMQ_de6bf02d-e262-4e8c-a824-4245568d8c2d">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="idffd6c8c86e648aea58449550ba84ab6_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzQtMS0xLTEtNTU5Njg_68f19426-40ba-4061-ba90-8beae8200e74"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzctMS0xLTEtNTU5Njg_8fc8367d-2390-4454-8fc9-60c09c47c4c4"
      unitRef="usd">8800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzgtMS0xLTEtODcyMzU_714cb4aa-8bd7-4f55-9c4f-cef177bb5689"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiMzQyOTQ3YWFiNGI0MTQ0YTc3YjkyMDFjYTEzNjVlOC90YWJsZXJhbmdlOmIzNDI5NDdhYWI0YjQxNDRhNzdiOTIwMWNhMTM2NWU4XzgtMS0xLTEtNTU5Njg_04675795-1074-46d1-a9e3-93383325bf29"
      unitRef="usd">10200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxMTM2_dafdfbaa-ba35-40c7-9ffd-e9c3c742cb08">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for this acquisition is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired, net of $0.8 million of cash acquired in 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Information regarding the net cash paid for this acquisition is as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired, net of $0.8 million of cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of redeemable noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of equity interest prior to acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the home health acquisitions during 2020 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Information regarding the net cash paid for all inpatient rehabilitation acquisitions during 2019 is as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;Information regarding the net cash paid for Alacare is as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;Information regarding the net cash paid for the home health acquisitions during 2019 is as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTplYTE0NjhiYzFmMGM0N2E0YTA3NzE0NWU5ZGFkZjg1OS90YWJsZXJhbmdlOmVhMTQ2OGJjMWYwYzQ3YTRhMDc3MTQ1ZTlkYWRmODU5XzAtMS0xLTEtNTU5Njg_68004e56-2bb8-4470-81bf-3bd983afb00a"
      unitRef="usd">1400000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTplYTE0NjhiYzFmMGM0N2E0YTA3NzE0NWU5ZGFkZjg1OS90YWJsZXJhbmdlOmVhMTQ2OGJjMWYwYzQ3YTRhMDc3MTQ1ZTlkYWRmODU5XzEtMS0xLTEtNTU5Njg_2a3ddea3-fd1f-49ab-a76b-c40c05cdbab9"
      unitRef="usd">8800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i89099d548c34496e95ffebc80afea24d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTplYTE0NjhiYzFmMGM0N2E0YTA3NzE0NWU5ZGFkZjg1OS90YWJsZXJhbmdlOmVhMTQ2OGJjMWYwYzQ3YTRhMDc3MTQ1ZTlkYWRmODU5XzMtMS0xLTEtNTU5Njg_b537af4a-a381-474e-9daa-241f91b68794"
      unitRef="usd">9100000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTplYTE0NjhiYzFmMGM0N2E0YTA3NzE0NWU5ZGFkZjg1OS90YWJsZXJhbmdlOmVhMTQ2OGJjMWYwYzQ3YTRhMDc3MTQ1ZTlkYWRmODU5XzUtMS0xLTEtNTU5Njg_47d3d958-9124-4077-b8c8-e01fc06df4b4"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9b4f00d1fd94454e92fb97f98bd493e9_I20210601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4NTI_9d86ccd1-f9f6-441f-b363-d2e679c014a7"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifa6dc46af56b486895888a4fb9a90e92_I20210601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4NTc_fae7fd56-0fa6-45a8-b117-f57c5dea7084"
      unitRef="number">0.90</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ehc:EquityMethodInvestmentAdditionalOwnershipPercentage
      contextRef="ifa6dc46af56b486895888a4fb9a90e92_I20210601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4NjI_52716df0-15bc-4cfb-bb08-dd05bd3fd0e1"
      unitRef="number">0.40</ehc:EquityMethodInvestmentAdditionalOwnershipPercentage>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i05d940caeea84febbbbf878bafbcdbae_D20210601-20210601"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4Njc_f86dcc8f-a527-4aa9-8c9f-f34836e28f1d"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <ehc:NumberofLocationsofanAcquiredEntity
      contextRef="i28b060236cfa44c0a9c3de61db94e9a3_I20210601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4ODQ_f28333ae-b32b-46c8-9ee5-d250e0cabc85"
      unitRef="location">9</ehc:NumberofLocationsofanAcquiredEntity>
    <ehc:NumberofLocationsofanAcquiredEntity
      contextRef="i13d51c190f6b4f5bb0c9fee6c0a3bc79_I20210601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MzE4OTY_2751d37d-18c8-42f8-ad23-238813c0534b"
      unitRef="location">11</ehc:NumberofLocationsofanAcquiredEntity>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzAtMS0xLTEtNjk4MTk_418c077b-bffb-41e2-b747-9292dd197529"
      unitRef="usd">800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzEtMS0xLTEtNjk4MTk_83aebc5f-daf2-489a-a485-6906d9d25f7a"
      unitRef="usd">900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzItMS0xLTEtNjk4MTk_bbb85ef8-efbc-42d4-af1a-95629a378592"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzMtMS0xLTEtNjk4MTk_c6ccd981-9cb2-484c-b952-e3a11d0619cd"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzQtMS0xLTEtNjk4MTk_643cda86-ce20-452e-990f-6c01dc2daa60"
      unitRef="usd">900000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie0ae29baed2346a6b2cfd2b07ef1858b_D20210601-20210601"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzYtMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjoxNTI3NTJhYmUyMzA0MzUyYTkwYjRiOThkNjVjZWRlN18zMjk4NTM0ODgzMzg0_37900647-f415-4ae9-9d9f-5fe952bbc3be">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="idcaa5db830d74c41b04e18e3d712cbb4_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzYtMS0xLTEtNjk4MTk_432fb3f9-65f2-4678-9622-81501b0c1561"
      unitRef="usd">1700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i2dee177e57f140e9a6c2ed09915a1349_D20210601-20210601"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzctMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjozNmZhMmRjZTMzYzQ0ZTZhOTZhNGRkYjgxZTY0N2EzZV8zMjk4NTM0ODgzMzc2_5fe72295-8c72-4436-85ac-f7527fcdcfc9">P3M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ic04050f083344efa8f61e38aff5f34c0_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzctMS0xLTEtNjk4MTk_e2fd5efc-4920-4e36-9ca5-28be2ce6aad4"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i978416f27dae4c0896c015487892aa22_D20210601-20210601"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzgtMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjo2NmVmM2U5NzAwNWI0NWQzOTE0N2NiYWU0YzhkYWYzOV8zMjk4NTM0ODgzMzg3_baeaf7e7-9aa8-4801-a214-0c51e53bb27d">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iecae4857993e469a9b571629b580ca06_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzgtMS0xLTEtNjk4MTk_d62971bf-5c36-4676-8aa4-f8c7b01b0784"
      unitRef="usd">3100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6a3cd10f3d534263a36b46884d9b5925_D20210601-20210601"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzktMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjo3NWM1YzA2ZDI4OGU0MGUwYWJlNzEzOTNkZDIzNGFkYV8zMjk4NTM0ODgzMzc1_7121d9e7-94a2-4176-81e0-91e133503b2a">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i0d2a18b64b144278ab7fc3ca1e5665a1_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzktMS0xLTEtNjk4MTk_596f0312-fd0c-4889-8573-f4f529c37228"
      unitRef="usd">4800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzEwLTEtMS0xLTY5ODE5_c8882cbd-7351-46df-abce-e2ba3b8c369b"
      unitRef="usd">92400000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzEyLTEtMS0xLTcxOTkw_c858ea5f-0663-4640-8fe7-f4ab991d2ef9"
      unitRef="usd">105100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzE0LTEtMS0xLTY5ODE5_ef041057-4c3a-422f-86cd-b5057cf9755b"
      unitRef="usd">300000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzE1LTEtMS0xLTY5ODE5_d3362981-4ec4-4ab4-8fad-3c8a924bdeb4"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzE2LTEtMS0xLTY5ODE5_cf12049c-4467-4a8a-ac85-91a2b4b3e52e"
      unitRef="usd">800000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzE4LTEtMS0xLTY5ODE5_88fc9f70-f74f-4708-9b85-0f78ba8ee8da"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzIwLTEtMS0xLTcxOTk0_1fce3b00-b25e-4386-a075-e990581bf1fa"
      unitRef="usd">2000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzIxLTEtMS0xLTY5ODE5_1342e73f-76e8-4ea3-a4d9-ae7bb9bf9494"
      unitRef="usd">3900000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowZjgxNzAzZDcyMzk0YTg3OGNjZjkwYTFlZmNmZDBmMy90YWJsZXJhbmdlOjBmODE3MDNkNzIzOTRhODc4Y2NmOTBhMWVmY2ZkMGYzXzIyLTEtMS0xLTcxOTk0_01898038-17a6-484b-9682-adc4ae6651aa"
      unitRef="usd">99200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ia6216b070ab640879f12d1cff0c7359e_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzItMC0xLTEtNjk4MTkvdGV4dHJlZ2lvbjozY2RkNmFlMjkyZDM0YTI1YjQyMWUyM2NmYTFjNTI5ZF8zMjk4NTM0ODgzNDE5_418c077b-bffb-41e2-b747-9292dd197529"
      unitRef="usd">800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzItMS0xLTEtNjk4MTk_f4019d1a-d035-4f39-90af-dc47cab81981"
      unitRef="usd">11900000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzMtMS0xLTEtNjk4MTk_e1d02ac4-bb31-49a8-9d64-9b7764d6f0b3"
      unitRef="usd">92400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzQtMS0xLTEtNjk4MTk_53523a5d-dccb-4acc-afe1-6a5a368dceca"
      unitRef="usd">2000000.0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzUtMS0xLTEtNjk4MTk_bf27653c-e74f-48dc-bf80-6c0706dd8a3f"
      unitRef="usd">3900000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7f58573f32794cbba8648421cb4a3c1d_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTowODQ2NGUwNmJmNTA0ZDQ1ODMyMzJmOTU4MjRlZGZhZS90YWJsZXJhbmdlOjA4NDY0ZTA2YmY1MDRkNDU4MzIzMmY5NTgyNGVkZmFlXzUtMS0xLTEtNzIwMTE_30879a36-baff-4352-8c80-e5e71e0ab2b0"
      unitRef="usd">98400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i8279db1c332d4e708d8b00d2ec28fcee_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzg3OTYwOTMwODE5MjM_5b042b09-14f1-489c-a0e7-73da14a3bac1"
      unitRef="number">0.29</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i46b6c4b37b72430bb27cc893622797e5_I20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzM4NDgyOTA3NTY5MzY_e060788a-7990-4f4b-8c89-d8ce226d6bff"
      unitRef="number">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i8279db1c332d4e708d8b00d2ec28fcee_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzM4NDgyOTA3NTY5NDE_0602856d-367a-4535-96a5-645c5e7e0178"
      unitRef="number">0.80</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i27a84b415d07493e8cb918d0e2ea7f5d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzE2NDkyNjc1MDcxMTc_c5b2ebc6-428a-40d3-842c-019922401eef"
      unitRef="usd">8000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i27a84b415d07493e8cb918d0e2ea7f5d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzE2NDkyNjc1MDcxMjE_822cb79a-956c-498d-b650-f37b5ffc05a6"
      unitRef="usd">3200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i8279db1c332d4e708d8b00d2ec28fcee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzEwOTk1MTE2OTg1MDM_972f722a-4c18-43d5-9ffe-917bc4f7587a"
      unitRef="usd">3900000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzAtMS0xLTEtODc1Njc_6ed4d717-66af-40db-bec7-b1b645a9234f"
      unitRef="usd">800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzEtMS0xLTEtODc2NDA_df9c297a-adb0-4589-b7e6-189049addfd8"
      unitRef="usd">2000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8e771317f044433ebf4a8a2a5d5eb059_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzQtMC0xLTEtODc1NjcvdGV4dHJlZ2lvbjpmMTNmNGQxMzRhOWQ0MDdkYWRlNGYzM2Y0OTRjZDFkY180Mw_e8d8897d-4ad7-4fe6-b907-55bc8a236113">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ibef0cafa72f949fabb0aba607529bb57_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzQtMS0xLTEtODc1Njc_d680c2d0-0c26-4676-89e2-285b221b8f77"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i25e23730767f47b9a77ab3f4c276bfa8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzctMC0xLTEtODc1NjcvdGV4dHJlZ2lvbjpjNWU3YzdjY2NiMWU0YmYyYjRmMzZkYjQ5NjQzMmE5Yl8zMA_828040b2-e559-4ae3-8b0b-69552dbf6f8a">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i32f460ce531347859d5a7bfeec5a762d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzctMS0xLTEtODc1Njc_ec6aaa1d-0657-4e86-8f32-6879f814d120"
      unitRef="usd">1700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzgtMS0xLTEtODc1Njc_e704ed21-7477-46c2-a1b9-218b97f8edd5"
      unitRef="usd">8000000.0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzExLTEtMS0xLTg5MDQ4_d949bfd9-f6e7-467a-ae26-338c53df255d"
      unitRef="usd">12600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzEyLTEtMS0xLTg3NTY3_cd5c7a7a-2006-43d3-8cb6-b7fdcc7541a8"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzEzLTEtMS0xLTg3NTY3_8672eadf-791e-4149-b18a-035f3a077c44"
      unitRef="usd">300000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE0LTEtMS0xLTg3NTY3_9c0d2da8-ec91-44ff-a61b-89c691c112dc"
      unitRef="usd">400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE3LTEtMS0xLTg3Njcx_1bf5e4b5-13a8-4ee4-ab1b-474d2c4bcb75"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE4LTEtMS0xLTg5MTAy_c5609457-5699-4df3-a7c4-4ccf80e056f7"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE5LTEtMS0xLTEwNjE0OA_d3f3817a-e4ec-4ae7-96d3-b2b1fa6d591b"
      unitRef="usd">2300000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjY2YxODYzZTQyZjA0Zjg1YWIxNzEwN2FlNWQ2MzA1Ni90YWJsZXJhbmdlOmNjZjE4NjNlNDJmMDRmODVhYjE3MTA3YWU1ZDYzMDU2XzE5LTEtMS0xLTg5MTAy_e5f19f62-c38d-4106-ad59-4a02ddd818e4"
      unitRef="usd">9300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzAtMC0xLTEtMTEzNzU1L3RleHRyZWdpb246ZGYwZjczYzgxMjcwNDNmZGJlNDhlNDQ3MGU1OTk5ZWVfMjE5OTAyMzI1NTYzNQ_6ed4d717-66af-40db-bec7-b1b645a9234f"
      unitRef="usd">800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzAtMS0xLTEtODc1Njc_1a5f2502-7ca1-4185-8ba6-29c7420f3b28"
      unitRef="usd">3800000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzEtMS0xLTEtODc1Njc_d15dc6d9-ea3d-401d-9edb-a9cca4548c70"
      unitRef="usd">8000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzItMS0xLTEtODc1Njc_01490bf7-9242-43e6-b553-62f942fb78d1"
      unitRef="usd">1000000.0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzMtMS0xLTEtODc1Njc_15a825e9-0f62-4359-b717-46fe16736ef5"
      unitRef="usd">-2300000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="ib9a8d3d5ad454cf0990137e147a296d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzQtMS0xLTEtMTA2MTg1_f3774179-2993-43e1-bff7-0879ae632370"
      unitRef="usd">-5300000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1f22a379b1e74009b5c6191923b8dc71_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpiNjA4ODM5MmZiZmU0OTQ5OTgzMDQxNjM0Yjk0ZGVhZi90YWJsZXJhbmdlOmI2MDg4MzkyZmJmZTQ5NDk5ODMwNDE2MzRiOTRkZWFmXzUtMS0xLTEtODkxMTA_b7b1ef6f-af1f-4aa0-9fa4-25d3510f4e4d"
      unitRef="usd">3200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i773106cd2a324d499116f825de895f7e_I20220101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzYwNDczMTQwMTkyMTQ_b80b87fe-34a2-41c3-9c1f-1ba4fce154bb"
      unitRef="number">0.50</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i9eb895620d9c4243b46d28ee569388c2_D20220101-20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzE2NDkyNjc1MDY2NTA_12a99fdb-4dc2-4dac-9e6f-228e744cba06"
      unitRef="usd">15900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxMTM5_a56c979a-0f01-47f0-b3ec-d1ccc62117e7">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,705.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,650.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,626.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net (Loss) Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alacare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2019-12/31/2019 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,674.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzItMS0xLTEtNTU5Njg_aea36ee7-4ed9-42ce-aa5a-cbe80266292f"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzItMy0xLTEtNTU5Njg_8bc363dc-6f35-43fb-a357-4f8e82679b2e"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzQtMS0xLTEtNTU5Njg_d06c78fc-130e-4e85-93a7-4e110bc36417"
      unitRef="usd">20600000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzQtMy0xLTEtNTU5Njg_fb0c0e31-0f40-4667-a785-1c2aedf696a6"
      unitRef="usd">600000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i53030c89936d407897671309bbeb1f7b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzUtMS0xLTEtNTU5Njg_40d604f4-c2e2-4fc0-8f35-66425259b14b"
      unitRef="usd">5152200000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i53030c89936d407897671309bbeb1f7b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzUtMy0xLTEtNTU5Njg_82f9637f-e2c5-400f-a7df-938e29048583"
      unitRef="usd">413000000.0</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i663e53be26e941ffbeb8afe0c5e46b4e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzYtMS0xLTEtNTU5Njg_107503f0-8c7f-45cd-896a-5e4ce9424517"
      unitRef="usd">4705200000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i663e53be26e941ffbeb8afe0c5e46b4e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo5MDhmNDE5MjVhZjM0MGViOWFkZWM5N2UxNzhhYTU5Ny90YWJsZXJhbmdlOjkwOGY0MTkyNWFmMzQwZWI5YWRlYzk3ZTE3OGFhNTk3XzYtMy0xLTEtNTU5Njg_b0153efe-7530-463e-bfb0-6b1031ec4f0b"
      unitRef="usd">286800000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0MDc_1e567517-7246-4657-94d5-cf974e97fe80"
      unitRef="number">0.68</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0MTU_34350452-6e74-443d-9d15-b1c5b450bb22"
      unitRef="bed">13</ehc:NumberofBedsAcquired>
    <ehc:NumberofBedsContributed
      contextRef="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0MjM_55fb2b21-afda-4d25-a05b-a2b6dba14715"
      unitRef="bed">40</ehc:NumberofBedsContributed>
    <ehc:NumberofBedsExpanded
      contextRef="ife006ab44e004a1e9b59eef13c6e6a6b_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0MzE_6192a4cb-62ed-47b2-891f-aa4790060207"
      unitRef="bed">20</ehc:NumberofBedsExpanded>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ibc1955f816c34df2ba0316a625c6ba30_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0Mzk_47a3c741-4117-4a03-afc9-1e3bb71c72f4"
      unitRef="number">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="ibc1955f816c34df2ba0316a625c6ba30_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0NDc_5dd7fc2f-0ef9-4f52-85df-d924a05de4c1"
      unitRef="bed">45</ehc:NumberofBedsAcquired>
    <ehc:NumberofDeNovoBeds
      contextRef="ibc1955f816c34df2ba0316a625c6ba30_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0NTU_2a18e7da-5a2e-416f-9ee4-87fb80cb412e"
      unitRef="bed">60</ehc:NumberofDeNovoBeds>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="if75c35d2f7dc4b22824f5f5f2725d6cf_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzIxOTkwMjMyOTk0NjM_94b0e4fd-06e7-41ed-96ea-7222a7006934"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ife9f063c376c4593a96e8f3e1c883a61_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzEtMS0xLTEtNTU5Njg_a330d58f-2fc6-4060-ab58-de63d117d377"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia02028d9ba724ca6b97593c19c98591a_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzMtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjphYTEyMzk3OTFkMjc0ODM2ODg0ZGNlNjdkMmMyNDVhZV8yMTk5MDIzMjU1NTk3_db53bf32-50ca-47af-8a03-cbc1c9cd072a">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if670737e9dbc4e9fabc500e7e933390e_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzMtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjphYTEyMzk3OTFkMjc0ODM2ODg0ZGNlNjdkMmMyNDVhZV80MQ_ce217c1c-aea8-4145-810d-c1b0fa52aa78">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i26c3e316666b47b9bfa8484b5183985c_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzMtMS0xLTEtNTU5Njg_426b5977-b64f-44ef-a635-f8d7a8f7b1cb"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if702652feabd4fd78b3453c3d867f5cb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzQtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjplNDVhYmFhMmQyNWU0NjIyODAzYTg1NzdlMTg2MzY4M18zMQ_37f92236-01f7-4289-8373-e59911346925">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iaddff5e45b144d06a0e4c066b7081b51_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzQtMS0xLTEtNTU5Njg_db4df60b-f851-4d64-a22b-094eb59ba683"
      unitRef="usd">900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="ife9f063c376c4593a96e8f3e1c883a61_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzctMS0xLTEtNTU5Njg_b7ce4256-9606-4e3e-9f4e-d6eec158452d"
      unitRef="usd">9200000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ife9f063c376c4593a96e8f3e1c883a61_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTozODYxMWE4YzM3ZTA0MWU1OTM4ZTUzODhhNDZmNzE5YS90YWJsZXJhbmdlOjM4NjExYThjMzdlMDQxZTU5MzhlNTM4OGE0NmY3MTlhXzgtMS0xLTEtNTU5Njg_aab2a88a-ec6a-494d-b25e-68606d4ccae9"
      unitRef="usd">10900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNjM1NTg4Njc1Zjc0ZmU1OTY3ZjkwZThjZmRhYWRjMy90YWJsZXJhbmdlOjI2MzU1ODg2NzVmNzRmZTU5NjdmOTBlOGNmZGFhZGMzXzAtMS0xLTEtNTU5Njg_a44ea03a-c246-4929-a66a-adc8b16b375e"
      unitRef="usd">1700000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNjM1NTg4Njc1Zjc0ZmU1OTY3ZjkwZThjZmRhYWRjMy90YWJsZXJhbmdlOjI2MzU1ODg2NzVmNzRmZTU5NjdmOTBlOGNmZGFhZGMzXzEtMS0xLTEtNTU5Njg_f6c6d42c-bc71-42e1-97b6-510d7f4be7bc"
      unitRef="usd">9200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="ib3eb83f5d9b54bc49973f50a399a5c57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNjM1NTg4Njc1Zjc0ZmU1OTY3ZjkwZThjZmRhYWRjMy90YWJsZXJhbmdlOjI2MzU1ODg2NzVmNzRmZTU5NjdmOTBlOGNmZGFhZGMzXzMtMS0xLTEtNTU5Njg_40c373b7-d7ea-4178-8860-65996e296b41"
      unitRef="usd">10900000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNjM1NTg4Njc1Zjc0ZmU1OTY3ZjkwZThjZmRhYWRjMy90YWJsZXJhbmdlOjI2MzU1ODg2NzVmNzRmZTU5NjdmOTBlOGNmZGFhZGMzXzUtMS0xLTEtNTU5Njg_72687810-6223-42af-8f51-3c2733f48361"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id50245be41454844ab31b7a2899757ad_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo3MDNhMDBkMjA4YzM0MmUzYTNhYTg1MzY2NmNiMmFiNC90YWJsZXJhbmdlOjcwM2EwMGQyMDhjMzQyZTNhM2FhODUzNjY2Y2IyYWI0XzctMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpjZjgxOTAyNDM2NmE0MjUxYTdjMjMyYWM2ZWZkZWFhMl8yOA_b6b8ba77-35e1-4830-9d5f-98d334956131">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1ac3c94284cc42dcaefa48344e6f041c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo3MDNhMDBkMjA4YzM0MmUzYTNhYTg1MzY2NmNiMmFiNC90YWJsZXJhbmdlOjcwM2EwMGQyMDhjMzQyZTNhM2FhODUzNjY2Y2IyYWI0XzctMS0xLTEtNTU5Njg_d4afdbf9-570a-44e4-b5e2-03d21336c0b5"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="ic19f96ec376141aa841d8f70ab86a81b_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo3MDNhMDBkMjA4YzM0MmUzYTNhYTg1MzY2NmNiMmFiNC90YWJsZXJhbmdlOjcwM2EwMGQyMDhjMzQyZTNhM2FhODUzNjY2Y2IyYWI0XzgtMS0xLTEtNTU5Njg_c2e62059-846d-4526-904f-318aa0840788"
      unitRef="usd">1000000.0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ic19f96ec376141aa841d8f70ab86a81b_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo3MDNhMDBkMjA4YzM0MmUzYTNhYTg1MzY2NmNiMmFiNC90YWJsZXJhbmdlOjcwM2EwMGQyMDhjMzQyZTNhM2FhODUzNjY2Y2IyYWI0XzktMS0xLTEtNTU5Njg_a6a6510a-1dca-4226-9373-569221c9add8"
      unitRef="usd">1100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i37157c8e16b448a999811b4aa3779421_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjYjM2YmJjZDk3ZTc0NzNkODEzZGZhNWJlYjhjZjAyZC90YWJsZXJhbmdlOmNiMzZiYmNkOTdlNzQ3M2Q4MTNkZmE1YmViOGNmMDJkXzAtMS0xLTEtNTU5Njg_88d4dab8-bbe4-457b-b9c9-b3771dc674fc"
      unitRef="usd">100000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i37157c8e16b448a999811b4aa3779421_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjYjM2YmJjZDk3ZTc0NzNkODEzZGZhNWJlYjhjZjAyZC90YWJsZXJhbmdlOmNiMzZiYmNkOTdlNzQ3M2Q4MTNkZmE1YmViOGNmMDJkXzEtMS0xLTEtNTU5Njg_4e4cf00b-0a04-427e-bc88-b9b26f2fd468"
      unitRef="usd">1000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i37157c8e16b448a999811b4aa3779421_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTpjYjM2YmJjZDk3ZTc0NzNkODEzZGZhNWJlYjhjZjAyZC90YWJsZXJhbmdlOmNiMzZiYmNkOTdlNzQ3M2Q4MTNkZmE1YmViOGNmMDJkXzQtMS0xLTEtNTU5Njg_9172d982-1900-4760-9c13-549748088443"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzItMS0xLTEtNTU5Njg_ae5f2de8-90c2-44bb-9e3e-2007e5431048"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i3ee432e306324c2a885e0b6c1f42490f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzItMy0xLTEtNTU5Njg_377a4f83-90db-430d-8301-859f715549f7"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i4ba70666ee904810aaab1057f142b141_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzQtMS0xLTEtNTU5Njg_39ae2548-5e27-493c-8329-3f81bb13aba7"
      unitRef="usd">1500000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i4ba70666ee904810aaab1057f142b141_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzQtMy0xLTEtNTU5Njg_27d6747c-1ec5-4cdd-b567-c1d15fe84bcd"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="id9b1260076c94869baae8e55f9ee99a1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzUtMS0xLTEtNTU5Njg_ed9b693d-9712-43cd-ad02-7f2ceafeed5c"
      unitRef="usd">4650300000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="id9b1260076c94869baae8e55f9ee99a1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzUtMy0xLTEtNTU5Njg_8736870d-b498-4dd5-bf66-9cd7ed8be653"
      unitRef="usd">284800000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i0ae1c4e4319c41439be0441090ee96a3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzYtMS0xLTEtNTU5Njg_844e8680-9ecf-44b8-a892-d9aa5060448b"
      unitRef="usd">4626000000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i0ae1c4e4319c41439be0441090ee96a3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMmJjMzBiOTUwNjM0YjRmOWQ0NjRlZjg1MjFjM2MzMy90YWJsZXJhbmdlOjEyYmMzMGI5NTA2MzRiNGY5ZDQ2NGVmODUyMWMzYzMzXzYtMy0xLTEtNTU5Njg_66061985-28b9-4a36-ac44-025b8e5dffb3"
      unitRef="usd">360800000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i5b80143fe808479d88a8c886e315b0de_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzYwNDczMTM5Nzg1MTU_d573524d-77d5-41a6-b43e-f5eb638309cc"
      unitRef="number">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="i5b80143fe808479d88a8c886e315b0de_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MDkwODk_e6ba5ff9-3eea-477b-869e-b0f1c481429e"
      unitRef="bed">30</ehc:NumberofBedsAcquired>
    <ehc:NumberofDeNovoBeds
      contextRef="i5b80143fe808479d88a8c886e315b0de_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MDkwOTc_4db4986e-3658-497d-9973-5e1159071cfc"
      unitRef="location">40</ehc:NumberofDeNovoBeds>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ic25b5ad20ca94b278f0bb86ed76fb546_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MDkxMDU_569a76d7-dc18-4d27-bf89-b80d18dbf328"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="ic25b5ad20ca94b278f0bb86ed76fb546_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MDkxMTM_be133253-bc1f-4926-bc42-aff10cd31104"
      unitRef="bed">11</ehc:NumberofBedsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzAtMS0xLTEtNTU5Njg_3807e9e7-29d4-4068-b5eb-0d68b6f82548"
      unitRef="usd">500000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzEtMS0xLTEtNTU5Njg_0ab5ed5d-f65e-4ed2-8614-9dc95b2511a8"
      unitRef="usd">4800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzItMS0xLTEtNTU5Njg_de279d78-edc4-49f5-b9d2-01d987e66088"
      unitRef="usd">200000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzMtMS0xLTEtNTU5Njg_e2a0acae-1c56-4c12-a793-2ee1912c2cac"
      unitRef="usd">-5100000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo4N2E5MDg4YTMxMDA0N2NkYmQ1YzYzMjQ5ZDUwNTY5Ni90YWJsZXJhbmdlOjg3YTkwODhhMzEwMDQ3Y2RiZDVjNjMyNDlkNTA1Njk2XzUtMS0xLTEtNTU5Njg_b7649a82-a710-4d52-84cc-c7e4bee37918"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MTMyMTA_95b39dbe-af84-4d6a-8cc0-66ac65607eaf"
      unitRef="usd">217800000</us-gaap:PaymentsToAcquireBusinessesGross>
    <ehc:NumberofLocationsofanAcquiredEntity
      contextRef="i0a832df04afc419bb4147b4b673a3a50_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MTMyMTg_84eb6e26-ea82-4e4e-88fa-3924f3fa18c5"
      unitRef="usd">23</ehc:NumberofLocationsofanAcquiredEntity>
    <ehc:NumberofLocationsofanAcquiredEntity
      contextRef="i83efdee8e727419e8877258c72d7d06e_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MTMyMjY_27985077-58b7-40c0-b996-fe2c40bc1c6f"
      unitRef="location">23</ehc:NumberofLocationsofanAcquiredEntity>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo2NGQ2ZWVhNWQxZmI0OTkwODRhNzVkYTc4M2I4M2U2ZC90YWJsZXJhbmdlOjY0ZDZlZWE1ZDFmYjQ5OTA4NGE3NWRhNzgzYjgzZTZkXzAtMS0xLTEtNTU5Njg_80fd664d-f635-4a67-b625-cbd329034865"
      unitRef="usd">68600000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo2NGQ2ZWVhNWQxZmI0OTkwODRhNzVkYTc4M2I4M2U2ZC90YWJsZXJhbmdlOjY0ZDZlZWE1ZDFmYjQ5OTA4NGE3NWRhNzgzYjgzZTZkXzEtMS0xLTEtNTU5Njg_34a64b88-00ae-4dc8-bc34-ed90995d7d38"
      unitRef="usd">163900000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo2NGQ2ZWVhNWQxZmI0OTkwODRhNzVkYTc4M2I4M2U2ZC90YWJsZXJhbmdlOjY0ZDZlZWE1ZDFmYjQ5OTA4NGE3NWRhNzgzYjgzZTZkXzItMS0xLTEtNTU5Njg_c1d46394-c6a8-4924-af1c-7b031f83a8b1"
      unitRef="usd">14700000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZTo2NGQ2ZWVhNWQxZmI0OTkwODRhNzVkYTc4M2I4M2U2ZC90YWJsZXJhbmdlOjY0ZDZlZWE1ZDFmYjQ5OTA4NGE3NWRhNzgzYjgzZTZkXzUtMS0xLTEtNTU5Njg_cac4784f-c22a-41e2-9f72-6b05992ad557"
      unitRef="usd">217800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <ehc:NumberofLocationsofanAcquiredEntity
      contextRef="i33168cd12e06476282380e6f2e0e09ab_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90ZXh0cmVnaW9uOmNiYTczMzY2NDU1ZjQ1NzVhMjk3YTVmMDE1OTFlZTlmXzMyOTg1MzQ5MTY1NDk_3556d253-6362-42b3-ab16-e97a5b31f682"
      unitRef="location">2</ehc:NumberofLocationsofanAcquiredEntity>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMTJhNGUwNjM2NTY0OWRmYmI3Yjk4YWVmOGM4ZTc3NC90YWJsZXJhbmdlOjExMmE0ZTA2MzY1NjQ5ZGZiYjdiOThhZWY4YzhlNzc0XzAtMS0xLTEtNTU5Njg_10e751d9-adb7-40a9-b111-7ef0f873ef6a"
      unitRef="usd">3200000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMTJhNGUwNjM2NTY0OWRmYmI3Yjk4YWVmOGM4ZTc3NC90YWJsZXJhbmdlOjExMmE0ZTA2MzY1NjQ5ZGZiYjdiOThhZWY4YzhlNzc0XzEtMS0xLTEtNTU5Njg_db4840cf-94c9-4427-a598-2abdbee2c620"
      unitRef="usd">10800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMTJhNGUwNjM2NTY0OWRmYmI3Yjk4YWVmOGM4ZTc3NC90YWJsZXJhbmdlOjExMmE0ZTA2MzY1NjQ5ZGZiYjdiOThhZWY4YzhlNzc0XzItMS0xLTEtNTU5Njg_afc26fb0-5a02-44cb-86fe-5d3f8129638f"
      unitRef="usd">300000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToxMTJhNGUwNjM2NTY0OWRmYmI3Yjk4YWVmOGM4ZTc3NC90YWJsZXJhbmdlOjExMmE0ZTA2MzY1NjQ5ZGZiYjdiOThhZWY4YzhlNzc0XzUtMS0xLTEtNTU5Njg_898b0ef5-5b8b-4d45-99bf-eb44cde77fdb"
      unitRef="usd">13700000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzItMS0xLTEtNTU5Njg_b3de91a9-608c-41fb-9222-cc23086d7df7"
      unitRef="usd">4400000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="ieacbbafee23b4f8eaa61d11b4612198e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzItMy0xLTEtNTU5Njg_58ea7468-9b8a-4056-b2fb-1509a23ad806"
      unitRef="usd">-1300000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="ibc3bbc643a1a4af4b94038c460a77df9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzMtMS0xLTEtNTU5Njg_2cc671f6-c6ba-4651-aba1-afb41bbc435d"
      unitRef="usd">58500000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="ibc3bbc643a1a4af4b94038c460a77df9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzMtMy0xLTEtNTU5Njg_fb1b4792-5796-4da1-b62b-4e2b06e2979f"
      unitRef="usd">1600000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzQtMS0xLTEtNTU5Njg_e56976ff-fdcd-49f1-ad01-dff06fdeaa9d"
      unitRef="usd">6500000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="ib576bae7173b4b469937c96df0ff51b7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzQtMy0xLTEtNTU5Njg_e52b1160-0bae-416e-aec1-12521a0b45d9"
      unitRef="usd">-1500000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i3480d46a606c42799ec28c3335bc60d5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzUtMS0xLTEtNTU5Njg_2044a2da-0cd5-46d3-9c25-d780392ade6b"
      unitRef="usd">4674600000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i3480d46a606c42799ec28c3335bc60d5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yMzgvZnJhZzpjYmE3MzM2NjQ1NWY0NTc1YTI5N2E1ZjAxNTkxZWU5Zi90YWJsZToyNTlhYTAzNjEwYjc0MjZjOTdjNTY4YzcyN2YyYzExMC90YWJsZXJhbmdlOjI1OWFhMDM2MTBiNzQyNmM5N2M1NjhjNzI3ZjJjMTEwXzUtMy0xLTEtNTU5Njg_efc64522-9eb8-411c-b3a7-b692641dfb41"
      unitRef="usd">364300000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzEyNjc_4baeb40f-5271-4272-b8eb-ba19862f4187">Variable Interest Entities:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and December&#160;31, 2020, we consolidated ten and nine, respectively, limited partnership-like entities that are VIEs and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 90.0% as of December&#160;31, 2021. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and classifications of the consolidated VIEs&#x2019; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <ehc:VariableInterestEntityNumberofEntitiesConsolidated
      contextRef="ib73cbdd803994190950116ec559457fb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzQz_aa6d8bc9-fe5c-435d-bc57-c835c3a2752b"
      unitRef="entity">10</ehc:VariableInterestEntityNumberofEntitiesConsolidated>
    <ehc:VariableInterestEntityNumberofEntitiesConsolidated
      contextRef="i8fdff6f27e5f4de9b71d55e1a259b5d1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzUw_ce466613-e648-4689-91ef-c1e2190f865b"
      unitRef="entity">9</ehc:VariableInterestEntityNumberofEntitiesConsolidated>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="iff4da371722344eb96f964534004f0a6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzIxNg_7d030961-b75f-4dfc-b5a2-3c1329b89caf"
      unitRef="number">0.500</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i7d3a2f947eea4354801d07d1f2e1e80c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzIyMg_74db1bbd-81bb-4429-bd86-9794b76d4fa3"
      unitRef="number">0.900</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90ZXh0cmVnaW9uOjYyMzViZDI0OTg2MDQ1ZmU5NzVlODBjMjY1ZjExZWM4XzEyNjI_5d18d65e-5b8f-4667-aebc-eef9a3ab6f34">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and classifications of the consolidated VIEs&#x2019; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzMtMS0xLTEtNTU5Njg_d7b71afd-9259-4e8b-be04-514b7a26a68c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzMtMy0xLTEtNTU5Njg_8be94427-0bc5-4152-b50f-9e789c66fbd6"
      unitRef="usd">100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzQtMS0xLTEtNTU5Njg_ae30b4a0-4d3a-4592-8fdb-e97214d4b95c"
      unitRef="usd">36300000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzQtMy0xLTEtNTU5Njg_b933ed61-9cdd-4592-a00e-92fd0dc2e036"
      unitRef="usd">33100000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzUtMS0xLTEtNTU5Njg_c9729c47-d55a-4580-8f48-5a2ff934be39"
      unitRef="usd">7700000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzUtMy0xLTEtNTU5Njg_b0350955-bb9f-4217-b299-9cbd32bdab78"
      unitRef="usd">8600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzYtMS0xLTEtNTU5Njg_46c38d97-57ff-4499-a814-6818d6248ed0"
      unitRef="usd">44000000.0</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzYtMy0xLTEtNTU5Njg_fca26430-fc59-463f-a33b-70546ba1a2d3"
      unitRef="usd">41800000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzctMS0xLTEtNTU5Njg_19556350-14a7-48eb-8f40-77c29b3cadde"
      unitRef="usd">116300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzctMy0xLTEtNTU5Njg_297991db-fb07-45ce-9019-f84549775243"
      unitRef="usd">121100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzgtMS0xLTEtNTU5Njg_f29ef1b1-c454-4158-88b1-83b4af28886a"
      unitRef="usd">3200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzgtMy0xLTEtNTU5Njg_efcd7171-8448-46a4-8f9b-02a0468fab75"
      unitRef="usd">4700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzktMS0xLTEtNTU5Njg_2b2c4f83-a2b2-4b97-aea1-1ee6eefc00a4"
      unitRef="usd">28300000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzktMy0xLTEtNTU5Njg_47cb32b1-a534-4b22-90f1-4c79774bc862"
      unitRef="usd">19200000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEwLTEtMS0xLTU1OTY4_64599434-a1d0-44ac-b3b9-77873a7cd138"
      unitRef="usd">3300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEwLTMtMS0xLTU1OTY4_87f6b2ad-fcc4-4a95-ad67-1d4a7824a64f"
      unitRef="usd">3300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzExLTEtMS0xLTU1OTY4_116b232c-6a43-4340-be9e-7362b6663bf7"
      unitRef="usd">600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzExLTMtMS0xLTU1OTY4_b7877a87-9f77-498e-9236-dfae3c2551fe"
      unitRef="usd">500000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEyLTEtMS0xLTU1OTY4_c4bc32fe-f7e5-4c85-9f01-4a46b52f4fa1"
      unitRef="usd">30500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEyLTMtMS0xLTU1OTY4_6578f6fc-009f-4928-b9de-6b5c0bb1b4be"
      unitRef="usd">30600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEzLTEtMS0xLTU1OTY4_212e0239-ea52-42f8-80d1-9ca62104117f"
      unitRef="usd">226200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzEzLTMtMS0xLTU1OTY4_49aa1981-5a0c-455a-9740-05ccd7b42981"
      unitRef="usd">221200000</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE2LTEtMS0xLTU1OTY4_65872e74-b2b3-4b28-adc5-f2f9d4e0dad7"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE2LTMtMS0xLTU1OTY4_566fbcbd-ee1e-4c5d-a80e-374b9273cb1b"
      unitRef="usd">900000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE3LTEtMS0xLTU1OTY4_f5625532-a648-4407-b5b5-1a3ece48216e"
      unitRef="usd">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE3LTMtMS0xLTU1OTY4_fb81fe07-4cf3-4769-8b57-bd524b41f625"
      unitRef="usd">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE4LTEtMS0xLTU1OTY4_7451c105-fd12-4932-b1d7-d868d20ca763"
      unitRef="usd">5900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE4LTMtMS0xLTU1OTY4_bf039be8-424d-43ed-b981-74bf7cd2bc2a"
      unitRef="usd">6100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE5LTEtMS0xLTU1OTY4_97883a0c-97cf-4370-a3d8-ae0511c6fcb7"
      unitRef="usd">10200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzE5LTMtMS0xLTU1OTY4_5a307f07-4cac-4b74-b7cd-4a84459788d9"
      unitRef="usd">11300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIxLTEtMS0xLTU1OTY4_b7841526-41b9-41c0-8dbf-946fd9a772b6"
      unitRef="usd">9200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIxLTMtMS0xLTU1OTY4_0b9a8ea0-6a73-479e-aaba-a01a53a341e7"
      unitRef="usd">11700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIyLTEtMS0xLTU1OTY4_37027b44-47c7-40c8-bef3-3a059ae403c5"
      unitRef="usd">27800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIyLTMtMS0xLTU1OTY4_796e82f4-eed5-4a36-a61b-731024089ed0"
      unitRef="usd">31500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIzLTEtMS0xLTU1OTY4_2e78a667-f6d0-49a0-b349-4b176b52c3ed"
      unitRef="usd">8600000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzIzLTMtMS0xLTU1OTY4_75515189-e65c-4b98-b62e-2226d6c5e425"
      unitRef="usd">9600000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI0LTEtMS0xLTU1OTY4_9f4831e3-21b8-40f4-8522-62ecb5ed3334"
      unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI0LTMtMS0xLTU1OTY4_b97339dd-813c-49f0-9500-5040e25927fa"
      unitRef="usd">3300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI1LTEtMS0xLTU1OTY4_660f2d0a-4dbe-47bf-a4de-eae25410c958"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI1LTMtMS0xLTU1OTY4_dc4baa98-139e-4789-b647-7552b36838df"
      unitRef="usd">2400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i879908aa2e6542e3a0652e1ed683b4b1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI2LTEtMS0xLTU1OTY4_d7c85b87-7930-4d99-9f57-45377e433fcc"
      unitRef="usd">38200000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ia426808899a640b5963caeffaa5e5bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDEvZnJhZzo2MjM1YmQyNDk4NjA0NWZlOTc1ZTgwYzI2NWYxMWVjOC90YWJsZTpmMmZiY2JlNzRjOTA0ZTM1YTg2NzM3M2U0Y2I4YjBmOC90YWJsZXJhbmdlOmYyZmJjYmU3NGM5MDRlMzVhODY3MzczZTRjYjhiMGY4XzI2LTMtMS0xLTU1OTY4_2f49281e-1cc8-4fd3-bfc4-80e21c5fcc26"
      unitRef="usd">46800000</us-gaap:Liabilities>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzI5ODM_ce44690e-28db-4243-8594-7bd62e611e17">Cash and Marketable Securities:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our investments as of December&#160;31, 2021 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our investments as of December&#160;31, 2020 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliate cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Self-insured captive funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Self-insured captive funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Affiliate cash represents cash accounts maintained by joint ventures in which we participate where one or more of our external partners requested, and we agreed, that the joint venture&#x2019;s cash not be commingled with other corporate cash accounts and be used only to fund the operations of those joint ventures. Self-insured captive funds represent cash held at our wholly owned insurance captive, HCS, Ltd., as discussed in Note&#160;11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Self-Insured Risks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These funds are committed to pay third-party administrators for claims incurred and are restricted by insurance regulations and requirements. These funds cannot be used for purposes outside HCS without the permission of the Cayman Islands Monetary Authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classification of restricted cash held by HCS as current or noncurrent depends on the classification of the corresponding claims liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS. HCS insures a substantial portion of Encompass Health&#x2019;s professional liability, workers&#x2019; compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of December&#160;31, 2021 and 2020, $82.2 million and $72.6 million, respectively, of restricted marketable securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated balance sheets. During the years ended December&#160;31, 2021, 2020, and 2019, $0.6&#160;million, $0.4 million, and $1.2&#160;million, respectively, of unrealized net gains were recognized in our consolidated statements of comprehensive income on marketable securities still held at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investing information related to our available-for-sale marketable securities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales and maturities of available-for-sale marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of marketable securities is comprised of investments in mutual funds that hold investments in a variety of industries and geographies. As discussed in Note&#160;1,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Marketable Securities,&#x201d; when our portfolio included marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, we examined the severity and duration of the impairments in relation to the cost of the individual investments. We also considered the industry and geography in which each investment is held and the near-term prospects for a recovery in each.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzMwMDQ_c62eff3e-f64d-4ef9-999c-8bfda4a8808e">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our investments as of December&#160;31, 2021 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our investments as of December&#160;31, 2020 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8aba592c2b964f6eb203562691351ad5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzEtMS0xLTEtNTU5Njg_637866f4-1ab8-4f69-852e-58f2bcccc567"
      unitRef="usd">54800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i8aba592c2b964f6eb203562691351ad5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzEtMy0xLTEtNTU5Njg_462a6946-ca41-451a-b9ae-dc8d2da292d1"
      unitRef="usd">65500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i8aba592c2b964f6eb203562691351ad5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzEtNS0xLTEtNTU5Njg_5a37ee3f-d7c7-457b-a629-a0b665ee935c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i8aba592c2b964f6eb203562691351ad5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzEtNy0xLTEtNTU5Njg_29a969d5-378a-48a6-8438-47dfd9d028c0"
      unitRef="usd">120300000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i602ba1aa1f984572880fe83f75fc4c63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzItMS0xLTEtNTU5Njg_90008f11-8d5a-4919-866e-93d73424023e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i602ba1aa1f984572880fe83f75fc4c63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzItMy0xLTEtNTU5Njg_70faf229-1836-44e3-ac94-63412620fa26"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i602ba1aa1f984572880fe83f75fc4c63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzItNS0xLTEtNTU5Njg_0f57f1f1-50f9-4114-9e12-f797d74f77ef"
      unitRef="usd">82200000</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i602ba1aa1f984572880fe83f75fc4c63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzItNy0xLTEtNTU5Njg_e17a0108-5e5c-46b9-8e5f-6d728cb991a2"
      unitRef="usd">82200000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzQtMS0xLTEtNTU5Njg_5278eeeb-2bd8-4527-9669-eee48d53a872"
      unitRef="usd">54800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzQtMy0xLTEtNTU5Njg_566c3aab-bc97-40f1-a15e-6efe8bad72b3"
      unitRef="usd">65500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzQtNS0xLTEtNTU5Njg_9e1d05ec-8bdd-4957-aef5-77562181b869"
      unitRef="usd">82200000</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTozOGRmZjhlOWRkMmY0YzExODIyODExODg0ZThlMDBkNy90YWJsZXJhbmdlOjM4ZGZmOGU5ZGQyZjRjMTE4MjI4MTE4ODRlOGUwMGQ3XzQtNy0xLTEtNTU5Njg_4cbdb952-b596-472a-9263-ae0c11ec84fa"
      unitRef="usd">202500000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i15222b6444e842b6bdb5604f4703b8e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzEtMS0xLTEtNTU5Njg_71d68330-7862-403a-8962-fca271e2eb7a"
      unitRef="usd">224000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i15222b6444e842b6bdb5604f4703b8e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzEtMy0xLTEtNTU5Njg_86be57ae-6568-40b0-a943-a181f2da847a"
      unitRef="usd">86900000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i15222b6444e842b6bdb5604f4703b8e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzEtNS0xLTEtNTU5Njg_1c8281d2-3855-40d2-ba3d-fc81df081fa9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i15222b6444e842b6bdb5604f4703b8e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzEtNy0xLTEtNTU5Njg_d90766bd-f1a0-4c2b-afb1-91321678f5cc"
      unitRef="usd">310900000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i10b6ec76120d47a3be5eb18921f9202b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzItMS0xLTEtNTU5Njg_c4f4f7b6-7247-4403-99d5-b8c656f74b4c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i10b6ec76120d47a3be5eb18921f9202b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzItMy0xLTEtNTU5Njg_29665196-9ce6-411b-ae5c-998c761c8f3d"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i10b6ec76120d47a3be5eb18921f9202b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzItNS0xLTEtNTU5Njg_9c170def-23ac-491d-bf37-fc1a5e768ffa"
      unitRef="usd">72600000</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i10b6ec76120d47a3be5eb18921f9202b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzItNy0xLTEtNTU5Njg_2467237e-a75a-41c8-a78c-da2990fb6ca6"
      unitRef="usd">72600000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzQtMS0xLTEtNTU5Njg_2c2de36f-b14a-4485-bd8a-eba12d75d2a5"
      unitRef="usd">224000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzQtMy0xLTEtNTU5Njg_6766618a-2458-4708-88ff-84afc1ca1f9f"
      unitRef="usd">86900000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzQtNS0xLTEtNTU5Njg_7d531d1c-0604-4f40-80ca-209478adf383"
      unitRef="usd">72600000</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo1ZWE4NTI5ZGMzMGE0ODlmOWQzMzIyNDkxNGU1NzMyMS90YWJsZXJhbmdlOjVlYTg1MjlkYzMwYTQ4OWY5ZDMzMjI0OTE0ZTU3MzIxXzQtNy0xLTEtNTU5Njg_27c7affb-69b8-4ed4-a76b-4d1bba10497a"
      unitRef="usd">383500000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzMwMTg_d9568887-30ec-4145-b5ea-bbd0242d0460">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliate cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Self-insured captive funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Self-insured captive funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="id746f8bfcc324f59bffb9b5c9b3a3d24_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzMtMS0xLTEtNTU5Njg_89c41d25-900c-4102-9d71-2de35305c94b"
      unitRef="usd">17300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i0d0a191d08204ba6a56d0168e6d7c236_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzMtMy0xLTEtNTU5Njg_0e044548-3dad-4366-a068-a75615c124ee"
      unitRef="usd">17500000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i6382b49a2de846faadc4af9c9f5ed24e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzQtMS0xLTEtNTU5Njg_9d18fc6d-96da-4038-8f8e-673001b2bfa2"
      unitRef="usd">47800000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="id841d4ad284e4f34936f643391714d19_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzQtMy0xLTEtNTU5Njg_209c72dc-9e2f-40a7-85c0-108cd247caa2"
      unitRef="usd">47900000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzYtMS0xLTEtNTU5Njg_e03d050d-9c2f-43cc-a0cd-083069b23342"
      unitRef="usd">65100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzYtMy0xLTEtNTU5Njg_f7395c1a-e3d9-4c47-a4ce-f81ddace775b"
      unitRef="usd">65400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i6382b49a2de846faadc4af9c9f5ed24e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzktMS0xLTEtNTU5Njg_78e0fead-65e0-45c3-94d5-f8e80034230c"
      unitRef="usd">400000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="id841d4ad284e4f34936f643391714d19_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzktMy0xLTEtNTU5Njg_f9a9719c-e6be-45be-bf95-023533f4756a"
      unitRef="usd">21500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzExLTEtMS0xLTU1OTY4_e35e0a6f-ae33-4111-9094-65d864a9f06a"
      unitRef="usd">65500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTo4Y2M3ZWNiMTE2YTE0YjU3OTlhNzI2NjMyZDc3MWZlZi90YWJsZXJhbmdlOjhjYzdlY2IxMTZhMTRiNTc5OWE3MjY2MzJkNzcxZmVmXzExLTMtMS0xLTU1OTY4_e4179469-835a-4953-a673-a111dd4e5157"
      unitRef="usd">86900000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <ehc:RestrictedDebtSecuritiesNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE1NjY_1e995935-187f-4c97-bfd7-6e9bd6220ce3"
      unitRef="usd">82200000</ehc:RestrictedDebtSecuritiesNoncurrent>
    <ehc:RestrictedDebtSecuritiesNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE1NzM_369a481d-5a72-4b92-957c-5f50df00c3c5"
      unitRef="usd">72600000</ehc:RestrictedDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE3NDE_9eb8c33a-1646-4b33-b478-1e2999031892"
      unitRef="usd">600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE3NDU_a1a03470-b243-4122-b428-079a6a029c23"
      unitRef="usd">400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzE3NTM_02f5d67e-39ef-47dd-b65e-25118ab5241d"
      unitRef="usd">1200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfRealizedGainLossTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90ZXh0cmVnaW9uOjJjOWE0NzE4ZDRjMTQ4NWVhN2NkMDNiZjAyODZmN2ZlXzI5NzU_858cc48b-a5c1-4cf2-9ace-b2bd936b2f46">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investing information related to our available-for-sale marketable securities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales and maturities of available-for-sale marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRealizedGainLossTableTextBlock>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTphN2RiNTNmNWYyMzQ0MjFiODVjY2U4MzBhYTMxNjUxNS90YWJsZXJhbmdlOmE3ZGI1M2Y1ZjIzNDQyMWI4NWNjZTgzMGFhMzE2NTE1XzItMS0xLTEtNTU5Njg_bc3bf1eb-f4e4-4a04-9032-aaf5f95116ad"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTphN2RiNTNmNWYyMzQ0MjFiODVjY2U4MzBhYTMxNjUxNS90YWJsZXJhbmdlOmE3ZGI1M2Y1ZjIzNDQyMWI4NWNjZTgzMGFhMzE2NTE1XzItMy0xLTEtNTU5Njg_96da0bbf-672d-4563-8e50-48de4ec10dc0"
      unitRef="usd">12600000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDQvZnJhZzoyYzlhNDcxOGQ0YzE0ODVlYTdjZDAzYmYwMjg2ZjdmZS90YWJsZTphN2RiNTNmNWYyMzQ0MjFiODVjY2U4MzBhYTMxNjUxNS90YWJsZXJhbmdlOmE3ZGI1M2Y1ZjIzNDQyMWI4NWNjZTgzMGFhMzE2NTE1XzItNS0xLTEtNTU5Njg_38b4bf10-2aed-46a0-bc98-96df3ca8cd94"
      unitRef="usd">6400000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90ZXh0cmVnaW9uOjg5YzEzMjBiNjJmYTQzMTA4NDA4NzI5YjA5NzE2YWY4XzUwMg_34664dfe-46ee-4cfc-9134-a293d8d560ba">Accounts Receivable:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because the resolution of claims that are part of Medicare audit programs can take several years, we review the patient receivables that are part of this adjudication process to determine their appropriate classification as either current or noncurrent. Amounts considered noncurrent are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheet. See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Net Operating Revenues,&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90ZXh0cmVnaW9uOjg5YzEzMjBiNjJmYTQzMTA4NDA4NzI5YjA5NzE2YWY4XzUwMQ_6b519274-c8d9-4546-a6a7-1a611ee5cbdb">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzMtMS0xLTEtNTU5Njg_34bef982-2113-4593-8a97-ad9b033d3a29"
      unitRef="usd">666600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzMtMy0xLTEtNTU5Njg_12891611-0b3a-459c-9663-311d2eee5238"
      unitRef="usd">563000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzQtMS0xLTEtNTU5Njg_9e3931af-c886-48c2-944c-f8b7275f7d6b"
      unitRef="usd">13700000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzQtMy0xLTEtNTU5Njg_1acdc67f-2818-4044-89cb-a2b1d35f2228"
      unitRef="usd">9800000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzUtMS0xLTEtNTU5Njg_8938b018-0650-476a-b9f4-b8ead46f89ed"
      unitRef="usd">680300000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzUtMy0xLTEtNTU5Njg_3d03cd32-baeb-469e-ac6e-6a38b1d4bfb7"
      unitRef="usd">572800000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzYtMS0xLTEtNTU5Njg_f25133a7-bfbd-4c08-914f-8f0dd61830f3"
      unitRef="usd">83500000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzYtMy0xLTEtNTU5Njg_d7b41ec7-aa70-4475-81a7-93145430a79b"
      unitRef="usd">123800000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzctMS0xLTEtNTU5Njg_af66c376-09ce-429b-a4f2-a0118107ea75"
      unitRef="usd">763800000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNDcvZnJhZzo4OWMxMzIwYjYyZmE0MzEwODQwODcyOWIwOTcxNmFmOC90YWJsZTo1ODkzMTY3OTg2MjM0OWVjYjRhNjVjYTZiZTI0MzBlMC90YWJsZXJhbmdlOjU4OTMxNjc5ODYyMzQ5ZWNiNGE2NWNhNmJlMjQzMGUwXzctMy0xLTEtNTU5Njg_720c981c-3613-458a-b890-aafccc094c0f"
      unitRef="usd">696600000</us-gaap:AccountsReceivableNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90ZXh0cmVnaW9uOjZlZDVmMWEzNTVhNTQxZGNiZjZhN2MzNjNlNTBkNGU1XzUwOQ_48025b0d-e2ac-459a-a3eb-8856787ff943">Property and Equipment:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,357.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,378.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,539.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,374.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,601.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, approximately 73% of our consolidated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; held by Encompass Health Corporation and its guarantor subsidiaries was pledged to the lenders under our credit agreement. See Note&#160;10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Item 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Liquidity and Capital Resources.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of depreciation expense and interest capitalized is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest capitalized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i4c1ca2c1f30a41728732fec700a16e4d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzItMS0xLTEtNTU5Njg_f6b4592e-d2ab-4c83-99be-0b56843649e2"
      unitRef="usd">259800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i8516a1fe22324229af025f40b32d77f2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzItMy0xLTEtNTU5Njg_57c58898-8d13-4aef-a4ee-fdbad77f2306"
      unitRef="usd">217200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i8bdb38e0060345f8a7f153c65b0ae589_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzMtMS0xLTEtNTU5Njg_8d88fb33-16e7-443c-8c4d-6cc0db9ad0f1"
      unitRef="usd">2632800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ic3869f5c4ac04881b2a7c48441f84658_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzMtMy0xLTEtNTU5Njg_3b6024aa-46a3-485b-a89c-38e23ba1588d"
      unitRef="usd">2357000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i17fc36ea770b490097eb1b8b155949d7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzQtMS0xLTEtNTU5Njg_3fe48a36-5e6f-4bcd-9c51-ade6743b673c"
      unitRef="usd">254100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i1e53fbc95c16440ebc2899f7ff225074_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzQtMy0xLTEtNTU5Njg_155c1139-dff9-41f7-af13-43613271115c"
      unitRef="usd">232500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i7f487c6319de4b2789e80cce58d82850_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzUtMS0xLTEtNTU5Njg_afe6b77b-3ccd-441e-b850-24f37ef13cef"
      unitRef="usd">35000000.0</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ifd0053d81c5643ee947bbd55082c4aa7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzUtMy0xLTEtNTU5Njg_866e86c8-ec43-4417-b770-40ccfdfe6102"
      unitRef="usd">33900000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i8a35614edf5643cda801a3adbda6f446_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzYtMS0xLTEtNTU5Njg_8260416d-25e2-456a-bdca-9cb1ad964cfb"
      unitRef="usd">606100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ia70f9dcbe8e24aeea62c485281cea06f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzYtMy0xLTEtNTU5Njg_2240a91e-f6a0-42f8-b90d-5ff4bb20d3be"
      unitRef="usd">537900000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzctMS0xLTEtNTU5Njg_442ff530-5ba9-41f5-b3e4-95fe71fbf5a6"
      unitRef="usd">3787800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i36f1e5c21e09435f94b9e6e1c8a4bc7a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzctMy0xLTEtNTU5Njg_21bcfb98-622d-4d44-849c-fdaf2da22089"
      unitRef="usd">3378500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzgtMS0xLTEtNTU5Njg_94765a3f-853c-4ccf-b2ca-1c67b1a61d58"
      unitRef="usd">1539400000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i36f1e5c21e09435f94b9e6e1c8a4bc7a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzgtMy0xLTEtNTU5Njg_1e2fb63c-9bb9-4938-8d9a-1c40fc27e5af"
      unitRef="usd">1374400000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzktMS0xLTEtNTU5Njg_9b152c72-4314-401e-91a1-6e850a7a0627"
      unitRef="usd">2248400000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i36f1e5c21e09435f94b9e6e1c8a4bc7a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzktMy0xLTEtNTU5Njg_88c0a775-f112-4343-aa4d-9732505fa55f"
      unitRef="usd">2004100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i39344a1ae54d4b5a8df1f9ea9760ee2f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzEwLTEtMS0xLTU1OTY4_6660eb93-7eaa-424e-bc10-0e973353b44e"
      unitRef="usd">353200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="iac6d18334d234593b48e1782c831116b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzEwLTMtMS0xLTU1OTY4_6a441922-507b-4ea3-b717-bfa745cde53c"
      unitRef="usd">202500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzExLTEtMS0xLTU1OTY4_614c1fb0-b8d5-4c67-a818-9b1dc51ab114"
      unitRef="usd">2601600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZToyM2JiMjBjMmVmZWY0Yjk2YTY5YzBmYjM5MGI2YjI3OS90YWJsZXJhbmdlOjIzYmIyMGMyZWZlZjRiOTZhNjljMGZiMzkwYjZiMjc5XzExLTMtMS0xLTU1OTY4_81f171fd-74a4-40db-a06e-abcc3faf2f98"
      unitRef="usd">2206600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <ehc:Percentageofassetspledgedtolendersundercreditagreement
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90ZXh0cmVnaW9uOjZlZDVmMWEzNTVhNTQxZGNiZjZhN2MzNjNlNTBkNGU1XzEwMA_f55fcd95-28fb-481a-b5ce-3b842810931c"
      unitRef="number">0.73</ehc:Percentageofassetspledgedtolendersundercreditagreement>
    <ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90ZXh0cmVnaW9uOjZlZDVmMWEzNTVhNTQxZGNiZjZhN2MzNjNlNTBkNGU1XzUyNQ_00cb52c0-a460-41da-a90c-40b439350ec6">&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of depreciation expense and interest capitalized is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest capitalized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock>
    <us-gaap:Depreciation
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzItMS0xLTEtNTU5Njg_3315177f-eb69-4276-9572-2f328042111a"
      unitRef="usd">166200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzItMy0xLTEtNTU5Njg_60360c62-c8f0-428c-8bc3-1133944eb4ea"
      unitRef="usd">151100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzItNS0xLTEtNTU5Njg_ea76d18b-cc14-4531-8cbd-c5c23869ac7b"
      unitRef="usd">130000000.0</us-gaap:Depreciation>
    <us-gaap:InterestCostsCapitalized
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzQtMS0xLTEtNTU5Njg_fdb552cf-988a-411f-96ad-701d1051b1f6"
      unitRef="usd">8900000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzQtMy0xLTEtNTU5Njg_66d426aa-1203-45ee-9726-2c2e666884e1"
      unitRef="usd">6000000.0</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTAvZnJhZzo2ZWQ1ZjFhMzU1YTU0MWRjYmY2YTdjMzYzZTUwZDRlNS90YWJsZTpmODcyNjQ1N2I4MWU0NWVmYjVkMzQ5MmIyZDgxNjljNS90YWJsZXJhbmdlOmY4NzI2NDU3YjgxZTQ1ZWZiNWQzNDkyYjJkODE2OWM1XzQtNS0xLTEtNTU5Njg_cdba6759-8f26-425a-8a96-c5503d5851d1"
      unitRef="usd">8300000</us-gaap:InterestCostsCapitalized>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDM_872a66be-90d9-4576-a069-354fba19bbf8">Leases:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1- to 25-year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term and variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated balance sheet information related to leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finance lease assets are recorded net of accumulated amortization of $147.8 million and $129.6 million as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to our leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDQ_90d8753c-c652-47f9-9d1c-7212bca6614e">Leases:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1- to 25-year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term and variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated balance sheet information related to leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finance lease assets are recorded net of accumulated amortization of $147.8 million and $129.6 million as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to our leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ehc:Operatingandfinanceleasecontractterm
      contextRef="if750783979f34735a047752b07b25985_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzIxNQ_7d6af2d4-ea79-4875-8e94-c1ed7886b75d">P1Y</ehc:Operatingandfinanceleasecontractterm>
    <ehc:Operatingandfinanceleasecontractterm
      contextRef="ib3d825afa781450ba456aff29ce70e22_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDE_3710d17f-06a6-4c26-bd84-e3532accc880">P25Y</ehc:Operatingandfinanceleasecontractterm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNTA_7a00f041-0452-4ff8-8108-cd457fce41e1">&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term and variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzItMS0xLTEtNTU5Njg_6516ffd2-1a50-4d7c-81f1-3ebbd528d898"
      unitRef="usd">66000000.0</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzItMy0xLTEtNTU5Njg_63f95596-e8d3-4447-bd42-4645ac384aa3"
      unitRef="usd">68500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzItNS0xLTEtMTIxMzcz_362f5ec3-2464-4eb5-9454-eeeb4fcf5c35"
      unitRef="usd">72900000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzQtMS0xLTEtNTU5Njg_c7ad2727-97bd-49e0-a609-5954402ef054"
      unitRef="usd">34000000.0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzQtMy0xLTEtNTU5Njg_b2d470c4-8596-448b-884f-1c79e4f09435"
      unitRef="usd">32100000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzQtNS0xLTEtMTIxMzcz_f265d4e7-1d98-41e9-b940-5db8ffdf26a0"
      unitRef="usd">30300000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzUtMS0xLTEtNTU5Njg_84ce68ce-a947-4413-ad28-5940986593fa"
      unitRef="usd">30900000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzUtMy0xLTEtNTU5Njg_5272336b-2fca-49a9-a3ce-7680a15207d4"
      unitRef="usd">29300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzUtNS0xLTEtMTIxMzcz_72ca7f6e-9fa6-40de-b324-0998e8eccdd8"
      unitRef="usd">29500000</us-gaap:FinanceLeaseInterestExpense>
    <ehc:Totalfinanceleasecost
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzYtMS0xLTEtNTU5Njg_ea23f3d1-54a2-4068-b8ee-add89578fce7"
      unitRef="usd">64900000</ehc:Totalfinanceleasecost>
    <ehc:Totalfinanceleasecost
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzYtMy0xLTEtNTU5Njg_6b441bc4-a72d-471f-b0e7-3f0a8011f002"
      unitRef="usd">61400000</ehc:Totalfinanceleasecost>
    <ehc:Totalfinanceleasecost
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzYtNS0xLTEtMTIxNDM4_a29b8d1b-d52e-487a-9bf9-34577adfc9e2"
      unitRef="usd">59800000</ehc:Totalfinanceleasecost>
    <ehc:Shorttermandvariableleasecost
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzctMS0xLTEtNTU5Njg_3365e4d3-2671-45fc-907b-834762620505"
      unitRef="usd">3000000.0</ehc:Shorttermandvariableleasecost>
    <ehc:Shorttermandvariableleasecost
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzctMy0xLTEtNTU5Njg_949acdf4-cbee-4380-b6fe-1a74fdfc83bb"
      unitRef="usd">3700000</ehc:Shorttermandvariableleasecost>
    <ehc:Shorttermandvariableleasecost
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzctNS0xLTEtMTIxMzgw_404533df-4b47-49e4-ba1b-21b76a54b7fd"
      unitRef="usd">1500000</ehc:Shorttermandvariableleasecost>
    <us-gaap:SubleaseIncome
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzgtMS0xLTEtNTU5Njg_f53cb485-5e02-43cb-8790-58b6432c4565"
      unitRef="usd">3100000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzgtMy0xLTEtNTU5Njg_3755fe68-9555-42b6-b2c2-51111a8c3c3b"
      unitRef="usd">3200000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzgtNS0xLTEtMTIxMzgw_547d533f-1d5a-46c2-b270-5078795b6c37"
      unitRef="usd">3200000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzktMS0xLTEtNTU5Njg_a4edb9f3-4ba5-4fa0-af8b-8e5ce238ed92"
      unitRef="usd">130800000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzktMy0xLTEtNTU5Njg_5f06b750-d72a-4d80-89d3-89aa23d3a366"
      unitRef="usd">130400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTphYWNhN2QxOWVjNWM0ZDlhOGY5ZTM1NWRlYTJjZWVjYi90YWJsZXJhbmdlOmFhY2E3ZDE5ZWM1YzRkOWE4ZjllMzU1ZGVhMmNlZWNiXzktNS0xLTEtMTIxNDM4_269e9356-fe95-4079-9d72-bc228b99759e"
      unitRef="usd">131000000.0</us-gaap:LeaseCost>
    <ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDg_2383a0e7-5e7f-4c50-a16a-014024f307d6">&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated balance sheet information related to leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_5d2f6b6f-c102-46d3-8edc-f37ab4cfec35"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtMi0xLTEtNjc0MDg_cddac7d5-d65c-4d0d-b06d-90514abaed46"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_355d6dd0-7db9-4c55-9450-722d3c218e06"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTItMS0xLTY3NDEw_86815f32-f034-4c20-ac3f-56edc8fad777"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_865e03c7-f93c-4678-958f-a60428c9386f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTItMS0xLTU1OTY4_feba957e-8de3-4e81-b0d4-2977ac670679"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finance lease assets are recorded net of accumulated amortization of $147.8 million and $129.6 million as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzMtNC0xLTEtNTU5Njg_6cab6fff-7c77-43ae-a18b-1023235c835c"
      unitRef="usd">242000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzMtNi0xLTEtNTU5Njg_0cfe754d-1630-448a-954d-0112da3fba6a"
      unitRef="usd">245700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtNC0xLTEtNTU5Njg_ed595647-68fd-43f0-afd1-85fe6f40f71e"
      unitRef="usd">309600000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzQtNi0xLTEtNTU5Njg_ebe00bfb-5eec-4d4c-8ba1-523089f38d4d"
      unitRef="usd">322800000</us-gaap:FinanceLeaseRightOfUseAsset>
    <ehc:Totaloperatingandfinanceleaseassets
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzUtNC0xLTEtNTU5Njg_330cfbbb-2bc6-4c68-9ae4-a448f3c2b283"
      unitRef="usd">551600000</ehc:Totaloperatingandfinanceleaseassets>
    <ehc:Totaloperatingandfinanceleaseassets
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzUtNi0xLTEtNTU5Njg_c2939e99-ab75-4e82-bd74-3f7030f0829c"
      unitRef="usd">568500000</ehc:Totaloperatingandfinanceleaseassets>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzktNC0xLTEtNTU5Njg_23c8bcf7-240e-405e-a187-bb540ec4006f"
      unitRef="usd">38400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzktNi0xLTEtNTU5Njg_38abe492-26a4-4cbc-98c9-21b225bfe622"
      unitRef="usd">44800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTQtMS0xLTU1OTY4_e5e115ea-c901-4194-b6a8-19109645ac05"
      unitRef="usd">23100000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEwLTYtMS0xLTU1OTY4_8a8ad2c2-df03-407a-93b4-94b4871f31ab"
      unitRef="usd">23800000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEyLTQtMS0xLTU1OTY4_3fb08401-987b-476e-bc2e-4bb485175957"
      unitRef="usd">213100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEyLTYtMS0xLTU1OTY4_18d5082a-5157-4e6e-9434-50b247fcc6c5"
      unitRef="usd">209600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTQtMS0xLTU1OTY4_54893b56-327d-4bda-94c3-0b80f552badc"
      unitRef="usd">363700000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzEzLTYtMS0xLTU1OTY4_5e98f410-790e-488e-a50d-0ff181c9366a"
      unitRef="usd">367900000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <ehc:Totalleaseliabilities
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzE0LTQtMS0xLTU1OTY4_db543d9e-b656-4017-a238-874b65c12f67"
      unitRef="usd">638300000</ehc:Totalleaseliabilities>
    <ehc:Totalleaseliabilities
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MmU0MGI2M2EwOWU0ZTQzOTYzNjFiYWNmNzQ0MDQ2NC90YWJsZXJhbmdlOjYyZTQwYjYzYTA5ZTRlNDM5NjM2MWJhY2Y3NDQwNDY0XzE0LTYtMS0xLTU1OTY4_0e24362d-85f6-468c-a6f1-d469d0e9b33e"
      unitRef="usd">646100000</ehc:Totalleaseliabilities>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3Xzk2NQ_c5d9a0b0-8083-46ae-9cda-21bc8341e7da"
      unitRef="usd">147800000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzEwOTk1MTE2Mjg5NjU_ab85f086-46d1-43b4-a31a-c19aa4cea448"
      unitRef="usd">129600000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDI_1af929d4-51d5-4e13-b8f3-feb71194acf7">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzMtMS0xLTEtNTU5Njg_5690f83c-4d3f-4edd-b132-ca56ac9dd810">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzMtMy0xLTEtNTU5Njg_3da66ffb-b4b3-4186-8129-c6b70df8938c">P8Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzQtMS0xLTEtNTU5Njg_6236c4ee-f2e3-4b2e-929d-d0ada5eb543c">P11Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzQtMy0xLTEtNTU5Njg_0a81b3c6-e368-43cd-ae92-3ec40b493406">P11Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzYtMS0xLTEtNTU5Njg_c60b3b37-945f-47ce-96e3-d9e13655d1e5"
      unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzYtMy0xLTEtNTU5Njg_ede984d8-1ed0-4f03-a8a1-4dfc55533b95"
      unitRef="number">0.061</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzctMS0xLTEtNTU5Njg_17b855de-e964-429d-bb9f-01304db0aee6"
      unitRef="number">0.079</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpkY2ZlNzkzMzU5ZTM0NTFlYjg3Y2Y2ZTU0N2Q0YTY0ZC90YWJsZXJhbmdlOmRjZmU3OTMzNTllMzQ1MWViODdjZjZlNTQ3ZDRhNjRkXzctMy0xLTEtNTU5Njg_09664187-acca-44f1-9170-a031758a1d5b"
      unitRef="number">0.081</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDY_62dab224-846d-4ac8-96ca-30c8e3af3e27">&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDk_36e2f9a0-5569-4e26-a2e4-4fa4b74dab64">&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzEtMS0xLTEtNTU5Njg_749247ae-50f1-4047-b9e8-dbcbf905b204"
      unitRef="usd">51400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzEtMy0xLTEtNTU5Njg_e70b8679-810e-4856-84ab-d7c944b2d61d"
      unitRef="usd">52100000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzItMS0xLTEtNTU5Njg_506bb108-fa2d-4b9d-93a6-34e633622c5c"
      unitRef="usd">50700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzItMy0xLTEtNTU5Njg_b0421d86-3c23-4e4c-9b2e-38622a805eba"
      unitRef="usd">51200000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzMtMS0xLTEtNTU5Njg_1f9fbe38-bf1a-432e-98bb-091cc87c36b0"
      unitRef="usd">44000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzMtMy0xLTEtNTU5Njg_a6927bfb-15fc-4f24-a23c-e42fc321ed91"
      unitRef="usd">50500000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzQtMS0xLTEtNTU5Njg_6d0f2b50-6d56-4e3f-934f-a67574f143ef"
      unitRef="usd">34800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzQtMy0xLTEtNTU5Njg_64599440-efaa-4255-8f09-99c5f986c5fc"
      unitRef="usd">50700000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzUtMS0xLTEtNTU5Njg_448d0fa3-ae8c-4f17-b928-5d9d293a6ca0"
      unitRef="usd">29200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzUtMy0xLTEtNTU5Njg_066fb219-6ffe-405c-b11c-8c60959807b5"
      unitRef="usd">51500000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <ehc:LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzYtMS0xLTEtNTU5Njg_89e0edf6-966e-4a1a-a6f9-d6b75aecc726"
      unitRef="usd">116500000</ehc:LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter>
    <ehc:FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzYtMy0xLTEtNTU5Njg_f924cc88-9b34-46ff-b6c3-7c4a41e9f986"
      unitRef="usd">350300000</ehc:FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzctMS0xLTEtNTU5Njg_bf0b6152-2ccd-4432-8cab-c26a90c23a72"
      unitRef="usd">326600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzctMy0xLTEtNTU5Njg_e0096684-c236-44a4-8ead-d449212f3736"
      unitRef="usd">606300000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzgtMS0xLTEtNTU5Njg_a056d32f-96fe-4a6c-8f8f-0fe686bd45bd"
      unitRef="usd">75100000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzgtMy0xLTEtNTU5Njg_115bbb92-c26b-4e57-b111-6f4b6aec2461"
      unitRef="usd">219500000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzktMS0xLTEtNTU5Njg_27c3edf1-ae24-45e6-89fc-677989418bce"
      unitRef="usd">251500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTpjNDZhMGIxN2VkMjk0MDRkYmNhZDE1M2ZhMDE4OGYzOC90YWJsZXJhbmdlOmM0NmEwYjE3ZWQyOTQwNGRiY2FkMTUzZmEwMTg4ZjM4XzktMy0xLTEtNTU5Njg_a01aa2dd-4600-4e61-bf78-af14bfc27843"
      unitRef="usd">386800000</us-gaap:FinanceLeaseLiability>
    <ehc:SupplementalCashFlowInformationTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90ZXh0cmVnaW9uOjAxYWMxOTZmZGQxODRmZWY4YjFkMjI1NmJkYTUzMDI3XzExNDc_b36b06e1-3e10-4e6f-ad89-2a6ba38224a7">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to our leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:SupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzMtMS0xLTEtNTU5Njg_85e52b84-3f18-4fd7-a925-723797c95dd4"
      unitRef="usd">61500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzMtMy0xLTEtNTU5Njg_8567fe92-020a-4942-90cf-b3bf7ee4cef4"
      unitRef="usd">66900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzMtNS0xLTEtMTIxNDA3_7eadbfa0-967b-4005-9f83-4c09a3a3af9e"
      unitRef="usd">70400000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzQtMS0xLTEtNTU5Njg_f9c3182b-8836-49f5-a93d-837c8bfe368e"
      unitRef="usd">31300000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzQtMy0xLTEtNTU5Njg_ff37617a-0331-4d3c-99b0-b98f5beec66a"
      unitRef="usd">29600000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzQtNS0xLTEtMTIxNDA3_cf93b374-499a-4f89-9112-43ab96ca8da1"
      unitRef="usd">30000000.0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzUtMS0xLTEtNTU5Njg_4acc0f96-27c5-4805-9c4b-eaf554d9b570"
      unitRef="usd">51800000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzUtMy0xLTEtNTU5Njg_4c1f1441-47f3-477a-9872-8991cac523e0"
      unitRef="usd">22500000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzUtNS0xLTEtMTIxNDA3_b8a1ab2d-3448-46ab-af09-fb0f31d3f3ee"
      unitRef="usd">19500000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzgtMS0xLTEtNTU5Njg_823b023b-643d-48dd-a408-217debf351ae"
      unitRef="usd">51100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzgtMy0xLTEtNTU5Njg_1f425617-5df3-449e-9ebb-a42f82adaf71"
      unitRef="usd">39000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzgtNS0xLTEtMTIxNDA3_84eb1c37-f4dc-4bd7-8b42-cb5380d51ece"
      unitRef="usd">43800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzktMS0xLTEtNTU5Njg_acbed204-b001-4be1-b6d8-e3a881c314ab"
      unitRef="usd">50500000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzktMy0xLTEtNTU5Njg_6b2fbffc-e911-4446-9f77-736868308215"
      unitRef="usd">29600000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTMvZnJhZzowMWFjMTk2ZmRkMTg0ZmVmOGIxZDIyNTZiZGE1MzAyNy90YWJsZTo2MTA4NTI3MTU1MWI0YWE1OWFlMmI1NTc2YTJlODg0Ny90YWJsZXJhbmdlOjYxMDg1MjcxNTUxYjRhYTU5YWUyYjU1NzZhMmU4ODQ3XzktNS0xLTEtMTIxNDA3_7d24d07d-670d-4e36-8182-3f511d4d6c9f"
      unitRef="usd">34200000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzEyODc_6017e310-ee31-4e23-8cc4-44219e91efb7">Goodwill and Other Intangible Assets:&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows changes in the carrying amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,318.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; increased in 2019 as a result of our consolidation of Yuma Rehabilitation Hospital and the remeasurement of our previously held equity interest at fair value and our acquisitions of Alacare and other inpatient and home health and hospice operations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; increased in 2020 as a result of our acquisitions of inpatient and home health operations as well as our consolidation of the Jupiter, Florida home health agency and the remeasurement of our previously held equity interest at fair value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; increased in 2021 as a result of our acquisitions of Frontier and other inpatient and home health and hospice operations as well as our consolidation of the Home Health of South Florida joint venture and the remeasurement of our previously held equity interest at fair value. See Note&#160;2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Note&#160;9,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments in and Advances to Nonconsolidated Affiliates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We performed impairment reviews as of October&#160;1, 2021, 2020, and 2019 and concluded no &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; impairment existed. As of December&#160;31, 2021, we had no accumulated impairment losses related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information regarding our other intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Certificates of need:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Licenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncompete agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Trade name - Encompass:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Trade names - all other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Internal-use software:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Market access assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(462.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for other intangible assets is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzEyNzI_ad1aea42-fcd9-4a1f-bcc3-9c124eca2ac1">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows changes in the carrying amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,318.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i76b51d815c2e4db38d2976c4fb0c1889_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEtMS0xLTEtNTU5Njg_6caf47d4-580f-44a2-91d4-f51a5099b95b"
      unitRef="usd">1189200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i45ca43a183ee4af097404ac760bab1eb_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEtMy0xLTEtNTU5Njg_86951d86-1e94-4e89-b09a-e30ffa75c8c9"
      unitRef="usd">911600000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEtNS0xLTEtNTU5Njg_d4002477-61d8-46a7-959c-cc0586584d35"
      unitRef="usd">2100800000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzItMS0xLTEtNTU5Njg_0e9efb04-0cb9-4cdb-bf2c-d06e2309e19b"
      unitRef="usd">4800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzItMy0xLTEtNTU5Njg_07d7f9cd-1593-46df-8a63-8c4f1aceb2b7"
      unitRef="usd">174700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzItNS0xLTEtNTU5Njg_fbd43ab9-72f1-42cb-8f60-e8470f9240ae"
      unitRef="usd">179500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzMtMS0xLTEtNTU5Njg_8fa94551-4ac5-4859-8983-48fd56bb7d52"
      unitRef="usd">24900000</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzMtMy0xLTEtNTU5Njg_fb2daea4-561e-4f9c-8e2a-108e7b1a77b7"
      unitRef="usd">0</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzMtNS0xLTEtNzE4NjQ_3a43e414-9610-44a5-9063-561066fd3822"
      unitRef="usd">24900000</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <us-gaap:Goodwill
      contextRef="i6908c604f9704fdd859cda5b310c3f22_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzUtMS0xLTEtNTU5Njg_6577a525-df8b-464f-9992-dd5b18aa6f02"
      unitRef="usd">1218900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8b8c9109fb524f078bf0bd4b28be8aa2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzUtMy0xLTEtNTU5Njg_901ea9a5-4f01-47dc-9f1c-eefc045c90ae"
      unitRef="usd">1086300000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzUtNS0xLTEtNTU5Njg_11192ef3-aa27-4db3-8b38-0f30b97af889"
      unitRef="usd">2305200000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzYtMS0xLTEtNTU5Njg_65bac8f0-f8fa-4933-9a2c-0b4305ea7a27"
      unitRef="usd">9200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzYtMy0xLTEtNTU5Njg_93389e46-0154-4e80-b716-146b6890b608"
      unitRef="usd">1000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzYtNS0xLTEtNTU5Njg_1477f83c-7ad9-4c81-863b-988a302cdd8c"
      unitRef="usd">10200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzctMS0xLTEtNTU5Njg_c2e738bb-9f53-426b-9be0-805a0e44ae6d"
      unitRef="usd">0</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzctMy0xLTEtNTU5Njg_d502a292-bd7e-497f-9255-aaf47691eed1"
      unitRef="usd">3300000</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzctNS0xLTEtNTU5Njg_0619f5cb-cd0a-46a2-be1b-34f518d579dc"
      unitRef="usd">3300000</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <us-gaap:Goodwill
      contextRef="i490945f79e4b4bb6aeef60a98f16bb9e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzgtMS0xLTEtNTU5Njg_8ddb618b-e1ef-420e-9a7f-bd8b1ca47b96"
      unitRef="usd">1228100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6da867bd58bd42c7829bba5db347624f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzgtMy0xLTEtNTU5Njg_e7abe5f1-09f6-4719-95b3-c1a8d210b1f7"
      unitRef="usd">1090600000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzgtNS0xLTEtNTU5Njg_ca7c40d9-4869-4791-aa02-1618698448a5"
      unitRef="usd">2318700000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzktMS0xLTEtNTU5Njg_c28e0447-0973-469d-8fc1-ca29ae1226a2"
      unitRef="usd">8800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzktMy0xLTEtNTU5Njg_1909ff7c-b3ae-4c2c-b5ab-f0a77f3c6c45"
      unitRef="usd">92400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzktNS0xLTEtNTU5Njg_0d6495f2-06cb-4683-a979-6ce6bc540a27"
      unitRef="usd">101200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEwLTEtMS0xLTU1OTY4_5725044b-9aac-4ea3-83c6-108add5d5ca1"
      unitRef="usd">0</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEwLTMtMS0xLTU1OTY4_0a717027-a55e-4307-bb57-db1c03ea3ba0"
      unitRef="usd">8000000.0</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzEwLTUtMS0xLTU1OTY4_7a3bf481-04dc-49a7-8021-f43f9ea87b43"
      unitRef="usd">8000000.0</ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod>
    <us-gaap:Goodwill
      contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzExLTEtMS0xLTU1OTY4_46d2c3c4-2fa0-4546-86fe-113ef5e0d823"
      unitRef="usd">1236900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzExLTMtMS0xLTU1OTY4_ddf56a8d-259d-47bb-95dd-e73131e0e1ae"
      unitRef="usd">1191000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo1M2I4YThiZGQxMDA0ZDQ5OTQ1MmFiNDNjZTQ2YTUzYi90YWJsZXJhbmdlOjUzYjhhOGJkZDEwMDRkNDk5NDUyYWI0M2NlNDZhNTNiXzExLTUtMS0xLTU1OTY4_1b377462-a66b-4c65-bb90-94f847246819"
      unitRef="usd">2427900000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic844601724a84290b07683e4c14534a9_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2Xzg2OA_2f6f3d70-11a8-4a4f-b0b4-01a302a52322"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if4f21e5f62784e5fad3a81733fafbc9b_D20201001-20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2Xzg2OA_53e4baf1-f675-45e8-a3ab-d45cec64d7e6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i04ac5a43d97b4d1f8b07571f7fd1b855_D20191001-20191001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2Xzg2OA_a29415fd-fe53-4f2e-96d3-88b4a21d4429"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzkxNw_248c2464-64e9-40b3-8c0d-4c44d815ba65"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7dfa4bde6170492bb1256171952a8047_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzItMS0xLTEtNTU5Njg_b66a039b-7fbf-4b10-a424-e4ddb952ed67"
      unitRef="usd">204500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7dfa4bde6170492bb1256171952a8047_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzItMy0xLTEtNTU5Njg_4d88fe8e-9d05-4e6b-b3da-81020089cb36"
      unitRef="usd">68800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7dfa4bde6170492bb1256171952a8047_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzItNS0xLTEtNTU5Njg_e9b2817b-062f-4e4c-a7fb-e43c4d1dabd1"
      unitRef="usd">135700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2bc3f06fe25e4000958cb09124165dec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzMtMS0xLTEtNTU5Njg_d29df009-f1d4-441c-8ed3-81ec5a262b09"
      unitRef="usd">197300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2bc3f06fe25e4000958cb09124165dec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzMtMy0xLTEtNTU5Njg_b1cfcdab-fa0d-4531-960e-0bdeb289f502"
      unitRef="usd">54500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2bc3f06fe25e4000958cb09124165dec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzMtNS0xLTEtNTU5Njg_0be3e49d-5fd6-448d-b6c8-c13db7763127"
      unitRef="usd">142800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9c9be624554e4aa4a376cd3b45cb1d46_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzUtMS0xLTEtNTU5Njg_9bb7858a-33ef-4d1f-b12a-8bc825d0cafb"
      unitRef="usd">194500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9c9be624554e4aa4a376cd3b45cb1d46_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzUtMy0xLTEtNTU5Njg_c80c98ef-6de6-4bc9-94f5-9ab2313660d4"
      unitRef="usd">121000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9c9be624554e4aa4a376cd3b45cb1d46_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzUtNS0xLTEtNTU5Njg_87f27b2a-a775-47cf-9793-64f3ee220c12"
      unitRef="usd">73500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5f74947a4ced47148dc5c2e32cdb11ad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzYtMS0xLTEtNTU5Njg_6079c76f-5c0a-4d99-85db-b40df2fd68f6"
      unitRef="usd">187900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5f74947a4ced47148dc5c2e32cdb11ad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzYtMy0xLTEtNTU5Njg_c50ab456-7eac-4c38-9370-17f0e7dc2775"
      unitRef="usd">107400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5f74947a4ced47148dc5c2e32cdb11ad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzYtNS0xLTEtNTU5Njg_73189d7d-5eb5-46d0-8f23-8322f3e20715"
      unitRef="usd">80500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7e11b04c0c5145c3b6c956ff071c1203_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzgtMS0xLTEtNTU5Njg_6ae5a419-ef0f-4eae-af99-7c18dbb02293"
      unitRef="usd">78500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7e11b04c0c5145c3b6c956ff071c1203_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzgtMy0xLTEtNTU5Njg_51af0027-4f26-4311-b52b-864b196387f8"
      unitRef="usd">69000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7e11b04c0c5145c3b6c956ff071c1203_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzgtNS0xLTEtNTU5Njg_a7331dd0-5c17-435f-9cf4-abc3dea9112c"
      unitRef="usd">9500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5716c39ae0e54b28a2f17fc8e1345352_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzktMS0xLTEtNTU5Njg_74f827a6-c0a2-4bc7-acd5-7df25141a2c7"
      unitRef="usd">75200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5716c39ae0e54b28a2f17fc8e1345352_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzktMy0xLTEtNTU5Njg_b1c0e73d-47ea-4694-bb48-3e3fece653a1"
      unitRef="usd">65800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5716c39ae0e54b28a2f17fc8e1345352_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzktNS0xLTEtNTU5Njg_717f9d91-018e-4d1b-975c-c9897d8a6b5c"
      unitRef="usd">9400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i142b52fe614942e2a17e645d7b8dd1ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzExLTEtMS0xLTU1OTY4_01d71db1-9616-488c-886b-d6da8894525e"
      unitRef="usd">135200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i142b52fe614942e2a17e645d7b8dd1ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzExLTMtMS0xLTU1OTY4_19642a52-e06e-4572-a358-185520350cbf"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i142b52fe614942e2a17e645d7b8dd1ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzExLTUtMS0xLTU1OTY4_61a0852f-4f2c-424d-8ce7-ef8992c7bc1b"
      unitRef="usd">135200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i40cc76eee7fb4c20a4d9ece9eadca6a6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzEyLTEtMS0xLTU1OTY4_1ed978d7-fc28-4c24-b11d-d5ac1c8c8bef"
      unitRef="usd">135200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i40cc76eee7fb4c20a4d9ece9eadca6a6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzEyLTMtMS0xLTU1OTY4_e23e99dc-06ae-4b27-996a-c6c8e041019e"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i40cc76eee7fb4c20a4d9ece9eadca6a6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzEyLTUtMS0xLTU1OTY4_bdb9e48e-09bb-49c2-af7c-60ee5ffb9e22"
      unitRef="usd">135200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idcc2019286614b4d9cb93eb114ddc287_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE0LTEtMS0xLTU1OTY4_ddadeda9-6d5d-4b7e-b632-c5a1f292087f"
      unitRef="usd">45000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idcc2019286614b4d9cb93eb114ddc287_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE0LTMtMS0xLTU1OTY4_a49de464-910e-451e-829b-2d870485b190"
      unitRef="usd">27000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idcc2019286614b4d9cb93eb114ddc287_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE0LTUtMS0xLTU1OTY4_c6c43fc1-417d-4cdd-80e2-63e3d8cc7c58"
      unitRef="usd">18000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibc1609b119ab410a9be9855c6f405555_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE1LTEtMS0xLTU1OTY4_bf2ee965-4d07-40bf-8a59-480202117459"
      unitRef="usd">44300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibc1609b119ab410a9be9855c6f405555_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE1LTMtMS0xLTU1OTY4_c004c28d-1ca8-4db0-b7a3-46e2b0b32783"
      unitRef="usd">25500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibc1609b119ab410a9be9855c6f405555_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE1LTUtMS0xLTU1OTY4_9c239252-49fa-4c35-bfbe-553270872acf"
      unitRef="usd">18800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iebc7abf48bdf4656b5449a56fc5811ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE3LTEtMS0xLTU1OTY4_49798452-00c6-4010-b64b-2c99db020032"
      unitRef="usd">209000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iebc7abf48bdf4656b5449a56fc5811ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE3LTMtMS0xLTU1OTY4_a8c2410c-3655-424b-b6a6-95235e4ac5cf"
      unitRef="usd">164900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iebc7abf48bdf4656b5449a56fc5811ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE3LTUtMS0xLTU1OTY4_5a075e9e-4a41-4ab3-847a-65ee304b8514"
      unitRef="usd">44100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2c7674e95c82459ba38b39ec46c8f9b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE4LTEtMS0xLTU1OTY4_1f6f549c-9d0b-4ec7-841b-a5e4db46aa15"
      unitRef="usd">184200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2c7674e95c82459ba38b39ec46c8f9b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE4LTMtMS0xLTU1OTY4_6229af44-4647-47ae-8c29-35d853a281c9"
      unitRef="usd">141400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2c7674e95c82459ba38b39ec46c8f9b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzE4LTUtMS0xLTU1OTY4_f8320eb9-f7af-4b30-8a01-b69848b57ff3"
      unitRef="usd">42800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifcab17e249fe430bad4f7616edebf373_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIwLTEtMS0xLTU1OTY4_422e866b-15b2-4ea5-a781-2da7d7088a9f"
      unitRef="usd">13200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifcab17e249fe430bad4f7616edebf373_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIwLTMtMS0xLTU1OTY4_d38d5b47-831d-4821-8c84-84d4227def04"
      unitRef="usd">11700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifcab17e249fe430bad4f7616edebf373_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIwLTUtMS0xLTU1OTY4_f1b85a43-6fe7-497f-9ab0-01b3e1a4440b"
      unitRef="usd">1500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifa18ceb2e4824a189bed176eccf7312e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIxLTEtMS0xLTU1OTY4_1076a46b-c258-45a7-9001-aaeb9589c6b0"
      unitRef="usd">13200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifa18ceb2e4824a189bed176eccf7312e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIxLTMtMS0xLTU1OTY4_be03e651-b910-4202-9360-eb70cdcb6efa"
      unitRef="usd">11400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifa18ceb2e4824a189bed176eccf7312e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIxLTUtMS0xLTU1OTY4_a5e923c7-140d-47b2-8154-4008680d85d3"
      unitRef="usd">1800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIzLTEtMS0xLTU1OTY4_720abec8-f023-4106-8f8b-612b8798b279"
      unitRef="usd">879900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIzLTMtMS0xLTU1OTY4_cc19e45c-7b31-4ec5-951d-5c8b241743e6"
      unitRef="usd">462400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzIzLTUtMS0xLTU1OTY4_b0bae5cb-1fea-4ca7-bd8a-9566d60cb191"
      unitRef="usd">417500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzI0LTEtMS0xLTU1OTY4_382b8e09-746d-4d8f-9464-6d9cf7f7b620"
      unitRef="usd">837300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzI0LTMtMS0xLTU1OTY4_65b9a898-c8b1-48e1-810a-919dc13b1efd"
      unitRef="usd">406000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZToyYWQ1MTM4N2MxOTA0OWNiYjlkMDdhNzYwODRmNzhmNi90YWJsZXJhbmdlOjJhZDUxMzg3YzE5MDQ5Y2JiOWQwN2E3NjA4NGY3OGY2XzI0LTUtMS0xLTU1OTY4_e0c295e4-afcd-4a1c-81c4-5c0f54f02a2b"
      unitRef="usd">431300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzEzMTM_8bb4697d-9a76-471f-9b20-c279fa4ede5f">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for other intangible assets is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo3OGFkMTJiMWJlNWQ0MzY1ODhmMGI1OTVkYWFlNWEyZC90YWJsZXJhbmdlOjc4YWQxMmIxYmU1ZDQzNjU4OGYwYjU5NWRhYWU1YTJkXzItMS0xLTEtNTU5Njg_6f2e843e-6464-4c96-a3bf-cc61e8b8a922"
      unitRef="usd">56400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo3OGFkMTJiMWJlNWQ0MzY1ODhmMGI1OTVkYWFlNWEyZC90YWJsZXJhbmdlOjc4YWQxMmIxYmU1ZDQzNjU4OGYwYjU5NWRhYWU1YTJkXzItMy0xLTEtNTU5Njg_e2ac7743-bb22-4fc7-bcdb-41da9310295d"
      unitRef="usd">59800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTo3OGFkMTJiMWJlNWQ0MzY1ODhmMGI1OTVkYWFlNWEyZC90YWJsZXJhbmdlOjc4YWQxMmIxYmU1ZDQzNjU4OGYwYjU5NWRhYWU1YTJkXzItNS0xLTEtNTU5Njg_6560f90a-db4e-498f-92fc-1b2ca946002c"
      unitRef="usd">58400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90ZXh0cmVnaW9uOmVlOWNjZGJjNDQ4ODQ4MjQ5ODIwN2YxMGVjMWVkYWE2XzEzMTc_ef5f572a-ad5b-4556-82fa-53097fb23d8f">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzEtMS0xLTEtNTU5Njg_acfeef44-68dd-4774-ad02-275479e112a3"
      unitRef="usd">53700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzItMS0xLTEtNTU5Njg_f05635a2-fdba-4178-8eca-d34837e8b1a8"
      unitRef="usd">45900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzMtMS0xLTEtNTU5Njg_6665e759-f335-4d26-b069-b9e9782558f1"
      unitRef="usd">37000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzQtMS0xLTEtNTU5Njg_43000c67-12c1-4d7e-bd91-966d65a17e75"
      unitRef="usd">24900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNTkvZnJhZzplZTljY2RiYzQ0ODg0ODI0OTgyMDdmMTBlYzFlZGFhNi90YWJsZTpjYWIwZTM0YTI3Njc0ZTFiOTI5M2M1ZDg4NGJmMzQwMC90YWJsZXJhbmdlOmNhYjBlMzRhMjc2NzRlMWI5MjkzYzVkODg0YmYzNDAwXzUtMS0xLTEtNTU5Njg_455c59ff-93ef-4ca0-9b9a-d10608d381d3"
      unitRef="usd">21300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI5NjI_b2a2a0ff-6c77-4ed2-ba2e-51f67fc3d337">Investments in and Advances to Nonconsolidated Affiliates:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in and advances to nonconsolidated affiliates as of December&#160;31, 2021 represents our investment in three partially owned subsidiaries, of which two are general or limited partnerships, limited liability companies, or joint ventures in which Encompass Health or one of its subsidiaries is a general or limited partner, managing member, member, or venturer, as applicable. We do not control these affiliates but have the ability to exercise significant influence over the operating and financial policies of certain of these affiliates. Our ownership percentages in these affiliates range from approximately 5% to 50%. We account for these investments using the equity method of accounting and measurement alternative. Our investments, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets, consist of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital contributions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative share of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative share of distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital contributions, net of distributions and impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the combined assets, liabilities, and equity and the combined results of operations of our equity method affiliates (on a 100% basis, in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities and equity&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partners&#x2019; capital and shareholders&#x2019; equity&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities and equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Condensed statements of comprehensive income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of an amendment to the joint venture agreement related to our Jupiter, Florida home health agency, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective January 1, 2020.  The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of the Jupiter, Florida agency did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this home health agency and the remeasurement of our previously held equity interest at fair value, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; increased by $3.3&#160;million and we recorded a $2.2&#160;million gain as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of an amendment to the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July&#160;1, 2019. The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of Yuma Rehabilitation Hospital did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; increased by $24.9 million and we recorded a $19.2 million gain as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See also Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock>
    <ehc:NumberOfPartiallyOwnedSubsidiariesNonconsolidated
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzEwNg_cd495213-a45e-4db2-926c-4fd899245465"
      unitRef="subsidiary">3</ehc:NumberOfPartiallyOwnedSubsidiariesNonconsolidated>
    <ehc:NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzE0OA_bcc28107-d74a-4d1e-8b10-29df92b66716"
      unitRef="subsidiary">2</ehc:NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures>
    <ehc:AffiliatesOwnershipPercentage
      contextRef="ie64cfb56dcaf4d2dbd074d8ae766d3ff_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzYwOQ_496f2014-5093-4fb6-8067-b58dfe437882"
      unitRef="number">0.05</ehc:AffiliatesOwnershipPercentage>
    <ehc:AffiliatesOwnershipPercentage
      contextRef="ib75c417944a447ca93f748d0d3afe2f8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzYxNQ_c341167f-edb8-4062-9e08-c9fe790898b9"
      unitRef="number">0.50</ehc:AffiliatesOwnershipPercentage>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI5NzI_72b65836-9cce-4f98-940f-0a0db0ce713e">Our investments, which are included in &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets, consist of the following (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital contributions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative share of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative share of distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital contributions, net of distributions and impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzMtMS0xLTEtNTU5Njg_9db90c40-d418-49dd-8c72-e3618111e807"
      unitRef="usd">800000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzMtMy0xLTEtNTU5Njg_49d10238-aa06-4713-ace0-8006dc7e0674"
      unitRef="usd">900000</us-gaap:EquityMethodInvestmentAggregateCost>
    <ehc:EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzQtMS0xLTEtNTU5Njg_a749bd4b-35b0-45d0-8ea4-153839bf0841"
      unitRef="usd">68500000</ehc:EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments>
    <ehc:EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzQtMy0xLTEtNTU5Njg_ad605854-ee9b-41cd-8a31-d5489de3dec7"
      unitRef="usd">68700000</ehc:EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments>
    <ehc:EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzUtMS0xLTEtNTU5Njg_5f5572e0-a515-46b9-9118-59d0bc7c63a1"
      unitRef="usd">-66900000</ehc:EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments>
    <ehc:EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzUtMy0xLTEtNTU5Njg_f92008d1-1fd4-439f-984e-9fe5b87cc863"
      unitRef="usd">-66100000</ehc:EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzYtMS0xLTEtNTU5Njg_f6028289-edc2-444d-921d-33d921d443a1"
      unitRef="usd">2400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzYtMy0xLTEtNTU5Njg_49d4da6a-b1a9-47ab-b41e-6749983bfa65"
      unitRef="usd">3500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzgtMS0xLTEtNTU5Njg_2c7ba024-68ac-464d-be7f-d8e3b2dc84db"
      unitRef="usd">1600000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzgtMy0xLTEtNTU5Njg_2d586ec8-8ec6-43de-8e8c-e49419bb2cbc"
      unitRef="usd">2000000.0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzktMS0xLTEtNTU5Njg_d6f0850c-0b6d-47e0-9204-3233bd7c2a2c"
      unitRef="usd">4000000.0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTpmMzRkOGQxMzEyNDU0NTJiYmQ3YTEyYTUyMWQyZjAyYi90YWJsZXJhbmdlOmYzNGQ4ZDEzMTI0NTQ1MmJiZDdhMTJhNTIxZDJmMDJiXzktMy0xLTEtNTU5Njg_f5985a12-0f96-4c87-b925-302947bc8828"
      unitRef="usd">5500000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI5Nzk_3e915170-6b6e-4573-af70-eea3159fd816">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the combined assets, liabilities, and equity and the combined results of operations of our equity method affiliates (on a 100% basis, in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities and equity&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partners&#x2019; capital and shareholders&#x2019; equity&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities and equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Condensed statements of comprehensive income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzMtMS0xLTEtNTU5Njg_6981cfcb-5ed7-4f3c-8cb5-1a1c2f1d667d"
      unitRef="usd">3000000.0</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzMtMy0xLTEtNTU5Njg_7f9cbe81-51d3-48f9-8707-fc6fe71652d8"
      unitRef="usd">2900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzQtMS0xLTEtNTU5Njg_f9d07cb2-9062-4ffb-85c9-72f7b302c1ed"
      unitRef="usd">4200000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzQtMy0xLTEtNTU5Njg_b11bdd00-6d08-478d-97ee-ccc337b473ce"
      unitRef="usd">7700000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzUtMS0xLTEtNTU5Njg_b8e24b1e-5438-46c2-8554-0eadf1181444"
      unitRef="usd">7200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzUtMy0xLTEtNTU5Njg_d2758769-f0ac-469d-9a48-65f7c13add9f"
      unitRef="usd">10600000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzctMS0xLTEtNTU5Njg_e42d0aab-3535-4ee1-b6c0-1ea076296bea"
      unitRef="usd">200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzctMy0xLTEtNTU5Njg_25079be9-3530-48ae-ad22-2ce3d6de3515"
      unitRef="usd">300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzgtMS0xLTEtNTU5Njg_dcd8f163-9c0f-46a6-8df9-f415d9c45e24"
      unitRef="usd">0</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzgtMy0xLTEtNTU5Njg_6062ca22-9562-4c30-be9f-fed770d63a9d"
      unitRef="usd">200000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity
      contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzEwLTEtMS0xLTU1OTY4_5f723492-329f-445c-b3c8-5b49563e6e8f"
      unitRef="usd">2300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzEwLTMtMS0xLTU1OTY4_bea8ba81-9f47-4532-b385-49e5db360a98"
      unitRef="usd">3500000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzExLTEtMS0xLTU1OTY4_53ef467d-cb5c-4f71-914c-6b25f97350cd"
      unitRef="usd">4700000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzExLTMtMS0xLTU1OTY4_f44d493c-97a8-4e34-a088-f00a1c1bf204"
      unitRef="usd">6600000</us-gaap:MinorityInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iee1bde62ffe249dfa8317c6305c6c843_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzEyLTEtMS0xLTU1OTY4_54eb9c74-33cd-40a9-be46-3a3b35e6f2bd"
      unitRef="usd">7200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i37665585786e4e83a76c3a3f771a86de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo5NTlkM2MwNTRhOGY0N2Y4YTg1OWNlYjQ1MmMyZDA4Ny90YWJsZXJhbmdlOjk1OWQzYzA1NGE4ZjQ3ZjhhODU5Y2ViNDUyYzJkMDg3XzEyLTMtMS0xLTU1OTY4_a02fe816-2f77-4234-8f97-43e97db87310"
      unitRef="usd">10600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzItMS0xLTEtNTU5Njg_39e6d99d-16b7-4049-882b-0bacddda74bb"
      unitRef="usd">11100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77309f128df04419abedd5fd33738b08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzItMy0xLTEtNTU5Njg_09cb9a85-25d9-4d66-be7c-fc2cee5341a6"
      unitRef="usd">16000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzItNS0xLTEtNTU5Njg_280b85c3-7c85-460c-b9b4-c20ff5794ff1"
      unitRef="usd">32600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzMtMS0xLTEtNTU5Njg_6cd15315-ebb2-4103-91b0-6e75eaf63ee2"
      unitRef="usd">3100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i77309f128df04419abedd5fd33738b08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzMtMy0xLTEtNTU5Njg_2aedd6aa-2da6-4d92-b772-f4dcee012632"
      unitRef="usd">8100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzMtNS0xLTEtNTU5Njg_658b140b-2bec-4161-9547-5814d9969db2"
      unitRef="usd">19100000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzQtMS0xLTEtNTU5Njg_1cdfe7f9-302a-4dd3-aee1-ea02493f5773"
      unitRef="usd">8000000.0</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77309f128df04419abedd5fd33738b08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzQtMy0xLTEtNTU5Njg_ffc1d978-2996-41ed-bbc3-f18a4df1fa68"
      unitRef="usd">7900000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzQtNS0xLTEtNTU5Njg_981a1287-f7ea-4772-9f52-ae108ba3a7f9"
      unitRef="usd">13400000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i8262d4a959484985a5bd320d15f77e63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzUtMS0xLTEtNTU5Njg_25d51b3f-b752-4f54-ae9c-96782818c2c6"
      unitRef="usd">8000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i77309f128df04419abedd5fd33738b08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzUtMy0xLTEtNTU5Njg_1c4146f1-fa9a-48c5-90d6-e8d6e607c864"
      unitRef="usd">7900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i609d57e612ab4e81869125f3e09bc79e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90YWJsZTo2ZGQwMDEyZGMzZDQ0N2QyYjBiMTQyOTVlNTg1ZGUwMS90YWJsZXJhbmdlOjZkZDAwMTJkYzNkNDQ3ZDJiMGIxNDI5NWU1ODVkZTAxXzUtNS0xLTEtNTU5Njg_e51fcd26-cf8d-45d3-ae0e-dcbc1f709540"
      unitRef="usd">13400000</us-gaap:ProfitLoss>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i196e74d41d844ce489461736995f7d1d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzE5NDM_577771c1-46f2-4366-a8d4-9f85d0b5df68"
      unitRef="usd">3300000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i196e74d41d844ce489461736995f7d1d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzE5NjQ_d1e6a00f-85af-493f-8804-4ccc8d44cecc"
      unitRef="usd">2200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i96f008123b074f85973c4425cc5d7c42_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI4NjE_1902a5c8-bd9f-4824-8d8f-31b729990e34"
      unitRef="usd">24900000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i96f008123b074f85973c4425cc5d7c42_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjIvZnJhZzo1NWY0NGJiMDU1OTc0NDVlOTExNThmNTliOTI1ZTRlNi90ZXh0cmVnaW9uOjU1ZjQ0YmIwNTU5NzQ0NWU5MTE1OGY1OWI5MjVlNGU2XzI4ODI_5f5edbaf-038e-4851-8301-e61efc38b4b7"
      unitRef="usd">19200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwNjY1_e8f97c95-63f4-4d4e-a726-684cc72edc58">Long-term Debt:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our long-term debt outstanding consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Agreement&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonds payable&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,288.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,243.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Face Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the redemptions discussed below, we recorded a $1.0&#160;million, $2.3 million, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.7 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Secured Credit Agreement&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit agreement, as amended in November 2019, provided for a $270 million term loan commitment and a $1 billion revolving credit facility, with a $260 million letter of credit subfacility and a swingline loan subfacility, all of which mature in November 2024. Outstanding term loan borrowings are payable in equal consecutive quarterly installments, commencing on December&#160;31, 2019, of 1.25% of the aggregate principal amount of the term loans outstanding as of December&#160;31, 2019, with the remainder due at maturity. We have the right at any time to prepay, in whole or in part, any borrowing under the term loan facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts drawn on the term loan facilities and the revolving credit facility bear interest at a rate per annum of, at our option, (1) LIBOR or (2)&#160;the higher of (a)&#160;Barclays Bank PLC&#x2019;s prime rate and (b)&#160;the federal funds rate plus 0.5%, in each case, plus, in each case, an applicable margin that varies depending upon our leverage ratio. We are also subject to a commitment fee of 0.375% per annum on the daily amount of the unutilized commitments under the revolving credit facility. The current interest rate on borrowings under the credit agreement is LIBOR plus 1.50%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit agreement contains affirmative and negative covenants and default and acceleration provisions, including a minimum interest coverage ratio and a maximum leverage ratio. Under one such negative covenant, we are restricted from paying common stock dividends, prepaying certain senior notes, making certain investments, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the credit agreement and (2) our senior secured leverage ratio, as defined in the credit agreement, does not exceed 2x. In the event the senior secured leverage ratio exceeds 2x, these payments are subject to a limit of $200 million plus an amount equal to a portion of available excess cash flows each fiscal year. Our obligations under the credit agreement are secured by the current and future personal property of the Company and its subsidiary guarantors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we amended our existing credit agreement and the amendments included the following material provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the definition of &#x201c;Material Adverse Effect&#x201d; to carve out the direct and indirect impacts of pandemic and the related legislative, regulatory and executive actions on us from that definition for a period of 364 days; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of 4.50x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of 2:00x) and the existence of no events of default in addition to the new leverage ratio condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, $200 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were drawn under the revolving credit facility with an interest rate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; no &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount was drawn under the revolving credit facility. As of December&#160;31, 2021 and 2020, $38.2 million and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $36.7 million, respectively, were being &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;utilized under the letter of credit subfacility, which were being used in the ordinary course of business to secure workers&#x2019; compensation and other insurance coverages and for general corporate purposes. Currently, there are no undrawn term loan commitments under the credit agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bonds Payable&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2023 Notes, 2024 Notes, 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively, the &#x201c;Senior Notes&#x201d;) were issued pursuant to an indenture (the &#x201c;Base Indenture&#x201d;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#x2019; respective supplemental indenture (together with the Base Indenture, the &#x201c;Indenture&#x201d;). Pursuant to the terms of the Indenture, the Senior Notes are jointly and severally guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our Credit Agreement and other capital markets debt. The Senior Notes are senior, unsecured obligations of Encompass Health and rank equally with our other senior indebtedness, senior to any of our subordinated indebtedness, and effectively junior to our secured indebtedness to the extent of the value of the collateral securing such indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the Indenture), each holder of the Senior Notes may require us to repurchase all or a portion of the notes in cash at a price equal to 101% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Notes contain covenants and default and acceleration provisions, that, among other things, limit our and certain of our subsidiaries&#x2019; ability to (1)&#160;incur additional debt, (2)&#160;make certain restricted payments, (3)&#160;consummate specified asset sales, (4)&#160;incur liens, and (5)&#160;merge or consolidate with another person.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively the &#x201c;Notes&#x201d;) for the adoption of certain amendments to the Indenture, which will provide us with greater flexibility in effecting the spin off discussed in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Organization and Description of Business.&#x201d; Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#x201c;Distribution&#x201d;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture by $200&#160;million and amends the definition of &#x201c;Consolidated Net Income&#x201d; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $40.5&#160;million, excluding fees. We paid $20&#160;million of this amount in January 2022. The remaining payment is contingent upon the execution of a Distribution and will be paid at such time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2023 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2015, we issued $300 million of 5.125%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Senior Notes due 2023 (&#x201c;the 2023 Notes&#x201d;)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at par, which resulted in approximately $295 million in net proceeds from the public offering. The 2023 Notes mature on March 15, 2023 and bear interest at a per annum rate of 5.125%. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inclusive of financing costs, the effective interest rate on the 2023 Notes is 5.4%.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Interest on the 2023 Notes is payable semiannually in arrears on March 15 and September 15. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In both April and June 2021, we redeemed $100&#160;million in outstanding principal amount of the 2023 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, these optional redemptions were made at a price of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In February 2022, we issued notice for redemption of the remaining $100&#160;million in outstanding principal amount of the 2023 Notes. Pursuant to the terms of the 2023 Notes, this full redemption will settle on March 15, 2022 and will be made at a price of par. We plan to use cash on hand and capacity under our revolving credit facility to fund the redemption. We expect to record an approximate $0.3&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2012, we completed a public offering of $275 million aggregate principal amount of the 5.75% Senior Notes due 2024 (&#x201c;the 2024 Notes&#x201d;) at par. In September 2014, we issued an additional $175 million of the 2024 Notes at a price of 103.625% of the principal amount, in January 2015, we issued an additional $400 million of the 2024 Notes at a price of 102% of the principal amount, and in August 2015, we issued an additional $350 million of our 2024 Notes at a price of 100.5% of the principal amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, we redeemed $100 million of outstanding principal amount of our 2024 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2024 Notes, this optional redemption was made at a price of 101.917%, which resulted in a total cash outlay of approximately $102 million. In November 2019, we redeemed $400 million of the outstanding principal amount of our 2024 Notes. Pursuant to the terms of the 2024 Notes, this optional redemption was made at a price of 100.958%, which resulted in a total cash outlay of approximately $404 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In November 2020, we redeemed the remaining $700&#160;million of outstanding principal amount of the 2024 Notes. Pursuant to the terms of the 2024 Notes, this full redemption was made at a price of par. We used the net proceeds from the 2031 Notes offering, discussed and defined below, together with approximately $300&#160;million of cash on hand to fund the redemption. The 2024 Notes would have matured on November&#160;1, 2024. Inclusive of premiums and financing costs, the effective interest rate on the 2024 Notes was 5.8%. Interest was payable semiannually in arrears on May 1 and November&#160;1 of each year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2015, we issued $350 million of 5.75% Senior Notes due 2025 (&#x201c;the 2025 Notes&#x201d;) at par. The 2025 Notes mature on September&#160;15, 2025 and bear interest at a per annum rate of 5.75%. Inclusive of financing costs, the effective interest rate on the 2025 Notes is 6.0%. Interest on the 2025 Notes is payable semiannually in arrears on March 15 and September&#160;15. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2021, at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2028 and 2030 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we issued $500 million of 4.50% Senior Notes due 2028 (the &#x201c;2028 Notes&#x201d;) at par and $500 million of 4.75% Senior Notes due 2030 (the &#x201c;2030 Notes&#x201d;) at par. The proceeds from this offering were used to fund the purchase of equity and vested stock appreciation rights from management investors of our home health and hospice segment, redeem a portion of our 2024 Notes as discussed above, and repay borrowings under our revolving credit facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we issued an additional $300&#160;million of our 2028 Notes at a price of 99.0% of the principal amount and an additional $300&#160;million of our 2030 Notes at a price of 98.5% of the principal amount, which resulted in approximately $583&#160;million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Notes mature on February 1, 2028. Inclusive of financing costs, the effective interest rate on the 2028 Notes is 4.8%. Interest on the 2028 Notes is payable semiannually in arrears on February 1 and August 1. We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes mature on February 1, 2030. Inclusive of financing costs, the effective interest rate on the 2030 Notes is 5.2%. Interest on the 2030 Notes is payable semiannually in arrears on February 1 and August 1. We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2031 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we issued $400&#160;million aggregate principal amount of 4.625% Senior Notes due 2031 (the &#x201c;2031 Notes&#x201d;) at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of 4.625%. Inclusive of financing costs, the effective interest rate on the 2031 Notes is 4.8%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Notes Payable&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our notes payable consist of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale/leaseback transactions involving real estate accounted for as financings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1% to 11.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction of a new hospital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwNjMw_c192689c-e62b-4bd0-88da-32c328296200">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our long-term debt outstanding consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Agreement&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonds payable&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,288.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,243.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our notes payable consist of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale/leaseback transactions involving real estate accounted for as financings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1% to 11.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction of a new hospital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="idda4f773f6c54fe581e21ee14d227bc7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzMtMS0xLTEtNTU5Njg_154561be-10ba-47b8-89bd-dff210b591ed"
      unitRef="usd">200000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i798f862fab8b4413a0c57906b428ab10_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzMtMy0xLTEtNTU5Njg_a62df214-f6f7-4b34-9374-b8ed62a7fdf3"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7915604b115c4cd6b70e206e17b2ce26_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzQtMS0xLTEtNTU5Njg_1c245fa9-73da-48c6-9283-69cd72dfd959"
      unitRef="usd">238500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i05884d3e63ee40d5907eaf0324564a18_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzQtMy0xLTEtNTU5Njg_4eaa07bd-976f-46fa-b044-1021d152cfa2"
      unitRef="usd">251600000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i475515e7171f46acb6ddebf2c000d90c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzgtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjplZmZjNGU1NjEwMTk0MGY5OTI2YTE2YTM5MDA3ODg4OV80_4bdce726-ae99-4a41-946f-8f042393b0b2"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i098be77d49ab41099bfe946d54e9bcd7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzgtMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjplZmZjNGU1NjEwMTk0MGY5OTI2YTE2YTM5MDA3ODg4OV80_c9bf4c77-f771-4be6-a17a-06f3e07b9c0c"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i098be77d49ab41099bfe946d54e9bcd7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzgtMS0xLTEtNTU5Njg_c54d539d-e52d-41ee-985d-c6c1d0872514"
      unitRef="usd">99600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i475515e7171f46acb6ddebf2c000d90c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzgtMy0xLTEtNTU5Njg_84ff540d-88bd-4ae6-9576-78e0dac304ed"
      unitRef="usd">298100000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6689accfbb7543808abafce304019012_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEwLTAtMS0xLTU1OTY4L3RleHRyZWdpb246YWY4ZTllY2JiNTBhNGZjNThjMjAwYmY3MWFkZWYzNThfNA_16ba9a7f-74a7-4e73-9138-bedad8e0629f"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8e8dcadb39154f309a2431ebb274d483_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEwLTAtMS0xLTU1OTY4L3RleHRyZWdpb246YWY4ZTllY2JiNTBhNGZjNThjMjAwYmY3MWFkZWYzNThfNA_5714a3a5-a7ce-47a5-8219-d1a0da65a9b8"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8e8dcadb39154f309a2431ebb274d483_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEwLTEtMS0xLTU1OTY4_cfb8caa9-4ace-44db-b126-41f24db13f25"
      unitRef="usd">347000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6689accfbb7543808abafce304019012_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEwLTMtMS0xLTU1OTY4_3655055c-864e-42a3-88df-0b6d8e9f6d52"
      unitRef="usd">346300000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i940f9d1a36544945a5314717176158e2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzExLTAtMS0xLTU1OTY4L3RleHRyZWdpb246NDFlMjY0NzRmNWQ5NGUxODliMDBiNDQxMTJmYmJjOWJfNA_32fe7804-f0de-4120-8be8-35966d287d05"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i42cd94791aee45c38596cfa00e2c22b0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzExLTAtMS0xLTU1OTY4L3RleHRyZWdpb246NDFlMjY0NzRmNWQ5NGUxODliMDBiNDQxMTJmYmJjOWJfNA_8d7b5273-0861-469c-a166-f39e3100ead2"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i42cd94791aee45c38596cfa00e2c22b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzExLTEtMS0xLTU1OTY4_852a0bb6-7760-445c-b2dd-fc6bd4c3aa87"
      unitRef="usd">786800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i940f9d1a36544945a5314717176158e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzExLTMtMS0xLTU1OTY4_92cd51ae-001c-425b-b6d8-39270ceb948f"
      unitRef="usd">785000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i62d481ea979b4b2dac6c075291e1ef68_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEyLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MGRjNTVjNDliNjJjNGE1ZjkyMmUxNzlhNGYxNWQwNTRfNA_12f9d30e-56d6-4ada-99a8-dc5b0b657b80"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i708722e52f7b4e87879527c09b19006d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEyLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MGRjNTVjNDliNjJjNGE1ZjkyMmUxNzlhNGYxNWQwNTRfNA_d32cdf23-f33e-4e77-9029-1b3970701065"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i708722e52f7b4e87879527c09b19006d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEyLTEtMS0xLTU1OTY4_68bafb55-eb4a-4a7a-966a-af630d82fb7e"
      unitRef="usd">784700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i62d481ea979b4b2dac6c075291e1ef68_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEyLTMtMS0xLTU1OTY4_6d680ae0-3912-49a8-ae74-75249278642e"
      unitRef="usd">783200000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3e435cfbee1d418aaa5b1e302438b2e3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEzLTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZDdiY2NiNDk2Mzg5NDhmYWI2OTk5MWVmZTFhODhiNTVfNA_08623970-0df8-46b6-9d2f-86bc244ff8b2"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if6c70ba1acd6484e874b7cbf5ce32af3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEzLTAtMS0xLTU1OTY4L3RleHRyZWdpb246ZDdiY2NiNDk2Mzg5NDhmYWI2OTk5MWVmZTFhODhiNTVfNA_64376f2c-6301-4ceb-88bc-548026db7c8a"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if6c70ba1acd6484e874b7cbf5ce32af3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEzLTEtMS0xLTU1OTY4_64c4c0ef-094f-42ff-838d-dd8db67c43e9"
      unitRef="usd">393700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3e435cfbee1d418aaa5b1e302438b2e3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzEzLTMtMS0xLTU1OTY4_dbbbffea-fe71-4b8c-902a-0920fd516f9a"
      unitRef="usd">393200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i95660f8d813c4751ade79f135d5b3a25_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE0LTEtMS0xLTU1OTY4_85f92389-0765-4c63-a13a-7f8a45ac9274"
      unitRef="usd">49600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5951de1720a942e0a0e71cfd9f206587_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE0LTMtMS0xLTU1OTY4_144156fc-ad43-47e8-a4bf-115a2ba9a4e3"
      unitRef="usd">39800000</us-gaap:LongTermDebt>
    <us-gaap:FinanceLeaseLiability
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE1LTEtMS0xLTU1OTY4_51e193d9-164c-4b2e-992a-f45e3b4961e9"
      unitRef="usd">386800000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE1LTMtMS0xLTU1OTY4_3ce59018-3fa2-4228-9761-26f8994a7434"
      unitRef="usd">391700000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE2LTEtMS0xLTU1OTY4_5aba3aec-0ccf-4958-be2b-30c0f5b7b394"
      unitRef="usd">3286700000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE2LTMtMS0xLTU1OTY4_3c4a785a-b386-40a5-b0a0-2d5b9593c63b"
      unitRef="usd">3288900000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE3LTEtMS0xLTU1OTY4_bf238518-c105-4589-ae85-84c696290ff1"
      unitRef="usd">42800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE3LTMtMS0xLTU1OTY4_e67b62ca-294c-4fd4-a9b0-ce3dcfad74ec"
      unitRef="usd">38300000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE4LTEtMS0xLTU1OTY4_3657be2b-f379-443c-83a4-1a52e2e8b4ac"
      unitRef="usd">3243900000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpmODk4ZWExMDU1YWY0NTAxYjhkMmM1NmY5MjIzNzM3My90YWJsZXJhbmdlOmY4OThlYTEwNTVhZjQ1MDFiOGQyYzU2ZjkyMjM3MzczXzE4LTMtMS0xLTU1OTY4_789ee1c2-f082-49d3-9788-9d40da7d41ee"
      unitRef="usd">3250600000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwNjYy_c750fab3-07fd-4b9b-9fa5-210d4a260e06">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Face Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearOne
      contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzEtMi0xLTEtNTU5Njg_b56544d9-eebd-4360-bae8-3a83cd63125a"
      unitRef="usd">42800000</ehc:LongTermDebtAndLeaseObligationsMaturityYearOne>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearOne
      contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzEtNC0xLTEtNTU5Njg_929726f4-ca12-4873-8a25-194e9672cc06"
      unitRef="usd">42800000</ehc:LongTermDebtAndLeaseObligationsMaturityYearOne>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo
      contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzItMi0xLTEtNTU5Njg_a0159776-01c3-45e1-8ea3-11f15ef4c0a3"
      unitRef="usd">143600000</ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo
      contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzItNC0xLTEtNTU5Njg_d272104e-0436-4cfb-8545-6c385c314e07"
      unitRef="usd">143200000</ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearThree
      contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzMtMi0xLTEtNTU5Njg_8506e3f8-d051-412a-9a20-4447ee188e77"
      unitRef="usd">453800000</ehc:LongTermDebtAndLeaseObligationsMaturityYearThree>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearThree
      contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzMtNC0xLTEtNTU5Njg_49864305-2c2b-4f70-a792-2364e2d77579"
      unitRef="usd">452700000</ehc:LongTermDebtAndLeaseObligationsMaturityYearThree>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearFour
      contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzQtMi0xLTEtNTU5Njg_161f2008-36b6-473d-9133-57354cec4064"
      unitRef="usd">384800000</ehc:LongTermDebtAndLeaseObligationsMaturityYearFour>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearFour
      contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzQtNC0xLTEtNTU5Njg_6060ab57-08b1-49fd-a952-4686bb4a4392"
      unitRef="usd">381800000</ehc:LongTermDebtAndLeaseObligationsMaturityYearFour>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearFive
      contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzUtMi0xLTEtNTU5Njg_d8a493ac-aa11-47be-8400-7c6c57b09d2e"
      unitRef="usd">29900000</ehc:LongTermDebtAndLeaseObligationsMaturityYearFive>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearFive
      contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzUtNC0xLTEtNTU5Njg_a4949c0c-d24d-40f7-9ee3-0a7b5dc36ea4"
      unitRef="usd">29900000</ehc:LongTermDebtAndLeaseObligationsMaturityYearFive>
    <ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive
      contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzYtMi0xLTEtNTU5Njg_6ae646ad-e7f7-4a5e-8cd8-ae437a951a1c"
      unitRef="usd">2271100000</ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive>
    <ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive
      contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzYtNC0xLTEtNTU5Njg_25202d5c-2d33-4f16-b62b-366f6bed1d4e"
      unitRef="usd">2236300000</ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzctMi0xLTEtNTU5Njg_4b5010b8-b894-4b89-ab16-54d25de53a6e"
      unitRef="usd">3326000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i844223c9a9da4adfb49e461dd0b62f85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyMjcxZDkyYTczZmU0YjQwODExM2YzYTUyYWZkYWYyMi90YWJsZXJhbmdlOjIyNzFkOTJhNzNmZTRiNDA4MTEzZjNhNTJhZmRhZjIyXzctNC0xLTEtNTU5Njg_ab88a3d3-0810-4654-801e-32756c05bff3"
      unitRef="usd">3286700000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzIxOTkwMjMyNjYzOTE_86b57416-d2dd-4709-bb29-3eab278fa6a1"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzI5Mw_aedec484-ea17-460d-a1e0-0bd55c51085b"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzMwMA_7f10eef9-3df6-4045-ac9c-38eaa9309401"
      unitRef="usd">-7700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i95d8e5cfdcdc4f0096543280be8e1479_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU0OQ_ab07d516-c073-4b37-b273-d46689ddfe40"
      unitRef="usd">270000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i797035a2e3fa4c98bd423b13b951a80e_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU3OQ_0b4cb001-ba59-49c2-9cb6-e6f654903878"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia643be6ec0c14729abfe4a71fb7d089d_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzYxNg_613d7746-c64c-4fec-a6e4-65b86beeaac3"
      unitRef="usd">260000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ehc:DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding
      contextRef="ic3208cda4b8e43a9a5f3510db5d5ced2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0Ng_1d303fe1-13ed-4823-833c-cf456e24d760"
      unitRef="number">0.0125</ehc:DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia259457e23e1485b8a1e9fd5e341cef6_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEzMjY_6ed1836b-ab21-4181-97c8-50d7784403ff"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i56bc6d52e31940afb1b7f3a0beb13a49_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzE0NzU_060f3ae5-f551-4570-9373-c71b0d944aa1"
      unitRef="number">0.00375</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i134cca390d7c4cd4b8104ec05d7b8066_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzE2ODE_d910efbf-7397-4309-a0a3-887b0ed63ff0"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ehc:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="i54ef59182ef74e5c957f25dd73b3a573_I20191130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzIyMjY_e3803522-1c4c-4aa3-a62f-3e20a12a8057"
      unitRef="number">2</ehc:DebtInstrumentCovenantLeverageRatioMaximum>
    <ehc:CreditAgreementRestriction
      contextRef="i56bc6d52e31940afb1b7f3a0beb13a49_D20191101-20191130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzIzMzA_84107f43-9468-44da-a34d-22a4499d77e8"
      unitRef="usd">200000000</ehc:CreditAgreementRestriction>
    <ehc:ScheduleOfFinancialCovenantsTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzE1MzkzMTYyODE3NDI2_ec09a34f-0edd-4df2-8a84-ec8d9be7d2eb">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ehc:ScheduleOfFinancialCovenantsTableTextBlock>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="ie5fed9bbb5d24489bde193826b885d42_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0MjgzNWIzOGY0ZGY0YTA1ODUwYzQ5MGJkNjI2YmRkMy90YWJsZXJhbmdlOjQyODM1YjM4ZjRkZjRhMDU4NTBjNDkwYmQ2MjZiZGQzXzEtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246YjUxMjFiMGQwODU4NGFmNzlkN2Q1YWRhOTQ3YmQ2MTBfMzI5ODUzNDg4MzM0OA_711ac61b-bd79-4dad-a2bd-a9bcd3a49a1c"
      unitRef="number">3.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="i16cf531547424c47bc386d720dfa4305_D20200701-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0MjgzNWIzOGY0ZGY0YTA1ODUwYzQ5MGJkNjI2YmRkMy90YWJsZXJhbmdlOjQyODM1YjM4ZjRkZjRhMDU4NTBjNDkwYmQ2MjZiZGQzXzItMS0xLTEtMTA0ODkwL3RleHRyZWdpb246NGQzNDk4NzhlZjYyNDFhYWIxOGUzN2I3NWIwYmM3OGZfMzI5ODUzNDg4MzM0OA_b781b80f-5f2c-4461-9ccd-e74bb8d6891a"
      unitRef="number">2.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="i0c917e5fed374c46a90bd9500b43d72a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0MjgzNWIzOGY0ZGY0YTA1ODUwYzQ5MGJkNjI2YmRkMy90YWJsZXJhbmdlOjQyODM1YjM4ZjRkZjRhMDU4NTBjNDkwYmQ2MjZiZGQzXzMtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246MGQ5ZWEzZmE3NDQ0NDkyODg2M2UzODk5ZjFhZTAxY2RfMzI5ODUzNDg4MzM0OA_669bae5a-abbe-4de5-a974-71999a07a46d"
      unitRef="number">3.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i5a551c0475024f75acffcd0aae3a51c2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzEtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246MTA3YTRjNGUwZGI2NDU5NmExMWY0MDJmYThlYmRlNTVfMzI5ODUzNDg4MzM0OA_2025cedc-d09c-41fe-93e3-316148b11bd1"
      unitRef="number">4.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i17a5c6dc46234ee6839769c452e0a31b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzItMS0xLTEtMTA0ODkwL3RleHRyZWdpb246YzI2YjhmYzM3NDZmNGIwNWE0MzI4YmJkMzZiNDg4MGRfMzI5ODUzNDg4MzM0OA_b30b2eef-1cd9-41c8-9a94-30f11ba96c31"
      unitRef="number">4.75</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i065696f54bd6452cb28eea433c352d7d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzMtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246ZmNiYzhjMGQ4NmJlNDYyYWJhYWI5OTMxN2Q0ZGJjMzhfMzI5ODUzNDg4MzM0OA_f11bdf03-b5d7-4a9d-8325-84d4dfea7ec9"
      unitRef="number">5.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzQtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246YTQ1MTgyOWIwMTM1NDZkYjhiYTkzNTQxZDk5MDMwZWFfMzI5ODUzNDg4MzM0OA_30203a83-f645-44d5-80fa-0df0a70e1fe8"
      unitRef="number">6.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="ibcf2f41f6d0848b4b6dc77ea02f235d2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzUtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246MTJiMTkyMmIzMmExNDE3ZTlkM2Y5NmU5Yjc1ODAzZDlfMzI5ODUzNDg4MzM0OA_911c8c98-523d-432b-b3c3-887f047159ef"
      unitRef="number">6.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i66424ae9b2c44a4fb7238c492c20dd64_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzYtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246ZDZlNTY2MDJhMzkyNDdhODljNTMzYjhiMzRkOWVhYTZfMzI5ODUzNDg4MzM0OA_20faa37e-6e68-4f2e-911a-49fcdf001321"
      unitRef="number">6.00</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i88e6abed3f9c4844a3856dbae44d3c29_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzctMS0xLTEtMTA0ODkwL3RleHRyZWdpb246OWY0MjQyZTliOWRkNGYyN2EwMmNjODliNDY0YTliY2ZfMzI5ODUzNDg4MzM0OA_12027374-a07e-4e2c-8cd7-ad4e9b23cf5e"
      unitRef="number">5.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzgtMS0xLTEtMTA0ODkwL3RleHRyZWdpb246MzY2Y2NiZjRmNGY3NGQxOGIwM2U0Y2FlZmQ4ZTk3Y2JfMzI5ODUzNDg4MzM0OA_8116b90f-0daf-4c0c-8e5c-9cc00c4773cb"
      unitRef="number">5.00</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="ie61970e957d24746b800b3a4ca061b38_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTpiNGQzNWU4YzVmMzI0MDBhOTUyNDRlZDYxZDA0NDYyNi90YWJsZXJhbmdlOmI0ZDM1ZThjNWYzMjQwMGE5NTI0NGVkNjFkMDQ0NjI2XzktMS0xLTEtMTA0ODkwL3RleHRyZWdpb246YzVkOGJiYTFiZWRlNGFkZmIzYjE5ZjNkN2EyMWU3NTBfMzI5ODUzNDg4MzM0OA_8c0b3a4e-f224-48fd-91e1-a3f00d77c807"
      unitRef="number">4.25</ehc:DebtInstrumentCovenantLeverageRatio>
    <us-gaap:LongTermDebt
      contextRef="idda4f773f6c54fe581e21ee14d227bc7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzM1NTk_ca8be397-45f5-4211-a8d5-fc18d866a69d"
      unitRef="usd">200000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i442e600335de44a4bcbc192cf1a0def6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzIxOTkwMjMyNjY1MDg_ecacc9af-5892-4b1b-87b6-0416b0325094"
      unitRef="number">0.026</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LongTermDebt
      contextRef="i798f862fab8b4413a0c57906b428ab10_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzM2Mzk_2d032cc0-1ccc-4324-bc7a-a9411f4fafef"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i3f1b2314ba3e4d2c9434f9205fc3dd2d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzM3NDc_d5b0d1e5-270c-4b3e-bf02-db91bc95bf85"
      unitRef="usd">38200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ia0738d83aff14b43981733b51cee43ee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzM3NTQ_0d734853-052f-4c75-94d9-a3fd22183f70"
      unitRef="usd">36700000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ibdd006cc199943069830e5f0df2c5322_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzUxODg_9040fc36-b0c9-4950-b400-e748b357b186"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="ibc45972689104b858888baba8d5c3b2a_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwOTk1MTE2NDg3ODc_2872f60a-81cc-447f-9b81-442216b7c4ac"
      unitRef="number">3.5</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket
      contextRef="ibc45972689104b858888baba8d5c3b2a_I20211209"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwOTk1MTE2NDg3OTU_da13f90a-5662-4842-8066-08031699f9fb"
      unitRef="usd">200000000</ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket>
    <ehc:DebtInstrumentAmendmentAgreementAmountToBePaid
      contextRef="i3bf76ad690ab486bb10282ca094adb84_D20211201-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzQ5NDc4MDIzNTQ3MjQ_5ad994d5-29b1-4794-b95d-cff2b300bc27"
      unitRef="usd">40500000</ehc:DebtInstrumentAmendmentAgreementAmountToBePaid>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6b2e62c3760743f3b11242bc8c1de996_D20220131-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzQ5NDc4MDIzNTQ3MTE_54f7e141-22d4-40cc-829a-73bbe0a57940"
      unitRef="usd">20000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU2NTA_ac796108-9b8a-4428-982d-f548e8b96337"
      unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU2NTY_ad556c1e-7f4f-40dc-9743-c8f758cd3e9a"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i543ec7b3b23f4ccaac5a0b5e29eb4329_D20150301-20150331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU3NDA_14f1dc80-6b67-43bd-9a26-f28a62150fbc"
      unitRef="usd">295000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU4NjY_81dfe447-3765-4c33-af30-c59ea4208f89"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iafa87b93fe3f4db2b2bc8bae7954ab76_I20150331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzU5NDk_dabe93c9-942b-4fb0-bf52-b6228402f613"
      unitRef="number">0.054</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i37408f6809d84596aad486f8a90f4e53_D20210430-20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwOTk1MTE2NTUzNDg_0afed242-08fd-412e-b869-e1bbc51443c2"
      unitRef="usd">100000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ic8a20418879d4e958becfe001883e69b_D20210630-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwOTk1MTE2NTUzNDg_42a75493-6844-4117-8bc1-ec3d280f2606"
      unitRef="usd">100000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic8b11fbba37e419697f8c888119ebb62_I20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzMyOTg1MzQ5MTM4Nzk_762257a0-a419-4b41-996b-f739cd9c3560"
      unitRef="usd">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icf18e7d48c9f48a98324da23bbf64a5a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzMyOTg1MzQ5MTM4NjU_ce6f16cb-0be2-440d-87b1-de2c9f930059"
      unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idf9cd76a2420419799ae4a84b2cb8f1b_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzYyOTA_9cb6e082-c0e0-4361-8476-78c218dcbf87"
      unitRef="usd">275000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf9cd76a2420419799ae4a84b2cb8f1b_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzYzMjc_408cb715-d2de-4d67-937b-593519d5d4e9"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9d83e601b2be40eb9289618472d20e28_I20140930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY0MjI_b6e24198-0bec-4361-b499-ec16a92a6158"
      unitRef="usd">175000000</us-gaap:DebtInstrumentFaceAmount>
    <ehc:DebtInstrumentIssuePricePercentage
      contextRef="i9d83e601b2be40eb9289618472d20e28_I20140930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY0NTc_2896a9e2-4968-41c2-800e-17551e535f9a"
      unitRef="number">1.03625</ehc:DebtInstrumentIssuePricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iebe8c7bfd4394f1197ca833de3df2c09_I20150131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY1MjY_bdf93de0-27cf-4998-b1c2-6565c14f4c35"
      unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <ehc:DebtInstrumentIssuePricePercentage
      contextRef="iebe8c7bfd4394f1197ca833de3df2c09_I20150131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY1NjE_181b2e3a-8fc6-4af9-b585-e64482461ace"
      unitRef="number">1.02</ehc:DebtInstrumentIssuePricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i120953c681a546c1a1f10597d05382b8_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY2MzM_5b8df3f6-3a58-4fd1-aee5-7a5dd121fcd0"
      unitRef="usd">350000000</us-gaap:DebtInstrumentFaceAmount>
    <ehc:DebtInstrumentIssuePricePercentage
      contextRef="i120953c681a546c1a1f10597d05382b8_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY2Njg_6b1942d2-deb5-4334-abf8-9234a33782cb"
      unitRef="number">1.005</ehc:DebtInstrumentIssuePricePercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i732f255021564a07ad138756673d00c8_D20190601-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY3MjM_1ab7f8fe-6ec3-4140-9791-af19656e3863"
      unitRef="usd">100000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i732f255021564a07ad138756673d00c8_D20190601-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY5MzQ_c8fbe42b-f25c-4b25-bdcc-b395fa3e9408"
      unitRef="number">1.01917</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="i732f255021564a07ad138756673d00c8_D20190601-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzY5OTM_ce815af5-334d-4804-a8c4-50c92d42c7ab"
      unitRef="usd">102000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i6bcc19b1cd384ad2803fa192d9fd6f72_D20191101-20191130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzcwMjc_36e4a8ac-d13f-49b1-a132-53af72f0e604"
      unitRef="usd">400000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i6bcc19b1cd384ad2803fa192d9fd6f72_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzcxNzQ_5ee4b6ce-50e5-47fb-ac8f-643e26c83e95"
      unitRef="number">1.00958</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6bcc19b1cd384ad2803fa192d9fd6f72_D20191101-20191130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzcyMzM_ac92b717-3c3c-41d1-b138-2b54e0ea5249"
      unitRef="usd">404000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebt
      contextRef="i735b93d85e2c4ffbbd677a2fed8689f2_I20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzcyODE_88dfd235-3cce-405c-8d03-23377c43a59b"
      unitRef="usd">700000000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ic4c39a1fe44b40aea3426508dc786fe3_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc1Mzc_c03d1b24-2a53-4848-bf91-4e244afe8e48"
      unitRef="usd">300000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i735b93d85e2c4ffbbd677a2fed8689f2_I20201130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc3Mjg_d622ef9b-81cd-4d61-b26c-398e796a6930"
      unitRef="number">0.058</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc4NTY_245c7298-d96c-4a76-a800-f58312400cae"
      unitRef="usd">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc4NjI_c70f8fd9-a227-468b-a2e1-c6ee49e19a83"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzc5OTk_98e2388c-7219-47ed-a3b7-9946a572ef0f"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i095b852ab9b04b6f8be3c1f2fcf413f5_I20150930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzgwODI_cf49eb20-a730-43fc-9358-f5675ab50f39"
      unitRef="number">0.060</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwNjM3_ecfd12a7-3a6c-4fdc-8edf-49bf1607fddc">&lt;div style="margin-bottom:7pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2021, at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtInstrumentRedemptionTableTextBlock>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i05599bd9faa5433482a7fd2c5e801eff_D20150901-20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyOGJlZThjMWY5N2I0ZjBkOGNlYjRkNGY2OGEwYWE4My90YWJsZXJhbmdlOjI4YmVlOGMxZjk3YjRmMGQ4Y2ViNGQ0ZjY4YTBhYTgzXzItMi0xLTEtNTU5Njg_935ca9d8-9e71-401c-a2e9-c1562bb49b0a"
      unitRef="number">1.01917</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="icc40e1fe47f0401b929feacafbeade4a_D20150901-20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyOGJlZThjMWY5N2I0ZjBkOGNlYjRkNGY2OGEwYWE4My90YWJsZXJhbmdlOjI4YmVlOGMxZjk3YjRmMGQ4Y2ViNGQ0ZjY4YTBhYTgzXzMtMi0xLTEtNTU5Njg_6e2c4e8d-5a7f-4500-9f3a-fc6afaacaeff"
      unitRef="number">1.00958</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i03c812649e8f461984f6a55bf31af65b_D20150901-20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToyOGJlZThjMWY5N2I0ZjBkOGNlYjRkNGY2OGEwYWE4My90YWJsZXJhbmdlOjI4YmVlOGMxZjk3YjRmMGQ4Y2ViNGQ0ZjY4YTBhYTgzXzQtMi0xLTEtNTU5Njg_9240c661-b3ec-4c79-8b1b-d97a3adb4c28"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6728ee3fbad74c3f9120c35eb6bbb03d_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0MTM_f595d34d-0b4b-40a4-a21b-a170323b71b1"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6728ee3fbad74c3f9120c35eb6bbb03d_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0MTk_27742dc4-11b8-4007-b68f-d6b2cae9f9ae"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i27ba4302b48948e6be58d84a07f42291_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0NzQ_127aa82b-6821-457a-a4e1-46a9deec6f20"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i27ba4302b48948e6be58d84a07f42291_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg0ODA_eaf5c532-2e68-46bf-9ced-5c0ae6dca7bd"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7aba6edb48cf4106a0de799690174657_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg4NTk_311c940e-6429-401a-b698-349fa3e4d7b7"
      unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue
      contextRef="i7aba6edb48cf4106a0de799690174657_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg4OTQ_e4a381ef-6b49-417b-a1ad-8cc322edfb9d"
      unitRef="number">0.990</ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie4d4f1c1e34b4547bb895f17359f6c52_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg5Mzk_b5ff1b2c-4680-4db3-9bae-1416afa6c884"
      unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue
      contextRef="ie4d4f1c1e34b4547bb895f17359f6c52_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzg5NzQ_765ddab9-1211-4384-b3f2-e77e27195259"
      unitRef="number">0.985</ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ia038a343f20045bc93b40477b4bb3e59_D20200501-20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzkwMzQ_3201cb0a-e746-49ea-9c1b-5d750890d5fc"
      unitRef="usd">583000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6728ee3fbad74c3f9120c35eb6bbb03d_I20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzkzMjA_f4468a16-3e67-4e91-a703-6ce4d06d9561"
      unitRef="number">0.048</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i5cf2c1b477bb4e80918f99b0e09a865b_D20190901-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo2NTgzNWFiNGVkYzM0ZjQ0ODAxZjRmMWY3NDYzOWZlZC90YWJsZXJhbmdlOjY1ODM1YWI0ZWRjMzRmNDQ4MDFmNGYxZjc0NjM5ZmVkXzEtMi0xLTEtNTU5Njg_37a78efb-8dfd-49fc-b8be-18713b5ad649"
      unitRef="number">1.02250</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i8791e911ccc94436a4ccde3614131c9c_D20190901-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo2NTgzNWFiNGVkYzM0ZjQ0ODAxZjRmMWY3NDYzOWZlZC90YWJsZXJhbmdlOjY1ODM1YWI0ZWRjMzRmNDQ4MDFmNGYxZjc0NjM5ZmVkXzItMi0xLTEtNTU5Njg_d191078c-1432-4113-9570-a10a055b33c6"
      unitRef="number">1.01125</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i1cdcf2b1d8654c6782039c26b7a57622_D20190901-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo2NTgzNWFiNGVkYzM0ZjQ0ODAxZjRmMWY3NDYzOWZlZC90YWJsZXJhbmdlOjY1ODM1YWI0ZWRjMzRmNDQ4MDFmNGYxZjc0NjM5ZmVkXzMtMi0xLTEtNTU5Njg_8f64c5f3-3ba0-44d1-b223-23fbe36cb96e"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie4d4f1c1e34b4547bb895f17359f6c52_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2Xzk3MTg_e4748863-0249-4bf4-be40-d789c6194551"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i1756ab5e169c478f9663bb9168588a4d_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToxN2JiMDc3NTQyZjU0NjVjYTlkYWRmMmFiYmQzMmU5NS90YWJsZXJhbmdlOjE3YmIwNzc1NDJmNTQ2NWNhOWRhZGYyYWJiZDMyZTk1XzEtMi0xLTEtNTU5Njg_d8e0c52b-2c10-411e-b561-0b7daee38e06"
      unitRef="number">1.02375</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="if45838f1a45e438091364b67a05bf7f6_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToxN2JiMDc3NTQyZjU0NjVjYTlkYWRmMmFiYmQzMmU5NS90YWJsZXJhbmdlOjE3YmIwNzc1NDJmNTQ2NWNhOWRhZGYyYWJiZDMyZTk1XzItMi0xLTEtNTU5Njg_96ef917a-2ffe-44dd-82ec-9a012bae70c8"
      unitRef="number">1.01583</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ic4a2dc69c68d4800929ad19f067a9d3f_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToxN2JiMDc3NTQyZjU0NjVjYTlkYWRmMmFiYmQzMmU5NS90YWJsZXJhbmdlOjE3YmIwNzc1NDJmNTQ2NWNhOWRhZGYyYWJiZDMyZTk1XzMtMi0xLTEtNTU5Njg_89e51d35-8a4d-41e6-a63f-bca2072db608"
      unitRef="number">1.00792</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i43e4a72722524946885cfe42cf42efa9_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZToxN2JiMDc3NTQyZjU0NjVjYTlkYWRmMmFiYmQzMmU5NS90YWJsZXJhbmdlOjE3YmIwNzc1NDJmNTQ2NWNhOWRhZGYyYWJiZDMyZTk1XzQtMi0xLTEtNTU5Njg_f16dbfb2-233b-482d-8e5e-8c98f0b29371"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i13bbad57db694aae95b5e5b28b57c341_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwMDMy_165f500c-2b9c-4131-b80b-e030055341be"
      unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i13bbad57db694aae95b5e5b28b57c341_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwMDY1_0a4ce1cf-e5ed-4bc4-9d1b-7b0b3838375d"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i13bbad57db694aae95b5e5b28b57c341_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwMTk3_fc23038e-6aec-47f5-adc9-7f664df34858"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i13bbad57db694aae95b5e5b28b57c341_I20201031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90ZXh0cmVnaW9uOmVlMWRiZjQxZDExNjQwMThhZTljMDgyYzQxYTIwMzY2XzEwMjgw_5b884554-b41d-4e25-9113-7b31c3f0a1b5"
      unitRef="number">0.048</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i2841dc9bff054904bae487294dbff306_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTplZDJlNjhjYmJlNTA0MjUzYjAyNTE0ZGMwMDFkMmE0ZS90YWJsZXJhbmdlOmVkMmU2OGNiYmU1MDQyNTNiMDI1MTRkYzAwMWQyYTRlXzEtMi0xLTEtNTU5Njg_10045bf9-b4b1-4d6f-bc47-d7f37845598f"
      unitRef="number">1.02313</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie4816d28c19945fea8ea5bedc380aed9_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTplZDJlNjhjYmJlNTA0MjUzYjAyNTE0ZGMwMDFkMmE0ZS90YWJsZXJhbmdlOmVkMmU2OGNiYmU1MDQyNTNiMDI1MTRkYzAwMWQyYTRlXzItMi0xLTEtNTU5Njg_838feb86-6e7b-43e4-9a20-be738ebab1ce"
      unitRef="number">1.01542</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i79ae10b8be3c4f858f5f9ac1d488a263_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTplZDJlNjhjYmJlNTA0MjUzYjAyNTE0ZGMwMDFkMmE0ZS90YWJsZXJhbmdlOmVkMmU2OGNiYmU1MDQyNTNiMDI1MTRkYzAwMWQyYTRlXzMtMi0xLTEtNTU5Njg_2dd8fca1-99c6-4bb0-9dcc-6a5710372a64"
      unitRef="number">1.00771</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ia3d7e73989884e299b452c135030ebcf_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTplZDJlNjhjYmJlNTA0MjUzYjAyNTE0ZGMwMDFkMmE0ZS90YWJsZXJhbmdlOmVkMmU2OGNiYmU1MDQyNTNiMDI1MTRkYzAwMWQyYTRlXzQtMi0xLTEtNTU5Njg_f6f646e7-0921-430e-a13a-1527cfe1ac34"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LongTermDebt
      contextRef="iff05368e33294deaba91e4d0daedb5b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItMS0xLTEtNTU5Njg_9a436e63-246d-4103-a45f-b0c44a3e14d1"
      unitRef="usd">28000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic786d7283c4945f58da42a6add61877d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItMy0xLTEtNTU5Njg_f59833a4-b97f-422f-868e-dbb990de14ee"
      unitRef="usd">28000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i21e3debe10554bb8adc998d7c9f34060_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2OTkzYzkzNjc0Mzg0YmYzYjYyZDNmOGU4NGI5MWU0ZF8yMTk5MDIzMjU1NTY1_12f459d3-65f6-4912-a25a-981cec646a1a"
      unitRef="number">0.061</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia058d22308374baab4f7f83f431b2a7e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2OTkzYzkzNjc0Mzg0YmYzYjYyZDNmOGU4NGI5MWU0ZF8yMTk5MDIzMjU1NTY1_689c6755-1d29-43b8-901d-fe707fbcf3a1"
      unitRef="number">0.061</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ied1386031d4644d3a4bd6b53278b051d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2OTkzYzkzNjc0Mzg0YmYzYjYyZDNmOGU4NGI5MWU0ZF8yMTk5MDIzMjU1NTY5_365a8cab-803f-4063-ac97-3d923b765d59"
      unitRef="number">0.112</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5e342b38454245b785b3717eda590962_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzItNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo2OTkzYzkzNjc0Mzg0YmYzYjYyZDNmOGU4NGI5MWU0ZF8yMTk5MDIzMjU1NTY5_a8912af8-c5af-4da7-8e33-c488324a486f"
      unitRef="number">0.112</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i50281083594e49c69e3436fc0ceb6eb9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzQtMS0xLTEtNTU5Njg_ec3abb06-3dd9-4808-a63f-55bfd1e5ed73"
      unitRef="usd">11000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ied075c1981574658804c0fe14ced2869_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzQtMy0xLTEtNTU5Njg_655a61f7-6cc7-4fa4-8f72-f2832387460d"
      unitRef="usd">11800000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ied075c1981574658804c0fe14ced2869_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzQtNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpiYjgyYWY0YzFjMzM0ZDlkYjg5MTRhNmVjY2EyZTFiYV80_34ab6fe5-4820-484f-8d82-fb93d8187734"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i50281083594e49c69e3436fc0ceb6eb9_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzQtNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpiYjgyYWY0YzFjMzM0ZDlkYjg5MTRhNmVjY2EyZTFiYV80_5ca55fb8-c1af-4676-84d0-10f707896d65"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i74efb2cbd6fa40438ef2310cb2d0fa56_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzUtMS0xLTEtNTU5Njg_c73b03cc-d130-4839-a2f3-4e9d71c90ed7"
      unitRef="usd">10600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifc42cb6979d645e294db913c6cc97edd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzUtMy0xLTEtNTU5Njg_206f23fc-48ac-4850-8eaa-698175f96d98"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6dcc3d612e364ad7a48e4ec4f0099438_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzUtNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo5YzY1MGM0MzU2ZjU0OWEzOTFjNWZlZGZiMjFmNDllNV8xMA_6206766c-8d12-46d6-b77d-cfa99856b8b1"
      unitRef="number">0.028</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if7048280062f4c379b09fb68447c12f9_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzUtNS0xLTEtNTU5NjgvdGV4dHJlZ2lvbjo5YzY1MGM0MzU2ZjU0OWEzOTFjNWZlZGZiMjFmNDllNV8xMA_c16b9e38-26ee-414e-b684-c028660b8a07"
      unitRef="number">0.028</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i95660f8d813c4751ade79f135d5b3a25_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzYtMS0xLTEtNTU5Njg_d4bd765d-0bca-40b9-af8e-84edda496832"
      unitRef="usd">49600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5951de1720a942e0a0e71cfd9f206587_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNjUvZnJhZzplZTFkYmY0MWQxMTY0MDE4YWU5YzA4MmM0MWEyMDM2Ni90YWJsZTo0NGYyYWNkYjg0OWM0MjE3ODhjOGJmZTE3NDA3MDMxNS90YWJsZXJhbmdlOjQ0ZjJhY2RiODQ5YzQyMTc4OGM4YmZlMTc0MDcwMzE1XzYtMy0xLTEtNTU5Njg_9140a0c1-4554-440b-9b5a-35bcd88b6174"
      unitRef="usd">39800000</us-gaap:LongTermDebt>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzIzMjU_2d2a47dd-18d0-4721-9992-bf211e4c1fce">Self-Insured Risks:We insure a substantial portion of our professional liability, general liability, and workers&#x2019; compensation risks through a self-insured retention program (&#x201c;SIR&#x201d;) underwritten by our consolidated wholly owned offshore captive insurance subsidiary, HCS, Ltd., which we fund via regularly scheduled premium payments. HCS is an insurance company licensed by the Cayman Island Monetary Authority. We use HCS to fund the first $36 million of insurance and an additional $4 million of insurance in excess of $46 million for annual aggregate losses associated with general and professional liability risks. Workers&#x2019; compensation exposures are capped on a per claim basis. Risks in excess of specified limits per claim and in excess of our aggregate SIR amount are covered by unrelated commercial carriers.&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in our self-insurance reserves for the years ended December&#160;31, 2021, 2020, and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for the provision of current year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease for the provision of prior year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses related to discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to current year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to prior year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, $45.6 million and $44.0 million, respectively, of these reserves are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these risks are based primarily upon actuarially determined estimates. These reserves represent the unpaid portion of the estimated ultimate cost of all reported and unreported losses incurred through the respective consolidated balance sheet dates. The reserves are estimated using individual case-basis valuations and actuarial analyses. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The changes to the estimated ultimate loss amounts are included in current operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reserves for these self-insured risks cover approximately 1,200 and 1,600 individual claims at December&#160;31, 2021 and 2020, respectively, and estimates for potential unreported claims. The time period required to resolve these claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in reserve estimates, management believes the reserves for losses and loss expenses are adequate; however, there can be no assurance the ultimate liability will not exceed management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <ehc:MaximumSelfInsuredAmountFirstLayerOfRisk
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzQ4MA_42962cda-5afe-4cb3-97d0-ca2520abbf5b"
      unitRef="usd">36000000</ehc:MaximumSelfInsuredAmountFirstLayerOfRisk>
    <ehc:MaximumSelfInsuredAmountThirdLayerRisk
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzIxOTkwMjMyNTc5MzE_d3821753-719f-4ac3-b6df-d25483facc1d"
      unitRef="usd">4000000</ehc:MaximumSelfInsuredAmountThirdLayerRisk>
    <ehc:SelfInsuredRiskThresholdGeneralAndProfessionalLiability
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzIxOTkwMjMyNTc5MTk_dbefd78f-d362-4cf4-af82-997b58e14a32"
      unitRef="usd">46000000</ehc:SelfInsuredRiskThresholdGeneralAndProfessionalLiability>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzIzMzM_91adb584-0120-4237-915f-59fdc7fdd67e">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in our self-insurance reserves for the years ended December&#160;31, 2021, 2020, and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for the provision of current year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease for the provision of prior year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses related to discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to current year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to prior year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEtMS0xLTEtNTU5Njg_37d800f7-9751-455a-8726-4499986c5732"
      unitRef="usd">165200000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEtMy0xLTEtNTU5Njg_6bdfcbab-df12-40ff-bcf4-89b5aba50436"
      unitRef="usd">157300000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEtNS0xLTEtNTU5Njg_2d9ef7af-46fd-465e-aa6e-d5a6ff649bca"
      unitRef="usd">160900000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzItMS0xLTEtNTU5Njg_c58b87ce-9b44-4f43-bca5-6015d34e0095"
      unitRef="usd">28300000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzItMy0xLTEtNTU5Njg_e811b0e0-8801-4ce7-bae8-3e3ec75ee070"
      unitRef="usd">26400000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzItNS0xLTEtNTU5Njg_cf5ccc75-4f0b-4d62-b744-e53bed1532f4"
      unitRef="usd">25600000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzMtMS0xLTEtNTU5Njg_f5f069dd-f6c1-4799-b8b3-b941367b86c7"
      unitRef="usd">136900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzMtMy0xLTEtNTU5Njg_68004ad7-95ce-478e-8519-c89bed9dd59f"
      unitRef="usd">130900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i1769921a6d9648258a5bf2ec2f81c72c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzMtNS0xLTEtNTU5Njg_47ae204a-34f4-4e5e-b4c6-d355923f80c3"
      unitRef="usd">135300000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzQtMS0xLTEtNTU5Njg_5ec9cd98-cef1-4c2a-82c1-8e21ea825c30"
      unitRef="usd">46900000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzQtMy0xLTEtNTU5Njg_d6790212-a2be-495c-9a4c-64a013c2966d"
      unitRef="usd">52500000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzQtNS0xLTEtNTU5Njg_339866b1-1663-4e34-8251-07d6bfab289d"
      unitRef="usd">46900000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzUtMS0xLTEtNTU5Njg_8bfac530-e641-4466-9d90-6ae1e782d7a9"
      unitRef="usd">6800000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzUtMy0xLTEtNTU5Njg_2712b075-a92e-4cde-ae2c-067c749b4dc7"
      unitRef="usd">15000000.0</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzUtNS0xLTEtNTU5Njg_397a01d1-df2b-46c4-9697-183730c0177a"
      unitRef="usd">12600000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzctMS0xLTEtNTU5Njg_947f50fe-3358-4935-b475-d0a6e52b8789"
      unitRef="usd">200000</ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations>
    <ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzctMy0xLTEtNTU5Njg_b007bdde-597a-4576-a215-57ea651217a5"
      unitRef="usd">200000</ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations>
    <ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzctNS0xLTEtNTU5Njg_f6001bea-5835-4783-a7eb-8294584363e4"
      unitRef="usd">100000</ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzgtMS0xLTEtNTU5Njg_9dc849bd-9a19-4985-a65b-d858b008d459"
      unitRef="usd">7000000.0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzgtMy0xLTEtNTU5Njg_6cc01855-b56e-42b7-8626-92bad3200472"
      unitRef="usd">8400000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzgtNS0xLTEtNTU5Njg_4b160d5e-7541-48c8-8410-0a1fc29044a3"
      unitRef="usd">7500000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzktMS0xLTEtNTU5Njg_a6a4f0af-ede6-4641-8801-d83b778c6324"
      unitRef="usd">30400000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzktMy0xLTEtNTU5Njg_68218744-92d5-499e-be8c-2d36c2ea9b70"
      unitRef="usd">22900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzktNS0xLTEtNTU5Njg_e762f756-9da0-4129-b938-56541c2555c0"
      unitRef="usd">31100000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzExLTEtMS0xLTU1OTY4_82d60993-3f02-41fa-aae3-96e527b53310"
      unitRef="usd">139400000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzExLTMtMS0xLTU1OTY4_cc12e12a-2c17-4c3e-83bb-c91eb0996dd4"
      unitRef="usd">136900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzExLTUtMS0xLTU1OTY4_0e1de70b-0cea-431e-b326-dc1865f6b35e"
      unitRef="usd">130900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEyLTEtMS0xLTU1OTY4_23f07d88-0416-4fb7-bbae-adcd2411bb5b"
      unitRef="usd">30000000.0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEyLTMtMS0xLTU1OTY4_2fa119b5-3d6b-4601-9f01-77117049bf26"
      unitRef="usd">28300000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEyLTUtMS0xLTU1OTY4_55c486ca-925f-4965-a6ec-7a1c9a7716af"
      unitRef="usd">26400000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEzLTEtMS0xLTU1OTY4_685f386f-a227-4022-bae8-b8357aa1f720"
      unitRef="usd">169400000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEzLTMtMS0xLTU1OTY4_0c40cada-4a0c-4584-81d9-842469d0d453"
      unitRef="usd">165200000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i7acb83d4e3604bb8b73ee2b124efcdcf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90YWJsZTplZDg2ZDIxODQ1M2U0NzY4ODRmNGJjNTkyZWJiNjU3Yy90YWJsZXJhbmdlOmVkODZkMjE4NDUzZTQ3Njg4NGY0YmM1OTJlYmI2NTdjXzEzLTUtMS0xLTU1OTY4_19c8ccfe-b382-4c29-9ee8-459c82660cc7"
      unitRef="usd">157300000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SelfInsuranceReserveCurrent
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzkwOQ_962aad04-62e1-4a47-937d-7242f742b626"
      unitRef="usd">45600000</us-gaap:SelfInsuranceReserveCurrent>
    <us-gaap:SelfInsuranceReserveCurrent
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzkxNg_4fc8902b-1a9a-42a7-8b16-71f2ce694b9a"
      unitRef="usd">44000000</us-gaap:SelfInsuranceReserveCurrent>
    <ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzE3NTE_c31efeb7-da86-4134-ad2f-445b5344adf9"
      unitRef="claim">1200</ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves>
    <ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzEvZnJhZzpmMDYxYTVlZjFmMTA0Nzk5YmQ0YzAxZWVhZDUxOThmZi90ZXh0cmVnaW9uOmYwNjFhNWVmMWYxMDQ3OTliZDRjMDFlZWFkNTE5OGZmXzE3NTg_2c9b49b8-3f2e-4011-bb6a-a3165f0e78d5"
      unitRef="claim">1600</ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQyMzk_91579e96-5b02-43c7-8d87-bd3fc6bec70a">Redeemable Noncontrolling Interests:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution to joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase of redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the net income attributable to nonredeemable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the shareholders&#x2019; equity section of the consolidated balance sheets, and the net income attributable to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the mezzanine section of the consolidated balance sheets, to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; presented in the consolidated statements of comprehensive income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to nonredeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2014, we acquired 83.3% of our home health and hospice business when we purchased EHHI Holdings, Inc. (&#x201c;EHHI&#x201d;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#x201c;Holdings&#x201d;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. In July 2019, we received additional exercise notices, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. In September&#160;2019, Encompass Health settled the acquisition of those shares upon payment of approximately $163 million in cash. As of December 31, 2019, the value of the outstanding shares of Holdings owned by management investors was approximately $208 million. In January 2020, we received additional exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#x201c;Exchange Agreement&#x201d;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#x201c;EHC Shares&#x201d;). Each of the Exchange Agreements provided &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that the management investor must deliver a written exchange notice (an &#x201c;Exchange Notice&#x201d;) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#x2019;s common stock on the New York Stock Exchange (the &#x201c;NYSE&#x201d;) on the date of delivery of the Exchange Notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors.  Based on the last sales price of Encompass Health&#x2019;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns 100% of Holdings and EHHI.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See also Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Note&#160;13, &lt;/span&gt;Fair Value Measurements</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQyNDA_bf1f9782-a671-4b3f-891f-f2201dc4797e">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution to joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase of redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ieedaeba272bb466387acacba6de2f02b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzItMS0xLTEtNTU5Njg_a733e649-2a13-4f53-8421-2de27cfffaaa"
      unitRef="usd">31600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ife388829092541459cbc207156259fe1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzItMy0xLTEtNTU5Njg_261f688b-4142-4b0b-bd5e-9fdeeb477555"
      unitRef="usd">239600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="iaa910c45e3ba432986f5de81016e67f2_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzItNS0xLTEtNTU5Njg_a5011702-e16a-4673-abc4-894c43aeea1a"
      unitRef="usd">261700000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzQtMS0xLTEtNTU5Njg_fd63ea93-b019-491b-b50d-a1236e143ded"
      unitRef="usd">9000000.0</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzQtMy0xLTEtNTU5Njg_e046c7ef-f478-4861-be72-94d65d594148"
      unitRef="usd">7400000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzQtNS0xLTEtNTU5Njg_eb784e53-1344-4c03-941f-c1dfbaccbd0b"
      unitRef="usd">12600000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzUtMS0xLTEtNTU5Njg_ae26b36a-2346-49c1-a650-dc7793298ff3"
      unitRef="usd">8000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzUtMy0xLTEtNTU5Njg_e239b6a4-4be8-4f03-9dbf-5ccf2ee6924b"
      unitRef="usd">8500000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzUtNS0xLTEtNTU5Njg_15d9ee25-3091-4e58-9aea-c10c371d3f8c"
      unitRef="usd">9200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <ehc:Contributiontojointventure
      contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzYtMS0xLTEtNTU5Njg_5a124d2f-815b-4f7a-9c60-52874a616f46"
      unitRef="usd">0</ehc:Contributiontojointventure>
    <ehc:Contributiontojointventure
      contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzYtMy0xLTEtNTU5Njg_b04bc8fa-751f-42b2-b255-ec28862d68a2"
      unitRef="usd">3100000</ehc:Contributiontojointventure>
    <ehc:Contributiontojointventure
      contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzYtNS0xLTEtNTU5Njg_62f1097f-f9ff-4b6b-a413-cf3f287d3cca"
      unitRef="usd">1000000.0</ehc:Contributiontojointventure>
    <ehc:Reclassificationtononcontrollinginterests
      contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzctMS0xLTEtNTU5Njg_42cfe9c7-9193-4cad-a25f-3f869a190da6"
      unitRef="usd">0</ehc:Reclassificationtononcontrollinginterests>
    <ehc:Reclassificationtononcontrollinginterests
      contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzctMy0xLTEtNTU5Njg_a05944f9-bebb-41df-8e6e-7f28fe1c0ffa"
      unitRef="usd">0</ehc:Reclassificationtononcontrollinginterests>
    <ehc:Reclassificationtononcontrollinginterests
      contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzctNS0xLTEtNTU5Njg_e50f9e7f-2f33-4ce4-ae16-44a4d40a3bdd"
      unitRef="usd">11200000</ehc:Reclassificationtononcontrollinginterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzgtMS0xLTEtNTU5Njg_3aa169d6-8bb6-4d81-ac37-44935c0b63d1"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzgtMy0xLTEtNTU5Njg_5742d141-1183-449e-b922-a73d11321dc7"
      unitRef="usd">162300000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzgtNS0xLTEtNTU5Njg_d6720f1c-7860-4b64-a11c-1ea5013e1505"
      unitRef="usd">162900000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <ehc:NoncontrollingInterestExchangeTransaction
      contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzktMS0xLTEtNTU5Njg_7a4fd949-6193-42e4-8cc9-24790f0d1d13"
      unitRef="usd">0</ehc:NoncontrollingInterestExchangeTransaction>
    <ehc:NoncontrollingInterestExchangeTransaction
      contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzktMy0xLTEtNTU5Njg_4b13fcc2-4f2f-4b1f-b40e-4271ebc9c28f"
      unitRef="usd">46300000</ehc:NoncontrollingInterestExchangeTransaction>
    <ehc:NoncontrollingInterestExchangeTransaction
      contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzktNS0xLTEtNTU5Njg_f04852d2-e581-44a6-908a-e8340c1019ac"
      unitRef="usd">0</ehc:NoncontrollingInterestExchangeTransaction>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzEwLTEtMS0xLTU1OTY4_2397d90f-b76b-4c62-aafd-b9196d7623f2"
      unitRef="usd">4500000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzEwLTMtMS0xLTU1OTY4_557653a3-ed5c-4d66-8aba-ef40aa8f28c7"
      unitRef="usd">-1400000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzEwLTUtMS0xLTU1OTY4_cc108b35-b36c-4260-bf51-adb92e9e5521"
      unitRef="usd">147600000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <ehc:NoncontrollingInterestOtherAdjustment
      contextRef="i4cd7571cd46942f0ae719acb0f4a1cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTEtMS0xLTEwMTQ5NA_36eec950-4d1f-49c6-a36b-682083c78969"
      unitRef="usd">5100000</ehc:NoncontrollingInterestOtherAdjustment>
    <ehc:NoncontrollingInterestOtherAdjustment
      contextRef="if68fb23c34d24424baf8d4305945e0bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTMtMS0xLTEwMTQ5NA_55907239-398d-46e6-8a79-41fa143f5399"
      unitRef="usd">0</ehc:NoncontrollingInterestOtherAdjustment>
    <ehc:NoncontrollingInterestOtherAdjustment
      contextRef="ib14c5335f68f417ebd17602358445c8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTUtMS0xLTEwMTQ5NA_c92b50a2-140f-46ca-a047-5dfd1bec96f0"
      unitRef="usd">0</ehc:NoncontrollingInterestOtherAdjustment>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ic1b3ec367aa84b1b8b9ef9bdc970188a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTEtMS0xLTU1OTY4_689ce2a4-459e-4fab-acc4-3f26ba5ffc25"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ieedaeba272bb466387acacba6de2f02b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTMtMS0xLTU1OTY4_e8fd8cec-29e6-45d8-8e73-d31018ee2052"
      unitRef="usd">31600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ife388829092541459cbc207156259fe1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTpjOTI0MmZmZDBkOWQ0ZjQ4ODBkOTQxODcxNmQ3NjRjZi90YWJsZXJhbmdlOmM5MjQyZmZkMGQ5ZDRmNDg4MGQ5NDE4NzE2ZDc2NGNmXzExLTUtMS0xLTU1OTY4_5460aaa7-5728-4770-a875-590564937ff1"
      unitRef="usd">239600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQyNTQ_41a9a7bb-c90f-4a8e-86db-916348f27d25">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the net income attributable to nonredeemable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the shareholders&#x2019; equity section of the consolidated balance sheets, and the net income attributable to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the mezzanine section of the consolidated balance sheets, to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; presented in the consolidated statements of comprehensive income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to nonredeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzItMS0xLTEtNTU5Njg_09187d45-5dbf-4d8f-bf9f-78ec3f2f2ae7"
      unitRef="usd">96000000.0</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzItMy0xLTEtNTU5Njg_3a64664e-9ebb-4b07-b607-9440d6415d09"
      unitRef="usd">77200000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzItNS0xLTEtNTU5Njg_8a7b2ea3-e961-4e1e-be75-d6367f4da0b8"
      unitRef="usd">74500000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzMtMS0xLTEtNTU5Njg_b1aab379-b30d-45c0-a7d1-130d8f714514"
      unitRef="usd">9000000.0</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzMtMy0xLTEtNTU5Njg_72d4ff63-302b-4bba-a217-0d109203dda5"
      unitRef="usd">7400000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzMtNS0xLTEtNTU5Njg_006ec56f-aeef-4383-9925-4a125332b7af"
      unitRef="usd">12600000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzQtMS0xLTEtNTU5Njg_f60f7630-cfe9-41d2-98e1-564693849056"
      unitRef="usd">105000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzQtMy0xLTEtNTU5Njg_5b569b61-a473-4956-b37d-08c35d879be9"
      unitRef="usd">84600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90YWJsZTowMzY2NjFhYzllYzA0NzhkYTMyZmMxNzE3YThmY2VjNy90YWJsZXJhbmdlOjAzNjY2MWFjOWVjMDQ3OGRhMzJmYzE3MTdhOGZjZWM3XzQtNS0xLTEtNTU5Njg_a7b3cf65-947a-4755-920e-d132677321ba"
      unitRef="usd">87100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent
      contextRef="i5c9d6a1911754260a1b0e06548e665cc_I20141231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzYyNw_5e5529db-0ced-444a-808a-2d57fd469d4b"
      unitRef="number">0.833</ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i5c9d6a1911754260a1b0e06548e665cc_I20141231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzExOTA_230eebe2-c81a-4594-a93a-cb2d7e95a746"
      unitRef="usd">64000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <ehc:SubsidiaryscommonstockheldbysubsidiarysmanagementPercent
      contextRef="i5c9d6a1911754260a1b0e06548e665cc_I20141231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzEyNDg_3419e705-7ed8-4f38-9479-f07f1d055651"
      unitRef="number">0.167</ehc:SubsidiaryscommonstockheldbysubsidiarysmanagementPercent>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="i372fc03d1c144d9b84eb20ceee3d1d0e_D20180201-20180228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzE3MTI_885182d0-23a5-4471-8593-b403670a7145"
      unitRef="number">0.056</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i37ce9b34009e450aaec6451916af0460_D20180221-20180221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzE4ODM_58dd517f-0257-4aac-afa9-467c3c629fef"
      unitRef="usd">65000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="ibe4b642f98b44d9297f662ae777e6a48_D20190701-20190731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzE5Nzc_18197d7d-ac1a-487f-96ec-11d849483ac4"
      unitRef="number">0.056</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i2b95d9baa2a3472f8501b1064a01c601_D20190901-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzIxNDU_9c959a63-bbef-4e8c-aabb-902ea997791c"
      unitRef="usd">163000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue
      contextRef="ib32b4f07fc6c4852aa189147f3ac8f4b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzIyNzg_22ff7d78-96fe-4732-a82b-db7697361f7d"
      unitRef="usd">208000000</us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="ie9a724185f6047b2a7b0f3655af7f015_D20200101-20200131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzIzNjc_feda4f78-4c79-4245-bd43-745bb8723636"
      unitRef="number">0.043</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i2460d2c0ba7b42f591cc57a3b40a1eac_D20200218-20200218"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzI1Mzg_c0f7f5e3-cdb3-4f09-a02a-08ce5fb37e69"
      unitRef="usd">162000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue
      contextRef="i6104f61239694a209a6dd8bf3ea4229d_I20200218"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzI2MDA_d01bc4cc-e322-43f3-a4bc-e68101748bff"
      unitRef="usd">46000000</us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="if2d67ea997974c2d910a1b10bd43ff0d_I20200220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzM4ODg_2465c1ae-0ab1-41c4-9747-0e90300e8b28"
      unitRef="shares">560957</us-gaap:TemporaryEquitySharesIssued>
    <ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages
      contextRef="i08537da18acf4dfaa0164d93a3f484c8_I20200306"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQwNDQ_dd644c06-101b-4638-9b6a-21bb24c01295"
      unitRef="number">0.006</ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i416581dd3fdc4322b8a32aa48b236e6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzQvZnJhZzoxMTQ4ZTkxNTA5ODc0M2E3YWQ1NjZjMzJiOGZhZGM0OS90ZXh0cmVnaW9uOjExNDhlOTE1MDk4NzQzYTdhZDU2NmMzMmI4ZmFkYzQ5XzQxOTg_aaeef123-dbca-4ea8-8374-f7b61f8313a9"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzI2MzI_e9421387-611d-4ed1-9ed9-df15bf929ca3">Fair Value Measurements:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our consolidation of certain joint venture entities and the remeasurement of our previously held equity interest at fair value, we recorded gains of $3.2 million, $2.2 million, and $19.2 million as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the years ended December 31, 2021, 2020, and 2019, respectively. We determined the fair value of our previously held equity interest using the income approach valuation technique. The income approach included the use of the hospital's or agency&#x2019;s projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital or agency. The projected operating results use management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. See Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Note&#160;9,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments in and Advances to Nonconsolidated Affiliates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Fair Value Measurements,&#x201d; the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our consolidated balance sheets. The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial commitments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inputs within the fair value hierarchy. See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Fair Value Measurements&#x201d; and &#x201c;Redeemable Noncontrolling Interests.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzI2NDI_8789eaae-51b5-436a-8c10-9254386ffa86">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ied40dc1098204db7afa17d466e5ee54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzMtMi0xLTEtNTU5Njg_4cfd6d6c-ecca-44b1-bd0d-1edc83d7321f"
      unitRef="usd">82200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id93bba85033d46889357eea3753fda21_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzMtNC0xLTEtNTU5Njg_a88d4e27-49f4-4c95-83a8-4217d9656115"
      unitRef="usd">4100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9114052e2fb44c2197290d9e9f558961_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzMtNi0xLTEtNTU5Njg_95404eea-ef44-463c-a866-5a4d2f8cc57f"
      unitRef="usd">78100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idb4ed8fefa5143e8a3f5ad38cf8cbf30_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzMtOC0xLTEtNTU5Njg_27f34689-2e7b-4cd2-a326-8a5d7f9ca539"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ied40dc1098204db7afa17d466e5ee54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzUtMi0xLTEtNTU5Njg_e24fb6a2-aa48-43b9-aabe-a06bd8b7f3b3"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="id93bba85033d46889357eea3753fda21_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzUtNC0xLTEtNTU5Njg_6078868a-0d0b-4c16-8a33-b902b290e16a"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i9114052e2fb44c2197290d9e9f558961_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzUtNi0xLTEtNTU5Njg_eef5995d-736a-4dff-8a16-baf8f028fae8"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="idb4ed8fefa5143e8a3f5ad38cf8cbf30_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzUtOC0xLTEtNTU5Njg_79567125-8449-45a1-a002-015078e47ce7"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i26344215630447e2a32f1bb8fb1577c3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzgtMi0xLTEtNTU5Njg_e52dfae2-cdea-457d-9765-ef05130f871a"
      unitRef="usd">72600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib8d9ef1925864bf6bd6ebd083ceffcf4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzgtNC0xLTEtNTU5Njg_71da9bda-f92d-4e1c-a3e2-87ed4af739d0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i72afa364a34540ae9695838e9d3f5468_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzgtNi0xLTEtNTU5Njg_86c167fd-8f6d-4512-8cb8-07963459b891"
      unitRef="usd">72600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1c3e10e7837748aaba2310ed38697364_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzgtOC0xLTEtNTU5Njg_8d3db53d-a46f-476e-a916-c6163b71b870"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i26344215630447e2a32f1bb8fb1577c3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzEwLTItMS0xLTU1OTY4_c3b5192f-95af-47dc-bf3a-1b2768f9d6f5"
      unitRef="usd">31600000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ib8d9ef1925864bf6bd6ebd083ceffcf4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzEwLTQtMS0xLTU1OTY4_0556ef45-7c7f-4a88-a5bb-f9ad07d9ca7f"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i72afa364a34540ae9695838e9d3f5468_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzEwLTYtMS0xLTU1OTY4_794212cc-e044-4765-8bd7-a5032ab53ba9"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i1c3e10e7837748aaba2310ed38697364_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZToyMTJkMTk1OWQyYTU0MTFmODkwMjkxZGNmZGU1ZjNlYi90YWJsZXJhbmdlOjIxMmQxOTU5ZDJhNTQxMWY4OTAyOTFkY2ZkZTVmM2ViXzEwLTgtMS0xLTU1OTY4_6316fb30-8347-466f-a600-662063bfdcdd"
      unitRef="usd">31600000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="ic07a527a70c444b8aa8dc851c08e1454_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzI5Njg2ODEzOTUzNzMz_92d13531-e7b6-4b72-bc9f-be9b8ed3d7a2"
      unitRef="usd">3200000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="ie630f132fb654f72bc20deb38a5299e9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzg5Ng_9c311897-1b61-46a8-93e1-86e2772721a1"
      unitRef="usd">2200000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i4bb6e84f060341ee8f3a82d5fe595b1f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzExMzA_ef540884-816f-4e2f-b5c0-609136c0f6ff"
      unitRef="usd">19200000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90ZXh0cmVnaW9uOmM3YzliNDNlZGJmMDRhNTRhZTEwNTc5NDRmYzdiODExXzI2NDk_158e1ff3-9093-4957-9e3d-7d6992a2a12d">The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial commitments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="i15a96226e9a74277befd57b95ce89cad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzMtMS0xLTEtNTU5Njg_f4afbe1f-ab7a-4564-9023-7f3e3feb1d90"
      unitRef="usd">200000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3f229fa2dcf94ada94372b94a004a511_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzMtMy0xLTEtNTU5Njg_b53bf2f3-ff31-4109-ac5d-472cb8dc6675"
      unitRef="usd">200000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="icedf57c7e28645bd80047694f8a37d7c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzMtNS0xLTEtNTU5Njg_85709e49-3217-4d58-b60a-3d0633997edd"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i478de2031cff4407b9b5bd814b8fffbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzMtNy0xLTEtNTU5Njg_e98d76cb-6687-4d73-a034-16edba4b8d64"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="idc784810eec245a793b5bdaf468ad33d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzQtMS0xLTEtNTU5Njg_7728515c-b730-49ed-8b34-6af7861e5974"
      unitRef="usd">238500000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic41ca53159bc4b10a192181b3bca89ab_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzQtMy0xLTEtNTU5Njg_a94d5f20-cddb-426b-adc1-755fea1e251d"
      unitRef="usd">239600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i854aba59b7df49a79105db7602e291c1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzQtNS0xLTEtNTU5Njg_f4493832-20a1-4559-9e4e-f3861b589b2b"
      unitRef="usd">251600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0a611dd035e44c8fb3fb11d3061619d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzQtNy0xLTEtNTU5Njg_3a1a552a-d199-4a32-bac6-7844da8b19a7"
      unitRef="usd">253100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i475515e7171f46acb6ddebf2c000d90c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjoxNDZhOTg4OThkMzg0MDc4ODAwYWY2MTVlMWQyYjU1OV80_4bdce726-ae99-4a41-946f-8f042393b0b2"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i098be77d49ab41099bfe946d54e9bcd7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjoxNDZhOTg4OThkMzg0MDc4ODAwYWY2MTVlMWQyYjU1OV80_c9bf4c77-f771-4be6-a17a-06f3e07b9c0c"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia5a1360b6acd4210bf3adb7d6d88bc50_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctMS0xLTEtNTU5Njg_76e3775c-2a68-496d-ba22-7809ed83535c"
      unitRef="usd">99600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i8f48f48c99b345bc8876378d756bf4e1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctMy0xLTEtNTU5Njg_57f9fd92-4173-4c24-b567-db30a7930de0"
      unitRef="usd">100200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i36387f8be3fa45d09cbd0c2a0ab073ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctNS0xLTEtNTU5Njg_ee20e2f2-1078-43c6-9877-318e2ed87afd"
      unitRef="usd">298100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i062d90846d5246a8a5ce15d4753ed256_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzctNy0xLTEtNTU5Njg_d3a49d82-3385-4418-b39b-a66fd28849a5"
      unitRef="usd">302600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6689accfbb7543808abafce304019012_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpiYjU1MDQyMmRiM2Y0M2Y5YTVkY2ZhOTZlNDdhNmYyOV80_16ba9a7f-74a7-4e73-9138-bedad8e0629f"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8e8dcadb39154f309a2431ebb274d483_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktMC0xLTEtNTU5NjgvdGV4dHJlZ2lvbjpiYjU1MDQyMmRiM2Y0M2Y5YTVkY2ZhOTZlNDdhNmYyOV80_5714a3a5-a7ce-47a5-8219-d1a0da65a9b8"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i003153e059144500ba846eaaf3124397_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktMS0xLTEtNTU5Njg_cfbedd30-f98e-40a1-8d7c-489b0737704f"
      unitRef="usd">347000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i04aa7dec6a244bcba19b7d980b858fd3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktMy0xLTEtNTU5Njg_16a477be-c2eb-4bc1-8387-d72b126d5f50"
      unitRef="usd">357900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ibc744be7bb2e4378aa9465a42c569d4d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktNS0xLTEtNTU5Njg_965c445b-34a6-46ca-8b81-d64247e4d551"
      unitRef="usd">346300000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3eda38234466449a8e337a5d2c3279da_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzktNy0xLTEtNTU5Njg_afd88513-0c62-450a-b1b1-ccaef0745a86"
      unitRef="usd">361400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i940f9d1a36544945a5314717176158e2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTAtMS0xLTU1OTY4L3RleHRyZWdpb246NTY5ZjMzNzExNDY0NDZjZWIzNTA1ZjRlNzIyOWVmZGFfNA_32fe7804-f0de-4120-8be8-35966d287d05"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i42cd94791aee45c38596cfa00e2c22b0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTAtMS0xLTU1OTY4L3RleHRyZWdpb246NTY5ZjMzNzExNDY0NDZjZWIzNTA1ZjRlNzIyOWVmZGFfNA_8d7b5273-0861-469c-a166-f39e3100ead2"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib71d169070664d258df1acb196a80bd8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTEtMS0xLTU1OTY4_bebc1d1f-04ab-4f46-b184-7e08c49b427a"
      unitRef="usd">786800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib23c7a2789b540b5b31a5bc6e512ff63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTMtMS0xLTU1OTY4_1af224a4-f38d-4abe-990c-56ab3ed3dfa7"
      unitRef="usd">823000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic3661453bf8d4cb888df6dfd0eb6ea49_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTUtMS0xLTU1OTY4_257ae67a-8bc4-4bfa-9a28-c0e4a2508cc7"
      unitRef="usd">785000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i4222e0b6d18348f19725e8257c08a4ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEwLTctMS0xLTU1OTY4_a48ec970-454f-4cf5-af4a-6fb684ee606e"
      unitRef="usd">840000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i62d481ea979b4b2dac6c075291e1ef68_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MzhhNzFiMmNmODUyNGMzODgzN2Y0MTk0ZWMwOTViNjZfNA_12f9d30e-56d6-4ada-99a8-dc5b0b657b80"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i708722e52f7b4e87879527c09b19006d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTAtMS0xLTU1OTY4L3RleHRyZWdpb246MzhhNzFiMmNmODUyNGMzODgzN2Y0MTk0ZWMwOTViNjZfNA_d32cdf23-f33e-4e77-9029-1b3970701065"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="id3d0325b6fab4784876511cde99c9a37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTEtMS0xLTU1OTY4_6ad6ab5b-6e29-431d-bd14-7c26bf61b708"
      unitRef="usd">784700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0971f6c0ba8347fb8bbf20251a8ef965_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTMtMS0xLTU1OTY4_9bf3f28b-dbf8-4bf7-aedc-69452c68f5f4"
      unitRef="usd">824000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i42e243e3007341bcaa8e6d60b76106d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTUtMS0xLTU1OTY4_3f265ec1-2c48-4e90-a155-dfc59c724740"
      unitRef="usd">783200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7c46ae7004334f3aaa8ec786ab9f4e60_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzExLTctMS0xLTU1OTY4_65a725e0-dc3c-4508-9adb-27b95e3e0154"
      unitRef="usd">856000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3e435cfbee1d418aaa5b1e302438b2e3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTAtMS0xLTU1OTY4L3RleHRyZWdpb246N2Y3YTA1ZGViMGUwNDRjMWI2MjEzMjg2YmRmOGQ1OTdfNA_08623970-0df8-46b6-9d2f-86bc244ff8b2"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if6c70ba1acd6484e874b7cbf5ce32af3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTAtMS0xLTU1OTY4L3RleHRyZWdpb246N2Y3YTA1ZGViMGUwNDRjMWI2MjEzMjg2YmRmOGQ1OTdfNA_64376f2c-6301-4ceb-88bc-548026db7c8a"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7ee5718dadc4409d81f3281961341d1e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTEtMS0xLTU1OTY4_78c55a69-3151-4cf6-b562-47b953ccc466"
      unitRef="usd">393700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id9d918faf5c945fb8f815f7f3e0db8d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTMtMS0xLTU1OTY4_5e3ec674-a120-4741-83a5-dbdd45778064"
      unitRef="usd">407000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i02851d306e4041dfa6105c00051182cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTUtMS0xLTU1OTY4_e71ad540-5911-4254-9857-04aee78830dc"
      unitRef="usd">393200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id57c054ef40d45489612bbab7e3e448f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEyLTctMS0xLTU1OTY4_2c489154-eb4d-4dc2-8d0a-9ebf68c47c76"
      unitRef="usd">424900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i20ffead8b6274baf8242167d98ee9096_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEzLTEtMS0xLTU1OTY4_15bb0e0b-fee2-4422-826c-9cd85db05ee0"
      unitRef="usd">49600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="icb0dba2d7c8a4826b1f482f1349b6e95_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEzLTMtMS0xLTU1OTY4_d1649869-755c-44ca-80e8-a6eea93904ea"
      unitRef="usd">49600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i1ac9bae069004607913ad2196139ca57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEzLTUtMS0xLTU1OTY4_eade97a0-4139-42ba-ba39-e2958cdd6863"
      unitRef="usd">39800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id35d77e9ba484f40ba51f2683301dea5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzEzLTctMS0xLTU1OTY4_c6329326-9254-493d-89a0-76039af79e6a"
      unitRef="usd">39800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id114ce728e2345d89f4bd7890b37ac2c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzE1LTEtMS0xLTU1OTY4_19dbf5f5-d11e-435c-bb42-6c3fe11eb2d1"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0d4b4be5983f48d581aeb5aad62c2ca9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzE1LTMtMS0xLTU1OTY4_8ec59e5a-7809-4ec5-b755-c5dacef90b26"
      unitRef="usd">38200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i299d52f28a4c4d0f9f975d70786c40f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzE1LTUtMS0xLTU1OTY4_ee26d40b-8ff6-42ce-a5d9-1f70f549705f"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i52cbb010926c4e229d2f2b20106351f2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yNzcvZnJhZzpjN2M5YjQzZWRiZjA0YTU0YWUxMDU3OTQ0ZmM3YjgxMS90YWJsZTpmNmRiZWMxYjI0YmI0MTBmYjE5ZDgwN2NhOTBiNGNkMC90YWJsZXJhbmdlOmY2ZGJlYzFiMjRiYjQxMGZiMTlkODA3Y2E5MGI0Y2QwXzE1LTctMS0xLTU1OTY4_bc165cec-7f84-44d4-9402-e630e431845d"
      unitRef="usd">36700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc4OTM_21d5c34a-1ef8-4a1c-b8a7-d0163e64bb5b">Share-Based Payments:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has awarded employee stock-based compensation in the form of stock options, SARs, and restricted stock awards (&#x201c;RSAs&#x201d;) under the terms of share-based incentive plans designed to align employee and executive interests to those of its stockholders. All employee stock-based compensation awarded during 2021, 2020, and 2019 was issued under the 2016 Omnibus Performance Incentive Plan, a stockholder-approved plan that reserves and provides for the grant of up to 14,000,000 shares of common stock. This plan allows for the grants of nonqualified stock options, incentive stock options, restricted stock, SARs, performance shares, performance share units, dividend equivalents, restricted stock units (&#x201c;RSUs&#x201d;),  and/or other stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our share-based incentive plans, officers and employees are given the right to purchase shares of Encompass Health common stock at a fixed grant price determined on the day the options are granted. The terms and conditions of the options, including exercise prices and the periods in which options are exercisable, are generally at the discretion of the compensation and human capital committee of our board of directors. However, no options are exercisable beyond ten years from the date of grant. Granted options vest over the awards&#x2019; requisite service periods, which are generally three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the options granted during the years ended December&#160;31, 2021, 2020, and 2019 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including the expected stock price volatility. We estimate our expected term through an analysis of actual, historical post-vesting exercise, cancellation, and expiration behavior by our officers and employees and projected post-vesting activity of outstanding options. We calculate volatility based on the historical volatility of our common stock over the period commensurate with the expected term of the options. The risk-free interest rate is the implied daily yield currently available on U.S. Treasury issues with a remaining term closely approximating the expected term used as the input to the Black-Scholes option-pricing model. We estimated our dividend yield based on our annual dividend rate and our stock price on the dividend payment dates. Under the Black-Scholes option-pricing model, the weighted-average grant date fair value per share of employee stock options granted during the years ended December&#160;31, 2021, 2020, and 2019 was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$19.21,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $15.48, and $15.45, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(In Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized approximatel&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y $2.3 million,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.5 million, and $1.4 million of compensation expense related to our stock options for the years ended December&#160;31, 2021, 2020, and 2019, respectively. As of December&#160;31, 2021, there was&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.4 million o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of 19 months. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020, and 2019 was $0.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $2.3 million, and $3.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Appreciation Rights&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the EHHI acquisition, we granted SARs based on Holdings common stock to certain members of EHHI management at closing on December 31, 2014. Under a separate plan, we granted 122,976 SARs that vested based on continued employment and an additional maximum number of 129,124 SARs that vested based on continued employment and the extent of the attainment of a specified 2017 performance measure. The maximum number of performance SARs was achieved. Half of the SARs of each type vested on December&#160;31, 2018 and the remainder vested on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings&#x2019; common stock on the exercise date exceeded the per share fair value on the grant date. The fair value of Holdings&#x2019; common stock was determined using the product of the trailing 12-month specified performance measure for Holdings and a specified median market price &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;multiple based on a basket of public home health companies and publicly disclosed home health acquisitions with a value of $400 million or more. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the SARs granted in conjunction with the EHHI acquisition has been estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not include a dividend payment as part of our pricing model because Holdings did not pay dividends on its common stock. Under the Black-Scholes option-pricing model, the weighted-average fair value per share of SARs granted in conjunction with the EHHI acquisition was $870.28 as of December 31, 2019. In February 2019, members of the management team exercised a portion of their vested SARs for approximately $13 million in cash. In July 2019, members of the management team exercised the remainder of the vested SARs for approximately $55 million in cash. As of December 31, 2019, the fair value of the remaining 115,545 SARs was approximately $101&#160;million, all of which was included in O&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ther current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet. In January 2020, members of the management team exercised the remaining SARs, and in February 2020, we settled those awards upon payment of approximately $101 million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized approximately $0.1 million and $81.9 million of compensation expense related to our SARs for the years ended December&#160;31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RSAs granted in 2021, 2020, and 2019 included service-based awards and performance-based awards (that also included a service requirement). These awards generally vest over a three-year requisite service period. For RSAs with a service and/or performance requirement, the fair value of the RSA is determined by the closing price of our common stock on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our issued restricted stock awards is as follows (share information in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested shares at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of restricted stock granted during the years ended&#160;December&#160;31, 2020 and 2019 was $61.81 and $49.84 per share, respectively. We recognized approximate&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ly $28.4 million, $25.8 million, and $29.5 million of compensation expense related to our restricted stock awards for the years ended December&#160;31, 2021, 2020, and 2019, respectively. As of December&#160;31, 2021, there was $37.1 million of unrecognized compensation expense related to unvested restricted stock. This cost is expected to be recognized over a weighted-average period of 21 months. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he remaining unrecognized compensation expense for the performance-based awards may vary each reporting period based on changes in the expected achievement of performance measures. The total fair value of shares vested during the years ended December 31, 2021, 2020, and 2019 wa&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s $46.0 million, $44.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $45.2 million, respectively. We accrue dividends on outstanding RSAs, which are paid upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nonemployee Stock-Based Compensation Plans&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, we provided incentives to our nonemployee members of our board of directors through the issuance of RSUs out of our share-based incentive plans. RSUs are fully vested when awarded and receive dividend equivalents in the form of additional RSUs upon the payment of a cash dividend on our common stock. During the years ended December&#160;31, 2021, 2020, and 2019, we &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued 24,043, 32,196, and 23,270 RSUs, respectively, with a fair value of $84.83, $65.39, and $64.48, respectively, per unit. We recognized approximately $2.0 million, $2.1 million, and $1.5 million, respectively, of compensation expense upon their issuance in 2021, 2020, and 2019. There was&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; no &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unrecognized compensation related to unvested shares as of December&#160;31, 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we issued an a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dditional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,577&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 8,987, and 8,876, respectively, of RSUs as dividend equivalents. As of December&#160;31, 2021, 610,461 RSUs were ou&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia1fb54362ed14ca5bf853364666f1665_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzQ4Mw_ab6e7b02-da86-4d49-b041-accae26b4b8e"
      unitRef="shares">14000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzEyNDI_d50c0e8c-bddb-4789-81eb-9f5d5e3f58c9">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzEzNTQ_1ddbe7de-3f73-4fea-8be1-eef99ea45700">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc4NjU_3a96ee1c-b2df-4139-9389-9ce19b910f74">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the options granted during the years ended December&#160;31, 2021, 2020, and 2019 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the SARs granted in conjunction with the EHHI acquisition has been estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzItMS0xLTEtNTU5Njg_b256da30-6d18-45e7-a2a2-ac5dc0111f67"
      unitRef="number">0.284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzItMy0xLTEtNTU5Njg_ae554b35-3d63-4b40-8987-d59105832e47"
      unitRef="number">0.248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzItNS0xLTEtNTU5Njg_1f33fa0b-4e81-4cf7-b019-8be71106f860"
      unitRef="number">0.253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzMtMS0xLTEtNTU5Njg_40b78976-c4a7-4c3a-8608-79a4f1add4a5"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzMtMy0xLTEtNTU5Njg_913e9c53-0064-47bb-83a0-5e73b36fc11f"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzMtNS0xLTEtNTU5Njg_81f514eb-dee3-4957-9cd1-ce183231ba1b"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzQtMS0xLTEtNTU5Njg_48c802d8-ce87-420d-96a4-014d30d27170">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzQtMy0xLTEtNTU5Njg_33549fe9-ed1e-4c7f-8351-e862c2d3414f">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzQtNS0xLTEtNTU5Njg_e7051845-a926-4538-8395-4adf2d63d67d">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzUtMS0xLTEtNTU5Njg_f8cd92c1-0f62-4230-a433-1f70b1ce6c5f"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzUtMy0xLTEtNTU5Njg_9a78dac7-1c22-4759-84e9-2b990b0179cc"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo2OGI3MTE1ODU2OTk0M2I3YTE3M2JhZGM4ZDBkMWVjNi90YWJsZXJhbmdlOjY4YjcxMTU4NTY5OTQzYjdhMTczYmFkYzhkMGQxZWM2XzUtNS0xLTEtNTU5Njg_434202cc-25f5-4bba-9346-40fe2ec149b1"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI3NjM_8569819f-174b-4710-b0db-eb5eb079487d"
      unitRef="usdPerShare">19.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI3Njc_3ba1c29f-1c3e-4014-bd16-8cc6878c52c3"
      unitRef="usdPerShare">15.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI3NzU_a136533c-32fc-4252-8cc3-d9aa913b9b73"
      unitRef="usdPerShare">15.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc5MDE_caf35b12-5471-4a4b-a2d2-d32a5a8cbfdd">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(In Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzEtMS0xLTEtNTU5Njg_b3abe0cc-431c-437b-b196-b41293cfefc0"
      unitRef="shares">628000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzEtMy0xLTEtNTU5Njg_5b630293-bd88-4147-9901-6af198ec528d"
      unitRef="usdPerShare">50.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzItMS0xLTEtNTU5Njg_6d5ab76d-4b17-4fb4-9495-99c08e74a0d1"
      unitRef="shares">109000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzItMy0xLTEtNTU5Njg_9a60ae86-0ed6-4413-855e-0dbfc07e464a"
      unitRef="usdPerShare">80.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzMtMS0xLTEtNTU5Njg_463780d1-084c-4903-ab2f-8e382c93a6b6"
      unitRef="shares">8000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzMtMy0xLTEtNTU5Njg_d0a9c57f-6191-45ba-876c-351df7c3713e"
      unitRef="usdPerShare">69.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzQtMS0xLTEtNTU5Njg_5448931d-243c-4383-913f-bde99e349c80"
      unitRef="shares">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzQtMy0xLTEtNTU5Njg_2b695e83-9a53-48dd-aa3a-44f494825ddf"
      unitRef="usdPerShare">77.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzYtMS0xLTEtNTU5Njg_ce5050c1-b0ed-4490-a903-228217c4272a"
      unitRef="shares">711000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzYtMy0xLTEtNTU5Njg_ef7bc807-1a9f-4b32-a446-7c01db49ffce"
      unitRef="usdPerShare">54.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzYtNS0xLTEtNTU5Njg_b91651c7-5fb1-46f8-80c7-cd5b8d29bfdf">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzYtNy0xLTEtNTU5Njg_9ab03291-bb46-470a-a7e6-f1a9f808d113"
      unitRef="usd">10400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzctMS0xLTEtNTU5Njg_a31d2037-a04e-4760-bfa0-b6841fd114f0"
      unitRef="shares">510000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzctMy0xLTEtNTU5Njg_8d994789-5a64-44d1-8d92-5b2498fde350"
      unitRef="usdPerShare">45.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzctNS0xLTEtNTU5Njg_26be4393-812a-4a98-84be-e094761be410">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTo1OGQyNDNiMGVlMWM0YjIzODdiYzdhMDJkNTNkOTBkMC90YWJsZXJhbmdlOjU4ZDI0M2IwZWUxYzRiMjM4N2JjN2EwMmQ1M2Q5MGQwXzctNy0xLTEtNTU5Njg_e58bc985-a3d7-4bf8-8df3-0b9284d92d35"
      unitRef="usd">10400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI5MDE_30ac92c5-d0b4-4310-b029-ce1829f14cb0"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4d969f7c862e4f279fe70f4f160ef5bd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI5MDU_37190c50-a44c-481c-905f-5398af9d0b43"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3ed038b6854b428ba26fbbc66b7bd045_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzI5MTM_9a1723ce-a3a1-4154-8cfa-15d243c8cdd4"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMwMzk_4fcb813b-a0ed-46fb-b520-25d6c127fb89"
      unitRef="usd">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic2f42760e052466297d45ac5cbad1140_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMxODQ_32673ca7-d839-497e-8cd7-69246027962d">P19M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMyOTc_3a7aeafc-35f9-4287-8cb1-035c5422c74a"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMzMDE_5c47bd10-d920-42e2-ba00-e60923144fb8"
      unitRef="usd">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzMzMDk_48026f36-abe2-46d3-8fe4-54e498855077"
      unitRef="usd">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="i7804d790b2414c79899e861637a8a2e5_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzM1NDg_1abe1219-2894-4fa2-9a85-dfcbeb58e69d"
      unitRef="shares">122976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="ib735bb4807dd484fbea2ba815c38a8a9_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzM2MzQ_5ee927c1-c17f-4042-bb8b-8a3012873955"
      unitRef="shares">129124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <ehc:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold
      contextRef="i3a8c982d4bb944d5b92f0c669ef3ef9a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzQ0MTQ_4887349d-fbb2-4551-a06c-84ecbc9f46b1"
      unitRef="usd">400000000</ehc:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTpmOGNiYzI4ZDViMWI0MjMzYjlmNDZiOWY1Njg4YzdkMC90YWJsZXJhbmdlOmY4Y2JjMjhkNWIxYjQyMzNiOWY0NmI5ZjU2ODhjN2QwXzEtMS0xLTEtNTU5Njg_747ebc5c-8e67-4d1a-8aa1-f18bbd1b8880"
      unitRef="number">0.386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTpmOGNiYzI4ZDViMWI0MjMzYjlmNDZiOWY1Njg4YzdkMC90YWJsZXJhbmdlOmY4Y2JjMjhkNWIxYjQyMzNiOWY0NmI5ZjU2ODhjN2QwXzItMS0xLTEtNTU5Njg_40ff9bbf-f1ec-469d-aa34-75de93837ad2"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTpmOGNiYzI4ZDViMWI0MjMzYjlmNDZiOWY1Njg4YzdkMC90YWJsZXJhbmdlOmY4Y2JjMjhkNWIxYjQyMzNiOWY0NmI5ZjU2ODhjN2QwXzMtMS0xLTEtNTU5Njg_4bb37239-2cdf-4054-9e1f-3b955c15cd1a">P0Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTpmOGNiYzI4ZDViMWI0MjMzYjlmNDZiOWY1Njg4YzdkMC90YWJsZXJhbmdlOmY4Y2JjMjhkNWIxYjQyMzNiOWY0NmI5ZjU2ODhjN2QwXzQtMS0xLTEtNTU5Njg_be1ce5eb-a3a1-40f9-bcd4-a71d5c4eca7c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzQ5MDU_bc883a07-b455-4135-b6b8-cb170b4b2cb3"
      unitRef="usdPerShare">870.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid
      contextRef="i2acf2cc0fd7d4d09af40dfa207a99bd2_D20190201-20190228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzUwMjY_f5f36dcd-9c2d-415f-8480-c1e79ff3481f"
      unitRef="usd">13000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid
      contextRef="i6853550297dd40fd9673cf39d8bba361_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzUxNDQ_e5a9767e-0a3d-423e-8091-16e0226a6281"
      unitRef="usd">55000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i94fd694f8fd3453eb2468c49bd5270ba_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzUyMTM_ac684dc3-ce2e-4d20-900d-c434a6641059"
      unitRef="shares">115545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ehc:AllocatedSharebasedCompensationLiability
      contextRef="i94fd694f8fd3453eb2468c49bd5270ba_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzUyMzk_c1f87329-20e8-434c-b299-0415fa4a6ce5"
      unitRef="usd">101000000</ehc:AllocatedSharebasedCompensationLiability>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="i80269d53cbb0459c9a42ac92da3a7665_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzU0ODc_98003a08-645a-4406-b615-58fe5bc74baa"
      unitRef="usd">101000000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c72f09fce4043719ce2db102fc528ff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzU1MzE_9c4bd0a6-0e42-424a-938a-46e7af8e0340"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia2d90cea62284fa0bec23ee61296627d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzU1Mzk_210d6eb2-0e2c-41fb-baf1-a97570f5095c"
      unitRef="usd">81900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzM4NDgyOTA3MDUzMDg_65d029cd-332b-4000-be44-ddff3645f9e8">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc4OTY_68af5f60-6008-4d20-88ff-8170a126ad0a">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our issued restricted stock awards is as follows (share information in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested shares at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6650fab69c11492c9077744e36f1f4c0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzEtMS0xLTEtNTU5Njg_8121bd23-e253-4b84-943a-9af125195bad"
      unitRef="shares">731000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6650fab69c11492c9077744e36f1f4c0_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzEtMy0xLTEtNTU5Njg_6896c2d2-258a-4f1b-93bf-cbbf25fd987e"
      unitRef="usdPerShare">61.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzItMS0xLTEtNTU5Njg_b8d7e053-cd13-419e-ad6a-2947f9b02f74"
      unitRef="shares">368000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzItMy0xLTEtNTU5Njg_3024a770-83a1-4f4e-b84a-684b85b99752"
      unitRef="usdPerShare">73.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzMtMS0xLTEtNTU5Njg_8b6b6c78-88b3-41c8-a8bd-41fc97be6627"
      unitRef="shares">560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzMtMy0xLTEtNTU5Njg_8dc8b68e-fefb-43e2-9fcf-dbee2d74f8b4"
      unitRef="usdPerShare">57.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzQtMS0xLTEtNTU5Njg_34079ecc-5e8a-4921-8c1d-c2b5e91493fb"
      unitRef="shares">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzQtMy0xLTEtNTU5Njg_a026e8d9-7439-45e8-a8ff-3a7b1aa48ac1"
      unitRef="usdPerShare">72.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia4a08b2b7b1b4149a37586883c795c5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzUtMS0xLTEtNTU5Njg_e678814c-2922-44af-b965-3e8130c09a14"
      unitRef="shares">454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia4a08b2b7b1b4149a37586883c795c5c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90YWJsZTphNDhkMmU4ZWFiZjU0MjEzYjFiMzA5OGU1N2E3NTI2Yi90YWJsZXJhbmdlOmE0OGQyZThlYWJmNTQyMTNiMWIzMDk4ZTU3YTc1MjZiXzUtMy0xLTEtNTU5Njg_def4cb59-3ffe-424a-9a3e-4e1bf281f1e5"
      unitRef="usdPerShare">74.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia6a233a73c164626b8371eab0e23471c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYyMjc_d01a05a4-3b4a-469a-8387-92dcbe2868a5"
      unitRef="usdPerShare">61.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0980bb7516a2462090a8eb088e642d56_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYyMzQ_c8c082fe-4f3e-41be-83e4-f138df7376ae"
      unitRef="usdPerShare">49.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYyOTA_3c2ea0ea-bf32-42d3-98af-d1efe5c8c8ab"
      unitRef="usd">28400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia6a233a73c164626b8371eab0e23471c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYyOTQ_af7ad7e9-537d-4a45-bb11-075d4c13d5c3"
      unitRef="usd">25800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0980bb7516a2462090a8eb088e642d56_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzYzMDI_1653ac29-729a-4ad3-9ba3-9319d414b3fb"
      unitRef="usd">29500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ia4a08b2b7b1b4149a37586883c795c5c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY0Mzg_dd71ee61-6192-459c-8fd2-9eb99eac40b5"
      unitRef="usd">37100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY1ODk_599b4643-14f2-49be-9159-aab1562a8122">P21M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i041f4e433735445c9c4b0b275631ba31_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY4NzU_2e93aa7b-f3a7-4013-acc8-354a24f5d64c"
      unitRef="usd">46000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ia6a233a73c164626b8371eab0e23471c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY4Nzk_79f56b69-b938-4bd7-93ae-fb32f9e83e02"
      unitRef="usd">44200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i0980bb7516a2462090a8eb088e642d56_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzY4ODc_306bc8d9-d3b2-4225-b37a-18d089a04be8"
      unitRef="usd">45200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1d2e0bbe25b944009128cefee2d0d142_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0MDg_d2238800-347a-4fb0-a52b-ed7af022403a"
      unitRef="shares">24043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id4d10387a093410d85237a92db5c4dec_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0MTI_3789b36c-23e6-4815-867a-2c0e13186489"
      unitRef="shares">32196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i23170992103f4aea877de6980dd955ef_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0MjA_63b7b64c-7dfa-4873-9b6a-a6c8ca25bbc9"
      unitRef="shares">23270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1d2e0bbe25b944009128cefee2d0d142_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0NjQ_8bac05ae-0f1e-4689-8701-83637cd348ca"
      unitRef="usdPerShare">84.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id4d10387a093410d85237a92db5c4dec_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0Njg_2c9f73e1-3964-4d78-9b44-46d8d34c8431"
      unitRef="usdPerShare">65.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i23170992103f4aea877de6980dd955ef_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc0NzY_cb9e49bd-eb9a-49a5-8358-17e0ffac401f"
      unitRef="usdPerShare">64.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i1d2e0bbe25b944009128cefee2d0d142_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc1MzI_8a2d6ec7-9485-424e-84fd-79e27b0f0d4c"
      unitRef="usd">2000000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="id4d10387a093410d85237a92db5c4dec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc1MzY_89066ceb-2260-40de-ae49-3d2ee8cc86d4"
      unitRef="usd">2100000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i23170992103f4aea877de6980dd955ef_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc1NDQ_d2ccfd73-668b-44a6-9d84-3661155aae43"
      unitRef="usd">1500000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <ehc:SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions
      contextRef="i4f4491cc424043bab594adb15a4e38fc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc2MzU_8e2cf433-21cd-4344-bca5-172dd898604a"
      unitRef="usd">0</ehc:SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5a8b7549430046a29b87cd735c3324cd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc3NjQ_c5f826da-ecef-4eab-819f-b0f1089b1e09"
      unitRef="shares">8577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5d403e9e176d4ad1a0337c0b47804c60_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc3Njg_539654be-e856-4ff2-9fdc-648974625780"
      unitRef="shares">8987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idca59813d6ce47e690d0ffdf1c9e577c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc3NzY_e3059bd6-5b22-4844-9276-1cdef6b6cf18"
      unitRef="shares">8876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i4f4491cc424043bab594adb15a4e38fc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODAvZnJhZzpkYWExODQ1N2U3MzA0OTQ2ODZhM2U4ZjkwZTE3YzhhMy90ZXh0cmVnaW9uOmRhYTE4NDU3ZTczMDQ5NDY4NmEzZThmOTBlMTdjOGEzXzc4Mzc_e2a732b9-208f-4ca9-92f3-1dd5cff476f2"
      unitRef="shares">610461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzMwMzQ_261df4fe-2682-4897-934b-ce5c989c7bc9">Employee Benefit Plans:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all Encompass Health employees are eligible to enroll in Encompass Health-sponsored healthcare plans, including coverage for medical and dental benefits. Our primary healthcare plans are national plans administered by third-party administrators. We are self-insured for these plans. During 2021, 2020, and 2019, costs associated with these plans, net of amounts paid by employees and stop-loss recoveries, approximated $207.6 million, $189.2 million, and $178.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health offers two qualified 401(k) savings plans, the Encompass Health Retirement Investment Plan (the &#x201c;RIP&#x201d;) and the Encompass Home Health Savings Plan (the &#x201c;HHSP&#x201d;). The RIP allows eligible employees to contribute up to 100% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. Inpatient rehabilitation employees who are at least 21 years of age are eligible to participate in the RIP and all contributions to the plan are in the form of cash. Encompass Health&#x2019;s employer matching contribution under the RIP is 50% of the first 6% of each participant&#x2019;s elective deferrals, which vest 100% after three years of service. Participants are always fully vested in their own contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The HHSP allows eligible employees to contribute up to 60% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. All home health and hospice full-time and part-time employees are eligible to participate in the HHSP and all contributions to the plan are in the form of cash. Encompass Health&#x2019;s employer matching contribution under the HHSP is 25% of the first 3% of each participant&#x2019;s elective deferrals, which vest gradually over a six-year service period. Participants are always fully vested in their own contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employer contributions to the RIP and HHSP approximated $28.8 million, $25.4 million, and $23.4 million in 2021, 2020, and 2019, respectively. In 2021, 2020, and 2019, approximately $1.3 million, $1.5 million, and $1.4 million, respectively, from forfeited accounts were used to fund the matching contributions in accordance with the terms of the RIP and HHSP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Management Bonus Program&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a Senior Management Bonus Program to reward senior management for performance based on a combination of corporate or regional goals for all periods presented and individual goals for 2019 and 2018 only. The corporate and regional goals are approved on an annual basis by our board of directors as part of our routine budgeting and financial planning process. The individual goals, which were weighted according to importance, were determined between each participant and his or her immediate supervisor. The program applies to persons who join the Company in, or are promoted to, senior management positions. In 2022, we expect to pay approximately $27.8 million under the program for the year ended December&#160;31, 2021. In March 2021 and February 2020, we paid $17.4 million and $18.4 million, respectively, under the program for the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <ehc:HealthcarePlanExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzQzNw_cb881066-d1d9-4f05-8ff2-d50ad6f255ed"
      unitRef="usd">207600000</ehc:HealthcarePlanExpense>
    <ehc:HealthcarePlanExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzQ0MQ_4a5a27a4-89bc-4f4a-a915-8080242f7fcf"
      unitRef="usd">189200000</ehc:HealthcarePlanExpense>
    <ehc:HealthcarePlanExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzQ0OQ_b6d6b2df-6e0d-48e0-966f-0108102cf009"
      unitRef="usd">178400000</ehc:HealthcarePlanExpense>
    <ehc:NumberOfQualifiedPlans
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzQ5MQ_e7823723-53a7-40aa-8a94-f06af9d9ed5c"
      unitRef="plan">2</ehc:NumberOfQualifiedPlans>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="if30d4b37dc324d81b38e9cf676a99627_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzY5Nw_543b23e3-227c-4662-a0aa-d9571ed91ebc"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <ehc:RetirementInvestmentPlanAgeRequirement
      contextRef="i5ad3ac221c7e416b8039eccf0be81c30_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzkyMA_ec31e3e4-d900-4471-968d-d8f27c798771"
      unitRef="y">21</ehc:RetirementInvestmentPlanAgeRequirement>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="if30d4b37dc324d81b38e9cf676a99627_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzExMDE_7a2664ba-5b18-4cf6-ab91-bfccffd17ac1"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <ehc:RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution
      contextRef="i5ad3ac221c7e416b8039eccf0be81c30_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzExMTc_4e9afe67-a225-4a48-9f29-7e28dacfc77c"
      unitRef="number">0.06</ehc:RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution>
    <ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage
      contextRef="i5ad3ac221c7e416b8039eccf0be81c30_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzExNzM_c9ef7ef3-394a-4602-84cd-61cf198bbb49"
      unitRef="number">1</ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage>
    <ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod
      contextRef="if30d4b37dc324d81b38e9cf676a99627_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzExODI_8050e2d5-ca5e-427c-9b6d-17f4d0f784a6">P3Y</ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i97f18be172de4a0895d8c7a7e9e5460a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzEzMTc_80242d2d-0121-4fc7-9bea-02b22b24c35b"
      unitRef="number">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i97f18be172de4a0895d8c7a7e9e5460a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE3MTc_c91f414a-6cdc-44a4-be4e-3093937d3d15"
      unitRef="number">0.25</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage
      contextRef="i0081857a985a4961b0157b55a3108ac9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE3MzM_acfe9368-3874-423d-8a1c-62b8988e6828"
      unitRef="number">0.03</ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage>
    <ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod
      contextRef="i97f18be172de4a0895d8c7a7e9e5460a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzMwMzU_8bc04b53-d492-44fc-9987-b46a279480f6">P6Y</ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE5NTE_653d7b21-8b49-4188-b567-50598431493c"
      unitRef="usd">28800000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE5NTU_1575226e-2478-42db-bfd7-66604d6153af"
      unitRef="usd">25400000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzE5NjM_240fe46c-0fa1-4ab8-b96d-afefea730471"
      unitRef="usd">23400000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzIwMzI_2c447f46-9bb9-4214-bb45-181e2778b8a9"
      unitRef="usd">1300000</ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount>
    <ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzIwMzY_b138f6c3-8d71-4350-bf1a-d0ec58f75b53"
      unitRef="usd">1500000</ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount>
    <ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzIwNDQ_8be93489-b7e4-47f0-8d0e-b7db2d79a85c"
      unitRef="usd">1400000</ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount>
    <ehc:SeniorManagementBonusProgramTotalCosts
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzI4NzM_8c7d5b14-d528-48a6-9845-e366cfedbbed"
      unitRef="usd">27800000</ehc:SeniorManagementBonusProgramTotalCosts>
    <ehc:SeniorManagementBonusProgramTotalCosts
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzI5NTQ_aa4b9680-81b4-4dfe-bfa1-b8b551403abf"
      unitRef="usd">17400000</ehc:SeniorManagementBonusProgramTotalCosts>
    <ehc:SeniorManagementBonusProgramTotalCosts
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODMvZnJhZzpiY2NjZDU5ZTVlZWE0NGVmYTNlNmVmMzI4ODcyMjk0Ny90ZXh0cmVnaW9uOmJjY2NkNTllNWVlYTQ0ZWZhM2U2ZWYzMjg4NzIyOTQ3XzI5NjE_9a628d4f-6f71-4b65-a937-3219caea780d"
      unitRef="usd">18400000</ehc:SeniorManagementBonusProgramTotalCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzcyMjA_84acc1c9-a9b8-45fc-9d3f-3e92f38927d2">Income Taxes:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to continuing operations are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense related to continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in tax rate resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government, class action, and related settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based windfall tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in 2021 was greater than the federal statutory rate primarily due to: (1) state and other income tax expense offset by (2) the impact of noncontrolling interests, (3) share-based windfall tax benefits and (4) the decrease in valuation allowance. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in 2020 was greater than the federal statutory rate primarily due to: &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) state and other income tax expense and (2) the increase in valuation allowance offset by (3) the impact of noncontrolling interests and (4) share-based windfall tax benefits. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in 2019 was less than the federal statutory rate primarily due to: &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) the impact of noncontrolling interests, (2) g&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;overnment, class action, and related settlements&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and (3) share-based windfall tax benefits offset by (4) state and other income tax expense. See Note&#160;1, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Income Taxes,&#x201d; for a discussion of the allocation of income or loss related to pass-through entities, which is referred to as the impact of noncontrolling interests in this discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the CARES Act provisions previously discussed in Note&#160;1, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Risks and Uncertainties,&#x201d; the CARES Act also includes provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, technical corrections to tax depreciation methods for qualified improvement property and deferral of employer payroll taxes. The CARES Act did not materially impact our effective tax rate for the years ended December 31, 2020 and 2021, although it has impacted the timing of cash payments for taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes recognize the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes and the impact of available NOLs. The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have state NOLs of $50.4 million that expire in various amounts at varying times through 2031. For the years ended December&#160;31, 2021 and 2020, the net (decrease) increase in our valuation allowance was $(3.1) million and $7.8 million, respectively. The decrease in our valuation allowance in 2021 related primarily to changes in forecasted income. The increase in our valuation allowance in 2020 related primarily to our expected ability to use related net operating losses prior to their expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we have a remaining valuation allowance of $43.1 million. This valuation allowance remains recorded due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management&#x2019;s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during 2021, 2020, and 2019 was not material. Accrued interest income related to income taxes as of December 31, 2021 and 2020 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, we signed an agreement with the IRS to participate in their Compliance Assurance Process (&#x201c;CAP&#x201d;) for the 2017 tax year and have renewed this agreement each year since. CAP is a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax returns. The IRS is currently examining the 2020, 2021, and 2022 tax years. In September 2021, the IRS issued a no-change letter effectively closing our 2019 tax year audit. The statute of limitations has expired or we have settled federal income tax examinations with the IRS for all tax years through 2019. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by two states for tax years ranging from 2017 - 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the tax years that remain open under the applicable statutes of limitations, management considered potential unrecognized tax benefits and determined there are no material unrecognized tax benefits that would impact prior years&#x2019; income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzcyMTg_3f2e4c46-6b01-47a3-b85e-ef3a46540750">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to continuing operations are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense related to continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzMtMS0xLTEtNTU5Njg_9a84f514-0eba-4e3a-b103-da4e7b6359c9"
      unitRef="usd">86800000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzMtMy0xLTEtNTU5Njg_aef480d2-2b81-4a62-9949-4be29da5a16b"
      unitRef="usd">37700000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzMtNS0xLTEtNTU5Njg_396cace6-6711-41fc-9923-d9d31dba1682"
      unitRef="usd">58100000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzQtMS0xLTEtNTU5Njg_288f3141-0805-429a-8f8b-ad6111ee1534"
      unitRef="usd">25000000.0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzQtMy0xLTEtNTU5Njg_2e3ee024-569f-4948-9c27-9d7e98c1b27e"
      unitRef="usd">13700000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzQtNS0xLTEtNTU5Njg_d6a2b8ee-607e-4247-884f-cf2cf3aa75b0"
      unitRef="usd">17800000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzUtMS0xLTEtNTU5Njg_36b91633-1c40-4720-8fd0-75c31493e61e"
      unitRef="usd">111800000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzUtMy0xLTEtNTU5Njg_136d3ca6-f7b1-433b-9143-7a5d8628f160"
      unitRef="usd">51400000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzUtNS0xLTEtNTU5Njg_448da15b-8ad4-4297-a0c5-6e5b6970380f"
      unitRef="usd">75900000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzctMS0xLTEtNTU5Njg_13ae265d-4c06-4145-bf08-a9552bd479a7"
      unitRef="usd">23600000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzctMy0xLTEtNTU5Njg_952cb7f3-09cf-4eed-be81-587976762635"
      unitRef="usd">39500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzctNS0xLTEtNTU5Njg_9cbb34d5-2ae2-494c-af74-276b2652ce41"
      unitRef="usd">32000000.0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzgtMS0xLTEtNTU5Njg_65f9f548-5382-4b6f-a823-b8889efa7595"
      unitRef="usd">4200000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzgtMy0xLTEtNTU5Njg_5425da19-2fe0-4c6a-8ce6-fe3904de39d8"
      unitRef="usd">12900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzgtNS0xLTEtNTU5Njg_bb945a01-272a-4c8e-9d2f-7e6ef9c5ed00"
      unitRef="usd">8000000.0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzktMS0xLTEtNTU5Njg_ba4c1cdd-8946-4066-a8af-615830ef18f6"
      unitRef="usd">27800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzktMy0xLTEtNTU5Njg_e132e069-1ca8-4dfb-86be-f83e45f16c6a"
      unitRef="usd">52400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzktNS0xLTEtNTU5Njg_2029e3e6-b4f5-4c1e-8115-3257d2933a16"
      unitRef="usd">40000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzEwLTEtMS0xLTU1OTY4_2b72c8f8-f83d-4d85-940e-692e505815c4"
      unitRef="usd">139600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzEwLTMtMS0xLTU1OTY4_0fcc75e1-c5f7-4870-8999-b5205b6507dc"
      unitRef="usd">103800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTo4ZmE4ODc2ZGQwMzk0MWNiOTY5OWFkYzk3YTAzOTcyYy90YWJsZXJhbmdlOjhmYTg4NzZkZDAzOTQxY2I5Njk5YWRjOTdhMDM5NzJjXzEwLTUtMS0xLTU1OTY4_c1f49791-50a3-460c-a855-443ef3bb30d6"
      unitRef="usd">115900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzcyMzA_851cfe84-3365-487f-b459-90d10fb09dbf">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in tax rate resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government, class action, and related settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based windfall tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzItMS0xLTEtNTU5Njg_0389e34b-8eff-4722-b60d-a1e6851263e5"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzItMy0xLTEtNTU5Njg_52de50e2-15b9-4cd8-a8a7-922f876a63fd"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzItNS0xLTEtNTU5Njg_d000fa13-3447-4b59-9d6e-e36dae8e3503"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzQtMS0xLTEtNTU5Njg_bc237a4c-26af-4e2b-a0f7-ba9e010dea76"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzQtMy0xLTEtNTU5Njg_bec5c86c-c4ff-444f-a861-06e165f76b92"
      unitRef="number">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzQtNS0xLTEtNTU5Njg_45c0c4c4-fb33-47da-b0a5-397ab2f7cab0"
      unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzUtMS0xLTEtNTU5Njg_f7ed483d-1721-4796-bb93-0058766a1773"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzUtMy0xLTEtNTU5Njg_3374c86e-bd64-4962-91cd-4b8c3fa81c20"
      unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzUtNS0xLTEtNTU5Njg_996b8ceb-035a-4719-9a0e-d6cdd2e4b02c"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzYtMS0xLTEtNTU5Njg_6fba2f55-1e5d-4f8d-92a6-fb526db89f5f"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzYtMy0xLTEtNTU5Njg_2b947916-cee0-46d4-864a-7a2f8dc1f5c3"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzYtNS0xLTEtNTU5Njg_a778b050-40c6-43d8-b905-09c2fc25ee46"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzctMS0xLTEtNTU5Njg_87e00720-aad3-4261-b4e7-b39d794070c3"
      unitRef="number">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzctMy0xLTEtNTU5Njg_50bdd5bc-3cd4-4893-8ee4-cd6b53ca19b8"
      unitRef="number">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzctNS0xLTEtNTU5Njg_577e283a-db4c-4170-9585-dd55ebd99cbe"
      unitRef="number">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzktMS0xLTEtNTU5Njg_2880f5ec-a314-4a8c-916d-615b148a3218"
      unitRef="number">-0.005</ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent>
    <ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzktMy0xLTEtNTU5Njg_6d589a00-626a-41a7-aa3d-9f30f06097ad"
      unitRef="number">-0.010</ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent>
    <ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzktNS0xLTEtNTU5Njg_f8a3199a-2c66-4304-8867-124a8838f40a"
      unitRef="number">-0.010</ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzExLTEtMS0xLTU1OTY4_eb255c91-90c3-4818-b575-ed009edbfe19"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzExLTMtMS0xLTU1OTY4_888f31c9-eb81-431e-83d3-a848ecc78e74"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzExLTUtMS0xLTU1OTY4_9b5df782-c050-493c-93d8-4797e3419590"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzEyLTEtMS0xLTU1OTY4_38e409e5-e19d-4809-8bcb-2e348f2c393a"
      unitRef="number">0.212</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzEyLTMtMS0xLTU1OTY4_d6bcc33e-fcdc-41d1-a7ef-3d81bb54fedf"
      unitRef="number">0.220</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTpiNTVhYzYzZWJkZjI0OWI2YjA5Y2UyNWFiZmMzZGNmMi90YWJsZXJhbmdlOmI1NWFjNjNlYmRmMjQ5YjZiMDljZTI1YWJmYzNkY2YyXzEyLTUtMS0xLTU1OTY4_9cec7e1a-3aff-4add-b209-bd9f3554300c"
      unitRef="number">0.206</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzcyMjI_22812dbd-96b8-45ca-9806-fac1904a2afe">The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzMtMS0xLTEtNTU5Njg_edb2ba6c-6f98-4ef5-a1d4-5dd10218e0f8"
      unitRef="usd">50400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzMtMy0xLTEtNTU5Njg_07b2507d-b3e3-4285-950b-94c98d9558ab"
      unitRef="usd">57600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzQtMS0xLTEtNTU5Njg_2e013dd3-f552-4d00-bae7-dda06e83a4e3"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzQtMy0xLTEtNTU5Njg_68e1f988-9008-460d-aec3-d657c1c78647"
      unitRef="usd">6600000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzUtMS0xLTEtNTU5Njg_f2af7342-e59b-4fe3-8aba-58a401207f71"
      unitRef="usd">18700000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzUtMy0xLTEtNTU5Njg_abca28d7-add4-4a7c-a17b-b122297e666c"
      unitRef="usd">17800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzYtMS0xLTEtNTU5Njg_d9da7510-f398-438a-bd5a-170fb57ee7fa"
      unitRef="usd">15200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzYtMy0xLTEtNTU5Njg_b7ff7588-cbb5-46df-8fa3-1eb0a16e88b6"
      unitRef="usd">15200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ehc:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzgtMS0xLTEtNTU5Njg_ded7b31c-bf6c-4ce1-ab8e-ae2955bd9c18"
      unitRef="usd">18200000</ehc:DeferredTaxAssetsOperatingLeaseLiability>
    <ehc:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzgtMy0xLTEtNTU5Njg_d9ed4df5-c679-4498-9563-445c0c576d22"
      unitRef="usd">22100000</ehc:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzExLTEtMS0xLTU1OTY4_b367e3c6-ed9f-404e-8878-134bf590215c"
      unitRef="usd">35100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzExLTMtMS0xLTU1OTY4_601458a1-1ca5-43fb-baa4-da374069a10f"
      unitRef="usd">43400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzEyLTEtMS0xLTU1OTY4_7842cf52-172e-4276-bb1d-2872e4de0e25"
      unitRef="usd">10900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzEyLTMtMS0xLTU1OTY4_97f5d8cb-09fb-45ac-b055-adc9044b72db"
      unitRef="usd">10500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzEzLTEtMS0xLTU1OTY4_6b77510f-5949-4f67-8751-6626e4fb8434"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzEzLTMtMS0xLTU1OTY4_ddf2a90a-527b-46f9-bb3a-af0216c42e66"
      unitRef="usd">100000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE0LTEtMS0xLTU1OTY4_54a030a8-101a-4777-b2c9-5969a0726b81"
      unitRef="usd">148500000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE0LTMtMS0xLTU1OTY4_78a201dd-cc3e-4497-a7c1-7d2d5fcb7ba6"
      unitRef="usd">173300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE1LTEtMS0xLTU1OTY4_0870e8bd-c8da-498b-8095-838ea33e9cbe"
      unitRef="usd">43100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE1LTMtMS0xLTU1OTY4_e2e8d386-d4bc-4500-a9c7-313e3968125f"
      unitRef="usd">46200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE2LTEtMS0xLTU1OTY4_dd649109-a79c-4caa-a450-092762d27726"
      unitRef="usd">105400000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE2LTMtMS0xLTU1OTY4_6878ed2f-c2db-43ad-ac38-31c90f060713"
      unitRef="usd">127100000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE4LTEtMS0xLTU1OTY4_7c86943b-f9ba-4011-a0ca-e3d73e44585c"
      unitRef="usd">700000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE4LTMtMS0xLTU1OTY4_9d9b93d9-da41-499b-b21b-f4e64fd05738"
      unitRef="usd">5700000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE5LTEtMS0xLTU1OTY4_8222820a-f3f0-49c5-906e-6cf4a2b5e427"
      unitRef="usd">102900000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzE5LTMtMS0xLTU1OTY4_0adbff10-4dcb-4a18-bb07-5ab366e55466"
      unitRef="usd">99700000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIwLTEtMS0xLTU1OTY4_fe0a3c9d-0ec0-4863-bce9-4f0150d57083"
      unitRef="usd">17700000</ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIwLTMtMS0xLTU1OTY4_a5d49158-30e0-40ab-9b43-8baa4abb2f77"
      unitRef="usd">21700000</ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIxLTEtMS0xLTk4NzU2_94960259-8ce3-435d-bab4-8c995fb17d17"
      unitRef="usd">3400000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIxLTMtMS0xLTk4NzU2_621abe82-d028-4370-8b84-553ba5b829c2"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIyLTEtMS0xLTU1OTY4_e5a8bfce-5c8b-4207-867e-cd63cb09f820"
      unitRef="usd">67000000.0</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIyLTMtMS0xLTU1OTY4_0fd51154-86f9-4ba2-80fe-3897b43b5559"
      unitRef="usd">51400000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIzLTEtMS0xLTU1OTY4_815ede73-2b82-4051-a88f-5dc9e66e1273"
      unitRef="usd">400000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzIzLTMtMS0xLTU1OTY4_81704805-a92a-4540-8335-8d5429cd7fa9"
      unitRef="usd">400000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzI0LTEtMS0xLTU1OTY4_32891a0a-1ff6-4fa1-b121-812322e14452"
      unitRef="usd">192100000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzI0LTMtMS0xLTU1OTY4_a36e4c1d-edce-4884-8a50-fbc8c3e11f95"
      unitRef="usd">178900000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzI1LTEtMS0xLTU1OTY4_d75c0b29-bafe-4317-946c-ad5c29708a50"
      unitRef="usd">86700000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90YWJsZTphOTY0MDNhZGMxZTA0NWQyYjI3YTRiNWJjNGM2ZDQxNi90YWJsZXJhbmdlOmE5NjQwM2FkYzFlMDQ1ZDJiMjdhNGI1YmM0YzZkNDE2XzI1LTMtMS0xLTU1OTY4_3c5e7552-2651-48a7-b11f-ab9367ead440"
      unitRef="usd">51800000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic9210832b6dd4034a40b13798dc82f01_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzIzODA_4f58ae1b-ba11-4108-beec-a84a40acba10"
      unitRef="usd">50400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzI1Mzc_a4f02110-7fbc-404f-a443-0dbed9a78931"
      unitRef="usd">-3100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzI1NDU_69ac4756-1a0b-4070-852a-e56fcd45291b"
      unitRef="usd">7800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODYvZnJhZzo2ODVmOGYzMGEyZGM0ZWEwOGJiNDYwODJmNWY4ZDliOC90ZXh0cmVnaW9uOjY4NWY4ZjMwYTJkYzRlYTA4YmI0NjA4MmY1ZjhkOWI4XzI3OTE_0870e8bd-c8da-498b-8095-838ea33e9cbe"
      unitRef="usd">43100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzIwNjI_3a2c8166-0c36-4972-a16e-91fe3d4db1e8">Earnings per Common Share:&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards, dilutive stock options, and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase approximately 0.2 million, 0.2 million, and 0.1 million shares of common stock were outstanding as of December&#160;31, 2021, 2020, and 2019, respectively, but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2014, our board of directors approved an increase in our common stock repurchase authorization from $200 million to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. There were no repurchases of our common stock during 2021. During 2020 and 2019, we repurchased 0.1&#160;million and 0.8 million shares of our common stock in the open market for $6.1 million and $45.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.27 per share. The cash dividend of $0.27 per common share was declared and paid in each quarter through July 2019. In July 2019, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.28 per share. The cash dividend of $0.28 per common share was declared and paid in each quarter through January 2022. Future dividend payments are subject to declaration by our board of directors.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzIwNzE_ff0e9093-b816-4cfb-9a72-72f5d87c4b42">&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzQtMS0xLTEtNTU5Njg_565ab567-53b4-43ee-be4f-0adb96f91d10"
      unitRef="usd">517600000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzQtMy0xLTEtNTU5Njg_d12fc63f-73e5-4324-ae94-7aef53307f84"
      unitRef="usd">368800000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzQtNS0xLTEtNTU5Njg_4876cb64-6a8a-4a6b-97de-7a99110d3bb9"
      unitRef="usd">446400000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzUtMS0xLTEtNTU5Njg_c14b064e-9a45-488a-b739-42576de6a145"
      unitRef="usd">105000000.0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzUtMy0xLTEtNTU5Njg_ab423cf5-d4bb-4f5d-bfa4-bfdfa79ff573"
      unitRef="usd">84600000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzUtNS0xLTEtNTU5Njg_5f8a6dea-f2b8-4db8-8f07-37433d1f6523"
      unitRef="usd">87100000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzYtMS0xLTEtNTU5Njg_a5cc5041-c503-45a6-aa92-336b35206bdc"
      unitRef="usd">1800000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzYtMy0xLTEtNTU5Njg_713e0aea-c157-4a90-a4e0-c4ed52a3d77b"
      unitRef="usd">1000000.0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzYtNS0xLTEtNTU5Njg_133c6b3d-e148-4d3c-adb3-81a808dbc12f"
      unitRef="usd">1300000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzktMS0xLTEtNTU5Njg_f849f61c-6cf8-4ea6-8173-236f3b917072"
      unitRef="usd">410800000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzktMy0xLTEtNTU5Njg_d78c3860-3768-4def-9224-138dfa92fb2a"
      unitRef="usd">283200000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzktNS0xLTEtNTU5Njg_b8475c7a-891e-4f0b-8feb-f83f786ad6e9"
      unitRef="usd">358000000.0</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEwLTEtMS0xLTU1OTY4_c93def55-71fb-46da-bd43-b7d2ce1c3fba"
      unitRef="usd">-400000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEwLTMtMS0xLTU1OTY4_0f6dabe8-03d5-4b54-8929-32c49e1cddcd"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEwLTUtMS0xLTU1OTY4_c77333d3-ec2a-4c18-bec6-3949a001ed5d"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEyLTEtMS0xLTU1OTY4_0862a4c5-56ad-47ad-a825-dd2940b694af"
      unitRef="usd">410400000</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEyLTMtMS0xLTU1OTY4_9d7999ef-e63f-41e1-8404-5585083797bb"
      unitRef="usd">283200000</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzEyLTUtMS0xLTU1OTY4_8d5b08db-7f57-4a3e-bac8-01be4e081c7b"
      unitRef="usd">357400000</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE0LTEtMS0xLTU1OTY4_8317ff40-200a-4853-804f-2fe7334131f3"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE0LTMtMS0xLTU1OTY4_52ecaf27-73b5-4b43-a5d2-719bbdd81f85"
      unitRef="shares">98600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE0LTUtMS0xLTU1OTY4_bd3b3bb5-ca74-4d32-9a39-78cda6cddef1"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE2LTEtMS0xLTU1OTY4_1860c46b-3a32-4028-894c-ec27c9806cf3"
      unitRef="usdPerShare">4.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE2LTMtMS0xLTU1OTY4_de9e7505-b863-4e0f-9e84-054b993beb8d"
      unitRef="usdPerShare">2.87</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE2LTUtMS0xLTU1OTY4_d9b01077-46d2-4b4e-85d8-6a6dc64926ca"
      unitRef="usdPerShare">3.66</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE3LTEtMS0xLTU1OTY4_9e3cf7bb-2866-4a3d-b50e-860c540b05ec"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE3LTMtMS0xLTU1OTY4_69aea09a-6a85-4a71-9fb1-99578f4b4ab2"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE3LTUtMS0xLTU1OTY4_fb05621c-1752-4ad0-898a-5d1e9b9a6043"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE4LTEtMS0xLTU1OTY4_44fa3e3e-7f1c-4d05-966e-9670b13ea20c"
      unitRef="usdPerShare">4.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE4LTMtMS0xLTU1OTY4_6ac2a0b6-ad62-4d45-919c-b5cd986894a7"
      unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzE4LTUtMS0xLTU1OTY4_31abedad-c763-435d-81c8-23cda46901e2"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIyLTEtMS0xLTU1OTY4_3c63684e-0c44-466a-9a79-051732b7f8cb"
      unitRef="usd">517600000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIyLTMtMS0xLTU1OTY4_3960ebd1-e7a8-49b7-8dcc-6aa8d5c44ada"
      unitRef="usd">368800000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIyLTUtMS0xLTU1OTY4_de181995-ab42-4b6b-9f8d-0192de967e93"
      unitRef="usd">446400000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIzLTEtMS0xLTU1OTY4_0bd6d83e-104f-4596-b503-05fec3aa13ea"
      unitRef="usd">105000000.0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIzLTMtMS0xLTU1OTY4_10b7e624-f984-49dc-8168-c3f614be6960"
      unitRef="usd">84600000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzIzLTUtMS0xLTU1OTY4_9d1ddd1f-f654-4cbe-97ca-437c9065437d"
      unitRef="usd">87100000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI2LTEtMS0xLTU1OTY4_900903f7-5a0c-40cc-a107-43c7e65a79c9"
      unitRef="usd">412600000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI2LTMtMS0xLTU1OTY4_9f69199d-9a77-46d8-a64a-0fbe270684dd"
      unitRef="usd">284200000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI2LTUtMS0xLTU1OTY4_923f32d5-7914-4c87-98d5-5a5ca810aa59"
      unitRef="usd">359300000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI3LTEtMS0xLTU1OTY4_c93def55-71fb-46da-bd43-b7d2ce1c3fba"
      unitRef="usd">-400000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI3LTMtMS0xLTU1OTY4_0f6dabe8-03d5-4b54-8929-32c49e1cddcd"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI3LTUtMS0xLTU1OTY4_c77333d3-ec2a-4c18-bec6-3949a001ed5d"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI4LTEtMS0xLTU1OTY4_d52f46b4-4cb4-494f-b8fd-e5a66f42a788"
      unitRef="usd">412200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI4LTMtMS0xLTU1OTY4_346723ba-8cab-4503-b39f-6142b55f2995"
      unitRef="usd">284200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzI4LTUtMS0xLTU1OTY4_f909b079-82d7-4f9f-8fe4-6fe51e9f01d5"
      unitRef="usd">358700000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMwLTEtMS0xLTU1OTY4_6a4a841d-03f7-4085-9ff7-9ae438502bad"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMwLTMtMS0xLTU1OTY4_131f61fe-88f2-4f29-90c0-7667df457f65"
      unitRef="shares">99800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMwLTUtMS0xLTU1OTY4_d380091f-84de-47ef-84a8-6c063806ab65"
      unitRef="shares">99400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMyLTEtMS0xLTU1OTY4_6fba2c8c-3a5d-4e4e-af8f-4fcb3f2a668f"
      unitRef="usdPerShare">4.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMyLTMtMS0xLTU1OTY4_9f2e442b-ac26-4dda-a79c-0cf9c9db10cd"
      unitRef="usdPerShare">2.85</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMyLTUtMS0xLTU1OTY4_23acacf5-5fe6-47cf-8cd1-3b284f7df19c"
      unitRef="usdPerShare">3.62</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMzLTEtMS0xLTU1OTY4_06d9373e-7daa-42dc-9c25-cf53effa8c1b"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMzLTMtMS0xLTU1OTY4_e1440ee8-a779-40f7-9e66-098517dc284d"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzMzLTUtMS0xLTU1OTY4_3ef83916-c6ce-4ae4-a7e0-fc9d495ec7fb"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzM0LTEtMS0xLTU1OTY4_a3c66a06-5dcb-4181-938c-aa6f6fc5e321"
      unitRef="usdPerShare">4.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzM0LTMtMS0xLTU1OTY4_beacb91e-17b5-4d2b-9e9c-fd81970097ed"
      unitRef="usdPerShare">2.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo2N2JkMTk2ZmU0ZjE0YTEwYjZjNDM0N2VkYzUzYzdkZi90YWJsZXJhbmdlOjY3YmQxOTZmZTRmMTRhMTBiNmM0MzQ3ZWRjNTNjN2RmXzM0LTUtMS0xLTU1OTY4_2b41b97d-85c9-4113-9f10-5103a96aeb73"
      unitRef="usdPerShare">3.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzIwNzg_9d50ba3e-7622-449a-9690-0ee55cb3aa38">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards, dilutive stock options, and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzItMS0xLTEtNTU5Njg_8317ff40-200a-4853-804f-2fe7334131f3"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzItMy0xLTEtNTU5Njg_52ecaf27-73b5-4b43-a5d2-719bbdd81f85"
      unitRef="shares">98600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzItNS0xLTEtNTU5Njg_bd3b3bb5-ca74-4d32-9a39-78cda6cddef1"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzUtMS0xLTEtNTU5Njg_85125ba1-d5b4-4897-82fc-1524dd41fe97"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzUtMy0xLTEtNTU5Njg_61f3fee3-0ecb-40c5-81e9-54374a281b76"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzUtNS0xLTEtNTU5Njg_553bc5c7-7097-4d93-83c7-bccaf6207760"
      unitRef="shares">1400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzYtMS0xLTEtNTU5Njg_5c240dcc-d459-41d4-9822-38b304cf5a2d"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzYtMy0xLTEtNTU5Njg_21a1096c-10db-4b02-8726-f76b0aa93859"
      unitRef="shares">99800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90YWJsZTo0YzBkODMyOTJmOGM0ODFjYmUzNTkwZTBhOTQ1Y2JjYS90YWJsZXJhbmdlOjRjMGQ4MzI5MmY4YzQ4MWNiZTM1OTBlMGE5NDVjYmNhXzYtNS0xLTEtNTU5Njg_4840f4e6-851e-46a8-9121-a2edf582d170"
      unitRef="shares">99400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzM2Mg_24ee7317-1d91-4a52-8c05-386247fc4e02"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzM2OQ_336ae71d-8b2d-40d6-a68e-b772a91dcca8"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzIxOTkwMjMyNTc4NDA_c12e8ed8-76e3-4e70-9ecb-014ae5420b66"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ibcd77f4eb1a44cd19a0e1f02f5b4d30e_I20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzgwMg_18f973a9-c141-4bc3-977e-ed2e154b9500"
      unitRef="usd">200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i5509a74ccfac4681b49ffbf1a98e00a1_I20140201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzgwOA_140d3b0e-4797-447b-81c7-359144911740"
      unitRef="usd">250000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i32d7a3624fe641b1a56f6e162c46212e_I20180724"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzExMTA_8c42eaa6-fe5b-461c-a533-d1eed6d9d803"
      unitRef="usd">250000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i985e0db50aa74ba18de323dce42bcfc3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzMyOTg1MzQ4ODYwNzU_f54f0c0a-b26f-4c09-8458-9c47b6388e51"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic11d995353124469aeb3ecc87464738d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzExNTE_6b787bb5-7595-4e9b-8f38-af237c26b57b"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i45e50175dc9344b19c41346526f0d782_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzExNTg_706921f3-901c-48c2-8f33-b62e954eb08f"
      unitRef="shares">800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic11d995353124469aeb3ecc87464738d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzEyMTE_a99ecda8-ca29-461b-b73c-acdc0863de68"
      unitRef="usd">6100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i45e50175dc9344b19c41346526f0d782_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzEyMTg_bd70ca94-9321-45d2-86e8-d5ba1be28ba9"
      unitRef="usd">45900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i914b6b0bf40d480abbbf07849b027534_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzE2NDA_555f93a0-d074-4168-8e1a-ce5d54f104d4"
      unitRef="usdPerShare">0.27</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i914b6b0bf40d480abbbf07849b027534_D20180701-20180731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzE2NzU_5f78c6f8-b68d-49a5-bd56-b20d475399e6"
      unitRef="usdPerShare">0.27</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i7b7b3e61b74c4a53b71221db5581c78c_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzE4Njg_88fd2260-5944-4c7e-832d-5f0070f9ba93"
      unitRef="usdPerShare">0.28</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="id6a9857d4f284bb4be2223bfda243937_D20191001-20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yODkvZnJhZzo5ZjNjZDk2YzkyNzI0NzhlYjRiZTRjNmRmNzFhYmRiOC90ZXh0cmVnaW9uOjlmM2NkOTZjOTI3MjQ3OGViNGJlNGM2ZGY3MWFiZGI4XzE5MDM_d423e66d-b191-484a-84e7-b3100ec090ce"
      unitRef="usdPerShare">0.28</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUyNTU_d96ab13f-03e5-4a3a-ba08-b3479b8637f7">Contingencies and Other Commitments:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nichols Litigation&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We were named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Nichols v. HealthSouth Corp&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. In July 2019, we entered into settlement agreements with all but one plaintiff and paid those settling plaintiffs an aggregate amount of cash less than $0.1&#160;million. The remaining plaintiff alleged that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiff sought compensatory and punitive damages. On June 9, 2021, the trial court granted our renewed motion for summary judgment on all of the plaintiff&#x2019;s claims. The plaintiff did not appeal, so the matter has concluded. The conclusion of this matter did not have any impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The False Claims Act allows private citizens, called &#x201c;relators,&#x201d; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#x201c;whistleblower&#x201d; or &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; actions, can involve significant monetary damages, fines, attorneys&#x2019; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases brought pursuant to the False Claims Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Commitments&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to service and other contracts in connection with conducting our business. Minimum amounts due under these agreements are $55.4 million in 2022, $35.0 million in 2023, $25.2 million in 2024, $11.2 million in 2025, $9.0 million in 2026, and $13.0 million thereafter. These contracts primarily relate to software licensing and support.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i0a8048f934624676bc2bb342d07afd90_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzIxOTkwMjMyNjQwMjA_43ba324f-5b29-4806-bf5e-9d45979f86ca"
      unitRef="usd">100000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxMTc_9e9d9bd4-2b91-4020-9972-f5b835bb3741"
      unitRef="usd">55400000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <us-gaap:OtherCommitmentDueInSecondYear
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxMjc_ea82dae7-7a9b-4d8e-9bbf-2ff7a7dfc34c"
      unitRef="usd">35000000</us-gaap:OtherCommitmentDueInSecondYear>
    <us-gaap:OtherCommitmentDueInThirdYear
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxMzc_dc831de3-1963-46e1-8120-21a190518d96"
      unitRef="usd">25200000</us-gaap:OtherCommitmentDueInThirdYear>
    <us-gaap:OtherCommitmentDueInFourthYear
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxNDc_066dc8f1-5d0a-4d14-a1ed-2a961748b8ad"
      unitRef="usd">11200000</us-gaap:OtherCommitmentDueInFourthYear>
    <us-gaap:OtherCommitmentDueInFifthYear
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxNTc_0aec42d3-e5d4-48cb-9ec0-171c9bce1623"
      unitRef="usd">9000000</us-gaap:OtherCommitmentDueInFifthYear>
    <us-gaap:OtherCommitmentDueAfterFifthYear
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTIvZnJhZzpiOGYxY2M2MTQ1ZDk0NDBiYmFiN2FmMDQ5ODNmNTE0NC90ZXh0cmVnaW9uOmI4ZjFjYzYxNDVkOTQ0MGJiYWI3YWYwNDk4M2Y1MTQ0XzUxNzE_31b266fd-c34a-40b9-9eba-3a64004ae285"
      unitRef="usd">13000000</us-gaap:OtherCommitmentDueAfterFifthYear>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzMxODQ_97d206ad-c959-4390-a36f-59a4be2ea962">Segment Reporting: &lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our national network of inpatient rehabilitation hospitals stretches across 35 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of December&#160;31, 2021, we operate 145 inpatient rehabilitation hospitals. We are the sole owner of 91 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 54 jointly owned hospitals. In addition, we manage three inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Home Health and Hospice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- As of December&#160;31, 2021, we provide home health services in 251 locations and hospice services in 96 locations across 34 states with a concentration in the southern half of the United States. We are the sole owner of 336 of these locations. We retain 50.0% to 90.0% ownership in the remaining 11 jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of our reportable segments are the same as those described in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. All revenues for our services are generated through external customers. See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Net Operating Revenues,&#x201d; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#x201c;Segment Adjusted EBITDA&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected financial information for our reportable segments is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,513.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Occupancy costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of services (excluding depreciation and amortization)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Support and overhead costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,965.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,546.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Encompass Health Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,834.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Segment reconciliations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,095.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(247.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(243.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposal or impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government, class action, and related settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SARs mark-to-market impact on noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair market value of equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll taxes on SARs exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income from continuing operations before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional detail regarding the revenues of our operating segments by service line follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,918.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,496.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outpatient and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inpatient rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,513.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total home health and hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,644.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,605.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE3Mw_c4f4e4f4-f236-412a-9c49-4665a018b8c1"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzY2MA_46909067-56e7-4629-97d8-f6c4456e34d1"
      unitRef="state">35</us-gaap:NumberOfStatesInWhichEntityOperates>
    <ehc:NumberOfInpatientRehabilitationHospitals
      contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzc5NA_a874884f-dc04-455e-86e0-518893961a1b"
      unitRef="hospital">145</ehc:NumberOfInpatientRehabilitationHospitals>
    <ehc:Numberofsolelyownedinpatientrehabilitationhospitals
      contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzg1OA_1dff01fa-bf68-419a-81f2-2e06ab21979a"
      unitRef="hospital">91</ehc:Numberofsolelyownedinpatientrehabilitationhospitals>
    <ehc:Jointventureownershippercentage
      contextRef="ia3193970835f48d291309e71942e3c0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzg5MQ_050f8077-176f-4767-a869-7099a7108a97"
      unitRef="number">0.500</ehc:Jointventureownershippercentage>
    <ehc:Jointventureownershippercentage
      contextRef="ia3c49d5b00b54d92a4203a7b4d46fe21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzg5Nw_90746a17-f556-4fde-8791-9e7fd31522c5"
      unitRef="number">0.975</ehc:Jointventureownershippercentage>
    <ehc:Numberofjointlyownedinpatientrehabilitationhospitals
      contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzkyNw_abd4531e-18b6-4d8d-aa63-e79fd6d20aac"
      unitRef="hospital">54</ehc:Numberofjointlyownedinpatientrehabilitationhospitals>
    <ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts
      contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzk3OA_f174fbb5-5e72-4f8e-b194-74479a719574"
      unitRef="facility">3</ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts>
    <ehc:Numberofhomehealthlocations
      contextRef="i629acb7e34ff462d830466f2f0283b24_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE0OTk_6c7784d9-f09f-4203-b0e2-2a2c4c971f98"
      unitRef="location">251</ehc:Numberofhomehealthlocations>
    <ehc:Numberofhospicelocations
      contextRef="ibda439a47d5b4d4b820c4a0e2bc953fe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE1MzY_33004c37-377b-479e-a6a4-0300e3e3e724"
      unitRef="location">96</ehc:Numberofhospicelocations>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE1NTY_eb897e64-0712-457e-9fdc-7e746b98dcb6"
      unitRef="state">34</us-gaap:NumberOfStatesInWhichEntityOperates>
    <ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations
      contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE3ODk_3dac2d99-3803-4990-9afc-7567be30850f"
      unitRef="location">336</ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations>
    <ehc:Jointventureownershippercentage
      contextRef="i2ca76abaabe14804b27dbe68101f2b21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE4MjI_ccc2dbd1-63f2-4bb3-84c1-11939be9d71c"
      unitRef="number">0.500</ehc:Jointventureownershippercentage>
    <ehc:Jointventureownershippercentage
      contextRef="i886bc836155e45d099f360bf9159bb7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE4Mjg_5f5e1ffe-65fc-4246-b420-2c1ef5e5ffdb"
      unitRef="number">0.900</ehc:Jointventureownershippercentage>
    <ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations
      contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE4NTg_e6f41668-c776-4f72-b673-8f02fab643e9"
      unitRef="location">11</ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzMxOTA_4e92be71-d5a0-438e-85dd-97f68508abe2">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected financial information for our reportable segments is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,513.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Occupancy costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of services (excluding depreciation and amortization)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Support and overhead costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,965.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,546.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtMS0xLTEtNTU5Njg_3c94ff46-663f-4950-9d69-186dc32d5bdf"
      unitRef="usd">4015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtMy0xLTEtNTU5Njg_2cae42cc-962e-4d33-b364-dc83b1624ddf"
      unitRef="usd">3566200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtNS0xLTEtNTU5Njg_d3d71313-7dc9-42e0-bd88-2052e4b440ab"
      unitRef="usd">3513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtNy0xLTEtNTU5Njg_c94546a9-da23-47ae-9643-d57a4f12260c"
      unitRef="usd">1106600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtOS0xLTEtNTU5Njg_923725b7-c99a-4954-8508-29335e261a62"
      unitRef="usd">1078200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzMtMTEtMS0xLTU1OTY4_e1601a4a-ff4b-44b0-9481-3ed08e2a8053"
      unitRef="usd">1092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtMS0xLTEtNTU5Njg_d9da852e-dd96-46b6-8438-1ed5c5d8fc51"
      unitRef="usd">2127300000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtMy0xLTEtNTU5Njg_69837e49-f4e0-46f8-907d-bcf26e747024"
      unitRef="usd">1903800000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtNS0xLTEtNTU5Njg_2d3f1122-1e74-4794-b566-1226645f8ffa"
      unitRef="usd">1813100000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtNy0xLTEtNTU5Njg_1c396487-09e8-40c1-9833-ca4819462896"
      unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtOS0xLTEtNTU5Njg_91cac5ab-e56b-4f66-9ac9-e213028181b0"
      unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzYtMTEtMS0xLTU1OTY4_31dff74f-6769-4815-b7ed-1fa183f0d646"
      unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctMS0xLTEtNTU5Njg_edf3ef8b-e922-4e5b-8abf-9d30913c19d4"
      unitRef="usd">594800000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctMy0xLTEtNTU5Njg_8a2f119d-22fd-4af5-a763-000772bd43b7"
      unitRef="usd">534700000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctNS0xLTEtNTU5Njg_0f79d162-a611-4f4d-bc2f-b20fea44fd9c"
      unitRef="usd">521900000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctNy0xLTEtNTU5Njg_e9ccc175-e002-4127-b7c2-b3fd4a9c7399"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctOS0xLTEtNTU5Njg_6c39af18-8ad6-4696-a0a9-eeadd1d6af1c"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzctMTEtMS0xLTU1OTY4_40b2e10c-27b1-4d49-92f8-a7fb0235175f"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SuppliesExpense
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtMS0xLTEtNTU5Njg_6aa37b3c-dd65-444d-9028-f2f78d393b97"
      unitRef="usd">184200000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtMy0xLTEtNTU5Njg_a6e6549c-ec5c-4ca0-beed-138c3f963687"
      unitRef="usd">171000000.0</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtNS0xLTEtNTU5Njg_e5760662-ff1b-4c31-8e27-4c524e9c6912"
      unitRef="usd">147000000.0</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtNy0xLTEtNTU5Njg_a97b2a76-dba4-4756-8c37-d20da8f9ec3e"
      unitRef="usd">0</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtOS0xLTEtNTU5Njg_ec7b0583-0a20-4b0a-877a-cab5e91b5398"
      unitRef="usd">0</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzgtMTEtMS0xLTU1OTY4_74751b8a-8c92-4c30-8016-9818d6668bbd"
      unitRef="usd">0</us-gaap:SuppliesExpense>
    <ehc:OccupancyCost
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktMS0xLTEtNTU5Njg_00c21434-64fc-47d8-af75-818c8ff04ca3"
      unitRef="usd">59000000.0</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktMy0xLTEtNTU5Njg_639c603a-dbd7-40db-a702-b667751457d2"
      unitRef="usd">61400000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktNS0xLTEtNTU5Njg_00d7e70b-eadb-48ad-8e75-28ee35e280bb"
      unitRef="usd">64800000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktNy0xLTEtNTU5Njg_5ef54195-143a-47fc-a6a9-22ef42c22761"
      unitRef="usd">0</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktOS0xLTEtNTU5Njg_2cf4520b-e0be-4682-ad53-ceed659cc02c"
      unitRef="usd">0</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzktMTEtMS0xLTU1OTY4_4b0edf6e-7e5a-480c-9642-c82bb2393987"
      unitRef="usd">0</ehc:OccupancyCost>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTEtMS0xLTU1OTY4_f4a109a0-4bf2-42ca-a6b4-4aba2747dc58"
      unitRef="usd">0</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTMtMS0xLTU1OTY4_0796933a-42ab-46cf-af18-8f687e6ca627"
      unitRef="usd">0</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTUtMS0xLTU1OTY4_f7d675c8-db9d-4c1c-8843-2ea5641149a7"
      unitRef="usd">0</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTctMS0xLTU1OTY4_00df56bb-237a-4980-91e3-19f24e78d926"
      unitRef="usd">489300000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTktMS0xLTU1OTY4_d39b0d03-d1f6-4ed8-92a7-df3de1e854ec"
      unitRef="usd">511300000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzExLTExLTEtMS01NTk2OA_36d844ae-657a-4e92-be26-bbb94a961765"
      unitRef="usd">506200000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTEtMS0xLTU1OTY4_6ceed021-a574-45d0-9122-b32c1f6c4280"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTMtMS0xLTU1OTY4_14385f92-767d-4787-b6e2-a32a514ca75a"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTUtMS0xLTU1OTY4_0b7d1349-7d0a-4b79-ac7d-53a13a719832"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTctMS0xLTU1OTY4_ae88bb3f-5f10-47c0-b904-61647a406d03"
      unitRef="usd">406200000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTktMS0xLTU1OTY4_5d2a115a-2a92-4dff-9073-5197dba9aa48"
      unitRef="usd">402800000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEyLTExLTEtMS01NTk2OA_bc6118ef-094c-48bd-9d31-3cd89dc20b78"
      unitRef="usd">381700000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostsAndExpenses
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTEtMS0xLTU1OTY4_36d8701c-ab88-42de-89e8-eb16edcc5927"
      unitRef="usd">2965300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTMtMS0xLTU1OTY4_7f27137f-1f90-4560-a490-b56630621bea"
      unitRef="usd">2670900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTUtMS0xLTU1OTY4_b24fa91f-9df7-4375-bc6d-be47b91e1816"
      unitRef="usd">2546800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTctMS0xLTU1OTY4_f5391cee-73c4-4144-a3af-b6579e90411f"
      unitRef="usd">895500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTktMS0xLTU1OTY4_2f25ef73-0bce-423e-9434-1715334cf639"
      unitRef="usd">914100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzEzLTExLTEtMS01NTk2OA_c5410fd3-ecb1-4a56-b947-2504dc22fb4b"
      unitRef="usd">887900000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTEtMS0xLTU1OTY4_c5293aaa-e00a-43a9-8103-5aab86ef3b1b"
      unitRef="usd">6900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTMtMS0xLTU1OTY4_1ef17b5e-9307-4286-8423-799797d9cc23"
      unitRef="usd">8000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTUtMS0xLTU1OTY4_8cafdf87-e2e9-478b-8311-e721ca9dacc8"
      unitRef="usd">10500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTctMS0xLTU1OTY4_65034580-de5c-45e4-ac60-aa7c2afd8589"
      unitRef="usd">1600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTktMS0xLTU1OTY4_2869dc56-7436-42ed-8ca2-f31f6470e622"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE0LTExLTEtMS01NTk2OA_af85a122-f105-421d-815e-2d8c2eceabc1"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTEtMS0xLTU1OTY4_3546869c-b4a6-4b66-8477-a6b25feadf26"
      unitRef="usd">3400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTMtMS0xLTU1OTY4_3196e7d9-1400-47e9-9b7e-2e8fa38c1a43"
      unitRef="usd">3000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTUtMS0xLTU1OTY4_5099595b-f30b-4810-bcad-73834c18198d"
      unitRef="usd">5500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTctMS0xLTU1OTY4_6e987f11-3534-4543-874c-1f91ced69bf0"
      unitRef="usd">600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTktMS0xLTU1OTY4_b92e9080-09c1-4b2d-a36e-6fdacc0d46cd"
      unitRef="usd">500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE1LTExLTEtMS01NTk2OA_bc2979f2-3333-400c-a996-f5a1c15e0483"
      unitRef="usd">1200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTEtMS0xLTU1OTY4_82e2ae68-6dbc-44e0-a1ea-3925fb3d7980"
      unitRef="usd">-103200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTMtMS0xLTU1OTY4_67a53347-a837-46c6-a745-1abb96933c0f"
      unitRef="usd">-83300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTUtMS0xLTU1OTY4_8f886943-77a3-4076-a71b-9f3f1807178b"
      unitRef="usd">-82600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTctMS0xLTU1OTY4_8efb1968-a156-4381-a55b-6129567aeecc"
      unitRef="usd">-1800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTktMS0xLTU1OTY4_e9344377-5d7d-4137-9443-c29e519ed0cd"
      unitRef="usd">-1300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE2LTExLTEtMS01NTk2OA_7738c86c-43c2-4e31-8ca7-9e9cf01b7524"
      unitRef="usd">-9500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <ehc:AdjustedEBITDA
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTEtMS0xLTU1OTY4_52ed9e69-0652-499a-8765-fbfe1087d068"
      unitRef="usd">956800000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTMtMS0xLTU1OTY4_375b5434-d43b-490a-acac-956969f37306"
      unitRef="usd">823000000.0</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTUtMS0xLTU1OTY4_08df4973-c27f-4ca2-b001-43c1073c91dd"
      unitRef="usd">899600000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTctMS0xLTU1OTY4_4ae89d17-6f1c-4dfc-80aa-2f91b43ed0eb"
      unitRef="usd">211500000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTktMS0xLTU1OTY4_4ec3ed34-0c69-4c76-8c49-6cd17bcfcd4f"
      unitRef="usd">163300000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE3LTExLTEtMS01NTk2OA_c7ee4f39-f846-41f2-a81c-04aad1ea0644"
      unitRef="usd">195800000</ehc:AdjustedEBITDA>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTEtMS0xLTU1OTY4_919c0a02-08be-43b9-b183-ff54f3df6af0"
      unitRef="usd">545600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTMtMS0xLTU1OTY4_49c5469d-2415-4520-8e36-8d542c173bac"
      unitRef="usd">404600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTUtMS0xLTU1OTY4_2e60acf3-4549-4cbc-a0c5-31fc711aa871"
      unitRef="usd">391400000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTctMS0xLTU1OTY4_99a92f1f-b4c3-46a4-831b-983a787b8430"
      unitRef="usd">5600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTktMS0xLTU1OTY4_d25526dd-b4cc-463b-b816-6b45c086b573"
      unitRef="usd">3600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTo3ZjZlN2EyYTVkZWE0YzBlOWVhNDY1MTM4NWY1MThiOC90YWJsZXJhbmdlOjdmNmU3YTJhNWRlYTRjMGU5ZWE0NjUxMzg1ZjUxOGI4XzE5LTExLTEtMS01NTk2OA_4270f7af-be2b-4bd9-9b20-d6c86ca80105"
      unitRef="usd">12700000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzE1OTQyOTE4NjA2MTE5_f3ffa8f0-441a-4e7b-8944-f53366a3d52a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Encompass Health Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,834.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzItMS0xLTEtMTAwNjY2_d4cbeca4-dd09-4d15-97d0-71723aaad0cb"
      unitRef="usd">5143000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzItMy0xLTEtMTAwNjY2_ffaf5306-4d78-43a2-b1fb-700fcebd08d6"
      unitRef="usd">1721900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzItNS0xLTEtMTAwNjcw_bdb13f7c-7aad-458c-966e-09980e63a88d"
      unitRef="usd">6864900000</us-gaap:Assets>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iec5091f5ce8647a69ad189e4df7acdc5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzMtMS0xLTEtMTAwODk1_e84804b1-a5b5-434e-a6cd-26b34a918885"
      unitRef="usd">2400000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ice2be078a38c485caf0f9d2aff094488_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzMtMy0xLTEtMTAwNjcz_31272d3d-ca67-478b-8b2b-af495376c0dd"
      unitRef="usd">1600000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="idfa9d6dc91c64c829cb06ea80b8c0282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzMtNS0xLTEtMTAwNjcz_c57835dd-154c-4838-9da0-1cd074a4b6fc"
      unitRef="usd">4000000.0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="i490945f79e4b4bb6aeef60a98f16bb9e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzUtMS0xLTEtMTAwNjU0_7761213f-8d94-4d0b-927d-ed8d9df52bbb"
      unitRef="usd">4834700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6da867bd58bd42c7829bba5db347624f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzUtMy0xLTEtMTAwNjU0_1822ab05-9aef-49de-ad7e-899f40fe273d"
      unitRef="usd">1611200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzUtNS0xLTEtMTAwNjU4_cc22832c-0544-4ba0-9fe2-07aa1acae0b4"
      unitRef="usd">6445900000</us-gaap:Assets>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i490945f79e4b4bb6aeef60a98f16bb9e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzYtMS0xLTEtMTAwOTEz_1cec43e2-9106-4c0a-99be-57520d99a172"
      unitRef="usd">1500000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i6da867bd58bd42c7829bba5db347624f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzYtMy0xLTEtMTAwNjYw_81b37db3-b566-4bd9-93ba-f8d9fd1704e5"
      unitRef="usd">4000000.0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="idb5aa4ae49684bf895fa6b9c4d819454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTpiMWQzZDdkYmRlZjg0ODg3YjU0ZDU1MTIyNTY1NTFhMy90YWJsZXJhbmdlOmIxZDNkN2RiZGVmODQ4ODdiNTRkNTUxMjI1NjU1MWEzXzYtNS0xLTEtMTAwNjYw_9d8e43ff-fc5b-4745-a24e-7e4cc320afc3"
      unitRef="usd">5500000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzMyMDQ_7859b67b-f4fc-488e-8e46-2f575a3b8d10">Segment reconciliations (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,095.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(247.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(243.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposal or impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government, class action, and related settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SARs mark-to-market impact on noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair market value of equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll taxes on SARs exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income from continuing operations before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <ehc:AdjustedEBITDA
      contextRef="i2b20d1c1a4664c29b6e46e8c2743fd6d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzItMS0xLTEtNTU5Njg_fc02d0d0-40a4-4209-bf58-b3fe84f47dea"
      unitRef="usd">1168300000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i0f9c5d61928d45b991a621d141539dfb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzItMy0xLTEtNTU5Njg_2164fda4-4add-42ec-b546-bd5aab45b482"
      unitRef="usd">986300000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i776c682b8b6f439fb66cde932ed76f45_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzItNS0xLTEtNTU5Njg_4945f825-d981-4d34-b100-9dc0a06c0ccd"
      unitRef="usd">1095400000</ehc:AdjustedEBITDA>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzMtMS0xLTEtNTU5Njg_c5e13bfc-f143-4e85-947a-b0549023c914"
      unitRef="usd">197300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzMtMy0xLTEtNTU5Njg_28b2c2b2-44a5-4835-83f2-64f4bdea0e2f"
      unitRef="usd">155500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzMtNS0xLTEtNTU5Njg_0d13b5c0-f31a-4652-8c64-4f4fd4c1e72c"
      unitRef="usd">247000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzQtMS0xLTEtNTU5Njg_630c0c10-2b4a-4c48-bc67-58a38d440141"
      unitRef="usd">256600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzQtMy0xLTEtNTU5Njg_bf669b55-53d9-48c9-be8f-d341d971a73f"
      unitRef="usd">243000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzQtNS0xLTEtNTU5Njg_0494ab6b-4803-4440-9720-01d34813cf4e"
      unitRef="usd">218700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzUtMS0xLTEtNTU5Njg_fd0befa6-16be-4be7-bc29-782a83d33fe7"
      unitRef="usd">-400000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzUtMy0xLTEtNTU5Njg_785f85b1-c453-448d-8627-1c467ca9c712"
      unitRef="usd">-11600000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzUtNS0xLTEtNTU5Njg_c8872ccc-1b44-499d-9dce-39d4eb855270"
      unitRef="usd">-11100000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzYtMS0xLTEtNTU5Njg_ac991380-4fb8-4057-b7fd-6c12249ee463"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzYtMy0xLTEtNTU5Njg_fc31b8f4-05eb-44eb-823f-dea2c903221f"
      unitRef="usd">2800000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzYtNS0xLTEtNTU5Njg_74ae8645-caf9-4dcd-bd34-dfb19121c12e"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzgtMS0xLTEtNTU5Njg_b598fcbc-dfba-41c6-8aa8-204e590ac251"
      unitRef="usd">-1000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzgtMy0xLTEtNTU5Njg_4fed73ab-2a6c-4c6e-ac1f-91b6ae0da315"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzgtNS0xLTEtNTU5Njg_f0ba3726-6a38-4eb8-a9dc-2ee1608421ef"
      unitRef="usd">-7700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzktMS0xLTEtNTU5Njg_e1decec7-5674-4e17-934b-ae64afae3e46"
      unitRef="usd">164600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzktMy0xLTEtNTU5Njg_0c1af2a5-08e2-4545-a8c3-391efc649e32"
      unitRef="usd">184200000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzktNS0xLTEtNTU5Njg_5acbb72e-e8aa-4b40-b7a3-c5bb52ed506e"
      unitRef="usd">159700000</us-gaap:InterestExpenseDebt>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEwLTEtMS0xLTU1OTY4_bdfa76b7-5173-4710-885c-b9a17cc8fbd7"
      unitRef="usd">-105000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEwLTMtMS0xLTU1OTY4_4b895b5e-ee30-461a-9f5f-4351176fa729"
      unitRef="usd">-84600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEwLTUtMS0xLTU1OTY4_e7a5da1c-856b-4ab7-9b83-9ef644f9640a"
      unitRef="usd">-87100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <ehc:SARsmarktomarketimpactonnoncontrollinginterests
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzExLTEtMS0xLTU1OTY4_258edacd-d6a2-478d-a302-9963a5245d60"
      unitRef="usd">0</ehc:SARsmarktomarketimpactonnoncontrollinginterests>
    <ehc:SARsmarktomarketimpactonnoncontrollinginterests
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzExLTMtMS0xLTU1OTY4_16afd369-8009-436c-92c7-db7e7a636228"
      unitRef="usd">0</ehc:SARsmarktomarketimpactonnoncontrollinginterests>
    <ehc:SARsmarktomarketimpactonnoncontrollinginterests
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzExLTUtMS0xLTU1OTY4_cc1fb2a3-a392-4d29-8e59-ddb42689dcf9"
      unitRef="usd">5000000.0</ehc:SARsmarktomarketimpactonnoncontrollinginterests>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEyLTEtMS0xLTU1OTY4_d7f63c6c-ee28-472c-810c-7e4eeb7d3bc6"
      unitRef="usd">600000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEyLTMtMS0xLTU1OTY4_e8e8df27-eb7a-407c-b74b-737ea5a1a809"
      unitRef="usd">400000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzEyLTUtMS0xLTU1OTY4_f1a3af9d-76ce-4a87-b763-b2fe21c5de64"
      unitRef="usd">800000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE0LTEtMS0xLTU1OTY4_5c6a61b4-9b7b-4011-953e-1550e5239d95"
      unitRef="usd">3200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE0LTMtMS0xLTU1OTY4_df6ea5b7-c14e-4f1c-a6b2-a31efccdf817"
      unitRef="usd">2200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE0LTUtMS0xLTU1OTY4_ed39f106-f8bf-43ec-a758-a90828c023e3"
      unitRef="usd">19200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <ehc:PayrolltaxesonSARsexercise
      contextRef="i71f88c5a159d4592a986c8b29d758379_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE1LTEtMS0xLTU1OTY4_2216c2e6-4c45-4882-8d51-e5f0de6368ce"
      unitRef="usd">0</ehc:PayrolltaxesonSARsexercise>
    <ehc:PayrolltaxesonSARsexercise
      contextRef="i61c1cf9dcf2944f3b65856f036150996_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE1LTMtMS0xLTU1OTY4_3df251a1-215d-443b-9251-b7d76862f20d"
      unitRef="usd">1500000</ehc:PayrolltaxesonSARsexercise>
    <ehc:PayrolltaxesonSARsexercise
      contextRef="i88ed54edb0a244cbbf29e90cb8271531_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE1LTUtMS0xLTU1OTY4_a3af49a2-9a4b-42ce-a039-d315b3d9af97"
      unitRef="usd">1000000.0</ehc:PayrolltaxesonSARsexercise>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE2LTEtMS0xLTU1OTY4_f2e9aea0-60b9-4e78-840a-13ca7bfd95fe"
      unitRef="usd">657200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE2LTMtMS0xLTU1OTY4_ec94408c-bb32-4aa4-abc0-717ac87d70e9"
      unitRef="usd">472600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTozNTRhZGY1NGM3Y2I0YTYyOGVjYWFlZTJkNDQ0YjdkYy90YWJsZXJhbmdlOjM1NGFkZjU0YzdjYjRhNjI4ZWNhYWVlMmQ0NDRiN2RjXzE2LTUtMS0xLTU1OTY4_b66109e2-5118-4082-9a0a-29b2e9b04557"
      unitRef="usd">562300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90ZXh0cmVnaW9uOmNmNDE5ZGQzY2YzYjQ4OTFhN2Y0Y2YzMzU3M2YyNWIxXzMxOTU_575511e8-bcf1-4d88-93a3-bdc6ce92eb55">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional detail regarding the revenues of our operating segments by service line follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,918.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,496.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outpatient and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inpatient rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,513.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total home health and hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,644.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,605.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31a9deb44ebc4734990673dcfd5a1fa2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzMtMS0xLTEtNTU5Njg_986b1bf9-1b4b-4ffe-b6a7-0382a12b2c86"
      unitRef="usd">3918100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3de5b67d1c443a38dfa663c544d2ffa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzMtMy0xLTEtNTU5Njg_e5a7961f-a69e-4e80-9c4d-fe7b20c3e892"
      unitRef="usd">3496100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7deb25afaae4201a2e97e69747672e8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzMtNS0xLTEtNTU5Njg_7b773abb-8144-4bf1-b4ab-a3569f07716c"
      unitRef="usd">3423500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5571918fc1b480a932b9aaa18cb0053_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzQtMS0xLTEtNTU5Njg_62f5ff2a-76c2-478c-b916-bcd052480181"
      unitRef="usd">96900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i941a80b49d3743a78f06a9e20d555c80_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzQtMy0xLTEtNTU5Njg_e9e28278-48af-4949-8424-85014f1c7aaf"
      unitRef="usd">70100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1af801ecbfb49d2bc7b43640349d670_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzQtNS0xLTEtNTU5Njg_7728bfd3-54b4-4254-a2bc-eb41393e7be2"
      unitRef="usd">89500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzUtMS0xLTEtNTU5Njg_aa83c786-0262-40bc-b2fd-cf50bfc4cb73"
      unitRef="usd">4015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id212a936c98944b38ad417ce9ff8a4cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzUtMy0xLTEtNTU5Njg_263eb77d-ebc1-4bd3-9e64-90eb57ecf834"
      unitRef="usd">3566200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i702f98649cff4e8c868a271821368090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzUtNS0xLTEtNTU5Njg_7e057b9d-e98d-42f5-814f-b70843ad82f3"
      unitRef="usd">3513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia681297da5504ffaacf633a76dcb7a2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzctMS0xLTEtNTU5Njg_57421265-1b36-4d7b-953a-db7fea871e4a"
      unitRef="usd">897300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4752f09b329c46a7a5c722bebaadac64_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzctMy0xLTEtNTU5Njg_fea75f36-c7b2-43f5-9752-ad90c2bc07f7"
      unitRef="usd">877600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i301c2e1d8eb641efb1ef724b3603ec49_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzctNS0xLTEtNTU5Njg_70af22e8-a9e8-470e-9999-b57acf30c847"
      unitRef="usd">918000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36e9398a071b4c9a98203be3ab77177f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzgtMS0xLTEtNTU5Njg_c68ba7d6-643e-44c7-8d44-b43a831f98cb"
      unitRef="usd">209300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8db2ff79c3674a52a089ddcc64324e9f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzgtMy0xLTEtNTU5Njg_bea2a2f4-0b5c-4810-90d0-e0f1d22b5a08"
      unitRef="usd">200600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18c6808319b14ca9b78c39dcbbbd0052_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzgtNS0xLTEtNTU5Njg_22709387-ac9c-42e7-9801-688ad3ec827b"
      unitRef="usd">174000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51e4885ae5f242ce93b6bc4b1198b3d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzktMS0xLTEtNTU5Njg_0253dbc7-4137-4946-85de-3e3b1fa4bfdd"
      unitRef="usd">1106600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53d98cc7c7804a20ba969e0ae90cf773_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzktMy0xLTEtNTU5Njg_d7c5e538-cdc7-486c-8e78-0929bbe31603"
      unitRef="usd">1078200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2583215bdc1749f5851758facd2ed865_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzktNS0xLTEtNTU5Njg_2e2de395-3224-4590-a28e-80afed9649bd"
      unitRef="usd">1092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e94b8af65474af790515c80eb731e5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzEwLTEtMS0xLTU1OTY4_24d0d68e-9668-402c-ad33-3d9a5e942e80"
      unitRef="usd">5121600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02f5c65d7aeb46cb8c5c0c03edff41b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzEwLTMtMS0xLTU1OTY4_147aa084-e114-47c5-9361-459c1346559c"
      unitRef="usd">4644400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i748e41776c704fd5bc008d839fc11bcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8yOTUvZnJhZzpjZjQxOWRkM2NmM2I0ODkxYTdmNGNmMzM1NzNmMjViMS90YWJsZTowN2MwYWZhYjU5NjU0N2U4YmZkN2VkMWUyZWE4MDlmNS90YWJsZXJhbmdlOjA3YzBhZmFiNTk2NTQ3ZThiZmQ3ZWQxZTJlYTgwOWY1XzEwLTUtMS0xLTU1OTY4_729872c6-4c62-4ff0-8faa-c22dcd9cdf5b"
      unitRef="usd">4605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTMtMS0xLTU1OTY4_37065a94-0044-4a86-8cd6-196ede9333a6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTMtMS0xLTU1OTY4_37065a94-0044-4a86-8cd6-196ede9333a6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTMtMS0xLTU1OTY4_b1625715-3198-4ba4-b240-797414be8947"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTMtMS0xLTU1OTY4_b1625715-3198-4ba4-b240-797414be8947"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTEtMS0xLTU1OTY4_0b58a3fa-b14c-46c1-b573-7fcf0c82ac10"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTEtMS0xLTU1OTY4_0b58a3fa-b14c-46c1-b573-7fcf0c82ac10"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTEtMS0xLTU1OTY4_8c08c71d-5cc5-4114-a2b5-a12015439158"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTEtMS0xLTU1OTY4_8c08c71d-5cc5-4114-a2b5-a12015439158"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzM0NA_295907de-de5c-4a62-9d8b-958e93adf76f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzM0NA_295907de-de5c-4a62-9d8b-958e93adf76f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of December&#160;31, 2021 and December&#160;31, 2020 include total assets of variable interest entities of $226.2 million and $221.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2021 and December&#160;31, 2020 include total liabilities of the variable interest entities of $38.2 million and $46.8 million, respectively. See Note&#160;3, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTMtMS0xLTU1OTY4_37065a94-0044-4a86-8cd6-196ede9333a6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzM0NA_295907de-de5c-4a62-9d8b-958e93adf76f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTMtMS0xLTU1OTY4_b1625715-3198-4ba4-b240-797414be8947"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzM0NA_295907de-de5c-4a62-9d8b-958e93adf76f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzE2LTEtMS0xLTU1OTY4_0b58a3fa-b14c-46c1-b573-7fcf0c82ac10"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzM0NA_295907de-de5c-4a62-9d8b-958e93adf76f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90YWJsZTpmNThkY2IzMGU3ZTg0MTA2ODViNjM4MGM1N2NjZTc2OS90YWJsZXJhbmdlOmY1OGRjYjMwZTdlODQxMDY4NWI2MzgwYzU3Y2NlNzY5XzQ1LTEtMS0xLTU1OTY4_8c08c71d-5cc5-4114-a2b5-a12015439158"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjM0ZjYyMjZhNjNkYzQzNTI4NTM0YzJiZmFiZDg2ZGVkL3NlYzozNGY2MjI2YTYzZGM0MzUyODUzNGMyYmZhYmQ4NmRlZF8xNDIvZnJhZzplZDliNmJhZjMxN2U0MmE1ODIwODZmM2JlODYzNWYxMS90ZXh0cmVnaW9uOmVkOWI2YmFmMzE3ZTQyYTU4MjA4NmYzYmU4NjM1ZjExXzM0NA_295907de-de5c-4a62-9d8b-958e93adf76f"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>125
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!XVN2\.T=,\B&._@]H]:X\GP!_0/;?H74$L#!!0    ( +>$650U?*O/L@<
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M6;9OMX)#R]$ ^'XCI3I\T#<X/BQU_S]02P,$%     @ MX195)(U]?/ !P
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M29G5S?_.4X=U9TYRJFF9=\&,09X6[=_XN9N(7@! A@#8!<"I :@+0%(  H8
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M#_R[C.LT?V@=)*U357UP/$<>GR.;YTC+<[Y!1$GS5;%5E [;L4$S5@>.Q^N
M32_XU>5C?V.QE AG%[.A5(2EI QZ4H/E!\?E!\[E_[VHN@U*TFH%!I7F>[#?
M;K? ,L^]'!""$=?Q,X6PG7[66Y5_(4?X6IFP+S/"1LT2TLC"([+0:0 WR7_
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M==O#TGH/#-L)3K"=_T?L)!@,%3LI"D/$3D+,$3L-U0G<5,?IQ5VD="@64Y@
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M&(!ESE0144/OZM5)U8!+$@]Q5^<,_'PQ&4#J<D6GR7[FC*-#)*198CS^EC4
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M[N*"@VL?368-0B.D1CLY _[@^[%<NR$]B>FYMTU J1&- 2NU7N9OBS7'FYB
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M ; ?DDR0PMEK2^"3">I.AO8$_YO-!4O4(0LLJ."-YK)-1*R6S/.KBA/=VI5
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MN2AY]2< U2Y&[T>[Q)6MH'"[C%X%@>L?>3$;C[2OY\DA#D5KM1XLUGSKO >
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M7KV'P@[0%3,->-#Z?0 !ZL<D*A+R<4#+D3J>R!7QA()HOD=\(D92A\$#FDM
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M G1= *\,TV*QB@538S:?RF *>5K@R5#>RC#C472/&$V%ECQBJ6(JTVP,I>.
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M=F\Q@,>OJ)ZQC?4%X0%,!:01Y. [%B)\[@"CS=:T[). ]H"5)#<25+$3?N^
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M&/R=Q2D@J[Z?3OT0#YW@0JJ69[@<K<F'HF"$$Z5RQ->0IK2*V*^A__+T$!G
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M93"F85(:9^-@2QM[V'SWODI<1X+*2#3.Q^EH[1ZI,H$DZT/YC;EKU4X2=T@
M1WU2?2=GW\Y3;4&6$M$L(SD>)G0*>MJ;'#]*Z]0D/Z:T+MGSFP<!](I37,6C
M4+E*3NEW;_YT6">2LL?YF-KLBS=/5@/1Z>PS6)Y(:E9'A/6MR]%B<E%MT%=R
M'0\@.O9WUG%TO/%?]1?=>_/^WX6WRE>:6H;!#2U-D^/#65^[^X_H6KGVKEVD
M2[2\4M<MT;,!S6\<G33#!SL8_P^Z_!=02P,$%     @ MX195&AL:.X!!P
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MTS_'"^L,<N3?-TP-=Z:&P=3P?Y/Z)HXOR /;BI+G$2K.LKGCZ!7P WJVS[O
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MY'&0@G_T/RF0P5KT]PT%(N='<3+%"3B/RLG,Y$EI/-L]/MD6J'8&7.#E[N
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M@G!#BCS>MW&#ED[)/71%,T=JL'OB<!Q,!)0/BNK0+=<:@#(T3%07]])I3'M
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M*YF/:#8=4C;)I@_HFW7!F$5]LX\+QL;Y(;U#=12-EF07U!?[Z6SN@T.N_?P
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MS*M?OB^+]7_6JMJ*-VI1/[^HL2;=N4CM_%=F?CPP/XK%KV51;[1X6RS5LKO
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M"V"O>%"RT@)F2[\CA*PPN&^D_X,QA"5$0,=4?X&7B)MMV8"'W\"2_0H]QN"
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MJZ'7Y79'($YC,_ ,?G6VS%#1BS4"&XRSK#0+]0;XE]OL@XS )@JD276/BB5
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;*5876_;.!;]*X0W6"2
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MKU7>:76?OXGXDRHR,9T,13[.)V_@3?=63AEO^@,\-E#:0HE_WRU"].#"?]Z
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MA!HWVC G4QG5E4LP92KA44TJLH9Y((N'5Z,@G'P/:9/P:F5Z<>X<:E)&:J]
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M@S!BM'^\6?$WU)GQWE3\<ZDD#$8+\'YN8+7XAQAT']7?_A=02P,$%     @
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M8@7P?2&EV32L@>Z2[/0?4$L#!!0    ( +>$653+L?%<MP@   X4   9
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M2-C(O,A$FS/4_ ^@.F_I&#(A5$6YJ['Y^J!]R;YL.6&YW\5$A %!]"['9;U
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M^]!GG_)D<.K\(.*3(C/-D?<28;278+82>^3&0*VAEDQFMS1RG :R(6F2W$C
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M_JN0OW"FX2\Q&^.P&>13ZK542P/P?&NP+>PO2,'X:>[-?P%02P,$%     @
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ML)&\^&TPH0-3 &,!'1"-5>2)LI.OLH=7CYRX(;BOZ"0+#TM:7TAA"IBP'#I
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ME)D\0+,CMP!1!OFV4"P0)M&\??XN=5."N4,BL-^"#-ML49T6Q1)%-DQJ#M)
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M?#74)%(P*B#WA;J&^%,M.;DNIN\E0UDS"T1T-&D<<UZCKJ)P'QN(]-9M[C
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M9]XV],@C"^_FJD#$IL',%7'>B]NB2X/]]#"A*QU]>+\"TP(X^]_,@THBC9[
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MQ=4O+V*#V8N3#/E:@XZO+>@XVS_V@T=)F#IQ@)GX)NMTDW"\9!V4[<G )N,
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M9C8?%L0YM&@TO,]7H5V2FWV^"//T.?Z7Z1+E4K0E9F8=8,U6IE+O3GV2W(C
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MFD2)!WJ$]2DH+V-4#)?HX[ESX:>)L:BQ &Z';WF!%#9#+4HZJ@D<T3"1OFS
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M23_TS1Z'1"6A;W;TYS: N=SB _#[N@&]4S[@!+=-^XZ6]^U_ E!+ P04
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M"-3.@=;72MG=Q 48_I@L_@502P,$%     @ MX195 >W'F6H P  - H  !D
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M"LE!(7&\.T..Y2MFV&*FY!Z4E28T.W&N.FTBQVM[*4]&T2DG/;-8*[I?97X
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M "HK0.=;*<UQ80WT/Q6+?P%02P,$%     @ MX195"I&NY3Q!0  41(  !D
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MT95&,42X3=1SB.R]AF-,VQ='#OZM% 7:?4%RL"\<3OH)\)-"<!M17^W1XSB
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M*VW=X$5Q_;?:>E_"' F4.\'8]Z*07>?W2*1?"$U9&I$VSN?ELKZPYQ0$):B
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MCZ\"W1Q2FX%5E3L8CI3%,=,]3G&NEYH%,#]6Z(_%@!=H_Q2<_0-02P,$%
M  @ MX195+]@]DM! P  ; <  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULA57;;MLX$/V5@; /-I#5S9;C&+:!N.UB [1 D'2[#XL^T-+8(D*1*H>.
MD[_OD'(49^NX+[S.G#ES2 [G>V,?J$9T\-0H38NH=JZ=)0F5-3:"8M.BYIV-
ML8UP/+7;A%J+H@I.C4KR-)TDC9 Z6L[#VJU=SLW.*:GQU@+MFD;8YQ4JLU]$
M6?2R<">WM?,+R7+>BBW>H_NGO;4\2WJ42C:H21H-%C>+Z#J;K<;>/AA\D[BG
MHS'X3-;&//C)3;6(4D\(%9;.(PCN'O$#*N6!F,:/ V;4A_2.Q^,7]+]"[IS+
M6A!^,.I?6;EZ$4TCJ' C=LK=F?W?>,BG\'BE411:V'>V.1N7.W*F.3@S@T;J
MKA=/!QV.'*;I.P[YP2$/O+M @>5'X<1R;LT>K+=F-#\(J09O)B>U/Y1[9WE7
MLI];WJ/:_'FC:6>Q@CM)#P2#KV*MD(;SQ'$ ;Y:4![!5!Y:_ Y;E\,5H5Q-\
MTA56;P$29M;3RU_HK?*SB!^QC&&474">YMD9O%&?[BC@C=[!"YD*72+\=[TF
M9_E2?#\#.^YAQP%V_%L5 _8=$MI'I%,*G@7R3W!&K2AQ$?$;"RC1\FN-L#&*
MWX_46W#^="#L:D?@>+.LA=XB@=1@=OSB/!O9LSG@$&/88/Z,PA*@/R)@@;%9
MH^U%#FUZ 4)7/,JN8,"HC52*WQ -9\$FF'2[*Z%"$.%@C5NIM:=H-M"BE::Z
M@*TU1/ '9),BSGU?7,:C,$_C*_B,1#.6ZYALB?(Q7$ 8Y--X-.1N$H]]5\23
MX6\#:BYDV6C"X-DH#6W! 6]TR26+L->@M>91ALK"ON7.6A8S" .E$K(A&'N(
M(H^+;L0ZG0%H.;9]XSZ8Q%/FG!5QZKO<4__TQ*64.#&+2C@6WQFH))7\9*3>
M\9Q+K16^6+%_&N?#US8;PJUX;L*)'WF?(CZX#"&G0;/+N#CM>8(QRQ5DSN,K
M[D:9#WJD-M^77W6^BL=OU+ZNJO?/DRWXUO"9@C_1,]BOE\;C___RG'JOR5$%
M;-!N0YTG*,U.NZX8]JO]5W+=5=!7\^X?^B(L7RL"A1MV3>/+(@+;U?9NXDP;
MZNG:.*[.85CS=XC6&_#^QACW,O$!^@]V^1-02P,$%     @ MX195!VD&87Q
M P  X0H  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULI59M;]LV$/XK
M!RT88J#0FV7+3FT#<=*A^= N2+L-P[ /M'2VN$JD2U)VVE^_(R7+=A"[6?:%
M%,F[YQ[R^% WV4KU11>(!AZK4NBI5QBSO@H"G158,>W+-0I:64I5,4-#M0KT
M6B'+G5-5!G$8#H.*<>'-)F[N7LTFLC8E%WBO0-=5Q=2W.99R._4B;S?QP%>%
ML1/!;+)F*_R$YK?UO:)1T*'DO$*AN12@<#GUKJ.K^<#:.X/?.6[UP3?8G2RD
M_&('=_G4"RTA+#$S%H%1M\$;+$L+1#2^MIA>%](Z'G[OT']Q>Z>]+)C&&UG^
MP7-33+V1!SDN65V:![E]C^U^',%,EMJUL&ULT]"#K-9&5JTS,:BX:'KVV)[#
M@</HE$/<.L2.=Q/(L;QEALTF2FY!66M"LQ]NJ\Z;R'%AD_+)*%KEY&=F#Y@C
MI7E1(GR4(I/"*%F2T0KNA$&%VFBX_&S7=6\2&(IH_8*L19\WZ/$)]"B&#P19
M:'@G<LR/ 0*BVO&-=WSG\5G$6\Q\Z$=O( [CZ Q>O]M_W^'U3^"=V#3\=;W0
M1M&=^?M,D*0+DK@@R:L/^;FC/8MIQ7JEURS#J4=JU*@VZ,T^%PA+@I9;"\XU
ML)W:0"[!T*I3 3??2% E,YB#D2!K!0<4Q3%%OK\'7- 5I%DI=.\*2!4.\D]D
MJLDO4':P6J#J,F2;D)IH#'-6,I$1 P,+7'$A+#BQ6J/B,H<+\O&'U,7]<=,/
M(S^%C_0N<>)364>C^*(VCB31/LES[(>0^@E$,0'=<MVX6=:DUZQDBIA>CORP
M9]L!M6,_[L&-Q6H-+?P_DA!A@\+4! L__S2*H_@M]/T((@KP8)&TYDN>L9W+
M248[YUU_&44VY'VMLH*>%'L,Z@4)V+L/8[_?:_IQ#]X]$HQ8T:DH)C1KWKO.
M.!E:V]WPIK&D5"X95[!A98V0^ ,"\Y,>1$E*A_8KY57!@+;ZE/E!%E'D1_E+
M8C]^FL8SXAETXAG\0#QT&!DO>7/,%-'>B;OF3EP_N1.GWK#G]'4V[$OTU415
M+3^Z(U8-XNR%52=?@GV6WP#3#E5925&B+*PNZ-H6LLQ1:9>+]"W@U]HJ6;<_
MN%;A!*IER7.G[D6;+O>#T(1,.?L!RY>\!,]2K/#[=T:JQO_$B"):F]?HW.5%
MF#V#HT#:4$?E QD2#T(F\\)6$QO<1?I_#]IYRB_1\P6,A_247$":.NFD5H=G
M8%^">?3XO>94+R *!X[5*'%*'J7T#CPGY."@[*A0K5QQI>FH:V&:"J2;[>JW
MZZ9LV9LWQ=\'INB7H*'$);F&?DKB5$U!U0R,7+LB9B$-E43NLZ :%)4UH/6E
ME&8WL &ZJG;V+U!+ P04    " "WA%E4*HC?^[8$  !3"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,2YX;6R55MMNXS80_17"O6 #I+)ULV4W,9!D$]1
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M(<W!>J8V+,&)0R>G0KE%9SK;'X3&D*CHH+3&ZE+4IY5)E.DQB3FK2U^?PD:
M*TI^4QK*O1UKZF'(P'[*7-RA3+A"N*;B(FRH,%;V!=$%FE/<U/E/F^^?=;YG
MZ[7$M:G*5:EI0"B>-(/I2Z65)@=)Y?A9LWD0!3&\@]!SHQ ^->SUO5.(/7?H
MM8ZET(N/(#IU@X'IX15R79E0>CXMCT:NYW?;H<[R?0B'[F  (374.[)!;=S
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M=S2>,PQ0E>6PMNNP;8V&BJ"[?Z' U;$*O#\@]#9@]ZJN7Q<?LD6!BZ(Z=P'
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MAOX(LTNZ^XGK:%';.\%2:+QAV+\%7NE F@'X?26$WG:,@^Z2./\'4$L#!!0
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M,'=*&9$103QAE9Q=\@VBOO:Q64G;:I=H:9*Z34F8N.>LH #"=__FDRR&S0^
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MZB)+GU%6HG5MY8>J,ZO2NOE14A)_4V3ZUTB7*ZYN=H2C] [=1/=)=!<MPZ1
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M]\VS^T+?5IXYVP7CEZ8V>DLN*DX;<+5X4"Y>SVZO-BU3R&$*Y,9P!:6A.&W
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M*AZ7@L^%S NHWQ=)DKU_R%\-WKXQ?_%?4$L#!!0    ( +>$650%T!^N=@<
M '8I   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;,6:X6_B-A3 _Q4+
M3=.== 5L)P%N;:4"!3I==U6[NWV8]L& "]DE,><XY2KMCY^3&)R0V 4&6C_<
M0?![?G[/[^=GQY=KQK_%2TH%^!$&47S56 JQ^MAJQ;,E#4G<9"L:R5^>&0^)
MD%_YHA6O."7S3"@,6JC=]EHA\:/&]67V[(%?7[)$!'Y$'SB(DS D_+5/ [:^
M:L#&YL&COUB*]$'K^G)%%O2)BB^K!RZ_M;9:YGY(H]AG$>#T^:IQ S]./"\5
MR%I\]>DZ+GP&Z5"FC'U+O]S-KQKMU"(:T)E(51#YWPL=T"!(-4D[OBNEC6V?
MJ6#Q\T;[*!N\',R4Q'3 @C_\N5A>-;H-,*?/) G$(UM/J!J0F^J;L2#._@5K
MU;;= +,D%BQ4PM*"T(_R_\D/Y8B"@-13+X"4 -H5< P"6 G@?7MPE("S*^ 9
M!%PEX.YKDJ<$O'T%.DJ@LZ] 5PETL^CFX<AB.22"7%]RM@8\;2VUI1^R"9%)
MRQ#Z43IWGP27O_I23ESWDU@^B6,P8.'4CT@ZH6)P 7Z3:3,@\1(\$'\.9(Z
MF]GWQ(_];,:]&U)!_"!^+UM^>1J"=S^]!S\!/P+W?A"D&BY;0AJ7=M&:*4/Z
MN2'(8 @$]RP2RQC<1G,ZKY$?VN7Q6_*W;_2/+ I:TJM;UZ*-:_O(JO&>\";
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M@??&HVTV3+IKO$%M=YG%X>26:D87',BE1-!@D+R7R)"!(<?D*VRPI-R0@PM
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MT#."3B5T!2&&Q"*)-]63^:HC487=H6L/:8-NK?3_&GF['6BDE')B"LJ(Z<Y
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MAMW9#!W?\']GXP:WSS5;4P[":/+K9JZ-PG?F]X$R<5<F=F7B/64> +E8;J#
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M[_Q3'(UADAUHPES%U[-BTA .#5(F@UM4I,.L"H95:_]ZE\KB+/#+%L<[:!>
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M!Q#%0;AH*)[;L^2<*WTRM9<;_?) A!F@[Z\X5Q\-<SRM7D<F_P!02P,$%
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MB#0!\#X70G\,S +MO6W^#U!+ P04    " "WA%E4]J_\J4 $  !0$0  &0
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MX6"">%6WC[HP<N>N[$H:; !NF&/'!64WX/I&2G,L;!=H>WCZ&U!+ P04
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MR+J\P%@H>[\ZI#:CS27IK+P:?#-^3I>GZJK3PE0WKVMNUD)9D+@BR'!X3&O
M5)>9ZL7IO#S>+[6CRT+YF-(%$(V?0-]76KO'%^^@N5+._P)02P,$%     @
MMX195"X*Y>CV @  L@@  !D   !X;"]W;W)K<VAE971S+W-H965T-S8N>&UL
ME59=;]HP%/TK5M2'5FJ3$"! !4@M;%JE=:O*NCV;Y(98=>S4=J#]][M.TBB%
M@-H\@!W?>WS.N?[(="?5LTX!#'G-N- S)S4FO_8\':604>W*' 2.)%)EU&!7
M;3R=*Z!QF91Q+_#]T,LH$\Y\6KY[4/.I+ QG AX4T4664?5V"USN9D[/>7_Q
MR#:IL2^\^32G&UB!><H?%/:\!B5F&0C-I" *DIEST[M>3&Q\&?"7P4ZWVL0J
M64OY;#MW\<SQ+2'@$!F+0/%O"PO@W (AC9<:TVFFM(GM]COZ]U([:EE3#0O)
M_['8I#-G[) 8$EIP\RAW/Z#6,[1XD>2Z_"6[.M9W2%1H([,Z&1ED3%3_]+7V
MH970&QQ)".J$X+,)_3JA7PJMF)6REM30^53)'5$V&M%LH_2FS$8U3-@JKHS"
M489Y9GXGMJ -EL5HPM!5$9.;>$M%!)H827Y)$4FA)6<Q-8!C2<(XPZ8F5V2%
M2RHN.!"9D-\F!45^2K&Y,J R<J,U(.3Y$@QE7%]@^--J2<[/+LB9G>B><8YE
MU%//H K+Q8MJQK<5X^ (XR5$+NGW+DG@![V.],7GT_V/Z1YZUQ@8- 8&)5[_
M"-ZWEX*9-Y*!266,RAH[KT^ ]QOP?@D^. *^H#DSE!.L@5%L79ACEE4PPQ+&
M;MSMW'?'4V_;]J4K9M+$?. W:/@-3O,KLH)3NQ&)3JDJ5P+#%9-!%\D*:]PB
M$([=X1[+SJ!1-\UA0W/X99HQTZ<M'1X0N0I#=^*WGMX>]^X4?])^NI6$C9+P
MI)*CJZU+07A )W '>Y0/8_JMDGS@.&HXCD[NB'N@NE!@:1'*\300E?6?W!OC
M9IKQU_?&)1%X\^V7MSS66)93IHZ:-3XPHN>&>V95,6';T&ZK)HV&R4D-?Z15
MP [/8-HZ@\7>&4R;,[A+1S7AJ,5QO^23@W-@>%!RKW6CV-O\GJH-0R,Y))CE
MNR-,5]4-676,S,M+9BT-7EEE,\6/"E V ,<3*<U[Q]Y;S6?*_#]02P,$%
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M9:E$WH!U!7E:U)_L9T/$!@!'>P"D 9!# ;0!T+> ?24%#2 X%! V@/!00-0
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M,!/T^RWGZFU@#C+U.73^!U!+ P04    " "WA%E40%G:W@,#  !@"P  &0
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MPG=^U2QN&F3"NLSTO4STUN*V02:JR]QU,9IU<6C>&'PO;%[SR*QYU+KFLAZ
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M801SZ:QDMU)J&13*J& Z#%/='=M48[>JOZY!9&78L0#!>1@FO3OV&(>/O+M
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M@?Y](W29JQ.3H-[=F_\+4$L#!!0    ( +>$652&]"LVD ,  -<.   9
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M @&)=10,+UN8@!"."?WXIR -RG<Z8/W^*_L?/G@,9LX,3)3XQ!=V-0KZ 5E
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M+)V?HO*%56M_$)DKB\<:?[O"DR=H9X#[J4+M+Q;N;%.>9<?_ E!+ P04
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M,,.ZF@/5QJJ-?TK7RN+#[)<YCD[0S@"_ITK9_<81-,-X]@]02P,$%     @
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M^2I0%4>?6[I3V@O]+9%SRA5B,#,TK]DU?)G=D;.)%LOTFCD5VEQ:T^'"?%>
MM #S?B:$7D_LS;7X4AG^ U!+ P04    " "WA%E43PQD 9,"  !N!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6R-55U/VS 4_2M7$0\@0=,D+1LH
MC43IV)#HA&"PAVD/;G+;6#AV9SL4_OVNG31T?'1]2>R;>\X]QQ\WZ4KI!U,B
M6GBJA#2CH+1V>1J&)B^Q8J:GEBCIRUSIBEF:ZD5HEAI9X4&5".-^_SBL&)=!
MEOK8M<Y255O!)5YK,'55,?T\1J%6HR *UH$;OBBM"X19NF0+O$5[M[S6- L[
MEH)7* U7$C3.1\%9=#H9NGR?<,]Q93;&X)S,E'IPD\MB%/2=(!286\? Z/6(
MYRB$(R(9?UK.H"OI@)OC-?N%]TY>9LS@N1(_>6'+4? Y@ +GK!;V1JV^8>O'
M"\R5,/X)JS:W'T!>&ZNJ%DP**BZ;-WMJUV$#$!U_ (A;0/P:,/@ D+2 9%?
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M/#KSQ#3<2?&3%V8S"R8!*6#%ML(\R-V?<'!H:/ER*;3[);O#NW% \JTVLCR
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M"G.#_G_!N3H,3("R#Q[]!U!+ P04    " "WA%E4WWO=A5P#  "<"P  &0
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M\$%KS*(P-PCMYM;(0U#)F5;O161P)-?O!0<AN<(G.N43GH["L(W"\&(4=L_
M_TO_\'B3GG<D]]AK/.Z-#O2>= J]SN<?J'<[KVD.<FNKDD(Q)=?U^]%:V\+W
M8-_[ _L<"V)=O_[1U-7TB<HMXXIDL$%*K_<1LR+K"E4/M"CLF[T6&BN [:98
MU$$:!YS?"*%W [- ^S=A]A=02P,$%     @ MX195"R6?L[X P  L0\  !H
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M(#" X!00G@%T#:#;%A :0'@*Z)\!] R@U]9"WP#Z;0$# QBT!0P-8-@6,#*
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MU$A!U F:6?V*U3_&BII8_3V6[Q]B#2K6X!BKU\0:[.W@L!DTK$##5M"#_N@
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M    >&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6R]F%V/FS@4AO^*A7K12EW
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M!')\0ZDXWJ@)FO\'EK\!4$L#!!0    ( +>$653TVC!K' ,   H2   -
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M- N[T2SGRV:^S#L!&'L?9Z=5)5:?!"]DR=SF7QQP/*)KOV"N-'^TT:!59M;
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M'9]9.H<P;]W]7-Y#,9%V?&;M',)T^82XMG1(U$<"\ID%!!+:JH)23"0@GUE
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M=Y/"'8]E&D]S4?VIK^6-_6I_ZGR=IA?NV _SS<ID]\LSNU_-^?(?4$L#!!0
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MKWI[@-Y>]?8 O;WJ[0%Z!]4[ /0.JG< Z!U4[P#0.W0?2P!Z!]4[ /0.JG<
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M+GAM;%!+ 0(4 Q0    ( +>$650O8]:_[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +>$65297)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ MX195%ET.<4R!@  :QD  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +>$651&R=+B( (
M '0%   8              " @74.  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " "WA%E4-7RKS[('   X)0  &               @('+
M$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ MX195)(U
M]?/ !P  N1\  !@              ("!LQ@  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( +>$651EYO"A^0,  'H,   8
M  " @:D@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "W
MA%E4D?*0,3P(  #I*@  &               @('8)   >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ MX195,?=U:!K @  [04  !@
M         ("!2BT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( +>$653>CW!V  P  ,TY   8              " @>LO  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "WA%E4LV$C;LXL   =A@
M&               @($A/   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ MX195)^&:M&%$@  -5P  !D              ("!)6D  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "WA%E4\J;$S[D%
M   3#0  &0              @('A>P  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( +>$651H;&CN 0<  %P2   9              "
M@=&!  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ MX19
M5":M:]]7 P  1P<  !D              ("!"8D  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " "WA%E4!'1PP!,$  "6"   &0
M        @(&7C   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( +>$652&HIP:N 8  +P<   9              " @>&0  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ MX195#>#(DI.!@  >1
M !D              ("!T)<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " "WA%E4;-WEOPP'  "!%   &0              @(%5G@
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +>$650AK/:J
M$Q0  /Y    9              " @9BE  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ MX195)'OMB0&!P  :A   !D
M ("!XKD  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "W
MA%E4X+)6#A@(   Q&0  &0              @($?P0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( +>$652U*Y&+/0<  .81   9
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M970R-2YX;6Q02P$"% ,4    " "WA%E4R['Q7+<(   .%   &0
M    @(%B]P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M +>$653V=QR@^0H  *8;   9              " @5   0!X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ MX195"$6]%0A0   $M\  !D
M             ("!@ L! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " "WA%E4G(<G)OD'  !0%@  &0              @('82P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +>$653/SFRQ2P<
M ,D=   9              " @0A4 0!X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ MX195.I3_2#@ P  I @  !D              ("!
MBEL! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "WA%E4
M![<>9:@#   T"@  &0              @(&A7P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( +>$653C!SVL=0(  'P%   9
M      " @8!C 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ MX195$YVJQ>= P  8 @  !D              ("!+&8! 'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "WA%E4*D:[E/$%  !1$@
M&0              @($ :@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( +>$651^5M1C"08  ((0   9              " @2AP 0!X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ MX195%57"[AX
M!   T@H  !D              ("!:'8! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " "WA%E4 >.*SOL%   U$   &0
M@($7>P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( +>$
M652_8/9+00,  &P'   9              " @4F! 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ MX195!VD&87Q P  X0H  !D
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M=#0T+GAM;%!+ 0(4 Q0    ( +>$651O9(AT3 <  ,(2   9
M  " @3V= 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
MMX195*3E '3I P  > L  !D              ("!P*0! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " "WA%E4?'9*-XX)   %20  &0
M            @('@J $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( +>$651LA5K>#@,  .L,   9              " @:6R 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ MX195*C)<EZF P
MK1,  !D              ("!ZK4! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " "WA%E4B'(60#<(  !3,@  &0              @(''
MN0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( +>$650L
MNL0@L0D  #T_   9              " @37" 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ MX195 70'ZYV!P  =BD  !D
M     ("!'<P! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +>$652A##@SN0(  .P(   9              "
M@7SG 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ MX19
M5.5UBY&/ @  CP8  !D              ("!;.H! 'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    " "WA%E4.<%*UH0"   \!@  &0
M        @($R[0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( +>$650IA6NP?P(  "T'   9              " @>WO 0!X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ MX195*A'C['P P  .A(
M !D              ("!H_(! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    " "WA%E47R%JO?\!   J!   &0              @('*]@$
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( +>$65243/TO
MD (  *@&   9              " @0#Y 0!X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ MX195-K?5^\_ @  %P8  !D
M ("!Q_L! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "W
MA%E4AT=LAUT#  #8"@  &0              @($]_@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( +>$652:==A=V@,  &$.   9
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M970W,"YX;6Q02P$"% ,4    " "WA%E4E[8H?#T"   ,!@  &0
M    @('?$P( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    (
M +>$652H#I!#N00  'X8   9              " @5,6 @!X;"]W;W)K<VAE
M971S+W-H965T-S(N>&UL4$L! A0#%     @ MX195"TT#$%A @  W 4  !D
M             ("!0QL" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"
M% ,4    " "WA%E4JU^8F$L"  #/!0  &0              @(';'0( >&PO
M=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( +>$6502R;!2_P,
M %X.   9              " @5T@ @!X;"]W;W)K<VAE971S+W-H965T-S4N
M>&UL4$L! A0#%     @ MX195"X*Y>CV @  L@@  !D              ("!
MDR0" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " "WA%E4
M*<,^XSX&  ")&@  &0              @(' )P( >&PO=V]R:W-H965T<R]S
M:&5E=#<W+GAM;%!+ 0(4 Q0    ( +>$651U4LJ3S 0  )P9   9
M      " @34N @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%
M  @ MX195!</\/'_ @  DPH  !D              ("!.#," 'AL+W=O<FMS
M:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " "WA%E40%G:W@,#  !@"P
M&0              @(%N-@( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+
M 0(4 Q0    ( +>$6519DY!3Z H  $Q%   9              " @:@Y @!X
M;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ MX195'QPETIK
M!   Z1L  !D              ("!QT0" 'AL+W=O<FMS:&5E=',O<VAE970X
M,BYX;6Q02P$"% ,4    " "WA%E4AO0K-I #  #7#@  &0
M@(%I20( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( +>$
M650876JZ\0(  )@'   9              " @3!- @!X;"]W;W)K<VAE971S
M+W-H965T.#0N>&UL4$L! A0#%     @ MX195*AO'*L6!   B X  !D
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M=#@Y+GAM;%!+ 0(4 Q0    ( +>$651/#&0!DP(  &X&   9
M  " @4]D @!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @
MMX195 U)T7&5!@  OS$  !D              ("!&6<" 'AL+W=O<FMS:&5E
M=',O<VAE970Y,2YX;6Q02P$"% ,4    " "WA%E4>*/\,W\'  #S)   &0
M            @('E;0( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4
M Q0    ( +>$651M/^:=60,  !,-   9              " @9MU @!X;"]W
M;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @ MX195"_FO*SC P
M$P\  !D              ("!*WD" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX
M;6Q02P$"% ,4    " "WA%E4WWO=A5P#  "<"P  &0              @(%%
M?0( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( +>$650C
MG=O??P0  ",1   9              " @=B  @!X;"]W;W)K<VAE971S+W-H
M965T.38N>&UL4$L! A0#%     @ MX195&=.<R-0 P  N H  !D
M     ("!CH4" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4
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M,#$N>&UL4$L! A0#%     @ MX195 F^BXOF @  ,@@  !H
M ("!^9D" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @
MMX195"R6?L[X P  L0\  !H              ("!%YT" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,#,N>&UL4$L! A0#%     @ MX195->#>=WJ @  50@  !H
M             ("!1Z$" 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL4$L!
M A0#%     @ MX195'EZS @W!   5A0  !H              ("!::0" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%     @ MX195(/R$F@X
M!P  %20  !H              ("!V*@" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,#8N>&UL4$L! A0#%     @ MX195+ H6.'J P  & T  !H
M ("!2+ " 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N>&UL4$L! A0#%     @
MMX195,<+!VS^!0  NQ@  !H              ("!:K0" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,#@N>&UL4$L! A0#%     @ MX195#(:,8'0 P  *Q   !H
M             ("!H+H" 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL4$L!
M A0#%     @ MX195/3:,&L< P  "A(   T              ( !J+X" 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "WA%E4EXJ[',     3 @  "P
M        @ 'OP0( 7W)E;',O+G)E;'-02P$"% ,4    " "WA%E4]NWQRX('
M  "Y1P  #P              @ '8P@( >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ MX195!1DIV83 P  !$   !H              ( !A\H" 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ MX195-&<,ZAW @
MG3T  !,              ( !TLT" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     '4 =0 T(   >M "

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>515</ContextCount>
  <ElementCount>667</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>129</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100010003 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100020004 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100030005 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100040006 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100050007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100060008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210081002 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210141003 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210181004 - Disclosure - Cash and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecurities</Role>
      <ShortName>Cash and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210241005 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/AccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210271006 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210321007 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210401008 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210471009 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliates</Role>
      <ShortName>Investments in and Advances to Nonconsolidated Affiliates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210521010 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210601011 - Disclosure - Self-Insured Risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SelfInsuredRisks</Role>
      <ShortName>Self-Insured Risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210641012 - Disclosure - Redeemable Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests</Role>
      <ShortName>Redeemable Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210691013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210741014 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210801015 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210821016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210881017 - Disclosure - Earnings per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShare</Role>
      <ShortName>Earnings per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210931018 - Disclosure - Contingencies and Other Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ContingenciesandOtherCommitments</Role>
      <ShortName>Contingencies and Other Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>210951019 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>220022001 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>230033001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>230093002 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/BusinessCombinations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>230153003 - Disclosure - Variable Interest Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesTables</Role>
      <ShortName>Variable Interest Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/VariableInterestEntities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>230193004 - Disclosure - Cash and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables</Role>
      <ShortName>Cash and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/CashandMarketableSecurities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230253005 - Disclosure - Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/AccountsReceivable</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230283006 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/PropertyandEquipment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230333007 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230413008 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230483009 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables</Role>
      <ShortName>Investments in and Advances to Nonconsolidated Affiliates (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliates</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230533010 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/LongtermDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230613011 - Disclosure - Self-Insured Risks (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SelfInsuredRisksTables</Role>
      <ShortName>Self-Insured Risks (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SelfInsuredRisks</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230653012 - Disclosure - Redeemable Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables</Role>
      <ShortName>Redeemable Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230703013 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/FairValueMeasurements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230753014 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/ShareBasedPayments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230833015 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230893016 - Disclosure - Earnings Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsPerCommonShareTables</Role>
      <ShortName>Earnings Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230963017 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SegmentReporting</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>240044001 - Disclosure - Summary of Significant Accounting Policies - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>240054002 - Disclosure - Summary of Significant Accounting Policies - Net Operating Revenues &amp; Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Operating Revenues &amp; Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>240064003 - Disclosure - Summary of Significant Accounting Policies - PP&amp;E Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - PP&amp;E Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>240074004 - Disclosure - Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240104005 - Disclosure - Business Combinations - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails</Role>
      <ShortName>Business Combinations - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240114006 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240124007 - Disclosure - Business Combinations - Net Cash Paid for Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails</Role>
      <ShortName>Business Combinations - Net Cash Paid for Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240134008 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails</Role>
      <ShortName>Business Combinations - Pro Forma Results of Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240164009 - Disclosure - Variable Interest Entities - Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails</Role>
      <ShortName>Variable Interest Entities - Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240174010 - Disclosure - Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails</Role>
      <ShortName>Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240204011 - Disclosure - Cash and Marketable Securities - Components of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails</Role>
      <ShortName>Cash and Marketable Securities - Components of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240214012 - Disclosure - Cash and Marketable Securities - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails</Role>
      <ShortName>Cash and Marketable Securities - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240224013 - Disclosure - Cash and Marketable Securities - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails</Role>
      <ShortName>Cash and Marketable Securities - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240234014 - Disclosure - Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails</Role>
      <ShortName>Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240264015 - Disclosure - Accounts Receivable - Components of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable - Components of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240294016 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240304017 - Disclosure - Property and Equipment - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails</Role>
      <ShortName>Property and Equipment - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240314018 - Disclosure - Property and Equipment - Depreciation, Capitalized Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails</Role>
      <ShortName>Property and Equipment - Depreciation, Capitalized Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240344019 - Disclosure - Leases - Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesTextualsDetails</Role>
      <ShortName>Leases - Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240354020 - Disclosure - Leases - Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails</Role>
      <ShortName>Leases - Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240364021 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240374022 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails</Role>
      <ShortName>Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240384023 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240394024 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240424025 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240434026 - Disclosure - Goodwill and Other Intangible Assets - Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240444027 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240454028 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240464029 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240494030 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails</Role>
      <ShortName>Investments in and Advances to Nonconsolidated Affiliates - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240504031 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Schedule of Other Long-term Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails</Role>
      <ShortName>Investments in and Advances to Nonconsolidated Affiliates - Schedule of Other Long-term Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240514032 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Combined Assets, Liabilities and Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails</Role>
      <ShortName>Investments in and Advances to Nonconsolidated Affiliates - Combined Assets, Liabilities and Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240544033 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails</Role>
      <ShortName>Long-term Debt - Long-term Debt Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240554034 - Disclosure - Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails</Role>
      <ShortName>Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240564035 - Disclosure - Long-term Debt - Financial Covenants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails</Role>
      <ShortName>Long-term Debt - Financial Covenants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240574036 - Disclosure - Long-term Debt - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtTextualDetails</Role>
      <ShortName>Long-term Debt - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240584037 - Disclosure - Long-term Debt - Senior Notes Redemption Prices (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails</Role>
      <ShortName>Long-term Debt - Senior Notes Redemption Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240594038 - Disclosure - Long-term Debt - Schedule of Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails</Role>
      <ShortName>Long-term Debt - Schedule of Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240624039 - Disclosure - Self-Insured Risks - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails</Role>
      <ShortName>Self-Insured Risks - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240634040 - Disclosure - Self-Insured Risks - Changes in Self-insurance Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails</Role>
      <ShortName>Self-Insured Risks - Changes in Self-insurance Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240664041 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240674042 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240684043 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240714044 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240724045 - Disclosure - Fair Value Measurements - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails</Role>
      <ShortName>Fair Value Measurements - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240734046 - Disclosure - Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240764047 - Disclosure - Share-Based Payments - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails</Role>
      <ShortName>Share-Based Payments - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240774048 - Disclosure - Share-Based Payments - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails</Role>
      <ShortName>Share-Based Payments - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240784049 - Disclosure - Share-Based Payments - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails</Role>
      <ShortName>Share-Based Payments - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240794050 - Disclosure - Share-Based Payments - Summary of Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails</Role>
      <ShortName>Share-Based Payments - Summary of Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240814051 - Disclosure - Employee Benefit Plans - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails</Role>
      <ShortName>Employee Benefit Plans - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240844052 - Disclosure - Income Taxes - Components of Provision for Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Provision for Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240854053 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240864054 - Disclosure - Income Taxes - Deferred Tax Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240874055 - Disclosure - Income Taxes - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesTextualDetails</Role>
      <ShortName>Income Taxes - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240904056 - Disclosure - Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails</Role>
      <ShortName>Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240914057 - Disclosure - Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails</Role>
      <ShortName>Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240924058 - Disclosure - Earnings Per Common Share - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails</Role>
      <ShortName>Earnings Per Common Share - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240944059 - Disclosure - Contingencies and Other Commitments - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails</Role>
      <ShortName>Contingencies and Other Commitments - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240974060 - Disclosure - Segment Reporting - Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingTextualsDetails</Role>
      <ShortName>Segment Reporting - Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240984061 - Disclosure - Segment Reporting - Selected Financial Information of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails</Role>
      <ShortName>Segment Reporting - Selected Financial Information of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240994062 - Disclosure - Segment Reporting - Reconciliation of Segment Assets and Investments to Consolidated Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Assets and Investments to Consolidated Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>241004063 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="ehc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>241014064 - Disclosure - Segment Reporting - Revenues of Operating Segments by Service Line (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails</Role>
      <ShortName>Segment Reporting - Revenues of Operating Segments by Service Line (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ehc-20211231.htm">ehc-20211231.htm</File>
    <File>ehc-20211231.xsd</File>
    <File>ehc-20211231_cal.xml</File>
    <File>ehc-20211231_def.xml</File>
    <File>ehc-20211231_lab.xml</File>
    <File>ehc-20211231_pre.xml</File>
    <File>ehc10k123121ex211.htm</File>
    <File>ehc10k123121ex221.htm</File>
    <File>ehc10k123121ex231.htm</File>
    <File>ehc10k123121ex311.htm</File>
    <File>ehc10k123121ex312.htm</File>
    <File>ehc10k123121ex321.htm</File>
    <File>ehc10k123121ex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ehc-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1740">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>130
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ehc-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 38,
   "contextCount": 515,
   "dts": {
    "calculationLink": {
     "local": [
      "ehc-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ehc-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ehc-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ehc-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ehc-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ehc-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 924,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 10
   },
   "keyCustom": 96,
   "keyStandard": 571,
   "memberCustom": 71,
   "memberStandard": 54,
   "nsprefix": "ehc",
   "nsuri": "http://www.encompasshealth.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover Page",
     "role": "http://www.encompasshealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210081002 - Disclosure - Business Combinations",
     "role": "http://www.encompasshealth.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874055 - Disclosure - Income Taxes - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails",
     "shortName": "Income Taxes - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240904056 - Disclosure - Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)",
     "role": "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
     "shortName": "Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914057 - Disclosure - Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails",
     "shortName": "Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240924058 - Disclosure - Earnings Per Common Share - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails",
     "shortName": "Earnings Per Common Share - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240944059 - Disclosure - Contingencies and Other Commitments - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails",
     "shortName": "Contingencies and Other Commitments - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240974060 - Disclosure - Segment Reporting - Textuals (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
     "shortName": "Segment Reporting - Textuals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984061 - Disclosure - Segment Reporting - Selected Financial Information of Reportable Segments (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails",
     "shortName": "Segment Reporting - Selected Financial Information of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i49fbd10e90fa4818b8b4a8b5346b3cd5_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994062 - Disclosure - Segment Reporting - Reconciliation of Segment Assets and Investments to Consolidated Amounts (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Assets and Investments to Consolidated Amounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "iec5091f5ce8647a69ad189e4df7acdc5_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241004063 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i2b20d1c1a4664c29b6e46e8c2743fd6d_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ehc:AdjustedEBITDA",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241014064 - Disclosure - Segment Reporting - Revenues of Operating Segments by Service Line (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails",
     "shortName": "Segment Reporting - Revenues of Operating Segments by Service Line (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i31a9deb44ebc4734990673dcfd5a1fa2_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210141003 - Disclosure - Variable Interest Entities",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntities",
     "shortName": "Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210181004 - Disclosure - Cash and Marketable Securities",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecurities",
     "shortName": "Cash and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210241005 - Disclosure - Accounts Receivable",
     "role": "http://www.encompasshealth.com/role/AccountsReceivable",
     "shortName": "Accounts Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210271006 - Disclosure - Property and Equipment",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210321007 - Disclosure - Leases",
     "role": "http://www.encompasshealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210401008 - Disclosure - Goodwill and Other Intangible Assets",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210471009 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates",
     "role": "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliates",
     "shortName": "Investments in and Advances to Nonconsolidated Affiliates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210521010 - Disclosure - Long-term Debt",
     "role": "http://www.encompasshealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210601011 - Disclosure - Self-Insured Risks",
     "role": "http://www.encompasshealth.com/role/SelfInsuredRisks",
     "shortName": "Self-Insured Risks",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "000020002 - Document - Audit Information",
     "role": "http://www.encompasshealth.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210641012 - Disclosure - Redeemable Noncontrolling Interests",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests",
     "shortName": "Redeemable Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210691013 - Disclosure - Fair Value Measurements",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210741014 - Disclosure - Share-Based Payments",
     "role": "http://www.encompasshealth.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210801015 - Disclosure - Employee Benefit Plans",
     "role": "http://www.encompasshealth.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210821016 - Disclosure - Income Taxes",
     "role": "http://www.encompasshealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210881017 - Disclosure - Earnings per Common Share",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShare",
     "shortName": "Earnings per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210931018 - Disclosure - Contingencies and Other Commitments",
     "role": "http://www.encompasshealth.com/role/ContingenciesandOtherCommitments",
     "shortName": "Contingencies and Other Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210951019 - Disclosure - Segment Reporting",
     "role": "http://www.encompasshealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220022001 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230033001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010003 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230093002 - Disclosure - Business Combinations (Tables)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230153003 - Disclosure - Variable Interest Entities (Tables)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesTables",
     "shortName": "Variable Interest Entities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230193004 - Disclosure - Cash and Marketable Securities (Tables)",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables",
     "shortName": "Cash and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230253005 - Disclosure - Accounts Receivable (Tables)",
     "role": "http://www.encompasshealth.com/role/AccountsReceivableTables",
     "shortName": "Accounts Receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230283006 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230333007 - Disclosure - Leases (Tables)",
     "role": "http://www.encompasshealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230413008 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230483009 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates (Tables)",
     "role": "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables",
     "shortName": "Investments in and Advances to Nonconsolidated Affiliates (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230533010 - Disclosure - Long-term Debt (Tables)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230613011 - Disclosure - Self-Insured Risks (Tables)",
     "role": "http://www.encompasshealth.com/role/SelfInsuredRisksTables",
     "shortName": "Self-Insured Risks (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020004 - Statement - Consolidated Balance Sheets",
     "role": "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230653012 - Disclosure - Redeemable Noncontrolling Interests (Tables)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables",
     "shortName": "Redeemable Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230703013 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230753014 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230833015 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230893016 - Disclosure - Earnings Per Common Share (Tables)",
     "role": "http://www.encompasshealth.com/role/EarningsPerCommonShareTables",
     "shortName": "Earnings Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230963017 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240044001 - Disclosure - Summary of Significant Accounting Policies - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
     "shortName": "Summary of Significant Accounting Policies - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240054002 - Disclosure - Summary of Significant Accounting Policies - Net Operating Revenues & Accounts Receivable (Details)",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Operating Revenues & Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i3a7f4b3fa057413aa60a6ff5a64dbacd_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i86b3dd4016124cdc94f5fc2e5ae4ee7c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064003 - Disclosure - Summary of Significant Accounting Policies - PP&E Useful Lives (Details)",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - PP&E Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i86b3dd4016124cdc94f5fc2e5ae4ee7c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i50efb55c2089401caaa0a82d59fa749b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074004 - Disclosure - Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i50efb55c2089401caaa0a82d59fa749b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030005 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104005 - Disclosure - Business Combinations - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
     "shortName": "Business Combinations - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i45c128c0259a41b39e92b5c3cc9150de_D20190701-20190731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240114006 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
     "shortName": "Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ie9eedb5d92f94ea99ae509bc1e6bab38_I20210731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124007 - Disclosure - Business Combinations - Net Cash Paid for Acquisition (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
     "shortName": "Business Combinations - Net Cash Paid for Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i95e6c12052b947fca1d97db42e6e9864_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueOfAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i53030c89936d407897671309bbeb1f7b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134008 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
     "shortName": "Business Combinations - Pro Forma Results of Operation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i53030c89936d407897671309bbeb1f7b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ib73cbdd803994190950116ec559457fb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:VariableInterestEntityNumberofEntitiesConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "entity",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164009 - Disclosure - Variable Interest Entities - Textuals (Details)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails",
     "shortName": "Variable Interest Entities - Textuals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ib73cbdd803994190950116ec559457fb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:VariableInterestEntityNumberofEntitiesConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "entity",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174010 - Disclosure - Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
     "shortName": "Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i879908aa2e6542e3a0652e1ed683b4b1_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240204011 - Disclosure - Cash and Marketable Securities - Components of Investments (Details)",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails",
     "shortName": "Cash and Marketable Securities - Components of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240214012 - Disclosure - Cash and Marketable Securities - Restricted Cash (Details)",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails",
     "shortName": "Cash and Marketable Securities - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:RestrictedDebtSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240224013 - Disclosure - Cash and Marketable Securities - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails",
     "shortName": "Cash and Marketable Securities - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:RestrictedDebtSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRealizedGainLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234014 - Disclosure - Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails",
     "shortName": "Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRealizedGainLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0cab8f26574d455bb0e444a22064322e_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040006 - Statement - Consolidated Statements of Shareholders' Equity",
     "role": "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0cab8f26574d455bb0e444a22064322e_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240264015 - Disclosure - Accounts Receivable - Components of Accounts Receivable (Details)",
     "role": "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails",
     "shortName": "Accounts Receivable - Components of Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294016 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Components of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i6b3f7a9c05fa4726b65312cfe7ac7a5b_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ehc:Percentageofassetspledgedtolendersundercreditagreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304017 - Disclosure - Property and Equipment - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails",
     "shortName": "Property and Equipment - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ehc:Percentageofassetspledgedtolendersundercreditagreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314018 - Disclosure - Property and Equipment - Depreciation, Capitalized Interest Expense (Details)",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails",
     "shortName": "Property and Equipment - Depreciation, Capitalized Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "if750783979f34735a047752b07b25985_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ehc:Operatingandfinanceleasecontractterm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344019 - Disclosure - Leases - Textuals (Details)",
     "role": "http://www.encompasshealth.com/role/LeasesTextualsDetails",
     "shortName": "Leases - Textuals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "if750783979f34735a047752b07b25985_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ehc:Operatingandfinanceleasecontractterm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354020 - Disclosure - Leases - Components of Lease Costs (Details)",
     "role": "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails",
     "shortName": "Leases - Components of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364021 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "role": "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240374022 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "role": "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails",
     "shortName": "Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240384023 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "role": "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:SupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394024 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "role": "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:SupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "role": "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idb5aa4ae49684bf895fa6b9c4d819454_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240424025 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails",
     "shortName": "Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ehc:GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ic844601724a84290b07683e4c14534a9_D20211001-20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240434026 - Disclosure - Goodwill and Other Intangible Assets - Textuals (Details)",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails",
     "shortName": "Goodwill and Other Intangible Assets - Textuals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ic844601724a84290b07683e4c14534a9_D20211001-20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444027 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets - Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454028 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464029 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:NumberOfPartiallyOwnedSubsidiariesNonconsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494030 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails",
     "shortName": "Investments in and Advances to Nonconsolidated Affiliates - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:NumberOfPartiallyOwnedSubsidiariesNonconsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240504031 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Schedule of Other Long-term Assets (Details)",
     "role": "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails",
     "shortName": "Investments in and Advances to Nonconsolidated Affiliates - Schedule of Other Long-term Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514032 - Disclosure - Investments in and Advances to Nonconsolidated Affiliates - Combined Assets, Liabilities and Equity (Details)",
     "role": "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails",
     "shortName": "Investments in and Advances to Nonconsolidated Affiliates - Combined Assets, Liabilities and Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "iee1bde62ffe249dfa8317c6305c6c843_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240544033 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
     "shortName": "Long-term Debt - Long-term Debt Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:LongTermDebtAndLeaseObligationsMaturityYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240554034 - Disclosure - Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
     "shortName": "Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ib8c36dcc9f764af7a4f206552ce0bcf0_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:LongTermDebtAndLeaseObligationsMaturityYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ehc:ScheduleOfFinancialCovenantsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ie5fed9bbb5d24489bde193826b885d42_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:DebtInstrumentCovenantInterestCoverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240564035 - Disclosure - Long-term Debt - Financial Covenants (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
     "shortName": "Long-term Debt - Financial Covenants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ehc:ScheduleOfFinancialCovenantsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ie5fed9bbb5d24489bde193826b885d42_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:DebtInstrumentCovenantInterestCoverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574036 - Disclosure - Long-term Debt - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
     "shortName": "Long-term Debt - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ibc45972689104b858888baba8d5c3b2a_I20211209",
      "decimals": "-6",
      "lang": "en-US",
      "name": "ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ibdd006cc199943069830e5f0df2c5322_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584037 - Disclosure - Long-term Debt - Senior Notes Redemption Prices (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
     "shortName": "Long-term Debt - Senior Notes Redemption Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtInstrumentRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i05599bd9faa5433482a7fd2c5e801eff_D20150901-20150930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i95660f8d813c4751ade79f135d5b3a25_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594038 - Disclosure - Long-term Debt - Schedule of Notes Payable (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
     "shortName": "Long-term Debt - Schedule of Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "iff05368e33294deaba91e4d0daedb5b5_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:MaximumSelfInsuredAmountFirstLayerOfRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240624039 - Disclosure - Self-Insured Risks - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails",
     "shortName": "Self-Insured Risks - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:MaximumSelfInsuredAmountFirstLayerOfRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idb5aa4ae49684bf895fa6b9c4d819454_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240634040 - Disclosure - Self-Insured Risks - Changes in Self-insurance Reserves (Details)",
     "role": "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails",
     "shortName": "Self-Insured Risks - Changes in Self-insurance Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i1769921a6d9648258a5bf2ec2f81c72c_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idb5aa4ae49684bf895fa6b9c4d819454_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240664041 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
     "shortName": "Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "iaa910c45e3ba432986f5de81016e67f2_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240674042 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
     "shortName": "Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684043 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
     "shortName": "Redeemable Noncontrolling Interests - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ie9a724185f6047b2a7b0f3655af7f015_D20200101-20200131",
      "decimals": "3",
      "lang": "en-US",
      "name": "ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ied40dc1098204db7afa17d466e5ee54c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714044 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ied40dc1098204db7afa17d466e5ee54c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ic07a527a70c444b8aa8dc851c08e1454_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724045 - Disclosure - Fair Value Measurements - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails",
     "shortName": "Fair Value Measurements - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ic07a527a70c444b8aa8dc851c08e1454_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i20ffead8b6274baf8242167d98ee9096_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734046 - Disclosure - Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i20ffead8b6274baf8242167d98ee9096_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764047 - Disclosure - Share-Based Payments - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
     "shortName": "Share-Based Payments - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ic2f42760e052466297d45ac5cbad1140_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774048 - Disclosure - Share-Based Payments - Weighted-average Assumptions (Details)",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails",
     "shortName": "Share-Based Payments - Weighted-average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "ic2f42760e052466297d45ac5cbad1140_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idb5aa4ae49684bf895fa6b9c4d819454_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784049 - Disclosure - Share-Based Payments - Stock Option Activity (Details)",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails",
     "shortName": "Share-Based Payments - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idb5aa4ae49684bf895fa6b9c4d819454_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i6650fab69c11492c9077744e36f1f4c0_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794050 - Disclosure - Share-Based Payments - Summary of Restricted Stock Awards (Details)",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
     "shortName": "Share-Based Payments - Summary of Restricted Stock Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i041f4e433735445c9c4b0b275631ba31_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:HealthcarePlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814051 - Disclosure - Employee Benefit Plans - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails",
     "shortName": "Employee Benefit Plans - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:HealthcarePlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844052 - Disclosure - Income Taxes - Components of Provision for Income Tax Expense (Details)",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails",
     "shortName": "Income Taxes - Components of Provision for Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854053 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "i0e94b8af65474af790515c80eb731e5c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864054 - Disclosure - Income Taxes - Deferred Tax Asset and Liabilities (Details)",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Asset and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20211231.htm",
      "contextRef": "idfa9d6dc91c64c829cb06ea80b8c0282_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 129,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ehc_A2016OmnibusPerformanceIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Omnibus Performance Incentive Plan [Member]",
        "label": "2016 Omnibus Performance Incentive Plan [Member]",
        "terseLabel": "2016 Omnibus Performance Incentive Plan"
       }
      }
     },
     "localname": "A2016OmnibusPerformanceIncentivePlanMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_A2019AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2019 Acquisitions",
        "label": "A2019 Acquisitions [Member]",
        "terseLabel": "2019 Acquisitions"
       }
      }
     },
     "localname": "A2019AcquisitionsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_A2020AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Acquisitions",
        "label": "2020 Acquisitions [Member]",
        "terseLabel": "2020 Acquisitions"
       }
      }
     },
     "localname": "A2020AcquisitionsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_A2021AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Acquisitions",
        "label": "2021 Acquisitions [Member]",
        "terseLabel": "2021 Acquisitions"
       }
      }
     },
     "localname": "A2021AcquisitionsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_AdjustedEBITDA": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.",
        "label": "Adjusted EBITDA",
        "terseLabel": "Segment Adjusted EBITDA",
        "verboseLabel": "Total Segment Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEBITDA",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_AffiliateCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash held and maintained by joint ventures in which we have an ownership interest.",
        "label": "Affiliate Cash [Member]",
        "terseLabel": "Affiliate cash"
       }
      }
     },
     "localname": "AffiliateCashMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_AffiliatesOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership by the Company in the investee accounted for under the equity or cost methods of accounting.",
        "label": "Affiliates Ownership Percentage",
        "terseLabel": "Affiliates ownership percentage"
       }
      }
     },
     "localname": "AffiliatesOwnershipPercentage",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_AlacareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alacare Home Health &amp; Hospice (\"Alacare\") [Member]",
        "label": "Alacare [Member]",
        "terseLabel": "Alacare"
       }
      }
     },
     "localname": "AlacareMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_AllocatedSharebasedCompensationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocated Share-based Compensation Liability",
        "label": "Allocated Share-based Compensation Liability",
        "terseLabel": "Fair value of SARs"
       }
      }
     },
     "localname": "AllocatedSharebasedCompensationLiability",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ehc_BaptistOutpatientServicesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baptist Outpatient Services, Inc",
        "label": "Baptist Outpatient Services, Inc [Member]",
        "terseLabel": "Baptist Outpatient Services, Inc"
       }
      }
     },
     "localname": "BaptistOutpatientServicesIncMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_BusinessCombinationNoncontrollingInterestFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Noncontrolling Interest, Fair Value",
        "label": "Business Combination, Noncontrolling Interest, Fair Value",
        "negatedLabel": "Fair value of redeemable noncontrolling interest owned by joint venture partner"
       }
      }
     },
     "localname": "BusinessCombinationNoncontrollingInterestFairValue",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets",
        "terseLabel": "Operating lease right-of-use-assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued payroll assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Payroll",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_CareResourceGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Care Resource Group [Member]",
        "label": "Care Resource Group [Member]",
        "terseLabel": "Care Resource Group"
       }
      }
     },
     "localname": "CareResourceGroupMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]",
        "label": "Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A statement or certificate issued by a governmental agency for proposed construction or modification of a health facility. The certificate process is intended to prevent duplication of services in a community.",
        "label": "Certificate of Need [Member]",
        "verboseLabel": "Certificates of need"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Contributiontojointventure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution of primarily intangible assets relating to a joint venture agreement.",
        "label": "Contribution to joint venture",
        "terseLabel": "Contribution to joint ventures"
       }
      }
     },
     "localname": "Contributiontojointventure",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_CostofServicesExcludingDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.",
        "label": "Cost of Services, Excluding Depreciation and Amortization",
        "terseLabel": "Cost of services (excluding depreciation and amortization)"
       }
      }
     },
     "localname": "CostofServicesExcludingDepreciationandAmortization",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_CreditAgreementRestriction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "We are restricted from paying common stock dividends, prepaying certain senior notes, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the Credit Agreement and (2)\u00a0the amount of such payments, when added to the aggregate amount of prior restricted payments (as defined in the Credit Agreement) does not exceed $200 million, which amount is subject to increase by a portion of excess cash flows each fiscal year.",
        "label": "Credit Agreement, Restriction",
        "terseLabel": "Payment limit under the credit agreement's negative covenant"
       }
      }
     },
     "localname": "CreditAgreementRestriction",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DebtInstrumentAmendmentAgreementAmountToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Amendment Agreement, Amount To Be Paid",
        "label": "Debt Instrument, Amendment Agreement, Amount To Be Paid",
        "terseLabel": "Amendment agreement, amount to be paid"
       }
      }
     },
     "localname": "DebtInstrumentAmendmentAgreementAmountToBePaid",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DebtInstrumentCovenantInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio",
        "terseLabel": "Interest Coverage Ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatio",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentCovenantLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio",
        "label": "Debt Instrument, Covenant, Leverage Ratio",
        "terseLabel": "Leverage Ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatio",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Max senior secured leverage ratio to permit restricted payments under credit agreement.",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Senior secured leverage ratio maximum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Discount Rate at Issuance of Face Value",
        "label": "Debt Instrument, Discount Rate At Issuance Of Face Value",
        "terseLabel": "Issuance of face value (percent)"
       }
      }
     },
     "localname": "DebtInstrumentDiscountRateAtIssuanceOfFaceValue",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_DebtInstrumentIssuePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Par value of debt instrument issued plus or minus a premium or a discount.",
        "label": "Debt Instrument, Issue Price, Percentage",
        "terseLabel": "Debt issue price as percentage of principal (percent)"
       }
      }
     },
     "localname": "DebtInstrumentIssuePricePercentage",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage owed on principal amount outstanding for amounts drawn under the debt instrument.",
        "label": "Debt Instrument, Periodic Payment, Percentage of Principal Outstanding",
        "terseLabel": "Percentage of aggregate principal amount outstanding (percent)"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentageofPrincipalOutstanding",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket",
        "label": "Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket",
        "terseLabel": "Debt instrument, reduction in capacity under restricted payments builder basket"
       }
      }
     },
     "localname": "DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount",
        "label": "Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount",
        "terseLabel": "Employer contributions funded by forfeited accounts"
       }
      }
     },
     "localname": "DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DividendEquivalentRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Equivalent, RSU [Member]",
        "label": "Dividend Equivalent, RSU [Member]",
        "terseLabel": "Dividend Equivalent, RSU"
       }
      }
     },
     "localname": "DividendEquivalentRSUMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ECHDVenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ECHD Ventures",
        "label": "ECHD Ventures [Member]",
        "terseLabel": "ECHD Ventures"
       }
      }
     },
     "localname": "ECHDVenturesMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_EHHIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EHHI [Member]",
        "label": "EHHI [Member]",
        "terseLabel": "EHHI"
       }
      }
     },
     "localname": "EHHIMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, percent",
        "label": "Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, Percent",
        "terseLabel": "Share-based windfall tax benefits (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_EmploymentBasedSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Based SARS [Member]",
        "label": "Employment Based SARS [Member]",
        "terseLabel": "Employment Based SARS"
       }
      }
     },
     "localname": "EmploymentBasedSARSMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_EncompassHealthRetirementInvestmentPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Encompass Health Retirement Investment Plan [Member]",
        "label": "Encompass Health Retirement Investment Plan [Member]",
        "terseLabel": "Encompass Health Retirement Investment Plan"
       }
      }
     },
     "localname": "EncompassHealthRetirementInvestmentPlanMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_EncompassHomeHealthSavingsPlanHHSPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Encompass Home Health Savings Plan HHSP [Member]",
        "label": "Encompass Home Health Savings Plan HHSP [Member]",
        "terseLabel": "Encompass Home Health Savings Plan HHSP"
       }
      }
     },
     "localname": "EncompassHomeHealthSavingsPlanHHSPMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_EquityMethodInvestmentAdditionalOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Additional Ownership Percentage",
        "label": "Equity Method Investment, Additional Ownership Percentage",
        "terseLabel": "Equity method investment, additional ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalOwnershipPercentage",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Company's cumulative and proportionate receipt of distributed earnings since inception of its investment in an equity method affiliate.",
        "label": "Equity Method Investments, Accumulated Dividends or Distributions from Equity Method Investments",
        "terseLabel": "Cumulative share of distributions"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAccumulatedDividendsorDistributionsfromEquityMethodInvestments",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Company's cumulative and proportionate share of income earned since inception of its investment in an equity method affiliate as of the balance sheet date.",
        "label": "Equity Method Investments, Accumulated Income (Loss) from Equity Method Investments",
        "terseLabel": "Cumulative share of income"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAccumulatedIncomeLossfromEquityMethodInvestments",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_FaceAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount.",
        "label": "Face Amount [Member]",
        "terseLabel": "Face Amount"
       }
      }
     },
     "localname": "FaceAmountMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in the sixth fiscal year following the latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Six And Thereafter",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_FrontierHomeHealthAndHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frontier Home Health And Hospice",
        "label": "Frontier Home Health And Hospice [Member]",
        "terseLabel": "Frontier Home Health And Hospice"
       }
      }
     },
     "localname": "FrontierHomeHealthAndHospiceMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_GenerationSolutionsOfLynchburgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generation Solutions of Lynchburg",
        "label": "Generation Solutions of Lynchburg [Member]",
        "terseLabel": "Generation Solutions of Lynchburg"
       }
      }
     },
     "localname": "GenerationSolutionsOfLynchburgMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Consolidation Of Joint Venture Formerly Accounted For Under Equity Method",
        "label": "Goodwill, Consolidation Of Joint Venture Formerly Accounted For Under Equity Method",
        "terseLabel": "Consolidation of joint venture formerly accounted for under the equity method of accounting"
       }
      }
     },
     "localname": "GoodwillConsolidationOfJointVentureFormerlyAccountedForUnderEquityMethod",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_HealthcarePlanExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs for the period associated with the Company's sponsored self-insured healthcare plans that include coverage for medical and dental benefits.",
        "label": "Healthcare Plan Expense",
        "terseLabel": "Company healthcare plan costs, net of employee payments"
       }
      }
     },
     "localname": "HealthcarePlanExpense",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_HeartOfTheRockiesHomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heart of the Rockies Home Health",
        "label": "Heart of the Rockies Home Health [Member]",
        "terseLabel": "Heart of the Rockies Home Health"
       }
      }
     },
     "localname": "HeartOfTheRockiesHomeHealthMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HeritageValleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heritage Valley [Member]",
        "label": "Heritage Valley [Member]",
        "terseLabel": "Heritage Valley"
       }
      }
     },
     "localname": "HeritageValleyMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HoldingsAndEHHIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Holdings And EHHI [Member]",
        "label": "Holdings And EHHI [Member]",
        "terseLabel": "Holdings And EHHI"
       }
      }
     },
     "localname": "HoldingsAndEHHIMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HomeHealthandHospiceSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health and Hospice Segment [Member]",
        "label": "Home Health and Hospice Segment [Member]",
        "terseLabel": "Home Health and Hospice",
        "verboseLabel": "Home Health and Hospice"
       }
      }
     },
     "localname": "HomeHealthandHospiceSegmentMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HomehealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home health [Member]",
        "label": "Home health [Member]",
        "terseLabel": "Home health"
       }
      }
     },
     "localname": "HomehealthMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HospiceOfSouthwestMontanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice of Southwest Montana",
        "label": "Hospice of Southwest Montana [Member]",
        "terseLabel": "Hospice of Southwest Montana"
       }
      }
     },
     "localname": "HospiceOfSouthwestMontanaMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "ehc_NetIncomeLossAvailabletoCommonStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.",
        "label": "Income Loss from Continuing Operations Attributable to Common Shareholders Basic",
        "totalLabel": "Income from continuing operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss from continuing operations attributable to common shareholders diluted.",
        "label": "Income Loss from Continuing Operations Attributable to Common Shareholders Diluted",
        "totalLabel": "Income from continuing operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_InpatientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inpatient [Member]",
        "label": "Inpatient [Member]",
        "terseLabel": "Inpatient"
       }
      }
     },
     "localname": "InpatientMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_InpatientRehabilitationSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inpatient Rehabilitation Segment [Member]",
        "label": "Inpatient Rehabilitation Segment [Member]",
        "terseLabel": "Inpatient Rehabilitation",
        "verboseLabel": "Inpatient Rehabilitation Segment"
       }
      }
     },
     "localname": "InpatientRehabilitationSegmentMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_InternalUseSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalizable costs for computer software developed internally by the Company which will have future probable benefits to the Company.",
        "label": "Internal Use Software [Member]",
        "terseLabel": "Internal-use software"
       }
      }
     },
     "localname": "InternalUseSoftwareMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_InvestmentsCashandRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total investments of the Company which includes cash, cash equivalents, restricted cash, and marketable securities.",
        "label": "Investments, Cash and Restricted Cash",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InvestmentsCashandRestrictedCash",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Jointventureownershippercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint venture ownership percentage",
        "label": "Joint venture ownership percentage",
        "terseLabel": "Joint venture ownership percentage"
       }
      }
     },
     "localname": "Jointventureownershippercentage",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_JupiterFloridaHomeHealthAgencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jupiter Florida Home Health Agency",
        "label": "Jupiter Florida Home Health Agency [Member]",
        "terseLabel": "Jupiter Florida Home Health Agency"
       }
      }
     },
     "localname": "JupiterFloridaHomeHealthAgencyMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Land, Building, Improvements, Equipment, Vehicles and Furniture [Member]",
        "label": "Land, Building, Improvements, Equipment, Vehicles and Furniture [Member]",
        "terseLabel": "Land, Building, Improvements, Equipment, Vehicles and Furniture"
       }
      }
     },
     "localname": "LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Six And Thereafter",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations",
        "negatedTerseLabel": "Expenses related to discontinued operations"
       }
      }
     },
     "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of the Company's long-lived assets and intangible assets with finite lives.",
        "label": "Long-lived Assets and Other Intangible Assets, Impairment [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets and Other Intangible Assets"
       }
      }
     },
     "localname": "LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, After Year Five",
        "label": "Long-Term Debt And Lease Obligations, Maturity, After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityAfterYearFive",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year Five",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearFive",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year Four",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearFour",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year One",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearOne",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year Three",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearThree",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year Two",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearTwo",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum dollar amount that must be accrued for a loss contingency related to a specific legal dispute that can be utilized for consideration prior to accruing an estimate of the legal fees related to this specific legal dispute.",
        "label": "Loss Contingency, Minimum Amount to Consider Accruing an Estimate of Related Legal Fees",
        "terseLabel": "Minimum accrual of loss contingency needed to accrue for related legal fees"
       }
      }
     },
     "localname": "LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Managed Care, Medicare Advantage and Other Discount Plans [Member]",
        "label": "Managed Care, Medicare Advantage and Other Discount Plans [Member]",
        "terseLabel": "Managed care and other discount plans, including Medicare Advantage"
       }
      }
     },
     "localname": "ManagedCareMedicareAdvantageandOtherDiscountPlansMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Managed Care [Member]",
        "label": "Managed Care [Member]",
        "terseLabel": "Managed Care"
       }
      }
     },
     "localname": "ManagedCareMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MarketAccessAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalizable costs associated with gaining access to and pentetrating a historical market base.",
        "label": "Market Access Assets [Member]",
        "verboseLabel": "Market access assets"
       }
      }
     },
     "localname": "MarketAccessAssetsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MaximumSelfInsuredAmountFirstLayerOfRisk": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Self Insured Amount, First Layer of Risk",
        "label": "Maximum Self Insured Amount, First Layer of Risk",
        "terseLabel": "Self-insured amount"
       }
      }
     },
     "localname": "MaximumSelfInsuredAmountFirstLayerOfRisk",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_MaximumSelfInsuredAmountThirdLayerRisk": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Self Insured Amount, Third Layer Risk",
        "label": "Maximum Self Insured Amount, Third Layer Risk",
        "terseLabel": "Additional insurance"
       }
      }
     },
     "localname": "MaximumSelfInsuredAmountThirdLayerRisk",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid [Member]",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage [Member]",
        "label": "Medicare Advantage [Member]",
        "terseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare [Member]",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NetAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount.",
        "label": "Net Amount [Member]",
        "terseLabel": "Net Amount"
       }
      }
     },
     "localname": "NetAmountMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NetIncomeLossAvailabletoCommonStockholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.",
        "label": "Net Income (Loss) Available to Common Stockholders",
        "totalLabel": "Net income attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailabletoCommonStockholders",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NicholsLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nichols Litigation",
        "label": "Nichols Litigation [Member]",
        "terseLabel": "Nichols Litigation"
       }
      }
     },
     "localname": "NicholsLitigationMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Financing Activities, Adoption Of Accounting Standard Update",
        "label": "Noncash Financing Activities, Adoption Of Accounting Standard Update",
        "terseLabel": "Adoption of ASC 842"
       }
      }
     },
     "localname": "NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NoncontrollingInterestExchangeTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Exchange Transaction",
        "label": "Noncontrolling Interest, Exchange Transaction",
        "negatedTerseLabel": "Exchange transaction"
       }
      }
     },
     "localname": "NoncontrollingInterestExchangeTransaction",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NoncontrollingInterestOtherAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Other Adjustment",
        "label": "Noncontrolling Interest, Other Adjustment",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "NoncontrollingInterestOtherAdjustment",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.",
        "label": "Noncontrolling Interests, Decrease from Redemptions or Purchase of Interests, Percent",
        "terseLabel": "Purchase of redeemable noncontrolling interests, percent"
       }
      }
     },
     "localname": "NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_NonemployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee Directors [Member]",
        "label": "Non-employee Directors [Member]",
        "terseLabel": "Non-employee Directors"
       }
      }
     },
     "localname": "NonemployeeDirectorsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, LIBOR plus 2.5% Construction Financing [Member]",
        "label": "Notes Payable, LIBOR plus 2.5% Construction Financing [Member]",
        "terseLabel": "Construction of a new hospital"
       }
      }
     },
     "localname": "NotesPayableLIBORplus2.5ConstructionFinancingMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NotesPayableRealEstateSaleLeasebackFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, Real Estate Sale / Leaseback Financing [Member]",
        "label": "Notes Payable, Real Estate Sale / Leaseback Financing [Member]",
        "terseLabel": "Sale/leaseback transactions involving real estate accounted for as financings"
       }
      }
     },
     "localname": "NotesPayableRealEstateSaleLeasebackFinancingMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NotesPayableSoftwareContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, Software Contracts",
        "label": "Notes Payable, Software Contracts [Member]",
        "terseLabel": "Software contracts"
       }
      }
     },
     "localname": "NotesPayableSoftwareContractsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of general or limited partnerships, limited liability companies, or joint ventures of which the Company has investments.",
        "label": "Number of General or Limited Partnerships, Limited Liability Companies, or Joint Ventures",
        "terseLabel": "Number of general or limited partnerships, limited liability companies, or joint ventures"
       }
      }
     },
     "localname": "NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual claims covered by the Company's self-insured risk reserves.",
        "label": "Number of Individual Claims Covered by Self-Insured Risk Reserves",
        "terseLabel": "Number of individual claims covered by reserves"
       }
      }
     },
     "localname": "NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfInpatientRehabilitationHospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of Inpatient Rehabilitation Hospitals",
        "terseLabel": "Number of inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "NumberOfInpatientRehabilitationHospitals",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.",
        "label": "Number of Inpatient Rehabilitation Units Under Management Contracts",
        "terseLabel": "Number of inpatient rehabilitation units under management contracts"
       }
      }
     },
     "localname": "NumberOfInpatientRehabilitationUnitsUnderManagementContracts",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfPartiallyOwnedSubsidiariesNonconsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of partially owned subsidiaries in which the Company has investments but are not consolidated.",
        "label": "Number of Partially Owned Subsidiaries Nonconsolidated",
        "terseLabel": "Number of partially-owned subsidiaries"
       }
      }
     },
     "localname": "NumberOfPartiallyOwnedSubsidiariesNonconsolidated",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfQualifiedPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Qualified Plans",
        "label": "Number Of Qualified Plans",
        "terseLabel": "Number of qualified savings plans offered"
       }
      }
     },
     "localname": "NumberOfQualifiedPlans",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofBedsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of hospital beds acquired as part of a facility acquisition.",
        "label": "Number of Beds Acquired",
        "terseLabel": "Number of beds acquired"
       }
      }
     },
     "localname": "NumberofBedsAcquired",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofBedsContributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Beds Contributed",
        "label": "Number of Beds Contributed",
        "terseLabel": "Number of beds contributed"
       }
      }
     },
     "localname": "NumberofBedsContributed",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofBedsExpanded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Beds Expanded",
        "label": "Number of Beds Expanded",
        "terseLabel": "Number of beds expanded"
       }
      }
     },
     "localname": "NumberofBedsExpanded",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofDeNovoBeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of De Novo Beds",
        "label": "Number of De Novo Beds",
        "terseLabel": "Number of de novo beds"
       }
      }
     },
     "localname": "NumberofDeNovoBeds",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofLocationsofanAcquiredEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of locations acquired as part of a facility acquisition.",
        "label": "Number of Locations of an Acquired Entity",
        "terseLabel": "Number of locations"
       }
      }
     },
     "localname": "NumberofLocationsofanAcquiredEntity",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofhomehealthlocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of home health locations the Company owns and operates as of the balance sheet date.",
        "label": "Number of home health locations",
        "terseLabel": "Number of home health locations"
       }
      }
     },
     "localname": "Numberofhomehealthlocations",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of hospice locations the Company owns and operates as of the balance sheet date.",
        "label": "Number of hospice locations",
        "terseLabel": "Number of hospice locations"
       }
      }
     },
     "localname": "Numberofhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.",
        "label": "Number of jointly owned hospital based home health and hospice locations",
        "terseLabel": "Number of jointly owned hospital based home health and hospice locations"
       }
      }
     },
     "localname": "Numberofjointlyownedhospitalbasedhomehealthandhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofjointlyownedinpatientrehabilitationhospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of jointly owned inpatient rehabilitation hospitals",
        "terseLabel": "Number of jointly owned inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "Numberofjointlyownedinpatientrehabilitationhospitals",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.",
        "label": "Number of solely owned hospital based home health and hospice locations",
        "terseLabel": "Number of solely owned hospital based home health and hospice locations"
       }
      }
     },
     "localname": "Numberofsolelyownedhospitalbasedhomehealthandhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofsolelyownedinpatientrehabilitationhospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of solely owned inpatient rehabilitation hospitals",
        "terseLabel": "Number of solely owned inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "Numberofsolelyownedinpatientrehabilitationhospitals",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_OccupancyCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.",
        "label": "Occupancy Cost",
        "terseLabel": "Occupancy costs"
       }
      }
     },
     "localname": "OccupancyCost",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Operatingandfinanceleasecontractterm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating and finance leases, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating and finance lease contract term",
        "terseLabel": "Operating and finance lease contract term"
       }
      }
     },
     "localname": "Operatingandfinanceleasecontractterm",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTextualsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ehc_OtherHomeHealthAndHospiceAcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Home Health and Hospice Acquisitions",
        "label": "Other Home Health and Hospice Acquisitions [Member]",
        "terseLabel": "Other Home Health and Hospice Acquisitions"
       }
      }
     },
     "localname": "OtherHomeHealthAndHospiceAcquisitionsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OtherIncomeSourceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Source [Member]",
        "label": "Other Income Source [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncomeSourceMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OtherThirdpartyPayorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Third-party Payors [Member]",
        "label": "Other Third-party Payors [Member]",
        "terseLabel": "Other third-party payors"
       }
      }
     },
     "localname": "OtherThirdpartyPayorsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OutpatientandotherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outpatient and other [Member]",
        "label": "Outpatient and other [Member]",
        "terseLabel": "Outpatient and other"
       }
      }
     },
     "localname": "OutpatientandotherMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patients [Member]",
        "label": "Patients [Member]",
        "terseLabel": "Patients"
       }
      }
     },
     "localname": "PatientsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PayorSourceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Source [Member]",
        "label": "Payor Source [Member]",
        "terseLabel": "Payor Source"
       }
      }
     },
     "localname": "PayorSourceMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PayrolltaxesonSARsexercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll taxes on SARs exercise",
        "label": "Payroll taxes on SARs exercise",
        "negatedTerseLabel": "Payroll taxes on SARs exercise"
       }
      }
     },
     "localname": "PayrolltaxesonSARsexercise",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Percentageofassetspledgedtolendersundercreditagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of assets pledged to lenders under credit agreement.",
        "label": "Percentage of assets pledged to lenders under credit agreement",
        "terseLabel": "Percentage of property and equipment, net pledged to lenders under credit agreement (percent)"
       }
      }
     },
     "localname": "Percentageofassetspledgedtolendersundercreditagreement",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_PerformanceandEmploymentBasedSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance and Employment Based SARS [Member]",
        "label": "Performance and Employment Based SARS [Member]",
        "terseLabel": "Performance and Employment Based SARS"
       }
      }
     },
     "localname": "PerformanceandEmploymentBasedSARSMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PortercareAdventistAndPremierHealthPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portercare Adventist and Premier Health Partners",
        "label": "Portercare Adventist and Premier Health Partners [Member]",
        "terseLabel": "Portercare Adventist and Premier Health Partners"
       }
      }
     },
     "localname": "PortercareAdventistAndPremierHealthPartnersMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PortercareAdventistMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portercare Adventist [Member]",
        "label": "Portercare Adventist [Member]",
        "terseLabel": "Portercare Adventist"
       }
      }
     },
     "localname": "PortercareAdventistMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PremierHealthPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premier Health Partners [Member]",
        "label": "Premier Health Partners [Member]",
        "terseLabel": "Premier Health Partners"
       }
      }
     },
     "localname": "PremierHealthPartnersMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_RACAuditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMS post-payment audit initiative of inpatient rehabilitation providers",
        "label": "RAC Audits [Member]",
        "terseLabel": "RAC Audits"
       }
      }
     },
     "localname": "RACAuditsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Reclassificationtononcontrollinginterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of redeemable noncontrolling interests reclassified to noncontrolling interests during the period.",
        "label": "Reclassification to noncontrolling interests",
        "negatedTerseLabel": "Reclassification to noncontrolling interests"
       }
      }
     },
     "localname": "Reclassificationtononcontrollinginterests",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of Noncontrolling Interests [Table Text Block]",
        "label": "Reconciliation of Noncontrolling Interests [Table Text Block]",
        "terseLabel": "Reconciliation of Net Income Attributable to Noncontrolling Interests"
       }
      }
     },
     "localname": "ReconciliationOfNoncontrollingInterestsTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Equity, Acquired Percent",
        "label": "Redeemable Noncontrolling Interest, Equity, Acquired Percent",
        "terseLabel": "Redeemable noncontrolling interest, equity, acquired percent"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityAcquiredPercent",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract]",
        "terseLabel": "Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract] [Abstract]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold",
        "label": "Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold",
        "verboseLabel": "Fair value of the Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_RestrictedDebtSecuritiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for greater than one year or the normal operating cycle, whichever is longer and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.",
        "label": "Restricted Debt Securities, Noncurrent",
        "terseLabel": "Restricted marketable securities"
       }
      }
     },
     "localname": "RestrictedDebtSecuritiesNoncurrent",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_RetirementInvestmentPlanAgeRequirement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum age required for an employee to be eligible to participate in the Company's Retirement Investment Plan.",
        "label": "Retirement Investment Plan, Age Requirement",
        "terseLabel": "Age requirement to participate in the Plan"
       }
      }
     },
     "localname": "RetirementInvestmentPlanAgeRequirement",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution",
        "label": "Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution",
        "terseLabel": "Vesting percentage in employer contributions (percent)"
       }
      }
     },
     "localname": "RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total percentage of the Company's matching contributions that will vest in the Retirement Investment Plan after an employee service requirement has been met.",
        "label": "Retirement Investment Plan, Company Match, Vesting Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "RetirementInvestmentPlanCompanyMatchVestingPercentage",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time over which the Company's contributions to a participant's retirement account fully vests.",
        "label": "Retirement Investment Plan, Company Match, Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "RetirementInvestmentPlanCompanyMatchVestingPeriod",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]",
        "label": "Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_SARsmarktomarketimpactonnoncontrollinginterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in noncontrolling interest during the period as a result of SARs mark-to-market adjustment.",
        "label": "SARs mark-to-market impact on noncontrolling interests",
        "terseLabel": "SARs mark-to-market impact on noncontrolling interests"
       }
      }
     },
     "localname": "SARsmarktomarketimpactonnoncontrollinginterests",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_SaintAlphonsusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Saint Alphonsus [Member]",
        "label": "Saint Alphonsus [Member]",
        "terseLabel": "Saint Alphonsus"
       }
      }
     },
     "localname": "SaintAlphonsusMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SaintAlphonsusandHeritageValleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Saint Alphonsus and Heritage Valley",
        "label": "Saint Alphonsus and Heritage Valley [Member]",
        "terseLabel": "Saint Alphonsus and Heritage Valley"
       }
      }
     },
     "localname": "SaintAlphonsusandHeritageValleyMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ScheduleOfFinancialCovenantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Financial Covenants",
        "label": "Schedule Of Financial Covenants [Table Text Block]",
        "terseLabel": "Schedule of Financial Covenants"
       }
      }
     },
     "localname": "ScheduleOfFinancialCovenantsTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of depreciation expense, interest capitalized, under operating leases.",
        "label": "Schedule of Depreciation, Interest Capitalized Expense [Table Text Block]",
        "verboseLabel": "Schedule of depreciation expense and interest capitalized"
       }
      }
     },
     "localname": "ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "label": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]",
        "label": "Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Remaining Lease Term and Discount Rate"
       }
      }
     },
     "localname": "ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_SelfInsuredCaptiveFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash held by the Company's wholly owned captive subsidiary which is restricted for use in paying self-insured work comp or professional liability claims.",
        "label": "Self Insured Captive Funds [Member]",
        "terseLabel": "Self-insured captive funds"
       }
      }
     },
     "localname": "SelfInsuredCaptiveFundsMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SelfInsuredRiskThresholdGeneralAndProfessionalLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Self Insured Risk, Threshold, General And Professional Liability",
        "label": "Self Insured Risk, Threshold, General And Professional Liability",
        "terseLabel": "Threshold of annual aggregate losses associated with general and professional liability"
       }
      }
     },
     "localname": "SelfInsuredRiskThresholdGeneralAndProfessionalLiability",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_SeniorManagementBonusProgramTotalCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of payments made or expected to be made during a reporting period to participants that are entitled under the Senior Management Bonus Program.",
        "label": "Senior Management Bonus Program, Total Costs",
        "terseLabel": "Payments under the Senior Management Bonus Program"
       }
      }
     },
     "localname": "SeniorManagementBonusProgramTotalCosts",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_SeniorNotes04.750Due2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 04.750%, Due 2030 [Member]",
        "label": "Senior Notes, 04.750%, Due 2030 [Member]",
        "terseLabel": "4.75% Senior Notes due 2030"
       }
      }
     },
     "localname": "SeniorNotes04.750Due2030Member",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes04625Due2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 04.625%, Due 2031",
        "label": "Senior Notes, 04.625%, Due 2031 [Member]",
        "terseLabel": "4.625% Senior Notes due 2031"
       }
      }
     },
     "localname": "SeniorNotes04625Due2031Member",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes05.125Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 05.125%, Due 2023 [Member]",
        "label": "Senior Notes, 05.125%, Due 2023 [Member]",
        "terseLabel": "5.125% Senior Notes due 2023",
        "verboseLabel": "5.125% Senior Notes due 2023"
       }
      }
     },
     "localname": "SeniorNotes05.125Due2023Member",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes05.75Due2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes; 05.75%; Due 2025 [Member]",
        "label": "Senior Notes; 05.75%; Due 2025 [Member]",
        "terseLabel": "5.75% Senior Notes due 2025",
        "verboseLabel": "5.75% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotes05.75Due2025Member",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes0575Due2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.75% Senior Notes Due 2024 [Member]",
        "label": "Senior Notes; 05.75%; Due 2024 [Member]",
        "terseLabel": "Senior Notes; 05.75%; Due 2024"
       }
      }
     },
     "localname": "SeniorNotes0575Due2024Member",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes4.50Due2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.50%, Due 2028 [Member]",
        "label": "Senior Notes, 4.50%, Due 2028 [Member]",
        "terseLabel": "4.50% Senior Notes due 2028"
       }
      }
     },
     "localname": "SeniorNotes4.50Due2028Member",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shannon Medical, Heritage Valley Health System And ECHD Ventures",
        "label": "Shannon Medical, Heritage Valley Health System And ECHD Ventures [Member]",
        "terseLabel": "Shannon Medical, Heritage Valley &amp; ECHD Ventures"
       }
      }
     },
     "localname": "ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ShannonMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shannon Medical",
        "label": "Shannon Medical [Member]",
        "terseLabel": "Shannon Medical"
       }
      }
     },
     "localname": "ShannonMedicalMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Determination Based On Home Health Acquisitions, Value Threshold",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Determination Based On Home Health Acquisitions, Value Threshold",
        "terseLabel": "Value threshold for determining fair value of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options",
        "label": "Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Shorttermandvariableleasecost": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less, plus the amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Short-term and variable lease cost",
        "terseLabel": "Short-term and variable lease cost"
       }
      }
     },
     "localname": "Shorttermandvariableleasecost",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement of Comprehensive Income and Income Statement",
        "label": "Statement of Comprehensive Income and Income Statement [Abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAndIncomeStatementAbstract",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsidiary's common stock held by subsidiary 's management, Percent",
        "label": "Subsidiary's common stock held by subsidiary 's management, Percent",
        "terseLabel": "Subsidiary's common stock held by subsidiary 's management, percent"
       }
      }
     },
     "localname": "SubsidiaryscommonstockheldbysubsidiarysmanagementPercent",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_SupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Cash Flow Information [Table Text Block]",
        "label": "Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Shares to Management Investors Exchange Agreements Percentages",
        "label": "Temporary Equity, Shares to Management Investors Exchange Agreements Percentages",
        "terseLabel": "Shares to issued to the management investors pursuant to the exchange agreements represents (in percent)"
       }
      }
     },
     "localname": "TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_TermLoanFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facilities [Member]",
        "label": "Term Loan Facilities [Member]",
        "terseLabel": "Term loan facilities",
        "verboseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "TermLoanFacilitiesMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_TheCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Credit Agreement [Member]",
        "label": "The Credit Agreement [Member]",
        "terseLabel": "The Credit Agreement"
       }
      }
     },
     "localname": "TheCreditAgreementMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_TidewaterandCareResourceGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tidewater and Care Resource Group [Member]",
        "label": "Tidewater and Care Resource Group [Member]",
        "terseLabel": "Tidewater and Care Resource Group"
       }
      }
     },
     "localname": "TidewaterandCareResourceGroupMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Totalfinanceleasecost": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of finance lease cost recognized by lessee for lease contract.",
        "label": "Total finance lease cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "Totalfinanceleasecost",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Totalleaseliabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases.",
        "label": "Total lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "Totalleaseliabilities",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Totaloperatingandfinanceleaseassets": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating and finance leases.",
        "label": "Total operating and finance lease assets",
        "totalLabel": "Total leased assets"
       }
      }
     },
     "localname": "Totaloperatingandfinanceleaseassets",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_TradeNameEncompassMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Name - Encompass [Member]",
        "label": "Trade Name - Encompass [Member]",
        "terseLabel": "Trade name - Encompass"
       }
      }
     },
     "localname": "TradeNameEncompassMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_VariableInterestEntityNumberofEntitiesConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of facilities consolidated as variable interest entities.",
        "label": "Variable Interest Entity, Number of Entities Consolidated",
        "terseLabel": "Number of consolidated limited partnership-like entities"
       }
      }
     },
     "localname": "VariableInterestEntityNumberofEntitiesConsolidated",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Discount Rate [Abstract]",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term [Abstract]",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_WorkersCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workers' Compensation [Member]",
        "label": "Workers' Compensation [Member]",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "WorkersCompensationMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_YumaRehabilitationHospitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yuma Rehabilitation Hospital",
        "label": "Yuma Rehabilitation Hospital [Member]",
        "terseLabel": "Yuma Rehabilitation Hospital"
       }
      }
     },
     "localname": "YumaRehabilitationHospitalMember",
     "nsuri": "http://www.encompasshealth.com/20211231",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r149",
      "r313",
      "r318",
      "r326",
      "r595",
      "r596",
      "r604",
      "r605",
      "r684",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r149",
      "r313",
      "r318",
      "r326",
      "r595",
      "r596",
      "r604",
      "r605",
      "r684",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r149",
      "r212",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r232",
      "r236",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r149",
      "r212",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r232",
      "r236",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r77",
      "r79",
      "r147",
      "r148",
      "r332",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r331",
      "r375",
      "r471",
      "r478",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r777",
      "r778",
      "r816",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails",
      "http://www.encompasshealth.com/role/LeasesTextualsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r331",
      "r375",
      "r471",
      "r478",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r777",
      "r778",
      "r816",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails",
      "http://www.encompasshealth.com/role/LeasesTextualsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r331",
      "r375",
      "r424",
      "r471",
      "r478",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r777",
      "r778",
      "r816",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails",
      "http://www.encompasshealth.com/role/LeasesTextualsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r331",
      "r375",
      "r424",
      "r471",
      "r478",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r777",
      "r778",
      "r816",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails",
      "http://www.encompasshealth.com/role/LeasesTextualsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r78",
      "r79",
      "r147",
      "r148",
      "r332",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r159",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r159",
      "r164",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r159",
      "r164",
      "r301",
      "r476",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r243",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Other accounts receivable"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r60",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r46",
      "r747",
      "r808"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "totalLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r46",
      "r244",
      "r245"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]",
        "verboseLabel": "Schedule of Accounts Receivable, Net, Current"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetNoncurrent": {
     "auth_ref": [
      "r46",
      "r244",
      "r725",
      "r747"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Noncurrent patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Finite-lived intangible asset useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r47",
      "r520",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r517",
      "r518",
      "r519",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities\u2014"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Receipt of treasury stock"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r480",
      "r482",
      "r523",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "verboseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r482",
      "r513",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r128",
      "r351",
      "r361",
      "r362",
      "r657"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt-related items"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r128",
      "r275",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from computation of diluted weighted-average shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r143",
      "r220",
      "r227",
      "r234",
      "r261",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r595",
      "r604",
      "r643",
      "r685",
      "r687",
      "r719",
      "r749"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r75",
      "r143",
      "r261",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r595",
      "r604",
      "r643",
      "r685",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r143",
      "r261",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r595",
      "r604",
      "r643",
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "terseLabel": "Noncurrent"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss) [Abstract]",
        "verboseLabel": "Investment information related to restricted marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r483",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r467",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r467",
      "r477",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Fair value of equity interest prior to acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "verboseLabel": "Summary of Actual and Pro Forma Results of Operations for Acquisitions"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be tax-deductible"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r568",
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Business acquisition, pro forma net income (loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r568",
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Business acquisition, pro forma revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "negatedLabel": "Fair value of noncontrolling interest owned by joint venture partner",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Escrow agent cost"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, revenue of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r572",
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r572",
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "negatedTerseLabel": "Gain on consolidation of Yuma Rehabilitation Hospital",
        "terseLabel": "Gain on consolidation of joint venture formerly accounted for under the equity method of accounting"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r14",
      "r55",
      "r130"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ehc_InvestmentsCashandRestrictedCash",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash &amp; Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Cash and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r123",
      "r130",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents. and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r123",
      "r645"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of noncash financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r10",
      "r123"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash used in operating activities of discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r141",
      "r143",
      "r167",
      "r171",
      "r176",
      "r180",
      "r184",
      "r193",
      "r194",
      "r195",
      "r261",
      "r313",
      "r318",
      "r319",
      "r320",
      "r326",
      "r327",
      "r373",
      "r374",
      "r377",
      "r378",
      "r643",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r68",
      "r300",
      "r727",
      "r756"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r307",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Other Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r310",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "verboseLabel": "Litigation Reserves"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid per common share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "verboseLabel": "Cash dividends declared per common share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r151",
      "r152",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r45",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r45",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $.01 par value; 200,000,000 shares authorized; issued: 114,211,057 in 2021; 113,835,708 in 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r401",
      "r402",
      "r479",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "verboseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r81",
      "r83",
      "r84",
      "r97",
      "r735",
      "r765"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net and comprehensive income attributable to Encompass Health"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r83",
      "r96",
      "r591",
      "r592",
      "r616",
      "r734",
      "r764"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net and comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r83",
      "r95",
      "r590",
      "r616",
      "r733",
      "r763"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net and comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r276",
      "r281",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Internal-use Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r640",
      "r641",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r640",
      "r641",
      "r784",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r640",
      "r641",
      "r784",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Net operating revenues by payor source (percent)",
        "verboseLabel": "Percentage of Medicare patient discharges (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r640",
      "r642",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r241",
      "r640",
      "r641",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Noncontrolling Interests in Consolidated Affiliates and Redeemable Noncontrolling Interests"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r603",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldOverhead": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indirect cost incurred related to good produced and service rendered.",
        "label": "Cost, Overhead",
        "terseLabel": "Support and overhead costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldOverhead",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "negatedTerseLabel": "Operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "verboseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r144",
      "r547",
      "r554"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r144",
      "r547",
      "r554",
      "r556"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r144",
      "r547",
      "r554"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and other"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r726",
      "r757"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "totalLabel": "Total debt and Capital lease obligations"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r345",
      "r352",
      "r353",
      "r355",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r35",
      "r37",
      "r38",
      "r142",
      "r149",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r359",
      "r360",
      "r361",
      "r362",
      "r658",
      "r720",
      "r722",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Spread on variable rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r328",
      "r359",
      "r360",
      "r656",
      "r658",
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r65",
      "r357",
      "r656",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r65",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Debt instrument interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r66",
      "r142",
      "r149",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r359",
      "r360",
      "r361",
      "r362",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument, Redemption [Line Items]",
        "terseLabel": "Debt Instrument, Redemption [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Four [Member]",
        "terseLabel": "Redemption Period Four"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Redemption Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Redemption Period Three"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Redemption Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, (percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.",
        "label": "Debt Instrument Redemption [Table]",
        "terseLabel": "Debt Instrument Redemption [Table]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.",
        "label": "Debt Instrument Redemption [Table Text Block]",
        "terseLabel": "Schedule of Redemption Prices for Senior Notes"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r66",
      "r142",
      "r149",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r359",
      "r360",
      "r361",
      "r362",
      "r380",
      "r381",
      "r382",
      "r383",
      "r655",
      "r656",
      "r658",
      "r659",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "verboseLabel": "Financing Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRestricted": {
     "auth_ref": [
      "r699",
      "r805",
      "r807"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ehc_InvestmentsCashandRestrictedCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Restricted",
        "terseLabel": "Restricted Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRestricted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r144",
      "r548",
      "r554"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "verboseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r530",
      "r531"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r144",
      "r548",
      "r554",
      "r555",
      "r556"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense",
        "totalLabel": "Total deferred expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r40",
      "r41",
      "r538",
      "r721",
      "r745"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r530",
      "r531"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r144",
      "r548",
      "r554"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and other"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r544",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance",
        "terseLabel": "Insurance reserve"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "terseLabel": "Remaining valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r531",
      "r541"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "negatedLabel": "Carrying value of partnerships"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.",
        "label": "Deferred Tax Liabilities, Tax Deferred Income",
        "negatedLabel": "Revenue reserves"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r417",
      "r425",
      "r426",
      "r462",
      "r464",
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Contribution as percentage of salary allowed under the Plan (percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r128",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r128",
      "r215"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "negatedTerseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Concentration of Net Operating Revenues by Payor"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "verboseLabel": "Assets and Liabilities in and Results of Discontinued Operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r98",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r165",
      "r167",
      "r180",
      "r183",
      "r184",
      "r189",
      "r190",
      "r621",
      "r622",
      "r736",
      "r766"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per share attributable to Encompass Health common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r98",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r167",
      "r180",
      "r183",
      "r184",
      "r189",
      "r190",
      "r621",
      "r622",
      "r736",
      "r766"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per share attributable to Encompass Health common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r185",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Earnings per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r185",
      "r187",
      "r188",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax expense (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Increase (decrease) in tax rate resulting from:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r145",
      "r533",
      "r557"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax expense at statutory rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r533",
      "r557"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "(Decrease) increase in valuation allowance (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r533",
      "r557"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "terseLabel": "Noncontrolling interests (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r533",
      "r557"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r533",
      "r557"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and other income taxes, net of federal tax benefit (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r533",
      "r557"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Government, class action, and related settlements (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Share-based Payment Arrangement, Cash Used to Settle Award",
        "terseLabel": "Settled the acquisition shares upon payment"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average recognition period for unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "verboseLabel": "Partners\u2019 capital and shareholders\u2019 equity\u2014"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r86",
      "r87",
      "r88",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r192",
      "r263",
      "r379",
      "r385",
      "r517",
      "r518",
      "r519",
      "r550",
      "r551",
      "r620",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r779",
      "r780",
      "r781",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Capital contributions"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r92",
      "r122",
      "r128",
      "r758"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Distributions from nonconsolidated affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentFinancialStatementReportedAmountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Financial Statement, Reported Amounts [Abstract]",
        "verboseLabel": "Equity method investments:"
       }
      }
     },
     "localname": "EquityMethodInvestmentFinancialStatementReportedAmountsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r12",
      "r143",
      "r261",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "verboseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r12",
      "r143",
      "r261",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r12",
      "r143",
      "r261",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r56",
      "r221",
      "r258"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "totalLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Combined Assets, Liabilities, and Equity of Equity Method Affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r257",
      "r767"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized net gain (loss) on marketable securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r29",
      "r36",
      "r254",
      "r748",
      "r801",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Capital contributions, net of distributions and impairments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.",
        "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]",
        "verboseLabel": "Investments in and Advances to Nonconsolidated Affiliates"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r343",
      "r359",
      "r360",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt redeemed"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r623",
      "r624",
      "r625",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r623",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r343",
      "r359",
      "r360",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r464",
      "r624",
      "r690",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r343",
      "r359",
      "r360",
      "r623",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r623",
      "r624",
      "r626",
      "r627",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r343",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value, Disclosure Item Amounts [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r343",
      "r425",
      "r426",
      "r431",
      "r464",
      "r624",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r343",
      "r359",
      "r360",
      "r425",
      "r426",
      "r431",
      "r464",
      "r624",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r343",
      "r359",
      "r360",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r464",
      "r624",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r343",
      "r359",
      "r360",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r464",
      "r690",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r623",
      "r624",
      "r626",
      "r627",
      "r628",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r629",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r133",
      "r134",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r633",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "terseLabel": "Gains or losses related to non-financial assets and liabilities"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r663",
      "r669",
      "r678"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "ehc_Totalfinanceleasecost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r665",
      "r672"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r661",
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease obligations",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r661"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 4.0,
       "parentTag": "ehc_Totalleaseliabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Finance Lease, Liability, Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r661"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "ehc_Totalleaseliabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r664",
      "r672"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments under finance lease obligations",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "ehc_Totaloperatingandfinanceleaseassets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r663",
      "r669"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use asset accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r663",
      "r669",
      "r678"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "ehc_Totalfinanceleasecost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r675",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance lease (in percent)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r674",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance lease (in years)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Amortization Expense, Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r276",
      "r278",
      "r282",
      "r286",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "netLabel": "Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "verboseLabel": "Schedule of Future Estimated Amortization Expense, Other Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r282",
      "r703"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r276",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived or Indefinite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r282",
      "r702"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Schedule of Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "terseLabel": "Loss on disposal or impairment of assets"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r128",
      "r363",
      "r364"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on early extinguishment of debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt",
        "terseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedTerseLabel": "General and administrative expenses",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r264",
      "r266",
      "r687",
      "r718"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r271",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r267",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r128",
      "r265",
      "r269",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Goodwill increase"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Schedule of Changes in the Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r102",
      "r129",
      "r156",
      "r157",
      "r158",
      "r159",
      "r177",
      "r184",
      "r589"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r587",
      "r590"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Net income attributable to noncontrolling interests included in continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r220",
      "r226",
      "r230",
      "r233",
      "r236",
      "r716",
      "r730",
      "r739",
      "r768"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r143",
      "r154",
      "r220",
      "r226",
      "r230",
      "r233",
      "r236",
      "r261",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r590",
      "r622",
      "r643"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r89",
      "r98",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r167",
      "r180",
      "r183",
      "r622",
      "r728",
      "r731",
      "r736",
      "r759"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r89",
      "r98",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r167",
      "r180",
      "r183",
      "r184",
      "r622",
      "r736",
      "r759",
      "r762",
      "r766"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r11",
      "r12",
      "r560",
      "r760"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Loss from discontinued operations, net of tax",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r9",
      "r11",
      "r590"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "ehc_NetIncomeLossAvailabletoCommonStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from discontinued operations, net of tax",
        "verboseLabel": "Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r93",
      "r98",
      "r171",
      "r180",
      "r183",
      "r736",
      "r760",
      "r762",
      "r766"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r171",
      "r180",
      "r183",
      "r617"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r92",
      "r128",
      "r217",
      "r258",
      "r729",
      "r758"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in net income of nonconsolidated affiliates",
        "negatedTerseLabel": "Equity in net income of nonconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r534",
      "r536",
      "r543",
      "r552",
      "r558",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r146",
      "r162",
      "r163",
      "r218",
      "r532",
      "r553",
      "r559",
      "r769"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income tax expense",
        "totalLabel": "Total income tax expense related to continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r528",
      "r529",
      "r536",
      "r537",
      "r542",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r125",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "negatedTerseLabel": "Income tax payments"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of acquisitions \u2014"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r184"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Restricted stock awards, dilutive stock options, and restricted stock units (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "verboseLabel": "Self-Insured Risks"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisks"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r274",
      "r280"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r654"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r90",
      "r214",
      "r653",
      "r657",
      "r738"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense and amortization of debt discounts and fees"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r106",
      "r349",
      "r358",
      "r361",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedTerseLabel": "Interest expense and amortization of debt discounts and fees"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r120",
      "r124",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r63"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "verboseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "verboseLabel": "Measurement alternative investments:"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "totalLabel": "Total investments in and advances to nonconsolidated affiliates",
        "verboseLabel": "Investments in and advances to nonconsolidated affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesScheduleofOtherLongtermAssetsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in and Advances to Affiliates, Schedule of Investments [Abstract]",
        "terseLabel": "Investments in and Advances to Affiliates, Schedule of Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.",
        "label": "Investments in and Advances to Affiliates, Schedule of Investments [Text Block]",
        "verboseLabel": "Investments in and Advances to Nonconsolidated Affiliates"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock": {
     "auth_ref": [
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investments in and advances to affiliates.  Does not include the tabular disclosure of the disaggregation of investments in and advances to affiliates across legal entities.",
        "label": "Investments in and Advances to Affiliates [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Equity and Cost Method Investments"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Compensation expense recognized"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r676",
      "r678"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Least Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest portion"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "verboseLabel": "Amounts outstanding under letter of credit facility"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r62",
      "r143",
      "r228",
      "r261",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r596",
      "r604",
      "r605",
      "r643",
      "r685",
      "r686"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r51",
      "r143",
      "r261",
      "r643",
      "r687",
      "r724",
      "r754"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r64",
      "r143",
      "r261",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r596",
      "r604",
      "r605",
      "r643",
      "r685",
      "r686",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r38",
      "r39",
      "r143",
      "r261",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r596",
      "r604",
      "r605",
      "r643",
      "r685",
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r771",
      "r774"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Balance at end of period, gross",
        "periodStartLabel": "Balance at beginning of period, gross"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r773"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedTerseLabel": "Payments related to current year claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r773"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedTerseLabel": "Payments related to prior year claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": {
     "auth_ref": [
      "r744",
      "r771",
      "r774"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net",
        "periodEndLabel": "Balance at end of period, net",
        "periodStartLabel": "Balance at beginning of period, net"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Applicable interest rate under credit facility (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "negatedTerseLabel": "Government, class action, and related settlements",
        "terseLabel": "Government, class action, and related settlements",
        "verboseLabel": "Provision for government, class action, and related settlements"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r38",
      "r342",
      "r356",
      "r359",
      "r360",
      "r722",
      "r750"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Total debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term debt, net of current portion",
        "verboseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt and Lease Obligation [Abstract]",
        "verboseLabel": "Schedule of Outstanding Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "negatedLabel": "Less: Current portion",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt and Lease Obligation, Including Current Maturities [Abstract]",
        "terseLabel": "Long-term Debt by Maturity"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Carrying amounts and estimated fair values of financial instruments"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r66",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingencies by Nature of Contingency [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss contingency accrual, payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Gain (Loss)",
        "verboseLabel": "Change in fair market value of equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r73",
      "r143",
      "r261",
      "r313",
      "r318",
      "r319",
      "r320",
      "r326",
      "r327",
      "r643",
      "r723",
      "r753"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "terseLabel": "Change in fair value",
        "verboseLabel": "Fair value adjustments to redeemable noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestChangeInRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions declared",
        "negatedTerseLabel": "Distributions declared"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r385",
      "r593",
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of redeemable noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Redeemable Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r73",
      "r103",
      "r588",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r123",
      "r126",
      "r129"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r80",
      "r82",
      "r88",
      "r94",
      "r129",
      "r143",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r177",
      "r220",
      "r226",
      "r230",
      "r233",
      "r236",
      "r261",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r622",
      "r643",
      "r732",
      "r761"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net and comprehensive income attributable to Encompass Health"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Amounts attributable to Encompass Health:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r82",
      "r88",
      "r162",
      "r163",
      "r599",
      "r615"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Net and comprehensive income attributable to noncontrolling interests",
        "negatedNetLabel": "Net income attributable to noncontrolling interests",
        "negatedTerseLabel": "Noncontrolling interests",
        "totalLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to nonredeemable noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to redeemable noncontrolling interests",
        "verboseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r166",
      "r172",
      "r173",
      "r174",
      "r175",
      "r179",
      "r184"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r368",
      "r599",
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r133",
      "r134",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedTerseLabel": "Fair value of liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r386",
      "r574",
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Consolidation of Yuma Rehabilitation Hospital"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r385",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "verboseLabel": "Other notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r670",
      "r678"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r661"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r661"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 3.0,
       "parentTag": "ehc_Totalleaseliabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r661"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "ehc_Totalleaseliabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r666",
      "r672"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "ehc_Totaloperatingandfinanceleaseassets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r675",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r674",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Inpatient Rehabilitation Hospital and Home Health and Hospice"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r74",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueAfterFifthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OtherCommitmentDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInFifthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OtherCommitmentDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInFourthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OtherCommitmentDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OtherCommitmentDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OtherCommitmentDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Other Commitments [Abstract]"
       }
      }
     },
     "localname": "OtherCommitmentFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r63",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PartnersCapitalAccountContributions": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners).",
        "label": "Partners' Capital Account, Contributions",
        "terseLabel": "Capital contributions from consolidated affiliates"
       }
      }
     },
     "localname": "PartnersCapitalAccountContributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r110",
      "r113"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock, including fees and expenses"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedTerseLabel": "Additions to capitalized software costs"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Debt amendment and issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDistributionsToAffiliates": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Payments of Distributions to Affiliates",
        "negatedLabel": "Purchase of equity interests in consolidated affiliates"
       }
      }
     },
     "localname": "PaymentsOfDistributionsToAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedTerseLabel": "Dividends paid on common stock"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid on behalf of employees for shares withheld"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r111",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Fair value of equity interest prior to acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of businesses, net of cash acquired",
        "verboseLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to settle the acquisition of Holdings common stock"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r112",
      "r583",
      "r584",
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedTerseLabel": "Purchases of restricted investments"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Distributions paid to noncontrolling interests of consolidated affiliates"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r483",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r16",
      "r53",
      "r54"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Contributions from noncontrolling interests of consolidated affiliates"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r126",
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Income tax refunds"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Net proceeds for offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-term Debt",
        "terseLabel": "Proceeds from bond issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowings on revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r115",
      "r119"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r108",
      "r109",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of available-for-sale marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from sale of restricted investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r80",
      "r82",
      "r88",
      "r121",
      "r143",
      "r154",
      "r162",
      "r163",
      "r220",
      "r226",
      "r230",
      "r233",
      "r236",
      "r261",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r322",
      "r324",
      "r326",
      "r327",
      "r590",
      "r598",
      "r600",
      "r615",
      "r616",
      "r622",
      "r643",
      "r739"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net and comprehensive income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r291",
      "r663",
      "r669"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r76",
      "r292",
      "r669"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r30",
      "r290",
      "r660"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment by Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r294",
      "r812",
      "r813",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "verboseLabel": "Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r292",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r30",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Useful Lives of Property and Equipment",
        "verboseLabel": "Components of Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentTables",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r30",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r46",
      "r52",
      "r687",
      "r755",
      "r786"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Accounts receivable, current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r246",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "verboseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": {
     "auth_ref": [
      "r227",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r227",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r226",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r228",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.",
        "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense"
       }
      }
     },
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r225",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r225",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest, by Legal Entity [Table]",
        "terseLabel": "Redeemable Noncontrolling Interest, by Legal Entity [Table]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestByLegalEntityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r366",
      "r367",
      "r369",
      "r370"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "auth_ref": [
      "r366",
      "r367",
      "r369",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue": {
     "auth_ref": [
      "r366",
      "r367",
      "r369",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of noncontrolling interests which are redeemable by the parent entity and classified as other equity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Other, Fair Value",
        "terseLabel": "Value of outstanding shares of Holdings"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityOtherFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Redeemable Noncontrolling Interest [Line Items]",
        "terseLabel": "Redeemable Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": {
     "auth_ref": [
      "r743",
      "r770",
      "r771",
      "r774"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.",
        "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments",
        "negatedPeriodStartLabel": "Less: Reinsurance receivables",
        "periodEndLabel": "Add: Reinsurance receivables"
       }
      }
     },
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r449",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r449",
      "r680",
      "r683",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "negatedLabel": "Payments on revolving credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Principal payments on debt, including pre-payments"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r26",
      "r130",
      "r136",
      "r717",
      "r751"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ehc_InvestmentsCashandRestrictedCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r14",
      "r26",
      "r130",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r18",
      "r34",
      "r130",
      "r136",
      "r806"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Noncurrent restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r14",
      "r26",
      "r136"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "periodEndLabel": "Restricted cash at end of period",
        "periodStartLabel": "Restricted cash at beginning of period",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r18",
      "r34",
      "r136",
      "r806"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "periodEndLabel": "Restricted cash included in other long-term assets at end of period",
        "periodStartLabel": "Restricted cash included in other long-term assets at beginning of period"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r48",
      "r385",
      "r520",
      "r687",
      "r752",
      "r782",
      "r783"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated income (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r263",
      "r517",
      "r518",
      "r519",
      "r550",
      "r551",
      "r620",
      "r779",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated (Deficit) Income"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r211",
      "r212",
      "r225",
      "r231",
      "r232",
      "r238",
      "r239",
      "r241",
      "r397",
      "r398",
      "r701"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net operating revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r201",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Net Operating Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r673",
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r673",
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Noncash or Part Noncash Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Investment Components"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r66",
      "r149",
      "r359",
      "r361",
      "r380",
      "r381",
      "r382",
      "r383",
      "r655",
      "r656",
      "r659",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Earnings per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r167",
      "r171",
      "r180",
      "r184",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r12",
      "r143",
      "r260",
      "r261",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r276",
      "r281",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r276",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets by Major Class",
        "verboseLabel": "Estimated Useful Lives and Amortization Basis of Other Finite-lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r285",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "verboseLabel": "Estimated Basis of Other Indefinite-lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Self-Insurance Reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt Maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.",
        "label": "Schedule of Realized Gain (Loss) [Table Text Block]",
        "verboseLabel": "Investment Information Related to Restricted Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfRealizedGainLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "verboseLabel": "Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r26",
      "r136",
      "r717",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r26",
      "r136",
      "r717",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r220",
      "r223",
      "r229",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r220",
      "r223",
      "r229",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Selected Financial Information of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r483",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r490",
      "r502",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Weighted-Average Assumptions Used to Determine Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r595",
      "r596",
      "r604",
      "r605",
      "r606",
      "r608",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r606",
      "r608",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Weighted Average Number of Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Estimated Amortization Expense, Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r640",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Concentration of Net Operating Revenues and Net Patient Service Accounts Receivable by Payor and Payor Class"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r241",
      "r295",
      "r296",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAssetReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingAssetReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r209",
      "r210",
      "r220",
      "r224",
      "r230",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SelfInsuranceReserveCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).",
        "label": "Self Insurance Reserve, Current",
        "terseLabel": "Self-insurance reserves included in Other current liabilities"
       }
      }
     },
     "localname": "SelfInsuranceReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfInsuranceReserveNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).",
        "label": "Self Insurance Reserve, Noncurrent",
        "terseLabel": "Self-insured risks"
       }
      }
     },
     "localname": "SelfInsuranceReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfPayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed.",
        "label": "Self-Pay [Member]",
        "terseLabel": "Self-Pay"
       }
      }
     },
     "localname": "SelfPayMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Awards issued during period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollar per share)",
        "verboseLabel": "Weighted-average fair value per share of awards granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested shares, Ending Balance (in shares)",
        "periodStartLabel": "Nonvested shares, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested shares, Ending Balance (in dollar per share)",
        "periodStartLabel": "Nonvested shares, Beginning Balance (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid to settle liability for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Share-based Liabilities Paid",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, share-based liabilities paid"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of vested shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "verboseLabel": "Expected volatility (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Shares granted during the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r491",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Number of remaining shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized for grant under the Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable, December 31, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable, December 31, 2021 (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding, December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r492",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, December 31, 2021 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, December 31, 2021 (in dollars per share)",
        "periodStartLabel": "Outstanding, December 31, 2020 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r481",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeitures (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r483",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r508",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Exercisable, December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Receipt of treasury stock (shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r137",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r7",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r241",
      "r271",
      "r293",
      "r295",
      "r296",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentstoConsolidatedAmountsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r141",
      "r143",
      "r167",
      "r171",
      "r176",
      "r180",
      "r184",
      "r193",
      "r194",
      "r195",
      "r261",
      "r313",
      "r318",
      "r319",
      "r320",
      "r326",
      "r327",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r643",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r71",
      "r86",
      "r87",
      "r88",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r192",
      "r263",
      "r379",
      "r385",
      "r517",
      "r518",
      "r519",
      "r550",
      "r551",
      "r620",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r779",
      "r780",
      "r781",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r192",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r70",
      "r346",
      "r379",
      "r380",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exchange of Holdings shares (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r45",
      "r379",
      "r385",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Stock options exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments",
        "verboseLabel": "Exchange of Holdings shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r379",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock repurchase authorization"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r45",
      "r49",
      "r50",
      "r143",
      "r247",
      "r261",
      "r643",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "terseLabel": "Encompass Health shareholders\u2019 equity",
        "totalLabel": "Total Encompass Health shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/InvestmentsinandAdvancestoNonconsolidatedAffiliatesCombinedAssetsLiabilitiesandEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Encompass Health shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r87",
      "r143",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r261",
      "r263",
      "r385",
      "r517",
      "r518",
      "r519",
      "r550",
      "r551",
      "r587",
      "r588",
      "r614",
      "r620",
      "r643",
      "r646",
      "r647",
      "r651",
      "r780",
      "r781",
      "r829"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Other (shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r671",
      "r678"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingRevenuesofOperatingSegmentsbyServiceLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r652",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r652",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r652",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r772"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Increase for the provision of current year claims"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r772"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "negatedTerseLabel": "Decrease for the provision of prior year claims"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r737"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SegmentReportingSelectedFinancialInformationofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Delivering EHC shares to management investors (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]",
        "terseLabel": "Third-Party Payor"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Trade names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r69",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r69",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r45",
      "r379",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchases of common stock in open market (in shares)",
        "terseLabel": "Common stock repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r69",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost (14,719,662 shares in 2021 and 14,428,235 shares in 2020)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r379",
      "r385",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchases of common stock in open market",
        "terseLabel": "Common stock repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r178",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 3.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedTerseLabel": "Less: Income allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Changes to valuation allowance during the period"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]",
        "terseLabel": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]",
        "terseLabel": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Ownership interest in the consolidated entities (percent)"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r595",
      "r596",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r166",
      "r184"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted weighted average common shares outstanding (in shares)",
        "verboseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r165",
      "r184"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "16(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "http://asc.fasb.org/topic&trid=2303980"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r818": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r819": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r820": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r821": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r822": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r823": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r824": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r825": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r826": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r827": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r828": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>131
<FILENAME>0000785161-22-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000785161-22-000008-xbrl.zip
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M4W<SD]3G#B.Q)M82' 1I$K&K\1Q; $\AV03T^<SNF=WC9_=6Q#EPM(+DB<'
ME\C$4='WT&W>)YW"-.29W3.[1\_N+2GS5!5*#!R+@N3*%#B@QQ88G6B>@#*?
M>37S:G2:&)K5D!QI" F@,.=DR3Q +7FHKC(!33SS:N;5Z-1HY>3$<<Z8(E0
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M/MLZG^G%&;X3!M#;"C%?6B%>./1#"F:B= 2%F+4Q@#HFC=6RK[(>98ZSC]R
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M]YO!OW7 M8QJ/>3%\OC&_O.G'38G&_.!<T_;^SCE<)%7'S*STJ2S(@=722%
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MH3PV*(\%.=Q/%K"2\+ /<E>75#I^>CA7PD2>SS*'=)8YC!E"4YS ,M(- W>
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MI9)]Z EQX2B63#Q2Z'3I%Y)I&^):V;'!M6@%<D-IJG&HMD?2F@S[I9!$CC7
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M.R]I.X-F/*"Y./%H4W4#0"-U 6(  HZ-(X3<M4?5@KG9Z:""\Z^V_)H!,1Y
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MX9ZNVY9E1Q9!'J6>[Y(PB&SNZAV/=D)TO0S*N>,9/B.,VK8>,-^(+-,W M<
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M;X>FQT+N^H9N8-/0IR%^FQ@J29FB3Z=_51L#'ZP+WW(-Q^&VP_0@B"Q7#Z/
M<((P])X&!GMD!MATY3LK 4)39P8U""A(FYIXGHKM<I^:GFU%S-V&=&]<]+TL
M+;(D9@)8'0)#S!E_)[ D\%LZJ+CC*09.]"B@#G.-P/29[81!8!#7-)AA&XX5
ML"C<@L#))M)R+7$3SW.IZYNA'[H1H*8H=%W*>&"9G'GPS3;T&MU 6JZIW:@1
M^3YU".A4V)=@Y :^2_W0#)CG^)87/!$9>P3+D\<D.>4P>[3<TH&XZBF*6A=4
M)HT"1B,SL.W("EW'=]Q(1R0%(,I](J)V321=B\3U?<X<F[-0)Z9MTS $TO)
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M#C*Y).)+@"6@<V-^W8-%H<E$J$.!"1)8?M1T'-"!U+$PF^74%'!8#!PDEZ+
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MF< B=9@B,RH3OFBL09"EL@I!QGGEO3+#6=7%1.C3B$B<U'G!4]$30#*V=$C
M]22IBR;:V=*UA(P!>1<ROJJR=Z0W0GP2+@_.:D/Q>LB%@!X!%;'4$ZU$V")I
M5HK 6-B*0HNH]B6??6E36_ECVZ;#Z@^:?:!<7TE&2=)3H$3L(P558(_@[L(L
ML&8WT 7;L!5B4DG=A<03N4I5K[(9JOVE\33/DD0*WI9CM\GO$>D_1V?S.3QW
MQC=78JN-S=R4)L!)M5D49&R:ZST!BV"K]L\A+#N3?EF995,59LO=4TLUD--7
M()[51I.9 ]614<H05KD"P*TLRPM5_2)L7]@IZ ^IOFK7E]9H?*XN7*7ES%P*
M0KHJ5JMVBDR ;BN:)!/=:Q:'?&?DM%0],^D,52Y=.V5']*6!*8HDO#Q+1<51
MX^X6$6WQ4"6#^%=">1Z*JGYTUJ^2Y=-Q]#UD&F.P0%(><XDIEOP ^2H_,$*F
M28S"N!T42?A 9K/DC7-"N*&YZK?3KO8J,%=2Y:9-TN;S9I7&@M[12C)ZZ%'=
M.0:QTFJK IZJ*\Y$D9@L[5=Y@+>Z1.\NKZJ$SORNKJ$CPLP\%B5V30Y>C1=;
MZ%!LY0($&GX88 N0$LN[^8 +Q1YQT=Q+X(9JIS<VOF2E;I>O$?<!M,*@431)
M1'&6JBRL)/1 &, ,"]^OP,1!WU0V5J",4-@J,C%';'0T(:J?X/8O8-N7J-5$
M\P[1H"LN,*FB,9E5&Y&J TI;6LBZQKJS2;N\L4DS%24$!;F2HF:L/%)7HJ '
M0[A7=4N)N*@#6]+!)<VVAOVEXKO*8D946>DD;;^T7?39:Y((*J9&ZZK5N@!?
MR.7KVJLD/0ER5<7G']Z_W999XY91!;_M?,P4/4;2-YJ3<3R;M#_G2ZA%HJP>
M;@HC1V->QL*=Q=.K&"#3J-DM$>P<0(Y76.^V(*M:F%%U]? D%:95M1=J9\"B
MXH*[DOP:'FSZ%';)H&OS<U7< 0B@D#4GRO^_(.1P(YZOG.IU/%9(*U4YV3+)
MA8>T$?VL<<!6+M:9A..XZE!SC44DHCU*\S#EI)+&>+N&)RO:DU@RKCO/DEO.
MA+>BTJT*C-V0C57E$6DI?* IRK@Z?0]#,@1MT98O7[1$ I*BTT66*W%,?BYD
MK6(Q;.<LWXN[I^.'QW4KB@(* 1\E^JI/8Q7ZK?);W)+TL2*EGV?&>9=ROB%C
MZ5+.MPY>H=QB/"SK#B:M"&_>JL.A8%.B75@))I%'6[="1)4G@HTHN:H:L+I7
MDO"788'R?.4N_\I%%@01O4R*RB]<WXC=>V;L]&W5<=O(&>=WM06Y"[MB>QEX
M6DWZ%L';[5:')-]>T+*-!/U8-XR9I%+VYO"7HI8,H\N&IR*HSVE2U="/14]-
MV3M7M!>XT22F"V _8K<(3!46-19U<%E9PZ"2TVPDW<Q5'V%8[4OL>]LV.5(D
M9X'5YR).)UHCM,)T3=NZ:3O-@^0CX0E/HP2]\'AP@7"UB-PEP*Y9'A<C,'QG
M V2Q.!J!BVH+3#0!*PGC)C+=Z4,J^HF*\]&*.LX>3MB 5R]H$MMD#PRAJR@7
M?2M[\@*5#"5\[>( #.V:Y&(F@(SPO;"BJ;JQW?'E![R/,\LHU%(UKKGU7G9'
M;%1O<YR%2$?#+F2MYK?2-N&J+X'L*EIPJH[(*#)-]H46K:C0]@4R2E.68JL_
M>9TP=L2Q(Y-00H52N\ZQZDB&9)#PWVN/KJ177!23NE$M1HM%3\%"DZT(*_D4
M\B%)(G%F1IV!KZ4@V"92%4W&3$9<[^[\VQ,]AM%U@^49HK0]+B?2/2\::LG3
M7&;R47>TMY,<G3:C#&UV#"V1%#U$ ]DEA=>)JW4?\*I?NTR"%8Y_Y<3LS344
M!ZZF0^R)+8;7F8(SIN#5O1RR876';#P'\]%=E/:TIBPG/.Y;.UQGY'WNN.!5
M]XS[8BD,/X-H/',>[>$W:Z* [%>^\S@D6#2$V;4!\:&+Q:C:1J_0>W!=F7I7
M6.R()>RJ]9SL);H)XUXQ$T9!["T\IN\C%W7DI*F#2>0Y(;.QK5;<K*I0[6&7
M42ZR642=3M7G3142R.;'H[JN0+FMQ2.JXE5$1RDOL7&<S*UNG-M#:6!(W-0Z
M3FZFO_) %OOV9CHM5]_N:+L"%^USRD6K;<OH::9N&O*0E7J^49:5XQPS,'#]
M"\TV)9J3OHCW$T""F78:TZRJF\%S#@K-L)UF7.(GTS%NM'\.W'I<F"8LL[<U
MM>AH$<LR>F$_B^@A+B>&@/HJ!"0S*/IU@[(V4=IKNGKN[OIY3SNH9_4'22=H
M1 @2&;[$P (I5V>,J*,$@&XCE2\B6^:?99.Y(_26.=P1Q<WQQ=F!5L;T$LO*
MIZ,P2VI/Y(SG2KQ,]7O]_<^SUJ& ]1EV>_41=B?B<![@DG@L#N5!?Z4\^R42
M9=WB\*-,G@X)%DJ@ZX;V9QSBT8G:>S % 2/VM-]B[#\P&!(PCW<3$I(1T4")
MVF:O'GS)$SX>8C/"II&\ZLM[Z[O!"GMIZLXO4G,'KM?W#,/=$6.^YJ&H3 .5
M@N%FO/;Z^GJ'5PLI>7H'/FT9IQDF:IJT$0.!D *Z8#&TLM![ ;30A,F4U*T!
MA+=Y#,-K#GJ:Z?O>N*V_U_)="*+V83#"'E;O$<.09Q^)'#/9=EZ6Y7WW3 '!
MF3=X'21$)AT=C..94*)X1O:Q;;IU2P%,1+OH/K:+QI,J\SB4U665=1KG1:FA
M68S#AE4S@5G29K/*I33GEG*IH5]7#H"<ASEV)YTYX5-:X+)!.N[W@Q3U03ES
M5,;_D='X=758ACQV5#U+E6,*13!MY"[RM%QI*7%#(*F8ZBAF_5W8.(F8C=QB
M^+.6X!E0K62_^HQ6]%K@:2SM4KRJ\?:6[0^)99N#4FN_F3PA1JA?KKP2* TF
M.:QK^T QX:47, X1L90MW3$^MQ_CTZR2N6F+]%X>XHN0:IUK)'9@LTS>IBW3
MT<T#6/:;W8*#WP5@.47',<B&IO)HK\XIQVM.*W=QU!0KK9DU98*:R++$[V<;
M-$D_;94#' +LJJ 2JI3;I=Z&B+B/[;,IY $S<WG]0NM=9ZWLS8(/5+?0^MP[
MX;Z6N37864WXE*K+7FDO#06N;C5ED/(O3775+5I2*C/Y;'&Z5Y4KAE[T1.JO
M9I"BXK#F,5%;6R&3^S:HSCB@YJSD2L@'#RTE5MR7,+Z![/Y;=;U;KQA3FI10
MM4=D)G'K].V&;*W(123ROTH2)S-7M.O4\)+J/#W9/'?P'>?^+/1P9J.JSBU^
M3<7=E9<?6[WW\=!O,B[XJ^J/UP 4Q@F9OHI3L03BIM<WWW>%BH621+U$O$_^
MK#S>@;,3Z"XZO<L<_I]5+U;^\!WA#_^U9#=_<[P=/[!N_5G?,7[P-\<U?^C.
MNP9KP(^!<^^#-79<,^@&&WA+/?97P6*2S8"1<=/\ZX7UHHG=",?J*UTSA+ZJ
MGO<CEQK.C6O-\5>\>D$)]=PFD?OC\;VS(O8DO6<@:=ZJIE07G.1@B:&IUO:I
MU3+GD1>VN52))A1E<*TFY*M6+=!V+3KZ)V<6]"=FO/S*51;IC4<]K975NY5]
MF)4U@A\1 @MFAY&LC9K;7ANN(;9^M00/K:(3GA ?O%1G;._*/KJ_;#%/+&]X
MZ-)]MMC.6H990D(O!SFL&.NK"43B?RL)F^X9/_&,[[#FS8=1RGGK88IG-?%?
M<\=TUL^_=W+K<1TPJMT /\2G<\MP*UW,U992UQ8( =%Z=*-6T;"=N0R86:-C
M);;1EY]K1Z+E261Y'8DVG436^DBTLN"?TR+;)O@Q2#'$D.:/R?ME]?!=G+I@
M!;>%4P.OYUK!BMQZ!\<\E$!YYF3RC9X?K"KW.S(].IG<GF^;ZR/3\P7]LBLI
MYK)PU@'_U5<RZ 6FW>'*32>2HW?VV<83R;17!53W#_^K=ZFAR0R53?%-=<_8
M6'_?NM7]BC[JWQ?G&OV8BWI9N=4]XWZ><4^>BJ59MI4Y--M2P!!(=^T8MIVT
MUN1W/TBREXM-%+X[N 7ETAC2ZUL["W*?L")*UM*^-'Z93=GJ3,BEN<%TC,[*
MWW 2V1V)-IY$JYI)G1/FAQ>[C<'*#+N_X/FTHFR@\\3\ ._J>L\UW<[,WVPR
M&8&]7D._(].R9+(#?^W^F&<3CIW+PVFW".CBLZL[$U?5 QW4?&0*^6L,]W44
M6HI"JR;C=+; 3]@"JKJRLP!^)GVL9QAKS"#KJ+04E<R>[ZT16'946HI*>L]V
M5E71SS@<VR[BZ>*/W[=VL$-SZUPL>3+)YH<?@Y\BS":6:1VFVA'V< ?(\<N]
M+_]S,^+KTJ^',-E_VL38N.7ZGY\Q+5;0*.N8F]4+#']G^R->'==M%]?9@=MQ
M7<=UC\UUIK73A8X?;<%/)F558UZ?EMLYC'X@2K#3!2(WG$:>OK(ZZVCTV)&"
M8&7AOWF1XI].AS6#=:;#GHL,HMMZ/&Y&7NG2[6VVA._MGFXX._J/X9Y5>OUL
M2Y3SJ1'8ZCFNN_.#D>J.P%M!8,/:V!W\W,R:5D9L9\W\  KS=KKH]Z83R?-V
MNASE#2<2>NY7U0F;9]!LD=@7R4]=FNL/U#P$*XO\S7/V/WDBZ2N+_(Y(CYWO
MY-D_:@9L$-)_$CZL6\Y!^0D7UCVBF:=F !L]0W=_%)%NC(>C(_ =!-8]?V47
M5D?@;2)P8/ZHN;)Y+JP[E*IM[7B;;LLL3FQ=1SK@[)D3%JPARR9XA-/*ATX\
MT02;>UR@S9803L\PC1\U0>YOE38\I:S;+]U^J<*ZKFWOK-K5L]LOW7YYMOM%
M_]DTB#7N%P%1?Q4G5;ZY>5:FFJEM2NQYL[.;.FY0K$3[1C4CO;F%A##X27G[
M+8N.W7QD@HJS2HTY7TOKWV%=DC<F ]X/<TXN^R2"L;XBR369%B]^G3UJ-$[[
M<TLX/_M;YQA%#S9'R2*,TTP>]_MJ@D?,RS9\_R0;,Q9MF//H7R_^$5MVY)JF
M2UR+4=MR3-^Q;&J&$0F9[S+./GLOWIR+ UJS"$^6+O$ V'_^2MXLHN3=A]#/
M^ /QB.:98^G[IG?_[L$ENBJ:/]-544JFF_^N\SS@\R$ON$;DZ6A:G-)DPH!Z
M*1<^3SQYNFEE2<3AF^UC-C4\P% >S(P'[O7 TBS&G.*B)-/JZ.YK>=HPO$"<
M$3PIT"3%LSOY?R=Q.=5&O!QF#!^M+H/?ESTT&&>Y"=6DYNR):Z=W9#W>S?:;
M<S Y'BR.5$K%'.I#Y1-Q5DNI9=<I\(!(^Q=^ADPT#?K^X=[B0'.>CP0OJ8L+
MK00!7G+6JUT5DJG2FZ>"[6@P-G7TN(;,%@-UOG$V\\(K+I\H#MZ&MX]SSK(1
M'EN-!ZW#<C;CA!T:RX?*>?#9H5J.)H[!+L1XWD]@>V?::4PSX.ZX' +$35%'
MMD]K1\XF!<P19DV2"$>/WWU(8SRO\:QYVCG_2N#5AVE]ICV>SHUG9[>.0H?=
MHPZ&+T$*\]M7> +/+_"B;#(8JGO$_&&(,#YZUTG<Z^<ZPQ'U),L<#P\+&@%3
MW$%[BKQ+:)X5N-# R3F9(AE83 9I5JCE9R"905QK>! Z/("G!7SL:4,84/^_
M$WAR"2*,9D79Y_!"(=0JAI5O@%E>Q13/H-\MX!<4_#&L6EFSP1%GL;@2^'60
MDU%OEKC:: (;*>3-Z1<X+(H:)(K5)U%3<QV#C,9A O,*KKLB>9Q-"I@WB-!<
MG=%>#DDI=BV+"SHIY&D:279=C0:WL*F_/H,QP*!Q/4[59A.;VWQ=#_>4QZ-P
MDA?BP>K'VX2;>*KQ&A:#XL<=[6P2PHX!*4X2W&M)HKT,C/_]I=H&]9:_E@LH
M!0TVG"G%Z?-Y-@+2 3R5:]PL5I0E,!G4'>/AM("E!LH"+.% W$0>4"\X(HJI
MNG\Q)RGVV-&.,I1B."C@B&980P)7\*\@"^ SA1$5H,?QJ3 E]69LD8F$RN '
M\4!8</G\&-<5>?C+),>_V83CEAZ)A4UP)\I]#ONZF(!J!(U:E'EVB?)N&(]A
M]K!/)WDE_H@@-"\E\_)J"K $*9_DL"D'-QY;,\& @WP6)$CQYX+F'"\A^13Y
M 83Z))<Z7O'0_"+)R.<,G^.-1(L(Q:NF?<0VL#R\% I;VX<I*\6^=_+WX7[?
M"+3W\ (^ HJ\;#'@6'VI..>7^5TA** 4 E)G B*%S:J+8H(B %\'JYT#9+V2
MGP3WS(S@*LXGL$%1LD09[ K4!M^5'$F!- -!)I<3I@VB;0H_HNB8'2Q>#YH(
MJ* 60K*B&'ZU'#.4D[*DJ+;#[$!;;-'B.A 3%"#U-=@X*2^*7HOSXM&8Q+G8
M_W#O,,M+O (?CB812 HA+@@*+R'.D. CDJ23,H_E=L65*3F1^AAE'W!,<1DG
M"4?UFU?"LN)\(!:ED['8^O@)?X/UY#!JE%1D'!<PN4D9X_(*/<U1W]-ABNPZ
ME1L')+]@7/BYS-!))(>)ZY&%7Y2HA>' 1@!<(<@,HZRHKZ#(;9NQWHD[P'XM
M:1T7%6P N3@5<\,G"Y@K1CY%31]%N/H,-@0MY86-M!$>@ )1;<(%,R@M"]^-
M,G@[T)T36 @UT!HR">G/"[60"KHPX$:DFU1N0M0#$Q>H#5NL+L '\@4\-P9I
M+0%-I TR 0Y8=7B>-DY(FL)\)$6B24HEA6#E2M <7.V!AG&K<9!9_0?,#L@%
MGQN/@4PH+FIRD3'<A!,$D=; *[%%$AA;#DN!,B+-KA0$J\@>*R8B[(H(F:I8
M17V=< +[&QY:3%#L(I*L!KTJ8GGSSS#_]<TV&@\BZ?SW)MUD/AMQ>VP'R6=-
M\DR(%A^R?UPL,B@BV-MX8H*R*Q1?"M!? 9)^@XDJT=1^05L_U:9%94BT^)[R
M[XVEO.9)M/Q@JJ=^9P SML7"I"(-MDY*8_D$RU8FAS(QR*R14<&Y C;)\$XC
M8T5<6H]!P-(UP\W6=J@0)JZ7>FA]D5B].0@J5YQ0,58$43,(#E0D+B(,)YOC
MTS8]:CZY!KF(4'4,LQ@*P'/P^^^'L#L3]$X!B0Y3NJ.]5./"WRI8@TBC\I5(
M/X]TF!BV,/EPB<08I3.I)]TD:LR^M6/];T73N"@FE34P*1%;,P$DI/=$R&M>
M2$2![^_55@1!X"+>7__8L@M[S>OP+4!6N!X?7#]1C/.(P,25GZ<]1'2<2B=
M@<A5/1_@/]BHAR4?R2E[O8<Y .6'Q>Q1/?]ZT^]+_JW4\"YH3=#X8LG>HLL
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M@@!"C5;PLHDJJ4"#<C[,!EO!<$=?,F!"^ ZN:*,]D&WI0&H,1!U-TCQ/KV+
MB@A*!4X';9S > 9IY<F5V&4Z&\?.0 ?QRX71$X%=0@Y@,>4#(G,D-"+" =+3
MC$9W'DOO]PCDN@P$51$!P,1PAQ:2M)'0(/]+(I1.#_54CF&WM)+%Q9##A',@
M6A^D-^7*?[VCO151$J"*4)/XWSAM@F= ^TN.XITG5= SST"5X6A:<T"@/\[2
M.1^Y6IE%\3OAZ44]*&\9("X3JXM.:AR9,!_@)2(H2,D8 ":LKHBF#*6&%0N%
M*F8D=V7%SS.Z'4#<A,K4A3PN+BL.*>#1A+5OJ^,#Q0V86$]=HN0:>4K#6)D:
M.1>C37%0PC7^-1X!N\$OP*D+#>3Z5 UE(GP4*"#-RGDG%<]16Y%!;6??"IK'
MV7B2D-J#)!#%37CRG?DII#F"#1*/$Q%JSO(0W0@5SA0@*)+4N'4LTE#;5;D,
MN$8]&3C#@"/G8O&;N$%4F60%Q@[X@B"I7'.*\=E4K%*UNP1GA9P2P&GXT(B3
M?(8AXC2JPM'G;>D@06^+\3!?"06)V+EQJ=ZH[ L95\(M)<.X_"OLHCQ$/ZZ(
M%.%R@O@ LTA($)G<U$3MVT*@<B0+ZPQM_"JH-6_O[6A_-?M80BI"88,+&YG)
MU)'&VD*VDUZ("CF6(M#4,LAGI*.87B)_J*<@PH8B=B/SM5"$3H1?N;D8!IUS
M8?XG),QRD18A'07B*@'&9X+FDS%ZCV%UX&D@I?+)N,XA(TH6S\ON]M(T[Q/R
M*>3E-0H=(2>JJ!TP-9>FJGA;S%L#:H]%2*0<0?@E;DZ8S2Q1JRMGMV".R+8:
MAO"<UX:<>EM/^=9A_^7P7(G?5513;2_T%HP%MU<>XO?O#RH'L>3-B#.,T[?8
M4J@K@5A*<HF<#^(N1_=[@E:JQ,AJ 0:X]S,1TH<M(WXIP K$B2AWC#*0@"%B
M'E7\T&),T.@38)JIQIKP?;-=Q,-H'H=+._>_Z]N?R161[J_VX 7UZC@M3X<R
M8!@E_&NL].U\CI0D<.4A0/)**RZ?B1K+JX2/8[%^$E'^."V5%[SZH=%$:NIT
MDN=(I1OXH,$@F-6!-B<'7755L:OP^$R$\Q2C]K14+G>D]66:7<L-S&+8E!1W
MA]2&L(QEKPF/JSO15=N E<J)%=7>:O@>YC_"M0.ZX0@8'W,!WO#>FJ,BHBR_
M9N<)AV\ZR$26":E\O;/[M((D."41UH(KI'[M(1\I=22$+4<7X7@H/&XR1/Q:
MJF:\#:\ 6"FBR)F2/OBCR(4 ==2DR@D-CGI" 2[Q><Y*QB@51KF:%XB?I/QL
MPNS2@N43V+E( 5AAKFZ!_85.G69;J2P<4-LIL(UR:3(81I*-1PHX+!:TH(35
MQN[)8)Y\%.;2)B)8GK20W;R$QVO+N*\^@L2]5EHEEQKD%F"'#RP$E5D-.GN5
M]JY4RFL51\IK'3DI:C="XZ*M=5^>)9BR AH"@6.V*%K0L%V3#2K=8));1:K7
M3:G<4@1SW#4303)V-RB$)$R04T25;]7.65/01PQ$K/=FQMK$^)Y>K$U,:UF'
MJ;\15K/*3)>J2^(>V/(2FZ4# 4,7F;R+\$"OWL@2F(C-7V=E%B4?"_4+<'2B
M<L<+$G$5BD3(VI>Z2-DT,YJ9C\9)-N7MPY?N7EWT>ZEOL/S"650R@H=T"1=.
M[4 4-5RPZ@D9%_Q5]<=K$&H@2:>OXE2LG;CI]<WWS15W".+*GY4+SO;<JG&-
M:C:@WJP\=#OZHMI&]:-9W;KXYSOOO>M'V]5W]&5O7GS@F:7?<>+9RB=- ;V6
MWP<?X=$BU>*V'6 L51SX?_\P'?-&5>#W9R-*^;RE&CZL-*U[K7P$A#$5QJB"
MIC5<W)/!/0&&]Y62WU-:7=0SU J_EM#M3-V]_;TZFV4PB9G DQ@6X479RIW4
ME!D.MDU5\Q-C=!.L'RX*+B9C!#)L=OD7<YJJZWJ&G+8<>]W6,<L5++HF_L-
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MHEPJK(T2QDB=GS5)54$N1D-%_TF-E"6 !)DS#"@#.V74:]-.9%6I=JNPUPS
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M-FT\XINKA!O376X:!+=T_??L/W^-!5E@RZ<6WC$/:#XCTQ7V&KQ?DIZSEB$
M>-!?_)_>,J-R_#<XK[ER/5XBTL"D[W%=J]]96$92*8<]0O) !H4G1BI'?[-
MY:P8VVI2!OXCTE0-^^-<_%?QQFN9-$A[SZM]4.^V3+DM7*MT*93EP6O-B6G
MZ)\(X!Q\S^'N9W3.;]?>D]%(\-WS^LL=E9TW@HJ1>(U4HVL%(VA UPC;N\5R
MGN.5/5=&/9%I@R \M"W'K9*H"AV_]:9"YWI\$O7A&+^\'47J$TLJ^ ">*NS
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MCX%WQT=)DB-)6?:8TR?U =L:;NM^R#T;N<V,ZA1B/]*$"\[Q3"3VP/^>-7D
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MD*[:>:SLP .V()7$[49&RCNJI.PP@AFO27/"#W3MH]JR\#1=9LF.O/W!=0^
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M['Y8RNDTR"@]YS2ZUFP9LE]-QAQB5WN/M2WOD<=:SG_.7706^5K7F1LJT":
MEC:/-A=EG]*E9W!G>Z<!;*,F:J R!-;928O!D*7N/4HQD.0B"X\AE^ *FV Z
M6..;;.!+-]IAD;.OG"W)%TX!D_0VK)4XV_8M*68%%(^F%];\?_W7\:.C[Z14
M"G*3\F""(AQ93>Y*M%:J15TP*UC!R[FF2OI2AZ:.*87X="15_&"WEV2DM3+2
M.EK]0-P.20MNEITNE5&7<^<@_R*5;3FGM/YK(S'GUC6#.F\Y7[?%I,A14U-;
MQY_&T5KBR+>D,B:N337CR#^R<>>TW2L 7,=YTQ0,E4<Q"ET$#%SVE<)\';
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M@9=VE^2@9*+X80.*-::ID+?JG-'DWVBL4S?'CSHQ+#Z83<$?)5/"YPG5F))
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MPO,<&T2KF4]K4MBRS_W5YE>/LC%)^A2;5W<K1 &QGC07=\%R"<F2E:2%GY"
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M-SQD.:,_TNMK6A]@_CHV=CV,^^0H<4J?G;WY\>T0@)M.^;)NR$TD9;RM(,7
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MQ7LD]/S1W\3NPS((2.?-4H T-*2OCK@NDB$ P0\> "1"Z'(]-YM.SCE>0=J
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M#EFD 0KE^JPHW=?M-^!/'$L=AQ ?,[P)2"PU;J4,@^E;RCJ?[J!'=E6>Z 4
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MP=;%T-)'4_<XVA;*)@&QBWHT](#@T6T:#D%GHT=>J<WAJF%EY34Z,_>LEZ&
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M&066\U7,1@XWHBQ1J. OG=CKB+>?M79R&YH41!L>U^Y(='D!>TR[GLH=,9G
M#%.(#O9LFC?"#H73_#>DM4CW+<P%81>&KT78B_&35IQS]Q^D_S]+GDU/3!O,
M(_BGWQ8M+R8LO3"7+%+TY0^!@Z+J*Q?[:BJ.<H\6%>8W\9\J_%)PB)?I%AT
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M&;I7"L&6:R->43L^Z.S#T?*@ZT8?A ML =0:O(3O2]] -1FKKXVN 73A4-'
M&HAC %OBDY@H[TS\-;A6(C:_.#?=0>U"5I?4&4I>'=O]CT.Z5**N$)J!CQ."
MRC82PK/L#-+P#?K<!QO$H4\NGU)R^BA5'C4G&UD93X'HYM3>P3E54@#35G2\
MWO-7H)W]1;%Y]VCW\?%:P[1P0)FNX2)G+R[!IN&@C\E?=*%5I18B!3O-R0#I
M*K)F;J'%V[-7O_C?DI_#*23Z]+:"P1YMQ)$O#?3>$R\"!GX:Z@:W.6$AN2OX
M3=MK&M[&5DNS>VA[&K*&<^U?$46N+!Z7T,7I'CWJ2;](-@$ 0I[PXD@3N@!0
M-,'!+3_?2 )8%#U ^P31+7DY:,?@\/G1Z28J<#J7$NVD$%>"'%*6_<$8#]DB
M; $./DF3I ;/#LTT>_Z,7\,B/6\VZ*X5&@@D#,?KF!Z0UU9)A1:+0H'2><M)
M8",*FWGAY3W!ZY!56_N;+9SA#89]'1KG+%E)UV-^=X%8U Q9?#Z\#=N\I $J
M_@=I\!+X3ZYN'X5ME/=O[N2:<S)2<"%$S4/V8MW8&^Q#D4SWB2+7.VK-+6L$
M2J6JE-$NZ+'ITT+"]XK-4!I")^8K;U@ ,\OR8-L74GR,;60$M&.0@^R98TI:
M4[8L%<S5$KT1FC%G'A)M)<WF >P4QU^J\G!221L::[GA46O]@B*3HQQSK,N]
M3Z5>H"!%T& S>I/:0@IQ:620SGP(@9%BEKH8A]FK, O-I">/P,RX6[H@>CC+
MQ9_2L@R/X2']"7TZBH<?M\H$F)(-6&$+U=M'ZX8E1=T*=8!UT9"PD;U 75;)
M(%D<4XL?O+*"BG-ZL,?DN142<:0Q*P?#7.,L7GSP9V8HMC7TJH"TR==%&*X_
M^]!,<N*_"31>O:T9_*+ JV5N\GU& ?)%$30P8XRUA>VL*SERRKI$A8\7KJ41
MEWFX:V->M>U6OI&"Y9,Y-T.RI^C;4CJP8+66Q3M7%O.ZYDY4]N$+*7,B/<M2
MR_Z+P7%W4:>\E$XC*_"_JFVCW5\3F)47V4A<1E#]B/ U*K\7[,O'1!NHKY!2
M(CN$W-/-ETXT@MWBYDB-6SHQGX+YP&18QT]'UKZ(1%KZ='G*53F_^EU_4TH]
MAXS'QQ# RY,P"+Y\\UP0J=8FB[[O^[3%;TA1/ :0CQ]%.SNW4>36I,T,6@PK
M]GI&FR1UXTA/T5I&+O?*A>X&N%'I* D87-CK]GG@. _\=)\'OAMCN<_5T\_I
M8B)=4N;%8A>KIV%N6%PVG@I7^<0TZL^?G?E^DI(2::/*(]-9[ZKZ4N+0C+'U
M-0((=N'A$SS<8E3_J!@$+^TEXRH4A4,)=Y9TM[9X+[?"D@<P1)#70N(&*_Q%
M.VO44JB+1_KJV&6)6N EV[R)V_SGD],1K3+WE> !AMKN?L&2U:OZ[B!L0 MW
M[XR-O9E>&YZUM>??8:RTEM;*QOAJ)6Y-EP56L()QI^O.&APP3HL*<%=M-8=+
M9)DMTM#:=>27+K?.]HC8PE>P;8K6&G5DOF+)J0,;'LWH,^^BDYDG\+>:$9AD
MAQI#E)/P+X?MA+T1Q:#TJU(S+T"/:H96+:SX/6+W]D3 IBZ>!WQXC<)&:%.-
M16-%^S+(ELQ"2B>Y?[TF-SUL%6\ D9LO)Z\OG0^@)A5=@*5RKWM0!U9<A8?M
MX[@ 3G!2'XK^3$'N0O]WO[-YV%L.Q,=GPWA2^NL!!KAVX&5&UV8UY7!O)A/R
M-&BK*A$ Y$/FN7@J[9S#Q9J1-)(Q-(1GK3RETPQ?A@SCN)Z>P]7)K+++O+5Z
M6LE;T;FL-(W>&],N&LI&*F%DM',2D\9-5=[(6,LK^6$BVC(7=B^(H"^*2* G
M"<XD2MV9[M6$L;HCB+ZU'#T3\ZU<2]]N8==S$K!?: 2*2TO1MP;BZ)JF;D9Q
MA;[_+;?;+5KNT"B) 9Q37YOLL:O_ZJ;G_'=)+832PKA:8IHO\G,CYKNB%#!B
M%7P.5JL-=CXYU]-ZR>7!ZJQI$-&#;S7&&IV'A/-@L+3W5R'2\F$/4Q-PE3D
MI17",XZ>6##:'\21H'C>]6MOA]2G15\$A\MU$VD5Z4@<]'EN)<$^D]DXIN=C
MM:3:3GQI](UBUGP+QT9<%\%S'AFO!!T;IU,:%A(N#A9A59A+F(4LEHEB-#M$
M$L:.221"90_8L,Z%A)>)MCG7U&C9>LX)=-93?#X@>96#=V,2RM$A0(VS=\XM
M)8]O[;*P/Y%RUSJ_B78(L)+B#4'E-DY3AV@KRT94;B_&P9B+D[%]>O6Z@$[K
M&APX%"&-N*KR0&+0W+'95?2=B9R6?&(HKZD$\7TV:\O")2O60M7ZKG@QPT8+
M9)R*.>UBDR\Q?Q>/DN,W8,ZGXUK79:QX:KV,9]S[RLPQP\Y9G!=73^FFPA8)
M(5?*LRBS+\]#%M-O0'RYDLQTEFSLTVXH2YJUD>F6VD3;ZH9&$9F.N9DCU2L\
MEYA-@2/Q[3R;P3PZS'ZT=+ *F9F389#QF*JM8VE7]>0=K*V)$PE<=BL%X^V)
M]CZ]K\HO]<II^Z,G=VVEA [5XPM]TXUG(4MRNPMH*?N)!,O7VF0@4'N&X\/W
MH/!/W55^FYO*\29=RNN4+D5VZ[7%G7?.FKPJB'-&HGGPW\7D'9!AV=_SR]ME
M2/UG'(E,^ ?4(N.HJ.MQW%@KE A ^<%^+@O?\B@+;#P1]BPP<2@O1?1"NJ2X
M%,L7XEN9IA5:,L^7,B?SE=U&Z#.:B>>-,8L">)1F9$8EZ7TNS%IIR;!8+*Y8
MK@31LN@J*R]COI/ UVWP.(4(H\Z5H^O"]*/=V13?GK 017Y",)@'X9X>?Q\'
M9S;$*.UQUS>#;2DVOI8R6^3!@.A[W$7+ZSBMG0"6+#OM$\L2C8GLCB84\BO9
MK>",D96*KO-0XLD#%BIP9<"9E/"Q>%R;(X]&J&FAU/!3>ZGGCOR:<."(4X"$
MW-1C)_-Q?:$"'X(#]-V1>-@T@S$[R:RY#$O&'=IME:,F<2.VY#G7M!8!\9S"
MD;N@E7/!]!0*$I^[&N+8\KFU#=(! _+Y\0PP\GAP<WQ$$3LIVCH*R05:HID&
MTOY\?'3$L;.9]=L-AAG'V^@0+DONHBO^(@?)+"@C>S+2[PA@6@B0-[9W$Y;3
M@ZDE!X9&^Y>A0_/[!_:.GSX]]N11I&C:SB4UX"9)<J<O4,5IA:D,N8V <1@X
MSA( ,Q \VF]V <I4Y00)WE@ER'/=INQ =IQC;D!0=I'%W(RQY#P[C2MAWLB;
M6;7[]M$RA1\R>6M%*NH1&$DJU@788!4$5W[7<5(W/%!F;TOH$9=2&B1:*($@
M"J+%A)BAA*V[:EDX1=]W!!GN<*4$#>A< YLE$,?>$;IYXX\_\)X_?BCM=G\A
MI<:4'B='UG+7H[>QK.S]YMP*D^,@-2UN1;_<LL#CM622Q9L/0#A!)TC7%@$F
M<6/RH.4 O"^M')JC0+JHZ/WN#J1WLV=QD[(T"4!B2&7;[_1ZE)W]]]^'N[R&
M/T$]MCYC#'3,QH&(7Y_(/M< <%;;A4=XW$SR' ^I/J\ETTT>"+FB^;G R:KZ
M(J:R2\A52RDPLDJX.>+]5E'&4!M?8HPWGG>,TY:[&P76GM>@1U$WN!:(OTE
M3(Y(- =1&FLP3+A))]!E-YE7Z,JQ%LI%Y:A--)1!+.I&2.ZV/6 #K\=[$:WP
M--F'9''YC%[D16D=4;;B\P3@&,!AP4K5VH&XP"DTTL4+P*&T>9IWO,--5.:%
M1BA&_)$G&^\-.\;N%AQ/S#<C0QN:0#A<395(%$S"9=,X!;/]Q5RYI9=\7J77
M1+"7IBAY 7'P>C!@-:B@.H&*5<[3*RD:EIO\@"U%@)I?8HQKCQN)#L#)T1XW
M<C?&<H_Y W[S-1));U@A$-Y&@X)[G-RXRT$<OR]-UK1N3ZVQ-5*H,I=(]T E
MH#%[B;<E=*(1<E8J?,4;ZI GCF(;PI>6@AV&VM]>EQ]Y:'0WB" =9F^Q.CX@
MM"V8%-AS-&:1_A4K@7LPOK$49[SR_*\S:ZR6W&6'V0\.6^?ZY%1BX3#%&2=G
MQ;N_JG1M$_"P><5YQVEL%XF@"V.T:\4W3Z5O&O<;ZF*<4R?^E)F0G*^5NE:[
MG"[Y-F)OW/*0NYCC3W@I3%+Y8N*%0P# 4N6M"'_%_=:2 G=ON]>7E<A >NX.
MLY\1H?1B&#T2[/S-LE8=$%IDJKD;R??,,6E0@GWFF&;?5A>T!_($%EB4FF7_
M)'\\1A+$BQ^@,;SV"J8KI'T9)I0$!Y;PD34R)N]J @8(*!(3V@ ]@/ X[>YP
M(>63OH^';]!L<S=U).M25\EJB4J1KD<CC6ZZQ&ZT(\QTA3SK")X;]6F[#-#@
MWA@2#Q"3;F>20K=XWV9Q[,?O3*#66@<7<C/4LW,'[BJ;Q&=\LK>NG!V\,6K\
M6T^(Q+@(!+R%\I=VQH.YHOC#VU7>O,/'#,/%?'L_O^W'XQ9=><X>48A9^:\&
M2OOH4N3P%-V]XFG;A3L+58-3!VP./U/- 1,S&TH4UO6.,M^UW:K//Q/E:V0,
M"$<8H37 94LK]/&_!4NN^/3ANWV_._P%FK4R'@%/(\NWJI>#KR5$5RP ]H#&
MD0U6PLMOV+5D:@)_JS,@T;6K4$44M_ )=_HHX170B"BJ\Y91!4[8#XZ/V*:T
MFA[P21[>F5G!^(V R#"HR__/WKLVMW%E6:)_!='1=<.. -FB7G[=Z0B9MLNJ
M&9?4DJHKYGY+ DDRRV F&@F09OWZ>];:C[-/(D%2LET"+4[$=,D$D(_SV&<_
MUEYKH!@LJ5E,7QT3'_\]S'Z'FY>$HJ/-J2DV7&JCP8 E(5.6?*;9^L?/=R7K
ME3Y#>\8-)[L%LA5T+=]4.S1Y'1N?_%Z?:V-$D6&%+S$D7O39VM7=7VCT.+C)
MIB4#79')OXZ5B2\>^\M6:6A6L\V%TA=.0+EQ4?_&U8!W6>3617#SNK(#,D\N
MF=N)4E9VV'2K9+/ &^@+MSAYO,Y:NLNCWO'V>5,>,.#;PN+STR^25^'-*3!<
MSZ.C2P<W/[^_FQZ[8P\M?:+Q-*N9R0U'ICL'.0WG5[Y_I]R__>??<B$"5<+U
M>7B?[44@"AB;9!*D<PJ86V#5\Q1SDP/>Y?G@])?0=!SLY[6GB()=Q 9+OND*
MMB\;24'VI<4T3WNK6JNZ"?&"XL;*JG)0'P\]?ZH#\7;S4PA%12"4<4^O02&0
MO:NM=[%/I(']Z)$*K;(;S6LP6LI,[A[U!GIX!';J'4Z^MUS[[H=1JV$6B1<>
MJ)+D@R:/3? IK=#JLMT4SOJI6J5Q?OQ$GGTH\/RKGB<0K)>-^R,WGNIZT@*T
MGF#2B1E/#'*.&$_!6&;;^C+;;AC0>(1'K=HY(Z+A^YGS(E" W3OUXV_+&XI>
M)(X;%KP*W6]KSC.,P/8.SI")9* Q7<HFI>X5T+/:Q6(;&)435#?%:TB'A^SN
M<_U:%-YCLV_8^IK<42SQ/%?4\&\617* N54;DX<NJV-_[<#5<RV&:O M><J:
MG.MI @A%R ?:L$YV2WG;6<Z-[!&I^*+.)GQ UR8/4%R"Y\BI8'6W?KG<K-"0
M%'4%E*/KZ\EG1Y^'LJ.VA3#NHA%1WQ=#]\WDL\>?"SCA,C(6H81E3EPU60.'
M"SGTI7IEZ6=//L_E3^GP%I8#8W]0?:Y ::E?'MQ"(H;/GGX.XO=6TF[D/H'%
MB.)'XQ71&FNTZ2]B1=%"YLMNL;FHI?N=2_*FVJI218UT+@T7"$NVO7(,Y&,.
M68+5W(TM!M3:8\MJ8&.45 .?1C0/\[+C*;I(?L@JC<C,QD)QY/F^(P'5^Y?C
M[VUE[UUFS=)%M1U-:)G):/)B<*$?-ZOX!4'1!6BY3Z;68!V=7P];,8)?"K(X
M4W5D&25S(DK-6WK"0G])))-= >DO97'Z+TM0^(=ZG].\#.47(#^4>]V%@XA<
M8ELR?:;^&LN#-_CN4N;$G^( %N=&X??)6,W38S?&\Z<3=0B=(5JG,QCA*]?1
M5!@-=[+YS/F)#733*P;'$T5YW=_#!5PZ5#$#[J ^XX>K)#.M/$)@OSDS$%Y$
MSMT>49.24P>\7A58Q#%S\COFT 5=E%X,MC1(V@@8ERM<8N3"^RT7,N-I_+[<
M*'U!I36X%)]L<)4P+%)L1M./E)L']1O+FP?*OV%-A[EE:R+;QD\%6"&%6\<J
M^GD"_[B-* ]%^EBD/WHHTN_'LWS*Y X_OGS]XL4]/$CA":J,X<O63J;7Z)%0
M+P['X M):-J?0/B0)N[HJZ^>3T?J'!I'<D2<BT"D>EMM*^AGR7[2Q]><Q% A
MEP</LHASQ@8&G\Q=P]FW'/B2<B7%^EI\LUP*BAZE>8T(S)O,26,^L'49SQGD
M>_='4(""6&]+C+ZT)\PEZ9N!#FEOZ*/%1NX(,G?T)CFC*O<:/2G&,"XDZYAE
M-E'J7 \H@BYY?(G#YQ)E!?<FAGSLICBIMD"?,2M<0)Q?4D,+4_\Z$N,S>ZB#
MX=2^X@G)L\>&%]&>E3>HMKJ:<S9#"D_4;9.C,]#(#E<))Q=<MCZ"B/-,QMG3
M!_GWZ>'2L+UV-R(H"*OK(Z-HO-TC_>K;S-)2;OCQQ[>35Q /%:/&'[[!1NLG
MG]F. -CQ^$TD1Y$H0-::A["Z$"$[[,.Z*V)2+KTKY$L:LF(]OXT)],J3>6NE
M5V.\;#R:N.U]# ETU(P-)+T.IJ20/^Y$:,.,3C5/4YH\W15](U *I$#)*3."
MB>$ZL\8E+#,57-^D(!30Y9!OH"@H<S(FA)OIL6-C19A+(X8(:15>P-K(^\W)
M1;/&"UE[&9@T\CVEET=>OXC28<F\$<\>6T7"9HNN5[+LO$N3D;3^#I[.\I!.
M?1:VY=0)7F:BABO W?*AIA-"/I8H&I%40I[TW?EXWTFAYU*&^+*/0FL5K0Q'
MUA)U4>C^O+O2_(0:^VA0FGXBNNPK&P>-LVV"Q\%N7=ZN@X63B]_*L0#<.FOA
M004S(^YY_EE6ZP[#'Q_^/N[+PL/(T_ NH_NQ+[Y/\]==0&T=2(AT%0Z@_LX-
MZ,MWWQ__Z/83?HAW6#B[GC8GJ""=M@[H< _Q-]PT:K]Y;5Z3]44D$G2O:F0I
M.^SVZ[IH .JC)HCJB3+MF+IDI<30 ?((D0-19.4L#K?-'>[B:6NG.M:R\Y;>
M!6OO.S*BP%A@KHA-"GVPG96);'OAZ(1V*IEY"=C@'-.CRV'YL!TQI >YJ0<\
M^&_S'K>Z0IP&]IMXMJ"G3W,!8\ID7Q;^';QK.M<*XB-$?;-S&?B<3G:Z9MV7
M&1 3]]M$SVR6>T;R=N%Q U5,IE,M><\J?98[WET\-<#C>N%5*>7+*YP,5JL'
MU  6LE^B#F<:.4R;VNO+TY%V94RE S"9V=HT:S7_XH[ZO";'"):9LW/GI)=9
M9GL:N>Z9(M:L>5;&,'.[DE''ZT[RG(&[[**N-(^2B=ZG6C*;RA&\&AQE-XXF
M,<K*R@7?1RKHZZSF5&[PH)XMWBSUD9.-ZA7BDHWXRG]TRS,<3KSF;^,QS4VN
MN]YS.GC11B1;-A<N_U@I@Q./#1E(Z,4L8'F*!0E&77XL):T5><#;-!,79-X7
M@.FB([CLQ):N%>5V#ZUC!/(8W2!%^?$/)M9Y7P:806AL3)O=*5>E6B6]C;G:
M33M]O>UQA0P]YD6OYHHU<DFI&Y>QHTMICW8^%I73:E6[ K9<<%!NUJ?B5HO0
M)V$16*_2MDQ?:R7,\O!,-;/-TQ(0DZZ>AK"0D6F/\6(X8,(WO@E%TKA>>G#0
MHUS)U.G82ZOR5P;W=JOXO-\8![Q4:L\8]:X,^B<7 +/X)16@*3]H&!,"J*JA
MZ]NS"IOB\9;EUO3ME;5)>.2%(+"'!HW4U/D"J*"=F*S :;%/B;BQ"YET-9Z3
M@R\P,Y??-4$H8H673=>(3WK\ZK]??G=P])7)'>B#A,?[1GU7K1,/8AJ1JN=Y
MKOD!]3Q&G5PYUZ7W<5&U8OD6KFNKZ]H<V9'E,V(:S#(:GJ@/^'36T!0%O>8!
MHO5Y!S@6VX;T')F*>O05](6GD1@^$!EV>BS)89"Q-%EA2-,CM>#Z0R^&]H Z
M \2JSGB0N!/XA1LUF_,WJD(\F9Z+ ;ZW/<<(V.!9;I+O5]WJ9_I<)O)NRYS&
M*[A'GU"%VTSYB%,D#JIY<!%?*!"[@6\N_B0URS3K%9E<4+#NZSN>CG;2PT2)
MEL+<#GK\:\/_&^-2IOA<N ,XS*DN$BDIF3OIC0KF$) (A3[4O*D Y%C41ITZ
MZKAO*15.B*B11"2H.PB4??;(V6]S,8O@5'2NY$0:'YME[4LMK88DVUR8S9'2
M1"FSK<\6$A8'8@N5<]*P(;W[DT>3>76-;>V/3.D/)/G&'XM3I9<KM$G*KV4
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M\QS@+Q_IM'VYKI/->W'XK['L8\]0#LZ3IX=?8C#>H-7H!S(F[ ;>[>_A_ZJ
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MST]=;T-OX9.;3\\W-7?T*$!I*C(=MJO@%C8LR4Y% 8'2VW?<RP^8JHBI>OJ
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MRJQX][D ^R+F^6.L@T^.M^1-01GW >F>?6'[>).K\"C997:MDA2/X4( 01(
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MX_LD6):'1?L&N::/'AU(G)=I*D-$I==6BL\#=OXFA_\2B[/MVM,JV7?/I%[
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M!I1&PV'4F>KG=)6^(F;F!)ZL,,<*P8,M='6$^$[#*TL(IJ%KR/:(MW1!,KG
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M)K*5T#=@>7NVWLBVPRT 4A0+)F5<5IP7UR7)K,57(7T^Z"-6F@5$VJ:](SV
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M7]Y-!1VW8F +!NWX0G$:CZL9N[?:,/\F%U]>>?&%P=/C;UZZG7Q3V$G]>+Q
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MD"&1O7&.E;+AP5]DGUFYJ.=*"?/TP@)(#_$L993KB>A9Q<X?RE8)_QXBV4!
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M#*XRUJ'<^;=M'A@(90>QKJ4%]6C?6E"_U1:!CSN+5I8,_8%L;(VC6O8*HR"
M[^@OWVII.,W<&UV7VE'LV[6XVJ%>XP'\$<$?7SR /_;C6?Y0X(_W;,0^'N1
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M2=T(W=2Z1"F3A1N[DUMR2D:&MI88@A'DS-A,<EO.A63Q"-0ZO=96^>@,2NK
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MT,R*8.$0Z!4AP'Q_XQ_M?"DQ"QK3,+,U&KYQ.'0US^I$:<N+IB\79>@]V*Z
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MY)1XW81Y TM%"9K-?O*XP5/3'7LEPWO9-BCC'24W/2$CD6SBGR<[:0\FEO>
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MV87O>O 1N/GL8"N4,KL5_DZ^>' L$RLZ]UEO49)T&Z6W]VW;K>VQ5#+J2%A
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MXK[P6PUN7:Y6&A1O"?QV -@3K;T@YE*RDYBKE((Z.L\,CO2[:M*9Z12IW\U
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M62J5!U$V;A8D)+-6PI- _LY@$W)BY#:D%V[,C1TN]-+T7'G.=(94($]28:+
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MRV -Y)$7;!9>083,HAS'J""?44&8&@,T0]F70#SQS Q#3A53)%"9'RZ&)J?
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M#Z6F(,0_X:(.9AXHQ:$*B;_&SX@4!(/<)2^"%-:?;GC#*-^N?(/'WNO0AR"
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MJ_ '!MFP&G-Y\H+Z(U2;;.:Y#?5N=%H98D<5QWH!(Q"'OB5O9 ;CMT4*7<M
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M2>=6TI*L67B;S47]!A<%8\(4%CZ"$$VG&)S9:9EMZTIF0 WO!+5YQZE=Z2>
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M#!YR9/9IV[H@P;+6KX=!-+/U3L,P00LJL9#^L=7OLHW$A_1S"O96"%:-$]*
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ML_,H0^MKE,X7%!BF.R/XK2]N54(7;+J K4]CZ\)S6[#W.'/V03[ +$(@$QC
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MV=IR#N.F/D!P/UQBPRER"6+I3W'J$8+'!9*Z#+([$,8*RRXS/,)H;0QTSM)
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M^0Z^01K1GF5;KPY&@:XDF<(87 /\3"]=BH2%S^4V\:0_9O98<[A@P1'+(+D
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M0#L \1U54N>Z+KO.W3)+"MM@OF] =0R<("R=60 SO5X6PC>S%&:%(CE,(_H
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M!A_%?='M>J-V?_P$&&R=]F \> + N$%O^TO-9,UD'S;98:=O< -9@#\<-_!
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M&@CK#DP0\2"].QJT!@=Z.@T/$MF]?2[C3R5*9)ACMX+1SH8JY9-GCB;TQ[N
MR8AK:?DRN$YF6*(?)V)IO73%,GZ4&N%:Z0^[:YI7'$JXI^W <,*$.WK*:ATU
M4F<?H)E3<9X-;^S6M:)O@BNG&US)\)P?Q9*OE;(8==J=I_5?3I5RPU%[9"AW
M$.7&[8'QF0^Y MI7"YV*VVSXPV1E-3FD\A\81?$]!]N 8K=S][#[GSI[M>/6
MN&O:)AQ&N4'G23*U&D"Y;M]T 3TD%Z&I[K+AC]W"*?NB!)T*?S0AG/)+ZOMG
M"8QHR;]2[T;X,DCB_].XR$JWU[+'!IWO(-)U6YW1T^+SG2SI[-9X^+29/J?I
M/ _VSJ\]%0?:\,=NR(;[-BX_%?YH0H#EPWSAATL) V+U6H@70AY'6AH7:.FU
M>R;.<F!X_FD+6TZ8<(<5Z3?;B]XOW'\J'K3AC=VLE::V%2%KY:=$3'RIJ\X+
M=?1S$5U[P1G/EU]0*JWO#RI16]_%=?T?WL'U/S<&6+ CEI^Z8+1X@97,I"4F
MX8VTB!!6)!>1C+%Z*$PC2V;&SNTLM!8"M]);B$3B3\/(BM/%(HP2&B4$>T@D
M7AC$> 6%OYZ%\<)+A!];(G#U6^'OEHQA3C@*/#C=.,5(^M2B*PDMZGPAG,3R
M89Y1NPP3</>&%;>G-SS:]OP!BW82[T;Z2PL&PXQG)-@B"MV4/K>0B$ Y33B]
MQB>:+(WX&G?&<W:8_I7P1>1)WL6)#.2T4%5V#'I::>+YWO_"4;0<D"X">'$N
MD\ASXI;B,OQ*;C746\BZ__D?Y]UNY\V'SY_>MNGO]AOKZ\R+U5 6_,V5B8SF
M\'KXU=("5O-H8-R[()U/<-0M_%N<QT[\/HW".0W,2Q.:&\K,W\)YE%]?7!?,
M.(UHZ<*9X:J]T&W#HK8_O[;(>>HGWL)?KJ^S=*>,CR*CAED^'+P-L>2 M_<_
MH:P9&(KN^4'GB*4^L?""57_XOL!U K?#_ZP?<>D(79(_\(7!2^)]EJD^0L1
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MA_<:*08](*;"'*$?LEZEC6#M1!RAI+N507"N7@PG\IR)",B%3&92DA^H;T#
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MP]>PRTF6ZZ@*!12)P,C]6BEQ645/H@P&0$D+-_>7*N&J,3[P'@C;Z[A+( =
MX$0&T2UY+?FVR,*DD@Y@5("!WA["()2H.T&UD.(($^'R*<Z$QN5/QNERTDO0
M\( ?"B AE5Y'!L&=X"&907+(+CGSB>]-3 L5;P46"R@_6@%MAF^8T25- O(L
M JH#B:4+B2B3. >12OC"&F0R!TQ<P"XIN*!5\:\:>I\(>F>BI,1EB09?HHH/
M(P49,$B<?GN(<,0Z4+3>#1-K(A(,,F)V PNAJ5DB:Q@D3IE&*S@708)RT\M<
MJ>ON5PO^\@!#;HQ-,A\QAR\$+UD]3/O.BW4*)IJ O]%;J>J@5G>PCZ2F-$HA
M_(UIE>!MZ?=D9VH.!AB8UQ)44)6-M34_16I"I0/45A1DEK'QDE#(EHSN-(D$
M!K9@C+8@)=+8A,8'3:(L[JE6!+$2T$:=F<&8^$]5#OK>4 "YX? O$9;K5/'*
M,<@A76C)5JDT7E(CC=EH*1#?=O[(2\-*1:?%(ZQZT!"APV)ETKJ= Q&R(P0?
M?C?H%"%MTW1$D'+%J? ]I(AR64P1'0<6,,_,-%L4WNI;N_ #SM]?X[^RA3)Q
M2C=2Q"I^=$DL[4(HVQVONQVBQ0#0]")R,L#ZPMHF$7, ,Y:%51[[R=>6%CT,
MXZ1DVFTR/WEUJ@+!4%_*)9D#UC<L:7!9KCVFNN/5HFFC(K]R-;!%;YU$* 90
M *OW<$G.D*]\R25\S8%#0[%CSA"OIV= =1^*J&15NY,2(H[P0Y*1]*G!PRK&
MFJ]5CI/6.BH'2BCDO\94+F;6K!@UC-MH.S#99(B289$!QLGS>?O++^^=7T L
ML.D#DK;MG&G["[[+=7445H'9'9#0J[1F8,F3;[=0S'FEJE>B7V5-:+> L(8O
M;N5&&0!\Y2'".EDE1 AO0PJKP@FY(0.<"""1_UU[.OVQ/F&K;&O@-JJKYJ$K
M#P[G4O6?4D6\X\DR-_D2";8W6T<@12D4091,U4'<#Z-BZ>C]H,C$@B.] E\_
M(<#GP %>"T'I<8!(*:YE"2C5^E9_TZMY]S<B( 2EU7CCJ$C&12OX=CPJ[:J>
ML[Q$=]0>YR6])O:W <=52LH:Q;P26E5"'+?8?BF@HLQKV BZT:1KD:&<,X .
M"47:2"XN7N9%<*C*\%?2A)?>B]I=+ O^ 92OD F=G\.&^D%5W;S0RR)%<[D8
M>?8"T$/@9WU9_)M;KDA4"V1A\J4H+HR.P/#+[: \7I/>RN!&1QI$):@QEX)N
M?.$.\T-QNX1D(5T0*Y@ !#4"5,YY0+7Q.4;\%GAE4,=+A+8?\3I*!I!T2^*'
MTQR^[O]A. 4MA41N/E94TGEHR)+UB1)W KLFD<75CCKY6*6?HJI8I]=41BM4
MTD*E6Q#GRD@S[@YU+S80#M@BL>OKRF,F'RSOPVQ:A)-A9G[LD:>^!<D8F1!;
M]8557SU;]=6,O1Q5U==&FJO*Z18*<F!7&7*I=4EC#=NC.Q167;2B4%H?"D'#
MOG./515(G!5]P;< O;HF5WR77[V4W"3M0:&#5%'3I6(DE*LD[_Z5!23K+LO^
MIW%O1TLZ=7LR>5+ P(X^RT6J_63<UE,!I#OJKT*D-H&!N\"7L<[-7U-_OERT
M<X7[9%FG/A+2W)4-]3IY_1VCIO"4.X^#G4&[_U#LF'=K.T^)G-XJ<OY8<!02
M7C O@CR)S(& UD-YG<&H>D.G!E,S&1"BTMNH'ED<H9 EUZ2I+<7N2D,8"&RM
M0R+I?DX71H7A;M0!G:%=A+Y%$8Q7#UWIAW+7T,BLK0-P"RWA_+8T9P[(9RF;
MYZ7-%*YC$3_:A-N9G-_A8JV X<S,-OSRQOE,/]4'4QD%M8E5 "0Z[^&QE<H9
ML%5+<IYAWDX&P-GH&-S&F,<W_"5U:?VL!MB_TU<YI.M<78R_QQ0.-(!GV*0;
M@8?P*@ZN#KQZTKR7Q.J!PXSD*'F1>AVZJBOUD=E%7P<<%)/Z\=S-F6!?&7B1
M=G8,AV@+)E_S)N6[HK^Z'J=Z@4!@IE>B$PW[243 =ZBX>J&* \1/=_PZJ1 <
MOP\9^]]1_-7Y3)_FKS1I[_=_?WYK1EK,?2HH+E?VS+1QB &M+854H0W#ZJDY
M&"\-]JR3.FVGR._G2'T0+@%/^/<VNR^H7YCW8(>C3NMR.*YPR_H38#R X_.U
MG*:B:HM*+XHZD9YWF1BU=+=%94=(O'S.OG;H=.XT\%:.:H*J72.A>(]$O,7.
M"8/8\BZ-*2JQ5&^H62",;M'82ASTZ$H\CX$#C%YQB)D28L;=M5[3*E0_T2UC
M<J)^CT**UT5!P!DW%=JT9:K/5:8*Y_I+MZW**U@HNEH-9U_'@IB$90$:H/G4
M+[);DCRH_/GJ4U%9D<?*<G(MR10LW5+1XO7A70S'ND&4D#WZBPBFFC7Q30Y*
M"7Z%=FB8\I57<Y$G-=D(0"MA]2>Y#Z3L;VUKJ]@8O(@MF(G,;7\T&RAPIPHV
M5/(/=&=NVAFQSK+V-N/N(&AKY6SN\Y 2!&%&%_[7K\J_(C313U8"?9<M$\85
M:9M*,3?"?36A<P4T@OEJ=/N[;HV?J3QOY?SOMH,RQM3CQA[JFF 0.LHU)*M.
MUW!8^)\;'>%5@ZLP(^LDU-K)3,_%S]WNL#4<#/=Z=8G(H\;M[W:Z14Y=N36J
M>$HDC;_?Y*JKD8'/U4][ODJ1BYRU*JITT:8FSG(/-L1W$':YMWPU1G(KC:@(
MAD"H\>[=(9!.=U5NU-DQC;MI0R;<.=O6'U5=D35<GJT8( 07R%^@:L3*7*R)
MN5\S#%4#66YLM&LSCA;OP*SF4HTR@*;55(F(FLYF(=\EU/=#](;].8859+E?
M5*E"CQABY:"(7]]3J405+36Z;[#^.N?VE^3!J(:V,N'"(9$8J=RBSM*T1ZJ%
MF2M1)0I38"6<V16%#)4($R1(;QH&+&Y4*3WPO]+8_'NT8:IO;U&7H.O0_YL7
MY8@+BA=57HF%BWF#_&CE@HPA3(Q8PU4&,BI65P#8G/E$34SP)6^*/B:?4_%5
M]S'96'=[@$R$<,&].]VKIHG63W[RU7D'& ;O?[\BE<L85-&7OB<,NV,&QIIV
M<EZ(I5$88#&:;6Y23G/W;9J[&7LYJC3WKM::ZM^/;/N'TG1OC#X/!R2XJ3HJ
M0E.#5")W*9BA:<,%\+FEDR<J)DM,A&3J=DG>X5Y?P* _J;-^7G*+VO6&+15=
MC8W7H)+*A2TSTL+)?70%^ Y.]Q(;)FCC/GGY:A=0JX_2:/%J2(!6Q]32$),]
MZ&4'8I'(5_J/UWB])!#+5WY(8*,?O2XOCS*C,LV1\,I?*W%R>=D>=\8H4=0\
M8O5B)6S:)&PJ(R;YNU&OW1OTUW[=:7?7?K=IV6ZG/>JO_WK3LIN_&_;M9D?]
M[39TQX#JRBC11L^>KA^6FA^J.]SF5&Q6[.E<*U-HZ%SOE+#Z-P@KY^W*Y=*'
MS1NO'[1^R'C>XK1*UJ(DQOFX%$QP],8/BSA01STY*-9.7CXY6'<LK)\+UMW+
MATFV^F'8C99L>">2KQ>85FXQO"DW8'>="+XU8=3.1F\<G+Y[NO,W>TSZN#ML
M7]QO*/PNLF'7B?$[R:H*7U;EG27E$R'ESJ ]MJ1L2?GP27G4'^I)28TCY5-P
M"'.S24<#\Q#@!I,I!T9O-V#4\F+S:/)L-!JU^R^WIL=ZM#^I]*R\<JWC<Z0(
M&G3&[:%%4',1-!J.VX.](.BD?-TS);5?EKS>NK3-O41X#6@.A0![@TZ[NST!
MUA/!/@W@8T=0=S!L7UH$-19!@XMV[WYV>8-,;WKWF M#FBS0W^N"-57RVEII
MQMU2[8-KAU)LJU^5QZ0RW_T%ML/*,(^N3WBR7O7C ZC9W'W6O>RT1SL;:(\'
MGSW;WY93+*=L!YGNL+MS@,IRB^66T^26WJC=/51F(9OS>ZH1;&[+IDVEQ=1A
M]PW>]5'])>A&>S,K6G>]=E>3R&_O=9S5%QI_4)CMS;HQL7,UQ%ZN+:I9$$2W
M[CJZ;=25VF($67[/>+I/$.KVV\VF1!ZGLU=2.TO*[98_$?JH[/]#?O=OTY6N
MES3SC5OK1],IC@50;7% &.>P7X@E=J_ .Y=Q)@+5JV33$WPY.N7;='IH%5W;
MQ/NR=$.VN,E'/;ZIZ2O.B,#F1O-%$"TE-J(NYJK ]J/0T[?J< EB*)[&N<"N
MZOH=@ E/SGTW[XG@R:F,8VY\KG>:BF]R9<(13\:B2[RQ#'PYQ<;\49R6-J*7
M+W=I**]+K7SI7'ZE67RKZ$!1W#B>X4)>)JM/]QIZY6Y';GF_(?NZ#[YA^FVV
M=-DZ?=T\'5>G3K1(K_015#,\Z.MW<817#&-U]9Z1XSFE:[N@^'%N)L]IP4#B
M IFU[6!%O"%1S"[RJF5(L;K9\@7EIW'_OG%MA'[4_=S! )[X(0MT>_]^3]AX
MMR$%:>78%G)L4P[W<.18(9M"'/:$ P[SD3OKS*F\/3P(L949!V8_PW63':K-
M2PR#A,?%50RC2G\1YQ!;I.U]/+G1F:73-/#]FH_!_@DH\,AU0F-4P)J!-LU4
M;YN#3]6QY=O-URE?AJ;IJ3C(EVYJ)X=[%[K;Z;0[W%[A'I>A^\/[702^X\KN
M\'+X)/>+[69'G>V6/9W+T%L=JH'7 K]@Q]P=3K7%;<K# L ;[MIWRB#(3:&3
MNQ]:&('DAAAJ^]46!/$HEU :#9\'= ;8ME#2@O-0P-F\PH(:>#[W]2S#*E=+
MG./SK[H7%5?E_'(?KDJ-E#.GU:X?;U]T>L(QV!1Y,7R:)W&71^WA%L>IZ8>'
ME'S>;]<X*MA8G,L@SL3+LCMUG^LG1UJ(=$BE1*W1Y67[\G[51 =4/&>IKDEG
MZU[N?+/>DIPEN0<*NHO.SI=M#OC*Y"$84I_6F4OUIL617P;K8<QW?[?![(V]
M[5RDBUZW]]JBJ=EHVC,O[<%KWM>=2DZ-8UE34 [^':!/.UGCTV[%+(?;2.*B
M.V@/#]X>/W(D=?N=]L@BJ=E(&EWT]QE,V8./L1\XOSNF2*K[$*USN";:J#.Z
M;U,Z:T<_%Y*&O9VOFEH</3>.AH,CZ"+3?*537(\]"K7CG::ST^^-K!W=="0-
MN^V!Q5&S<=0;#T\LG[(?.'_,K^H<MKZ1I^GF= <7]YV(8$WHYS.A=]8W%D?/
MC*/+_CYQ=&*],FNO,=QUUHW=I=:7R9Y"I<RC@*;9_#EHC2^?IC'9EO!I>#V8
MY8Y3YHY^Y_*^WI+E#<L;1\T;@];@8G3?O.D^N6/79I;ZI5R)B9?MRY686)OY
MV#@8MB_N].I[F[SZ[K;W0!YUVY=;[;E4V-IM#_L(O_<A7L?A#B^5FB1J#S '
M*L*F=+?P"#9DRF)G$H4>-DM9TB5_O*L3I3,9.V&4ROQS:F^32'@XCFD,?$+K
M3;.8GI7?%H& '=)[GZ%31PXA6O"^C3I:>\/>BQ^>H7?3$3+<I$$,UV-^*VH
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MAC2%ZA!\!>1%[U_B%_+M5_?3[5[F^X'?A+H;O!&+0_R8(R%46_AE#BD<@D*
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MW)_C,$J>5Q)+[("-LP7TL#8>%B"]MO-^RM-]P!KR%P0^X2PB;'AKGLJY\:-
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ML>]3R&:%'+T<"B:&QD&Z#;^)$$0UB535FHWDO1*J2BLRIZVB3:&4/XA0Q2"
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MUJUCL7=-'$U92P(9Z%;ERU:NC(V/D.QNH_BKC(D2N^/7U+A*AHDHM!2(5-"
M479-;4:C";W6[-ECJ"6M(;&%FC_W63N2[,'FVDR^V J79'R+NFQ,4'U0;TUJ
M;FJ(WT<^A^K8RR!,9S&=2(":C;!K5'0;4L<H?13<F._Y(&%6)&'S1.%:0M^/
MR+N?F.*6FO,H;U)7VU>SQ A,GP?(U1^J)S%&"E"_*.2QO*4T?:H;U<^+CHCS
M+$GKYQ^4IQM0/WW=H1<QHQO.P:N2E UKU7E;6U]%@RN?0]P>68QH@Q23$1+=
M[E<UP7&2F00UASAF@Q=-I/A&68_4(JYH\OLD[,U]1 -LM(D]N1=D5<W]<Q&&
MU(\4K2KJQ:;[E=)V\MD'DW)O4?6X/,S6F1_);])-ZHK9#'4V(R)1]6)G@*AN
M?NL 4M,[SY/_R82[7.53H@Q-"6WG2[F=/'*[[MW*Q/15+E?V5]/6U1@F$"R-
M7JY1I1WUFHV\,F=J*%(OFK>^9J>1&M-/2<?"<6]D$"VX*2)OY+7A6AJ-05V>
M/9%@YT+TI[!3';W@=:$@23MJTVQ5D[Z&U\VQ:^<"G$!S3,]KDIBP<]YW%$X!
M3WBN +<';YA3U\^ .1NAHGX&_E(,4'<\;!*$6\<MSJ)DX9N]IEP<NW&0$O6+
MGF6B6J-3F]X$VVYJ[&*3K!OT&#RY4+@E 8&8^RL#&0* XTZK-!9 X#R08I8+
M]58G24G-]72GKIE>G@G;Z#BK.Z$#HIF*M.L,DGP9H8QVEE+$Q;9*!%WI_>I/
M\UDON"$UK$0=S!PP8A"U'@IC,H17B&1JM&ZJ(+6:<AC+[,6Q#FQ]^6$];^=>
M*FIM]&'@>=OOT*#1BTX9'+;?H>UW^.Q$^#,P%PN],*,(&1Q,*]9,A8A 7,"9
M_62V296W2L.E<! *]F$EQ8:6 YAQ4Y];#P-[<M@#? '020 FWR-S+-?R%.<5
ML9BC35',9@$30_@!RB8P]S(.DZ&V4LV\R4K5AIQJ@>V#Q\'36J@[-W],YD)X
M#5C$J1(H6Y-4"J]Z CAIB#+EQB==K".6>%JC#3"VJ\=1&GX0@/T="]7SU6@&
M3DMM4-,,9U]W?\R/!DKDCX3@!'+\&BV>C:OHP'E2Z5^_I>FE>@E2N\OJX?,A
M!C@[:_V2VM/;N,TS;(^N6P:]VL6T*+<_7.V,].P-$<?=]JA_OX:(79#1XT?O
M,=@;M3N#[5H7'F3CK?HF5!A+76N#U(?_MVG9]#@=D0ZPK=55DCOU+<XK##O_
MV,C4)W;1MMO?O=5+\VYQ-IH&_T2R&S\%V1UPE=[@8N^=!.Y;@##HM(?[3)IH
MLXZ\WRDXNSQ6%,S#.+HI,NZ)F,J4XS44F@D"-8B!PS8T.DS@&-4@(-527BW&
M!+FDV"38%S3E#",):!O3#(B9#!9DO7) %W]=A%XI/XYAFM4!8#;#\'09AMKI
MUX<8\:H0^::@# =G4S69YD92]/TO'I*B*%#-K5']Z&E $IG6-Q@O5X4A>K:+
M'GO) U;<F3G9A1U!U9 ^C,C'XQV5$@]Y=!_L#6 MC!K);RZ.XBSR&RK6;XP,
M;$AIQ'TSZ./.@670?XXBC_!S@.QQ-4DX7+JDF( ?SYEB,3R>\K0DJ0?08B&8
M.BG*".-Y=B<^N&F$WD27LV4TC Z#MS3K-<5@P-K?F]/$*>0<^JERC"E15S?-
M7"=$BGFVJORJ,L^6A^H581PUG[:EZLHHDK!V,+J.]933.#@[FS)!^8#9M>5*
MG$"82U4B5R04W.IY>9XPC;)+2G..=-P)9_TA3"M@*NWN=B8I">23" JI$I"&
M 4:ET:>EL4HY5@R,(+HX%%)ZM/*$0_4R"B]1B!FFJ1I"Q25[O W*5@?^5\PV
M@K (21*)RCER.68 %R-E-(\.?^33?/$X7A9#P0XRX_A^VBJ/G#5QS>CGXL-;
MR75R-)*>51C*8TQG[XQ+7HTGK6\@Y4HE9(72,@J[J=0SYCO >UN@=LR3HO N
M=Q;Z_\ED8K 711Q#%[D %H\C)&*=,0(\?<6A,>ISX@'>)RQ*9DIEOAA7#=8M
M.:'I;$!ZP'WJK46X;_6<%>XS)]:O?X>:FZ5V[0I*#/I_%[Q>^\;:I5=._G_Q
MV:2(Z]:!K/(C!2IXFBP)+:AYVAQ3H9IW&<=$7FD%+.+Z.I;7".4[ 72(UM^7
M&C#F,Y;)U$IDKJO6R*/""#1'3BNSBF+KR<R9!AP@5I-4B]R>8AJ18^-<Y/71
MK"<5$>GIEU,L?DXTHC'C[>/\9M*RN99BT;QI9^4BF/PPI?'6I+7SJG.#O(P"
M=+*#56I7PE'Q;?E<[3K]R54KL&<UO?XF"K(YCIK/MX@%!&$^L%4?GSZ%M^(\
M][;#?2",]&IE"+SY1ET?C@ ]3\0-3]P%(77MJZ=3\4VG6G0!,A>GNV[,%KVH
M SCSJC!98P[J-?* >J^7C(,J0Q;;-'ZEZ^@,BHLFZ'F0E 7;(4M+]@@^]X9]
MMAQS21JY7WEDZR%RHJV3?LPZZ=SE0.IF7GD?IIC)PVL(+;-@N@#Z1=. OO$4
MSA680JF-H.R=<\OY4"S)UXK/C]ULCH7)KHJ@5&K4ZIR8VR)R0@Z-,AUAY;+K
M4NLSK!JL52_B3I=AI]2JB@^?8Q[@U7!0P<EY]V)O2"$.'[W>'W>48=,=<!Q[
M+MPXJKG'IL;_"F5E^ZK6Y([;;RVNDU#EEFA@NW2S#9F0K896<=7)J#QD5QG<
M4A6S=L$]]5.EJI/7E@*>D ( ,ECOL:R8DQPJ+2(L1AV(<7?0F-ENFD.5(=\Z
MR..K$"[%'QCOA7>U><B[I8&GI 'R;)3 +S@?Y;&JQ4&T!V(2Q?@M%N&WS#G0
MB>71I\6/SN$5QHLQ_;M 6(B! 35WW9,NK,V2-W=WZ2H*?T,H53D'^-AP%F.^
MQ(>?2A'C$ANP>Y+UKEU;[]J,O>RCWM4*KUV%%VD)$ C@.N!=#';,SO'&/'KM
MRD$II)C.1YHFAW$[#,027J4! 9A$82CY[GQQ6]_!VV;7?#O$ZJ0G]1P4FJKX
M$PIQ9B6PDO&(JXI[=U<PEP;44V"AE/]SP89,_,(\Q5)8]1)KBSRQK6CX!D7F
M07D!,W^A,ZSU*1>5CYE$T5<."I0*D?#F=((1">H_4=B>5 DR0^^ XJD4*+-8
M?D(L!S*\QFJ3*=\^ Q<>/+<YN@G8+038MI3$!.D<+!/_(#-.[]4E1R Q.# <
M*TZY[ #KJRD+JVQMS-I@\0W?N95%"A6>O38#HT;R$"N%O+^ I/5]9<[R%L_?
M"B/I_] Z(*->J;X.J";7#+(ZOL8$SB_1+=[L;''*T4\(\2T5_@.YG)7RVH]5
M0I&?#U-I?O*50['EXA:]Q7O7)_4/K#[I/2= OXAO\D![>ZB;UEPVQ*=)\30J
MN4HA>E3J1!I%T1PGZ[BL)DBBHHX)R0US@KF.U_2N[G.QA5!:S6?+$3,!L4>!
M)^*;:NNH(E]TG?G\7&3V** ;4^81; >AQ\V,F<2^)@_6'34-QG4<>G )KXU-
M24I<2W7DV+M&$8[9EZ?$&P<HK;X4 B%=.;L3B%NS-#A8ZG+%MO.KN$U4H[<\
M",X^CT]J39!NHVH*/XRR)"^,C*:@QL']F?C7&7S.XJZN8'*.BM"LEEQ7]XM;
M$#'W=<A,B9LW*<(:8PR9+6*9IV>FM$@N]N QNG*!JY0AL'I,Y>%QK0E@@_K3
MH0/8,KUVLMJWV3[656M_,K^6GS?LPQHQD&-_\^52;DQX!X$?9)WA%[.2' \-
MT.7[&D66%D_OR:FDUC6('J7Y_$3U?Z 026@T3N1ZFKQ= _Q&U; 0AK'($"U"
M_5Z /N?WTMQ_YZX,Y?LB9M\2P#W=ZX4-8!]&?$G>H<<L-UTIR@6H4WK(J$84
MF+56/7=T?7K>M450'7M:=_ZV\P%KAI7U#H>8"+"6R7I5];GX0LI.^S.P@KGE
M1>&5;H"L]G<I[(#'OQ%^0""4-WR)JP7>+%@6;)NHHF8=BN?.$D4IE1&W1_@J
M9PJ+KOF2@9.X,^EE@8K#QPF&YP%K<@YF,W7YH*X8^%K5 T-'[FN0BZU!N:6&
M;C:J*Y(-"PB/6NX30JZ%OAL1:8\<XSJ4XJ<B;XK:<'*@:":B0./K>T:+."-Z
M),LM ,>)"KWH;CE7>L54H S^  <&2TE'Q>I%?2V#TCRN.IS>2%$H6)(TD\CH
M"<K%;7DOU5*BLL4I+DYHM8HN,NL*X7P4J%2>QQ^WG1]UE3!"@WF=Q&P-R=P:
M1:98A+VAB&(=91+C3J0BY.+J/8/E($4@8KAP!]!*R4)#_)?* M7UL^3NAF(5
M*53;6@Q+"C=W%\M5*?XV H6#RB?WQ?%"$2KY*=<R%XX*][L5.1-RYRKNG:I:
M42%*,_!\8O):*CURU-T\I4,-Q<PR.LF;V%2[-;#N9JE297)Z@G=VJWL,&UV!
M=/"A; MQ[]I#M/%^RF+M=E)S(M237GZ;GIT,?:5>L:9NWLRX7=5/ .SOSOKM
M[DO=!*+:HK=FU9GPJ/X).PSC?NK6A16^&\"Z>==>QA+W2@;(F*8W-WO&"'DA
MHOB*%VPFS5M8E/M L0 O"R /Q4\I%,5\XH=*\M?MU..(4)G[C-U5U$B6^BBE
M8#&C(2;U:ZG9/W Q"GK\?HF,YZ,\^U+8-.JG==O"WM$3"0:V<;HIY;+Q-D"%
M#XI['16)O4;14SU4XL;^!.V1"5AH9E9BTQV_&O6<[ZJTHQK&+&JZ#3U>]-'6
M,-^L([A'&S7M/D ._G/F!R69K@*1B8XE58O+21OZ[.JN-1C8ZQ))%'(P*/3N
M*F9$8EV%<]XI4FP0 2OZNH7A894U4[=)$WW%5!N]%!*NHZMOV'!<%!7\ZFBK
M]PHBMMP,AXEL8ZH%V2PCN'\;W6ZI!*45ZV]1$[:Q6# O(<I+CU38.I1Y;(%3
M0&ND,"W!=K(LN8O4W4>UEJ,VBNO$18M#(4' M3&57KVUGL9G\*4"$6,-E )Z
M$>)/M."KDTPJ(%_(6+_:2T^MAV]33>J)HI/<ZD^9&HN3,1WH#G9EQQ]MTAH?
MH"!#O.7O.1RB5>I.A9.4:X9@F$[AV$116BDFYD\ :47W>X2)LMOK *#0H&ZC
MW,Y4PZXB75PN4(Y<."??G$ED3FQ\;YGZ$(C2?1/=(HO?7V%UV[&O5,'46U_!
MM$->9?3"ECV=2-E38W)C5WD\ ,_T*[:P?4/Y2= T9D[CD&P;R>(LD-=J7(LN
MK#7.939M8#5,;2H,^:<LY[SYJQ%*-'N[DL%16MIFM!XWH_5K7H'F?-)-)=<D
MMAIWPZO$2\8UKS?1?.ZSB7.P^:ZCN>"E!48>&9\6O5U(**2ZX_DMM:VY5<_K
M+@_:RX'?3]CQX5[@N>N,8YJ4E9CWR<^#O+D'3K^AV)KRH);*W24G\ZHDG(I?
MF;D!/[S!5M;DJVEWW;Q9)O)W%%NE3-3J"[5/0I*OE+VO?\5J/D!;C,5].=WV
M6CU>0UE&7U;N&'3#V:?WN%R\>LV)W!53&HM"%*>JT<D#6_]HWRD/FU;,9*ZF
MH=*(LF=@QFZ IN4W;%?'W%7>X/T+<2X/K!#G1SV,#<3?!+!/<#],@:$*75@2
MFM6SF,G!2K[<QJ!+H%,<5E ,HW.-\QMWMHR%5.V.,2@.:*;M_+'ULRI0':7<
M(-&H,<48-_B0KB9.#FBK2\<4LT'X GVKX%KQG:H*<E7LOUH>1,S$ 9$\".C'
MM1U!$ATL,8_!$T&H0?XWEV?VL8.;Q<!EB2I6-3HR&,OQH^B@FYM?5\=D1#4
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M]K#")>?\V9,SRK@6;.\!#LY%^WDP5[>%,GSZ (L> N-=CJO/.:Z(13YGBT5
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M=??A:KHN3-8&/O#MZ]SZZW4R_NWI'_OOWVVIV7)OHOP=#)3*+"OFOL/.4BI
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MVP]?:V-3HF[*B[R A^$O[:L[JD?L24"S$-#8*7="$BFBXP P40%H>,: AD8
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M\'/#QQ\B-(VP(R'20HAT>!W1J/! /J*3TS/Z#V99,!\P!YDBP?UPP8HP4&B
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MQ\;E;KX2P'((=::1U-I&W&%25J>O.)54]I=9U2C*;UP=IZZ%:S*3:O56NQ-
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M O42.5H)U%\6U"=<*"(@9UI1 "&E@&K)@;2. Z2X=UX10C2/H!X3@=.@OJG
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MCJ+_S]ZW-J=U9&O_%8KW?)A3E:7I^\7S%E6.+S,Z%=D>QSEYDR^IOEHX"#2
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M<0B^IOD<@G=OP-NZ88+@W0)XERV1J"DGAG$P5)ERZBL"E@<!C&H7?.;"&5O
M2\V:GL$[G^R[*W;(]1U?LWMC\G.XBI@,Y^D,8R7W9XQ<%\;+_'S1OW+\]LED
M-I\5=FJ29R[&<ZQ#V(R:?E\Q2+A321-6G21U4D2D&:R6":1V,E"2HE*A/]#W
M-6 (@R,[1AW=,T>0.K9%'4LF"1>R_.-D]640$-)9<,:1HM7XP*J]$D*LU+%:
M(([PW1OXMFZ0('RW!-]EHR1GYZCR'E3@%(27%(K@'$0FG O..<)8?R".9(?@
M>V"AD:84L> ON>GH8Z_<:'F&B^'LM$8/KTP4C)#<?Y'A/]UP/*O"2;.7XV=?
MB>5E?EJ$@N2T$3D]^^-RV,:7T:=6>^*R"\4DX<4N(3&"IUF#UHF&% /)5O8'
M]+Y&;6"89,?8HPMV";+'O;''R=+@9$)82D6W,<%&$$E:L$)J8)QX690<PU4-
MLQ[Q#KE;$<'=,TT0P?>&X)^^1G 0*O(Z5Y%;+HH2X!4XDR0D8J1SD4>59'4N
M8,#DP:"X&%;7&XZOU]L5JV3<#*C[,LO#Y3P<#<O+0PN@;#*,N_4(RM?5Q@M9
MG:3YZ20>C]^GR[))Y*G->.K#BIW"#&$VZ;);'9<@G W@E'/EE>,\JV*GI%2]
M**MVRNWG;*/_\YZ9;2/@;K>1" *W+> NF0@D.Z%(),",L\5$(!F\< 9D(DP5
M5'.G8W_ U[@_$;A[ =S6(Q<(W.T =\DRD%)$I;@#1WP!KN<9#$L&:+'L::'8
M2+3K#]0:R^!!@'M@(8NGP]EB6'7M9K-HH]BR/; +OHLNQ"Z^)J?U=/1T6!NB
MC./LY?0KP2%+;<92'U?L AIC8,P5:R#6UH@A2_ ^:HBR*(DR)Z58JAY(B_$+
M]'YV-'Z!#'*O#+(<PS!):1TX4$H<"&(2V,C*)M;"BA@EL8Y7 Z5+_:$1Q=V+
M82"*[Q7%2]9*<DJZ[ /X( 6(.DS'.:V+M$3,P5%CB*W6RIW[$&(<XUOA^.-\
M$GX'[V:I/NY9;<KP[;7GN^ [Z9YU\N.IFZ;OJP2>7!, LL]F[/-IU0KA(025
M&1"J"_L0QQ?MKP1C2BCAE>>LZ!#KNMGLD!F";M;N*C"MFR%(%2U1Q9*YD8PB
M)D<!,E %(@L#WF@#@4E-D^>9^= ?,-NI?'"$:]?M#81K2W!=LBN\-<P+79":
M5!V]HHM=(60$88U-WG.=:>H/*!5KAJ]@_<:]M;;*:3HM9L7<?>BE1;LWC'G<
M8T>KQ?(O K-OW(?+CGO?IW'*0TS2W)"$R(IY450X+H(DH)@C-4E3@E="0E:,
MJD 35:ZF6>]X]3CZ1[NKKVRAF15R1KN<L61G%"621LD\2.\+9PCCP/-@JFN4
M:AJB4;HH+I+=76]!W'87MUOH8X6X;1>W*VE7FGCB-9@F7Y)*"]Y%5<!K J$Y
M":E(?R!(I_K/'5@DH]8EU7KQ+^E6E[VL?KDX<[W7Z=3YX6@X7[S]K\GLO+P>
M89CCW@R2[R]FY7YFLR>3,S\<+]J!S]/YX_"?B^%L6/]S$9X]+C<Q3;/Y\;CY
M:)K2ZW26W.QBVC0.KV+&KN'M$!U=,6HTT]D898&E7(B.JP0^EE=&DJ)?<E6V
M (X,03_LCMDU2#U=I)YEVRA3:A4CP%UB(++C8%2AGAB5RDJ%K(CNXL0"A'_G
MBU-:Q3_B?$.<+]E25(JB26H-*B0-0B4.UA(.7A7=LL ^)%MP3NV:UGE8P[)]
MH+Z<GZ;I=[6J_<""-0]:L-ZL^HO)N([J77AQ<*39-_$-6S%IG-9&<4J!!J%
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M'\7NE%"&P.TP<+=JKB!PVP+NDLT2F:8L:P-9&ED.?:G!&)_ 9*]D>=_I)!;
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MYV*/0L2$V@5 \M'1 \./5EMGQTWLVV0BSSKC]60UZ0XU!(>+ SNT0:O0BXG
MNIB2.@&;'P!*8-<)2(E)2.%H[>7->9,-X_Q[Z+3 #%?O?5^>8CK(W4_9@XT#
MFYQM']@DXKMMBX_G%-^K"!T,87-M"-OW15Z!2:QW!NQY;>3]5VMC'C0):JR0
M>O))S! _ EQZMQCWY=/WI4LGV4ML[9DALEQ_7&[>1%;S_+67&(L-!VWI V*]
M'ZD-\3*%*2@^=O0?T$NU._?>G<;64[5JVI"7$E+3#Q"DH*3X24[:.5ZB9YLN
M*PD5&; V'G2*<L2C@Y]'XOB&Q*'GIDM 4G7,$/6NO7# <=R+;[@70R[H@@]%
M]M]!?];>Y;D\!1!X.I^8R%^(T3L>VXN_U>&,B#<&DP>G]<0T=A:]K+UI_;CW
MHO[9S$\:.4U^>OK@]\=__IP\"KH;T!S SG"@)2M'.OBF=!#1S&F]: .@6IR>
MMYB^$&V0 &J"-$73"BP)?YQY'2GI7PA>^OY1KXH!EJ:O:_T:R^)Y&#5N[S?<
M7J\SESX/9>H9%FQA8-]Q#[[A'F#<.9CJ&.::=8D[W7ZT6#*^[F*V()47*)3'
M'?J&.S3<&=R%UNI5$]FF.](\=/SXW8S;%Q*>1ZGV+??+.^="$+0K5(#AW'C(
M='$J8:.T7?E(0QO= B'8',\_+6.0'+X:]^W;[1ONT[Q%*W M_OQ19/E.-@83
M+L]D>S,/ CR.Q[.]3WVO<_9&SW7G0/*&Z]I_- _'J:'O6:@@$S)CX;-S[_&R
M*'+P^'9PP@+AOL+4)._W7H%I._,'*A:P9,G"5V?0(6(C@<Y/NCX<YK?X(Q86
M!1KTX[\-J*")37<.^I5_?RI?V^$,PHGZOKY(KZ/V,(FHG</HT9?6U[G1TC\9
M\H_ EE\%;QX"?ZR"TSO'_7%[ ]_B.\/T( "/T/4@W:F3P=),ZZ7GW?6$O2O[
MS$XF^!.7\TR>;YQ+1 \#GH"YZOQ[-_ ;274^ =G)>K+M%5T?U[S4=^F]JGI]
MX'_M6FTL;-@L\6EBD8 VG"UM@DD\F)*$&1J!Z&6HE.!SCD/(*!P8[4_V8,PC
M].9=,Y@7'(@Y]+F12;>V*_J,,MWX(S83H#?X-SS69X?I^DV]\<VZ@>E\9I>8
MAMU_VV?/85)S%T0*SL3 .UVU SS%!NSA(T/QL9X%\(O-PCI]1IE]"WU[@Q8=
M&ZN@EF*XZGTM^L@*IL2#';60PX(/%RWNO8%9%EW9 ;5X(WS3A>Z9+O#"'B9Y
M3^SL9'GJ&00X;X!FX-4&(V>P!"O/C]NYW,NF/CE!AQ[LOY-8-B-X!;PT\MY6
M6)/&VA#/^V<\E=C[Y'Q^58V++#=RPB.==2NR>P=4U_*J2Z[\GH=*]CRSHT3=
MXG=/TY<%*4)(H\O_[/<CTD9\?.+CI_&TPY"#-LWWWJ!WC5R9#4]J1S(=(4U"
MX%D:Z+W%@ATQKW:%&:<+J_W^3S!J#+2SBB?AZMF6K-GKT!H286+D%-BNW=MP
M2R".0*K",PH^4_($P'R+'<41Q7/I/87'(<4P-P96D?"Z5-&]C;.1 6/N]=%0
MI-*N1E;,&_27>DWF9S"O1T ?_?G]GJQE\J:>3^(KH?R+!ZHS7W%@)B-@^)BQ
MKA9QM"$-$QA*VP J%JL0[+B)2NSW&J;3=.1PL5#"@_D,!$L;2+M%+1XD'<"8
MNIWX]6O#RH6<YM 24CAL( +^@;@9H)JKF618O>\<\.AT/SG (YS] >^N%=]I
MH(V0I>#SH3OD%6@!>*G!'%[?IR^G #_]+#1^NK<Q/#114F2UB!6'G.$YW <E
M@UD:+O#V>O=BU+3=\*Q'43W%20Q"G)M!E$Y;^) G2FR@!(7ZW&<E--$E+)<1
MXPX:\FD1P"FQ")//N$ 8$,LKP=B14KT(W9B? W7QKCM9-!S*>N)K37)F^^-'
M6QK$-IA<YFO8!2729\%[K;I6H.T*$.&  CH"0D:=(D%^I*SX6 G17A 1GU"Y
MZT=,$B9CDO"8)#PF"8])PF.2\)@D_($DX4O3 3^8WK=]ME<1R3(F&5,4?PK'
MM2,LI\SF(%K+C[OFY_M#:*S=$G-4/8)N0LI<Q)[!V681Q76@:!I*3M:-2<-!
M?,"3\Z:[%\A7H!F@2JS=TG9%&#TX\V:'1[N; '<+QWG\CDBT#W9USK;DR .U
M"\'G4(W8^"BE[W&&.:\#I'G)H/'1=2VV\'0H##FS)W/$I=XNC,Z)/J=O_4F"
MQP!AF-&.[@Y4QL1#?[I^TGG' @3M"OJLY_-\X$_;MGJ#<>!!?TRU"(?FVG4!
ML,[OM"XIL)IUQ;#Z6:S#B'B<S\DW((O\L<+U3*(S8'N-;J)=B!1RR6YCQC-Z
M$?=B.G(]]8N$/_>\2P(+4\B5J=>)+=V&+KSW;-[$6J+A3^_QNL[]\SUB_Y[O
M<-#!(V_;#6\&DFEOQ?E:@U-I;!A.8E;1P^-]!;9I<.;(<NB&@3&8N5Y-^^):
M6*5VM4!76L]H(:,;G?Q=P8G :3>1$.ZW_FCUJHUG 5#K!'<K$;M6*?I!?_*B
M\S8?>4?5@_D4A.6&*OP^_L,H760LP.)+MLU\"75_W%B>M:MZ&?DA' ")IS\\
M7<]72QW98'"FQ/GJ<FO/V[X'1EMN.R3?X+3KW?+?T7OW(=M\]\X@O<^2>'#T
MK\</4U(E?V+=YFFMKY_+J?_O*Y*FKQ8M%_57KU+YWE$ 9=CNDL/DPK(F/^''
ML=K1(G[8E3QZS["_^N(!G^"!+7]:2J*T;%:+3C7X*R36=7XQ,?,2#^=3=(X-
M7NR+7E[T0LHWLIYTQ^'1%^FCP*%0^Q++.+RQZR!Q7QSJSS_7Q:%@5 OOI5LF
M+?PB35^JLFX12W8E*[K [Q*>6882A*%4[AIQAJH9K=\SZ&(_^74;%7C='4,.
MG>+>2^PDCG0=AHX5?Z&QQ3P"R*U<2'\C2^K7;1V["P?L0B$,=;[I%^V+1BWB
MN3N,CDN-"^=B^+^O?_YF/ED%T=K379Q_%]7QP-N7\:C;U^LBY]T"=J]AN:HZ
MA.VZ,HW=I-9%-X:N:C_OLQIVV[>U#QKV;&^=A^!#EK', WJ5O?>]7U&?@-/4
M&/N(I=C]B9R>B3HV"9OEBT_A[NU_5S;_==[T1;[^LP)-")+TO*N),BR8THV^
MOQ0@'!$T>"=)$VIS=$0:]B]D3%R,]?:U2' P;:BI/"R<&BN(P5OG5C;K\BS/
ML=S6I+8^TH $<+'#/@+A ?%0G0\.4W1!OJZK]:[$6-_=6*OS$AI/_&&;4$K&
M=BV8+LT7:^ITS 0FYHEM.NC3GEJL& K*)5T <K6!'7PMZU!1!%]Y@YE< 4=T
MIT=\R,"_X"ND7<)S/A#1PJ(TB-*#(8I%N,,M$1ML@V^>8 9(B_3IP]6P!3%W
M;^.:DDDMZ[8[>ND[]'4Z0YZ9GON#KG(YQPD,1QH.6?KJ,V_\F89PLU-MXS##
MZ$+8#NR)L$M^U@,1U]W0XXG4SOS="V]]RDXX6K8QI7!.-S &('[<;=S@$^F/
MXFY(""#94)$(G32=6(GT/5A9GV6SOG,J3CX*75_^[GU72,1K8 *XQ 2/RQC%
MKY6?=HO4G=@%++:Q4:*W8&.OXAFA+H'\8G'CGAG]%5KP:<CRF?ETIS>VKYB'
M3!)#3BAF!^/^P%W%W_]>E,?^B/8"<4C/J^&FD+CP(,.;>+*[;><Z>#?Z'(#U
M$FV$31]XSVKPQ?0Y /A%?XSC:1<K[/3U@X.GO;Z69N[+VWN.B^>K5\ )Y\-T
M _PS5@MN?44??X6(UWT^*(DBJ+;NRHAE/:BQ& [WK:G^K"L!Z9UW?;(1&,S_
M">>H>]['1OV5* >R =*@97>W#*;O0N-X$T+M+V Y;E;3A0\E>K,2\Y#D6<!]
M\P8(\4W=@':XCSZ")W[D@44?=26;GG99POW9%9IM ,0']Y\\>HK?=NNXUV7X
MV2FZD1MDWY D9/SB>M]%="]W\" H FS_0)XGI+\GIK\\)R=AAN$0?=]G8$2Y
M I7; /F%K"=O[FQ<*^/3N_RV.+ G!A4=-V/P#_'D?4!@\,;@UH3?5T#Q%XGG
M]]^?#L'>9?OM59NIC0\5APL4$O1*KF<P'%B<W=#-?+]/,/,*#M[P"T$V]L!_
M\,^5.;'+S9W8WO?YX#ZBCFBZP892W(,J -TDMH;XW$:Z#ZY"%S+_SS_XYGI+
MUL4.8I2]*^DYV,CU13Q;DUM;V(/(=EBX3=H:)*:AW>#3]3QH\X6[!_@!X3-:
M\QMO8Y75D'Z*Y*M/ 97TWE$LP^;+(+@D7-\3B).&VPXP,6 ^"X5!94+^N\MB
M6-L8/7G_L9I%'T^>[<5[CGQ>@H_Y[L4E@O;H?P^2FBXTY[L,PP++(";+#59G
MF.NTW&2?F"BXM<9!!H!L'$H]V=M'X0Z/X1*&#?';WL;,2R\#<+QKKQ9 /(3<
MP=WHTX-6VTD1Z[N8.EO,*\'N"K:+BNW]=P[OLM?/*\+[/=-T:4']YNQ=OBL2
MW?%U*+IW)@/DP\]/5G4H:E^W[2H8:;B!4?+V=L" C *^[H\,:Q#SZ'X*MLZ&
MZ[6'BAL'*GVJ#_JHT"6[H0%[FHG\CP5/)N_5\KTBZ! [LJQG5:!HS.>^XM:]
MO5CP<;O'WK#'KSM-=+Z5K!I>[6<4@&ROC;N#V5V 8CF?!.^W3*8 K:>K:6BC
ML8@95TWGB&_DPAM9B9%A7@X- /@C(,(S:T..8=@\;\"L;[_8&E*[S;J#U-N!
M!8TIX[X*X$"U#<ZX@A6@8Q;80*[B0=@G(-3"I0C#P-K&HOBS)MW11T#]-EW.
M4_S9P5P$_Q;3\\-2^(G*,$V,8B@OPESMCZ6$VS278$E%H.HW=X!<N_XO;F)?
M]A%'-$.!$=/C<=@=$ZQ'&NP5B1L9IMPM\L!:1"#EZRH ZX'DAXVNVZ#P-W+L
M&ONFM@$S82%&OV,^U6J0D]^N%H@.VJY(=A2$_F2"OXHDG+B*  *I8EU N^YS
MUS:25X=V2*Q%W54\E:A.!]5>APNZ*5%0!(07(C@"@]:GL86Q1?R 7:DYC"$B
M!UR93LSW_#"SUI-A^SKL93^;L]-YT@W8M^(-:( P:*H$= ^&W-HNJ^7);.ZO
M[&K6K0-G(CBJ([-U1R4&[IY *=X6NYI*UJR^9B_\?,Q)>V].&AUSTL:<M#$G
M;<Q)&W/2QIRTS\E)^V".V?9%2JQR6A+-*"L9=;S26:ZKS$F3E;S(V?<K4?=>
M<VW#6IA[^(7Q"6">#H$&[(*6N3>0$:9ZG(SU& &5+,_F'AJ'>Y[[ HD8E;IP
MQK/';1=07J@.-5\M\8:5'H<-#Y%B"M>@8MAM28A)2+9KN3#_-Y^=I)A\E#RT
M:OE]TUY@E?K[I.-%X]/@[[KL &.\RZ<.*+VSWM$?,//'= *\CL&P/K*WCIX/
MC,W.;(\U3K'3::@GX;&YN:QVX%YTUC9O; JD?"&2VC>^:;)<E22#+)$7+-J?
MF$((!EQ'_VT79>@O=>K='CY,;+NR:>&ZR;4U-CCM>=,OI']/A=\/2N,MZ<U%
MQ71N2J9=P3)M*ETR5I#*N,H9:8J0YP([8D,EU_51QB'UQ*R-GK+D]FWU&^Z@
M-WC=4RC$A<;FI'X=S<N+\9+9!Q*H8K&,S\F\NB++:IV0U;L7+F9>;5-,<E$H
M?V3!V)*^OV#L!_=G^\+V3%N7466<JUAF364LMYF5A:.ET^KFW!J$9YF/^K/,
M3^(1N4OKQ7[=ZZP>UJT\.6EBA8HC%X?B ?S.7$7_[G%_1^/!\6MZ^/S)Y/#=
MR^GAP\?9BU?_/#UZ^.LK[/?HH29'#U^^.G@%WU^XY>K%VZ/C%^3E;\_RP^F+
M#)ZI#WY[Q Z>'] #^A?>G 7]'9P?_O:,XE7TA\>:_%U9+DE.;<JED2G319Y6
MO,I2:ZTI<VD+47WB+8V[(EZ/QM/]'\[B,VO>B/EG/GT\U-R+CM)P2:&/WZ.[
M%'V_;?)3C4=8)Q.4N3]_4NGA04TC?IGE^SU\3V56?J[OB;-K=Q(5^U7Q>:V^
M_SN>Y^-8Q[&.8QW'^J./M;SZV\_PP6\XZX:/$MX_&]58IPD7R\3["I-.R7^R
M1SBT])V<PH_['( G&SD G^OA_"$6[7>,(@]3V4($=5RS]ZS9T*>^L5#7SYJ(
M2&_Z<KW 5/Y'WLTXS-?\.B0V+MBX8)<NV)?R9GX;%P[=4Q]!5A\UXQ]NY;)Q
MY3YOY4AU':+LEB[.R) C0XX,N4.+,S+DR)#?F2$_@%VQENA)@YG5:1RBUM8Z
M][YI7Y:/^8TF?5D&Y)U[75[[-LE\:(X?O>]9<A.6X?]]O?D/Y]U@ESLU\1AP
M_[4)Y\B2U:P.X?95:^YLQM]YIAF1SEBJ"7-Y)@KAI,U9)<I,VJ*\-/YNK*ZG
M<M+^?W=2OAV-C]%W+)KQ(!XL>%XO3Q^L6E@/VSQZ&X_8W(\5>H[EVSM)N D'
MAO-V>7>VFJ9F[E-XL1/@3%A5Z*"XH2'\%\__:%\>S_G+X\?G1\=F>O#;X[.#
MA_?AG2>O7DS_51\=3R8'O[VL#Q[JL\/IX?3H07SGWW^<JJF9'+V"[U\]YH?T
MQ=F+5_?AW2?UX6^']<OGC_G1\V=G+Z>/SP[?W:<OZ OV[W<'RX.GV=O_.WZT
M/#Q^Q@]?G?Q=<%=6%=%I510\94**5%6L2'.0C)03DZE"@9S<XZ+:+WWFS(!T
M[H4CDU^-D?#;3V2H]^FM#PGO;=TW"L11(&X)Q(*61#MGB:XRIK6JA)+,V5)K
M3@1\Z 5BU@G$;!2(NR\0SS<%(G&J*H3F( 9MGK+*EFEEG$N-=DH828AE% 5B
M7O)]/@K$42#^V *1$*WQL(G+M66:EHH4.I>B=*4M=)%1%(BDB@*15*- W'F!
M>+B%$%W%I0%UEQ9*5RF3E4UE)6U*@>()9Z5BA1>(/"_W\U$@C@+QQQ:(%NQA
MHWAN5688H59:2TSAM):$$T6R;V,RCS+OTV3>%@BD>4&,*6U:EDRFC%5E*C-1
MIIDB6F:V(EG![]RKLF*$@*/$^]$E7F'1TBVSRN45*W0F9"&5@/_ES!E19-_&
M)AXEWB=)O*,ME">5+;7*55HQ6:1,V2(5-&,IP'E08X95E.D[]T15[&>CQ!LE
MWH\M\:RSD@F6EY0I)E16&68<2#9C\:BB9-_&Z!TEWJ<Y^D#:A>C',W)T_(+]
M[2@50,$ZU5F5 \C3>2IYX5)1<?1<*$U+ R"/9J/(&T7>CR[RG"Z )X0#4*<9
M*4TE7"%E5E'NE'2L&"/!-T\>'FS*0UT*2VWF4NLX&+VR0*.7TM146JF<<D8U
MR,-\CP$(I*-$'"7BCRT1E>,@>@@MK ,PZ*PJ6 D2D62FJLI"R#$4?/,DXK--
MB5C1HJ099ZFK*I8RP5TJ<\'3"I CQ5L^52Y0(M*2C([ 42+^Z!+158P1!_Q2
M2LIR256I./PK"L4R68AO9!:/$O$Z):+>E(@F+WAN'$^)H&7*RHRFHJ15JO/2
M6JJ,9IQZC,AO4##X>FOM]FT/"N'$)E)\_FZU524IK;Y'E:2-5/#DOGDC9TMY
MLDX*O[R&+7V/PG#^OP_+]ALMXS)+&5-5Y8JJ8*+BE<TRE><V$R2W!35C>'?G
MQ-A?%Y*>*^XJS&I/!2,E6KJ ZX@B::YHP4MFM17YG7M%5NT77RK#+F&*KPW<
MMKJ\\D3/#\_+KJ":"<D,C(@Q].A7@N94*5&RO&!L#%SN(B]OI6HX5^@J*UFJ
M*F%29KD 7C8RI99D/!>E!;ARYQYG;+\:>?GV\C(8XT;R(I=&:U;82@BME< T
MGJR0M"C&D-P.\O)VJJFFI""R*M,\+W4*TEBGE5,<]#)QP@KF"+%@75Q'YOW(
MR[O+RY)H*H03#*0Y$YI5CCK@ZZS4F5;<V!%C[R(O;^EEG7/"P3Y*%? K8&Q#
M4\5IE1:45V ID;QT^LX]0LI]-O+R[>5E[C*=4R*I=I9)R:60UMC,V)P#*U<C
MQMY%7MY.#E1*4LJ<3"M.9<H<U8"V.4VM@\TDSN1E99"7KR$N//+R[O)R[G*6
M 0QC8"(SFFM9,<JSG&@BN<GIF/:VB[Q\(>W-$J%-H8LT(X*EK&0D%8J4*> K
MZA0P,]>>F<EH,-]J9JZD%<"X8%(1)BLN.*CA/&."*.8**T>0O9/,O)6SQ6TI
M3)[G:5Y4)F5%J5)%*I;:@I>"5%:8LKQSKZ3EE^>PCLR\N\P,UI7)RD+K0I=,
M.:98";87\+-B%2O%B+)WDYFWTHTT%UH4IDB5P@1,EM%4TM*DEG-;R=PH0X"9
MBX+LDY&9;R\S4T>RO"ID:8%]<PM8VW(-HMS*K"A9[D:8O9/,O)4IHX1P4CB:
M,JUTRDP.,)MHF0*PYJY2&O[-[]QC8K?\7]^Z_N%-R)&1,WEB\0;!YDNR8RY9
MJ-LGNDR5Y45."7.<,6N8+#.KG.)6&6F$J$:C8N=$U[.+V3&5L& /DI03#C8%
M _%5E64%XHNBET=+A@X")MBUY3SO4%KSR,OK$U]EQ0N*9[P(RS,C+%&<469E
M*9TI1YMB)WEY*PHG6%7F"IC7.>L A5">*@TFA<PS#B*9VES@F:Z2?#D*&7EY
M=WF9"&=,9HTS108"/)/&%;:H2N%$)5E)1I-B!WEY.SN&.$(K4[&T*%21LHS8
M%#A8IZ[062%Y55D%%D7.Z+45ZAUY>0=YF3)AN<+:S(PPJ:L*A'BIC)/0<BFR
M$6/O)"]OZ65N#*<@<5,C,I&RTH%>SB1+;<8,E[E3VHH[]PH^JN7;S,IH$CM%
M<\Y=SFSN9%')+*=&RRI3565&B+V#K+R='"-RKG(+RIC"KJ6,*YM6K !^IK:$
M752RP#(RK-P7(RO?7E;&[+9<,4DP248H4,@VL\P@U*Z K[,18>\@*U_(C<EX
M7F5 KBD5.4!L*W4JX;^TTHX(T,D<=A,@=O7E ;B1EW>8E[5A3/'"9 R,8R,5
M,25PM62@GPM;?J-;;T9>_D1>WDJ-00AEB"S20J*Y3$B6JHJHE!"I39&5P,P4
M#X957Y[G-C+S[C*S,9J"QB6B4(HQHD1!E<MT5CJK<S$FH.\H,V^GQC!5,0<@
MVP%V2IDK52J5Q;H3C&5X9*R28"\S4EU;9;*1F7>0F2LCN2A%25V6,RJL,ADO
M2,F)-*6H"C&B[)UDYNTB,IER*BM8FJE<IBRK6%K9RJ4@J!V +8!<.3JR!=DI
MD_DK58GY?F5?:G/EI;%C#EXFLBK/JC*O<N:$KAQ1I"@K(9T63.>C";!S@N;%
MA406F5F6E=JDA558X!G,@"K+BA30GN%9S@W-LSOW2)&/^;2WF9<)P'U:EF56
M5A437"I!7$ZH QA1$$?RT0+815[>OI&'8V!$R-0RRH&769$*9\NT*&'#M,Y$
M3AWP,LM&7K[-O"R$5$4I*\*E84YK910'OE;:TH+F?#0 =I&7MQ-92I-)EU.1
M2@&HGV568LFF++5&E!51VE64X0G4[,M+2(Z\O,.\3 2U-'.5,!G3!<'(BRHR
MK"^:6<-'-_M.\O*67F8Y &RKL+A+J5*6@TI6FA(PZ M-7&%+J@CP\EBQZ5:S
M,@<%K*QVDA#"F*-"4*F+G&G+B*9:C1![!UEY.Y$%A+#E&BQEGA',2;-Y6HG2
MI06U-K<NEY1FGI7'HJBWF96UL@)D>D4KL+(JH419B$HY7KC*,3J>/MU%5KZ0
MR)(K8K7F/"6%(2FCAJ>P>WF:NY(88ETE,P6\+';J\.G(R]==K+PL\CP7(JMT
MSBBAE2J=</ '0&]ERO$NZMWDY:U$%D*XUE*JE L)O"Q!)4L 46FNI1,9$X(+
MA-BE&!7S;6;FBF7"*LVMU17+:2X,4X:1'(RODE,[NK%WDYFW$EF<+!Q3UJ6Z
M(!RKK_%4EB9+J5%E40A+N/ @FW_Y(:Z1F7>7F864EAB1\5)E8"]3Y9C.)=-$
M$F-I.,0UHNR=8^:M1):L*#+',I[:4E*\-)VETAF5YCQ3 +@R44C4S%3L%#-_
MZQHOWX,5CY:GMDF6IW5CTH5LEN?)0I[/F_:S,EY^B-0Z7C(B &<J7FDF2BJ5
MT5(868*UB$5!1UMAYR22OI#QD@NEF30LS;B_PM?D6'2J2CD1F56%(075=^ZQ
MXMIN-!^S9'>0E351U I1 ,+ V[HSR9E1H@(V5I975HR6PBZR\O8)<<<<*;1+
MN4*KGQ.: FCDJ2$9!5.PL(6H@)7SD95O,RMG1!15)IP$JX"A4"^YTKDIP$;(
MRU*HT4[805;>SG?AJ'BE!%8NI4D9R<%,4%RGREGM-'=.%-JS\ECLX1:S<I7G
M3$AK 8L1IEPEK5997G&@!%7E4GP;@#V\'=G5;ZU)W]EF/K+XI[+XEK;.JLR:
M7)NT(AFPN+&8W&9YJC.AA'-,4EK< 6X6E-!?1BZ_O5R>B;R2FDM=THQ1Y50N
M &D7N:.,5)3;;X.]1RZ_%B[?SI QI;%EQ4RJ1)FE3!&3 B K4\'*3''";56-
M7/XC<#F3N2U%12K)+"-E+BN9:T% E5N,UGZC-/21RZ_'\MY.GJDHJT0N7$JH
MM6!Z8^UC2G2:YX:;@L&V:CNR^0_ YA4WFI4YE7FIF2J,K*BD@@A'I<B4+D:?
M^$ZR\U;^C"WS0E$G4DH9Q;JI-(4_=5IH+&7.,EHY/CK%;SLO,V<-Y5FE*>6,
ME5(6W')+&#-E@36>1J?X3O+R5OJ,42(3I&!IKK(J9=190.!8V8GHJF(V!X$M
M1J_X;>=E(WFF,ED4@N?,,":MIGFNJAPDO :)/GK%=Y*7M[)GM!0<V+9(L:1&
MRD15I9+#GY8*5526:<KISKG%;U$5F.?SYK5M6F_'E+_ ;*8+.VLE+O!8&.;*
MPC"RLMP057"6LTS32B.0H ;ED<RL&DV"G1,])Q?29)1UACJ\EBTG@"(J1@!%
M").2K 1U 5:]EN[./3K6A;G5K&R,S11WW.9",)*+2I64.E-90KDF8DR3V4E6
MWDZ38<[AM9AIP11/F=' RC23:>Z,5H6DQ#@#K$S&\^>WF97+O,QY056EB&*Y
M<;+*-,NUTZPLM6%F- AVD)6WTV0J5Q"75V5JF,52$J5)A7; SX1H0W51"J*
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M+@F61*3Y3IG+MZA62[C/J)YI(/&Q.,N5-D!5E@;,/R:SBDEI*BLJ2DK#K,V
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MYC]RU<1*+\8 72'<P\6%<9W*-S9H%S_"!3(.,$"0]_ [,%G?AX_J*)"'N-!
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M]NV'SEL$,](+K/DLXH7Y=I1Y.WP3 -E:=L>6+@M-^N;C-EMTWT8XL(8[?3.
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MHC5F"[/L%[55,("?9GA,Z-S,D7*P2-D>?]B^>;B?F:+ #%7IM-(6*&48EK'
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M"SF^I_-/DL_&FD;J')3 : ;OUP1J]0I_VCM8C<^X&*_-QNOD-M[U1?MZWER
M739H8)R0-.M'%+X/]ML?8/_A[=Z9VWK?[*_'##_V6^T3OW'>''06&"<$^[#>
MA;Z=W#;>@_V'MWM@XX&M&'Q9P-]ZG<O(#4F04NE(A@7H7NH[L2"I$RC.8Y^&
MTHWYKMIX0]#ZTX*@3P/!B*_&9(#MI\OM*K[4D5)PS",^RNY:>"M#QG-2LT_>
M%MQNN/'&HWXMG4V78K==9@.WE2L8>2?''#%))QFH0P2/T<C("C9/<>AKEKD"
M@1GG6!4^Z0WN, N]:LP'[)TTE$&69$X:W5M>*$F]DPL@V./JK_8-E@5O+$OJ
M-(::-H-58?V2\KF <C48SACHZ,]SB] H>#1DD:P:;9W1$&W(21=?O-+CB349
MM8%FK[PLI#)>MV!P5']?<WEJ#,Z\GZ#@A0&EUCT;FCLO#4LZ8$(B\#7R<P[%
MQ%(P5[X W91XC)E#HF).V'9+ F9-TU->^6CYQJZ.9<&/7B)FFDE;GNC\E2@T
M=SHRO]U\U01W^?C,;2X(T-6,C4$^9)5T4(_IUJQWB7"+Q(?9M ">-?RD:C;6
MIW\I/9/9C3[.K8W,\NVYB_>M%9I/:RL:/JJ^O@#7J*MXQUGA7;2K4Q5X_'-I
M!]HO3(HC+]_A>B=O)'LM#1'CX)8O+/7#T_7 8>VLV+Q;!G> ^,)?<6]L&!8;
M&RG+S#8N=R\JB7P'CX:685*+D8,VHC.5 PP1CG&4'.=<BV\YR*6M5VGQ8'VG
M":RV%M9.1*I<L&^'QIS3.1:[*',--F26/GE)_YD0@-P6!$"-N*P:<#&V2>W2
M0@Y7E4H1,UC&XC6>00[GS#"F4*$ -G>Z&O5Y%2]\M:^EBC:J5N\+-D;_TW1G
M"+\YFH43](P&."X46Z%/#C9!PILW"Q"^,:)[E\0"ZT_G\1#;KR4WLSPLS=5G
ML2*KKS%0QB8X4_$7"C>LA%,O0?DSF\"B<R]@@^G>E%.V,7/CH  )U4-!EV>"
M<Z/]1C.6(@O(.G2LO]8,0M>O' .C5:FI<A+D:UUL,2,+4A38I'8'XP8N0-PK
M[F"QU0L>XK'0-]5EGVJW8PQ%B='M\WI.R?V>TX.>T"JN,/@[+O?\A(/ODY(X
MCHF?!%$:>20) \T^\[R>4UVFKR[<?5UQA?I9L]VYO>@U%LW>&;DX_]COG'?F
M\)9^LWZZP(3FB]ZI?Y%M<(7.3]QF[X]!8]'PFFUX]_O/\-T/O>;@#%RJ!NV<
MOQLTZV+P97%%FZ>7E"C!"4\=GX6I0_TP<>*(^8Y@J1?Y*@U 'G;4$[+71* 4
M=/;<[OHW5<Q[50S*Y"F67"92*0ME7]"+6Z54N"Q%Q%6'*7..<JO_,4\+/(\B
M+K?:T@IUR%A^'?6_FIBG0;CGH-JR:>TW8USII$:3FJ43K9[Y&O&)LM$JXY+Z
MH%S.6W^)1?[]8&W&<0IM*ES.L&%S5&%.9]P0G.?T\W"<RY5H>_$^&UK.5S#G
MSLXFKWB%3G(ASGNKK>.5\#S*;''D6_->RA==QYQS[(D,L;MH:Y_K>,88H9N6
MUZ#05C#,038;_&@U5<2/;>R[;'TT+MO<OF&T+Y2[2:#0#A[<0<L;J(R%[+?2
MJ]]*/](0!G/R?D/X0<-VQ1".$TEDY"DWCA(*UE;"I!_Y/%%")2J-HF<WA(N+
M 4V@8H)0)T-P &=ZCHV-_+*F\;Q1/[&F\8@TO+, S.*[5KT#GS?0I+WK](X6
M'<0\JG_.&CU..F#L-E9O"7JG"S"KP2P^ILW>E0=]A#;?98UZL]OTP#0^/YDW
M%Q^SAM>Y^[)H!(W>Z:7@*0^H2AP:"^)0P923N$0XL%@D$=P/XX2O+2B5 8@-
MK(-+* /1@3]0+^:)\&64LIVUI=$[UW)2:Y1!D1VVJ=^5X8;,T"W=@>V*A&#R
M (\58W;EAY8]%0Q[6<[UE0>J\UM-[9KK&VD\A9"H"T,J2,FE,. #IUD>Q-'W
M,C6=^(NA^9*U"UX[O96:'<R6<&"F8@;SH\N*)K7)C'</JK$231-GONV8N$DU
M:*4[/.GF/=YTU5VE1MO0JATNQG&S884PK1QI,:P]5_R3<MBQ(F'/%;_/1M]G
MH^^ST??9Z/ML]*=GHS_H/*S8ID3*./1B*EQD?E=A+.-$P(,\\6E:1-TWM/.0
M3;LC-E^[*RL,<.L4V> BP\QGDR[>%&/2IH2#+I-+N6Q=^)V->7>>YQ*"233"
MJ^B%O5O,AC<S'9<UD0!CC>EX:OF2;^20LR+CH-K_5T!7)M9Y&3Q&SQ!PQ:!&
M__V:PA[+L^720TV[]Q?6.-?<%XUJ:*?)_7>ME2*H@+W_U4*#UCT*QW]G(T-=
MGYE$[QHS$3-CGT^>Y&]5B ?#O0S].!GR7H4,G6C!.:C>&C\@/):#6R<GE0(H
M,_V" MABI"L=[&__QM-_+W,O+W/^JY"YL^%H37,5294H1CHJT<^FT[Z.D0]'
M>6 !#":6GYMCJ>MC;&Q?IR(B& OF;NKTJQR-0A?1WR[%*7;QKJ12894'3#![
MK2C 8-,E V%<R8+1!.+CVF"49V@BED:9&C.5O#O,_JMK#]#"V?ZY22[;VQXO
MM(=SI#0+&O,J]O+?XP+4R!PA8]F77VVF8YZ2MER$9?=R)6J)VS]/!C!E2HA"
MD^.OC%FE3*D2+P3QWQLR+RJ0?^JDT]<DCD>;X^RVDE+GL-_TF4TLM)!<F*W*
M>%ZIF >F?\L.Y>%!_GT=#,>DBM_WMLR+B]W),GC6JQ"\=GE(@I3QT1"C<IN+
M4ED-<QGZ16I.4:^8G]=609HL!EL1\%N9H;H,;E6>SF#$:_/&R2]9!B,A^S8]
MM<^F4Y1U\[??=]$"0O2ULLXA*^^83:(LYH&P#!/>=0(ZS#B.6_^ ^Q]FRV2Q
M8R(#3%">X+OT!S/SYCZCJ! XR"L,\M(2@_-5_/&&S<U?^A+!G29E*IN=^B))
MS&3(M=?K0R9/[?/F'F%6QDJOS"ZYT[G+2RG2DC.\D[-Y*I,NV,^FD_!-''B>
M*:[O[8JI-KVOO,>FOJ\-'2WXI?* Y2)?Z)U6J47YBS%4X4VI[+*^,L7:V5@X
M>)<X7UGW;&H*$'3Z=Q64;F/7EJ;?)A)9'S>_K]1&C*F>+Y/J\X*'#4!^E01S
M@V!G<^&KB>3%/$YX5XI9'QO 4H*:DOB)M!M3HR$.IWE7T$K:2?^D-=05(#@<
M'+T.DQ[D54PK)S"F7)D4T/MWWK)3LRI[DWR%'W[->//5]28I6 ]XH!@LQ40.
MX&6P,\U?C7XV"6&5"H]<!T^@@_A66Y9E+."-[F_>6A%=L76'RR4 IFN[*" G
MPR)C[L!Z^<:=W.C7+LU"57S2W-M?\WE'&R3PL/:?T2T"8APL8S$BWD6Z7 BY
M'%YGMDQP!9& =V%^I18)X^Y4JP>Q,C&O@MF"-W!S V9/Q9_9ID^Q/D.BXLNK
M@VYT\UJI%G)\']2HAIRMU)W-UF,N!_#'OH4U&>=9+".%N29880ARV\7B>AM3
MGNC0GPF]\-RRGBY=B%0Q,;9OVWR(:Q 4![5U3(>#'SOD[7U9*@ >KM0X%_5&
MDXW=60N8YF5[1<1T<X<Q_=.676G]8?70 *M3;[#""#:^S@\R=:HUG2^C*D[Q
MUO%LV528I8D]L7=Z>06R=L!_Y#0_6;!6>YH+VNV/$+1J2=5]8RPQ.\K*;*,$
M)J599LO!<N18C%K(!Z7N(73.G=#?G[ "O3\QZDW[BN3?'R7:>'JH!A< B^3[
M.'%YRK#.\// 09I(7F+B9 9 ]U$3\]C$VN#^Q-H'[ZY7D==21KPTI!XE 0U9
M%(?2E90JSTNX[_\$;(XR1P#&4,V<:(TM#%NALZKI!,<6O."5)-Z>%9"^G7:S
MUQE\N.YX'WN-0<>2;)P$%^\[;G-P>MOHG=U=U#MW%VOP',UNPVMFG<'''K0W
MO^A][#;.X?=>__JB=^9=U(_FS?:[ZV;O7?_+HD,:IY=N#,HFCGR'A#'RM4>!
MDT;P#W5#CT11[-,D7%UO%3/N)X*D7NC2P),I5QX\G@9)X@51L*MH'MNV)1Y3
M?_[3<#RT9UT=5 46H<SZMW46IH+:6AY+9\\8P=-FLBCLU34/^O3$4\U4T6-"
MCS.Z'2Y;![<R1PHYK!UQM"TQTF/*;RW @#4XA\OKDE779:T>VY8(8^4QGIDY
M/DD5EF(5Q6+;ZVWB"@Y^9 Q1"^)A\#>J$!WXGA(X8>L;NZ.^0-=? _UCS_J%
MBS6[&>G1P(E<:47'&RKZS,!280%RK;X$+P#MYR^'Q[9V8 GQP)K?\,F-K1)Z
MJ.,Y1HD%J-HG(3\M"=G=GH3\E-,[W@-I[U.7]ZG+^]3E?>KR/G7Y$:G+#[IG
MJX A*J$QCY+0"T-*N$@\*6$+>H*R(%01W9:Z_*!;L"N.P"-=]=TT_/\$/8+$
M1S;BTQME>#\*G<+;5W8UEK*X*-3?T_!I$V-DZD SYC.9P"L;3X=H<>J;"I-A
M-ILLQ:V,0;MFL:\TNAQ0GM:X[>(-?JUXR%P0'];^RJXEHKP=%-\;R$%J+5_\
M8A<-\Z[13:B/NJ/)C;[/+<&1II(-#"SK)(,Y9C"8V;0VQFG">\(K-LXQH5:[
MCP/?UD"*<3)P>S28$4;+9A.;F8XJX?_\/VY(_NUZ!Z^L8OT1TOZ2:0.'M3_L
M_:NYE=CJHQ0X?R.\YA+2)# 65XC+UR2@EV5_KI&<R\)W?*GV/PM,86@2\4I>
M[XIMFXT73?08S:9X$Z<OK^48WH=;KL#E6X<96,([QMI;@W@LAQI(63*=P9IG
MK1JD.;-,.KHO[[E$VJ_;4];-! 1 X^4(;J*ZD>S%P8F9V>U?T8C?X(E."V@U
M7!Y[=;^\3 >;E@[O0%9"%-L;.S!@[#I,4PGK%+&C' V^E#Z-I:V!X, (>V4"
M\J?!@ES&2 41-V-]42V\@Y;.^A777B4\5254@,B^S]HJ&#%^I*%5NV4;[BDU
M>>!XA"!$.DVUYGK. (;:K5EN2H/7K%.N\=C)N15T3ECE.P,)3NQP*>6EN'"N
M8#K@C]?FNOEFEL*RYSTVC)B93?DVGR%@+AB&?<T2L#0\I#"96 A0K=-8*;?_
M8^_/WHTM=,5LF)G;L]G$NF_%=9I0+!&AX(G+0\IC\/%2$DH6DS3FQ(N]RY/R
M%DW 4 >L/_F_;YRPRF942N6R19@;A 6030%[C[WZ Z>D-?P/C,I$!HXJ8])?
M;W?A:8PE+_%J_FLX&SABI(,PV!WP?3E#*0]?_$KN*K^2&R"<8[/W8=#I'?GP
M7=(Z/X7G&GYS(0:M\P]9Z[SC=[P.78>)[$ ;5UY#H^MSZ-=I<%$_H8T%]YM>
M)]#7>CW1N^AU!U\6QXMF[^12>'[DBU0ZB:>D0R/%G)ARW^'<Y7[H4U_%\9NW
ML&/SD'LN%V]KH /Z^N[ U+!LN^??*\%O@,9:]EH+Y/OE5 E0$Z P$!B[5$8;
M&8Q7_EA2Z^(3E733S:WF-S&/3\2HIF_D++^:Z7B9>74=EF:I;+NX$RNSLS9T
M<*YS=%Z7D-FJON?NU;U]J&96W;=RN/SE^5D<G:G&E:NB*Q<<N!I!VRQ=%4HZ
M1_G+R:0+IH+\:E?+P<KZEL!#PM),'U3ZF-_QVI1<:['JOT*SZ&E_(\/N(Z^_
M7/<!5+B'HI>KQ#(1-)'$DI-$42GB1 @W2-*$Q,IS8S=^]N253T@'H<_./\%@
M@+G5@VGI!3D:BI,A7@!D7^7?X"2_DE25]G&.$1>TZIT[.-_F%X,/@U;[E#0]
M/ M/%O#\HED_"9KMSX.F=W+;7,.(NX;S]'B!3(*=02=HUD]]/ L[",,,_6ST
MKMTFGJF](_?+HN,VCBZ#R(U#%3,X$3EQ* BTD_B1<)*41US*0(3NKD*^:1EP
MM!#4_C;Y_CL<8EZ[(>J"F:Y93TP>@:,/O:\:8'+$KRV6&J](?^T&A=T<3=6X
M'NJR*ZR"0$V$.1[;GJ_X*W)PTQ_-I37#39W]:(QAIG[?],J^P!9:Z AV\5 U
MTU:WID_LG$$K]V1^LTE^GXX^YEE\OQ\4_#$Y!]RPBG.ZG&A3N!.K 1@]6D>L
ME*14@5^M%S*9CAEVQM'!#9, 6I(2EL>UCM1/D+HNK^DS)\)A[=-#<U&, &QW
MG'T<[7<,,H\)K8S+'C "K1/H\7SC*%;Z_HPHI"Y] ([_H?-C-7G.39/0I3)1
M442ESY)0J" DW$LB[JO(_0G)DDB.HU<$CI<_=>>NY) 7B9"O!*4?CIG3_)B!
M=W[H@XO4;]3/J(83'9PLX+NDU;ZZO>A=7%_4._!\<]!9=;]Z5VYC\'G0>G]V
MVVQW>W#,S#N])O3K%(ZN/^")C]?@UF4=[R+[LN!N\_;2\V7(1, =2EWAT%1(
M/&9")XEBGK((Q$.Y.WK,_ 5VH>%-JGV4N(5V.8/1(F+/S,F@L_!X59C1KAVA
MG@95H@,J>"TQ!0UC</2+F2@YBBHAJ^YR8,D4Z<%)E)J"E-7FY@AI.K$^UW+Y
MGOEFSE+*)J.A5FJ%AB\BZF8P(G]TM?<;VEP-M/^$,%&P3'H]F93Z8][(AME@
M-C!UY=/1G[8>ZPC'!5]APV,[YI'Z:,**?\DKUG\')\N.Q(-^ND)JW(+=&Z5I
M(HC/G%2D,1B_J718X N'^P%!WI> AOZ;M\'A]G"0*2[$@@2[8TK[PI9=]W$E
M- CYFN 9\M%ET4,7-IODM_Z3I6#OJ'C[ZDXHVS"@ UAHDNI("%H"A>T@I-+(
MZ38 4FY5[3A/9,4%7L9NF8V7"\'S!%H.WBN6' ^O<#@C;2GV9<ZL9'Z[JQ ^
M\3[+!F @GE03#Y:XOI9+V5;JXR8/M6K1.LI&MV@F2T?]K-9-=+]U\Z"ULF+=
M<$H31I@7)2ZCJ8P2D49*@;*A3,(GS^]-'PF=*(<!+LU$\]I,&IYKD'EG 9YQ
MF\^;[0YIU$])Y_P$M,?'7NO]1VC[8W;1>S> MH(U#E8D&#KON,T%D@^=WC;K
M'[N=WFD [=&+]\=>\_V'0>/\XKI5OPY @Y#&[:4 :Q3^ZSM4I=2A,,E.JE3H
M!'X<>2%-(R:#'35I*NO]#Z >RDDC#"<-WBB-,Z2=&S.1(7,& @;I9*R#"HP0
MLU-@O2PV*33J8:TZ/67DK@Q2OUXB#<,:M!YW?-&; )LO9,TU?;\W-QQ"3V+-
MP/-XO/$^/V7\^FH,)Z9P[*"4_L^_?]H07W)^GV+ ?M-9L<F2W7!R'!M9VQ6K
M]&>?*?"=T\L4)E02IIR NL2A'@7[U&-80A@J[L9N$G@A6J7A5JOT5<K_P8OJ
MER=M $\%/ P$'-XI#3GX;0$GG/A2*$7=U-,;@.0;@.PWP(_< *W32]\5"64!
M<0@EB4-]WW-BXC$G!/,ZIM(-.??>O*7W; !SB#]ES2,:2^I&4<@C0I4(4DY(
M+&(_@2WGIEPK/3>Q:^XF^S7_@6ON-6\O(P4^.&P\)_$BL*9C'CH)%;$3R3AF
M'.S.* W>O T/W>V9&7@C@??]UM><2S:>8*HK& YUR75N5<UW#VIX:.E_B1$3
M7,^#2K%F_]LX8![I%WKD?K_P03]OQ2\$ ?7AB%",44*I(*G+!7B3GB=#&9/P
M^?U" X379G>OS"'L'>5R[#?A.YWS=_U&&]."SI!:J]MI\]MF^RIH]*[H1;O?
M:[7_Z#;^7)5C3IIM^.[YV5VSU\\NVDBM]:[;7!RY(+O0=K??.F\$C??'MR#'
MI-GCEPE5/$P\X00!NH7"\QRF:.1$4<S"A$L5<K)&:1!(D02QGW(?UMB/TRA-
MPQ36)@Y)Y*ED1SU("Y$(HK'CT?#J1:G-+IKBH"J92 :OLXH@D[-IOR[G[_!%
MK3 =VRP2LXK+S<E*/'-ICG,,05U\HL!^U;_E=];Y52=J>UT==*LYS"8ZUJEC
MG_"6;5!$^4MLJ!:_B?ZF_*_A?<<TH*]%UOOR->S#" _86#D0> 6T@6B!];QC
ME0^W]&\55*#H1H6#U+C")IZI.P>OZS,+[#1D.@]*M[^KF'Y'%11P72*G4XO+
M&+DPB(GF(DG#B_>S:RQ!TC<WIB1I(%>Q'S:)APZ;XP/F0JF/ZWU8^ZA_LB<T
MRA7F8Z'(E9#2.H5AIE3&,WWM7HB3Q5_2ZYQ'-\JK=FRZ-QMG$Y%Q$X77^(7_
MG;'Q5'/J5? +H8<&R\J,+NN.1KJ&9USIG4U!W32T',)/9Y_A!LGQ)4'"$>P:
M^0)A[;LU __PU20,#.651HV CLTP[74RU5"?./8B>E3)]SZPX7F#-"DTA,EX
M@B#:,.=R@*7,8\S21A N;!(!QQ!.U:;0X=?VN!=/PKWP5N9K3[ZW1[#8(UCL
M$2SV"!9[!(M'(5@\&#U8]51!W"/%61B)D%(W2 D(NQ=&TJ7P41AL0[!XT,-]
M,9_VWB-VW82SMEV>ZY_.ERPX8]#D_A\R*H/MCJFR#.91)X-@J80NO<XA5XN\
M)F.1F2?U_>1,6YEHQ&'.[M#DR:(9?Y7[!AG:5%,V+"&:<R#588' .IF@..VB
MX8^WML;TEWHT>B9&>26?3FC-J0ZW.5 :1ANS1[3/4!8T5Q"0#52]AON=9>9[
M.E)LDYQ-:7/5(;6 =U\S&*4!3L".E0_8=OLXDL(W,R"Q/*\=RL9\-L#$%&T$
MYX1YMKSR:FSKD[7]/A/9U(J)<04M=$()[*<[I(']-%TCO@5'ZL C#OXPFDUM
M*,(P4N5(]=IMNI7&[2E=2UL?C8VGX-XHI*[2V+_;4L)W4;;6#BKMK6M'R1Q8
M*^B *M/)B<M>O\0-UU]W\@]KG_ /2R]8?G)4)9&H(##,H/&)W=SHB&*Q6)$[
M57T#WN3=F/>L]Z)\S5"8GD\D@C5CIONV/H-8Z[-GPR>Z-_B:/!_>ONP I2#%
M+$Z;>+4$/(%9\ANV7\',I",E)E*!W1S+JUF?64*%ORW^33>[T;"8@PS?60;6
MBOK?:K(&KJ93H!+D-82W2Q.G ?+-CM>35\;O+(R!W2=8W%PJALU3J"&HMTR9
MWI(YQ.=6I$M]6['>[7E1EK8"A6FU^CUR=YZW-,TIZ9"-Q-1[+KWJGM9S:(A\
M5BT4$=:]VOKTV^[(%B=,;O#<J<3CUD$VC<Y\UL(USW\ =?DAHV7%R/$HC7F2
M,D4]ERI)8R%#$1'E1U'$J2N?_4JE7L%';Q7PZ*_M?J61WZ_<->H7_5:=WS;K
MC:#9QE+L?J]5%[W.^8G7;!_/\:ZEL?@#>K-ZOW)\VQR<T>;B"-JZ=IN+C[W6
M>8,VO6:WT^NXC?8'O&M9--XW>U\6QWZC?GU)?.ER$L+D@37I4$ZE$T<>=Y3P
M4I]+&D1D5V&2*^R*?ZT8,?"GC[:$%?9553YJI8 \_8[EQ4B^$+!K_=]C'='&
MZ.,'!CMX/*_IBUHW0$H;W&5#B]]N\_:'T!V=WLO&<'I/)C/#;()JY]W1IS\,
ME)$.C0N#C32&@V2<L37\?E.E@ &JT83US8EG&:Y,WO$6QH+#VG\R,(O&Z'PC
MPC(;FL-II(&9="YVER%W %A:YNU2'RY8& %OM6A8F6E#HZ9ASZ +$J/ ??.1
MRAF -C FE+;#$ML!OKS*!V"?-0>!I@O0&>6%05STK>R\.='SI\IJ=YV\K9$$
MV&2J9W@XNLWY=,IWV:AO5Y:OU%:",5QL]I[^<PGJMFF (^32R@/\T(I9E(DM
MRT-?B-? 3E#%;!L6"VW3HDT,+Z\-6 \O0[1PY>GLE2:,E51:8WJ;'=:.2OX5
M&]AFYA:J.L""1FW-H 1KW_IR>.1R<QP-1YH)2K/VF.6=&)Z7S<.WQ0 54\1(
MLUY?3?0"[D(E;:'6'.D]4<ZM3H>L7E_=,]4P$LU)B,4ON2N$#%V#_*II=SE_
MM&>E779MQ!<RKJD6K=F#A4F;-NH]FU2+/TQN!=2N0!K A\NYQ2?RJTJ-60-]
M&5<0 ZJ,?'!RF4I;C6+^NJZ/:UB99-S!+6)T !(XM=[KRZ(;+G$]K6 /WD-.
M P[ 1%:W$"KJRM(AD$K^Z^:7V%SFU[5R?X/R9%F%2:#TG):'\Y*+]MH0/$VJ
M?$G>MY^AS3.42U!E%[SL)*%PO\:)*D7IE4S5HV!#SVV-8Z%!*^!'%1R[;88%
MFVCV]Q(;TBI('8' 6,75:%P2IIK7;NK62OE':9(^9[IF>']LX<%8P6H9GQ](
M\&C",'43&J8B\7WH 4M)Q(CO\^<'*3BV-P]_R[&&I7AM485.#@S7;=6O%YW>
MZ;QU_J[;\3KP?@2QP?><N9W!<=!9-'N-]I%_L9JU.3BFK78S0Y"<SOF[WD7O
M8Z_1ZV>ZS^W/6:?=[S6\QEVC+JZ_+*Z#YM4EXAH%L2^<Q.7"H8$;.VDH7,=5
M24I21D,WV%4 G'R]T=BL(4(%2*Y>^-W-R#3<Q7UN \;5^S0]2FY&J1%H,&6K
MBHY2,V^6P@'G<,S EQK.=&:X39ZJ/CM9*A\6LW&1[%G>'^40+ZM],DX[YA&)
M>SJWD@&9NZA*YVC=C#!7 'U2_2(,BRSWSM1ZHX.WI9\5 B+K:E3I-A$7%%Q6
M7B&I1_R?O+'U,=T[S^: L->0J\,I0.],JEQ!BHN7#EMPAM@M&PL[QAPQ']0B
MS*N2F4DXLA!!^N3166PB1R(RORW35^>W;"MDO09Z""M#)@97J,)VNZW;YC9N
M7(3X*UFA@YO9]!&S=3,;3V;,%/7K*/GMR-&GJ[V!,-X+B-D\7\O5;QQ4V+G&
M9=C?T-..#$BJ;D^/STJ,=CVW#6H%1*@B/&M[9L/VR'-IGQ\WR$L>J*!XZ(A=
M.9+=*"(!YRX< @%E89PDC#/ND2#B" +A/3].'2Z1)0([UO=0K^U0OBY"_1?G
MG:#1OIYW>AUH\XHTX;MPV/9:[>N[B_KQ' [I!3S?7T?G>->_Z%W?M=H?LF;O
MXZ!5/_4NX!"'@SAHM=]=-]H?X)!N0E\_9U\69QJ5+H9EB%W/<=TT=&A$I)-@
MS%_"3YX'IS+'_)2=/)3;8XV,/#?J;W=/XD]6#ZAE;3.6.4^)CL?/2BRSG.<:
MR_!URD,^$?I!\#0PTILK*_V,">OK  Z"=\(8<R6DW[$IL0$_,*=7F6L,I]OT
M%J-[1DU/BFOUBF8T1Z:#+6KWQP!3:]1\812KOC9 ^.N<#_EU^9BO&.6^=BZ7
M;M[-7$^SL;F)P,58$H6<_APGVYZF\'6F,:/R@V_/DOBT;''_A[ D^MZ>)7&?
M8[[/,=_GF.]SS/<YYH_(,7_0OUKQQT"H64 #E'9&E<MB%4OA1QY/O1 \*?HS
M<%Q+8"%3Q&P<LE?FEBU."J0&>&_0K!^[C?9G<*.NR$6]L6C5K^87=7C7XB.2
M;'B-]M5M<ZW"_<0%]XXTVF=WS?,&M/7QNK%HT%;]PS7TNP?]@3YT[EKU(_)E
M<3('MXR&<1I*+W0"(C%6&G G@7ET?$6"D$F6NH3MJ%NVM/ UL_*OVCG[KO&9
ME-"7O7R:&!2OS*9;O"YWJBFG>=[L2\Z2KA@H"[QGP[PVN78%_M DS^E%/WQ8
M%O8ZX&4Y.F5I)6Z933:$+9\$LO:<P3T_N#^X]^*' RSJ49&/]?=X-!QAZ8>>
MK]=Y2)SE%VJ]9D\,&HMFUAF<(/L#:7AGM'-^#.UT@D;OZ*Y9A[;K5V0M=C=H
M>$TX1AK>AZS3$UD#OG?1[G8[[8_PSNMYHWY,X( A<'@@LNY=<\$O4R$\6!4X
M%B+A.302B.>3I X3/G-Y))F*R8Z>$A]-"7PI!;5E,7A)7?&J3ZN'LO0*E":#
MR)2G\>:9O4>?SO0G#C+]6EJ(*L1,[;?VZ 9V?$3)[_^J?<H&-_U,%?<GE>7"
M^%/UP4-++*%#AD4^\5@.1E^Q<B=GN[CCTG+YV$L;@_[0UU"B'+GKM,8\^O0G
M=L'4AYA.Z,PR@RB*0:[B*HHM]REG=S7%,Q6<!'V7M%2@D@VA:P8FV40Z,>VS
MR-K$]- B9=,6NM12"2NOLYUM<K6E3<X!L4K:(LT-E@V*],0"FU/362W3Q9K6
MF1C=E$4?U012D0E=R:3KTS 55R=@]_.;1XRIKJ9Y;$)3V<6\TW,8_<CBB?0S
MJ3$UYE8.#(P&PL3:\'8ZF^JOSL'F*);NH"HAN6!.RN3FZH0NIS=OF= \;'FP
M.4W5U'']E+P:/W[SN,6T#JB#022]FDO+Z_R4]5WSL_7Z>C\)2VE3Z\O3XL6'
M@9Z&YS5]_K#DH'_JLC^]YG5#N3D;R]=C\!34DKW.X-@';]9K]DZ1\HHTV]SM
MH*?L';L7:/#@I>7Y6;!.+0E&4ILOP//UFO4S^"X\O_C<!4_9[[0_#\#@<5OM
M=_V+=G\ 7O%=HWWB7KH1C3P5*H<'*:)6IL1A/(D=@45)?LPB,%M70QV!1WP1
MQ%$:IC%5J6 JH"%A2>0JC[G>6LY1O@*URA),_K6^,ZO;=J,9_7##*W7_\&$4
M^R3T(Y^&-(AIFH1$N($?AK%D?&>,-Y3M6I4^];572]T7JSX98A8'&J,?9=>D
MD^KO[.!A63=92\84L0STR.D@+"\6 G\9VR0?\GAIR$LTOP>8*:2#X::P2^=(
MP1@Q+VB&E5KEL6D-D&\^(FO'F,1::;RLS4&^CF'7( K,QL6+3?)0"1&1@PMN
M'9EEY-)FI_U*01A6R42[DJ.K,;OI(F<E6IE/,ID>.&7=^ 5K!<$V#__]<D[5
M\MRXU!RUX*X<@=W?+R56RP!FC6U%'3:9AJMT08*E5-&4^2*DL2^PF)4))H7T
M2$2X;^B""/5)%6_8VW8V5U3;WW*,1B:[DBWU>32ML$R;;T%?"]1AQ_OECNW&
MO-6^<AN+TZ"!+)AM?DE9R&/%F!.RB#F4"SC!P\1U_#BFE/D<EB=Z\S98AR#^
MWSR9I%JXB,6!6T4AE6NT4=\D!R?-=U7>J*:6L)'Z0XKU-2:_^A+W3BY)P%-%
M?>Z($/ZA<1PZS LC)V$T3H5,TDBX;]ZZ=&V)G52'2[>H:%Q75,F?0#D=#:]D
M?W10 X,8X4@QH>D3G +PLEI#"KQ"->6S63HSQQN6FU4$QYY(FO8,3[Q-+-![
MW?[,NOW##.R'[U7MD4=YZ(-70&!+NY%(PR11OLL1;PM<KL1NZ7"OVI]YWW<N
MD\0%!]BE3A00ZM"(<2?U:>"D"4T$\XE*//;F;10\BVK_-CG8J_8G+/'B^%)2
MDN@S6TH:&N!UT.;$B2.E%&=NS'T*JGV=-.)QJKW!_S_DU_LXXM?@!/PMA\/)
MO/^5#3-6R_%S[E';&FGA/Z"B<,_6/H,/(N=Y_LJG^60J!P<8DK;1U!5O D&O
MH8L&K$C['O !'"FK6?;[8^#''P/@*W[O,>"[$0'A=%W% RH8 W$#6Y)%J?12
MRCFWVS]:9A39'P,_7$><78:QHD%,4B=E5(#YYU,G]EWB( 2EGPH"_Q>^>1L^
MSS'P;7*P/P8>O\3-^M%E2CTN9<R="%PYAU+.G"2(8)U3%7'JNXD4Z9NWB)S]
M3<= 2\ 69$O6_?&?_ZG7/AM%/_G)MOTKB=Z5R?T6K\@"8X[AG69Z)S4=M[0$
M?^7YMA%PSP "XD6CS*LR-H&JC%3Y.E3+,-NZ_L$"E&2:N*$H8C/X?ZK:.H+\
M& 2/_!4%7$Y>J&)JX2JLOBRSY12FKEVMC0C;.:P=;WQ"O[ZHL_O*QMEH-JGP
M&YC9@$6[,L!?]D;V7UCV8C.1"O8,8PZ4A).Z^MZL0!&?K$TE[PZS_\XJ9!>(
M7X*%EAJX<(K8I!H'M80RV=36%';"HBPK[6=2F4D>C^9@Q!3WTGDCL/)":K6U
MUHBU<1#U'Z]V8=@E%X9YR\2V)ROLQP4F8DE1#'-OT7A+-H)<4'3.5(DF4)D;
M,VULO:8Q+PKBMHC&7G>KOB;9@$F^EM.R>-+ I<P&-Q8'#,=4UMSHF'6Q[E4$
MSP*D%W_[*N<H"5_MOEA_@JV*)YLLT2%?C48";X--^_EO9:\W$3>O(!1?,8/2
MJ8N"1Z9"5 ZE!M?:O+V*I>@6V&=Y7%K+=E%+5<#'0JNIU-.N:2]&&@=93WJQ
MF\T-MB;0X#F&#DS(U]'8!+?'HULDFK]!I8"Z>*E@M2"M$')0!,&G8UT0K /E
M6;Z A]L/['5...6Y(8])%$>>1RF1<2IE(F-/<CBO9>QO9G*O'-CWF6ZV0.YO
MK#$[ZN<(8>_M$A[K19.BS>[JI@8*9L'POR_3R*GL#F1X 2;!W@HHK(#K2T9(
MS,/ <Q+J(B^SDDZLP"/TN!=Y,@VD%!(SY8=RG4_.[KW*;BHW7(X(9Y3?AE-.
M,\3D"_800.^#L*B_>,$:W=.;[$O/]J5G^]*S?>G9OO3L6TK/'DQ;6DMS"D3J
M^]+W?9>Z@L:,A#P)/.6'-.0_ ?G[DR5/:ZF/!6;K"7KW&H#4>*MYV.=H*"HP
MT4?HC:#!"#/S2^?BU3N8BY=R3X6^(V6*U[Q1XB22I4X<4.5+5Q+79VM$NI2"
MK:]D1$%6?!*G2H#%3UPIHB!,O2>"BK^6R$S[47ZE"72LA3%LP *O('0"UJ3V
M&[A3EF]Y\ON_GA*ILG\"Y:W-H%=A9U$W^!8[*XX.7?_'VUDN.0S#Q[WV 8,H
MGR+,@GMSKX[=],V7?'G*^#5"A ^%8W<(YU*"#?1$&\^L],_?<_H4S!6VI8Y:
MB;']ZQ%'W[=,@T9#>U7S8 I,EH;[Y.57^C_?O/P5G;1\Q_<BMYW61BKBK^QJ
M+&VIY6^SB52S?JV??36AS7L-#3 QPDAX"8T(3:A,F.MA79T,/4EY&C_"T,B-
M"+#-LJG\"UH5)X6D&COCW$9(CTRL[DQW\*],R:4(%$P#_Y>8C9& >4?-C<[Y
MA\E%^R9K+$[GK?:IWSE_ES7?GY!&^Y2 Z>%W=(WCNUZG?;QH]C[W6W_:9[Y\
MZ*8#T6\-3A8(-MJLBV[G_(1T>J=WS?K';G,ALE;[Y+9QWNPVVM"7\S/Z9=&8
M-OXD=W^UCZ?-]EG0[%U]%>\_4_&?#_T+K_\U[8W<B_=G06,!?1A\'#3?'T,_
MN->JP_/OCX.+.K^#<=RVWC<'K7<Q:=Q>@FJ(*(E21P9NZ-!4QDX*9HX#]FJ2
M2.&[8,N\>>NO5@F@F7Z?D'$1*N42)EP0*C\)8Y:FGDB4%"*049SLA>R7$;+6
MZ24)9)RX+G&8+V(0LC1R6$*D0V08I E5>-'ZYFVP)F2X8I/?-P<#GJ+T26T7
M3O[_63W;GS3$UWV:/^'B)(F2)$X$(X$7@>I0*06=H6)"?9I&\-GF3 <G>$3!
MV;I;S I=<J]C7"J>27%3$NYUR>-TR:<E77():Q@)1:7C)S&FVB6>DRJ6.-0C
M21H0*J44;]Z"K[-VN;+!)'SB+@$54'OB;GD1Q^,56I[M\E*^-#>5?,C:]'E,
M11S&H?!\&C(:,TFBR!4\I#P6"=D; J]X\YX^8 A WWO=7F/P^1KZX#8&T/<Z
M)RUXMK.X\O ZM3/HW':\#STP!!:-TTLAPU013SC2"SV'8J85BST*>Y\&01B+
MF'L"RRR?9 D4&])[VH;<:!7L]-$IE!(ACWD<RA!W&@MB2I,@("F+*4O#_=&Y
M8[MOY>@,8^4FU(-3$U84_@E=)P5#VHE3R63L$0*^W)NWY-#_WJ-S\_'U'$?G
M/RG:^)WAII=0+GG*T-:PXGTZ];&>UD[K5)F /9H&8*:JA$J6)$P&8*AR%XXR
MEOKQ8W5J/M-[)?@D)<C7E&"L>.R'D7 \'U0?I0%UX$^)$Q).$DXC3CDHP?@P
M_H7]AY?84_?3W>V-M>=2+#_26--KV"PX*LT3>XWU)(UU56BL5ITCA.)EY%*>
M4L; 3A.10U40.*"HE,.E<J,H3<'S2=!L6\<&>+5FVY.T9708!:]<>;5'F+6_
MDMGPU)/"9AW8/ (?1B]&,[R[Q?[GGV(. TZ,SG RG_P"H>H?,C5[U?^,JG^O
MZ[]+U^?6*:%A%$1)X,#R48<B#R1+I.\DOA_[OA>D"AG(7'*X7D/X;>;IC]A9
MOZAOOY()NH*#][-R-3?4]TS^F%=^^Z43,F&K70JFA$K!?DJ9'SB4\,A)E!*.
M3+C/(^KQE,2K"9F^E(S ;E,> ]/+I[%B+@U\-_3C-'#C)Q*ROI:$S).AN<[
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MLSE/VC[]>G?DK8]M2>C#/-^-[\?$N=PD_ 6C<;%S5JUO'V;I> E8,+(F@M$
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MN;GY9V@!W9M@-$/__]G>?][-(Z&/U[X;'_E4'53K)J,,=/7]Y([=ATO>^L\
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ME%?ADPF1!9[90$70C,0(X*5,#-CQP(1E(4<Q/$8Q7!*4%0.W_1F"0K#D.(M
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MLV!5%KG7EC/KF-82?L(FT]IPQV6QR_8@ <N)\@R[\1/\KMXP'6CAJ&Y;[=J
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M"[-*(8Q-0,P[A:S+& I>8ZVYESY3;]X1D6WH,FN@S!I8DQC:I6/0J\\:>"*
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MI1\Z91AN'H:[3VI;)X<9Y\*GLJ4B$Q0Q:C-D+!$H:&FXS4@4BKYY-SCKWC<
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M?-#$:"2P<HB1:)&FE"+G:(:5\-)'F?3GV J=<#T0>Z<M10E;ZP1;SRO'M!B
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MEJ]NPLJ8C,:5GOP-TV6IA+!H4E#-^MC#4=#F(6@S6]+ P\EO/%<H")$9@<;
M"+A&PM*4#.,N,K.QI1[?1FOY["5%/NLF!$4^'R^?TVP ,X&-$,@YDQ"G1"%'
MC0%RX *C+EBG],:67JIR(W4Z,*E8?@_F7C\73JJ!#-QL-?AS#_SZ(5%=3*&
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M;U_L"H]+V>ST>U]0+O5<(@V>/FFSU>_Y$KS]$,0YGZ$&GCO/:(HHJ2@0]UH
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MYG%\SZ/8"0UXC/SL9T?]#MRL?Y;GLOJV[?EX^?U7C?_][>.KQI^CL DS,6R
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M/C4*?IGM8<F5%)8EI 7SB'N?D*/>(N*E<L1*$H3>V"*O!#.;? 8%_UDL1.N
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M(F)%V_/]#CPR<\6#: ? /P- 4NG5M[8=YTJOOGIZ]969N_?,$?/BNAQNW\(
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MU@4M@5Q]5AM;>Y5\ #S^EH_&7B[P;+>F1/=N:\/<(2A/D9MS>X&UG9[O=T^
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MN;7YPNO[[+6YO?*UMF9_S#56>(1W#O*%M3&\JFG_G:$#]1[TNXW^S1[1]W=
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M+>_?_KF(^G*)NK+>:19R22;,G=-.L1BIR\F^R0>?BJ@_I:A/NID((8;&Q!"
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M^]/ZI'YPW&CN'?[1KI]_:-8//6V<?VC7=^%[AT?G>^>?C_+]]X[WSAL;ZZ?
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M_20?ZKUAO'K,7SV7J]U=X4X+$+ S>,WD4Q2DJ&C/3C."^M%N=T]A[]=\T_:
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M'#A=1G8S:NDM-5%QVWY+MZ.76A&]+<'LG&RL DXE0"-',;**Y;J\Y)%A0H-
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M!7D/)@H2F$#9; !U-$ID)4O(>4NQHL%)7#535&;>$_F:\QY>OL:I[R)_K%9
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M)#/^T[D2+RK&]_)U5?W8NNJ+!TYE;"0XMPQDGB<M=!+)6$\"U]I2R6K@?"+
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MYW@P\:.\K*GO9MW@XJ% BQB-^RW3T<#@+&7R\+ ?N\5CPD)!;?19"_*VW^_
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M5YBG()S'6 ?-3/*$.%_H ,14"' 37T:- $\6 68M(,:,EM(11*3,XX\8!QU
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M\A@/3 AR3EID&9$BX:AT$)D,Y"(RF!0QQ5GD</*U%MVTLI??OQ ,&8R.>L>
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MIV6H&;S&HC\\/LX.[<@#SC&"[]D/G"ADFO<CUFOK9@+.G6DXM\9P?M1-G%_
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MGG('0T<2<AQ'@+(BT7GCJ4ZO-KF\ES=0 W=]#?)*]PUJ@_S0>)YU$1+F6M!
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M89I11$%[(BZ$02;RB!(#.^J$-HXZ *EXWD4.7SQ(L96$A("9B)Q[G1Q+#O[
ML"22F*!JD#XH2&<L*;/$"D$M"L08Q"W %>14(G!1>+#:$5"K&:1L@ZP12%>4
M0W)KIWKBW-)464E9^N;KAL'.,"?$SP7 !+@U41%%P-.T^8QLB"Y1#X,,!E\1
MCM_9?3>+P^GS?>,*P1_L()8'?<-?L9=34NW72W B6J/S%NCT@\9TUZWOX8^_
M>?CS7^TOM/W='75_[&Y_@6=]Y7O[S6^-\Z^XL>TYW.?TX#/,Q?[?[4:N8WST
MB>S]K?$A=\%'126RL80V)\CDYETZ80[4F#GLZ+)2A(UV4:D ;,OEC4KC4H2;
M!L$C.$HC93[G%M52]'2ER,,2<Z\42DH!BW,1Y(DHB[!,+.8XNL?^U:;8('0^
M'C+WA_\I/L9.J]LKJIH!81CSD1UV0]F(ZRC4;?=EGC2%LL(2)K$#M1TX)3AW
MYP$_)\B@M?,"U\&(!X77;,101J:4\(A:J1$W,@"%HA0H%#8Q:":8 (28%<0B
MUF^_M,;H12PB\?S_'DPBX\)YK95D2@<E)"C06*=8/2Q&9]P<H9))P5#$B6*(
M>\J1$U*AX!C..S X1/QJ$Q9]0;71&J3/!J1,,JT24%B6+!<!&^\"]M1BZ[!B
M,=2QB(<$Z6S ,$:*(TT4$:S D#(OD=' /!G1D8(E53;EJ+[1]X]%U"!=7Y!B
M28/!.GN5--<(M\)'(@)7 A!*A:Q!^J @G;&D@5EN@J:(,2T0YT0CQXQ#5LH4
MJ-;<V-PL%-.UHKL/?>#X&00,I=3&>I^<4X(SC;5U-OG(,"_KY=,Z8/CHZ/QV
M0ZCGI)7#.(WM]V<-&$^#'F#XGSC8_SLW*(,Q?&GO;H?F[O'!61GJ(=)98U5"
MBEN%> 2F; @#?,=@@XZ@ETU:5HITU,%;H-F&")X8-I9R1J)S5/' -:L#AL]-
MBH0BW#(KD%4^(J[@)TV)08%8'*P4UN0:;0(4X5WCA>(>\<*7L>6*&0&RA(4A
MG N,G04V%:U-C #ZS!51^II!_21TS;@Y8%)C" RC9#0 )"='Z* \XMID+U0I
MS$'-,J[N?]RKSHM88Y!R:Q6@3X)%Y,X[2W(>D]'8::%3N,(RUB#]22"=<7.(
MM#R?S4>>1H=@?0"D3"L4%'6$@FN:! :0"K5A:I ^7Y ZKP"<40%?C9PI;:WA
M0&$X]4*:P.N X8."=#9@:*3P0' <8MQ*Q*6W2#M-4)"<<A5Y$()D2RHW6 W2
MYPM2!OXITY1Q+B7GQNK(&+@=@7I&E0FV!NF#@G0V5S\%K05A"'M)$;@C%CGB
M"/+>QH05%U9+ *DD&WR-0%IG&"X=,#0<)P->/I,"4 CK*ACA.=]0R5S_O@X8
M/CXZWY[^>W]KY)!^(GO[!_S?[$,[_OGA[,OG<.(HE[O[!^++4>-\]_SMC]WM
M [R[_>7HR^<=F*LM\N7H0WOW?.=L[_/?QU_^>)=VMPX935%IS%'" 7Q90C%8
MX*@1$T;*0+4*6"R=J4I],%P98F/DPC,-]_+)8ARII]1=D>U4R]%3EB,=E!-4
M@9'096=@XY$E4J+$3&2@C*(-]-4FWQ#S(9%;!@UUG61X@ZNC2"#28(6!104J
M=$C$>D>,M!J[H.MXQ,/BZ^T4O@Y==!X6*"',K4,\<0DT2G.D(M:>&\>ILJ\V
ME98;>HWV7>ODB%6CE#*O+%7:.,&Q$XX1*YR741":DJRCA@^,TL8T2HE-E'++
M\R''@ "I$1F#/1+2.G!364CY.!7XJL^QE%N-THOJ 4Q*PG-9/QVX=UJ#,94A
M!1R=C):;.B+QL"C]-(U2*I2-4N5HH>>(NV21L50CCR.W5(!!]2K;4E&C]#FC
ME%-*(W8R$,VX3L0H*J(&X?!86V[O6Z&P1NF2*/73*+5<1V\41ESPA+A/ MG$
M+9+)2<UCE%A&L*5\O<JBUIF&RV<:TL UB=8H<&,<#=9+CY6@AD02D]1UX/#Q
MX?GCIH!/X[S9W,WW@A'!NY[!NY[O;7\]W\WY8OO?,(SQ=&__[];NT9<<\ %O
MQ02&(S#C(%&N20U$V6H4O'"@DH5R&B\K1PIK!1I=T*0<CUII900%96X<,1C+
M*PJKU7+TE.4H,.I#H@P<+A9SSJK*]?H-(HZ!Z5"88"ERX/#.V88,U]F&-]0S
M9 $S*IQ,UO%<VE!)07*37F.\L:S.-GQ@?,T$#J4-TCKAD(R "\Y(0"X0CI2G
MTB5)'*C-[.P 1M9H_[5.DEAUNJ%1) &O<A:<'96<=B[E7&IB=4Q&BAJE#XO2
MF<"A<8DEJAT*+ND<DE#(QN"1-%Q0+W42B>? (:^3@I\S2CF-E+/(,%:,$^<M
MH!,(,G9* I,)5^10U"C]62B="1P"1*6(GB#J.: T&HPL$0*%Y(7QBG+%<;:E
M[/YE!&J4KB]*E>?21H4Q9XPG9C-*O=) LTSB4>(:I0^+TIG H10V1W(Q"I[Y
MG'&HD;'!(9J[[$46,1'9E@JY5K:TSCA<.G#((F<B'Z>*)'"B 8?"$3">8$*U
MHY'5@</'A^?9C9EB]( =Y*RP/_YN-?[X=+J[_>&H\7D'YN'M>>/H*STX_G"\
M]\=[^&[( 1^L)<VA'81#)LK2260"34A+YRGG*>GEJQJ"7Z3 ,2+6!\EU#AUR
MI[Q+PD=&;:H/*3]#.9*<*9DH>%@,$\1]="@7TT.":TQE@/77-@<.Y9WK&C)2
MIQS>P*-B%(KH8(/G')N@26)4$R,).#^!Q#HF\;  FXD<*NV%L-(@1D2&2)*Y
M:!I%//,HYCVPX'QRP[#[1P[K-(GU16DPP1"=+)A#PT5R.FDB4FZ(C(/3H:YL
M^, HG8D<9H_&2\61S:<ON.+YI+(5*+@0N%!*X]PCC>,5E!.H4;J^*,6Y;57N
MJA Y!N.9K"18Y.+N@A!-?9W,], HG8D<1D5L$!PC80C84BHX,EJHG,T?H]*:
MX> K6UH7('W&* TYN5#PF#@&Y<PU4%WJG'4*E#CG.M4H?5B4SD0.<U@_%RI#
MT?& >/ 4Z8 M,M$EJ3U77@'CY93?O^K'^J4</I5NHWN#9NP5G=+3/K%GUK5C
MW6ST*H5#<4K1!NTD5=S9I"FG1.8Z0S$:;&1-WA]0X9S/N=A$.(<C=BC%"(XU
MIZ!PJ/3(^*!%<%C$7)><UWT,GS5(O0-/VM*08XX<UM^1!/])A''C9#1U;LX#
M@W3&PPY$<J.ER>U%/8 TEQG"42,K8[2&&<RCK4'ZW$%*K#?.1BP-QEQB90BS
M@9;!:N.MJ/L8/C!(9QUL&Z)1%B,.ZP$.MK/(6?@I4B.T#T%JR;*#??_C\35(
MUQ>D@8F@5 2@<LW!R796D$2E9@R3$*VH0?JP()WQK[UDU# JD<D!,&Y80-H
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M^@CP:R6 8F=0;'D/B!YDH?JK"W=JQ?YC3O;K(O,'BG\M450:A*(1;7_8BR5
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M]%/LY5G>*'8Z19::_,'7MRU^4-:0R]4?\^?+6OUY7$V8 +A]?^B.8M478:(
MPF1EQORM.-XWJJI$5D4A+\_8;12?XT6QAK)JXL47RI8.@R;(_]=FD0NK=FS[
MK-\J2T< >H:V_1J& K?M91DO3KK] 1K/RK@FY.O"YW*H[;:MWKNJ>#RN7UBX
M"-/9@N5P9^6SKRJ16=4//JK&-?6@LC$$O$=5\W'0'\!G\]]'BU:^'HS.#W,1
M](GW+JHBG:.2F!.O,?&141G)J2J;%\7^JF)^Y44P"<.<MWE9JV)Z#J=+;50U
M-GN+4S^+UFBMX=USF=I@ 3-5C*/PPUX/X)8K9'Z'/U>5ECK%IXV/<,M>V4?@
MK"KG7#5T*"S(S[%M=4I1R /)]>%C_GZNU?QC4O"G!SPLZ\I.2EU9D?HV(CLE
M3Z&<OS 5JKF<^'S-=CH@1Y<?*><@+W=9375"8L>U2\<?/*GL;%E0!*;TTT7Y
MZIN'6*%OKHC(1(&2"35P$D=57?,J3E?=7G'ME*RC%A5LNM((/92._>_KNB?]
M%7LE^9EM57B7^D>7'(RNC(.-"B25A3O[.Z.*J3,G(<J+V[#P\WV:7EZ=[AVV
M>]0XU$(:34Q"1/%<0)5@Y'!P*#H1'5:&ZQR()F:#SE.JUXND^*&$M;B3M-(D
MO!1!V>BX]$Y[X;''X$BDQ(FC-T0J:FE]5&GUA\Q9XFF65L\BD'["D0M$(NV]
MU I6DWH&TBHV^/RYP4H#WT5J%->1$Z6D5YBG()S'6 ?-3$X,==[?X&?64O.8
M4G/^Z= 2)@5C'C&:/.)4T"PP# 5CK2',&;!5E=2(!5(#E.VD8M_MLYGBO0]?
M%W!28";K FZ-V/%+KP4H&MMO#[U-3#A"$<P]0=R"8;,T4!08M<)J[U((3[.V
MWQ;X@A<-T"Z9<\5/+UVDJM--V0T*:'VU<U_6Q^QGLE_5UWLA!?28WL#<K+[,
M&]L0DCZ5FG3U8'_F8&5=[6]599X?M1I7U>"IK*?\RTZGV&]VAW"[<*ODZR4R
MV9[6I(S9)2I&_+)X.^X"\U=OU.NB*&>NGJ7)6?IP$9#[=YG&?W#;-/YG.T=;
M7[_VXM<<==OI#'JM3A\H<^F?7""NT6JW,YG]QXL[\[%W&=!^/55AM+BVN&)=
MIN6&[H'!"6NYC=Q(S5W21B0KG?$\:&*XX%?T>%_=SO#(/9M8W]W13O;()V=/
MU$<;;023O3_>G^UN[[8:?_S=;GR&,1WMG.]MA];!>6@VMO_U;7=_]QOX://]
MX8_@GML[>>/X],OG3S\.SC^T&D<-ODO_=;1+WYXVCM^3!GTO&G^4_>'GB]\Q
MZR+VX,XSDO]1#CEB)'*<4,-\BLGC5YN2/H7Z4:M,G?^Y^F#M%.=__[1U7/-=
M_CN$,>^F#%<>O9S0A3.ARS&S+(GEDX]:/KB&G$G1$TXR#+H0N: UXH0K9 PF
M2-I$C(Y>4!U>;0J\(>>CGL];1RYSC[M6FUX[37G[FN[U=-YM.E_":9Q17\SZ
M&,XU3L<]4R)6[WU,[Q?^T>OV^[7_L91UG2^^+8.P3LF N",*\>0X,MP(,+$>
MZPCKC@-YM4GPFAR\J7/0?R:S?O DJ/Y],@1JFGTO13!W$D9B&[5$. :)."<,
M:2$BPL$ECU7DDMM7FQIO\#4Y"_-35,$SHSGW(,OUC+VDP/U8E]Z-$2]XX2=B
M)']Y;$J<\UYV<@I\V"Z3L2M+5VWA3B9&72Q0S7B7,G0+BO-*IC2P6H0U]X@;
MS)!U-"$=F:;>,"N=!$,W9^3F-CV7Q/]:1(J>)XJ? ]4= [QFNS]%"<RPW8"M
M\4(E)(DAB MGD5;2(R9(2,HS15A\M2G-!EU5\X-UU ;/C,2L1VCXB<_82XC^
MONOV4FP-ACE-[F5%@!^=[]XS!#RQ<F,[61/BI6SA?(52P;DVC 1$.<LI*)HA
M0UA"+D1C(N,&%OS5)KD/(U[CB,_SQ/ES8,0+L%YSXE7J@1E.3)TT(F;T6\$0
MUR$@:YE%G"=NN*8BA%PZ56W@-:E*4L<SZPCP.G#B\>DP $2\?H+J3TY_\B6$
MUJ_-B2<_)2?^63&6Q0GQR9H@@S?$2^XU-=YA&:W&3GM,-2US0!_ 'ZD3XN_'
M0@[FO!$?!1;8$^1P#, ]#$8VQ^@IK"I1GE-%+; 0<F\.LA2(UB5B5\?O[Z4
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M":CW1#AH^-SX;7X;LSBNRHJN<;>2U?93K05P]0+XZ9 I8K 7N;]R/OZJB4=
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M1715ABQ.!CD?.+**!.%Y]%;YW"^FBJ"M&=@MI4%NC+Q9W=.#S[$1FJ'1Z0[
M2/6M88@-"W^IL/345D%M??BU5QP%YESGZTY_@ \[[,>KL*71#>';E[?JYR/%
MYN!Z%/(H?OANIPM%MO/T><+8V<=5K!<,]'XG(#_,*+NAA. #,75QM02G8D3W
M<X[XP;&M8DC+F-&;FLT5'[X!P+T$YA<</OJ^J"7AO-;,8H4<%P)QP@1RTFGD
M'5'8<4>]8QM;6N%-.MT],FO.K!.(S<9.I_$NNM[0]LZKO/^Q./Q!$?IY&88_
MB+8]EBYI&Z?=WJ"J30"7-B^C- N9SR&$XU5^YBNH0ZU/U'N<@@H\8&,3QR%9
MBI4UQ@5:"3*M!!F#O,\^:E^^)%]][3]-Z[*CNQG[?]EF?<Y^@T!_.ML].3Q*
M(C$9?$#&TY!K8B2DN<;(DZA,2HQKDC:VR,T99P6:VOYQ(<1_#EMS"_#U"./J
M\L6)L-2""8%SXGD 0A-,SF9.S 3MG&625"*L1B*L;HH6J45X]43XG[TW[X^B
ML$9)%1&V#$08=EJDL2&(R(B+4$.JR<:6N+F\SY4(WW!$7)*-Z;B*WJA8YYSI
M)(:G(.&'3H%QP:*C7&K/ 5$%A6VD"%Q:KJEU<Q;)C/YN=3[)3.$[SS6%K)>:
M!\^0CS0B'BA&!F.P<3CC5DI.L,C538AX)?@,";Q*VK@WP-U/F*Y'P5VO+C7E
M#!S!T7D-1#?*PL6W(T^25HP:V$BB1B  'CEJ#,)Y6[4@#F!;Y\*6-S7RN\KA
M;K4RQ)3I,%DZ*FNL,%WVEQR0.V>>;=[#&G[8Z^6MO76U;SUIS;XJL\B/1PT[
MVRJ2:_K',0Y*MF([%>/.=43N05@R\F<-+K/NF]=(?+[EV572T^"X"U:Q+8K3
M-(8Y4VID3N<4L'LK?\[T-D$P[QSFPGAC.<WE%H-E5DDIJB(0M"H" ?NAN9W=
MW*G8SN^P6;YK=<_>IA3](/_K$UQQT/U8O&Q9@:>&BAN@ N^_\4=&8PQVI$:2
MB]QO'$NP(XE 0J<HG%?<63L;*J9(RQHFLM]<A'8^Z5=>T81-\I%CGLL\PB8<
M',$T>4%U2G6YS<<5;;)[\?;(>.X"MA+AR"G0<6Z181J$7$9EDXZ8<7Q[#9ZY
M:Y@\T-]6R\'BY>#;$24X2&"C( ?4(TYRW3^;" )C32B<!#;";VQI<M7)\-[E
M-B_=!'>JLHEO+*^YCG5./D0PW9I%=$11\F1]RYODW(4/'[>O^>EG%GJ[9,/]
MDJ2@,DVI(E=%!M)5,O7U#W\J<O=!Z[M7=[&C^X T@#7<*TC?ST42^!5E^QH[
ML0>\_+QP38TJ-=[:9@1$GD?.F&*"<^$S+F)'E9",.,O(7=N,W,>\+WY\B.5)
MQHC+E3[^V5$99UUXR=AY<5"U"]=]/=\_V&:[,*;=-U^/I B8&A\08]0AD%2,
M7.0<A9 2 [:63-39ZNG%B#+43)4][(VF_5*LRO*=FXUW@%"%@%=);Z//06)_
M@8_&*P",2>)-SB>X4ZXF.E9WP)V75D]5I*<L"5"=TLTJE#!6\6 J16J)S7,N
M2W5>05>!7(4H][<S&C<'YT42\ $\]S?8BK^].,'T?/_@\$C"3(LD,9(8;(7"
MNZ2!UR)-%+:$2@M$:Z,1@6F<YEH#O6%<ET2U[49_V&YG4[D2T&:_GXNG]*ZV
MLU)6*_P%2;?]*I,,8+P\V&UV2BBKS"&PL8<PIM#_>9URR8S95%C=)Y5,ZDW-
M;TX7NV\J&6&;0M)[W?;VSP1CRQGL0O/>UB&^;7:DS=IGZ)4[P'U3^9_##(PB
M,% 5@M$H8C :.0BCD:,P&D48QHL+ +^D#&5$3S_7(IPL"(V7DL3XW/(89YY'
M2BEPLDX:3P@WU!NLE.(\,IG AO&X**0P[3Y;7'[-#X_&+P7@635,/CW>>W/\
M;;<-GW^&<9Q\PKLG;R\.3]XUX?MB_X]/<*^W#,9+#YN3@9YO<>[?!L2Q!7]O
M[QV\/]\]V,O!HKD$+/]R\(D='G@"[]V<E;VH"24N4(8B%0P!H^?(<&:1L8E0
M08QP-FQL :5?=O+B O(7'Y( ,KF!+!<G5@Y7_[6T=5SQ"-Y[!'7>#R0?,9;S
M$B.??QCGH\/G1 M+J8WT-%!$13[92,0APUQ"WKE$10I&*[#$)=E4#\Y3?"P
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M0NDMR#9 ]HX7-E4A83_!WT%%6]F,^?GUU$'C'/Z$ZD_Y4%84T# 3LWXX%4]
M2!56]R&DBL,WY<*9(\&;DMW\\6VWO?TSP=AR!GNW 2V6YC[I>?WLL(;+ES+W
M9W^/]%JS^<UV 2_C'H%Y8O*?T0*.!8W-$6FRXJN;M_]%O?&-H7+/=>;PB\M.
MF4&R*Z+Q^B'!EO<5BY6;G[M#R+WC3E_X="ZR8@<5FTJL^!3L39UP/"3M;V8<
M\<J]\[\>](JK'=5Y8XCTL!\FXJ-#LB;(X WQDGM-C7=81JNQTQY338]V9B6E
M(3%IRD\9\/LC>?H/B-/OV;V1NKTSVPM7@=%R30WY*B[Z>/_@$.^^V3N&Z__Y
M<K"-]SZ_/S\\V6&'!Q^:>Y__/(%GTB]OWO^S-Q47_5;LG;P_VZ7OX)W>M7;?
MO"=?WOS9W#T)QWM_[)##=GZ_+]_VWKRE_[W8G:J@&8.CSDJ/9#(:\9@$LB1P
M)$(@L%@ZXJ0WM@3>Y*M1=F21B?HU$#U7('+"6FXC-U)SE[01R4IG/ ^:&"YX
M 413Z64U$#TJ$$V4VL3*48%50([%W,!&"V0$=LAP;W0P0FCK (C4P_,S%@A$
MBRQ%O@[D[J\JUN/^1=G6MW+G*A"AT?S_U;*=P78GO/V_8?.T793B_$%KTQJ6
M[@)+[Z<KC$=,6 @,)2$HX@%CY&Q4* 0+2ZJ9Y7'5.IO6U7C7BE/<HM.U[LZG
MNY/5NW4D8-5H9# &VT;B@&ST# 4IE"=>:<G5QI9<6,;GDS"*-7<7[73ZPUZ1
MYI3/>'O?[U<]:'VKJ:T"JX!?1G^KNEI]*-<B1TYL>]\;PIT^QE:Z7*P:FN:"
MID]3M")1FQ3C%$5A'.()3!ZP;RP"*X?#)H)54F1CB^A5J?9:UT=<*TY1:_3R
M-7J";%CG+=5!(9#8W(I(>62)<L@12JE144KI0:/5IEXAC7YI_HN/@Z[_5N4Z
MYG TT(PBJJMV9:P Z?A];$$ IGZKTD^+3B2_Y24;O^#W;K\VD.;#K,,I%A),
ML$H0C!++AS],6^2"L(@HG)Q0,:J4VX^(A54DK#T;JZCBC\=":A5?NHI/T!*G
M4E)":^2=$XC+D)!.EB$2';9$1JV=7#D57[M6/R_-:[-_%>!35*X9"]BO_3?+
MHE*Y==LM)])Y(49I+N<U;LZ%FU^GJ5$,RC'BD4O2(^XC0=;IB&RD1@@7C,^=
M98E^.&[6#IH55MD'4J-:99>ILN>3UDP,/"2!O%0&<0XFC1&2P6^YRK10,E!:
M%"@F*Z2RSXWJK-V GYV/J^AYT["5D[?V;*V 9VN&\[U8I1KRYX+\&4T372X=
MP+Q$,9B$..81::TT(@RV:V%@ 87?V&+BX9A?>[!66)6?]!RM5N7[J?)$?PF)
M"1?:$D2\%8BSY)"#547!,L6Q-);@M+'%V<,S$>IPG7LKY<%E%;K:T?,DS.+W
M8O+KU(,'0,]T9RZE.?5)4$04C8A3)9%S)""JX=\\1!RIV-@B>-.LD.58.WO6
MB$74:KL(M9U@#$8E$;1W"!L@"UQ8CQP6 EF 7LRY4S2X0FW%"JGMBW1'U%Z(
MQ\^9+JV2.BUH$=AS,449I%,Y<B8A8;A!/$F%-/P!24EEY,EISGB=%_02%'AI
MN<:U6^%>BCK9MC(D:@VV2% %)$$F ]R>6603X*KTG$8I<[_R57(0+M*KP-GJ
M<X2#[L"VKJI!3M5J>HBKX<6TK'Q$;O%'K]NO[9<YH0E/<0C!+6;8:D0PL8@K
MI9"CW@"ED,9B1:73.0F(ZX49,,ML.?E43HF7K.#+XAZU@M]/P7<G_8H6IC^
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MOR;O\Q14N%?7\[L607FY@WPFM2:*.[YN#N!I_B[5)[(QG4\C[R>WJSD'"Z(
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M5@5#5OH>=9[&_1IAUCD;SSON<-D%1'X<< A7M(9Y*O_*=>2[G>OEY?>ZG3S
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M"@,4!GC(NH6% 1IA@*T9&< %YI@#\'NK..*!460L,TAI'ZST(<1$*@9X,C+
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M>UAMH(UN^*U:^_W8]>TXR"UC.SU0!)>G)O;.NS'VC]O;O^]^AV_2S9WW!#@
M;[W^M;T+U]^B;X\V7[\7VZ^WCK9VWN"M6>P?O>-?#M\>[O[8_;[U^B_@@/=X
M\_<_V[N?W['=S[LG6Z^_\DVZ2^"Z^&\8R];.I[U@I'6$)819%(A;9I&S&(06
MQI5QH-6KI&J.KOKK;F2M6$@:(B7&$D9X/JZ3\HX))0T)BFD\6T/[PM17G+ ]
M/  2.+= KR[W.#D/WKFUUV\>QL5A:]@L5!F;4G0\4*,]".51,DFH=3B(IU+L
M^W-E6>MG!R#0JFT=P'L@GO7C_JA3E<.'(8X&0V!5>/ODH VT>U!U$_"91K.D
M!^S:KTD56!AF* =RGJ/73GO8WJ\F>JVU 9_+ZOJH,UQM?;/]=F\T:'7LR6#4
M'@Y66\##[:-Q?9!.W+>=<:60:B@]& +<SL>8L3^X$.420%[(5<A;\7NV!,"H
MX<8N/]%@V!Y6,32]?LL.8(ZJ;,!]F]]IC083MV_59&8<=9-=KH,1/.?E@<%%
M;AR7KV)P<D!KOVT[,!?YLS9\@TG*,Y,W#$Q,/F72M-' I-W-ZGAR:D/HM/OT
MZO@1021*G=[)H%ZI_?8W>'CX4+L7%C%[W-]&JZ[XJCVTG;:_Q=;;@LW4ZPQ:
M_Y[ND&D_]Z=DPR&TAE$=U06'1L@!8A;DB@1BA^T.Z^4:[R98]0Y\8M/V88=1
MG3WVF&6Y8Q!S<%<GXRU++"/XM;)_PQ15 !N;P7]K]WV^S&^P@X9YF_P984?U
M![!W?\L>\-/5UD;'.GMD8=O:*N(Z>]?N]["^_<)7DS59^&]KX\XD'X$XZO8D
M#R-5S!_6K'Y[ GR2JR]7) B$DL,F.E7F/#!(/]8Y]*V3-@P=@%Y%]L%DMXZ!
M+."D2.E,8!T>] :Q_G[VA$X_406%G$5@V"J&H8H_S%COQ,$ O@H?6<3*C:W&
M7"?#N*1<*NE ^(3SEP:L; H&WZ#[7K9R_[LW&)P=NJ<;WO=A<X[+"0R>B'W[
MP06B<P&JA^_AWXT]SIQEE"<D7/9X:"R12R(BD]-JE4E:>GL+3^GDR#J"/71A
M,^5-&/?SV7=@<XSI:FO0.XH3EUI>I2HF*;4]T$5]I)Q[H]W]%@>5^-1RMOL5
M=OZ^W:\C4RVLX@'L]GRH]O(Y-JPV*WS_J#WHQ^,<4-2MC[0X#F*NWKU\OM5C
M/QOQ(*MMPRKL-78']5E:@2;O[UPX+ "/[<=)C!. RTRB;#,7#O,)FP]<8,+]
M/C!MK!^I'[OQ!'X_ZM6AG7!L#T9'1UDU/!R%_>HAL_\(0 NS,SP_I.H$4K\,
MQD?^[( #@#F'@=GC8R"N/,/5UV'_9STT1WGEOBA53._8CE'].1B+%L.#]F#R
MX<FE*CDFRQSMHV/KJX'5+M!S+8G.9G(P;4GT)(_\6E3?K&9@\"1/^VF'G+=
MEW <5]NDM0$+9SN5;';<;W^KPNE@!_^(67CS&9BAE1^7XE^J)H@]0&#U-_DE
MHVHJI\*WOK4[%^3)JKW.@>VDR5[]E.,'0]V<:E"#/O/ MW:O4XN+DP_.CK#:
MD?#*F5P+'^BUOG9[)]TLLHP'"$+^ ,XY!T^3@]OK00*$QF\OC2A1K<1_1^W6
MT!X]DMA0#6$R13595^N=#=_?>IU<^;"]W\TQH5D,/ +I8)A):,QJJQG7^1^
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MY@73CX;I&5NZ5#;GH2ID-5.YUZE$5G&!B'6NZH+J<<Y!9W<O-O4D(/V\D=N
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M!BOYC?XK(BY]=HY4ZV,6+I;*7/ZV5T?G[T;;;[T!Q@JMU]''(Q?[+496+YS
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MV5IO1%49'W3!RDE1WC2KI6.\&X[2L.!*P%W[XO;($/G0@+4C2YG'ZA[_\[>
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MY8"!3THSTIH1<M#;L['#F]:4O]ST )^]2E53 XMWZUO93V<7*:8>6@G,M7;
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M4YBK<%(HS6,\!]#$>%EOUHG"1G7*2;;*WE.#8#.R(W0AE2(?:I'M\V:S>OI
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MT,<WZ_P]S-UH[,TFL/.-<9O^&1H4@7[\1CR/SIM5CV9E Y3/-<B/VCI=+F5
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M2<MO9\]*&4_&84EKUM9J5NH4C5I1K0H:"$D)B-EXC=YZK?M8/WL0-ZATN2?
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M5'K;%"*-V=(,+F^N+B\G8UQ<8Y9CB<8)7SL?D>4E:A&19 4<1J\C9LE"G^X
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M\/^^?_?ZFQ\FZ?(<Q_-O7DXQS#%_\\=P?O;-/S/.?ONF3"?GW_QS,OUM^'L
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M3$M?^C O4II<CN<OZ_ZXVC$'.2@>DXN0G?,D!%+TZ*4&)$]=^9K0R=H$?SN
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M+R;316C__57D=C9@Q@@=R97#O,BM9Q9\#)[L-]JO530JYC:EW)LQG;".[$E
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MH]KL<76'D;(AW\="4HK0<++;HB!PWJ+T0J RIDUFS&T<3\APWI6J26]R;C&
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M#R<MHI4Q,="8:I^C0L>4E &D8)E@68FJ34O%.T"^#G-^#^$W2-2] 6?U G0
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M4[Y&E?>^;5P!_:E2@Z^'O]],Z+A:RS^Q)BS1>?([3L-'_,<,R^7H];#@(,J
M0HO:"U.3ERLU^;LZ,0A!>UGKV+QLDV:Q#^H34LJ#D;=&\W:^+-RYR)Y;Q8MW
M]7J(U2+[HJ$V @1MI)0IT3)8HW+2+9'VJ&%A-#J"7C6E9EV)QC=5 'G^ES2:
MS##_]=OY]!*_?)-, ?PT_W&$->WWK]\N)S;VT_U+6^_)FY-00I&@$DIPV40(
M6D1I4ZCU55V4ZD2[?VU%[-KN7]L(N&&[J"XP3K7[UU84;.@;M8O\6G;_2M&:
MVC50U";\RC$$A\B %6VS$<F7;JEZ3X/&3MV_^F!Q&[$U[?X5E<&H,('/A?PV
MICB9O;3#V*""DG0T(7:R')]5]Z]MA+^Q^]<VDFO:_4L*X7F0"9((N5YQV6H_
MZMKXR!NR'5G U!^%3Z3[UZX4[BRY%LU:YF&^,*56-L#[F_/E2Y"^Z.# H""W
MP!A'2_06M$?+ IF0J=%U]H.P3MI@ZI^8!B6>2RS+!C9=P+3M 783SI'Z?O5'
MUUU%V%O6+;:-6Z!88,XB;5J)K!)0VM?>S9*!3T(ZDYB6LE/[U:=(_&.=O0[$
M^S8B[GE6[*OQLFGW.SR[BEHN(IY+?,MC3$3K&<<(G-,1J!BW$$-2$"WW7# 3
M!':9$-GE64?HW;4[%9.&<NQ[OO/U&+MP/<;N-CBC76%E,8^A%ED3%@B%)S(W
MF8HJV\COMAO:,!7RD0<]5X;[E6#/K_$B.V?=J,*;1LRJJW"VP7FL"-UB'G4M
M'<DU=RT2SB*T[30:>(M'/E?*6TFU@='VP,7 ]Y]_#O\]F;X<A=G5P>6+$45+
M![ED#\IBG8,5&)0H0S0I2G-WK'M/)_H6(+\*-Z 5:3WVP.@ ]0O07\+YJN]E
M%[A-W88M 1_'L6BF -T5K3?V&C@B6\..W 1)VZ\(6,<P,P1?R"+G] -IG)).
M''QC.YRR/>+,/%E=VX*T!CJVR$ ZO\ YOO@XQ86W=WVDJR!CY@J8J.>ZE(0L
MD5#0\NPL(RG(3G'/K=5I,Z;#6U)-Z9PTX:)!+\P/TY"QKG*%1^;:@],$.O%C
M;>XM)7A9ASL45!F=S G;;#5WD9RV1NPE]YY]K)<XK:E?]"MD'?Z"F%=NG\LE
MD/D/1BO:+%TPX'(64&QV7"2N,<H._M2&CS]-?ON29P-/ZC7Y=W2BCC_>VX-D
MLDIPK2 )06ZDR?)J>KB7#&,4DOG0IAIJ(Z335(Y^F6C@#*V;I5C-IIP*!J4=
M:*XX*$[+]J8(L(E[88QPRK?-ZKT#Z*MPHOL@HV&OO<WS-KL ;.HB/PKQ.$YQ
M+X1V4)+]V6C8@WHS4)]C]E;4G +: %6DM\8G;D%I';DN2ECI3TE='G%KCZ,M
MVY#0LQGZ_BR,QY/QSYC)=!K=GG9_%:=^_WDVQ_/:0??EWW_XE8[-R^FU_1R"
M=8) @[&Q@&*B0+!T'@N5$QVJ-C!?.ABK>X%X$GGY^Q Z.08;/5\(_C2=C.?#
M]=<;2W1,QZ"3)RO+:@8J20W.88#B7$I(WK<572Z*'G_2*2E$SW+M>?/H,*L[
MI11*L 8B2K*M9;6M4V#DC=6LAER8DK$#Z\]S!OJNK/<LUQ[=VHKN[60Z)^L]
M3/%%KI/$""DIY=LIGE=%72CIVS"=CW%Z[6#QXDPHF<[,.@L^! _1:PXAT.DI
M-1?>=E&"K1]\2CK15NH]][G_&XX73?LFX_>3T>7"3WM37G\>I[-X.?VXQ.>B
MHU.)">!21E+APB!H+L&*;+@6"HMX;&!;UV>=DB+T+ML>W=6%#4.+F[\879P1
ML,LZ(NZV&;.*P!?,T2H!2(LE@)$ JJC ,^:*8(%)UZ4E9Z>'G1+[_4NWQW[J
M%>"+4:B;U J(SR76ZE EN".3-/JKF>/<^>2U)SVT7=[Q6Q]Z2G3N+JT>.Z57
M(!^&&?\(=,*02KTD1.]P-KF<)OS;=')YL4HXQ.+JL%DP7M"FPI,AK9*D9%)I
MAIEG5D(',CL\ZI0H[ENR&UN''VH*ZR\XK^,%WX9A+I/I#8'U.WCUT<>TG;6Z
MW2KOC%<UY(%I;8)7Q:J"UO,4DS/**Q\U%K9VO.JC3VPX495%S%+*#"99!(*<
M($K'('O%Z0SQ'F7;+D[K4.V=\+-J_/*FW.ZN,1 !,_G& A*OYV.*#H(0"H3S
MT4HRDFRW,L+M4WLV07H2.]YN^G O9:<7L3=(N[ANJK+$\\/E=#C^^)8,J$D>
MD%V$Z% "[?(<5,X:G/2$+?&0#+W*.F 3E7@(U0EI16_";Y2U13OOFVGUH)=?
MW!# 4IGO-^+A@U)24?4BP.7(J\5&?RM9@LS6<C0V&MVF<=C.D$](I0Y#6\_1
MLS4G_V-MR\A]=\H+06Z!DF1Y,EF]N41:8>C%\3I+O>/XBN?53&X773F R ^3
M$E+G5\X_KY"^(DW&_&9:_UMS'A:H2;V''\=TSLHZ"\ 5VC=<(5>%20V1_@\,
MUEK"DIU+;=()]\-] NIV! (/,]EQS\Z+)IA$+XV'$ETA!]?3AJM<!.^=RT4F
M)ZUKJI&GVF"S#R4]#LT-YCB^#9\7>7T?)DLK<[5"K,[UF_)R92 LG)&"=#QJ
MLC13W>=11@@V%<C1!BN#M0Y%$Y7<!N4):5LS<I[XS,C%NJ[F3_\>1E4" T6;
MN"Q<UC?$DG41,KTF)- L!9/.6&2FC>JU7=<)*>L34H &HR*WSJA%SJ-P9(48
M9C(HR4B419%1$DIPC$QDI]J,9'Z6+33W4;RFU!R[A6:W3B@HN2LIU!75BQ:9
M71UF)D":C#F5P@)OI&PGT4EJ*X78JI/4-L0T;R34!<S7W4EJ*[H>["BTBZR;
M*T (6L?D/$1Z?,U[K&/%$_G(O!;L2&]3H_+LI]Y)JC_>MQ'Q,3I)19=]<;)6
M]FC:ZKQ5$*2)P(/WUEI>Q)=>U<^\D]165&S;26H;.1Z\DY2,3*1%DBO9S* <
M*G(*O8 BM%,H1!*=DD>??">I71GN5X)'["25B+*41(&4:Q*,TY%$42)@E%;4
M\@43NE0^/Z-.4KM2WDJJ#>J?-Q546:>5-2*0;9IS]8 M>%]JEROGZFPII7.;
M;AC/O;AU'_.^#S(.I".W<^^Z /RSN'5'0K<N5]R%C:,4MZI:!5/#;'X!E-5
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M$1D]LGXS!-*[9%O$.M:N_>JJ@@=CF&<60I$"E H!O(L>+)V55D:66:..(@^
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MFGO(JQ7AI(UD"0JH"P!4)O<P(CH@>X)9*40QN5.'TSW'?^I\.9KL>^ZNN,4
M6+WTE;LO?>/)N^M)^DP_&)>;WUW-PJ"2@J."@.1@*,\8!.4#8.3*D=^OZ2][
M7VOO@^@2.'4B_32H)/(N?*^<GWX<+P_C%<#7HYN%,\3IBU%^4<KP:AAF.!WP
M7"L/QQHY:BVH$@J)C2%MK%P5$9A';'/MO0_:I\ZWHVFJ0:YIMW-Z_A+T*@PG
MBY="E+'0/_.0[+S99F 0HR4ZD/OK##?U+?J$%M5=M)?"KN:::A#"])$VV/&$
M#N\%N ^? R%]/9U>8QX8H:*7FDYK'\G8RY*,O6 <N1+684Z9ZZR;D.@!4)?"
ME;[DWG/0T498L_$?-X;=Z]&W^HW)=!4 \^+3!.<_F?[H@# =1*<]SU*"EK4[
M'2L:?*W(8)"QK$4HY(UVL)AZ@O/427,JS1PA2.GM7R.<3#\/O_[ ^,OW=S0W
M,NN*C,P8J:!@-"0J%<!94W>+C)Q.92++<2[1'@#YU*G56B\]AB%M@[IXFPW1
MQE@;@<<@ H%B#AQ+":130:08O< VC28WPCE6),1QR+"[A$\=W+":R8=:2ZQ^
MT"_74Q+-=/IA\;G3^>LAB4!CD0R8922CI P$7DO>9JX20\&E>.B]='_./ CK
M5 $1/6A]W$KZ#5(IEUB6+X]=P#0MWW,'SFDJ]_2HKG4B'"SKY@100HCHD@&-
MM::@X+[VAU)@O-6%,R<EMLG1.(+B'ZG;<RR][R+BGA\/?A]_P=_G#]-AE'\?
M3[\.$R[!K9I6&$]^ER _/!>:IF 2HE >O(D\>V'0RRZARX\.='R#\0 EC%M)
ML,'+XXJ\\YN]Z4*FE;_&)8E$56 RU"<(1M8J*X%45U*0='XIW>9Q<0N@RSG>
M^Y!X@S3T3; 6M[TW!:@Z &QZV#\*\30&0"\*[4"2P[71P!QX'&@D=XJ'1 JM
MS<F4]0)\"0$*2RYD)Y5L=*E^(KH\8C:<ABV[**%G(^*WWW]_O8HD3%*Q(@IX
M29:1B@0@*.1 ?G7M91'H.Z6#M?#C$X]O%O0LZO'!<NJYF]O-#=:BNV"TF3NA
MZC-+#?W49)<XD<$KSD/A@179Z7JH4S>W.T,__?/^,&GV^.!^!\B2I%V@]-[X
M= W$\9N?'J".34H]0)8]M]%<AR22\BFB!^-*7)0-=\QFD-F16C1WJML;P/FH
M]8%FJ&VTNHL(>W>[K_)P]*D&5-PZ%+(6SMMZ"OBDZ5"@B05F(A0AC61,V6QS
MA\-SXX<?MW?F0:(>]RFGHZ8KW$0O_(%A>CU9/#(NFS"$JQ?3*<ZF893?#$,<
M7M&@M=77_!?S>!3>8[J>3&BVOX3I<+I_1D,#$/TE/;26T'I>1.%2J^!*;74@
M?78N$5&X5\XC<NX'#? <YFW= %J,_6+CV&]'-T/3+_PY'DWN(/GQV*6D2=K7
M=$P3/2A%YJI+V@(ZLE*+$3GX-I$JO4[C4 ]V&1E0/WP^_JMO?PX'F9PN9+Z
MR#4"UPH)@0@"T5H336$YY#9QAIO0'-_+.1W/UEW;@[5SLFR-'\%JF70M?0K
MDJ@F"2?7/@@-GB%+M55CXIW:TC<**SQA1.'Y\*RE3AM<N_4AN(5K*R4&;X(
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MF@<=?MQG=&"5KFU6.8+/(8 64;/$Z3C$-O>1&^$\,_(<KI*6IN<OWS?)9!D
M%@4+F")PK!W9N,T03)80,62%WJ,VC>\,'T!W].O 4W"G=S6=R^7>W1UU$;)C
M%?V?32!I99"]+C-$DA$8FQAW&@MO=$-]'\O)K^YZ4_>#!]G.8F^P$=U%]&?X
MLBI U 57TYNW;<A.<]UVJ.8>),*!8C\F+;SG,DA=P)'71/B<AJB+ )9BR,DS
M=(V>5H]+AT<NSX[%AEVDW7/YF&HRO1F'T:N0;MXNYG<N4=K$9=&T_QD)*B""
MLTY DM[)I*4/K$OYM6V??WSKM!_ICWL678_.R;R+'(Z&X\F?XQE.F?X'%_K7
M:ZS)YTMDTN=2BB*WB<G:Q0LCN$R&L; *66$^.?'81=/CHUR :GL48]\M&N\@
MLTM@>@G,^4HOZ4"G8LG=*1(<4Q)2[3O"A4\6N_2#?7"0BU/O(4+LN:'B+6#J
M'YHM<+G5+7A.*?# 0*E(N'P@BU2J L)QU-YER7#'Q7MOC,O2[6$B[+&HXCKG
M%'%N@4RRFXADS8(N'A*F $H&VE*T"U"C3!475FB7=ERY]T>Y+/4>*L8>&PG>
M0V:61X9<)29@B99+LA8#Y@0JFEJT7030WGBM.+=N/83F<?VN#W)IZCU(B T:
M^;V<8![.EN;>XND\:&*721Z,RF3J,:> D&3PMG"KN8V>B29^TGTL%WN;<J#8
M&R2TWD6TI'P73$UO4C:A.LTMRJ$:>Y  !XB[P0W*1FQ&9!1:,^ IAUJ>O4#0
MS-$?A5Q#XQ-MCT^< H_<G!R# ;M(N8'FW^.W\=4WVN'N@EM9FB4PM)[FF&N#
MT=HO.SHO()$A$JL=8F*;0+0'81W?0CA<<_=J[_4E]A;OPCB;X>1M66"[R2)3
MT6$PP'6U6@1+0*>A@"P,F4)<8Y!M;(1-:"Z  0<+N<%F4%^?9\O7YX_T;Q:%
MASCR^OH(O'@D3/1'D#%!*H7,WX*6G-%F\0#K:"[6/#Q8]#TZ^MLPK2J-=4#5
MU$3<C.LT1N+A>GN$" <(_0@[Q*K*E'$Y)R;IP))T8*4HP=6O:'?DS-MZ896>
M/!4>,1:/Q81=9-V$ 6$T?1>^UQUO>6IY+8L1Z &1*S)7#*=]K_9Z%DD9B2I;
MU2IB;!W+\0V#/K1T3_$'B;B!17CK0FMEH@;&; D9M*035!4AP#EN0":T,B/7
M1;4)P+D'Y2)4?IB &RSS.90E!]_./N-D^?4*GK8V*T8&K_:8R0^V'IRL6UQ0
MT0CF?%%MTDP> 781;.A3^"TKX=W)QIKG@LX//9MT5D621Z2< *6SAR"R(+0Z
M.Y6*4*I-3/HCP"[6>>A3(3V^)ZW@O1M/YF+^$=%\\\6OPVF-)"7$J][ ': V
M=2YV 'M.N;1[*GM\7$VU#$[_ ;"&4B^SGE:]K(VC39)SB,H25DY87::OK,'H
MI;'&ES:];;J@.Z.,VGY8U+M*&M!F%Z:SI*43/ .3M2JDM R\Q0#:BF)-CB2K
M-K;NB?:B'?-D>M/R 9O1+BIJX!^M<BW?XU<"C7DAA.UPO=8F2I:A)"3C,/H
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MN92D8F0ZL9]Q(VL('JTB>U/]_/WXZNK5>%+_T4"'8F/M=FH%TM;CDP5'HH?
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MF*HNZFTK\TO3FB>^B(/O+S;S<7=+MWLJ.S<Q%H4V 3$[C4OPFCCJ<,\'9H(
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M:='&M]N-ZPSTH:+@3YSGOY@^UDWR(PT/WU;MYHO=7C/C?]@;6^;^'[#VC2H
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M^6A>3\R359<]/YD)/+2:+W B'3LH2B]F]""VF8;;SGMBX4(MU:,H,4X4XS9
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MU[\/4\T964:VUJ\UGMVP!N+UEK3X0(HW2&G@ S_],$O9*PM\W;MX$(2$6*$
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MESFZW(T\!*8'S$G@N\%554]+<:94??/9X9 HW2S:=[<+.<%W/@#K@_PO:ET
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M$C<XQH;"[W8P_GB4>'=IVX838GNFM:X%D-QG*"C(M!,^Z,(TAK^$\1Q^G>;
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M7;."(H"VN07)$'S.:D'[QZY19W#?/HVU\2VO_YO>ZCKYIC8'D-823"5;020
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M..4,;7Z\YMMO"0>R]\H>G:\,^.[V5\\%L,AH B<UB>S#U91T'6._,!7T,]K
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MAE&ES_<B,&L'9I2ZY8-/BF@,#!MIG=L;=BO40JCS3P"XNU"0AFY'2G1U=DD
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M]XJ]=_FKGJ<7L3_[X$K;SVK+3J',_=="]C]-W#>^WTR.*+ %(1_>@L2](N.
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M(:S' GUWT?2S8Z^\W(6@T@F=-_&WLP;-/BVJ?C2/LAELL>?P@\;(\VN<8QJ
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MG4ZP8NUE<OBY*3-!=HW&-Y%*+$?>*;M]-/Z+F7*7+A]?^(.;:5L<-N7;UIL
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M*ERT;?7J3CQ4-SMBY/UHTZ#DJ.412YG?#*XR,)E":]@PSK'Q'H) )JVPK\B
M XIWHR?D7QAM@,@'0J)"]SP*[_EPW[K[Q8&_=I]WE"=Q]6O"*%P3/<FUY44S
M1A3JTM06#N]%SP!RRY!GNT^]8?(01Q(7] K/-S3"Z_K' V!%%]9;V@,3GUP^
M[5>2>(A:6)ICXLZ]M"0M<\VPS(\#XMZ:FP@\+V4OEJ9V 9"BO=CH-N$'XL@*
M!8&LLWW[K='#(2<EO;/W()/5:QQ,/JZ= _'^$DSYG=K3(I8&]2/@RRF6O01>
MY,1W,>*PX#0I*;;M7./A._BP+ZFRY54$M])B]0Q7BFT33\^^8NO]D]VUQ?DF
MI[F2"=H6PE#!=)WE@'R*P>@N:#VX+]V\=^$8$*<.5F@SH(@]F/XS_[*)=.KY
MB8![#63WP16E<Q?MU4 UO[?S2#+P8%/HY4-8'59#FQX9(\7^T&'<0(WH0T@B
M3]HW4HO*P@*K@2N+\I ;V8;63W:]5[\BW\^J>J??<?EZC#I8E$N0=P&XOB(H
M]P\3IBBM/(-I7[%R[U,Y::@RW<9I<N/FNW>MN0U*+\9LM./;TJ+J)&U!T4GG
M42P*!FB'4B]S0'R "":JA"E/C6=#)F&OTT.=Y!0]\M=:# \UC U-1+_<2U&+
M&,8TI$_W07=CNKIPM0<3^ 8X(,4% -[OH4J;']Z.#6X(LU45>//+O^V))%XZ
MW;VS^7H'_'C_:*+R5]Y?3BF_"6Q!KM+> Z*.,*40=.M)J)^*>8\8&2*^$"#[
M1RX&I2&<<'.Z8:YV*-"/_RODP^9IY0?DZ&>-7&[NB0,QM6@-8\A\>@JK"J5#
MPU'6'F<ZT-(SBBF'(/7<U;NO.\D6^.0(#\L6B[22]9J/LUXXF:EG2SI>Y5W!
M_YMNCI7FVBWU>]&QG>Q-L118!R^ (V?N#FBQBPE[>F'@&C7]J]-VLJZLU'MY
MR;;@4>SCBM[>*W8/041)?KZ&4?@1[MT7;[,CP^5WSHZP>9%-?2U;=&QE %BL
MJAJRI7)A;:FYY<F3(:/LT]JK=AJ/L^U<?T_3"=QKF@(K?> ZWPS,K4P%- $C
M_PN#YS.C]FVGO&':/D.=?5?_^:[-D)_J=_^\<(GX#)W3^I'[*)^T&-,^/IZ=
MX)>/8)\(U(L$O#G9<@ ,'(1W8_"I]*("$4/X5(<2?L7D\(1&O)ERROZCB">F
M0HI#DE5=@KLR3\;LW7.; ^+!>6](HR<PM2I)#XRB:9I]'D*-P"C9;>,!5/P-
M4Z?"YF6@'+TE4<EVS(-^4,K5<N]?+='U"_8N\-4+L><LLIQY5Q6U?K:R!1H8
M)YC.K(<[)\EP2NB]*"F@E6(GA?XDJ\HS5CUG2RM.KM;SIBZE51\4O;MBDYKG
M2^Y52H:%>!Y=0W7?B>=Z$-^A>=15*GS5X3GJ,N!/8_1WR.@3I)AZY?#O'4J3
M>9_&'1K?=6Q^L\E1%/CF)/S.')*'JGGTK9;GC]9YF9\CJ\D(@WY(,DX1&I 3
MK7T<*.ZS)1+XX-WB;6<TD_!1.LOM+I?67-T#[MXH<SU]X]3U]Z _BBE,ZDXK
MC!\8J3<88@4'U(3IW@ S;].2TE>96F3,'O-GUY ]S@977-R^^$]OV^X^\CK+
M3#[22D#R %'TY/"]IK5R+MK43V$0B P!FA Y8JV*ED/:3KRK(JMCV+T@ ^A1
M?$:=?'U.?"' !Z]CSL!\K++U>*X8WIY[4N9M*E;MA_T$ =2QJZCB75RK/<?5
MJRS=AP9 TL'B1@+4C8MC1F(W"-(=!^RJ!@P>'$PQ=KB*[)\A.^R^XO]0[&%+
MW1>1F5/84?R__0(2^PD+G*K>()?'HO<R-8!,Z@J% TI'&0CCP"B-DH %E<]A
MWO5O)W6.'BT]43;R*%6W*Z5O4_>ED87)Q3S--0X(K]F-DVV+H$;!J)9=8JJ0
M!-3Y-Y&REY%_G:VU*9VS-O(/"]O54JOW,;S?)_[,HY_Q45WN$SQS]O"'<.IE
ML9DXLAQ3TK*OF \:9#=C1Z\!WE<B,V' T#/ II\M"-RG[5JYUD#[J/C7FI*
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M-,CN)_M4C7!R"R<F(!WJ@?B40(-]5I5ZO7+YM3UJ%5G=-1<KH$>/'>/))V&
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M3P=W%. >(_7:EB<_&@+O!]_)/^@I];$X-?WFXISFMM..^D?(BC#@M7M! @0
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MU9$;PSD^.H6QCXYX/ FR3PU54085SZ<'$=$M\0%7C0_7)>SOW;/NFO?RPC+
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M4[<,?0@KS7M,*38Z%!EOQUT3?/OU\Q=_DN*D:0U_-/FZ6!0OB1LET-+F1_4
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MH JT9ZVF97Z?CK-[K/ *YIYU);(G%K.2F4#@!Q,ZU/';L$1>\DK1\R=4P(%
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M7U_J>*.LJ$<_<5'W5A)-XL_B/P<NE% L1!,DX!!F L,K 7^71^_)'.<8,6W
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M:#=U(M(T#AR4&B-&/[9TJ?Q>R?[JTCAL,AOXBI$Q]3J9\]YR'!+3R(U8#+-
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MNKW]\W>_?'H%X^_^]W_]V[_]Y_\%X?]Y]N$->)'1QWN^+<'SG..2,_ E+>_
MWQDO?@,BS^[!W[/\M_0SAO"_JIN>9P_?\O3VK@2>XWG'_YK_% L<^5$20A0B
M%R(WHC .$PQQS 5.(DX=%JUN?V(13I*04>A3S.2U7$!"B O]Q(_<$#-Y&:\>
MNDFWO_VD_D-PP8$T;EM4?_WS=W=E^?#3CS]^^?+EAZ\DW_R0Y;<_>H[C_]A>
M_5US^=>3Z[_XU=5NDB0_5O^ZN[1(SUTH'^O^^']^?O.1WO%[#--M4>(M50**
M]*>B^N6;C.*RPORJ7N#B%>IOL+T,JE]!UX.^^\/7@GWW7_\&0 U'GFWX!RZ
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M-WS-M_"7CZTRE403<=\96%U>^'IS7F2/.=W/>_>;<Y.9G,?4S!?_N,7WO'C
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M>K&$ET5OSEGN*S#QQ/2\&N;3[E'G.AD=_^[@AAH$T*( ]J_5"NR@V$?P5\F
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MCMHA#B"F%(6^IU*9C-9A4RBY-/JH&Z*.J7,VQ4AJTM$3C\_$G&8R-/8[;XS
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M+;,3PF0P%'HD- V\$Q/2 :YGPI-JS<&OS9^3Y.V8 V>5L@S$STI?YK <4]F
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M#6LJK3,(-)S[)>@GY:4/[8P[QY7QU1&G-!^V]H,6 -!!8'6XS:Q D#>50,(
M]C@<;A?76#2[RI\ZN\H+?G<, F 7_ [-%5R[Y'?)+)#WB0:S+TAX;I7F"T!^
M(K /@IN?2H>AS?'R5.7?MN[:R[H9YZG3MDX20;"(,71#XD(4^Q3&PB,P#J1G
MA%D<DT0K+\18\M+<E_TJ)6T#+M,MD,,BW9=..5"N[%$'FM\WZT7#.@GZ(Z.W
M5IP$[XE]BE;G?6AKK?4*_+^/>).J:>@SE^^[^JOZA_KOK[<BR^]Q/2.<6U/:
M;-)G"*KEEGVZTF=NX&<(RFD[/],'#"._%YR4^]/:#YQ)GE9OS?NJQ,HK^1HW
M^[F41P["<0Q#AAA$GD\@80Z&(G \GR'A8&;4F$I7\-*H;Z\IJ%4%2E<S7M,&
M78_6IH!R8E93*G?"8U9@K_6JB^L$N^VF:%FE*VWAL[*5*23'9&5\_S"NJF-+
M?N;E7<;VU0U>I)]3QK?2+<P/@OK7?AC%/$&A]-'"$"*<<!B';@##Q$,D1C$1
M9MZ:F?BE\=9AYDR53+.M-J'W[AH6HBKD;=J.SW!<]$AM.K0GIK;W>48Y9PW&
M321@;4>G:,KJ()7)'KL-@\TJQQFJ,"O3#8/GF.\&/F7@627.?^.E\@4_JCJ#
MU8+J+SC=JM+Z:T[B( A# <- '4ZR,( $AYXJ?<_CD#FN'X5F95;ZQ)E\9?,4
M5GE^IP(2U>)3J+J:]Y7RX+,JTJBBE)J8[F)GB>%I91_TFL>3EN"<F+3V:H*]
MGBN@-&TZ?U@\>M2 Q.Y98Y_ >0\7-4P_.4W4N6<8M71*1-UL-M6V6O=7;<9:
M(/]'&4.0!I$#D<\#B.-$0(<0CB+?#3%%9B2C)WAY=-,I_ KP1KIMVWJ[)=TK
M_Y,9Q6@.@1[9V(=U8MKI:+<"4N5=;:Q.;;D)RM";X625BS1%S\I*9G <\Y/A
MW4.9JD[=;E.X7V]O*,T>I8 /G/+T<]6X*^0!3H0;2<P%AH@C!N-$)=<)/TIH
MX& 4^V:%2W3$:GU.LQ8E:74$^4Y)4U+20%N7DBPA.!<A-=4FOF\5_J-R+G>(
M?KB.Z  VTH?(,A=I")Z9B?2A..4A@WO-PZWJZKR9N,N*AY3R:EBK[0S5%3)P
M*(((,0:1(Q@D)/"AZS$4T,AGPO-TPZ(N"5G:9E*MIUIA-9J"G:KZ\2<7$>UG
M%ELX3<PDTT*D'TIC ZJ90EYZ(*O.EE6< -Y^ ]F7;1T-DU7-!KG\2Z'N4M<0
MO*E2F8H[SDN@]C5_L!/%<@W'GFB3B[?.%A5R3?EN],;5:X=Y<,\>BW3+BT(.
M(DFWU2/W$1ZOF0H5$-6)9UWA\X;^\S'-.;O9=O-$Y;_)%Y'MDX<Z_U9YGFL7
M^1Y''H=AP@5$A$4P1DD$$X=P[B#J^L(UV?2?1^VE\7N]#-MDVULHQ=UW"QV8
M>9(SC;J>+[J\L9QX#FH-!AV+5YTP0- UNBF:#%JS*X;M5B5H+.\FA7;_?54O
MWNWYQ?,.EU7/>B;59_7-YQV.8^]^9NG#YKCWN?)(RF_OY5=82M'JG.CAOI+3
M=H3P'!?S0,Y/%/,8(AX*2$+&(0ZQX_(H08YK-#]=%[FTN:75> 4JG2N:V6D]
MHA6'!OAZTX1=2*<_;1Z+IC$QZP-DE50UQ,Y*B/HP').9P9WF3='K2,&_\\WF
M_]G*E=)'CHML*SE2<I_TE'P18HI%!)EP/"@]8PRQ%R?2779"Y 7RET&DVR&]
M5]+2:*=6%BAMX6]*7=#J"VJ%];NG]R/<3S)6<9N86X9#9M1F70N.P3W7^Y\^
M6P-V+2.[W=CU;AA1]+ JNO0JRS_AKW]/R[N[;,/2[:W\Q?G:3^L Q4[D.!0R
M!X40J6JTV L"R$(FU]3$=1$*S4Y7AJBQO-.6:G?YH2J*4^;5^? W4)09_0U\
M/[PYI.G@Z'DVDP$^?WKEKN#>OB19D]16@,HLOF%5R5EI)NC8"=Z137J+[0;=
MC<'5?HD\4T7FKW$W$*JS1>J&/FL8<ZI'Y?Q.%27ZS.MJ.6]Y^4Y(Z?)OFT<E
M^WV65\7RRCH$4"U*+Q487U,'8>Y&,0Q\%TEW+, P08$GEX.!0WGD>W[HF876
M6-9P>3$XTIIJE4.[AH)T0.4BVX.I1\)/.$ 3\_.!94TMJ29Z< 74L,DI4EJY
M CL[06,HZ%K:T];!'F5/- I6V=RVCK,2_40 '\\!4XD97X3T?2XY*7W F\95
M*=;83Z(@<!.8> Z#R.4<XLA#T&$B27S'<3EQS3SH7GG+<Y5W*K:UMPOPN)7H
M M$4H-Q4L3?9SD4S/&WJA]]! 8Z$ET 42]!1&#$YS7("8X8B%PDB"#'*!QH/
M_NRU6A674ES< ;')OC09*@?86P5<;SZT!N/$L]M1D=3]N]SJ.DV=TXN03%:[
M]%3BD]4CO6A\7XW1RS<-W"UY?'C85"M,O.GDU<LE1KN/^URN^O&F*GO]F"L]
M?E&L]B5/U9<MU<GR?W"<7VMJL79\ZOLJ;(%2XD&$JYDBCF',74:0XT<X"@;T
M;YM+_P'SS2S]W78-Q+*\"A%ZR+//::&\3NF//BCKP#=I'J"568:;-7.]&YH;
M/$L:ZKD.P-0 *J6UV@I9W/29&6N[&T5S*3_OYM+,0W*R(36W_(%Y]$TIW?=\
MMTF6TK4?4Q[Z$8$!)W)U@F(N9Y^(0B>BKD.#T V9ORXS:9K>M'-6BI%;O),U
M[692VFQ4I%O Y&H0YX4J;ULW^C'<NS^/K!YWC\9KZM/ M@"V5+#>:5^!2D>+
MR>M]$-C-43\K:=Y4]#YC3S+.>R\>ZM>239THH=Y_^?TC&L:)!^,D\2%R*84)
MY0B&3/X#2ESB)GR0]]F5LE ?L55RT#;R$8ZZGIHQ+#,=LK507.D%,,!?.F>Q
M9:_F0,3,OL<Y\TX]A+-7+:UWX=NLRN#DK$X&6'.:4"82%\:>ZECHL03&@@D8
M^(F/F4O#*(G6#U6UGX\ESDN#\_\Y]#?YO(ZMF-#W:)6L78U"3J?\-MTJGI<3
M:YW&HIR2X5$$L[P;'@^%XQ-5!=,-(2*1ZI25<!@$;A!&H<=(+)IWX^76)#)D
MF6]&:\.<[X64^3M[*0SB498VS#,&L4S;77*'@?RQ0N'WT%+RPL#]3AI)'FO_
M/Z1]Y(5!F:]IY"4%S-.XW^?\/N7Y7SG>E'?OY22O"JHVU39#+\'<82X4/I$K
M($I<B%6KBP0)'G'F,-_7ZO1S1<[2C@8;54&M*VB5U<]2[L.T?R*PB-3DV\QG
M0;I>G]0(+?VT;DNHS939/1@]HQ1M#4QZLK3[[IXM45O#A&ZNML[E8TI=W/.[
MZM'[P@-$.,R)Y;0:\%"N!(7KP-A%<I8-_9!@%XO("\RK79S(61I'=DL3W'-0
M:SNNHL,IMM>YTA)B$W/E+& -J8 Q"K0G*()Q!KPE%<*X"*=6+8S3NY^@',9%
M$\Y7Q+A\^8#^;7R;9OG;3 Z;$_P0!2\>N40K:#P!QR<L"@2#2:C*N;H4056S
M&@9A0#V,"2(BT6ZVUB=I:4RK%/Q?H%895#H#]LB!4MB@M54OMMQS0Y9@#SH!
MB^4<Y@60$"S]?"R(B#"EU'7T@NZMHCM/^/P,^%Z?QZQA-O5F30>F/X%*U?_U
M)_"BP6N \]\/G$&#-%L SM7-;"209@W'=,#IZP[6>_]\K;QTS#CHNZ5UP] "
MG$T?FCH"175\6..0HT2U ?61VOFG40SCB#ERHF*^BB81A+D#3HS/B%KHL?&N
M)1.O5:U\,7ROT@W^56_J2F>,J58G+"V:"I+J$L%- ZW/P:^WQSX4S;GJ;;9-
MK6KU5D I:+.VYD7K+9?2/)4S<^7,BX:>%LJ\?*FY&_L<%W<J!5-D^<U]]8K7
M>3><I=M/=[Q3,3L357AVMQY/6]Z:4>%%2>A#7V5 (AX&$/. 0I%P' 4,AU&L
MO?-J0Z&E.<7*)O @C:J"F'%ME@I6J>QJ>^_==ZJ32^*IPS@ZI=LT2Y-;&]7K
M?N#<8S4QFU7#]+X=IL8B\+HS3-(H\//A,%5V'11:TRAY/M%GJ.U_SCUP,[FI
M\PV@D4-K$^T>O]>*F-G<8YN@=+UHJ\\=F$:*T_QOJH?-"^DV;C(E3U6%:M1Y
MD=WC=+N./>2PD(?0\ZIT1C>N\TI%Z @NAQ91EQBE,VH(7=J\J'0&E=)5/ZU&
M[:K@V>[K_;56W;":G-80Z'G@MH&=>!+;8WI =%=A-,]R-,#%;K*CCN!Y<QX-
MH#A)?32YUT["R(MT\RB7V/L&092&$8D]R).80!0( 9.8QU!X1'@Q]QB*C8I:
M7I&W-!9JU .\S9#8I8\ ?%37XJ6*^WW 1=$>A<N_WF=-.)^J72/5->P@=&UP
M]$C*(N03\].Y/)1V!*9H%J2)S*3I*<<RGS11Y0( UU)6+MTV((:+YU5NG=0>
M;]G+^X=-5L6257%E'V\^?&RVTU6_'^'C&%*7<JC\(1B'L0L)C2)/12UX$=6.
MY]*3N31JZJA=EX;=*0XJS8%2W2!V21/YZRO_"?"<F'>TH!P2#Z:)J4%LF'UL
MYXH3LX.Q6=28&5I]$62:3YHOFLS,M(/(,L-;S5G\9[F@IG*=W0;?^GZ(>(!A
M1+BCTDA"F*ACI81B$B5<<;F6#WGZZ*5Q<JN=/D4<076=78<#,#&)MHH-X,DC
M$/3I<#@8,[&>/BA&Q';>[A[^.KIA-IHZKVB7C2Y<,;KK[>OMS9;=L,^*YHI/
MV8T0Z295@70?Z1UGCQO^3ISKQLKD@I<*1F&,/ H1\AP8XS"&B0AHR/TXBK%6
M$75K&BV-XKH-7--M-96W-JE5\-ZJ%6CM4COIAGU?)QI=W7/U&<=L\E/X.89K
M3)O><1!/U<%WH%9/U=QW'(@]?7]'/GA@]ONY9W^J6M.2.,*8!1%TF2KWZ K)
MS['K04S<D$<1=9G@)OQ\6=32B/?BYUEI:TBE/0CK<:0=W"8FOZ&0F2?-7D7#
M;I;K97'SIJ5>-?LDC_3Z'<,HXP47/,\Y^X2_=@YMUY$3.R$/!&0Q=B%BC*E5
M)X8)CJ*0NHY@:%_Y1K\ UGEI6F_^42CC3(6P6*-P6Q&KQ%^'=WZ\@+4><8R
M;A[2:!6LVDL<-$&40-JCC'X<K-+%!5&S4D6_N<<T<>7J811199ZKVN"XN*N+
M]+05.)E#0Q(3"EWD>7+1AX1<[SD()L23ZSZ!U!&H6?7NB[(&<,3$]%"IN@+;
MGI?;$$X](A@'T3Q<4-?>:)3<M3UH]+Q<H<68#*YB894/+DN;E1*N&GW,"M=O
M&.T[U"U&Y0_M[QH)'WC!<^FPJ,40I?DCWA0?^4;L:GVNXX D/A,,,E<E3S/D
M0.P'+HQ\C\1!2#B/8I-UB06=EK: V2D&\EKSP5['X%$R=E'FP'Y.?Z:V9U7]
MO/N'78)&:U6]3=38M0+*,K S;1(7:"S.4_E+@_5Z*N=J+) ]GMCH1P]C9_GX
M,D^I=(14^*ZJG"S_4&6%/N--U8LB#+W 2>($TB3V(1)A DF8$!BY 4;,)UX4
M:&68Z I<&J_N]05*4S-6O8JN'F7:Q&QB/CR"JZXIKW[HJ&N/XW2!L4I@5X7.
MRDZZ$!Q3C_9]-G>,+O9O7O/((;&+ M5/.88(>QPF/N:04HII$$1(D'! 2JRA
M&D/VF&;M_&Z\CC0=AS';3.-@?>K]I]Z&\%/O3%V%;H8MJ\LZ+& OZRI >IM<
MUQ\SU(VB7#(GV?#B+2^?/TK)\F.*/9=RASG0"UT'(LH]2(@70B9PQ 1QO8 3
MLR:E9^68?%[SU$J1GFJ=0Y3O]#5UG,[AZ44N0C00D'#J0122 &(W0E @)\!!
MC(/ ,=H&&(WF' [H1%BZ/O4Y\CTYPTH$D1_Z,(D='X8A%CR*72K_-.E:,A[+
M&0YKSF"Y K36U0:HNN[\2*@F]^%W^E7',BOP_ I$ QSW'@@L>^OG),WLHO<8
M>^J7]UUL'BW\KJIPEVYOI3_3=*RLZAM4/5PQ+26%W:\I%4BXD5S:^U$$4>)'
MD@P$DBXX<>4_A(3'6AT^=04NC6-W.M=59@Z:JK9Z Z6X?M2M%N[]?#$%FE,?
MZ3P1D/I!S;8!G2G462XS[^O:)$7!^1^*IG+E6:0E:Z=;\(?WVW]L?]Z^^+3]
MJ_SCXQ] W59M555HX%_Q_8.:_/[PWOU'\+/KO_B#G!,?U-%!/3T^9+G:PQ%J
MO*38;,NK7H_R;M6B_%Z"=2?%*-'E72HOY5O \+?"4JE,DT'JB<O6>LQLT=HF
M1G5CN(WN&[9\:8[]WN6J%'+SEQLJUT9%JE[K*DOZG>C6:R@*^=8S=\VQ1P@E
M##+?"2&*J0N3T&=0Q 3Y*!!>$'@#]FT&*[30'9RJ-L#GJC: ^H@[)4]PK;B9
M]SE\O/0\U&GAGZF8<A-7(-E.6;&+,^C8L6K*-:A:-)TAN;DR),;>[F@XK7K$
MP[69U6L>#=JQ9SW^@4.WPDFY;]'Q@3-^7S7G>%^U1?KT)6L2LT24X( Q%P:1
MBJ9,'.F$>ZHX#7(((MA+!#<Z:=.4NS1??*\HJ#4%4E7336\]Q'4WNZWC./DF
M-RD[78Y4Z$&K]*H#JL6TN8%86=[5UI,]\VZV$2"GN]AFMYLQ%./I^N6V3,MO
M?\LVCW(-DW][E6[D-[XF7NC%B(?0#4+IU@51 #&-!'0B%C!!/.;I%::Y*&%I
MK%,K"79:@EI-/=ZYC&,_PUA!9V(N,05&FS*N&G^&'.2BYX?;[/./\MZ*%_Z)
MU(^P_K$B@\M/G>6SOVI4^X%?OW"8L_$FV]ZJO0)%'-6A_D.JMM75>O$=V:2W
M=?>%=K]:Q$X48^)#+PX2B#R.88Q" 86#'!=1+CT.;G9 921_>0=7C6) ;7\T
M9:@WTB*HUMA506HS1\1L-&*6\"2F&(8NIA"Y@5Q+^PZ'E%,WDIPKDD"K1=#D
M8S%+Y=ZG'(E(OOF1&R;2 4<8HH@CB'WFP21P?9<0!\4D-DM9L#\6LZ8QO.%%
M\1,X&I,I1T#/-9_L#9]X4GVS>Y,K5UUMH];%</=:3W#H-@@MJRZZF0:S.NJ#
MP#EVUX<]9-A,KT)8WLIW[.9K6JP#1C"*&(4N$:K/N.=+KJ+27W<#G[BQ@T-F
M%!G1??C29@:E&U#*@5^5>H:YV0>PZ;',4# F)A%M'(R)XIS!5GG@0,"LG_DY
MTXZ_XK/7C'?'USCQL$-\ OV82:]"2+\;LR" %+E$KK,]P=QPJ'^WM(^T2KT>
MZ:>M*64!C3T!N1L&$'%$8$(<!DG@>B'#?NB[R?#ER?)6'W57L0?\S3S(ZP W
M<^=I0;1VZ!M-X_U,[MP\G>^BXYJ,"">J6SJJ A,L_9RR1[QYOL'I??$\DY\(
M9\^^[9*3./N0%K^UZ4OKT'%IA*6'(CARY>)6?M6)7&-!C(+0"8/0=4-FUO_6
M7(FED>2^96FZLP30RA1 :UL ^=8F=!KW?QTP2OW,,1?V$S/,'O:]$:"V CS?
MPZX,@8TE0)FRR^"<82!,N_1..R"SM_#M_1XZG7S_4(!"#5/:#%.NAJG]7JSV
M[1T.\-6FO@,>/7/'W^'&G[8#'O$LN^?O=4$NP03SJ.-!AET$$8Y"B$-"(15A
M'(0LY XQ:L'0*VUI$]#107'GG'A8X;-^J/7<4FL 3CR+C,#.VK'Z=$70^B4N
MX@B]MQ2:WDT#"47U)-V6Z?:1LR8X,]L6[[--2K]]XE_+9U+[W]9.0%$HX@!&
MD4084<9A[*C^C Z.8I2XV/&8V>)52^[R5K5U98-ZD[L39=?42Y4D_RC?1S7I
M=^T#>P,-*4AK<#2IR#;@4U/2>0!7H%89_-K\J70'E?(V.<H$++M<I25Y7LXR
M >.$NXQN'MDI[_7VX;$LWO#/?..V@8C$QPX+?2@7Z5@NU7DD72)*)/+<"85#
M6)(8!2+VR%J:0]3MBU=KNP*5OL =V ;O#+YZY&,)M8DIIP>P"<(+-3"9IN'=
M&7E/T^?NLN$7V]OUW#*,.^H.;,]QSM_EMWC;M&S_( 5(QOI8O5I%=;Q&'$(]
M-XFAP%BMK3PDO9\X@CQAE#J814PX)D2B*WAIK-*TK%.*@Z[F*C"WTATTR@\Z
MT=0>#CW>F0+DB4G(&K[&A&0*EE5VTA8^*U690G+,6\;W#TQYXV75L#C//J=,
M;3[]4G#V>EL7SDZWMS>T3#\?=OD.$4T(1AXD*C(:)8)![+L>#*(H=#S,/!P:
MEO,P5V)YR[NJNI?89%\*H%X&N:YKE =XI[UA9\X!8Z/';=/B/?6Q!2_K4FJM
M^FHO_'ME@<3\CV!G!-A;,4EWD>$@VDUC,U=CWORUP3"=)*X-?](P;OQ+EK$O
MZ6;S^OY!.I%J ^U-5A1K5827X#"$ 28.1$BHK7+7A]3W7>8'\H_ *'[EO)BE
M.6^MEB#=J0DV4D\S2KL J1YMC0=J8FIJ%91KP#U(;_I ,F:=?@RL,LL%4;.R
M1[^YQPQQY>JA[=Y4$7!5D7;7'WTWW28^"OS(\541+@^BB"00)T*Z0D@Z09@3
MUZ%:T1P:LI;&!TV=^JK&\T[9$5W7+H.L1PZ6H)N8(0:C-J#YV54\++<UNRQO
MYH9E5PT_;45V_9:A*:4?[_%F\^RQ2+=<3G2($<=SD)!K)R%]!^DL0.)B 0-'
MD@?Q7(3CQ"RA].#Y2R.))FNRTA&T2IHFDQXBV,\&%G"9F ',(!F01GK6\)%)
MI(?/G#F%]*Q!IPFDYR\;V,6GK354Y:QT"Z?BJHMU\>)Q/S\%V"6)H![T"7<A
M\A*DRIL2F#B1Q!(["'&C]8")\*5]\/O"9Y7RAJL#(]CUW(*IP)R8)=Y4]<U6
MX C/U2YT0-5GKBU8 6G")"[$$.SL]A R46#>MD(#H#GI-#3D&0./N=-M6DH1
MG]6&22E?M)1L>!V0\D;RY>N2WQ=KSPO\,,8^3!AF<D7#'!A3AJ'GTHC&F(N8
MF9UW:PA=&G_5.L-*:;#7NFEI WY5BH-*<\,%CM8(:)Z(6\9UZJ-Q"Y":GY ;
M8&3WJ%Q'\+QGY@90G!R>F]P[C)J>9]LBVZ2L.M[Z^$B*E*4XERSX+J]:L75:
MN.XOY:SR^1175N% ZSB1'A</?<BX0R"*"8.$$0J=./(#$7LX3!RS,RDK>BWO
MF$H5?%,%,[/-1GD5<E2Y?'S=M[UK1Z=I>Q.?R#B_5U&CX-(CS C1SKCK,>;L
M8SDQI1[8LP)=BU2=Q[JA9,>HU>'0MG;-$Q!I%7RK7&U'LUG)W"J8QVQO]^'#
MIH.V-<&^_OM;7JX3Y,?<#4.8N()#Y$<)Q,B)($YP@#T>"$Y\DRX-9Z48^:)/
MTZ7!C&+/8ZE'F:,1FI@"=^!\Z+2PP$).1>!FL\F^5&7 58GOYSEGJ>U3N%YT
MK'+4>4FS<DZOL<<<TG_QN'/XNMKCZRW-U8+Y!:__7#O"]8DGT0LY4;6WO0 F
MGL]AR'R>A'$0(QP-.8\_+VYI*];]N7RCZ+ #^0O8FAW,CT=LM@/ZIOQKJROX
MOM768L-M/5@F.;._(/))SN[[S;]TAG_E+C,F*?)R_;&4SHIR7CY2OI5N358%
M R,WPJ[+*8Q=N69$7D)@$G,/,M]5[;2BP&-:F_<7)2R-+UK=C&*L+^/73Q!6
M4)F8$W0!T?[\KQK=]\7+FSM?N_S;\9=^^>FS?-Q7C6N_Y^L7#N_1D=T_\)+?
MW.:\>GK1)FPECBN= 0?&0K@0A8& F <)C#WJNZY'!8Z1B2-P6=32/NJ]I@#O
M5#7OI7$!5STGP Y:$W_L':#V6DZ0H74=#.N]+"Z(F[U91;_9Y[I17+ECX$8"
M8U4_"[QYCU/I1S1%*-<\=D+,!(/45R%[<>))NJ "^IQX$4X2+\1:$3A7Y"R-
M(1JUU#8O_TIY466:/^"F&X_AOL(%:#5W%L8#-O7>PDY#H%2LML9K)2WN(/2C
M8'</X8*L>7<1^@T^V4>X<OG .I2=KC9;]K',Z&]WV4;>7Z@.R.6W77 )81CY
MA$M7(G*PVG#T8>S$"/K"D>L%ZH21$QJ67-04O;PCHVZU"G44]/$.Y[S1_3_^
M/?;<Z$^@ML&P5J/N8.CQRA0 3TPTQ\C6BDX2RV.*CMV2D+K"YRT7:0C)22E)
MT_L'YQ\<;(&\WK9[K._K"JEK7RY[8M5:/0D2#E'D$)B(D*AVZX%+?!)&D3#,
M0NB7N#3G9G<8,*AF['6 ]0C(*FP3,\^9?4_EYNR ?'\%R"'I"'K@V$Y*N")U
M[M0$/1#.)"AHWC@T3:&*XJ@RE?D+7.)=9QSD!C02%+IN(OT@*@0D04QA&"6<
M1LQQO,@SRU<X+VAIC-)$Z7>4!4K;J\THS-#MYQ6;F$U,)T/A&I#>T(_%R#R'
M"P^?.>&AW\33S(<KUP]S.U[>/VRR;YQ_Y/GGE/+*Z7\FJ8>IDK-\6U1!(BH?
M^]4F^_)2"$ZK[&R5D_TI^\C+<L-OON"<%6N?8%_2A0-]^9/JKH5@XA!)URB)
M>"@\'CK8Q#VQIMG22*?6C56%??&^(RLHE(4%>'R0/S_4L>%F'HZ]L=3SA)YD
MA*8^)E)&0**L:#,OP$V>RTMXG851U:2HRE"4&:B- )45]IPHZ[A:=;;L:3>K
M4V8=U&/GS;X ZTD@-_>JE5E=8NCE5Z44_P?'^2OY]:Q=P@1UY<)2B#B"R'5"
MZ0(R!$7@.5P@BA W"J\9IL;2N%I^ X&U#) ^^/48=WI0)Z;7WBR1%5"*TRHL
MO6/-"BA#@+)DELP1#23GRB7I4V4IV24:<!GDF^@\;1@O5CMWKXOBD;,7CWFZ
MO:U#CZJBD=6_O:M*9A<OO_*<II*5U\1U'<XB1RZ(/57V@SJ0J/Y,)!3(IPR1
M,#;*E#/68&EL6"D)LEI+P%LUS0C2?!STN'%2=*?V.BM@:^5!K7T3NKAJR\W6
MES0V@)=7L3=FQ,'X625#<RUFY<'!(!U3X/ '#6._#UQ96*5ZR<>^$S7;OI(&
M?N2W:F7S*>LF>W0*^S,B.$$19%XD("(1@H0B#R81H<)U8AH'W(0$ARJR-"X\
MM$.%6329KE59R,86M4;L6F/&E(/'3(\PYQB)B7EST" T#4NF28,;"ZI5,AVL
MS*R<.A:R8VH=_;RA#%NF>;5)=-!T%X<,.QZ73J1/N?0D_01B-V;0)X(QGSK8
MX<2,/\^)61X[MEJ"<0V,+Z"JRW!CL9J<O\QA&D!)?2A8)IRSHF:FDSYS3\FB
M]^H1P>N[U/DV<WX7Z,0C1X1<A#"A5"6CQ Z,DRB"-!0<>2PBPLREZA>W-&JX
M4%=@<$W)*V#K,84]""=FC!'H#8MNOPJ*_0CWRR+GCW*_:O[92/?K=PVMHG+_
MD/,[OBW2S[PN9_F6E^_$)_SUIBSSE#R6RK7]E)W78LUY%"&')9"AD$(D7S;)
M08+!Q TY]V/AN@*MM_RV]HNT"6BD6EJ?5U)_7B?*3?>IJ>)L/P%5AUX%;=*N
MC2H+5Q5XQ1WKU#)C>_AUID-KIHP;93W*FV/0YJJ3TAV:IO;N]ZH4P!]7U?C)
M=:&T:@5NCH;K IG:+(IB!6/+Y5#&Z31S(10K )Z60+'SV)&EQF\>R[LL3\MO
M+[)[G&[7$76XB.4*D6 L%XS<%Y (WX$\)@2Q$!/'"0;5&3\2M#27L%,N>Z<I
M^+76=6B%\6-L]4C1!F(3L]TPL(87%K^ Q#15Q8^%/4U)\0LF7ZPG?NGZH1V\
M!<]SZ>/(!U=;5W_)5?,,E\LW@PH$$Q9+WXTY%.* ,^@0+A(<!G$HB$EQI/-B
MC*AAANI(GY0,P!I=6[^KE"\_KI0V[=A]%EH];A@/V,3,T"I8<T.EX@I42MKL
MS=T'@N6FW&=%S=R-N\_<TS;<O5</#=J7WLI]MJU.!:NHLN+=8UF4<E$B79*U
M&WH!#:GT%+##((HE06"!/,@HB]V $.&Y6KU)],0MS7-H(M)KE>LS\E6=N5B
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M&TH>#ER(/8] YHN()H)$OF>TPKLB;VF,T:A;19SB X4!KS4V].&NX>TB$HK
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M7JU7O)BXKL=#&$K2@8AB#$F$(AA0%#B<NR@07#=!M?O@I1%+FXY9:V>0F7J
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MBAPF-&80L32'C"L,":94L8)@HIQ,@<,'S^U;?V-7,"T<,-*Y?>='8/5_V-=
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ME9N%S$62%U)_\3+/(<**0JHR!#/&E<I326*.?8R*_N'F:5)T><IML*,?&US
MUXT6PJ$VME>KA6JOGV27GOM3*^U?PC&%&RQ!*>/"D)-RAYOZAR3B>-?0\"*F
MGUQO*GO0]4Z_)+</ZR>].U=<T#0I$HB36&].<A5!$O$(QAG*%,IP(:1?O\4S
M \W-EKB]NZML^+;Q4[8)&M1*ZALD= 98-P() =?(U&%$!#L9;X"1$MSV8S4@
M9J<?B, !.6<&FSC:IE_EXU":"]?[.U]^E=IH^:B^WLO/:_Z/4M:_:NYIO)BM
M>2PC0@G7*"(6"6UGY @6-,T@CDD41S(E+'<.E[DXVMQ(P@IL8ADV]Q*T,@,C
M=.OI=?=F7 ;ZLG<G*'PCD\8EY 8XA"Y#Z.XG"@KE1.ZCP2^CET?)&9D>1]/E
M9TSF?W)69]\MY7[3E=ZJ+_+.GA)UASH\5EDB$AAQGFJN)5CO[HH,BH))SF-1
MZ*V=CRUV9IRYL>S[U:.6TNQ./LO[YORLR>W^=5T_EF:C9Z*%]\FC^6_]1^ZY
MZ3N'O*>/:CB>DWFF.A%'. >Z ,,X3JB#L5[']71:X;,.IS.7#S#3MORCW_SV
MQ6\?WK[ '#."2($@+DS#YR13D"1*PE3@-&$JYB)W.@]V&FUN!'(5-;CA6Z@D
M)QQE9E],(1)4;Y.1"7-$><%C*9,BB]S"!X(C/$WHP 08.UC (7$;VP(^#5A'
MS$,,X(L(>AC (9&<R@"^%E$_0]@5H3Y#^.(SIC.$7=5Y80@[WW1MNP8;6OK'
MJMS4G[_\T9G#D2"QC".HHA1!5"1Z38L*H3D7ZU\(B;+4R\?9.]K<UK2][@%6
M6F#%!3]I@>OS)_4#4'8S?8-A-S+K]L(V@BWLA,M(O15.C?A*G11ZE#_?-Z'O
MIH$I*OQ>BJ>E_*B.BWE*X5#*\[!),$:)8)IR,#51%IA(;?71 K(TBU$D)4U3
MSZ#1P!+.ST[L%#0'58X5A '=V#,M>UU=VJW_6[KQW-J'GGLW7GS%^1R92?<G
M\D2):/VCZ_2.V<!X)/S#)OP$EG':+*%Q #Y*+1IIF( AO0M&(U(DA$&1\P0B
M4L2P4/H_59Q&.%<\S3/FMQJ<'&=^G+X?P#LX4> TI@DI,!()@4(P;>-39!+Q
MI8(QBS%A:5'D?G&,5R,ZA6W?!?<VB*[9LNTY&011MW7K:IQ&7GW.Q3^/'/$\
M"O^?'NGU8YO/<7'_Q=>5-]I&-^TQ^")#$28B0S!/9 H1BV/(:)Q A;'"69;$
MF93;8H_N(8U]8SJ]Z@=E'B>+:Q1=W9RRB=;;T!_#>;<7>3>RN!K(5ZA#M"?B
M#?A;M:X#MAUQP6.4 D(G!WR5"D%]JI\K =1[SW4]J?:VCA_T+]YOY$.]2",A
M:*;W[!$UMD6!<UC0G,.8BTBI&#%$G=+)70:;FXFQ;?6SOZG^TX@+K+R>W2UZ
M<78CD5#HC4PBPX$;W+VH#Y%1F@R='/!5>@'UJ7ZN94_O/0//#1N?QF?YN*Z,
MX][L05=<4]3JSCS^W;K:^O0_56M5;C[H]>2=UJJ]\>OZC;;>U\M2V(+RVR^C
M2&@F"U% )J@)KB8(L@3'4"5*48JU9<,3'P8:2<ZYD5?GT-OJV30I:S6UWZ&M
MU;R+=FFT!3\9??\"S/NV]0INUF!?Z2M(<*RWQ/&D\?7G?NP3QU>?=O_CQW$G
M)>PQY$BR3GL<.2[@1\>2(P\W;+EJ:B_])C?W:VU4?Y/UQH:9+1*L8J+M7!@7
MIF%J2H5>;I(()D+E)(UC&5/EDQ-X9AROY6*"37-;,>S!RJGWS%M!_>C]'*IN
M]!P JY'IM86I$1&\=X#)FPXO@!"4SLZ--2D=75#XD$XN77Z]U[OSK;^A]?WM
MRO[+#/J-+LU .^]FIG? (D<*IKG05"$R#(ED#-(L0@K)-,JPIR]C@!3S\W2\
M='IN0TF, L.]T:YSXN]Q'@'GD4FHD]EX.TP?+".R=1S;'_:$G\QK[(GA:)YA
M5SE>S?OK"52?A]?W40,K*.C''CSZ:.B7O]B[<EMH57$-G-),J3):&.>$"?\1
M36.J*!+F%#'UV<,'D6IN._:M74R[ZL]&\)NCK_K&?NM7,6N8677CVLGG:F3V
M/3<I!Q-R:I)><O,(57B#8AVVM$00R::M0!$2S*-"%4$?/I#;UY7>DNM-]7^:
M N=_E[; >9>KDY HQ1)!+I!F;%6DL"CB%)*$$%9PS!GQBBGI&6MN/+P5%5A9
M02NL)\/V8.O(FV$0&YL-3X,U0I2X QYA&:MGO&EYZ++B1^SB<(L?9PA9+GY9
M;?3.^[.\*PW]K#:_Z_=BD3*<(QY%4"9$0A1'>A-L++V4<JPHE8G^/Q>B.#?
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MQ'JYI%4-'F75-$_UK' S^0OA&*HSXVD>F=6M6I 9O<"^\F!?>\">P?Z%+0+
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M0.JI>@9?_"NU78;7C?.#@C8R99].<6KD!7^V_QZGA+ K2B-G0!V.^LJY4&=
MN)P5=>[&852S.S/1NZU[TZ[MJ:HT%2XRR2*:"05I+"E$4<$AS5EDRJ3SHLB)
M8+%8/-IJ)5\VM-JX\<RYX7R^E,-!Q_MH]HX3N1;7.#"73\)Z,L':)*>!I6F7
MHOGNH?5H KH!3-Z5*YNJOU:@$=:/G\[.B4B3HJ"&]6.3DX;2"+*"IWK#F=(B
MR7BF"&WGY)>5F'I&NB'G-A]26Y*A9\)M@0B![<CKPAZD1D9;8:"5,MP2< F'
MH,Q_=K!)"?^2RH<\?_'Z@>FO;0)9*7<!$FD<B23E!<1*TSN*N6811&,8RQC'
M28ZY0EZ]+TZ,,3=K<4]$S]S5$_BY??M7HC+ZZ?56NE$"1WJT#YLJ>F*<:;-
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MJGR:]:OB'@XWUU=FJF [Z\4Q&SWZD@-,G)#1R1S7F= YNO,6 5-\)%# W&O
MWQ..-ZDXDP7[O0;(^Z&$KS+^L$WJKC7%.PWAZ2H\]4+(7&%*,)0TUW9'6B2P
MR*C>?6*E4!X+P0OJ=Y#O-.[\SO;;6E?E"JQVS7,TF:P.*ET-;77H-AT12;'
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M--)4^FU.3W4UO;UGXZ(N[H%L9/4E-CN):BP2R3)F H>UV\B+%#))*,RXR*G
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M:B9N>Z&VW*3)SXW(8+[5R,^NC3#N;M9Q6J,9V,:VRH*.MJ9\1:LOZ"I<YX:
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M=7U*(RAX,I("6AE^OD9:L^'3OUX8QKTY^*'YPX\^YN<B_B[V?$A4Q_8EK;S
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M;?FMU/M78>M9Q5'*\T@(J-($0R2P@I1G'"8\Y[*("A5'TF^?&%SFZ>TY6^G
M2RGGHF]YLO"#[>AF36D 0[MJ1A'(C":@JRWHJ&O"M[K/-2H#J_-.99*.WC>@
MU1QLO@ZC^X#.X%C#-*Q#&5SJ<9W2L0;AP+$=K>-^*]>.5+I%N2[KS/JW9<7G
M2Y-GOPG&*M(TQRQ-8(J4WE4CE4,:L0)FF-$XE3PC//5QDSWZGIK#O)45-/7C
M*Y=(K*N'P&UE" 1L8!O?$U-O@]P#G4%-JT__HQK)'L#LF[L^3?2-5GM?SF6=
M=C:+#<$SPC&D+)40R4) )N,,2B1XFL8R+HK<+S1MV_C43$\3/F4$;')6?</-
M.L"=MR?7PA'88'@@T2->[%#E*X/#.@V.' EVJ,IAV->19_K6'A)2/IH;5W/8
M;[(GEG/]^/TF7_3?SZ:[UKV9*<QR(930<]=45R0BAPP5&#(6H3B-XCQ/O+(U
M/?N?VO3>B@\6._)O\J ];_5\Q\/-Q0B(<G W8P/PKN@;2@"])[32=_>,0]8\
MZH7<P(60_&08N3I2+X .2R;U:Z8OE3E;?UAHS\;&9)F^ZSW;IU7)95-(G=[+
M62P)HAF5,%?F9C+."60)H9!'E&9QE.2*>Y$!._8[12M7"PJ>C*0W?0_C7'%W
MLVH!T QLS6SBT%9D$YFW0?93C>Q6[B&YR[V &IBWW*WOD3G+O0 YY"OW>[UG
M(J7XYW.=]5=]7=X*49HNZ/P3+<6'Q1OZ5*[IW)Y&L?T#J\]26\NJ7,LO<O6M
M%JE<BB;0SCQ0^PX%XS&G5.FA4WH?QO06#.>)U"8N1G&A7;D\]PJ]"BWPU,SB
ME_62_ZLYON8=;3R3+4,/LYLQG=+@!;;"MY\^O+DY?OFP/>F] 9M;8V7SG*HU
MZ.@T8/KF2, /F^<96NAQ$T)'&H*#S-&Q^O7/_[KC_/F)+OB+^?!G2<Z4X#*%
M7,D(HMR0.#.50"D0451PI1UAUQ2MG9:G9M(WPEFV"8]4F%V\SIO<JU (;!NW
M +SQ(B?9U=\]6Z<W#J.2D53@2<])NQ"8:%@3K[WDI25?^%ZN'^J4.P$>EI6=
ML]6-*5H_?Q;FG$)[!H_:O=>SF )#?KV6-:F)*71?E8_EG*X UY/\?C"JO*.8
MGDESV7U^M$R4HV)VDT6./]#WG+.]V_BDQ_>C'O&:BGQ&$1(HRQ 44:%-FV(4
M,L9S*"-MY@B-4$&IWX'F\8ZF9NDZ]W=&4& D]62KOXBMZ^'D]8B-=]GI 5:/
MP\;S2 Q\JGBBLY&/#\^K?'A.>.%Y?U>G)<-\*S\NORU_DJ*:Y2GBB2)F4\R%
M.??+("-Y#&FA$(ERPK69</5W#IN?FBG8$KP*<XWQ;0F8/%,ZSP7 RP[0=; $
MGN];1-Z:>P>-R$_7(N+N$EV'S.BDP$X(>?DOIP$XX\0<>6DT3^:TP%UWYLQ3
M/7-45_=TT53KV3+XUK$<G_1@MU_!G7IO*=Y*O9ML,S>VI%UI3&F>H1RF&4DA
MHC+19B[.(<_R&,5<X803KP3,(:2:FHGL*G4#=M2RCGQ7,3,I-JJ!K6Z]0\Z&
M&6<W9VSTT0N]GQUIX/P34(<$>MB$U4$D&S?!=4@P#Q)B!VV\GZG_M5PW)4&^
MR/5Z;MLV\<6+2LX44I$J] Y6(NVBHDQAR"C'4!*I".-IJH33X9Q#7U,SRS\O
MO\G5HCZNYW-:54!#;6>ZF=LM/V:U4<,S&.<<ZE$441P3"FE6H*9.<!YS2*F(
MBX+P/(V87XK/0+B/DYSS:;7\5E;&:)I#L?O7&P<:1X)3PQ.;Y@E$BC*HMV>)
MR0;E7/ H1>FF>NK7\2;!;JW4K_^]YX*;:S'0]QW88=A*";9BUGE'6M#AUG\'
M- 9=U<_U-^I:[:#X_@KL\DK/=76W_%9SY[9?A6N6YY(KCF*8$"2TD2$"$D$4
MY(*F4:9RAO+,T]@[=3P]N[\ME"&TY#=@(2U3>T,3 IY,_5C?" C'01"J2")%
M(ACI_T 4Z?^A*M:#0#@6.<$X0Y&7GS/X$(SA\KSB #B:^<%A#6WQ=VN_T".U
M$@<T^U[H#+L"N'4][F+@!<?!NN#WMO_5P&^62_^6<UE5-2524YB9$8;3Q+C[
ML<8::1<4,N-_I@F5-,V+F&+'8@7GNIF>^:\EU9ZE$=6+MNPLG)>O"X: *+ =
M:;"I96RY-?^HQ70\\3L+DOL-PA!@C72/T,S9\K]LBH<-NCF(KKBGY<)$4C1?
MW7II;;1V_]9RW="24O!05MKRVHKC=04,8(*F!HJHN 3HF7N)DZ^.=CMQ2?CN
M'<7%9_NYV3\]EW,3#--:3T23*"<$YAHLB&2J($/:IT8RSU2<4)%(Z>/)[38_
M-8^ME<YSP[V'F9OSU1^)P,:Q%>RR0?1VJ8[K/*CKM-?%J"[2<?7V7:$33_6=
MK@<LO9]6R_>F\-"';?VA=W1ES')UMS)E3>Y40]8KOY1:+_N/RH:BOM66_):O
MG^E\1G*6%E)ED-$D@8@@"9G>O4%$6:S])E+DW*DH26A!IV="&EIOWJ7U?EHM
M@56R6Q7J!LA&75.>8ZX5-MM#VJ@,JM+&'FZ5!J;HZXTY*]1Z^UJH0)^)JZU[
M_<$/;C6/T;EK+8%5$WSHCON[SKC_VHS[[>ZX=_0%;^VXWYX?]Q[&..R@#&S6
M PD[\@(1%O+#I29P?R.S^M6IQ=M\OLHR(']]H(N[FLCI=UGIO<B'19UD86LF
M;A/PTRA/,68"$I(4VH-5!=3^JX(\PQG*$\:BU"M%^'74F-J"9U/YOUGZ-VW%
MOEG)067T]BV"_3I?A=L*-OVQ#KR^#4 46$/12:JN0,T>O]9H@+N6-[ &Q+"^
MUI"$88MXW0&=!J7@=:K\-7@&!QFNP<@'AY%F:JONS[J)==4*_0]IZKM(<?M-
MKNB]M'\TKL/6Y,8I8XD2,8R3-(<HHP5DA2Q@G#-%E$B*./*\HYV,;M.[!VA%
MAK26&:CM@OVDC:]=JNW&T^!1@7NCD[:_/V@#+);S.5U5V^?&8O0=_),K$(N(
MR@C,<Y,FPE!NPK\P3!!"YIB#8(ZFX?L%_.!&B?,[^'S^&WP]K^TC!OPF_MNX
MC35&7;>QQ0DT0-6/V-.4OYA+V7/\_R)>IJ]V_TT<SYZ#.IXOVE? OG'S"WFG
MWJRD*-?O*3<%!%^T1H^E9=UX+[ND8TB1M,#2Q/<A"5&:8TC2C$$<"92@%!&2
M>,;1._<]M?5V*R904O9E>_,!WS&V+ RDH0/,M-3&%Z[E!JW@)AUI [.6/0CU
M6P_$!@X[=N]_Y#!D;V .PY+]F_ S8]5J/?M:KN>ZFP\+8>H(/-/Y/\KUPV<3
MSF_,Z4/Y]'7YSG("-Z0+,BHDC@H"!3?EU(6DD B5PSS+:2Q)3E#LM"GIT??4
MS)@5W\R\K0*>%!=]!N"\*0L,:V!3U@M19Z-U!3;GC)9NMF.P]+_VC56??D<Q
M5E< TAJK:YKHYW-]6BVUO[!^,00=)BS7N(1/UD%<B#I#4AZKV/R35,N5O.7\
M^?'9YBJ]E4\K:>( ZU3+VT<3VEZG8<Z4B%)5T QR4ST H3R')(Y3F!0\9[Q0
M,4+*QU<;0>:I&<=6Y1OP9)2NT\1DJ[?]EZHUK^FMP,K6?%\J^*S_84-_;P"S
M )C(S!8!(#H0V%9H!P0_!W*,+\G-\9S8]Q'8RF\_C4_;3^/=SJ?1*-UD2GQN
M/PVM>!WYO/DT.LJ#M_N?QJW+I^'M\XXX6(/ZRF/(/:J//>) [/OF8W;=)Z_D
MS_+Q^?&+G.M%V939$37/X/MR5:U_I2]R=:<^E]6_9J@0:4HC"5.),40%2B A
M%$/*,58J0XK%3N4V?#J=VD)E!(9E+;%93)[/U('OC_3Y=2 4?H$->2,R,#*#
M1FA02WT#K-S "FX\>B-Z %Q]LE:&QW>D+);!</;,2O$#[&R6BF-3(V:M^"FW
MF\7B^6[/C4Y][FVXF^O@QL^R6J]*;F,M3,R:_>M,::@)33!,"940<;U-H1&*
M():XH"+)HBB/>C!4N/7N-%G&)ZOXI!MZT,NO#5)>;00'Y59RSZV"VU@X>OO#
M03N2P]X(;'+C&I'!5F;PP0%5?R_;"Z1A'66WKL?U=;W@.'!7_=[N3W)::97F
M+\OO"RG*Q9->%G6[*_E F3F]MJODAL1ZIKW-G*:<0*%,!5D584BR0H\&SC$1
MB"HEG @7>O8_-3]T2WE9*P&L%F"C!MC58\L&[L\;ZC-*EQW7P-@'MFT3A=V?
MSS40_".YN#9J%"SZ#D;SH#GT,1MS>QQ$[>J_?I" T;D]3:H>I%S;C+2!$K>O
MP-Z!:]:GU='):'NH?(RMMD\S?2GZVR7O#:T>+)]']6#.;;[1N5G]/JSE8V7N
M7.T/LYSC/,Y1!M-<^]9ZJ=(>-5,*YFF*"R$EI857N(9?]U-;G#K>GI';3C3[
M0T<#8"4'?]AX!/NS-]&_UPBY.=OA< ^\, T->8]R 7V0&[B(@)<((Y<6Z //
M8<&!7JWX>^B_+&N6"'-8_<LO'QK:!TI%DAINC!@;<M=<*LB(I%!F!4*DR(HB
M<ZY$<+2'J1FR5DAP:^Z<M)CN;MQQ!"_[QU?C$MC0'$#2@U7H.#;N3NS5&(WD
MIO; RLNA/(O#&9?Q^'NC.85GQ>ZZ?><?]+=J&R;L.V4BB;7G*!=5^4U^6/#E
MH]2]U#]L'G.DJ[^FZ0G-[(UL-CRTJP2HA;=.1?/C]F'?0@)7#82[C1AC0$8R
M(_T&9A@3<RV,9ZQ0[Z9',U37*M^U95>WU6\?NQL0W):9(XQ1S#',B-ZCHI@J
MB"7+(&6Y1'E&DUQYE9D[ULG47+F]>/>>U>6.PNFVM;P6I,#6WQL?[QWB.0 &
MW0<>[6C4W=XY5??W=&>?[5FLW9(E;A;-#+-(*93 #!7*L,)P2)4D,$N58BJA
M/$Z17S+Z;@<^7_$X&>&W'ERP)T!3C,HL*BB,A4(0(1Q#*J(,YE%$480B1947
MP7=_R,:PC@, YF8%^\,0V/ZU%+D!JBL=UWG8$NB[78Q;L/RH>@?EQ8\_U9/H
MXYE5\MY>0]_^658S0O(BPCB%*A(Q1+B((<N1@#BC!-,B(I1Y3=:]]J<V6SOB
MZ0]6"^CIQ>S#YS9UKP E],[5'0__E/?C6@^;>+[7Q[CIW\<5/$C"/O%8OPG\
M6[E8KFQNMIXOLEJ_>3"YW!\6GZ60CS8WNZ:ED"F3">$I3".:0R3T>DQ8AB%+
M4)2+0I""1'ZNBV//T_-I.BQT5/SSN8G",4%6VH&4\M%REB_TF"\7:RW6W/ ;
MEXV2GBN[Z^@PE2E6J CB.,<0<4H@0UD"2<Q8P1E*"/6BS@XP-J-L+:V8AI=C
M2SP4!G W0QT QL &_./N9]L*?@.VT&Z%'YK4Q!.N02V_:]^CK@B>@.RO%+ZO
M]UM!?EXNQ?=R/O_P^*0GG12=-)GZ5\8\&K;7&1%)7F#M%^9QQJ#>N66095D$
M]>]D0;#,:.)%C.7<\]3L5#?[[;Y1 I0;D?U,ECO^;D8K"*J!S58K\PUHI;[9
M23'<"FXYL(<S6=Y@#6JTW'L?U6QY@[)ON/P;Z,D#1!>BO?,F*BTBA:'DC$!$
M,P$9PP)2$><\*:)$2"_"YFW34S,^1C)/QIXM3&XFI)_R@6V$$2I G9%#78=E
MRMDV/RX1SH%:!SPWAT^,3!:[PV-K0A/^?)(F).OKTOQJ<QX:":8DBQ",(II!
MQ'@.L8HQS#,DL8:F*/@X7.QN\D[-7MS>WZ]L"IC9#:S*157R"X[_JXRRX]'9
M=,8N]%'<]6R8^S3IEN^AT=L<=YA?!SFG'VF4IL%9Z2CS7X.)TF\ !N.7].RV
M9R;"+BG$'5O3<F$R\=[]R>W.^OURU261^+6LTR%>9@))FN09A7DJ<HB0=BX)
M(@7$F$0%XCE/"?-*2N@KR=36EO==*B'/L]'^P^&V5(P"<N!%X)"!![1ZF*.\
M5A-3+VR/NV>CS8")"=<".FR.0F]IQDU7N!:T@\R%JQOL>=&D/<A52>>?I=&\
M-,?+-C>BV5A&,48%3Q1,HSB%B! .*55ZU'*<%USF0F O$WF^NZG9P2_UA1[H
M2%OG!7G>7IS'V/'28C#D0GNXIT +L,MW V78&XGS78Y[$>&D_L']@]M;TRXQ
M,Q,%CEF,"12,<X@8,[>L+(9<1$JFE!/.Z30KR$SOZORVKOM25M6SX81\7IDY
M^V2%M54\ZEIN$ZW=,2NPR),B$E!112!2<0$)I3'$LF!"HDCK[$2[-N7O8.RZ
M+=,>\<"'2@''<?JG2SUKK4S@E*GGL$WCN,E7^+_&N5//(7FM B?7^C[\08IG
M0][]6=)Y^5]2_*PW<>9"]*L)/OLJ_US_I&']URR/%&$FS4!OJF*(9*H@B5)3
MBU:**$GC+)6%I^_BV/7T?(\M8U:W0#:PA.?U>7:'NN$WNOJ77-M(OB^2:S]E
M77K7F'4=),=%)@#PH1>)1F3+;]D(#8S4X <C]X_@#RLZ,+(#*_R0=PB>> UK
MG5T[']>Z>D)R8!U]W[_>NIUGV;#=SE2D,!(JAGF.)40419!)H6#.8UG@/!8X
M]F+]]^Q_:MYU*[19=8 V<*=9:.KIYYNRX#DZ_M9M8,Q#'[$/!O=5)LX#M&"6
MSD6&5S-X'@"=LWL^S5P73VLST=?Z4RMUFW72UMNRXO.EH2[>>@]9IC+.$@:S
M3!L^E) (TB+-($]R%,>$8AFE?BZ>GP#3<_1:^>TLK+>46SU GP1+SR%Q,WGA
M8 YL\7;P/4 6;(77%B^$9]</N""!MXXBO$KTK1\\IT)P/5OIR8UA-%NL5W9'
M9BC8MR7RXEEJZ,Q,;I/$DIHJG#G$1$:PH#G"*)99Q*2?@3O7W?3,V58XLX_Z
M38J2FRKJ+;6JT*/Q0%?WLNI;D/,L^D3%"6$FW3XG&OV$(\B2%$-)8IK'7!#%
MO,Z\A\)^%&IGN6YH:<TUQ4I^DXMG#3-[T>"_+%>@[BD([&Y+R%!@!EXP=L2T
ME2YN@E0U=8%C6'Z3<QV.RW/BH/H!WXG+.P,7^_NTG)?\9>LJ82((X4Q!G"L.
M4<8*2+1#"SEC"$=9D>89]S/NKEU/T- WDN_651NH-MX^\&X&)@28@8W-7I6Z
M73#U+ZW@X(_FOT$<5%_4QBD7M]_Y-&J^G8#$N7#;J??[U\+XY[)<K%WY_EF>
M"!IA!14K)$0QQU ;+@FEH"J3$<L*A'V+8?@(,#F7:5,)H-$B8%T&KX$Z;^_&
M@#^PW9LL\OXE,4*-P"O5Q/ =CU<NBM$'?8>J&%[-CEX6HX_2Q^IB]&KG==(F
M[Y[7U5I_9'IO6TL_XT1DA!$&61PK<Y$F]&*&8NV6(ZG_0!.91+,Z6N_+FJ[6
MCM=I0\OI,^7WI0TWZSMBWH"WDML85Y#&-T!/B>@58MU.#G.A!&,%B6 BD?99
M),T,Z6P.DR+.&:=%DK&D&>9W"_&7&>16UE<:XGA*0^QXZ?J:@Q8Z]F3 ]->=
M<:\UG4 4XJ5!F$:XX4DI_QIQA9= 'CJ#]71'_9R$KRLJY$<S3YH<(%;@3"AJ
M;HH3KM=X@2#-$8,Q15DB>!)'-/<[<-OO8GH':U9"8)_P,\P'Z+G9U6L0"6P6
M:RBL; &RI$XI/J@I.NAD5$MR2L5]0W#RN7[S^*UDZVUTL>6*93@2"><(HI0)
MB(C*(34,V41$,DHQCC.4^-S,'78QM<,E(V$G7Z 7X^X1(-TF]77P!)[6GLAX
M3^S3R@\ZM8]T,^KD/JWF_O0^\Z3_R;--R5ZJYR8ENVISLLM-3K9:KFPR]AV;
ME_?6I=C2O<N<L%@5'&91;C*G"[V=R](<"DZBB!6<9,*Y%MQ5DDS-7&S(#[0Z
M@-;!2<L.^X'LLA]8!@K]YXU6_\?]6/2Z\;M\,CW:J 2V4CL#TD2+G:2CJ&DH
M.@KUJF]UW="X'UV/-D0CG6&''RJOL^E!X#US2'U=^Z.=5@\"0_?8>I@&^[FT
M'Q9\95I^*^O_?EA\6LDG6HJW4LG52EH2IT5E*G+9(-Y:PEFN4!%%,86,";W<
M24(AC:,$HC@2F,5Q1B(Y6UC".L>SRWZ".$U:4D_:KC@A(Q^LU'I=L^)6]0V2
MC7^F/8*>>XZ/FS<=$/-QUK)6 ?!#J\*/-D>Y&8-&_$X(^H6X<V^7_#H$!W7;
M>XHRJFM_'5S[[O^5K?4(3BGYPW)>_5JN&RO<TB8Q2BC/%,P(-17%< 1I$DNH
ME"H8RWB,J-,AP)D^IN;6-V*"K9P> 0PG8'2(#KD>G- !( >X]"@(?0H@CR".
MZX$:R<?U^)#\ BG.(W N5N+$F^.%0YP7?2?BX<*C/0LFBF]RM2ZK<G'_9EFM
MJ\-X89*FN8HA9=K*H2POM/>'"IAG0F8JS;),8L\*BN=[G-YM1D=@8"7V+!9X
M 6$W_VU U *;Q7VXPH;^.N(R;,G!"WV.6X/0#8"#HH2.K_6L\]!P6):R,@6.
MGK6'UBEECE/&HP@90GBE;4I*309MGL*XH&G!&2ZRV*MXUMG>)N=-;20$\ZW<
MCH>?;OBZ693!4 ML3SIRWH .>B%XT)TP&;;<Q-D>QZU X:+\05$*IY?Z61%3
M]* .YYC/E]]-$&[-<!%A1A6F.4Q,040D%8(LX@RF.,E3EF6IRC,?^W&BGZE9
MCHV88"-G/T:14[BZV8T!T IL,?H Y6TJ+L PJ)$XU=>HYN&"PON&X=+C?1/7
M'Q_+NOZG(0-9+DRFL%QP;7Z.$4-$BG(5I3G$$4H@XBB%I. 8"D82Q2*2IP7Q
M2Z;VZ7YJ!F1'WLY):4<KWXQJK]%PLR_A, YL=CJ"UWQ$.W '9^GHA]O Z=E>
M(HR<L-T'GL,4[EZM]*Q_4C,E?J*K]<O7%5U4M&:]^NFE^Q<;4E5@1263,40B
M0A 17D"*E1XCI4RM:$IR[N42N7<]-2/7TDM: 7M%K'G [F;1PH 9V)IYX>A?
MFL0;DF%KD;AW/V[Q$6]8#JJ-^+?@?SGVR;"Q?+&?6G-=(:,$*VEJ_)&,0%0P
M#DF2$)C3/&(B0PSESC%Q!ZU/S<18 4$MH?M-SR%HER_!KH(BL('HHM#CXNL0
M#O<KKZM@&>FRRP\>K_NND^J?N>DZ?&>T.ZZ3XG9OMTX_%*YVW%U+-;57KBR*
M!:**$IB0J( (QPI2RAAD290F0B)5,">.B0%DF9KIVX@9K(+<J4%Q=+7&@3JT
M[^5116X[(J]:1^X"J*-7DCLES^1JR5T KD\UN4M-]K.H/SU7NJ>JNN7_?BZK
MTJR>GU;+]X;7OT/OOSWM0;E,N6(YQ+G9ETJ!((E%#C/.(Z$8E2C*_"('/"68
M7B3!E^?'1[IZ,<PBMWS]3&M&5ZT#L$J8>@C/\[5E'FG&T,1VFUG>4=G3YOH.
MFYN=#3@4@6UK*WD7TIO.&'1+580LE] 3P4$-J:\,HQK/G@#M&\R^S5Q;2J$-
M3/U*_ZR#46\7HG-9NE\W!A6JB B#M& 2(A(G$.,D@EDD"99QS OBY7+VE&-J
M[F:WH(G)[U\N[.FZ_E>K%M!ZM?DRQIAV5.M;9L%OY-SLY0CC$=AN=H?" ?R1
M2LWT0C-0/08_65ZI+D,OP$[79^C77(^,7;DN5Y;/8UM5RE!3&J- %R^_T35_
MV++IWBESREGR\LG4 #.W-*N2/=MC)24D(PE&,&8B@8A2"4FJ32[&/(\I$BB+
M<^?DW8&$FIK5_5WKTM0);8G03?;NX]-\^2)7@'=$]^9 'W0P+Q^@OL80!;^8
M:54"G0IK1JD;T*@%K%Y=SF]PIT!'M[]5H*O=*PR=1Z;O*PSA6$F_(PZE7_KO
MP)B?RP0>JJOQDH('!F<G/WCHMGMDOFD$:/7POES0!=?+P"U?E]_L:GXKEI8T
MZT[=<KY\MK$/7PQY%EV)OS\99M194A2)C',%<Y,9A[C^'[W:"J@B%2&1T"3F
M3@%7UPHRM26UE=@>_7QY S!*/'+$KAF1RVOD6#@'7A<;-<!&#[!5Y 9L!N#.
MG+VURH!6&U"K,]*8>"3WC30V8V4 AAPCOYS! 8 ]EUAX3?/C91\. ,).BN(0
M[04,#-[RS B3KYT3&,L4091D A*29I 4+([R(B;"+5RE5^]36YO<XU8]^8#Z
MC8W;@5HPQ .O4D."'29$.&BZDY\$TPL0OI0.U:^1ZY(L7]XO5W]?&#*,-W-:
M/MJ.ZQ_$/Y_K+43#CE'_^I-^\M.J7*[^4])5%<^HHBB.> QQS 5$45) IF(.
MBYCSE%%%>$I:@I^O_EF95XKG-'=W:7^^CA,#6$_BU;:<_9.1&KQHL0&WJO1+
MZKQV/-T,Z)C#,VZBZ(N],:]U K70M:FM?]SJU9(&W;1_,KJ9NV SC%:]X3-+
M!X([2 [JM;*]2K;J0(">RFL=JOEKKY._R'O3UV?YM%R9-:5S=_W32_/'.HL3
MTXC$!4D@08I!)'"AW5I$H&+Z/SDNE*"JWU6RLPQ3\W"[=Y>-G&"C13?BX\96
M*&B>Z)5;VV?$?*^0@XS#B-?'PPW!%3?'WB &NC5VE^.5;HR]@3I]6^S?5#^S
M65=RN%.;0,BF[6J64<(+9H(2<48A,JPC)*=ZXT]8$K.L4"Q.?8SCR9ZF9@*W
MU>JV!9:K1E8_"W<:7#<[-@ADH<^2-VAMPZN_7$++VQA=1&)0DW.ZMU$-RT6E
M]\W'Y1?\[[ALWOLORT?YBZ3S]8-VZGXQ1>*X[,;9-FE),9-9CE4!96K."KG$
M)HZ9P#33E@,S[6UA)[8BSWZG9D!JJ@ C.ZB%MWNJ1OP>\<F^PW#Y'BL0N(%-
MC3NN/9+L? !VOY0*!/1(=U #?,A>-TT]T#ISL>33VFCW2#U4[%X;]7F]YY&I
MK"HI3^3'M$=Z;Y^EV;Q_U:,@9XAP2A5.8(%24[LQ)I!$ D&<%DE$BUSP#'EQ
MU?E*,+5U0'^1R/-<TQMTQQ/,D%"&/JNTLM_L9^_=;-/W;LR),I/-F:31 5@E
M!CR2[(O?L(>/WE*,>\S8%Z2# \7>#0U^(;[/0!M%B,F(4R@RA2%2>08I3C,8
M94Q;MTCID4O],O7<._>9D^,DZ77HO#_+2JZ^^6:2>"!_]5WW=&F SUYTWX"&
M$S@H-[ _;F/==;\J8[ _+!ZWW,/R"+\M*WI_OY+U?+Q3G^4WN7B6>RE8!6%(
M);(P5* I1%A12"1+(!9)(F1!D?;=O HSNO0Z-;_LC1G\Q;I.&C8G5Q\-:\#&
MO6ATJ,SINN7:\*SBZ#00;N9L<'@#6[)=>0VTC<1!<]R\4!JV**13S^/6B?0!
MXZ!TI-?+/2]J^Y:A?J=WN.N7;67+RFZ&OS[015.@^N/2)@)(\7DYG[]?KLQ+
M,Y7D!"&%8%*P'")BPNP)+F!"E)1(<!J)PNN.=U3QIV8ZK6J^Z<+C#KCC%?%D
MAS'T[;+1"C*C%NBJ#CJZVWOESG.-_L "< -J"#HU?:N&'7>M4?C_N7O7'L=U
M:TWXKPAX,9,=P,Q0$B61F4_5MZ2!O;L:W9T$+_8'@]<JG;CL.I9=O2N_?DA=
M;/DFDS*ETLP!SDY5ET2N]5!ZM+BX+D$-0UF O@)"_[@[)*H>H.!W TY0H^/S
MT/I-EM7O>?>X*HQ[5/XFRW-RROXV4MQ62TB+RO)E*>DWR5</R_P_4GP66HI<
MY>;[7">5&S_P6HK#Y'+]-RVP^+S<:!5S?7$Q1R%+54@%4)A#@$*: 2Q-F'^4
M19+#2 K.^]4<\BSI]-P>;5V"?"=IKTZ60RVOW5=P DLV\.=N5\.HI>(LV"L9
M'"QF7:"CT?.D4D>MZLQD9>4;"7[-7\P0>\W]%ST::&D&*8[D6]8W*:(T$."7
MBBT--5W/<+#=!TS_=YUS_=/WC=[S569;G:3V>N3+D!1"2KD :10K_2F1&6!<
M4!!QS!2&2<298^.[/F),[SO1#N3<*Q*4FC39G)=K3_I;'[MOP="8#TST._%/
MH:[W'(T*@_JB;D'1;PQ;'T'&#6^[ :J3R+=;QNK9#K3*SBV:/LJ:O67^8F8H
MOLC-^ZJ]UUQ&$H8(I8"'*0,(D41S(Y> QZ:N)T<"4^'B?K*:=6I>H\H[0&O1
M@_5.9L?VH%:(V[&==QP'IK=&WE8OHI;(,W.$,0MJL3VV#'5!R6_C4*N9QVT?
MZ@+&21-1IYM['@$>5YC3/[S7O^>;]W2]?E65/Z*88YXJD?(8Q#&B "D( 4X8
M!$P13L.81IE;9+_EO%-C)5.1D9=B.N[9;7&V/./SC][0IWRG-2UGY<^5V,&!
MW!Z/^=R \GO09SGWN$=];H"<'/8YWNZ>._!]^_R\*#VJ=/'>5#M9K'ZV*PD?
M;E-8HJ#$- 0I@Z9_.D$ 8VTT9;%*LY3&$8\BV^P!IYFG1DQMX8/W91$@+7X[
M\\\^K-UM";H9:U!@AS[VNHJIR[;P1ICM\P<&@WND# *_L#LE$_2"KB.=P&V\
MT1(*>JG93BGH-X#[Q^!C612W/%XSYVK?[[Y]K]-I(I&AC)B@-(XU\0L! <4B
M!3@4(<P0CU'&;(G_XBQ3(_F]H$$I:6!$M2><RVA>YW O& W,UV?AZ9'6=1DG
M>Q+V@M=(A-L3-R=FO8I'!XM>OG<TQKPJ?IL=KU_<TWNXJXE2U-TF?ZRT_?VO
M?//XN%J(?/GP:;4^'Z@P9TH)DDH!0DYC@%+! 86A!"%!J4)(9%'"FRI4EE[%
M_M)8O0.'1:<&9M;2M?*\,:<NF[6DQ7;]&A3&&>SH;;QAA2Q]D .C/GY V2Y0
M;!]+,PL^2+XN^ZV96E/&3=!2,+AGBSJ%Q*/7\G9<_?HR;Y!G7 _G[<"=^#T]
M##ERG'%31:$^.]IN'E=K<R@_5T@D2282@!AG .G/FC91&0+Z7QG-. UAXE8N
MRK>$4[-QZX-7NA.PI( 'K=\FV"Y%&3$JRR+^P2_Y,BC*RRV[8PRWS';D_::+
M-R*E]XP1/HGXW2LZ@6C?:VLPC8#>BU+^WQ&S>PUD;V&Y5R?J]P$Y3$!N\H[G
MB8@E%0P#B5@&]"<! 2:H_@\)XX@2%"NW%+KSTTR-RO?I<655>K58_2P"\["T
MBF3UZ7-\ 60[#KX=NH&)]*1F02.C/P[LQL KD5V8:E0VZE;WF%*N7-VS7[K,
MEWI32;6\)F+S14_!%O)Z\=-B3A.2<2$88"S6!J3D(2 1HT (Q!E5(:$(-AOW
MKW*=K\3W#5UO['BDMU@]=O#'P@WW!IE:$'\-6KJUHH=<6ZKW7C>5I9B3F +%
M<0P0E!D@*HL 3)((IPAQ@<3\N<3DX]+2Y3+L<M7T=BC3@-%)0KSY(ME],D:!
M?>"O2AOHEA*VM;P]?GQN1M-OL_O>THS;ZOY6T$X:W=\\8+\/X=]6*_$S7RS:
MV;<QID3I+QF(RRH3V/BF61H"QA4.4Q9"3JA;+L"965S>Q?%#_=\_F@U+81J!
M&O=&&4Q3]F]Z,A& YHI&)3=J/ >W'>G=".' =-9(-UA2<(?Z7OGGW#RC,DN'
MHL><T75I/S;XO.2K)_GKJB@^:<&J2C=;_=S7-OAJ66BK\4.^V)K8?+-3GX=Q
M%FDZ,!8520%*. .$:ZX@<1BE$8^U:0Q==M+.$DQMD[T7N=E5EVV#-9$(O4QT
M79@^PY6;U-%+ZKXX=LPR*.0#\TXE>_"+D?[/E2^CM0![#<J.LD&M1.7.],=-
MO0'TRESN4HS*:[U!.F:]_@/UX\2JO9\LO0_?\H?'S;WZ1U%E=,YQ1C-,4@;2
M2$)M*44QH%G(@-YB)B@CC$&<N+!?QUQ3X[E:U,IAZ$9D78C:498GG 8FIP:B
MVF]8"@I6"FA1JY#[64"57BO3_7/[M*T::VD+<[W)_^/Y.-T",*]DU#7?J+1C
MH?@QP=C<XAXZ^7>YSDT3ZW_2Q4*^UO%K<1K'DE,$.#4F5,(8H"1,0"H)5S1B
M.$NL&G->FF!JI-'(&%1"VH< GD6OFRM\8#(P01S!T2,T\BPN]E&1M^(S4D"D
M,TY.H9!=('1$09Z];;0 R"ZAV[&/G=?UR :2RWRU_K+:R +])8$?ME+C@NOG
M#A,2QZ%@()&9W@NRR!R2$ B(2BE,5!:EW*I,W[6)IL9J1L#_$502!Z7(@=C*
MP CLD'W2A>QUIO.%U\",UP9I%I3 S8(/-5@]^*\3-8<4'4_HC961<QN*;BDX
M%M!T9=QTW3Y>@HV%$@?Y-#;7W^)B^T'_J/MHOI-+J?+-N7WLKD<X9$D<Q9*
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MQ&X!TRO!]1)D5-*[!:IC(KQIK)M<>Q#]):MWO3%L^@)'-*4B8T#_EVEKBV4
M<Y@!'LE,4L@$3*V/*KJGFAK1&0G/NO=BV,M1=0Y=)P??C9B-ZN*K9-VYIV)X
MFY/O'':]W'PW8O@FCKX>6/9U]77 8^?L.S? 6[C[.A2YX/#KNL-'5-V'O.#5
MKEF*_:;YB]S<*TWQQR%<*J,8QER F(8"H)1+P"0R%;H)3%/!TC2^(;[.29:I
M\7);^&%C[=R6S,45./A"C.,2;,??'2Q+RQ-HMMGZ;\^K@BZ,O_;"=6497/-W
MK?>(47N]%F# ^#TW>=XPDJ\7<-TQ??V&[.EE7"T??LCUTP?)-B:]@C[GQG-G
M8G_V94WV;OZ4PU"E3(&8*U/?4O^$8X1!Q& :R9 3)!T[[K@),+U#F';6Q/UV
M4VST>UXFRVJ]@/X,:$+0FCGZ(]T6Q=([.1C00_LJ#Y"L^MF4M7CV8@]RS-(/
M,+\>33<1QO5O]H+GQ-O9;Y2>9.?0E/U3_B+G%"E$< P!21G7-F?$ <5(_PHI
ME2(CD-M%]/058&HFIWY,4T<J<X7<DLP&!')H.BM%G[6:-=?QT3OY9\%F%3 9
M?*6YF 5&A<#HX)'9>J+GE]M<A1B7W7I"=,)O?<=Q=V"6NW<]I$F<_;Y2FY_:
M.C3GTX8XB]I7)&,H4@PYP"%")F&# "Q1!$B6Q1D2&978NCZYQ7Q3XZ]&S( W
M<MI[X6S@O>[&] S:P%Q5>7MK<6?!#KZ=Q#V\F38XVKLT/>,YDE_S*JY^')H.
MX'1X-6U&&<VUZ:!2V[_I<MM I1J+2Z6_ZKZ['_^0:YX7LOB\K$K3_$N:Y!LI
M[DPQA ?9_/WK.N=R+@4-F4C,$3RDVC(-,T"E-D\)5R*!5"8HE&X;\7$5F-Y&
MOA%/>'&@COPXV%G-TUWBH<_D+(I!%E>J0>YZPN] ,-4Q*AAF00-$4".QNRHH
ML1BQ7N0@:SAN,4F_*DRKTN0@R^-<AG(8*?KL69:E*:[95N^./B_U)D 6>D-4
ME]LV^'Z30CY54JW67S4C/.H_K-3NVCK<9XXPB\,H2@ A@@"4Q1@0%F<@X0HF
M+(P2FG+[K8TOL::V VHD->[JM59!/I5EMY8'"IN&\)46L^#Y2C35D$MJLYUZ
MBX4:?-=UL!B?]XNQ+T-O3AI;FND7+F@O;>N>:^%P0RZ@RS[N+19RI.W>;MFT
MP7#A30M^,97OY!_TZ=GL"-EVHZ_<!(O\*3=6Q68UJU_7LK#..GBN]#>_F0)=
MNQ?6+/[1%*7Y6H<0SX*\*+9E509]856LW-B[]=U_-C:0&4\/ 7[J>Q:OP>KG
M4@M0;%F1BYRN7XUSTESR3$V[ST#_O^E';:1?E;&8FT>Z+ OLSLJC&JIU>664
M__O<A%;SE<]Z?=%9DOKSCJ7^XFO?[/MA[-Q>>YMLQ%VX;X .-^O>1[_EO*CT
MV7Z0!5_GS[MN8G-$L,)*$I"1%)M&"AG 49B 4(J$QRE#E#N5ONF8:VHV1'."
M49];M,2M&^%9>@-M8'8Y#KH9O)%.?GK@UO.(IQ.1 4YSSL_W!@<WG8J?/Z/I
MOJ4?@;PW,ALOHQGP6U[\^]=\*3]OY%,Q3V,>,90D /,0 A1# 5B$,)")C(C@
M88I8ZL(?EZ>:&GT<2!H848/?C;!!*:TC=W0@;$<=?G ;F#GZ0N9,&]?1\,H:
M'=.-2AK7U3[F#(L[^E'&U[4)Y=V\FHY")B+&)/T]FSW*%[G917P1"6DJ< H@
MSBA 5 F ">- *I8D.$(L"AW#\&RFG9[/_K "0J/#+J.U5,"-3ZS@MV,6WY .
MS#&-N+.RF=7F$,0J*GF(*#L7E+QRC]7$H[*0"Q3'?.1T;\_,8;I>ZOV8V5N5
MON-]+W">")5$7 &<,:'W0CP&)$ST3SPA0@I*(;/*C;LZT]1,F4;0\IA0D]&3
M_CIWA^D[(FO'-%[P&IA>=E"9E(922KWI\=DOW1H,ORFY%V<;-^_VFM(GR;57
M;^A'$C_J;K5EW8)_TL56WG%-16MS$E5L?I.;QY68RYBG2I((0)66#18B@&,A
M 4EQR!.D*":TZ2'TPYXV;.:V>B,.&P7]&(%(OLG:H2M+2X975%)V_#5.8\WM
MR^")KO\M'<T9J^4029024[*02Z2M2;,+U90=@Y1F/"(T@P(Z]03UM@ZC;DI;
MB*]WJW&YT6-_N.TXW3>( ]-[(VY0RCL+2HEG02.S*8]5;()*;']<[P*25]JW
MFGC4+X +%,<? Z=[>QJ/9>V::JC/RQ=9U6NX_[G4[_9C_ES[Z^F#G#-!(8I2
M"JAB$4 JS@!+*0%"B(1!R2*8./6FM)YY:I14"1X\E9+KKT C^JP\(BN%;\Z]
MM/2.%J?U<EA:H$. /+1%6N%;"1U\;N&[DSOX>AU?=P/5%2N_!JOU[.,:L*Z@
MG!BTS@/T[*AK#KF_[5L#ZOWU^^W:'(7OW$-A(IDVFA*@_QMJ>TH00$.J0(*9
MBF(*99P@I^ZZ5Z><&G75XOW5L8_N=6CMV,@O8 /34%7!JB5MZ6O3!E,E\2!.
M-WN _#;?O3[MN(UXK6$X:<IK?V??!KUZF)SK[>=[6CR6F;'%H^&X%[HP_N[S
M_UJGS_ PY(IG"F"!(4 D8X!%/ (\2Y(X$9(1+%T(Z!9AID9->UT"(V_57M3\
MT))\=OE/P>\?5D\T7SH>4]ZTG':D-]8B#7W4V1_Y'JU?;X?,<_?7&P0:N0'L
M[="=]H#U,.8-5IWQ >6EV?AA*S\O/^5J\VCR<N=$ Y2&B  44Z0-.L8 1AD%
M(J2IS"!/D\0J:]9JMJD1IGO.?S>8#B:<#XA&L=[V@@Z>NV\%C'^K[>*,XQML
MUY0_:ZM=O<F--XKU9OY;OLR?MD]-\Q\8B5!&4!M9A $D$@$HAP28OC\)P4QF
MQ,J)?C+RU/B@%LZ.$DYQZG[];])^X%>]ELMCT<F+VG:]O_JFUKNK?SM^;T]'
M'>4=O:A,\SY>OJ!WI!274NS:H*YSMBTCPLT_W"E5U@B6Q3S-LDQAE8(XA@J@
M3!% DC@%,D,\20E-2.KDCK&<=VKO[8&H55+%I82*Z@AR6:P6N2B;<M*=5L[1
M5%9+9&<3# #\P)312+SOS'RT G?7@>T34>4"D^^@*JNYQXZK<@'D3&B5T^W#
MUR;[\7,UIR*B,((9D+&  -$, :9"83HQLY!0Q0AQ.B9SG']J[*:?QWBXRF0&
M<#N.&A#&@;FJ5UTRK<+;E"5K8?=F5<F,#),M2M8"Z)::9.UAW-/[?Z-+^F#<
M.6O9;)-2O1M"+ 59!#E 2L: ( P!(00E,LHH3JUHZ^SH4R.E6L#@O75$Z'G0
MNJGG9BB&WC>U4.A1+^P4#ONL\IM@&2DYW T>ISSFB^IWI".?WC-:5O%%<=O)
MP9<OZM/R9:$^+XNM"72BSZ;5S*?M4NR*T,4DD2&/ (RPIJH4(T 8P2#1MA5+
M0BZR%-MW?.F8:6JT980%>25MP"MQ V7D=>E9T@7M=4+S!MC Y&;D#&I!@UK2
MH!2U5Z.7SN?1H<^+)_!&HL#RJ.]1+D13#L+D=='EZY^*X* H1/,LMHI#_'S,
M^6.0%\%Z?ZYK:E%LJVH;S_2U+('1?J)_KM;_-A'6SV4=C?5*:7-(J]?J)?D:
M\ 7-GPI/Y22LEJ.SK4S7_2-VE;%0X["IC,T- Y5;O%3@ZA/-UU6(:U%LZQ(2
M1\6M_KE:Z-',<V :CLU3(:-8JLQX#1.]T\;ZIYA1$&41IY&$D<+(<ZE%;\*[
MO.QCE5E\EN5;^K(3M&__Q!&? ;O-_S37=>@OH$5MQ2NE%8WZ5<9 T +@3%'%
M/0AE-\@1JRIZ7[EQ*RKZ$W]:U12]+XMS)47_$KCO8_Z^*IYSWFR/TU1O3I2$
M(",1-0D4 C 6F98]4(49S%!&K LA'HP\M7U*+9R]?7V(T_5-2&_M!Z;<6JX>
M.XQ#!.QW%+V1&&D'88V(D^%^5NL.0_WP^M$,\[-BM@WQ\Q>X\\Q1LY[C+CV_
MT<UVK=ELU\LE)5+A5""01"H&B.D/%TM$ O2_QTFH5 :%5?N<'G-/C:OLH^CZ
M 'V=R@:$;^AS*=/^Z\>N_=?=F?9?VE1L%+")N;L9;GO>'!#VD9C5/_Q.%-P3
MP Z2=AUQ-!KOJ6J;Z/L.T;>Z7;&Y5W];K42A)_LNUR_Z(U-\7RW$O39P'R45
M<QR'A*<T!1&/$$")::7&I 2(\Y1E!"DF0K<J=]>FG!KQ?]\^/Z_653FE52UC
MP+4:CJ%4%F#;.2G\0C@P^1MA9T$CF,\Z=[8@>*YW=W7:D>O>V<)P6O_.^LZ^
M3<.+[=H4JC;=<!<KXT7>ET6"<2QAF"4@0PD'")D",BCE(!1Q%$J<1&F:N;ED
MNZ:;GA.U/*%K3IU,]4%',ND$UXY&? $V,('LQ SV<@Y4>,H&$<\=LSLF'+DE
M]G753WM>6]SCOD?]L=K0Q:J);=)?794OS2P+8PO1HI";8HX883!A%&2"F>99
M$ ,6HQB$"2,1B5!&3.U=,]#U?:G%?$XFR6[6X=Z)4N2@%% $E8CV>R4;?*]O
M1SVC-C")5(#MQ"UMN5K@"L9!4+3?97I&<Z2=Y=W3:KO<F%R#11F0^*<B6!O_
MN(DR-<?WVZ5^XQ?E^7VI0_4/7<O@Z\#> <^.C:;-**-M+AU4:F\H76[K9^>]
MVQ;Y4J]_67&JR,TCMZ_5<J_^N=JT>T T=:GF$$G!168:/5$(D(PP()3K7Q,J
M4YDFF:9VEXUE/S&FMMELM CH7HU6C2CSKKV4FK1R?6BMBYL%V7/9[&S+X1=C
MX _&;AU:&LQ:Q:3,0E1:[#LU[6KE^;-(;\/1JZW:4Y11K=C;X#JV;V\<;9BR
M,::U3E6G9LX9C2AD B1AK(W@Q#2@@$D*E'ZZ.8ZH))%3 QO[J:?&FGO)VE&$
MIH65WR(O+?#M>' 82 ?F/KL".WO1QROG<@K7J,5;6M-/JE3+*2RNA5G.C- S
MI;M./OJQJOFP(=&RPM:]*J=O; F4B"P6- *0"PD0DP*0#&L3,$HR%=%0<B)Z
M5)%VD<'JM1N_FG3KDV,L#;938!8L9;GCXN6;V<OR<UJC%!&*8ZS?%9P86UVE
M>HW"$"@&0Q$I)A1*'!N5^%Z>41VWIHM&B?TSS:M ]9:E[II<[[(0=A^<H< =
M^)/3B&T\![5XP;O60_^E>NC+KY!_*[L/:'Z3[ET$&#?SO@<T)^GW?<;H]_DQ
MQ^;G3D3TUP2%249 E)BDU3"+ ,$<@RP23*D(0:RD&XM=F&EZA%6&?VR:\ \W
M@KH$IQT7>8!H8-HI V(&/U:Z@H-7)KDTUZBD<47A8WZX=GG/_"+^*,5VH3?J
M^QYC]^KSDJ^>Y _ZA\EB61;RG5Q*E6_*5I'[YSOBD&<,18#%TM!%F@(L% 19
M&*,HY9QGT*G\Z@VR3&VKW:A2?HX/FK=5Z@1:GZ!6*/BE5LDU+>B&I;.CII$6
M9&#ZZK<6=:O:8!"N\P"LW[R:&^09-U'F=N!.,E\\#-G3#-NQ>35WDW7S32[,
M#MJ$'A4G23=%RUS+<,1DE.A-)S?'^W$&*(H%4%G*L4AI&.L-D9NY=IM$TS/K
MJF2\=^UD/,?=YZV+9&D$C@?\T&Q[+OVQE2$YD/'H!S^_1N:-,HUKC/H!\,1H
M]31LCY),4N1<#WPG7FAY%%7G@A$9":E@#&A$)4 J4X )AD!(E))A0FB"K>K7
M=LPQ-6.T$3/8R>E0E>@"C-VTY@F<@:GJ%)<^99LN .10O.EVH,8JX=0#,+="
M3MU0=)5SNG#G>$6=ND4_*.UTY=*>.WFYS%?K+ZN-; KIX"C%H0ICD"7(Q X1
M$_Z)&: L)E!!I(=Q*IUY,L/4B*X2,"@E=-Q+GX!GN4.^!9*A+;$6&A[?TZNJ
M^]V9GLPR[G[SDI(GN\B+%[J;+M^DD/+)[#2_'!2N;H)H=B47/DCCL<Z7)>V7
M%M3]\N]ZV_IW21>;Q];I:%%>_D.O3/&X6H@Y9B@.4XRU$828WCDB;0YE* 2,
M1X3P+"51!NUVCJ/(.[U]95G)Y:6LY+)292FO/0@7RXW;&Q7#/P'7[;=)K>K
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M+,*48L"AT*9HF$2 9$( *FF"J8("$^'>@_#L7%/;*%1"]NDX>!Y*._;P!-#
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M+$=S%0J_%6DN3S=N49JK:I_4I;E^1S^*T!OMI]6R/ 2M2KI61Z%SG/)(D4P
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M,!%BD+$0\23-%(\2%_O-?NJIT6%51+@MNNDO5 E?]VYMQ'=J*M)C42Q=8H-
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MLKZ'\4:Z\IN7KY;WZIM\D<NM_*2E^RX?*H98[?L;F4[8S2>-*169UQA C"%
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MJWMLM5^YNN?A?[')GS0#W:N=;;_[P13?7ZQ,2[<ZTY-PAI-$(,!1K #2%C;
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M14+/6Q6 _2:?S3&:.2I3J_53^:R^>ZW_N*^HG)"0T,3D>D;:4$02([WGI G
M##-B2MUSY+33["G'U.S'=E..[W(A>5F*HPPBSNDB:.E2568V.I;GW$WY74='
M5\_5LW2!#;\F0X<<'"Q'*6:P4Z*]&K.R)&I]Q9"EL&_$U*^;K:<LXSK@;@/L
MQ#5WXW ^FQE5H0F[6MO5'V2S0412A1B1!$@1(\VP"@-,I-Z%QPD5(2.48J=
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ME&RE1IN4[6[HYQW]:G8A4E3QB]04@=P[7UN.V7DH,B$)Y""+.02(I G )"9
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M!2*0$8(BHBTQQKUB/(\-,C7:VLD(:B%[M?8\"J?K^=AE( U^/.:)3X_SL=,
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MB$(RFG.>B-SGB_<;?FITL)%^NVT!M?SF,,9J %HJ^/&$Y[RXD<AP: _,,%Y
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M1K%4&*HDUDLHC7)(TSB".$=Y+'/):2IFZ^6:SMWV^MLG>ZV#V^</]SG>F#'
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MU>]\85V'ZZV([AQ[T8R<7Q''PGEPSXE1XPIL%0&-+V6KRQ78:*/W,H\2&(6
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M+*F>3QXO*>HRU?=RH"Y\5#]S5S]36\[K9],T8JW',+ZN!_/F&N-:<ZX69Y?
MR%&6Q+E(M$T@"$0(4<B88E#2B*8Y2Q,F'8NN]AE^>H<$&^GMZK,5W<\:]IH
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M/\;Q";TZ-:&-CV/LJ71<G\::G*$7L-I-8B!_WYZ3%YZ4)KIX_W>M&P(N<R&
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M(HLY-706IQ2B*)*025+ /.)"9IAB7GC1V;D!I\9?5BCPCJY6S_;+NE\^=@1
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M]-3HIWT47<L.K?!@)WU3+,P$WO]*_WNY N_F)O*G5R-XCSERHZEAD!^8L#Q
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M^J?_\S\VO]'_,OG/_^=__']02P,$%     @ N(195#QU]5D*(P$ 7)$- !0
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MZ6#\[$S.;G<2.TZ6MA%\'V:(V%J'Q:MEQB__$[_.9%0974S G/:@1 X4@\5
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MY34/OO0B_A1G/*,IY\"; "^7K69K[G4'PM+BLD;4'IRFSFGP F*0'*)7C*%
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MT/<^OJKG;+C97LXGN9RI5%4YM-1_L_R/U0G^QW G]EGZS]/Y9CZT;1V^_H&
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MT\IEX[0#:Z6$V@()/N0 A2E44AFK)DHM="*O:=^Q#VZ>]QW'4$X#[N']<?Y
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M3MQ&)4T,.$T%?U<*6\SDCX.Y270T\U[0O7ST30;[X<E:Q#K/,Y-Q9O4'Q;F
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MD6OCI'P\-^F%H0_'4M34?30$9S,JJ!E8_B^L#T"87WTEM^XCW7&U//'6N_N
MQ/@JU[E0=9K='\3\8YY-*$91O.E8)*>/)7(#9"R FB?-5;3*Q5Z@/(Z>>1_U
M1H?D"973C$?^,+YXNPQQ>;'<?OLM;.LJMF^/IZUD%((E#<$%#PKI4G#!&JB[
M#+-5J*2?JCVG-['S3K@<]5Z>5E$-8'$_.'F)-1%=8EHDT%E$"H5B(E%J!09M
M0)Z$B!-E\'L0.4__Q038FTHQ<U_(>\Y'7=#ZZ\7ZKSW'XQ%CV@4C:JHE:,%
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MW)>/GL6)SW'&/K:3][R?^G !;=VT)4=2._']]1=4J_>M)!55E)-)QJ->7$4
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M\L_+Q<6WJZ,*\6H">DS2ZV0<:".)R84^N2P9&%2>\UQO;MK,"A]E^2<$Z7U
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MS@L+01D$;57A,I9D9)L\QW:Q@YNM<EGYI4OF4:8 4M5TPMH1R7'Z(Y0<,\.
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M2<Y<J*V(G*C=7UV*]@6CY['G]B3X?26U&(EM$XO\#US?6;K .@'">C!1UU9
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MK]FIM*-HQ770#@-6G#$A&"]Y'&#E/O7\GH"PK^06([.QHY:[C[2B9U8I9%)
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M_IRAD871 ;[>+N9Y,=\D,<<P_\<[HHH64>EY^^:7=Q^N+N=TXLE%.GU](7=
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M )D/^'UQ_IWVSUUBKJRN$AA:3SS)=0Y#'844G2=/G@[66,]5$]MD8CV[K)Y
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M4"EFG<#Q[$!Q*\"[3'+T)@N-)NG>9B^W$<291J-G\PS;#)0_=""ZN_@F@=>
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MB[JUY)]7VW^;!)E="D*13ZDX&? <( :RXCDE$1*&2M8.YF^W;QMYTV%[<]A
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MLH0Z$QF,LI)+)A3YFB?#W"U=XUJW\=!VH&8ZQ=F?GZ:+#3/<2ZFP! A.D*.
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MA?"P[.F'F.:TEQKWG>:TCTR[G^;D=?*<,:PKG#DH0\PXK>OF-A-TC P%TSL
MY*RF.1V*CF&EV<6S=AV+<=>26D$!K$\>A#>U+Z10I"V3 FF$$0Q=";+1[NO[
MA/358',*_^4(1?3@L=R2OSUD0@KF;(IT)^LJ#!G!K_..05C.75':-D=2%Y[+
M,8I]'B0'2+D7?V5K*\G:.F.%!LX2V4K)2^VZ3&"CERE%0;:X[..:=.&%'*>@
MISR1 Z0U]M[,J]66=KHFYW6QT8WC%!6WAH%3RI/CE#)XU!J*%JD(<M6=>^W1
M\*7/']G%&$SU@\BO \=S\\BZI;T$;Q(O&4S.A%\>$D0B"R03@A4F0A&[[,M\
M^+DC-_T,IO.CY#6ZKM>>\);P7'@Q3)-?G=:=F3& \R001?_CQ2NI'KY./Z/H
M.Q\Z<D_,@%H^5%(]N'A/YTB>'>+'B(MHL.X$J @.(D-@R@"FS+04& .W;1S
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MP-*$1_QJY/IMQ0'AB_'G9RP&2_R<BEB$S T5=MA98V;D(S%N6=Q+I4@")V9
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MX_]YOU^)9#+"7SV3\D__!5!+ P04    " "XA%E4FOB#-3D#  "("0  %0
M &5H8S$P:S$R,S$R,65X,C,Q+FAT;<U6VV[;1A!][U=,:-1I %&\RKI&0"+1
MB5!'%F0&1I^*)3D4%R&YQ.[*C/+U'9)2X\0VT+1H8#XL.)S;F3.[LYR]6%XO
MPC\V 62ZR&'S\>W5:@&&:5FWWL*REN$2WH<?KL#OVPZ$DI6*:RY*EEM6L#;
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MO[NV'\ZO[R_RD^/Q!K&_NK!(B7ROGW;Y@1OKF[7[1VG_EN9_ 5!+ P04
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MK8>JVS'GDEJA"DL''5V#)27AP2^=7RL5Z/-@FM!402 H432$J63I.;P/J;R
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MM;W+MN?!K0_719D_HYL'_8-_ 5!+ P04    " "XA%E4X-JZ3DT&  !.(
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M !               ( !     &5H8RTR,#(Q,3(S,2YH=&U02P$"% ,4
M" "WA%E46326M3(A  !N@0$ $               @ 'GA@8 96AC+3(P,C$Q
M,C,Q+GAS9%!+ 0(4 Q0    ( +>$6539E,C6$CP  '^" @ 4
M  "  4>H!@!E:&,M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( +>$6535
M'[-9L+8  )'\!P 4              "  8OD!@!E:&,M,C R,3$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( +>$6502J+I1M L! &N! 0 3              "
M 6V;!P!E:&,M,C R,3$R,S%?9S$N:G!G4$L! A0#%     @ N(195#CC!I=J
MRP$ U+82 !0              ( !4J<( &5H8RTR,#(Q,3(S,5]L86(N>&UL
M4$L! A0#%     @ N(195#QU]5D*(P$ 7)$- !0              ( ![G(*
M &5H8RTR,#(Q,3(S,5]P<F4N>&UL4$L! A0#%     @ N(195$ Z%7Q3'
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M,3!K,3(S,3(Q97@S,C$N:'1M4$L! A0#%     @ N(195.#:NDY-!@  3B
M !4              ( !A=P+ &5H8S$P:S$R,S$R,65X,S(R+FAT;5!+!08
1    #@ . )H#   %XPL    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
